Chr	Start	End	Ref	Alt	Allele	ExonicFunc.refGene	IMPACT	Gene.refGene	Gene	Feature_type	Feature	Func.refGene	EXON	INTRON	HGVSc	HGVSp	cDNA_position	CDS_position	Protein_position	Amino_acids	Codons	Existing_variation	REF_ALLELE	DISTANCE	STRAND	FLAGS	PICK	SYMBOL_SOURCE	HGNC_ID	CANONICAL	REFSEQ_MATCH	REFSEQ_OFFSET	GIVEN_REF	USED_REF	BAM_EDIT	SOURCE	NEAREST	HGVS_OFFSET	HGVSg	AF	AFR_AF	AMR_AF	EAS_AF	EUR_AF	SAS_AF	CLIN_SIG	SOMATIC	PHENO	MOTIF_NAME	MOTIF_POS	HIGH_INF_POS	MOTIF_SCORE_CHANGE	TRANSCRIPTION_FACTORS	LOVD	ada_score	rf_score	1000Gp3_AC	1000Gp3_AF	1000Gp3_AFR_AC	1000Gp3_AFR_AF	1000Gp3_AMR_AC	1000Gp3_AMR_AF	1000Gp3_EAS_AC	1000Gp3_EAS_AF	1000Gp3_EUR_AC	1000Gp3_EUR_AF	1000Gp3_SAS_AC	1000Gp3_SAS_AF	ALSPAC_AC	ALSPAC_AF	APPRIS	Aloft_Confidence	Aloft_Fraction_transcripts_affected	Aloft_pred	Aloft_prob_Dominant	Aloft_prob_Recessive	Aloft_prob_Tolerant	AltaiNeandertal	Ancestral_allele	BayesDel_addAF_pred	BayesDel_addAF_rankscore	BayesDel_addAF_score	BayesDel_noAF_pred	BayesDel_noAF_rankscore	BayesDel_noAF_score	CADD_phred	CADD_phred_hg19	CADD_raw	CADD_raw_hg19	CADD_raw_rankscore	CADD_raw_rankscore_hg19	ChagyrskayaNeandertal	ClinPred_pred	ClinPred_rankscore	ClinPred_score	DANN_rankscore	DANN_score	DEOGEN2_pred	DEOGEN2_rankscore	DEOGEN2_score	Denisova	ESP6500_AA_AC	ESP6500_AA_AF	ESP6500_EA_AC	ESP6500_EA_AF	Eigen-PC-phred_coding	Eigen-PC-raw_coding	Eigen-PC-raw_coding_rankscore	Eigen-phred_coding	Eigen-raw_coding	Eigen-raw_coding_rankscore	Ensembl_geneid	Ensembl_proteinid	Ensembl_transcriptid	ExAC_AC	ExAC_AF	ExAC_AFR_AC	ExAC_AFR_AF	ExAC_AMR_AC	ExAC_AMR_AF	ExAC_Adj_AC	ExAC_Adj_AF	ExAC_EAS_AC	ExAC_EAS_AF	ExAC_FIN_AC	ExAC_FIN_AF	ExAC_NFE_AC	ExAC_NFE_AF	ExAC_SAS_AC	ExAC_SAS_AF	ExAC_nonTCGA_AC	ExAC_nonTCGA_AF	ExAC_nonTCGA_AFR_AC	ExAC_nonTCGA_AFR_AF	ExAC_nonTCGA_AMR_AC	ExAC_nonTCGA_AMR_AF	ExAC_nonTCGA_Adj_AC	ExAC_nonTCGA_Adj_AF	ExAC_nonTCGA_EAS_AC	ExAC_nonTCGA_EAS_AF	ExAC_nonTCGA_FIN_AC	ExAC_nonTCGA_FIN_AF	ExAC_nonTCGA_NFE_AC	ExAC_nonTCGA_NFE_AF	ExAC_nonTCGA_SAS_AC	ExAC_nonTCGA_SAS_AF	ExAC_nonpsych_AC	ExAC_nonpsych_AF	ExAC_nonpsych_AFR_AC	ExAC_nonpsych_AFR_AF	ExAC_nonpsych_AMR_AC	ExAC_nonpsych_AMR_AF	ExAC_nonpsych_Adj_AC	ExAC_nonpsych_Adj_AF	ExAC_nonpsych_EAS_AC	ExAC_nonpsych_EAS_AF	ExAC_nonpsych_FIN_AC	ExAC_nonpsych_FIN_AF	ExAC_nonpsych_NFE_AC	ExAC_nonpsych_NFE_AF	ExAC_nonpsych_SAS_AC	ExAC_nonpsych_SAS_AF	FATHMM_converted_rankscore	FATHMM_pred	FATHMM_score	GENCODE_basic	GERP++_NR	GERP++_RS	GERP++_RS_rankscore	GM12878_confidence_value	GM12878_fitCons_rankscore	GM12878_fitCons_score	GTEx_V8_gene	GTEx_V8_tissue	GenoCanyon_rankscore	GenoCanyon_score	Geuvadis_eQTL_target_gene	H1-hESC_confidence_value	H1-hESC_fitCons_rankscore	H1-hESC_fitCons_score	HGVSc_ANNOVAR	HGVSc_VEP	HGVSc_snpEff	HGVSp_ANNOVAR	HGVSp_VEP	HGVSp_snpEff	HUVEC_confidence_value	HUVEC_fitCons_rankscore	HUVEC_fitCons_score	Interpro_domain	LINSIGHT	LINSIGHT_rankscore	LIST-S2_pred	LIST-S2_rankscore	LIST-S2_score	LRT_Omega	LRT_converted_rankscore	LRT_pred	LRT_score	M-CAP_pred	M-CAP_rankscore	M-CAP_score	MPC_rankscore	MPC_score	MVP_rankscore	MVP_score	MetaLR_pred	MetaLR_rankscore	MetaLR_score	MetaRNN_pred	MetaRNN_rankscore	MetaRNN_score	MetaSVM_pred	MetaSVM_rankscore	MetaSVM_score	MutPred_AAchange	MutPred_Top5features	MutPred_protID	MutPred_rankscore	MutPred_score	MutationAssessor_pred	MutationAssessor_rankscore	MutationAssessor_score	MutationTaster_AAE	MutationTaster_converted_rankscore	MutationTaster_model	MutationTaster_pred	MutationTaster_score	PROVEAN_converted_rankscore	PROVEAN_pred	PROVEAN_score	Polyphen2_HDIV_pred	Polyphen2_HDIV_rankscore	Polyphen2_HDIV_score	Polyphen2_HVAR_pred	Polyphen2_HVAR_rankscore	Polyphen2_HVAR_score	PrimateAI_pred	PrimateAI_rankscore	PrimateAI_score	REVEL_rankscore	REVEL_score	Reliability_index	SIFT4G_converted_rankscore	SIFT4G_pred	SIFT4G_score	SIFT_converted_rankscore	SIFT_pred	SIFT_score	SiPhy_29way_logOdds	SiPhy_29way_logOdds_rankscore	SiPhy_29way_pi	TSL	TWINSUK_AC	TWINSUK_AF	UK10K_AC	UK10K_AF	Uniprot_acc	Uniprot_entry	VEP_canonical	VEST4_rankscore	VEST4_score	VindijiaNeandertal	aaalt	aapos	aaref	alt	bStatistic	bStatistic_converted_rankscore	cds_strand	chr	clinvar_MedGen_id	clinvar_OMIM_id	clinvar_Orphanet_id	clinvar_clnsig	clinvar_hgvs	clinvar_id	clinvar_golden_stars	clinvar_trait	clinvar_var_source	codon_degeneracy	codonpos	fathmm-MKL_coding_group	fathmm-MKL_coding_pred	fathmm-MKL_coding_rankscore	fathmm-MKL_coding_score	fathmm-XF_coding_pred	fathmm-XF_coding_rankscore	fathmm-XF_coding_score	genename	gnomAD_exomes_AC	gnomAD_exomes_AF	gnomAD_exomes_AFR_AC	gnomAD_exomes_AFR_AF	gnomAD_exomes_AFR_AN	gnomAD_exomes_AFR_nhomalt	gnomAD_exomes_AMR_AC	gnomAD_exomes_AMR_AF	gnomAD_exomes_AMR_AN	gnomAD_exomes_AMR_nhomalt	gnomAD_exomes_AN	gnomAD_exomes_ASJ_AC	gnomAD_exomes_ASJ_AF	gnomAD_exomes_ASJ_AN	gnomAD_exomes_ASJ_nhomalt	gnomAD_exomes_EAS_AC	gnomAD_exomes_EAS_AF	gnomAD_exomes_EAS_AN	gnomAD_exomes_EAS_nhomalt	gnomAD_exomes_FIN_AC	gnomAD_exomes_FIN_AF	gnomAD_exomes_FIN_AN	gnomAD_exomes_FIN_nhomalt	gnomAD_exomes_NFE_AC	gnomAD_exomes_NFE_AF	gnomAD_exomes_NFE_AN	gnomAD_exomes_NFE_nhomalt	gnomAD_exomes_POPMAX_AC	gnomAD_exomes_POPMAX_AF	gnomAD_exomes_POPMAX_AN	gnomAD_exomes_POPMAX_nhomalt	gnomAD_exomes_SAS_AC	gnomAD_exomes_SAS_AF	gnomAD_exomes_SAS_AN	gnomAD_exomes_SAS_nhomalt	gnomAD_exomes_controls_AC	gnomAD_exomes_controls_AF	gnomAD_exomes_controls_AFR_AC	gnomAD_exomes_controls_AFR_AF	gnomAD_exomes_controls_AFR_AN	gnomAD_exomes_controls_AFR_nhomalt	gnomAD_exomes_controls_AMR_AC	gnomAD_exomes_controls_AMR_AF	gnomAD_exomes_controls_AMR_AN	gnomAD_exomes_controls_AMR_nhomalt	gnomAD_exomes_controls_AN	gnomAD_exomes_controls_ASJ_AC	gnomAD_exomes_controls_ASJ_AF	gnomAD_exomes_controls_ASJ_AN	gnomAD_exomes_controls_ASJ_nhomalt	gnomAD_exomes_controls_EAS_AC	gnomAD_exomes_controls_EAS_AF	gnomAD_exomes_controls_EAS_AN	gnomAD_exomes_controls_EAS_nhomalt	gnomAD_exomes_controls_FIN_AC	gnomAD_exomes_controls_FIN_AF	gnomAD_exomes_controls_FIN_AN	gnomAD_exomes_controls_FIN_nhomalt	gnomAD_exomes_controls_NFE_AC	gnomAD_exomes_controls_NFE_AF	gnomAD_exomes_controls_NFE_AN	gnomAD_exomes_controls_NFE_nhomalt	gnomAD_exomes_controls_POPMAX_AC	gnomAD_exomes_controls_POPMAX_AF	gnomAD_exomes_controls_POPMAX_AN	gnomAD_exomes_controls_POPMAX_nhomalt	gnomAD_exomes_controls_SAS_AC	gnomAD_exomes_controls_SAS_AF	gnomAD_exomes_controls_SAS_AN	gnomAD_exomes_controls_SAS_nhomalt	gnomAD_exomes_controls_nhomalt	gnomAD_exomes_flag	gnomAD_exomes_nhomalt	gnomAD_exomes_non_cancer_AC	gnomAD_exomes_non_cancer_AF	gnomAD_exomes_non_cancer_AFR_AC	gnomAD_exomes_non_cancer_AFR_AF	gnomAD_exomes_non_cancer_AFR_AN	gnomAD_exomes_non_cancer_AFR_nhomalt	gnomAD_exomes_non_cancer_AMR_AC	gnomAD_exomes_non_cancer_AMR_AF	gnomAD_exomes_non_cancer_AMR_AN	gnomAD_exomes_non_cancer_AMR_nhomalt	gnomAD_exomes_non_cancer_AN	gnomAD_exomes_non_cancer_ASJ_AC	gnomAD_exomes_non_cancer_ASJ_AF	gnomAD_exomes_non_cancer_ASJ_AN	gnomAD_exomes_non_cancer_ASJ_nhomalt	gnomAD_exomes_non_cancer_EAS_AC	gnomAD_exomes_non_cancer_EAS_AF	gnomAD_exomes_non_cancer_EAS_AN	gnomAD_exomes_non_cancer_EAS_nhomalt	gnomAD_exomes_non_cancer_FIN_AC	gnomAD_exomes_non_cancer_FIN_AF	gnomAD_exomes_non_cancer_FIN_AN	gnomAD_exomes_non_cancer_FIN_nhomalt	gnomAD_exomes_non_cancer_NFE_AC	gnomAD_exomes_non_cancer_NFE_AF	gnomAD_exomes_non_cancer_NFE_AN	gnomAD_exomes_non_cancer_NFE_nhomalt	gnomAD_exomes_non_cancer_POPMAX_AC	gnomAD_exomes_non_cancer_POPMAX_AF	gnomAD_exomes_non_cancer_POPMAX_AN	gnomAD_exomes_non_cancer_POPMAX_nhomalt	gnomAD_exomes_non_cancer_SAS_AC	gnomAD_exomes_non_cancer_SAS_AF	gnomAD_exomes_non_cancer_SAS_AN	gnomAD_exomes_non_cancer_SAS_nhomalt	gnomAD_exomes_non_cancer_nhomalt	gnomAD_exomes_non_neuro_AC	gnomAD_exomes_non_neuro_AF	gnomAD_exomes_non_neuro_AFR_AC	gnomAD_exomes_non_neuro_AFR_AF	gnomAD_exomes_non_neuro_AFR_AN	gnomAD_exomes_non_neuro_AFR_nhomalt	gnomAD_exomes_non_neuro_AMR_AC	gnomAD_exomes_non_neuro_AMR_AF	gnomAD_exomes_non_neuro_AMR_AN	gnomAD_exomes_non_neuro_AMR_nhomalt	gnomAD_exomes_non_neuro_AN	gnomAD_exomes_non_neuro_ASJ_AC	gnomAD_exomes_non_neuro_ASJ_AF	gnomAD_exomes_non_neuro_ASJ_AN	gnomAD_exomes_non_neuro_ASJ_nhomalt	gnomAD_exomes_non_neuro_EAS_AC	gnomAD_exomes_non_neuro_EAS_AF	gnomAD_exomes_non_neuro_EAS_AN	gnomAD_exomes_non_neuro_EAS_nhomalt	gnomAD_exomes_non_neuro_FIN_AC	gnomAD_exomes_non_neuro_FIN_AF	gnomAD_exomes_non_neuro_FIN_AN	gnomAD_exomes_non_neuro_FIN_nhomalt	gnomAD_exomes_non_neuro_NFE_AC	gnomAD_exomes_non_neuro_NFE_AF	gnomAD_exomes_non_neuro_NFE_AN	gnomAD_exomes_non_neuro_NFE_nhomalt	gnomAD_exomes_non_neuro_POPMAX_AC	gnomAD_exomes_non_neuro_POPMAX_AF	gnomAD_exomes_non_neuro_POPMAX_AN	gnomAD_exomes_non_neuro_POPMAX_nhomalt	gnomAD_exomes_non_neuro_SAS_AC	gnomAD_exomes_non_neuro_SAS_AF	gnomAD_exomes_non_neuro_SAS_AN	gnomAD_exomes_non_neuro_SAS_nhomalt	gnomAD_exomes_non_neuro_nhomalt	gnomAD_exomes_non_topmed_AC	gnomAD_exomes_non_topmed_AF	gnomAD_exomes_non_topmed_AFR_AC	gnomAD_exomes_non_topmed_AFR_AF	gnomAD_exomes_non_topmed_AFR_AN	gnomAD_exomes_non_topmed_AFR_nhomalt	gnomAD_exomes_non_topmed_AMR_AC	gnomAD_exomes_non_topmed_AMR_AF	gnomAD_exomes_non_topmed_AMR_AN	gnomAD_exomes_non_topmed_AMR_nhomalt	gnomAD_exomes_non_topmed_AN	gnomAD_exomes_non_topmed_ASJ_AC	gnomAD_exomes_non_topmed_ASJ_AF	gnomAD_exomes_non_topmed_ASJ_AN	gnomAD_exomes_non_topmed_ASJ_nhomalt	gnomAD_exomes_non_topmed_EAS_AC	gnomAD_exomes_non_topmed_EAS_AF	gnomAD_exomes_non_topmed_EAS_AN	gnomAD_exomes_non_topmed_EAS_nhomalt	gnomAD_exomes_non_topmed_FIN_AC	gnomAD_exomes_non_topmed_FIN_AF	gnomAD_exomes_non_topmed_FIN_AN	gnomAD_exomes_non_topmed_FIN_nhomalt	gnomAD_exomes_non_topmed_NFE_AC	gnomAD_exomes_non_topmed_NFE_AF	gnomAD_exomes_non_topmed_NFE_AN	gnomAD_exomes_non_topmed_NFE_nhomalt	gnomAD_exomes_non_topmed_POPMAX_AC	gnomAD_exomes_non_topmed_POPMAX_AF	gnomAD_exomes_non_topmed_POPMAX_AN	gnomAD_exomes_non_topmed_POPMAX_nhomalt	gnomAD_exomes_non_topmed_SAS_AC	gnomAD_exomes_non_topmed_SAS_AF	gnomAD_exomes_non_topmed_SAS_AN	gnomAD_exomes_non_topmed_SAS_nhomalt	gnomAD_exomes_non_topmed_nhomalt	gnomAD_genomes_AC	gnomAD_genomes_AF	gnomAD_genomes_AFR_AC	gnomAD_genomes_AFR_AF	gnomAD_genomes_AFR_AN	gnomAD_genomes_AFR_nhomalt	gnomAD_genomes_AMI_AC	gnomAD_genomes_AMI_AF	gnomAD_genomes_AMI_AN	gnomAD_genomes_AMI_nhomalt	gnomAD_genomes_AMR_AC	gnomAD_genomes_AMR_AF	gnomAD_genomes_AMR_AN	gnomAD_genomes_AMR_nhomalt	gnomAD_genomes_AN	gnomAD_genomes_ASJ_AC	gnomAD_genomes_ASJ_AF	gnomAD_genomes_ASJ_AN	gnomAD_genomes_ASJ_nhomalt	gnomAD_genomes_EAS_AC	gnomAD_genomes_EAS_AF	gnomAD_genomes_EAS_AN	gnomAD_genomes_EAS_nhomalt	gnomAD_genomes_FIN_AC	gnomAD_genomes_FIN_AF	gnomAD_genomes_FIN_AN	gnomAD_genomes_FIN_nhomalt	gnomAD_genomes_MID_AC	gnomAD_genomes_MID_AF	gnomAD_genomes_MID_AN	gnomAD_genomes_MID_nhomalt	gnomAD_genomes_NFE_AC	gnomAD_genomes_NFE_AF	gnomAD_genomes_NFE_AN	gnomAD_genomes_NFE_nhomalt	gnomAD_genomes_POPMAX_AC	gnomAD_genomes_POPMAX_AF	gnomAD_genomes_POPMAX_AN	gnomAD_genomes_POPMAX_nhomalt	gnomAD_genomes_SAS_AC	gnomAD_genomes_SAS_AF	gnomAD_genomes_SAS_AN	gnomAD_genomes_SAS_nhomalt	gnomAD_genomes_controls_and_biobanks_AC	gnomAD_genomes_controls_and_biobanks_AF	gnomAD_genomes_controls_and_biobanks_AFR_AC	gnomAD_genomes_controls_and_biobanks_AFR_AF	gnomAD_genomes_controls_and_biobanks_AFR_AN	gnomAD_genomes_controls_and_biobanks_AFR_nhomalt	gnomAD_genomes_controls_and_biobanks_AMI_AC	gnomAD_genomes_controls_and_biobanks_AMI_AF	gnomAD_genomes_controls_and_biobanks_AMI_AN	gnomAD_genomes_controls_and_biobanks_AMI_nhomalt	gnomAD_genomes_controls_and_biobanks_AMR_AC	gnomAD_genomes_controls_and_biobanks_AMR_AF	gnomAD_genomes_controls_and_biobanks_AMR_AN	gnomAD_genomes_controls_and_biobanks_AMR_nhomalt	gnomAD_genomes_controls_and_biobanks_AN	gnomAD_genomes_controls_and_biobanks_ASJ_AC	gnomAD_genomes_controls_and_biobanks_ASJ_AF	gnomAD_genomes_controls_and_biobanks_ASJ_AN	gnomAD_genomes_controls_and_biobanks_ASJ_nhomalt	gnomAD_genomes_controls_and_biobanks_EAS_AC	gnomAD_genomes_controls_and_biobanks_EAS_AF	gnomAD_genomes_controls_and_biobanks_EAS_AN	gnomAD_genomes_controls_and_biobanks_EAS_nhomalt	gnomAD_genomes_controls_and_biobanks_FIN_AC	gnomAD_genomes_controls_and_biobanks_FIN_AF	gnomAD_genomes_controls_and_biobanks_FIN_AN	gnomAD_genomes_controls_and_biobanks_FIN_nhomalt	gnomAD_genomes_controls_and_biobanks_MID_AC	gnomAD_genomes_controls_and_biobanks_MID_AF	gnomAD_genomes_controls_and_biobanks_MID_AN	gnomAD_genomes_controls_and_biobanks_MID_nhomalt	gnomAD_genomes_controls_and_biobanks_NFE_AC	gnomAD_genomes_controls_and_biobanks_NFE_AF	gnomAD_genomes_controls_and_biobanks_NFE_AN	gnomAD_genomes_controls_and_biobanks_NFE_nhomalt	gnomAD_genomes_controls_and_biobanks_SAS_AC	gnomAD_genomes_controls_and_biobanks_SAS_AF	gnomAD_genomes_controls_and_biobanks_SAS_AN	gnomAD_genomes_controls_and_biobanks_SAS_nhomalt	gnomAD_genomes_controls_and_biobanks_nhomalt	gnomAD_genomes_flag	gnomAD_genomes_nhomalt	gnomAD_genomes_non_cancer_AC	gnomAD_genomes_non_cancer_AF	gnomAD_genomes_non_cancer_AFR_AC	gnomAD_genomes_non_cancer_AFR_AF	gnomAD_genomes_non_cancer_AFR_AN	gnomAD_genomes_non_cancer_AFR_nhomalt	gnomAD_genomes_non_cancer_AMI_AC	gnomAD_genomes_non_cancer_AMI_AF	gnomAD_genomes_non_cancer_AMI_AN	gnomAD_genomes_non_cancer_AMI_nhomalt	gnomAD_genomes_non_cancer_AMR_AC	gnomAD_genomes_non_cancer_AMR_AF	gnomAD_genomes_non_cancer_AMR_AN	gnomAD_genomes_non_cancer_AMR_nhomalt	gnomAD_genomes_non_cancer_AN	gnomAD_genomes_non_cancer_ASJ_AC	gnomAD_genomes_non_cancer_ASJ_AF	gnomAD_genomes_non_cancer_ASJ_AN	gnomAD_genomes_non_cancer_ASJ_nhomalt	gnomAD_genomes_non_cancer_EAS_AC	gnomAD_genomes_non_cancer_EAS_AF	gnomAD_genomes_non_cancer_EAS_AN	gnomAD_genomes_non_cancer_EAS_nhomalt	gnomAD_genomes_non_cancer_FIN_AC	gnomAD_genomes_non_cancer_FIN_AF	gnomAD_genomes_non_cancer_FIN_AN	gnomAD_genomes_non_cancer_FIN_nhomalt	gnomAD_genomes_non_cancer_MID_AC	gnomAD_genomes_non_cancer_MID_AF	gnomAD_genomes_non_cancer_MID_AN	gnomAD_genomes_non_cancer_MID_nhomalt	gnomAD_genomes_non_cancer_NFE_AC	gnomAD_genomes_non_cancer_NFE_AF	gnomAD_genomes_non_cancer_NFE_AN	gnomAD_genomes_non_cancer_NFE_nhomalt	gnomAD_genomes_non_cancer_SAS_AC	gnomAD_genomes_non_cancer_SAS_AF	gnomAD_genomes_non_cancer_SAS_AN	gnomAD_genomes_non_cancer_SAS_nhomalt	gnomAD_genomes_non_cancer_nhomalt	gnomAD_genomes_non_neuro_AC	gnomAD_genomes_non_neuro_AF	gnomAD_genomes_non_neuro_AFR_AC	gnomAD_genomes_non_neuro_AFR_AF	gnomAD_genomes_non_neuro_AFR_AN	gnomAD_genomes_non_neuro_AFR_nhomalt	gnomAD_genomes_non_neuro_AMI_AC	gnomAD_genomes_non_neuro_AMI_AF	gnomAD_genomes_non_neuro_AMI_AN	gnomAD_genomes_non_neuro_AMI_nhomalt	gnomAD_genomes_non_neuro_AMR_AC	gnomAD_genomes_non_neuro_AMR_AF	gnomAD_genomes_non_neuro_AMR_AN	gnomAD_genomes_non_neuro_AMR_nhomalt	gnomAD_genomes_non_neuro_AN	gnomAD_genomes_non_neuro_ASJ_AC	gnomAD_genomes_non_neuro_ASJ_AF	gnomAD_genomes_non_neuro_ASJ_AN	gnomAD_genomes_non_neuro_ASJ_nhomalt	gnomAD_genomes_non_neuro_EAS_AC	gnomAD_genomes_non_neuro_EAS_AF	gnomAD_genomes_non_neuro_EAS_AN	gnomAD_genomes_non_neuro_EAS_nhomalt	gnomAD_genomes_non_neuro_FIN_AC	gnomAD_genomes_non_neuro_FIN_AF	gnomAD_genomes_non_neuro_FIN_AN	gnomAD_genomes_non_neuro_FIN_nhomalt	gnomAD_genomes_non_neuro_MID_AC	gnomAD_genomes_non_neuro_MID_AF	gnomAD_genomes_non_neuro_MID_AN	gnomAD_genomes_non_neuro_MID_nhomalt	gnomAD_genomes_non_neuro_NFE_AC	gnomAD_genomes_non_neuro_NFE_AF	gnomAD_genomes_non_neuro_NFE_AN	gnomAD_genomes_non_neuro_NFE_nhomalt	gnomAD_genomes_non_neuro_SAS_AC	gnomAD_genomes_non_neuro_SAS_AF	gnomAD_genomes_non_neuro_SAS_AN	gnomAD_genomes_non_neuro_SAS_nhomalt	gnomAD_genomes_non_neuro_nhomalt	gnomAD_genomes_non_topmed_AC	gnomAD_genomes_non_topmed_AF	gnomAD_genomes_non_topmed_AFR_AC	gnomAD_genomes_non_topmed_AFR_AF	gnomAD_genomes_non_topmed_AFR_AN	gnomAD_genomes_non_topmed_AFR_nhomalt	gnomAD_genomes_non_topmed_AMI_AC	gnomAD_genomes_non_topmed_AMI_AF	gnomAD_genomes_non_topmed_AMI_AN	gnomAD_genomes_non_topmed_AMI_nhomalt	gnomAD_genomes_non_topmed_AMR_AC	gnomAD_genomes_non_topmed_AMR_AF	gnomAD_genomes_non_topmed_AMR_AN	gnomAD_genomes_non_topmed_AMR_nhomalt	gnomAD_genomes_non_topmed_AN	gnomAD_genomes_non_topmed_ASJ_AC	gnomAD_genomes_non_topmed_ASJ_AF	gnomAD_genomes_non_topmed_ASJ_AN	gnomAD_genomes_non_topmed_ASJ_nhomalt	gnomAD_genomes_non_topmed_EAS_AC	gnomAD_genomes_non_topmed_EAS_AF	gnomAD_genomes_non_topmed_EAS_AN	gnomAD_genomes_non_topmed_EAS_nhomalt	gnomAD_genomes_non_topmed_FIN_AC	gnomAD_genomes_non_topmed_FIN_AF	gnomAD_genomes_non_topmed_FIN_AN	gnomAD_genomes_non_topmed_FIN_nhomalt	gnomAD_genomes_non_topmed_MID_AC	gnomAD_genomes_non_topmed_MID_AF	gnomAD_genomes_non_topmed_MID_AN	gnomAD_genomes_non_topmed_MID_nhomalt	gnomAD_genomes_non_topmed_NFE_AC	gnomAD_genomes_non_topmed_NFE_AF	gnomAD_genomes_non_topmed_NFE_AN	gnomAD_genomes_non_topmed_NFE_nhomalt	gnomAD_genomes_non_topmed_SAS_AC	gnomAD_genomes_non_topmed_SAS_AF	gnomAD_genomes_non_topmed_SAS_AN	gnomAD_genomes_non_topmed_SAS_nhomalt	gnomAD_genomes_non_topmed_nhomalt	hg18_chr	hg18_pos(1-based)	hg19_chr	hg19_pos(1-based)	integrated_confidence_value	integrated_fitCons_rankscore	integrated_fitCons_score	phastCons100way_vertebrate	phastCons100way_vertebrate_rankscore	phastCons17way_primate	phastCons17way_primate_rankscore	phastCons30way_mammalian	phastCons30way_mammalian_rankscore	phyloP100way_vertebrate	phyloP100way_vertebrate_rankscore	phyloP17way_primate	phyloP17way_primate_rankscore	phyloP30way_mammalian	phyloP30way_mammalian_rankscore	pos(1-based)	ref	refcodon	rs_dbSNP	satMutMPRA	GeneSplicer	MES-NCSS_downstream_acceptor	MES-NCSS_downstream_donor	MES-NCSS_upstream_acceptor	MES-NCSS_upstream_donor	MaxEntScan_alt	MaxEntScan_diff	MaxEntScan_ref	SpliceAI_pred_DP_AG	SpliceAI_pred_DP_AL	SpliceAI_pred_DP_DG	SpliceAI_pred_DP_DL	SpliceAI_pred_DS_AG	SpliceAI_pred_DS_AL	SpliceAI_pred_DS_DG	SpliceAI_pred_DS_DL	SpliceAI_pred_SYMBOL	pLI_gene_value	NearestExonJB	ClinVar	ClinVar_CLNSIG	ClinVar_CLNREVSTAT	ClinVar_CLNDN	ClinVar_CLNDISDB	ClinVar_CLNALLELEID	exac03	exac03_AF	exac03_AC	exac03_AC_Het	exac03_AC_Hom	exac03_AC_AFR	exac03_AC_AMR	exac03_AC_EAS	exac03_AC_FIN	exac03_AC_NFE	exac03_AC_OTH	exac03_AC_SAS	exac03_AN_AFR	exac03_AN_AMR	exac03_AN_EAS	exac03_AN_FIN	exac03_AN_NFE	exac03_AN_OTH	exac03_AN_SAS	exac03_Het_AFR	exac03_Het_AMR	exac03_Het_EAS	exac03_Het_FIN	exac03_Het_NFE	exac03_Het_OTH	exac03_Het_SAS	exac03_Hom_AFR	exac03_Hom_AMR	exac03_Hom_EAS	exac03_Hom_FIN	exac03_Hom_NFE	exac03_Hom_OTH	exac03_Hom_SAS	gnomad_exomes	gnomad_exomes_AF_AFR	gnomad_exomes_AF_AMR	gnomad_exomes_AF_ASJ	gnomad_exomes_AF_EAS	gnomad_exomes_AF_FIN	gnomad_exomes_AF_NFE	gnomad_exomes_AF_OTH	gnomad_exomes_AF_SAS	gnomad_exomes_AF_Male	gnomad_exomes_AF_Female	gnomad_exomes_AF_POPMAX	gnomad_exomes_AF_raw	gnomad_genomes	gnomad_genomes_AF_AFR	gnomad_genomes_AF_AMR	gnomad_genomes_AF_ASJ	gnomad_genomes_AF_EAS	gnomad_genomes_AF_FIN	gnomad_genomes_AF_NFE	gnomad_genomes_AF_OTH	gnomad_genomes_AF_SAS	gnomad_genomes_AF_Male	gnomad_genomes_AF_Female	gnomad_genomes_AF_POPMAX	gnomad_genomes_AF_raw	esp6500siv2	esp6500siv2_MAF	avsnp152	avsnp152_RS	hg19_genomicSuperDups_name	hg19_genomicSuperDups_fracMatch	hg19_genomicSuperDups_fracMatchIndel	Gene.refGene.split	Func.refGene.split	ExonicFunc.refGene.split	OMIM_DN	OMIM_ID	OMIM_MK	OMIM_SG	familyClass	pLi	pRec	pNull	Disease_description.refGene	FORMAT	AB_sample	PVS1_contrib	PS1_contrib	PS2_contrib_merged	PS3_contrib	PS4_contrib	PM1_contrib	PM2_contrib	PM4_contrib	PM5_contrib	PP2_contrib	PP3_contrib	PP5_contrib	BS1_contrib	BS2_contrib	BS3_contrib	BP1_contrib	BP3_contrib	BP4_contrib	BP6_contrib	BP7_contrib	BA_1_contrib	Probability_Path	Prediction_ACMG_tapes
6	76538307	76538307	C	T	T	stop_gained	HIGH	MYO6	4646	Transcript	NM_004999.4	protein_coding	4/35	.	NM_004999.4:c.238C>T	NP_004990.3:p.Arg80Ter	470	238	80	R/*	Cga/Tga	rs727504567	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	MYO6	.	chr6:g.76538307C>T	.	.	.	.	.	.	pathogenic&likely_pathogenic	.	1	.	.	.	.	.	MYO6&NM_004999.3&c.238C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.99412	0.625005	D	0.99401	0.66	36	38	6.880280	7.392520	0.96894	0.97786	C/C	.	.	.	0.88372	0.99798241123808862	.	.	.	C/C	.	.	.	.	8.823432	0.750985974823783	0.86231	10.17942	0.864758012152659	0.89930	.	.	.	1	8.238e-06	0	0	0	0	1	8.268e-06	0	0	0	0	1	1.503e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1.102e-05	0	0	0	0	1	1.108e-05	0	0	0	0	1	2.384e-05	0	0	.	.	.	.	5.51	5.51	0.81769	0	0.55848	0.633656	.	.	0.44625	0.999878818970866	.	0	0.59346	0.659464	.	.	.	.	.	.	0	0.95156	0.727631	Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VI_myosin&_motor_domain&.&.&.&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VI_myosin&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VI_myosin&_motor_domain	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae&complex_aae&complex_aae	A&A&A&A	1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19.415	0.94681	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.89465	.	C/C	X	.	R	T	598	0.68232	.	6	C2931767&CN043648&CN169374&CN517202&CN826980	606346	ORPHA87884&ORPHA96210	Likely_pathogenic	NC_000006.12:g.75828590C>T	178957	reviewed_by_expert_panel	Autosomal_dominant_nonsyndromic_deafness_22&Nonsyndromic_hearing_loss_and_deafness&not_specified&not_provided&Rare_genetic_deafness	ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:138707	.	.	AEFBI	D	0.67482	0.96089	N	0.23302	0.119382	.	1	3.987080e-06	0	0.000000e+00	16166	0	0	0.000000e+00	34540	0	250810	0	0.000000e+00	10072	0	0	0.000000e+00	18386	0	0	0.000000e+00	21628	0	1	8.823790e-06	113330	0	1	8.823790e-06	113330	0	0	0.000000e+00	30582	0	0	0.000000e+00	0	0.000000e+00	7156	0	0	0.000000e+00	17082	0	109304	0	0.000000e+00	2320	0	0	0.000000e+00	9040	0	0	0.000000e+00	13386	0	0	0.000000e+00	42726	0	.	.	.	.	0	0.000000e+00	15686	0	0	.	0	0	0.000000e+00	0	0.000000e+00	14816	0	0	0.000000e+00	34208	0	236286	0	0.000000e+00	9566	0	0	0.000000e+00	17684	0	0	0.000000e+00	21612	0	0	0.000000e+00	102322	0	.	.	.	.	0	0.000000e+00	30492	0	0	1	4.814310e-06	0	0.000000e+00	16128	0	0	0.000000e+00	30476	0	207714	0	0.000000e+00	6206	0	0	0.000000e+00	13408	0	0	0.000000e+00	16726	0	1	1.119190e-05	89350	0	1	1.119190e-05	89350	0	0	0.000000e+00	30574	0	0	1	4.094640e-06	0	0.000000e+00	11952	0	0	0.000000e+00	34406	0	244222	0	0.000000e+00	9990	0	0	0.000000e+00	18382	0	0	0.000000e+00	21626	0	1	8.988440e-06	111254	0	1	8.988440e-06	111254	0	0	0.000000e+00	30582	0	0	1	6.581980e-06	0	0.000000e+00	41366	0	0	0.000000e+00	910	0	0	0.000000e+00	15246	0	151930	0	0.000000e+00	3472	0	0	0.000000e+00	5188	0	0	0.000000e+00	10548	0	0	0.000000e+00	316	0	1	1.471020e-05	67980	0	1	1.471020e-05	67980	0	0	0.000000e+00	4822	0	0	0.000000e+00	0	0.000000e+00	9078	0	0	0.000000e+00	60	0	0	0.000000e+00	4678	0	32792	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5440	0	0	0.000000e+00	246	0	0	0.000000e+00	6834	0	0	0.000000e+00	3108	0	0	.	0	0	0.000000e+00	0	0.000000e+00	41046	0	0	0.000000e+00	910	0	0	0.000000e+00	15058	0	147680	0	0.000000e+00	3302	0	0	0.000000e+00	4952	0	0	0.000000e+00	10548	0	0	0.000000e+00	304	0	0	0.000000e+00	64758	0	0	0.000000e+00	4790	0	0	1	7.432070e-06	0	0.000000e+00	32406	0	0	0.000000e+00	862	0	0	0.000000e+00	14800	0	134552	0	0.000000e+00	3388	0	0	0.000000e+00	5188	0	0	0.000000e+00	6916	0	0	0.000000e+00	310	0	1	1.565730e-05	63868	0	0	0.000000e+00	4820	0	0	1	1.241800e-05	0	0.000000e+00	24748	0	0	0.000000e+00	110	0	0	0.000000e+00	12874	0	80528	0	0.000000e+00	998	0	0	0.000000e+00	3746	0	0	0.000000e+00	10456	0	0	0.000000e+00	272	0	1	4.756920e-05	21022	0	0	0.000000e+00	4794	0	0	6	76595027	6	76538307	0	0.92422	0.732398	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	4.458000	0.59832	0.599000	0.40250	1.026000	0.45946	75828590	C	.	rs727504567	.	.	7.955	6.693	8.798	8.591	.	.	.	-2	-50	43	23	0.00	0.05	0.00	0.04	MYO6	0.02	exon-NM_001368865.1-4+23+end+74	178957	Pathogenic	reviewed_by_expert_panel	Rare_genetic_deafness&not_provided&Nonsyndromic_genetic_hearing_loss&Autosomal_dominant_nonsyndromic_hearing_loss_22&not_specified	MedGen:CN826980&Orphanet:96210&MedGen:CN517202&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0011660&MedGen:C2931767&OMIM:606346&Orphanet:228012&MedGen:CN169374	.	6:76538307-76538307	8.238e-06	1	1	0	0	0	0	0	1	0	0	10250	11508	8638	6602	66548	904	16496	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs727504567	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.98295e-06	0.00000e+00	0.00000e+00	7.42876e-06	0.00000e+00	8.98295e-06	8.12222e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs727504567	727504567	.	.	.	MYO6	MYO6:exonic	MYO6:stopgain	MYO6:Deafness\x2cautosomal_dominant_22\x2cwith_hypertrophic_cardiomyopathy\x3bDeafness\x2cautosomal_dominant_22\x3bDeafness\x2cautosomal_recessive_37	MYO6:606346\x3b606346\x3b607821	MYO6:3\x3b3\x3b3	MYO6:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_recessive	0	0.0177883990936548	0.982211600378647	5.27698444208756e-10	DISEASE: Deafness, autosomal dominant, 22 (DFNA22) [MIM:606346]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA22 is progressive and postlingual, with onset during childhood. By the age of approximately 50 years, affected individuals invariably have profound sensorineural deafness. {ECO:0000269|PubMed:11468689}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 37 (DFNB37) [MIM:607821]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:12687499}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, sensorineural, with hypertrophic cardiomyopathy (DFNHCM) [MIM:606346]: An autosomal dominant sensorineural deafness associated with hypertrophic cardiomyopathy. {ECO:0000269|PubMed:15060111}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,485	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103237476	103237476	G	A	A	stop_gained	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1147C>T	NP_000268.1:p.Gln383Ter	1261	1147	383	Q/*	Cag/Tag	rs1037293795&CM126840	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103237476G>A	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1147C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.99412	0.625005	D	0.99401	0.66	45	43	8.735813	8.419076	0.99541	0.99284	G/G	.	.	.	0.79909	0.99690590699776049	.	.	.	G/G	.	.	.	.	16.66716	0.961587735360505	0.97736	19.29932	1.13708937792892	0.98765	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.34	5.34	0.75982	0	0.26702	0.573888	.	.	0.74766	0.999999994970937	.	0	0.59346	0.659464	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19.0479	0.93009	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.96187	.	G/G	X	.	Q	A	503	0.75780	.	12	C0031485	261600	ORPHA716	Pathogenic	NC_000012.12:g.102843698G>A	370701	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.92664	0.99197	N	0.52618	0.487432	.	1	3.980230e-06	1	6.152330e-05	16254	0	0	0.000000e+00	34534	0	251242	0	0.000000e+00	10074	0	0	0.000000e+00	18388	0	0	0.000000e+00	21640	0	0	0.000000e+00	113606	0	1	6.152330e-05	16254	0	0	0.000000e+00	30614	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17096	0	109380	0	0.000000e+00	2320	0	0	0.000000e+00	9042	0	0	0.000000e+00	13394	0	0	0.000000e+00	42760	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	1	4.224650e-06	1	6.711410e-05	14900	0	0	0.000000e+00	34202	0	236706	0	0.000000e+00	9566	0	0	0.000000e+00	17686	0	0	0.000000e+00	21624	0	0	0.000000e+00	102592	0	1	6.711410e-05	14900	0	0	0.000000e+00	30524	0	0	1	4.807180e-06	1	6.166750e-05	16216	0	0	0.000000e+00	30468	0	208022	0	0.000000e+00	6208	0	0	0.000000e+00	13410	0	0	0.000000e+00	16726	0	0	0.000000e+00	89528	0	1	6.166750e-05	16216	0	0	0.000000e+00	30606	0	0	1	4.087910e-06	1	8.316700e-05	12024	0	0	0.000000e+00	34400	0	244624	0	0.000000e+00	9992	0	0	0.000000e+00	18384	0	0	0.000000e+00	21638	0	0	0.000000e+00	111516	0	1	8.316700e-05	12024	0	0	0.000000e+00	30614	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101761606	12	103237476	0	0.56070	0.693126	1.000000	0.71638	0.410000	0.27006	1.000000	0.86279	9.999000	0.99362	0.618000	0.50648	1.176000	0.78918	102843698	G	.	rs1037293795	.	.	8.924	9.158	3.163	9.459	.	.	.	-13	42	-3	-47	0.00	0.00	0.00	0.07	PAH	0.00	exon-NM_001354304.2-12+52+start+134	370701	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1037293795	1037293795	.	.	.	PAH	PAH:exonic	PAH:stopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,663	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
21	36206833	36206833	C	A	A	stop_gained	HIGH	RUNX1	861	Transcript	NM_001754.5	protein_coding	7/9	.	NM_001754.5:c.679G>T	NP_001745.2:p.Glu227Ter	873	679	227	E/*	Gaa/Taa	rs1555889984	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36206833C>A	.	.	.	.	.	.	pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.99412	0.625005	D	0.99401	0.66	37	38	7.128266	7.406147	0.97261	0.97809	C/C	.	.	.	0.79108	0.99678595893066646	.	.	.	C/C	.	.	.	.	12.60771	0.872098604284395	0.94238	15.06472	1.03521588258054	0.96728	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.86	4.86	0.62624	0	0.57511	0.643519	.	.	0.74766	0.999999999900658	.	0	0.07944	0.491513	.	.	.	.	.	.	0	0.95156	0.727631	.&.&.&.&.	.	.	.	.	.	0.120785	0.62929	D	0.000018	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae&complex_aae&complex_aae&complex_aae&without_aae	A&A&A&A&A&D	1&1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	17.9888	0.89084	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.98840	.	C/C	X	.	E	A	355	0.85216	.	21	C1832388	601399	.	Pathogenic	NC_000021.9:g.34834536C>A	545522	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:1c4b6804-f641-4dd6-931b-84e1443249f2	.	.	AEFDBCI	D	0.52658	0.90996	N	0.22247	0.112581	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35128703	21	36206833	0	0.92422	0.732398	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	6.185000	0.71948	0.599000	0.40250	0.947000	0.34431	34834536	C	.	rs1555889984	.	.	11.087	10.451	9.171	9.815	.	.	.	3	1	3	-32	0.00	0.00	0.00	0.02	RUNX1	0.45	exon-NM_001754.5-7+65+end+192	545522	Pathogenic	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555889984	1555889984	.	.	.	RUNX1	RUNX1:exonic	RUNX1:stopgain	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,956	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
21	36171704	36171704	G	T	T	stop_gained	HIGH	RUNX1	861	Transcript	NM_001754.5	protein_coding	8/9	.	NM_001754.5:c.861C>A	NP_001745.2:p.Tyr287Ter	1055	861	287	Y/*	taC/taA	rs121912499&CM025983&COSV100276401&COSV55888341	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36171704G>T	.	.	.	.	.	.	pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.99412	0.625005	D	0.99401	0.66	37	38	7.017339	7.578976	0.97092	0.98096	G/G	.	.	.	0.84382	0.99752407868643167	.	.	.	G/G	.	.	.	.	9.032346	0.759667736510913	0.86876	10.22738	0.866775834389509	0.90041	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.78	5.78	0.91418	0	0.81188	0.709663	.	.	0.74766	0.99999999980894	.	0	0.15389	0.547309	.	.	.	.	.	.	0	0.83352	0.714379	.&.&.&.	.	.	.	.	.	0.118019	0.62929	D	0.000012	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae&complex_aae&complex_aae&complex_aae	A&A&A&A&A	1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	13.8721	0.63127	0.0737:0.0:0.9263:0.0	.	.	.	.	.	.	.	.	0.95608	.	G/G	X	.	Y	T	379	0.83778	.	21	C1832388	601399	.	Pathogenic	NC_000021.9:g.34799407G>T	14467	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:fed802a7-8c1d-4396-89f1-65546e996764&OMIM_Allelic_Variant:151385.0005	.	.	AEFBI	D	0.68342	0.96274	N	0.16914	0.083491	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35093574	21	36171704	0	0.61202	0.706298	1.000000	0.71638	0.996000	0.76049	1.000000	0.86279	3.072000	0.49747	0.676000	0.76740	1.176000	0.78918	34799407	G	.	rs121912499	.	.	9.279	7.470	11.087	10.451	.	.	.	-35	48	-35	48	0.08	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-8+55+end+162	14467	Pathogenic	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121912499	121912499	.	.	.	RUNX1	RUNX1:exonic	RUNX1:stopgain	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,953	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
16	68867259	68867259	G	T	T	stop_gained	HIGH	CDH1	999	Transcript	NM_004360.5	protein_coding	16/16	.	NM_004360.5:c.2506G>T	NP_004351.1:p.Glu836Ter	2630	2506	836	E/*	Gaa/Taa	rs1555518239	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68867259G>T	.	.	.	.	.	.	likely_pathogenic&pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.98769	0.622132	D	0.98747	0.655873	44	44	8.677924	8.568219	0.99498	0.99424	G/G	.	.	.	0.82833	0.9973212039983862	.	.	.	G/G	.	.	.	.	37.2831	1.16425070461449	0.99980	36.32504	1.2864921121428	0.99975	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.04	6.04	0.98025	0	0.63936	0.670034	.	.	0.74766	0.999999991632606	.	0	0.64325	0.697927	.	.	.	.	.	.	0	0.14980	0.542086	Cadherin&_cytoplasmic_domain&Cadherin&_cytoplasmic_domain&.	.	.	.	.	.	0.000000	0.52346	D	0.000078	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	D&D	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	20.1899	0.98230	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.85554	.	G/G	X	.	E	T	363	0.84772	.	16	C1708349&C0027672	137215	ORPHA26106&ORPHA140162	Pathogenic	NC_000016.10:g.68833356G>T	479504	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome	ClinGen_CDH1_Variant_Curation_Expert_Panel&:1a5e5e0d-db23-4e6c-a7f2-002891504b0f	.	.	AEFBI	D	0.96181	0.99450	N	0.49698	0.437000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	67424760	16	68867259	0	0.41029	0.631515	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	10.003000	0.99689	0.676000	0.76740	1.176000	0.78918	68833356	G	.	rs1555518239	.	.	.	.	10.931	9.815	.	.	.	4	-35	4	-16	0.18	0.00	0.00	0.00	CDH1	0.34	exon-NM_001317185.2-16+66+start+2248	479504	Pathogenic	reviewed_by_expert_panel	Hereditary_diffuse_gastric_adenocarcinoma&Hereditary_cancer-predisposing_syndrome	MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555518239	1555518239	.	.	.	CDH1	CDH1:exonic	CDH1:stopgain	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,922	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
16	68845757	68845757	C	T	T	stop_gained	HIGH	CDH1	999	Transcript	NM_004360.5	protein_coding	7/16	.	NM_004360.5:c.1003C>T	NP_004351.1:p.Arg335Ter	1127	1003	335	R/*	Cga/Tga	rs587780784&CM022775&COSV55727261	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	.	chr16:g.68845757C>T	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.1003C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.92700	0.454922	D	0.94890	0.512542	36	36	6.494486	6.814251	0.96401	0.96899	C/C	.	.	.	0.90238	0.99819046928379473	.	.	.	C/C	.	.	.	.	4.917183	0.472418657802419	0.66167	6.183298	0.624606674260196	0.74736	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.47	3.22	0.36041	0	0.40923	0.588066	.	.	0.51787	0.999986706055925	.	0	0.64325	0.697927	.	.	.	.	.	.	0	0.26826	0.564101	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&.	.	.	.	.	.	0.000000	0.44522	D	0.000437	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	13.3929	0.60279	0.4318:0.5681:0.0:0.0	.	.	.	.	.	.	.	.	0.93370	.	C/C	X	.	R	T	315	0.87208	.	16	C1708349&C0027672&CN517202	137215	ORPHA26106&ORPHA140162	Pathogenic	NC_000016.10:g.68811854C>T	136055	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:ce612d02-2bbe-433b-a871-e4ddcfeca78d	.	.	AEFDGBCI	D	0.43483	0.84401	N	0.52315	0.482172	.	2	7.960330e-06	0	0.000000e+00	16254	0	0	0.000000e+00	34580	0	251246	0	0.000000e+00	10076	0	0	0.000000e+00	18394	0	0	0.000000e+00	21614	0	1	8.803900e-06	113586	0	1	3.266690e-05	30612	0	1	3.266690e-05	30612	0	2	1.828720e-05	0	0.000000e+00	7162	0	0	0.000000e+00	17110	0	109366	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13362	0	1	2.338520e-05	42762	0	1	6.373490e-05	15690	0	1	6.373490e-05	15690	0	0	.	0	2	8.448370e-06	0	0.000000e+00	14900	0	0	0.000000e+00	34248	0	236732	0	0.000000e+00	9568	0	0	0.000000e+00	17692	0	0	0.000000e+00	21598	0	1	9.747350e-06	102592	0	1	3.276330e-05	30522	0	1	3.276330e-05	30522	0	0	2	9.613540e-06	0	0.000000e+00	16216	0	0	0.000000e+00	30516	0	208040	0	0.000000e+00	6210	0	0	0.000000e+00	13416	0	0	0.000000e+00	16702	0	1	1.117140e-05	89514	0	1	3.267550e-05	30604	0	1	3.267550e-05	30604	0	0	2	8.175680e-06	0	0.000000e+00	12024	0	0	0.000000e+00	34446	0	244628	0	0.000000e+00	9994	0	0	0.000000e+00	18390	0	0	0.000000e+00	21612	0	1	8.968930e-06	111496	0	1	3.266690e-05	30612	0	1	3.266690e-05	30612	0	0	1	6.574880e-06	0	0.000000e+00	41428	0	0	0.000000e+00	910	0	0	0.000000e+00	15262	0	152094	0	0.000000e+00	3470	0	0	0.000000e+00	5182	0	0	0.000000e+00	10584	0	0	0.000000e+00	316	0	1	1.469900e-05	68032	0	1	1.469900e-05	68032	0	0	0.000000e+00	4822	0	0	0.000000e+00	0	0.000000e+00	9088	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32858	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5462	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3108	0	0	.	0	1	6.764070e-06	0	0.000000e+00	41110	0	0	0.000000e+00	910	0	0	0.000000e+00	15074	0	147840	0	0.000000e+00	3302	0	0	0.000000e+00	4946	0	0	0.000000e+00	10584	0	0	0.000000e+00	304	0	1	1.543160e-05	64802	0	0	0.000000e+00	4790	0	0	1	7.424570e-06	0	0.000000e+00	32460	0	0	0.000000e+00	860	0	0	0.000000e+00	14816	0	134688	0	0.000000e+00	3386	0	0	0.000000e+00	5182	0	0	0.000000e+00	6942	0	0	0.000000e+00	310	0	1	1.564600e-05	63914	0	0	0.000000e+00	4820	0	0	1	1.239830e-05	0	0.000000e+00	24802	0	0	0.000000e+00	112	0	0	0.000000e+00	12890	0	80656	0	0.000000e+00	996	0	0	0.000000e+00	3740	0	0	0.000000e+00	10492	0	0	0.000000e+00	272	0	1	4.751950e-05	21044	0	0	0.000000e+00	4794	0	0	16	67403258	16	68845757	0	0.41029	0.631515	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	1.335000	0.33444	0.599000	0.40250	1.026000	0.45946	68811854	C	.	rs587780784	.	.	10.172	4.939	8.102	7.878	.	.	.	-49	-40	5	12	0.00	0.00	0.01	0.05	CDH1	0.34	exon-NM_004360.5-7+5+end+176	136055	Pathogenic	reviewed_by_expert_panel	Familial_cancer_of_breast&Blepharocheilodontic_syndrome_1&Endometrial_carcinoma&Hereditary_diffuse_gastric_adenocarcinoma&Neoplasm_of_ovary&Malignant_tumor_of_prostate&Gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_provided	MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MONDO:MONDO:0054740&MedGen:C4551988&OMIM:119580&Orphanet:1997&Human_Phenotype_Ontology:HP:0012114&MONDO:MONDO:0002447&MedGen:C0476089&OMIM:608089&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267&OMIM:167000&Human_Phenotype_Ontology:HP:0012125&MONDO:MONDO:0008315&MedGen:C0376358&OMIM:176807&Orphanet:1331&Human_Phenotype_Ontology:HP:0012126&MONDO:MONDO:0001056&MeSH:D013274&MedGen:C0024623&OMIM:613659&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587780784	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.96507e-06	0.00000e+00	3.24886e-05	1.48381e-05	0.00000e+00	3.24886e-05	8.12110e-06	rs587780784	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66489e-05	0.00000e+00	.	0.00000e+00	7.22126e-05	6.66489e-05	3.22664e-05	.	.	rs587780784	587780784	.	.	.	CDH1\x3bTANGO6	CDH1:exonic\x7cTANGO6:regulatory	CDH1:stopgain\x7cTANGO6:open_chromatin_region	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,899	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
13	20763650	20763650	C	T	T	stop_gained	HIGH	GJB2	2706	Transcript	NM_004004.6	protein_coding	2/2	.	NM_004004.6:c.71G>A	NP_003995.2:p.Trp24Ter	249	71	24	W/*	tGg/tAg	rs104894396&CM970678	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	GJB2	.	chr13:g.20763650C>T	.	0	0	0	0	0.002	conflicting_interpretations_of_pathogenicity&likely_benign&pathogenic	.	1&1	.	.	.	.	.	GJB2&NM_004004.5&c.71G>A	.	.	2	3.9936102236421724E-4	0	0.0	0	0.0	0	0.0	0	0.0	2	0.002044989775051125	.	.	.	.	.	.	.	.	.	C/C	C	D	0.77288	0.236036	D	0.96104	0.566539	41	40	8.140401	7.949551	0.98919	0.98686	C/C	.	.	.	0.64081	0.99427613845037288	.	.	.	C/C	.	.	.	.	7.37963	0.679140159111123	0.80797	9.611787	0.839918321381731	0.88526	.	.	.	70	5.765e-04	0	0	0	0	70	5.767e-04	0	0	0	0	2	2.998e-05	66	3.997e-03	67	6.308e-04	0	0	0	0	67	6.310e-04	0	0	0	0	1	1.841e-05	64	3.901e-03	68	7.493e-04	0	0	0	0	68	7.496e-04	0	0	0	0	2	4.749e-05	66	4.000e-03	.	.	.	.	5.21	5.21	0.72005	0	0.52368	0.61073	.	.	0.98316	1.0	.	0	0.40942	0.61531	.	.	.	.	.	.	0	0.10902	0.530356	Connexin&_N-terminal&Connexin&_N-terminal&Connexin&_N-terminal	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19.1211	0.93349	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.87157	.	C/C	X	.	W	T	682	0.59757	.	13	C1384666&C0265964&C0265336&C1835672&C0266004&C2673759&C1844678&C2675750&C1865234&C2675235&CN043648&C1846647&C3887873&CN517202&CN826980	124500&148210&148350&149200&220290&304400&601544&602540&612645&607197&PS220290	ORPHA494&ORPHA2202&ORPHA2698&ORPHA383&ORPHA87884&ORPHA96210	Pathogenic	NC_000013.11:g.20189511C>T	17002	reviewed_by_expert_panel	Hearing_impairment&Mutilating_keratoderma&Keratitis-ichthyosis-deafness_syndrome&_autosomal_dominant&Palmoplantar_keratoderma-deafness_syndrome&Knuckle_pads&_deafness_AND_leukonychia_syndrome&Deafness&_autosomal_recessive_1A&Deafness&_X-linked_2&Deafness&_autosomal_dominant_3a&Hystrix-like_ichthyosis_with_deafness&Deafness&_autosomal_recessive_1b&Nonsyndromic_hearing_loss_and_deafness&Deafness&_autosomal_recessive&Hearing_loss&not_provided&Rare_genetic_deafness	OMIM_Allelic_Variant:121011.0003&ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:2576&Illumina_Laboratory_Services&Illumina:210657	.	.	AEFBHCI	D	0.72889	0.97134	N	0.46169	0.378197	.	146	5.839070e-04	0	0.000000e+00	16256	0	1	2.890840e-05	34592	0	250040	0	0.000000e+00	10068	0	0	0.000000e+00	18394	0	0	0.000000e+00	21646	0	7	6.231420e-05	112334	1	134	4.376800e-03	30616	0	134	4.376800e-03	30616	0	69	6.306670e-04	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	2	4.676390e-05	42768	0	63	4.015300e-03	15690	0	63	4.015300e-03	15690	0	0	.	1	144	6.114600e-04	0	0.000000e+00	14902	0	1	2.918860e-05	34260	0	235502	0	0.000000e+00	9560	0	0	0.000000e+00	17692	0	0	0.000000e+00	21630	0	7	6.908940e-05	101318	1	132	4.324180e-03	30526	0	132	4.324180e-03	30526	0	1	142	6.867870e-04	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	206760	0	0.000000e+00	6208	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	4	4.535660e-05	88190	1	134	4.377940e-03	30608	0	134	4.377940e-03	30608	0	1	146	5.997810e-04	0	0.000000e+00	12026	0	1	2.902080e-05	34458	0	243422	0	0.000000e+00	9986	0	0	0.000000e+00	18390	0	0	0.000000e+00	21644	0	7	6.349550e-05	110244	1	134	4.376800e-03	30616	0	134	4.376800e-03	30616	0	1	21	1.379960e-04	1	2.412890e-05	41444	0	0	0.000000e+00	912	0	0	0.000000e+00	15280	0	152178	0	0.000000e+00	3472	0	0	0.000000e+00	5184	0	0	0.000000e+00	10612	0	0	0.000000e+00	316	0	3	4.409300e-05	68038	0	17	3.522590e-03	4826	0	17	3.522590e-03	4826	0	6	1.823820e-04	0	0.000000e+00	9094	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32898	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5488	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	6	1.929260e-03	3110	0	0	.	0	18	1.216820e-04	1	2.431670e-05	41124	0	0	0.000000e+00	912	0	0	0.000000e+00	15092	0	147926	0	0.000000e+00	3302	0	0	0.000000e+00	4948	0	0	0.000000e+00	10612	0	0	0.000000e+00	304	0	2	3.085750e-05	64814	0	15	3.128910e-03	4794	0	0	20	1.484080e-04	0	0.000000e+00	32468	0	0	0.000000e+00	862	0	0	0.000000e+00	14834	0	134764	0	0.000000e+00	3388	0	0	0.000000e+00	5184	0	0	0.000000e+00	6978	0	0	0.000000e+00	310	0	3	4.693950e-05	63912	0	17	3.524050e-03	4824	0	0	20	2.477090e-04	1	4.028360e-05	24824	0	0	0.000000e+00	112	0	0	0.000000e+00	12906	0	80740	0	0.000000e+00	998	0	0	0.000000e+00	3742	0	0	0.000000e+00	10520	0	0	0.000000e+00	272	0	2	9.502090e-05	21048	0	17	3.543140e-03	4798	0	0	13	19661650	13	20763650	0	0.22052	0.533608	1.000000	0.71638	0.433000	0.27516	0.996000	0.59523	7.854000	0.85267	0.599000	0.40250	1.026000	0.45946	20189511	C	.	rs104894396	.	.	.	.	10.295	9.602	.	.	.	-2	14	-2	37	0.00	0.00	0.00	0.00	GJB2	0.00	exon-NM_004004.6-2+92+end+2134	17002	Pathogenic	reviewed_by_expert_panel	Rare_genetic_deafness&Mutilating_keratoderma&Autosomal_dominant_nonsyndromic_hearing_loss_3A&X-linked_mixed_hearing_loss_with_perilymphatic_gusher&Knuckle_pads&_deafness_AND_leukonychia_syndrome&Autosomal_dominant_keratitis-ichthyosis-hearing_loss_syndrome&Palmoplantar_keratoderma-deafness_syndrome&Ichthyosis&_hystrix-like&_with_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_1A&Hearing_loss&not_provided&Nonsyndromic_genetic_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_1B&Hearing_loss&_autosomal_recessive&Hearing_impairment	MedGen:CN826980&Orphanet:96210&MONDO:MONDO:0007422&MedGen:C0265964&OMIM:124500&Orphanet:494&MONDO:MONDO:0011103&MedGen:C2675750&OMIM:601544&Orphanet:90635&MONDO:MONDO:0010576&MedGen:C1844678&OMIM:304400&Orphanet:383&MONDO:MONDO:0007866&MedGen:C0266004&OMIM:149200&Orphanet:2698&MONDO:MONDO:0007850&MedGen:C0265336&OMIM:148210&Orphanet:477&MONDO:MONDO:0007852&MedGen:C1835672&OMIM:148350&Orphanet:2202&MONDO:MONDO:0011245&MedGen:C1865234&OMIM:602540&Orphanet:477&MONDO:MONDO:0009076&MedGen:C2673759&OMIM:220290&Orphanet:90636&MedGen:C3887873&MedGen:CN517202&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0012977&MedGen:C2675235&OMIM:612645&Orphanet:90636&MONDO:MONDO:0019588&MedGen:C1846647&OMIM:607197&OMIM:PS220290&Orphanet:90635&Orphanet:90636&Human_Phenotype_Ontology:HP:0000365&Human_Phenotype_Ontology:HP:0000404&Human_Phenotype_Ontology:HP:0001728&Human_Phenotype_Ontology:HP:0001729&Human_Phenotype_Ontology:HP:0001754&Human_Phenotype_Ontology:HP:0008560&Human_Phenotype_Ontology:HP:0008563&MONDO:MONDO:0005365&MedGen:C1384666	.	rs104894396	5.765e-04	70	70	0	0	0	0	0	2	2	66	10404	11578	8654	6614	66710	908	16512	0	0	0	0	2	2	66	0	0	0	0	0	0	0	rs104894396	6.53424e-05	2.97779e-05	0.00000e+00	0.00000e+00	0.00000e+00	6.35001e-05	5.47845e-04	4.45065e-03	7.52328e-04	4.34303e-04	4.45065e-03	6.05037e-04	rs104894396	1.14600e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66578e-05	0.00000e+00	.	5.84249e-05	7.22022e-05	1.14600e-04	6.45369e-05	.	.	rs104894396	104894396	.	.	.	GJB2	GJB2:exonic	GJB2:stopgain	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,871	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103306610	103306610	C	A	A	stop_gained	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	2/13	.	NM_000277.3:c.127G>T	NP_000268.1:p.Glu43Ter	241	127	43	E/*	Gaa/Taa	rs1555209575&CM1511456&COSV61020435	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103306610C>A	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.127G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.99412	0.625005	D	0.99401	0.66	38	40	7.607497	7.941114	0.98064	0.98674	C/C	.	.	.	0.86433	0.99776908283751831	.	.	.	C/C	.	.	.	.	15.90205	0.946589349917965	0.97300	17.18723	1.09245750597728	0.97992	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.46	5.46	0.80021	0	0.26702	0.573888	.	.	0.74766	0.999999997037945	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16.2217	0.82082	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.94077	.	C/C	X	.	E	A	768	0.49510	.	12	C0031485	261600	ORPHA716	Pathogenic	NC_000012.12:g.102912832C>A	557124	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.54735	0.92005	N	0.31917	0.191998	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101830740	12	103306610	0	0.43195	0.638212	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	5.034000	0.63942	0.599000	0.40250	1.026000	0.45946	102912832	C	.	rs1555209575	.	.	11.785	7.700	8.002	9.602	.	.	.	-41	-1	-5	-41	0.00	0.00	0.00	0.10	PAH	0.00	exon-NM_001354304.2-3+41+start+108	557124	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555209575	1555209575	.	.	.	PAH	PAH:exonic	PAH:stopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,839	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103288669	103288669	C	A	A	stop_gained	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.196G>T	NP_000268.1:p.Glu66Ter	310	196	66	E/*	Gaa/Taa	rs281865454&CM135793&CM1514923&COSV100188125	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103288669C>A	.	.	.	.	.	.	pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.196G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.99412	0.625005	D	0.99401	0.66	38	39	7.557678	7.819313	0.97979	0.98486	C/C	.	.	.	0.89973	0.99815988719634752	.	.	.	C/C	.	.	.	.	28.90083	1.11533571501738	0.99864	27.64109	1.23737509515669	0.99819	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.17	6.17	0.99707	0	0.45803	0.59043	.	.	0.74766	0.999999999999998	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	20.8794	0.99870	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.96644	.	C/C	X	.	E	A	716	0.55970	.	12	C0031485	261600	ORPHA716	Pathogenic	NC_000012.12:g.102894891C>A	120270	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.83201	0.98478	N	0.48600	0.418316	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101812799	12	103288669	0	0.37627	0.615465	1.000000	0.71638	0.992000	0.67800	0.999000	0.70432	7.033000	0.76234	0.599000	0.40250	1.026000	0.45946	102894891	C	.	rs281865454	.	.	11.038	10.766	11.785	7.700	.	.	.	-24	27	19	-31	0.03	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+27+end+184	120270	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865454	281865454	.	.	.	PAH	PAH:exonic	PAH:stopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,818	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103288534	103288534	G	A	A	stop_gained	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.331C>T	NP_000268.1:p.Arg111Ter	445	331	111	R/*	Cga/Tga	rs76296470&CM920544&COSV61019395	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103288534G>A	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.331C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.91553	0.430471	D	0.99401	0.66	36	36	6.697910	6.893682	0.96651	0.97011	G/G	.	.	.	0.85172	0.9976219614934414	.	.	.	G/G	.	.	.	.	8.069371	0.716329765020404	0.83620	9.368916	0.828741096792302	0.87867	.	.	.	6	4.942e-05	3	2.889e-04	0	0	6	4.943e-05	0	0	0	0	2	2.997e-05	1	6.056e-05	5	4.708e-05	2	2.211e-04	0	0	5	4.709e-05	0	0	0	0	2	3.680e-05	1	6.095e-05	5	5.510e-05	3	2.894e-04	0	0	5	5.511e-05	0	0	0	0	1	2.373e-05	1	6.060e-05	.	.	.	.	6.17	5.27	0.73797	0	0.45803	0.59043	.	.	0.74766	0.999999452787289	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&ACT_domain&Aromatic_amino_acid_hydroxylase&_C-terminal&ACT_domain&Aromatic_amino_acid_hydroxylase&_C-terminal&ACT_domain&ACT_domain	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	14.4578	0.67005	0.0:0.0:0.7318:0.2682	.	.	.	.	.	.	.	.	0.97535	.	G/G	X	.	R	A	717	0.55835	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102894756G>A	581	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.R111X&OMIM_Allelic_Variant:612349.0005	.	.	AEFBI	D	0.68013	0.96204	N	0.35776	0.235108	.	7	2.784010e-05	2	1.230310e-04	16256	0	0	0.000000e+00	34592	0	251436	0	0.000000e+00	10078	0	0	0.000000e+00	18394	0	0	0.000000e+00	21646	0	4	3.517600e-05	113714	0	2	1.230310e-04	16256	0	1	3.266270e-05	30616	0	5	4.570130e-05	1	1.395870e-04	7164	0	0	0.000000e+00	17112	0	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13392	0	3	7.014590e-05	42768	0	1	1.395870e-04	7164	0	1	6.373490e-05	15690	0	0	.	0	7	2.954860e-05	2	1.342100e-04	14902	0	0	0.000000e+00	34260	0	236898	0	0.000000e+00	9570	0	0	0.000000e+00	17692	0	0	0.000000e+00	21630	0	4	3.894920e-05	102698	0	2	1.342100e-04	14902	0	1	3.275900e-05	30526	0	0	6	2.882950e-05	2	1.233200e-04	16218	0	0	0.000000e+00	30524	0	208120	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16732	0	3	3.350310e-05	89544	0	2	1.233200e-04	16218	0	1	3.267120e-05	30608	0	0	5	2.042330e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244818	0	0.000000e+00	9996	0	0	0.000000e+00	18390	0	0	0.000000e+00	21644	0	4	3.583460e-05	111624	0	4	3.583460e-05	111624	0	1	3.266270e-05	30616	0	0	6	3.946540e-05	2	4.833950e-05	41374	0	0	0.000000e+00	912	0	0	0.000000e+00	15262	0	152032	0	0.000000e+00	3468	0	0	0.000000e+00	5194	0	0	0.000000e+00	10570	0	0	0.000000e+00	316	0	4	5.879590e-05	68032	0	4	5.879590e-05	68032	0	0	0.000000e+00	4812	0	0	0.000000e+00	0	0.000000e+00	9086	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32836	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5446	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3102	0	0	.	0	6	4.059980e-05	2	4.871870e-05	41052	0	0	0.000000e+00	912	0	0	0.000000e+00	15074	0	147784	0	0.000000e+00	3302	0	0	0.000000e+00	4962	0	0	0.000000e+00	10570	0	0	0.000000e+00	304	0	4	6.172270e-05	64806	0	0	0.000000e+00	4780	0	0	6	4.457060e-05	2	6.172080e-05	32404	0	0	0.000000e+00	862	0	0	0.000000e+00	14816	0	134618	0	0.000000e+00	3384	0	0	0.000000e+00	5194	0	0	0.000000e+00	6930	0	0	0.000000e+00	310	0	4	6.259190e-05	63906	0	0	0.000000e+00	4810	0	0	1	1.240730e-05	0	0.000000e+00	24748	0	0	0.000000e+00	112	0	0	0.000000e+00	12888	0	80598	0	0.000000e+00	994	0	0	0.000000e+00	3752	0	0	0.000000e+00	10478	0	0	0.000000e+00	272	0	1	4.750140e-05	21052	0	0	0.000000e+00	4784	0	0	12	101812664	12	103288534	0	0.37627	0.615465	1.000000	0.71638	0.996000	0.76049	0.996000	0.59523	4.797000	0.62197	0.676000	0.76740	1.176000	0.78918	102894756	G	.	rs76296470	.	.	11.038	10.766	11.785	7.700	.	.	.	-27	42	-3	-21	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+21+start+184	581	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs76296470	4.942e-05	6	6	0	3	0	0	0	2	0	1	10384	11578	8654	6614	66736	908	16512	3	0	0	0	2	0	1	0	0	0	0	0	0	0	rs76296470	1.96027e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.58250e-05	0.00000e+00	3.24865e-05	3.70766e-05	2.69435e-05	1.96027e-04	3.24844e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs76296470	76296470	.	.	.	PAH	PAH:exonic	PAH:stopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,807	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103249059	103249059	C	T	T	stop_gained	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.561G>A	NP_000268.1:p.Trp187Ter	675	561	187	W/*	tgG/tgA	rs62507336&CM930542&CM981435	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103249059C>T	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.561G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.98017	0.614224	D	0.99401	0.66	39	38	7.650110	7.623988	0.98138	0.98171	C/C	.	.	.	0.70648	0.99543401364589701	.	.	.	C/C	.	.	.	.	8.009409	0.71333647895482	0.83392	10.00606	0.857324665164003	0.89522	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.73	5.73	0.89730	0	0.26702	0.573888	.	.	0.74766	0.9999999994012	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19.8989	0.96978	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.97207	.	C/C	X	.	W	T	532	0.73501	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102855281C>T	102736	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.W187X	.	.	AEFBI	D	0.86006	0.98721	D	0.57301	0.567425	.	2	7.958740e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34580	0	251296	0	0.000000e+00	10076	0	0	0.000000e+00	18378	0	0	0.000000e+00	21640	0	2	1.760130e-05	113628	0	2	1.760130e-05	113628	0	0	0.000000e+00	30612	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17108	0	109374	0	0.000000e+00	2320	0	0	0.000000e+00	9034	0	0	0.000000e+00	13394	0	0	0.000000e+00	42752	0	.	.	.	.	0	0.000000e+00	15688	0	0	.	0	2	8.447230e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34248	0	236764	0	0.000000e+00	9568	0	0	0.000000e+00	17676	0	0	0.000000e+00	21624	0	2	1.948980e-05	102618	0	2	1.948980e-05	102618	0	0	0.000000e+00	30522	0	0	1	4.806580e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30512	0	208048	0	0.000000e+00	6210	0	0	0.000000e+00	13400	0	0	0.000000e+00	16728	0	1	1.117090e-05	89518	0	1	1.117090e-05	89518	0	0	0.000000e+00	30604	0	0	2	8.174010e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34446	0	244678	0	0.000000e+00	9994	0	0	0.000000e+00	18374	0	0	0.000000e+00	21638	0	2	1.793110e-05	111538	0	2	1.793110e-05	111538	0	0	0.000000e+00	30612	0	0	2	1.314680e-05	0	0.000000e+00	41416	0	0	0.000000e+00	912	0	0	0.000000e+00	15266	0	152128	0	0.000000e+00	3472	0	0	0.000000e+00	5192	0	0	0.000000e+00	10618	0	0	0.000000e+00	316	0	2	2.940050e-05	68026	0	2	2.940050e-05	68026	0	0	0.000000e+00	4820	0	0	0.000000e+00	0	0.000000e+00	9084	0	0	0.000000e+00	60	0	0	0.000000e+00	4682	0	32874	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3110	0	0	.	0	2	1.352500e-05	0	0.000000e+00	41096	0	0	0.000000e+00	912	0	0	0.000000e+00	15080	0	147874	0	0.000000e+00	3302	0	0	0.000000e+00	4956	0	0	0.000000e+00	10618	0	0	0.000000e+00	304	0	2	3.086520e-05	64798	0	0	0.000000e+00	4788	0	0	2	1.484410e-05	0	0.000000e+00	32458	0	0	0.000000e+00	862	0	0	0.000000e+00	14820	0	134734	0	0.000000e+00	3388	0	0	0.000000e+00	5192	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	2	3.129400e-05	63910	0	0	0.000000e+00	4818	0	0	1	1.239280e-05	0	0.000000e+00	24792	0	0	0.000000e+00	112	0	0	0.000000e+00	12892	0	80692	0	0.000000e+00	998	0	0	0.000000e+00	3752	0	0	0.000000e+00	10526	0	0	0.000000e+00	272	0	1	4.752850e-05	21040	0	0	0.000000e+00	4792	0	0	12	101773189	12	103249059	0	0.43195	0.638212	1.000000	0.71638	0.250000	0.23263	0.121000	0.20115	7.905000	0.86479	0.599000	0.40250	1.026000	0.45946	102855281	C	.	rs62507336	.	.	7.651	9.354	7.292	9.092	.	.	.	44	13	-1	-29	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+51+end+197	102736	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62507336	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79263e-05	0.00000e+00	0.00000e+00	7.41840e-06	8.98779e-06	1.79263e-05	8.12110e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62507336	62507336	.	.	.	PAH	PAH:exonic	PAH:stopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,767	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103246708	103246708	G	A	A	stop_gained	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.727C>T	NP_000268.1:p.Arg243Ter	841	727	243	R/*	Cga/Tga	rs5030846&CM900176&COSV61015179	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246708G>A	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.727C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.594706798131811E-4	.	.	.	.	.	.	.	G/G	G	D	0.93932	0.487412	D	0.99401	0.66	45	40	8.763587	7.970341	0.99560	0.98718	G/G	.	.	.	0.87043	0.99783725786547084	.	.	.	G/G	.	.	.	.	4.715393	0.447740419742257	0.64572	5.727187	0.58012120563961	0.71934	.	.	.	6	4.942e-05	0	0	0	0	6	4.952e-05	0	0	0	0	6	9.010e-05	0	0	3	2.825e-05	0	0	0	0	3	2.829e-05	0	0	0	0	3	5.529e-05	0	0	6	6.611e-05	0	0	0	0	6	6.627e-05	0	0	0	0	6	1.428e-04	0	0	.	.	.	.	5.92	3.03	0.34070	0	0.45803	0.59043	.	.	0.30417	0.982553188484764	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.9352	0.40717	0.0645:0.0:0.686:0.2495	.	0	0.0	1	1.322401481089659E-4	.	.	.	0.95841	.	G/G	X	.	R	A	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852930G>A	588	reviewed_by_expert_panel	Phenylketonuria&not_provided	HGMD:CM900176&DeBelle_Laboratory_for_Biochemical_Genetics:p.R243X&OMIM_Allelic_Variant:612349.0011&Illumina_Laboratory_Services&Illumina:669669	.	.	AEFBI	D	0.78131	0.97920	D	0.55430	0.535848	.	11	4.381140e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34568	0	251076	0	0.000000e+00	10064	0	0	0.000000e+00	18378	0	0	0.000000e+00	21636	0	11	9.697270e-05	113434	0	11	9.697270e-05	113434	0	0	0.000000e+00	30612	0	3	2.742830e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17108	0	109376	0	0.000000e+00	2320	0	0	0.000000e+00	9038	0	0	0.000000e+00	13384	0	3	7.015900e-05	42760	0	3	7.015900e-05	42760	0	0	0.000000e+00	15688	0	0	.	0	7	2.959310e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34236	0	236542	0	0.000000e+00	9556	0	0	0.000000e+00	17676	0	0	0.000000e+00	21620	0	7	6.834470e-05	102422	0	7	6.834470e-05	102422	0	0	0.000000e+00	30522	0	0	11	5.288510e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30506	0	207998	0	0.000000e+00	6208	0	0	0.000000e+00	13400	0	0	0.000000e+00	16724	0	11	1.229380e-04	89476	0	11	1.229380e-04	89476	0	0	0.000000e+00	30604	0	0	11	4.499750e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34434	0	244458	0	0.000000e+00	9982	0	0	0.000000e+00	18374	0	0	0.000000e+00	21634	0	11	9.879290e-05	111344	0	11	9.879290e-05	111344	0	0	0.000000e+00	30612	0	0	6	3.944620e-05	0	0.000000e+00	41436	0	0	0.000000e+00	910	0	1	6.550500e-05	15266	0	152106	0	0.000000e+00	3472	0	0	0.000000e+00	5174	0	0	0.000000e+00	10600	0	0	0.000000e+00	316	0	5	7.350130e-05	68026	0	5	7.350130e-05	68026	0	0	0.000000e+00	4814	0	0	0.000000e+00	0	0.000000e+00	9082	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32872	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5478	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3110	0	0	.	0	5	3.381580e-05	0	0.000000e+00	41114	0	0	0.000000e+00	910	0	1	6.631300e-05	15080	0	147860	0	0.000000e+00	3302	0	0	0.000000e+00	4938	0	0	0.000000e+00	10600	0	0	0.000000e+00	304	0	4	6.172080e-05	64808	0	0	0.000000e+00	4782	0	0	6	4.454480e-05	0	0.000000e+00	32462	0	0	0.000000e+00	862	0	1	6.747640e-05	14820	0	134696	0	0.000000e+00	3388	0	0	0.000000e+00	5174	0	0	0.000000e+00	6962	0	0	0.000000e+00	310	0	5	7.824240e-05	63904	0	0	0.000000e+00	4812	0	0	3	3.719130e-05	0	0.000000e+00	24810	0	0	0.000000e+00	110	0	1	7.756750e-05	12892	0	80664	0	0.000000e+00	998	0	0	0.000000e+00	3732	0	0	0.000000e+00	10508	0	0	0.000000e+00	272	0	2	9.506610e-05	21038	0	0	0.000000e+00	4786	0	0	12	101770838	12	103246708	0	0.43195	0.638212	1.000000	0.71638	0.992000	0.67800	0.999000	0.70432	8.100000	0.89381	-0.148000	0.12190	0.213000	0.24097	102852930	G	.	rs5030846	.	.	11.570	9.399	7.651	9.354	.	.	.	25	20	20	26	0.00	0.07	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+20+end+136	588	Pathogenic	reviewed_by_expert_panel	not_provided&Inborn_genetic_diseases&Phenylketonuria	MedGen:CN517202&MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030846	4.942e-05	6	6	0	0	0	0	0	6	0	0	10392	11536	8634	6598	66592	908	16502	0	0	0	0	6	0	0	0	0	0	0	0	0	0	rs5030846	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.97972e-05	0.00000e+00	0.00000e+00	4.45540e-05	3.59809e-05	8.97972e-05	4.46661e-05	rs5030846	2.29253e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84522e-05	7.21813e-05	2.29253e-04	6.45328e-05	.	.	rs5030846	5030846	.	.	.	PAH	PAH:exonic	PAH:stopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,752	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103245493	103245493	G	C	C	stop_gained	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.884C>G	NP_000268.1:p.Ser295Ter	998	884	295	S/*	tCa/tGa	rs62642910&CM990998&COSV100188344	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103245493G>C	.	.	.	.	.	.	pathogenic&not_provided	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.884C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.99412	0.625005	D	0.99401	0.66	40	40	8.034036	8.023790	0.98765	0.98795	G/G	.	.	.	0.73807	0.99594336018875118	.	.	.	G/G	.	.	.	.	28.51416	1.11231493872691	0.99851	29.24199	1.2496179865442	0.99874	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.51	5.51	0.81769	0	0.45803	0.59043	.	.	0.74766	0.999999999971142	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	.	.	0.113998	0.62929	D	0.000017	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19.7791	0.96406	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.90476	.	G/G	X	.	S	C	514	0.74853	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102851715G>C	102884	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.S295X	.	.	AEFBCI	D	0.81803	0.98341	N	0.49159	0.427801	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101769623	12	103245493	0	0.43195	0.638212	1.000000	0.71638	0.995000	0.73285	1.000000	0.86279	9.602000	0.97623	0.676000	0.76740	1.176000	0.78918	102851715	G	.	rs62642910	.	.	9.506	11.083	11.570	9.399	.	.	.	-28	41	-28	-33	0.00	0.03	0.00	0.00	PAH	0.00	exon-NM_001354304.2-9+28+start+70	102884	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62642910	62642910	.	.	.	PAH	PAH:exonic	PAH:stopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,697	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103246654	103246654	G	A	A	stop_gained	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.781C>T	NP_000268.1:p.Arg261Ter	895	781	261	R/*	Cga/Tga	rs5030850&CM1514931&CM910288&COSV61016430	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246654G>A	.	.	.	.	.	.	pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.781C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.96378	0.567317	D	0.99401	0.66	42	43	8.377716	8.528129	0.99217	0.99388	G/G	.	.	.	0.92925	0.99849942869065944	.	.	.	G/G	.	.	.	.	5.663907	0.5514402982798	0.71497	6.971311	0.689243434992311	0.78928	.	.	.	1	8.236e-06	0	0	0	0	1	8.239e-06	0	0	0	0	1	1.498e-05	0	0	1	9.415e-06	0	0	0	0	1	9.418e-06	0	0	0	0	1	1.840e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.72	3.79	0.42757	0	0.45803	0.59043	.	.	0.30287	0.98161880251868	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	14.3299	0.66106	0.0:0.0:0.6162:0.3838	.	.	.	.	.	.	.	.	0.93370	.	G/G	X	.	R	A	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852876G>A	610	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.R261X&OMIM_Allelic_Variant:612349.0036	.	.	AEFBI	D	0.60591	0.94256	N	0.42877	0.327959	.	5	1.989380e-05	0	0.000000e+00	16256	0	1	2.891840e-05	34580	0	251334	0	0.000000e+00	10078	0	0	0.000000e+00	18392	0	0	0.000000e+00	21644	0	4	3.520140e-05	113632	0	4	3.520140e-05	113632	0	0	0.000000e+00	30616	0	2	1.828150e-05	0	0.000000e+00	7164	0	1	5.844540e-05	17110	0	109400	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13390	0	1	2.338200e-05	42768	0	1	5.844540e-05	17110	0	0	0.000000e+00	15690	0	0	.	0	5	2.111520e-05	0	0.000000e+00	14902	0	1	2.919880e-05	34248	0	236796	0	0.000000e+00	9570	0	0	0.000000e+00	17690	0	0	0.000000e+00	21628	0	4	3.898030e-05	102616	0	4	3.898030e-05	102616	0	0	0.000000e+00	30526	0	0	4	1.922040e-05	0	0.000000e+00	16218	0	1	3.276750e-05	30518	0	208112	0	0.000000e+00	6212	0	0	0.000000e+00	13414	0	0	0.000000e+00	16730	0	3	3.350230e-05	89546	0	3	3.350230e-05	89546	0	0	0.000000e+00	30608	0	0	4	1.634550e-05	0	0.000000e+00	12026	0	1	2.903090e-05	34446	0	244716	0	0.000000e+00	9996	0	0	0.000000e+00	18388	0	0	0.000000e+00	21642	0	3	2.689570e-05	111542	0	1	2.903090e-05	34446	0	0	0.000000e+00	30616	0	0	4	2.629850e-05	1	2.413830e-05	41428	0	0	0.000000e+00	910	0	0	0.000000e+00	15258	0	152100	0	0.000000e+00	3470	0	0	0.000000e+00	5192	0	0	0.000000e+00	10596	0	0	0.000000e+00	316	0	3	4.410860e-05	68014	0	3	4.410860e-05	68014	0	0	0.000000e+00	4824	0	2	6.084580e-05	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32870	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5472	0	0	0.000000e+00	246	0	2	2.920560e-04	6848	0	0	0.000000e+00	3108	0	0	.	0	4	2.705440e-05	1	2.432730e-05	41106	0	0	0.000000e+00	910	0	0	0.000000e+00	15070	0	147850	0	0.000000e+00	3302	0	0	0.000000e+00	4956	0	0	0.000000e+00	10596	0	0	0.000000e+00	304	0	3	4.630200e-05	64792	0	0	0.000000e+00	4792	0	0	3	2.227140e-05	0	0.000000e+00	32462	0	0	0.000000e+00	862	0	0	0.000000e+00	14812	0	134702	0	0.000000e+00	3386	0	0	0.000000e+00	5192	0	0	0.000000e+00	6960	0	0	0.000000e+00	310	0	3	4.695280e-05	63894	0	0	0.000000e+00	4822	0	0	1	1.239710e-05	1	4.031930e-05	24802	0	0	0.000000e+00	110	0	0	0.000000e+00	12886	0	80664	0	0.000000e+00	996	0	0	0.000000e+00	3750	0	0	0.000000e+00	10504	0	0	0.000000e+00	272	0	0	0.000000e+00	21030	0	0	0.000000e+00	4796	0	0	12	101770784	12	103246654	0	0.43195	0.638212	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	2.806000	0.47644	0.676000	0.76740	1.176000	0.78918	102852876	G	.	rs5030850	.	.	11.570	9.399	7.651	9.354	.	.	.	-21	-4	-46	-19	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+61+start+136	610	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030850	8.236e-06	1	1	0	0	0	0	0	1	0	0	10404	11556	8652	6610	66734	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs5030850	0.00000e+00	2.97903e-05	0.00000e+00	0.00000e+00	0.00000e+00	2.68904e-05	1.82349e-04	0.00000e+00	2.22572e-05	1.79685e-05	2.97903e-05	2.43633e-05	rs5030850	1.14679e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	0.00000e+00	7.22022e-05	1.14679e-04	3.22664e-05	.	.	rs5030850	5030850	.	.	.	PAH	PAH:exonic	PAH:stopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,739	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
21	36231783	36231783	G	A	A	stop_gained	HIGH	RUNX1	861	Transcript	NM_001754.5	protein_coding	6/9	.	NM_001754.5:c.601C>T	NP_001745.2:p.Arg201Ter	795	601	201	R/*	Cga/Tga	rs1057519748&CM992141&COSV55866784&COSV55869614	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36231783G>A	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	RUNX1&NM_001754.4&c.601C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.99412	0.625005	D	0.99401	0.66	39	40	7.655422	7.892275	0.98147	0.98600	G/G	.	.	.	0.88906	0.99804749215094801	.	.	.	G/G	.	.	.	.	5.45072	0.530684258426355	0.70064	6.852174	0.680304944969342	0.78340	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.12	4.21	0.48984	0	0.89359	0.724815	.	.	0.74766	0.999999999903414	.	0	0.18855	0.563428	.	.	.	.	.	.	0	0.83352	0.714379	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae&complex_aae&complex_aae&complex_aae&complex_aae&complex_aae	A&A&A&A&A&A&D	1&1&1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.147	0.53332	0.0:0.0:0.8085:0.1914	.	.	.	.	.	.	.	.	0.91276	.	G/G	X	.	R	A	267	0.89517	.	21	C0023467&C1832388&CN517202	601626&601399	ORPHA519	Pathogenic	NC_000021.9:g.34859486G>A	376018	reviewed_by_expert_panel	Acute_myeloid_leukemia&Familial_platelet_disorder_with_associated_myeloid_malignancy&not_provided	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:86145d7f-0d2f-4234-81b7-bd179ea8e91f	.	.	AEFBHCI	D	0.47004	0.87458	N	0.21218	0.106329	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35153653	21	36231783	0	0.73137	0.706548	1.000000	0.71638	0.997000	0.79791	0.993000	0.55118	4.537000	0.60354	0.676000	0.76740	0.184000	0.21609	34859486	G	.	rs1057519748	.	.	9.171	9.815	11.926	10.199	.	.	.	-12	28	50	-12	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-6+12+start+105	376018	Pathogenic	reviewed_by_expert_panel	not_provided&Acute_myeloid_leukemia&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&Human_Phenotype_Ontology:HP:0001914&Human_Phenotype_Ontology:HP:0004808&Human_Phenotype_Ontology:HP:0004843&Human_Phenotype_Ontology:HP:0005516&Human_Phenotype_Ontology:HP:0006724&Human_Phenotype_Ontology:HP:0006728&MONDO:MONDO:0018874&MeSH:D015470&MedGen:C0023467&OMIM:601626&Orphanet:519&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1057519748	1057519748	.	.	.	RUNX1	RUNX1:exonic	RUNX1:stopgain	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,961	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89685300	89685300	C	G	G	stop_gained	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	3/9	.	NM_000314.8:c.195C>G	NP_000305.3:p.Tyr65Ter	1040	195	65	Y/*	taC/taG	rs878853936&CM110159&CM1513010&COSV64291341&COSV64293906	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89685300C>G	.	.	.	.	.	.	pathogenic	0&0&0&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.195C>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.97200	0.58478	D	0.97155	0.60222	36	36	6.634075	6.460960	0.96571	0.96419	./.	.	.	.	0.68499	0.9950902319528836	.	.	.	./.	.	.	.	.	7.852003	0.705254530391199	0.82777	10.66851	0.884950967805078	0.91003	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.46	3.6	0.40374	0	0.89359	0.724815	.	.	0.74766	0.999998468563056	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.63922	0.662026	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae	A	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.1595	0.47733	0.0:0.8515:0.0:0.1485	.	.	.	.	.	.	.	.	0.88798	.	./.	X	.	Y	G	930	0.16408	.	10	C1959582	.	ORPHA306498	Pathogenic	NC_000010.11:g.87925543C>G	237643	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome	ClinGen_PTEN_Variant_Curation_Expert_Panel:994ade45-e2c0-40c5-9bb6-a646666f386c	.	.	AEFGBI	D	0.62737	0.94905	N	0.41006	0.301578	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89675280	10	89685300	0	0.97996	0.741868	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	1.854000	0.39008	0.599000	0.40250	1.026000	0.45946	87925543	C	.	rs878853936	.	.	8.389	7.964	10.295	10.567	.	.	.	-30	4	18	12	0.01	0.00	0.03	0.00	PTEN	0.98	exon-NM_001304717.5-4+14+end+45	237643	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs878853936	878853936	.	.	.	PTEN	PTEN:exonic	PTEN:stopgain	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,528	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89692985	89692985	G	T	T	stop_gained	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.469G>T	NP_000305.3:p.Glu157Ter	1314	469	157	E/*	Gaa/Taa	rs121909220&CM971274&COSV64290058&COSV64298444&COSV64303803	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89692985G>T	.	.	.	.	.	.	pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.469G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.98769	0.622132	D	0.98747	0.655873	41	40	8.192894	7.969402	0.98991	0.98716	./.	.	.	.	0.84615	0.99755747117917393	.	.	.	./.	.	.	.	.	21.27572	1.03652799664501	0.99216	22.86223	1.19021894652495	0.99456	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.09	5.09	0.68647	0	0.70079	0.698795	.	.	0.74766	0.999999999999966	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae	A	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	18.493	0.90803	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.98368	.	./.	X	.	E	T	940	0.13648	.	10	C1959582&C0391826	.	ORPHA306498&ORPHA65285	Pathogenic	NC_000010.11:g.87933228G>T	7814	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Lhermitte-Duclos_disease	OMIM_Allelic_Variant:601728.0003&ClinGen_PTEN_Variant_Curation_Expert_Panel:c8a8caba-2251-491c-8758-14da15b51065	.	.	AEFBI	D	0.91875	0.99144	N	0.45744	0.371416	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682965	10	89692985	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	9.525000	0.97093	0.676000	0.76740	1.176000	0.78918	87933228	G	.	rs121909220	.	gain/donor/89692984-89692985/Medium/2.774585	10.752	10.998	5.352	9.651	.	.	.	-2	-27	-2	23	0.00	0.00	0.75	0.11	PTEN	0.98	exon-NM_001304717.5-6+23+end+239	7814	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Lhermitte-Duclos_disease&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&Human_Phenotype_Ontology:HP:0500009&MONDO:MONDO:0019002&MedGen:C0391826&Orphanet:65285&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909220	121909220	.	.	.	PTEN	PTEN:exonic	PTEN:stopgain	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,553	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89711893	89711893	C	T	T	stop_gained	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	6/9	.	NM_000314.8:c.511C>T	NP_000305.3:p.Gln171Ter	1356	511	171	Q/*	Cag/Tag	rs786204864&CM142087&HM971504&COSV64288951&COSV64296078&COSV64302138	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89711893C>T	.	.	.	.	.	.	pathogenic	0&0&0&1&1&1	1&1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.511C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.96804	0.574913	D	0.96750	0.588046	38	39	7.539092	7.831111	0.97946	0.98505	./.	.	.	.	0.86867	0.99781566161886937	.	.	.	./.	.	.	.	.	23.67496	1.06633536339736	0.99548	23.73187	1.20042504223051	0.99554	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.74	5.74	0.90070	0	0.74545	0.702456	.	.	0.74766	0.999999999999992	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.98432	0.735409	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	.	.	0.114128	0.62929	D	0.000007	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae	A	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19.9308	0.97119	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.96758	.	./.	X	.	Q	T	926	0.17793	.	10	C0027672&C1959582&CN517202	.	ORPHA140162&ORPHA306498	Pathogenic	NC_000010.11:g.87952136C>T	189411	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	.	.	.	AEFDGBCI	D	0.63230	0.95043	N	0.42406	0.321187	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89701873	10	89711893	0	0.85440	0.722319	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	7.464000	0.79911	0.549000	0.26987	1.026000	0.45946	87952136	C	.	rs786204864	.	.	6.460	9.066	10.752	10.998	.	.	.	26	-18	-18	13	0.00	0.03	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-7+18+start+142	189411	Pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Hereditary_cancer-predisposing_syndrome&not_provided	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786204864	786204864	.	.	.	PTEN	PTEN:exonic	PTEN:stopgain	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,561	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89717741	89717741	G	T	T	stop_gained	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	7/9	.	NM_000314.8:c.766G>T	NP_000305.3:p.Glu256Ter	1611	766	256	E/*	Gag/Tag	rs121909228&CM981674&COSV64288912&COSV64292115&COSV64297607	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89717741G>T	.	.	.	.	.	.	pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.766G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.98345	0.619807	D	0.98317	0.652534	39	38	7.848980	7.399662	0.98475	0.97798	./.	.	.	.	0.83264	0.99737461150660767	.	.	.	./.	.	.	.	.	22.20227	1.04864217446054	0.99367	23.74079	1.20052470654647	0.99555	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.15	5.15	0.70287	0	0.89359	0.724815	.	.	0.74766	0.999999999999833	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.49550	0.631631	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	.	.	0.047328	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae	A	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	18.6161	0.91258	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.99822	.	./.	X	.	E	T	908	0.22609	.	10	CN072330&C1959582	158350	ORPHA306498	Pathogenic	NC_000010.11:g.87957984G>T	7828	reviewed_by_expert_panel	Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	ClinGen_PTEN_Variant_Curation_Expert_Panel:4284ff17-816f-4321-a0b3-e3baeb0afc95&OMIM_Allelic_Variant:601728.0016	.	.	AEFGBI	D	0.87055	0.98803	N	0.47567	0.401015	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89707721	10	89717741	0	0.61202	0.706298	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	9.525000	0.97093	0.618000	0.50648	1.176000	0.78918	87957984	G	.	rs121909228	.	.	12.930	7.806	6.460	9.066	.	.	.	3	1	-4	35	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-8+35+end+167	7828	Pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909228	121909228	.	.	.	PTEN	PTEN:exonic	PTEN:stopgain	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,580	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
11	532698	532698	T	A	A	stop_gained	HIGH	HRAS	3265	Transcript	NM_005343.4	protein_coding	5/6	.	NM_005343.4:c.508A>T	NP_005334.1:p.Lys170Ter	722	508	170	K/*	Aag/Tag	rs372936166	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	HRAS	.	chr11:g.532698T>A	.	.	.	.	.	.	likely_benign&uncertain_significance	.	1	.	.	.	.	.	HRAS&NM_176795.3&c.*77A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.93994	0.489946	D	0.98317	0.652534	47	46	9.102453	8.936450	0.99742	0.99672	T/T	.	.	.	0.69346	0.99522167737878708	.	.	.	T/T	0	0.0	2	2.3255813953488373E-4	5.164676	0.500641106350847	0.68034	6.756574	0.672929079507126	0.77860	.	.	.	4	3.295e-05	0	0	0	0	4	3.356e-05	0	0	0	0	4	6.141e-05	0	0	2	1.883e-05	0	0	0	0	2	1.893e-05	0	0	0	0	2	3.691e-05	0	0	4	4.409e-05	0	0	0	0	4	4.508e-05	0	0	0	0	4	9.858e-05	0	0	.	.	.	.	3.94	3.94	0.44807	0	0.74545	0.702456	.	.	0.74766	0.999999999228554	.	0	0.19454	0.570548	.	.	.	.	.	.	0	0.98432	0.735409	.&.&.	.	.	.	.	.	0.522241	0.18701	U	0.129258	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae&complex_aae&without_aae&without_aae	A&D&D&D&D	1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.4107	0.54800	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.90590	.	T/T	X	.	K	A	889	0.27310	.	11	C0587248&CN517202	218040	ORPHA3071	Uncertain_significance	NC_000011.10:g.532698T>A	40447	reviewed_by_expert_panel	Costello_syndrome&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:073e5f90-a343-456a-b175-656a2f84718f	.	.	AEFDBI	D	0.93399	0.99247	N	0.18803	0.092904	.	8	3.208240e-05	0	0.000000e+00	16176	0	0	0.000000e+00	34562	0	249358	0	0.000000e+00	10040	0	0	0.000000e+00	18366	0	0	0.000000e+00	21532	0	8	7.144640e-05	111972	0	8	7.144640e-05	111972	0	0	0.000000e+00	30612	0	1	9.150810e-06	0	0.000000e+00	7162	0	0	0.000000e+00	17098	0	109280	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13292	0	1	2.338420e-05	42764	0	1	2.338420e-05	42764	0	0	0.000000e+00	15690	0	0	.	0	5	2.121470e-05	0	0.000000e+00	14874	0	0	0.000000e+00	34238	0	235686	0	0.000000e+00	9568	0	0	0.000000e+00	17692	0	0	0.000000e+00	21516	0	5	4.918070e-05	101666	0	5	4.918070e-05	101666	0	0	0.000000e+00	30526	0	0	7	3.395320e-05	0	0.000000e+00	16138	0	0	0.000000e+00	30494	0	206166	0	0.000000e+00	6174	0	0	0.000000e+00	13388	0	0	0.000000e+00	16632	0	7	7.963230e-05	87904	0	7	7.963230e-05	87904	0	0	0.000000e+00	30604	0	0	8	3.295570e-05	0	0.000000e+00	11950	0	0	0.000000e+00	34428	0	242750	0	0.000000e+00	9958	0	0	0.000000e+00	18362	0	0	0.000000e+00	21530	0	8	7.280140e-05	109888	0	8	7.280140e-05	109888	0	0	0.000000e+00	30612	0	0	7	4.598180e-05	0	0.000000e+00	41460	0	0	0.000000e+00	912	0	0	0.000000e+00	15288	0	152234	0	0.000000e+00	3472	0	0	0.000000e+00	5194	0	0	0.000000e+00	10628	0	0	0.000000e+00	316	0	7	1.028840e-04	68038	0	7	1.028840e-04	68038	0	0	0.000000e+00	4832	0	0	0.000000e+00	0	0.000000e+00	9098	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32916	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5496	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3116	0	0	.	0	6	4.054770e-05	0	0.000000e+00	41140	0	0	0.000000e+00	912	0	0	0.000000e+00	15102	0	147974	0	0.000000e+00	3302	0	0	0.000000e+00	4960	0	0	0.000000e+00	10628	0	0	0.000000e+00	304	0	6	9.258970e-05	64802	0	0	0.000000e+00	4800	0	0	7	5.192260e-05	0	0.000000e+00	32482	0	0	0.000000e+00	862	0	0	0.000000e+00	14842	0	134816	0	0.000000e+00	3388	0	0	0.000000e+00	5194	0	0	0.000000e+00	6986	0	0	0.000000e+00	310	0	7	1.095150e-04	63918	0	0	0.000000e+00	4830	0	0	1	1.237720e-05	0	0.000000e+00	24836	0	0	0.000000e+00	112	0	0	0.000000e+00	12914	0	80794	0	0.000000e+00	998	0	0	0.000000e+00	3752	0	0	0.000000e+00	10536	0	0	0.000000e+00	272	0	1	4.750590e-05	21050	0	0	0.000000e+00	4804	0	0	11	522698	11	532698	0	0.85440	0.722319	1.000000	0.71638	0.995000	0.73285	0.999000	0.70432	4.127000	0.57698	0.661000	0.55757	1.134000	0.58424	532698	T	.	rs372936166	.	.	5.016	10.068	10.489	10.068	.	.	.	12	48	31	-46	0.00	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-5+57+end+125	40447	Uncertain_significance	reviewed_by_expert_panel	Malignant_tumor_of_urinary_bladder&Linear_nevus_sebaceous_syndrome&Epidermal_nevus&Large_congenital_melanocytic_nevus&Costello_syndrome&Thyroid_cancer&_nonmedullary&_2&not_provided	MONDO:MONDO:0001187&MedGen:C0005684&OMIM:109800&Orphanet:157980&Human_Phenotype_Ontology:HP:0010817&MONDO:MONDO:0008097&MedGen:C4552097&OMIM:163200&Orphanet:2612&Human_Phenotype_Ontology:HP:0010816&MONDO:MONDO:0008093&MedGen:C0334082&OMIM:162900&Orphanet:79414&Human_Phenotype_Ontology:HP:0005600&Human_Phenotype_Ontology:HP:0005604&MONDO:MONDO:0044792&MedGen:C1842036&OMIM:137550&Orphanet:626&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071&MONDO:MONDO:0008566&MedGen:C4225426&OMIM:188470&MedGen:CN517202	.	11:532698-532698	3.295e-05	4	4	0	0	0	0	0	4	0	0	10166	11492	8584	6438	65134	868	16496	0	0	0	0	4	0	0	0	0	0	0	0	0	0	rs372936166	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.25610e-05	0.00000e+00	0.00000e+00	3.72401e-05	2.72005e-05	7.25610e-05	3.24868e-05	rs372936166	1.14679e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	5.85206e-05	0.00000e+00	1.14679e-04	6.45369e-05	rs372936166	0.0233&0.0&0.0154	rs372936166	372936166	.	.	.	HRAS	HRAS:exonic	HRAS:stopgain	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,611	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89720813	89720813	A	T	T	stop_gained	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	8/9	.	NM_000314.8:c.964A>T	NP_000305.3:p.Lys322Ter	1809	964	322	K/*	Aaa/Taa	rs786202004&COSV64299161	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89720813A>T	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.96476	0.567668	D	0.96417	0.577639	39	38	7.803338	7.445883	0.98399	0.97874	./.	.	.	.	0.71892	0.99562631604007779	.	.	.	./.	.	.	.	.	18.87728	1.00059402224825	0.98639	19.94594	1.14852455941227	0.98936	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.37	5.37	0.76949	0	0.89359	0.724815	.	.	0.74766	0.999999999998002	.	0	0.39905	0.608884	.	.	.	.	.	.	0	0.36755	0.591603	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae	A	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	15.3536	0.74123	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99260	.	./.	X	.	K	T	899	0.25060	.	10	C0027672&C1959582&CN517202	.	ORPHA140162&ORPHA306498	Likely_pathogenic	NC_000010.11:g.87961056A>T	185213	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:bfdfbf81-6f26-43f8-aa4b-bbb17ebaf54a	.	.	AEFGBCI	D	0.72000	0.96980	N	0.44228	0.347990	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89710793	10	89720813	0	0.73137	0.706548	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	8.823000	0.91645	0.691000	0.84096	1.312000	0.94714	87961056	A	.	rs786202004	.	.	11.857	8.679	12.930	7.806	.	.	.	28	-44	-16	-49	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-9+62+end+225	185213	Likely_pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&not_provided&Hereditary_cancer-predisposing_syndrome	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MedGen:CN517202&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786202004	786202004	.	.	.	PTEN	PTEN:exonic	PTEN:stopgain	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,588	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
10	89720741	89720741	C	T	T	stop_gained	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	8/9	.	NM_000314.8:c.892C>T	NP_000305.3:p.Gln298Ter	1737	892	298	Q/*	Caa/Taa	rs371387815&CM110128&COSV64288370&COSV64295841	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89720741C>T	.	.	.	.	.	.	pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.892C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.97860	0.607496	D	0.97827	0.634849	37	38	7.103386	7.526233	0.97222	0.98008	./.	.	.	.	0.85583	0.99767277330947568	.	.	.	./.	.	.	.	.	12.31825	0.864636336125245	0.93842	14.70485	1.02438234545357	0.96446	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.13	5.13	0.69729	0	0.89359	0.724815	.	.	0.74766	0.999999999082029	.	0	0.96076	0.743671	.	.	.	.	.	.	0	0.50027	0.635259	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	.	.	0.221302	0.46924	D	0.000259	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae	A	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	18.5632	0.91063	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99337	.	./.	X	.	Q	T	900	0.24599	.	10	C0027672&C1959582&CN517202	.	ORPHA140162&ORPHA306498	Pathogenic	NC_000010.11:g.87960984C>T	187657	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	.	.	.	AEFGBI	D	0.76123	0.97645	N	0.28758	0.161515	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89710721	10	89720741	0	0.92422	0.732398	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	2.692000	0.46685	0.549000	0.26987	1.026000	0.45946	87960984	C	.	rs371387815	.	.	11.857	8.679	12.930	7.806	.	.	.	23	-47	-6	21	0.00	0.01	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-9+90+start+225	187657	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs371387815	371387815	.	.	.	PTEN	PTEN:exonic	PTEN:stopgain	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,586	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9971	Pathogenic
12	103260411	103260411	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.472C>T	NP_000268.1:p.Arg158Trp	586	472	158	R/W	Cgg/Tgg	rs75166491&CM930539&COSV61014403	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103260411G>A	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.472C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.87813	0.367228	D	0.95129	0.52639	25.8	25.0	3.785871	3.496909	0.71777	0.67044	G/G	D	0.94534	0.998573899269104	0.95733	0.99881198343087174	.	0.99998	.	G/G	1	2.2696323195642307E-4	1	1.1627906976744187E-4	3.863193	0.324583991660559	0.56988	4.758383	0.462666048468011	0.64926	.	.	.	3	2.471e-05	2	1.922e-04	0	0	3	2.474e-05	0	0	0	0	1	1.500e-05	0	0	3	2.825e-05	2	2.206e-04	0	0	3	2.829e-05	0	0	0	0	1	1.842e-05	0	0	3	3.306e-05	2	1.925e-04	0	0	3	3.311e-05	0	0	0	0	1	2.376e-05	0	0	0.99791	.	.	.	6.08	1.79	0.23992	0	0.26702	0.573888	.	.	0.05486	1.32784229729592E-4	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.99079	.	0.046743	0.84330	D	0.000000	D	0.97668	0.713038	0.26966	.	0.98711	.	D	0.99855	0.9937	.	0.99401	.	D	0.97161	0.9984	.	.	.	.	.	.	0.98900	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95765	.	.	.	0.90584	.	.	0.97372	.	D	0.82935	0.806367516518	0.98672	.	10	0.92824	.	.	0.91255	.	.	15.9325	0.79463	0.0:0.0:0.2582:0.7418	.	.	.	.	.	.	.	.	0.99670	.	G/G	W	.	R	A	700	0.57880	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102866633G>A	102693	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_000902&DeBelle_Laboratory_for_Biochemical_Genetics:p.R158W	.	.	AEFBI	D	0.40663	0.81211	D	0.86248	0.907893	.	7	2.784940e-05	2	1.230470e-04	16254	0	0	0.000000e+00	34556	0	251352	1	9.926540e-05	10074	0	2	1.087550e-04	18390	0	0	0.000000e+00	21648	0	2	1.759390e-05	113676	0	2	1.230470e-04	16254	0	0	0.000000e+00	30616	0	2	1.828250e-05	2	2.791740e-04	7164	0	0	0.000000e+00	17102	0	109394	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	0	0.000000e+00	42766	0	2	2.791740e-04	7164	0	0	0.000000e+00	15690	0	0	.	0	7	2.955910e-05	2	1.342280e-04	14900	0	0	0.000000e+00	34224	0	236814	1	1.045370e-04	9566	0	2	1.130710e-04	17688	0	0	0.000000e+00	21632	0	2	1.948180e-05	102660	0	2	1.342280e-04	14900	0	0	0.000000e+00	30526	0	0	6	2.883480e-05	2	1.233350e-04	16216	0	0	0.000000e+00	30490	0	208082	0	0.000000e+00	6210	0	2	1.491200e-04	13412	0	0	0.000000e+00	16734	0	2	2.233490e-05	89546	0	2	1.491200e-04	13412	0	0	0.000000e+00	30608	0	0	6	2.451640e-05	1	8.316700e-05	12024	0	0	0.000000e+00	34422	0	244734	1	1.000800e-04	9992	0	2	1.087780e-04	18386	0	0	0.000000e+00	21646	0	2	1.792340e-05	111586	0	2	1.087780e-04	18386	0	0	0.000000e+00	30616	0	0	5	3.286530e-05	4	9.656700e-05	41422	0	0	0.000000e+00	908	0	0	0.000000e+00	15264	0	152136	0	0.000000e+00	3470	0	0	0.000000e+00	5184	0	0	0.000000e+00	10614	0	0	0.000000e+00	316	0	1	1.469850e-05	68034	0	4	9.656700e-05	41422	0	0	0.000000e+00	4832	0	0	0.000000e+00	0	0.000000e+00	9098	0	0	0.000000e+00	58	0	0	0.000000e+00	4684	0	32894	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3112	0	0	.	0	5	3.380850e-05	4	9.732360e-05	41100	0	0	0.000000e+00	908	0	0	0.000000e+00	15076	0	147892	0	0.000000e+00	3302	0	0	0.000000e+00	4952	0	0	0.000000e+00	10614	0	0	0.000000e+00	304	0	1	1.542920e-05	64812	0	0	0.000000e+00	4800	0	0	4	2.968720e-05	3	9.241570e-05	32462	0	0	0.000000e+00	860	0	0	0.000000e+00	14818	0	134738	0	0.000000e+00	3386	0	0	0.000000e+00	5184	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	1	1.564700e-05	63910	0	0	0.000000e+00	4830	0	0	2	2.478380e-05	2	8.065170e-05	24798	0	0	0.000000e+00	108	0	0	0.000000e+00	12890	0	80698	0	0.000000e+00	996	0	0	0.000000e+00	3742	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	0	0.000000e+00	21048	0	0	0.000000e+00	4804	0	0	12	101784541	12	103260411	0	0.43195	0.638212	1.000000	0.71638	0.954000	0.50415	0.910000	0.38299	1.433000	0.34556	-0.154000	0.11915	0.194000	0.22150	102866633	G	.	rs75166491	.	.	7.292	9.092	8.810	7.211	.	.	.	-37	30	30	-37	0.00	0.01	0.00	0.01	PAH	0.00	exon-NM_001354304.2-6+30+end+68	102693	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs75166491	2.471e-05	3	3	0	2	0	0	0	1	0	0	10406	11502	8646	6604	66684	908	16510	2	0	0	0	1	0	0	0	0	0	0	0	0	0	rs75166491	1.30719e-04	0.00000e+00	1.01585e-04	1.15969e-04	0.00000e+00	1.79192e-05	0.00000e+00	0.00000e+00	2.22529e-05	3.59376e-05	1.30719e-04	2.84241e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	rs75166491	0.0116&0.0227&0.0154	rs75166491	75166491	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,791	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103271247	103271247	T	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	4/13	.	NM_000277.3:c.434A>T	NP_000268.1:p.Asp145Val	548	434	145	D/V	gAc/gTc	rs140175796&CM961070	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103271247T>A	.	.	.	.	.	.	pathogenic&likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.434A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.90291	0.406581	D	0.96251	0.571951	29.7	26.4	4.312529	3.830682	0.88511	0.76465	T/T	D	0.91766	0.997520625591278	0.61368	0.99369621335823477	.	0.99945	.	T/T	1	2.2696323195642307E-4	1	1.1627906976744187E-4	10.0454	0.797334473718617	0.89608	11.13806	0.903393028933509	0.91925	.	.	.	5	4.118e-05	1	9.610e-05	0	0	5	4.118e-05	0	0	0	0	4	5.993e-05	0	0	4	3.766e-05	1	1.103e-04	0	0	4	3.766e-05	0	0	0	0	3	5.520e-05	0	0	4	4.408e-05	1	9.626e-05	0	0	4	4.408e-05	0	0	0	0	3	7.119e-05	0	0	0.99705	.	.	.	5.86	5.86	0.93936	0	0.14657	0.547309	.	.	0.74766	0.999997650377572	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.95972	.	0.000000	0.84330	D	0.000000	D	0.98977	0.866491	0.29633	.	0.98194	.	D	0.99813	0.9923	.	0.98869	.	D	0.96458	0.9542	.	.	.	.	.	.	0.98282	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.97104	.	.	.	0.68779	.	.	0.65913	.	T	0.80306	0.789104342461	0.99952	.	10	0.92824	.	.	0.91255	.	.	16.2436	0.82253	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.96531	.	T/T	V	.	D	A	674	0.60593	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102877469T>A	102667	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_011566&Illumina_Laboratory_Services&Illumina:679193&DeBelle_Laboratory_for_Biochemical_Genetics:p.D145V	.	.	AEFBCI	D	0.59753	0.93980	D	0.99588	0.974932	.	16	6.362230e-05	0	0.000000e+00	16256	0	4	1.156340e-04	34592	0	251484	1	9.920630e-05	10080	0	0	0.000000e+00	18392	0	0	0.000000e+00	21646	0	11	9.669310e-05	113762	0	4	1.156340e-04	34592	0	0	0.000000e+00	30616	0	6	5.484260e-05	0	0.000000e+00	7164	0	4	2.337540e-04	17112	0	109404	1	4.310340e-04	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13392	0	1	2.338200e-05	42768	0	4	2.337540e-04	17112	0	0	0.000000e+00	15690	0	0	.	0	15	6.330560e-05	0	0.000000e+00	14902	0	4	1.167540e-04	34260	0	236946	1	1.044710e-04	9572	0	0	0.000000e+00	17690	0	0	0.000000e+00	21630	0	10	9.732740e-05	102746	0	4	1.167540e-04	34260	0	0	0.000000e+00	30526	0	0	13	6.246040e-05	0	0.000000e+00	16218	0	4	1.310440e-04	30524	0	208132	1	1.609790e-04	6212	0	0	0.000000e+00	13414	0	0	0.000000e+00	16732	0	8	8.932760e-05	89558	0	4	1.310440e-04	30524	0	0	0.000000e+00	30608	0	0	15	6.125800e-05	0	0.000000e+00	12026	0	4	1.160830e-04	34458	0	244866	1	1.000200e-04	9998	0	0	0.000000e+00	18388	0	0	0.000000e+00	21644	0	10	8.954800e-05	111672	0	4	1.160830e-04	34458	0	0	0.000000e+00	30616	0	0	13	8.559500e-05	1	2.419780e-05	41326	0	0	0.000000e+00	908	0	0	0.000000e+00	15252	0	151878	0	0.000000e+00	3472	0	0	0.000000e+00	5160	0	0	0.000000e+00	10574	0	0	0.000000e+00	316	0	11	1.618270e-04	67974	0	11	1.618270e-04	67974	0	0	0.000000e+00	4808	0	0	0.000000e+00	0	0.000000e+00	9062	0	0	0.000000e+00	58	0	0	0.000000e+00	4680	0	32802	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5454	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3100	0	0	.	0	13	8.806280e-05	1	2.438790e-05	41004	0	0	0.000000e+00	908	0	0	0.000000e+00	15064	0	147622	0	0.000000e+00	3302	0	0	0.000000e+00	4924	0	0	0.000000e+00	10574	0	0	0.000000e+00	304	0	11	1.698950e-04	64746	0	0	0.000000e+00	4776	0	0	12	8.921670e-05	1	3.088520e-05	32378	0	0	0.000000e+00	860	0	0	0.000000e+00	14806	0	134504	0	0.000000e+00	3388	0	0	0.000000e+00	5160	0	0	0.000000e+00	6932	0	0	0.000000e+00	310	0	10	1.565780e-04	63866	0	0	0.000000e+00	4806	0	0	2	2.484410e-05	0	0.000000e+00	24730	0	0	0.000000e+00	108	0	0	0.000000e+00	12880	0	80502	0	0.000000e+00	998	0	0	0.000000e+00	3722	0	0	0.000000e+00	10482	0	0	0.000000e+00	272	0	1	4.758280e-05	21016	0	0	0.000000e+00	4780	0	0	12	101795377	12	103271247	0	0.37627	0.615465	1.000000	0.71638	0.395000	0.26670	0.992000	0.54103	7.382000	0.79001	0.665000	0.62972	1.138000	0.64695	102877469	T	.	rs140175796	.	.	8.810	7.211	11.038	10.766	.	.	.	2	-7	-11	-7	0.00	0.00	0.00	0.03	PAH	0.00	exon-NM_001354304.2-5+7+start+89	102667	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria&See_cases	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&.	.	rs140175796	4.118e-05	5	5	0	1	0	0	0	4	0	0	10406	11578	8654	6614	66740	908	16512	1	0	0	0	4	0	0	0	0	0	0	0	0	0	rs140175796	0.00000e+00	1.19111e-04	1.01523e-04	0.00000e+00	0.00000e+00	9.84710e-05	0.00000e+00	0.00000e+00	6.67151e-05	6.28626e-05	1.19111e-04	6.49688e-05	rs140175796	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.67913e-05	0.00000e+00	.	5.84932e-05	0.00000e+00	6.67913e-05	3.22664e-05	rs140175796	0.0116&0.0227&0.0154	rs140175796	140175796	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,799	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103260419	103260419	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.464G>A	NP_000268.1:p.Arg155His	578	464	155	R/H	cGt/cAt	rs199475663&CM000544&CM981433&COSV61016854	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103260419C>T	.	.	.	.	.	.	pathogenic&not_provided	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.464G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.91895	0.437356	D	0.95942	0.559584	27.9	29.8	4.122299	4.243254	0.82872	0.89108	C/C	D	0.95280	0.998826444149017	0.99886	0.99945150651728565	.	0.99988	.	C/C	.	.	.	.	17.32275	0.973818795422237	0.98054	15.44988	1.04644687289437	0.97006	.	.	.	3	2.471e-05	0	0	0	0	3	2.474e-05	1	1.157e-04	0	0	1	1.500e-05	1	6.057e-05	3	2.825e-05	0	0	0	0	3	2.829e-05	1	1.273e-04	0	0	1	1.842e-05	1	6.095e-05	2	2.204e-05	0	0	0	0	2	2.208e-05	1	1.777e-04	0	0	0	0	1	6.061e-05	0.99782	.	.	.	6.08	6.08	0.98982	0	0.26702	0.573888	.	.	0.33875	0.994943344109113	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.89738	.	0.000000	0.84330	D	0.000000	D	0.98486	0.806129	0.28397	.	0.99337	.	D	0.99870	0.9943	.	0.96436	.	D	0.96528	0.9588	.	.	.	.	.	.	0.98503	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.79571	.	.	.	0.90584	.	.	0.84481	.	T	0.63620	0.675471842289	0.98990	.	10	0.79402	.	.	0.91255	.	.	17.8194	0.88557	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.84922	.	C/C	H	.	R	T	700	0.57880	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102866641C>T	102686	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.R155H	.	.	AEFBI	D	0.68762	0.96361	D	0.94879	0.943222	.	5	1.989270e-05	0	0.000000e+00	16256	0	1	2.894020e-05	34554	0	251348	0	0.000000e+00	10072	0	1	5.437740e-05	18390	0	0	0.000000e+00	21646	0	2	1.759360e-05	113678	0	1	5.437740e-05	18390	0	1	3.266270e-05	30616	0	3	2.742430e-05	0	0.000000e+00	7164	0	1	5.847950e-05	17100	0	109392	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	2	4.676610e-05	42766	0	1	5.847950e-05	17100	0	0	0.000000e+00	15690	0	0	.	0	5	2.111400e-05	0	0.000000e+00	14902	0	1	2.922100e-05	34222	0	236810	0	0.000000e+00	9564	0	1	5.653550e-05	17688	0	0	0.000000e+00	21630	0	2	1.948140e-05	102662	0	1	5.653550e-05	17688	0	1	3.275900e-05	30526	0	0	5	2.402970e-05	0	0.000000e+00	16218	0	1	3.279980e-05	30488	0	208076	0	0.000000e+00	6208	0	1	7.456010e-05	13412	0	0	0.000000e+00	16732	0	2	2.233540e-05	89544	0	1	7.456010e-05	13412	0	1	3.267120e-05	30608	0	0	5	2.043070e-05	0	0.000000e+00	12026	0	1	2.905290e-05	34420	0	244730	0	0.000000e+00	9990	0	1	5.438920e-05	18386	0	0	0.000000e+00	21644	0	2	1.792310e-05	111588	0	1	5.438920e-05	18386	0	1	3.266270e-05	30616	0	0	4	2.629300e-05	0	0.000000e+00	41414	0	0	0.000000e+00	910	0	0	0.000000e+00	15270	0	152132	1	2.880180e-04	3472	0	1	1.926040e-04	5192	0	0	0.000000e+00	10606	0	0	0.000000e+00	316	0	2	2.939710e-05	68034	0	1	1.926040e-04	5192	0	0	0.000000e+00	4828	0	1	3.042470e-05	0	0.000000e+00	9084	0	0	0.000000e+00	60	0	0	0.000000e+00	4684	0	32868	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5476	0	0	0.000000e+00	246	0	1	1.459430e-04	6852	0	0	0.000000e+00	3110	0	0	.	0	4	2.704970e-05	0	0.000000e+00	41092	0	0	0.000000e+00	910	0	0	0.000000e+00	15082	0	147876	1	3.028470e-04	3302	0	1	2.017760e-04	4956	0	0	0.000000e+00	10606	0	0	0.000000e+00	304	0	2	3.086130e-05	64806	0	0	0.000000e+00	4796	0	0	3	2.226810e-05	0	0.000000e+00	32444	0	0	0.000000e+00	862	0	0	0.000000e+00	14824	0	134722	1	2.951590e-04	3388	0	1	1.926040e-04	5192	0	0	0.000000e+00	6964	0	0	0.000000e+00	310	0	1	1.564650e-05	63912	0	0	0.000000e+00	4826	0	0	3	3.717470e-05	0	0.000000e+00	24792	0	0	0.000000e+00	110	0	0	0.000000e+00	12896	0	80700	0	0.000000e+00	998	0	1	2.665250e-04	3752	0	0	0.000000e+00	10514	0	0	0.000000e+00	272	0	2	9.501190e-05	21050	0	0	0.000000e+00	4800	0	0	12	101784549	12	103260419	0	0.43195	0.638212	1.000000	0.71638	0.925000	0.46118	0.862000	0.35736	5.240000	0.65201	0.599000	0.40250	1.026000	0.45946	102866641	C	.	rs199475663	.	.	7.292	9.092	8.810	7.211	.	.	.	-45	22	22	-45	0.00	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-6+22+end+68	102686	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103260419-103260419	2.471e-05	3	3	0	0	0	1	0	1	0	1	10406	11502	8644	6604	66684	908	16510	0	0	1	0	1	0	1	0	0	0	0	0	0	0	rs199475663	0.00000e+00	2.98116e-05	0.00000e+00	5.79845e-05	0.00000e+00	1.79195e-05	0.00000e+00	3.24865e-05	1.48350e-05	2.69551e-05	5.79845e-05	2.43635e-05	rs199475663	0.00000e+00	0.00000e+00	0.00000e+00	6.17284e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	5.83908e-05	0.00000e+00	6.17284e-04	3.22664e-05	.	.	rs199475663	199475663	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,794	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103249091	103249091	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.529G>A	NP_000268.1:p.Val177Met	643	529	177	V/M	Gtg/Atg	rs199475602&CM961073&CM993954	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103249091C>T	.	.	.	.	.	.	not_provided&pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.529G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.90090	0.403076	D	0.92871	0.424079	25.6	26.5	3.739683	3.834284	0.70454	0.76570	C/C	D	0.85300	0.99416720867157	0.95491	0.99877833469755695	.	0.99963	.	C/C	.	.	.	.	8.544147	0.738767250676882	0.85314	9.065167	0.814222465800467	0.86989	.	.	.	2	1.647e-05	0	0	0	0	2	1.657e-05	0	0	0	0	2	3.010e-05	0	0	2	1.883e-05	0	0	0	0	2	1.894e-05	0	0	0	0	2	3.695e-05	0	0	2	2.204e-05	0	0	0	0	2	2.218e-05	0	0	0	0	2	4.770e-05	0	0	0.99729	.	.	.	5.73	4.84	0.62125	0	0.26702	0.573888	.	.	0.17252	0.139821981339524	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.86318	.	0.054222	0.84330	D	0.000001	D	0.94526	0.461768	0.16256	.	0.98306	.	D	0.99731	0.9901	.	0.99419	.	D	0.97064	0.9926	V177M	Gain_of_disorder_(P_=_0.0559)&_Loss_of_phosphorylation_at_Y179_(P_=_0.1128)&_Loss_of_sheet_(P_=_0.1158)&_Gain_of_loop_(P_=_0.2045)&_Loss_of_catalytic_residue_at_E181_(P_=_0.325)	P00439	0.99502	0.955	.	0.95479	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.56144	.	.	.	0.67487	.	.	0.65306	.	T	0.53914	0.607160449028	0.96836	.	10	0.55341	.	.	0.91255	.	.	14.1556	0.64950	0.0:0.9284:0.0:0.0716	.	.	.	.	.	.	.	.	0.81063	.	C/C	M	.	V	T	532	0.73501	.	12	C0751435&C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102855313C>T	102726	reviewed_by_expert_panel	Hyperphenylalaninemia&_non-pku&Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.V177M&UniProtKB_(protein):P00439#VAR_068002	.	.	AEFBI	D	0.71708	0.96928	D	0.67685	0.728999	.	4	1.592430e-05	0	0.000000e+00	16254	0	1	2.893350e-05	34562	0	251188	0	0.000000e+00	10074	0	0	0.000000e+00	18372	0	0	0.000000e+00	21640	0	3	2.642050e-05	113548	0	1	2.893350e-05	34562	0	0	0.000000e+00	30616	0	1	9.142610e-06	0	0.000000e+00	7162	0	0	0.000000e+00	17106	0	109378	0	0.000000e+00	2318	0	0	0.000000e+00	9038	0	0	0.000000e+00	13394	0	1	2.338850e-05	42756	0	1	2.338850e-05	42756	0	0	0.000000e+00	15690	0	0	.	0	4	1.690220e-05	0	0.000000e+00	14900	0	1	2.921410e-05	34230	0	236656	0	0.000000e+00	9566	0	0	0.000000e+00	17670	0	0	0.000000e+00	21624	0	3	2.925800e-05	102536	0	3	2.925800e-05	102536	0	0	0.000000e+00	30526	0	0	2	9.613810e-06	0	0.000000e+00	16216	0	0	0.000000e+00	30494	0	208034	0	0.000000e+00	6208	0	0	0.000000e+00	13394	0	0	0.000000e+00	16730	0	2	2.234040e-05	89524	0	2	2.234040e-05	89524	0	0	0.000000e+00	30608	0	0	4	1.635520e-05	0	0.000000e+00	12024	0	1	2.904610e-05	34428	0	244570	0	0.000000e+00	9992	0	0	0.000000e+00	18368	0	0	0.000000e+00	21638	0	3	2.691600e-05	111458	0	1	2.904610e-05	34428	0	0	0.000000e+00	30616	0	0	2	1.314560e-05	0	0.000000e+00	41418	0	0	0.000000e+00	912	0	0	0.000000e+00	15272	0	152142	0	0.000000e+00	3472	0	0	0.000000e+00	5186	0	0	0.000000e+00	10610	0	0	0.000000e+00	316	0	2	2.939450e-05	68040	0	2	2.939450e-05	68040	0	0	0.000000e+00	4828	0	0	0.000000e+00	0	0.000000e+00	9084	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32876	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5482	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3112	0	0	.	0	2	1.352450e-05	0	0.000000e+00	41096	0	0	0.000000e+00	912	0	0	0.000000e+00	15084	0	147880	0	0.000000e+00	3302	0	0	0.000000e+00	4952	0	0	0.000000e+00	10610	0	0	0.000000e+00	304	0	2	3.086130e-05	64806	0	0	0.000000e+00	4796	0	0	2	1.484410e-05	0	0.000000e+00	32452	0	0	0.000000e+00	862	0	0	0.000000e+00	14826	0	134734	0	0.000000e+00	3388	0	0	0.000000e+00	5186	0	0	0.000000e+00	6968	0	0	0.000000e+00	310	0	2	3.129010e-05	63918	0	0	0.000000e+00	4826	0	0	0	0.000000e+00	0	0.000000e+00	24794	0	0	0.000000e+00	112	0	0	0.000000e+00	12898	0	80702	0	0.000000e+00	998	0	0	0.000000e+00	3744	0	0	0.000000e+00	10518	0	0	0.000000e+00	272	0	0	0.000000e+00	21052	0	0	0.000000e+00	4800	0	0	12	101773221	12	103249091	0	0.43195	0.638212	0.996000	0.39380	0.949000	0.49496	0.897000	0.37483	3.388000	0.52247	0.599000	0.40250	1.026000	0.45946	102855313	C	.	rs199475602	.	.	7.651	9.354	7.292	9.092	.	.	.	19	-1	-4	1	0.01	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+19+end+197	102726	Pathogenic	reviewed_by_expert_panel	Hyperphenylalaninemia&not_provided&Phenylketonuria	Human_Phenotype_Ontology:HP:0004923&MedGen:C0751435&MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103249091-103249091	1.647e-05	2	0	0	0	0	0	0	2	0	0	10372	11446	8586	6578	66442	904	16394	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs199475602	0.00000e+00	2.98027e-05	0.00000e+00	0.00000e+00	0.00000e+00	1.79430e-05	0.00000e+00	0.00000e+00	7.42258e-06	1.79827e-05	2.98027e-05	1.62422e-05	rs199475602	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66756e-05	0.00000e+00	.	5.84454e-05	0.00000e+00	6.66756e-05	3.22664e-05	.	.	rs199475602	199475602	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,772	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103260410	103260410	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.473G>A	NP_000268.1:p.Arg158Gln	587	473	158	R/Q	cGg/cAg	rs5030843&CM015340&CM890093&COSV61019642	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103260410C>T	.	.	.	.	.	.	pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.473G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.594706798131811E-4	.	.	.	.	.	.	.	C/C	C	D	0.87063	0.357562	D	0.95956	0.56055	29.6	28.9	4.302056	4.132208	0.88268	0.86544	C/C	D	0.84819	0.993845760822296	0.99994	0.99959646412474568	.	0.99998	.	C/C	0	0.0	3	3.488372093023256E-4	11.20415	0.833890981720758	0.92042	11.93077	0.93280768020157	0.93272	.	.	.	12	9.884e-05	0	0	0	0	12	9.896e-05	0	0	0	0	12	1.800e-04	0	0	10	9.415e-05	0	0	0	0	10	9.429e-05	0	0	0	0	10	1.842e-04	0	0	9	9.917e-05	0	0	0	0	9	9.934e-05	0	0	0	0	9	2.139e-04	0	0	0.99769	.	.	.	6.08	5.17	0.70848	0	0.26702	0.573888	.	.	0.15965	0.0848159718721622	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.98861	.	0.046743	0.84330	D	0.000000	D	0.98523	0.810549	0.27787	.	0.99243	.	D	0.99862	0.9940	.	0.97342	.	D	0.96007	0.9234	.	.	.	.	.	.	0.98900	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.72594	.	.	.	0.90584	.	.	0.97372	.	T	0.68471	0.709157526493	0.99518	.	9	0.83351	.	.	0.91255	.	.	14.6498	0.68393	0.0:0.8551:0.1449:0.0	.	0	0.0	1	1.322401481089659E-4	.	.	.	0.96416	.	C/C	Q	.	R	T	700	0.57880	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102866632C>T	587	reviewed_by_expert_panel	Phenylketonuria&not_provided	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2838466&UniProtKB_(protein):P00439#VAR_000901&HGMD:CM890093&OMIM_Allelic_Variant:612349.0010&DeBelle_Laboratory_for_Biochemical_Genetics:p.R158Q	.	.	AEFBI	D	0.65180	0.95553	D	0.92162	0.931976	.	23	9.150080e-05	0	0.000000e+00	16254	0	0	0.000000e+00	34558	0	251364	0	0.000000e+00	10072	0	1	5.437740e-05	18390	0	0	0.000000e+00	21646	0	22	1.935090e-04	113690	0	22	1.935090e-04	113690	0	0	0.000000e+00	30616	0	6	5.484860e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17102	0	109392	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13392	0	6	1.402980e-04	42766	0	6	1.402980e-04	42766	0	0	0.000000e+00	15690	0	0	.	0	22	9.289520e-05	0	0.000000e+00	14900	0	0	0.000000e+00	34226	0	236826	0	0.000000e+00	9564	0	1	5.653550e-05	17688	0	0	0.000000e+00	21630	0	21	2.045310e-04	102674	0	21	2.045310e-04	102674	0	0	0.000000e+00	30526	0	0	17	8.169930e-05	0	0.000000e+00	16216	0	0	0.000000e+00	30492	0	208080	0	0.000000e+00	6208	0	1	7.456010e-05	13412	0	0	0.000000e+00	16732	0	16	1.786790e-04	89546	0	16	1.786790e-04	89546	0	0	0.000000e+00	30608	0	0	23	9.397500e-05	0	0.000000e+00	12024	0	0	0.000000e+00	34424	0	244746	0	0.000000e+00	9990	0	1	5.438920e-05	18386	0	0	0.000000e+00	21644	0	22	1.971330e-04	111600	0	22	1.971330e-04	111600	0	0	0.000000e+00	30616	0	0	10	6.575310e-05	0	0.000000e+00	41402	0	0	0.000000e+00	908	0	0	0.000000e+00	15262	0	152084	0	0.000000e+00	3472	0	0	0.000000e+00	5184	0	0	0.000000e+00	10610	0	0	0.000000e+00	316	0	10	1.470330e-04	68012	0	10	1.470330e-04	68012	0	0	0.000000e+00	4824	0	0	0.000000e+00	0	0.000000e+00	9096	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32886	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5482	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3106	0	0	.	0	10	6.764070e-05	0	0.000000e+00	41082	0	0	0.000000e+00	908	0	0	0.000000e+00	15074	0	147840	0	0.000000e+00	3302	0	0	0.000000e+00	4950	0	0	0.000000e+00	10610	0	0	0.000000e+00	304	0	10	1.543350e-04	64794	0	0	0.000000e+00	4792	0	0	9	6.681910e-05	0	0.000000e+00	32444	0	0	0.000000e+00	862	0	0	0.000000e+00	14818	0	134692	0	0.000000e+00	3388	0	0	0.000000e+00	5184	0	0	0.000000e+00	6968	0	0	0.000000e+00	310	0	9	1.408630e-04	63892	0	0	0.000000e+00	4822	0	0	2	2.479610e-05	0	0.000000e+00	24782	0	0	0.000000e+00	108	0	0	0.000000e+00	12888	0	80658	0	0.000000e+00	998	0	0	0.000000e+00	3742	0	0	0.000000e+00	10518	0	0	0.000000e+00	272	0	2	9.508410e-05	21034	0	0	0.000000e+00	4796	0	0	12	101784540	12	103260410	0	0.43195	0.638212	1.000000	0.71638	0.967000	0.53440	0.932000	0.39996	5.240000	0.65201	0.599000	0.40250	1.026000	0.45946	102866632	C	.	rs5030843	.	.	7.292	9.092	8.810	7.211	.	.	.	-2	31	31	-36	0.00	0.02	0.00	0.01	PAH	0.00	exon-NM_001354304.2-6+31+end+68	587	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030843	9.884e-05	12	1	0	0	0	0	0	12	0	0	10406	11504	8646	6604	66680	908	16508	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs5030843	0.00000e+00	0.00000e+00	0.00000e+00	5.79845e-05	0.00000e+00	2.14996e-04	0.00000e+00	0.00000e+00	1.48342e-04	4.49196e-05	2.14996e-04	1.01515e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	rs5030843	0.0349&0.0&0.0231	rs5030843	5030843	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,790	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103260393	103260393	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.490A>G	NP_000268.1:p.Ile164Val	604	490	164	I/V	Att/Gtt	rs199475647&CM992945	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103260393T>C	.	.	.	.	.	.	likely_pathogenic&not_provided	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.490A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.74725	0.208881	D	0.85326	0.243794	22.5	22.2	2.531796	2.342195	0.41935	0.40237	T/T	D	0.36372	0.599291443824768	0.82975	0.99733975637242811	.	0.95014	.	T/T	.	.	.	.	5.625169	0.547775328328001	0.71244	4.972575	0.491823068339933	0.66610	.	.	.	2	1.647e-05	0	0	0	0	2	1.649e-05	0	0	0	0	0	0	2	1.211e-04	2	1.883e-05	0	0	0	0	2	1.886e-05	0	0	0	0	0	0	2	1.219e-04	2	2.204e-05	0	0	0	0	2	2.207e-05	0	0	0	0	0	0	2	1.212e-04	0.99632	.	.	.	6.08	6.08	0.98982	0	0.26702	0.573888	.	.	0.25950	0.895263147148426	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.57379	.	0.044424	0.84330	D	0.000000	D	0.86512	0.196997	0.05090	.	0.95159	.	D	0.99191	0.9741	.	0.93967	.	D	0.99547	1.0973	I164V	Gain_of_phosphorylation_at_Y168_(P_=_0.0896)&_Gain_of_MoRF_binding_(P_=_0.1222)&_Loss_of_methylation_at_K159_(P_=_0.1413)&_Loss_of_catalytic_residue_at_I164_(P_=_0.2132)&_Gain_of_disorder_(P_=_0.3445)	P00439	0.96983	0.883	.	0.80896	.	.	0.58761	simple_aae&simple_aae	D&D	0.999995&0.999995	0.22727	.	.	.	0.40793	.	.	0.41795	.	T	0.34325	0.467411935329	0.88679	.	10	0.25987	.	.	0.25873	.	.	14.3847	0.66504	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.82257	.	T/T	V	.	I	C	700	0.57880	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102866615T>C	102698	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.I164V	.	.	AEFBI	D	0.67597	0.96114	D	0.95486	0.945957	.	4	1.591280e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34556	0	251370	0	0.000000e+00	10074	0	0	0.000000e+00	18390	0	0	0.000000e+00	21640	0	2	1.758980e-05	113702	0	2	6.532530e-05	30616	0	2	6.532530e-05	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17100	0	109386	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13392	0	0	0.000000e+00	42762	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	4	1.688960e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34224	0	236832	0	0.000000e+00	9566	0	0	0.000000e+00	17688	0	0	0.000000e+00	21624	0	2	1.947690e-05	102686	0	2	6.551790e-05	30526	0	2	6.551790e-05	30526	0	0	4	1.922410e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30490	0	208072	0	0.000000e+00	6210	0	0	0.000000e+00	13412	0	0	0.000000e+00	16726	0	2	2.233540e-05	89544	0	2	6.534240e-05	30608	0	2	6.534240e-05	30608	0	0	4	1.634310e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34422	0	244752	0	0.000000e+00	9992	0	0	0.000000e+00	18386	0	0	0.000000e+00	21638	0	2	1.791920e-05	111612	0	2	6.532530e-05	30616	0	2	6.532530e-05	30616	0	0	1	6.572720e-06	0	0.000000e+00	41420	0	0	0.000000e+00	910	0	1	6.547070e-05	15274	0	152144	0	0.000000e+00	3470	0	0	0.000000e+00	5188	0	0	0.000000e+00	10622	0	0	0.000000e+00	316	0	0	0.000000e+00	68022	0	1	6.547070e-05	15274	0	0	0.000000e+00	4832	0	1	3.040440e-05	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	1	2.134930e-04	4684	0	32890	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5492	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3114	0	0	.	0	1	6.761230e-06	0	0.000000e+00	41102	0	0	0.000000e+00	910	0	1	6.628660e-05	15086	0	147902	0	0.000000e+00	3302	0	0	0.000000e+00	4954	0	0	0.000000e+00	10622	0	0	0.000000e+00	304	0	0	0.000000e+00	64800	0	0	0.000000e+00	4800	0	0	1	7.421480e-06	0	0.000000e+00	32456	0	0	0.000000e+00	862	0	1	6.744000e-05	14828	0	134744	0	0.000000e+00	3386	0	0	0.000000e+00	5188	0	0	0.000000e+00	6982	0	0	0.000000e+00	310	0	0	0.000000e+00	63902	0	0	0.000000e+00	4830	0	0	1	1.239070e-05	0	0.000000e+00	24794	0	0	0.000000e+00	110	0	1	7.751940e-05	12900	0	80706	0	0.000000e+00	996	0	0	0.000000e+00	3746	0	0	0.000000e+00	10530	0	0	0.000000e+00	272	0	0	0.000000e+00	21038	0	0	0.000000e+00	4804	0	0	12	101784523	12	103260393	0	0.43195	0.638212	1.000000	0.71638	0.969000	0.54022	0.997000	0.62031	5.310000	0.65568	0.665000	0.62972	1.138000	0.64695	102866615	T	.	rs199475647	.	.	7.292	9.092	8.810	7.211	.	.	.	48	-19	-19	-23	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-6+19+start+68	102698	Likely_pathogenic	reviewed_by_expert_panel	not_provided&6-Pyruvoyl-tetrahydrobiopterin_synthase_deficiency&See_cases&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009863&MedGen:C0878676&OMIM:261640&Orphanet:13&Orphanet:238583&.&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103260393-103260393	1.647e-05	2	2	0	0	0	0	0	0	0	2	10406	11508	8650	6604	66682	908	16510	0	0	0	0	0	0	2	0	0	0	0	0	0	0	rs199475647	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79147e-05	0.00000e+00	6.49730e-05	1.48342e-05	1.79685e-05	6.49730e-05	1.62423e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475647	199475647	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,788	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103249087	103249087	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.533A>G	NP_000268.1:p.Glu178Gly	647	533	178	E/G	gAa/gGa	rs77958223&CM002085&CM941131	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103249087T>C	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.533A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.70011	0.157965	D	0.87968	0.295106	26.5	25.9	3.919730	3.730435	0.75923	0.73353	T/T	D	0.38244	0.644893195396696	0.96513	0.9989136052389187	.	0.99819	.	T/T	.	.	.	.	5.935919	0.576035953252372	0.73226	5.525497	0.558493639875747	0.70599	.	.	.	6	4.942e-05	0	0	2	1.746e-04	6	4.965e-05	0	0	0	0	4	6.014e-05	0	0	5	4.708e-05	0	0	2	1.803e-04	5	4.730e-05	0	0	0	0	3	5.537e-05	0	0	6	6.611e-05	0	0	2	1.748e-04	6	6.647e-05	0	0	0	0	4	9.531e-05	0	0	0.99678	.	.	.	5.73	5.73	0.89730	0	0.26702	0.573888	.	.	0.17651	0.165024456640776	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.83996	.	0.262458	0.42656	D	0.000644	D	0.97711	0.717595	0.08163	.	0.98105	.	D	0.99492	0.9833	.	0.97391	.	D	0.97838	1.0363	E178G	Loss_of_catalytic_residue_at_E178_(P_=_0.0599)&_Loss_of_disorder_(P_=_0.0849)&_Gain_of_sheet_(P_=_0.1208)&_Loss_of_stability_(P_=_0.1698)&_Loss_of_loop_(P_=_0.2237)	P00439	0.96632	0.876	.	0.89043	.	.	0.44438	simple_aae&simple_aae	D&D	0.998033&0.998033	0.77881	.	.	.	0.40359	.	.	0.40506	.	T	0.21985	0.378091990948	0.95026	.	10	0.69154	.	.	0.50132	.	.	11.5074	0.49724	0.0:0.0:0.2698:0.7302	.	.	.	.	.	.	.	.	0.61002	.	T/T	G	.	E	C	532	0.73501	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102855309T>C	92746	reviewed_by_expert_panel	Phenylketonuria&not_provided	HGMD:CM941131&DeBelle_Laboratory_for_Biochemical_Genetics:p.E178G&UniProtKB_(protein):P00439#VAR_000916	.	.	AEFBI	D	0.64140	0.95288	D	0.86869	0.910584	.	18	7.164690e-05	0	0.000000e+00	16256	0	3	8.679050e-05	34566	0	251232	0	0.000000e+00	10074	0	0	0.000000e+00	18374	0	0	0.000000e+00	21646	0	14	1.232590e-04	113582	0	14	1.232590e-04	113582	0	0	0.000000e+00	30610	0	5	4.571300e-05	0	0.000000e+00	7164	0	2	1.169180e-04	17106	0	109378	0	0.000000e+00	2318	0	0	0.000000e+00	9036	0	0	0.000000e+00	13394	0	2	4.677270e-05	42760	0	2	1.169180e-04	17106	0	0	0.000000e+00	15686	0	0	.	0	16	6.759730e-05	0	0.000000e+00	14902	0	3	8.763220e-05	34234	0	236696	0	0.000000e+00	9566	0	0	0.000000e+00	17672	0	0	0.000000e+00	21630	0	12	1.169960e-04	102568	0	12	1.169960e-04	102568	0	0	0.000000e+00	30520	0	0	15	7.209870e-05	0	0.000000e+00	16218	0	3	9.836710e-05	30498	0	208048	0	0.000000e+00	6208	0	0	0.000000e+00	13396	0	0	0.000000e+00	16732	0	11	1.228580e-04	89534	0	11	1.228580e-04	89534	0	0	0.000000e+00	30602	0	0	18	7.358530e-05	0	0.000000e+00	12026	0	3	8.712830e-05	34432	0	244614	0	0.000000e+00	9992	0	0	0.000000e+00	18370	0	0	0.000000e+00	21644	0	14	1.255700e-04	111492	0	14	1.255700e-04	111492	0	0	0.000000e+00	30610	0	0	14	9.201570e-05	3	7.242180e-05	41424	0	0	0.000000e+00	912	0	0	0.000000e+00	15282	0	152148	0	0.000000e+00	3472	0	0	0.000000e+00	5186	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	11	1.617030e-04	68026	0	11	1.617030e-04	68026	0	0	0.000000e+00	4830	0	0	0.000000e+00	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32886	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5478	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3116	0	0	.	0	13	8.789840e-05	3	7.298910e-05	41102	0	0	0.000000e+00	912	0	0	0.000000e+00	15094	0	147898	0	0.000000e+00	3302	0	0	0.000000e+00	4950	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	10	1.543070e-04	64806	0	0	0.000000e+00	4798	0	0	10	7.420930e-05	0	0.000000e+00	32470	0	0	0.000000e+00	862	0	0	0.000000e+00	14836	0	134754	0	0.000000e+00	3388	0	0	0.000000e+00	5186	0	0	0.000000e+00	6966	0	0	0.000000e+00	310	0	10	1.564800e-04	63906	0	0	0.000000e+00	4828	0	0	10	1.239070e-04	3	1.209770e-04	24798	0	0	0.000000e+00	112	0	0	0.000000e+00	12908	0	80706	0	0.000000e+00	998	0	0	0.000000e+00	3744	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	7	3.327310e-04	21038	0	0	0.000000e+00	4802	0	0	12	101773217	12	103249087	0	0.43195	0.638212	1.000000	0.71638	0.977000	0.56843	0.998000	0.65909	5.253000	0.65268	0.665000	0.62972	1.138000	0.64695	102855309	T	.	rs77958223	.	.	7.651	9.354	7.292	9.092	.	.	.	49	23	23	-6	0.00	0.05	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+23+end+197	92746	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs77958223	4.942e-05	6	6	0	0	2	0	0	4	0	0	10378	11456	8600	6584	66508	904	16408	0	2	0	0	4	0	0	0	0	0	0	0	0	0	rs77958223	0.00000e+00	5.96019e-05	0.00000e+00	0.00000e+00	0.00000e+00	1.25561e-04	0.00000e+00	0.00000e+00	5.93683e-05	7.19205e-05	1.25561e-04	6.49688e-05	rs77958223	1.14548e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.33422e-04	0.00000e+00	.	1.16918e-04	2.88725e-04	3.33422e-04	1.93598e-04	.	.	rs77958223	77958223	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,771	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103249061	103249061	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.559T>C	NP_000268.1:p.Trp187Arg	673	559	187	W/R	Tgg/Cgg	rs62507272&CD011180&CM950886	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103249061A>G	.	.	.	.	.	.	likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.559T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96978	0.578805	D	0.96928	0.593637	29.3	25.3	4.267698	3.576450	0.87426	0.69073	A/A	D	0.99874	0.999950408935547	0.68206	0.99504044113768142	.	0.99995	.	A/A	.	.	.	.	10.38428	0.808633557897322	0.90386	12.52148	0.953577009716365	0.94126	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99942	.	.	.	5.73	5.73	0.89730	0	0.26702	0.573888	.	.	0.74766	0.999996727770682	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.97401	.	0.000000	0.84330	D	0.000000	D	0.97801	0.727237	0.31654	.	0.99688	.	D	0.99955	0.9983	.	0.99999	.	D	0.95881	0.9146	W187R	Gain_of_disorder_(P_=_0.0058)&_Gain_of_ubiquitination_at_K184_(P_=_0.0539)&_Gain_of_methylation_at_K192_(P_=_0.0604)&_Gain_of_phosphorylation_at_T189_(P_=_0.0613)&_Gain_of_MoRF_binding_(P_=_0.1103)	P00439	0.99828	0.982	.	0.99705	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.99962	.	.	.	0.90584	.	.	0.97372	.	T	0.72563	0.737217187881	0.97890	.	10	0.92824	.	.	0.91255	.	.	16.0172	0.80250	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99337	.	A/A	R	.	W	G	532	0.73501	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102855283A>G	102735	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.W187R	.	.	AEFBI	D	0.92187	0.99165	D	0.99582	0.974824	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.573070e-06	1	2.413590e-05	41432	0	0	0.000000e+00	912	0	0	0.000000e+00	15278	0	152136	0	0.000000e+00	3470	0	0	0.000000e+00	5190	0	0	0.000000e+00	10610	0	0	0.000000e+00	316	0	0	0.000000e+00	68018	0	1	2.413590e-05	41432	0	0	0.000000e+00	4818	0	0	0.000000e+00	0	0.000000e+00	9094	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32884	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5480	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3112	0	0	.	0	1	6.762150e-06	1	2.432380e-05	41112	0	0	0.000000e+00	912	0	0	0.000000e+00	15090	0	147882	0	0.000000e+00	3302	0	0	0.000000e+00	4954	0	0	0.000000e+00	10610	0	0	0.000000e+00	304	0	0	0.000000e+00	64790	0	0	0.000000e+00	4786	0	0	0	0.000000e+00	0	0.000000e+00	32476	0	0	0.000000e+00	862	0	0	0.000000e+00	14832	0	134742	0	0.000000e+00	3386	0	0	0.000000e+00	5190	0	0	0.000000e+00	6970	0	0	0.000000e+00	310	0	0	0.000000e+00	63898	0	0	0.000000e+00	4816	0	0	1	1.239100e-05	1	4.030630e-05	24810	0	0	0.000000e+00	112	0	0	0.000000e+00	12904	0	80704	0	0.000000e+00	996	0	0	0.000000e+00	3748	0	0	0.000000e+00	10518	0	0	0.000000e+00	272	0	0	0.000000e+00	21036	0	0	0.000000e+00	4790	0	0	12	101773191	12	103249061	0	0.43195	0.638212	1.000000	0.71638	0.280000	0.24017	0.104000	0.19553	9.325000	0.96006	0.756000	0.94297	1.312000	0.94714	102855283	A	.	rs62507272	.	.	7.651	9.354	7.292	9.092	.	.	.	49	42	-31	2	0.01	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+49+end+197	102735	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62507272	62507272	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,768	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103271296	103271296	C	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	4/13	.	NM_000277.3:c.385G>T	NP_000268.1:p.Asp129Tyr	499	385	129	D/Y	Gac/Tac	rs199475606&CM010952	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103271296C>A	.	.	.	.	.	.	pathogenic&likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.385G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.96364	0.566568	D	0.96305	0.576059	32	29.9	4.468877	4.265228	0.90945	0.89500	C/C	D	0.99418	0.99986732006073	0.64921	0.99443617488733815	.	0.99993	.	C/C	.	.	.	.	11.21118	0.834099863215886	0.92055	12.04323	0.93683002023685	0.93443	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99845	.	.	.	5.86	4.97	0.65419	0	0.14657	0.547309	.	.	0.41644	0.999670536736234	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.94195	.	0.087840	0.84330	D	0.000000	D	0.98558	0.814885	0.28330	.	0.99202	.	D	0.99882	0.9948	.	0.99921	.	D	0.95875	0.9142	D129Y	Gain_of_MoRF_binding_(P_=_0.0999)&_Gain_of_helix_(P_=_0.2294)&_Loss_of_phosphorylation_at_T124_(P_=_0.2407)&_Loss_of_solvent_accessibility_(P_=_0.2517)&_Loss_of_relative_solvent_accessibility_(P_=_0.3219)	P00439	0.99803	0.979	.	0.98464	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.97995	.	.	.	0.90584	.	.	0.92359	.	D	0.84727	0.818033158779	0.99969	.	10	0.92824	.	.	0.91255	.	.	14.717	0.68892	0.0:0.9306:0.0:0.0694	.	.	.	.	.	.	.	.	0.99863	.	C/C	Y	.	D	A	675	0.60470	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic/Likely_pathogenic	NC_000012.12:g.102877518C>A	102660	criteria_provided&_multiple_submitters&_no_conflicts	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.D129Y&UniProtKB_(protein):P00439#VAR_000894	.	.	AEFBI	D	0.77635	0.97855	D	0.99610	0.975286	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101795426	12	103271296	0	0.37627	0.615465	1.000000	0.71638	0.992000	0.67800	1.000000	0.86279	7.279000	0.77969	0.599000	0.40250	1.026000	0.45946	102877518	C	.	rs199475606	.	.	8.810	7.211	11.038	10.766	.	.	.	-5	32	32	-25	0.00	0.12	0.00	0.00	PAH	0.00	exon-NM_001354304.2-5+32+end+89	102660	Pathogenic/Likely_pathogenic	criteria_provided&_multiple_submitters&_no_conflicts	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475606	199475606	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,801	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103288623	103288623	G	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.242C>A	NP_000268.1:p.Thr81Asn	356	242	81	T/N	aCc/aAc	rs796064502&CM142218	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103288623G>T	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.242C>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.79527	0.259977	D	0.79263	0.135662	24.0	24.5	3.241440	3.343440	0.57587	0.63124	G/G	D	0.65703	0.96006453037262	0.51028	0.99040761937390276	.	0.98329	.	G/G	.	.	.	.	5.602597	0.545616622753351	0.71093	4.733554	0.45915868025201	0.64725	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98352	.	.	.	6.17	5.28	0.74118	0	0.51514	0.610034	.	.	0.74766	0.999999974683207	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.61165	.	0.046984	0.84330	D	0.000000	D	0.97424	0.687728	0.10434	.	0.98852	.	D	0.96162	0.8844	.	0.81133	.	D	0.94259	0.7877	T81N	Gain_of_catalytic_residue_at_T81_(P_=_0.0135)&_Loss_of_sheet_(P_=_0.0817)&_Gain_of_ubiquitination_at_K85_(P_=_0.1111)&_Loss_of_stability_(P_=_0.1322)&_Loss_of_phosphorylation_at_T81_(P_=_0.1525)	P00439	0.68217	0.562	.	0.50365	.	.	0.42255	simple_aae&simple_aae	D&D	0.994369&0.994369	0.55983	.	.	.	0.37206	.	.	0.42107	.	T	0.35390	0.475144922733	0.95581	.	10	0.79402	.	.	0.91255	.	.	5.9915	0.18700	0.241:0.0:0.759:0.0	.	.	.	.	.	.	.	.	0.85343	.	G/G	N	.	T	T	716	0.55970	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102894845G>T	208180	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.61102	0.94418	D	0.89982	0.923395	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101812753	12	103288623	0	0.37627	0.615465	1.000000	0.71638	0.713000	0.34548	0.941000	0.40850	5.354000	0.65806	0.676000	0.76740	1.176000	0.78918	102894845	G	.	rs796064502	.	.	11.038	10.766	11.785	7.700	.	.	.	22	-19	20	15	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+73+end+184	208180	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs796064502	796064502	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,813	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103288554	103288554	G	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.311C>A	NP_000268.1:p.Ala104Asp	425	311	104	A/D	gCc/gAc	rs62642929&CM920543	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103288554G>T	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.311C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.83723	0.309679	D	0.92265	0.404699	18.97	20.3	1.962948	2.062838	0.29870	0.34237	G/G	T	0.16216	0.139321222901344	0.49170	0.98952543049107877	.	0.74755	.	G/G	.	.	.	.	2.40242	0.0124910230500298	0.40293	1.893455	-0.193961422939161	0.33384	.	.	.	4	3.295e-05	0	0	0	0	4	3.295e-05	0	0	0	0	4	5.994e-05	0	0	3	2.825e-05	0	0	0	0	3	2.825e-05	0	0	0	0	3	5.520e-05	0	0	4	4.408e-05	0	0	0	0	4	4.408e-05	0	0	0	0	4	9.492e-05	0	0	0.98229	.	.	.	6.17	5.29	0.74430	0	0.45803	0.59043	.	.	0.51787	0.999987928910562	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.70803	.	0.098719	0.62929	D	0.000002	D	0.86681	0.199943	0.04164	.	0.96520	.	D	0.94753	0.8429	.	0.53792	.	D	0.92345	0.6344	.	.	.	.	.	.	0.34509	.	.	0.48980	simple_aae&simple_aae	D&D	0.999774&0.999774	0.31375	.	.	.	0.09854	.	.	0.06944	.	T	0.40960	0.515269100666	0.84666	.	10	0.18395	.	.	0.40832	.	.	13.5379	0.61116	0.1288:0.0:0.8712:0.0	.	.	.	.	.	.	.	.	0.92200	.	G/G	D	.	A	T	717	0.55835	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102894776G>T	102650	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.A104D&UniProtKB_(protein):P00439#VAR_000892&Illumina_Laboratory_Services&Illumina:712688	.	.	AEFBI	D	0.51576	0.90417	D	0.70142	0.764703	.	13	5.170100e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34592	0	251446	0	0.000000e+00	10078	0	0	0.000000e+00	18394	0	3	1.385810e-04	21648	0	10	8.793220e-05	113724	0	10	8.793220e-05	113724	0	0	0.000000e+00	30616	0	4	3.656040e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	4	9.352790e-05	42768	0	4	9.352790e-05	42768	0	0	0.000000e+00	15690	0	0	.	0	12	5.065260e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236908	0	0.000000e+00	9570	0	0	0.000000e+00	17692	0	3	1.386830e-04	21632	0	9	8.762710e-05	102708	0	9	8.762710e-05	102708	0	0	0.000000e+00	30526	0	0	12	5.765740e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208126	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	3	1.792760e-04	16734	0	9	1.005030e-04	89550	0	9	1.005030e-04	89550	0	0	0.000000e+00	30608	0	0	13	5.309850e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244828	0	0.000000e+00	9996	0	0	0.000000e+00	18390	0	3	1.385940e-04	21646	0	10	8.957840e-05	111634	0	10	8.957840e-05	111634	0	0	0.000000e+00	30616	0	0	4	2.629430e-05	0	0.000000e+00	41422	0	0	0.000000e+00	912	0	0	0.000000e+00	15280	0	152124	0	0.000000e+00	3468	0	0	0.000000e+00	5200	0	0	0.000000e+00	10594	0	0	0.000000e+00	316	0	4	5.879590e-05	68032	0	4	5.879590e-05	68032	0	0	0.000000e+00	4808	0	0	0.000000e+00	0	0.000000e+00	9088	0	0	0.000000e+00	60	0	0	0.000000e+00	4684	0	32862	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5478	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3100	0	0	.	0	3	2.028700e-05	0	0.000000e+00	41100	0	0	0.000000e+00	912	0	0	0.000000e+00	15092	0	147878	0	0.000000e+00	3302	0	0	0.000000e+00	4966	0	0	0.000000e+00	10594	0	0	0.000000e+00	304	0	3	4.628920e-05	64810	0	0	0.000000e+00	4776	0	0	2	1.484470e-05	0	0.000000e+00	32462	0	0	0.000000e+00	862	0	0	0.000000e+00	14834	0	134728	0	0.000000e+00	3384	0	0	0.000000e+00	5200	0	0	0.000000e+00	6962	0	0	0.000000e+00	310	0	2	3.129600e-05	63906	0	0	0.000000e+00	4806	0	0	3	3.718210e-05	0	0.000000e+00	24796	0	0	0.000000e+00	112	0	0	0.000000e+00	12906	0	80684	0	0.000000e+00	994	0	0	0.000000e+00	3758	0	0	0.000000e+00	10502	0	0	0.000000e+00	272	0	3	1.425450e-04	21046	0	0	0.000000e+00	4780	0	0	12	101812684	12	103288554	0	0.37627	0.615465	1.000000	0.71638	0.945000	0.48827	0.995000	0.57719	2.770000	0.47346	0.676000	0.76740	1.176000	0.78918	102894776	G	.	rs62642929	.	.	11.038	10.766	11.785	7.700	.	.	.	22	50	-41	-45	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+41+start+184	102650	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62642929	3.295e-05	4	4	0	0	0	0	0	4	0	0	10404	11578	8654	6614	66738	908	16512	0	0	0	0	4	0	0	0	0	0	0	0	0	0	rs62642929	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.96861e-05	8.95528e-05	1.82349e-04	0.00000e+00	5.93190e-05	4.49035e-05	8.96861e-05	5.27872e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62642929	62642929	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,809	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103288572	103288572	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.293T>C	NP_000268.1:p.Leu98Ser	407	293	98	L/S	tTg/tCg	rs62517167&CM930537	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103288572A>G	.	.	.	.	.	.	uncertain_significance&pathogenic&not_provided	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.293T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.89241	0.388584	D	0.96541	0.580076	24.3	25.0	3.365656	3.506736	0.60666	0.67292	A/A	D	0.55643	0.903269588947296	0.94726	0.99869568932191943	.	0.89624	.	A/A	.	.	.	.	12.08543	0.858489204488795	0.93503	10.772	0.889093340185846	0.91216	.	.	.	1	8.236e-06	0	0	0	0	1	8.237e-06	0	0	0	0	0	0	1	6.056e-05	1	9.415e-06	0	0	0	0	1	9.415e-06	0	0	0	0	0	0	1	6.095e-05	1	1.102e-05	0	0	0	0	1	1.102e-05	0	0	0	0	0	0	1	6.060e-05	0.99551	.	.	.	6.17	6.17	0.99707	0	0.51514	0.610034	.	.	0.74766	0.999999999994017	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.54988	.	0.000000	0.84330	D	0.000000	D	0.97048	0.651118	0.27304	.	0.99385	.	D	0.99623	0.9872	.	0.97839	.	D	0.99311	1.0918	L98S	Loss_of_stability_(P_=_0.0088)&_Gain_of_sheet_(P_=_0.0166)&_Loss_of_helix_(P_=_0.0167)&_Gain_of_loop_(P_=_0.0195)&_Gain_of_relative_solvent_accessibility_(P_=_0.0479)	P00439	0.97320	0.89	.	0.94896	.	.	0.81001	simple_aae&simple_aae	A&A	1&1	0.50830	.	.	.	0.73220	.	.	0.67658	.	T	0.64986	0.684994399548	0.95212	.	10	0.53426	.	.	0.91255	.	.	16.8222	0.85699	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.95841	.	A/A	S	.	L	G	717	0.55835	.	12	C0031485&C2678416&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102894794A>G	627	reviewed_by_expert_panel	Phenylketonuria&Mild_non-PKU_hyperphenylalanemia&not_provided	UniProtKB_(protein):P00439#VAR_000891&OMIM_Allelic_Variant:612349.0053&DeBelle_Laboratory_for_Biochemical_Genetics:p.L98S	.	.	AEFBI	D	0.85820	0.98706	D	0.99465	0.973002	.	4	1.590790e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34592	0	251448	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21644	0	0	0.000000e+00	113728	0	4	1.306510e-04	30616	0	4	1.306510e-04	30616	0	3	2.742030e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	3	1.912050e-04	15690	0	3	1.912050e-04	15690	0	0	.	0	4	1.688400e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236910	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21628	0	0	0.000000e+00	102712	0	4	1.310360e-04	30526	0	4	1.310360e-04	30526	0	0	4	1.921930e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208124	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89548	0	4	1.306850e-04	30608	0	4	1.306850e-04	30608	0	0	4	1.633790e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244830	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21642	0	0	0.000000e+00	111638	0	4	1.306510e-04	30616	0	4	1.306510e-04	30616	0	0	1	6.571680e-06	0	0.000000e+00	41436	0	0	0.000000e+00	912	0	0	0.000000e+00	15276	0	152168	0	0.000000e+00	3472	0	0	0.000000e+00	5200	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	0	0.000000e+00	68034	0	1	2.073830e-04	4822	0	1	2.073830e-04	4822	0	0	0.000000e+00	0	0.000000e+00	9092	0	0	0.000000e+00	60	0	0	0.000000e+00	4682	0	32880	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5482	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3112	0	0	.	0	1	6.760590e-06	0	0.000000e+00	41114	0	0	0.000000e+00	912	0	0	0.000000e+00	15088	0	147916	0	0.000000e+00	3302	0	0	0.000000e+00	4968	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	0	0.000000e+00	64808	0	1	2.087680e-04	4790	0	0	1	7.421150e-06	0	0.000000e+00	32462	0	0	0.000000e+00	862	0	0	0.000000e+00	14830	0	134750	0	0.000000e+00	3388	0	0	0.000000e+00	5200	0	0	0.000000e+00	6968	0	0	0.000000e+00	310	0	0	0.000000e+00	63908	0	1	2.074690e-04	4820	0	0	1	1.238790e-05	0	0.000000e+00	24810	0	0	0.000000e+00	112	0	0	0.000000e+00	12902	0	80724	0	0.000000e+00	998	0	0	0.000000e+00	3758	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	0	0.000000e+00	21044	0	1	2.085940e-04	4794	0	0	12	101812702	12	103288572	0	0.37627	0.615465	1.000000	0.71638	0.791000	0.37352	0.924000	0.39322	8.297000	0.89867	0.756000	0.94297	1.312000	0.94714	102894794	A	.	rs62517167	.	.	11.038	10.766	11.785	7.700	.	.	.	32	-32	5	-3	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+59+start+184	627	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Mild_non-PKU_hyperphenylalanemia&Phenylketonuria	MedGen:CN517202&MedGen:C2678416&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62517167	8.236e-06	1	1	0	0	0	0	0	0	0	1	10406	11578	8654	6614	66738	908	16512	0	0	0	0	0	0	1	0	0	0	0	0	0	0	rs62517167	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.62433e-04	2.96573e-05	8.98150e-06	1.62433e-04	2.03028e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62517167	62517167	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,811	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103249052	103249052	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.568G>A	NP_000268.1:p.Val190Met	682	568	190	V/M	Gtg/Atg	rs281865441	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103249052C>T	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	PAH&NM_000277.1&c.568G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.91415	0.427687	D	0.91308	0.376566	24.1	23.3	3.288292	2.902876	0.58741	0.52540	C/C	D	0.73384	0.980485558509827	0.91714	0.99836519634740362	.	0.99967	.	C/C	.	.	.	.	4.980395	0.479829424708282	0.66656	6.031488	0.610453423902714	0.73834	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99684	.	.	.	5.73	4.82	0.61641	0	0.26702	0.573888	.	.	0.39577	0.999413015438178	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.93484	.	0.053759	0.84330	D	0.000001	D	0.95911	0.554841	0.20674	.	0.98804	.	D	0.99759	0.9908	.	0.94933	.	D	0.96685	0.9690	V190M	Gain_of_catalytic_residue_at_V190_(P_=_0.0186)&_Gain_of_disorder_(P_=_0.0802)&_Gain_of_MoRF_binding_(P_=_0.0985)&_Loss_of_methylation_at_K185_(P_=_0.1261)&_Gain_of_ubiquitination_at_K185_(P_=_0.1418)	P00439	0.89129	0.763	.	0.81115	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.54702	.	.	.	0.64738	.	.	0.59331	.	T	0.65501	0.688569307327	0.94840	.	10	0.69154	.	.	0.52492	.	.	16.5411	0.84233	0.0:0.8692:0.1308:0.0	.	.	.	.	.	.	.	.	0.76481	.	C/C	M	.	V	T	532	0.73501	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102855274C>T	120279	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.76584	0.97711	D	0.94849	0.943092	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101773182	12	103249052	0	0.43195	0.638212	1.000000	0.71638	0.170000	0.20979	0.413000	0.25885	6.170000	0.71810	0.599000	0.40250	1.026000	0.45946	102855274	C	.	rs281865441	.	.	7.651	9.354	7.292	9.092	.	.	.	-9	-1	-15	-22	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+58+end+197	120279	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865441	281865441	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,766	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103306573	103306573	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	2/13	.	NM_000277.3:c.164T>C	NP_000268.1:p.Phe55Ser	278	164	55	F/S	tTt/tCt	rs281865438&CM1514921	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103306573A>G	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.164T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96287	0.562477	D	0.96228	0.570183	26.9	27.1	3.990878	3.933432	0.78291	0.79943	A/A	D	0.95630	0.998932898044586	0.95970	0.99884399568826332	.	0.99952	.	A/A	.	.	.	.	11.23023	0.834661524556062	0.92089	12.42109	0.950101149733884	0.93990	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99473	.	.	.	5.46	5.46	0.80021	0	0.26702	0.573888	.	.	0.74766	0.999999961848894	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.84033	.	0.000000	0.84330	D	0.000000	D	0.98442	0.800934	0.31443	.	0.96961	.	D	0.99724	0.9899	.	0.97855	.	D	0.96866	0.9804	F55S	Gain_of_disorder_(P_=_0.0067)&_Gain_of_phosphorylation_at_F55_(P_=_0.0422)&_Loss_of_stability_(P_=_0.0697)&_Gain_of_ubiquitination_at_K50_(P_=_0.0728)&_Gain_of_methylation_at_K50_(P_=_0.2922)	P00439	0.93785	0.827	.	0.99205	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.96218	.	.	.	0.90584	.	.	0.86255	.	T	0.50519	0.583087325096	0.99376	.	10	0.92824	.	.	0.91255	.	.	13.0732	0.58486	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.97750	.	A/A	S	.	F	G	768	0.49510	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102912795A>G	120266	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.63006	0.94981	D	0.85189	0.903149	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101830703	12	103306573	0	0.43195	0.638212	1.000000	0.71638	0.965000	0.52897	1.000000	0.86279	5.968000	0.70121	0.756000	0.94297	1.312000	0.94714	102912795	A	.	rs281865438	.	.	11.785	7.700	8.002	9.602	.	.	.	-4	14	-1	-4	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-3+4+start+108	120266	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865438	281865438	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,833	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103306594	103306594	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	2/13	.	NM_000277.3:c.143T>C	NP_000268.1:p.Leu48Ser	257	143	48	L/S	tTg/tCg	rs5030841&CM910281	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103306594A>G	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.143T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.86588	0.351208	D	0.96002	0.564269	26.9	25.7	3.993120	3.687354	0.78367	0.72108	A/A	D	0.78722	0.988387644290924	0.96049	0.99885000875272945	.	0.99963	.	A/A	0	0.0	1	1.1627906976744187E-4	11.23145	0.834697920067128	0.92092	12.61568	0.9568228711878	0.94252	.	.	.	10	8.237e-05	0	0	0	0	10	8.238e-05	0	0	0	0	10	1.499e-04	0	0	8	7.532e-05	0	0	0	0	8	7.533e-05	0	0	0	0	8	1.472e-04	0	0	6	6.612e-05	0	0	0	0	6	6.613e-05	0	0	0	0	6	1.424e-04	0	0	0.99760	.	.	.	5.46	5.46	0.80021	0	0.26702	0.573888	.	.	0.74766	0.999999961214906	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.78595	.	0.000000	0.62929	D	0.000001	D	0.98622	0.822707	0.29362	.	0.99620	.	D	0.99875	0.9945	.	0.94304	.	D	0.96050	0.9264	.	.	.	.	.	.	0.98503	.	.	0.81001	simple_aae&simple_aae	A&A	1&1	0.89029	.	.	.	0.90584	.	.	0.97372	.	T	0.53500	0.604221940041	0.99647	.	10	0.92824	.	.	0.91255	.	.	13.057	0.58397	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99973	.	A/A	S	.	L	G	768	0.49510	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102912816A>G	608	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_000877&DeBelle_Laboratory_for_Biochemical_Genetics:p.L48S&HGMD:CM910281&OMIM_Allelic_Variant:612349.0034	.	.	AEFBI	D	0.56763	0.92876	D	0.81161	0.883019	.	29	1.153470e-04	0	0.000000e+00	16256	0	9	2.601760e-04	34592	0	251416	0	0.000000e+00	10078	0	0	0.000000e+00	18394	0	0	0.000000e+00	21642	0	18	1.583000e-04	113708	0	9	2.601760e-04	34592	0	0	0.000000e+00	30610	0	9	8.226540e-05	0	0.000000e+00	7164	0	2	1.168770e-04	17112	0	109402	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13388	0	7	1.636740e-04	42768	0	7	1.636740e-04	42768	0	0	0.000000e+00	15690	0	0	.	0	28	1.182040e-04	0	0.000000e+00	14902	0	9	2.626970e-04	34260	0	236878	0	0.000000e+00	9570	0	0	0.000000e+00	17692	0	0	0.000000e+00	21626	0	17	1.655440e-04	102692	0	9	2.626970e-04	34260	0	0	0.000000e+00	30520	0	0	15	7.207800e-05	0	0.000000e+00	16218	0	2	6.552220e-05	30524	0	208108	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16728	0	13	1.451800e-04	89544	0	13	1.451800e-04	89544	0	0	0.000000e+00	30602	0	0	29	1.184650e-04	0	0.000000e+00	12026	0	9	2.611880e-04	34458	0	244798	0	0.000000e+00	9996	0	0	0.000000e+00	18390	0	0	0.000000e+00	21640	0	18	1.612640e-04	111618	0	9	2.611880e-04	34458	0	0	0.000000e+00	30610	0	0	30	1.970470e-04	2	4.822760e-05	41470	0	0	0.000000e+00	912	0	15	9.815470e-04	15282	0	152248	0	0.000000e+00	3468	0	0	0.000000e+00	5204	0	0	0.000000e+00	10630	0	0	0.000000e+00	316	0	13	1.910640e-04	68040	0	15	9.815470e-04	15282	0	0	0.000000e+00	4834	0	2	6.074230e-05	1	1.098180e-04	9106	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32926	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5500	0	0	0.000000e+00	246	0	1	1.459430e-04	6852	0	0	0.000000e+00	3116	0	0	.	0	29	1.959540e-04	2	4.860500e-05	41148	0	0	0.000000e+00	912	0	15	9.937720e-04	15094	0	147994	0	0.000000e+00	3302	0	0	0.000000e+00	4968	0	0	0.000000e+00	10630	0	0	0.000000e+00	304	0	12	1.851510e-04	64812	0	0	0.000000e+00	4802	0	0	29	2.150790e-04	2	6.153850e-05	32500	0	0	0.000000e+00	862	0	14	9.436510e-04	14836	0	134834	0	0.000000e+00	3384	0	0	0.000000e+00	5204	0	0	0.000000e+00	6988	0	0	0.000000e+00	310	0	13	2.033920e-04	63916	0	0	0.000000e+00	4832	0	0	18	2.227500e-04	1	4.025120e-05	24844	0	0	0.000000e+00	112	0	15	1.162070e-03	12908	0	80808	0	0.000000e+00	994	0	0	0.000000e+00	3762	0	0	0.000000e+00	10538	0	0	0.000000e+00	272	0	2	9.499380e-05	21054	0	0	0.000000e+00	4806	0	0	12	101830724	12	103306594	0	0.43195	0.638212	0.998000	0.41325	0.988000	0.63387	0.990000	0.52443	5.968000	0.70121	0.756000	0.94297	1.312000	0.94714	102912816	A	.	rs5030841	.	.	11.785	7.700	8.002	9.602	.	.	.	12	-25	-25	11	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-3+25+start+108	608	Pathogenic	reviewed_by_expert_panel	not_provided&Inborn_genetic_diseases&Phenylketonuria	MedGen:CN517202&MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030841	8.237e-05	10	10	0	0	0	0	0	10	0	0	10404	11578	8654	6612	66732	908	16508	0	0	0	0	10	0	0	0	0	0	0	0	0	0	rs5030841	0.00000e+00	2.68017e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.61233e-04	3.64697e-04	0.00000e+00	1.55742e-04	7.18559e-05	2.68017e-04	1.17757e-04	rs5030841	1.14469e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.66596e-04	0.00000e+00	.	1.75316e-04	1.44279e-04	2.66596e-04	1.61332e-04	rs5030841	0.0116&0.0&0.0077	rs5030841	5030841	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,836	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103306627	103306627	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	2/13	.	NM_000277.3:c.110T>C	NP_000268.1:p.Leu37Pro	224	110	37	L/P	cTg/cCg	rs869312996&CM1314660&COSV100187727	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103306627A>G	.	.	.	.	.	.	likely_pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.110T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96250	0.560653	D	0.96190	0.567563	28.3	26.0	4.161218	3.748272	0.84187	0.73866	A/A	D	0.94028	0.998395383358002	0.97426	0.99902444019543457	.	0.99862	.	A/A	.	.	.	.	9.037734	0.759880970736485	0.86892	10.00064	0.857087556160069	0.89507	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99468	.	.	.	5.46	5.46	0.80021	0	0.26702	0.573888	.	.	0.74766	0.999999961214906	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.71216	.	0.135499	0.50451	D	0.000109	D	0.98978	0.866623	0.30540	.	0.96511	.	D	0.99613	0.9869	.	0.97108	.	D	0.97543	1.0205	L37P	Loss_of_stability_(P_=_0.0158)&_Gain_of_catalytic_residue_at_L37_(P_=_0.0331)&_Loss_of_sheet_(P_=_0.0817)&_Gain_of_ubiquitination_at_K42_(P_=_0.1215)&_Gain_of_loop_(P_=_0.2045)	P00439	0.92923	0.814	.	0.96539	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.82575	.	.	.	0.90584	.	.	0.80445	.	T	0.62887	0.67033970356	0.99904	.	10	0.83351	.	.	0.91255	.	.	13.057	0.58397	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99822	.	A/A	P	.	L	G	768	0.49510	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102912849A>G	225133	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.57175	0.93040	D	0.95941	0.948120	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101830757	12	103306627	0	0.43195	0.638212	1.000000	0.71638	0.996000	0.76049	0.998000	0.65909	5.968000	0.70121	0.756000	0.94297	1.312000	0.94714	102912849	A	.	rs869312996	.	.	11.785	7.700	8.002	9.602	.	.	.	49	-21	-40	49	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-3+49+end+108	225133	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs869312996	869312996	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,842	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	112926910	112926910	G	C	C	missense_variant	MODERATE	PTPN11	5781	Transcript	NM_002834.5	protein_coding	13/16	.	NM_002834.5:c.1530G>C	NP_002825.3:p.Gln510His	1695	1530	510	Q/H	caG/caC	rs397507550&CM117756&COSV61005626&COSV61006865	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTPN11	.	chr12:g.112926910G>C	.	.	.	.	.	.	pathogenic&pathogenic/likely_pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	PTPN11&NM_002834.3&c.1530G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.96057	0.55794	D	0.95994	0.563665	24.9	24.5	3.567191	3.356417	0.65836	0.63453	./.	D	0.91055	0.997229397296906	0.81005	0.99706337742151863	.	0.99010	.	./.	.	.	.	.	4.947122	0.475948569908924	0.66399	5.979343	0.605449951768662	0.73520	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99672	.	.	.	5.13	2.29	0.27658	0	0.89359	0.724815	.	.	0.16025	0.0870890854109086	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.98432	0.735409	.&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&Tyrosine_specific_protein_phosphatases_domain&PTP_type_protein_phosphatase&Protein-tyrosine_phosphatase&_catalytic&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&Tyrosine_specific_protein_phosphatases_domain&PTP_type_protein_phosphatase&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.91380	.	0.000000	0.84330	D	0.000000	D	0.97995	0.748792	0.92161	.	0.99745	.	D	0.99670	0.9885	.	0.98798	.	D	0.98977	1.0829	Q510H	Loss_of_MoRF_binding_(P_=_0.1112)&_Gain_of_disorder_(P_=_0.201)&_Loss_of_stability_(P_=_0.2171)&_Gain_of_helix_(P_=_0.2294)&_Gain_of_phosphorylation_at_Y511_(P_=_0.2319)	ENST00000351677	0.99019	0.934	.	0.92553	.	.	0.81001	simple_aae	D	1	0.77554	.	.	.	0.90584	.	.	0.88582	.	D	0.87183	0.834049701691	0.98708	.	10	0.83351	.	.	0.91255	.	.	9.2895	0.36938	0.2656:0.0:0.7344:0.0	.	.	.	.	.	.	.	.	0.99611	.	./.	H	.	Q	C	34	0.98095	.	12	CN166718&CN517202	.	ORPHA536391	Pathogenic	NC_000012.12:g.112489106G>C	40567	reviewed_by_expert_panel	Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:c1682ae1-ce46-41b9-b916-5efef827298a&HGMD:CM117756	.	.	AEFBI	D	0.70156	0.96639	D	0.60353	0.617298	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	111411293	12	112926910	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	3.711000	0.54596	0.676000	0.76740	1.176000	0.78918	112489106	G	.	rs397507550	.	.	7.386	7.879	9.697	8.230	.	.	.	28	-44	-2	-1	0.00	0.00	0.00	0.00	PTPN11	1.00	exon-NM_001330437.2-13+69+end+152	40567	Pathogenic	reviewed_by_expert_panel	Cardiovascular_phenotype&not_provided&Noonan_syndrome_1&Juvenile_myelomonocytic_leukemia&Metachondromatosis&LEOPARD_syndrome_1&RASopathy	MedGen:CN230736&MedGen:CN517202&MONDO:MONDO:0008104&MedGen:C4551602&OMIM:163950&Orphanet:648&Human_Phenotype_Ontology:HP:0012209&MONDO:MONDO:0011908&MedGen:C0349639&OMIM:607785&Orphanet:86834&MONDO:MONDO:0007979&MedGen:C0410530&OMIM:156250&Orphanet:2499&MONDO:MONDO:0100082&MedGen:C4551484&OMIM:151100&Orphanet:500&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397507550	397507550	.	.	.	PTPN11	PTPN11:exonic	PTPN11:missense	PTPN11:Noonan_syndrome_1\x3bLEOPARD_syndrome_1\x3bMetachondromatosis\x3bLeukemia\x2cjuvenile_myelomonocytic\x2csomatic	PTPN11:163950\x3b151100\x3b156250\x3b607785	PTPN11:3\x3b3\x3b3\x3b3	PTPN11:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999877230878678	0.000122769057470549	6.38519788034449e-11	DISEASE: LEOPARD syndrome 1 (LPRD1) [MIM:151100]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:12058348, ECO:0000269|PubMed:14961557, ECO:0000269|PubMed:15121796, ECO:0000269|PubMed:15389709, ECO:0000269|PubMed:15520399, ECO:0000269|PubMed:15690106, ECO:0000269|PubMed:16679933, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 1 (NS1) [MIM:163950]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints. {ECO:0000269|PubMed:11704759, ECO:0000269|PubMed:11992261, ECO:0000269|PubMed:12161469, ECO:0000269|PubMed:12325025, ECO:0000269|PubMed:12529711, ECO:0000269|PubMed:12634870, ECO:0000269|PubMed:12717436, ECO:0000269|PubMed:12739139, ECO:0000269|PubMed:12960218, ECO:0000269|PubMed:15384080, ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry. Mutations in PTPN11 account for more than 50% of the cases.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:12717436}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Metachondromatosis (MC) [MIM:156250]: A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest. {ECO:0000269|PubMed:20577567}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,860	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
19	4110574	4110574	G	T	T	missense_variant	MODERATE	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	3/11	.	NM_030662.4:c.383C>A	NP_109587.1:p.Pro128Gln	630	383	128	P/Q	cCg/cAg	rs267607230&CM071854&CM101871&COSV53567689&COSV53569132	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	MAP2K2	.	chr19:g.4110574G>T	.	.	.	.	.	.	pathogenic	0&0&0&1&1	1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.94618	0.510713	D	0.94539	0.495827	25.2	25.3	3.658684	3.582452	0.68242	0.69242	./.	D	0.91668	0.997480343648293	0.49442	0.98966972242457296	.	0.79239	.	./.	.	.	.	.	6.373083	0.611707437025894	0.75790	7.262479	0.710084266498522	0.80293	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.94388	.	.	.	5.3	5.3	0.74745	0	0.70079	0.698795	.	.	0.74766	0.999999999974026	.	0	0.80598	0.723109	.	.	.	.	.	.	0	0.83352	0.714379	Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain	.	.	.	0.84591	.	0.000000	0.84330	D	0.000000	D	0.97695	0.715879	0.81924	.	0.97443	.	D	0.96919	0.9071	.	0.99498	.	D	0.97572	1.0221	P128Q	Loss_of_catalytic_residue_at_N126_(P_=_0.0506)&_Loss_of_stability_(P_=_0.1273)&_Gain_of_solvent_accessibility_(P_=_0.28)&_Loss_of_loop_(P_=_0.2897)&_Loss_of_sheet_(P_=_0.302)	P36507	0.99502	0.955	.	0.60977	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.89985	.	.	.	0.90584	.	.	0.97372	.	D	0.98568	0.923346161842	0.98267	.	10	0.69154	.	.	0.78490	.	.	17.5089	0.87649	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.86941	.	./.	Q	.	P	T	934	0.15400	.	19	C3809007&C1275081&CN517202	615280&PS115150	ORPHA1340	Pathogenic	NC_000019.10:g.4110576G>T	8275	reviewed_by_expert_panel	Cardiofaciocutaneous_syndrome_4&Cardio-facio-cutaneous_syndrome&not_provided	UniProtKB_(protein):P36507#VAR_069782&ClinGen_RASopathy_Variant_Curation_Expert_Panel:307f4b6c-ef49-48bd-98e2-5cf382642800&OMIM_Allelic_Variant:601263.0004	.	.	AEFGBHCI	D	0.69666	0.96543	D	0.92180	0.932044	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19	4061574	19	4110574	0	0.85440	0.722319	1.000000	0.71638	0.085000	0.17524	0.428000	0.26121	9.865000	0.98453	0.672000	0.70159	1.172000	0.72986	4110576	G	.	rs267607230	.	.	11.063	10.126	12.786	9.597	.	.	.	-2	-34	0	-7	0.00	0.00	0.00	0.00	MAP2K2	0.86	exon-NM_030662.4-3+67+start+147	8275	Pathogenic	reviewed_by_expert_panel	not_provided&Cardio-facio-cutaneous_syndrome&Cardiofaciocutaneous_syndrome_4	MedGen:CN517202&MONDO:MONDO:0015280&MedGen:C1275081&OMIM:PS115150&Orphanet:1340&MONDO:MONDO:0014114&MedGen:C3809007&OMIM:615280&Orphanet:1340	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs267607230	267607230	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:missense	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,935	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
7	140501333	140501333	A	G	G	missense_variant	MODERATE	BRAF	673	Transcript	NM_001374258.1	protein_coding	6/20	.	NM_001374258.1:c.739T>C	NP_001361187.1:p.Phe247Leu	965	739	247	F/L	Ttt/Ctt	rs397516903	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	NDUFB2	.	chr7:g.140501333A>G	.	.	.	.	.	.	likely_pathogenic&pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.87190	0.359161	D	0.87024	0.278133	25.1	24.9	3.613535	3.470661	0.67044	0.66357	./.	D	0.83698	0.993047893047333	0.95491	0.99878698387577358	.	0.99305	.	./.	.	.	.	.	7.590719	0.691193547939381	0.81711	6.782707	0.674966369561795	0.77992	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.93587	.	.	.	5.43	5.43	0.79006	0	0.79440	0.708844	.	.	0.74766	0.999999316022839	.	0	0.39905	0.608884	.	.	.	.	.	.	0	0.67416	0.683762	Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain	.	.	.	0.50622	.	0.000000	0.84330	D	0.000000	D	0.91771	0.33177	0.83621	.	0.94923	.	D	0.94337	0.8311	.	0.89622	.	D	0.95101	0.8559	F247L	Loss_of_helix_(P_=_0.028)&_Gain_of_loop_(P_=_0.0435)&_Gain_of_relative_solvent_accessibility_(P_=_0.09)&_Gain_of_solvent_accessibility_(P_=_0.1319)&_Loss_of_MoRF_binding_(P_=_0.1971)	P15056	0.83212	0.695	.	0.91202	.	.	0.81001	simple_aae	D	1	0.74582	.	.	.	0.45366	.	.	0.45591	.	D	0.99815	0.953254520893	0.97286	.	10	0.65728	.	.	0.72154	.	.	15.4983	0.75406	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.76853	.	./.	L	.	F	G	794	0.45591	.	7	CN029449&C4551602&C3150970&C0028326&CN260604&CN166718&CN517202	115150&163950&613706&PS163950	ORPHA648&ORPHA98733&ORPHA536391	Pathogenic	NC_000007.14:g.140801533A>G	180784	reviewed_by_expert_panel	Cardiofaciocutaneous_syndrome_1&Noonan_syndrome_1&Noonan_syndrome_7&Noonan_syndrome&Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:9a18dc91-2016-4b25-ab42-a9f679412ae8	.	.	AEFBI	D	0.91358	0.99109	D	0.79287	0.871464	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7	140147802	7	140501333	0	0.46895	0.6512	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	9.270000	0.94909	0.751000	0.87719	1.307000	0.88494	140801533	A	.	rs397516903	.	.	9.582	8.819	11.030	2.507	.	.	.	27	-21	0	28	0.00	0.10	0.00	0.00	BRAF	1.00	exon-NM_001378474.1-6+27+end+149	180784	Pathogenic	reviewed_by_expert_panel	RASopathy&Noonan_syndrome&Cardiofaciocutaneous_syndrome_1&Noonan_syndrome_1&Noonan_syndrome_and_Noonan-related_syndrome&not_provided&Noonan_syndrome_7	MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0018997&MeSH:D009634&MedGen:C0028326&OMIM:PS163950&Orphanet:648&MONDO:MONDO:0007265&MedGen:CN029449&OMIM:115150&Orphanet:1340&MONDO:MONDO:0008104&MedGen:C4551602&OMIM:163950&Orphanet:648&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN517202&MONDO:MONDO:0013379&MedGen:C3150970&OMIM:613706&Orphanet:648	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397516903	397516903	.	.	.	BRAF	BRAF:exonic	BRAF:missense	BRAF:Melanoma\x2cmalignant\x2csomatic\x3bLEOPARD_syndrome_3\x3bCardiofaciocutaneous_syndrome\x3bAdenocarcinoma_of_lung\x2csomatic\x3bNoonan_syndrome_7\x3bColorectal_cancer\x2csomatic\x3bNonsmall_cell_lung_cancer\x2csomatic	BRAF:155600\x3b613707\x3b115150\x3b211980\x3b613706\x3b114500\x3b211980	BRAF:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	BRAF:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant\x3b.\x3b.	0	0.999978196041997	2.18039579639691e-05	3.88216441101404e-14	DISEASE: Note=Defects in BRAF are found in a wide range of cancers. {ECO:0000269|PubMed:18974108}.; DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:23263490, ECO:0000269|PubMed:24455489}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation. {ECO:0000269|PubMed:18974108}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,495	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	25398304	25398304	T	A	A	missense_variant	MODERATE	KRAS	3845	Transcript	NM_004985.5	protein_coding	2/5	.	NM_004985.5:c.15A>T	NP_004976.2:p.Lys5Asn	205	15	5	K/N	aaA/aaT	rs104894361&CM070963&COSV56027504&COSV56100680	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	KRAS	.	chr12:g.25398304T>A	.	.	.	.	.	.	likely_pathogenic&uncertain_significance&pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.72079	0.180387	D	0.71716	0.0213364	24.6	27.0	3.477472	3.918841	0.63510	0.79455	./.	D	0.93375	0.998155415058136	0.93820	0.99859761066323194	.	0.95439	.	./.	.	.	.	.	5.797508	0.563747131663172	0.72359	6.077792	0.614844979912789	0.74111	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.85875	.	.	.	5.68	4.55	0.55429	0	0.81188	0.709663	.	.	0.74766	0.999997805199581	.	0	0.96076	0.743671	.	.	.	.	.	.	0	0.49550	0.631631	Small_GTP-binding_protein_domain&.&Small_GTP-binding_protein_domain&.	.	.	.	0.69252	.	0.000000	0.84330	D	0.000000	D	0.86664	0.199646	0.99114	.	0.98789	.	D	0.90622	0.7261	.	0.88888	.	D	0.93462	0.7231	K5N	Gain_of_catalytic_residue_at_E3_(P_=_8e-04)&_Loss_of_methylation_at_T5_(P_=_0.0037)&_Loss_of_ubiquitination_at_K5_(P_=_0.021)&_Gain_of_glycosylation_at_K2_(P_=_0.1048)&_Loss_of_disorder_(P_=_0.1189)	P01116	0.87733	0.746	.	0.84406	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae	A&A&A&A	0.999999&1&1&1	0.80682	.	.	.	0.90584	.	.	0.80445	.	D	0.96259	0.898385763168	0.92004	.	9	0.92824	.	.	0.91255	.	.	8.8972	0.34631	0.0:0.1185:0.0:0.8815	.	.	.	.	.	.	.	.	0.99410	.	./.	N	.	K	A	707	0.57054	.	12	C3809005&C0028326&C0950123&CN517202	615278&PS163950	ORPHA648	Pathogenic	NC_000012.12:g.25245370T>A	12594	reviewed_by_expert_panel	Cardiofaciocutaneous_syndrome_2&Noonan_syndrome&Inborn_genetic_diseases&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:15c2f120-e3bd-4bf0-8ecb-86290c93de7c&OMIM_Allelic_Variant:190070.0017&UniProtKB_(protein):P01116#VAR_064849&HGMD:CM070963	.	.	AEFBI	D	0.48408	0.88467	N	0.45718	0.371023	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	25289571	12	25398304	0	0.92422	0.732398	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	0.726000	0.25653	-0.137000	0.12594	0.193000	0.22078	25245370	T	.	rs104894361	.	.	11.388	8.395	4.988	9.402	.	.	.	-11	25	-11	26	0.19	0.01	0.00	0.00	KRAS	0.00	exon-NM_001369787.1-2+25+end+122	12594	Pathogenic	reviewed_by_expert_panel	not_provided&Inborn_genetic_diseases&Cardiofaciocutaneous_syndrome_2&Noonan_syndrome	MedGen:CN517202&MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0014112&MedGen:C3809005&OMIM:615278&Orphanet:1340&MONDO:MONDO:0018997&MeSH:D009634&MedGen:C0028326&OMIM:PS163950&Orphanet:648	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs104894361	104894361	.	.	.	KRAS	KRAS:exonic	KRAS:missense	KRAS:Gastric_cancer\x2csomatic\x3bOculoectodermal_syndrome\x2csomatic\x3bBreast_cancer\x2csomatic\x3bNoonan_syndrome_3\x3bRAS-associated_autoimmune_leukoproliferative_disorder\x3bArteriovenous_malformation_of_the_brain\x2csomatic\x3bLung_cancer\x2csomatic\x3bPancreatic_carcinoma\x2csomatic\x3bLeukemia\x2cacute_myeloid\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bCardiofaciocutaneous_syndrome_2\x3bBladder_cancer\x2csomatic	KRAS:613659\x3b600268\x3b114480\x3b609942\x3b614470\x3b108010\x3b211980\x3b260350\x3b601626\x3b163200\x3b615278\x3b109800	KRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	KRAS:.\x3b.\x3b.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3b.\x3b.\x3bAutosomal_dominant\x3b.	0	0.00106119304255182	0.603148256118395	0.395790550839053	DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes. {ECO:0000269|PubMed:8955068}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:17332249}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 3 (NS3) [MIM:609942]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:16474405, ECO:0000269|PubMed:16773572, ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:17468812, ECO:0000269|PubMed:19396835}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:7773929}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in KRAS are a cause of pylocytic astrocytoma (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. {ECO:0000269|PubMed:16247081}.; DISEASE: Cardiofaciocutaneous syndrome 2 (CFC2) [MIM:615278]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. CFC2 patients often do not have the skin abnormalities, such as ichthyosis, hyperkeratosis, and hemangioma observed in CFC1. {ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:16474405, ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:21797849}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=KRAS mutations are involved in cancer development. {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:1553789, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:3627975, ECO:0000269|PubMed:6092920, ECO:0000269|PubMed:6695174, ECO:0000269|PubMed:7773929}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,641	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103234255	103234255	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1238G>C	NP_000268.1:p.Arg413Pro	1352	1238	413	R/P	cGc/cCc	rs79931499&CM920563&COSV61015579	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103234255C>G	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1238G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.88929	0.383451	D	0.94259	0.482152	20.8	22.7	2.197146	2.563170	0.34647	0.45106	C/C	D	0.85705	0.994429647922516	0.42192	0.98498999730443326	.	0.99907	.	C/C	.	.	.	.	1.531814	-0.315847037052848	0.27586	2.077492	-0.131300011813917	0.36035	.	.	.	1	8.236e-06	0	0	0	0	1	8.241e-06	1	1.156e-04	0	0	0	0	0	0	1	9.415e-06	0	0	0	0	1	9.421e-06	1	1.271e-04	0	0	0	0	0	0	1	1.102e-05	0	0	0	0	1	1.103e-05	1	1.774e-04	0	0	0	0	0	0	0.99669	.	.	.	5.63	-1.62	0.07926	0	0.26702	0.573888	.	.	0.05573	1.41154585654687E-4	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.78979	.	0.144791	0.62929	D	0.000004	D	0.98490	0.806619	0.28143	.	0.94431	.	D	0.99648	0.9879	.	0.99949	.	D	0.99939	1.1423	R413P	Loss_of_methylation_at_R413_(P_=_0.0508)&_Loss_of_catalytic_residue_at_R413_(P_=_0.1005)&_Gain_of_glycosylation_at_S411_(P_=_0.13)&_Gain_of_phosphorylation_at_Y414_(P_=_0.1388)&_Loss_of_sheet_(P_=_0.1398)	P00439	0.99502	0.955	.	0.97289	.	.	0.81001	simple_aae&simple_aae	A&A	1&1	0.87143	.	.	.	0.48338	.	.	0.61700	.	T	0.02590	0.237739115953	0.97022	.	9	0.57104	.	.	0.72154	.	.	11.1608	0.47740	0.0:0.5529:0.0:0.4471	.	.	.	.	.	.	.	.	0.96187	.	C/C	P	.	R	G	496	0.76301	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102840477C>G	592	reviewed_by_expert_panel	Phenylketonuria&not_provided	OMIM_Allelic_Variant:612349.0016&DeBelle_Laboratory_for_Biochemical_Genetics:p.R413P&UniProtKB_(protein):P00439#VAR_001036	.	.	AEFBCI	D	0.44799	0.85644	D	0.82562	0.890520	.	1	3.977090e-06	0	0.000000e+00	16254	0	0	0.000000e+00	34566	0	251440	0	0.000000e+00	10080	0	1	5.436560e-05	18394	0	0	0.000000e+00	21648	0	0	0.000000e+00	113746	0	1	5.436560e-05	18394	0	0	0.000000e+00	30616	0	1	9.140770e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17106	0	109400	0	0.000000e+00	2320	0	1	1.105460e-04	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42766	0	1	1.105460e-04	9046	0	0	0.000000e+00	15690	0	0	.	0	1	4.221150e-06	0	0.000000e+00	14900	0	0	0.000000e+00	34234	0	236902	0	0.000000e+00	9572	0	1	5.652270e-05	17692	0	0	0.000000e+00	21632	0	0	0.000000e+00	102730	0	1	5.652270e-05	17692	0	0	0.000000e+00	30526	0	0	1	4.805470e-06	0	0.000000e+00	16216	0	0	0.000000e+00	30498	0	208096	0	0.000000e+00	6212	0	1	7.453790e-05	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89548	0	1	7.453790e-05	13416	0	0	0.000000e+00	30608	0	0	1	4.084600e-06	0	0.000000e+00	12024	0	0	0.000000e+00	34432	0	244822	0	0.000000e+00	9998	0	1	5.437740e-05	18390	0	0	0.000000e+00	21646	0	0	0.000000e+00	111656	0	1	5.437740e-05	18390	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101758385	12	103234255	0	0.43195	0.638212	0.945000	0.32849	0.698000	0.34080	0.969000	0.44821	0.933000	0.28497	-0.848000	0.02741	-0.234000	0.08775	102840477	C	.	rs79931499	.	.	10.477	9.491	8.924	9.158	.	.	.	34	38	38	-28	0.00	0.12	0.00	0.00	PAH	0.00	exon-NM_001354304.2-13+38+end+116	592	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs79931499	8.236e-06	1	0	0	0	0	1	0	0	0	0	10406	11530	8654	6614	66722	908	16510	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs79931499	0.00000e+00	0.00000e+00	0.00000e+00	5.79777e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.41411e-06	0.00000e+00	5.79777e-05	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs79931499	79931499	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,651	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103234270	103234270	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1223G>A	NP_000268.1:p.Arg408Gln	1337	1223	408	R/Q	cGg/cAg	rs5030859&CM920562&COSV61014466	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103234270C>T	.	0	0.0014	0	0	0	pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1223G>T	.	.	1	1.9968051118210862E-4	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	C/C	C	D	0.83496	0.306735	D	0.94667	0.503151	26.5	25.9	3.924644	3.734655	0.76084	0.73481	C/C	D	0.64156	0.953989505767822	0.99923	0.99948145906074759	.	0.99815	.	C/C	.	.	.	.	5.344767	0.519873390841347	0.69329	6.647162	0.664249589192175	0.77293	.	.	.	6	4.942e-05	0	0	1	8.684e-05	6	4.945e-05	1	1.156e-04	0	0	4	5.995e-05	0	0	4	3.766e-05	0	0	1	8.965e-05	4	3.769e-05	1	1.271e-04	0	0	2	3.682e-05	0	0	3	3.306e-05	0	0	1	8.693e-05	3	3.309e-05	0	0	0	0	2	4.748e-05	0	0	0.99769	.	.	.	5.63	4.74	0.59717	0	0.26702	0.573888	.	.	0.17643	0.164507498063403	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.98587	.	0.106718	0.62929	D	0.000010	D	0.97882	0.736239	0.27293	.	0.98327	.	D	0.99835	0.9930	.	0.98933	.	D	0.96427	0.9522	R408Q	Loss_of_methylation_at_R408_(P_=_0.052)&_Loss_of_phosphorylation_at_S411_(P_=_0.0679)&_Loss_of_MoRF_binding_(P_=_0.0755)&_Loss_of_solvent_accessibility_(P_=_0.2073)&_Loss_of_sheet_(P_=_0.3635)	P00439	0.99467	0.953	.	0.95404	.	.	0.58761	simple_aae&simple_aae	A&A	0.999999&0.999992	0.64019	.	.	.	0.90584	.	.	0.77487	.	T	0.35190	0.473699271679	0.97549	.	10	0.79402	.	.	0.78490	.	.	13.2361	0.59399	0.0:0.9224:0.0:0.0776	.	1	2.6968716289104636E-4	1	1.322401481089659E-4	.	.	.	0.86833	.	C/C	Q	.	R	T	496	0.76301	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102840492C>T	612	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_001034&OMIM_Allelic_Variant:612349.0038&DeBelle_Laboratory_for_Biochemical_Genetics:p.R408Q	.	.	AEFBCI	D	0.44131	0.85030	D	0.71658	0.786525	.	12	4.772550e-05	0	0.000000e+00	16254	0	1	2.893350e-05	34562	0	251438	0	0.000000e+00	10080	0	5	2.718570e-04	18392	0	0	0.000000e+00	21648	0	6	5.274630e-05	113752	0	5	2.718570e-04	18392	0	0	0.000000e+00	30616	0	5	4.570380e-05	0	0.000000e+00	7164	0	1	5.845900e-05	17106	0	109400	0	0.000000e+00	2320	0	2	2.211410e-04	9044	0	0	0.000000e+00	13394	0	2	4.676390e-05	42768	0	2	2.211410e-04	9044	0	0	0.000000e+00	15690	0	0	.	0	10	4.221190e-05	0	0.000000e+00	14900	0	1	2.921410e-05	34230	0	236900	0	0.000000e+00	9572	0	5	2.826460e-04	17690	0	0	0.000000e+00	21632	0	4	3.893470e-05	102736	0	5	2.826460e-04	17690	0	0	0.000000e+00	30526	0	0	7	3.363860e-05	0	0.000000e+00	16216	0	1	3.279330e-05	30494	0	208094	0	0.000000e+00	6212	0	2	1.490980e-04	13414	0	0	0.000000e+00	16734	0	4	4.466680e-05	89552	0	2	1.490980e-04	13414	0	0	0.000000e+00	30608	0	0	12	4.901560e-05	0	0.000000e+00	12024	0	1	2.904610e-05	34428	0	244820	0	0.000000e+00	9998	0	5	2.719160e-04	18388	0	0	0.000000e+00	21646	0	6	5.373360e-05	111662	0	5	2.719160e-04	18388	0	0	0.000000e+00	30616	0	0	6	3.947630e-05	0	0.000000e+00	41362	0	0	0.000000e+00	912	0	1	6.557380e-05	15250	0	151990	0	0.000000e+00	3468	0	0	0.000000e+00	5186	0	0	0.000000e+00	10602	0	0	0.000000e+00	316	0	5	7.353160e-05	67998	0	5	7.353160e-05	67998	0	0	0.000000e+00	4802	0	2	6.088280e-05	0	0.000000e+00	9084	0	0	0.000000e+00	60	0	1	2.134020e-04	4686	0	32850	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5472	0	0	0.000000e+00	246	0	1	1.459850e-04	6850	0	0	0.000000e+00	3098	0	0	.	0	5	3.384320e-05	0	0.000000e+00	41040	0	0	0.000000e+00	912	0	1	6.639220e-05	15062	0	147740	0	0.000000e+00	3300	0	0	0.000000e+00	4950	0	0	0.000000e+00	10602	0	0	0.000000e+00	304	0	4	6.175130e-05	64776	0	0	0.000000e+00	4770	0	0	6	4.457060e-05	0	0.000000e+00	32428	0	0	0.000000e+00	862	0	1	6.754930e-05	14804	0	134618	0	0.000000e+00	3384	0	0	0.000000e+00	5186	0	0	0.000000e+00	6960	0	0	0.000000e+00	310	0	5	7.827180e-05	63880	0	0	0.000000e+00	4800	0	0	3	3.723470e-05	0	0.000000e+00	24738	0	0	0.000000e+00	112	0	1	7.766390e-05	12876	0	80570	0	0.000000e+00	996	0	0	0.000000e+00	3744	0	0	0.000000e+00	10510	0	0	0.000000e+00	272	0	2	9.511130e-05	21028	0	0	0.000000e+00	4774	0	0	12	101758400	12	103234270	0	0.43195	0.638212	0.998000	0.41325	0.976000	0.56436	0.999000	0.70432	3.769000	0.55013	0.599000	0.40250	1.026000	0.45946	102840492	C	.	rs5030859	.	.	10.477	9.491	8.924	9.158	.	.	.	42	23	23	-43	0.00	0.06	0.00	0.00	PAH	0.00	exon-NM_001354304.2-13+23+end+116	612	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030859	4.942e-05	6	6	0	0	1	1	0	4	0	0	10406	11516	8654	6614	66718	908	16510	0	1	1	0	4	0	0	0	0	0	0	0	0	0	rs5030859	0.00000e+00	0.00000e+00	0.00000e+00	2.89922e-04	0.00000e+00	5.37182e-05	0.00000e+00	0.00000e+00	3.70722e-05	5.38900e-05	2.89922e-04	4.46661e-05	rs5030859	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.33369e-04	0.00000e+00	.	5.85001e-05	7.22543e-05	1.33369e-04	6.45328e-05	.	.	rs5030859	5030859	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,652	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246623	103246623	T	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.812A>T	NP_000268.1:p.His271Leu	926	812	271	H/L	cAt/cTt	rs199475692&CM113432&CM1511441	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103246623T>A	.	.	.	.	.	.	uncertain_significance	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.812A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.96997	0.580071	D	0.96948	0.595456	27.7	27.2	4.089298	3.940845	0.81717	0.80207	T/T	D	0.99958	0.999970674514771	0.36710	0.97896953981415225	.	0.99994	.	T/T	.	.	.	.	14.51444	0.917358816027626	0.96285	14.1437	1.00700352979636	0.95957	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99734	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999997298143	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.97209	.	0.000000	0.84330	D	0.000000	D	0.96806	0.628804	0.28385	.	0.99179	.	D	0.99835	0.9930	.	0.99446	.	D	0.96226	0.9385	H271L	Loss_of_disorder_(P_=_0.0402)&_Loss_of_methylation_at_K274_(P_=_0.0697)&_Loss_of_catalytic_residue_at_I269_(P_=_0.0923)&_Loss_of_ubiquitination_at_K274_(P_=_0.1062)&_Gain_of_glycosylation_at_S273_(P_=_0.2211)	P00439	0.96477	0.873	.	0.98819	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.99077	.	.	.	0.90584	.	.	0.97372	.	T	0.79426	0.783300042152	0.99284	.	10	0.83351	.	.	0.91255	.	.	16.0142	0.80222	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.96302	.	T/T	L	.	H	A	518	0.74548	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102852845T>A	120287	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.83657	0.98520	D	0.99825	0.979934	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770753	12	103246623	0	0.43195	0.638212	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	8.017000	0.88732	0.665000	0.62972	1.138000	0.64695	102852845	T	.	rs199475692	.	.	11.570	9.399	7.651	9.354	.	.	.	12	27	12	-30	0.00	0.00	0.00	0.01	PAH	0.00	exon-NM_001354304.2-8+30+start+136	120287	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475692	199475692	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,722	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103234271	103234271	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1222C>T	NP_000268.1:p.Arg408Trp	1336	1222	408	R/W	Cgg/Tgg	rs5030858&CD941753&CM870016&COSV61018595	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103234271G>A	.	0.0008	0	0	0.001	0	pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1222C>T	.	.	2	3.9936102236421724E-4	1	7.564296520423601E-4	0	0.0	0	0.0	1	9.940357852882703E-4	0	0.0	1	2.594706798131811E-4	.	.	.	.	.	.	.	G/G	G	D	0.75071	0.212564	D	0.95239	0.530452	28.9	24.8	4.230139	3.438265	0.86374	0.65533	G/G	T	0.30625	0.445344179868698	0.97275	0.9990073255801234	.	0.99947	.	G/G	0	0.0	15	0.0017441860465116279	3.530572	0.267049475906098	0.53624	4.794436	0.467694703181464	0.65213	.	.	.	80	6.589e-04	3	2.883e-04	0	0	80	6.594e-04	0	0	3	4.536e-04	74	1.109e-03	0	0	59	5.555e-04	3	3.309e-04	0	0	59	5.559e-04	0	0	3	4.536e-04	53	9.756e-04	0	0	51	5.620e-04	3	2.888e-04	0	0	51	5.625e-04	0	0	2	5.260e-04	46	1.092e-03	0	0	0.99791	.	.	.	5.63	1.44	0.21647	0	0.26702	0.573888	.	.	0.05650	1.60116311755976E-4	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.98917	.	0.106718	0.62929	D	0.000010	D	0.96936	0.640636	0.26966	.	0.98407	.	D	0.99830	0.9928	.	0.80882	.	D	0.97687	1.0284	.	.	.	.	.	.	0.97575	.	.	0.58761	simple_aae&simple_aae	A&A	0.999999&0.999995	0.93020	.	.	.	0.90584	.	.	0.97372	.	T	0.55251	0.61661696434	0.96725	.	10	0.92824	.	.	0.91255	.	.	14.5102	0.67364	0.0:0.0:0.5437:0.4563	.	8	0.002157497303128371	9	0.0011901613329806928	.	.	.	0.91391	.	G/G	W	.	R	A	496	0.76301	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102840493G>A	577	reviewed_by_expert_panel	Phenylketonuria&not_provided	Illumina_Laboratory_Services&Illumina:109319&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2791326&DeBelle_Laboratory_for_Biochemical_Genetics:p.R408W&UniProtKB_(protein):P00439#VAR_001035&OMIM_Allelic_Variant:612349.0002&HGMD:CM870016	.	.	AEFBCI	D	0.41784	0.82576	D	0.82124	0.888278	.	191	7.596310e-04	4	2.460930e-04	16254	0	0	0.000000e+00	34562	0	251438	4	3.968250e-04	10080	0	0	0.000000e+00	18392	0	12	5.543240e-04	21648	0	168	1.476980e-03	113746	0	168	1.476980e-03	113746	0	0	0.000000e+00	30616	0	66	6.032800e-04	1	1.395870e-04	7164	0	0	0.000000e+00	17108	0	109402	1	4.310340e-04	2320	0	0	0.000000e+00	9044	0	5	3.733010e-04	13394	0	59	1.379540e-03	42768	0	59	1.379540e-03	42768	0	0	0.000000e+00	15690	0	0	.	0	172	7.260450e-04	4	2.684560e-04	14900	0	0	0.000000e+00	34230	0	236900	3	3.134140e-04	9572	0	0	0.000000e+00	17690	0	12	5.547340e-04	21632	0	151	1.469870e-03	102730	0	151	1.469870e-03	102730	0	0	0.000000e+00	30526	0	0	160	7.688690e-04	4	2.466700e-04	16216	0	0	0.000000e+00	30496	0	208098	2	3.219580e-04	6212	0	0	0.000000e+00	13414	0	10	5.975860e-04	16734	0	142	1.585670e-03	89552	0	142	1.585670e-03	89552	0	0	0.000000e+00	30608	0	0	189	7.719960e-04	3	2.495010e-04	12024	0	0	0.000000e+00	34428	0	244820	4	4.000800e-04	9998	0	0	0.000000e+00	18388	0	12	5.543750e-04	21646	0	167	1.495670e-03	111656	0	167	1.495670e-03	111656	0	0	0.000000e+00	30616	0	0	131	8.611740e-04	8	1.931810e-04	41412	0	0	0.000000e+00	912	0	2	1.309760e-04	15270	0	152118	2	5.763690e-04	3470	0	0	0.000000e+00	5194	0	4	3.768610e-04	10614	0	0	0.000000e+00	316	0	113	1.661230e-03	68022	0	113	1.661230e-03	68022	0	0	0.000000e+00	4814	0	15	4.560930e-04	2	2.200220e-04	9090	0	0	0.000000e+00	60	0	1	2.134020e-04	4686	0	32888	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	2	3.642990e-04	5490	0	0	0.000000e+00	246	0	9	1.313490e-03	6852	0	0	0.000000e+00	3108	0	0	.	0	126	8.521230e-04	8	1.946950e-04	41090	0	0	0.000000e+00	912	0	2	1.325910e-04	15084	0	147866	1	3.028470e-04	3302	0	0	0.000000e+00	4960	0	4	3.768610e-04	10614	0	0	0.000000e+00	304	0	110	1.697740e-03	64792	0	0	0.000000e+00	4784	0	0	119	8.832090e-04	4	1.232210e-04	32462	0	0	0.000000e+00	862	0	2	1.349160e-04	14824	0	134736	2	5.906670e-04	3386	0	0	0.000000e+00	5194	0	2	2.867790e-04	6974	0	0	0.000000e+00	310	0	107	1.674280e-03	63908	0	0	0.000000e+00	4812	0	0	54	6.692780e-04	6	2.420530e-04	24788	0	0	0.000000e+00	112	0	2	1.550870e-04	12896	0	80684	2	2.008030e-03	996	0	0	0.000000e+00	3752	0	4	3.801560e-04	10522	0	0	0.000000e+00	272	0	38	1.806080e-03	21040	0	0	0.000000e+00	4786	0	0	12	101758401	12	103234271	0	0.43195	0.638212	1.000000	0.71638	0.974000	0.55675	0.997000	0.62031	4.590000	0.60722	0.676000	0.76740	1.176000	0.78918	102840493	G	.	rs5030858	.	.	10.477	9.491	8.924	9.158	.	.	.	-13	22	22	-44	0.00	0.09	0.00	0.00	PAH	0.00	exon-NM_001354304.2-13+22+end+116	577	Pathogenic	reviewed_by_expert_panel	not_provided&Inborn_genetic_diseases&Phenylketonuria&Reduced_phenylalanine_hydroxylase_level	MedGen:CN517202&MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&Human_Phenotype_Ontology:HP:0005982&MedGen:C4025094	.	rs5030858	6.589e-04	80	80	0	3	0	0	3	74	0	0	10406	11518	8654	6614	66718	908	16510	3	0	0	3	74	0	0	0	0	0	0	0	0	0	rs5030858	2.61404e-04	0.00000e+00	3.04569e-04	0.00000e+00	5.38117e-04	1.49516e-03	9.11411e-04	0.00000e+00	8.45233e-04	6.91575e-04	1.49516e-03	7.75565e-04	rs5030858	3.43800e-04	0.00000e+00	0.00000e+00	0.00000e+00	5.72410e-04	3.46528e-03	3.06748e-03	.	2.10379e-03	1.73335e-03	3.46528e-03	1.93598e-03	rs5030858	0.1744&0.0&0.1153	rs5030858	5030858	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,653	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103237460	103237460	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1163T>C	NP_000268.1:p.Val388Ala	1277	1163	388	V/A	gTg/gCg	rs281865435&CM1514932	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103237460A>G	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1163T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.94136	0.494399	D	0.94059	0.472394	24.8	24.3	3.522128	3.269243	0.64663	0.61239	A/A	D	0.72429	0.978648960590363	0.83482	0.99740841124095858	.	0.99779	.	A/A	.	.	.	.	5.534941	0.539058115853177	0.70638	5.676765	0.574852952842219	0.71607	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99752	.	.	.	5.34	5.34	0.75982	0	0.26702	0.573888	.	.	0.51787	0.999983827747907	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.86559	.	0.058265	0.62929	D	0.000002	D	0.98302	0.784243	0.23893	.	0.99062	.	D	0.99588	0.9862	.	0.99263	.	D	0.97089	0.9941	V388A	Loss_of_stability_(P_=_0.0037)&_Loss_of_sheet_(P_=_0.0817)&_Gain_of_disorder_(P_=_0.0867)&_Gain_of_phosphorylation_at_Y387_(P_=_0.2662)&_Loss_of_catalytic_residue_at_E390_(P_=_0.3283)	P00439	0.95995	0.864	.	0.68279	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.63669	.	.	.	0.45613	.	.	0.58006	.	T	0.63902	0.677445411682	0.97928	.	10	0.48080	.	.	0.59928	.	.	15.322	0.73838	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.94786	.	A/A	A	.	V	G	503	0.75780	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102843682A>G	120260	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.92128	0.99161	D	0.98488	0.963093	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101761590	12	103237460	0	0.43195	0.638212	1.000000	0.71638	0.177000	0.21203	0.956000	0.42626	9.322000	0.95579	0.691000	0.84096	1.312000	0.94714	102843682	A	.	rs281865435	.	.	8.924	9.158	3.163	9.459	.	.	.	-31	1	-36	2	0.00	0.00	0.08	0.00	PAH	0.00	exon-NM_001354304.2-12+36+start+134	120260	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865435	281865435	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,661	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103237461	103237461	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1162G>A	NP_000268.1:p.Val388Met	1276	1162	388	V/M	Gtg/Atg	rs62516101&CM930564&CM981455	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103237461C>T	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1162G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.83017	0.300602	D	0.95079	0.521978	24.4	24.9	3.382544	3.473776	0.61096	0.66439	C/C	D	0.47327	0.813917458057404	0.96666	0.99892842256568148	.	0.98614	.	C/C	1	2.2696323195642307E-4	0	0.0	6.677248	0.634034134678081	0.77426	8.036372	0.759317748407603	0.83510	.	.	.	8	6.589e-05	0	0	5	4.350e-04	8	6.600e-05	0	0	0	0	3	4.499e-05	0	0	8	7.533e-05	0	0	5	4.492e-04	8	7.545e-05	0	0	0	0	3	5.524e-05	0	0	8	8.816e-05	0	0	5	4.355e-04	8	8.834e-05	0	0	0	0	3	7.128e-05	0	0	0.99762	.	.	.	5.34	5.34	0.75982	0	0.26702	0.573888	.	.	0.38343	0.99906671525654	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.96320	.	0.058265	0.62929	D	0.000002	D	0.98198	0.772002	0.26279	.	0.99045	.	D	0.99800	0.9919	.	0.93440	.	D	0.96817	0.9774	.	.	.	.	.	.	0.94485	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.44471	.	.	.	0.90584	.	.	0.77976	.	T	0.65807	0.690692901611	0.95802	.	9	0.67890	.	.	0.61437	.	.	12.4028	0.54755	0.0:0.923:0.0:0.077	.	.	.	.	.	.	.	.	0.94196	.	C/C	M	.	V	T	503	0.75780	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102843683C>T	619	reviewed_by_expert_panel	Phenylketonuria&not_provided	HGMD:CM930564&UniProtKB_(protein):P00439#VAR_001026&OMIM_Allelic_Variant:612349.0045&DeBelle_Laboratory_for_Biochemical_Genetics:p.V388M	.	.	AEFBI	D	0.68719	0.96352	D	0.86736	0.910006	.	21	8.357010e-05	0	0.000000e+00	16254	0	14	4.053740e-04	34536	0	251286	0	0.000000e+00	10076	0	0	0.000000e+00	18384	0	0	0.000000e+00	21646	0	5	4.399630e-05	113646	0	14	4.053740e-04	34536	0	0	0.000000e+00	30614	0	8	7.314090e-05	0	0.000000e+00	7164	0	7	4.094530e-04	17096	0	109378	0	0.000000e+00	2320	0	0	0.000000e+00	9040	0	0	0.000000e+00	13394	0	1	2.338630e-05	42760	0	7	4.094530e-04	17096	0	0	0.000000e+00	15690	0	0	.	0	20	8.447660e-05	0	0.000000e+00	14900	0	14	4.093090e-04	34204	0	236752	0	0.000000e+00	9568	0	0	0.000000e+00	17682	0	0	0.000000e+00	21630	0	5	4.871770e-05	102632	0	14	4.093090e-04	34204	0	0	0.000000e+00	30524	0	0	20	9.613810e-05	0	0.000000e+00	16216	0	14	4.594680e-04	30470	0	208034	0	0.000000e+00	6208	0	0	0.000000e+00	13406	0	0	0.000000e+00	16732	0	4	4.467380e-05	89538	0	14	4.594680e-04	30470	0	0	0.000000e+00	30606	0	0	21	8.583060e-05	0	0.000000e+00	12024	0	14	4.069530e-04	34402	0	244668	0	0.000000e+00	9994	0	0	0.000000e+00	18380	0	0	0.000000e+00	21644	0	5	4.482050e-05	111556	0	14	4.069530e-04	34402	0	0	0.000000e+00	30614	0	0	7	4.607080e-05	3	7.255140e-05	41350	0	0	0.000000e+00	912	0	3	1.964380e-04	15272	0	151940	0	0.000000e+00	3472	0	0	0.000000e+00	5144	0	0	0.000000e+00	10606	0	0	0.000000e+00	314	0	0	0.000000e+00	67992	0	3	1.964380e-04	15272	0	0	0.000000e+00	4794	0	2	6.090500e-05	0	0.000000e+00	9078	0	0	0.000000e+00	60	0	1	2.135840e-04	4682	0	32838	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5482	0	0	0.000000e+00	244	0	0	0.000000e+00	6850	0	0	0.000000e+00	3092	0	0	.	0	7	4.739530e-05	3	7.312080e-05	41028	0	0	0.000000e+00	912	0	3	1.988860e-04	15084	0	147694	0	0.000000e+00	3302	0	0	0.000000e+00	4912	0	0	0.000000e+00	10606	0	0	0.000000e+00	302	0	0	0.000000e+00	64772	0	0	0.000000e+00	4762	0	0	4	2.972030e-05	1	3.083940e-05	32426	0	0	0.000000e+00	862	0	2	1.348980e-04	14826	0	134588	0	0.000000e+00	3388	0	0	0.000000e+00	5144	0	0	0.000000e+00	6972	0	0	0.000000e+00	308	0	0	0.000000e+00	63876	0	0	0.000000e+00	4792	0	0	6	7.451560e-05	2	8.087340e-05	24730	0	0	0.000000e+00	112	0	3	2.325940e-04	12898	0	80520	0	0.000000e+00	998	0	0	0.000000e+00	3704	0	0	0.000000e+00	10514	0	0	0.000000e+00	270	0	0	0.000000e+00	21018	0	0	0.000000e+00	4766	0	0	12	101761591	12	103237461	0	0.43195	0.638212	1.000000	0.71638	0.170000	0.20979	0.945000	0.41273	5.037000	0.63964	0.549000	0.26987	1.026000	0.45946	102843683	C	.	rs62516101	.	.	8.924	9.158	3.163	9.459	.	.	.	-7	12	-2	-37	0.00	0.00	0.00	0.08	PAH	0.00	exon-NM_001354304.2-12+37+start+134	619	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62516101	6.589e-05	8	8	0	0	5	0	0	3	0	0	10404	11494	8636	6590	66686	906	16504	0	5	0	0	3	0	0	0	0	0	0	0	0	0	rs62516101	0.00000e+00	4.47441e-04	0.00000e+00	0.00000e+00	0.00000e+00	4.48101e-05	0.00000e+00	0.00000e+00	7.42005e-05	8.98683e-05	4.47441e-04	8.93328e-05	rs62516101	1.14732e-04	2.39234e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	1.16973e-04	7.22752e-05	2.39234e-03	9.67992e-05	rs62516101	0.0&0.0227&0.0077	rs62516101	62516101	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,662	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103234253	103234253	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1240T>C	NP_000268.1:p.Tyr414His	1354	1240	414	Y/H	Tac/Cac	rs281865437	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103234253A>G	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	PAH&NM_000277.1&c.1240T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96008	0.555335	D	0.95946	0.559924	25.6	26.2	3.758903	3.794054	0.71000	0.75290	A/A	D	0.83527	0.992919385433197	0.93820	0.99859535157169843	.	0.99978	.	A/A	.	.	.	.	10.68148	0.81812406000595	0.91024	11.17282	0.904714052689343	0.91989	.	.	.	1	8.236e-06	0	0	0	0	1	8.241e-06	0	0	0	0	1	1.499e-05	0	0	1	9.415e-06	0	0	0	0	1	9.421e-06	0	0	0	0	1	1.841e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99715	.	.	.	5.63	5.63	0.86108	0	0.26702	0.573888	.	.	0.42865	0.999773153494431	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.68911	.	0.000000	0.84330	D	0.000000	D	0.97312	0.676498	0.28750	.	0.98461	.	D	0.99762	0.9909	.	0.99906	.	D	0.96827	0.9780	Y414H	Loss_of_stability_(P_=_0.0169)&_Gain_of_disorder_(P_=_0.0528)&_Gain_of_catalytic_residue_at_D415_(P_=_0.1116)&_Loss_of_methylation_at_R413_(P_=_0.1547)&_Loss_of_phosphorylation_at_S411_(P_=_0.2098)	P00439	0.99280	0.944	.	0.93643	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.78472	.	.	.	0.77913	.	.	0.73820	.	T	0.60339	0.652487277985	0.99622	.	10	0.63109	.	.	0.52492	.	.	14.8162	0.69665	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.93018	.	A/A	H	.	Y	G	496	0.76301	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102840475A>G	120265	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBCI	D	0.74083	0.97332	D	0.99574	0.974691	.	1	3.977030e-06	0	0.000000e+00	16254	0	0	0.000000e+00	34564	0	251444	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	1	8.791050e-06	113752	0	1	8.791050e-06	113752	0	0	0.000000e+00	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17108	0	109402	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42766	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	1	4.221080e-06	0	0.000000e+00	14900	0	0	0.000000e+00	34232	0	236906	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	1	9.733690e-06	102736	0	1	9.733690e-06	102736	0	0	0.000000e+00	30526	0	0	0	0.000000e+00	0	0.000000e+00	16216	0	0	0.000000e+00	30496	0	208094	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89548	0	.	.	.	.	0	0.000000e+00	30608	0	0	1	4.084530e-06	0	0.000000e+00	12024	0	0	0.000000e+00	34430	0	244826	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	1	8.955600e-06	111662	0	1	8.955600e-06	111662	0	0	0.000000e+00	30616	0	0	1	6.571860e-06	0	0.000000e+00	41430	0	0	0.000000e+00	912	0	0	0.000000e+00	15274	0	152164	0	0.000000e+00	3466	0	0	0.000000e+00	5200	0	0	0.000000e+00	10624	0	1	3.164560e-03	316	0	0	0.000000e+00	68028	0	.	.	.	.	0	0.000000e+00	4820	0	1	3.040440e-05	0	0.000000e+00	9082	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32890	0	0.000000e+00	134	0	0	0.000000e+00	2428	0	0	0.000000e+00	5496	0	1	4.065040e-03	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3112	0	0	.	0	1	6.760690e-06	0	0.000000e+00	41108	0	0	0.000000e+00	912	0	0	0.000000e+00	15086	0	147914	0	0.000000e+00	3296	0	0	0.000000e+00	4964	0	0	0.000000e+00	10624	0	1	3.289470e-03	304	0	0	0.000000e+00	64806	0	0	0.000000e+00	4790	0	0	1	7.420820e-06	0	0.000000e+00	32464	0	0	0.000000e+00	862	0	0	0.000000e+00	14828	0	134756	0	0.000000e+00	3382	0	0	0.000000e+00	5200	0	0	0.000000e+00	6982	0	1	3.225810e-03	310	0	0	0.000000e+00	63906	0	0	0.000000e+00	4818	0	0	1	1.238730e-05	0	0.000000e+00	24804	0	0	0.000000e+00	112	0	0	0.000000e+00	12900	0	80728	0	0.000000e+00	994	0	0	0.000000e+00	3758	0	0	0.000000e+00	10532	0	1	3.676470e-03	272	0	0	0.000000e+00	21044	0	0	0.000000e+00	4792	0	0	12	101758383	12	103234253	0	0.43195	0.638212	1.000000	0.71638	0.726000	0.34967	0.984000	0.49151	8.892000	0.92141	0.756000	0.94297	1.312000	0.94714	102840475	A	.	rs281865437	.	.	10.477	9.491	8.924	9.158	.	.	.	36	40	-7	-26	0.00	0.02	0.00	0.00	PAH	0.00	exon-NM_001354304.2-13+40+end+116	120265	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103234253-103234253	8.236e-06	1	1	0	0	0	0	0	1	0	0	10406	11530	8654	6614	66724	908	16510	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs281865437	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95223e-06	0.00000e+00	0.00000e+00	7.41389e-06	0.00000e+00	8.95223e-06	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865437	281865437	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,650	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103245482	103245482	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.895T>C	NP_000268.1:p.Phe299Leu	1009	895	299	F/L	Ttt/Ctt	rs796064504	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103245482A>G	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	PAH&NM_000277.1&c.895T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96956	0.577351	D	0.96907	0.591548	31	31	4.393990	4.329327	0.90008	0.90400	A/A	D	0.96429	0.999171018600464	0.95244	0.99875661580182507	.	0.99946	.	A/A	.	.	.	.	14.15264	0.909231405651852	0.95964	13.32444	0.980608264268669	0.95118	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99813	.	.	.	5.51	5.51	0.81769	0	0.45803	0.59043	.	.	0.74766	0.999999957073323	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.91165	.	0.092795	0.84330	D	0.000000	D	0.98342	0.789003	0.27889	.	0.98686	.	D	0.99862	0.9940	.	0.99502	.	D	0.96265	0.9412	F299L	Gain_of_helix_(P_=_0.132)&_Gain_of_disorder_(P_=_0.1909)&_Loss_of_catalytic_residue_at_A300_(P_=_0.2472)&_Gain_of_phosphorylation_at_S298_(P_=_0.3445)&_Loss_of_methylation_at_R297_(P_=_0.4067)	P00439	0.99157	0.939	.	0.95055	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.88361	.	.	.	0.90584	.	.	0.97372	.	D	0.93533	0.876851558685	0.99376	.	10	0.57104	.	.	0.78490	.	.	15.9194	0.79334	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.96531	.	A/A	L	.	F	G	514	0.74853	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102851704A>G	208182	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBCI	D	0.78413	0.97956	D	0.99741	0.977836	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101769612	12	103245482	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	0.999000	0.70432	8.947000	0.92735	0.756000	0.94297	1.312000	0.94714	102851704	A	.	rs796064504	.	.	9.506	11.083	11.570	9.399	.	.	.	-38	8	-14	-17	0.00	0.00	0.00	0.01	PAH	0.00	exon-NM_001354304.2-9+17+start+70	208182	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs796064504	796064504	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,693	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103245487	103245487	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.890G>A	NP_000268.1:p.Arg297His	1004	890	297	R/H	cGc/cAc	rs62642939&CM071054&CM971133&COSV100187604	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103245487C>T	.	.	.	.	.	.	pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.890G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.72746	0.187633	D	0.83175	0.200873	27.3	28.6	4.042775	4.099092	0.80085	0.85568	C/C	D	0.48440	0.828835785388947	0.98238	0.99913605392423721	.	0.93536	.	C/C	.	.	.	.	5.488136	0.534430114654404	0.70321	4.91577	0.484268511724287	0.66171	.	.	.	1	8.236e-06	0	0	0	0	1	8.262e-06	0	0	0	0	1	1.502e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1.102e-05	0	0	0	0	1	1.106e-05	0	0	0	0	1	2.381e-05	0	0	0.99542	.	.	.	5.51	5.51	0.81769	0	0.45803	0.59043	.	.	0.37330	0.998625943422796	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.77272	.	0.214651	0.45977	D	0.000310	D	0.93175	0.390413	0.14172	.	0.97882	.	D	0.98707	0.9599	.	0.96392	.	D	0.99299	1.0915	R297H	Gain_of_disorder_(P_=_0.1384)&_Gain_of_loop_(P_=_0.2045)&_Loss_of_methylation_at_R297_(P_=_0.2856)&_Loss_of_phosphorylation_at_S298_(P_=_0.311)&_Gain_of_catalytic_residue_at_D296_(P_=_0.3185)	P00439	0.97773	0.9	.	0.39878	.	.	0.38630	simple_aae&simple_aae	D&D	0.967988&0.967988	0.15986	.	.	.	0.52645	.	.	0.49854	.	T	0.57697	0.633889317513	0.86283	.	10	0.64786	.	.	0.59928	.	.	14.3009	0.65906	0.0:0.737:0.263:0.0	.	.	.	.	.	.	.	.	0.83987	.	C/C	H	.	R	T	514	0.74853	.	12	C0751435&C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102851709C>T	92750	reviewed_by_expert_panel	Hyperphenylalaninemia&_non-pku&Phenylketonuria&not_provided	HGMD:CM971133&UniProtKB_(protein):P00439#VAR_000986&DeBelle_Laboratory_for_Biochemical_Genetics:p.R297H	.	.	AEFBCI	D	0.43103	0.84016	D	0.73985	0.818646	.	1	3.983490e-06	0	0.000000e+00	16244	0	0	0.000000e+00	34566	0	251036	0	0.000000e+00	10064	0	1	5.439510e-05	18384	0	0	0.000000e+00	21616	0	0	0.000000e+00	113426	0	1	5.439510e-05	18384	0	0	0.000000e+00	30610	0	1	9.145450e-06	0	0.000000e+00	7160	0	0	0.000000e+00	17098	0	109344	0	0.000000e+00	2320	0	1	1.106190e-04	9040	0	0	0.000000e+00	13364	0	0	0.000000e+00	42762	0	1	1.106190e-04	9040	0	0	0.000000e+00	15686	0	0	.	0	1	4.227970e-06	0	0.000000e+00	14898	0	0	0.000000e+00	34236	0	236520	0	0.000000e+00	9556	0	1	5.654190e-05	17686	0	0	0.000000e+00	21600	0	0	0.000000e+00	102418	0	1	5.654190e-05	17686	0	0	0.000000e+00	30520	0	0	1	4.806950e-06	0	0.000000e+00	16206	0	0	0.000000e+00	30502	0	208032	0	0.000000e+00	6210	0	1	7.459350e-05	13406	0	0	0.000000e+00	16702	0	0	0.000000e+00	89538	0	1	7.459350e-05	13406	0	0	0.000000e+00	30602	0	0	1	4.091320e-06	0	0.000000e+00	12016	0	0	0.000000e+00	34432	0	244420	0	0.000000e+00	9982	0	1	5.440700e-05	18380	0	0	0.000000e+00	21614	0	0	0.000000e+00	111336	0	1	5.440700e-05	18380	0	0	0.000000e+00	30610	0	0	4	2.629330e-05	1	2.413940e-05	41426	0	0	0.000000e+00	912	0	1	6.552220e-05	15262	0	152130	0	0.000000e+00	3472	0	0	0.000000e+00	5180	0	0	0.000000e+00	10612	0	0	0.000000e+00	316	0	1	1.469940e-05	68030	0	1	6.552220e-05	15262	0	0	0.000000e+00	4830	0	0	0.000000e+00	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32888	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5488	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3110	0	0	.	0	4	2.705010e-05	1	2.432850e-05	41104	0	0	0.000000e+00	912	0	1	6.633940e-05	15074	0	147874	0	0.000000e+00	3302	0	0	0.000000e+00	4946	0	0	0.000000e+00	10612	0	0	0.000000e+00	304	0	1	1.543160e-05	64802	0	0	0.000000e+00	4798	0	0	3	2.226740e-05	1	3.080710e-05	32460	0	0	0.000000e+00	862	0	1	6.749460e-05	14816	0	134726	0	0.000000e+00	3388	0	0	0.000000e+00	5180	0	0	0.000000e+00	6974	0	0	0.000000e+00	310	0	0	0.000000e+00	63908	0	0	0.000000e+00	4828	0	0	3	3.717560e-05	1	4.030960e-05	24808	0	0	0.000000e+00	112	0	1	7.759160e-05	12888	0	80698	0	0.000000e+00	998	0	0	0.000000e+00	3738	0	0	0.000000e+00	10520	0	0	0.000000e+00	272	0	1	4.751950e-05	21044	0	0	0.000000e+00	4802	0	0	12	101769617	12	103245487	0	0.43195	0.638212	0.999000	0.42656	0.998000	0.85391	0.993000	0.55118	3.046000	0.49536	0.599000	0.40250	1.026000	0.45946	102851709	C	.	rs62642939	.	.	9.506	11.083	11.570	9.399	.	.	.	-22	47	47	-22	0.00	0.06	0.00	0.04	PAH	0.00	exon-NM_001354304.2-9+22+start+70	92750	Pathogenic	reviewed_by_expert_panel	not_provided&Hyperphenylalaninemia&Phenylketonuria	MedGen:CN517202&Human_Phenotype_Ontology:HP:0004923&MedGen:C0751435&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62642939	8.236e-06	1	1	0	0	0	0	0	1	0	0	10348	11500	8620	6608	66586	908	16460	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs62642939	0.00000e+00	0.00000e+00	0.00000e+00	5.80114e-05	0.00000e+00	8.98085e-06	0.00000e+00	0.00000e+00	1.48542e-05	0.00000e+00	5.80114e-05	8.12130e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62642939	62642939	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,694	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103245490	103245490	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.887A>G	NP_000268.1:p.Asp296Gly	1001	887	296	D/G	gAt/gGt	rs281865446&CM1111673	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103245490T>C	.	.	.	.	.	.	uncertain_significance	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.887A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.96613	0.570279	D	0.96557	0.58139	31	29.9	4.433554	4.251612	0.90552	0.89262	T/T	D	0.96158	0.999091386795044	0.95491	0.99878036255351321	.	0.99986	.	T/T	.	.	.	.	14.26054	0.91169657895367	0.96062	14.08801	1.00526261509881	0.95904	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99702	.	.	.	5.51	5.51	0.81769	0	0.45803	0.59043	.	.	0.74766	0.999999957073323	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.89589	.	0.045522	0.84330	N	0.000000	D	0.98896	0.856459	0.28730	.	0.99427	.	D	0.99826	0.9927	.	0.95473	.	D	0.96333	0.9458	D296G	Loss_of_stability_(P_=_0.0188)&_Gain_of_methylation_at_R297_(P_=_0.0357)&_Gain_of_catalytic_residue_at_S298_(P_=_0.0622)&_Gain_of_glycosylation_at_S295_(P_=_0.0849)&_Gain_of_disorder_(P_=_0.2809)	P00439	0.86714	0.734	.	0.96988	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.89759	.	.	.	0.90584	.	.	0.86255	.	T	0.82062	0.800649285316	0.99695	.	10	0.76473	.	.	0.78490	.	.	15.9194	0.79334	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.99100	.	T/T	G	.	D	C	514	0.74853	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102851712T>C	120291	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBCI	D	0.71809	0.96946	D	0.99825	0.979938	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101769620	12	103245490	0	0.43195	0.638212	1.000000	0.71638	0.996000	0.76049	0.998000	0.65909	7.674000	0.83146	0.665000	0.62972	1.138000	0.64695	102851712	T	.	rs281865446	.	.	9.506	11.083	11.570	9.399	.	.	.	0	44	44	-25	0.00	0.14	0.00	0.09	PAH	0.00	exon-NM_001354304.2-9+25+start+70	120291	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865446	281865446	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,696	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103234252	103234252	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1241A>G	NP_000268.1:p.Tyr414Cys	1355	1241	414	Y/C	tAc/tGc	rs5030860&CM910294	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103234252T>C	.	0	0	0	0.001	0	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1241A>G	.	.	1	1.9968051118210862E-4	0	0.0	0	0.0	0	0.0	1	9.940357852882703E-4	0	0.0	.	.	.	.	.	.	.	.	.	T/T	T	D	0.83655	0.308803	D	0.96529	0.579248	26.4	26.9	3.917533	3.898498	0.75849	0.78747	T/T	D	0.60958	0.938729166984558	0.90150	0.99818679746895511	.	0.99976	.	T/T	0	0.0	4	4.6511627906976747E-4	10.93148	0.825778334675477	0.91527	11.76057	0.926643141649773	0.93002	.	.	.	60	4.942e-04	0	0	3	2.602e-04	60	4.945e-04	0	0	2	3.024e-04	55	8.243e-04	0	0	50	4.708e-04	0	0	3	2.687e-04	50	4.711e-04	0	0	2	3.024e-04	45	8.283e-04	0	0	23	2.534e-04	0	0	3	2.605e-04	23	2.536e-04	0	0	0	0	20	4.747e-04	0	0	0.99727	.	.	.	5.63	5.63	0.86108	0	0.26702	0.573888	.	.	0.42865	0.999773153494431	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.91859	.	0.000000	0.84330	D	0.000000	D	0.98623	0.822868	0.28467	.	0.98755	.	D	0.99810	0.9922	.	0.98013	.	D	0.96477	0.9555	.	.	.	.	.	.	0.98178	.	.	0.81001	simple_aae&simple_aae	A&A	1&1	0.96707	.	.	.	0.90584	.	.	0.97372	.	T	0.59551	0.646943926811	0.99890	.	10	0.92824	.	.	0.78490	.	.	14.8162	0.69665	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.99481	.	T/T	C	.	Y	C	496	0.76301	.	12	C0751435&C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102840474T>C	593	reviewed_by_expert_panel	Hyperphenylalaninemia&_non-pku&Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_001038&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2830416&OMIM_Allelic_Variant:612349.0017&Institute_of_Human_Genetics&_University_of_Leipzig_Medical_Center:CV_varv_1188&DeBelle_Laboratory_for_Biochemical_Genetics:p.Y414C&HGMD:CM910294	.	.	AEFBCI	D	0.68120	0.96227	D	0.99179	0.969394	.	92	3.658920e-04	0	0.000000e+00	16254	0	5	1.446680e-04	34562	0	251440	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	1	4.619360e-05	21648	0	82	7.208920e-04	113748	0	82	7.208920e-04	113748	0	0	0.000000e+00	30616	0	25	2.285230e-04	0	0.000000e+00	7164	0	1	5.846590e-05	17104	0	109398	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	23	5.378100e-04	42766	0	23	5.378100e-04	42766	0	0	0.000000e+00	15690	0	0	.	0	84	3.545770e-04	0	0.000000e+00	14900	0	5	1.460710e-04	34230	0	236902	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	1	4.622780e-05	21632	0	75	7.300550e-04	102732	0	75	7.300550e-04	102732	0	0	0.000000e+00	30526	0	0	57	2.739170e-04	0	0.000000e+00	16216	0	5	1.639670e-04	30494	0	208092	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	50	5.583600e-04	89548	0	50	5.583600e-04	89548	0	0	0.000000e+00	30608	0	0	91	3.716990e-04	0	0.000000e+00	12024	0	5	1.452310e-04	34428	0	244822	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	1	4.619790e-05	21646	0	81	7.254290e-04	111658	0	81	7.254290e-04	111658	0	0	0.000000e+00	30616	0	0	39	2.562380e-04	0	0.000000e+00	41438	0	0	0.000000e+00	912	0	0	0.000000e+00	15278	0	152202	0	0.000000e+00	3468	0	0	0.000000e+00	5200	0	1	9.410880e-05	10626	0	0	0.000000e+00	316	0	38	5.584290e-04	68048	0	38	5.584290e-04	68048	0	0	0.000000e+00	4824	0	4	1.215810e-04	0	0.000000e+00	9092	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32900	0	0.000000e+00	134	0	0	0.000000e+00	2430	0	0	0.000000e+00	5494	0	0	0.000000e+00	246	0	4	5.837710e-04	6852	0	0	0.000000e+00	3112	0	0	.	0	33	2.230570e-04	0	0.000000e+00	41116	0	0	0.000000e+00	912	0	0	0.000000e+00	15090	0	147944	0	0.000000e+00	3300	0	0	0.000000e+00	4964	0	1	9.410880e-05	10626	0	0	0.000000e+00	304	0	32	4.937050e-04	64816	0	0	0.000000e+00	4794	0	0	35	2.596630e-04	0	0.000000e+00	32470	0	0	0.000000e+00	862	0	0	0.000000e+00	14832	0	134790	0	0.000000e+00	3384	0	0	0.000000e+00	5200	0	0	0.000000e+00	6984	0	0	0.000000e+00	310	0	35	5.475420e-04	63922	0	0	0.000000e+00	4822	0	0	14	1.733490e-04	0	0.000000e+00	24816	0	0	0.000000e+00	112	0	0	0.000000e+00	12904	0	80762	0	0.000000e+00	994	0	0	0.000000e+00	3758	0	1	9.493070e-05	10534	0	0	0.000000e+00	272	0	13	6.173430e-04	21058	0	0	0.000000e+00	4796	0	0	12	101758382	12	103234252	0	0.43195	0.638212	1.000000	0.71638	0.742000	0.35507	0.989000	0.51752	7.628000	0.82379	0.665000	0.62972	1.138000	0.64695	102840474	T	.	rs5030860	.	.	10.477	9.491	8.924	9.158	.	.	.	6	41	41	-25	0.00	0.03	0.00	0.00	PAH	0.00	exon-NM_001354304.2-13+41+end+116	593	Pathogenic	reviewed_by_expert_panel	not_provided&Reduced_phenylalanine_hydroxylase_level&Phenylketonuria&Hyperphenylalaninemia	MedGen:CN517202&Human_Phenotype_Ontology:HP:0005982&MedGen:C4025094&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&Human_Phenotype_Ontology:HP:0004923&MedGen:C0751435	.	rs5030860	4.942e-04	60	60	0	0	3	0	2	55	0	0	10406	11528	8654	6614	66724	908	16510	0	3	0	2	55	0	0	0	0	0	0	0	0	0	rs5030860	0.00000e+00	1.49014e-04	0.00000e+00	0.00000e+00	8.96861e-05	7.34109e-04	3.64697e-04	0.00000e+00	3.63286e-04	3.77223e-04	7.34109e-04	3.69510e-04	rs5030860	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.86205e-04	3.99787e-04	1.02041e-03	.	1.75336e-04	3.60907e-04	3.99787e-04	2.58131e-04	rs5030860	0.0465&0.0&0.0308	rs5030860	5030860	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,649	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103245512	103245512	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.865G>C	NP_000268.1:p.Gly289Arg	979	865	289	G/R	Gga/Cga	rs199475693&CM136526&CM1610373&COSV61015308	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103245512C>G	.	.	.	.	.	.	not_provided&pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.865G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.96914	0.575066	D	0.96863	0.588266	27.7	29.8	4.089162	4.246035	0.81717	0.89167	C/C	D	0.97675	0.999503493309021	0.99868	0.99943714803350281	.	0.99998	.	C/C	.	.	.	.	17.59919	0.978781454342417	0.98173	16.38414	1.07218693216396	0.97585	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99912	.	.	.	5.51	5.51	0.81769	0	0.45803	0.59043	.	.	0.74766	0.999999999971142	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.97720	.	0.048453	0.84330	D	0.000000	D	0.98995	0.868753	0.28073	.	0.99087	.	D	0.99947	0.9979	.	0.99920	.	D	0.95944	0.9190	G289R	Loss_of_catalytic_residue_at_H290_(P_=_0.0783)&_Gain_of_helix_(P_=_0.1736)&_Gain_of_loop_(P_=_0.2045)&_Gain_of_disorder_(P_=_0.4591)&_Loss_of_stability_(P_=_0.4899)	P00439	0.99667	0.966	.	0.99725	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95924	.	.	.	0.90584	.	.	0.97372	.	D	0.97770	0.913266539574	0.99858	.	10	0.63918	.	.	0.91255	.	.	19.7791	0.96406	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99973	.	C/C	R	.	G	G	514	0.74853	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102851734C>G	102882	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.G289R	.	.	AEFBCI	D	0.76409	0.97686	D	0.99753	0.978112	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101769642	12	103245512	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	7.568000	0.81546	0.599000	0.40250	1.026000	0.45946	102851734	C	.	rs199475693	.	.	9.506	11.083	11.570	9.399	.	.	.	22	-47	-47	22	0.05	0.00	0.05	0.00	PAH	0.00	exon-NM_001354304.2-9+22+end+70	102882	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475693	199475693	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,698	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246606	103246606	A	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.829T>G	NP_000268.1:p.Tyr277Asp	943	829	277	Y/D	Tat/Gat	rs78655458&CM910291	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103246606A>C	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.829T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.94171	0.495919	D	0.95800	0.557442	27.9	25.5	4.120485	3.641715	0.82795	0.70823	A/A	D	0.96710	0.999259293079376	0.50984	0.99039573523060098	.	0.99997	.	A/A	.	.	.	.	7.455892	0.683580156227005	0.81133	9.397118	0.830054823261171	0.87946	.	.	.	1	8.236e-06	0	0	0	0	1	8.237e-06	0	0	0	0	1	1.498e-05	0	0	1	9.415e-06	0	0	0	0	1	9.416e-06	0	0	0	0	1	1.840e-05	0	0	1	1.102e-05	0	0	0	0	1	1.102e-05	0	0	0	0	1	2.373e-05	0	0	0.99820	.	.	.	5.73	4.58	0.56077	0	0.45803	0.59043	.	.	0.44174	0.999858183039457	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.77922	.	0.112587	0.62929	D	0.000007	D	0.97783	0.725291	0.31654	.	0.98883	.	D	0.99884	0.9949	.	0.98474	.	D	0.96349	0.9469	.	.	.	.	.	.	0.99623	.	.	0.81001	simple_aae&simple_aae	A&A	1&1	0.98511	.	.	.	0.90584	.	.	0.97372	.	D	0.90088	0.853141546249	0.99189	.	9	0.62352	.	.	0.63226	.	.	11.5161	0.49773	0.9299:0.0:0.0701:0.0	.	.	.	.	.	.	.	.	0.97207	.	A/A	D	.	Y	C	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852828A>C	603	reviewed_by_expert_panel	Phenylketonuria&not_provided	HGMD:CM910291&UniProtKB_(protein):P00439#VAR_000977&OMIM_Allelic_Variant:612349.0029&DeBelle_Laboratory_for_Biochemical_Genetics:p.Y277D	.	.	AEFBI	D	0.81627	0.98323	D	0.99674	0.976465	.	4	1.591390e-05	0	0.000000e+00	16256	0	1	2.891340e-05	34586	0	251352	0	0.000000e+00	10076	0	0	0.000000e+00	18392	0	0	0.000000e+00	21648	0	3	2.639780e-05	113646	0	1	2.891340e-05	34586	0	0	0.000000e+00	30616	0	1	9.140270e-06	0	0.000000e+00	7164	0	1	5.843850e-05	17112	0	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	1	5.843850e-05	17112	0	0	0.000000e+00	15690	0	0	.	0	4	1.689090e-05	0	0.000000e+00	14902	0	1	2.919370e-05	34254	0	236814	0	0.000000e+00	9568	0	0	0.000000e+00	17690	0	0	0.000000e+00	21632	0	3	2.923120e-05	102630	0	3	2.923120e-05	102630	0	0	0.000000e+00	30526	0	0	3	1.441570e-05	0	0.000000e+00	16218	0	1	3.276330e-05	30522	0	208106	0	0.000000e+00	6210	0	0	0.000000e+00	13414	0	0	0.000000e+00	16734	0	2	2.233790e-05	89534	0	1	3.276330e-05	30522	0	0	0.000000e+00	30608	0	0	4	1.634430e-05	0	0.000000e+00	12026	0	1	2.902590e-05	34452	0	244734	0	0.000000e+00	9994	0	0	0.000000e+00	18388	0	0	0.000000e+00	21646	0	3	2.689230e-05	111556	0	1	2.902590e-05	34452	0	0	0.000000e+00	30616	0	0	2	1.314160e-05	1	2.412660e-05	41448	0	0	0.000000e+00	910	0	0	0.000000e+00	15272	0	152188	0	0.000000e+00	3472	0	0	0.000000e+00	5196	0	0	0.000000e+00	10618	0	0	0.000000e+00	316	0	1	1.469940e-05	68030	0	1	2.412660e-05	41448	0	0	0.000000e+00	4832	0	0	0.000000e+00	0	0.000000e+00	9100	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32906	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3110	0	0	.	0	2	1.351880e-05	1	2.431550e-05	41126	0	0	0.000000e+00	910	0	0	0.000000e+00	15084	0	147942	0	0.000000e+00	3302	0	0	0.000000e+00	4962	0	0	0.000000e+00	10618	0	0	0.000000e+00	304	0	1	1.542920e-05	64812	0	0	0.000000e+00	4800	0	0	2	1.483880e-05	1	3.078630e-05	32482	0	0	0.000000e+00	860	0	0	0.000000e+00	14826	0	134782	0	0.000000e+00	3388	0	0	0.000000e+00	5196	0	0	0.000000e+00	6980	0	0	0.000000e+00	310	0	1	1.564800e-05	63906	0	0	0.000000e+00	4830	0	0	2	2.476780e-05	1	4.028680e-05	24822	0	0	0.000000e+00	112	0	0	0.000000e+00	12898	0	80750	0	0.000000e+00	998	0	0	0.000000e+00	3754	0	0	0.000000e+00	10526	0	0	0.000000e+00	272	0	1	4.751950e-05	21044	0	0	0.000000e+00	4804	0	0	12	101770736	12	103246606	0	0.43195	0.638212	1.000000	0.71638	0.801000	0.37776	0.984000	0.49151	7.517000	0.80687	0.756000	0.94297	1.312000	0.94714	102852828	A	.	rs78655458	.	.	11.570	9.399	7.651	9.354	.	.	.	27	29	-13	2	0.00	0.00	0.04	0.00	PAH	0.00	exon-NM_001354304.2-8+13+start+136	603	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs78655458	8.236e-06	1	1	0	0	0	0	0	1	0	0	10406	11570	8652	6614	66738	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs78655458	0.00000e+00	2.97832e-05	0.00000e+00	0.00000e+00	0.00000e+00	2.68861e-05	0.00000e+00	0.00000e+00	1.48348e-05	1.79691e-05	2.97832e-05	1.62422e-05	rs78655458	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66134e-05	0.00000e+00	.	0.00000e+00	7.21709e-05	6.66134e-05	3.22664e-05	.	.	rs78655458	78655458	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,711	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246714	103246714	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.721C>T	NP_000268.1:p.Arg241Cys	835	721	241	R/C	Cgc/Tgc	rs76687508&CM930548&COSV61018094	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246714G>A	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.721C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.74232	0.203629	D	0.94188	0.479189	28.1	28.1	4.136221	4.046592	0.83350	0.83909	G/G	T	0.14277	0.118441709032521	0.95410	0.99877154948279456	.	0.99654	.	G/G	.	.	.	.	11.2792	0.836092690442628	0.92177	9.687241	0.843316721079752	0.88724	.	.	.	17	1.400e-04	4	3.856e-04	0	0	17	1.405e-04	11	1.278e-03	0	0	2	3.008e-05	0	0	16	1.506e-04	4	4.417e-04	0	0	16	1.511e-04	11	1.406e-03	0	0	1	1.845e-05	0	0	8	8.815e-05	4	3.862e-04	0	0	8	8.850e-05	2	3.571e-04	0	0	2	4.767e-05	0	0	0.99556	.	.	.	5.92	5.92	0.95557	0	0.45803	0.59043	.	.	0.74766	0.999999793196112	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.41827	.	0.000000	0.84330	D	0.000000	D	0.92749	0.37113	0.09686	.	0.97260	.	D	0.99548	0.9850	.	0.72656	.	D	0.98710	1.0743	.	.	.	.	.	.	0.63091	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.55025	.	.	.	0.90584	.	.	0.81110	.	D	0.92933	0.872562408447	0.95618	.	10	0.50809	.	.	0.43085	.	.	20.3167	0.98654	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.92784	.	G/G	C	.	R	A	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852936G>A	102803	reviewed_by_expert_panel	Phenylketonuria&not_provided	HGMD:CM930548&DeBelle_Laboratory_for_Biochemical_Genetics:p.R241C&UniProtKB_(protein):P00439#VAR_000943	.	.	AEFBI	D	0.76172	0.97652	D	0.98933	0.966867	.	36	1.434510e-04	4	2.460930e-04	16254	0	0	0.000000e+00	34560	0	250956	0	0.000000e+00	10064	0	26	1.415200e-03	18372	0	0	0.000000e+00	21630	0	5	4.411430e-05	113342	0	26	1.415200e-03	18372	0	1	3.266910e-05	30610	0	21	1.920190e-04	3	4.187600e-04	7164	0	0	0.000000e+00	17106	0	109364	0	0.000000e+00	2320	0	17	1.880950e-03	9038	0	0	0.000000e+00	13380	0	0	0.000000e+00	42754	0	17	1.880950e-03	9038	0	1	6.374300e-05	15688	0	0	.	0	35	1.480330e-04	4	2.684560e-04	14900	0	0	0.000000e+00	34228	0	236434	0	0.000000e+00	9556	0	26	1.471250e-03	17672	0	0	0.000000e+00	21614	0	4	3.908540e-05	102340	0	26	1.471250e-03	17672	0	1	3.276540e-05	30520	0	0	23	1.106090e-04	4	2.466700e-04	16216	0	0	0.000000e+00	30498	0	207940	0	0.000000e+00	6208	0	13	9.705840e-04	13394	0	0	0.000000e+00	16718	0	5	5.590210e-05	89442	0	13	9.705840e-04	13394	0	1	3.267760e-05	30602	0	0	33	1.350590e-04	2	1.663340e-04	12024	0	0	0.000000e+00	34426	0	244338	0	0.000000e+00	9982	0	26	1.415510e-03	18368	0	0	0.000000e+00	21628	0	4	3.595440e-05	111252	0	26	1.415510e-03	18368	0	1	3.266910e-05	30610	0	0	14	9.205560e-05	5	1.206970e-04	41426	0	0	0.000000e+00	912	0	0	0.000000e+00	15262	0	152082	0	0.000000e+00	3470	0	4	7.742930e-04	5166	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	4	5.880280e-05	68024	0	4	7.742930e-04	5166	0	0	0.000000e+00	4814	0	2	6.084210e-05	0	0.000000e+00	9094	0	0	0.000000e+00	60	0	0	0.000000e+00	4682	0	32872	0	0.000000e+00	136	0	1	4.115230e-04	2430	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3102	0	0	.	0	13	8.793410e-05	5	1.216430e-04	41104	0	0	0.000000e+00	912	0	0	0.000000e+00	15076	0	147838	0	0.000000e+00	3302	0	4	8.110300e-04	4932	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	3	4.629340e-05	64804	0	0	0.000000e+00	4782	0	0	13	9.652220e-05	5	1.540070e-04	32466	0	0	0.000000e+00	862	0	0	0.000000e+00	14816	0	134684	0	0.000000e+00	3386	0	4	7.742930e-04	5166	0	0	0.000000e+00	6970	0	0	0.000000e+00	310	0	3	4.694690e-05	63902	0	0	0.000000e+00	4812	0	0	6	7.440480e-05	0	0.000000e+00	24800	0	0	0.000000e+00	112	0	0	0.000000e+00	12888	0	80640	0	0.000000e+00	996	0	3	8.055850e-04	3724	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	2	9.507510e-05	21036	0	0	0.000000e+00	4786	0	0	12	101770844	12	103246714	0	0.43195	0.638212	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	6.646000	0.74203	0.676000	0.76740	1.176000	0.78918	102852936	G	.	rs76687508	.	.	11.570	9.399	7.651	9.354	.	.	.	19	14	14	-36	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+14+end+136	102803	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs76687508	1.400e-04	17	17	0	4	0	11	0	2	0	0	10374	11522	8604	6586	66482	906	16488	4	0	11	0	2	0	0	0	0	0	0	0	0	0	rs76687508	2.61370e-04	0.00000e+00	0.00000e+00	1.33535e-03	0.00000e+00	4.49341e-05	0.00000e+00	3.24929e-05	1.41136e-04	1.26013e-04	1.33535e-03	1.33999e-04	rs76687508	0.00000e+00	0.00000e+00	0.00000e+00	1.84957e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	1.16904e-04	7.22126e-05	1.84957e-03	9.67992e-05	.	.	rs76687508	76687508	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,754	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246617	103246617	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.818C>T	NP_000268.1:p.Ser273Phe	932	818	273	S/F	tCc/tTc	rs62514953&CM910289	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246617G>A	.	.	.	.	.	.	not_provided&likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.818C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.96995	0.579943	D	0.96946	0.595271	29.1	28.9	4.251765	4.136375	0.86990	0.86664	G/G	D	0.94420	0.998531103134155	0.94093	0.9986240629476324	.	0.99988	.	G/G	.	.	.	.	15.25787	0.933363766360079	0.96869	13.92744	1.00019999509016	0.95749	.	.	.	1	8.236e-06	0	0	0	0	1	8.238e-06	0	0	0	0	1	1.498e-05	0	0	1	9.415e-06	0	0	0	0	1	9.417e-06	0	0	0	0	1	1.840e-05	0	0	1	1.102e-05	0	0	0	0	1	1.102e-05	0	0	0	0	1	2.373e-05	0	0	0.99581	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999999999505	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.93790	.	0.000000	0.84330	D	0.000000	D	0.96655	0.615435	0.27277	.	0.99276	.	D	0.99751	0.9906	.	0.98771	.	D	0.97193	1.0003	S273F	Loss_of_disorder_(P_=_0.0089)&_Gain_of_methylation_at_K274_(P_=_0.0619)&_Loss_of_ubiquitination_at_K274_(P_=_0.0811)&_Loss_of_glycosylation_at_T278_(P_=_0.0815)&_Loss_of_sheet_(P_=_0.0817)	P00439	0.96319	0.87	.	0.96382	.	.	0.81001	simple_aae&simple_aae	A&A	1&1	0.86372	.	.	.	0.90584	.	.	0.84481	.	T	0.65096	0.685766458511	0.99822	.	9	0.92824	.	.	0.91255	.	.	19.8956	0.96955	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.94314	.	G/G	F	.	S	A	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852839G>A	598	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.S273F&UniProtKB_(protein):P00439#VAR_000973&OMIM_Allelic_Variant:612349.0023	.	.	AEFBI	D	0.84326	0.98580	D	0.99721	0.977398	.	2	7.957220e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34584	0	251344	0	0.000000e+00	10078	0	0	0.000000e+00	18392	0	0	0.000000e+00	21648	0	2	1.759970e-05	113638	0	2	1.759970e-05	113638	0	0	0.000000e+00	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	2	8.445730e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34252	0	236806	0	0.000000e+00	9570	0	0	0.000000e+00	17690	0	0	0.000000e+00	21632	0	2	1.948900e-05	102622	0	2	1.948900e-05	102622	0	0	0.000000e+00	30526	0	0	2	9.610760e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30520	0	208100	0	0.000000e+00	6210	0	0	0.000000e+00	13414	0	0	0.000000e+00	16734	0	2	2.233890e-05	89530	0	2	2.233890e-05	89530	0	0	0.000000e+00	30608	0	0	2	8.172340e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34450	0	244728	0	0.000000e+00	9996	0	0	0.000000e+00	18388	0	0	0.000000e+00	21646	0	2	1.792920e-05	111550	0	2	1.792920e-05	111550	0	0	0.000000e+00	30616	0	0	1	6.572980e-06	0	0.000000e+00	41418	0	0	0.000000e+00	912	0	0	0.000000e+00	15276	0	152138	0	0.000000e+00	3470	0	0	0.000000e+00	5194	0	0	0.000000e+00	10612	0	0	0.000000e+00	316	0	1	1.470030e-05	68026	0	1	1.470030e-05	68026	0	0	0.000000e+00	4828	0	0	0.000000e+00	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32880	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5484	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3108	0	0	.	0	1	6.761690e-06	0	0.000000e+00	41096	0	0	0.000000e+00	912	0	0	0.000000e+00	15088	0	147892	0	0.000000e+00	3302	0	0	0.000000e+00	4960	0	0	0.000000e+00	10612	0	0	0.000000e+00	304	0	1	1.543070e-05	64806	0	0	0.000000e+00	4796	0	0	1	7.422140e-06	0	0.000000e+00	32452	0	0	0.000000e+00	862	0	0	0.000000e+00	14830	0	134732	0	0.000000e+00	3386	0	0	0.000000e+00	5194	0	0	0.000000e+00	6970	0	0	0.000000e+00	310	0	1	1.564800e-05	63906	0	0	0.000000e+00	4826	0	0	0	0.000000e+00	0	0.000000e+00	24794	0	0	0.000000e+00	112	0	0	0.000000e+00	12902	0	80696	0	0.000000e+00	996	0	0	0.000000e+00	3752	0	0	0.000000e+00	10520	0	0	0.000000e+00	272	0	0	0.000000e+00	21036	0	0	0.000000e+00	4800	0	0	12	101770747	12	103246617	0	0.43195	0.638212	1.000000	0.71638	0.993000	0.69303	1.000000	0.86279	8.129000	0.89477	0.676000	0.76740	1.176000	0.78918	102852839	G	.	rs62514953	.	.	11.570	9.399	7.651	9.354	.	.	.	-24	16	-24	-9	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+24+start+136	598	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62514953	8.236e-06	1	1	0	0	0	0	0	1	0	0	10406	11566	8652	6614	66738	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs62514953	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.96282e-06	0.00000e+00	0.00000e+00	7.41829e-06	0.00000e+00	8.96282e-06	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62514953	62514953	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,718	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246630	103246630	T	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.805A>C	NP_000268.1:p.Ile269Leu	919	805	269	I/L	Atc/Ctc	rs62508692&CM981444	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103246630T>G	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.805A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.594706798131811E-4	.	.	.	.	.	.	.	T/T	T	D	0.80652	0.272377	D	0.92832	0.422774	24.8	24.2	3.521328	3.247270	0.64639	0.60670	T/T	T	0.17377	0.153485879302025	0.62794	0.99401068790117997	.	0.97530	.	T/T	.	.	.	.	5.287207	0.513846599856067	0.68921	4.569413	0.43521704024054	0.63369	.	.	.	11	9.060e-05	0	0	3	2.594e-04	11	9.061e-05	0	0	0	0	8	1.199e-04	0	0	7	6.591e-05	0	0	3	2.678e-04	7	6.592e-05	0	0	0	0	4	7.360e-05	0	0	11	1.212e-04	0	0	3	2.597e-04	11	1.212e-04	0	0	0	0	8	1.898e-04	0	0	0.99658	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.50053	0.999970484650511	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.67517	.	0.000000	0.84330	D	0.000000	D	0.94990	0.490428	0.22577	.	0.93827	.	D	0.99548	0.9850	.	0.89553	.	D	0.96996	0.9884	.	.	.	.	.	.	0.63355	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.39503	.	.	.	0.28271	.	.	0.59863	.	T	0.78403	0.776519656181	0.93425	.	10	0.44302	.	.	0.42487	.	.	16.0142	0.80222	0.0:0.0:0.0:1.0	.	1	2.6968716289104636E-4	2	2.644802962179318E-4	.	.	.	0.91276	.	T/T	L	.	I	G	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852852T>G	102842	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.I269L&Illumina_Laboratory_Services&Illumina:685433&UniProtKB_(protein):P00439#VAR_000969	.	.	AEFBI	D	0.74407	0.97384	D	0.97616	0.957154	.	23	9.150080e-05	0	0.000000e+00	16256	0	8	2.313340e-04	34582	0	251364	0	0.000000e+00	10078	0	0	0.000000e+00	18392	0	0	0.000000e+00	21648	0	14	1.231720e-04	113662	0	8	2.313340e-04	34582	0	0	0.000000e+00	30616	0	6	5.484260e-05	0	0.000000e+00	7164	0	1	5.844540e-05	17110	0	109404	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	5	1.169100e-04	42768	0	5	1.169100e-04	42768	0	0	0.000000e+00	15690	0	0	.	0	18	7.600520e-05	0	0.000000e+00	14902	0	8	2.335770e-04	34250	0	236826	0	0.000000e+00	9570	0	0	0.000000e+00	17690	0	0	0.000000e+00	21632	0	9	8.768000e-05	102646	0	8	2.335770e-04	34250	0	0	0.000000e+00	30526	0	0	20	9.609560e-05	0	0.000000e+00	16218	0	7	2.293730e-04	30518	0	208126	0	0.000000e+00	6212	0	0	0.000000e+00	13414	0	0	0.000000e+00	16734	0	12	1.339940e-04	89556	0	7	2.293730e-04	30518	0	0	0.000000e+00	30608	0	0	23	9.397420e-05	0	0.000000e+00	12026	0	8	2.322340e-04	34448	0	244748	0	0.000000e+00	9996	0	0	0.000000e+00	18388	0	0	0.000000e+00	21646	0	14	1.254770e-04	111574	0	8	2.322340e-04	34448	0	0	0.000000e+00	30616	0	0	13	8.548690e-05	2	4.831150e-05	41398	0	0	0.000000e+00	912	0	0	0.000000e+00	15262	0	152070	0	0.000000e+00	3468	0	0	0.000000e+00	5186	0	0	0.000000e+00	10600	0	0	0.000000e+00	316	0	11	1.617460e-04	68008	0	11	1.617460e-04	68008	0	0	0.000000e+00	4828	0	2	6.083840e-05	1	1.100110e-04	9090	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32874	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5476	0	0	0.000000e+00	246	0	1	1.459850e-04	6850	0	0	0.000000e+00	3112	0	0	.	0	12	8.117210e-05	2	4.869020e-05	41076	0	0	0.000000e+00	912	0	0	0.000000e+00	15074	0	147834	0	0.000000e+00	3302	0	0	0.000000e+00	4952	0	0	0.000000e+00	10600	0	0	0.000000e+00	304	0	10	1.543310e-04	64796	0	0	0.000000e+00	4796	0	0	13	9.653370e-05	2	6.166370e-05	32434	0	0	0.000000e+00	862	0	0	0.000000e+00	14820	0	134668	0	0.000000e+00	3384	0	0	0.000000e+00	5186	0	0	0.000000e+00	6960	0	0	0.000000e+00	310	0	11	1.721870e-04	63884	0	0	0.000000e+00	4826	0	0	5	6.200550e-05	1	4.036160e-05	24776	0	0	0.000000e+00	112	0	0	0.000000e+00	12888	0	80638	0	0.000000e+00	994	0	0	0.000000e+00	3744	0	0	0.000000e+00	10508	0	0	0.000000e+00	272	0	4	1.902410e-04	21026	0	0	0.000000e+00	4800	0	0	12	101770760	12	103246630	0	0.43195	0.638212	1.000000	0.71638	0.996000	0.76049	1.000000	0.86279	6.271000	0.72566	0.665000	0.62972	1.138000	0.64695	102852852	T	.	rs62508692	.	.	11.570	9.399	7.651	9.354	.	.	.	3	5	-22	-37	0.00	0.00	0.00	0.04	PAH	0.00	exon-NM_001354304.2-8+37+start+136	102842	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62508692	9.060e-05	11	2	0	0	3	0	0	8	0	0	10406	11566	8652	6614	66740	908	16512	0	0	0	0	2	0	0	0	0	0	0	0	0	0	rs62508692	0.00000e+00	1.78720e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.25455e-04	5.47246e-04	0.00000e+00	5.93428e-05	1.34749e-04	1.78720e-04	9.33927e-05	rs62508692	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.33298e-04	0.00000e+00	.	5.84522e-05	7.21605e-05	1.33298e-04	6.45328e-05	.	.	rs62508692	62508692	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,726	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246635	103246635	T	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.800A>T	NP_000268.1:p.Gln267Leu	914	800	267	Q/L	cAg/cTg	rs778154939&CM1111581&CM112742	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103246635T>A	.	.	.	.	.	.	uncertain_significance	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.800A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.93062	0.463218	D	0.96961	0.596733	29.7	28.4	4.309391	4.084689	0.88442	0.85134	T/T	D	0.95098	0.998767733573914	0.76695	0.99641661357832623	.	0.99937	.	T/T	.	.	.	.	12.8773	0.878880753968125	0.94586	12.16136	0.941037657147278	0.93619	.	.	.	1	8.236e-06	0	0	0	0	1	8.237e-06	1	1.156e-04	0	0	0	0	0	0	1	9.415e-06	0	0	0	0	1	9.417e-06	1	1.272e-04	0	0	0	0	0	0	1	1.102e-05	0	0	0	0	1	1.102e-05	1	1.774e-04	0	0	0	0	0	0	0.99715	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999997298143	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.86445	.	0.000000	0.84330	D	0.000000	D	0.96935	0.640547	0.26511	.	0.98361	.	D	0.99770	0.9911	.	0.99262	.	D	0.96751	0.9732	Q267L	Gain_of_sheet_(P_=_0.0827)&_Loss_of_disorder_(P_=_0.0831)&_Gain_of_catalytic_residue_at_Y268_(P_=_0.2022)&_Loss_of_loop_(P_=_0.2237)&_Gain_of_MoRF_binding_(P_=_0.2515)	P00439	0.96785	0.879	.	0.96283	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.92518	.	.	.	0.90584	.	.	0.97372	.	T	0.75103	0.754445672035	0.99762	.	10	0.76473	.	.	0.91255	.	.	16.0142	0.80222	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.96871	.	T/T	L	.	Q	A	518	0.74548	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102852857T>A	225135	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.83657	0.98520	D	0.99757	0.978192	.	1	3.978230e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34586	0	251368	0	0.000000e+00	10076	0	1	5.436560e-05	18394	0	0	0.000000e+00	21648	0	0	0.000000e+00	113662	0	1	5.436560e-05	18394	0	0	0.000000e+00	30616	0	1	9.140270e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17110	0	109406	0	0.000000e+00	2320	0	1	1.105460e-04	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	1	1.105460e-04	9046	0	0	0.000000e+00	15690	0	0	.	0	1	4.222440e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34254	0	236830	0	0.000000e+00	9568	0	1	5.652270e-05	17692	0	0	0.000000e+00	21632	0	0	0.000000e+00	102646	0	1	5.652270e-05	17692	0	0	0.000000e+00	30526	0	0	1	4.804830e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30520	0	208124	0	0.000000e+00	6210	0	1	7.453790e-05	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89552	0	1	7.453790e-05	13416	0	0	0.000000e+00	30608	0	0	1	4.085770e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34452	0	244752	0	0.000000e+00	9994	0	1	5.437740e-05	18390	0	0	0.000000e+00	21646	0	0	0.000000e+00	111574	0	1	5.437740e-05	18390	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770765	12	103246635	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	8.017000	0.88732	0.665000	0.62972	1.138000	0.64695	102852857	T	.	rs778154939	.	.	11.570	9.399	7.651	9.354	.	.	.	-10	-2	-46	-42	0.00	0.00	0.00	0.03	PAH	0.00	exon-NM_001354304.2-8+42+start+136	225135	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103246635-103246635	8.236e-06	1	1	0	0	0	1	0	0	0	0	10406	11566	8652	6614	66740	908	16512	0	0	1	0	0	0	0	0	0	0	0	0	0	0	rs778154939	0.00000e+00	0.00000e+00	0.00000e+00	5.79777e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.98343e-06	5.79777e-05	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs778154939	778154939	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,730	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246639	103246639	T	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.796A>C	NP_000268.1:p.Thr266Pro	910	796	266	T/P	Aca/Cca	rs62508752&CM123355	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103246639T>G	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.796A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.97006	0.580695	D	0.96957	0.596351	29.2	27.3	4.259807	3.951046	0.87211	0.80585	T/T	D	0.98532	0.999697804450989	0.79775	0.99688978104628112	.	0.99995	.	T/T	.	.	.	.	15.22884	0.932752252389254	0.96848	14.75987	1.0260523193366	0.96490	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99734	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999997298143	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.99241	.	0.000000	0.84330	D	0.000000	D	0.96658	0.615674	0.28783	.	0.98384	.	D	0.99844	0.9933	.	0.94089	.	D	0.96136	0.9324	.	.	.	.	.	.	0.99256	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.87760	.	.	.	0.90584	.	.	0.97372	.	D	0.87038	0.833102107048	0.99858	.	10	0.83351	.	.	0.91255	.	.	16.0142	0.80222	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.69125	.	T/T	P	.	T	G	518	0.74548	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852861T>G	120286	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.84566	0.98601	D	0.99995	0.990697	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770769	12	103246639	0	0.43195	0.638212	1.000000	0.71638	0.997000	0.79791	0.999000	0.70432	8.017000	0.88732	0.665000	0.62972	1.138000	0.64695	102852861	T	.	rs62508752	.	.	11.570	9.399	7.651	9.354	.	.	.	-6	-4	-31	-46	0.00	0.00	0.00	0.03	PAH	0.00	exon-NM_001354304.2-8+46+start+136	120286	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508752	62508752	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,733	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246650	103246650	A	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.785T>G	NP_000268.1:p.Val262Gly	899	785	262	V/G	gTc/gGc	rs281865445&CM1514935	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103246650A>C	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.785T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.97043	0.583189	D	0.96995	0.599934	29.2	27.4	4.259305	3.963446	0.87199	0.81002	A/A	D	0.97978	0.999578297138214	0.82406	0.99725734495696783	.	0.99993	.	A/A	.	.	.	.	16.59118	0.960144690377744	0.97696	15.46793	1.04696347845762	0.97017	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99738	.	.	.	5.72	5.72	0.89380	0	0.45803	0.59043	.	.	0.74766	0.999999997183774	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.87125	.	0.000000	0.84330	D	0.000000	D	0.97549	0.700583	0.28819	.	0.98373	.	D	0.99835	0.9930	.	0.96323	.	D	0.96221	0.9382	V262G	Loss_of_stability_(P_=_9e-04)&_Gain_of_methylation_at_R261_(P_=_0.0545)&_Loss_of_loop_(P_=_0.2237)&_Loss_of_MoRF_binding_(P_=_0.2256)&_Loss_of_sheet_(P_=_0.302)	P00439	0.89447	0.767	.	0.98915	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.91786	.	.	.	0.90584	.	.	0.97372	.	T	0.81361	0.796040773392	0.99189	.	10	0.92824	.	.	0.91255	.	.	15.998	0.80060	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.84505	.	A/A	G	.	V	C	518	0.74548	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852872A>C	120285	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.90640	0.99060	D	0.99802	0.979304	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770780	12	103246650	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	9.325000	0.96006	0.756000	0.94297	1.312000	0.94714	102852872	A	.	rs281865445	.	.	11.570	9.399	7.651	9.354	.	.	.	0	-17	1	-15	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+57+start+136	120285	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865445	281865445	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,736	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246653	103246653	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.782G>C	NP_000268.1:p.Arg261Pro	896	782	261	R/P	cGa/cCa	rs5030849&CM910287&CM950891&COSV61020894	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246653C>G	.	.	.	.	.	.	pathogenic&not_provided	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.782G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.96058	0.558006	D	0.95995	0.563761	29.5	31	4.289916	4.337082	0.87981	0.90502	C/C	D	0.94977	0.998720169067383	0.86260	0.99775344853478443	.	0.99994	.	C/C	.	.	.	.	17.78403	0.982044229966473	0.98249	16.27719	1.06935998589158	0.97524	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99786	.	.	.	5.72	5.72	0.89380	0	0.45803	0.59043	.	.	0.74766	0.999999999999476	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.91818	.	0.000000	0.84330	D	0.000000	D	0.96661	0.615998	0.28314	.	0.99384	.	D	0.99880	0.9947	.	0.99696	.	D	0.96247	0.9400	R261P	Loss_of_methylation_at_R261_(P_=_0.0162)&_Loss_of_MoRF_binding_(P_=_0.07)&_Loss_of_stability_(P_=_0.0932)&_Loss_of_catalytic_residue_at_R261_(P_=_0.1356)&_Loss_of_loop_(P_=_0.2237)	P00439	0.99568	0.959	.	0.99414	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.91353	.	.	.	0.77913	.	.	0.70309	.	D	0.92361	0.868555307388	0.99822	.	10	0.62352	.	.	0.56456	.	.	19.8761	0.96868	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.97856	.	C/C	P	.	R	G	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852875C>G	102832	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_000964&DeBelle_Laboratory_for_Biochemical_Genetics:p.R261P	.	.	AEFBI	D	0.87762	0.98856	D	0.99996	0.991229	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770783	12	103246653	0	0.43195	0.638212	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	7.905000	0.86479	0.599000	0.40250	1.026000	0.45946	102852875	C	.	rs5030849	.	.	11.570	9.399	7.651	9.354	.	.	.	-3	-20	-45	-18	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+60+start+136	102832	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs5030849	5030849	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,737	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
7	140501331	140501331	A	C	C	missense_variant	MODERATE	BRAF	673	Transcript	NM_001374258.1	protein_coding	6/20	.	NM_001374258.1:c.741T>G	NP_001361187.1:p.Phe247Leu	967	741	247	F/L	ttT/ttG	rs397509343&COSV56165267&COSV56257859	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	NDUFB2	.	chr7:g.140501331A>C	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&1&1	1&1&1	.	.	.	.	.	BRAF&NM_004333.4&c.741T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.84758	0.324081	D	0.84559	0.227743	23.6	23.5	3.079095	2.991185	0.53795	0.54516	./.	D	0.78586	0.988228380680084	0.92489	0.99844986203178299	.	0.99305	.	./.	.	.	.	.	3.950478	0.338724355373116	0.57831	4.114685	0.361686240334421	0.59360	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.93587	.	.	.	5.43	3.08	0.34576	0	0.79440	0.708844	.	.	0.17217	0.137939894440609	.	0	0.39905	0.608884	.	.	.	.	.	.	0	0.67416	0.683762	Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain&Protein_kinase_C-like&_phorbol_ester/diacylglycerol-binding_domain	.	.	.	0.50622	.	0.000000	0.84330	D	0.000000	D	0.92096	0.344169	0.83621	.	0.96027	.	D	0.92429	0.7772	.	0.84398	.	D	0.90605	0.5042	F247L	Loss_of_helix_(P_=_0.028)&_Gain_of_loop_(P_=_0.0435)&_Gain_of_relative_solvent_accessibility_(P_=_0.09)&_Gain_of_solvent_accessibility_(P_=_0.1319)&_Loss_of_MoRF_binding_(P_=_0.1971)	P15056	0.83212	0.695	.	0.91202	.	.	0.58761	simple_aae	D	0.999999	0.74582	.	.	.	0.45366	.	.	0.45591	.	D	0.99815	0.953254520893	0.94085	.	10	0.65728	.	.	0.72154	.	.	4.5974	0.11728	0.5182:0.0:0.4818:0.0	.	.	.	.	.	.	.	.	0.76853	.	./.	L	.	F	C	794	0.45591	.	7	C0028326&CN260604&CN166718&CN517202	PS163950	ORPHA648&ORPHA98733&ORPHA536391	Pathogenic	NC_000007.14:g.140801531A>C	55793	reviewed_by_expert_panel	Noonan_syndrome&Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:66924744-6ed6-4985-8479-1c8bab448ed0	.	.	AEFBI	D	0.58030	0.93368	N	0.50453	0.449922	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7	140147800	7	140501331	0	0.46895	0.6512	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	3.428000	0.52560	0.751000	0.87719	1.307000	0.88494	140801531	A	.	rs397509343	.	.	9.582	8.819	11.030	2.507	.	.	.	29	-19	4	30	0.00	0.08	0.00	0.00	BRAF	1.00	exon-NM_001378474.1-6+29+end+149	55793	Pathogenic	reviewed_by_expert_panel	RASopathy&Noonan_syndrome_and_Noonan-related_syndrome&not_provided&Noonan_syndrome	MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN517202&MONDO:MONDO:0018997&MeSH:D009634&MedGen:C0028326&OMIM:PS163950&Orphanet:648	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397509343	397509343	.	.	.	BRAF	BRAF:exonic	BRAF:missense	BRAF:Melanoma\x2cmalignant\x2csomatic\x3bLEOPARD_syndrome_3\x3bCardiofaciocutaneous_syndrome\x3bAdenocarcinoma_of_lung\x2csomatic\x3bNoonan_syndrome_7\x3bColorectal_cancer\x2csomatic\x3bNonsmall_cell_lung_cancer\x2csomatic	BRAF:155600\x3b613707\x3b115150\x3b211980\x3b613706\x3b114500\x3b211980	BRAF:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	BRAF:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant\x3b.\x3b.	0	0.999978196041997	2.18039579639691e-05	3.88216441101404e-14	DISEASE: Note=Defects in BRAF are found in a wide range of cancers. {ECO:0000269|PubMed:18974108}.; DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:23263490, ECO:0000269|PubMed:24455489}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation. {ECO:0000269|PubMed:18974108}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,494	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246654	103246654	G	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.781C>G	NP_000268.1:p.Arg261Gly	895	781	261	R/G	Cga/Gga	rs5030850&CM1514931&CM910288&COSV61016430	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246654G>C	.	.	.	.	.	.	uncertain_significance	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.781C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.91288	0.425203	D	0.95444	0.542126	26.2	25.5	3.877037	3.650873	0.74555	0.71089	G/G	D	0.87065	0.99523913860321	0.97502	0.99903397549535711	.	0.99810	.	G/G	.	.	.	.	5.906849	0.573499252470914	0.73044	6.465663	0.64932592312207	0.76325	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99776	.	.	.	5.72	3.79	0.42757	0	0.45803	0.59043	.	.	0.30287	0.98161880251868	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.96278	.	0.000000	0.84330	D	0.000000	D	0.97711	0.717581	0.28657	.	0.97598	.	D	0.99743	0.9904	.	0.99168	.	D	0.96840	0.9788	R261G	Gain_of_catalytic_residue_at_V262_(P_=_0.015)&_Loss_of_methylation_at_R261_(P_=_0.0162)&_Loss_of_stability_(P_=_0.0289)&_Loss_of_MoRF_binding_(P_=_0.0847)&_Loss_of_sheet_(P_=_0.3635)	P00439	0.98270	0.912	.	0.91563	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.91998	.	.	.	0.90584	.	.	0.92359	.	D	0.89300	0.847920536995	0.99434	.	10	0.83351	.	.	0.91255	.	.	14.3299	0.66106	0.0:0.0:0.6162:0.3838	.	.	.	.	.	.	.	.	0.98466	.	G/G	G	.	R	C	518	0.74548	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102852876G>C	133314	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.63924	0.95231	D	0.90811	0.926663	.	1	3.978770e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34580	0	251334	0	0.000000e+00	10078	0	1	5.437150e-05	18392	0	0	0.000000e+00	21644	0	0	0.000000e+00	113632	0	1	5.437150e-05	18392	0	0	0.000000e+00	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17110	0	109400	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13390	0	0	0.000000e+00	42768	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	1	4.223040e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34248	0	236796	0	0.000000e+00	9570	0	1	5.652910e-05	17690	0	0	0.000000e+00	21628	0	0	0.000000e+00	102616	0	1	5.652910e-05	17690	0	0	0.000000e+00	30526	0	0	1	4.805100e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30518	0	208112	0	0.000000e+00	6212	0	1	7.454900e-05	13414	0	0	0.000000e+00	16730	0	0	0.000000e+00	89546	0	1	7.454900e-05	13414	0	0	0.000000e+00	30608	0	0	1	4.086370e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34446	0	244716	0	0.000000e+00	9996	0	1	5.438330e-05	18388	0	0	0.000000e+00	21642	0	0	0.000000e+00	111542	0	1	5.438330e-05	18388	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770784	12	103246654	0	0.43195	0.638212	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	2.806000	0.47644	0.676000	0.76740	1.176000	0.78918	102852876	G	.	rs5030850	.	.	11.570	9.399	7.651	9.354	.	.	.	-4	-21	-19	15	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+61+start+136	133314	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs5030850	0.00000e+00	0.00000e+00	0.00000e+00	5.79845e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.41906e-06	0.00000e+00	5.79845e-05	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs5030850	5030850	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,740	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246680	103246680	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.755G>A	NP_000268.1:p.Arg252Gln	869	755	252	R/Q	cGg/cAg	rs62644503&CM112731&CM941134	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246680C>T	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.755G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.92498	0.450337	D	0.96517	0.578229	29.1	32	4.249452	4.468923	0.86928	0.91627	C/C	D	0.96328	0.999145269393921	0.99997	0.99961009328578809	.	0.99916	.	C/C	.	.	.	.	14.87982	0.925342427191912	0.96585	12.62195	0.957036472825479	0.94260	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99769	.	.	.	5.92	5.92	0.95557	0	0.45803	0.59043	.	.	0.74766	0.999999999999832	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.98718	.	0.000000	0.84330	D	0.000000	D	0.94379	0.453126	0.27787	.	0.99374	.	D	0.99796	0.9918	.	0.99056	.	D	0.97286	1.0058	R252Q	Loss_of_methylation_at_R252_(P_=_0.0335)&_Loss_of_stability_(P_=_0.0614)&_Loss_of_phosphorylation_at_S250_(P_=_0.1868)&_Loss_of_MoRF_binding_(P_=_0.1871)&_Loss_of_catalytic_residue_at_S251_(P_=_0.3313)	P00439	0.99641	0.964	.	0.88152	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.72240	.	.	.	0.90584	.	.	0.97372	.	T	0.76881	0.766379714012	0.98672	.	10	0.79402	.	.	0.91255	.	.	20.3167	0.98654	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.84922	.	C/C	Q	.	R	T	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852902C>T	102824	reviewed_by_expert_panel	Phenylketonuria&not_provided	Molecular_Diagnostic_Laboratory_for_Inherited_Cardiovascular_Disease&Montreal_Heart_Institute:2018004&DeBelle_Laboratory_for_Biochemical_Genetics:p.R252Q&UniProtKB_(protein):P00439#VAR_000957	.	.	AEFBI	D	0.85537	0.98683	D	0.99679	0.976543	.	2	7.959820e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34572	0	251262	0	0.000000e+00	10072	0	1	5.438330e-05	18388	0	0	0.000000e+00	21636	0	1	8.803750e-06	113588	0	1	5.438330e-05	18388	0	0	0.000000e+00	30614	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17108	0	109388	0	0.000000e+00	2320	0	0	0.000000e+00	9042	0	0	0.000000e+00	13394	0	0	0.000000e+00	42758	0	.	.	.	.	0	0.000000e+00	15688	0	0	.	0	2	8.448510e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34240	0	236728	0	0.000000e+00	9564	0	1	5.654190e-05	17686	0	0	0.000000e+00	21620	0	1	9.748870e-06	102576	0	1	5.654190e-05	17686	0	0	0.000000e+00	30524	0	0	2	9.612520e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30510	0	208062	0	0.000000e+00	6210	0	1	7.457120e-05	13410	0	0	0.000000e+00	16724	0	1	1.117090e-05	89518	0	1	7.457120e-05	13410	0	0	0.000000e+00	30606	0	0	2	8.175140e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34438	0	244644	0	0.000000e+00	9990	0	1	5.439510e-05	18384	0	0	0.000000e+00	21634	0	1	8.968770e-06	111498	0	1	5.439510e-05	18384	0	0	0.000000e+00	30614	0	0	2	1.315530e-05	1	2.417210e-05	41370	0	0	0.000000e+00	912	0	0	0.000000e+00	15272	0	152030	0	0.000000e+00	3472	0	0	0.000000e+00	5186	0	0	0.000000e+00	10588	0	0	0.000000e+00	316	0	1	1.470330e-05	68012	0	1	2.417210e-05	41370	0	0	0.000000e+00	4818	0	0	0.000000e+00	0	0.000000e+00	9080	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32842	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5466	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3102	0	0	.	0	2	1.353290e-05	1	2.436170e-05	41048	0	0	0.000000e+00	912	0	0	0.000000e+00	15084	0	147788	0	0.000000e+00	3302	0	0	0.000000e+00	4950	0	0	0.000000e+00	10588	0	0	0.000000e+00	304	0	1	1.543210e-05	64800	0	0	0.000000e+00	4786	0	0	1	7.427880e-06	0	0.000000e+00	32410	0	0	0.000000e+00	862	0	0	0.000000e+00	14826	0	134628	0	0.000000e+00	3388	0	0	0.000000e+00	5186	0	0	0.000000e+00	6948	0	0	0.000000e+00	310	0	1	1.565290e-05	63886	0	0	0.000000e+00	4816	0	0	1	1.240790e-05	1	4.041060e-05	24746	0	0	0.000000e+00	112	0	0	0.000000e+00	12898	0	80594	0	0.000000e+00	998	0	0	0.000000e+00	3744	0	0	0.000000e+00	10496	0	0	0.000000e+00	272	0	0	0.000000e+00	21028	0	0	0.000000e+00	4790	0	0	12	101770810	12	103246680	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	0.991000	0.53220	7.905000	0.86479	0.599000	0.40250	1.026000	0.45946	102852902	C	.	rs62644503	.	gain/acceptor/103246680-103246681/Medium/7.027102	11.570	9.399	7.651	9.354	.	.	.	-2	48	-2	-45	0.11	0.02	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+48+end+136	102824	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62644503	0.00000e+00	0.00000e+00	0.00000e+00	5.79979e-05	0.00000e+00	8.96620e-06	0.00000e+00	0.00000e+00	7.42060e-06	8.98666e-06	5.79979e-05	8.12110e-06	rs62644503	1.14653e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84454e-05	0.00000e+00	1.14653e-04	3.22664e-05	.	.	rs62644503	62644503	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,743	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246690	103246690	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.745C>T	NP_000268.1:p.Leu249Phe	859	745	249	L/F	Ctt/Ttt	rs74503222&CM950890	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246690G>A	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.745del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.92439	0.449076	D	0.96635	0.587586	26.8	26.1	3.979334	3.761247	0.77909	0.74257	G/G	D	0.86174	0.99471789598465	0.98022	0.99910564401216306	.	0.99992	.	G/G	.	.	.	.	12.40565	0.866914131603806	0.93965	12.76946	0.962078626811514	0.94452	.	.	.	3	2.471e-05	0	0	0	0	3	2.473e-05	0	0	0	0	3	4.498e-05	0	0	3	2.825e-05	0	0	0	0	3	2.827e-05	0	0	0	0	3	5.524e-05	0	0	1	1.102e-05	0	0	0	0	1	1.103e-05	0	0	0	0	1	2.376e-05	0	0	0.99710	.	.	.	5.92	5.03	0.67015	0	0.45803	0.59043	.	.	0.74766	0.999999822753513	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.97952	.	0.000000	0.84330	D	0.000000	D	0.97568	0.702505	0.27304	.	0.98416	.	D	0.99820	0.9925	.	0.98927	.	D	0.96303	0.9438	L249F	Gain_of_catalytic_residue_at_L249_(P_=_0.0553)&_Gain_of_methylation_at_R252_(P_=_0.1442)&_Gain_of_MoRF_binding_(P_=_0.2988)&_Loss_of_sheet_(P_=_0.302)&_Loss_of_phosphorylation_at_S250_(P_=_0.3174)	P00439	0.97773	0.9	.	0.97100	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.72240	.	.	.	0.90584	.	.	0.92359	.	D	0.85542	0.823348283768	0.99874	.	10	0.83351	.	.	0.78490	.	.	14.9695	0.70875	0.0684:0.0:0.9316:0.0	.	.	.	.	.	.	.	.	0.95374	.	G/G	F	.	L	A	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852912G>A	102821	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.L249F&UniProtKB_(protein):P00439#VAR_000955&HGMD:CM950890	.	.	AEFBI	D	0.84418	0.98588	D	0.99797	0.979181	.	10	3.980540e-05	0	0.000000e+00	16252	0	0	0.000000e+00	34574	0	251222	0	0.000000e+00	10070	0	0	0.000000e+00	18386	0	3	1.386830e-04	21632	0	7	6.164140e-05	113560	0	7	6.164140e-05	113560	0	0	0.000000e+00	30616	0	8	7.314490e-05	0	0.000000e+00	7162	0	0	0.000000e+00	17108	0	109372	0	0.000000e+00	2320	0	0	0.000000e+00	9040	0	3	2.240480e-04	13390	0	5	1.169590e-04	42750	0	5	1.169590e-04	42750	0	0	0.000000e+00	15690	0	0	.	0	10	4.224940e-05	0	0.000000e+00	14900	0	0	0.000000e+00	34242	0	236690	0	0.000000e+00	9562	0	0	0.000000e+00	17684	0	3	1.387860e-04	21616	0	7	6.826200e-05	102546	0	7	6.826200e-05	102546	0	0	0.000000e+00	30526	0	0	10	4.806810e-05	0	0.000000e+00	16214	0	0	0.000000e+00	30510	0	208038	0	0.000000e+00	6210	0	0	0.000000e+00	13408	0	3	1.794470e-04	16718	0	7	7.820530e-05	89508	0	7	7.820530e-05	89508	0	0	0.000000e+00	30608	0	0	9	3.679390e-05	0	0.000000e+00	12022	0	0	0.000000e+00	34440	0	244606	0	0.000000e+00	9988	0	0	0.000000e+00	18382	0	3	1.386960e-04	21630	0	6	5.382520e-05	111472	0	6	5.382520e-05	111472	0	0	0.000000e+00	30616	0	0	6	3.943480e-05	0	0.000000e+00	41432	0	0	0.000000e+00	908	0	0	0.000000e+00	15272	0	152150	0	0.000000e+00	3472	0	0	0.000000e+00	5188	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	6	8.818860e-05	68036	0	6	8.818860e-05	68036	0	0	0.000000e+00	4830	0	2	6.083100e-05	0	0.000000e+00	9078	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32878	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	2	2.918000e-04	6854	0	0	0.000000e+00	3110	0	0	.	0	6	4.056800e-05	0	0.000000e+00	41110	0	0	0.000000e+00	908	0	0	0.000000e+00	15084	0	147900	0	0.000000e+00	3302	0	0	0.000000e+00	4952	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	6	9.256970e-05	64816	0	0	0.000000e+00	4798	0	0	6	4.453020e-05	0	0.000000e+00	32462	0	0	0.000000e+00	862	0	0	0.000000e+00	14826	0	134740	0	0.000000e+00	3388	0	0	0.000000e+00	5188	0	0	0.000000e+00	6968	0	0	0.000000e+00	310	0	6	9.388200e-05	63910	0	0	0.000000e+00	4828	0	0	0	0.000000e+00	0	0.000000e+00	24806	0	0	0.000000e+00	108	0	0	0.000000e+00	12898	0	80704	0	0.000000e+00	998	0	0	0.000000e+00	3746	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	0	0.000000e+00	21044	0	0	0.000000e+00	4802	0	0	12	101770820	12	103246690	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	0.998000	0.65909	8.154000	0.89585	0.676000	0.76740	1.176000	0.78918	102852912	G	.	rs74503222	.	.	11.570	9.399	7.651	9.354	.	.	.	-40	38	38	34	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+38+end+136	102821	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs74503222	2.471e-05	3	3	0	0	0	0	0	3	0	0	10398	11550	8648	6600	66692	908	16512	0	0	0	0	3	0	0	0	0	0	0	0	0	0	rs74503222	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.34602e-04	6.27780e-05	0.00000e+00	0.00000e+00	4.45229e-05	3.59596e-05	1.34602e-04	4.06055e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs74503222	74503222	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,746	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103234250	103234250	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1243G>A	NP_000268.1:p.Asp415Asn	1357	1243	415	D/N	Gac/Aac	rs62644499&CM113433&CM920564&COSV61015980	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103234250C>T	.	.	.	.	.	.	pathogenic/likely_pathogenic&pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1243G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	5.189413596263622E-4	.	.	.	.	.	.	.	C/C	C	T	0.41522	-0.0687729	D	0.68630	-0.0260454	17.11	19.01	1.712594	1.907415	0.25298	0.31108	C/C	T	0.07953	0.0651551562214875	0.01813	0.31825538576440615	.	0.88378	.	C/C	.	.	.	.	1.5717	-0.29631580815548	0.28219	1.023569	-0.580359479633839	0.19541	.	.	.	7	5.765e-05	0	0	1	8.673e-05	7	5.769e-05	0	0	0	0	6	8.992e-05	0	0	5	4.708e-05	0	0	1	8.954e-05	5	4.711e-05	0	0	0	0	4	7.362e-05	0	0	5	5.510e-05	0	0	1	8.682e-05	5	5.513e-05	0	0	0	0	4	9.495e-05	0	0	0.99508	.	.	.	5.63	4.74	0.59717	0	0.26702	0.573888	.	.	0.13608	0.0248598976737437	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.71628	.	0.043804	0.84330	D	0.000000	D	0.90767	0.297365	0.03175	.	0.88853	.	D	0.93114	0.7967	.	0.85532	.	D	0.91531	0.5721	D415N	Gain_of_methylation_at_R413_(P_=_0.0949)&_Gain_of_MoRF_binding_(P_=_0.1682)&_Loss_of_phosphorylation_at_S411_(P_=_0.1793)&_Loss_of_sheet_(P_=_0.302)&_Loss_of_solvent_accessibility_(P_=_0.4141)	P00439	0.97729	0.899	.	0.01558	.	.	0.45564	simple_aae&simple_aae	A&A	0.998854&0.998854	0.00109	.	.	.	0.15535	.	.	0.16862	.	T	0.24470	0.395695507526	0.82346	.	9	0.01155	.	.	0.00964	.	.	7.6145	0.27317	0.0:0.7537:0.0:0.2463	.	1	2.6968716289104636E-4	3	3.9672044432689763E-4	.	.	.	0.76946	.	C/C	N	.	D	T	496	0.76301	.	12	C0751435&C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102840472C>T	617	reviewed_by_expert_panel	Hyperphenylalaninemia&_non-pku&Phenylketonuria&not_provided	Illumina_Laboratory_Services&Illumina:828996&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2840561&DeBelle_Laboratory_for_Biochemical_Genetics:p.D415N&OMIM_Allelic_Variant:612349.0043&UniProtKB_(protein):P00439#VAR_001039	.	.	AEFBCI	D	0.30919	0.59451	D	0.54867	0.526220	.	27	1.073840e-04	0	0.000000e+00	16254	0	12	3.471820e-04	34564	0	251434	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21644	0	15	1.318730e-04	113746	0	12	3.471820e-04	34564	0	0	0.000000e+00	30616	0	12	1.096870e-04	0	0.000000e+00	7164	0	8	4.676170e-04	17108	0	109402	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	4	9.353220e-05	42766	0	8	4.676170e-04	17108	0	0	0.000000e+00	15690	0	0	.	0	25	1.055320e-04	0	0.000000e+00	14900	0	12	3.505490e-04	34232	0	236896	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21628	0	13	1.265450e-04	102730	0	12	3.505490e-04	34232	0	0	0.000000e+00	30526	0	0	20	9.611040e-05	0	0.000000e+00	16216	0	10	3.279120e-04	30496	0	208094	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	10	1.116720e-04	89548	0	10	3.279120e-04	30496	0	0	0.000000e+00	30608	0	0	27	1.102870e-04	0	0.000000e+00	12024	0	12	3.485330e-04	34430	0	244816	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21642	0	15	1.343410e-04	111656	0	12	3.485330e-04	34430	0	0	0.000000e+00	30616	0	0	16	1.052520e-04	1	2.418730e-05	41344	0	0	0.000000e+00	910	0	5	3.272680e-04	15278	0	152016	0	0.000000e+00	3470	0	0	0.000000e+00	5194	0	0	0.000000e+00	10584	0	0	0.000000e+00	316	0	6	8.820160e-05	68026	0	5	3.272680e-04	15278	0	0	0.000000e+00	4802	0	8	2.437390e-04	1	1.102290e-04	9072	0	0	0.000000e+00	60	0	3	6.399320e-04	4688	0	32822	0	0.000000e+00	134	0	0	0.000000e+00	2426	0	0	0.000000e+00	5460	0	0	0.000000e+00	246	0	1	1.460280e-04	6848	0	0	0.000000e+00	3098	0	0	.	0	15	1.015210e-04	1	2.437720e-05	41022	0	0	0.000000e+00	910	0	5	3.313450e-04	15090	0	147752	0	0.000000e+00	3300	0	0	0.000000e+00	4960	0	0	0.000000e+00	10584	0	0	0.000000e+00	304	0	5	7.717240e-05	64790	0	0	0.000000e+00	4770	0	0	16	1.188460e-04	1	3.086990e-05	32394	0	0	0.000000e+00	862	0	5	3.371090e-04	14832	0	134628	0	0.000000e+00	3386	0	0	0.000000e+00	5194	0	0	0.000000e+00	6942	0	0	0.000000e+00	310	0	6	9.388790e-05	63906	0	0	0.000000e+00	4800	0	0	13	1.613260e-04	1	4.045310e-05	24720	0	0	0.000000e+00	110	0	5	3.874770e-04	12904	0	80582	0	0.000000e+00	996	0	0	0.000000e+00	3752	0	0	0.000000e+00	10492	0	0	0.000000e+00	272	0	3	1.425580e-04	21044	0	0	0.000000e+00	4774	0	0	12	101758380	12	103234250	0	0.43195	0.638212	1.000000	0.71638	0.817000	0.38496	0.996000	0.59523	3.759000	0.54939	0.599000	0.40250	1.026000	0.45946	102840472	C	.	rs62644499	.	.	10.477	9.491	8.924	9.158	.	.	.	-17	43	43	-23	0.00	0.07	0.00	0.00	PAH	0.00	exon-NM_001354304.2-13+43+end+116	617	Pathogenic	reviewed_by_expert_panel	not_provided&Hyperphenylalaninemia&Phenylketonuria	MedGen:CN517202&Human_Phenotype_Ontology:HP:0004923&MedGen:C0751435&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62644499	5.765e-05	7	7	0	0	1	0	0	6	0	0	10406	11530	8654	6614	66724	908	16510	0	1	0	0	6	0	0	0	0	0	0	0	0	0	rs62644499	0.00000e+00	3.57611e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.34291e-04	0.00000e+00	0.00000e+00	1.18626e-04	9.87983e-05	3.57611e-04	1.09635e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62644499	62644499	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,647	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103246713	103246713	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.722G>A	NP_000268.1:p.Arg241His	836	722	241	R/H	cGc/cAc	rs62508730&CD034766&CM930547&CM950889&COSV100187953	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246713C>T	.	.	.	.	.	.	pathogenic	0&0&0&0&1	1&1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.722G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.87288	0.360413	D	0.93223	0.436298	28.2	27.9	4.150969	4.022102	0.83839	0.83068	C/C	T	0.30590	0.444383484455002	0.96126	0.99885826761811347	.	0.98810	.	C/C	0	0.0	1	1.1627906976744187E-4	7.157594	0.665787619877865	0.79792	7.284282	0.711600476796111	0.80393	.	.	.	12	9.884e-05	0	0	0	0	12	9.912e-05	0	0	0	0	11	1.653e-04	1	6.060e-05	10	9.415e-05	0	0	0	0	10	9.436e-05	0	0	0	0	9	1.659e-04	1	6.098e-05	12	1.322e-04	0	0	0	0	12	1.326e-04	0	0	0	0	11	2.619e-04	1	6.064e-05	0.99546	.	.	.	5.92	5.01	0.66477	0	0.45803	0.59043	.	.	0.43459	0.999815590521672	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.89589	.	0.000000	0.84330	D	0.000000	D	0.97883	0.736342	0.27172	.	0.97348	.	D	0.99568	0.9856	.	0.69534	.	D	0.97759	1.0322	.	.	.	.	.	.	0.87999	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.46146	.	.	.	0.90584	.	.	0.73820	.	D	0.87839	0.838322997093	0.96985	.	10	0.35205	.	.	0.50132	.	.	16.379	0.83274	0.1328:0.8672:0.0:0.0	.	.	.	.	.	.	.	.	0.74462	.	C/C	H	.	R	T	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852935C>T	102804	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_000944&DeBelle_Laboratory_for_Biochemical_Genetics:p.R241H	.	.	AEFBI	D	0.64948	0.95495	D	0.93894	0.938973	.	42	1.673110e-04	0	0.000000e+00	16254	0	0	0.000000e+00	34566	0	251030	29	2.881560e-03	10064	0	0	0.000000e+00	18376	0	1	4.622350e-05	21634	0	5	4.409170e-05	113400	0	5	4.409170e-05	113400	0	1	3.266480e-05	30614	0	8	7.314090e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17108	0	109378	3	1.293100e-03	2320	0	0	0.000000e+00	9038	0	1	7.471610e-05	13384	0	3	7.015900e-05	42760	0	3	7.015900e-05	42760	0	0	0.000000e+00	15690	0	0	.	0	40	1.691320e-04	0	0.000000e+00	14902	0	0	0.000000e+00	34234	0	236502	27	2.825450e-03	9556	0	0	0.000000e+00	17674	0	1	4.625770e-05	21618	0	5	4.883190e-05	102392	0	5	4.883190e-05	102392	0	1	3.276110e-05	30524	0	0	27	1.298150e-04	0	0.000000e+00	16216	0	0	0.000000e+00	30504	0	207988	16	2.577320e-03	6208	0	0	0.000000e+00	13398	0	1	5.980150e-05	16722	0	4	4.470670e-05	89472	0	4	4.470670e-05	89472	0	1	3.267330e-05	30606	0	0	42	1.718410e-04	0	0.000000e+00	12024	0	0	0.000000e+00	34432	0	244412	29	2.905230e-03	9982	0	0	0.000000e+00	18372	0	1	4.622780e-05	21632	0	5	4.491960e-05	111310	0	5	4.491960e-05	111310	0	1	3.266480e-05	30614	0	0	7	4.605020e-05	1	2.417210e-05	41370	0	0	0.000000e+00	912	0	0	0.000000e+00	15266	0	152008	4	1.152070e-03	3472	0	0	0.000000e+00	5170	0	0	0.000000e+00	10592	0	0	0.000000e+00	316	0	1	1.470160e-05	68020	0	1	2.082470e-04	4802	0	1	2.082470e-04	4802	0	1	3.044880e-05	0	0.000000e+00	9066	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32842	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5468	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	1	3.219580e-04	3106	0	0	.	0	7	4.737410e-05	1	2.436170e-05	41048	0	0	0.000000e+00	912	0	0	0.000000e+00	15078	0	147760	4	1.211390e-03	3302	0	0	0.000000e+00	4934	0	0	0.000000e+00	10592	0	0	0.000000e+00	304	0	1	1.543160e-05	64802	0	1	2.096440e-04	4770	0	0	6	4.456990e-05	0	0.000000e+00	32420	0	0	0.000000e+00	862	0	0	0.000000e+00	14820	0	134620	4	1.180640e-03	3388	0	0	0.000000e+00	5170	0	0	0.000000e+00	6954	0	0	0.000000e+00	310	0	1	1.565040e-05	63896	0	1	2.083330e-04	4800	0	0	2	2.482190e-05	1	4.041380e-05	24744	0	0	0.000000e+00	112	0	0	0.000000e+00	12892	0	80574	0	0.000000e+00	998	0	0	0.000000e+00	3728	0	0	0.000000e+00	10500	0	0	0.000000e+00	272	0	0	0.000000e+00	21040	0	1	2.094680e-04	4774	0	0	12	101770843	12	103246713	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	4.912000	0.63031	0.599000	0.40250	1.026000	0.45946	102852935	C	.	rs62508730	.	.	11.570	9.399	7.651	9.354	.	.	.	-2	15	15	-35	0.00	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+15+end+136	102804	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62508730	9.884e-05	12	12	0	0	0	0	0	11	0	1	10382	11528	8618	6586	66544	908	16502	0	0	0	0	11	0	1	0	0	0	0	0	0	0	rs62508730	0.00000e+00	0.00000e+00	2.84669e-03	0.00000e+00	4.48672e-05	5.38948e-05	9.14077e-04	3.24886e-05	1.26263e-04	2.15932e-04	2.84669e-03	1.66483e-04	rs62508730	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66578e-05	0.00000e+00	.	5.84385e-05	0.00000e+00	6.66578e-05	3.22664e-05	rs62508730	0.0116&0.0&0.0077	rs62508730	62508730	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,753	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103249029	103249029	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.591G>C	NP_000268.1:p.Leu197Phe	705	591	197	L/F	ttG/ttC	rs281865442&CM081728	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103249029C>G	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.591G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.93376	0.471064	D	0.93292	0.438874	23.8	23.0	3.180991	2.716396	0.56140	0.48473	C/C	D	0.81933	0.991615951061249	0.94457	0.99866418058086892	.	0.99882	.	C/C	.	.	.	.	3.86686	0.325179294866971	0.57024	4.822881	0.471637302731991	0.65439	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99799	.	.	.	5.87	2.96	0.33383	0	0.26702	0.573888	.	.	0.10376	0.00400393539443259	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.94289	.	0.065347	0.62929	D	0.000010	D	0.98036	0.753418	0.27230	.	0.98441	.	D	0.99701	0.9893	.	0.99477	.	D	0.98014	1.0451	L197F	Gain_of_methylation_at_K192_(P_=_0.0709)&_Loss_of_stability_(P_=_0.1223)&_Loss_of_MoRF_binding_(P_=_0.1399)&_Gain_of_loop_(P_=_0.2754)&_Gain_of_ubiquitination_at_K199_(P_=_0.3134)	P00439	0.98028	0.906	.	0.91266	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.71276	.	.	.	0.90584	.	.	0.92359	.	T	0.55602	0.619096517563	0.94238	.	10	0.83351	.	.	0.78490	.	.	8.0815	0.29909	0.0:0.6914:0.1172:0.1914	.	.	.	.	.	.	.	.	0.93959	.	C/C	F	.	L	G	528	0.73785	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102855251C>G	120280	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.49596	0.89246	D	0.72313	0.795817	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101773159	12	103249029	0	0.43195	0.638212	0.990000	0.36992	0.980000	0.58198	1.000000	0.86279	0.367000	0.20116	0.599000	0.40250	0.126000	0.18019	102855251	C	.	rs281865442	.	.	7.651	9.354	7.292	9.092	.	.	.	-4	-44	-23	1	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+81+end+197	120280	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865442	281865442	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,764	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9941	Pathogenic
12	103245479	103245479	C	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.898G>T	NP_000268.1:p.Ala300Ser	1012	898	300	A/S	Gcc/Tcc	rs5030853&CM920555	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103245479C>A	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.898G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.85691	0.337868	D	0.96534	0.579612	26.9	29.4	3.986150	4.188412	0.78138	0.87975	C/C	T	0.18692	0.171648024188298	0.80112	0.99693122948966317	.	0.99885	.	C/C	0	0.0	4	4.6511627906976747E-4	15.30441	0.93434704324232	0.96902	13.99934	1.00247571485204	0.95820	.	.	.	54	4.448e-04	0	0	2	1.739e-04	54	4.462e-04	0	0	0	0	48	7.209e-04	4	2.431e-04	45	4.237e-04	0	0	2	1.794e-04	45	4.247e-04	0	0	0	0	39	7.185e-04	4	2.447e-04	47	5.179e-04	0	0	2	1.741e-04	47	5.202e-04	0	0	0	0	41	9.764e-04	4	2.433e-04	0.99828	.	.	.	5.51	5.51	0.81769	0	0.45803	0.59043	.	.	0.74766	0.999999999971142	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.88631	.	0.047013	0.84330	D	0.000000	D	0.97424	0.687776	0.25988	.	0.99226	.	D	0.99870	0.9943	.	0.37483	.	D	0.96476	0.9554	.	.	.	.	.	.	0.93219	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.61129	.	.	.	0.90584	.	.	0.92359	.	T	0.81765	0.798704922199	0.98851	.	10	0.79402	.	.	0.91255	.	.	19.7791	0.96406	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.92550	.	C/C	S	.	A	A	514	0.74853	.	12	C0751435&C0031485&C0950123&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102851701C>A	92751	reviewed_by_expert_panel	Hyperphenylalaninemia&_non-pku&Phenylketonuria&Inborn_genetic_diseases&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.A300S&HGMD:CM920555&UniProtKB_(protein):P00439#VAR_000988&Illumina_Laboratory_Services&Illumina:68131&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2831545	.	.	AEFBCI	D	0.75717	0.97585	D	0.99529	0.973973	.	147	5.856110e-04	0	0.000000e+00	16242	0	3	8.680560e-05	34560	0	251020	69	6.858850e-03	10060	0	0	0.000000e+00	18376	0	0	0.000000e+00	21624	0	55	4.849060e-04	113424	0	15	4.900680e-04	30608	0	15	4.900680e-04	30608	0	45	4.115230e-04	0	0.000000e+00	7162	0	1	5.848640e-05	17098	0	109350	13	5.603450e-03	2320	0	0	0.000000e+00	9036	0	0	0.000000e+00	13370	0	23	5.378360e-04	42764	0	23	5.378360e-04	42764	0	6	3.825070e-04	15686	0	0	.	0	140	5.919310e-04	0	0.000000e+00	14900	0	3	8.764240e-05	34230	0	236514	67	7.011300e-03	9556	0	0	0.000000e+00	17680	0	0	0.000000e+00	21608	0	50	4.882050e-04	102416	0	15	4.915130e-04	30518	0	15	4.915130e-04	30518	0	0	107	5.143690e-04	0	0.000000e+00	16204	0	3	9.836710e-05	30498	0	208022	42	6.767640e-03	6206	0	0	0.000000e+00	13398	0	0	0.000000e+00	16710	0	44	4.914000e-04	89540	0	44	4.914000e-04	89540	0	15	4.901960e-04	30600	0	0	147	6.014630e-04	0	0.000000e+00	12012	0	3	8.714340e-05	34426	0	244404	69	6.915210e-03	9978	0	0	0.000000e+00	18372	0	0	0.000000e+00	21622	0	55	4.940000e-04	111336	0	55	4.940000e-04	111336	0	15	4.900680e-04	30608	0	0	49	3.221140e-04	1	2.414530e-05	41416	0	0	0.000000e+00	912	0	4	2.620200e-04	15266	0	152120	23	6.624420e-03	3472	0	0	0.000000e+00	5174	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	19	2.792390e-04	68042	0	19	2.792390e-04	68042	0	0	0.000000e+00	4822	0	5	1.520960e-04	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	1	2.134930e-04	4684	0	32874	2	1.470590e-02	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5482	0	0	0.000000e+00	246	0	2	2.918000e-04	6854	0	0	0.000000e+00	3104	0	0	.	0	45	3.043380e-04	1	2.433450e-05	41094	0	0	0.000000e+00	912	0	4	2.652870e-04	15078	0	147862	21	6.359780e-03	3302	0	0	0.000000e+00	4940	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	17	2.622970e-04	64812	0	0	0.000000e+00	4790	0	0	49	3.637170e-04	1	3.080900e-05	32458	0	0	0.000000e+00	862	0	4	2.699060e-04	14820	0	134720	23	6.788670e-03	3388	0	0	0.000000e+00	5174	0	0	0.000000e+00	6970	0	0	0.000000e+00	310	0	19	2.972650e-04	63916	0	0	0.000000e+00	4820	0	0	14	1.735210e-04	0	0.000000e+00	24794	0	0	0.000000e+00	112	0	4	3.102700e-04	12892	0	80682	4	4.008020e-03	998	0	0	0.000000e+00	3732	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	5	2.374850e-04	21054	0	0	0.000000e+00	4794	0	0	12	101769609	12	103245479	0	0.43195	0.638212	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	7.568000	0.81546	0.599000	0.40250	1.026000	0.45946	102851701	C	.	rs5030853	.	.	9.506	11.083	11.570	9.399	.	.	.	-6	11	-18	-14	0.00	0.00	0.00	0.01	PAH	0.00	exon-NM_001354304.2-9+14+start+70	92751	Pathogenic	reviewed_by_expert_panel	Inborn_genetic_diseases&not_provided&Hyperphenylalaninemia&Phenylketonuria	MeSH:D030342&MedGen:C0950123&MedGen:CN517202&Human_Phenotype_Ontology:HP:0004923&MedGen:C0751435&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030853	4.448e-04	54	54	0	0	2	0	0	48	0	4	10348	11498	8614	6608	66582	908	16452	0	2	0	0	48	0	4	0	0	0	0	0	0	0	rs5030853	0.00000e+00	8.94188e-05	6.61376e-03	0.00000e+00	0.00000e+00	4.67013e-04	9.12742e-04	4.54929e-04	6.46196e-04	4.67887e-04	6.61376e-03	5.64426e-04	rs5030853	0.00000e+00	0.00000e+00	6.62252e-03	0.00000e+00	0.00000e+00	2.66631e-04	0.00000e+00	.	2.33727e-04	1.44404e-04	6.62252e-03	1.93598e-04	rs5030853	0.0465&0.0&0.0308	rs5030853	5030853	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,691	0	1	0	0	0	1	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0.8999	Pathogenic
12	103234285	103234285	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1208C>T	NP_000268.1:p.Ala403Val	1322	1208	403	A/V	gCt/gTt	rs5030857&CM930567&COSV61020906	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103234285G>A	.	0	0.0014	0	0.002	0	pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1208C>T	.	.	3	5.990415335463259E-4	0	0.0	1	0.001440922190201729	0	0.0	2	0.0019880715705765406	0	0.0	2	5.189413596263622E-4	.	.	.	.	.	.	.	G/G	G	D	0.76717	0.229952	D	0.93994	0.469587	27.1	26.5	4.020128	3.835128	0.79307	0.76605	G/G	T	0.15324	0.129372326220391	0.96436	0.99889948430705777	.	0.99204	.	G/G	0	0.0	5	5.813953488372093E-4	9.963209	0.794518518075883	0.89409	9.034041	0.812693920190126	0.86895	.	.	.	65	5.354e-04	1	9.610e-05	1	8.688e-05	65	5.358e-04	0	0	0	0	62	9.294e-04	0	0	50	4.708e-04	1	1.103e-04	1	8.970e-05	50	4.712e-04	0	0	0	0	47	8.653e-04	0	0	61	6.722e-04	1	9.626e-05	1	8.697e-05	61	6.729e-04	0	0	0	0	59	1.401e-03	0	0	0.99572	.	.	.	5.63	5.63	0.86108	0	0.26702	0.573888	.	.	0.31212	0.987217501382752	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.70434	.	0.000000	0.84330	D	0.000000	D	0.92327	0.353384	0.25870	.	0.99096	.	D	0.99514	0.9840	.	0.29054	.	D	0.99481	1.0958	.	.	.	.	.	.	0.78713	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.64939	.	.	.	0.68779	.	.	0.69275	.	T	0.46256	0.552825927734	0.98041	.	10	0.25061	.	.	0.27544	.	.	18.445	0.90628	0.0:0.0:1.0:0.0	.	1	2.6968716289104636E-4	3	3.9672044432689763E-4	.	.	.	0.84922	.	G/G	V	.	A	A	496	0.76301	.	12	C0031485&C0950123&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102840507G>A	92731	reviewed_by_expert_panel	Phenylketonuria&Inborn_genetic_diseases&not_provided	HGMD:CM930567&UniProtKB_(protein):P00439#VAR_001033&Illumina_Laboratory_Services&Illumina:658622&DeBelle_Laboratory_for_Biochemical_Genetics:p.A403V&Institute_of_Human_Genetics&_University_of_Leipzig_Medical_Center:CV_varv_891	.	.	AEFBCI	D	0.61369	0.94501	D	0.98990	0.967426	.	151	6.006030e-04	1	6.152330e-05	16254	0	8	2.315750e-04	34546	0	251414	51	5.060530e-03	10078	0	0	0.000000e+00	18392	0	0	0.000000e+00	21648	0	87	7.648890e-04	113742	0	87	7.648890e-04	113742	0	1	3.266480e-05	30614	0	46	4.205060e-04	1	1.395870e-04	7164	0	4	2.339180e-04	17100	0	109392	8	3.448280e-03	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	29	6.781090e-04	42766	0	29	6.781090e-04	42766	0	1	6.373490e-05	15690	0	0	.	0	137	5.783620e-04	1	6.711410e-05	14900	0	8	2.338220e-04	34214	0	236876	49	5.120170e-03	9570	0	0	0.000000e+00	17690	0	0	0.000000e+00	21632	0	75	7.300980e-04	102726	0	75	7.300980e-04	102726	0	1	3.276110e-05	30524	0	0	116	5.574890e-04	1	6.166750e-05	16216	0	7	2.296590e-04	30480	0	208076	31	4.991950e-03	6210	0	0	0.000000e+00	13414	0	0	0.000000e+00	16734	0	73	8.151870e-04	89550	0	73	8.151870e-04	89550	0	1	3.267330e-05	30606	0	0	149	6.086700e-04	1	8.316700e-05	12024	0	8	2.324770e-04	34412	0	244796	50	5.002000e-03	9996	0	0	0.000000e+00	18388	0	0	0.000000e+00	21646	0	86	7.702500e-04	111652	0	86	7.702500e-04	111652	0	1	3.266480e-05	30614	0	0	88	5.784680e-04	4	9.658100e-05	41416	0	0	0.000000e+00	912	0	4	2.618490e-04	15276	0	152126	24	6.920420e-03	3468	0	0	0.000000e+00	5190	0	0	0.000000e+00	10618	0	0	0.000000e+00	316	0	52	7.644140e-04	68026	0	52	7.644140e-04	68026	0	0	0.000000e+00	4812	0	12	3.651190e-04	1	1.101080e-04	9082	0	0	0.000000e+00	60	0	2	4.268030e-04	4686	0	32866	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	8	1.168220e-03	6848	0	0	0.000000e+00	3104	0	0	.	0	86	5.815760e-04	4	9.733780e-05	41094	0	0	0.000000e+00	912	0	4	2.651110e-04	15088	0	147874	24	7.272730e-03	3300	0	0	0.000000e+00	4958	0	0	0.000000e+00	10618	0	0	0.000000e+00	304	0	50	7.716290e-04	64798	0	0	0.000000e+00	4780	0	0	84	6.234690e-04	2	6.161810e-05	32458	0	0	0.000000e+00	862	0	4	2.697240e-04	14830	0	134730	24	7.092200e-03	3384	0	0	0.000000e+00	5190	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	50	7.823750e-04	63908	0	0	0.000000e+00	4810	0	0	24	2.974420e-04	3	1.210070e-04	24792	0	0	0.000000e+00	112	0	4	3.100290e-04	12902	0	80688	2	2.008030e-03	996	0	0	0.000000e+00	3748	0	0	0.000000e+00	10526	0	0	0.000000e+00	272	0	14	6.654620e-04	21038	0	0	0.000000e+00	4784	0	0	12	101758415	12	103234285	0	0.43195	0.638212	1.000000	0.71638	0.991000	0.66497	1.000000	0.86279	7.702000	0.83553	0.676000	0.76740	1.176000	0.78918	102840507	G	.	rs5030857	.	.	10.477	9.491	8.924	9.158	.	.	.	27	8	44	4	0.00	0.07	0.00	0.00	PAH	0.00	exon-NM_001354304.2-13+8+end+116	92731	Pathogenic	reviewed_by_expert_panel	Inborn_genetic_diseases&not_provided&Phenylketonuria	MeSH:D030342&MedGen:C0950123&MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030857	5.354e-04	65	65	0	1	1	0	0	62	1	0	10406	11510	8652	6612	66708	908	16510	1	1	0	0	62	1	0	0	0	0	0	0	0	0	rs5030857	6.53509e-05	2.08743e-04	4.97563e-03	0.00000e+00	0.00000e+00	7.61021e-04	9.11743e-04	3.24886e-05	6.30283e-04	5.65906e-04	4.97563e-03	6.00962e-04	rs5030857	2.29305e-04	0.00000e+00	6.62252e-03	0.00000e+00	0.00000e+00	5.99760e-04	0.00000e+00	.	3.50836e-04	5.05123e-04	6.62252e-03	4.19463e-04	rs5030857	0.0581&0.0&0.0384	rs5030857	5030857	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,657	0	1	0	0	0	1	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0.8999	Pathogenic
12	103246628	103246629	GA	G	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.806del	NP_000268.1:p.Ile269ThrfsTer72	920	806	269	I/X	aTc/ac	rs62508687&CD011182&CM981443	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103246629del	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.806T>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.570	9.399	7.651	9.354	.	.	.	5	22	-39	-35	0.00	0.00	0.00	0.03	PAH	0.00	exon-NM_001354304.2-8+36+start+136	102844	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508687	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66134e-05	0.00000e+00	.	5.84385e-05	0.00000e+00	6.66134e-05	3.22664e-05	.	.	rs62508687	62508687	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,725	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103234176	103234176	A	G	G	splice_donor_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	.	12/12	NM_000277.3:c.1315+2T>C	.	.	.	.	.	.	rs1799970&CS982307	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103234176A>G	.	.	.	.	.	.	likely_pathogenic&not_provided	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1315+2T>C	0.991057824102482	0.624	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/donor/103234175-103234176/Medium/3.739496	10.477	.	8.924	9.491	1.737	7.754	9.491	0	-48	-2	2	0.00	0.00	0.13	0.94	PAH	0.00	.	102588	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1799970	1799970	.	.	.	PAH	PAH:splicing	PAH:splice_donor_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,642	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103260442	103260442	C	T	T	splice_acceptor_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	.	4/12	NM_000277.3:c.442-1G>A	.	.	.	.	.	.	rs62514907&CS910453&COSV100188291	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103260442C>T	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.442-1G>C	0.999990361384395	0.938	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/acceptor/103260441-103260442/Medium/9.925164&gain/acceptor/103260442-103260443/Medium/8.776338	8.810	9.092	11.038	7.211	0.060	8.750	8.810	-2	-1	-2	-11	0.95	0.99	0.00	0.00	PAH	0.00	.	594	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62514907	62514907	.	.	.	PAH	PAH:splicing	PAH:splice_acceptor_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,795	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103260385	103260385	G	T	T	stop_gained	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.498C>A	NP_000268.1:p.Tyr166Ter	612	498	166	Y/*	taC/taA	rs199475645&CM990993&CM994293	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103260385G>T	.	.	.	.	.	.	pathogenic&not_provided	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.498C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.99412	0.625005	D	0.99401	0.66	39	40	7.838951	7.899230	0.98457	0.98611	G/G	.	.	.	0.81984	0.99719835178436034	.	.	.	G/G	.	.	.	.	4.673662	0.442421323265729	0.64231	6.172258	0.623600172988802	0.74669	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.08	2.98	0.33575	0	0.26702	0.573888	.	.	0.06935	4.25308996322507E-4	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.1648	0.30380	0.2682:0.0:0.7318:0.0	.	.	.	.	.	.	.	.	0.88466	.	G/G	X	.	Y	T	699	0.57969	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102866607G>T	102702	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.Y166X	.	.	AEFBI	D	0.53921	0.91626	N	0.53313	0.499449	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101784515	12	103260385	0	0.25195	0.553676	1.000000	0.71638	0.988000	0.63387	1.000000	0.86279	1.459000	0.34844	0.676000	0.76740	1.176000	0.78918	102866607	G	.	rs199475645	.	.	7.292	9.092	8.810	7.211	.	.	.	-11	46	40	-11	0.00	0.00	0.00	0.09	PAH	0.00	exon-NM_001354304.2-6+11+start+68	102702	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475645	199475645	.	.	.	PAH	PAH:exonic	PAH:stopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,785	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103260379	103260380	GT	G	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.503del	NP_000268.1:p.Tyr168SerfsTer27	617	503	168	Y/X	tAc/tc	rs199475661&CD043413	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103260380del	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.503del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.292	9.092	8.810	7.211	.	.	.	-5	5	-9	-5	0.00	0.00	0.00	0.01	PAH	0.00	exon-NM_001354304.2-6+6+start+68	102705	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103260380-103260381	8.237e-06	1	1	0	0	0	0	0	1	0	0	10406	11502	8648	6604	66678	908	16510	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs281865455	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95800e-06	0.00000e+00	0.00000e+00	7.41730e-06	0.00000e+00	8.95800e-06	4.06062e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475661	199475661	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,782	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103260379	103260379	G	T	T	stop_gained	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.504C>A	NP_000268.1:p.Tyr168Ter	618	504	168	Y/*	taC/taA	rs281865455&CM1514929	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103260379G>T	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.504C>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.99412	0.625005	D	0.99401	0.66	39	37	7.775630	7.056121	0.98352	0.97250	G/G	.	.	.	0.82125	0.99722293476881807	.	.	.	G/G	.	.	.	.	3.768007	0.308710541942193	0.56050	4.727556	0.458306095240453	0.64676	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.08	3.27	0.36580	0	0.26702	0.573888	.	.	0.07505	6.34054180398493E-4	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	.	.	0.000000	0.84330	D	0.000000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.7005	0.33484	0.2329:0.0:0.7671:0.0	.	.	.	.	.	.	.	.	0.91852	.	G/G	X	.	Y	T	699	0.57969	.	12	C0031485	261600	ORPHA716	Pathogenic	NC_000012.12:g.102866601G>T	120277	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.55845	0.92495	N	0.39450	0.280750	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101784509	12	103260379	0	0.25195	0.553676	1.000000	0.71638	0.983000	0.59808	0.999000	0.70432	3.102000	0.49982	-0.106000	0.15538	0.230000	0.25697	102866601	G	.	rs281865455	.	.	7.292	9.092	8.810	7.211	.	.	.	-5	33	-1	-5	0.00	0.00	0.00	0.01	PAH	0.00	exon-NM_001354304.2-6+5+start+68	120277	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865455	281865455	.	.	.	PAH	PAH:exonic	PAH:stopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,781	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103248987	103248988	TG	T	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.632del	NP_000268.1:p.Pro211HisfsTer130	746	632	211	P/X	cCa/ca	rs62514929&CD962116&CM1314659	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103248989del	.	.	.	.	.	.	not_provided&pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.632C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.651	9.354	7.292	9.092	.	.	.	-12	-14	48	-12	0.00	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+74+start+197	102767	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62514929	1.647e-05	2	2	0	0	0	0	0	2	0	0	10406	11544	8640	6612	66718	908	16510	0	0	0	0	2	0	0	0	0	0	0	0	0	0	rs62514929	0.00000e+00	0.00000e+00	1.01564e-04	0.00000e+00	0.00000e+00	8.96234e-06	0.00000e+00	0.00000e+00	7.41796e-06	8.98586e-06	1.01564e-04	8.12110e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62514929	62514929	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,763	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
1	215932085	215932085	G	T	T	stop_gained	HIGH	USH2A	7399	Transcript	NM_206933.4	protein_coding	58/72	.	NM_206933.4:c.11241C>A	NP_996816.3:p.Tyr3747Ter	11680	11241	3747	Y/*	taC/taA	rs777465132&COSV56413504	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	KCTD3	.	chr1:g.215932085G>T	.	.	.	.	.	.	pathogenic	0&1	1&1	.	.	.	.	.	USH2A&NM_206933.2&c.11241C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.91553	0.430471	D	0.99401	0.66	47	44	9.017297	8.625003	0.99705	0.99470	G/G	.	.	.	0.62337	0.99390832824374475	.	.	.	G/G	.	.	.	.	3.375467	0.238064205573341	0.51974	4.592096	0.438615750040392	0.63562	.	.	.	2	1.647e-05	2	1.939e-04	0	0	2	1.651e-05	0	0	0	0	0	0	0	0	2	1.883e-05	2	2.227e-04	0	0	2	1.887e-05	0	0	0	0	0	0	0	0	2	2.204e-05	2	1.943e-04	0	0	2	2.210e-05	0	0	0	0	0	0	0	0	.	.	.	.	5.8	1.84	0.24348	0	0.26702	0.573888	.	.	0.03989	4.23592895727006E-5	.	0	0.23631	0.573888	.	.	.	.	.	.	0	0.26826	0.564101	Fibronectin_type_III&Fibronectin_type_III&Fibronectin_type_III	.	.	.	.	.	0.000000	0.38917	U	0.001462	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.6345	0.38965	0.2788:0.0:0.7212:0.0	.	.	.	.	.	.	.	.	0.93135	.	G/G	X	.	Y	T	581	0.69614	.	1	C1848634&C0271097&CN517202&CN826980	276901&PS276900	ORPHA886&ORPHA96210	Pathogenic	NC_000001.11:g.215758743G>T	506273	reviewed_by_expert_panel	Usher_syndrome&_type_2A&Usher_syndrome&not_provided&Rare_genetic_deafness	.	.	.	AEFI	D	0.60703	0.94292	N	0.31220	0.184878	.	3	1.194510e-05	3	1.847750e-04	16236	0	0	0.000000e+00	34570	0	251150	0	0.000000e+00	10076	0	0	0.000000e+00	18392	0	0	0.000000e+00	21544	0	0	0.000000e+00	113594	0	3	1.847750e-04	16236	0	0	0.000000e+00	30612	0	1	9.151140e-06	1	1.397040e-04	7158	0	0	0.000000e+00	17104	0	109276	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13294	0	0	0.000000e+00	42754	0	1	1.397040e-04	7158	0	0	0.000000e+00	15688	0	0	.	0	3	1.267870e-05	3	2.015590e-04	14884	0	0	0.000000e+00	34238	0	236618	0	0.000000e+00	9568	0	0	0.000000e+00	17690	0	0	0.000000e+00	21528	0	0	0.000000e+00	102582	0	3	2.015590e-04	14884	0	0	0.000000e+00	30522	0	0	3	1.442790e-05	3	1.852080e-04	16198	0	0	0.000000e+00	30504	0	207930	0	0.000000e+00	6210	0	0	0.000000e+00	13414	0	0	0.000000e+00	16634	0	0	0.000000e+00	89504	0	3	1.852080e-04	16198	0	0	0.000000e+00	30604	0	0	2	8.178820e-06	2	1.665560e-04	12008	0	0	0.000000e+00	34436	0	244534	0	0.000000e+00	9994	0	0	0.000000e+00	18388	0	0	0.000000e+00	21542	0	0	0.000000e+00	111504	0	2	1.665560e-04	12008	0	0	0.000000e+00	30612	0	0	3	1.971630e-05	3	7.239380e-05	41440	0	0	0.000000e+00	912	0	0	0.000000e+00	15272	0	152158	0	0.000000e+00	3468	0	0	0.000000e+00	5190	0	0	0.000000e+00	10606	0	0	0.000000e+00	316	0	0	0.000000e+00	68028	0	3	7.239380e-05	41440	0	0	0.000000e+00	4834	0	2	6.084580e-05	2	2.201670e-04	9084	0	0	0.000000e+00	60	0	0	0.000000e+00	4684	0	32870	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5480	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3114	0	0	.	0	3	2.028260e-05	3	7.296070e-05	41118	0	0	0.000000e+00	912	0	0	0.000000e+00	15084	0	147910	0	0.000000e+00	3300	0	0	0.000000e+00	4956	0	0	0.000000e+00	10606	0	0	0.000000e+00	304	0	0	0.000000e+00	64806	0	0	0.000000e+00	4802	0	0	3	2.226310e-05	3	9.239300e-05	32470	0	0	0.000000e+00	862	0	0	0.000000e+00	14826	0	134752	0	0.000000e+00	3384	0	0	0.000000e+00	5190	0	0	0.000000e+00	6968	0	0	0.000000e+00	310	0	0	0.000000e+00	63908	0	0	0.000000e+00	4832	0	0	2	2.477820e-05	2	8.059970e-05	24814	0	0	0.000000e+00	112	0	0	0.000000e+00	12898	0	80716	0	0.000000e+00	996	0	0	0.000000e+00	3748	0	0	0.000000e+00	10514	0	0	0.000000e+00	272	0	0	0.000000e+00	21036	0	0	0.000000e+00	4808	0	0	1	213998708	1	215932085	0	0.14033	0.487112	1.000000	0.71638	0.976000	0.56436	0.999000	0.70432	2.214000	0.42493	0.618000	0.50648	0.222000	0.24560	215758743	G	.	rs777465132	.	.	12.053	8.594	6.980	7.823	.	.	.	-4	9	16	9	0.00	0.37	0.00	0.00	USH2A	0.00	exon-NM_206933.4-58+9+end+158	506273	Pathogenic	reviewed_by_expert_panel	Rare_genetic_deafness&not_provided&Usher_syndrome_type_2A&Usher_syndrome	MedGen:CN826980&Orphanet:96210&MedGen:CN517202&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886	.	1:215932085-215932085	1.647e-05	2	2	0	2	0	0	0	0	0	0	10314	11532	8640	6610	66642	908	16500	2	0	0	0	0	0	0	0	0	0	0	0	0	0	rs777465132	1.96155e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.42236e-06	1.79840e-05	1.96155e-04	1.21819e-05	rs777465132	1.14600e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	0.00000e+00	7.21709e-05	1.14600e-04	3.22664e-05	.	.	rs777465132	777465132	.	.	.	USH2A	USH2A:exonic	USH2A:stopgain	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,450	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103246621	103246621	C	A	A	stop_gained	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.814G>T	NP_000268.1:p.Gly272Ter	928	814	272	G/*	Gga/Tga	rs62514952&CD972373&CM900177&COSV100188143	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246621C>A	.	.	.	.	.	.	pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.814G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.94275	0.499488	D	0.99401	0.66	38	45	7.406656	8.795418	0.97718	0.99592	C/C	.	.	.	0.62383	0.99392172510521881	.	.	.	C/C	.	.	.	.	5.621495	0.547430805689063	0.71217	7.5275	0.727890697033199	0.81459	.	.	.	4	3.295e-05	0	0	0	0	4	3.295e-05	0	0	0	0	4	5.994e-05	0	0	3	2.825e-05	0	0	0	0	3	2.825e-05	0	0	0	0	3	5.520e-05	0	0	2	2.204e-05	0	0	0	0	2	2.204e-05	0	0	0	0	2	4.746e-05	0	0	.	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.27055	0.931601541782463	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	.	.	0.285616	0.40743	D	0.000997	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	13.371	0.60157	0.2753:0.7247:0.0:0.0	.	.	.	.	.	.	.	.	0.79599	.	C/C	X	.	G	A	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852843C>A	596	reviewed_by_expert_panel	Phenylketonuria&not_provided	OMIM_Allelic_Variant:612349.0020&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2844953&OMIM_Allelic_Variant:612349.0022&DeBelle_Laboratory_for_Biochemical_Genetics:p.G272X	.	.	AEFBI	N	0.26023	0.38593	D	0.61542	0.636179	.	9	3.580550e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34586	0	251358	0	0.000000e+00	10078	0	0	0.000000e+00	18392	0	0	0.000000e+00	21648	0	8	7.039160e-05	113650	0	8	7.039160e-05	113650	0	0	0.000000e+00	30616	0	6	5.484160e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	6	1.402920e-04	42768	0	6	1.402920e-04	42768	0	0	0.000000e+00	15690	0	0	.	0	8	3.378090e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34254	0	236820	0	0.000000e+00	9570	0	0	0.000000e+00	17690	0	0	0.000000e+00	21632	0	8	7.794690e-05	102634	0	8	7.794690e-05	102634	0	0	0.000000e+00	30526	0	0	9	4.324640e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30522	0	208110	0	0.000000e+00	6212	0	0	0.000000e+00	13414	0	0	0.000000e+00	16734	0	8	8.934950e-05	89536	0	8	8.934950e-05	89536	0	0	0.000000e+00	30608	0	0	9	3.677340e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34452	0	244742	0	0.000000e+00	9996	0	0	0.000000e+00	18388	0	0	0.000000e+00	21646	0	8	7.170900e-05	111562	0	8	7.170900e-05	111562	0	0	0.000000e+00	30616	0	0	9	5.917320e-05	0	0.000000e+00	41408	0	0	0.000000e+00	912	0	0	0.000000e+00	15260	0	152096	0	0.000000e+00	3466	0	0	0.000000e+00	5192	0	0	0.000000e+00	10600	0	0	0.000000e+00	316	0	9	1.323060e-04	68024	0	9	1.323060e-04	68024	0	0	0.000000e+00	4826	0	2	6.083470e-05	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32876	0	0.000000e+00	134	0	0	0.000000e+00	2430	0	0	0.000000e+00	5478	0	0	0.000000e+00	246	0	2	2.920560e-04	6848	0	0	0.000000e+00	3114	0	0	.	0	9	6.087330e-05	0	0.000000e+00	41090	0	0	0.000000e+00	912	0	0	0.000000e+00	15072	0	147848	0	0.000000e+00	3298	0	0	0.000000e+00	4958	0	0	0.000000e+00	10600	0	0	0.000000e+00	304	0	9	1.388930e-04	64798	0	0	0.000000e+00	4794	0	0	7	5.196810e-05	0	0.000000e+00	32448	0	0	0.000000e+00	862	0	0	0.000000e+00	14816	0	134698	0	0.000000e+00	3382	0	0	0.000000e+00	5192	0	0	0.000000e+00	6960	0	0	0.000000e+00	310	0	7	1.095430e-04	63902	0	0	0.000000e+00	4824	0	0	4	4.959090e-05	0	0.000000e+00	24784	0	0	0.000000e+00	112	0	0	0.000000e+00	12886	0	80660	0	0.000000e+00	994	0	0	0.000000e+00	3750	0	0	0.000000e+00	10508	0	0	0.000000e+00	272	0	4	1.901320e-04	21038	0	0	0.000000e+00	4798	0	0	12	101770751	12	103246621	0	0.43195	0.638212	0.031000	0.20493	0.996000	0.76049	0.999000	0.70432	0.394000	0.20559	0.599000	0.40250	1.026000	0.45946	102852843	C	.	rs62514952	.	.	11.570	9.399	7.651	9.354	.	.	.	14	29	14	-28	0.00	0.00	0.00	0.10	PAH	0.00	exon-NM_001354304.2-8+28+start+136	596	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62514952	3.295e-05	4	4	0	0	0	0	0	4	0	0	10406	11568	8652	6614	66738	908	16512	0	0	0	0	4	0	0	0	0	0	0	0	0	0	rs62514952	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.27319e-05	3.64697e-04	0.00000e+00	3.70887e-05	3.59350e-05	6.27319e-05	3.65450e-05	rs62514952	1.14626e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.66525e-04	0.00000e+00	.	1.75316e-04	1.44383e-04	2.66525e-04	1.61332e-04	.	.	rs62514952	62514952	.	.	.	PAH	PAH:exonic	PAH:stopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,720	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103246597	103246598	CG	C	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.837del	NP_000268.1:p.Glu280AsnfsTer61	951	837	279	P/X	ccC/cc	rs281865429&CD993067&COSV104596248&COSV61015202	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246602del	.	.	.	.	.	.	pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.837C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.570	9.399	7.651	9.354	.	.	.	35	37	-5	10	0.00	0.00	0.04	0.00	PAH	0.00	exon-NM_001354304.2-8+5+start+136	120288	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865429	281865429	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,710	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103246592	103246592	C	T	T	splice_donor_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	.	7/12	NM_000277.3:c.842+1G>A	.	.	.	.	.	.	rs5030852&CD068113&CS1314673&CS910454	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246592C>T	.	.	.	.	.	.	pathogenic	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.842+1G>T	0.999989072007339	0.932	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/donor/103246592-103246593/Medium/3.818123	11.570	11.083	7.651	9.399	1.217	8.182	9.399	-18	41	43	1	0.00	0.00	0.01	0.94	PAH	0.00	.	599	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030852	3.295e-05	4	4	0	0	0	0	0	4	0	0	10406	11572	8652	6614	66740	908	16512	0	0	0	0	4	0	0	0	0	0	0	0	0	0	rs5030852	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.07189e-05	0.00000e+00	0.00000e+00	3.70991e-05	3.59512e-05	8.07189e-05	3.65450e-05	rs5030852	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66134e-05	0.00000e+00	.	5.84249e-05	0.00000e+00	6.66134e-05	3.22664e-05	.	.	rs5030852	5030852	.	.	.	PAH	PAH:splicing	PAH:splice_donor_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,707	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103246592	103246592	C	A	A	splice_donor_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	.	7/12	NM_000277.3:c.842+1G>T	.	.	.	.	.	.	rs5030852&CD068113&CS1314673&CS910454	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246592C>A	.	.	.	.	.	.	not_provided&pathogenic	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.842+1G>T	0.999989072007339	0.932	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/donor/103246592-103246593/Medium/3.818123	11.570	11.083	7.651	9.399	0.895	8.504	9.399	-18	41	43	1	0.00	0.00	0.01	0.94	PAH	0.00	.	102869	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs5030852	5030852	.	.	.	PAH	PAH:splicing	PAH:splice_donor_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,706	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103245536	103245536	T	A	A	splice_acceptor_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	.	7/12	NM_000277.3:c.843-2A>T	.	.	.	.	.	.	rs62509019&CS982303	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103245536T>A	.	.	.	.	.	.	pathogenic&not_provided	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.843-2A>T	0.999988247793601	0.95	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/acceptor/103245536-103245537/Medium/6.410904	11.570	11.083	7.651	9.399	3.203	8.367	11.570	-18	-2	50	-2	0.00	0.83	0.00	0.00	PAH	0.00	.	102873	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62509019	62509019	.	.	.	PAH	PAH:splicing	PAH:splice_acceptor_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,703	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103245469	103245470	GA	G	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.907del	NP_000268.1:p.Ser303ProfsTer38	1021	907	303	S/X	Tcc/cc	rs62642920&CD056833&CM010973&CM981448	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103245473del	.	.	.	.	.	.	not_provided&pathogenic	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.907T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.506	11.083	11.570	9.399	.	.	.	20	3	-4	-5	0.00	0.00	0.00	0.02	PAH	0.00	exon-NM_001354304.2-9+5+start+70	102888	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62642920	0.00000e+00	0.00000e+00	0.00000e+00	6.18047e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84180e-05	0.00000e+00	6.18047e-04	3.22664e-05	.	.	rs62642920	62642920	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,689	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103245464	103245464	C	T	T	splice_donor_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	.	8/12	NM_000277.3:c.912+1G>A	.	.	.	.	.	.	rs62514956&CS1414079&CS961660&CS993021	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103245464C>T	.	.	.	.	.	.	pathogenic	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.912+1G>A	0.999990361384395	0.938	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/donor/103245464-103245465/Medium/5.700184	9.506	9.491	11.570	11.083	2.901	8.182	11.083	-28	26	-33	1	0.00	0.00	0.00	0.88	PAH	0.00	.	92752	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62514956	3.295e-05	4	4	0	0	0	0	0	4	0	0	10346	11492	8606	6598	66554	908	16452	0	0	0	0	4	0	0	0	0	0	0	0	0	0	rs62514956	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79620e-05	0.00000e+00	3.24929e-05	7.42854e-06	1.79979e-05	3.24929e-05	1.62425e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62514956	0.0233&0.0&0.0154	rs62514956	62514956	.	.	.	PAH	PAH:splicing	PAH:splice_donor_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,687	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103240709	103240711	CAG	C	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	9/13	.	NM_000277.3:c.931_932del	NP_000268.1:p.Leu311GlyfsTer4	1045-1046	931-932	311	L/X	CTg/g	rs281865430	AG	.	-1	.	.	EntrezGene	.	.	.	.	AG	AG	.	.	PAH	.	chr12:g.103240714_103240715del	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.709	9.491	9.506	11.083	.	.	.	42	19	19	-37	0.00	0.09	0.00	0.14	PAH	0.00	exon-NM_001354304.2-10+18+end+57	120297	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865430	281865430	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,684	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103238154	103238155	GC	G	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	10/13	.	NM_000277.3:c.1024del	NP_000268.1:p.Ala342HisfsTer58	1138	1024	342	A/X	Gca/ca	rs63581460&CD982849&CM930558&CM971134	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103238156del	.	.	.	.	.	.	pathogenic	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1024G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.163	9.459	7.709	9.491	.	.	.	-42	40	-41	1	0.00	0.00	0.09	0.00	PAH	0.00	exon-NM_001354304.2-11+41+start+96	102475	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs63581460	63581460	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,678	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103238123	103238124	AC	A	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	10/13	.	NM_000277.3:c.1055del	NP_000268.1:p.Gly352ValfsTer48	1169	1055	352	G/X	gGt/gt	rs62516094&CD941750	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103238125del	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.163	9.459	7.709	9.491	.	.	.	-11	-26	-11	-10	0.00	0.00	0.00	0.02	PAH	0.00	exon-NM_001354304.2-11+10+start+96	102498	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62516094	8.237e-06	1	1	0	0	0	0	0	1	0	0	10280	11300	8598	6564	66030	892	16080	0	0	0	0	1	0	0	0	0	0	0	0	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62516094	62516094	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,676	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103237559	103237559	T	A	A	splice_acceptor_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	.	10/12	NM_000277.3:c.1066-2A>T	.	.	.	.	.	.	rs281865447&CS112746	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103237559T>A	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1066-2A>T	0.999989408297863	0.906	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/acceptor/103237559-103237560/Medium/3.417725	3.163	9.158	7.709	9.459	-5.203	8.367	3.163	-15	-2	-15	-2	0.42	0.80	0.00	0.00	PAH	0.00	.	120258	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865447	281865447	.	.	.	PAH	PAH:splicing	PAH:splice_acceptor_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,673	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103237555	103237555	G	T	T	stop_gained&splice_region_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1068C>A	NP_000268.1:p.Tyr356Ter	1182	1068	356	Y/*	taC/taA	rs62516095&CM930560&CM941138	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103237555G>T	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1068C>R	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.92065	0.440918	D	0.99401	0.66	38	38	7.587621	7.377523	0.98031	0.97763	G/G	.	.	.	0.62157	0.99386870645766878	.	.	.	G/G	.	.	.	.	3.392356	0.241297361311317	0.52155	4.793478	0.46756172715164	0.65207	.	.	.	1	8.236e-06	0	0	0	0	1	8.255e-06	1	1.157e-04	0	0	0	0	0	0	1	9.415e-06	0	0	0	0	1	9.436e-06	1	1.274e-04	0	0	0	0	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.24	2.43	0.28797	0	0.26702	0.573888	.	.	0.05997	2.20166018399172E-4	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	.	.	0.057817	0.84330	D	0.000001	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.3794	0.37467	0.3485:0.0:0.6515:0.0	.	.	.	.	.	.	.	.	0.98563	.	G/G	X	.	Y	T	503	0.75780	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102843777G>T	92729	reviewed_by_expert_panel	Phenylketonuria&not_provided	HGMD:CM941138&DeBelle_Laboratory_for_Biochemical_Genetics:p.Y356X	.	.	AEFBI	D	0.68982	0.96406	D	0.82959	0.892555	.	3	1.195200e-05	0	0.000000e+00	16248	0	0	0.000000e+00	34560	0	251004	0	0.000000e+00	10074	0	3	1.631500e-04	18388	0	0	0.000000e+00	21540	0	0	0.000000e+00	113458	0	3	1.631500e-04	18388	0	0	0.000000e+00	30616	0	2	1.830060e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17108	0	109286	0	0.000000e+00	2320	0	2	2.211900e-04	9042	0	0	0.000000e+00	13286	0	0	0.000000e+00	42764	0	2	2.211900e-04	9042	0	0	0.000000e+00	15690	0	0	.	0	3	1.268670e-05	0	0.000000e+00	14894	0	0	0.000000e+00	34228	0	236468	0	0.000000e+00	9566	0	3	1.696260e-04	17686	0	0	0.000000e+00	21524	0	0	0.000000e+00	102444	0	3	1.696260e-04	17686	0	0	0.000000e+00	30526	0	0	2	9.617600e-06	0	0.000000e+00	16212	0	0	0.000000e+00	30496	0	207952	0	0.000000e+00	6210	0	2	1.491420e-04	13410	0	0	0.000000e+00	16626	0	0	0.000000e+00	89530	0	2	1.491420e-04	13410	0	0	0.000000e+00	30608	0	0	3	1.227570e-05	0	0.000000e+00	12018	0	0	0.000000e+00	34426	0	244386	0	0.000000e+00	9992	0	3	1.631850e-04	18384	0	0	0.000000e+00	21538	0	0	0.000000e+00	111368	0	3	1.631850e-04	18384	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101761685	12	103237555	0	0.43195	0.638212	1.000000	0.71638	0.382000	0.26379	0.978000	0.47047	1.311000	0.33168	0.676000	0.76740	1.176000	0.78918	102843777	G	.	rs62516095	.	.	8.924	9.158	3.163	9.459	2.868	0.295	3.163	13	2	2	4	0.00	0.05	0.00	0.00	PAH	0.00	exon-NM_001354304.2-12+2+end+134	92729	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62516095	8.236e-06	1	4	0	0	0	1	0	0	0	0	10298	11528	8640	6602	66660	908	16502	0	0	0	0	4	0	0	0	0	0	0	0	0	0	rs62516095	0.00000e+00	0.00000e+00	0.00000e+00	1.73994e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.22773e-05	0.00000e+00	1.73994e-04	1.21819e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62516095	62516095	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bstopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,672	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103237555	103237555	G	C	C	stop_gained&splice_region_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1068C>G	NP_000268.1:p.Tyr356Ter	1182	1068	356	Y/*	taC/taG	rs62516095&CM930560&CM941138	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103237555G>C	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1068C>R	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.95802	0.550057	D	0.99401	0.66	40	40	8.051331	7.900426	0.98791	0.98613	G/G	.	.	.	0.63075	0.99406618381356471	.	.	.	G/G	.	.	.	.	3.392356	0.241297361311317	0.52155	4.793478	0.46756172715164	0.65207	.	.	.	4	3.295e-05	0	0	0	0	4	3.302e-05	0	0	0	0	4	6.001e-05	0	0	2	1.883e-05	0	0	0	0	2	1.887e-05	0	0	0	0	2	3.684e-05	0	0	2	2.204e-05	0	0	0	0	2	2.210e-05	0	0	0	0	2	4.755e-05	0	0	.	.	.	.	5.24	2.43	0.28797	0	0.26702	0.573888	.	.	0.05997	2.20166018399172E-4	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	.	.	0.057817	0.84330	D	0.000001	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.3794	0.37467	0.3485:0.0:0.6515:0.0	.	.	.	.	.	.	.	.	0.98563	.	G/G	X	.	Y	C	503	0.75780	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102843777G>C	595	reviewed_by_expert_panel	Phenylketonuria&not_provided	OMIM_Allelic_Variant:612349.0019&DeBelle_Laboratory_for_Biochemical_Genetics:p.Y356X__1	.	.	AEFBI	D	0.69726	0.96555	D	0.86310	0.908158	.	5	1.992000e-05	0	0.000000e+00	16248	0	0	0.000000e+00	34560	0	251004	0	0.000000e+00	10074	0	0	0.000000e+00	18388	0	0	0.000000e+00	21540	0	5	4.406920e-05	113458	0	5	4.406920e-05	113458	0	0	0.000000e+00	30616	0	1	9.150300e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17108	0	109286	0	0.000000e+00	2320	0	0	0.000000e+00	9042	0	0	0.000000e+00	13286	0	1	2.338420e-05	42764	0	1	2.338420e-05	42764	0	0	0.000000e+00	15690	0	0	.	0	3	1.268670e-05	0	0.000000e+00	14894	0	0	0.000000e+00	34228	0	236468	0	0.000000e+00	9566	0	0	0.000000e+00	17686	0	0	0.000000e+00	21524	0	3	2.928430e-05	102444	0	3	2.928430e-05	102444	0	0	0.000000e+00	30526	0	0	4	1.923520e-05	0	0.000000e+00	16212	0	0	0.000000e+00	30496	0	207952	0	0.000000e+00	6210	0	0	0.000000e+00	13410	0	0	0.000000e+00	16626	0	4	4.467780e-05	89530	0	4	4.467780e-05	89530	0	0	0.000000e+00	30608	0	0	5	2.045940e-05	0	0.000000e+00	12018	0	0	0.000000e+00	34426	0	244386	0	0.000000e+00	9992	0	0	0.000000e+00	18384	0	0	0.000000e+00	21538	0	5	4.489620e-05	111368	0	5	4.489620e-05	111368	0	0	0.000000e+00	30616	0	0	3	1.972080e-05	0	0.000000e+00	41422	0	0	0.000000e+00	912	0	1	6.545360e-05	15278	0	152124	0	0.000000e+00	3472	0	0	0.000000e+00	5192	0	0	0.000000e+00	10604	0	0	0.000000e+00	316	0	2	2.940660e-05	68012	0	1	6.545360e-05	15278	0	0	0.000000e+00	4822	0	1	3.042660e-05	0	0.000000e+00	9080	0	0	0.000000e+00	60	0	1	2.133110e-04	4688	0	32866	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5478	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3108	0	0	.	0	3	2.028700e-05	0	0.000000e+00	41100	0	0	0.000000e+00	912	0	1	6.626910e-05	15090	0	147878	0	0.000000e+00	3302	0	0	0.000000e+00	4960	0	0	0.000000e+00	10604	0	0	0.000000e+00	304	0	2	3.086800e-05	64792	0	0	0.000000e+00	4790	0	0	3	2.226870e-05	0	0.000000e+00	32452	0	0	0.000000e+00	862	0	1	6.742180e-05	14832	0	134718	0	0.000000e+00	3388	0	0	0.000000e+00	5192	0	0	0.000000e+00	6966	0	0	0.000000e+00	310	0	2	3.130280e-05	63892	0	0	0.000000e+00	4820	0	0	1	1.239310e-05	0	0.000000e+00	24796	0	0	0.000000e+00	112	0	1	7.748330e-05	12906	0	80690	0	0.000000e+00	998	0	0	0.000000e+00	3750	0	0	0.000000e+00	10512	0	0	0.000000e+00	272	0	0	0.000000e+00	21030	0	0	0.000000e+00	4794	0	0	12	101761685	12	103237555	0	0.43195	0.638212	1.000000	0.71638	0.382000	0.26379	0.978000	0.47047	1.311000	0.33168	0.676000	0.76740	1.176000	0.78918	102843777	G	.	rs62516095	.	.	8.924	9.158	3.163	9.459	2.161	1.003	3.163	-1	2	-1	4	0.16	0.21	0.00	0.00	PAH	0.00	exon-NM_001354304.2-12+2+end+134	595	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62516095	3.295e-05	4	0	0	0	0	0	0	4	0	0	10298	11528	8640	6602	66660	908	16502	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs62516095	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.59092e-05	0.00000e+00	0.00000e+00	2.22773e-05	8.99977e-06	3.59092e-05	1.62425e-05	rs62516095	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.67200e-05	0.00000e+00	.	0.00000e+00	7.22543e-05	6.67200e-05	3.22664e-05	.	.	rs62516095	62516095	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bstopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,671	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103237533	103237534	GC	G	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1089del	NP_000268.1:p.Lys363AsnfsTer37	1203	1089	363	K/X	aaG/aa	rs5030654&CD962117&CM068054&COSV100187990	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103237534del	.	.	.	.	.	.	pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1089G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.924	9.158	3.163	9.459	.	.	.	24	11	-15	24	0.04	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-12+23+end+134	102518	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs5030654	5030654	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,670	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103237423	103237423	C	G	G	splice_donor_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	.	11/12	NM_000277.3:c.1199+1G>C	.	.	.	.	.	.	rs62509015&CS011056&CS982306	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103237423C>G	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1199+1G>T	0.999986675681007	0.94	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.924	9.491	3.163	9.158	0.885	8.273	9.158	6	1	-16	1	0.00	0.00	0.56	0.64	PAH	0.00	.	102557	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62509015	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.96186e-06	0.00000e+00	3.24907e-05	7.41939e-06	8.98763e-06	3.24907e-05	8.12137e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62509015	62509015	.	.	.	PAH	PAH:splicing	PAH:splice_donor_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,658	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103288514	103288515	TG	T	-	frameshift_variant&splice_region_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.350del	NP_000268.1:p.Thr117LysfsTer78	464	350	117	T/X	aCa/aa	rs281865428&CD082169	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103288515del	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.350del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.038	10.766	11.785	7.700	.	.	.	11	-13	-1	-7	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+2+start+184	120274	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865428	281865428	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bframeshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,805	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103288698	103288698	T	C	C	splice_acceptor_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	.	2/12	NM_000277.3:c.169-2A>G	.	.	.	.	.	.	rs1226613045&CS102228&COSV61016487&COSV61017046	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103288698T>C	.	.	.	.	.	.	pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.169-2A>G	0.999988247793601	0.932	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/acceptor/103288698-103288699/Medium/10.646507	11.785	10.766	8.002	7.700	3.830	7.955	11.785	-37	-2	46	-2	0.04	1.00	0.00	0.00	PAH	0.00	.	555212	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12:103288698-103288698	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.49815e-05	7.44624e-06	9.03359e-06	6.49815e-05	8.12110e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1226613045	1226613045	.	.	.	PAH	PAH:splicing	PAH:splice_acceptor_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,827	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103306568	103306568	C	T	T	splice_donor_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	.	2/12	NM_000277.3:c.168+1G>A	.	.	.	.	.	.	rs62514898&CS1411214&CS961655&CX921034	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103306568C>T	.	.	.	.	.	.	not_provided&pathogenic	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.168+1G>T	0.999967335026411	0.93	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.785	10.766	8.002	7.700	-0.482	8.182	7.700	-40	38	19	1	0.00	0.00	0.01	1.00	PAH	0.00	.	102604	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62514898	62514898	.	.	.	PAH	PAH:splicing	PAH:splice_donor_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,831	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
16	68846113	68846114	GT	G	-	frameshift_variant	HIGH	CDH1	999	Transcript	NM_004360.5	protein_coding	8/16	.	NM_004360.5:c.1085del	NP_004351.1:p.Val362GlyfsTer31	1209	1085	362	V/X	gTg/gg	rs1555515739	T	.	1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	TANGO6	.	chr16:g.68846114del	.	.	.	.	.	.	pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.382	7.312	10.172	4.939	.	.	.	-8	10	50	-30	0.00	0.00	0.00	0.08	CDH1	0.34	exon-NM_004360.5-8+52+end+129	483264	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Hereditary_diffuse_gastric_adenocarcinoma	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555515739	1555515739	.	.	.	CDH1	CDH1:exonic	CDH1:frameshift_deletion	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,903	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
21	36259139	36259139	C	G	G	splice_donor_variant	HIGH	RUNX1	861	Transcript	NM_001754.5	protein_coding	.	4/8	NM_001754.5:c.351+1G>C	.	.	.	.	.	.	rs1060502579&CS086072&CS1312705&CS1612377&COSV104611305&COSV55897469	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36259139C>G	.	.	.	.	.	.	likely_pathogenic	0&0&0&0&1&1	1&1&1&1&1&1	.	.	.	.	.	.	0.999986675681007	0.954	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/donor/36259139-36259140/Medium/12.070451	5.882	10.199	8.426	8.558	0.286	8.273	8.558	-16	21	-19	1	0.00	0.00	0.00	0.99	RUNX1	0.45	.	409822	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1&not_provided	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1060502579	1060502579	.	.	.	RUNX1	RUNX1:splicing	RUNX1:splice_donor_variant	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,977	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
21	36253011	36253011	C	T	T	splice_acceptor_variant	HIGH	RUNX1	861	Transcript	NM_001754.5	protein_coding	.	4/8	NM_001754.5:c.352-1G>A	.	.	.	.	.	.	rs587776809&CS1515469&CS992234&COSV55881362&COSV55890980&COSV55895694	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36253011C>T	.	.	.	.	.	.	pathogenic	0&0&0&1&1&1	1&1&1&1&1&1	.	.	.	.	.	.	0.999988630721284	0.94	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/acceptor/36253010-36253011/Medium/3.841726	5.882	10.199	8.426	8.558	-2.868	8.750	5.882	-2	-1	-14	-1	0.88	0.99	0.00	0.00	RUNX1	0.45	.	436616	Pathogenic	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587776809	587776809	.	.	.	RUNX1	RUNX1:splicing	RUNX1:splice_acceptor_variant	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,975	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
21	36253011	36253011	C	A	A	splice_acceptor_variant	HIGH	RUNX1	861	Transcript	NM_001754.5	protein_coding	.	4/8	NM_001754.5:c.352-1G>T	.	.	.	.	.	.	rs587776809&CS1515469&CS992234&COSV55881362&COSV55890980&COSV55895694	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36253011C>A	.	.	.	.	.	.	pathogenic	0&0&0&1&1&1	1&1&1&1&1&1	.	.	.	.	.	.	0.999988630721284	0.94	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/acceptor/36253010-36253011/Medium/3.841726	5.882	10.199	8.426	8.558	-2.716	8.598	5.882	-14	-1	-26	-1	0.99	0.99	0.00	0.00	RUNX1	0.45	.	14463	Pathogenic	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587776809	587776809	.	.	.	RUNX1	RUNX1:splicing	RUNX1:splice_acceptor_variant	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,974	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
21	36252912	36252920	GGCTGCGGT	G	-	frameshift_variant	HIGH	RUNX1	861	Transcript	NM_001754.5	protein_coding	5/9	.	NM_001754.5:c.442_449del	NP_001745.2:p.Thr148HisfsTer9	636-643	442-449	148-150	TAA/X	ACCGCAGCc/c	rs587776811	GCTGCGGT	.	-1	.	1	EntrezGene	.	YES	.	.	GCTGCGGT	GCTGCGGT	.	.	RUNX1	.	chr21:g.36252913_36252920del	.	.	.	.	.	.	pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.926	10.199	5.882	8.558	.	.	.	.	.	.	.	.	.	.	.	.	0.45	exon-NM_001754.5-5+59+start+157	14470	Pathogenic	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587776811	587776811	.	.	.	RUNX1	RUNX1:exonic	RUNX1:frameshift_deletion	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,969	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
21	36164712	36164712	G	T	T	stop_gained	HIGH	RUNX1	861	Transcript	NM_001754.5	protein_coding	9/9	.	NM_001754.5:c.1163C>A	NP_001745.2:p.Ser388Ter	1357	1163	388	S/*	tCg/tAg	rs1569002296&CM099539&COSV55892449	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36164712G>T	.	.	.	.	.	.	likely_pathogenic	0&0&1	1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.99412	0.625005	D	0.99401	0.66	39	41	7.837311	8.088585	0.98455	0.98886	G/G	.	.	.	0.69407	0.99523407138108455	.	.	.	G/G	.	.	.	.	7.393616	0.679963795566454	0.80859	8.989813	0.810511126675116	0.86760	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.22	5.22	0.72285	0	0.67091	0.694456	.	.	0.74766	0.999999999999993	.	0	0.29568	0.578056	.	.	.	.	.	.	0	0.53088	0.635551	.&.&.&.	.	.	.	.	.	0.327305	0.33730	N	0.004449	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae&complex_aae&complex_aae&complex_aae	D&D&D&D&D	1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	18.3819	0.90397	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.76019	.	G/G	X	.	S	T	399	0.82780	.	21	C1832388&CN517202	601399	.	Likely_pathogenic	NC_000021.9:g.34792415G>T	561222	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy&not_provided	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:37cf5142-fd3f-4896-9da9-ca4c54b542ea	.	.	AEFDBCI	D	0.50627	0.89874	N	0.11935	0.062177	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35086582	21	36164712	0	0.49826	0.660377	1.000000	0.71638	0.929000	0.46594	0.990000	0.52443	8.951000	0.92928	0.654000	0.53741	1.158000	0.71245	34792415	G	.	rs1569002296	.	.	.	.	9.279	7.470	.	.	.	-2	-14	4	-17	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-9+195+end+4810	561222	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	RUNX1	RUNX1:exonic	RUNX1:stopgain	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,949	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
21	36164461	36164461	G	GGC	GC	frameshift_variant	HIGH	RUNX1	861	Transcript	NM_001754.5	protein_coding	9/9	.	NM_001754.5:c.1412_1413dup	NP_001745.2:p.Leu472AlafsTer123	1607-1608	1413-1414	471-472	-/X	-/GC	rs1555884790	.	.	-1	.	1	EntrezGene	.	YES	.	.	.	.	.	.	RUNX1	.	chr21:g.36164467_36164468dup	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.279	7.470	.	.	.	.	.	.	.	.	.	.	.	.	0.45	exon-NM_001754.5-9+446+end+4810	532664	Pathogenic	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555884790	1555884790	.	.	.	RUNX1	RUNX1:exonic	RUNX1:frameshift_insertion	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,944	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
16	68863687	68863688	AT	A	-	frameshift_variant	HIGH	CDH1	999	Transcript	NM_004360.5	protein_coding	15/16	.	NM_004360.5:c.2430del	NP_004351.1:p.Phe810LeufsTer6	2551	2427	809	N/X	aaT/aa	rs786203752	T	.	1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	TANGO6	3	chr16:g.68863691del	.	.	.	.	.	.	pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.931	9.815	9.586	8.564	.	.	.	-18	-17	-40	12	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_001317185.2-15+12+end+144	187464	Pathogenic	reviewed_by_expert_panel	not_provided&Hereditary_cancer-predisposing_syndrome&Hereditary_diffuse_gastric_adenocarcinoma	MedGen:CN517202&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786203752	786203752	.	.	.	CDH1	CDH1:exonic	CDH1:frameshift_deletion	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,921	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
16	68863655	68863656	TC	T	-	frameshift_variant	HIGH	CDH1	999	Transcript	NM_004360.5	protein_coding	15/16	.	NM_004360.5:c.2398del	NP_004351.1:p.Arg800AlafsTer16	2519	2395	799	P/X	Ccc/cc	rs587783048&COSV55731664	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	3	chr16:g.68863659del	.	.	.	.	.	.	pathogenic	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.931	9.815	9.586	8.564	.	.	.	5	17	41	48	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_001317185.2-15+44+end+144	156497	Pathogenic	reviewed_by_expert_panel	Hereditary_diffuse_gastric_adenocarcinoma&not_provided&Hereditary_cancer-predisposing_syndrome	MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MedGen:CN517202&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587783048	587783048	.	.	.	CDH1	CDH1:exonic	CDH1:frameshift_deletion	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,918	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
16	68855984	68855984	C	T	T	stop_gained	HIGH	CDH1	999	Transcript	NM_004360.5	protein_coding	12/16	.	NM_004360.5:c.1792C>T	NP_004351.1:p.Arg598Ter	1916	1792	598	R/*	Cga/Tga	rs121964877&CM980318&COSV55731120&COSV55734398	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	.	chr16:g.68855984C>T	.	.	.	.	.	.	pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.1792C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.97860	0.607496	D	0.97827	0.634849	37	37	7.040341	7.110614	0.97127	0.97332	C/C	.	.	.	0.84228	0.9975062383098342	.	.	.	C/C	.	.	.	.	5.621041	0.547387993821871	0.71213	7.548586	0.729252338377496	0.81550	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.34	5.34	0.75982	0	0.55848	0.633656	.	.	0.74766	0.999999999999287	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.26826	0.564101	.&.&.&.&.	.	.	.	.	.	0.368613	0.19687	N	0.104789	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	18.6991	0.91575	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.87373	.	C/C	X	.	R	T	334	0.86273	.	16	C1708349&C0027672&CN517202	137215	ORPHA26106&ORPHA140162	Pathogenic	NC_000016.10:g.68822081C>T	12241	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:8d966550-3108-4786-8d4d-092988c239d6&OMIM_Allelic_Variant:192090.0012	.	.	AEFBI	D	0.91890	0.99145	N	0.32355	0.196582	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	67413485	16	68855984	0	0.73137	0.706548	1.000000	0.71638	0.094000	0.17991	0.916000	0.38718	5.425000	0.66208	0.589000	0.31548	1.018000	0.39106	68822081	C	.	rs121964877	.	.	8.251	4.820	10.720	9.332	.	.	.	23	-5	-31	38	0.00	0.00	0.00	0.01	CDH1	0.34	exon-NM_001317185.2-12+80+start+225	12241	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&Hereditary_diffuse_gastric_adenocarcinoma	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121964877	121964877	.	.	.	CDH1	CDH1:exonic	CDH1:stopgain	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,913	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
16	68844245	68844245	G	T	T	splice_donor_variant	HIGH	CDH1	999	Transcript	NM_004360.5	protein_coding	.	6/15	NM_004360.5:c.832+1G>T	.	.	.	.	.	.	rs878854697&CS134642&COSV55727488&COSV55728175&COSV55737650	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68844245G>T	.	.	.	.	.	.	pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	.	0.999986675681007	0.94	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/donor/68844245-68844246/Medium/2.565564	8.102	4.939	8.533	7.878	-0.626	8.504	7.878	32	-40	-13	-1	0.00	0.00	0.74	0.99	CDH1	0.34	.	239914	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Hereditary_diffuse_gastric_adenocarcinoma	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs878854697	878854697	.	.	.	CDH1	CDH1:splicing	CDH1:splice_donor_variant	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,898	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103306571	103306572	CA	C	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	2/13	.	NM_000277.3:c.165del	NP_000268.1:p.Phe55LeufsTer6	279	165	55	F/X	ttT/tt	rs199475566&CD011178&CD910542&CM971122	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103306574del	.	.	.	.	.	.	pathogenic	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.165T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.785	7.700	8.002	9.602	.	.	.	34	15	-20	-3	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-3+3+start+108	611	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103306572-103306573	1.647e-05	2	2	0	0	0	0	0	2	0	0	10404	11578	8652	6610	66722	908	16506	0	0	0	0	2	0	0	0	0	0	0	0	0	0	rs199475566	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.68769e-05	0.00000e+00	0.00000e+00	2.22512e-05	0.00000e+00	2.68769e-05	1.21819e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475566	199475566	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,832	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
16	68835787	68835788	GC	G	-	frameshift_variant	HIGH	CDH1	999	Transcript	NM_004360.5	protein_coding	3/16	.	NM_004360.5:c.382del	NP_004351.1:p.His128IlefsTer87	503	379	127	P/X	Ccc/cc	rs1555514492	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	3	chr16:g.68835791del	.	.	.	.	.	.	pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.196	9.802	8.175	8.409	.	.	.	8	-38	12	8	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-3+8+end+224	486824	Pathogenic	reviewed_by_expert_panel	Blepharocheilodontic_syndrome_1&Endometrial_carcinoma&Hereditary_diffuse_gastric_adenocarcinoma&Familial_cancer_of_breast&Neoplasm_of_ovary&Malignant_tumor_of_prostate&Hereditary_cancer-predisposing_syndrome	MONDO:MONDO:0054740&MedGen:C4551988&OMIM:119580&Orphanet:1997&Human_Phenotype_Ontology:HP:0012114&MONDO:MONDO:0002447&MedGen:C0476089&OMIM:608089&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267&OMIM:167000&Human_Phenotype_Ontology:HP:0012125&MONDO:MONDO:0008315&MedGen:C0376358&OMIM:176807&Orphanet:1331&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555514492	1555514492	.	.	.	CDH1\x3bTANGO6	CDH1:exonic\x7cTANGO6:regulatory	CDH1:frameshift_deletion\x7cTANGO6:promoter_flanking_region	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,893	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
16	68835692	68835692	C	T	T	stop_gained	HIGH	CDH1	999	Transcript	NM_004360.5	protein_coding	3/16	.	NM_004360.5:c.283C>T	NP_004351.1:p.Gln95Ter	407	283	95	Q/*	Cag/Tag	rs781409616&CM014037&COSV104378470	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	.	chr16:g.68835692C>T	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.283C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.75363	0.215637	D	0.75042	0.0719712	33	32	5.038159	4.448684	0.93340	0.91494	C/C	.	.	.	0.53329	0.9913373882815999	.	.	.	C/C	.	.	.	.	1.861233	-0.169281529224511	0.32673	2.834451	0.0867862568260387	0.45848	.	.	.	1	8.236e-06	0	0	0	0	1	8.237e-06	0	0	0	0	1	1.498e-05	0	0	1	9.415e-06	0	0	0	0	1	9.416e-06	0	0	0	0	1	1.840e-05	0	0	1	1.102e-05	0	0	0	0	1	1.102e-05	0	0	0	0	1	2.373e-05	0	0	.	.	.	.	5.43	3.42	0.38259	0	0.55848	0.633656	.	.	0.46732	0.999937687960431	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.14980	0.542086	Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&.	.	.	.	.	.	0.441187	0.18903	N	0.123856	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	15.1598	0.72457	0.0:0.4207:0.5793:0.0	.	.	.	.	.	.	.	.	0.69737	.	C/C	X	.	Q	T	315	0.87208	.	16	C1708349&C0027672	137215	ORPHA26106&ORPHA140162	Pathogenic	NC_000016.10:g.68801789C>T	463775	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome	ClinGen_CDH1_Variant_Curation_Expert_Panel&:b376ba62-95aa-49c6-8b93-54ef1ce4448e	.	.	AEFBI	N	0.26048	0.38702	N	0.27642	0.151855	.	1	3.978830e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34590	0	251330	0	0.000000e+00	10074	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	1	8.801270e-06	113620	0	1	8.801270e-06	113620	0	0	0.000000e+00	30614	0	1	9.140270e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	1	2.338200e-05	42768	0	1	2.338200e-05	42768	0	0	0.000000e+00	15688	0	0	.	0	1	4.223120e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34258	0	236792	0	0.000000e+00	9566	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	1	9.746210e-06	102604	0	1	9.746210e-06	102604	0	0	0.000000e+00	30524	0	0	1	4.804780e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208126	0	0.000000e+00	6210	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	1	1.116640e-05	89554	0	1	1.116640e-05	89554	0	0	0.000000e+00	30606	0	0	1	4.086440e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34456	0	244712	0	0.000000e+00	9992	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	1	8.966200e-06	111530	0	1	8.966200e-06	111530	0	0	0.000000e+00	30614	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	67393193	16	68835692	0	0.73137	0.706548	0.751000	0.29144	0.007000	0.07825	0.023000	0.14501	1.713000	0.37570	-0.184000	0.09925	0.177000	0.21290	68801789	C	.	rs781409616	.	.	12.196	9.802	8.175	8.409	.	.	.	41	3	-42	14	0.00	0.02	0.00	0.00	CDH1	0.34	exon-NM_004360.5-3+104+end+224	463775	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Hereditary_diffuse_gastric_adenocarcinoma	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	16:68835692-68835692	8.236e-06	1	1	0	0	0	0	0	1	0	0	10400	11574	8654	6614	66738	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs781409616	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.96475e-06	0.00000e+00	0.00000e+00	7.41873e-06	0.00000e+00	8.96475e-06	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs781409616	781409616	.	.	.	CDH1\x3bTANGO6	CDH1:exonic\x7cTANGO6:regulatory	CDH1:stopgain\x7cTANGO6:promoter_flanking_region	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,891	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
16	68835596	68835596	C	T	T	stop_gained	HIGH	CDH1	999	Transcript	NM_004360.5	protein_coding	3/16	.	NM_004360.5:c.187C>T	NP_004351.1:p.Arg63Ter	311	187	63	R/*	Cga/Tga	rs587783047&CM980317&COSV55728388&COSV55734769&COSV55741582	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	.	chr16:g.68835596C>T	.	.	.	.	.	.	pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.187C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.88369	0.374752	D	0.88222	0.300529	33	34	5.206234	5.830676	0.93765	0.95274	C/C	.	.	.	0.77005	0.99646264151011144	.	.	.	C/C	.	.	.	.	2.870176	0.132157174396913	0.46203	4.208308	0.377740509113097	0.60217	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.43	4.37	0.51830	0	0.55848	0.633656	.	.	0.74766	0.999996644420812	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.35598	0.584449	Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&.	.	.	.	.	.	0.335920	0.20687	N	0.084609	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	14.645	0.68357	0.1811:0.8189:0.0:0.0	.	.	.	.	.	.	.	.	0.63883	.	C/C	X	.	R	T	315	0.87208	.	16	C1708349&C0027672	137215	ORPHA26106&ORPHA140162	Pathogenic	NC_000016.10:g.68801693C>T	156496	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome	ClinGen_CDH1_Variant_Curation_Expert_Panel&:be4384f2-4317-4809-956c-12533c2847e1	.	.	AEFDBI	N	0.19943	0.17684	N	0.28538	0.159567	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	67393097	16	68835596	0	0.73137	0.706548	0.000000	0.06391	0.263000	0.23594	0.167000	0.21380	0.477000	0.21906	0.599000	0.40250	1.018000	0.39106	68801693	C	.	rs587783047	.	.	12.196	9.802	8.175	8.409	.	.	.	-11	-23	-3	41	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-3+23+start+224	156496	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Hereditary_diffuse_gastric_adenocarcinoma	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587783047	587783047	.	.	.	CDH1\x3bTANGO6	CDH1:exonic\x7cTANGO6:regulatory	CDH1:stopgain\x7cTANGO6:CTCF_binding_site\x3bpromoter_flanking_region	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,889	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
13	20763744	20763744	T	G	G	splice_acceptor_variant	HIGH	GJB2	2706	Transcript	NM_004004.6	protein_coding	.	1/1	NM_004004.6:c.-22-2A>C	.	.	.	.	.	.	rs201895089&CS139159	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	GJB2	.	chr13:g.20763744T>G	.	0	0	0	0.002	0	uncertain_significance&pathogenic&pathogenic/likely_pathogenic&benign&conflicting_interpretations_of_pathogenicity	.	1&1	.	.	.	.	.	GJB2&NM_004004.5&c.-22-2A>C	0.999978952611685	0.924	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/acceptor/20763744-20763745/Medium/10.092431	10.295	.	.	9.602	2.253	8.042	10.295	36	-2	36	-16	0.23	0.91	0.00	0.00	GJB2	0.00	.	375406	Likely_pathogenic	reviewed_by_expert_panel	not_provided&not_specified&Ichthyosis&_hystrix-like&_with_hearing_loss&Palmoplantar_keratoderma-deafness_syndrome&Autosomal_dominant_keratitis-ichthyosis-hearing_loss_syndrome&Mutilating_keratoderma&Knuckle_pads&_deafness_AND_leukonychia_syndrome&Autosomal_dominant_nonsyndromic_hearing_loss_3A&X-linked_mixed_hearing_loss_with_perilymphatic_gusher&Autosomal_recessive_nonsyndromic_hearing_loss_1A&Nonsyndromic_genetic_hearing_loss	MedGen:CN517202&MedGen:CN169374&MONDO:MONDO:0011245&MedGen:C1865234&OMIM:602540&Orphanet:477&MONDO:MONDO:0007852&MedGen:C1835672&OMIM:148350&Orphanet:2202&MONDO:MONDO:0007850&MedGen:C0265336&OMIM:148210&Orphanet:477&MONDO:MONDO:0007422&MedGen:C0265964&OMIM:124500&Orphanet:494&MONDO:MONDO:0007866&MedGen:C0266004&OMIM:149200&Orphanet:2698&MONDO:MONDO:0011103&MedGen:C2675750&OMIM:601544&Orphanet:90635&MONDO:MONDO:0010576&MedGen:C1844678&OMIM:304400&Orphanet:383&MONDO:MONDO:0009076&MedGen:C2673759&OMIM:220290&Orphanet:90636&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884	.	13:20763744-20763744	6.754e-04	82	82	0	1	3	0	0	76	2	0	10354	11566	8650	6614	66386	906	16510	1	3	0	0	76	2	0	0	0	0	0	0	0	0	rs201895089	6.54793e-05	2.38237e-04	4.57689e-03	0.00000e+00	4.48471e-05	8.32784e-04	3.65898e-04	0.00000e+00	7.02090e-04	4.91517e-04	4.57689e-03	6.01724e-04	rs201895089	1.14653e-04	0.00000e+00	3.31126e-03	0.00000e+00	0.00000e+00	6.00160e-04	0.00000e+00	.	5.25947e-04	1.44467e-04	3.31126e-03	3.54930e-04	rs201895089	0.0582&0.0&0.0385	rs201895089	201895089	.	.	.	GJB2	GJB2:splicing	GJB2:splice_acceptor_variant	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,874	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103310860	103310862	CAG	C	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	1/13	.	NM_000277.3:c.47_48del	NP_000268.1:p.Ser16Ter	161-162	47-48	16	S/X	tCT/t	rs62642906	AG	.	-1	.	.	EntrezGene	.	.	.	.	AG	AG	.	.	PAH	.	chr12:g.103310865_103310866del	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.002	9.602	.	.	.	.	.	-13	-15	-16	-12	0.00	0.00	0.00	0.02	PAH	0.00	exon-NM_000277.3-1+12+start+174	102696	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	rs62642906	8.236e-06	1	1	0	0	0	0	0	1	0	0	10404	11574	8654	6614	66730	908	16510	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs62642906	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95544e-06	0.00000e+00	0.00000e+00	7.41378e-06	0.00000e+00	8.95544e-06	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62642906	62642906	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,846	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103310851	103310851	G	A	A	stop_gained&splice_region_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	1/13	.	NM_000277.3:c.58C>T	NP_000268.1:p.Gln20Ter	172	58	20	Q/*	Cag/Tag	rs199475585&CM971121	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103310851G>A	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.58C>T	0.998674500609981	0.87	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.99412	0.625005	D	0.99401	0.66	43	44	8.423530	8.593977	0.99267	0.99446	G/G	.	.	.	0.88817	0.99804104865595689	.	.	.	G/G	.	.	.	.	7.309179	0.674993214885087	0.80484	9.444174	0.832240877000348	0.88076	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.2	5.2	0.71720	0	0.06741	0.475579	.	.	0.74766	0.999999999863142	.	0	0.62441	0.685912	.	.	.	.	.	.	0	0.26826	0.564101	.&.&.	.	.	.	.	.	0.435185	0.23712	N	0.043707	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&without_aae	A&D	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	14.4281	0.66804	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.75009	.	G/G	X	.	Q	A	776	0.48302	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102917073G>A	102744	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.Q20X	.	.	AEFDGBHCI	D	0.49110	0.88935	D	0.71745	0.787761	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101834981	12	103310851	1	0.06251	0.40479	1.000000	0.71638	0.463000	0.28185	0.397000	0.25631	4.095000	0.57456	0.676000	0.76740	1.176000	0.78918	102917073	G	.	rs199475585	.	.	8.002	9.602	.	.	7.962	1.640	9.602	-3	-39	2	-2	0.00	0.00	0.00	0.18	PAH	0.00	exon-NM_000277.3-1+2+start+174	102744	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475585	199475585	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bstopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,845	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103306625	103306625	T	TC	C	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	2/13	.	NM_000277.3:c.111dup	NP_000268.1:p.Ile38AspfsTer19	225-226	111-112	37-38	-/X	-/G	rs199475674	.	.	-1	.	.	EntrezGene	.	.	.	.	.	.	.	.	PAH	.	chr12:g.103306626dup	.	.	.	.	.	.	not_provided&pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.785	7.700	8.002	9.602	.	.	.	42	43	-39	43	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-3+51+end+108	102531	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475674	199475674	.	.	.	PAH	PAH:exonic	PAH:frameshift_insertion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,841	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103306599	103306600	AC	A	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	2/13	.	NM_000277.3:c.137del	NP_000268.1:p.Gly46ValfsTer15	251	137	46	G/X	gGt/gt	rs199475591&CD992536	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103306601del	.	.	.	.	.	.	not_provided&pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.137G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.785	7.700	8.002	9.602	.	.	.	6	9	-48	-31	0.00	0.00	0.00	0.01	PAH	0.00	exon-NM_001354304.2-3+31+start+108	102597	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475591	199475591	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,837	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103306581	103306582	CA	C	-	frameshift_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	2/13	.	NM_000277.3:c.155del	NP_000268.1:p.Leu52CysfsTer9	269	155	52	L/X	tTg/tg	rs281865165&CD1514937&CM981426	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103306583del	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.155T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.785	7.700	8.002	9.602	.	.	.	24	-19	5	-13	0.00	0.00	0.09	0.00	PAH	0.00	exon-NM_001354304.2-3+13+start+108	120310	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865165	281865165	.	.	.	PAH	PAH:exonic	PAH:frameshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,835	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
12	103234177	103234177	C	T	T	splice_donor_variant	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	.	12/12	NM_000277.3:c.1315+1G>A	.	.	.	.	.	.	rs5030861&CS860021&CS993022&COSV61014963&COSV61017004	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103234177C>T	.	.	.	.	.	.	pathogenic	0&0&0&1&1	1&1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1315+1G>A	0.999986675681007	0.93	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/donor/103234177-103234178/Medium/3.739496	10.477	.	8.924	9.491	1.309	8.182	9.491	-40	-1	-3	1	0.00	0.00	0.02	0.94	PAH	0.00	.	576	Pathogenic	reviewed_by_expert_panel	not_provided&Inborn_genetic_diseases&Phenylketonuria	MedGen:CN517202&MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030861	3.459e-04	42	42	0	2	0	0	0	40	0	0	10404	11498	8650	6596	66664	908	16508	2	0	0	0	40	0	0	0	0	0	0	0	0	0	rs5030861	1.30702e-04	2.98169e-05	0.00000e+00	0.00000e+00	0.00000e+00	8.23664e-04	1.82482e-04	0.00000e+00	3.85585e-04	3.95229e-04	8.23664e-04	3.89816e-04	rs5030861	1.14626e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.33040e-04	0.00000e+00	.	4.67946e-04	2.88684e-04	7.33040e-04	3.87197e-04	rs5030861	0.1047&0.0227&0.0769	rs5030861	5030861	.	.	.	PAH	PAH:splicing	PAH:splice_donor_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,643	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
21	36259274	36259274	T	TCC	CC	frameshift_variant	HIGH	RUNX1	861	Transcript	NM_001754.5	protein_coding	4/9	.	NM_001754.5:c.215_216dup	NP_001745.2:p.Ser73GlyfsTer50	410-411	216-217	72-73	-/X	-/GG	rs1555899813	.	.	-1	.	1	EntrezGene	.	YES	.	.	.	.	.	.	RUNX1	.	chr21:g.36259275_36259276dup	.	.	.	.	.	.	pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.882	8.558	8.426	9.942	.	.	.	.	.	.	.	.	.	.	.	.	0.45	exon-NM_001754.5-4+119+end+254	463988	Pathogenic	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555899813	1555899813	.	.	.	RUNX1	RUNX1:exonic	RUNX1:frameshift_insertion	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,984	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89720832	89720836	CAAAT	C	-	frameshift_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	8/9	.	NM_000314.8:c.987_990del	NP_000305.3:p.Asn329LysfsTer14	1829-1832	984-987	328-329	AN/X	gcAAAT/gc	rs587782304	AAAT	.	1	.	.	EntrezGene	.	.	.	.	AAAT	TAAA	.	.	PTEN	3	chr10:g.89720836_89720839del	.	.	.	.	.	.	pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.857	8.679	12.930	7.806	.	.	.	-3	8	46	42	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-9+39+end+225	189441	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587782304	587782304	.	.	.	PTEN	PTEN:exonic	PTEN:frameshift_deletion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,589	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89720876	89720876	G	A	A	splice_donor_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	8/8	NM_000314.8:c.1026+1G>A	.	.	.	.	.	.	rs786201041&CS043794&CS110216&CS176421&COSV64288702&COSV64289135&COSV64293873	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89720876G>A	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&0&0&0&1&1&1	1&1&1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.1026+1G>T	0.999986675681007	0.934	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.857	.	12.930	8.679	0.497	8.182	8.679	-1	0	3	-1	0.00	0.00	0.03	0.99	PTEN	0.98	.	183722	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Cowden_syndrome_1&not_provided&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786201041	786201041	.	.	.	PTEN	PTEN:splicing	PTEN:splice_donor_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,590	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89711946	89711946	T	A	A	stop_gained	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	6/9	.	NM_000314.8:c.564T>A	NP_000305.3:p.Tyr188Ter	1409	564	188	Y/*	taT/taA	rs606231170&COSV64301503&COSV64310336	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89711946T>A	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&1&1	1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.95413	0.539151	D	0.95345	0.536677	35	35	6.086191	6.176688	0.95856	0.95978	./.	.	.	.	0.76881	0.99644815749039328	.	.	.	./.	.	.	.	.	5.51391	0.536979229117587	0.70497	7.62464	0.734142826936525	0.81872	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.73	1.78	0.23918	0	0.74545	0.702456	.	.	0.39577	0.999417397455624	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.98432	0.735409	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	.	.	0.118515	0.62929	D	0.000014	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae	A	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.3204	0.25697	0.0:0.4841:0.0:0.5159	.	.	.	.	.	.	.	.	0.98750	.	./.	X	.	Y	A	920	0.19381	.	10	C1959582&C4015779	.	ORPHA306498	Likely_pathogenic	NC_000010.11:g.87952189T>A	7831	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Prostate_cancer&_somatic	OMIM_Allelic_Variant:601728.0019&ClinGen_PTEN_Variant_Curation_Expert_Panel:3026a8af-72dd-459e-be90-922c578fc8f6	.	.	AEFGBCI	D	0.43010	0.83920	N	0.41560	0.309247	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89701926	10	89711946	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	1.202000	0.31878	0.609000	0.47794	0.200000	0.23007	87952189	T	.	rs606231170	.	.	6.460	9.066	10.752	10.998	.	.	.	-27	3	-27	-40	0.01	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-7+70+end+142	7831	Likely_pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Prostate_cancer&_somatic	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MedGen:C4015779	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs606231170	606231170	.	.	.	PTEN	PTEN:exonic	PTEN:stopgain	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,567	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89711916	89711917	TA	AT	AT	stop_gained	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	6/9	.	NM_000314.8:c.534_535delinsAT	NP_000305.3:p.Tyr178_Ser179delinsTer	1379-1380	534-535	178-179	YS/*C	taTAgc/taATgc	rs397515374	TA	.	1	.	.	EntrezGene	.	.	.	.	TA	TA	.	.	PTEN	.	chr10:g.89711916_89711917delinsAT	.	.	.	.	.	.	pathogenic	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.534_535delinsAT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.460	9.066	10.752	10.998	.	.	.	.	.	.	.	.	.	.	.	.	0.98	exon-NM_001304717.5-7+41+start+142	7824	Pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397515374	397515374	.	.	.	PTEN	PTEN:exonic	PTEN:stopgain	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,565	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89711893	89711893	C	CA	A	frameshift_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	6/9	.	NM_000314.8:c.512dup	NP_000305.3:p.Arg172GlufsTer8	1356-1357	511-512	171	Q/QX	cag/cAag	rs1114167632&CI075689	.	.	1	.	.	EntrezGene	.	.	.	.	.	.	.	.	PTEN	1	chr10:g.89711894dup	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.460	9.066	10.752	10.998	.	.	.	-22	-19	-19	-4	0.00	0.01	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-7+19+start+142	428206	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1114167632	1114167632	.	.	.	PTEN	PTEN:exonic	PTEN:frameshift_insertion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,560	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89711886	89711887	TC	T	-	frameshift_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	6/9	.	NM_000314.8:c.507del	NP_000305.3:p.Ser170ValfsTer13	1350	505	169	P/X	Ccc/cc	rs587776673&COSV64289424	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	2	chr10:g.89711889del	.	.	.	.	.	.	pathogenic	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.460	9.066	10.752	10.998	.	.	.	-20	32	19	-12	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-7+12+start+142	7843	Pathogenic	reviewed_by_expert_panel	Proteus-like_syndrome&PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	MONDO:MONDO:0017571&MedGen:C1866398&Orphanet:2969&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587776673	587776673	.	.	.	PTEN	PTEN:exonic	PTEN:frameshift_deletion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,558	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89711873	89711873	A	G	G	splice_acceptor_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	5/8	NM_000314.8:c.493-2A>G	.	.	.	.	.	.	rs587781784&CS075218&COSV64297091&COSV64308401	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89711873A>G	.	.	.	.	.	.	pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.493-2A>G	0.999988247793601	0.93	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/acceptor/89711873-89711874/Medium/7.567827	10.752	9.066	5.352	10.998	2.797	7.955	10.752	19	2	19	17	0.09	0.99	0.00	0.00	PTEN	0.98	.	141485	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587781784	587781784	.	.	.	PTEN	PTEN:splicing	PTEN:splice_acceptor_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,556	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89693010	89693010	T	G	G	splice_donor_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	5/8	NM_000314.8:c.492+2T>G	.	.	.	.	.	.	rs1554898244&CD115958&CS982333&COSV64288576&COSV64288590	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89693010T>G	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&0&0&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.492+2T>G	0.999989917668626	0.928	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/donor/89693009-89693010/Medium/6.480066	10.752	9.066	5.352	10.998	3.351	7.647	10.998	-2	-17	-23	-2	0.00	0.00	0.03	0.93	PTEN	0.98	.	7821	Likely_pathogenic	reviewed_by_expert_panel	not_provided&PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1554898244	1554898244	.	.	.	PTEN	PTEN:splicing	PTEN:splice_donor_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,555	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89692957	89692958	GG	A	A	frameshift_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.441_442delinsA	NP_000305.3:p.Ala148HisfsTer5	1286-1287	441-442	147-148	KA/KX	aaGGca/aaAca	rs1114167641	GG	.	1	.	.	EntrezGene	.	.	.	.	GG	GG	.	.	PTEN	.	chr10:g.89692957_89692958delinsA	.	.	.	.	.	.	pathogenic&likely_pathogenic	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.441_442delinsA	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.752	10.998	5.352	9.651	.	.	.	.	.	.	.	.	.	.	.	.	0.98	exon-NM_001304717.5-6+50+end+239	428216	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1114167641	1114167641	.	.	.	PTEN	PTEN:exonic	PTEN:frameshift_deletion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,552	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89717734	89717739	CAAAGT	C	-	frameshift_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	7/9	.	NM_000314.8:c.761_765del	NP_000305.3:p.Lys254ArgfsTer42	1605-1609	760-764	254-255	KV/X	AAAGTa/a	rs606231169	AAAGT	.	1	.	.	EntrezGene	.	.	.	.	AAAGT	AAGTA	.	.	PTEN	1	chr10:g.89717736_89717740del	.	.	.	.	.	.	likely_pathogenic&pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.930	7.806	6.460	9.066	.	.	.	.	.	.	.	.	.	.	.	.	0.98	exon-NM_001304717.5-8+37+end+167	7830	Likely_pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Prostate_cancer&_somatic	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MedGen:C4015779	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs606231169	606231169	.	.	.	PTEN	PTEN:exonic	PTEN:frameshift_deletion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,579	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89692782	89692782	C	CT	T	frameshift_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.270dup	NP_000305.3:p.Glu91Ter	1111-1112	266-267	89	P/PX	cct/ccTt	rs1114167678	.	.	1	.	.	EntrezGene	.	.	.	.	.	.	.	.	PTEN	4	chr10:g.89692786dup	.	.	.	.	.	.	likely_pathogenic&pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.752	10.998	5.352	9.651	.	.	.	-31	-13	-31	-7	0.04	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+13+start+239	428271	Likely_pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Hereditary_cancer-predisposing_syndrome	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1114167678	1114167678	.	.	.	PTEN	PTEN:exonic	PTEN:frameshift_insertion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,534	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89720649	89720649	A	T	T	splice_acceptor_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	7/8	NM_000314.8:c.802-2A>T	.	.	.	.	.	.	rs587782455&CS1513175&COSV64297401&COSV64297403&COSV64301847&COSV64304652	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89720649A>T	.	.	.	.	.	.	pathogenic	0&0&1&1&1&1	1&1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.802-2A>T	0.999989917668626	0.928	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/acceptor/89720649-89720650/Medium/12.302911	12.930	8.679	6.460	7.806	4.563	8.367	12.930	45	2	31	22	0.88	1.00	0.00	0.02	PTEN	0.98	.	142423	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587782455	0.00000e+00	1.37855e-04	0.00000e+00	2.08247e-04	1.64727e-04	0.00000e+00	0.00000e+00	0.00000e+00	5.10610e-05	3.82059e-05	2.08247e-04	1.99466e-04	rs587782455	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	9.39673e-05	0.00000e+00	.	0.00000e+00	1.11483e-04	9.39673e-05	3.89307e-04	.	.	rs587782455	587782455	.	.	.	PTEN	PTEN:splicing	PTEN:splice_acceptor_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,582	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89685269	89685269	G	A	A	splice_acceptor_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	2/8	NM_000314.8:c.165-1G>A	.	.	.	.	.	.	rs786203847&CS110220&COSV64291262&COSV64292036&COSV64304032	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89685269G>A	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.165-1G>A	0.999981760802075	0.936	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/acceptor/89685268-89685269/Medium/6.522922&gain/acceptor/89685269-89685270/Medium/5.831376	10.295	7.964	-2.595	10.567	1.544	8.750	10.295	2	1	2	49	0.86	0.98	0.00	0.08	PTEN	0.98	.	187590	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome&not_provided	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786203847	786203847	.	.	.	PTEN	PTEN:splicing	PTEN:splice_acceptor_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,525	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89720733	89720749	TATGTGATCAAGAAATC	G	G	frameshift_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	8/9	.	NM_000314.8:c.884_900delinsG	NP_000305.3:p.Leu295ArgfsTer7	1729-1745	884-900	295-300	LCDQEI/X	cTATGTGATCAAGAAATC/cG	rs1114167680	TATGTGATCAAGAAATC	.	1	.	.	EntrezGene	.	.	.	.	TATGTGATCAAGAAATC	TATGTGATCAAGAAATC	.	.	PTEN	.	chr10:g.89720733_89720749delinsG	.	.	.	.	.	.	likely_pathogenic&pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.857	8.679	12.930	7.806	.	.	.	.	.	.	.	.	.	.	.	.	0.98	exon-NM_001304717.5-9+82+start+225	428274	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1114167680	1114167680	.	.	.	PTEN	PTEN:exonic	PTEN:frameshift_deletion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,585	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89717670	89717671	CA	C	-	frameshift_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	7/9	.	NM_000314.8:c.696del	NP_000305.3:p.Arg233AspfsTer23	1541	696	232	T/X	acA/ac	rs587776669&CD982916&COSV64298220	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89717671del	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&0&1	1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.696dup	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.930	7.806	6.460	9.066	.	.	.	-25	-6	21	-6	0.00	0.04	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-8+61+start+167	7822	Likely_pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587776669	587776669	.	.	.	PTEN	PTEN:exonic	PTEN:frameshift_deletion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,571	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89711967	89711968	TC	T	-	frameshift_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	6/9	.	NM_000314.8:c.586del	NP_000305.3:p.His196ThrfsTer3	1431	586	196	H/X	Cac/ac	rs587776670&CD982915&COSV64297990	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89711968del	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.586del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.460	9.066	10.752	10.998	.	.	.	36	-48	11	49	0.00	0.00	0.00	0.05	PTEN	0.98	exon-NM_001304717.5-7+48+end+142	7823	Pathogenic	reviewed_by_expert_panel	Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587776670	587776670	.	.	.	PTEN	PTEN:exonic	PTEN:frameshift_deletion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,568	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89725043	89725043	G	A	A	splice_acceptor_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	8/8	NM_000314.8:c.1027-1G>A	.	.	.	.	.	.	rs1057517809&CS1413088&COSV64290834&COSV64293694&COSV64298429	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89725043G>A	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.1027-1G>T	0.999986675681007	0.932	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	loss/acceptor/89725042-89725043/Medium/10.869466&gain/acceptor/89725043-89725044/Medium/3.568404	11.857	.	12.930	8.679	3.106	8.750	11.857	2	1	7	48	0.09	0.99	0.00	0.00	PTEN	0.98	.	372482	Pathogenic	reviewed_by_expert_panel	not_provided&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&Neoplasm_of_ovary	MedGen:CN517202&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267&OMIM:167000	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1057517809	1057517809	chr9:33674357	0.98265	0.97956	PTEN	PTEN:splicing	PTEN:splice_acceptor_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,592	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89624262	89624262	C	CA	A	frameshift_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	1/9	.	NM_000314.8:c.40dup	NP_000305.3:p.Arg14LysfsTer30	881-882	36-37	12-13	-/X	-/A	rs587776671	.	.	1	.	.	EntrezGene	.	.	.	.	.	.	.	.	PTEN	4	chr10:g.89624266dup	.	.	.	.	.	.	pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-2.595	-3.496	.	.	.	.	.	-4	-46	-47	42	0.00	0.00	0.00	0.05	PTEN	0.98	exon-NM_000314.8-1+43+end+924	7834	Pathogenic	reviewed_by_expert_panel	Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587776671	587776671	.	.	.	PTEN\x3bKLLN	PTEN:exonic\x7cKLLN:upstream	PTEN:frameshift_insertion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,513	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
7	107312637	107312637	C	CT	T	frameshift_variant	HIGH	SLC26A4	5172	Transcript	NM_000441.2	protein_coding	4/21	.	NM_000441.2:c.365dup	NP_000432.1:p.Ile124TyrfsTer58	390-391	359-360	120	A/AX	gct/gcTt	rs786204730	.	.	1	.	1	EntrezGene	.	YES	.	.	.	.	.	.	SLC26A4	6	chr7:g.107312643dup	.	.	.	.	.	.	likely_pathogenic&pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.693	5.730	8.981	10.567	.	.	.	42	-34	43	-14	0.00	0.00	0.00	0.00	SLC26A4	0.00	exon-NM_000441.2-4+55+start+111	189148	Pathogenic	reviewed_by_expert_panel	not_provided&Pendred_syndrome	MedGen:CN517202&MONDO:MONDO:0010134&MedGen:C0271829&OMIM:274600&Orphanet:705	.	7:107312638-107312638	8.236e-06	1	1	0	0	0	0	0	0	0	1	10406	11566	8654	6612	66728	906	16502	0	0	0	0	0	0	1	0	0	0	0	0	0	0	rs773738163	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79109e-05	0.00000e+00	3.24865e-05	1.48302e-05	8.98150e-06	3.24865e-05	1.21817e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786204730	786204730	.	.	.	SLC26A4	SLC26A4:exonic	SLC26A4:frameshift_insertion	SLC26A4:Deafness\x2cautosomal_recessive_4\x2cwith_enlarged_vestibular_aqueduct\x3bPendred_syndrome	SLC26A4:600791\x3b274600	SLC26A4:3\x3b3	SLC26A4:Autosomal_recessive\x3bAutosomal_recessive	0	6.36692519367205e-13	0.204987783815785	0.795012216183578	DISEASE: Deafness, autosomal recessive, 4 (DFNB4) [MIM:600791]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNB4 is associated with an enlarged vestibular aqueduct. {ECO:0000269|PubMed:10190331, ECO:0000269|PubMed:10700480, ECO:0000269|PubMed:11748854, ECO:0000269|PubMed:12676893, ECO:0000269|PubMed:14508505, ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:19204907, ECO:0000269|PubMed:20108392, ECO:0000269|PubMed:20597900, ECO:0000269|PubMed:9500541}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,490	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
1	216348710	216348710	C	CT	T	frameshift_variant	HIGH	USH2A	7399	Transcript	NM_206933.4	protein_coding	21/72	.	NM_206933.4:c.4510dup	NP_996816.3:p.Arg1504LysfsTer26	4949-4950	4510-4511	1504	R/KX	agg/aAgg	rs727503731	.	.	-1	.	1	EntrezGene	.	YES	.	.	.	.	.	.	USH2A	.	chr1:g.216348713dup	.	.	.	.	.	.	pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.108	10.646	4.329	9.884	.	.	.	6	-2	-1	14	0.00	0.00	0.00	0.00	USH2A	0.00	exon-NM_206933.4-21+114+end+231	166504	Pathogenic	reviewed_by_expert_panel	Rare_genetic_deafness&Usher_syndrome&Retinal_dystrophy&Usher_syndrome_type_2A&Retinitis_pigmentosa_39&not_provided&Retinitis_pigmentosa	MedGen:CN826980&Orphanet:96210&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&Human_Phenotype_Ontology:HP:0000556&Human_Phenotype_Ontology:HP:0007736&Human_Phenotype_Ontology:HP:0007910&Human_Phenotype_Ontology:HP:0007974&Human_Phenotype_Ontology:HP:0007982&MONDO:MONDO:0019118&MeSH:D058499&MedGen:C0854723&Orphanet:71862&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886&MONDO:MONDO:0013436&MedGen:C3151138&OMIM:613809&Orphanet:791&MedGen:CN517202&Human_Phenotype_Ontology:HP:0000547&MONDO:MONDO:0019200&MeSH:D012174&MedGen:C0035334&OMIM:268000&OMIM:PS268000&Orphanet:791	.	1:216348711-216348711	8.238e-06	1	1	0	0	0	0	0	1	0	0	10398	11454	8518	6562	66494	904	16468	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs727503731	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.69935e-05	0.00000e+00	0.00000e+00	7.43826e-06	1.80174e-05	2.69935e-05	1.21826e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs727503731	727503731	.	.	.	USH2A	USH2A:exonic	USH2A:frameshift_insertion	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,455	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
1	216363621	216363623	CAG	C	-	frameshift_variant	HIGH	USH2A	7399	Transcript	NM_206933.4	protein_coding	20/72	.	NM_206933.4:c.4338_4339del	NP_996816.3:p.Cys1447GlnfsTer29	4777-4778	4338-4339	1446-1447	LC/LX	ctCTgc/ctgc	rs111033367	AG	.	-1	.	1	EntrezGene	.	YES	.	.	AG	AG	.	.	USH2A	.	chr1:g.216363626_216363627del	.	.	.	.	.	.	.	.	1	.	.	.	.	.	USH2A&NM_206933.2&c.4338_4339delCT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.329	9.884	9.199	8.348	.	.	.	44	-10	-46	25	0.00	0.01	0.00	0.00	USH2A	0.00	exon-NM_206933.4-20+57+start+145	2353	Pathogenic	reviewed_by_expert_panel	USH2A-Related_Disorders&Usher_syndrome&Retinitis_pigmentosa_39&Usher_syndrome_type_2A&Retinal_dystrophy&not_provided	MedGen:CN239332&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&MONDO:MONDO:0013436&MedGen:C3151138&OMIM:613809&Orphanet:791&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886&Human_Phenotype_Ontology:HP:0000556&Human_Phenotype_Ontology:HP:0007736&Human_Phenotype_Ontology:HP:0007910&Human_Phenotype_Ontology:HP:0007974&Human_Phenotype_Ontology:HP:0007982&MONDO:MONDO:0019118&MeSH:D058499&MedGen:C0854723&Orphanet:71862&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs111033367	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.98876e-06	0.00000e+00	0.00000e+00	0.00000e+00	9.00901e-06	8.98876e-06	4.06081e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs111033367	111033367	.	.	.	USH2A	USH2A:exonic	USH2A:frameshift_deletion	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,456	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
10	89624275	89624277	CAA	C	-	frameshift_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	1/9	.	NM_000314.8:c.50_51del	NP_000305.3:p.Gln17ArgfsTer26	895-896	50-51	17	Q/X	cAA/c	rs587781912&COSV64297849	AA	.	1	.	.	EntrezGene	.	.	.	.	AA	AA	.	.	PTEN	.	chr10:g.89624276_89624277del	.	.	.	.	.	.	pathogenic	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-2.595	-3.496	.	.	.	.	.	-16	-41	30	-5	0.00	0.00	0.01	0.00	PTEN	0.98	exon-NM_000314.8-1+28+end+924	141654	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	10:89624276-89624278	8.236e-06	1	1	0	0	0	0	0	1	0	0	10406	11578	8654	6614	66740	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs786204910	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95095e-06	0.00000e+00	0.00000e+00	7.41235e-06	0.00000e+00	8.95095e-06	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587781912	587781912	.	.	.	PTEN\x3bKLLN	PTEN:exonic\x7cKLLN:upstream	PTEN:frameshift_deletion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,515	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
1	216373231	216373233	AAT	A	-	frameshift_variant	HIGH	USH2A	7399	Transcript	NM_206933.4	protein_coding	17/72	.	NM_206933.4:c.3547_3548del	NP_996816.3:p.Ile1183PhefsTer19	3986-3987	3547-3548	1183	I/X	ATt/t	rs397518013	AT	.	-1	.	1	EntrezGene	.	YES	.	.	AT	AT	.	.	USH2A	.	chr1:g.216373236_216373237del	.	.	.	.	.	.	.	.	1	.	.	.	.	.	USH2A&NM_007123.5&c.3547_3548del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.731	9.477	12.679	8.340	.	.	.	9	-32	-50	-8	0.00	0.00	0.00	0.00	USH2A	0.00	exon-NM_206933.4-17+230+end+495	48503	Likely_pathogenic	reviewed_by_expert_panel	Rare_genetic_deafness&Usher_syndrome&not_provided&USH2A-Related_Disorders&Retinitis_pigmentosa_39&Usher_syndrome_type_2A	MedGen:CN826980&Orphanet:96210&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&MedGen:CN517202&MedGen:CN239332&MONDO:MONDO:0013436&MedGen:C3151138&OMIM:613809&Orphanet:791&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886	.	1:216373232-216373234	8.237e-06	1	1	0	0	0	0	0	1	0	0	10392	11576	8614	6614	66738	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs397518013	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.98683e-06	0.00000e+00	0.00000e+00	7.42876e-06	0.00000e+00	8.98683e-06	4.06065e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	1:216373232-216373234	0.206&0.0938&0.1677	rs397518013	397518013	.	.	.	USH2A	USH2A:exonic	USH2A:frameshift_deletion	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,457	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9941	Likely Pathogenic
21	36252962	36252962	C	G	G	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	5/9	.	NM_001754.5:c.400G>C	NP_001745.2:p.Ala134Pro	594	400	134	A/P	Gct/Cct	rs74315451&CM021675&COSV55873549	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36252962C>G	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.96270	0.561787	D	0.96212	0.569192	26.8	29.0	3.970613	4.141352	0.77605	0.86812	C/C	D	0.96710	0.999250590801239	0.87484	0.9978910134586908	.	0.99994	.	C/C	.	.	.	.	12.92127	0.879984357811428	0.94640	12.25876	0.944449472928409	0.93760	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99632	.	.	.	5.31	5.31	0.75063	0	0.89359	0.724815	.	.	0.98316	1.0	.	0	0.30614	0.59043	.	.	.	.	.	.	0	0.98432	0.735409	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain&Runt_domain&Runt_domain	.	.	.	0.98400	.	0.000000	0.84330	D	0.000000	D	0.98601	0.820112	0.91893	.	0.98334	.	D	0.99689	0.9890	.	0.95473	.	D	0.97425	1.0139	A107P	Loss_of_catalytic_residue_at_A107_(P_=_0.0091)&_Loss_of_sheet_(P_=_0.0457)&_Gain_of_glycosylation_at_T104_(P_=_0.0558)&_Gain_of_disorder_(P_=_0.0818)&_Gain_of_loop_(P_=_0.1069)	Q01196	0.92228	0.804	.	0.83451	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	A&A&A&A&A&A&A	1&1&1&1&1&1&1	0.79060	.	.	.	0.90584	.	.	0.92359	.	D	0.96689	0.90228331089	0.98886	.	9	0.83351	.	.	0.78490	.	.	19.3355	0.94304	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99548	.	C/C	P	.	A	G	190	0.92594	.	21	C1832388	601399	.	Pathogenic	NC_000021.9:g.34880665C>G	14468	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:d5e03ae0-3ff2-428d-87e3-ae93412f6bf1&OMIM_Allelic_Variant:151385.0006	.	.	AEFDGBI	D	0.92173	0.99164	D	0.97637	0.957290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35174832	21	36252962	0	0.85440	0.722319	1.000000	0.71638	0.986000	0.61781	0.966000	0.44233	7.568000	0.81546	0.599000	0.40250	1.026000	0.45946	34880665	C	.	rs74315451	.	.	11.926	10.199	5.882	8.558	.	.	.	48	23	-3	35	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-5+48+end+157	14468	Pathogenic	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs74315451	74315451	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,971	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
21	36259163	36259163	T	C	C	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	4/9	.	NM_001754.5:c.328A>G	NP_001745.2:p.Lys110Glu	522	328	110	K/E	Aag/Gag	rs121912498&CM025982&COSV55885342&COSV55887229	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	RUNX1	.	chr21:g.36259163T>C	.	.	.	.	.	.	pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.96260	0.561197	D	0.96201	0.568344	30	29.3	4.347400	4.186603	0.89227	0.87950	T/T	D	0.79455	0.989209711551666	0.89531	0.99811405326005598	.	0.99989	.	T/T	.	.	.	.	8.594099	0.740995457614561	0.85483	9.238263	0.822578448066081	0.87495	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99729	.	.	.	4.72	4.72	0.59248	0	0.08562	0.516746	.	.	0.98316	1.0	.	0	0.08637	0.503968	.	.	.	.	.	.	0	0.19341	0.56214	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain&Runt_domain&Runt_domain	.	.	.	0.87317	.	0.051260	0.84330	D	0.000000	D	0.99442	0.923904	0.92669	.	0.97639	.	D	0.99708	0.9895	.	0.92890	.	D	0.96963	0.9864	K83E	Loss_of_methylation_at_K83_(P_=_0.009)&_Gain_of_solvent_accessibility_(P_=_0.0128)&_Gain_of_relative_solvent_accessibility_(P_=_0.0166)&_Loss_of_MoRF_binding_(P_=_0.1169)&_Gain_of_helix_(P_=_0.1736)	Q01196	0.88232	0.752	.	0.82106	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	A&A&A&A&A&A&A	1&1&1&1&1&1&1	0.70432	.	.	.	0.77913	.	.	0.80445	.	D	0.92452	0.869186520576	0.99157	.	10	0.83351	.	.	0.63226	.	.	14.3606	0.66331	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.95608	.	T/T	E	.	K	C	188	0.92666	.	21	C1832388&CN517202	601399	.	Pathogenic	NC_000021.9:g.34886866T>C	14465	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy&not_provided	OMIM_Allelic_Variant:151385.0003&ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:37efba9c-0430-4e4f-a3ce-fc8c501d717a	.	.	ALL	D	0.64140	0.95288	D	0.87213	0.912039	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35181033	21	36259163	1	0.06251	0.40479	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	5.758000	0.68429	0.665000	0.62972	1.138000	0.64695	34886866	T	.	rs121912498	.	.	5.882	8.558	8.426	9.942	.	.	.	-24	-3	-23	-3	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-4+23+start+254	14465	Pathogenic	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121912498	121912498	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,979	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
12	103260378	103260378	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.505C>T	NP_000268.1:p.Arg169Cys	619	505	169	R/C	Cgc/Tgc	rs281865440&CM1414716&CM1511435&CM1511436&COSV61018549	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103260378G>A	.	.	.	.	.	.	likely_pathogenic	0&0&0&0&1	1&1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.505C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.68018	0.136802	D	0.73952	0.055584	23.7	23.1	3.115573	2.774147	0.54619	0.49736	G/G	D	0.66543	0.963043510913849	0.65325	0.99451473496860321	.	0.99956	.	G/G	.	.	.	.	2.305729	-0.0158621203569936	0.38997	2.518197	0.00198249815702531	0.41945	.	.	.	2	1.647e-05	0	0	0	0	2	1.649e-05	0	0	0	0	2	2.999e-05	0	0	2	1.883e-05	0	0	0	0	2	1.886e-05	0	0	0	0	2	3.684e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99592	.	.	.	5.81	-0.0596	0.13124	0	0.26702	0.573888	.	.	0.04910	9.30461066731538E-5	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.67928	.	0.139623	0.62929	N	0.000004	D	0.94026	0.433441	0.04473	.	0.94719	.	D	0.98389	0.9505	.	0.86283	.	D	0.95530	0.8896	.	.	.	.	.	.	0.79541	.	.	0.81001	simple_aae&simple_aae	D&D	0.999999&1	0.87611	.	.	.	0.39896	.	.	0.36449	.	T	0.49974	0.579212784767	0.88157	.	10	0.92824	.	.	0.68238	.	.	8.7903	0.34005	0.0811:0.0:0.2533:0.6657	.	.	.	.	.	.	.	.	0.56058	.	G/G	C	.	R	A	699	0.57969	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102866600G>A	125436	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.38018	0.77346	D	0.70103	0.764145	.	3	1.193570e-05	0	0.000000e+00	16250	0	0	0.000000e+00	34548	0	251346	0	0.000000e+00	10076	0	0	0.000000e+00	18390	0	0	0.000000e+00	21638	0	2	1.759170e-05	113690	0	1	3.266270e-05	30616	0	1	3.266270e-05	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17100	0	109374	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13390	0	0	0.000000e+00	42752	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	3	1.266830e-05	0	0.000000e+00	14896	0	0	0.000000e+00	34216	0	236812	0	0.000000e+00	9568	0	0	0.000000e+00	17688	0	0	0.000000e+00	21622	0	2	1.947840e-05	102678	0	1	3.275900e-05	30526	0	1	3.275900e-05	30526	0	0	1	4.806860e-06	0	0.000000e+00	16212	0	0	0.000000e+00	30482	0	208036	0	0.000000e+00	6210	0	0	0.000000e+00	13412	0	0	0.000000e+00	16724	0	0	0.000000e+00	89524	0	1	3.267120e-05	30608	0	1	3.267120e-05	30608	0	0	3	1.225850e-05	0	0.000000e+00	12020	0	0	0.000000e+00	34414	0	244728	0	0.000000e+00	9994	0	0	0.000000e+00	18386	0	0	0.000000e+00	21636	0	2	1.792110e-05	111600	0	1	3.266270e-05	30616	0	1	3.266270e-05	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101784508	12	103260378	0	0.25195	0.553676	1.000000	0.71638	0.985000	0.61073	0.998000	0.65909	1.070000	0.30265	0.676000	0.76740	0.184000	0.21609	102866600	G	.	rs281865440	.	.	7.292	9.092	8.810	7.211	.	.	.	34	-4	-4	-8	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-6+4+start+68	125436	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103260378-103260378	1.647e-05	2	2	0	0	0	0	0	2	0	0	10402	11502	8648	6600	66680	908	16510	0	0	0	0	2	0	0	0	0	0	0	0	0	0	rs281865440	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79147e-05	0.00000e+00	3.24865e-05	1.48339e-05	8.98440e-06	3.24865e-05	1.21819e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865440	281865440	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,780	0	1	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
21	36252995	36252995	C	G	G	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	5/9	.	NM_001754.5:c.367G>C	NP_001745.2:p.Asp123His	561	367	123	D/H	Gat/Cat	rs373498347&CM086911	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36252995C>G	.	.	.	.	.	.	uncertain_significance	.	1&1	.	.	.	.	.	RUNX1&NM_001001890.2&c.286G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.94304	0.500767	D	0.95560	0.545187	27.8	31	4.109006	4.319437	0.82405	0.90280	C/C	D	0.82494	0.992090225219727	0.76387	0.99636565494352025	.	0.99951	.	C/C	0	0.0	1	1.1627906976744187E-4	10.6634	0.817555811121047	0.90984	9.81725	0.849083593265853	0.89055	.	.	.	2	1.647e-05	0	0	0	0	2	1.650e-05	0	0	0	0	2	3.000e-05	0	0	2	1.883e-05	0	0	0	0	2	1.885e-05	0	0	0	0	2	3.684e-05	0	0	2	2.204e-05	0	0	0	0	2	2.207e-05	0	0	0	0	2	4.754e-05	0	0	0.99525	.	.	.	5.31	5.31	0.75063	0	0.59785	0.653731	.	.	0.98316	1.0	.	0	0.28860	0.577349	.	.	.	.	.	.	0	0.98432	0.735409	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain&Runt_domain&Runt_domain	.	.	.	0.79107	.	0.048017	0.84330	D	0.000000	D	0.95777	0.544775	0.90445	.	0.98808	.	D	0.99568	0.9856	.	0.91056	.	D	0.98137	1.0509	.	.	.	.	.	.	0.66631	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	1&1&1&1&1&1&1	0.83695	.	.	.	0.77913	.	.	0.74104	.	D	0.90077	0.853069245815	0.98816	.	10	0.83351	.	.	0.78490	.	.	19.3355	0.94304	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.88798	.	C/C	H	.	D	G	190	0.92594	.	21	C1832388&CN517202	601399	.	Uncertain_significance	NC_000021.9:g.34880698C>G	429813	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy&not_provided	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:7e5378c7-f9d9-470d-9323-32fe9a5a69f7	.	.	AEFDGBI	D	0.92173	0.99164	D	0.85518	0.904637	.	3	1.193410e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34580	0	251380	0	0.000000e+00	10080	0	0	0.000000e+00	18392	0	0	0.000000e+00	21630	0	3	2.638750e-05	113690	0	3	2.638750e-05	113690	0	0	0.000000e+00	30614	0	2	1.828520e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17106	0	109378	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13378	0	2	4.677270e-05	42760	0	2	4.677270e-05	42760	0	0	0.000000e+00	15690	0	0	.	0	3	1.266550e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34248	0	236864	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21614	0	3	2.921360e-05	102692	0	3	2.921360e-05	102692	0	0	0.000000e+00	30524	0	0	3	1.441840e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30514	0	208068	0	0.000000e+00	6212	0	0	0.000000e+00	13414	0	0	0.000000e+00	16716	0	3	3.351060e-05	89524	0	3	3.351060e-05	89524	0	0	0.000000e+00	30606	0	0	2	8.171200e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34446	0	244762	0	0.000000e+00	9998	0	0	0.000000e+00	18388	0	0	0.000000e+00	21628	0	2	1.792110e-05	111600	0	2	1.792110e-05	111600	0	0	0.000000e+00	30614	0	0	2	1.314440e-05	0	0.000000e+00	41430	0	0	0.000000e+00	912	0	0	0.000000e+00	15282	0	152156	0	0.000000e+00	3470	0	0	0.000000e+00	5202	0	0	0.000000e+00	10604	0	0	0.000000e+00	316	0	2	2.940230e-05	68022	0	2	2.940230e-05	68022	0	0	0.000000e+00	4828	0	0	0.000000e+00	0	0.000000e+00	9084	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32866	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5478	0	0	0.000000e+00	246	0	0	0.000000e+00	6846	0	0	0.000000e+00	3110	0	0	.	0	2	1.352170e-05	0	0.000000e+00	41108	0	0	0.000000e+00	912	0	0	0.000000e+00	15094	0	147910	0	0.000000e+00	3300	0	0	0.000000e+00	4968	0	0	0.000000e+00	10604	0	0	0.000000e+00	304	0	2	3.086230e-05	64804	0	0	0.000000e+00	4796	0	0	2	1.484230e-05	0	0.000000e+00	32462	0	0	0.000000e+00	862	0	0	0.000000e+00	14836	0	134750	0	0.000000e+00	3386	0	0	0.000000e+00	5202	0	0	0.000000e+00	6964	0	0	0.000000e+00	310	0	2	3.129790e-05	63902	0	0	0.000000e+00	4826	0	0	0	0.000000e+00	0	0.000000e+00	24804	0	0	0.000000e+00	112	0	0	0.000000e+00	12908	0	80714	0	0.000000e+00	998	0	0	0.000000e+00	3760	0	0	0.000000e+00	10512	0	0	0.000000e+00	272	0	0	0.000000e+00	21032	0	0	0.000000e+00	4800	0	0	21	35174865	21	36252995	0	0.85440	0.722319	1.000000	0.71638	0.937000	0.47636	0.971000	0.45248	7.568000	0.81546	0.599000	0.40250	1.026000	0.45946	34880698	C	.	rs373498347	.	.	11.926	10.199	5.882	8.558	.	.	.	2	15	2	-26	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-5+15+end+157	429813	Uncertain_significance	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	21:36252995-36252995	1.647e-05	2	1	0	0	0	0	0	2	0	0	10386	11548	8650	6604	66664	906	16490	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs373498347	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.68692e-05	0.00000e+00	0.00000e+00	2.22456e-05	0.00000e+00	2.68692e-05	1.21819e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	rs373498347	0.0116&0.0&0.0077	rs373498347	373498347	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,973	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
21	36252895	36252895	G	T	T	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	5/9	.	NM_001754.5:c.467C>A	NP_001745.2:p.Ala156Glu	661	467	156	A/E	gCa/gAa	rs267607026&CM093277	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36252895G>T	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.96687	0.574329	D	0.96631	0.587208	28.1	25.7	4.142132	3.688665	0.83550	0.72139	G/G	D	0.97549	0.999471247196198	0.68558	0.99509818564300545	.	0.99978	.	G/G	.	.	.	.	8.109431	0.718303309223487	0.83769	9.612561	0.839955795146297	0.88530	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99702	.	.	.	5.31	5.31	0.75063	0	0.89359	0.724815	.	.	0.98316	1.0	.	0	0.28860	0.577349	.	.	.	.	.	.	0	0.98432	0.735409	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain	.	.	.	0.97754	.	0.000000	0.84330	D	0.000000	D	0.97715	0.717982	0.90647	.	0.99889	.	D	0.99762	0.9909	.	0.93787	.	D	0.97087	0.9940	A129E	Gain_of_solvent_accessibility_(P_=_0.0145)&_Gain_of_relative_solvent_accessibility_(P_=_0.0215)&_Loss_of_MoRF_binding_(P_=_0.0493)&_Gain_of_helix_(P_=_0.0496)&_Gain_of_ubiquitination_at_K125_(P_=_0.0726)	Q01196	0.90153	0.776	.	0.84121	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	1&1&1&1&1&1&1	0.78976	.	.	.	0.90584	.	.	0.97372	.	D	0.93012	0.873120188713	0.97436	.	10	0.92824	.	.	0.91255	.	.	19.3355	0.94304	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.99929	.	G/G	E	.	A	T	190	0.92594	.	21	C1832388	601399	.	Likely_pathogenic	NC_000021.9:g.34880598G>T	14471	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	OMIM_Allelic_Variant:151385.0010&ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:1023c045-33cc-4c4b-9297-ea4832be8def	.	.	AEFDGBI	D	0.95993	0.99435	D	0.85824	0.906003	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35174765	21	36252895	0	0.85440	0.722319	1.000000	0.71638	0.921000	0.45669	0.808000	0.33754	9.602000	0.97623	0.672000	0.70159	1.172000	0.72986	34880598	G	.	rs267607026	.	.	11.926	10.199	5.882	8.558	.	.	.	-19	18	5	-18	0.00	0.00	0.00	0.03	RUNX1	0.45	exon-NM_001754.5-5+41+start+157	14471	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs267607026	267607026	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,968	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
21	36252865	36252865	C	T	T	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	5/9	.	NM_001754.5:c.497G>A	NP_001745.2:p.Arg166Gln	691	497	166	R/Q	cGa/cAa	rs1060499616&CM992139&COSV55866502&COSV55867644&COSV55875824	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36252865C>T	.	.	.	.	.	.	pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.96251	0.560693	D	0.96191	0.56762	31	32	4.441131	4.628328	0.90644	0.92344	C/C	D	0.98435	0.999671339988708	0.99951	0.99952166665243825	.	0.99988	.	C/C	.	.	.	.	12.83749	0.877891712229578	0.94537	12.1245	0.939721623574795	0.93565	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99702	.	.	.	5.31	5.31	0.75063	0	0.59785	0.653731	.	.	0.98316	1.0	.	0	0.28860	0.577349	.	.	.	.	.	.	0	0.98432	0.735409	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain	.	.	.	0.99155	.	0.000000	0.84330	D	0.000000	D	0.96558	0.607036	0.90490	.	0.98483	.	D	0.99759	0.9908	.	0.90523	.	D	0.97116	0.9957	.	.	.	.	.	.	0.83701	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	1&1&1&1&1&1&1	0.71762	.	.	.	0.90584	.	.	0.83170	.	D	0.83145	0.807734847069	0.99434	.	10	0.79402	.	.	0.78490	.	.	19.3355	0.94304	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99611	.	C/C	Q	.	R	T	190	0.92594	.	21	C0005818&C1832388	PS231200&601399	.	Pathogenic	NC_000021.9:g.34880568C>T	417961	reviewed_by_expert_panel	Inherited_bleeding_disorder&_platelet-type&Familial_platelet_disorder_with_associated_myeloid_malignancy	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:ba8c0c9c-028c-473b-9259-a8316db5b16d	.	.	AEFDGBI	D	0.86525	0.98762	D	0.75875	0.841566	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35174735	21	36252865	0	0.85440	0.722319	1.000000	0.71638	0.998000	0.85391	0.995000	0.57719	7.568000	0.81546	0.596000	0.33519	1.022000	0.39869	34880568	C	.	rs1060499616	.	.	11.926	10.199	5.882	8.558	.	.	.	12	11	12	-11	0.00	0.00	0.10	0.00	RUNX1	0.45	exon-NM_001754.5-5+11+start+157	417961	Pathogenic	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1&Inherited_bleeding_disorder&_platelet-type	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290&MONDO:MONDO:0000009&MeSH:D001791&MedGen:C0005818&OMIM:PS231200&Orphanet:248326	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1060499616	1060499616	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,967	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
14	31346846	31346846	C	T	T	missense_variant	MODERATE	COCH	1690	Transcript	NM_004086.3	protein_coding	4/12	.	NM_004086.3:c.151C>T	NP_004077.1:p.Pro51Ser	207	151	51	P/S	Cca/Tca	rs28938175&CM990378	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	COCH	.	chr14:g.31346846C>T	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	STRN3&NM_014574.3&c.*17771G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.94569	0.509922	D	0.94489	0.494691	25.4	26.4	3.686223	3.818780	0.68979	0.76079	C/C	D	0.85913	0.994554877281189	0.83264	0.99737588416269984	.	0.93628	.	C/C	.	.	.	.	10.06993	0.798171407123114	0.89665	9.218403	0.821632449904175	0.87439	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.95317	.	.	.	5.67	5.67	0.87673	0	0.66719	0.688494	.	.	0.74766	0.999999999999952	.	0	0.93749	0.732669	.	.	.	.	.	.	0	0.10902	0.530356	LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&.&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain	.	.	.	0.76011	.	0.000000	0.84330	D	0.000000	D	0.90586	0.291701	0.66683	.	0.97826	.	D	0.97415	0.9219	.	0.98779	.	D	0.97151	0.9978	P51S	Loss_of_sheet_(P_=_0.0228)&_Gain_of_glycosylation_at_P51_(P_=_0.0768)&_Gain_of_loop_(P_=_0.0851)&_Gain_of_catalytic_residue_at_P51_(P_=_0.299)&_Gain_of_disorder_(P_=_0.3506)	O43405	0.99467	0.953	.	0.86684	.	.	0.81001	simple_aae&simple_aae&simple_aae&without_aae	A&A&A&A	1&1&1&1	0.95246	.	.	.	0.57599	.	.	0.61644	.	T	0.63559	0.675052285194	0.96207	.	10	0.92824	.	.	0.91255	.	.	19.3726	0.94485	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.92433	.	C/C	S	.	P	T	938	0.14419	.	14	C1384666&C1832425&CN043648&CN517202&CN826980	601369	ORPHA87884&ORPHA96210	Pathogenic	NC_000014.9:g.30877640C>T	6611	reviewed_by_expert_panel	Hearing_impairment&Deafness&_autosomal_dominant_9&Nonsyndromic_hearing_loss_and_deafness&not_provided&Rare_genetic_deafness	OMIM_Allelic_Variant:603196.0004&UniProtKB_(protein):O43405#VAR_008532	.	.	AEFDBHI	D	0.98173	0.99632	D	0.74153	0.820837	.	1	3.976590e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34590	0	251472	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21644	0	1	8.791050e-06	113752	0	1	8.791050e-06	113752	0	0	0.000000e+00	30616	0	1	9.140430e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109404	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13390	0	1	2.338200e-05	42768	0	1	2.338200e-05	42768	0	0	0.000000e+00	15690	0	0	.	0	1	4.220370e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34258	0	236946	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21628	0	1	9.732550e-06	102748	0	1	9.732550e-06	102748	0	0	0.000000e+00	30526	0	0	1	4.805060e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30522	0	208114	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16730	0	1	1.116790e-05	89542	0	1	1.116790e-05	89542	0	0	0.000000e+00	30608	0	0	1	4.084070e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34456	0	244854	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21642	0	1	8.955600e-06	111662	0	1	8.955600e-06	111662	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	14	30416597	14	31346846	0	0.97449	0.736574	1.000000	0.71638	0.960000	0.51673	0.987000	0.50568	7.094000	0.76602	0.596000	0.33519	1.022000	0.39869	30877640	C	.	rs28938175	.	.	9.328	9.884	9.368	10.898	.	.	.	-40	4	4	31	0.00	0.00	0.00	0.00	COCH	0.00	exon-NM_001347720.2-3+68+start+157	6611	Pathogenic	reviewed_by_expert_panel	Rare_genetic_deafness&Nonsyndromic_genetic_hearing_loss&not_provided&Autosomal_dominant_nonsyndromic_hearing_loss_9&Hearing_impairment	MedGen:CN826980&Orphanet:96210&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN517202&MONDO:MONDO:0011058&MedGen:C1832425&OMIM:601369&Orphanet:90635&Human_Phenotype_Ontology:HP:0000365&Human_Phenotype_Ontology:HP:0000404&Human_Phenotype_Ontology:HP:0001728&Human_Phenotype_Ontology:HP:0001729&Human_Phenotype_Ontology:HP:0001754&Human_Phenotype_Ontology:HP:0008560&Human_Phenotype_Ontology:HP:0008563&MONDO:MONDO:0005365&MedGen:C1384666	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs28938175	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95127e-06	0.00000e+00	0.00000e+00	0.00000e+00	8.98021e-06	8.95127e-06	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs28938175	28938175	.	.	.	COCH\x3bLOC100506071	COCH:exonic\x7cLOC100506071:ncRNA_intronic	COCH:missense	COCH:Deafness\x2cautosomal_dominant_9\x3b?Deafness\x2cautosomal_recessive_110	COCH:601369\x3b618094	COCH:3\x3b3	COCH:Autosomal_dominant\x3bAutosomal_recessive	0	0.000262849456488043	0.983542807336405	0.0161943432071074	DISEASE: Deafness, autosomal dominant, 9 (DFNA9) [MIM:601369]: A form of non-syndromic hearing loss characterized by onset in the fourth or fifth decade of life and initially involves the high frequencies. Hearing loss is progressive and usually complete by the sixth decade. In addition to cochlear involvement, DFNA9 patients also exhibit a spectrum of vestibular dysfunctions. Penetrance of the vestibular symptoms is often incomplete, and some patients are minimally affected, whereas others suffer from severe balance disturbances and episodes of vertigo. Affected individuals have mucopolysaccharide depositions in the channels of the cochlear and vestibular nerves. These depositions apparently cause strangulation and degeneration of dendritic fibers. {ECO:0000269|PubMed:10400989, ECO:0000269|PubMed:11295836, ECO:0000269|PubMed:14512963, ECO:0000269|PubMed:16835921, ECO:0000269|PubMed:17561763, ECO:0000269|PubMed:18312449, ECO:0000269|PubMed:22610276, ECO:0000269|PubMed:22931125, ECO:0000269|PubMed:23993205, ECO:0000269|PubMed:9806553, ECO:0000269|PubMed:9931344}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,879	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
14	31348132	31348132	G	A	A	missense_variant	MODERATE	COCH	1690	Transcript	NM_004086.3	protein_coding	5/12	.	NM_004086.3:c.355G>A	NP_004077.1:p.Ala119Thr	411	355	119	A/T	Gct/Act	rs121908931&CM032215	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	COCH	.	chr14:g.31348132G>A	.	.	.	.	.	.	pathogenic&uncertain_significance	.	1&1	.	.	.	.	.	COCH&NM_004086.2&c.355G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.70213	0.16012	D	0.69830	-0.00777504	19.91	22.4	2.086107	2.444453	0.32339	0.42490	G/G	D	0.36496	0.602405548095703	0.63028	0.99405902829403647	.	0.70544	.	G/G	.	.	.	.	2.019159	-0.109864175504047	0.34991	1.559998	-0.322292998432892	0.28303	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.89145	.	.	.	5.87	3.9	0.44240	0	0.81188	0.709663	.	.	0.38317	0.999056060094005	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.45549	0.616125	LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&LCCL_domain&.&LCCL_domain&LCCL_domain&.&LCCL_domain&LCCL_domain	.	.	.	0.29438	.	0.108055	0.62929	D	0.000003	D	0.48322	0.025346	0.30087	.	0.84622	.	T	0.74481	0.3906	.	0.46616	.	T	0.65916	-0.5725	A119T	Gain_of_loop_(P_=_0.0851)&_Gain_of_sheet_(P_=_0.1208)&_Gain_of_disorder_(P_=_0.123)&_Gain_of_phosphorylation_at_S118_(P_=_0.1947)&_Loss_of_MoRF_binding_(P_=_0.2129)	O43405	0.86541	0.732	.	0.14455	.	.	0.45049	simple_aae&simple_aae&simple_aae&simple_aae	A&A&A&A	0.998539&0.998539&0.998539&0.968228	0.25118	.	.	.	0.02946	.	.	0.04355	.	T	0.13286	0.319113016129	0.70924	.	10	0.48336	.	.	0.56456	.	.	6.5543	0.21648	0.0922:0.0:0.6289:0.2789	.	.	.	.	.	.	.	.	0.67218	.	G/G	T	.	A	A	932	0.16191	.	14	C1832425&CN043648	601369	ORPHA87884	Uncertain_significance	NC_000014.9:g.30878926G>A	6613	reviewed_by_expert_panel	Deafness&_autosomal_dominant_9&Nonsyndromic_hearing_loss_and_deafness	OMIM_Allelic_Variant:603196.0006&UniProtKB_(protein):O43405#VAR_017175	.	.	AEFGBI	D	0.45571	0.86315	N	0.41782	0.312359	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	14	30417883	14	31348132	0	0.61202	0.706298	0.980000	0.35271	0.999000	0.91618	0.629000	0.29470	0.954000	0.28772	0.672000	0.70159	-0.131000	0.11560	30878926	G	.	rs121908931	.	.	7.050	4.336	9.328	9.884	.	.	.	13	-5	22	-5	0.00	0.00	0.01	0.01	COCH	0.00	exon-NM_001347720.2-4+18+end+134	6613	Uncertain_significance	reviewed_by_expert_panel	Nonsyndromic_genetic_hearing_loss&Autosomal_dominant_nonsyndromic_hearing_loss_9	MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0011058&MedGen:C1832425&OMIM:601369&Orphanet:90635	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121908931	121908931	.	.	.	COCH\x3bLOC100506071	COCH:exonic\x7cLOC100506071:ncRNA_intronic	COCH:missense	COCH:Deafness\x2cautosomal_dominant_9\x3b?Deafness\x2cautosomal_recessive_110	COCH:601369\x3b618094	COCH:3\x3b3	COCH:Autosomal_dominant\x3bAutosomal_recessive	0	0.000262849456488043	0.983542807336405	0.0161943432071074	DISEASE: Deafness, autosomal dominant, 9 (DFNA9) [MIM:601369]: A form of non-syndromic hearing loss characterized by onset in the fourth or fifth decade of life and initially involves the high frequencies. Hearing loss is progressive and usually complete by the sixth decade. In addition to cochlear involvement, DFNA9 patients also exhibit a spectrum of vestibular dysfunctions. Penetrance of the vestibular symptoms is often incomplete, and some patients are minimally affected, whereas others suffer from severe balance disturbances and episodes of vertigo. Affected individuals have mucopolysaccharide depositions in the channels of the cochlear and vestibular nerves. These depositions apparently cause strangulation and degeneration of dendritic fibers. {ECO:0000269|PubMed:10400989, ECO:0000269|PubMed:11295836, ECO:0000269|PubMed:14512963, ECO:0000269|PubMed:16835921, ECO:0000269|PubMed:17561763, ECO:0000269|PubMed:18312449, ECO:0000269|PubMed:22610276, ECO:0000269|PubMed:22931125, ECO:0000269|PubMed:23993205, ECO:0000269|PubMed:9806553, ECO:0000269|PubMed:9931344}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,880	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
21	36231827	36231827	A	T	T	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	6/9	.	NM_001754.5:c.557T>A	NP_001745.2:p.Val186Asp	751	557	186	V/D	gTc/gAc	rs797045927	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	RUNX1	.	chr21:g.36231827A>T	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.95857	0.553281	D	0.95794	0.556973	24.5	24.2	3.448882	3.247065	0.62786	0.60670	A/A	D	0.85178	0.994088649749756	0.42002	0.98483100986791994	.	0.99992	.	A/A	.	.	.	.	7.85522	0.705419844305895	0.82790	7.488918	0.725371659277272	0.81294	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99632	.	.	.	5.11	5.11	0.69188	0	0.59785	0.653731	.	.	0.74766	0.999999999999398	.	0	0.30614	0.59043	.	.	.	.	.	.	0	0.83352	0.714379	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain	.	.	.	0.97982	.	0.000000	0.84330	D	0.000000	D	0.99156	0.888733	0.74855	.	0.98391	.	D	0.99541	0.9848	.	0.97277	.	D	0.97883	1.0386	V159D	Gain_of_relative_solvent_accessibility_(P_=_0.0215)&_Gain_of_solvent_accessibility_(P_=_0.0306)&_Gain_of_loop_(P_=_0.0312)&_Gain_of_disorder_(P_=_0.0363)&_Loss_of_helix_(P_=_0.0444)	Q01196	0.95604	0.857	.	0.67893	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	1&1&1&1&1&1&1	0.92260	.	.	.	0.90584	.	.	0.97372	.	D	0.92426	0.869013667107	0.99157	.	10	0.92824	.	.	0.91255	.	.	12.8771	0.57385	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.98466	.	A/A	D	.	V	T	265	0.89590	.	21	C1832388	601399	.	Uncertain_significance	NC_000021.9:g.34859530A>T	212089	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:3ff9a59f-f463-4e1a-942e-a60afc15686a	.	.	AEFBHCI	D	0.64034	0.95260	D	0.82210	0.888712	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35153697	21	36231827	0	0.73137	0.706548	1.000000	0.71638	0.952000	0.50033	0.982000	0.48367	9.318000	0.95450	0.756000	0.94297	1.312000	0.94714	34859530	A	.	rs797045927	.	.	9.171	9.815	11.926	10.199	.	.	.	48	-16	-31	6	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-6+48+end+105	212089	Uncertain_significance	reviewed_by_expert_panel	not_specified&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN169374&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs797045927	797045927	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,963	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
21	36231782	36231782	C	T	T	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	6/9	.	NM_001754.5:c.602G>A	NP_001745.2:p.Arg201Gln	796	602	201	R/Q	cGa/cAa	rs74315450&CM992140&COSV55867719&COSV55890900	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36231782C>T	.	.	.	.	.	.	pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	RUNX1&NM_001754.4&c.602G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.95333	0.536365	D	0.95264	0.532675	23.9	24.3	3.218271	3.269232	0.57024	0.61239	C/C	D	0.86786	0.995071411132812	0.99969	0.99955094968161085	.	0.99926	.	C/C	.	.	.	.	7.773388	0.70111854912629	0.82462	7.212904	0.70663276281024	0.80067	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99702	.	.	.	5.12	5.12	0.69459	0	0.89359	0.724815	.	.	0.74766	0.999999999999999	.	0	0.18855	0.563428	.	.	.	.	.	.	0	0.83352	0.714379	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain	.	.	.	0.99030	.	0.000000	0.84330	D	0.000000	D	0.95450	0.521315	0.83545	.	0.99745	.	D	0.99634	0.9875	.	0.92694	.	D	0.97563	1.0216	R174Q	Loss_of_MoRF_binding_(P_=_0.019)&_Gain_of_relative_solvent_accessibility_(P_=_0.0479)&_Gain_of_helix_(P_=_0.0696)&_Gain_of_solvent_accessibility_(P_=_0.0704)&_Loss_of_catalytic_residue_at_R174_(P_=_0.1924)	Q01196	0.90153	0.776	.	0.84121	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	A&A&A&A&A&A&A	1&1&1&1&1&1&1	0.71882	.	.	.	0.73220	.	.	0.74843	.	D	0.89856	0.851600885391	0.98708	.	9	0.47581	.	.	0.41364	.	.	16.0721	0.80748	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99548	.	C/C	Q	.	R	T	267	0.89517	.	21	C1832388&CN517202	601399	.	Pathogenic	NC_000021.9:g.34859485C>T	14464	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy&not_provided	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:52b9ca56-4641-4652-8c86-bee9650bacf2&OMIM_Allelic_Variant:151385.0002	.	.	AEFBHCI	D	0.61137	0.94429	D	0.83068	0.893094	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35153652	21	36231782	0	0.73137	0.706548	1.000000	0.71638	0.998000	0.85391	0.997000	0.62031	7.899000	0.85994	0.599000	0.40250	1.026000	0.45946	34859485	C	.	rs74315450	.	.	9.171	9.815	11.926	10.199	.	.	.	-3	29	-14	-11	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-6+11+start+105	14464	Pathogenic	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs74315450	74315450	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,960	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
11	534289	534289	C	T	T	missense_variant	MODERATE	HRAS	3265	Transcript	NM_005343.4	protein_coding	2/6	.	NM_005343.4:c.34G>A	NP_005334.1:p.Gly12Ser	248	34	12	G/S	Ggc/Agc	rs104894229&CM053283&CM061797&COSV54236795&COSV54236828&COSV54237299	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	HRAS	.	chr11:g.534289C>T	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&0&0&1&1&1	1&1&1&1&1&1	.	.	.	.	.	LRRC56&NM_198075.3&c.-3738C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.83968	0.312991	D	0.83759	0.211813	23.1	22.9	2.842055	2.661154	0.48633	0.47252	C/C	D	0.85562	0.994338572025299	0.80180	0.99694634134846027	.	0.96165	.	C/C	.	.	.	.	2.574252	0.0594999978466745	0.42531	3.026651	0.134953730610592	0.48099	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.76168	.	.	.	3.0	3.0	0.33773	0	0.66316	0.685571	.	.	0.74766	0.99999999999891	.	0	0.99655	0.851219	.	.	.	.	.	.	0	0.57140	0.638787	.&Small_GTP-binding_protein_domain&.&Small_GTP-binding_protein_domain&Small_GTP-binding_protein_domain	.	.	.	.	.	0.000000	0.84330	D	0.000000	D	0.85426	0.179477	0.88600	.	0.90436	.	T	0.72963	0.3702	.	0.97990	.	T	0.78338	-0.1737	G12S	Gain_of_glycosylation_at_G12_(P_=_0.0044)&_Loss_of_ubiquitination_at_K16_(P_=_0.1037)&_Loss_of_sheet_(P_=_0.1158)&_Loss_of_loop_(P_=_0.1242)&_Gain_of_methylation_at_K16_(P_=_0.1777)	P01112	0.99429	0.951	.	0.18813	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D	1&1&1&1&1	0.78222	.	.	.	0.46109	.	.	0.46003	.	D	0.91167	0.860381364822	0.88960	.	10	0.62352	.	.	0.47320	.	.	14.1517	0.64924	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.90363	.	C/C	S	.	G	T	889	0.27310	.	11	C2239176&C0023467&C0035412&C0281361&C0553723&C0279680&C0026764&C1458155&C3854181&C0152018&C0151779&C0152013&C0007873&C0278701&C0040136&C0027439&C0009404&C0010606&C0007112&C0279663&C0280630&C0587248&C1168401&C0017636&C3463824&C0343114&CN260604&CN166718&C0220641&C1336078&C0950123&C0153574&C1968782&C3277679&CN517202	114550&601626&254500&218040&275355&614286	ORPHA88673&ORPHA519&ORPHA780&ORPHA29073&ORPHA70482&ORPHA100087&ORPHA3071&ORPHA360&ORPHA52688&ORPHA79414&ORPHA98733&ORPHA536391	Pathogenic	NC_000011.10:g.534289C>T	12602	reviewed_by_expert_panel	Hepatocellular_carcinoma&Acute_myeloid_leukemia&Rhabdomyosarcoma&Pancreatic_adenocarcinoma&Squamous_cell_carcinoma_of_the_skin&Transitional_cell_carcinoma_of_the_bladder&Multiple_myeloma&Breast_neoplasm&Nevus_sebaceous&Carcinoma_of_esophagus&Malignant_melanoma_of_skin&Lung_adenocarcinoma&Neoplasm_of_uterine_cervix&Adenocarcinoma_of_stomach&Neoplasm_of_the_thyroid_gland&Nasopharyngeal_Neoplasms&Neoplasm_of_the_large_intestine&Adenoid_cystic_carcinoma&Adenocarcinoma_of_prostate&Ovarian_Serous_Cystadenocarcinoma&Uterine_Carcinosarcoma&Costello_syndrome&Squamous_cell_carcinoma_of_the_head_and_neck&Glioblastoma&Myelodysplastic_syndrome&Nevus&_woolly_hair&Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&Lip_and_oral_cavity_carcinoma&Papillary_renal_cell_carcinoma&_sporadic&Inborn_genetic_diseases&Malignant_neoplasm_of_body_of_uterus&Myopathy&_congenital&_with_excess_of_muscle_spindles&Epidermal_nevus_with_urothelial_cancer&_somatic&not_provided	OMIM_Allelic_Variant:190020.0003&UniProtKB_(protein):P01112#VAR_006837&ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:149306&HGMD:CM053283&ClinGen_RASopathy_Variant_Curation_Expert_Panel:51947641-2e77-498f-93d6-ca73b8e343de&Center_for_Human_Genetics&_Inc&Center_for_Human_Genetics&_Inc:HRAS-A1	.	.	AEFDBI	D	0.94478	0.99322	D	0.90326	0.924751	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11	524289	11	534289	0	0.99359	0.766844	1.000000	0.71638	0.309000	0.24713	0.214000	0.22434	6.086000	0.71002	0.599000	0.40250	1.026000	0.45946	534289	C	.	rs104894229	.	.	10.582	8.703	5.136	11.453	.	.	.	-2	-15	-3	-15	0.00	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-2+77+start+164	12602	Pathogenic	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&Lip_and_oral_cavity_carcinoma&Epidermal_nevus_with_urothelial_cancer&_somatic&Carcinoma_of_esophagus&Pancreatic_adenocarcinoma&Breast_neoplasm&Rhabdomyosarcoma&Hepatocellular_carcinoma&not_provided&Costello_syndrome&RASopathy&Myelodysplastic_syndrome&Nevus_sebaceous&Multiple_myeloma&Malignant_melanoma_of_skin&Acute_myeloid_leukemia&Squamous_cell_carcinoma_of_the_head_and_neck&Myopathy&_congenital&_with_excess_of_muscle_spindles&Lung_adenocarcinoma&Squamous_cell_carcinoma_of_the_skin&Transitional_cell_carcinoma_of_the_bladder&See_cases&Papillary_renal_cell_carcinoma&_sporadic&Uterine_carcinosarcoma&Adenoid_cystic_carcinoma&Neoplasm_of_uterine_cervix&Prostate_adenocarcinoma&Malignant_neoplasm_of_body_of_uterus&Thyroid_tumor&Ovarian_serous_cystadenocarcinoma&Nasopharyngeal_neoplasm&Gastric_adenocarcinoma&Neoplasm_of_the_large_intestine&Inborn_genetic_diseases&Glioblastoma&Woolly_hair_nevus	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MONDO:MONDO:0023644&MedGen:C0220641&MedGen:C3277679&Human_Phenotype_Ontology:HP:0011459&MONDO:MONDO:0019086&MedGen:C0152018&Orphanet:70482&Human_Phenotype_Ontology:HP:0006725&MONDO:MONDO:0006047&MedGen:C0281361&Human_Phenotype_Ontology:HP:0010623&Human_Phenotype_Ontology:HP:0100013&MONDO:MONDO:0021100&MeSH:D001943&MedGen:C1458155&Human_Phenotype_Ontology:HP:0002859&MONDO:MONDO:0005212&MeSH:D012208&MedGen:C0035412&Orphanet:780&Human_Phenotype_Ontology:HP:0001402&Human_Phenotype_Ontology:HP:0002899&Human_Phenotype_Ontology:HP:0003007&Human_Phenotype_Ontology:HP:0006750&MONDO:MONDO:0007256&MedGen:C2239176&OMIM:114550&Orphanet:88673&MedGen:CN517202&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0018881&MeSH:D009190&MedGen:C3463824&OMIM:614286&Orphanet:52688&Human_Phenotype_Ontology:HP:0010815&MedGen:C3854181&Human_Phenotype_Ontology:HP:0006775&MONDO:MONDO:0009693&MeSH:D009101&MedGen:C0026764&OMIM:254500&Orphanet:29073&Orphanet:85443&Human_Phenotype_Ontology:HP:0012056&MONDO:MONDO:0005012&MeSH:C562393&MedGen:C0151779&Human_Phenotype_Ontology:HP:0001914&Human_Phenotype_Ontology:HP:0004808&Human_Phenotype_Ontology:HP:0004843&Human_Phenotype_Ontology:HP:0005516&Human_Phenotype_Ontology:HP:0006724&Human_Phenotype_Ontology:HP:0006728&MONDO:MONDO:0018874&MeSH:D015470&MedGen:C0023467&OMIM:601626&Orphanet:519&MONDO:MONDO:0010150&MeSH:D000077195&MedGen:C1168401&OMIM:275355&Orphanet:67037&MONDO:MONDO:0800299&MedGen:C1968782&Human_Phenotype_Ontology:HP:0030078&MONDO:MONDO:0005061&MeSH:D000077192&MedGen:C0152013&Orphanet:415268&Human_Phenotype_Ontology:HP:0006739&Human_Phenotype_Ontology:HP:0007614&MONDO:MONDO:0002529&MedGen:C0553723&Human_Phenotype_Ontology:HP:0006740&MONDO:MONDO:0005611&MedGen:C0279680&.&MeSH:C538614&MedGen:C1336078&MONDO:MONDO:0006485&MedGen:C0280630&MONDO:MONDO:0004971&MeSH:D003528&MedGen:C0010606&Human_Phenotype_Ontology:HP:0032241&MONDO:MONDO:0021230&MeSH:D002583&MedGen:C0007873&MONDO:MONDO:0005082&MedGen:C0007112&MedGen:C0153574&Human_Phenotype_Ontology:HP:0100031&MONDO:MONDO:0015074&MeSH:D013964&MedGen:C0040136&Orphanet:100087&MONDO:MONDO:0006046&MedGen:C0279663&Human_Phenotype_Ontology:HP:0100630&MONDO:MONDO:0005375&MeSH:D009303&MedGen:C0027439&Human_Phenotype_Ontology:HP:0033770&MONDO:MONDO:0005036&MedGen:C0278701&Orphanet:464463&Human_Phenotype_Ontology:HP:0100834&MONDO:MONDO:0005335&MeSH:D015179&MedGen:C0009404&MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0018177&MeSH:D005909&MedGen:C0017636&Orphanet:360&MONDO:MONDO:0019311&MedGen:C0343114&Orphanet:79414	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs104894229	104894229	.	.	.	HRAS	HRAS:exonic	HRAS:missense	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,626	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
12	103249094	103249094	G	A	A	stop_gained	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.526C>T	NP_000268.1:p.Arg176Ter	640	526	176	R/*	Cga/Tga	rs199475575&CM930541&COSV100188294	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103249094G>A	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.526C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.94255	0.498631	D	0.99401	0.66	38	39	7.637061	7.806547	0.98115	0.98466	G/G	.	.	.	0.76756	0.99642075372614392	.	.	.	G/G	.	.	.	.	3.448622	0.25192576862423	0.52757	4.628988	0.444073109394918	0.63867	.	.	.	3	2.471e-05	1	9.653e-05	0	0	3	2.488e-05	0	0	0	0	2	3.014e-05	0	0	3	2.825e-05	1	1.108e-04	0	0	3	2.844e-05	0	0	0	0	2	3.699e-05	0	0	3	3.306e-05	1	9.669e-05	0	0	3	3.331e-05	0	0	0	0	2	4.776e-05	0	0	.	.	.	.	5.73	3.76	0.42368	0	0.26702	0.573888	.	.	0.08159	0.00104241667624005	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	.	.	0.382752	0.28488	N	0.014599	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&complex_aae	A&A	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.129	0.47560	0.0755:0.0:0.7463:0.1782	.	.	.	.	.	.	.	.	0.88909	.	G/G	X	.	R	A	532	0.73501	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102855316G>A	102723	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.R176X&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2846734	.	.	AEFBI	N	0.24906	0.33759	N	0.49586	0.435077	.	3	1.194570e-05	1	6.152330e-05	16254	0	0	0.000000e+00	34560	0	251136	0	0.000000e+00	10074	0	0	0.000000e+00	18374	0	0	0.000000e+00	21634	0	2	1.762020e-05	113506	0	1	6.152330e-05	16254	0	0	0.000000e+00	30612	0	3	2.743080e-05	1	1.396260e-04	7162	0	0	0.000000e+00	17104	0	109366	0	0.000000e+00	2318	0	0	0.000000e+00	9036	0	0	0.000000e+00	13390	0	2	4.677710e-05	42756	0	1	1.396260e-04	7162	0	0	0.000000e+00	15686	0	0	.	0	3	1.267910e-05	1	6.711410e-05	14900	0	0	0.000000e+00	34228	0	236610	0	0.000000e+00	9566	0	0	0.000000e+00	17672	0	0	0.000000e+00	21618	0	2	1.951220e-05	102500	0	1	6.711410e-05	14900	0	0	0.000000e+00	30522	0	0	3	1.442220e-05	1	6.166750e-05	16216	0	0	0.000000e+00	30492	0	208012	0	0.000000e+00	6208	0	0	0.000000e+00	13396	0	0	0.000000e+00	16722	0	2	2.234340e-05	89512	0	1	6.166750e-05	16216	0	0	0.000000e+00	30604	0	0	2	8.179360e-06	0	0.000000e+00	12024	0	0	0.000000e+00	34426	0	244518	0	0.000000e+00	9992	0	0	0.000000e+00	18370	0	0	0.000000e+00	21632	0	2	1.795070e-05	111416	0	2	1.795070e-05	111416	0	0	0.000000e+00	30612	0	0	5	3.287870e-05	3	7.247780e-05	41392	0	0	0.000000e+00	912	0	0	0.000000e+00	15250	0	152074	0	0.000000e+00	3472	0	0	0.000000e+00	5184	0	0	0.000000e+00	10598	0	0	0.000000e+00	316	0	1	1.469810e-05	68036	0	3	7.247780e-05	41392	0	0	0.000000e+00	4822	0	2	6.087540e-05	1	1.100840e-04	9084	0	0	0.000000e+00	60	0	0	0.000000e+00	4680	0	32854	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5470	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3112	0	0	.	0	5	3.382680e-05	3	7.304600e-05	41070	0	0	0.000000e+00	912	0	0	0.000000e+00	15062	0	147812	0	0.000000e+00	3302	0	0	0.000000e+00	4948	0	0	0.000000e+00	10598	0	0	0.000000e+00	304	0	1	1.543110e-05	64804	0	0	0.000000e+00	4790	0	0	4	2.969870e-05	2	6.164090e-05	32446	0	0	0.000000e+00	862	0	0	0.000000e+00	14804	0	134686	0	0.000000e+00	3388	0	0	0.000000e+00	5184	0	0	0.000000e+00	6958	0	0	0.000000e+00	310	0	1	1.564650e-05	63912	0	0	0.000000e+00	4820	0	0	3	3.720330e-05	2	8.074940e-05	24768	0	0	0.000000e+00	112	0	0	0.000000e+00	12876	0	80638	0	0.000000e+00	998	0	0	0.000000e+00	3742	0	0	0.000000e+00	10506	0	0	0.000000e+00	272	0	0	0.000000e+00	21052	0	0	0.000000e+00	4794	0	0	12	101773224	12	103249094	0	0.25195	0.553676	0.018000	0.19461	0.934000	0.47231	0.763000	0.32463	0.975000	0.29046	0.676000	0.76740	0.220000	0.24387	102855316	G	.	rs199475575	.	.	7.651	9.354	7.292	9.092	.	.	.	9	16	16	-7	0.00	0.13	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+16+end+197	102723	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103249094-103249094	2.471e-05	3	3	0	1	0	0	0	2	0	0	10360	11428	8580	6576	66364	902	16378	1	0	0	0	2	0	0	0	0	0	0	0	0	0	rs199475575	6.53595e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79495e-05	0.00000e+00	0.00000e+00	1.48480e-05	8.99329e-06	6.53595e-05	1.21817e-05	rs199475575	1.14626e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	0.00000e+00	7.21813e-05	1.14626e-04	3.22664e-05	.	.	rs199475575	199475575	.	.	.	PAH	PAH:exonic	PAH:stopgain	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,773	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.9878	Likely Pathogenic
11	533883	533883	G	A	A	missense_variant	MODERATE	HRAS	3265	Transcript	NM_005343.4	protein_coding	3/6	.	NM_005343.4:c.173C>T	NP_005334.1:p.Thr58Ile	387	173	58	T/I	aCc/aTc	rs121917758&CM081303&COSV54240842	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	HRAS	.	chr11:g.533883G>A	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.93228	0.467247	D	0.93143	0.433392	25.0	23.5	3.596099	2.958794	0.66585	0.53786	G/G	D	0.95567	0.998912692070007	0.86519	0.9977817251576494	.	0.97945	.	G/G	.	.	.	.	4.581738	0.430490704289424	0.63474	6.350845	0.639493944579887	0.75689	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.87750	.	.	.	3.64	2.72	0.31179	0	0.66316	0.685571	.	.	0.74766	0.999999998736683	.	0	0.80598	0.723109	.	.	.	.	.	.	0	0.98432	0.735409	.&Small_GTP-binding_protein_domain&.&Small_GTP-binding_protein_domain&Small_GTP-binding_protein_domain	.	.	.	.	.	0.000000	0.84330	D	0.000000	D	0.88271	0.231337	0.95953	.	0.98587	.	D	0.94132	0.8253	.	0.99538	.	D	0.95682	0.9007	T58I	Loss_of_glycosylation_at_T58_(P_=_0.0515)&_Loss_of_disorder_(P_=_0.0696)&_Gain_of_helix_(P_=_0.132)&_Loss_of_phosphorylation_at_T58_(P_=_0.1979)&_Loss_of_loop_(P_=_0.2237)	P01112	0.99641	0.964	.	0.91674	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	A&A&A&A&A	1&1&1&1&1	0.88289	.	.	.	0.90584	.	.	0.97372	.	D	0.97968	0.915580391884	0.92542	.	9	0.92824	.	.	0.91255	.	.	10.2769	0.42694	0.0993:0.0:0.9007:0.0	.	.	.	.	.	.	.	.	0.99611	.	G/G	I	.	T	A	889	0.27310	.	11	C0587248	218040	ORPHA3071	Pathogenic	NC_000011.10:g.533883G>A	12610	reviewed_by_expert_panel	Costello_syndrome	ClinGen_RASopathy_Variant_Curation_Expert_Panel:4fa14d9d-3bce-4dd8-affa-771b6298c4fc&UniProtKB_(protein):P01112#VAR_045978&OMIM_Allelic_Variant:190020.0011	.	.	AEFDGBI	D	0.79119	0.98043	D	0.83612	0.895765	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11	523883	11	533883	0	0.85440	0.722319	1.000000	0.71638	0.294000	0.24357	0.585000	0.28671	9.802000	0.98244	0.676000	0.76740	1.176000	0.78918	533883	G	.	rs121917758	.	.	8.862	5.560	10.582	8.703	.	.	.	-11	43	-36	44	0.01	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-3+61+end+179	12610	Pathogenic	reviewed_by_expert_panel	not_provided&Costello_syndrome	MedGen:CN517202&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121917758	121917758	.	.	.	HRAS	HRAS:exonic	HRAS:missense	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,622	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
11	533881	533881	C	T	T	missense_variant	MODERATE	HRAS	3265	Transcript	NM_005343.4	protein_coding	3/6	.	NM_005343.4:c.175G>A	NP_005334.1:p.Ala59Thr	389	175	59	A/T	Gcc/Acc	rs727503093&COSV54244375	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	HRAS	.	chr11:g.533881C>T	.	.	.	.	.	.	likely_pathogenic	0&1	1&1	.	.	.	.	.	LRRC56&NM_198075.3&c.-4146C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.84412	0.319195	D	0.84209	0.220725	21.2	20.5	2.248252	2.088472	0.35738	0.34773	C/C	D	0.86360	0.994820952415466	0.75052	0.99614631443293167	.	0.97826	.	C/C	.	.	.	.	2.761365	0.106514176756491	0.44881	3.368027	0.214513499006759	0.51904	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.88611	.	.	.	3.64	3.64	0.40864	0	0.66316	0.685571	.	.	0.74766	0.999999999999944	.	0	0.80598	0.723109	.	.	.	.	.	.	0	0.98432	0.735409	.&Small_GTP-binding_protein_domain&.&Small_GTP-binding_protein_domain&Small_GTP-binding_protein_domain	.	.	.	.	.	0.000000	0.84330	D	0.000000	D	0.91810	0.333235	0.84650	.	0.95716	.	D	0.90305	0.7174	.	0.94448	.	D	0.93092	0.6934	A59T	Gain_of_glycosylation_at_T58_(P_=_0.066)&_Gain_of_helix_(P_=_0.132)&_Gain_of_phosphorylation_at_A59_(P_=_0.153)&_Loss_of_catalytic_residue_at_A59_(P_=_0.1551)&_Gain_of_disorder_(P_=_0.1651)	P01112	0.90076	0.775	.	0.95841	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D	1&1&1&1&1	0.70920	.	.	.	0.45342	.	.	0.39516	.	D	0.93194	0.874418854713	0.91626	.	10	0.55341	.	.	0.55530	.	.	14.8426	0.69869	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.98563	.	C/C	T	.	A	T	889	0.27310	.	11	C0007131&C0587248	218040	ORPHA3071	Likely_pathogenic	NC_000011.10:g.533881C>T	40435	reviewed_by_expert_panel	Non-small_cell_lung_carcinoma&Costello_syndrome	ClinGen_RASopathy_Variant_Curation_Expert_Panel:2bb21939-344a-41a8-be46-3787926538b9	.	.	AEFDGBI	D	0.73660	0.97263	D	0.75812	0.840870	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11	523881	11	533881	0	0.85440	0.722319	1.000000	0.71638	0.209000	0.22154	0.180000	0.21692	7.768000	0.84170	0.599000	0.40250	1.026000	0.45946	533881	C	.	rs727503093	.	.	8.862	5.560	10.582	8.703	.	.	.	45	-9	-13	-34	0.00	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-3+63+end+179	40435	Likely_pathogenic	reviewed_by_expert_panel	Non-small_cell_lung_carcinoma&Costello_syndrome	Human_Phenotype_Ontology:HP:0030358&MONDO:MONDO:0005233&MeSH:D002289&MedGen:C0007131&Orphanet:488201&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs727503093	727503093	.	.	.	HRAS	HRAS:exonic	HRAS:missense	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,621	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
11	533553	533553	T	C	C	missense_variant	MODERATE	HRAS	3265	Transcript	NM_005343.4	protein_coding	4/6	.	NM_005343.4:c.350A>G	NP_005334.1:p.Lys117Arg	564	350	117	K/R	aAg/aGg	rs104894227&CM061796	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	HRAS	.	chr11:g.533553T>C	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.91666	0.432677	D	0.91562	0.383734	27.0	28.8	4.003891	4.129256	0.78736	0.86454	T/T	D	0.87730	0.995602965354919	0.95410	0.99877180747101513	.	0.99042	.	T/T	.	.	.	.	9.399211	0.774087090937339	0.87938	11.9849	0.934751588113759	0.93354	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.87038	.	.	.	4.08	4.08	0.46880	0	0.70079	0.698795	.	.	0.74766	0.999999999854179	.	0	0.19454	0.570548	.	.	.	.	.	.	0	0.98432	0.735409	.&Small_GTP-binding_protein_domain&.&Small_GTP-binding_protein_domain&Small_GTP-binding_protein_domain	.	.	.	.	.	0.000000	0.84330	D	0.000000	D	0.93227	0.392848	0.93298	.	0.96821	.	D	0.95992	0.8793	.	0.94765	.	D	0.98236	1.0555	K117R	Loss_of_methylation_at_K117_(P_=_0.0042)&_Loss_of_ubiquitination_at_K117_(P_=_0.0167)&_Gain_of_sheet_(P_=_0.0827)&_Gain_of_catalytic_residue_at_G115_(P_=_0.1979)&_Gain_of_MoRF_binding_(P_=_0.2673)	P01112	0.98347	0.914	.	0.98135	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	A&A&A&A&A	1&1&1&1&1	0.58733	.	.	.	0.77913	.	.	0.73157	.	T	0.81096	0.794301211834	0.97814	.	9	0.83351	.	.	0.65419	.	.	12.54	0.55511	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.87265	.	T/T	R	.	K	C	889	0.27310	.	11	C0587248&CN517202	218040	ORPHA3071	Pathogenic	NC_000011.10:g.533553T>C	12605	reviewed_by_expert_panel	Costello_syndrome&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:42e841f0-7121-4d9d-a2ae-ebc27adacd88&OMIM_Allelic_Variant:190020.0006&UniProtKB_(protein):P01112#VAR_045981	.	.	AEFDBI	D	0.88280	0.98894	D	0.90905	0.927024	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11	523553	11	533553	0	0.85440	0.722319	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	4.136000	0.57766	0.665000	0.62972	1.138000	0.64695	533553	T	.	rs104894227	.	.	10.489	10.068	8.862	5.560	.	.	.	-1	-38	0	44	0.09	0.03	0.01	0.00	HRAS	0.01	exon-NM_005343.4-4+59+end+160	12605	Pathogenic	reviewed_by_expert_panel	not_provided&Costello_syndrome	MedGen:CN517202&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs104894227	104894227	.	.	.	HRAS	HRAS:exonic	HRAS:missense	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,616	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9878	Likely Pathogenic
15	66727442	66727442	T	C	C	missense_variant	MODERATE	MAP2K1	5604	Transcript	NM_002755.4	protein_coding	2/11	.	NM_002755.4:c.158T>C	NP_002746.1:p.Phe53Ser	594	158	53	F/S	tTt/tCt	rs121908594&CM061105&COSV61068705&COSV61070226	T	.	1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	MAP2K1	.	chr15:g.66727442T>C	.	.	.	.	.	.	pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.93967	0.488863	D	0.93890	0.464442	26.3	25.2	3.898358	3.552935	0.75226	0.68484	./.	D	0.80902	0.990673056834346	0.94902	0.99870998733195837	.	0.96454	.	./.	.	.	.	.	7.28423	0.673506475474554	0.80373	7.204583	0.706048593310069	0.80031	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.93414	.	.	.	5.07	5.07	0.68106	0	0.89359	0.724815	.	.	0.74766	0.999999999717078	.	1	0.18673	0.554053	.	.	.	.	.	.	0	0.83352	0.714379	.	.	.	.	0.95418	.	0.000000	0.84330	D	0.000000	D	0.97992	0.748504	0.98432	.	0.98831	.	D	0.95536	0.8658	.	0.95604	.	D	0.95897	0.9157	F53S	Loss_of_stability_(P_=_0.017)&_Gain_of_relative_solvent_accessibility_(P_=_0.0215)&_Gain_of_phosphorylation_at_F53_(P_=_0.0399)&_Gain_of_loop_(P_=_0.0502)&_Gain_of_solvent_accessibility_(P_=_0.0611)	Q02750	0.88232	0.752	.	0.79018	.	.	0.81001	simple_aae	A	1	0.90294	.	.	.	0.66517	.	.	0.68939	.	D	0.97865	0.914363145828	0.98636	.	9	0.32144	.	.	0.68238	.	.	14.0473	0.64233	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.94196	.	./.	S	.	F	C	859	0.33891	.	15	C3809006&C1275081&CN517202	615279&PS115150	ORPHA1340	Pathogenic	NC_000015.10:g.66435104T>C	13350	reviewed_by_expert_panel	Cardiofaciocutaneous_syndrome_3&Cardio-facio-cutaneous_syndrome&not_provided	OMIM_Allelic_Variant:176872.0001&UniProtKB_(protein):Q02750#VAR_035093&ClinGen_RASopathy_Variant_Curation_Expert_Panel:b78d797f-9630-4e8f-a1e3-8bf3ece401f5	.	.	AEFBI	D	0.77189	0.97795	D	0.88587	0.917776	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	15	64514496	15	66727442	0	0.73137	0.706548	1.000000	0.71638	0.991000	0.66497	0.997000	0.62031	7.902000	0.86082	0.609000	0.47794	1.138000	0.64695	66435104	T	.	rs121908594	.	.	9.579	10.474	5.944	8.569	.	.	.	-49	11	19	-5	0.00	0.00	0.00	0.00	MAP2K1	0.99	exon-NM_002755.4-2+77+start+211	13350	Pathogenic	reviewed_by_expert_panel	Cardio-facio-cutaneous_syndrome&Cardiofaciocutaneous_syndrome_3&not_provided	MONDO:MONDO:0015280&MedGen:C1275081&OMIM:PS115150&Orphanet:1340&MONDO:MONDO:0014113&MedGen:C3809006&OMIM:615279&Orphanet:1340&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121908594	121908594	.	.	.	MAP2K1	MAP2K1:exonic	MAP2K1:missense	MAP2K1:Cardiofaciocutaneous_syndrome_3\x3bMelorheostosis\x2cisolated\x2csomatic_mosaic	MAP2K1:615279\x3b155950	MAP2K1:3\x3b3	MAP2K1:Autosomal_dominant\x3b.	0	0.994501270366062	0.00549805295620231	6.76677735529064e-07	DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. Distinctive features of CFC3 include macrostomia and horizontal shape of palpebral fissures. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,884	0	1	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
12	103306601	103306601	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	2/13	.	NM_000277.3:c.136G>C	NP_000268.1:p.Gly46Arg	250	136	46	G/R	Ggt/Cgt	rs74603784&CM155188&CM930535	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103306601C>G	.	.	.	.	.	.	likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.137del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.95148	0.528744	D	0.95076	0.521728	26.0	26.4	3.836403	3.817069	0.73289	0.76009	C/C	D	0.91454	0.997390687465668	0.99334	0.99930015677539863	.	0.99909	.	C/C	.	.	.	.	13.45192	0.892891303887484	0.95255	14.12038	1.00628238652907	0.95934	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99931	.	.	.	5.46	5.46	0.80021	0	0.26702	0.573888	.	.	0.74766	0.999999997037945	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.61581	.	0.000000	0.84330	D	0.000000	D	0.97606	0.706523	0.28073	.	0.99138	.	D	0.99955	0.9983	.	0.96064	.	D	0.96164	0.9343	G46R	Gain_of_solvent_accessibility_(P_=_0.0456)&_Loss_of_ubiquitination_at_K42_(P_=_0.07)&_Gain_of_MoRF_binding_(P_=_0.1176)&_Gain_of_helix_(P_=_0.2294)&_Gain_of_relative_solvent_accessibility_(P_=_0.2363)	P00439	0.93125	0.817	.	0.99424	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.96218	.	.	.	0.90584	.	.	0.92359	.	T	0.67482	0.702336013317	0.97436	.	10	0.92824	.	.	0.91255	.	.	16.2217	0.82082	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.91621	.	C/C	R	.	G	G	768	0.49510	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102912823C>G	619156	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.55738	0.92449	D	0.88070	0.915642	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101830731	12	103306601	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	5.034000	0.63942	0.599000	0.40250	1.026000	0.45946	102912823	C	.	rs74603784	.	.	11.785	7.700	8.002	9.602	.	.	.	5	-32	-32	0	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-3+32+start+108	619156	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,838	0	0	0	0	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
12	103246701	103246701	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.734T>C	NP_000268.1:p.Val245Ala	848	734	245	V/A	gTg/gCg	rs76212747&CM930549&CM941133	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103246701A>G	.	0.0008	0	0	0.001	0	pathogenic&uncertain_significance	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.734T>C	.	.	2	3.9936102236421724E-4	1	7.564296520423601E-4	0	0.0	0	0.0	1	9.940357852882703E-4	0	0.0	3	7.784120394395433E-4	.	.	.	.	.	.	.	A/A	A	D	0.79008	0.254366	D	0.95224	0.529224	24.9	24.6	3.570767	3.379151	0.65929	0.64027	A/A	T	0.19308	0.181154774186941	0.96513	0.99891540258645317	.	0.99833	.	A/A	1	2.2696323195642307E-4	6	6.976744186046512E-4	10.78914	0.821442009252834	0.91243	9.261238	0.8236659402428	0.87562	.	.	.	86	7.083e-04	2	1.923e-04	7	6.064e-04	86	7.092e-04	0	0	0	0	76	1.140e-03	0	0	78	7.344e-04	1	1.104e-04	7	6.260e-04	78	7.352e-04	0	0	0	0	69	1.271e-03	0	0	69	7.603e-04	2	1.927e-04	7	6.070e-04	69	7.615e-04	0	0	0	0	59	1.402e-03	0	0	0.99764	.	.	.	5.92	5.92	0.95557	0	0.45803	0.59043	.	.	0.74766	0.999999998807801	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.63821	.	0.053982	0.84330	N	0.000001	D	0.90070	0.276367	0.28107	.	0.95452	.	D	0.99663	0.9883	.	0.70295	.	D	0.98569	1.0692	.	.	.	.	.	.	0.84406	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.72240	.	.	.	0.90584	.	.	0.92359	.	T	0.80819	0.792471528053	0.97248	.	9	0.28391	.	.	0.28520	.	.	16.3594	0.83084	1.0:0.0:0.0:0.0	.	1	2.6968716289104636E-4	4	5.289605924358636E-4	.	.	.	0.89353	.	A/A	A	.	V	G	518	0.74548	.	12	C0751435&C0031485&CN221596&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852923A>G	632	reviewed_by_expert_panel	Hyperphenylalaninemia&_non-pku&Phenylketonuria&Hyperphenylalaninaemia&not_provided	OMIM_Allelic_Variant:612349.0059&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2846671&Illumina_Laboratory_Services&Illumina:692718&UniProtKB_(protein):P00439#VAR_000949&DeBelle_Laboratory_for_Biochemical_Genetics:p.V245A	.	.	AEFBI	D	0.91756	0.99136	D	0.99599	0.975103	.	121	4.816730e-04	2	1.230310e-04	16256	0	11	3.181770e-04	34572	0	251208	0	0.000000e+00	10068	0	0	0.000000e+00	18382	0	1	4.620220e-05	21644	0	104	9.159930e-04	113538	0	104	9.159930e-04	113538	0	0	0.000000e+00	30616	0	50	4.570800e-04	1	1.395870e-04	7164	0	6	3.507130e-04	17108	0	109390	0	0.000000e+00	2320	0	0	0.000000e+00	9040	0	0	0.000000e+00	13390	0	41	9.587060e-04	42766	0	41	9.587060e-04	42766	0	0	0.000000e+00	15690	0	0	.	0	115	4.859050e-04	2	1.342100e-04	14902	0	11	3.212620e-04	34240	0	236672	0	0.000000e+00	9560	0	0	0.000000e+00	17680	0	1	4.623640e-05	21628	0	98	9.558740e-04	102524	0	98	9.558740e-04	102524	0	0	0.000000e+00	30526	0	0	106	5.094880e-04	2	1.233200e-04	16218	0	11	3.605610e-04	30508	0	208052	0	0.000000e+00	6210	0	0	0.000000e+00	13404	0	0	0.000000e+00	16730	0	91	1.016620e-03	89512	0	91	1.016620e-03	89512	0	0	0.000000e+00	30608	0	0	116	4.742630e-04	1	8.315320e-05	12026	0	11	3.194150e-04	34438	0	244590	0	0.000000e+00	9986	0	0	0.000000e+00	18378	0	1	4.620650e-05	21642	0	100	8.972790e-04	111448	0	100	8.972790e-04	111448	0	0	0.000000e+00	30616	0	0	71	4.665470e-04	4	9.647390e-05	41462	0	0	0.000000e+00	912	0	2	1.309590e-04	15272	0	152182	0	0.000000e+00	3472	0	0	0.000000e+00	5174	0	1	9.412650e-05	10624	0	0	0.000000e+00	316	0	64	9.406780e-04	68036	0	64	9.406780e-04	68036	0	0	0.000000e+00	4822	0	14	4.255320e-04	2	2.199250e-04	9094	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32900	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	1	1.819510e-04	5496	0	0	0.000000e+00	246	0	11	1.605370e-03	6852	0	0	0.000000e+00	3106	0	0	.	0	68	4.596770e-04	4	9.722900e-05	41140	0	0	0.000000e+00	912	0	2	1.325910e-04	15084	0	147930	0	0.000000e+00	3302	0	0	0.000000e+00	4938	0	1	9.412650e-05	10624	0	0	0.000000e+00	304	0	61	9.411550e-04	64814	0	0	0.000000e+00	4790	0	0	63	4.674910e-04	2	6.156880e-05	32484	0	0	0.000000e+00	862	0	2	1.348980e-04	14826	0	134762	0	0.000000e+00	3388	0	0	0.000000e+00	5174	0	1	1.431430e-04	6986	0	0	0.000000e+00	310	0	58	9.075260e-04	63910	0	0	0.000000e+00	4820	0	0	26	3.220210e-04	4	1.610440e-04	24838	0	0	0.000000e+00	112	0	2	1.550630e-04	12898	0	80740	0	0.000000e+00	998	0	0	0.000000e+00	3732	0	1	9.494870e-05	10532	0	0	0.000000e+00	272	0	19	9.027840e-04	21046	0	0	0.000000e+00	4794	0	0	12	101770831	12	103246701	0	0.43195	0.638212	1.000000	0.71638	0.995000	0.73285	1.000000	0.86279	9.325000	0.96006	0.756000	0.94297	1.312000	0.94714	102852923	A	.	rs76212747	.	.	11.570	9.399	7.651	9.354	.	.	.	27	3	19	27	0.01	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+27+end+136	632	Pathogenic	reviewed_by_expert_panel	Inborn_genetic_diseases&not_provided&Phenylketonuria&Hyperphenylalaninemia	MeSH:D030342&MedGen:C0950123&MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&Human_Phenotype_Ontology:HP:0004923&MedGen:C0751435	.	rs76212747	7.083e-04	86	0	0	2	7	0	0	76	1	0	10398	11544	8642	6600	66654	908	16510	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs76212747	6.53424e-05	2.68128e-04	0.00000e+00	0.00000e+00	4.48471e-05	9.50894e-04	1.09449e-03	0.00000e+00	5.78893e-04	4.04531e-04	9.50894e-04	5.03508e-04	rs76212747	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.86205e-04	4.66418e-04	1.01833e-03	.	3.50508e-04	2.16481e-04	4.66418e-04	2.90398e-04	rs76212747	0.0698&0.0227&0.0538	rs76212747	76212747	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,751	0	0	0	0	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
10	89692836	89692836	A	T	T	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.320A>T	NP_000305.3:p.Asp107Val	1165	320	107	D/V	gAt/gTt	rs786204858&CM142082&COSV64290655&COSV64294121	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89692836A>T	.	.	.	.	.	.	pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.93176	0.466003	D	0.93091	0.431605	27.9	27.6	4.118109	3.988196	0.82717	0.81871	./.	D	0.98435	0.999679207801819	0.63263	0.99410434783121271	.	0.98678	.	./.	.	.	.	.	7.937144	0.709661990771444	0.83111	7.647775	0.735627327507823	0.81968	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.86010	.	.	.	5.07	5.07	0.68106	0	0.70079	0.698795	.	.	0.74766	0.999999999999151	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.84924	.	0.000000	0.84330	D	0.000000	D	0.95315	0.511978	0.98605	.	0.98719	.	D	0.91841	0.7604	.	0.92659	.	D	0.91782	0.5911	D107V	Loss_of_disorder_(P_=_0.0952)&_Loss_of_glycosylation_at_K102_(P_=_0.2182)&_Gain_of_methylation_at_K102_(P_=_0.2265)&_Loss_of_helix_(P_=_0.2271)&_Gain_of_catalytic_residue_at_D107_(P_=_0.2439)	P60484	0.48815	0.436	.	0.84639	.	.	0.81001	simple_aae	D	1	0.97364	.	.	.	0.90584	.	.	0.92359	.	D	0.92499	0.869510352612	0.95802	.	9	0.83351	.	.	0.91255	.	.	14.8406	0.69852	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.98268	.	./.	V	.	D	T	940	0.13648	.	10	C1959582&CN517202	.	ORPHA306498	Pathogenic	NC_000010.11:g.87933079A>T	372481	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&not_provided	Herman_Laboratory&Nationwide_Children's_Hospital:PTENv2017-12&ClinGen_PTEN_Variant_Curation_Expert_Panel:af7069ee-474b-491e-9317-5e91eeba5b76	.	.	AEFDGBI	D	0.85068	0.98644	D	0.82334	0.889355	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682816	10	89692836	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	8.871000	0.91978	0.756000	0.94297	1.312000	0.94714	87933079	A	.	rs786204858	.	.	10.752	10.998	5.352	9.651	.	.	.	42	-45	-2	50	0.01	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+66+start+239	372481	Pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Macrocephaly-autism_syndrome&not_provided	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786204858	786204858	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,540	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
10	89692800	89692800	C	T	T	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.284C>T	NP_000305.3:p.Pro95Leu	1129	284	95	P/L	cCa/cTa	rs786204856&CD132274&CM110120&COSV64288477&COSV64302636	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89692800C>T	.	.	.	.	.	.	pathogenic	0&0&0&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.284C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.96693	0.574774	D	0.96638	0.587846	26.5	27.6	3.919479	3.987006	0.75908	0.81833	./.	D	0.96605	0.999221563339233	0.93729	0.99858418971179452	.	0.98225	.	./.	.	.	.	.	9.104698	0.762569980320129	0.87095	8.951379	0.808617085259176	0.86641	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98507	.	.	.	5.07	5.07	0.68106	0	0.89359	0.724815	.	.	0.74766	0.999999999999999	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.95156	0.727631	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.96090	.	0.000000	0.84330	D	0.000000	D	0.98303	0.784338	0.96273	.	0.98492	.	D	0.98869	0.9646	.	0.94891	.	D	0.99645	1.0996	P95L	Loss_of_disorder_(P_=_0.0206)&_Loss_of_glycosylation_at_P95_(P_=_0.0942)&_Gain_of_stability_(P_=_0.1879)&_Loss_of_sheet_(P_=_0.3635)&_Loss_of_helix_(P_=_0.3949)	P60484	0.65577	0.543	.	0.91022	.	.	0.81001	simple_aae	D	1	0.95870	.	.	.	0.90584	.	.	0.92359	.	D	0.89375	0.848419427872	0.98304	.	9	0.76473	.	.	0.78490	.	.	18.4584	0.90676	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.89353	.	./.	L	.	P	T	940	0.13648	.	10	C0027672&C1959582	.	ORPHA140162&ORPHA306498	Pathogenic	NC_000010.11:g.87933043C>T	189403	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome	Herman_Laboratory&Nationwide_Children's_Hospital:PTENv2017-10&ClinGen_PTEN_Variant_Curation_Expert_Panel:43eee6bc-e0e1-4ce0-8d9a-b838428c1884	.	.	AEFDGBIJ	D	0.77733	0.97868	D	0.89248	0.920462	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682780	10	89692800	0	0.92422	0.732398	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	7.506000	0.80535	0.599000	0.40250	1.026000	0.45946	87933043	C	.	rs786204856	.	.	10.752	10.998	5.352	9.651	.	.	.	-48	-9	-2	-24	0.02	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+30+start+239	189403	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786204856	786204856	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,536	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
12	103246695	103246695	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.740G>A	NP_000268.1:p.Gly247Asp	854	740	247	G/D	gGc/gAc	rs199475579&CD130700&CM043314&CM920551	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246695C>T	.	.	.	.	.	.	uncertain_significance&not_provided	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.740G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.94642	0.512029	D	0.96938	0.594572	26.3	28.2	3.892567	4.055436	0.75040	0.84195	C/C	D	0.97759	0.999521255493164	0.94637	0.99868947672984076	.	0.99999	.	C/C	.	.	.	.	18.80161	0.99935888847546	0.98615	16.40708	1.07277044952182	0.97596	.	.	.	1	8.236e-06	0	0	0	0	1	8.243e-06	0	0	0	0	0	0	1	6.056e-05	1	9.415e-06	0	0	0	0	1	9.422e-06	0	0	0	0	0	0	1	6.095e-05	1	1.102e-05	0	0	0	0	1	1.103e-05	0	0	0	0	0	0	1	6.060e-05	0.99830	.	.	.	5.92	5.92	0.95557	0	0.45803	0.59043	.	.	0.74766	0.999999999999832	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.95158	.	0.045450	0.84330	D	0.000000	D	0.97099	0.655955	0.28800	.	0.99033	.	D	0.99898	0.9955	.	0.99872	.	D	0.96230	0.9388	G247D	Loss_of_methylation_at_R243_(P_=_0.0553)&_Loss_of_catalytic_residue_at_A246_(P_=_0.1404)&_Gain_of_phosphorylation_at_S250_(P_=_0.2103)&_Gain_of_helix_(P_=_0.2684)&_Loss_of_stability_(P_=_0.2911)	P00439	0.99935	0.994	.	0.98631	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.92518	.	.	.	0.90584	.	.	0.97372	.	D	0.97204	0.907256007195	0.99762	.	10	0.92824	.	.	0.91255	.	.	20.3167	0.98654	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99260	.	C/C	D	.	G	T	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102852917C>T	102817	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.G247D	.	.	AEFBI	D	0.85537	0.98683	D	0.99813	0.979575	.	1	3.980570e-06	0	0.000000e+00	16254	0	0	0.000000e+00	34574	0	251220	0	0.000000e+00	10068	0	0	0.000000e+00	18384	0	0	0.000000e+00	21642	0	0	0.000000e+00	113548	0	1	3.266270e-05	30616	0	1	3.266270e-05	30616	0	1	9.141770e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17108	0	109388	0	0.000000e+00	2320	0	0	0.000000e+00	9040	0	0	0.000000e+00	13390	0	0	0.000000e+00	42762	0	1	6.373490e-05	15690	0	1	6.373490e-05	15690	0	0	.	0	1	4.225010e-06	0	0.000000e+00	14900	0	0	0.000000e+00	34242	0	236686	0	0.000000e+00	9560	0	0	0.000000e+00	17682	0	0	0.000000e+00	21626	0	0	0.000000e+00	102534	0	1	3.275900e-05	30526	0	1	3.275900e-05	30526	0	0	1	4.806630e-06	0	0.000000e+00	16216	0	0	0.000000e+00	30510	0	208046	0	0.000000e+00	6210	0	0	0.000000e+00	13406	0	0	0.000000e+00	16728	0	0	0.000000e+00	89504	0	1	3.267120e-05	30608	0	1	3.267120e-05	30608	0	0	1	4.088270e-06	0	0.000000e+00	12024	0	0	0.000000e+00	34440	0	244602	0	0.000000e+00	9986	0	0	0.000000e+00	18380	0	0	0.000000e+00	21640	0	0	0.000000e+00	111458	0	1	3.266270e-05	30616	0	1	3.266270e-05	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770825	12	103246695	0	0.43195	0.638212	1.000000	0.71638	0.995000	0.73285	1.000000	0.86279	7.905000	0.86479	0.599000	0.40250	1.026000	0.45946	102852917	C	.	rs199475579	.	.	11.570	9.399	7.651	9.354	.	.	.	33	3	-26	33	0.01	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+33+end+136	102817	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	12:103246695-103246695	8.236e-06	1	1	0	0	0	0	0	0	0	1	10400	11554	8644	6602	66698	908	16512	0	0	0	0	0	0	1	0	0	0	0	0	0	0	rs199475579	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.24865e-05	7.42104e-06	0.00000e+00	3.24865e-05	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475579	199475579	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,747	0	0	0	0	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
10	89685286	89685286	C	G	G	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	3/9	.	NM_000314.8:c.181C>G	NP_000305.3:p.His61Asp	1026	181	61	H/D	Cat/Gat	rs121909236&CM013961&CM110134&COSV64293209&COSV64297250	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89685286C>G	.	.	.	.	.	.	uncertain_significance&likely_pathogenic	0&0&0&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.181C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.96262	0.561331	D	0.96203	0.568536	26.8	27.6	3.976403	3.993033	0.77802	0.82059	./.	D	0.91171	0.997276246547699	0.59584	0.99326013353110065	.	0.99555	.	./.	.	.	.	.	14.14878	0.909146739073863	0.95959	13.87006	0.998369365010591	0.95693	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98562	.	.	.	5.46	5.46	0.80021	0	0.89359	0.724815	.	.	0.74766	0.999999999999999	.	0	0.34648	0.602189	.	.	.	.	.	.	0	0.68540	0.695668	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.97821	.	0.000000	0.84330	D	0.000000	D	0.98316	0.785845	0.98580	.	0.97579	.	D	0.99392	0.9802	.	0.96603	.	D	0.98098	1.0491	H61D	Gain_of_relative_solvent_accessibility_(P_=_0.0479)&_Gain_of_ubiquitination_at_K60_(P_=_0.0506)&_Gain_of_loop_(P_=_0.069)&_Loss_of_helix_(P_=_0.079)&_Gain_of_solvent_accessibility_(P_=_0.0808)	P60484	0.92157	0.803	.	0.95329	.	.	0.81001	simple_aae	A	1	0.96946	.	.	.	0.90584	.	.	0.88582	.	D	0.98532	0.922836482525	0.99315	.	9	0.66756	.	.	0.68238	.	.	19.2989	0.94121	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.93018	.	./.	D	.	H	G	930	0.16408	.	10	C1959582&C2749240	.	ORPHA306498	Likely_pathogenic	NC_000010.11:g.87925529C>G	7841	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Vater_association_with_macrocephaly_and_ventriculomegaly	UniProtKB_(protein):P60484#VAR_018101&OMIM_Allelic_Variant:601728.0030&ClinGen_PTEN_Variant_Curation_Expert_Panel:37398c37-6caa-4c1d-a1b1-3881be31e38b	.	.	AEFGBI	D	0.90115	0.99024	D	0.90114	0.923919	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89675266	10	89685286	0	0.73137	0.706548	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	7.323000	0.78378	0.599000	0.40250	1.026000	0.45946	87925529	C	.	rs121909236	.	.	8.389	7.964	10.295	10.567	.	.	.	-16	-15	32	17	0.01	0.00	0.01	0.00	PTEN	0.98	exon-NM_001304717.5-4+16+start+45	7841	Likely_pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Vater_association_with_macrocephaly_and_ventriculomegaly	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MedGen:C2749240	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909236	121909236	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,527	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
12	103238146	103238146	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	10/13	.	NM_000277.3:c.1033G>A	NP_000268.1:p.Ala345Thr	1147	1033	345	A/T	Gct/Act	rs62516062&CM010983&CM920560	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103238146C>T	.	.	.	.	.	.	not_provided&likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1033G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.96660	0.572899	D	0.96604	0.585154	28.6	32	4.197364	4.425060	0.85372	0.91324	C/C	D	0.96500	0.999199569225311	0.98449	0.99916525186847871	.	0.99998	.	C/C	.	.	.	.	20.31219	1.02280856888031	0.99021	18.19517	1.11531265388869	0.98407	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99829	.	.	.	5.81	5.81	0.92413	0	0.26702	0.573888	.	.	0.74766	0.99999999961916	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.98066	.	0.000000	0.84330	D	0.000000	D	0.98370	0.7923	0.26390	.	0.96956	.	D	0.99908	0.9960	.	0.99974	.	D	0.95927	0.9178	A345T	Gain_of_ubiquitination_at_K341_(P_=_0.115)&_Gain_of_loop_(P_=_0.2045)&_Gain_of_methylation_at_K341_(P_=_0.2425)&_Gain_of_disorder_(P_=_0.2562)&_Loss_of_sheet_(P_=_0.302)	P00439	0.99785	0.977	.	0.99532	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.71639	.	.	.	0.90584	.	.	0.86255	.	T	0.71328	0.7287748456	0.99803	.	10	0.83351	.	.	0.78490	.	.	20.0776	0.97749	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99260	.	C/C	T	.	A	T	503	0.75780	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102844368C>T	102483	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_001010&DeBelle_Laboratory_for_Biochemical_Genetics:p.A345T	.	.	AEFDBI	D	0.89172	0.98958	D	0.99157	0.969147	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101762276	12	103238146	0	0.43195	0.638212	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	7.905000	0.86479	0.599000	0.40250	1.026000	0.45946	102844368	C	.	rs62516062	.	.	3.163	9.459	7.709	9.491	.	.	.	-33	-48	3	-32	0.00	0.00	0.00	0.11	PAH	0.00	exon-NM_001354304.2-11+32+start+96	102483	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62516062	62516062	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,677	0	0	0	0	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
10	89653806	89653806	T	G	G	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	2/9	.	NM_000314.8:c.104T>G	NP_000305.3:p.Met35Arg	949	104	35	M/R	aTg/aGg	rs121909225&CM014083&CM981665&COSV100911372&COSV64292490	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89653806T>G	.	.	.	.	.	.	pathogenic	0&0&0&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.104T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.96970	0.578261	D	0.96920	0.592856	32	29.4	4.471928	4.188251	0.90977	0.87975	./.	D	0.93945	0.998365938663483	0.44206	0.98651882501240962	.	0.99638	.	./.	.	.	.	.	9.75167	0.787077632999351	0.88879	10.36481	0.872530047693383	0.90351	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98629	.	.	.	5.19	5.19	0.71428	0	0.97443	0.743671	.	.	0.74766	0.999999999983518	.	0	0.34648	0.602189	.	.	.	.	.	.	0	0.61905	0.655142	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.92108	.	0.000000	0.84330	D	0.000000	D	0.99087	0.880181	0.99982	.	0.99714	.	D	0.99316	0.9779	.	0.99976	.	D	0.98463	1.0651	M35R	Loss_of_sheet_(P_=_0.0315)&_Gain_of_methylation_at_M35_(P_=_0.0453)&_Loss_of_stability_(P_=_0.0892)&_Gain_of_relative_solvent_accessibility_(P_=_0.1259)&_Gain_of_solvent_accessibility_(P_=_0.1319)	P60484	0.99704	0.969	.	0.95591	.	.	0.81001	simple_aae	A	1	0.88431	.	.	.	0.68779	.	.	0.73157	.	D	0.93384	0.875788450241	0.99976	.	8	0.92824	.	.	0.78490	.	.	14.0135	0.64028	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.99776	.	./.	R	.	M	G	916	0.20744	.	10	CN072330&C1959582	158350	ORPHA306498	Pathogenic	NC_000010.11:g.87894049T>G	7825	reviewed_by_expert_panel	Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	UniProtKB_(protein):P60484#VAR_008036&ClinGen_PTEN_Variant_Curation_Expert_Panel:2374c339-e2d7-4496-9d9a-d33c1abd8dce&OMIM_Allelic_Variant:601728.0011	.	.	AEFGBI	D	0.70862	0.96773	D	0.91287	0.928523	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89643786	10	89653806	0	0.92422	0.732398	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	7.532000	0.80879	0.665000	0.62972	1.138000	0.64695	87894049	T	.	rs121909225	.	.	10.295	10.567	-2.595	-3.496	.	.	.	1	-31	1	-31	0.37	0.34	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-3+24+start+85	7825	Pathogenic	reviewed_by_expert_panel	Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909225	121909225	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,523	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
10	89692854	89692854	G	T	T	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.338G>T	NP_000305.3:p.Ser113Ile	1183	338	113	S/I	aGt/aTt	rs587781254&COSV64303847	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89692854G>T	.	.	.	.	.	.	uncertain_significance	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.93798	0.482685	D	0.93719	0.455567	27.8	27.1	4.111051	3.933610	0.82467	0.79981	./.	D	0.75646	0.984281063079834	0.75413	0.99621293395592947	.	0.98884	.	./.	.	.	.	.	9.487463	0.777410648563567	0.88185	8.486439	0.784615819674521	0.85133	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98715	.	.	.	5.22	5.22	0.72285	0	0.70079	0.698795	.	.	0.74766	0.999999999999999	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.77758	.	0.000000	0.84330	D	0.000000	D	0.98011	0.75061	0.90831	.	0.97258	.	D	0.98639	0.9579	.	0.91271	.	D	0.99222	1.0896	S113I	Loss_of_disorder_(P_=_0.0141)&_Gain_of_catalytic_residue_at_N117_(P_=_0.2041)&_Gain_of_loop_(P_=_0.2754)&_Loss_of_glycosylation_at_S113_(P_=_0.3396)&_Loss_of_helix_(P_=_0.3949)	P60484	0.37837	0.369	.	0.42436	.	.	0.81001	simple_aae	D	1	0.74821	.	.	.	0.66517	.	.	0.60170	.	T	0.66853	0.697982311249	0.93346	.	9	0.47828	.	.	0.45756	.	.	18.7776	0.91883	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.84194	.	./.	I	.	S	T	940	0.13648	.	10	C1959582	.	ORPHA306498	Uncertain_significance	NC_000010.11:g.87933097G>T	139567	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome	ClinGen_PTEN_Variant_Curation_Expert_Panel:f5fca852-9b72-4798-a482-88fe3941f654	.	.	AEFDGBI	D	0.85307	0.98664	D	0.88460	0.917250	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682834	10	89692854	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	9.525000	0.97093	0.676000	0.76740	1.176000	0.78918	87933097	G	.	rs587781254	.	.	10.752	10.998	5.352	9.651	.	.	.	24	-46	32	-1	0.03	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+84+start+239	139567	Uncertain_significance	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587781254	587781254	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,542	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
10	89692884	89692884	A	G	G	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.368A>G	NP_000305.3:p.His123Arg	1213	368	123	H/R	cAc/cGc	rs121909222&CM971270&COSV64296710&COSV64309701	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89692884A>G	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.368A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.97379	0.593413	D	0.97337	0.61462	26.0	25.2	3.832191	3.556177	0.73166	0.68568	./.	D	0.98115	0.999604046344757	0.87661	0.99790467878822486	.	0.99614	.	./.	.	.	.	.	13.18013	0.886354078668865	0.94949	13.81756	0.996674621537307	0.95641	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99903	.	.	.	5.22	5.22	0.72285	0	0.70079	0.698795	.	.	0.74766	0.999999999999512	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.98615	.	0.000000	0.84330	D	0.000000	D	0.98681	0.829894	0.98043	.	0.99568	.	D	0.99938	0.9975	.	0.99899	.	D	0.95533	0.8898	H123R	Gain_of_MoRF_binding_(P_=_0.0376)&_Loss_of_ubiquitination_at_K125_(P_=_0.0675)&_Loss_of_methylation_at_K125_(P_=_0.0926)&_Loss_of_helix_(P_=_0.2662)&_Loss_of_disorder_(P_=_0.299)	P60484	0.99502	0.955	.	0.97724	.	.	0.81001	simple_aae	A	1	0.95924	.	.	.	0.90584	.	.	0.88582	.	D	0.98283	0.919472336769	0.99931	.	8	0.79402	.	.	0.91255	.	.	15.1019	0.71955	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99725	.	./.	R	.	H	G	940	0.13648	.	10	CN072330&C1959582&CN517202	158350	ORPHA306498	Likely_pathogenic	NC_000010.11:g.87933127A>G	7816	reviewed_by_expert_panel	Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:4ed5aa0a-d183-4c08-b6f6-23ffb9904a78&UniProtKB_(protein):P60484#VAR_007463&OMIM_Allelic_Variant:601728.0005	.	.	AEFDGBI	D	0.79301	0.98065	D	0.93081	0.935643	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682864	10	89692884	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	8.875000	0.92004	0.756000	0.94297	1.312000	0.94714	87933127	A	.	rs121909222	.	.	10.752	10.998	5.352	9.651	.	.	.	-6	2	28	2	0.01	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+114+start+239	7816	Pathogenic	reviewed_by_expert_panel	not_provided&PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909222	121909222	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,545	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
12	103246635	103246635	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.800A>G	NP_000268.1:p.Gln267Arg	914	800	267	Q/R	cAg/cGg	rs778154939&CM1111581&CM112742	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103246635T>C	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.800A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.96914	0.575129	D	0.96864	0.588356	28.0	27.0	4.124967	3.919329	0.82950	0.79455	T/T	D	0.93453	0.998187959194183	0.93102	0.99851727449522609	.	0.99944	.	T/T	.	.	.	.	12.8773	0.878880753968125	0.94586	12.16136	0.941037657147278	0.93619	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99708	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999997298143	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.70348	.	0.000000	0.84330	D	0.000000	D	0.95570	0.529732	0.27222	.	0.98758	.	D	0.99770	0.9911	.	0.98820	.	D	0.96751	0.9732	Q267R	Gain_of_MoRF_binding_(P_=_0.0249)&_Gain_of_methylation_at_Q267_(P_=_0.031)&_Gain_of_catalytic_residue_at_Q267_(P_=_0.1754)&_Gain_of_sheet_(P_=_0.1945)&_Loss_of_loop_(P_=_0.2237)	P00439	0.97130	0.886	.	0.91388	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.72120	.	.	.	0.90584	.	.	0.97372	.	T	0.80610	0.791096329689	0.99840	.	10	0.92824	.	.	0.91255	.	.	16.0142	0.80222	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.93841	.	T/T	R	.	Q	C	518	0.74548	.	12	C0031485	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852857T>C	556296	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.81569	0.98317	D	0.99841	0.980393	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770765	12	103246635	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	8.017000	0.88732	0.665000	0.62972	1.138000	0.64695	102852857	T	.	rs778154939	.	.	11.570	9.399	7.651	9.354	.	.	.	0	-2	0	-46	0.00	0.00	0.06	0.00	PAH	0.00	exon-NM_001354304.2-8+42+start+136	556296	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs778154939	778154939	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,731	0	0	0	0	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
19	4117550	4117550	A	C	C	missense_variant	MODERATE	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	2/11	.	NM_030662.4:c.170T>G	NP_109587.1:p.Phe57Cys	417	170	57	F/C	tTt/tGt	rs121434497&CM061106&COSV53562150	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	MAP2K2	.	chr19:g.4117550A>C	.	.	.	.	.	.	pathogenic	0&0&1	1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.94347	0.501652	D	0.94268	0.482812	31	27.8	4.382493	4.018875	0.89834	0.82957	./.	D	0.92514	0.997825801372528	0.69100	0.99518764989457853	.	0.95260	.	./.	.	.	.	.	6.951003	0.652621707569109	0.78807	7.496391	0.725860457150591	0.81326	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.93532	.	.	.	4.14	4.14	0.47821	0	0.68747	0.697927	.	.	0.74766	0.99999996709992	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.71501	0.711	.	.	.	.	0.83579	.	0.000000	0.84330	D	0.000000	D	0.99171	0.890665	0.88233	.	0.95281	.	D	0.95762	0.8725	.	0.96865	.	D	0.97776	1.0331	F57C	Gain_of_catalytic_residue_at_L58_(P_=_0.0195)&_Loss_of_stability_(P_=_0.0723)&_Loss_of_ubiquitination_at_K61_(P_=_0.2014)&_Loss_of_MoRF_binding_(P_=_0.2346)&_Loss_of_methylation_at_K61_(P_=_0.2561)	P36507	0.92923	0.814	.	0.68882	.	.	0.81001	simple_aae&without_aae	A&A	1&1	0.90450	.	.	.	0.90584	.	.	0.92359	.	D	0.90671	0.857036530972	0.99346	.	9	0.44106	.	.	0.78490	.	.	12.1528	0.53364	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.90363	.	./.	C	.	F	C	940	0.13648	.	19	C3809007&C1275081&CN517202	615280&PS115150	ORPHA1340	Pathogenic	NC_000019.10:g.4117552A>C	8272	reviewed_by_expert_panel	Cardiofaciocutaneous_syndrome_4&Cardio-facio-cutaneous_syndrome&not_provided	OMIM_Allelic_Variant:601263.0001&ClinGen_RASopathy_Variant_Curation_Expert_Panel:07aecf91-9cf2-48c7-b101-b21e809f57a4&UniProtKB_(protein):P36507#VAR_035095	.	.	AEFDBI	D	0.93355	0.99244	D	0.96747	0.952208	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19	4068550	19	4117550	0	0.52595	0.67177	1.000000	0.71638	0.978000	0.57271	1.000000	0.86279	9.113000	0.93637	0.756000	0.94297	1.312000	0.94714	4117552	A	.	rs121434497	.	.	12.786	9.597	6.148	8.492	.	.	.	19	-11	1	-19	0.00	0.00	0.00	0.00	MAP2K2	0.86	exon-NM_030662.4-2+77+end+211	8272	Pathogenic	reviewed_by_expert_panel	not_provided&Cardiofaciocutaneous_syndrome_4&Cardio-facio-cutaneous_syndrome	MedGen:CN517202&MONDO:MONDO:0014114&MedGen:C3809007&OMIM:615280&Orphanet:1340&MONDO:MONDO:0015280&MedGen:C1275081&OMIM:PS115150&Orphanet:1340	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121434497	121434497	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:missense	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,939	0	1	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
10	89711892	89711892	T	A	A	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	6/9	.	NM_000314.8:c.510T>A	NP_000305.3:p.Ser170Arg	1355	510	170	S/R	agT/agA	rs121909221&CM109591&CM971275&COSV64295950	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89711892T>A	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.510T>R	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.96055	0.557809	D	0.95992	0.563477	27.1	26.3	4.010270	3.805448	0.78967	0.75630	./.	D	0.98435	0.999673128128052	0.90326	0.99820081102598035	.	0.99612	.	./.	.	.	.	.	7.399548	0.680309177994589	0.80887	8.163817	0.766700718622556	0.83987	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98866	.	.	.	5.74	4.6	0.56512	0	0.74545	0.702456	.	.	0.47345	0.999946836867284	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.98432	0.735409	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.99094	.	0.077988	0.84330	D	0.000000	D	0.99376	0.91581	0.97582	.	0.99738	.	D	0.99234	0.9754	.	0.99569	.	D	0.99920	1.1273	S170R	Gain_of_MoRF_binding_(P_=_0.0159)&_Loss_of_phosphorylation_at_S170_(P_=_0.0585)&_Loss_of_glycosylation_at_T167_(P_=_0.0989)&_Loss_of_disorder_(P_=_0.1588)&_Loss_of_catalytic_residue_at_R172_(P_=_0.1888)	P60484	0.97552	0.895	.	0.97446	.	.	0.81001	simple_aae	A	1	0.78807	.	.	.	0.90584	.	.	0.92359	.	D	0.93307	0.875228404999	0.99157	.	8	0.79402	.	.	0.91255	.	.	9.2896	0.36938	0.0:0.1395:0.0:0.8605	.	.	.	.	.	.	.	.	0.99973	.	./.	R	.	S	A	926	0.17793	.	10	CN072330&C1959582	158350	ORPHA306498	Likely_pathogenic	NC_000010.11:g.87952135T>A	7815	reviewed_by_expert_panel	Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	UniProtKB_(protein):P60484#VAR_007470&OMIM_Allelic_Variant:601728.0004&ClinGen_PTEN_Variant_Curation_Expert_Panel:67ade3e6-3038-4022-903b-9caf929577ba	.	.	AEFDGBCI	D	0.45403	0.86173	D	0.54624	0.522079	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89701872	10	89711892	0	0.85440	0.722319	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	2.790000	0.47512	0.609000	0.47794	1.138000	0.64695	87952135	T	.	rs121909221	.	.	6.460	9.066	10.752	10.998	.	.	.	-17	27	4	-2	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-7+17+start+142	7815	Pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909221	121909221	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,559	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
12	103240708	103240708	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	9/13	.	NM_000277.3:c.934G>C	NP_000268.1:p.Gly312Arg	1048	934	312	G/R	Ggt/Cgt	rs763115697&CM1310345	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103240708C>G	.	.	.	.	.	.	uncertain_significance	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.934G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.95165	0.529802	D	0.95093	0.523248	27.5	26.3	4.064625	3.799409	0.80854	0.75460	C/C	D	0.94534	0.998576641082764	0.99661	0.99937560880871268	.	0.99814	.	C/C	.	.	.	.	7.67866	0.696034047069495	0.82077	7.92315	0.752606181097362	0.83076	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99831	.	.	.	5.38	5.38	0.77279	0	0.45803	0.59043	.	.	0.74766	0.999999994855309	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.97507	.	0.000000	0.84330	D	0.000000	D	0.98620	0.82244	0.28073	.	0.97724	.	D	0.99762	0.9909	.	0.96920	.	D	0.96978	0.9873	G312R	Gain_of_methylation_at_G312_(P_=_0.0292)&_Gain_of_solvent_accessibility_(P_=_0.0306)&_Loss_of_catalytic_residue_at_A313_(P_=_0.0961)&_Gain_of_helix_(P_=_0.132)&_Gain_of_phosphorylation_at_S310_(P_=_0.155)	P00439	0.91726	0.797	.	0.71042	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95842	.	.	.	0.90584	.	.	0.97372	.	D	0.88245	0.840993821621	0.99058	.	10	0.83351	.	.	0.91255	.	.	19.1358	0.93413	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.95725	.	C/C	R	.	G	G	499	0.76092	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102846930C>G	619151	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.97394	0.99555	D	0.99826	0.979949	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101764838	12	103240708	0	0.43195	0.638212	1.000000	0.71638	0.807000	0.38039	0.995000	0.57719	7.565000	0.81337	0.595000	0.32841	1.023000	0.40393	102846930	C	.	rs763115697	.	.	7.709	9.491	9.506	11.083	.	.	.	21	-35	-35	21	0.22	0.00	0.12	0.00	PAH	0.00	exon-NM_001354304.2-10+21+end+57	619151	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,683	0	0	0	0	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
10	89711902	89711902	T	A	A	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	6/9	.	NM_000314.8:c.520T>A	NP_000305.3:p.Tyr174Asn	1365	520	174	Y/N	Tat/Aat	rs587782316&CM1411653&CM176427&COSV64288862&COSV64310637&COSV64311330	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89711902T>A	.	.	.	.	.	.	likely_pathogenic	0&0&0&1&1&1	1&1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.520T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.92766	0.456488	D	0.92677	0.417937	28.5	27.6	4.185505	3.995052	0.84984	0.82134	./.	D	0.98882	0.999769389629364	0.52906	0.99117534550993036	.	0.99584	.	./.	.	.	.	.	11.94353	0.854665728593585	0.93288	11.7304	0.925550402049872	0.92953	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98892	.	.	.	5.74	5.74	0.90070	0	0.74545	0.702456	.	.	0.74766	0.999999999987444	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.98432	0.735409	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.97927	.	0.119975	0.62929	D	0.000014	D	0.99345	0.912074	0.99179	.	0.96488	.	D	0.99401	0.9805	.	0.99309	.	D	0.98023	1.0455	Y174N	Loss_of_stability_(P_=_0.111)&_Gain_of_MoRF_binding_(P_=_0.1271)&_Gain_of_disorder_(P_=_0.1529)&_Gain_of_helix_(P_=_0.2294)&_Loss_of_phosphorylation_at_S170_(P_=_0.2662)	P60484	0.95433	0.854	.	0.96601	.	.	0.81001	simple_aae	D	1	0.96869	.	.	.	0.60036	.	.	0.64351	.	D	0.98716	0.925537884235	0.98921	.	9	0.74150	.	.	0.91255	.	.	16.0449	0.80517	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.99822	.	./.	N	.	Y	A	926	0.17793	.	10	C0027672&C1959582	.	ORPHA140162&ORPHA306498	Likely_pathogenic	NC_000010.11:g.87952145T>A	142220	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome	UniProtKB_(protein):P60484#VAR_026270&ClinGen_PTEN_Variant_Curation_Expert_Panel:58b7be5a-c98e-4344-9f4f-cff2dd70911d	.	.	AEFDGBCI	D	0.64243	0.95315	D	0.89352	0.920884	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89701882	10	89711902	0	0.85440	0.722319	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	7.568000	0.81546	0.609000	0.47794	1.138000	0.64695	87952145	T	.	rs587782316	.	.	6.460	9.066	10.752	10.998	.	.	.	-27	17	2	17	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-7+27+start+142	142220	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587782316	587782316	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,563	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
10	89717715	89717715	T	C	C	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	7/9	.	NM_000314.8:c.740T>C	NP_000305.3:p.Leu247Ser	1585	740	247	L/S	tTa/tCa	rs1057519368&CM170778&COSV64289211&COSV64294730&COSV64302434	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89717715T>C	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.92406	0.448327	D	0.92313	0.406214	29.4	27.5	4.277953	3.976357	0.87693	0.81457	./.	D	0.93161	0.998077511787415	0.95076	0.99873044957774337	.	0.98843	.	./.	.	.	.	.	7.498341	0.686016125707253	0.81318	7.507407	0.726578193015598	0.81373	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.86624	.	.	.	5.15	5.15	0.70287	0	0.82719	0.723133	.	.	0.74766	0.999999996024359	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.49550	0.631631	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	0.77317	.	0.000000	0.84330	D	0.000000	D	0.96099	0.569295	0.95915	.	0.96357	.	D	0.92712	0.7853	.	0.91023	.	D	0.93070	0.6916	L247S	Loss_of_catalytic_residue_at_L247_(P_=_0.0355)&_Loss_of_sheet_(P_=_0.0357)&_Gain_of_disorder_(P_=_0.0365)&_Gain_of_phosphorylation_at_L247_(P_=_0.118)&_Loss_of_stability_(P_=_0.2179)	P60484	0.87396	0.742	.	0.84822	.	.	0.81001	simple_aae	D	1	0.75058	.	.	.	0.90584	.	.	0.92359	.	D	0.89773	0.851050138474	0.97890	.	9	0.76473	.	.	0.72154	.	.	14.9657	0.70844	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.95139	.	./.	S	.	L	C	908	0.22609	.	10	C1854416&C1959582	605309	ORPHA210548&ORPHA306498	Likely_pathogenic	NC_000010.11:g.87957958T>C	223142	reviewed_by_expert_panel	Macrocephaly/autism_syndrome&PTEN_hamartoma_tumor_syndrome	ClinGen_PTEN_Variant_Curation_Expert_Panel:33e47859-5909-4f34-ac6c-c5bf41ab8544	.	.	AEFGBI	D	0.74176	0.97347	D	0.93137	0.935879	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89707695	10	89717715	0	0.83141	0.719381	1.000000	0.71638	0.985000	0.61073	0.999000	0.70432	7.615000	0.82207	0.609000	0.47794	1.138000	0.64695	87957958	T	.	rs1057519368	.	.	12.930	7.806	6.460	9.066	.	.	.	-4	44	22	-24	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-8+61+end+167	223142	Likely_pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Macrocephaly-autism_syndrome	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1057519368	1057519368	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,577	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
12	103246623	103246623	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.812A>G	NP_000268.1:p.His271Arg	926	812	271	H/R	cAt/cGt	rs199475692&CM113432&CM1511441	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103246623T>C	.	.	.	.	.	.	likely_pathogenic&not_provided	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.812A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.93926	0.487165	D	0.95933	0.558857	26.4	25.6	3.915083	3.663829	0.75762	0.71444	T/T	D	0.90511	0.996980607509613	0.91456	0.99832648286992764	.	0.99876	.	T/T	.	.	.	.	10.2299	0.803560832234733	0.90039	9.370412	0.828812573284087	0.87870	.	.	.	1	8.236e-06	0	0	0	0	1	8.237e-06	0	0	0	0	0	0	1	6.056e-05	1	9.415e-06	0	0	0	0	1	9.416e-06	0	0	0	0	0	0	1	6.095e-05	1	1.102e-05	0	0	0	0	1	1.102e-05	0	0	0	0	0	0	1	6.060e-05	0.99732	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999997298143	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.97886	.	0.000000	0.84330	D	0.000000	D	0.95434	0.520185	0.28250	.	0.99371	.	D	0.99616	0.9870	.	0.97704	.	D	0.97554	1.0211	H271R	Gain_of_MoRF_binding_(P_=_0.0332)&_Gain_of_phosphorylation_at_S273_(P_=_0.0644)&_Loss_of_sheet_(P_=_0.0817)&_Loss_of_catalytic_residue_at_I269_(P_=_0.0918)&_Gain_of_ubiquitination_at_K274_(P_=_0.1204)	P00439	0.95317	0.852	.	0.74443	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95542	.	.	.	0.90584	.	.	0.97372	.	D	0.82985	0.806698799133	0.99622	.	10	0.83351	.	.	0.91255	.	.	16.0142	0.80222	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.89353	.	T/T	R	.	H	C	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852845T>C	102850	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:H271R	.	.	AEFBI	D	0.81569	0.98317	D	0.99837	0.980276	.	1	3.978260e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34586	0	251366	0	0.000000e+00	10076	0	0	0.000000e+00	18392	0	0	0.000000e+00	21648	0	0	0.000000e+00	113658	0	1	3.266270e-05	30616	0	1	3.266270e-05	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	1	4.222470e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34254	0	236828	0	0.000000e+00	9568	0	0	0.000000e+00	17690	0	0	0.000000e+00	21632	0	0	0.000000e+00	102642	0	1	3.275900e-05	30526	0	1	3.275900e-05	30526	0	0	1	4.805100e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30522	0	208112	0	0.000000e+00	6212	0	0	0.000000e+00	13414	0	0	0.000000e+00	16734	0	0	0.000000e+00	89538	0	1	3.267120e-05	30608	0	1	3.267120e-05	30608	0	0	1	4.085840e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34452	0	244748	0	0.000000e+00	9994	0	0	0.000000e+00	18388	0	0	0.000000e+00	21646	0	0	0.000000e+00	111568	0	1	3.266270e-05	30616	0	1	3.266270e-05	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770753	12	103246623	0	0.43195	0.638212	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	8.017000	0.88732	0.665000	0.62972	1.138000	0.64695	102852845	T	.	rs199475692	.	.	11.570	9.399	7.651	9.354	.	.	.	10	12	-30	12	0.00	0.00	0.02	0.00	PAH	0.00	exon-NM_001354304.2-8+30+start+136	102850	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103246623-103246623	8.236e-06	1	1	0	0	0	0	0	0	0	1	10406	11570	8652	6614	66738	908	16512	0	0	0	0	0	0	1	0	0	0	0	0	0	0	rs199475692	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.24865e-05	0.00000e+00	8.98392e-06	3.24865e-05	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475692	199475692	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,723	0	0	0	0	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
10	89711882	89711882	C	A	A	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	6/9	.	NM_000314.8:c.500C>A	NP_000305.3:p.Thr167Asn	1345	500	167	T/N	aCt/aAt	rs397514559&CM124578&COSV100910397&COSV64291531&COSV64303272	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89711882C>A	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.81720	0.284762	D	0.81485	0.171265	25.3	26.4	3.674287	3.829772	0.68651	0.76429	./.	D	0.89608	0.996563613414764	0.60987	0.99360553328316203	.	0.98599	.	./.	.	.	.	.	11.35105	0.838160181109092	0.92305	10.09857	0.861309835791529	0.89741	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98648	.	.	.	5.74	5.74	0.90070	0	0.74545	0.702456	.	.	0.74766	0.999999999999992	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.98432	0.735409	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.90930	.	0.045733	0.84330	D	0.000000	D	0.98782	0.84234	0.97597	.	0.95334	.	D	0.99105	0.9715	.	0.92177	.	D	0.99439	1.0948	T167N	Gain_of_catalytic_residue_at_T167_(P_=_0.003)&_Loss_of_glycosylation_at_T167_(P_=_0.0273)&_Loss_of_methylation_at_K163_(P_=_0.0875)&_Gain_of_MoRF_binding_(P_=_0.1138)&_Gain_of_relative_solvent_accessibility_(P_=_0.1259)	P60484	0.39306	0.378	.	0.82355	.	.	0.81001	simple_aae	D	1	0.78807	.	.	.	0.77913	.	.	0.69585	.	D	0.87017	0.832960128784	0.91456	.	9	0.79402	.	.	0.91255	.	.	19.9308	0.97119	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.92784	.	./.	N	.	T	A	926	0.17793	.	10	C1854416&C1959582	605309	ORPHA210548&ORPHA306498	Likely_pathogenic	NC_000010.11:g.87952125C>A	39668	reviewed_by_expert_panel	Macrocephaly/autism_syndrome&PTEN_hamartoma_tumor_syndrome	OMIM_Allelic_Variant:601728.0042&ClinGen_PTEN_Variant_Curation_Expert_Panel:73986d71-3b36-4038-80e9-66da44231b6f&UniProtKB_(protein):P60484#VAR_076763	.	.	AEFDGBCI	D	0.66404	0.95846	D	0.88622	0.917913	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89701862	10	89711882	0	0.85440	0.722319	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	7.464000	0.79911	0.549000	0.26987	1.026000	0.45946	87952125	C	.	rs397514559	.	.	6.460	9.066	10.752	10.998	.	.	.	37	-7	-7	8	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-7+7+start+142	39668	Likely_pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Macrocephaly-autism_syndrome	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397514559	397514559	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,557	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
10	89692908	89692908	C	T	T	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.392C>T	NP_000305.3:p.Thr131Ile	1237	392	131	T/I	aCt/aTt	rs397514560&CM1212354&COSV64293891&COSV64295025&COSV64300549	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89692908C>T	.	.	.	.	.	.	pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.392dup	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.96660	0.572935	D	0.96605	0.585205	25.5	26.1	3.734558	3.774148	0.70315	0.74652	./.	D	0.93833	0.998326003551483	0.98022	0.99910252953282397	.	0.99463	.	./.	.	.	.	.	10.04168	0.797206795980103	0.89597	10.2799	0.868997803300442	0.90162	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99422	.	.	.	5.09	5.09	0.68647	0	0.70079	0.698795	.	.	0.74766	0.999999999999999	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.98899	.	0.101247	0.62929	D	0.000003	D	0.99082	0.879506	0.97221	.	0.99385	.	D	0.99616	0.9870	.	0.98639	.	D	0.97498	1.0180	T131I	Loss_of_methylation_at_R130_(P_=_0.1176)&_Gain_of_MoRF_binding_(P_=_0.1246)&_Loss_of_disorder_(P_=_0.129)&_Gain_of_helix_(P_=_0.1736)&_Loss_of_ubiquitination_at_K128_(P_=_0.32)	P60484	0.93655	0.825	.	0.87590	.	.	0.81001	simple_aae	D	1	0.88065	.	.	.	0.90584	.	.	0.92359	.	D	0.98471	0.921981811523	0.99518	.	9	0.92824	.	.	0.91255	.	.	18.493	0.90803	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99100	.	./.	I	.	T	T	940	0.13648	.	10	C1854416&C1959582	605309	ORPHA210548&ORPHA306498	Pathogenic	NC_000010.11:g.87933151C>T	39669	reviewed_by_expert_panel	Macrocephaly/autism_syndrome&PTEN_hamartoma_tumor_syndrome	ClinGen_PTEN_Variant_Curation_Expert_Panel:78613fd1-ded6-4249-b54d-0894617cf17d&OMIM_Allelic_Variant:601728.0043&UniProtKB_(protein):P60484#VAR_076762	.	.	AEFDGBIJ	D	0.72590	0.97083	D	0.78472	0.865588	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682888	10	89692908	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	7.510000	0.80594	0.599000	0.40250	1.026000	0.45946	87933151	C	.	rs397514560	.	.	10.752	10.998	5.352	9.651	.	.	.	50	-30	-22	10	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+100+end+239	39669	Pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Macrocephaly-autism_syndrome	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397514560	397514560	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,549	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
10	89692923	89692923	G	A	A	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.407G>A	NP_000305.3:p.Cys136Tyr	1252	407	136	C/Y	tGt/tAt	rs786204859&CD110173&CM983501&COSV64288670&COSV64294671	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89692923G>A	.	.	.	.	.	.	pathogenic	0&0&0&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.407G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.96925	0.575805	D	0.96875	0.589328	27.9	27.6	4.118556	3.988322	0.82733	0.81871	./.	D	0.97759	0.999520659446716	0.85172	0.99762586023359578	.	0.99529	.	./.	.	.	.	.	14.74338	0.922385517200514	0.96475	14.13659	1.00678048858334	0.95950	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98715	.	.	.	5.22	5.22	0.72285	0	0.70079	0.698795	.	.	0.74766	0.999999999999996	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.47523	.	0.000000	0.84330	D	0.000000	D	0.99416	0.920646	0.97924	.	0.97299	.	D	0.99444	0.9818	.	0.99766	.	D	0.97988	1.0438	C136Y	Gain_of_MoRF_binding_(P_=_0.0809)&_Gain_of_catalytic_residue_at_I135_(P_=_0.0916)&_Gain_of_phosphorylation_at_Y138_(P_=_0.2398)&_Gain_of_disorder_(P_=_0.6293)&_Loss_of_helix_(P_=_0.6555)	P60484	0.98533	0.919	.	0.94693	.	.	0.81001	simple_aae	D	1	0.97901	.	.	.	0.90584	.	.	0.92359	.	D	0.99414	0.938915014267	0.99740	.	9	0.83351	.	.	0.58626	.	.	18.7776	0.91883	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.94077	.	./.	Y	.	C	A	940	0.13648	.	10	C0027672&C1959582&CN517202	.	ORPHA140162&ORPHA306498	Pathogenic	NC_000010.11:g.87933166G>A	189406	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	UniProtKB_(protein):P60484#VAR_007808	.	.	AEFGBI	D	0.83480	0.98504	D	0.98209	0.961027	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682903	10	89692923	0	0.85440	0.722319	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	9.525000	0.97093	0.676000	0.76740	1.176000	0.78918	87933166	G	.	rs786204859	.	.	10.752	10.998	5.352	9.651	.	.	.	42	-45	-11	-37	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+85+end+239	189406	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786204859	786204859	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,551	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
12	103260410	103260410	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.473G>C	NP_000268.1:p.Arg158Pro	587	473	158	R/P	cGg/cCg	rs5030843&CM015340&CM890093&COSV61019642	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103260410C>G	.	.	.	.	.	.	uncertain_significance&not_provided	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.473G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.95641	0.546074	D	0.95975	0.562107	29.3	28.0	4.273344	4.034703	0.87566	0.83509	C/C	D	0.93889	0.998346328735352	0.83629	0.99742754814571633	.	0.99998	.	C/C	.	.	.	.	11.20415	0.833890981720758	0.92042	11.93077	0.93280768020157	0.93272	.	.	.	1	8.237e-06	0	0	0	0	1	8.247e-06	0	0	0	0	1	1.500e-05	0	0	1	9.415e-06	0	0	0	0	1	9.429e-06	0	0	0	0	1	1.842e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99786	.	.	.	6.08	5.17	0.70848	0	0.26702	0.573888	.	.	0.15965	0.0848159718721622	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.98139	.	0.046743	0.84330	D	0.000000	D	0.98562	0.815387	0.29707	.	0.99141	.	D	0.99862	0.9940	.	0.99967	.	D	0.96007	0.9234	R158P	Loss_of_MoRF_binding_(P_=_0.005)&_Loss_of_methylation_at_K159_(P_=_0.0791)&_Loss_of_stability_(P_=_0.0815)&_Gain_of_glycosylation_at_R158_(P_=_0.152)&_Gain_of_phosphorylation_at_Y154_(P_=_0.1608)	P00439	0.99860	0.986	.	0.98900	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.92825	.	.	.	0.90584	.	.	0.97372	.	T	0.78410	0.776558578014	0.99858	.	10	0.83351	.	.	0.91255	.	.	14.6498	0.68393	0.0:0.8551:0.1449:0.0	.	.	.	.	.	.	.	.	0.99337	.	C/C	P	.	R	G	700	0.57880	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102866632C>G	102694	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.R158P	.	.	AEFBI	D	0.69560	0.96522	D	0.99601	0.975134	.	2	7.956590e-06	0	0.000000e+00	16254	0	0	0.000000e+00	34558	0	251364	0	0.000000e+00	10072	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	2	1.759170e-05	113690	0	2	1.759170e-05	113690	0	0	0.000000e+00	30616	0	2	1.828290e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17102	0	109392	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13392	0	2	4.676610e-05	42766	0	2	4.676610e-05	42766	0	0	0.000000e+00	15690	0	0	.	0	2	8.445020e-06	0	0.000000e+00	14900	0	0	0.000000e+00	34226	0	236826	0	0.000000e+00	9564	0	0	0.000000e+00	17688	0	0	0.000000e+00	21630	0	2	1.947910e-05	102674	0	2	1.947910e-05	102674	0	0	0.000000e+00	30526	0	0	2	9.611690e-06	0	0.000000e+00	16216	0	0	0.000000e+00	30492	0	208080	0	0.000000e+00	6208	0	0	0.000000e+00	13412	0	0	0.000000e+00	16732	0	2	2.233490e-05	89546	0	2	2.233490e-05	89546	0	0	0.000000e+00	30608	0	0	2	8.171740e-06	0	0.000000e+00	12024	0	0	0.000000e+00	34424	0	244746	0	0.000000e+00	9990	0	0	0.000000e+00	18386	0	0	0.000000e+00	21644	0	2	1.792110e-05	111600	0	2	1.792110e-05	111600	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101784540	12	103260410	0	0.43195	0.638212	1.000000	0.71638	0.967000	0.53440	0.932000	0.39996	5.240000	0.65201	0.599000	0.40250	1.026000	0.45946	102866632	C	.	rs5030843	.	.	7.292	9.092	8.810	7.211	.	.	.	49	31	31	-36	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-6+31+end+68	102694	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	rs5030843	8.237e-06	1	0	0	0	0	0	0	1	0	0	10406	11504	8646	6604	66680	908	16508	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs5030843	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79163e-05	0.00000e+00	0.00000e+00	7.41708e-06	8.98392e-06	1.79163e-05	8.12123e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs5030843	5030843	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,789	0	0	0	0	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
12	103260419	103260419	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.464G>C	NP_000268.1:p.Arg155Pro	578	464	155	R/P	cGt/cCt	rs199475663&CM000544&CM981433&COSV61016854	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103260419C>G	.	.	.	.	.	.	uncertain_significance&likely_pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.464G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.96023	0.556063	D	0.95961	0.560969	28.1	29.4	4.134687	4.190072	0.83289	0.88025	C/C	D	0.97549	0.999471366405487	0.84537	0.99754294231330187	.	0.99987	.	C/C	.	.	.	.	17.24747	0.972461078841844	0.98019	15.39917	1.04498702937521	0.96970	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99786	.	.	.	6.08	6.08	0.98982	0	0.26702	0.573888	.	.	0.33875	0.994943344109113	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.95079	.	0.000000	0.84330	D	0.000000	D	0.98828	0.848081	0.29707	.	0.99254	.	D	0.99867	0.9942	.	0.99978	.	D	0.96579	0.9622	R155P	Loss_of_MoRF_binding_(P_=_0.001)&_Loss_of_catalytic_residue_at_R155_(P_=_0.0562)&_Loss_of_helix_(P_=_0.079)&_Gain_of_loop_(P_=_0.1069)&_Loss_of_phosphorylation_at_Y154_(P_=_0.1145)	P00439	0.99553	0.958	.	0.98503	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.91741	.	.	.	0.90584	.	.	0.92359	.	T	0.66638	0.696494579315	0.99571	.	10	0.79402	.	.	0.91255	.	.	17.8194	0.88557	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99100	.	C/C	P	.	R	G	700	0.57880	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102866641C>G	102687	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.R155P&UniProtKB_(protein):P00439#VAR_009242	.	.	AEFBI	D	0.73672	0.97265	D	0.99677	0.976510	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101784549	12	103260419	0	0.43195	0.638212	1.000000	0.71638	0.925000	0.46118	0.862000	0.35736	5.240000	0.65201	0.599000	0.40250	1.026000	0.45946	102866641	C	.	rs199475663	.	.	7.292	9.092	8.810	7.211	.	.	.	40	22	-49	-45	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-6+22+end+68	102687	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475663	199475663	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,793	0	0	0	0	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0.9749	Likely Pathogenic
10	89717730	89717730	A	G	G	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	7/9	.	NM_000314.8:c.755A>G	NP_000305.3:p.Asp252Gly	1600	755	252	D/G	gAt/gGt	rs121909239&CM051216&CM159947&COSV64289881&COSV64296805&COSV64297163	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89717730A>G	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&0&0&1&1&1	1&1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.755A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.96632	0.571327	D	0.96576	0.582895	29.9	28.3	4.337676	4.064557	0.89037	0.84478	./.	D	0.91964	0.997605800628662	0.94366	0.9986533399932005	.	0.99470	.	./.	.	.	.	.	8.123364	0.718987968186161	0.83823	7.941734	0.753721706774602	0.83147	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99204	.	.	.	5.15	5.15	0.70287	0	0.89359	0.724815	.	.	0.74766	0.999999999871693	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.49550	0.631631	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	0.90777	.	0.092939	0.84330	D	0.000001	D	0.99277	0.90365	0.98348	.	0.99401	.	D	0.99218	0.9749	.	0.97926	.	D	0.98856	1.0792	D252G	Loss_of_ubiquitination_at_K254_(P_=_0.0432)&_Loss_of_stability_(P_=_0.0555)&_Gain_of_catalytic_residue_at_P248_(P_=_0.0665)&_Loss_of_sheet_(P_=_0.1398)&_Gain_of_loop_(P_=_0.2754)	P60484	0.95142	0.849	.	0.90016	.	.	0.81001	simple_aae	A	1	0.91564	.	.	.	0.62824	.	.	0.61339	.	D	0.97737	0.912896096706	0.99671	.	8	0.65728	.	.	0.91255	.	.	14.9657	0.70844	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99822	.	./.	G	.	D	G	908	0.22609	.	10	C1854416&C1959582&CN517202	605309	ORPHA210548&ORPHA306498	Likely_pathogenic	NC_000010.11:g.87957973A>G	7849	reviewed_by_expert_panel	Macrocephaly/autism_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	UniProtKB_(protein):P60484#VAR_032637&OMIM_Allelic_Variant:601728.0038&ClinGen_PTEN_Variant_Curation_Expert_Panel:d7efe33c-ab88-4472-ad12-90db0ed372bf	.	.	AEFGBI	D	0.81395	0.98299	D	0.97015	0.953662	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89707710	10	89717730	0	0.61202	0.706298	1.000000	0.71638	0.991000	0.66497	0.998000	0.65909	8.875000	0.92004	0.691000	0.84096	1.312000	0.94714	87957973	A	.	rs121909239	.	.	12.930	7.806	6.460	9.066	.	.	.	29	12	-39	46	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-8+46+end+167	7849	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome&Macrocephaly-autism_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909239	121909239	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,578	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
10	89692993	89692993	G	T	T	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.477G>T	NP_000305.3:p.Arg159Ser	1322	477	159	R/S	agG/agT	rs1057519724&COSV64288957&COSV64298985	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89692993G>T	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&1&1	1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.477G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.97381	0.593855	D	0.97338	0.615255	32	31	4.495318	4.334318	0.91199	0.90464	./.	D	0.97351	0.999427318572998	0.87928	0.99793677671318215	.	0.99613	.	./.	.	.	.	.	13.71255	0.899072382856997	0.95532	13.67096	0.991939982548988	0.95492	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99760	.	.	.	5.09	5.09	0.68647	0	0.70079	0.698795	.	.	0.74766	0.999999999999966	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.89869	.	0.000000	0.84330	D	0.000000	D	0.99128	0.885239	0.97613	.	0.99500	.	D	0.99867	0.9942	.	0.98512	.	D	0.95971	0.9209	R159S	Gain_of_glycosylation_at_R159_(P_=_0.0328)&_Gain_of_ubiquitination_at_K163_(P_=_0.0497)&_Loss_of_MoRF_binding_(P_=_0.0683)&_Gain_of_methylation_at_K163_(P_=_0.0732)&_Gain_of_disorder_(P_=_0.0766)	P60484	0.94783	0.843	.	0.97575	.	.	0.81001	simple_aae	D	1	0.88065	.	.	.	0.90584	.	.	0.88582	.	D	0.95467	0.891667723656	0.99858	.	9	0.92824	.	.	0.91255	.	.	18.493	0.90803	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.99100	.	./.	S	.	R	T	940	0.13648	.	10	C1458155&C0009404&C1959582	.	ORPHA306498	Likely_pathogenic	NC_000010.11:g.87933236G>T	375959	reviewed_by_expert_panel	Breast_neoplasm&Neoplasm_of_the_large_intestine&PTEN_hamartoma_tumor_syndrome	ClinGen_PTEN_Variant_Curation_Expert_Panel:6ba47371-001e-4be9-8252-885e7e1a5f99	.	.	AEFBI	D	0.91875	0.99144	D	0.94207	0.940299	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682973	10	89692993	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	9.525000	0.97093	0.676000	0.76740	1.176000	0.78918	87933236	G	.	rs1057519724	.	.	10.752	10.998	5.352	9.651	.	.	.	-35	0	-6	15	0.00	0.00	0.25	0.01	PTEN	0.98	exon-NM_001304717.5-6+15+end+239	375959	Likely_pathogenic	reviewed_by_expert_panel	Neoplasm_of_the_large_intestine&Breast_neoplasm&PTEN_hamartoma_tumor_syndrome	Human_Phenotype_Ontology:HP:0100834&MONDO:MONDO:0005335&MeSH:D015179&MedGen:C0009404&Human_Phenotype_Ontology:HP:0010623&Human_Phenotype_Ontology:HP:0100013&MONDO:MONDO:0021100&MeSH:D001943&MedGen:C1458155&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1057519724	1057519724	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,554	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
1	216246634	216246634	C	T	T	missense_variant	MODERATE	USH2A	7399	Transcript	NM_206933.4	protein_coding	28/72	.	NM_206933.4:c.5581G>A	NP_996816.3:p.Gly1861Ser	6020	5581	1861	G/S	Ggt/Agt	rs375668376&CM135008	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	USH2A	.	chr1:g.216246634C>T	.	.	.	.	.	.	pathogenic&likely_pathogenic	.	1&1	.	.	.	.	.	USH2A&NM_206933.2&c.5581G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0.0	.	.	.	.	.	.	.	C/C	C	D	0.70288	0.160939	D	0.85991	0.25783	25.6	32	3.747547	4.440490	0.70682	0.91442	C/C	D	0.88560	0.996045053005219	0.96359	0.99889404714403263	.	0.84434	.	C/C	1	2.2696323195642307E-4	0	0.0	11.58451	0.844790202970767	0.92708	10.56314	0.880685783135845	0.90782	.	.	.	1	8.238e-06	0	0	0	0	1	8.313e-06	1	1.167e-04	0	0	0	0	0	0	1	9.418e-06	0	0	0	0	1	9.502e-06	1	1.285e-04	0	0	0	0	0	0	1	1.102e-05	0	0	0	0	1	1.114e-05	1	1.801e-04	0	0	0	0	0	0	0.98487	.	.	.	5.93	5.93	0.95888	0	0.26702	0.573888	.	.	0.74766	0.999999942335605	.	0	0.23631	0.573888	.	.	.	.	.	.	0	0.26826	0.564101	Laminin_G_domain&Laminin_G_domain&Laminin_G_domain	.	.	.	0.58094	.	0.000000	0.45700	D	0.000322	D	0.99341	0.911581	0.25167	.	0.74576	.	D	0.99058	0.9701	.	0.94458	.	D	0.99542	1.0972	.	.	.	.	.	.	0.89746	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.73893	.	.	.	0.90584	.	.	0.97372	.	T	0.32785	0.456163227558	0.92908	.	10	0.92824	.	.	0.91255	.	.	20.3507	0.98814	0.0:1.0:0.0:0.0	.	1	2.6968716289104636E-4	1	1.322401481089659E-4	.	.	.	0.93605	.	C/C	S	.	G	T	722	0.55239	.	1	C0854723&C1848634&C3151138&C0271097&CN517202&CN826980	276901&613809&PS276900	ORPHA71862&ORPHA886&ORPHA96210	Pathogenic	NC_000001.11:g.216073292C>T	48535	reviewed_by_expert_panel	Retinal_dystrophy&Usher_syndrome&_type_2A&Retinitis_pigmentosa_39&Usher_syndrome&not_provided&Rare_genetic_deafness	UniProtKB_(protein):O75445#VAR_072008	.	.	AEFDI	D	0.75872	0.97608	D	0.69898	0.761186	.	3	1.198960e-05	0	0.000000e+00	16212	0	0	0.000000e+00	34428	0	250216	0	0.000000e+00	10048	0	3	1.636840e-04	18328	0	0	0.000000e+00	21614	0	0	0.000000e+00	112914	0	3	1.636840e-04	18328	0	0	0.000000e+00	30584	0	1	9.154490e-06	0	0.000000e+00	7144	0	0	0.000000e+00	17070	0	109236	0	0.000000e+00	2320	0	1	1.108890e-04	9018	0	0	0.000000e+00	13384	0	0	0.000000e+00	42714	0	1	1.108890e-04	9018	0	0	0.000000e+00	15678	0	0	.	0	3	1.272520e-05	0	0.000000e+00	14876	0	0	0.000000e+00	34096	0	235752	0	0.000000e+00	9542	0	3	1.701840e-04	17628	0	0	0.000000e+00	21598	0	0	0.000000e+00	101948	0	3	1.701840e-04	17628	0	0	0.000000e+00	30494	0	0	2	9.634470e-06	0	0.000000e+00	16174	0	0	0.000000e+00	30368	0	207588	0	0.000000e+00	6204	0	2	1.498130e-04	13350	0	0	0.000000e+00	16700	0	0	0.000000e+00	89376	0	2	1.498130e-04	13350	0	0	0.000000e+00	30576	0	0	3	1.231470e-05	0	0.000000e+00	11996	0	0	0.000000e+00	34294	0	243612	0	0.000000e+00	9966	0	3	1.637200e-04	18324	0	0	0.000000e+00	21612	0	0	0.000000e+00	110824	0	3	1.637200e-04	18324	0	0	0.000000e+00	30584	0	0	2	1.321270e-05	1	2.431320e-05	41130	0	0	0.000000e+00	910	0	0	0.000000e+00	15126	0	151370	0	0.000000e+00	3464	0	1	1.974720e-04	5064	0	0	0.000000e+00	10574	0	0	0.000000e+00	316	0	0	0.000000e+00	67948	0	1	1.974720e-04	5064	0	0	0.000000e+00	4750	0	1	3.062600e-05	1	1.113090e-04	8984	0	0	0.000000e+00	58	0	0	0.000000e+00	4660	0	32652	0	0.000000e+00	136	0	0	0.000000e+00	2404	0	0	0.000000e+00	5468	0	0	0.000000e+00	246	0	0	0.000000e+00	6840	0	0	0.000000e+00	3070	0	0	.	0	2	1.359450e-05	1	2.450380e-05	40810	0	0	0.000000e+00	910	0	0	0.000000e+00	14942	0	147118	0	0.000000e+00	3294	0	1	2.070390e-04	4830	0	0	0.000000e+00	10574	0	0	0.000000e+00	304	0	0	0.000000e+00	64718	0	0	0.000000e+00	4718	0	0	2	1.491400e-05	1	3.098470e-05	32274	0	0	0.000000e+00	860	0	0	0.000000e+00	14682	0	134102	0	0.000000e+00	3382	0	1	1.974720e-04	5064	0	0	0.000000e+00	6944	0	0	0.000000e+00	310	0	0	0.000000e+00	63840	0	0	0.000000e+00	4748	0	0	1	1.250060e-05	1	4.078300e-05	24520	0	0	0.000000e+00	110	0	0	0.000000e+00	12756	0	79996	0	0.000000e+00	992	0	0	0.000000e+00	3622	0	0	0.000000e+00	10482	0	0	0.000000e+00	272	0	0	0.000000e+00	21006	0	0	0.000000e+00	4722	0	0	1	214313257	1	216246634	0	0.14033	0.487112	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	4.591000	0.60729	0.599000	0.40250	1.026000	0.45946	216073292	C	.	rs375668376	.	.	6.084	9.429	5.468	10.998	.	.	.	-2	8	-2	-30	0.05	0.04	0.00	0.00	USH2A	0.00	exon-NM_206933.4-28+8+end+204	48535	Pathogenic	reviewed_by_expert_panel	Rare_genetic_deafness&Usher_syndrome&Retinal_dystrophy&not_provided&Usher_syndrome_type_2A&Retinitis_pigmentosa_39	MedGen:CN826980&Orphanet:96210&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&Human_Phenotype_Ontology:HP:0000556&Human_Phenotype_Ontology:HP:0007736&Human_Phenotype_Ontology:HP:0007910&Human_Phenotype_Ontology:HP:0007974&Human_Phenotype_Ontology:HP:0007982&MONDO:MONDO:0019118&MeSH:D058499&MedGen:C0854723&Orphanet:71862&MedGen:CN517202&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886&MONDO:MONDO:0013436&MedGen:C3151138&OMIM:613809&Orphanet:791	.	1:216246634-216246634	8.238e-06	1	1	0	0	0	1	0	0	0	0	10280	11330	8570	6546	66286	898	16390	0	0	1	0	0	0	0	0	0	0	0	0	0	0	rs375668376	0.00000e+00	0.00000e+00	0.00000e+00	1.74581e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.23490e-05	0.00000e+00	1.74581e-04	1.21837e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	rs375668376	0.0&0.0227&0.0077	rs375668376	375668376	.	.	.	USH2A\x3bLOC102723833	USH2A:exonic\x7cLOC102723833:ncRNA_intronic	USH2A:missense	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,453	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
10	89711927	89711927	T	C	C	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	6/9	.	NM_000314.8:c.545T>C	NP_000305.3:p.Leu182Ser	1390	545	182	L/S	tTa/tCa	rs794729664&CM110161&CM115999&COSV104677089&COSV64292171	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89711927T>C	.	.	.	.	.	.	pathogenic&uncertain_significance	0&0&0&1&1	1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.96045	0.557375	D	0.95984	0.562854	28.1	27.1	4.143014	3.931218	0.83581	0.79868	./.	D	0.81877	0.991563320159912	0.94989	0.9987199773420703	.	0.98241	.	./.	.	.	.	.	8.77187	0.748782808112522	0.86064	8.126079	0.764532166661146	0.83846	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98979	.	.	.	5.73	5.73	0.89730	0	0.74545	0.702456	.	.	0.74766	0.999999999986936	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.98432	0.735409	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.81072	.	0.000000	0.84330	D	0.000000	D	0.98665	0.827904	0.95671	.	0.99717	.	D	0.99071	0.9705	.	0.94739	.	D	0.99191	1.0888	L182S	Loss_of_stability_(P_=_0.0047)&_Gain_of_disorder_(P_=_0.0536)&_Gain_of_methylation_at_K183_(P_=_0.0851)&_Loss_of_ubiquitination_at_K183_(P_=_0.1704)&_Gain_of_helix_(P_=_0.2684)	P60484	0.85931	0.725	.	0.86425	.	.	0.81001	simple_aae	D	1	0.74051	.	.	.	0.67487	.	.	0.58796	.	D	0.95245	0.889877319336	0.99695	.	9	0.76473	.	.	0.72154	.	.	16.0287	0.80362	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.99410	.	./.	S	.	L	C	926	0.17793	.	10	CN072330&C1854416&C1959582	158350&605309	ORPHA210548&ORPHA306498	Uncertain_significance	NC_000010.11:g.87952170T>C	187827	reviewed_by_expert_panel	Cowden_syndrome_1&Macrocephaly/autism_syndrome&PTEN_hamartoma_tumor_syndrome	ClinGen_PTEN_Variant_Curation_Expert_Panel:37c0f7de-70de-4f9e-93c7-c0ada6770ecc	.	.	AEDGBCI	D	0.67266	0.96041	D	0.86301	0.908120	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89701907	10	89711927	0	0.85440	0.722319	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	7.568000	0.81546	0.609000	0.47794	1.138000	0.64695	87952170	T	.	rs794729664	.	.	6.460	9.066	10.752	10.998	.	.	.	-8	22	-8	-37	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-7+52+start+142	187827	Uncertain_significance	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1&Macrocephaly-autism_syndrome	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs794729664	794729664	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,566	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
10	89692847	89692847	T	C	C	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.331T>C	NP_000305.3:p.Trp111Arg	1176	331	111	W/R	Tgg/Cgg	rs398123321&CM014084&COSV100911417&COSV64288542&COSV64290246	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89692847T>C	.	.	.	.	.	.	likely_pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.331T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.96298	0.563049	D	0.96239	0.571004	29.2	27.2	4.255447	3.937264	0.87088	0.80094	./.	D	0.95344	0.998840034008026	0.75716	0.99626045421232023	.	0.99410	.	./.	.	.	.	.	8.017061	0.713723353814256	0.83421	8.244189	0.771264161971411	0.84280	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98594	.	.	.	5.07	5.07	0.68106	0	0.70079	0.698795	.	.	0.74766	0.999999999999151	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.35895	.	0.000000	0.84330	D	0.000000	D	0.98433	0.799795	0.99306	.	0.97720	.	D	0.99122	0.9720	.	0.99740	.	D	0.98910	1.0809	W111R	Gain_of_disorder_(P_=_0.003)&_Gain_of_phosphorylation_at_S113_(P_=_0.1117)&_Loss_of_helix_(P_=_0.1299)&_Gain_of_relative_solvent_accessibility_(P_=_0.2363)&_Gain_of_solvent_accessibility_(P_=_0.2455)	P60484	0.97944	0.904	.	0.96017	.	.	0.81001	simple_aae	D	1	0.99740	.	.	.	0.51611	.	.	0.60432	.	D	0.99494	0.941041469574	0.99405	.	9	0.92824	.	.	0.54683	.	.	14.8407	0.69852	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.97317	.	./.	R	.	W	C	940	0.13648	.	10	CN072330&C1959582&CN517202	158350	ORPHA306498	Likely_pathogenic	NC_000010.11:g.87933090T>C	92820	reviewed_by_expert_panel	Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome&not_provided	HGMD:CM014084&ClinGen_PTEN_Variant_Curation_Expert_Panel:59486401-1daa-48dc-813f-bde6605d8cfd	.	.	AEFDGBI	D	0.76612	0.97715	D	0.87142	0.911741	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682827	10	89692847	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	7.611000	0.82163	0.665000	0.62972	1.138000	0.64695	87933090	T	.	rs398123321	.	.	10.752	10.998	5.352	9.651	.	.	.	-11	31	39	6	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+77+start+239	92820	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Hereditary_cancer-predisposing_syndrome&Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	MedGen:CN517202&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs398123321	398123321	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,541	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.9749	Likely Pathogenic
11	534286	534286	C	A	A	missense_variant	MODERATE	HRAS	3265	Transcript	NM_005343.4	protein_coding	2/6	.	NM_005343.4:c.37G>T	NP_005334.1:p.Gly13Cys	251	37	13	G/C	Ggt/Tgt	rs104894228&CM060018&COSV54236651&COSV54236730&COSV54241641	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	HRAS	.	chr11:g.534286C>A	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	LRRC56&NM_198075.3&c.-3741C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.87407	0.362045	D	0.87244	0.282276	23.1	23.0	2.821745	2.754886	0.48202	0.49316	C/C	D	0.93453	0.998182415962219	0.70025	0.99533098961827582	.	0.98531	.	C/C	.	.	.	.	2.973952	0.155553100956765	0.47437	3.679755	0.280380557955162	0.55153	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.73949	.	.	.	3.0	3.0	0.33773	0	0.66316	0.685571	.	.	0.74766	0.99999999999891	.	0	0.99655	0.851219	.	.	.	.	.	.	0	0.57140	0.638787	.&Small_GTP-binding_protein_domain&.&Small_GTP-binding_protein_domain&Small_GTP-binding_protein_domain	.	.	.	.	.	0.000000	0.84330	D	0.000000	D	0.93939	0.428737	0.93810	.	0.94056	.	T	0.80296	0.4836	.	0.99512	.	D	0.89598	0.4339	G13C	Loss_of_disorder_(P_=_0.0963)&_Loss_of_ubiquitination_at_K16_(P_=_0.1037)&_Loss_of_methylation_at_K16_(P_=_0.1557)&_Loss_of_helix_(P_=_0.2271)&_Loss_of_sheet_(P_=_0.302)	P01112	0.99599	0.961	.	0.72568	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D	1&1&1&1&1	0.95696	.	.	.	0.44460	.	.	0.46037	.	D	0.94104	0.881068646908	0.91198	.	9	0.92824	.	.	0.91255	.	.	14.1517	0.64924	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.91276	.	C/C	C	.	G	A	889	0.27310	.	11	C2239176&C0023467&C0027651&C0023434&C1842036&C0281361&C0206682&C0553723&C0279680&C0026764&C1458155&C0334082&C4552097&C0151779&C0152013&C0149782&C0007873&C0278701&C0040136&C0009404&C0005684&C0587248&C1168401&C0028326&CN260604&CN166718&C0153574&CN517202	114550&601626&151400&137550&188470&254500&162900&163200&109800&218040&275355&PS163950	ORPHA88673&ORPHA519&ORPHA67038&ORPHA626&ORPHA29073&ORPHA2612&ORPHA100087&ORPHA157980&ORPHA3071&ORPHA648&ORPHA98733&ORPHA536391	Pathogenic	NC_000011.10:g.534286C>A	12606	reviewed_by_expert_panel	Hepatocellular_carcinoma&Acute_myeloid_leukemia&Neoplasm&B-cell_chronic_lymphocytic_leukemia&Large_congenital_melanocytic_nevus&Pancreatic_adenocarcinoma&Thyroid_cancer&_nonmedullary&_2&Squamous_cell_carcinoma_of_the_skin&Transitional_cell_carcinoma_of_the_bladder&Multiple_myeloma&Breast_neoplasm&Epidermal_nevus&Linear_sebaceous_nevus_sequence&Malignant_melanoma_of_skin&Lung_adenocarcinoma&Squamous_cell_lung_carcinoma&Neoplasm_of_uterine_cervix&Adenocarcinoma_of_stomach&Neoplasm_of_the_thyroid_gland&Neoplasm_of_the_large_intestine&Malignant_tumor_of_urinary_bladder&Costello_syndrome&Squamous_cell_carcinoma_of_the_head_and_neck&Noonan_syndrome&Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&Malignant_neoplasm_of_body_of_uterus&not_provided	OMIM_Allelic_Variant:190020.0007&UniProtKB_(protein):P01112#VAR_026107&ClinGen_RASopathy_Variant_Curation_Expert_Panel:77fd6395-3146-46f0-86ca-08fb626eb660	.	.	AEFDBI	D	0.95489	0.99396	D	0.95540	0.946207	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11	524286	11	534286	0	0.99359	0.766844	1.000000	0.71638	0.292000	0.24309	0.395000	0.25599	6.086000	0.71002	0.599000	0.40250	1.026000	0.45946	534286	C	.	rs104894228	.	.	10.582	8.703	5.136	11.453	.	.	.	50	21	-2	0	0.00	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-2+74+start+164	12606	Pathogenic	reviewed_by_expert_panel	Linear_nevus_sebaceous_syndrome&Thyroid_cancer&_nonmedullary&_2&Epidermal_nevus&Costello_syndrome&Large_congenital_melanocytic_nevus&Malignant_tumor_of_urinary_bladder&Neoplasm&Noonan_syndrome_and_Noonan-related_syndrome&Thyroid_tumor&Gastric_adenocarcinoma&Neoplasm_of_the_large_intestine&Neoplasm_of_uterine_cervix&Malignant_neoplasm_of_body_of_uterus&Breast_neoplasm&Pancreatic_adenocarcinoma&not_provided&B-cell_chronic_lymphocytic_leukemia&Multiple_myeloma&RASopathy&Noonan_syndrome&Acute_myeloid_leukemia&Hepatocellular_carcinoma&Squamous_cell_lung_carcinoma&Malignant_melanoma_of_skin&Lung_adenocarcinoma&Squamous_cell_carcinoma_of_the_head_and_neck&Squamous_cell_carcinoma_of_the_skin&Transitional_cell_carcinoma_of_the_bladder	Human_Phenotype_Ontology:HP:0010817&MONDO:MONDO:0008097&MedGen:C4552097&OMIM:163200&Orphanet:2612&MONDO:MONDO:0008566&MedGen:C4225426&OMIM:188470&Human_Phenotype_Ontology:HP:0010816&MONDO:MONDO:0008093&MedGen:C0334082&OMIM:162900&Orphanet:79414&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071&Human_Phenotype_Ontology:HP:0005600&Human_Phenotype_Ontology:HP:0005604&MONDO:MONDO:0044792&MedGen:C1842036&OMIM:137550&Orphanet:626&MONDO:MONDO:0001187&MedGen:C0005684&OMIM:109800&Orphanet:157980&Human_Phenotype_Ontology:HP:0002664&Human_Phenotype_Ontology:HP:0003008&Human_Phenotype_Ontology:HP:0006741&MONDO:MONDO:0005070&MeSH:D009369&MedGen:C0027651&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&Human_Phenotype_Ontology:HP:0100031&MONDO:MONDO:0015074&MeSH:D013964&MedGen:C0040136&Orphanet:100087&Human_Phenotype_Ontology:HP:0033770&MONDO:MONDO:0005036&MedGen:C0278701&Orphanet:464463&Human_Phenotype_Ontology:HP:0100834&MONDO:MONDO:0005335&MeSH:D015179&MedGen:C0009404&Human_Phenotype_Ontology:HP:0032241&MONDO:MONDO:0021230&MeSH:D002583&MedGen:C0007873&MedGen:C0153574&Human_Phenotype_Ontology:HP:0010623&Human_Phenotype_Ontology:HP:0100013&MONDO:MONDO:0021100&MeSH:D001943&MedGen:C1458155&Human_Phenotype_Ontology:HP:0006725&MONDO:MONDO:0006047&MedGen:C0281361&MedGen:CN517202&Human_Phenotype_Ontology:HP:0005550&Human_Phenotype_Ontology:HP:0006734&Human_Phenotype_Ontology:HP:0006760&MONDO:MONDO:0004948&MeSH:D015451&MedGen:C0023434&OMIM:151400&Orphanet:67038&Human_Phenotype_Ontology:HP:0006775&MONDO:MONDO:0009693&MeSH:D009101&MedGen:C0026764&OMIM:254500&Orphanet:29073&Orphanet:85443&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0018997&MeSH:D009634&MedGen:C0028326&OMIM:PS163950&Orphanet:648&Human_Phenotype_Ontology:HP:0001914&Human_Phenotype_Ontology:HP:0004808&Human_Phenotype_Ontology:HP:0004843&Human_Phenotype_Ontology:HP:0005516&Human_Phenotype_Ontology:HP:0006724&Human_Phenotype_Ontology:HP:0006728&MONDO:MONDO:0018874&MeSH:D015470&MedGen:C0023467&OMIM:601626&Orphanet:519&Human_Phenotype_Ontology:HP:0001402&Human_Phenotype_Ontology:HP:0002899&Human_Phenotype_Ontology:HP:0003007&Human_Phenotype_Ontology:HP:0006750&MONDO:MONDO:0007256&MedGen:C2239176&OMIM:114550&Orphanet:88673&Human_Phenotype_Ontology:HP:0030359&MONDO:MONDO:0005097&MedGen:C0149782&Human_Phenotype_Ontology:HP:0012056&MONDO:MONDO:0005012&MeSH:C562393&MedGen:C0151779&Human_Phenotype_Ontology:HP:0030078&MONDO:MONDO:0005061&MeSH:D000077192&MedGen:C0152013&Orphanet:415268&MONDO:MONDO:0010150&MeSH:D000077195&MedGen:C1168401&OMIM:275355&Orphanet:67037&Human_Phenotype_Ontology:HP:0006739&Human_Phenotype_Ontology:HP:0007614&MONDO:MONDO:0002529&MedGen:C0553723&Human_Phenotype_Ontology:HP:0006740&MONDO:MONDO:0005611&MedGen:C0279680	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs104894228	104894228	.	.	.	HRAS	HRAS:exonic	HRAS:missense	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,624	0	0	0	0	0	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0.9492	Likely Pathogenic
13	20763687	20763687	C	A	A	missense_variant	MODERATE	GJB2	2706	Transcript	NM_004004.6	protein_coding	2/2	.	NM_004004.6:c.34G>T	NP_003995.2:p.Gly12Cys	212	34	12	G/C	Ggt/Tgt	rs104894408&CM020941&CM042706	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	GJB2	.	chr13:g.20763687C>A	.	0	0.0043	0	0	0	likely_pathogenic&conflicting_interpretations_of_pathogenicity&pathogenic	.	1&1&1	.	.	.	.	.	.	.	.	3	5.990415335463259E-4	0	0.0	3	0.004322766570605188	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	./.	C	D	0.76895	0.231851	D	0.95936	0.559105	25.3	25.4	3.665040	3.625028	0.68410	0.70387	./.	T	0.28881	0.398375792777952	0.78846	0.99674811940301633	.	0.98234	.	./.	.	.	.	.	7.713617	0.697920932962246	0.82219	8.673373	0.794501363190062	0.85761	.	.	.	52	4.292e-04	0	0	51	4.441e-03	52	4.338e-04	1	1.156e-04	0	0	0	0	0	0	52	4.906e-04	0	0	51	4.584e-03	52	4.955e-04	1	1.271e-04	0	0	0	0	0	0	51	5.630e-04	0	0	51	4.446e-03	51	5.686e-04	0	0	0	0	0	0	0	0	0.99124	.	.	.	5.36	5.36	0.76624	0	0.52368	0.61073	.	.	0.98316	1.0	.	0	0.31596	0.596491	.	.	.	.	.	.	0	0.10902	0.530356	Connexin&_N-terminal&Connexin&_N-terminal&Connexin&_N-terminal	.	.	.	0.86559	.	0.061221	0.62929	D	0.000004	D	0.94670	0.470432	0.31200	.	0.98827	.	D	0.99051	0.9699	.	0.32656	.	D	0.95749	0.9053	.	.	.	.	.	.	0.90016	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.97008	.	.	.	0.90584	.	.	0.92359	.	T	0.77779	0.772363781929	0.94914	.	10	0.72224	.	.	0.78490	.	.	19.4436	0.94829	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.86941	.	./.	C	.	G	A	682	0.59757	.	13	C1384666&C0265964&C0265336&C1835672&C0266004&C2673759&C1844678&C2675750&C1865234&C2675235&CN043648&C3887873&CN517202&CN826980	124500&148210&148350&149200&220290&304400&601544&602540&612645	ORPHA494&ORPHA2202&ORPHA2698&ORPHA383&ORPHA87884&ORPHA96210	Likely_pathogenic	NC_000013.11:g.20189548C>A	44740	reviewed_by_expert_panel	Hearing_impairment&Mutilating_keratoderma&Keratitis-ichthyosis-deafness_syndrome&_autosomal_dominant&Palmoplantar_keratoderma-deafness_syndrome&Knuckle_pads&_deafness_AND_leukonychia_syndrome&Deafness&_autosomal_recessive_1A&Deafness&_X-linked_2&Deafness&_autosomal_dominant_3a&Hystrix-like_ichthyosis_with_deafness&Deafness&_autosomal_recessive_1b&Nonsyndromic_hearing_loss_and_deafness&Hearing_loss&not_provided&Rare_genetic_deafness	ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:2580&HGMD:CM042706	.	.	AEFBCI	D	0.78847	0.98010	D	0.96319	0.949998	.	126	5.111600e-04	0	0.000000e+00	16218	0	125	3.648360e-03	34262	1	246498	0	0.000000e+00	10010	0	1	5.436560e-05	18394	0	0	0.000000e+00	21306	0	0	0.000000e+00	109704	0	125	3.648360e-03	34262	1	0	0.000000e+00	30566	0	58	5.364110e-04	0	0.000000e+00	7146	0	58	3.425060e-03	16934	0	108126	0	0.000000e+00	2298	0	0	0.000000e+00	9046	0	0	0.000000e+00	13208	0	0	0.000000e+00	41950	0	58	3.425060e-03	16934	0	0	0.000000e+00	15660	0	0	.	1	126	5.426080e-04	0	0.000000e+00	14866	0	125	3.683620e-03	33934	1	232212	0	0.000000e+00	9510	0	1	5.652270e-05	17692	0	0	0.000000e+00	21290	0	0	0.000000e+00	98922	0	125	3.683620e-03	33934	1	0	0.000000e+00	30476	0	1	117	5.741260e-04	0	0.000000e+00	16180	0	117	3.868790e-03	30242	1	203788	0	0.000000e+00	6164	0	0	0.000000e+00	13416	0	0	0.000000e+00	16490	0	0	0.000000e+00	85936	0	117	3.868790e-03	30242	1	0	0.000000e+00	30558	0	1	126	5.251400e-04	0	0.000000e+00	12004	0	125	3.662680e-03	34128	1	239936	0	0.000000e+00	9930	0	1	5.437740e-05	18390	0	0	0.000000e+00	21304	0	0	0.000000e+00	107652	0	125	3.662680e-03	34128	1	0	0.000000e+00	30566	0	1	15	9.985490e-05	0	0.000000e+00	41310	0	0	0.000000e+00	908	0	15	9.933770e-04	15100	0	150218	0	0.000000e+00	3442	0	0	0.000000e+00	5184	0	0	0.000000e+00	10408	0	0	0.000000e+00	312	0	0	0.000000e+00	66688	0	15	9.933770e-04	15100	0	0	0.000000e+00	4820	0	3	9.210930e-05	0	0.000000e+00	9058	0	0	0.000000e+00	60	0	3	6.462730e-04	4642	0	32570	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5384	0	0	0.000000e+00	242	0	0	0.000000e+00	6744	0	0	0.000000e+00	3102	0	0	.	0	15	1.027100e-04	0	0.000000e+00	40988	0	0	0.000000e+00	908	0	15	1.005630e-03	14916	0	146042	0	0.000000e+00	3274	0	0	0.000000e+00	4948	0	0	0.000000e+00	10408	0	0	0.000000e+00	300	0	0	0.000000e+00	63534	0	0	0.000000e+00	4788	0	0	13	9.775910e-05	0	0.000000e+00	32366	0	0	0.000000e+00	858	0	13	8.867670e-04	14660	0	132980	0	0.000000e+00	3358	0	0	0.000000e+00	5184	0	0	0.000000e+00	6830	0	0	0.000000e+00	306	0	0	0.000000e+00	62638	0	0	0.000000e+00	4818	0	0	14	1.754740e-04	0	0.000000e+00	24720	0	0	0.000000e+00	112	0	14	1.096150e-03	12772	0	79784	0	0.000000e+00	992	0	0	0.000000e+00	3746	0	0	0.000000e+00	10320	0	0	0.000000e+00	268	0	0	0.000000e+00	20580	0	0	0.000000e+00	4792	0	0	13	19661687	13	20763687	0	0.34471	0.59774	1.000000	0.71638	0.147000	0.20199	0.869000	0.36046	7.854000	0.85267	0.599000	0.40250	1.026000	0.45946	20189548	C	.	rs104894408	.	.	.	.	10.295	9.602	.	.	.	36	-33	2	0	0.00	0.00	0.00	0.00	GJB2	0.00	exon-NM_004004.6-2+55+end+2134	44740	Likely_pathogenic	reviewed_by_expert_panel	Hearing_loss&Nonsyndromic_genetic_hearing_loss&not_provided&Autosomal_recessive_nonsyndromic_hearing_loss_1B&Autosomal_recessive_nonsyndromic_hearing_loss_1A&Mutilating_keratoderma&Autosomal_dominant_nonsyndromic_hearing_loss_3A&Rare_genetic_deafness&Ichthyosis&_hystrix-like&_with_hearing_loss&Knuckle_pads&_deafness_AND_leukonychia_syndrome&Autosomal_dominant_keratitis-ichthyosis-hearing_loss_syndrome&Palmoplantar_keratoderma-deafness_syndrome&X-linked_mixed_hearing_loss_with_perilymphatic_gusher&Hearing_impairment	MedGen:C3887873&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN517202&MONDO:MONDO:0012977&MedGen:C2675235&OMIM:612645&Orphanet:90636&MONDO:MONDO:0009076&MedGen:C2673759&OMIM:220290&Orphanet:90636&MONDO:MONDO:0007422&MedGen:C0265964&OMIM:124500&Orphanet:494&MONDO:MONDO:0011103&MedGen:C2675750&OMIM:601544&Orphanet:90635&MedGen:CN826980&Orphanet:96210&MONDO:MONDO:0011245&MedGen:C1865234&OMIM:602540&Orphanet:477&MONDO:MONDO:0007866&MedGen:C0266004&OMIM:149200&Orphanet:2698&MONDO:MONDO:0007850&MedGen:C0265336&OMIM:148210&Orphanet:477&MONDO:MONDO:0007852&MedGen:C1835672&OMIM:148350&Orphanet:2202&MONDO:MONDO:0010576&MedGen:C1844678&OMIM:304400&Orphanet:383&Human_Phenotype_Ontology:HP:0000365&Human_Phenotype_Ontology:HP:0000404&Human_Phenotype_Ontology:HP:0001728&Human_Phenotype_Ontology:HP:0001729&Human_Phenotype_Ontology:HP:0001754&Human_Phenotype_Ontology:HP:0008560&Human_Phenotype_Ontology:HP:0008563&MONDO:MONDO:0005365&MedGen:C1384666	.	rs104894408	4.292e-04	52	52	0	0	51	1	0	0	0	0	10372	11484	8654	6482	65502	892	16488	0	51	1	0	0	0	0	0	0	0	0	0	0	0	rs104894408	0.00000e+00	3.78765e-03	0.00000e+00	5.79777e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	4.07972e-04	6.70352e-04	3.78765e-03	5.17126e-04	rs104894408	0.00000e+00	3.60577e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	1.77999e-04	0.00000e+00	3.60577e-03	9.73141e-05	.	.	rs104894408	104894408	.	.	.	GJB2	GJB2:exonic	GJB2:missense	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,873	0	0	0	0	0	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0.9492	Likely Pathogenic
1	41285565	41285565	G	A	A	missense_variant	MODERATE	KCNQ4	9132	Transcript	NM_004700.4	protein_coding	6/14	.	NM_004700.4:c.853G>A	NP_004691.2:p.Gly285Ser	1160	853	285	G/S	Ggc/Agc	rs28937588&CM990769&CM990770&COSV61273409	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	KCNQ4	.	chr1:g.41285565G>A	.	.	.	.	.	.	pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	KCNQ4&NM_004700.3&c.853G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.97336	0.58697	D	0.97294	0.605365	32	32	4.540014	4.515839	0.91560	0.91890	G/G	D	0.96856	0.999292492866516	0.95892	0.99883642035907427	.	0.99889	.	G/G	.	.	.	.	10.0701	0.798177887040043	0.89665	8.451218	0.782702959811669	0.85012	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99884	.	.	.	5.71	5.71	0.89031	0	0.40923	0.588066	.	.	0.98316	1.0	.	0	0.80598	0.723109	.	.	.	.	.	.	0	0.58350	0.63947	Ion_transport_domain&Ion_transport_domain&.	.	.	.	0.98573	.	0.112753	0.62929	D	0.000015	D	0.90932	0.302623	0.96362	.	0.99565	.	D	0.86601	0.6199	.	0.98881	.	D	0.90056	0.4655	G285S	Gain_of_glycosylation_at_G285_(P_=_0.0172)&_Gain_of_ubiquitination_at_K289_(P_=_0.0737)&_Loss_of_sheet_(P_=_0.0817)&_Gain_of_disorder_(P_=_0.1149)&_Gain_of_helix_(P_=_0.1736)	P56696	0.99157	0.939	.	0.94653	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.87223	.	.	.	0.90584	.	.	0.97372	.	D	0.95764	0.894131660461	0.99545	.	10	0.59159	.	.	0.91255	.	.	17.3353	0.87166	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.98268	.	G/G	S	.	G	A	759	0.50631	.	1	C2677637&CN043648&CN826980	600101	ORPHA87884&ORPHA96210	Pathogenic	NC_000001.11:g.40819893G>A	6241	reviewed_by_expert_panel	Autosomal_dominant_nonsyndromic_hearing_loss_2A&Nonsyndromic_hearing_loss_and_deafness&Rare_genetic_deafness	UniProtKB_(protein):P56696#VAR_001547&OMIM_Allelic_Variant:603537.0001	.	.	AEFDBI	D	0.99310	0.99766	D	0.96341	0.950107	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	41058152	1	41285565	0	0.57023	0.695654	1.000000	0.71638	0.995000	0.73285	0.998000	0.65909	10.003000	0.99689	0.676000	0.76740	1.176000	0.78918	40819893	G	.	rs28937588	.	.	10.949	8.559	9.437	10.247	.	.	.	2	-18	-18	6	0.01	0.04	0.00	0.00	KCNQ4	0.99	exon-NM_004700.4-6+18+start+111	6241	Pathogenic	reviewed_by_expert_panel	Nonsyndromic_genetic_hearing_loss&Rare_genetic_deafness&not_provided&Autosomal_dominant_nonsyndromic_hearing_loss_2A	MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN826980&Orphanet:96210&MedGen:CN517202&MONDO:MONDO:0010817&MedGen:C2677637&OMIM:600101&Orphanet:90635	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs28937588	28937588	.	.	.	KCNQ4	KCNQ4:exonic	KCNQ4:missense	KCNQ4:Deafness\x2cautosomal_dominant_2A	KCNQ4:600101	KCNQ4:3	KCNQ4:Autosomal_dominant	0	0.985178281898531	0.0148214036876789	3.14413790434247e-07	DISEASE: Deafness, autosomal dominant, 2A (DFNA2A) [MIM:600101]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10025409, ECO:0000269|PubMed:10369879, ECO:0000269|PubMed:10571947, ECO:0000269|PubMed:10925378, ECO:0000269|PubMed:21242547}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,442	0	0	0	0	0	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0.9492	Likely Pathogenic
10	73464800	73464800	G	A	A	missense_variant	MODERATE	CDH23	64072	Transcript	NM_022124.6	protein_coding	25/70	.	NM_022124.6:c.2866G>A	NP_071407.4:p.Glu956Lys	3270	2866	956	E/K	Gag/Aag	rs756147087&CM127228	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	C10orf105	.	chr10:g.73464800G>A	.	.	.	.	.	.	likely_pathogenic&pathogenic&uncertain_significance	.	1&1	.	.	.	.	.	CDH23&NM_022124.5&c.2866G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.81118	0.277694	D	0.93775	0.458671	31	29.3	4.393141	4.176093	0.90001	0.87696	G/G	D	0.84499	0.993623971939087	0.99488	0.99933565284975068	.	0.85660	.	G/G	.	.	.	.	14.54437	0.918023703853725	0.96310	12.76477	0.96191981238305	0.94446	.	.	.	4	3.310e-05	3	3.277e-04	0	0	4	3.433e-05	0	0	0	0	0	0	1	6.102e-05	4	3.781e-05	3	3.754e-04	0	0	4	3.853e-05	0	0	0	0	0	0	1	6.138e-05	4	4.435e-05	3	3.284e-04	0	0	4	4.656e-05	0	0	0	0	0	0	1	6.106e-05	.	.	.	.	5.5	5.5	0.81386	0	0.40923	0.588066	.	.	0.98316	1.0	.	0	0.38828	0.608075	.	.	.	.	.	.	0	0.14980	0.542086	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like	.	.	.	0.79569	.	0.000000	0.62929	D	0.000001	D	0.95756	0.54321	.	.	0.91672	.	D	0.83901	0.5584	.	0.86157	.	D	0.85837	0.1958	.	.	.	.	.	.	0.97183	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	.	.	.	.	0.90584	.	.	0.92359	.	T	0.68879	0.711974918842	0.85039	.	9	0.92824	.	.	.	.	.	19.3744	0.94492	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.97426	.	G/G	K	.	E	A	814	0.42100	.	10	C0018784&C1832394&C1846647&CN517202	601386&607197&PS220290	.	Likely_pathogenic	NC_000010.11:g.71705043G>A	444219	reviewed_by_expert_panel	Sensorineural_hearing_loss_disorder&Deafness&_autosomal_recessive_12&Deafness&_autosomal_recessive&not_provided	.	.	.	AEFDGBI	D	0.92349	0.99176	D	0.96176	0.949279	.	8	3.248840e-05	4	2.645500e-04	15120	0	1	2.903430e-05	34442	0	246242	0	0.000000e+00	9960	0	1	5.595970e-05	17870	0	0	0.000000e+00	21484	0	0	0.000000e+00	110812	0	4	2.645500e-04	15120	0	2	6.546220e-05	30552	0	3	2.770340e-05	1	1.407660e-04	7104	0	0	0.000000e+00	17024	0	108290	0	0.000000e+00	2306	0	0	0.000000e+00	8614	0	0	0.000000e+00	13244	0	0	0.000000e+00	42474	0	1	1.407660e-04	7104	0	2	1.278940e-04	15638	0	0	.	0	8	3.425360e-05	4	2.881840e-04	13880	0	1	2.928600e-05	34146	0	233552	0	0.000000e+00	9518	0	1	5.793740e-05	17260	0	0	0.000000e+00	21472	0	0	0.000000e+00	101286	0	4	2.881840e-04	13880	0	2	6.564260e-05	30468	0	0	7	3.443630e-05	4	2.651820e-04	15084	0	0	0.000000e+00	30384	0	203274	0	0.000000e+00	6098	0	1	7.756750e-05	12892	0	0	0.000000e+00	16580	0	0	0.000000e+00	86950	0	4	2.651820e-04	15084	0	2	6.547500e-05	30546	0	0	5	2.082430e-05	1	8.971830e-05	11146	0	1	2.914600e-05	34310	0	240104	0	0.000000e+00	9890	0	1	5.597220e-05	17866	0	0	0.000000e+00	21482	0	0	0.000000e+00	108922	0	1	8.971830e-05	11146	0	2	6.546220e-05	30552	0	0	12	7.886330e-05	12	2.895470e-04	41444	0	0	0.000000e+00	912	0	0	0.000000e+00	15292	0	152162	0	0.000000e+00	3468	0	0	0.000000e+00	5176	0	0	0.000000e+00	10616	0	0	0.000000e+00	316	0	0	0.000000e+00	68026	0	12	2.895470e-04	41444	0	0	0.000000e+00	4826	0	0	0.000000e+00	0	0.000000e+00	9104	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32902	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5494	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3108	0	0	.	0	12	8.113590e-05	12	2.918150e-04	41122	0	0	0.000000e+00	912	0	0	0.000000e+00	15104	0	147900	0	0.000000e+00	3302	0	0	0.000000e+00	4940	0	0	0.000000e+00	10616	0	0	0.000000e+00	304	0	0	0.000000e+00	64790	0	0	0.000000e+00	4794	0	0	11	8.162780e-05	11	3.386700e-04	32480	0	0	0.000000e+00	862	0	0	0.000000e+00	14846	0	134758	0	0.000000e+00	3384	0	0	0.000000e+00	5176	0	0	0.000000e+00	6978	0	0	0.000000e+00	310	0	0	0.000000e+00	63902	0	0	0.000000e+00	4824	0	0	3	3.716000e-05	3	1.208410e-04	24826	0	0	0.000000e+00	112	0	0	0.000000e+00	12918	0	80732	0	0.000000e+00	994	0	0	0.000000e+00	3734	0	0	0.000000e+00	10524	0	0	0.000000e+00	272	0	0	0.000000e+00	21042	0	0	0.000000e+00	4798	0	0	10	73134806	10	73464800	0	0.28877	0.554377	1.000000	0.71638	0.958000	0.51230	0.997000	0.62031	9.964000	0.99056	0.676000	0.76740	1.176000	0.78918	71705043	G	.	rs756147087	.	.	8.441	7.614	12.154	9.095	.	.	.	-40	-37	26	45	0.00	0.00	0.00	0.00	CDH23	0.05	exon-NM_022124.6-25+87+end+220	444219	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Hearing_loss&_autosomal_recessive&Autosomal_recessive_nonsyndromic_hearing_loss_12&Sensorineural_hearing_loss_disorder	MedGen:CN517202&MONDO:MONDO:0019588&MedGen:C1846647&OMIM:607197&OMIM:PS220290&Orphanet:90635&Orphanet:90636&MONDO:MONDO:0011067&MedGen:C1832394&OMIM:601386&Orphanet:90636&Human_Phenotype_Ontology:HP:0000374&Human_Phenotype_Ontology:HP:0000407&Human_Phenotype_Ontology:HP:0001753&Human_Phenotype_Ontology:HP:0001916&Human_Phenotype_Ontology:HP:0008538&Human_Phenotype_Ontology:HP:0008553&Human_Phenotype_Ontology:HP:0008565&Human_Phenotype_Ontology:HP:0008576&Human_Phenotype_Ontology:HP:0008611&Human_Phenotype_Ontology:HP:0008613&Human_Phenotype_Ontology:HP:0008614&MONDO:MONDO:0020678&MeSH:D006319&MedGen:C0018784	.	10:73464800-73464800	3.310e-05	4	4	0	3	0	0	0	0	0	1	9154	11448	8478	6560	63636	860	16388	3	0	0	0	0	0	1	0	0	0	0	0	0	0	rs756147087	2.66667e-04	2.98187e-05	0.00000e+00	5.83090e-05	0.00000e+00	0.00000e+00	0.00000e+00	6.50533e-05	4.46708e-05	1.82979e-05	2.66667e-04	3.24907e-05	rs756147087	2.29727e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	5.85823e-05	7.24008e-05	2.29727e-04	6.45328e-05	.	.	rs756147087	756147087	.	.	.	CDH23	CDH23:exonic	CDH23:missense	CDH23:Usher_syndrome\x2ctype_1D\x3b{Pituitary_adenoma_5\x2cmultiple_types}\x3bUsher_syndrome\x2ctype_1D/F_digenic\x3bDeafness\x2cautosomal_recessive_12	CDH23:601067\x3b617540\x3b601067\x3b601386	CDH23:3\x3b3\x3b3\x3b3	CDH23:Autosomal_recessive\x2cDigenic_recessive\x3bAutosomal_dominant\x3bAutosomal_recessive\x2cDigenic_recessive\x3bAutosomal_recessive	0	0.0506929591139338	0.949268622794338	3.84180917276542e-05	DISEASE: Usher syndrome 1D (USH1D) [MIM:601067]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. {ECO:0000269|PubMed:11138009, ECO:0000269|PubMed:12075507, ECO:0000269|PubMed:15660226, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:18429043}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Usher syndrome 1D/F (USH1DF) [MIM:601067]: USH1DF patients are heterozygous for mutations in CDH23 and PCDH15, indicating a digenic inheritance pattern. {ECO:0000269|PubMed:15537665}. Note=The disease is caused by mutations affecting distinct genetic loci, including the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 12 (DFNB12) [MIM:601386]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:11090341, ECO:0000269|PubMed:12075507, ECO:0000269|PubMed:12522556, ECO:0000269|PubMed:15829536, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:17850630, ECO:0000269|PubMed:22899989, ECO:0000269|PubMed:24767429}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,497	0	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.9492	Likely Pathogenic
12	103240702	103240702	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	9/13	.	NM_000277.3:c.940C>T	NP_000268.1:p.Pro314Ser	1054	940	314	P/S	Cct/Tct	rs199475650&CD991829&CM024623&CM040238	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103240702G>A	.	.	.	.	.	.	pathogenic&not_provided	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.941del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.91644	0.432224	D	0.91541	0.383083	22.6	19.38	2.576293	1.955453	0.42917	0.32046	G/G	D	0.69256	0.971273303031921	0.00254	0.13225683647951966	.	0.98685	.	G/G	.	.	.	.	2.799068	0.115523315166316	0.45341	2.596151	0.0236366408822262	0.42930	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99416	.	.	.	5.38	5.38	0.77279	0	0.45803	0.59043	.	.	0.41316	0.999645886580118	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.78138	.	0.000000	0.84330	D	0.000000	D	0.94732	0.4742	0.18886	.	0.95322	.	D	0.97039	0.9107	.	0.93915	.	D	0.97112	0.9955	P314S	Gain_of_disorder_(P_=_0.0905)&_Loss_of_stability_(P_=_0.0961)&_Gain_of_phosphorylation_at_P314_(P_=_0.1088)&_Gain_of_catalytic_residue_at_G312_(P_=_0.3348)&_Loss_of_helix_(P_=_0.3949)	P00439	0.94230	0.834	.	0.08292	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.77554	.	.	.	0.48285	.	.	0.48040	.	T	0.71433	0.72950398922	0.92746	.	10	0.01155	.	.	0.00964	.	.	19.1358	0.93413	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.80473	.	G/G	S	.	P	A	499	0.76092	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102846924G>A	102905	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_068006&DeBelle_Laboratory_for_Biochemical_Genetics:p.P314S	.	.	AEFBI	D	0.80848	0.98241	D	0.93181	0.936056	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101764832	12	103240702	0	0.43195	0.638212	1.000000	0.71638	0.545000	0.30055	0.988000	0.51130	5.493000	0.66618	0.671000	0.69459	1.172000	0.72986	102846924	G	.	rs199475650	.	.	7.709	9.491	9.506	11.083	.	.	.	-29	27	27	-29	0.00	0.06	0.00	0.03	PAH	0.00	exon-NM_001354304.2-10+27+end+57	102905	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475650	199475650	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,682	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103237523	103237523	A	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1100T>G	NP_000268.1:p.Leu367Arg	1214	1100	367	L/R	cTg/cGg	rs62508574&CM101160&CM993959	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103237523A>C	.	.	.	.	.	.	uncertain_significance	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1100T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96039	0.556992	D	0.95978	0.562304	25.2	24.8	3.649611	3.447077	0.67992	0.65753	A/A	D	0.82119	0.991773307323456	0.84694	0.99756555394200908	.	0.99994	.	A/A	.	.	.	.	6.478154	0.619651910752903	0.76369	7.263758	0.710173487184126	0.80300	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99658	.	.	.	5.24	5.24	0.72863	0	0.26702	0.573888	.	.	0.50053	0.99997582703059	.	0	0.59346	0.659464	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.72182	.	0.062853	0.62929	D	0.000004	D	0.99189	0.892843	0.29081	.	0.99274	.	D	0.99528	0.9844	.	0.99942	.	D	0.97791	1.0339	L367R	Gain_of_disorder_(P_=_0.0313)&_Loss_of_ubiquitination_at_K363_(P_=_0.0699)&_Gain_of_methylation_at_K363_(P_=_0.0966)&_Gain_of_glycosylation_at_P362_(P_=_0.1274)&_Loss_of_helix_(P_=_0.1299)	P00439	0.99584	0.96	.	0.81503	.	.	0.52935	simple_aae&simple_aae	D&D	0.999848&0.999966	0.64939	.	.	.	0.67487	.	.	0.66185	.	T	0.23746	0.3905403018	0.98489	.	10	0.92824	.	.	0.91255	.	.	15.1404	0.72285	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.96644	.	A/A	R	.	L	C	503	0.75780	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102843745A>C	619161	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.95128	0.99369	D	0.99028	0.967802	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101761653	12	103237523	0	0.56070	0.693126	1.000000	0.71638	0.032000	0.13371	0.294000	0.23929	9.322000	0.95579	0.691000	0.84096	1.312000	0.94714	102843745	A	.	rs62508574	.	.	8.924	9.158	3.163	9.459	.	.	.	34	21	34	-5	0.02	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-12+34+end+134	619161	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,666	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288675	103288675	G	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.190C>A	NP_000268.1:p.His64Asn	304	190	64	H/N	Cac/Aac	rs199475569&CD1111268&CP931380	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103288675G>T	.	.	.	.	.	.	not_provided&uncertain_significance	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.190C>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.84152	0.315531	D	0.83945	0.215462	26.1	27.4	3.863348	3.965149	0.74120	0.81077	G/G	D	0.89073	0.996303796768188	0.57188	0.99260731835687344	.	0.99814	.	G/G	.	.	.	.	13.11239	0.884700088239823	0.94871	10.43867	0.875604033007674	0.90513	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98428	.	.	.	6.17	6.17	0.99707	0	0.45803	0.59043	.	.	0.74766	0.999999999999998	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.96764	.	0.000000	0.84330	D	0.000000	D	0.98784	0.842674	0.27222	.	0.98565	.	D	0.98718	0.9602	.	0.93347	.	D	0.99503	1.0963	H64N	Loss_of_catalytic_residue_at_E66_(P_=_0.0639)&_Loss_of_sheet_(P_=_0.0817)&_Gain_of_disorder_(P_=_0.1214)&_Loss_of_phosphorylation_at_S67_(P_=_0.2241)&_Gain_of_methylation_at_R68_(P_=_0.3648)	P00439	0.83025	0.693	.	0.65703	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.92302	.	.	.	0.65571	.	.	0.70672	.	T	0.75504	0.757139980793	0.87479	.	10	0.92824	.	.	0.78490	.	.	20.8794	0.99870	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.90476	.	G/G	N	.	H	T	716	0.55970	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102894897G>T	102620	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:[p.T63P&p.H64N]__1	.	.	AEFBI	D	0.84440	0.98590	D	0.95792	0.947402	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101812805	12	103288675	0	0.37627	0.615465	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	7.060000	0.76393	0.676000	0.76740	1.176000	0.78918	102894897	G	.	rs199475569	.	.	11.038	10.766	11.785	7.700	.	.	.	18	-14	-37	-30	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+21+end+184	102620	Uncertain_significance	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475569	199475569	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,821	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288678	103288678	T	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.187A>C	NP_000268.1:p.Thr63Pro	301	187	63	T/P	Acc/Ccc	rs199475568	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103288678T>G	.	.	.	.	.	.	not_provided&uncertain_significance	.	1	.	.	.	.	.	PAH&NM_000277.1&c.187A>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.95480	0.541129	D	0.95413	0.539518	25.2	25.0	3.648000	3.512094	0.67956	0.67430	T/T	D	0.94253	0.998473942279816	0.74219	0.99601034074472439	.	0.99693	.	T/T	.	.	.	.	13.56315	0.895551188839432	0.95375	12.59006	0.955942263179934	0.94218	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99165	.	.	.	6.17	6.17	0.99707	0	0.45803	0.59043	.	.	0.74766	0.999999999994017	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.82627	.	0.000000	0.84330	D	0.000000	D	0.94210	0.443504	0.19819	.	0.98007	.	D	0.99514	0.9840	.	0.84567	.	D	0.99895	1.1162	T63P	Loss_of_stability_(P_=_0.0496)&_Gain_of_disorder_(P_=_0.0525)&_Gain_of_catalytic_residue_at_N61_(P_=_0.0719)&_Loss_of_sheet_(P_=_0.0817)&_Gain_of_phosphorylation_at_S67_(P_=_0.1404)	P00439	0.55970	0.48	.	0.98836	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.66206	.	.	.	0.53183	.	.	0.63913	.	T	0.68192	0.707232534885	0.92170	.	10	0.41405	.	.	0.63226	.	.	16.8222	0.85699	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.78927	.	T/T	P	.	T	G	716	0.55970	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102894900T>G	102619	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:[p.T63P&p.H64N]	.	.	AEFBI	D	0.80839	0.98240	D	0.99962	0.985570	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101812808	12	103288678	0	0.37627	0.615465	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	7.131000	0.76850	0.665000	0.62972	1.138000	0.64695	102894900	T	.	rs199475568	.	.	11.038	10.766	11.785	7.700	.	.	.	15	18	10	-40	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+18+end+184	102619	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475568	199475568	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,822	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288681	103288681	G	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.184C>G	NP_000268.1:p.Leu62Val	298	184	62	L/V	Ctg/Gtg	rs1565866640&CD066690	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103288681G>C	.	.	.	.	.	.	uncertain_significance	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.184C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.91448	0.428288	D	0.91342	0.377429	18.88	21.8	1.951152	2.257303	0.29643	0.38377	G/G	D	0.69866	0.972869396209717	0.64374	0.99433227661026091	.	0.97658	.	G/G	.	.	.	.	3.680481	0.29371138689808	0.55173	3.384717	0.218208575700048	0.52082	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98700	.	.	.	6.17	5.28	0.74118	0	0.51514	0.610034	.	.	0.74766	0.999992746798828	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.81867	.	0.000000	0.84330	D	0.000000	D	0.95331	0.513039	0.19140	.	0.91262	.	D	0.97662	0.9292	.	0.79246	.	D	0.97245	1.0034	L62V	Loss_of_sheet_(P_=_0.1501)&_Loss_of_stability_(P_=_0.1621)&_Gain_of_disorder_(P_=_0.2245)&_Gain_of_glycosylation_at_T63_(P_=_0.2348)&_Loss_of_phosphorylation_at_S67_(P_=_0.2417)	P00439	0.60527	0.509	.	0.83903	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.57110	.	.	.	0.38813	.	.	0.40804	.	T	0.55513	0.618467330933	0.91328	.	10	0.67890	.	.	0.68238	.	.	10.8566	0.46009	0.1972:0.0:0.8028:0.0	.	.	.	.	.	.	.	.	0.77507	.	G/G	V	.	L	C	716	0.55970	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102894903G>C	619149	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.64681	0.95428	D	0.74263	0.822265	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101812811	12	103288681	0	0.37627	0.615465	1.000000	0.71638	0.993000	0.69303	1.000000	0.86279	2.380000	0.43982	0.676000	0.76740	1.176000	0.78918	102894903	G	.	rs1565866640	.	.	11.038	10.766	11.785	7.700	.	.	.	15	12	-43	-20	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+15+end+184	619149	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,823	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288689	103288689	T	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.176A>T	NP_000268.1:p.Asp59Val	290	176	59	D/V	gAt/gTt	rs199475672&COSV61020465	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103288689T>A	.	.	.	.	.	.	uncertain_significance	0&1	1&1	.	.	.	.	.	PAH&NM_000277.1&c.176A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.86376	0.34811	D	0.86198	0.262259	21.3	21.9	2.255432	2.269630	0.35892	0.38635	T/T	D	0.57469	0.917023897171021	0.32022	0.97020302555445026	.	0.99526	.	T/T	.	.	.	.	2.56789	0.0578235497726437	0.42452	2.49436	-0.00472745470855124	0.41642	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99117	.	.	.	6.17	3.8	0.42887	0	0.51514	0.610034	.	.	0.39259	0.999351164906966	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.90829	.	0.238971	0.49130	D	0.000150	D	0.97210	0.666604	0.04348	.	0.95308	.	D	0.97849	0.9347	.	0.77664	.	D	0.95534	0.8899	D59V	Loss_of_disorder_(P_=_0.0791)&_Loss_of_sheet_(P_=_0.1398)&_Gain_of_catalytic_residue_at_T63_(P_=_0.3451)&_Loss_of_solvent_accessibility_(P_=_0.3473)&_Loss_of_phosphorylation_at_T63_(P_=_0.3688)	P00439	0.74053	0.608	.	0.87444	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.60348	.	.	.	0.16265	.	.	0.24114	.	T	0.26630	0.41124728322	0.91285	.	10	0.29639	.	.	0.50676	.	.	5.5949	0.16603	0.0:0.1775:0.1444:0.6781	.	.	.	.	.	.	.	.	0.70088	.	T/T	V	.	D	A	716	0.55970	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102894911T>A	619154	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.46410	0.86999	D	0.67710	0.729365	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.571940e-06	0	0.000000e+00	41444	0	0	0.000000e+00	912	0	0	0.000000e+00	15276	0	152162	0	0.000000e+00	3466	0	0	0.000000e+00	5194	0	0	0.000000e+00	10614	0	0	0.000000e+00	316	0	1	1.469940e-05	68030	0	1	1.469940e-05	68030	0	0	0.000000e+00	4824	0	0	0.000000e+00	0	0.000000e+00	9100	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32902	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3112	0	0	.	0	1	6.760230e-06	0	0.000000e+00	41122	0	0	0.000000e+00	912	0	0	0.000000e+00	15088	0	147924	0	0.000000e+00	3302	0	0	0.000000e+00	4960	0	0	0.000000e+00	10614	0	0	0.000000e+00	304	0	1	1.542970e-05	64810	0	0	0.000000e+00	4794	0	0	1	7.420270e-06	0	0.000000e+00	32482	0	0	0.000000e+00	862	0	0	0.000000e+00	14830	0	134766	0	0.000000e+00	3382	0	0	0.000000e+00	5194	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	1	1.564650e-05	63912	0	0	0.000000e+00	4822	0	0	0	0.000000e+00	0	0.000000e+00	24818	0	0	0.000000e+00	112	0	0	0.000000e+00	12902	0	80716	0	0.000000e+00	992	0	0	0.000000e+00	3752	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	0	0.000000e+00	21038	0	0	0.000000e+00	4796	0	0	12	101812819	12	103288689	0	0.37627	0.615465	0.995000	0.38783	0.928000	0.46473	0.995000	0.57719	1.266000	0.32641	0.665000	0.62972	1.138000	0.64695	102894911	T	.	rs199475672	.	.	11.038	10.766	11.785	7.700	.	.	.	4	7	4	-1	0.03	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+7+end+184	619154	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,824	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288689	103288689	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.176A>G	NP_000268.1:p.Asp59Gly	290	176	59	D/G	gAt/gGt	rs199475672&COSV61020465	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103288689T>C	.	.	.	.	.	.	not_provided&uncertain_significance	0&1	1&1	.	.	.	.	.	PAH&NM_000277.1&c.176A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.78945	0.253689	D	0.78672	0.12663	16.71	17.72	1.652688	1.735413	0.24291	0.27854	T/T	T	0.21277	0.216280743479729	0.04092	0.48738008255271364	.	0.87352	.	T/T	.	.	.	.	1.347328	-0.413900326060631	0.24589	0.8521879	-0.676803832771583	0.16684	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.97989	.	.	.	6.17	3.8	0.42887	0	0.51514	0.610034	.	.	0.39259	0.999351164906966	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.57326	.	0.238971	0.49130	N	0.000150	D	0.70124	0.067294	0.03774	.	0.83533	.	D	0.86363	0.6142	.	0.31611	.	T	0.78079	-0.1840	D59G	Loss_of_stability_(P_=_0.1178)&_Loss_of_solvent_accessibility_(P_=_0.1813)&_Gain_of_catalytic_residue_at_V60_(P_=_0.243)&_Loss_of_disorder_(P_=_0.2517)&_Gain_of_loop_(P_=_0.3485)	P00439	0.50780	0.448	.	0.01252	.	.	0.47157	simple_aae&simple_aae	D&D	0.999462&0.999462	0.03824	.	.	.	0.02946	.	.	0.01387	.	T	0.27532	0.417777061462	0.82232	.	10	0.04555	.	.	0.03421	.	.	5.5949	0.16603	0.0:0.1775:0.1444:0.6781	.	.	.	.	.	.	.	.	0.39457	.	T/T	G	.	D	C	716	0.55970	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102894911T>C	102616	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.D59V	.	.	AEFBI	D	0.34597	0.70455	N	0.51049	0.460206	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101812819	12	103288689	0	0.37627	0.615465	0.995000	0.38783	0.928000	0.46473	0.995000	0.57719	1.266000	0.32641	0.665000	0.62972	1.138000	0.64695	102894911	T	.	rs199475672	.	.	11.038	10.766	11.785	7.700	.	.	.	4	-28	4	-1	0.04	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+7+end+184	102616	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475672	199475672	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,825	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103234208	103234208	G	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1285C>A	NP_000268.1:p.Gln429Lys	1399	1285	429	Q/K	Cag/Aag	rs764974157&CM1511455	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103234208G>T	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1285C>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0.0	.	.	.	.	.	.	.	G/G	G	D	0.84868	0.325646	D	0.85408	0.245478	19.99	20.4	2.096397	2.071302	0.32541	0.34415	G/G	T	0.25294	0.307074248790741	0.13899	0.81863981121906249	.	0.93195	.	G/G	.	.	.	.	3.265407	0.216595620742627	0.50767	2.633443	0.033777028158695	0.43398	.	.	.	1	8.236e-06	0	0	0	0	1	8.242e-06	0	0	0	0	1	1.499e-05	0	0	1	9.415e-06	0	0	0	0	1	9.423e-06	0	0	0	0	1	1.841e-05	0	0	1	1.102e-05	0	0	0	0	1	1.103e-05	0	0	0	0	1	2.374e-05	0	0	0.99493	.	.	.	5.33	5.33	0.75683	0	0.26702	0.573888	.	.	0.74766	0.999999238961856	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.58827	.	0.000000	0.84330	D	0.000000	D	0.90459	0.287841	0.06337	.	0.95073	.	D	0.97113	0.9129	.	0.77049	.	D	0.99259	1.0905	Q429K	Gain_of_ubiquitination_at_Q429_(P_=_0.0155)&_Loss_of_helix_(P_=_0.1299)&_Gain_of_loop_(P_=_0.2045)&_Gain_of_relative_solvent_accessibility_(P_=_0.2363)&_Gain_of_solvent_accessibility_(P_=_0.2689)	P00439	0.63547	0.529	.	0.16426	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.37759	.	.	.	0.35927	.	.	0.30313	.	T	0.48176	0.566442430019	0.89741	.	10	0.01155	.	.	0.00964	.	.	18.1473	0.89594	0.0:0.0:1.0:0.0	.	1	2.6968716289104636E-4	1	1.322401481089659E-4	.	.	.	0.81758	.	G/G	K	.	Q	T	496	0.76301	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102840430G>T	551555	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBCI	D	0.60479	0.94220	D	0.96751	0.952234	.	2	7.954060e-06	0	0.000000e+00	16254	0	0	0.000000e+00	34566	0	251444	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	2	1.758300e-05	113746	0	2	1.758300e-05	113746	0	0	0.000000e+00	30616	0	1	9.140600e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17108	0	109402	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	1	2.338310e-05	42766	0	1	2.338310e-05	42766	0	0	0.000000e+00	15690	0	0	.	0	2	8.442170e-06	0	0.000000e+00	14900	0	0	0.000000e+00	34234	0	236906	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	2	1.946850e-05	102730	0	2	1.946850e-05	102730	0	0	0.000000e+00	30526	0	0	2	9.610670e-06	0	0.000000e+00	16216	0	0	0.000000e+00	30500	0	208102	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	2	2.233390e-05	89550	0	2	2.233390e-05	89550	0	0	0.000000e+00	30608	0	0	2	8.169070e-06	0	0.000000e+00	12024	0	0	0.000000e+00	34432	0	244826	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	2	1.791220e-05	111656	0	2	1.791220e-05	111656	0	0	0.000000e+00	30616	0	0	1	6.572370e-06	0	0.000000e+00	41434	0	0	0.000000e+00	912	0	0	0.000000e+00	15268	0	152152	0	0.000000e+00	3472	0	0	0.000000e+00	5196	0	0	0.000000e+00	10614	0	0	0.000000e+00	316	0	1	1.470110e-05	68022	0	1	1.470110e-05	68022	0	0	0.000000e+00	4824	0	1	3.040440e-05	0	0.000000e+00	9092	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32890	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	1	1.459850e-04	6850	0	0	0.000000e+00	3112	0	0	.	0	1	6.761140e-06	0	0.000000e+00	41114	0	0	0.000000e+00	912	0	0	0.000000e+00	15080	0	147904	0	0.000000e+00	3302	0	0	0.000000e+00	4960	0	0	0.000000e+00	10614	0	0	0.000000e+00	304	0	1	1.543210e-05	64800	0	0	0.000000e+00	4794	0	0	1	7.421590e-06	0	0.000000e+00	32462	0	0	0.000000e+00	862	0	0	0.000000e+00	14824	0	134742	0	0.000000e+00	3388	0	0	0.000000e+00	5196	0	0	0.000000e+00	6974	0	0	0.000000e+00	310	0	1	1.564950e-05	63900	0	0	0.000000e+00	4822	0	0	0	0.000000e+00	0	0.000000e+00	24808	0	0	0.000000e+00	112	0	0	0.000000e+00	12894	0	80714	0	0.000000e+00	998	0	0	0.000000e+00	3754	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	0	0.000000e+00	21038	0	0	0.000000e+00	4796	0	0	12	101758338	12	103234208	0	0.43195	0.638212	1.000000	0.71638	0.999000	0.91618	0.997000	0.62031	7.500000	0.80424	0.676000	0.76740	1.176000	0.78918	102840430	G	.	rs764974157	.	.	10.477	9.491	8.924	9.158	.	.	.	50	-3	-30	-34	0.00	0.00	0.01	0.00	PAH	0.00	exon-NM_001354304.2-13+30+start+116	551555	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103234208-103234208	8.236e-06	1	1	0	0	0	0	0	1	0	0	10406	11520	8654	6612	66714	908	16510	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs764974157	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79057e-05	0.00000e+00	0.00000e+00	1.48282e-05	0.00000e+00	1.79057e-05	8.12110e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs764974157	764974157	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,644	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103234222	103234222	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1271T>C	NP_000268.1:p.Leu424Ser	1385	1271	424	L/S	tTg/tCg	rs199475670&CM1314654&CM993961	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103234222A>G	.	.	.	.	.	.	uncertain_significance&not_provided	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1271T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96669	0.573397	D	0.96614	0.585869	29.4	27.4	4.283364	3.967667	0.87827	0.81153	A/A	D	0.93508	0.998203754425049	0.94726	0.99869803590085693	.	0.99839	.	A/A	.	.	.	.	10.65784	0.817381418356924	0.90973	10.35956	0.87231106100499	0.90339	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99802	.	.	.	5.33	5.33	0.75683	0	0.26702	0.573888	.	.	0.40238	0.999535459040794	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.83260	.	0.000000	0.84330	D	0.000000	D	0.98028	0.752547	0.27578	.	0.99257	.	D	0.99743	0.9904	.	0.99873	.	D	0.96976	0.9872	L424S	Gain_of_disorder_(P_=_0.0182)&_Loss_of_stability_(P_=_0.0414)&_Loss_of_catalytic_residue_at_L424_(P_=_0.0632)&_Gain_of_relative_solvent_accessibility_(P_=_0.1259)&_Gain_of_sheet_(P_=_0.1539)	P00439	0.99389	0.949	.	0.91388	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.82575	.	.	.	0.77913	.	.	0.74843	.	T	0.50305	0.581559658051	0.99545	.	10	0.92824	.	.	0.91255	.	.	14.5687	0.67789	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.96758	.	A/A	S	.	L	G	496	0.76301	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102840444A>G	102584	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.L424S	.	.	AEFBCI	D	0.66726	0.95920	D	0.99313	0.970971	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101758352	12	103234222	0	0.43195	0.638212	1.000000	0.71638	0.987000	0.62547	0.999000	0.70432	8.813000	0.91586	0.756000	0.94297	1.312000	0.94714	102840444	A	.	rs199475670	.	.	10.477	9.491	8.924	9.158	.	.	.	36	-17	-44	38	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-13+44+start+116	102584	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475670	199475670	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,646	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103234275	103234275	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1218A>G	NP_000268.1:p.Ile406Met	1332	1218	406	I/M	atA/atG	rs773526027&CM130695	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103234275T>C	.	.	.	.	.	.	uncertain_significance&likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1218A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.90866	0.417112	D	0.91317	0.376862	23.1	23.0	2.858152	2.713650	0.48978	0.48402	T/T	T	0.32609	0.499458143281827	0.46672	0.98813820262869356	.	0.96998	.	T/T	.	.	.	.	1.90505	-0.152182544165421	0.33324	2.256972	-0.0744683917730079	0.38515	.	.	.	2	1.647e-05	0	0	0	0	2	1.648e-05	0	0	0	0	2	2.998e-05	0	0	1	9.415e-06	0	0	0	0	1	9.423e-06	0	0	0	0	1	1.841e-05	0	0	2	2.204e-05	0	0	0	0	2	2.206e-05	0	0	0	0	2	4.749e-05	0	0	0.99681	.	.	.	5.63	-1.78	0.07527	0	0.26702	0.573888	.	.	0.05486	1.31846868474899E-4	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.91883	.	0.000000	0.84330	D	0.000000	D	0.98748	0.838126	0.25922	.	0.94356	.	D	0.99047	0.9698	.	0.95364	.	D	0.97574	1.0222	I406M	Gain_of_methylation_at_R408_(P_=_0.0643)&_Gain_of_sheet_(P_=_0.1208)&_Gain_of_MoRF_binding_(P_=_0.1686)&_Gain_of_phosphorylation_at_S411_(P_=_0.1948)&_Loss_of_helix_(P_=_0.2271)	P00439	0.92855	0.813	.	0.35681	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.49684	.	.	.	0.56581	.	.	0.68407	.	T	0.51458	0.589745283127	0.92460	.	10	0.26386	.	.	0.32769	.	.	6.6079	0.21930	0.4604:0.0:0.4233:0.1164	.	.	.	.	.	.	.	.	0.84922	.	T/T	M	.	I	C	496	0.76301	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102840497T>C	552907	reviewed_by_expert_panel	Phenylketonuria&not_provided	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2849939	.	.	AEFBCI	D	0.32560	0.64906	D	0.66052	0.704989	.	3	1.193170e-05	0	0.000000e+00	16254	0	0	0.000000e+00	34560	0	251432	0	0.000000e+00	10080	0	0	0.000000e+00	18392	0	0	0.000000e+00	21648	0	3	2.637550e-05	113742	0	3	2.637550e-05	113742	0	0	0.000000e+00	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17106	0	109398	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	0	0.000000e+00	42766	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	2	8.442590e-06	0	0.000000e+00	14900	0	0	0.000000e+00	34228	0	236894	0	0.000000e+00	9572	0	0	0.000000e+00	17690	0	0	0.000000e+00	21632	0	2	1.946930e-05	102726	0	2	1.946930e-05	102726	0	0	0.000000e+00	30526	0	0	3	1.441660e-05	0	0.000000e+00	16216	0	0	0.000000e+00	30494	0	208094	0	0.000000e+00	6212	0	0	0.000000e+00	13414	0	0	0.000000e+00	16734	0	3	3.350080e-05	89550	0	3	3.350080e-05	89550	0	0	0.000000e+00	30608	0	0	3	1.225420e-05	0	0.000000e+00	12024	0	0	0.000000e+00	34426	0	244814	0	0.000000e+00	9998	0	0	0.000000e+00	18388	0	0	0.000000e+00	21646	0	3	2.686920e-05	111652	0	3	2.686920e-05	111652	0	0	0.000000e+00	30616	0	0	3	1.974520e-05	0	0.000000e+00	41338	0	0	0.000000e+00	912	0	0	0.000000e+00	15244	0	151936	0	0.000000e+00	3470	0	0	0.000000e+00	5182	0	0	0.000000e+00	10588	0	0	0.000000e+00	316	0	3	4.411120e-05	68010	0	3	4.411120e-05	68010	0	0	0.000000e+00	4796	0	0	0.000000e+00	0	0.000000e+00	9056	0	0	0.000000e+00	60	0	0	0.000000e+00	4682	0	32796	0	0.000000e+00	136	0	0	0.000000e+00	2424	0	0	0.000000e+00	5466	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3096	0	0	.	0	3	2.031340e-05	0	0.000000e+00	41016	0	0	0.000000e+00	912	0	0	0.000000e+00	15056	0	147686	0	0.000000e+00	3302	0	0	0.000000e+00	4950	0	0	0.000000e+00	10588	0	0	0.000000e+00	304	0	3	4.630770e-05	64784	0	0	0.000000e+00	4764	0	0	2	1.486300e-05	0	0.000000e+00	32396	0	0	0.000000e+00	862	0	0	0.000000e+00	14798	0	134562	0	0.000000e+00	3386	0	0	0.000000e+00	5182	0	0	0.000000e+00	6948	0	0	0.000000e+00	310	0	2	3.130090e-05	63896	0	0	0.000000e+00	4794	0	0	1	1.241960e-05	0	0.000000e+00	24720	0	0	0.000000e+00	112	0	0	0.000000e+00	12870	0	80518	0	0.000000e+00	996	0	0	0.000000e+00	3742	0	0	0.000000e+00	10496	0	0	0.000000e+00	272	0	1	4.753760e-05	21036	0	0	0.000000e+00	4768	0	0	12	101758405	12	103234275	0	0.43195	0.638212	0.816000	0.29934	0.958000	0.51230	0.997000	0.62031	-0.030000	0.12257	-0.118000	0.14412	0.216000	0.24218	102840497	T	.	rs773526027	.	.	10.477	9.491	8.924	9.158	.	.	.	37	18	-1	3	0.00	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-13+18+end+116	552907	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs141953705	1.647e-05	2	2	0	0	0	0	0	2	0	0	10406	11520	8654	6614	66714	908	16510	0	0	0	0	2	0	0	0	0	0	0	0	0	0	rs773526027	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79067e-05	0.00000e+00	0.00000e+00	1.48287e-05	0.00000e+00	1.79067e-05	8.12110e-06	rs773526027	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66400e-05	0.00000e+00	.	5.84727e-05	0.00000e+00	6.66400e-05	3.22664e-05	.	.	rs773526027	773526027	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,654	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103240716	103240716	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	9/13	.	NM_000277.3:c.926C>T	NP_000268.1:p.Ala309Val	1040	926	309	A/V	gCc/gTc	rs62642935&CM930556&CM941135&COSV100187930	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103240716G>A	.	.	.	.	.	.	pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.926C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.93483	0.47387	D	0.95416	0.539759	32	29.4	4.464209	4.197611	0.90899	0.88194	G/G	D	0.61639	0.942310690879822	0.96436	0.99889782600391341	.	0.99908	.	G/G	0	0.0	1	1.1627906976744187E-4	11.10968	0.831107266010154	0.91867	11.02287	0.898960040421716	0.91708	.	.	.	1	8.237e-06	0	0	0	0	1	8.247e-06	0	0	0	0	1	1.500e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1.102e-05	0	0	0	0	1	1.104e-05	0	0	0	0	1	2.377e-05	0	0	0.99758	.	.	.	5.38	5.38	0.77279	0	0.45803	0.59043	.	.	0.74766	0.999999994855309	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.91380	.	0.000000	0.84330	D	0.000000	D	0.98008	0.750262	0.22587	.	0.98458	.	D	0.99774	0.9912	.	0.95268	.	D	0.97081	0.9936	.	.	.	.	.	.	0.82803	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.67241	.	.	.	0.90584	.	.	0.74104	.	T	0.63345	0.673555731773	0.98003	.	10	0.59732	.	.	0.54683	.	.	19.1358	0.93413	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.97207	.	G/G	V	.	A	A	499	0.76092	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102846938G>A	92753	reviewed_by_expert_panel	Phenylketonuria&not_provided	HGMD:CM930556&UniProtKB_(protein):P00439#VAR_000994&DeBelle_Laboratory_for_Biochemical_Genetics:p.A309V	.	.	AEFBI	D	0.98468	0.99664	D	0.99821	0.979813	.	4	1.591820e-05	0	0.000000e+00	16254	0	0	0.000000e+00	34570	0	251284	0	0.000000e+00	10074	0	0	0.000000e+00	18392	0	0	0.000000e+00	21642	0	3	2.640610e-05	113610	0	1	3.266690e-05	30612	0	1	3.266690e-05	30612	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17106	0	109394	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	0	0.000000e+00	42762	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	3	1.267170e-05	0	0.000000e+00	14900	0	0	0.000000e+00	34238	0	236748	0	0.000000e+00	9566	0	0	0.000000e+00	17690	0	0	0.000000e+00	21626	0	2	1.949390e-05	102596	0	1	3.276330e-05	30522	0	1	3.276330e-05	30522	0	0	3	1.441790e-05	0	0.000000e+00	16216	0	0	0.000000e+00	30502	0	208074	0	0.000000e+00	6208	0	0	0.000000e+00	13414	0	0	0.000000e+00	16728	0	2	2.233640e-05	89540	0	1	3.267550e-05	30604	0	1	3.267550e-05	30604	0	0	4	1.634880e-05	0	0.000000e+00	12024	0	0	0.000000e+00	34436	0	244666	0	0.000000e+00	9992	0	0	0.000000e+00	18388	0	0	0.000000e+00	21640	0	3	2.690100e-05	111520	0	1	3.266690e-05	30612	0	1	3.266690e-05	30612	0	0	2	1.315100e-05	0	0.000000e+00	41396	0	0	0.000000e+00	912	0	0	0.000000e+00	15264	0	152080	0	0.000000e+00	3468	0	0	0.000000e+00	5180	0	0	0.000000e+00	10610	0	0	0.000000e+00	316	0	2	2.940400e-05	68018	0	2	2.940400e-05	68018	0	0	0.000000e+00	4826	0	0	0.000000e+00	0	0.000000e+00	9082	0	0	0.000000e+00	60	0	0	0.000000e+00	4684	0	32864	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5480	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3112	0	0	.	0	1	6.764440e-06	0	0.000000e+00	41076	0	0	0.000000e+00	912	0	0	0.000000e+00	15076	0	147832	0	0.000000e+00	3300	0	0	0.000000e+00	4944	0	0	0.000000e+00	10610	0	0	0.000000e+00	304	0	1	1.543350e-05	64794	0	0	0.000000e+00	4794	0	0	2	1.485050e-05	0	0.000000e+00	32434	0	0	0.000000e+00	862	0	0	0.000000e+00	14818	0	134676	0	0.000000e+00	3384	0	0	0.000000e+00	5180	0	0	0.000000e+00	6968	0	0	0.000000e+00	310	0	2	3.130090e-05	63896	0	0	0.000000e+00	4824	0	0	1	1.240050e-05	0	0.000000e+00	24772	0	0	0.000000e+00	112	0	0	0.000000e+00	12890	0	80642	0	0.000000e+00	994	0	0	0.000000e+00	3738	0	0	0.000000e+00	10518	0	0	0.000000e+00	272	0	1	4.754660e-05	21032	0	0	0.000000e+00	4798	0	0	12	101764846	12	103240716	0	0.43195	0.638212	1.000000	0.71638	0.935000	0.47363	0.998000	0.65909	9.598000	0.97461	0.671000	0.69459	1.172000	0.72986	102846938	G	.	rs62642935	.	.	7.709	9.491	9.506	11.083	.	.	.	-43	13	37	-43	0.00	0.05	0.00	0.03	PAH	0.00	exon-NM_001354304.2-10+13+end+57	92753	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62642935	8.237e-06	1	1	0	0	0	0	0	1	0	0	10404	11530	8644	6596	66670	908	16504	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs62642935	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.68952e-05	0.00000e+00	3.24907e-05	2.22611e-05	8.98666e-06	3.24907e-05	1.62422e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62642935	0.0116&0.0&0.0077	rs62642935	62642935	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,685	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103234276	103234276	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1217T>C	NP_000268.1:p.Ile406Thr	1331	1217	406	I/T	aTa/aCa	rs62644469&CM992376	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103234276A>G	.	.	.	.	.	.	likely_pathogenic&not_provided	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1217T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96369	0.566871	D	0.96310	0.576494	28.8	27.6	4.211362	3.990508	0.85805	0.81946	A/A	D	0.91454	0.997395992279053	0.83629	0.99742352082165131	.	0.99900	.	A/A	.	.	.	.	11.24907	0.83521643283091	0.92122	10.75937	0.888593489337971	0.91190	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99702	.	.	.	5.63	5.63	0.86108	0	0.26702	0.573888	.	.	0.42865	0.999773153494431	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.93739	.	0.000000	0.84330	D	0.000000	D	0.97781	0.725096	0.28504	.	0.99204	.	D	0.99708	0.9895	.	0.99347	.	D	0.97148	0.9976	I406T	Gain_of_glycosylation_at_I406_(P_=_0.019)&_Gain_of_phosphorylation_at_I406_(P_=_0.029)&_Gain_of_methylation_at_R408_(P_=_0.0453)&_Gain_of_disorder_(P_=_0.0587)&_Gain_of_sheet_(P_=_0.1208)	P00439	0.98533	0.919	.	0.95097	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.76576	.	.	.	0.90584	.	.	0.86255	.	T	0.70418	0.722547769547	0.99518	.	10	0.58089	.	.	0.68238	.	.	14.8162	0.69665	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.98065	.	A/A	T	.	I	G	496	0.76301	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102840498A>G	102567	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.I406T	.	.	AEFBCI	D	0.74083	0.97332	D	0.99468	0.973052	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101758406	12	103234276	0	0.43195	0.638212	1.000000	0.71638	0.957000	0.51019	0.997000	0.62031	8.892000	0.92141	0.756000	0.94297	1.312000	0.94714	102840498	A	.	rs62644469	.	.	10.477	9.491	8.924	9.158	.	.	.	17	-18	-49	17	0.02	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-13+17+end+116	102567	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62644469	62644469	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,655	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103234277	103234277	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1216A>G	NP_000268.1:p.Ile406Val	1330	1216	406	I/V	Ata/Gta	rs749613899&CM1511454	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103234277T>C	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1216A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.71316	0.172097	D	0.84914	0.235131	26.5	25.5	3.918165	3.642856	0.75864	0.70853	T/T	D	0.44669	0.773793436520109	0.93279	0.99853530556471792	.	0.94795	.	T/T	.	.	.	.	9.102994	0.762502825552704	0.87091	8.841117	0.803101258250414	0.86301	.	.	.	2	1.647e-05	0	0	0	0	2	1.649e-05	2	2.311e-04	0	0	0	0	0	0	2	1.883e-05	0	0	0	0	2	1.885e-05	2	2.543e-04	0	0	0	0	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99614	.	.	.	5.63	5.63	0.86108	0	0.26702	0.573888	.	.	0.42865	0.999773153494431	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.78763	.	0.000000	0.84330	D	0.000000	D	0.97232	0.668746	0.23080	.	0.98916	.	D	0.99588	0.9862	.	0.83734	.	D	0.97439	1.0147	I406V	Gain_of_methylation_at_R408_(P_=_0.0872)&_Loss_of_helix_(P_=_0.1706)&_Gain_of_MoRF_binding_(P_=_0.2072)&_Gain_of_phosphorylation_at_S411_(P_=_0.2179)&_Loss_of_sheet_(P_=_0.3635)	P00439	0.89049	0.762	.	0.89262	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.23372	.	.	.	0.50062	.	.	0.61580	.	T	0.44551	0.540750980377	0.92501	.	10	0.45530	.	.	0.45393	.	.	14.8162	0.69665	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.64563	.	T/T	V	.	I	C	496	0.76301	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102840499T>C	619167	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBCI	D	0.68120	0.96227	D	0.99090	0.968439	.	2	7.954250e-06	0	0.000000e+00	16254	0	0	0.000000e+00	34556	0	251438	0	0.000000e+00	10080	0	2	1.087310e-04	18394	0	0	0.000000e+00	21648	0	0	0.000000e+00	113750	0	2	1.087310e-04	18394	0	0	0.000000e+00	30616	0	2	1.828190e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17104	0	109398	0	0.000000e+00	2320	0	2	2.210920e-04	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42766	0	2	2.210920e-04	9046	0	0	0.000000e+00	15690	0	0	.	0	2	8.442380e-06	0	0.000000e+00	14900	0	0	0.000000e+00	34224	0	236900	0	0.000000e+00	9572	0	2	1.130450e-04	17692	0	0	0.000000e+00	21632	0	0	0.000000e+00	102734	0	2	1.130450e-04	17692	0	0	0.000000e+00	30526	0	0	0	0.000000e+00	0	0.000000e+00	16216	0	0	0.000000e+00	30490	0	208092	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89550	0	.	.	.	.	0	0.000000e+00	30608	0	0	2	8.169270e-06	0	0.000000e+00	12024	0	0	0.000000e+00	34422	0	244820	0	0.000000e+00	9998	0	2	1.087550e-04	18390	0	0	0.000000e+00	21646	0	0	0.000000e+00	111660	0	2	1.087550e-04	18390	0	0	0.000000e+00	30616	0	0	2	1.314990e-05	0	0.000000e+00	41402	0	0	0.000000e+00	910	0	0	0.000000e+00	15272	0	152092	0	0.000000e+00	3470	0	1	1.926040e-04	5192	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	1	1.470290e-05	68014	0	1	1.926040e-04	5192	0	0	0.000000e+00	4816	0	1	3.043950e-05	0	0.000000e+00	9068	0	0	0.000000e+00	58	0	0	0.000000e+00	4690	0	32852	0	0.000000e+00	136	0	1	4.118620e-04	2428	0	0	0.000000e+00	5480	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3106	0	0	.	0	2	1.352800e-05	0	0.000000e+00	41080	0	0	0.000000e+00	910	0	0	0.000000e+00	15084	0	147842	0	0.000000e+00	3302	0	1	2.017760e-04	4956	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	1	1.543400e-05	64792	0	0	0.000000e+00	4784	0	0	2	1.484830e-05	0	0.000000e+00	32442	0	0	0.000000e+00	860	0	0	0.000000e+00	14826	0	134696	0	0.000000e+00	3386	0	1	1.926040e-04	5192	0	0	0.000000e+00	6968	0	0	0.000000e+00	310	0	1	1.565040e-05	63896	0	0	0.000000e+00	4814	0	0	1	1.239800e-05	0	0.000000e+00	24778	0	0	0.000000e+00	110	0	0	0.000000e+00	12898	0	80658	0	0.000000e+00	996	0	1	2.666670e-04	3750	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	0	0.000000e+00	21032	0	0	0.000000e+00	4788	0	0	12	101758407	12	103234277	0	0.43195	0.638212	1.000000	0.71638	0.951000	0.49849	0.994000	0.56301	7.628000	0.82379	0.665000	0.62972	1.138000	0.64695	102840499	T	.	rs749613899	.	.	10.477	9.491	8.924	9.158	.	.	.	16	-19	1	16	0.02	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-13+16+end+116	619167	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103234277-103234277	1.647e-05	2	2	0	0	0	2	0	0	0	0	10406	11516	8654	6614	66712	908	16510	0	0	2	0	0	0	0	0	0	0	0	0	0	0	rs749613899	0.00000e+00	0.00000e+00	0.00000e+00	1.15955e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.48289e-05	0.00000e+00	1.15955e-04	8.12110e-06	rs749613899	0.00000e+00	0.00000e+00	0.00000e+00	6.20347e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84795e-05	0.00000e+00	6.20347e-04	3.22664e-05	.	.	rs749613899	749613899	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,656	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103237454	103237454	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1169A>G	NP_000268.1:p.Glu390Gly	1283	1169	390	E/G	gAg/gGg	rs5030856&CM941139	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103237454T>C	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1169A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.86431	0.348843	D	0.95451	0.542747	28.6	27.4	4.195569	3.969862	0.85315	0.81229	T/T	D	0.43870	0.760324478149414	0.91886	0.99838479419165205	.	0.99978	.	T/T	0	0.0	1	1.1627906976744187E-4	6.939857	0.65189077747287	0.78750	7.704796	0.739236869938369	0.82204	.	.	.	12	9.884e-05	0	0	0	0	12	9.901e-05	0	0	0	0	12	1.800e-04	0	0	8	7.532e-05	0	0	0	0	8	7.546e-05	0	0	0	0	8	1.473e-04	0	0	11	1.212e-04	0	0	0	0	11	1.215e-04	0	0	0	0	11	2.614e-04	0	0	0.99700	.	.	.	5.34	5.34	0.75982	0	0.26702	0.573888	.	.	0.51787	0.999983827747907	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.91107	.	0.048788	0.84330	D	0.000000	D	0.98571	0.816505	0.06130	.	0.99229	.	D	0.99644	0.9878	.	0.97405	.	D	0.97347	1.0094	.	.	.	.	.	.	0.87590	.	.	0.81001	simple_aae&simple_aae	A&A	1&1	0.82141	.	.	.	0.64738	.	.	0.60313	.	T	0.41897	0.521927714348	0.99718	.	10	0.76473	.	.	0.58626	.	.	15.322	0.73838	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.93487	.	T/T	G	.	E	C	503	0.75780	.	12	C0751435&C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102843676T>C	625	reviewed_by_expert_panel	Hyperphenylalaninemia&_non-pku&Phenylketonuria&not_provided	OMIM_Allelic_Variant:612349.0051&Illumina_Laboratory_Services&Illumina:1342257&UniProtKB_(protein):P00439#VAR_001027&DeBelle_Laboratory_for_Biochemical_Genetics:p.E390G&HGMD:CM941139	.	.	AEFBI	D	0.83865	0.98539	D	0.99199	0.969627	.	25	9.947790e-05	0	0.000000e+00	16254	0	4	1.158080e-04	34540	0	251312	0	0.000000e+00	10078	0	0	0.000000e+00	18384	0	0	0.000000e+00	21646	0	20	1.759570e-04	113664	0	20	1.759570e-04	113664	0	0	0.000000e+00	30614	0	11	1.005670e-04	0	0.000000e+00	7164	0	3	1.754390e-04	17100	0	109380	0	0.000000e+00	2320	0	0	0.000000e+00	9040	0	0	0.000000e+00	13394	0	8	1.870990e-04	42758	0	8	1.870990e-04	42758	0	0	0.000000e+00	15690	0	0	.	0	22	9.291400e-05	0	0.000000e+00	14900	0	4	1.169320e-04	34208	0	236778	0	0.000000e+00	9570	0	0	0.000000e+00	17682	0	0	0.000000e+00	21630	0	17	1.656080e-04	102652	0	17	1.656080e-04	102652	0	0	0.000000e+00	30524	0	0	23	1.105580e-04	0	0.000000e+00	16216	0	4	1.312590e-04	30474	0	208036	0	0.000000e+00	6210	0	0	0.000000e+00	13406	0	0	0.000000e+00	16732	0	18	2.010450e-04	89532	0	18	2.010450e-04	89532	0	0	0.000000e+00	30606	0	0	24	9.808170e-05	0	0.000000e+00	12024	0	4	1.162590e-04	34406	0	244694	0	0.000000e+00	9996	0	0	0.000000e+00	18380	0	0	0.000000e+00	21644	0	20	1.792530e-04	111574	0	20	1.792530e-04	111574	0	0	0.000000e+00	30614	0	0	12	7.896090e-05	0	0.000000e+00	41386	0	0	0.000000e+00	912	0	0	0.000000e+00	15258	0	151974	0	0.000000e+00	3466	0	0	0.000000e+00	5158	0	0	0.000000e+00	10614	0	1	3.164560e-03	316	0	11	1.618170e-04	67978	0	11	1.618170e-04	67978	0	0	0.000000e+00	4802	0	1	3.044140e-05	0	0.000000e+00	9080	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32850	0	0.000000e+00	134	0	0	0.000000e+00	2426	0	0	0.000000e+00	5488	0	1	4.065040e-03	246	0	0	0.000000e+00	6846	0	0	0.000000e+00	3096	0	0	.	0	11	7.445810e-05	0	0.000000e+00	41064	0	0	0.000000e+00	912	0	0	0.000000e+00	15070	0	147734	0	0.000000e+00	3298	0	0	0.000000e+00	4924	0	0	0.000000e+00	10614	0	1	3.289470e-03	304	0	10	1.544070e-04	64764	0	0	0.000000e+00	4770	0	0	12	8.914770e-05	0	0.000000e+00	32446	0	0	0.000000e+00	862	0	0	0.000000e+00	14812	0	134608	0	0.000000e+00	3382	0	0	0.000000e+00	5158	0	0	0.000000e+00	6976	0	1	3.225810e-03	310	0	11	1.722300e-04	63868	0	0	0.000000e+00	4800	0	0	5	6.207480e-05	0	0.000000e+00	24766	0	0	0.000000e+00	112	0	0	0.000000e+00	12884	0	80548	0	0.000000e+00	994	0	0	0.000000e+00	3718	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	5	2.381410e-04	20996	0	0	0.000000e+00	4774	0	0	12	101761584	12	103237454	0	0.43195	0.638212	1.000000	0.71638	0.377000	0.26268	0.985000	0.49585	8.015000	0.88319	0.609000	0.47794	1.138000	0.64695	102843676	T	.	rs5030856	.	.	8.924	9.158	3.163	9.459	.	.	.	0	-47	5	-30	0.00	0.00	0.00	0.15	PAH	0.00	exon-NM_001354304.2-12+30+start+134	625	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria&Hyperphenylalaninemia	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&Human_Phenotype_Ontology:HP:0004923&MedGen:C0751435	.	rs5030856	9.884e-05	12	12	0	0	0	0	0	12	0	0	10404	11494	8636	6586	66674	906	16502	0	0	0	0	12	0	0	0	0	0	0	0	0	0	rs5030856	0.00000e+00	1.19303e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.97111e-04	1.82615e-04	0.00000e+00	1.33545e-04	8.08654e-05	1.97111e-04	1.13696e-04	rs5030856	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.67111e-05	0.00000e+00	.	5.84795e-05	0.00000e+00	6.67111e-05	3.22664e-05	rs5030856	0.0116&0.0&0.0077	rs5030856	5030856	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,660	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692905	89692905	G	A	A	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.389G>A	NP_000305.3:p.Arg130Gln	1234	389	130	R/Q	cGa/cAa	rs121909229&CM981670&CM991081&COSV64288376&COSV64288604&COSV64290765&COSV64291054	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89692905G>A	.	.	.	.	.	.	pathogenic&pathogenic/likely_pathogenic&likely_pathogenic	0&0&0&1&1&1&1	1&1&1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.389G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.97373	0.592226	D	0.97331	0.612915	31	29.8	4.396039	4.248638	0.90042	0.89205	./.	D	0.96639	0.999237179756165	0.99998	0.99961930974453017	.	0.99494	.	./.	.	.	.	.	14.89159	0.925592549412273	0.96593	14.29803	1.01183373457018	0.96097	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98296	.	.	.	5.22	5.22	0.72285	0	0.70079	0.698795	.	.	0.74766	0.999999999999999	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.98441	.	0.000000	0.84330	D	0.000000	D	0.98834	0.848829	0.97662	.	0.99760	.	D	0.99322	0.9781	.	0.99946	.	D	0.98376	1.0615	R130Q	Loss_of_methylation_at_R130_(P_=_0.0398)&_Gain_of_ubiquitination_at_K128_(P_=_0.0511)&_Loss_of_MoRF_binding_(P_=_0.0517)&_Gain_of_disorder_(P_=_0.2581)&_Gain_of_glycosylation_at_K128_(P_=_0.2627)	P60484	0.99811	0.98	.	0.93875	.	.	0.81001	simple_aae	A	1	0.72471	.	.	.	0.90584	.	.	0.88582	.	D	0.95063	0.888432264328	0.99783	.	8	0.92824	.	.	0.91255	.	.	18.7776	0.91883	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.98065	.	./.	Q	.	R	A	940	0.13648	.	10	C0027651&C1458155&C1336839&C0151779&C0149925&C0149782&C0007873&C0278701&C0919267&C0009404&C0007112&C0280630&CN072330&C1168401&C0027672&C1959582&C0017636&C0153574&CN517202	605074&182280&167000&158350&275355	ORPHA70573&ORPHA140162&ORPHA306498&ORPHA360	Pathogenic	NC_000010.11:g.87933148G>A	7829	reviewed_by_expert_panel	Neoplasm&Breast_neoplasm&Renal_cell_carcinoma&_papillary&_1&Malignant_melanoma_of_skin&Small_cell_lung_carcinoma&Squamous_cell_lung_carcinoma&Neoplasm_of_uterine_cervix&Adenocarcinoma_of_stomach&Neoplasm_of_ovary&Neoplasm_of_the_large_intestine&Adenocarcinoma_of_prostate&Uterine_Carcinosarcoma&Cowden_syndrome_1&Squamous_cell_carcinoma_of_the_head_and_neck&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&Glioblastoma&Malignant_neoplasm_of_body_of_uterus&not_provided	OMIM_Allelic_Variant:601728.0017&UniProtKB_(protein):P60484#VAR_007468	.	.	AEFDGBIJ	D	0.83480	0.98504	D	0.92341	0.932686	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682885	10	89692905	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	9.525000	0.97093	0.676000	0.76740	1.176000	0.78918	87933148	G	.	rs121909229	.	.	10.752	10.998	5.352	9.651	.	.	.	24	-27	-19	-5	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+103+end+239	7829	Pathogenic	reviewed_by_expert_panel	Malignant_neoplasm_of_body_of_uterus&Glioblastoma&Neoplasm&Prostate_adenocarcinoma&Neoplasm_of_uterine_cervix&Uterine_carcinosarcoma&Gastric_adenocarcinoma&Neoplasm_of_the_large_intestine&Hereditary_cancer-predisposing_syndrome&Cowden_syndrome&Breast_neoplasm&not_provided&Neoplasm_of_ovary&Malignant_melanoma_of_skin&Small_cell_lung_carcinoma&Papillary_renal_cell_carcinoma_type_1&Squamous_cell_lung_carcinoma&PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1&Squamous_cell_carcinoma_of_the_head_and_neck	MedGen:C0153574&MONDO:MONDO:0018177&MeSH:D005909&MedGen:C0017636&Orphanet:360&Human_Phenotype_Ontology:HP:0002664&Human_Phenotype_Ontology:HP:0003008&Human_Phenotype_Ontology:HP:0006741&MONDO:MONDO:0005070&MeSH:D009369&MedGen:C0027651&MONDO:MONDO:0005082&MedGen:C0007112&Human_Phenotype_Ontology:HP:0032241&MONDO:MONDO:0021230&MeSH:D002583&MedGen:C0007873&MONDO:MONDO:0006485&MedGen:C0280630&Human_Phenotype_Ontology:HP:0033770&MONDO:MONDO:0005036&MedGen:C0278701&Orphanet:464463&Human_Phenotype_Ontology:HP:0100834&MONDO:MONDO:0005335&MeSH:D015179&MedGen:C0009404&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0016063&MedGen:C0018553&OMIM:PS158350&Orphanet:201&Human_Phenotype_Ontology:HP:0010623&Human_Phenotype_Ontology:HP:0100013&MONDO:MONDO:0021100&MeSH:D001943&MedGen:C1458155&MedGen:CN517202&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267&OMIM:167000&Human_Phenotype_Ontology:HP:0012056&MONDO:MONDO:0005012&MeSH:C562393&MedGen:C0151779&Human_Phenotype_Ontology:HP:0030357&MONDO:MONDO:0008433&MeSH:D055752&MedGen:C0149925&OMIM:182280&Orphanet:70573&Human_Phenotype_Ontology:HP:0011797&MedGen:C1336839&OMIM:605074&Orphanet:47044&Human_Phenotype_Ontology:HP:0030359&MONDO:MONDO:0005097&MedGen:C0149782&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0010150&MeSH:D000077195&MedGen:C1168401&OMIM:275355&Orphanet:67037	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909229	121909229	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,548	0	0	0	0	0	1	1	0	1	0	1	0	0	0	0	1	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288671	103288671	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.194T>C	NP_000268.1:p.Ile65Thr	308	194	65	I/T	aTt/aCt	rs75193786&CM024620&CM920541&CM981428	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103288671A>G	.	.	.	.	.	.	pathogenic	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.194T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0.0	.	.	.	.	.	.	.	A/A	A	D	0.84221	0.316519	D	0.96894	0.590332	27.2	27.0	4.026111	3.915582	0.79509	0.79343	A/A	D	0.61102	0.939506590366364	0.94902	0.99871673064097666	.	0.99954	.	A/A	0	0.0	5	5.813953488372093E-4	20.06401	1.01912436758871	0.98965	17.72616	1.10502426950058	0.98225	.	.	.	22	1.812e-04	1	9.649e-05	0	0	22	1.815e-04	0	0	0	0	21	3.151e-04	0	0	16	1.506e-04	1	1.104e-04	0	0	16	1.507e-04	0	0	0	0	15	2.760e-04	0	0	21	2.314e-04	1	9.666e-05	0	0	21	2.318e-04	0	0	0	0	20	4.757e-04	0	0	0.99268	.	.	.	6.17	6.17	0.99707	0	0.45803	0.59043	.	.	0.74766	0.999999999994017	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.98736	.	0.000000	0.84330	D	0.000000	D	0.99032	0.87329	0.28504	.	0.97866	.	D	0.99697	0.9892	.	0.92313	.	D	0.96883	0.9815	.	.	.	.	.	.	0.98135	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.81755	.	.	.	0.90584	.	.	0.92359	.	T	0.75973	0.760298788548	0.99931	.	9	0.83351	.	.	0.91255	.	.	16.8222	0.85699	1.0:0.0:0.0:0.0	.	4	0.0010787486515641855	4	5.289605924358636E-4	.	.	.	0.96416	.	A/A	T	.	I	G	716	0.55970	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102894893A>G	636	reviewed_by_expert_panel	Phenylketonuria&not_provided	HGMD:CM920541&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2607076&OMIM_Allelic_Variant:612349.0063&UniProtKB_(protein):P00439#VAR_000883&DeBelle_Laboratory_for_Biochemical_Genetics:p.I65T	.	.	AEFBI	D	0.85820	0.98706	D	0.98550	0.963565	.	68	2.706980e-04	1	6.153850e-05	16250	0	3	8.673530e-05	34588	0	251202	0	0.000000e+00	10078	0	0	0.000000e+00	18394	0	0	0.000000e+00	21570	0	61	5.370950e-04	113574	0	61	5.370950e-04	113574	0	1	3.266480e-05	30614	0	27	2.469680e-04	1	1.395870e-04	7164	0	0	0.000000e+00	17110	0	109326	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13316	0	25	5.845770e-04	42766	0	25	5.845770e-04	42766	0	1	6.373490e-05	15690	0	0	.	0	62	2.619640e-04	1	6.710510e-05	14902	0	3	8.757590e-05	34256	0	236674	0	0.000000e+00	9570	0	0	0.000000e+00	17692	0	0	0.000000e+00	21554	0	56	5.460110e-04	102562	0	56	5.460110e-04	102562	0	1	3.276110e-05	30524	0	0	62	2.980510e-04	1	6.168270e-05	16212	0	1	3.276330e-05	30522	0	208018	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16656	0	57	6.366580e-04	89530	0	57	6.366580e-04	89530	0	1	3.267330e-05	30606	0	0	66	2.698460e-04	0	0.000000e+00	12020	0	3	8.707260e-05	34454	0	244584	0	0.000000e+00	9996	0	0	0.000000e+00	18390	0	0	0.000000e+00	21568	0	60	5.381940e-04	111484	0	60	5.381940e-04	111484	0	1	3.266480e-05	30614	0	0	45	2.956130e-04	7	1.688460e-04	41458	0	0	0.000000e+00	912	0	2	1.308560e-04	15284	0	152226	0	0.000000e+00	3472	0	0	0.000000e+00	5204	0	0	0.000000e+00	10614	0	0	0.000000e+00	316	0	36	5.290690e-04	68044	0	36	5.290690e-04	68044	0	0	0.000000e+00	4834	0	6	1.823600e-04	3	3.296700e-04	9100	0	0	0.000000e+00	60	0	1	2.133110e-04	4688	0	32902	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	2	2.918000e-04	6854	0	0	0.000000e+00	3114	0	0	.	0	44	2.973620e-04	7	1.701590e-04	41138	0	0	0.000000e+00	912	0	2	1.324850e-04	15096	0	147968	0	0.000000e+00	3302	0	0	0.000000e+00	4968	0	0	0.000000e+00	10614	0	0	0.000000e+00	304	0	35	5.400070e-04	64814	0	0	0.000000e+00	4802	0	0	43	3.189490e-04	6	1.846950e-04	32486	0	0	0.000000e+00	862	0	2	1.347890e-04	14838	0	134818	0	0.000000e+00	3388	0	0	0.000000e+00	5204	0	0	0.000000e+00	6974	0	0	0.000000e+00	310	0	35	5.475080e-04	63926	0	0	0.000000e+00	4832	0	0	17	2.104480e-04	5	2.013530e-04	24832	0	0	0.000000e+00	112	0	1	7.745930e-05	12910	0	80780	0	0.000000e+00	998	0	0	0.000000e+00	3762	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	11	5.225160e-04	21052	0	0	0.000000e+00	4806	0	0	12	101812801	12	103288671	0	0.37627	0.615465	1.000000	0.71638	0.996000	0.76049	1.000000	0.86279	8.297000	0.89867	0.756000	0.94297	1.312000	0.94714	102894893	A	.	rs75193786	.	.	11.038	10.766	11.785	7.700	.	.	.	-26	-10	-28	-29	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+25+end+184	636	Pathogenic	reviewed_by_expert_panel	not_provided&See_cases&Phenylketonuria	MedGen:CN517202&.&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs75193786	1.812e-04	22	22	0	1	0	0	0	21	0	0	10364	11562	8650	6614	66640	908	16502	1	0	0	0	21	0	0	0	0	0	0	0	0	0	rs75193786	6.53680e-05	8.93442e-05	0.00000e+00	0.00000e+00	0.00000e+00	5.11192e-04	1.82482e-04	3.24886e-05	2.59748e-04	2.51771e-04	5.11192e-04	2.55817e-04	rs75193786	4.58085e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.32552e-04	0.00000e+00	.	6.42448e-04	2.88642e-04	7.32552e-04	4.83996e-04	rs75193786	0.0581&0.0&0.0384	rs75193786	75193786	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,819	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103237523	103237523	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1100T>C	NP_000268.1:p.Leu367Pro	1214	1100	367	L/P	cTg/cCg	rs62508574&CM101160&CM993959	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103237523A>G	.	.	.	.	.	.	uncertain_significance&not_provided	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1100T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96267	0.561623	D	0.96209	0.568956	25.5	24.8	3.714188	3.453287	0.69742	0.65918	A/A	D	0.90201	0.996849596500397	0.94989	0.99871963318324264	.	0.99998	.	A/A	.	.	.	.	6.63115	0.630775139206566	0.77185	7.497473	0.725932886079715	0.81334	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99662	.	.	.	5.24	5.24	0.72863	0	0.26702	0.573888	.	.	0.50053	0.99997582703059	.	0	0.59346	0.659464	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.64678	.	0.062853	0.62929	D	0.000004	D	0.99509	0.931954	0.30403	.	0.99535	.	D	0.99558	0.9853	.	0.99932	.	D	0.97724	1.0303	L367P	Gain_of_disorder_(P_=_0.0106)&_Gain_of_glycosylation_at_L367_(P_=_0.0228)&_Gain_of_catalytic_residue_at_P366_(P_=_0.0231)&_Loss_of_stability_(P_=_0.0618)&_Gain_of_ubiquitination_at_K371_(P_=_0.0651)	P00439	0.99502	0.955	.	0.81503	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.75058	.	.	.	0.73220	.	.	0.73820	.	T	0.26477	0.410149604082	0.99284	.	10	0.63109	.	.	0.91255	.	.	15.1404	0.72285	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.94314	.	A/A	P	.	L	G	503	0.75780	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102843745A>G	102525	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.L367P	.	.	AEFBI	D	0.94506	0.99324	D	0.99960	0.985463	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101761653	12	103237523	0	0.56070	0.693126	1.000000	0.71638	0.032000	0.13371	0.294000	0.23929	9.322000	0.95579	0.691000	0.84096	1.312000	0.94714	102843745	A	.	rs62508574	.	.	8.924	9.158	3.163	9.459	.	.	.	34	21	34	-5	0.01	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-12+34+end+134	102525	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508574	62508574	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,667	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
19	4117551	4117551	A	C	C	missense_variant	MODERATE	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	2/11	.	NM_030662.4:c.169T>G	NP_109587.1:p.Phe57Val	416	169	57	F/V	Ttt/Gtt	rs121434498&CM080435&CM086853&COSV53562382&COSV53564387	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	MAP2K2	.	chr19:g.4117551A>C	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&0&0&1&1	1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.92974	0.461124	D	0.92886	0.424596	28.8	26.5	4.214488	3.834021	0.85901	0.76570	./.	D	0.84009	0.993279197044399	0.52100	0.99086374363722196	.	0.94021	.	./.	.	.	.	.	6.888632	0.648502775168648	0.78499	7.43147	0.721565896664568	0.81047	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.92407	.	.	.	4.14	4.14	0.47821	0	0.68747	0.697927	.	.	0.74766	0.99999996709992	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.71501	0.711	.	.	.	.	0.80823	.	0.000000	0.84330	D	0.000000	D	0.98712	0.833693	0.86693	.	0.92377	.	D	0.94987	0.8497	.	0.97865	.	D	0.96939	0.9849	F57V	Loss_of_stability_(P_=_0.0955)&_Gain_of_MoRF_binding_(P_=_0.1544)&_Gain_of_phosphorylation_at_T59_(P_=_0.2106)&_Loss_of_ubiquitination_at_K61_(P_=_0.2258)&_Loss_of_catalytic_residue_at_F57_(P_=_0.226)	P36507	0.95259	0.851	.	0.68882	.	.	0.81001	simple_aae&without_aae	A&A	1&1	0.86988	.	.	.	0.77913	.	.	0.86255	.	D	0.86668	0.830689072609	0.98744	.	9	0.29056	.	.	0.61437	.	.	12.1528	0.53364	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.91162	.	./.	V	.	F	C	940	0.13648	.	19	C0281361&C0151779&C0278701&C1168401&C3809007&C1275081	275355&615280&PS115150	ORPHA1340	Pathogenic	NC_000019.10:g.4117553A>C	8273	reviewed_by_expert_panel	Pancreatic_adenocarcinoma&Malignant_melanoma_of_skin&Adenocarcinoma_of_stomach&Squamous_cell_carcinoma_of_the_head_and_neck&Cardiofaciocutaneous_syndrome_4&Cardio-facio-cutaneous_syndrome	OMIM_Allelic_Variant:601263.0002&ClinGen_RASopathy_Variant_Curation_Expert_Panel:ac054f0f-9da0-455d-8a0f-343d2f4ad540&UniProtKB_(protein):P36507#VAR_069781	.	.	AEFDBI	D	0.93355	0.99244	D	0.95566	0.946322	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19	4068551	19	4117551	0	0.52595	0.67177	1.000000	0.71638	0.974000	0.55675	1.000000	0.86279	9.113000	0.93637	0.756000	0.94297	1.312000	0.94714	4117553	A	.	rs121434498	.	.	12.786	9.597	6.148	8.492	.	.	.	15	-12	-20	11	0.00	0.00	0.00	0.00	MAP2K2	0.86	exon-NM_030662.4-2+76+end+211	8273	Pathogenic	reviewed_by_expert_panel	Gastric_adenocarcinoma&Cardio-facio-cutaneous_syndrome&Pancreatic_adenocarcinoma&Cardiofaciocutaneous_syndrome_4&Malignant_melanoma_of_skin&Squamous_cell_carcinoma_of_the_head_and_neck	Human_Phenotype_Ontology:HP:0033770&MONDO:MONDO:0005036&MedGen:C0278701&Orphanet:464463&MONDO:MONDO:0015280&MedGen:C1275081&OMIM:PS115150&Orphanet:1340&Human_Phenotype_Ontology:HP:0006725&MONDO:MONDO:0006047&MedGen:C0281361&MONDO:MONDO:0014114&MedGen:C3809007&OMIM:615280&Orphanet:1340&Human_Phenotype_Ontology:HP:0012056&MONDO:MONDO:0005012&MeSH:C562393&MedGen:C0151779&MONDO:MONDO:0010150&MeSH:D000077195&MedGen:C1168401&OMIM:275355&Orphanet:67037	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121434498	121434498	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:missense	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,940	0	0	0	0	0	0	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103306612	103306612	T	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	2/13	.	NM_000277.3:c.125A>T	NP_000268.1:p.Lys42Ile	239	125	42	K/I	aAa/aTa	rs62635346&CM983348&COSV61017052	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103306612T>A	.	.	.	.	.	.	likely_pathogenic&not_provided	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.125A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.94299	0.500564	D	0.94220	0.481249	25.4	24.9	3.710687	3.465162	0.69656	0.66220	T/T	D	0.78166	0.987728595733643	0.64720	0.99439631439057974	.	0.99834	.	T/T	.	.	.	.	4.869067	0.466669663499789	0.65795	4.414227	0.411346057276621	0.62046	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99117	.	.	.	5.46	5.46	0.80021	0	0.26702	0.573888	.	.	0.74766	0.999999961214906	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.88939	.	0.047237	0.84330	D	0.000000	D	0.96957	0.642609	0.07386	.	0.98005	.	D	0.99132	0.9723	.	0.97153	.	D	0.99138	1.0874	K42I	Loss_of_ubiquitination_at_K42_(P_=_0.0255)&_Gain_of_stability_(P_=_0.0955)&_Loss_of_helix_(P_=_0.1299)&_Gain_of_sheet_(P_=_0.1539)&_Gain_of_loop_(P_=_0.2045)	P00439	0.94041	0.831	.	0.77386	.	.	0.58761	simple_aae&simple_aae	D&D	0.999999&0.999999	0.89534	.	.	.	0.26475	.	.	0.36449	.	T	0.56709	0.626929819584	0.98452	.	10	0.76473	.	.	0.78490	.	.	13.057	0.58397	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.90138	.	T/T	I	.	K	A	768	0.49510	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102912834T>A	102581	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.K42I&UniProtKB_(protein):P00439#VAR_000874	.	.	AEFBI	D	0.52260	0.90787	D	0.84088	0.898035	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101830742	12	103306612	0	0.43195	0.638212	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	5.101000	0.64402	0.665000	0.62972	1.138000	0.64695	102912834	T	.	rs62635346	.	.	11.785	7.700	8.002	9.602	.	.	.	-3	3	-47	-43	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-3+43+start+108	102581	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62635346	62635346	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,840	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
10	89692886	89692886	T	C	C	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.370T>C	NP_000305.3:p.Cys124Arg	1215	370	124	C/R	Tgt/Cgt	rs121909223&CD097201&CM971271&COSV64288968&COSV64294667&COSV64296578&COSV64297040	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89692886T>C	.	.	.	.	.	.	pathogenic	0&0&0&1&1&1&1	1&1&1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.370T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.97337	0.58708	D	0.97295	0.605524	29.0	27.3	4.236661	3.952116	0.86571	0.80623	./.	D	0.99418	0.999864459037781	0.84382	0.99752706230231303	.	0.99579	.	./.	.	.	.	.	11.81663	0.851234996343401	0.93089	12.83403	0.964274312489795	0.94534	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99894	.	.	.	5.22	5.22	0.72285	0	0.70079	0.698795	.	.	0.74766	0.999999999999512	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.99254	.	0.000000	0.84330	D	0.000000	D	0.98846	0.850283	0.99403	.	0.99545	.	D	0.99928	0.9970	.	0.99959	.	D	0.95508	0.8880	C124R	Gain_of_disorder_(P_=_0.003)&_Gain_of_MoRF_binding_(P_=_0.0115)&_Loss_of_methylation_at_K125_(P_=_0.0271)&_Loss_of_catalytic_residue_at_C124_(P_=_0.0494)&_Loss_of_ubiquitination_at_K125_(P_=_0.0982)	P60484	0.99208	0.941	.	0.97676	.	.	0.81001	simple_aae	A	1	0.99524	.	.	.	0.90584	.	.	0.92359	.	D	0.99204	0.934122622013	0.99545	.	8	0.92824	.	.	0.91255	.	.	15.1019	0.71955	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.99725	.	./.	R	.	C	C	940	0.13648	.	10	CN072330&C0027672&C1959582&CN517202	158350	ORPHA140162&ORPHA306498	Pathogenic	NC_000010.11:g.87933129T>C	7817	reviewed_by_expert_panel	Cowden_syndrome_1&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	UniProtKB_(protein):P60484#VAR_007464&OMIM_Allelic_Variant:601728.0006&ClinGen_PTEN_Variant_Curation_Expert_Panel:b3d1af7f-63db-40b7-9bb6-1937661a6003	.	.	AEFDGBIJ	D	0.72319	0.97036	D	0.95449	0.945786	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682866	10	89692886	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	7.615000	0.82207	0.665000	0.62972	1.138000	0.64695	87933129	T	.	rs121909223	.	.	10.752	10.998	5.352	9.651	.	.	.	-8	0	26	0	0.01	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+116+start+239	7817	Pathogenic	reviewed_by_expert_panel	Gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	Human_Phenotype_Ontology:HP:0012126&MONDO:MONDO:0001056&MeSH:D013274&MedGen:C0024623&OMIM:613659&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909223	121909223	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,546	0	0	0	0	0	1	1	0	1	0	1	0	0	0	0	1	0	0	0	0	0	0.8999	Likely Pathogenic
19	4101030	4101030	C	A	A	missense_variant	MODERATE	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	6/11	.	NM_030662.4:c.692G>T	NP_109587.1:p.Arg231Leu	939	692	231	R/L	cGc/cTc	rs730880511&COSV53566038	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MAP2K2	.	chr19:g.4101030C>A	.	.	.	.	.	.	uncertain_significance&likely_pathogenic	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.90745	0.414836	D	0.90630	0.358107	25.2	24.9	3.652568	3.466368	0.68075	0.66247	./.	D	0.74842	0.983015596866608	0.85091	0.99761860506185474	.	0.75334	.	./.	.	.	.	.	3.361308	0.235344888360785	0.51820	3.829535	0.309693835289339	0.56646	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.91851	.	.	.	4.22	4.22	0.49153	0	0.74545	0.702456	.	.	0.74766	0.999999995623177	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.83352	0.714379	Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain	.	.	.	0.87759	.	0.000000	0.84330	D	0.000000	D	0.96943	0.64132	0.85450	.	0.93296	.	D	0.91472	0.7499	.	0.89346	.	D	0.93272	0.7077	R231L	Gain_of_stability_(P_=_0.0068)&_Loss_of_methylation_at_R231_(P_=_0.0329)&_Loss_of_disorder_(P_=_0.0713)&_Loss_of_phosphorylation_at_T230_(P_=_0.091)&_Loss_of_catalytic_residue_at_R231_(P_=_0.093)	P36507	0.75452	0.62	.	0.12200	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.92042	.	.	.	0.90584	.	.	0.97372	.	D	0.94483	0.883923590183	0.94952	.	10	0.65728	.	.	0.65419	.	.	15.1887	0.72711	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.87481	.	./.	L	.	R	A	934	0.15400	.	19	C0175704&CN260604&CN166718&CN517202	PS151100	ORPHA500&ORPHA98733&ORPHA536391	Uncertain_significance	NC_000019.10:g.4101032C>A	40818	reviewed_by_expert_panel	Noonan_syndrome_with_multiple_lentigines&Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:c77c7f8b-de11-4d2a-b1e3-d7190a41ba9f	.	.	AEFDGBI	D	0.82945	0.98454	D	0.88247	0.916371	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	19	4052030	19	4101030	0	0.73137	0.706548	1.000000	0.71638	0.554000	0.30269	0.195000	0.22031	7.860000	0.85401	0.596000	0.33519	1.022000	0.39869	4101032	C	.	rs730880511	.	.	6.943	7.389	5.732	10.284	.	.	.	-12	50	-13	50	0.00	0.00	0.00	0.00	MAP2K2	0.86	exon-NM_030662.4-6+13+start+125	40818	Uncertain_significance	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiofaciocutaneous_syndrome_4&not_provided&RASopathy&Noonan_syndrome_with_multiple_lentigines	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MONDO:MONDO:0014114&MedGen:C3809007&OMIM:615280&Orphanet:1340&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0007893&MedGen:C0175704&OMIM:PS151100&Orphanet:500	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs730880511	730880511	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:missense	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,930	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103237524	103237524	G	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1099C>G	NP_000268.1:p.Leu367Val	1213	1099	367	L/V	Ctg/Gtg	rs1565842281&CD015350&HM971459	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103237524G>C	.	.	.	.	.	.	uncertain_significance	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1099C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.93958	0.488451	D	0.93881	0.463849	21.4	21.8	2.270748	2.252477	0.36220	0.38283	G/G	D	0.67695	0.966786444187164	0.85335	0.9976420690928991	.	0.97298	.	G/G	.	.	.	.	3.399758	0.242704173295106	0.52235	3.312945	0.202216028050172	0.51306	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99585	.	.	.	5.24	5.24	0.72863	0	0.26702	0.573888	.	.	0.26954	0.929075871729035	.	0	0.59346	0.659464	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.74278	.	0.062853	0.62929	D	0.000004	D	0.96237	0.580344	0.09392	.	0.96573	.	D	0.98989	0.9681	.	0.99690	.	D	0.98767	1.0763	L367V	Loss_of_ubiquitination_at_K363_(P_=_0.0618)&_Loss_of_glycosylation_at_P366_(P_=_0.0798)&_Loss_of_loop_(P_=_0.1242)&_Loss_of_helix_(P_=_0.1299)&_Loss_of_disorder_(P_=_0.1761)	P00439	0.99614	0.962	.	0.71042	.	.	0.44171	simple_aae&simple_aae	D&D	0.989963&0.997766	0.30140	.	.	.	0.32132	.	.	0.38982	.	T	0.13311	0.319281518459	0.89786	.	10	0.83351	.	.	0.91255	.	.	12.2166	0.53721	0.0783:0.0:0.9217:0.0	.	.	.	.	.	.	.	.	0.84090	.	G/G	V	.	L	C	503	0.75780	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102843746G>C	619153	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.71158	0.96828	D	0.85418	0.904193	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101761654	12	103237524	0	0.56070	0.693126	1.000000	0.71638	0.015000	0.10482	0.155000	0.21078	5.332000	0.65686	-0.167000	0.11441	0.223000	0.24683	102843746	G	.	rs1565842281	.	.	8.924	9.158	3.163	9.459	.	.	.	33	-6	33	9	0.04	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-12+33+end+134	619153	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,668	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103238196	103238196	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	10/13	.	NM_000277.3:c.983C>T	NP_000268.1:p.Thr328Ile	1097	983	328	T/I	aCt/aTt	rs886042096&CM1511448	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103238196G>A	.	.	.	.	.	.	uncertain_significance	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.983C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.97042	0.583061	D	0.96993	0.599751	32	32	4.471900	4.451846	0.90977	0.91516	G/G	D	0.98068	0.999597489833832	0.93548	0.9985696279694275	.	0.99890	.	G/G	.	.	.	.	23.26829	1.06163580315296	0.99504	19.59578	1.14243961423498	0.98846	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99843	.	.	.	5.81	5.81	0.92413	0	0.26702	0.573888	.	.	0.74766	0.99999999961916	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.91818	.	0.000000	0.84330	D	0.000000	D	0.98303	0.784346	0.27244	.	0.99014	.	D	0.99900	0.9956	.	0.99412	.	D	0.96187	0.9359	T328I	Loss_of_catalytic_residue_at_F331_(P_=_0.1222)&_Loss_of_sheet_(P_=_0.1398)&_Gain_of_helix_(P_=_0.2684)&_Loss_of_glycosylation_at_T323_(P_=_0.5097)&_Gain_of_MoRF_binding_(P_=_0.679)	P00439	0.97729	0.899	.	0.98135	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.88224	.	.	.	0.90584	.	.	0.97372	.	D	0.85313	0.821863293648	0.99124	.	10	0.56640	.	.	0.91255	.	.	20.0776	0.97749	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.98657	.	G/G	I	.	T	A	503	0.75780	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102844418G>A	281073	reviewed_by_expert_panel	Phenylketonuria&not_provided	.	.	.	AEFDBI	D	0.94896	0.99352	D	0.99559	0.974443	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101762326	12	103238196	0	0.43195	0.638212	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	10.003000	0.99689	0.672000	0.70159	1.172000	0.72986	102844418	G	.	rs886042096	.	.	3.163	9.459	7.709	9.491	.	.	.	-8	13	13	-47	0.00	0.09	0.00	0.00	PAH	0.00	exon-NM_001354304.2-11+13+end+96	281073	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs886042096	886042096	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,679	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103310863	103310863	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	1/13	.	NM_000277.3:c.46T>C	NP_000268.1:p.Ser16Pro	160	46	16	S/P	Tct/Cct	rs62642946&CM010947	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103310863A>G	.	.	.	.	.	.	uncertain_significance&not_provided	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.46T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.89656	0.395561	D	0.89525	0.330419	21.6	14.35	2.297656	1.146887	0.36802	0.18841	A/A	T	0.26658	0.340868592262268	0.27362	0.95609989189682232	.	0.67451	.	A/A	.	.	.	.	1.090849	-0.570565746968411	0.20262	0.8622173	-0.67097506598948	0.16852	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99398	.	.	.	5.2	4.05	0.46415	0	0.06741	0.475579	.	.	0.74766	0.999999899069835	.	0	0.60874	0.672317	.	.	.	.	.	.	0	0.26826	0.564101	.&.&.	.	.	.	0.27173	.	0.377447	0.27995	N	0.016381	D	0.90526	0.289879	0.05074	.	0.94561	.	D	0.95925	0.8773	.	0.83493	.	D	0.92777	0.6685	S16P	Loss_of_phosphorylation_at_S16_(P_=_0.0395)&_Loss_of_helix_(P_=_0.0444)&_Gain_of_loop_(P_=_0.0502)&_Loss_of_stability_(P_=_0.0903)&_Gain_of_methylation_at_K14_(P_=_0.0975)	P00439	0.89998	0.774	.	0.14455	.	.	0.27757	simple_aae&without_aae	N&N	1&0.897985	0.19085	.	.	.	0.02946	.	.	0.01387	.	T	0.42106	0.523407042027	0.82346	.	10	0.23097	.	.	0.41364	.	.	8.1374	0.30223	0.8076:0.0:0.0:0.1924	.	.	.	.	.	.	.	.	0.45331	.	A/A	P	.	S	G	776	0.48302	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102917085A>G	102689	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_000869&DeBelle_Laboratory_for_Biochemical_Genetics:p.S16P	.	.	AEFDGBHCI	D	0.31335	0.60922	D	0.57890	0.577226	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101834993	12	103310863	0	0.40530	0.627647	0.991000	0.37257	0.030000	0.13115	0.290000	0.23859	2.438000	0.44495	0.756000	0.94297	1.312000	0.94714	102917085	A	.	rs62642946	.	.	8.002	9.602	.	.	.	.	.	-43	-15	-41	-14	0.00	0.00	0.00	0.01	PAH	0.00	exon-NM_000277.3-1+14+start+174	102689	Uncertain_significance	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62642946	62642946	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,847	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	112888151	112888151	T	C	C	missense_variant	MODERATE	PTPN11	5781	Transcript	NM_002834.5	protein_coding	3/16	.	NM_002834.5:c.167T>C	NP_002825.3:p.Ile56Thr	332	167	56	I/T	aTt/aCt	rs1052382672	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTPN11	.	chr12:g.112888151T>C	.	.	.	.	.	.	uncertain_significance&likely_pathogenic	.	1	.	.	.	.	.	PTPN11&NM_002834.3&c.167T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.97338	0.587185	D	0.97295	0.605674	26.6	26.4	3.941888	3.824551	0.76643	0.76254	./.	D	0.96259	0.999123752117157	0.85750	0.99769380501123639	.	0.99466	.	./.	.	.	.	.	16.66967	0.961637469996227	0.97738	16.49416	1.07506466560761	0.97644	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98428	.	.	.	5.63	5.63	0.86108	0	0.89359	0.724815	.	.	0.74766	0.999999846929068	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.98432	0.735409	.&.&SH2_domain&SH2_domain&SH2_domain&SH2_domain&SH2_domain&SH2_domain	.	.	.	0.93712	.	0.000000	0.84330	D	0.000000	D	0.97600	0.705865	0.95323	.	0.98552	.	D	0.99456	0.9822	.	0.97947	.	D	0.97540	1.0203	I56T	Loss_of_stability_(P_=_0.027)&_Gain_of_disorder_(P_=_0.0281)&_Gain_of_glycosylation_at_I56_(P_=_0.079)&_Gain_of_phosphorylation_at_T52_(P_=_0.0886)&_Loss_of_sheet_(P_=_0.1501)	ENST00000351677	0.96734	0.878	.	0.96317	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.77965	.	.	.	0.77913	.	.	0.73562	.	D	0.98850	0.927669167519	0.99622	.	10	0.51112	.	.	0.91255	.	.	15.8552	0.78752	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.97207	.	./.	T	.	I	C	45	0.97767	.	12	CN260604&CN166718	.	ORPHA98733&ORPHA536391	Likely_pathogenic	NC_000012.12:g.112450347T>C	477669	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy	ClinGen_RASopathy_Variant_Curation_Expert_Panel:2a9a7233-77c0-4d04-a2e1-0a1ac478a404	.	.	AEFDBI	D	0.89243	0.98963	D	0.81190	0.883191	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	111372534	12	112888151	0	0.85440	0.722319	1.000000	0.71638	0.993000	0.69303	0.998000	0.65909	8.008000	0.88114	0.660000	0.55035	1.135000	0.58920	112450347	T	.	rs1052382672	.	.	7.703	8.679	4.729	9.664	.	.	.	-26	-1	-39	11	0.01	0.00	0.00	0.00	PTPN11	1.00	exon-NM_001330437.2-3+29+start+195	477669	Likely_pathogenic	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&RASopathy	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1052382672	1052382672	.	.	.	PTPN11	PTPN11:exonic	PTPN11:missense	PTPN11:Noonan_syndrome_1\x3bLEOPARD_syndrome_1\x3bMetachondromatosis\x3bLeukemia\x2cjuvenile_myelomonocytic\x2csomatic	PTPN11:163950\x3b151100\x3b156250\x3b607785	PTPN11:3\x3b3\x3b3\x3b3	PTPN11:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999877230878678	0.000122769057470549	6.38519788034449e-11	DISEASE: LEOPARD syndrome 1 (LPRD1) [MIM:151100]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:12058348, ECO:0000269|PubMed:14961557, ECO:0000269|PubMed:15121796, ECO:0000269|PubMed:15389709, ECO:0000269|PubMed:15520399, ECO:0000269|PubMed:15690106, ECO:0000269|PubMed:16679933, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 1 (NS1) [MIM:163950]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints. {ECO:0000269|PubMed:11704759, ECO:0000269|PubMed:11992261, ECO:0000269|PubMed:12161469, ECO:0000269|PubMed:12325025, ECO:0000269|PubMed:12529711, ECO:0000269|PubMed:12634870, ECO:0000269|PubMed:12717436, ECO:0000269|PubMed:12739139, ECO:0000269|PubMed:12960218, ECO:0000269|PubMed:15384080, ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry. Mutations in PTPN11 account for more than 50% of the cases.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:12717436}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Metachondromatosis (MC) [MIM:156250]: A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest. {ECO:0000269|PubMed:20577567}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,854	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
13	20763485	20763486	AG	A	-	frameshift_variant	HIGH	GJB2	2706	Transcript	NM_004004.6	protein_coding	2/2	.	NM_004004.6:c.235del	NP_003995.2:p.Leu79CysfsTer3	413	235	79	L/X	Ctg/tg	rs80338943&CD991730&CM110995	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	GJB2	.	chr13:g.20763488del	.	0	0	0.0079	0	0	pathogenic	.	1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.295	9.602	.	.	.	-28	-6	49	47	0.00	0.00	0.00	0.00	GJB2	0.00	exon-NM_004004.6-2+256+end+2134	17014	Pathogenic	reviewed_by_expert_panel	Rare_genetic_deafness&Mutilating_keratoderma&Autosomal_dominant_nonsyndromic_hearing_loss_3A&X-linked_mixed_hearing_loss_with_perilymphatic_gusher&Knuckle_pads&_deafness_AND_leukonychia_syndrome&Autosomal_dominant_keratitis-ichthyosis-hearing_loss_syndrome&Palmoplantar_keratoderma-deafness_syndrome&Ichthyosis&_hystrix-like&_with_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_1A&Hearing_loss&not_provided&Nonsyndromic_genetic_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_1B&Deafness&_digenic&_GJB2/GJB3&Hearing_impairment	MedGen:CN826980&Orphanet:96210&MONDO:MONDO:0007422&MedGen:C0265964&OMIM:124500&Orphanet:494&MONDO:MONDO:0011103&MedGen:C2675750&OMIM:601544&Orphanet:90635&MONDO:MONDO:0010576&MedGen:C1844678&OMIM:304400&Orphanet:383&MONDO:MONDO:0007866&MedGen:C0266004&OMIM:149200&Orphanet:2698&MONDO:MONDO:0007850&MedGen:C0265336&OMIM:148210&Orphanet:477&MONDO:MONDO:0007852&MedGen:C1835672&OMIM:148350&Orphanet:2202&MONDO:MONDO:0011245&MedGen:C1865234&OMIM:602540&Orphanet:477&MONDO:MONDO:0009076&MedGen:C2673759&OMIM:220290&Orphanet:90636&MedGen:C3887873&MedGen:CN517202&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0012977&MedGen:C2675235&OMIM:612645&Orphanet:90636&MedGen:C2673761&Human_Phenotype_Ontology:HP:0000365&Human_Phenotype_Ontology:HP:0000404&Human_Phenotype_Ontology:HP:0001728&Human_Phenotype_Ontology:HP:0001729&Human_Phenotype_Ontology:HP:0001754&Human_Phenotype_Ontology:HP:0008560&Human_Phenotype_Ontology:HP:0008563&MONDO:MONDO:0005365&MedGen:C1384666	.	rs80338943	3.624e-04	44	44	0	0	0	43	0	1	0	0	10398	11576	8648	6614	66722	906	16512	0	0	43	0	1	0	0	0	0	0	0	0	0	0	rs80338943	0.00000e+00	0.00000e+00	0.00000e+00	6.14564e-03	0.00000e+00	1.79080e-05	1.82349e-04	3.24865e-05	4.22610e-04	4.76113e-04	6.14564e-03	4.46661e-04	rs80338943	0.00000e+00	0.00000e+00	0.00000e+00	9.24784e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84249e-04	3.60959e-04	9.24784e-03	4.83996e-04	.	.	rs80338943	80338943	.	.	.	GJB2	GJB2:exonic	GJB2:frameshift_deletion	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,868	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
13	20763685	20763686	AC	A	-	frameshift_variant	HIGH	GJB2	2706	Transcript	NM_004004.6	protein_coding	2/2	.	NM_004004.6:c.35del	NP_003995.2:p.Gly12ValfsTer2	213	35	12	G/X	gGt/gt	rs80338939&CD972240&CM000167&CM022364	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	GJB2	.	chr13:g.20763691del	.	0	0.0029	0	0.0089	0.001	uncertain_significance&not_provided&likely_pathogenic&pathogenic	.	1&1&1&1	.	.	.	.	.	GJB2&NM_004004.5&c.35del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.295	9.602	.	.	.	42	-22	2	1	0.00	0.00	0.00	0.00	GJB2	0.00	exon-NM_004004.6-2+56+end+2134	17004	Pathogenic	reviewed_by_expert_panel	Rare_genetic_deafness&Nonsyndromic_Hearing_Loss&_Recessive&Inborn_genetic_diseases&Mutilating_keratoderma&Autosomal_dominant_nonsyndromic_hearing_loss_3A&X-linked_mixed_hearing_loss_with_perilymphatic_gusher&Knuckle_pads&_deafness_AND_leukonychia_syndrome&Autosomal_dominant_keratitis-ichthyosis-hearing_loss_syndrome&Palmoplantar_keratoderma-deafness_syndrome&Ichthyosis&_hystrix-like&_with_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_1A&Hearing_loss&Deafness&Autosomal_recessive_nonsyndromic_hearing_loss_1B&Nonsyndromic_genetic_hearing_loss&not_provided&Hearing_loss&_autosomal_recessive&Deafness&_digenic&_GJB2/GJB6&Severe_sensorineural_hearing_impairment&Hearing_impairment&Bilateral_conductive_hearing_impairment&Bilateral_sensorineural_hearing_impairment&Ear_malformation	MedGen:CN826980&Orphanet:96210&MedGen:CN239439&MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0007422&MedGen:C0265964&OMIM:124500&Orphanet:494&MONDO:MONDO:0011103&MedGen:C2675750&OMIM:601544&Orphanet:90635&MONDO:MONDO:0010576&MedGen:C1844678&OMIM:304400&Orphanet:383&MONDO:MONDO:0007866&MedGen:C0266004&OMIM:149200&Orphanet:2698&MONDO:MONDO:0007850&MedGen:C0265336&OMIM:148210&Orphanet:477&MONDO:MONDO:0007852&MedGen:C1835672&OMIM:148350&Orphanet:2202&MONDO:MONDO:0011245&MedGen:C1865234&OMIM:602540&Orphanet:477&MONDO:MONDO:0009076&MedGen:C2673759&OMIM:220290&Orphanet:90636&MedGen:C3887873&MedGen:C0011053&MONDO:MONDO:0012977&MedGen:C2675235&OMIM:612645&Orphanet:90636&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN517202&MONDO:MONDO:0019588&MedGen:C1846647&OMIM:607197&OMIM:PS220290&Orphanet:90635&Orphanet:90636&MedGen:C2673760&Human_Phenotype_Ontology:HP:0008534&Human_Phenotype_Ontology:HP:0008574&Human_Phenotype_Ontology:HP:0008625&MedGen:C4021533&Human_Phenotype_Ontology:HP:0000365&Human_Phenotype_Ontology:HP:0000404&Human_Phenotype_Ontology:HP:0001728&Human_Phenotype_Ontology:HP:0001729&Human_Phenotype_Ontology:HP:0001754&Human_Phenotype_Ontology:HP:0008560&Human_Phenotype_Ontology:HP:0008563&MONDO:MONDO:0005365&MedGen:C1384666&Human_Phenotype_Ontology:HP:0008513&Human_Phenotype_Ontology:HP:0008536&MedGen:C0452136&Human_Phenotype_Ontology:HP:0008530&Human_Phenotype_Ontology:HP:0008539&Human_Phenotype_Ontology:HP:0008579&Human_Phenotype_Ontology:HP:0008585&Human_Phenotype_Ontology:HP:0008619&MedGen:C0452138&Human_Phenotype_Ontology:HP:0000598&MONDO:MONDO:0007500&MedGen:C0266589&OMIM:128600	.	rs1801002	6.038e-03	733	727	3	13	47	0	68	585	8	12	10400	11578	8654	6614	66686	908	16512	13	47	0	64	583	8	12	0	0	0	2	1	0	0	rs398123814	1.30685e-03	4.73524e-03	3.45318e-03	0.00000e+00	8.11659e-03	9.32669e-03	7.13241e-03	7.47287e-04	6.10084e-03	5.99906e-03	9.32669e-03	6.06814e-03	rs398123814	9.19329e-04	3.57995e-03	9.93377e-03	0.00000e+00	8.87235e-03	1.23547e-02	1.33470e-02	.	7.95694e-03	7.74801e-03	1.23547e-02	7.87300e-03	rs80338939	1.0783&0.0938&0.7429	rs80338939	80338939	.	.	.	GJB2	GJB2:exonic	GJB2:frameshift_deletion	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,872	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288671	103288671	A	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.194T>A	NP_000268.1:p.Ile65Asn	308	194	65	I/N	aTt/aAt	rs75193786&CM024620&CM920541&CM981428	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103288671A>T	.	.	.	.	.	.	not_provided&likely_pathogenic	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.194T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.94639	0.511893	D	0.94560	0.497523	28.7	28.9	4.208821	4.137199	0.85723	0.86694	A/A	D	0.94393	0.99852979183197	0.65788	0.99460472913697817	.	0.99949	.	A/A	.	.	.	.	20.07086	1.01922952991816	0.98965	17.73285	1.10517318639473	0.98228	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99273	.	.	.	6.17	6.17	0.99707	0	0.45803	0.59043	.	.	0.74766	0.999999999994017	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.97476	.	0.000000	0.84330	D	0.000000	D	0.99279	0.903974	0.31654	.	0.99132	.	D	0.99697	0.9892	.	0.99791	.	D	0.96883	0.9815	I65N	Gain_of_disorder_(P_=_0.0063)&_Loss_of_catalytic_residue_at_S67_(P_=_0.0359)&_Loss_of_sheet_(P_=_0.0457)&_Gain_of_glycosylation_at_T63_(P_=_0.1)&_Gain_of_phosphorylation_at_T63_(P_=_0.1713)	P00439	0.99599	0.961	.	0.99292	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.93404	.	.	.	0.90584	.	.	0.97372	.	T	0.74309	0.749071121216	0.99284	.	10	0.92824	.	.	0.91255	.	.	16.8222	0.85699	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99863	.	A/A	N	.	I	T	716	0.55970	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102894893A>T	102623	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.I65N&UniProtKB_(protein):P00439#VAR_000882	.	.	AEFBI	D	0.85869	0.98710	D	0.99191	0.969520	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101812801	12	103288671	0	0.37627	0.615465	1.000000	0.71638	0.996000	0.76049	1.000000	0.86279	8.297000	0.89867	0.756000	0.94297	1.312000	0.94714	102894893	A	.	rs75193786	.	.	11.038	10.766	11.785	7.700	.	.	.	22	-10	1	-33	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+25+end+184	102623	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs75193786	75193786	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,820	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103245529	103245529	A	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.848T>A	NP_000268.1:p.Ile283Asn	962	848	283	I/N	aTc/aAc	rs62508693&CM981446	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103245529A>T	.	.	.	.	.	.	pathogenic&not_provided	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.848T>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.82224	0.290821	D	0.81994	0.179968	28.7	28.7	4.201290	4.107554	0.85499	0.85827	A/A	D	0.91406	0.997372627258301	0.63405	0.994131856470028	.	0.99941	.	A/A	.	.	.	.	8.671673	0.744425614600077	0.85740	8.965583	0.809321817449114	0.86686	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99647	.	.	.	5.51	5.51	0.81769	0	0.45803	0.59043	.	.	0.40495	0.99957234689505	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.87317	.	0.146830	0.62929	D	0.000009	D	0.99037	0.873975	0.30676	.	0.99781	.	D	0.99652	0.9880	.	0.99711	.	D	0.97338	1.0089	I283N	Gain_of_disorder_(P_=_0.0107)&_Loss_of_catalytic_residue_at_L288_(P_=_0.0457)&_Loss_of_stability_(P_=_0.0809)&_Gain_of_glycosylation_at_T278_(P_=_0.1312)&_Gain_of_helix_(P_=_0.132)	P00439	0.97902	0.903	.	0.93917	.	.	0.58761	simple_aae&simple_aae	D&D	0.999999&0.999995	0.85397	.	.	.	0.90584	.	.	0.78936	.	D	0.83605	0.810732841492	0.97135	.	10	0.70582	.	.	0.78490	.	.	15.9194	0.79334	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99481	.	A/A	N	.	I	T	514	0.74853	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102851751A>T	102877	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_000984&DeBelle_Laboratory_for_Biochemical_Genetics:p.I283N	.	.	AEFBCI	D	0.52805	0.91072	D	0.83534	0.895382	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.568490e-06	0	0.000000e+00	41468	0	0	0.000000e+00	912	0	0	0.000000e+00	15282	0	152242	0	0.000000e+00	3470	0	0	0.000000e+00	5196	0	0	0.000000e+00	10628	0	0	0.000000e+00	316	0	1	1.469770e-05	68038	0	1	1.469770e-05	68038	0	0	0.000000e+00	4838	0	0	0.000000e+00	0	0.000000e+00	9098	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32918	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5500	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3116	0	0	.	0	1	6.757490e-06	0	0.000000e+00	41146	0	0	0.000000e+00	912	0	0	0.000000e+00	15094	0	147984	0	0.000000e+00	3300	0	0	0.000000e+00	4962	0	0	0.000000e+00	10628	0	0	0.000000e+00	304	0	1	1.543020e-05	64808	0	0	0.000000e+00	4806	0	0	1	7.416970e-06	0	0.000000e+00	32492	0	0	0.000000e+00	862	0	0	0.000000e+00	14836	0	134826	0	0.000000e+00	3386	0	0	0.000000e+00	5196	0	0	0.000000e+00	6988	0	0	0.000000e+00	310	0	1	1.564550e-05	63916	0	0	0.000000e+00	4836	0	0	0	0.000000e+00	0	0.000000e+00	24842	0	0	0.000000e+00	112	0	0	0.000000e+00	12908	0	80796	0	0.000000e+00	996	0	0	0.000000e+00	3754	0	0	0.000000e+00	10536	0	0	0.000000e+00	272	0	0	0.000000e+00	21046	0	0	0.000000e+00	4810	0	0	12	101769659	12	103245529	0	0.43195	0.638212	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	4.006000	0.56798	0.756000	0.94297	1.312000	0.94714	102851751	A	.	rs62508693	.	.	9.506	11.083	11.570	9.399	.	.	.	5	-39	6	5	0.03	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-9+5+end+70	102877	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508693	62508693	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,702	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288641	103288641	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.224A>G	NP_000268.1:p.Asp75Gly	338	224	75	D/G	gAt/gGt	rs1565866547&CM1511422&CM159591	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103288641T>C	.	.	.	.	.	.	likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.224A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.78012	0.243728	D	0.77726	0.112322	24.2	24.5	3.325702	3.336230	0.59666	0.62933	T/T	D	0.60442	0.935862898826599	0.57903	0.99280827136199079	.	0.87194	.	T/T	.	.	.	.	2.755189	0.105021324522129	0.44804	1.954168	-0.17277086405612	0.34271	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98035	.	.	.	6.17	6.17	0.99707	0	0.45803	0.59043	.	.	0.74766	0.999999983640896	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.61435	.	0.138386	0.62929	D	0.000005	D	0.71561	0.072551	0.03857	.	0.97234	.	D	0.91967	0.7640	.	0.45911	.	D	0.88640	0.3698	D75G	Loss_of_ubiquitination_at_K73_(P_=_0.043)&_Loss_of_solvent_accessibility_(P_=_0.0477)&_Gain_of_sheet_(P_=_0.0827)&_Loss_of_phosphorylation_at_Y77_(P_=_0.0904)&_Gain_of_methylation_at_K73_(P_=_0.1508)	P00439	0.52740	0.46	.	0.02557	.	.	0.58761	simple_aae&simple_aae	D&D	0.999997&0.999997	0.37566	.	.	.	0.07471	.	.	0.11217	.	T	0.37808	0.492666244507	0.75347	.	10	0.12107	.	.	0.27783	.	.	16.8222	0.85699	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.85979	.	T/T	G	.	D	C	716	0.55970	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102894863T>C	619158	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFGBI	D	0.64634	0.95416	D	0.83956	0.897411	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101812771	12	103288641	0	0.37627	0.615465	1.000000	0.71638	0.886000	0.42526	0.977000	0.46756	7.131000	0.76850	0.665000	0.62972	1.138000	0.64695	102894863	T	.	rs1565866547	.	gain/donor/103288641-103288642/Medium/6.731309	11.038	10.766	11.785	7.700	.	.	.	-37	4	1	-3	0.00	0.00	0.92	0.00	PAH	0.00	exon-NM_001354304.2-4+55+end+184	619158	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,815	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103248923	103248923	A	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.697T>A	NP_000268.1:p.Phe233Ile	811	697	233	F/I	Ttc/Atc	rs1565848061&CM136850	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103248923A>T	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.697T>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.88111	0.370864	D	0.87960	0.294944	25.8	26.1	3.790427	3.776388	0.71909	0.74719	A/A	D	0.92212	0.997709969933796	0.57155	0.99259315527944358	.	0.99828	.	A/A	.	.	.	.	7.105144	0.662507209665133	0.79543	7.78939	0.744497127808323	0.82547	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99758	.	.	.	5.17	5.17	0.70848	0	0.26702	0.573888	.	.	0.50053	0.999979868533354	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.96601	.	0.046170	0.84330	D	0.000000	D	0.98648	0.825858	0.29118	.	0.98655	.	D	0.99693	0.9891	.	0.98097	.	D	0.97001	0.9887	F233I	Gain_of_disorder_(P_=_0.3114)&_Loss_of_helix_(P_=_0.3949)&_Gain_of_catalytic_residue_at_T238_(P_=_0.4837)&_Loss_of_phosphorylation_at_T238_(P_=_0.5428)&_Gain_of_MoRF_binding_(P_=_0.5711)	P00439	0.94601	0.84	.	0.76211	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.86836	.	.	.	0.90584	.	.	0.80445	.	T	0.81476	0.796797633171	0.97965	.	10	0.83351	.	.	0.91255	.	.	15.3088	0.73720	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.93252	.	A/A	I	.	F	T	528	0.73785	.	12	C0031485	261600	ORPHA716	Pathogenic	NC_000012.12:g.102855145A>T	619163	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.92811	0.99207	D	0.99649	0.975998	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101773053	12	103248923	0	0.43195	0.638212	1.000000	0.71638	0.701000	0.34172	0.972000	0.45474	9.325000	0.96006	0.756000	0.94297	1.312000	0.94714	102855145	A	.	rs1565848061	.	.	7.651	9.354	7.292	9.092	.	.	.	32	-9	-9	2	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+9+start+197	619163	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,758	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246696	103246696	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.739G>A	NP_000268.1:p.Gly247Ser	853	739	247	G/S	Ggc/Agc	rs62508731&CM043313&CM043315&COSV61020613	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246696C>T	.	.	.	.	.	.	likely_pathogenic&not_provided	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.740del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.96978	0.578774	D	0.96928	0.593593	28.2	31	4.145650	4.323310	0.83672	0.90334	C/C	D	0.98390	0.999668002128601	0.96666	0.99892980070384285	.	0.99999	.	C/C	.	.	.	.	20.34363	1.02328038657006	0.99029	17.96028	1.11022800794782	0.98319	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99826	.	.	.	5.92	5.92	0.95557	0	0.45803	0.59043	.	.	0.74766	0.999999999999832	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.98828	.	0.045450	0.84330	D	0.000000	D	0.97316	0.676932	0.26630	.	0.98901	.	D	0.99910	0.9961	.	0.99838	.	D	0.95987	0.9220	G247S	Loss_of_methylation_at_R243_(P_=_0.1194)&_Gain_of_phosphorylation_at_G247_(P_=_0.1676)&_Loss_of_catalytic_residue_at_A246_(P_=_0.2199)&_Gain_of_disorder_(P_=_0.2656)&_Loss_of_sheet_(P_=_0.302)	P00439	0.99820	0.981	.	0.97772	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.87835	.	.	.	0.90584	.	.	0.97372	.	D	0.92495	0.869485855103	0.99874	.	10	0.92824	.	.	0.91255	.	.	20.3167	0.98654	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.97643	.	C/C	S	.	G	T	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852918C>T	102815	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.G247S	.	.	AEFBI	D	0.85537	0.98683	D	0.99843	0.980443	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770826	12	103246696	0	0.43195	0.638212	1.000000	0.71638	0.993000	0.69303	0.999000	0.70432	7.905000	0.86479	0.599000	0.40250	1.026000	0.45946	102852918	C	.	rs62508731	.	.	11.570	9.399	7.651	9.354	.	.	.	-2	32	32	-18	0.00	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+32+end+136	102815	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508731	62508731	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,749	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246696	103246696	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.739G>C	NP_000268.1:p.Gly247Arg	853	739	247	G/R	Ggc/Cgc	rs62508731&CM043313&CM043315&COSV61020613	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246696C>G	.	.	.	.	.	.	not_provided&likely_pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.740del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.96982	0.579094	D	0.96933	0.594052	27.4	29.6	4.062763	4.213215	0.80791	0.88540	C/C	D	0.99146	0.999819099903107	0.99868	0.99944068096948824	.	0.99999	.	C/C	.	.	.	.	20.34363	1.02328038657006	0.99029	17.96028	1.11022800794782	0.98319	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99831	.	.	.	5.92	5.92	0.95557	0	0.45803	0.59043	.	.	0.74766	0.999999999999832	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.98917	.	0.045450	0.84330	D	0.000000	D	0.98174	0.769204	0.28073	.	0.99030	.	D	0.99910	0.9961	.	0.99890	.	D	0.95987	0.9220	G247R	Gain_of_methylation_at_G247_(P_=_0.0277)&_Gain_of_MoRF_binding_(P_=_0.032)&_Gain_of_phosphorylation_at_S250_(P_=_0.0682)&_Loss_of_catalytic_residue_at_A246_(P_=_0.0717)&_Gain_of_helix_(P_=_0.2684)	P00439	0.99767	0.975	.	0.99550	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95542	.	.	.	0.90584	.	.	0.97372	.	D	0.96931	0.904584288597	0.99874	.	10	0.92824	.	.	0.91255	.	.	20.3167	0.98654	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99015	.	C/C	R	.	G	G	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852918C>G	102816	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.G247R	.	.	AEFBI	D	0.90130	0.99025	D	0.99889	0.981990	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770826	12	103246696	0	0.43195	0.638212	1.000000	0.71638	0.993000	0.69303	0.999000	0.70432	7.905000	0.86479	0.599000	0.40250	1.026000	0.45946	102852918	C	.	rs62508731	.	.	11.570	9.399	7.651	9.354	.	.	.	32	2	-18	32	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+32+end+136	102816	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508731	62508731	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,748	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246681	103246681	G	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.754C>G	NP_000268.1:p.Arg252Gly	868	754	252	R/G	Cgg/Ggg	rs5030847&CD078127&CM910284&CM920552&COSV61019811	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246681G>C	.	.	.	.	.	.	pathogenic&not_provided	0&0&0&0&1	1&1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.754C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.95317	0.535342	D	0.95247	0.531205	25.3	25.6	3.684182	3.654949	0.68919	0.71177	G/G	D	0.88657	0.996091425418854	0.97651	0.99905876984318476	.	0.99995	.	G/G	.	.	.	.	6.227692	0.60034007322503	0.74966	6.65808	0.66512664326729	0.77350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99776	.	.	.	5.92	3.88	0.43959	0	0.45803	0.59043	.	.	0.25341	0.867188258956602	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.97813	.	0.000000	0.84330	D	0.000000	D	0.98464	0.803496	0.28688	.	0.98437	.	D	0.99747	0.9905	.	0.99883	.	D	0.96632	0.9656	R252G	Loss_of_stability_(P_=_0.0062)&_Loss_of_methylation_at_R252_(P_=_0.0335)&_Loss_of_MoRF_binding_(P_=_0.1835)&_Loss_of_phosphorylation_at_S250_(P_=_0.2508)&_Gain_of_disorder_(P_=_0.3871)	P00439	0.99614	0.962	.	0.88688	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.92518	.	.	.	0.90584	.	.	0.97372	.	T	0.82349	0.80253046751	0.99091	.	10	0.83351	.	.	0.78490	.	.	16.5846	0.84576	0.0:0.0:0.7517:0.2483	.	.	.	.	.	.	.	.	0.97750	.	G/G	G	.	R	C	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852903G>C	102823	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_000956&DeBelle_Laboratory_for_Biochemical_Genetics:p.R252G	.	.	AEFBI	D	0.63778	0.95192	D	0.86638	0.909575	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770811	12	103246681	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	0.997000	0.62031	3.291000	0.51470	0.676000	0.76740	1.176000	0.78918	102852903	G	.	rs5030847	.	.	11.570	9.399	7.651	9.354	.	.	.	-48	47	47	-46	0.00	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+47+end+136	102823	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs5030847	5030847	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,745	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246681	103246681	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.754C>T	NP_000268.1:p.Arg252Trp	868	754	252	R/W	Cgg/Tgg	rs5030847&CD078127&CM910284&CM920552&COSV61019811	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246681G>A	.	.	.	.	.	.	pathogenic	0&0&0&0&1	1&1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.754C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.91639	0.432094	D	0.95735	0.552025	27.4	28.4	4.052294	4.083942	0.80414	0.85101	G/G	D	0.92489	0.9978187084198	0.99222	0.99928266971703705	.	0.99997	.	G/G	0	0.0	2	2.3255813953488373E-4	7.132923	0.664244646706325	0.79674	8.137534	0.765191835062469	0.83888	.	.	.	6	4.942e-05	0	0	0	0	6	4.945e-05	0	0	0	0	6	8.995e-05	0	0	5	4.708e-05	0	0	0	0	5	4.711e-05	0	0	0	0	5	9.204e-05	0	0	5	5.510e-05	0	0	0	0	5	5.515e-05	0	0	0	0	5	1.187e-04	0	0	0.99791	.	.	.	5.92	3.88	0.43959	0	0.45803	0.59043	.	.	0.25341	0.867188258956602	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.98988	.	0.000000	0.84330	D	0.000000	D	0.98270	0.780396	0.26966	.	0.99438	.	D	0.99841	0.9932	.	0.98065	.	D	0.96056	0.9268	.	.	.	.	.	.	0.98946	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95511	.	.	.	0.90584	.	.	0.97372	.	D	0.90133	0.853435873985	0.99803	.	10	0.60972	.	.	0.91255	.	.	16.5846	0.84576	0.0:0.0:0.7517:0.2483	.	.	.	.	.	.	.	.	0.97856	.	G/G	W	.	R	A	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852903G>A	584	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.R252W&OMIM_Allelic_Variant:612349.0007&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2850886&UniProtKB_(protein):P00439#VAR_000958	.	.	AEFBI	D	0.60731	0.94301	D	0.92643	0.933882	.	7	2.785830e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34574	0	251272	0	0.000000e+00	10072	0	1	5.438920e-05	18386	0	0	0.000000e+00	21632	0	6	5.281600e-05	113602	0	1	5.438920e-05	18386	0	0	0.000000e+00	30616	0	1	9.141940e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17108	0	109386	0	0.000000e+00	2320	0	0	0.000000e+00	9040	0	0	0.000000e+00	13392	0	1	2.338630e-05	42760	0	1	2.338630e-05	42760	0	0	0.000000e+00	15690	0	0	.	0	6	2.534470e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34242	0	236736	0	0.000000e+00	9564	0	1	5.654830e-05	17684	0	0	0.000000e+00	21616	0	5	4.873860e-05	102588	0	1	5.654830e-05	17684	0	0	0.000000e+00	30526	0	0	5	2.403110e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30512	0	208064	0	0.000000e+00	6210	0	0	0.000000e+00	13408	0	0	0.000000e+00	16718	0	5	5.584970e-05	89526	0	5	5.584970e-05	89526	0	0	0.000000e+00	30608	0	0	6	2.452440e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34440	0	244654	0	0.000000e+00	9990	0	1	5.440100e-05	18382	0	0	0.000000e+00	21630	0	5	4.483820e-05	111512	0	1	5.440100e-05	18382	0	0	0.000000e+00	30616	0	0	8	5.257760e-05	0	0.000000e+00	41448	0	0	0.000000e+00	912	0	0	0.000000e+00	15274	0	152156	0	0.000000e+00	3472	0	0	0.000000e+00	5184	0	0	0.000000e+00	10606	0	0	0.000000e+00	316	0	8	1.176060e-04	68024	0	8	1.176060e-04	68024	0	0	0.000000e+00	4830	0	1	3.040070e-05	0	0.000000e+00	9094	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32894	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5484	0	0	0.000000e+00	246	0	1	1.459000e-04	6854	0	0	0.000000e+00	3112	0	0	.	0	8	5.408400e-05	0	0.000000e+00	41126	0	0	0.000000e+00	912	0	0	0.000000e+00	15088	0	147918	0	0.000000e+00	3302	0	0	0.000000e+00	4948	0	0	0.000000e+00	10606	0	0	0.000000e+00	304	0	8	1.234340e-04	64812	0	0	0.000000e+00	4798	0	0	8	5.937270e-05	0	0.000000e+00	32472	0	0	0.000000e+00	862	0	0	0.000000e+00	14828	0	134742	0	0.000000e+00	3388	0	0	0.000000e+00	5184	0	0	0.000000e+00	6970	0	0	0.000000e+00	310	0	8	1.251960e-04	63900	0	0	0.000000e+00	4828	0	0	0	0.000000e+00	0	0.000000e+00	24824	0	0	0.000000e+00	112	0	0	0.000000e+00	12900	0	80716	0	0.000000e+00	998	0	0	0.000000e+00	3742	0	0	0.000000e+00	10514	0	0	0.000000e+00	272	0	0	0.000000e+00	21036	0	0	0.000000e+00	4802	0	0	12	101770811	12	103246681	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	0.997000	0.62031	3.291000	0.51470	0.676000	0.76740	1.176000	0.78918	102852903	G	.	rs5030847	.	.	11.570	9.399	7.651	9.354	.	.	.	-48	47	47	-46	0.00	0.02	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+47+end+136	584	Pathogenic	reviewed_by_expert_panel	not_provided&See_cases&Phenylketonuria	MedGen:CN517202&.&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030847	4.942e-05	6	6	0	0	0	0	0	6	0	0	10402	11554	8648	6600	66704	908	16512	0	0	0	0	6	0	0	0	0	0	0	0	0	0	rs5030847	0.00000e+00	0.00000e+00	0.00000e+00	5.80046e-05	0.00000e+00	4.48246e-05	0.00000e+00	0.00000e+00	2.22595e-05	2.69605e-05	5.80046e-05	2.43633e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	rs5030847	0.0233&0.0&0.0154	rs5030847	5030847	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,744	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246662	103246662	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.773T>C	NP_000268.1:p.Leu258Pro	887	773	258	L/P	cTg/cCg	rs1565846899&CM102048&COSV100188526	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103246662A>G	.	.	.	.	.	.	likely_pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.773T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.97038	0.582817	D	0.96989	0.5994	29.7	28.5	4.309625	4.095596	0.88442	0.85469	A/A	D	0.98254	0.999636650085449	0.97949	0.99909484294030249	.	0.99999	.	A/A	.	.	.	.	18.00759	0.985985461829271	0.98337	16.86161	1.08445726095442	0.97836	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99813	.	.	.	5.72	5.72	0.89380	0	0.45803	0.59043	.	.	0.74766	0.999999997183774	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.96221	.	0.000000	0.84330	D	0.000000	D	0.98015	0.751009	0.30750	.	0.99739	.	D	0.99900	0.9956	.	0.99964	.	D	0.95701	0.9020	L258P	Loss_of_stability_(P_=_0.1169)&_Loss_of_methylation_at_R261_(P_=_0.1621)&_Loss_of_MoRF_binding_(P_=_0.1677)&_Gain_of_catalytic_residue_at_L258_(P_=_0.1756)&_Loss_of_helix_(P_=_0.2271)	P00439	0.99747	0.973	.	0.99583	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.91956	.	.	.	0.90584	.	.	0.97372	.	D	0.94895	0.887108325958	0.99695	.	10	0.92824	.	.	0.91255	.	.	15.998	0.80060	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99929	.	A/A	P	.	L	G	518	0.74548	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852884A>G	619159	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.89286	0.98966	D	0.99994	0.990344	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770792	12	103246662	0	0.43195	0.638212	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	9.325000	0.96006	0.756000	0.94297	1.312000	0.94714	102852884	A	.	rs1565846899	.	.	11.570	9.399	7.651	9.354	.	.	.	-2	-12	-34	-27	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+66+end+136	619159	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,741	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246647	103246647	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.788T>C	NP_000268.1:p.Phe263Ser	902	788	263	F/S	tTc/tCc	rs1565846863&CM130696	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103246647A>G	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.788T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.97052	0.583233	D	0.97004	0.599997	32	31	4.572848	4.318506	0.91778	0.90267	A/A	D	0.99146	0.999811828136444	0.96666	0.99892965871086703	.	0.99998	.	A/A	.	.	.	.	17.85068	0.983233762506945	0.98276	16.79673	1.08281918626927	0.97803	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99854	.	.	.	5.72	5.72	0.89380	0	0.45803	0.59043	.	.	0.74766	0.999999997183774	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.94639	.	0.000000	0.84330	D	0.000000	D	0.99010	0.870532	0.31583	.	0.98402	.	D	0.99918	0.9965	.	0.99883	.	D	0.95569	0.8925	F263S	Gain_of_methylation_at_R261_(P_=_0.0735)&_Loss_of_stability_(P_=_0.0883)&_Gain_of_helix_(P_=_0.2059)&_Loss_of_loop_(P_=_0.2237)&_Gain_of_MoRF_binding_(P_=_0.2477)	P00439	0.99368	0.948	.	0.99631	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.94958	.	.	.	0.90584	.	.	0.92359	.	D	0.97565	0.91100102663	0.99918	.	10	0.92824	.	.	0.91255	.	.	15.998	0.80060	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99954	.	A/A	S	.	F	G	518	0.74548	.	12	C0031485	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852869A>G	619150	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.89286	0.98966	D	0.99838	0.980282	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770777	12	103246647	0	0.43195	0.638212	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	9.325000	0.96006	0.756000	0.94297	1.312000	0.94714	102852869	A	.	rs1565846863	.	.	11.570	9.399	7.651	9.354	.	.	.	-44	-14	22	-12	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+54+start+136	619150	Pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,735	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246646	103246646	G	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.789C>G	NP_000268.1:p.Phe263Leu	903	789	263	F/L	ttC/ttG	rs62642944&CM930550	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246646G>C	.	.	.	.	.	.	not_provided&uncertain_significance	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.790del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.92385	0.447845	D	0.93987	0.469168	25.8	24.6	3.787420	3.388770	0.71830	0.64273	G/G	D	0.71069	0.975746989250183	0.92750	0.99848239719992204	.	0.99815	.	G/G	.	.	.	.	4.554139	0.426827797687333	0.63241	5.182957	0.518564226030049	0.68187	.	.	.	2	1.647e-05	0	0	0	0	2	1.648e-05	0	0	0	0	2	2.997e-05	0	0	2	1.883e-05	0	0	0	0	2	1.884e-05	0	0	0	0	2	3.680e-05	0	0	2	2.204e-05	0	0	0	0	2	2.205e-05	0	0	0	0	2	4.747e-05	0	0	0.99828	.	.	.	5.72	2.95	0.33285	0	0.45803	0.59043	.	.	0.18664	0.249504788912547	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.90093	.	0.000000	0.84330	D	0.000000	D	0.97709	0.71732	0.20141	.	0.96401	.	D	0.99751	0.9906	.	0.99737	.	D	0.98130	1.0506	F263L	Loss_of_methylation_at_R261_(P_=_0.1258)&_Loss_of_sheet_(P_=_0.1907)&_Gain_of_helix_(P_=_0.2059)&_Loss_of_MoRF_binding_(P_=_0.2631)&_Gain_of_loop_(P_=_0.4661)	P00439	0.99715	0.97	.	0.77738	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.85247	.	.	.	0.90584	.	.	0.86255	.	D	0.98425	0.921350240707	0.98304	.	10	0.83351	.	.	0.63226	.	.	10.2183	0.42359	0.326:0.0:0.674:0.0	.	.	.	.	.	.	.	.	0.99100	.	G/G	L	.	F	C	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102852868G>C	102833	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.F263L&UniProtKB_(protein):P00439#VAR_000966	.	.	AEFBI	D	0.57193	0.93047	D	0.75359	0.835724	.	3	1.193510e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34584	0	251360	0	0.000000e+00	10076	0	0	0.000000e+00	18392	0	0	0.000000e+00	21648	0	3	2.639590e-05	113654	0	3	2.639590e-05	113654	0	0	0.000000e+00	30616	0	1	9.140430e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109404	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	1	2.338310e-05	42766	0	1	2.338310e-05	42766	0	0	0.000000e+00	15690	0	0	.	0	3	1.266770e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34252	0	236822	0	0.000000e+00	9568	0	0	0.000000e+00	17690	0	0	0.000000e+00	21632	0	3	2.922890e-05	102638	0	3	2.922890e-05	102638	0	0	0.000000e+00	30526	0	0	3	1.441480e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30520	0	208120	0	0.000000e+00	6210	0	0	0.000000e+00	13414	0	0	0.000000e+00	16734	0	3	3.350080e-05	89550	0	3	3.350080e-05	89550	0	0	0.000000e+00	30608	0	0	3	1.225770e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34450	0	244744	0	0.000000e+00	9994	0	0	0.000000e+00	18388	0	0	0.000000e+00	21646	0	3	2.688990e-05	111566	0	3	2.688990e-05	111566	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770776	12	103246646	0	0.43195	0.638212	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	1.924000	0.39695	0.676000	0.76740	0.214000	0.24133	102852868	G	.	rs62642944	.	.	11.570	9.399	7.651	9.354	.	.	.	-34	-13	-38	-11	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+53+start+136	102833	Uncertain_significance	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62642944	1.647e-05	2	2	0	0	0	0	0	2	0	0	10404	11562	8652	6610	66732	908	16512	0	0	0	0	2	0	0	0	0	0	0	0	0	0	rs62642944	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.68846e-05	0.00000e+00	0.00000e+00	1.48353e-05	8.98392e-06	2.68846e-05	1.21817e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62642944	62642944	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,734	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246636	103246636	G	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.799C>G	NP_000268.1:p.Gln267Glu	913	799	267	Q/E	Cag/Gag	rs199475676&CM056666&CM085628&COSV61019636	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246636G>C	.	.	.	.	.	.	not_provided&pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.799C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.97015	0.58124	D	0.96965	0.597135	26.5	26.0	3.933215	3.750868	0.76363	0.73963	G/G	D	0.97310	0.999410510063171	0.72802	0.99577726607842876	.	0.99994	.	G/G	.	.	.	.	21.81063	1.04361006225262	0.99307	18.77424	1.12714541391348	0.98606	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99705	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999999999505	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.96561	.	0.000000	0.84330	D	0.000000	D	0.96302	0.585608	0.27269	.	0.99192	.	D	0.99855	0.9937	.	0.99664	.	D	0.96379	0.9490	Q267E	Gain_of_catalytic_residue_at_Q267_(P_=_0.0635)&_Loss_of_MoRF_binding_(P_=_0.1151)&_Gain_of_disorder_(P_=_0.1598)&_Loss_of_sheet_(P_=_0.1907)&_Gain_of_phosphorylation_at_Y268_(P_=_0.2751)	P00439	0.99183	0.94	.	0.97473	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.60507	.	.	.	0.90584	.	.	0.97372	.	T	0.75873	0.759625196457	0.98526	.	10	0.83351	.	.	0.91255	.	.	19.8956	0.96955	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.90251	.	G/G	E	.	Q	C	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852858G>C	102839	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.Q267E	.	.	AEFBI	D	0.94506	0.99324	D	0.99760	0.978258	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770766	12	103246636	0	0.43195	0.638212	1.000000	0.71638	0.997000	0.79791	0.998000	0.65909	10.003000	0.99689	0.676000	0.76740	1.176000	0.78918	102852858	G	.	rs199475676	.	.	11.570	9.399	7.651	9.354	.	.	.	-1	-3	-43	-3	0.00	0.00	0.03	0.00	PAH	0.00	exon-NM_001354304.2-8+43+start+136	102839	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475676	199475676	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,732	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246634	103246634	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.801G>C	NP_000268.1:p.Gln267His	915	801	267	Q/H	caG/caC	rs199475675&CM056670&COSV100187760&COSV61020569	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246634C>G	.	.	.	.	.	.	likely_pathogenic&not_provided	0&0&1&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.801G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.95627	0.545207	D	0.95562	0.545375	23.8	24.3	3.194095	3.283608	0.56447	0.61593	C/C	D	0.98115	0.99960058927536	0.78330	0.99666931769435974	.	0.99999	.	C/C	.	.	.	.	5.367772	0.522246656678623	0.69488	6.613499	0.661543932381618	0.77118	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99724	.	.	.	5.73	2.95	0.33285	0	0.45803	0.59043	.	.	0.25072	0.852576808062638	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.95568	.	0.000000	0.84330	D	0.000000	D	0.97722	0.718689	0.26224	.	0.98561	.	D	0.99778	0.9913	.	0.99843	.	D	0.97906	1.0398	Q267H	Gain_of_sheet_(P_=_0.0827)&_Gain_of_disorder_(P_=_0.0868)&_Gain_of_catalytic_residue_at_Q267_(P_=_0.0971)&_Loss_of_loop_(P_=_0.2237)&_Loss_of_MoRF_binding_(P_=_0.2403)	P00439	0.98901	0.93	.	0.97473	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.80595	.	.	.	0.90584	.	.	0.97372	.	T	0.80697	0.791676044464	0.99124	.	10	0.92824	.	.	0.91255	.	.	9.7435	0.39600	0.0:0.7246:0.0:0.2754	.	.	.	.	.	.	.	.	0.97750	.	C/C	H	.	Q	G	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852856C>G	102840	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.Q267H	.	.	AEFBI	D	0.63241	0.95046	D	0.78487	0.865706	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770764	12	103246634	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	2.247000	0.42803	0.599000	0.40250	1.026000	0.45946	102852856	C	.	rs199475675	.	.	11.570	9.399	7.651	9.354	.	.	.	-9	-1	-26	-41	0.00	0.00	0.00	0.03	PAH	0.00	exon-NM_001354304.2-8+41+start+136	102840	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475675	199475675	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,729	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246633	103246633	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.802T>C	NP_000268.1:p.Tyr268His	916	802	268	Y/H	Tac/Cac	rs62507263&CM010970	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103246633A>G	.	.	.	.	.	.	uncertain_significance&not_provided	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.802T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.97035	0.582612	D	0.96986	0.599105	29.6	28.4	4.305471	4.075038	0.88350	0.84826	A/A	D	0.97155	0.99937915802002	0.94902	0.99871333256873307	.	0.99999	.	A/A	.	.	.	.	16.84135	0.964899341406085	0.97826	15.65061	1.05216940929373	0.97140	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99786	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999997298143	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.99613	.	0.000000	0.84330	D	0.000000	D	0.97047	0.650996	0.28750	.	0.95699	.	D	0.99867	0.9942	.	0.99511	.	D	0.96000	0.9229	Y268H	Gain_of_disorder_(P_=_0.0436)&_Loss_of_sheet_(P_=_0.0817)&_Gain_of_catalytic_residue_at_Y268_(P_=_0.227)&_Gain_of_MoRF_binding_(P_=_0.2582)&_Loss_of_stability_(P_=_0.2674)	P00439	0.99257	0.943	.	0.98868	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.80595	.	.	.	0.90584	.	.	0.97372	.	D	0.94817	0.886498689651	0.99803	.	10	0.92824	.	.	0.91255	.	.	16.0142	0.80222	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.97426	.	A/A	H	.	Y	G	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102852855A>G	102841	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.Y268H	.	.	AEFBI	D	0.89372	0.98972	D	0.99760	0.978258	.	1	3.978420e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34584	0	251356	0	0.000000e+00	10076	0	0	0.000000e+00	18394	0	1	4.619360e-05	21648	0	0	0.000000e+00	113654	0	.	.	.	.	0	0.000000e+00	30614	0	1	9.140430e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17110	0	109404	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	1	7.466030e-05	13394	0	0	0.000000e+00	42768	0	.	.	.	.	0	0.000000e+00	15688	0	0	.	0	1	4.222650e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34252	0	236818	0	0.000000e+00	9568	0	0	0.000000e+00	17692	0	1	4.622780e-05	21632	0	0	0.000000e+00	102638	0	.	.	.	.	0	0.000000e+00	30524	0	0	1	4.804870e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30520	0	208122	0	0.000000e+00	6210	0	0	0.000000e+00	13416	0	1	5.975860e-05	16734	0	0	0.000000e+00	89552	0	.	.	.	.	0	0.000000e+00	30606	0	0	1	4.085970e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34450	0	244740	0	0.000000e+00	9994	0	0	0.000000e+00	18390	0	1	4.619790e-05	21646	0	0	0.000000e+00	111566	0	.	.	.	.	0	0.000000e+00	30614	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770763	12	103246633	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	9.325000	0.96006	0.756000	0.94297	1.312000	0.94714	102852855	A	.	rs62507263	.	.	11.570	9.399	7.651	9.354	.	.	.	0	2	-25	-40	0.00	0.00	0.00	0.02	PAH	0.00	exon-NM_001354304.2-8+40+start+136	102841	Uncertain_significance	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62507263	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	4.48430e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.98343e-06	4.48430e-05	4.06058e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62507263	62507263	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,728	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246632	103246632	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.803A>G	NP_000268.1:p.Tyr268Cys	917	803	268	Y/C	tAc/tGc	rs1565846805&CM160002	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103246632T>C	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.803A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.96604	0.569703	D	0.96547	0.580563	31	28.9	4.409871	4.131048	0.90241	0.86514	T/T	D	0.99255	0.999835968017578	0.92576	0.99846123718493363	.	0.99997	.	T/T	.	.	.	.	14.91243	0.926040278783197	0.96611	14.3963	1.01488255804426	0.96184	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99793	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999997298143	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.99817	.	0.000000	0.84330	D	0.000000	D	0.97585	0.704333	0.28467	.	0.98697	.	D	0.99867	0.9942	.	0.98693	.	D	0.96000	0.9229	Y268C	Loss_of_disorder_(P_=_0.1022)&_Loss_of_loop_(P_=_0.2237)&_Loss_of_MoRF_binding_(P_=_0.2469)&_Gain_of_catalytic_residue_at_H271_(P_=_0.288)&_Loss_of_sheet_(P_=_0.302)	P00439	0.97596	0.896	.	0.98868	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.97496	.	.	.	0.90584	.	.	0.97372	.	D	0.94387	0.883197963238	0.99434	.	10	0.92824	.	.	0.91255	.	.	16.0142	0.80222	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.87157	.	T/T	C	.	Y	C	518	0.74548	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852854T>C	619165	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.81569	0.98317	D	0.99920	0.983223	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770762	12	103246632	0	0.43195	0.638212	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	8.017000	0.88732	0.665000	0.62972	1.138000	0.64695	102852854	T	.	rs1565846805	.	.	11.570	9.399	7.651	9.354	.	.	.	1	3	-24	-39	0.00	0.00	0.00	0.03	PAH	0.00	exon-NM_001354304.2-8+39+start+136	619165	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,727	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246624	103246624	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.811C>T	NP_000268.1:p.His271Tyr	925	811	271	H/Y	Cat/Tat	rs62517164&CM010971	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246624G>A	.	.	.	.	.	.	uncertain_significance&not_provided	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.811C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.97026	0.582053	D	0.96977	0.598303	28.0	27.6	4.126658	3.993268	0.83012	0.82059	G/G	D	0.98068	0.999597489833832	0.90238	0.9981916522330585	.	0.99996	.	G/G	0	0.0	1	1.1627906976744187E-4	19.72607	1.01404101638928	0.98880	16.85742	1.0843511919393	0.97834	.	.	.	1	8.236e-06	0	0	0	0	1	8.237e-06	0	0	0	0	1	1.498e-05	0	0	1	9.415e-06	0	0	0	0	1	9.416e-06	0	0	0	0	1	1.840e-05	0	0	1	1.102e-05	0	0	0	0	1	1.102e-05	0	0	0	0	1	2.373e-05	0	0	0.99738	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999999999505	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.98498	.	0.000000	0.84330	D	0.000000	D	0.96641	0.614267	0.27827	.	0.99187	.	D	0.99830	0.9928	.	0.94967	.	D	0.96696	0.9697	.	.	.	.	.	.	0.97342	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.87760	.	.	.	0.90584	.	.	0.97372	.	D	0.82897	0.806121885777	0.99822	.	10	0.83351	.	.	0.91255	.	.	19.8956	0.96955	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.88356	.	G/G	Y	.	H	A	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102852846G>A	102849	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.H271Y&UniProtKB_(protein):P00439#VAR_000972	.	.	AEFBI	D	0.92054	0.99156	D	0.99797	0.979181	.	1	3.978610e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34586	0	251344	0	0.000000e+00	10078	0	0	0.000000e+00	18392	0	0	0.000000e+00	21648	0	1	8.800180e-06	113634	0	1	8.800180e-06	113634	0	0	0.000000e+00	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	1	4.222870e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34254	0	236806	0	0.000000e+00	9570	0	0	0.000000e+00	17690	0	0	0.000000e+00	21632	0	1	9.744880e-06	102618	0	1	9.744880e-06	102618	0	0	0.000000e+00	30526	0	0	1	4.805150e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30522	0	208110	0	0.000000e+00	6212	0	0	0.000000e+00	13414	0	0	0.000000e+00	16734	0	1	1.116870e-05	89536	0	1	1.116870e-05	89536	0	0	0.000000e+00	30608	0	0	0	0.000000e+00	0	0.000000e+00	12026	0	0	0.000000e+00	34452	0	244728	0	0.000000e+00	9996	0	0	0.000000e+00	18388	0	0	0.000000e+00	21646	0	0	0.000000e+00	111546	0	.	.	.	.	0	0.000000e+00	30616	0	0	1	6.572290e-06	0	0.000000e+00	41424	0	0	0.000000e+00	912	0	0	0.000000e+00	15272	0	152154	0	0.000000e+00	3472	0	0	0.000000e+00	5194	0	0	0.000000e+00	10612	0	0	0.000000e+00	316	0	1	1.470030e-05	68026	0	1	1.470030e-05	68026	0	0	0.000000e+00	4834	0	0	0.000000e+00	0	0.000000e+00	9092	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32894	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5488	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3116	0	0	.	0	1	6.760780e-06	0	0.000000e+00	41106	0	0	0.000000e+00	912	0	0	0.000000e+00	15084	0	147912	0	0.000000e+00	3302	0	0	0.000000e+00	4958	0	0	0.000000e+00	10612	0	0	0.000000e+00	304	0	1	1.542970e-05	64810	0	0	0.000000e+00	4802	0	0	1	7.421150e-06	0	0.000000e+00	32458	0	0	0.000000e+00	862	0	0	0.000000e+00	14826	0	134750	0	0.000000e+00	3388	0	0	0.000000e+00	5194	0	0	0.000000e+00	6974	0	0	0.000000e+00	310	0	1	1.564850e-05	63904	0	0	0.000000e+00	4832	0	0	0	0.000000e+00	0	0.000000e+00	24800	0	0	0.000000e+00	112	0	0	0.000000e+00	12898	0	80716	0	0.000000e+00	998	0	0	0.000000e+00	3754	0	0	0.000000e+00	10520	0	0	0.000000e+00	272	0	0	0.000000e+00	21038	0	0	0.000000e+00	4806	0	0	12	101770754	12	103246624	0	0.43195	0.638212	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	10.003000	0.99689	0.676000	0.76740	1.176000	0.78918	102852846	G	.	rs62517164	.	.	11.570	9.399	7.651	9.354	.	.	.	26	9	11	-31	0.00	0.00	0.00	0.02	PAH	0.00	exon-NM_001354304.2-8+31+start+136	102849	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_provided&Reduced_phenylalanine_hydroxylase_level	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202&Human_Phenotype_Ontology:HP:0005982&MedGen:C4025094	.	rs62517164	8.236e-06	1	1	0	0	0	0	0	1	0	0	10406	11570	8652	6614	66738	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62517164	0.0116&0.0&0.0077	rs62517164	62517164	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,724	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246622	103246622	A	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.813T>G	NP_000268.1:p.His271Gln	927	813	271	H/Q	caT/caG	rs1565846764&CM081725	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103246622A>C	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.813T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.94227	0.497436	D	0.94150	0.476756	23.0	22.9	2.802476	2.671224	0.47791	0.47487	A/A	D	0.85865	0.994522929191589	0.55291	0.99201364990495322	.	0.99887	.	A/A	.	.	.	.	1.739997	-0.21939682965695	0.30840	2.362763	-0.0426975354040023	0.39928	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99738	.	.	.	5.73	-2.18	0.06643	0	0.45803	0.59043	.	.	0.17592	0.160948495445208	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.97142	.	0.000000	0.84330	D	0.000000	D	0.98018	0.751454	0.26711	.	0.95255	.	D	0.99568	0.9856	.	0.99465	.	D	0.99590	1.0983	H271Q	Loss_of_sheet_(P_=_0.0817)&_Loss_of_catalytic_residue_at_I269_(P_=_0.0946)&_Gain_of_ubiquitination_at_K274_(P_=_0.1047)&_Loss_of_disorder_(P_=_0.1572)&_Gain_of_methylation_at_K274_(P_=_0.1798)	P00439	0.99347	0.947	.	0.81760	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95542	.	.	.	0.90584	.	.	0.97372	.	T	0.79782	0.785655379295	0.97776	.	10	0.83351	.	.	0.91255	.	.	13.7634	0.62465	0.4914:0.0:0.5086:0.0	.	.	.	.	.	.	.	.	0.97095	.	A/A	Q	.	H	C	518	0.74548	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852844A>C	619152	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.28818	0.51106	D	0.75677	0.839355	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770752	12	103246622	0	0.43195	0.638212	0.256000	0.24909	0.996000	0.76049	0.998000	0.65909	0.750000	0.25999	-0.050000	0.17177	-0.051000	0.13049	102852844	A	.	rs1565846764	.	.	11.570	9.399	7.651	9.354	.	.	.	3	28	13	-29	0.00	0.00	0.00	0.09	PAH	0.00	exon-NM_001354304.2-8+29+start+136	619152	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,721	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103245513	103245513	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.864G>C	NP_000268.1:p.Leu288Phe	978	864	288	L/F	ttG/ttC	rs62507327&CM010972	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103245513C>G	.	.	.	.	.	.	uncertain_significance&not_provided	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.864G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.93818	0.483432	D	0.93739	0.45664	25.0	25.2	3.591839	3.566450	0.66479	0.68821	C/C	D	0.66095	0.961484379119125	0.96895	0.99896241014181308	.	0.99390	.	C/C	.	.	.	.	5.427887	0.528379692022326	0.69908	5.420329	0.546684664455353	0.69881	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99758	.	.	.	5.51	3.56	0.39892	0	0.45803	0.59043	.	.	0.20533	0.450192849150504	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.92553	.	0.070879	0.55875	D	0.000022	D	0.95885	0.552833	0.22280	.	0.98798	.	D	0.99306	0.9776	.	0.97462	.	D	0.97058	0.9922	L288F	Gain_of_helix_(P_=_0.1736)&_Loss_of_stability_(P_=_0.198)&_Loss_of_loop_(P_=_0.2237)&_Loss_of_catalytic_residue_at_L288_(P_=_0.4393)&_Loss_of_disorder_(P_=_0.4894)	P00439	0.97414	0.892	.	0.44259	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.68999	.	.	.	0.90584	.	.	0.86255	.	D	0.85075	0.820309042931	0.91371	.	10	0.79402	.	.	0.78490	.	.	3.6508	0.07740	0.4347:0.4252:0.0:0.1402	.	.	.	.	.	.	.	.	0.82964	.	C/C	F	.	L	G	514	0.74853	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102851735C>G	102881	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.L288F	.	.	AEFBCI	D	0.42750	0.83647	D	0.68128	0.735487	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101769643	12	103245513	0	0.43195	0.638212	0.998000	0.41325	0.999000	0.91618	1.000000	0.86279	0.533000	0.22791	0.599000	0.40250	1.026000	0.45946	102851735	C	.	rs62507327	.	.	9.506	11.083	11.570	9.399	.	.	.	21	-48	-48	21	0.07	0.00	0.04	0.00	PAH	0.00	exon-NM_001354304.2-9+21+end+70	102881	Uncertain_significance	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62507327	62507327	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,699	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246618	103246618	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.817T>C	NP_000268.1:p.Ser273Pro	931	817	273	S/P	Tcc/Ccc	rs1565846754&HM972015	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103246618A>G	.	.	.	.	.	.	uncertain_significance	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.817T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96314	0.563939	D	0.96256	0.572283	29.4	28.8	4.283759	4.121835	0.87839	0.86269	A/A	D	0.96570	0.999216794967651	0.97275	0.9990089091676112	.	0.99978	.	A/A	.	.	.	.	12.66665	0.873592896433364	0.94315	12.59718	0.956186499234048	0.94229	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99568	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999997298143	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.73814	.	0.000000	0.84330	D	0.000000	D	0.97773	0.724235	0.28080	.	0.99610	.	D	0.99751	0.9906	.	0.99286	.	D	0.96747	0.9729	S273P	Gain_of_ubiquitination_at_K274_(P_=_0.0898)&_Gain_of_glycosylation_at_K274_(P_=_0.1009)&_Gain_of_phosphorylation_at_T278_(P_=_0.1083)&_Gain_of_methylation_at_K274_(P_=_0.1131)&_Loss_of_disorder_(P_=_0.2107)	P00439	0.97506	0.894	.	0.98199	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.78976	.	.	.	0.77913	.	.	0.75477	.	T	0.62393	0.666882634163	0.99783	.	10	0.79402	.	.	0.78490	.	.	16.0142	0.80222	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.91852	.	A/A	P	.	S	G	518	0.74548	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102852840A>G	619148	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.79454	0.98083	D	0.99983	0.987874	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770748	12	103246618	0	0.43195	0.638212	1.000000	0.71638	0.995000	0.73285	1.000000	0.86279	7.358000	0.78724	0.756000	0.94297	1.312000	0.94714	102852840	A	.	rs1565846754	.	.	11.570	9.399	7.651	9.354	.	.	.	-25	32	-29	-25	0.00	0.00	0.00	0.01	PAH	0.00	exon-NM_001354304.2-8+25+start+136	619148	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,719	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246612	103246612	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.823C>T	NP_000268.1:p.Pro275Ser	937	823	275	P/S	Ccc/Tcc	rs62508691&CM101156&CM992947	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246612G>A	.	.	.	.	.	.	not_provided&pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.823C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.97030	0.582273	D	0.96981	0.598619	28.9	28.3	4.227783	4.066217	0.86308	0.84549	G/G	D	0.99255	0.99983537197113	0.99334	0.99930610125621311	.	0.99996	.	G/G	0	0.0	1	1.1627906976744187E-4	18.85914	1.000300190921	0.98633	17.28504	1.09477115347637	0.98036	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99809	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999999999505	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.92407	.	0.000000	0.84330	D	0.000000	D	0.97042	0.650587	0.26752	.	0.99532	.	D	0.99880	0.9947	.	0.98419	.	D	0.96190	0.9361	.	.	.	.	.	.	0.98852	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95542	.	.	.	0.90584	.	.	0.97372	.	T	0.77979	0.773705244064	0.99189	.	10	0.83351	.	.	0.91255	.	.	19.8956	0.96955	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.93841	.	G/G	S	.	P	A	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852834G>A	102853	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.P275S	.	.	AEFBI	D	0.92054	0.99156	D	0.99729	0.977579	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770742	12	103246612	0	0.43195	0.638212	1.000000	0.71638	0.962000	0.52141	0.999000	0.70432	10.003000	0.99689	0.676000	0.76740	1.176000	0.78918	102852834	G	.	rs62508691	.	.	11.570	9.399	7.651	9.354	.	.	.	38	21	-19	-4	0.00	0.00	0.01	0.00	PAH	0.00	exon-NM_001354304.2-8+19+start+136	102853	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508691	0.0116&0.0&0.0077	rs62508691	62508691	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,716	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246611	103246611	G	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.824C>G	NP_000268.1:p.Pro275Arg	938	824	275	P/R	cCc/cGc	rs62508715&CM024621&CM992374	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246611G>C	.	.	.	.	.	.	not_provided&likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.824C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.97028	0.582174	D	0.96979	0.598476	29.8	28.3	4.328300	4.066430	0.88847	0.84549	G/G	D	0.98984	0.999789774417877	0.92489	0.99844458048746187	.	0.99997	.	G/G	.	.	.	.	18.38738	0.99243962870445	0.98476	17.04032	1.08889566489992	0.97923	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99815	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999999999505	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.94786	.	0.000000	0.84330	D	0.000000	D	0.95313	0.511858	0.27107	.	0.99585	.	D	0.99900	0.9956	.	0.99645	.	D	0.96042	0.9258	P275R	Gain_of_catalytic_residue_at_P275_(P_=_0.0194)&_Gain_of_MoRF_binding_(P_=_0.0532)&_Loss_of_glycosylation_at_T278_(P_=_0.0583)&_Loss_of_ubiquitination_at_K274_(P_=_0.093)&_Gain_of_phosphorylation_at_T278_(P_=_0.1205)	P00439	0.98673	0.923	.	0.98852	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.97496	.	.	.	0.90584	.	.	0.97372	.	D	0.84630	0.817402243614	0.99490	.	10	0.92824	.	.	0.91255	.	.	19.8956	0.96955	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.95021	.	G/G	R	.	P	C	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852833G>C	102854	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.P275R	.	.	AEFBI	D	0.94506	0.99324	D	0.99639	0.975802	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770741	12	103246611	0	0.43195	0.638212	1.000000	0.71638	0.948000	0.49324	0.998000	0.65909	10.003000	0.99689	0.676000	0.76740	1.176000	0.78918	102852833	G	.	rs62508715	.	.	11.570	9.399	7.651	9.354	.	.	.	22	24	-18	24	0.00	0.00	0.02	0.00	PAH	0.00	exon-NM_001354304.2-8+18+start+136	102854	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508715	62508715	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,715	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246609	103246609	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.826A>G	NP_000268.1:p.Met276Val	940	826	276	M/V	Atg/Gtg	rs62516149&CM930552	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103246609T>C	.	.	.	.	.	.	likely_pathogenic&not_provided	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.826A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.93331	0.469951	D	0.93247	0.437276	23.4	22.9	2.989832	2.697915	0.51816	0.48073	T/T	D	0.61337	0.940757215023041	0.41431	0.98433855419284699	.	0.97914	.	T/T	.	.	.	.	3.855539	0.323330535741728	0.56914	3.463608	0.235431874788196	0.52923	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99538	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.46280	0.999929546970039	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.50622	.	0.037200	0.84330	D	0.000000	D	0.94656	0.469538	0.04249	.	0.95418	.	D	0.99003	0.9685	.	0.97349	.	D	0.99542	1.0972	M276V	Loss_of_solvent_accessibility_(P_=_0.0217)&_Gain_of_phosphorylation_at_T278_(P_=_0.0785)&_Gain_of_glycosylation_at_S273_(P_=_0.0944)&_Loss_of_relative_solvent_accessibility_(P_=_0.107)&_Loss_of_disorder_(P_=_0.1123)	P00439	0.96632	0.876	.	0.89331	.	.	0.58761	simple_aae&simple_aae	D&D	0.999997&0.999997	0.42957	.	.	.	0.31720	.	.	0.24114	.	T	0.46444	0.554166436195	0.92908	.	10	0.50226	.	.	0.52492	.	.	16.0142	0.80222	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.86725	.	T/T	V	.	M	C	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852831T>C	102856	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.M276V&UniProtKB_(protein):P00439#VAR_000975	.	.	AEFBI	D	0.66678	0.95909	D	0.89982	0.923402	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770739	12	103246609	0	0.43195	0.638212	1.000000	0.71638	0.914000	0.44937	0.997000	0.62031	4.983000	0.63555	0.665000	0.62972	1.138000	0.64695	102852831	T	.	rs62516149	.	.	11.570	9.399	7.651	9.354	.	.	.	24	26	-16	-1	0.00	0.00	0.02	0.00	PAH	0.00	exon-NM_001354304.2-8+16+start+136	102856	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62516149	62516149	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,714	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246608	103246608	A	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.827T>A	NP_000268.1:p.Met276Lys	941	827	276	M/K	aTg/aAg	rs62508722&CM034745&CM034746	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103246608A>T	.	.	.	.	.	.	not_provided&likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.827T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.94069	0.492378	D	0.93992	0.46949	23.0	22.7	2.801000	2.550572	0.47762	0.44844	A/A	D	0.55848	0.90490061044693	0.25896	0.94969383492798931	.	0.99636	.	A/A	.	.	.	.	3.412814	0.245184413284757	0.52377	2.83199	0.0861522907835167	0.45817	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99572	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.48110	0.999950523435374	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.68205	.	0.037200	0.84330	D	0.000000	D	0.95296	0.510666	0.04348	.	0.97020	.	D	0.98585	0.9563	.	0.96605	.	D	0.97712	1.0297	M276K	Gain_of_methylation_at_M276_(P_=_0.0202)&_Gain_of_ubiquitination_at_M276_(P_=_0.0238)&_Gain_of_disorder_(P_=_0.0413)&_Gain_of_phosphorylation_at_T278_(P_=_0.061)&_Loss_of_stability_(P_=_0.0781)	P00439	0.97032	0.884	.	0.48079	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.70920	.	.	.	0.12183	.	.	0.11217	.	T	0.66428	0.695032835007	0.92787	.	10	0.42261	.	.	0.33923	.	.	16.0142	0.80222	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.78451	.	A/A	K	.	M	T	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852830A>T	102857	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.M276K	.	.	AEFBI	D	0.71404	0.96873	D	0.99481	0.973239	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770738	12	103246608	0	0.43195	0.638212	1.000000	0.71638	0.894000	0.43146	0.996000	0.59523	7.445000	0.79656	0.756000	0.94297	1.312000	0.94714	102852830	A	.	rs62508722	.	.	11.570	9.399	7.651	9.354	.	.	.	25	27	-15	27	0.00	0.00	0.02	0.00	PAH	0.00	exon-NM_001354304.2-8+15+start+136	102857	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508722	62508722	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,713	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246608	103246608	A	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.827T>G	NP_000268.1:p.Met276Arg	941	827	276	M/R	aTg/aGg	rs62508722&CM034745&CM034746	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103246608A>C	.	.	.	.	.	.	not_provided	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.827T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.95068	0.527244	D	0.94995	0.519573	26.9	25.9	3.990749	3.738111	0.78291	0.73577	A/A	D	0.73282	0.980290770530701	0.33780	0.97402032991027665	.	0.99658	.	A/A	.	.	.	.	4.665682	0.441397091523789	0.64165	4.187362	0.37419073538694	0.60026	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99576	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.48110	0.999950523435374	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.53348	.	0.037200	0.84330	D	0.000000	D	0.95824	0.548228	0.06755	.	0.98055	.	D	0.98989	0.9681	.	0.96967	.	D	0.99833	1.1064	M276R	Gain_of_phosphorylation_at_T278_(P_=_0.054)&_Gain_of_ubiquitination_at_K274_(P_=_0.0797)&_Gain_of_disorder_(P_=_0.0966)&_Gain_of_solvent_accessibility_(P_=_0.11)&_Loss_of_glycosylation_at_T278_(P_=_0.1664)	P00439	0.96319	0.87	.	0.83286	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.72120	.	.	.	0.36353	.	.	0.30390	.	T	0.63419	0.674081087112	0.96539	.	10	0.54541	.	.	0.56456	.	.	16.0142	0.80222	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.82257	.	A/A	R	.	M	C	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852830A>C	102858	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.M276R	.	.	AEFBI	D	0.74195	0.97350	D	0.99712	0.977208	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.571420e-06	0	0.000000e+00	41440	0	0	0.000000e+00	912	0	0	0.000000e+00	15262	0	152174	0	0.000000e+00	3466	0	1	1.924560e-04	5196	0	0	0.000000e+00	10622	0	0	0.000000e+00	316	0	0	0.000000e+00	68036	0	1	1.924560e-04	5196	0	0	0.000000e+00	4834	0	1	3.039330e-05	0	0.000000e+00	9096	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32902	0	0.000000e+00	134	0	1	4.115230e-04	2430	0	0	0.000000e+00	5494	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3114	0	0	.	0	1	6.760050e-06	0	0.000000e+00	41118	0	0	0.000000e+00	912	0	0	0.000000e+00	15074	0	147928	0	0.000000e+00	3300	0	1	2.015320e-04	4962	0	0	0.000000e+00	10622	0	0	0.000000e+00	304	0	0	0.000000e+00	64814	0	0	0.000000e+00	4802	0	0	1	7.420050e-06	0	0.000000e+00	32478	0	0	0.000000e+00	862	0	0	0.000000e+00	14816	0	134770	0	0.000000e+00	3382	0	1	1.924560e-04	5196	0	0	0.000000e+00	6982	0	0	0.000000e+00	310	0	0	0.000000e+00	63912	0	0	0.000000e+00	4832	0	0	1	1.238600e-05	0	0.000000e+00	24816	0	0	0.000000e+00	112	0	0	0.000000e+00	12890	0	80736	0	0.000000e+00	992	0	1	2.663830e-04	3754	0	0	0.000000e+00	10530	0	0	0.000000e+00	272	0	0	0.000000e+00	21048	0	0	0.000000e+00	4806	0	0	12	101770738	12	103246608	0	0.43195	0.638212	1.000000	0.71638	0.894000	0.43146	0.996000	0.59523	7.445000	0.79656	0.756000	0.94297	1.312000	0.94714	102852830	A	.	rs62508722	.	.	11.570	9.399	7.651	9.354	.	.	.	0	27	0	-15	0.00	0.00	0.83	0.09	PAH	0.00	exon-NM_001354304.2-8+15+start+136	102858	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508722	62508722	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,712	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103245518	103245518	G	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.859C>G	NP_000268.1:p.Leu287Val	973	859	287	L/V	Ctg/Gtg	rs781096854&CM024141	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103245518G>C	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.859C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.93643	0.478337	D	0.93897	0.464807	25.6	28.3	3.739036	4.069406	0.70442	0.84653	G/G	D	0.45883	0.792957544326782	0.84382	0.99752305593834767	.	0.99533	.	G/G	.	.	.	.	7.673024	0.695729179863372	0.82053	6.655657	0.664933515191895	0.77339	.	.	.	2	1.647e-05	0	0	0	0	2	1.654e-05	0	0	0	0	2	3.006e-05	0	0	2	1.883e-05	0	0	0	0	2	1.889e-05	0	0	0	0	2	3.686e-05	0	0	2	2.204e-05	0	0	0	0	2	2.216e-05	0	0	0	0	2	4.768e-05	0	0	0.99776	.	.	.	5.51	5.51	0.81769	0	0.45803	0.59043	.	.	0.74766	0.999999999971142	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.91743	.	0.000000	0.84330	D	0.000000	D	0.93422	0.402221	0.10314	.	0.99278	.	D	0.99427	0.9813	.	0.96734	.	D	0.98798	1.0773	L287V	Loss_of_helix_(P_=_0.1299)&_Loss_of_stability_(P_=_0.1511)&_Loss_of_disorder_(P_=_0.414)&_Gain_of_catalytic_residue_at_H290_(P_=_0.4879)&_Gain_of_sheet_(P_=_0.6509)	P00439	0.97859	0.902	.	0.39626	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.51319	.	.	.	0.54400	.	.	0.53639	.	D	0.82425	0.803018450737	0.94315	.	10	0.55341	.	.	0.46513	.	.	19.7791	0.96406	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.95021	.	G/G	V	.	L	C	514	0.74853	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102851740G>C	619164	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBCI	D	0.75112	0.97494	D	0.96773	0.952352	.	2	7.969020e-06	0	0.000000e+00	16244	0	0	0.000000e+00	34562	0	250972	0	0.000000e+00	10060	0	0	0.000000e+00	18382	0	0	0.000000e+00	21622	0	2	1.764170e-05	113368	0	2	1.764170e-05	113368	0	0	0.000000e+00	30608	0	0	0.000000e+00	0	0.000000e+00	7160	0	0	0.000000e+00	17102	0	109352	0	0.000000e+00	2320	0	0	0.000000e+00	9038	0	0	0.000000e+00	13370	0	0	0.000000e+00	42760	0	.	.	.	.	0	0.000000e+00	15688	0	0	.	0	2	8.458090e-06	0	0.000000e+00	14898	0	0	0.000000e+00	34232	0	236460	0	0.000000e+00	9554	0	0	0.000000e+00	17682	0	0	0.000000e+00	21606	0	2	1.953810e-05	102364	0	2	1.953810e-05	102364	0	0	0.000000e+00	30518	0	0	2	9.614550e-06	0	0.000000e+00	16206	0	0	0.000000e+00	30500	0	208018	0	0.000000e+00	6208	0	0	0.000000e+00	13404	0	0	0.000000e+00	16708	0	2	2.233990e-05	89526	0	2	2.233990e-05	89526	0	0	0.000000e+00	30600	0	0	2	8.184850e-06	0	0.000000e+00	12014	0	0	0.000000e+00	34428	0	244354	0	0.000000e+00	9978	0	0	0.000000e+00	18378	0	0	0.000000e+00	21620	0	2	1.797300e-05	111278	0	2	1.797300e-05	111278	0	0	0.000000e+00	30608	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101769648	12	103245518	0	0.43195	0.638212	1.000000	0.71638	0.994000	0.71098	0.996000	0.59523	6.553000	0.73817	0.676000	0.76740	1.176000	0.78918	102851740	G	.	rs781096854	.	.	9.506	11.083	11.570	9.399	.	.	.	0	16	16	17	0.00	0.04	0.00	0.00	PAH	0.00	exon-NM_001354304.2-9+16+end+70	619164	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103245518-103245518	1.647e-05	2	2	0	0	0	0	0	2	0	0	10330	11484	8622	6606	66536	904	16424	0	0	0	0	2	0	0	0	0	0	0	0	0	0	rs781096854	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79720e-05	0.00000e+00	0.00000e+00	1.48584e-05	0.00000e+00	1.79720e-05	8.12137e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs781096854	781096854	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,700	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288641	103288641	T	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.224A>T	NP_000268.1:p.Asp75Val	338	224	75	D/V	gAt/gTt	rs1565866547&CM1511422&CM159591	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103288641T>A	.	.	.	.	.	.	likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.224A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.88875	0.382594	D	0.88735	0.311794	23.3	23.4	2.956483	2.912902	0.51095	0.52778	T/T	D	0.75420	0.983938932418823	0.51505	0.990616794632732	.	0.97828	.	T/T	.	.	.	.	5.338373	0.519206596383535	0.69281	4.608811	0.441095478392525	0.63700	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98140	.	.	.	6.17	6.17	0.99707	0	0.45803	0.59043	.	.	0.74766	0.999999983640896	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.81930	.	0.138386	0.62929	D	0.000005	D	0.92168	0.347024	0.12758	.	0.98197	.	D	0.98139	0.9432	.	0.80632	.	D	0.98585	1.0698	D75V	Loss_of_disorder_(P_=_0.0182)&_Loss_of_ubiquitination_at_K73_(P_=_0.0327)&_Gain_of_methylation_at_K74_(P_=_0.0356)&_Loss_of_solvent_accessibility_(P_=_0.0544)&_Loss_of_phosphorylation_at_Y77_(P_=_0.0783)	P00439	0.70465	0.579	.	0.78151	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.73378	.	.	.	0.34173	.	.	0.37394	.	T	0.35835	0.478393882513	0.89422	.	10	0.36101	.	.	0.59928	.	.	16.8222	0.85699	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.90251	.	T/T	V	.	D	A	716	0.55970	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102894863T>A	619157	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFGBI	D	0.69373	0.96485	D	0.92175	0.932025	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101812771	12	103288641	0	0.37627	0.615465	1.000000	0.71638	0.886000	0.42526	0.977000	0.46756	7.131000	0.76850	0.665000	0.62972	1.138000	0.64695	102894863	T	.	rs1565866547	.	.	11.038	10.766	11.785	7.700	.	.	.	-37	4	2	1	0.00	0.00	0.02	0.00	PAH	0.00	exon-NM_001354304.2-4+55+end+184	619157	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,814	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103246723	103246723	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.712A>G	NP_000268.1:p.Thr238Ala	826	712	238	T/A	Act/Gct	rs199475577&CM135055&CM920548	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103246723T>C	.	.	.	.	.	.	likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.712A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.94818	0.517704	D	0.94742	0.505869	26.6	25.6	3.936967	3.656776	0.76480	0.71236	T/T	D	0.90354	0.996917963027954	0.92838	0.99848491918308735	.	0.99999	.	T/T	.	.	.	.	11.53052	0.843267248403724	0.92617	11.68637	0.923937941315628	0.92882	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99828	.	.	.	5.92	5.92	0.95557	0	0.45803	0.59043	.	.	0.48965	0.999964734852969	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.52334	.	0.000000	0.84330	D	0.000000	D	0.97038	0.650213	0.24062	.	0.99241	.	D	0.99884	0.9949	.	0.99638	.	D	0.95904	0.9162	T238A	Gain_of_methylation_at_R241_(P_=_0.1215)&_Gain_of_catalytic_residue_at_T238_(P_=_0.3433)&_Loss_of_helix_(P_=_0.3949)&_Loss_of_phosphorylation_at_T238_(P_=_0.4401)&_Gain_of_MoRF_binding_(P_=_0.4808)	P00439	0.98990	0.933	.	0.97890	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.77470	.	.	.	0.67487	.	.	0.72923	.	T	0.67754	0.704208850861	0.99024	.	10	0.83351	.	.	0.58626	.	.	16.3594	0.83084	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.97317	.	T/T	A	.	T	C	518	0.74548	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852945T>C	619166	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.68743	0.96357	D	0.83034	0.892924	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770853	12	103246723	0	0.43195	0.638212	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	4.910000	0.63017	0.665000	0.62972	1.138000	0.64695	102852945	T	.	rs199475577	.	.	11.570	9.399	7.651	9.354	.	.	.	5	-25	10	5	0.01	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+5+end+136	619166	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,755	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103248926	103248926	G	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.694C>G	NP_000268.1:p.Gln232Glu	808	694	232	Q/E	Cag/Gag	rs62507348	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103248926G>C	.	.	.	.	.	.	likely_pathogenic	.	1	.	.	.	.	.	PAH&NM_000277.1&c.694C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	T	0.58613	0.0521045	T	0.58086	-0.162932	15.26	16.34	1.426796	1.513094	0.20792	0.24095	G/G	T	0.28446	0.386900633573532	0.00851	0.21837970426083944	.	0.88723	.	G/G	.	.	.	.	2.021914	-0.108883310562652	0.35030	1.496699	-0.349248887656393	0.27299	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99411	.	.	.	5.17	5.17	0.70848	0	0.26702	0.573888	.	.	0.19992	0.384774595200584	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.73951	.	0.239155	0.45194	D	0.000378	D	0.85240	0.176726	0.03894	.	0.92395	.	D	0.95366	0.8608	.	0.61194	.	D	0.94589	0.8144	Q232E	Gain_of_disorder_(P_=_0.1708)&_Gain_of_relative_solvent_accessibility_(P_=_0.1894)&_Gain_of_solvent_accessibility_(P_=_0.2863)&_Loss_of_helix_(P_=_0.3949)&_Gain_of_catalytic_residue_at_Q232_(P_=_0.4042)	P00439	0.46023	0.419	.	0.09829	.	.	0.34908	simple_aae&simple_aae	D&D	0.830329&0.830329	0.14588	.	.	.	0.13644	.	.	0.13708	.	T	0.20545	0.368006706238	0.73299	.	10	0.01155	.	.	0.06691	.	.	12.2664	0.53998	0.0:0.0:0.7151:0.2849	.	.	.	.	.	.	.	.	0.45709	.	G/G	E	.	Q	C	528	0.73785	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102855148G>C	619160	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.63729	0.95179	D	0.82336	0.889364	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101773056	12	103248926	0	0.43195	0.638212	1.000000	0.71638	0.694000	0.33958	0.962000	0.43532	4.135000	0.57758	0.676000	0.76740	1.176000	0.78918	102855148	G	.	rs62507348	.	.	7.651	9.354	7.292	9.092	.	.	.	48	-3	50	-12	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+12+start+197	619160	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,759	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103245470	103245470	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.907T>C	NP_000268.1:p.Ser303Pro	1021	907	303	S/P	Tcc/Ccc	rs199475608&CD056833&CM010973&CM981448	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103245470A>G	.	.	.	.	.	.	likely_pathogenic&not_provided	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.907T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96941	0.576339	D	0.96891	0.590095	31	29.7	4.423313	4.237298	0.90422	0.89009	A/A	D	0.96500	0.999197065830231	0.94093	0.99862328148517809	.	0.99994	.	A/A	.	.	.	.	14.72728	0.922032342784826	0.96463	13.9391	1.00057695371561	0.95761	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99752	.	.	.	5.51	5.51	0.81769	0	0.45803	0.59043	.	.	0.74766	0.999999957073323	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.93484	.	0.000000	0.84330	D	0.000000	D	0.98217	0.774164	0.28431	.	0.99727	.	D	0.99838	0.9931	.	0.99613	.	D	0.96356	0.9474	S303P	Gain_of_catalytic_residue_at_S303_(P_=_0.0499)&_Loss_of_disorder_(P_=_0.16)&_Loss_of_helix_(P_=_0.2022)&_Loss_of_phosphorylation_at_S298_(P_=_0.403)&_Gain_of_loop_(P_=_0.4661)	P00439	0.98931	0.931	.	0.96873	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.80943	.	.	.	0.90584	.	.	0.86255	.	D	0.87087	0.833425104618	0.99990	.	10	0.63109	.	.	0.78490	.	.	15.9194	0.79334	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.96871	.	A/A	P	.	S	G	514	0.74853	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102851692A>G	102889	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.S303P&UniProtKB_(protein):P00439#VAR_000990	.	.	AEFBCI	D	0.78413	0.97956	D	0.99992	0.989598	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101769600	12	103245470	0	0.43195	0.638212	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	8.947000	0.92735	0.756000	0.94297	1.312000	0.94714	102851692	A	.	rs199475608	.	.	9.506	11.083	11.570	9.399	.	.	.	-34	20	-5	-3	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-9+5+start+70	102889	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475608	199475608	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,690	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103288566	103288566	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.299A>G	NP_000268.1:p.His100Arg	413	299	100	H/R	cAt/cGt	rs148393887&CM992944	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103288566T>C	.	.	.	.	.	.	uncertain_significance	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.299A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0.0	.	.	.	.	.	.	.	T/T	T	T	0.47791	-0.0274135	D	0.75062	0.0722773	12.39	14.32	1.063589	1.141960	0.15849	0.18770	T/T	T	0.00927	0.0221648476578283	0.22123	0.92647018238485757	.	0.62570	.	T/T	2	4.5392646391284613E-4	4	4.6511627906976747E-4	1.707617	-0.233534678324586	0.30343	1.393658	-0.395047322896892	0.25645	.	.	.	30	2.471e-04	1	9.610e-05	5	4.319e-04	30	2.471e-04	0	0	0	0	23	3.446e-04	0	0	22	2.071e-04	1	1.103e-04	4	3.566e-04	22	2.071e-04	0	0	0	0	17	3.128e-04	0	0	24	2.645e-04	1	9.626e-05	5	4.323e-04	24	2.645e-04	0	0	0	0	17	4.034e-04	0	0	0.98066	.	.	.	6.17	5.03	0.67015	0	0.51514	0.610034	.	.	0.39843	0.999460262168688	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.41560	.	0.482847	0.24300	N	0.038311	D	0.72844	0.077752	0.03595	.	0.97031	.	D	0.93593	0.8102	.	0.23535	.	D	0.83101	0.0427	.	.	.	.	.	.	0.08384	.	.	0.08975	simple_aae&simple_aae	N&N	1&1	0.04613	.	.	.	0.02946	.	.	0.01387	.	T	0.28941	0.428042113781	0.81544	.	10	0.10536	.	.	0.10623	.	.	10.9074	0.46299	0.0:0.129:0.0:0.871	.	1	2.6968716289104636E-4	1	1.322401481089659E-4	.	.	.	0.75466	.	T/T	R	.	H	C	717	0.55835	.	12	C0031485&CN169374	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102894788T>C	306914	reviewed_by_expert_panel	Phenylketonuria&not_specified	Illumina_Laboratory_Services&Illumina:649028	.	.	AEFBI	D	0.28849	0.51239	N	0.51335	0.465170	.	79	3.141700e-04	1	6.151570e-05	16256	0	13	3.758090e-04	34592	0	251456	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	1	4.619790e-05	21646	0	61	5.363390e-04	113734	0	61	5.363390e-04	113734	0	0	0.000000e+00	30616	0	25	2.285020e-04	0	0.000000e+00	7164	0	6	3.506310e-04	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	18	4.208750e-04	42768	0	18	4.208750e-04	42768	0	0	0.000000e+00	15690	0	0	.	0	72	3.039030e-04	1	6.710510e-05	14902	0	13	3.794510e-04	34260	0	236918	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	1	4.623210e-05	21630	0	56	5.451820e-04	102718	0	56	5.451820e-04	102718	0	0	0.000000e+00	30526	0	0	62	2.978960e-04	1	6.165990e-05	16218	0	13	4.258940e-04	30524	0	208126	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	45	5.025130e-04	89550	0	45	5.025130e-04	89550	0	0	0.000000e+00	30608	0	0	78	3.185780e-04	1	8.315320e-05	12026	0	13	3.772710e-04	34458	0	244838	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	1	4.620220e-05	21644	0	60	5.374230e-04	111644	0	60	5.374230e-04	111644	0	0	0.000000e+00	30616	0	0	52	3.415880e-04	2	4.823690e-05	41462	0	0	0.000000e+00	912	0	2	1.308730e-04	15282	0	152230	0	0.000000e+00	3472	0	0	0.000000e+00	5206	0	1	9.416200e-05	10620	0	0	0.000000e+00	316	0	45	6.613560e-04	68042	0	45	6.613560e-04	68042	0	0	0.000000e+00	4826	0	6	1.823260e-04	0	0.000000e+00	9102	0	0	0.000000e+00	60	0	1	2.133110e-04	4688	0	32908	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	1	1.821490e-04	5490	0	0	0.000000e+00	246	0	3	4.377010e-04	6854	0	0	0.000000e+00	3112	0	0	.	0	52	3.513890e-04	2	4.861210e-05	41142	0	0	0.000000e+00	912	0	2	1.325030e-04	15094	0	147984	0	0.000000e+00	3302	0	0	0.000000e+00	4972	0	1	9.416200e-05	10620	0	0	0.000000e+00	304	0	45	6.942090e-04	64822	0	0	0.000000e+00	4794	0	0	49	3.634750e-04	2	6.156500e-05	32486	0	0	0.000000e+00	862	0	2	1.348070e-04	14836	0	134810	0	0.000000e+00	3388	0	0	0.000000e+00	5206	0	1	1.432660e-04	6980	0	0	0.000000e+00	310	0	42	6.571120e-04	63916	0	0	0.000000e+00	4824	0	0	18	2.228160e-04	2	8.052830e-05	24836	0	0	0.000000e+00	112	0	2	1.549430e-04	12908	0	80784	0	0.000000e+00	998	0	0	0.000000e+00	3764	0	1	9.498480e-05	10528	0	0	0.000000e+00	272	0	11	5.225650e-04	21050	0	0	0.000000e+00	4798	0	0	12	101812696	12	103288566	0	0.37627	0.615465	0.781000	0.29485	0.507000	0.29175	0.141000	0.20704	1.730000	0.37748	0.665000	0.62972	1.138000	0.64695	102894788	T	.	rs148393887	.	.	11.038	10.766	11.785	7.700	.	.	.	38	-41	-49	3	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+53+start+184	306914	Uncertain_significance	reviewed_by_expert_panel	Inborn_genetic_diseases&not_specified&not_provided&Phenylketonuria	MeSH:D030342&MedGen:C0950123&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs148393887	2.471e-04	30	30	0	1	5	0	0	23	1	0	10406	11578	8654	6614	66738	908	16512	1	5	0	0	23	1	0	0	0	0	0	0	0	0	rs148393887	6.53424e-05	3.57334e-04	0.00000e+00	0.00000e+00	4.48511e-05	5.46213e-04	9.11743e-04	0.00000e+00	3.70711e-04	2.69426e-04	5.46213e-04	3.24844e-04	rs148393887	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.66454e-04	0.00000e+00	.	5.84044e-05	2.16513e-04	2.66454e-04	1.29066e-04	rs148393887	0.0465&0.0454&0.0461	rs148393887	148393887	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,810	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103240726	103240726	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	9/13	.	NM_000277.3:c.916A>G	NP_000268.1:p.Ile306Val	1030	916	306	I/V	Att/Gtt	rs62642934&CD086624&CM920556	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103240726T>C	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.916A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.93008	0.461851	D	0.94388	0.489286	23.7	23.0	3.110960	2.729082	0.54517	0.48753	T/T	D	0.49620	0.843553841114044	0.93191	0.99852708300222304	.	0.96964	.	T/T	.	.	.	.	6.131958	0.592597933307022	0.74405	6.405519	0.644216048895036	0.75996	.	.	.	1	8.237e-06	0	0	0	0	1	8.251e-06	0	0	0	0	1	1.501e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1.102e-05	0	0	0	0	1	1.104e-05	0	0	0	0	1	2.378e-05	0	0	0.99691	.	.	.	5.38	5.38	0.77279	0	0.45803	0.59043	.	.	0.74766	0.999994766550695	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.88824	.	0.000000	0.84330	D	0.000000	D	0.97938	0.7424	0.09400	.	0.96438	.	D	0.99475	0.9828	.	0.93260	.	D	0.98408	1.0628	.	.	.	.	.	.	0.79137	.	.	0.81001	simple_aae&simple_aae	A&A	1&1	0.25118	.	.	.	0.49677	.	.	0.46817	.	T	0.63646	0.67565536499	0.95101	.	9	0.56640	.	.	0.48642	.	.	15.3978	0.74533	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.88798	.	T/T	V	.	I	C	499	0.76092	.	12	C0751435&C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102846948T>C	618	reviewed_by_expert_panel	Hyperphenylalaninemia&_non-pku&Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.I306V&OMIM_Allelic_Variant:612349.0044&UniProtKB_(protein):P00439#VAR_000992	.	.	AEFBI	D	0.96329	0.99462	D	0.99837	0.980277	.	5	1.990160e-05	0	0.000000e+00	16252	0	0	0.000000e+00	34564	0	251236	0	0.000000e+00	10076	0	0	0.000000e+00	18390	0	0	0.000000e+00	21642	0	5	4.402490e-05	113572	0	5	4.402490e-05	113572	0	0	0.000000e+00	30612	0	0	0.000000e+00	0	0.000000e+00	7162	0	0	0.000000e+00	17104	0	109384	0	0.000000e+00	2320	0	0	0.000000e+00	9042	0	0	0.000000e+00	13394	0	0	0.000000e+00	42758	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	4	1.689890e-05	0	0.000000e+00	14898	0	0	0.000000e+00	34232	0	236702	0	0.000000e+00	9568	0	0	0.000000e+00	17688	0	0	0.000000e+00	21626	0	4	3.900160e-05	102560	0	4	3.900160e-05	102560	0	0	0.000000e+00	30522	0	0	5	2.403310e-05	0	0.000000e+00	16214	0	0	0.000000e+00	30496	0	208046	0	0.000000e+00	6210	0	0	0.000000e+00	13412	0	0	0.000000e+00	16728	0	5	5.585220e-05	89522	0	5	5.585220e-05	89522	0	0	0.000000e+00	30604	0	0	5	2.044000e-05	0	0.000000e+00	12022	0	0	0.000000e+00	34430	0	244618	0	0.000000e+00	9994	0	0	0.000000e+00	18386	0	0	0.000000e+00	21640	0	5	4.485030e-05	111482	0	5	4.485030e-05	111482	0	0	0.000000e+00	30612	0	0	5	3.285930e-05	0	0.000000e+00	41436	0	0	0.000000e+00	912	0	0	0.000000e+00	15278	0	152164	0	0.000000e+00	3470	0	0	0.000000e+00	5186	0	0	0.000000e+00	10620	0	0	0.000000e+00	316	0	5	7.350130e-05	68026	0	5	7.350130e-05	68026	0	0	0.000000e+00	4826	0	1	3.040070e-05	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32894	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5492	0	0	0.000000e+00	246	0	1	1.459430e-04	6852	0	0	0.000000e+00	3112	0	0	.	0	4	2.704270e-05	0	0.000000e+00	41118	0	0	0.000000e+00	912	0	0	0.000000e+00	15090	0	147914	0	0.000000e+00	3302	0	0	0.000000e+00	4952	0	0	0.000000e+00	10620	0	0	0.000000e+00	304	0	4	6.173030e-05	64798	0	0	0.000000e+00	4794	0	0	5	3.710300e-05	0	0.000000e+00	32476	0	0	0.000000e+00	862	0	0	0.000000e+00	14832	0	134760	0	0.000000e+00	3386	0	0	0.000000e+00	5186	0	0	0.000000e+00	6978	0	0	0.000000e+00	310	0	5	7.824480e-05	63902	0	0	0.000000e+00	4824	0	0	1	1.238730e-05	0	0.000000e+00	24810	0	0	0.000000e+00	112	0	0	0.000000e+00	12904	0	80728	0	0.000000e+00	996	0	0	0.000000e+00	3744	0	0	0.000000e+00	10528	0	0	0.000000e+00	272	0	1	4.751950e-05	21044	0	0	0.000000e+00	4798	0	0	12	101764856	12	103240726	0	0.43195	0.638212	1.000000	0.71638	0.824000	0.38829	0.996000	0.59523	7.671000	0.82936	0.660000	0.55035	1.135000	0.58920	102846948	T	.	rs62642934	.	.	7.709	9.491	9.506	11.083	.	.	.	-1	3	-1	3	0.00	0.12	0.00	0.00	PAH	0.00	exon-NM_001354304.2-10+3+end+57	618	Pathogenic	reviewed_by_expert_panel	not_provided&Hyperphenylalaninemia&Phenylketonuria	MedGen:CN517202&Human_Phenotype_Ontology:HP:0004923&MedGen:C0751435&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62642934	8.237e-06	1	1	0	0	0	0	0	1	0	0	10398	11518	8644	6588	66644	908	16500	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs62642934	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.69044e-05	0.00000e+00	0.00000e+00	2.22641e-05	0.00000e+00	2.69044e-05	1.21817e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62642934	62642934	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,686	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103271319	103271319	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	4/13	.	NM_000277.3:c.362T>C	NP_000268.1:p.Phe121Ser	476	362	121	F/S	tTc/tCc	rs1565859485&COSV100188252	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103271319A>G	.	.	.	.	.	.	uncertain_significance	0&1	1&1	.	.	.	.	.	PAH&NM_000277.1&c.362T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96942	0.57636	D	0.96892	0.590125	32	31	4.592016	4.337992	0.91893	0.90514	A/A	D	0.98729	0.999732792377472	0.95653	0.99880275359064108	.	0.99995	.	A/A	.	.	.	.	16.987	0.967647265347354	0.97897	15.52749	1.04867611661321	0.97059	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99076	.	.	.	5.86	5.86	0.93936	0	0.14657	0.547309	.	.	0.74766	0.999997650377572	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.95258	.	0.000000	0.84330	D	0.000000	D	0.98038	0.753652	0.31654	.	0.99343	.	D	0.99544	0.9849	.	0.99280	.	D	0.97587	1.0229	F121S	Gain_of_disorder_(P_=_0.0087)&_Gain_of_phosphorylation_at_F121_(P_=_0.0475)&_Loss_of_stability_(P_=_0.0517)&_Loss_of_catalytic_residue_at_P119_(P_=_0.1623)&_Gain_of_glycosylation_at_F121_(P_=_0.1712)	P00439	0.98870	0.929	.	0.98178	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.96395	.	.	.	0.90584	.	.	0.97372	.	D	0.88717	0.844080209732	0.99803	.	10	0.92824	.	.	0.91255	.	.	16.2436	0.82253	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99481	.	A/A	S	.	F	G	675	0.60470	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102877541A>G	619155	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.84508	0.98596	D	0.99606	0.975214	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101795449	12	103271319	0	0.37627	0.615465	1.000000	0.71638	0.950000	0.49671	0.999000	0.70432	8.567000	0.90529	0.756000	0.94297	1.312000	0.94714	102877541	A	.	rs1565859485	.	.	8.810	7.211	11.038	10.766	.	.	.	2	9	9	-40	0.00	0.04	0.00	0.00	PAH	0.00	exon-NM_001354304.2-5+9+end+89	619155	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,803	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103245521	103245521	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.856G>A	NP_000268.1:p.Glu286Lys	970	856	286	E/K	Gag/Aag	rs62508739&CM040236&COSV61014382	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103245521C>T	.	.	.	.	.	.	not_provided&pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.856G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.90823	0.41628	D	0.96614	0.585883	32	32	4.521307	4.763172	0.91418	0.92726	C/C	D	0.94420	0.998530387878418	0.98022	0.99911138879025052	.	0.99999	.	C/C	.	.	.	.	18.41332	0.992871430254202	0.98485	17.28387	1.09474461453735	0.98036	.	.	.	2	1.647e-05	0	0	0	0	2	1.655e-05	1	1.160e-04	0	0	1	1.503e-05	0	0	1	9.415e-06	0	0	0	0	1	9.446e-06	1	1.276e-04	0	0	0	0	0	0	1	1.102e-05	0	0	0	0	1	1.108e-05	0	0	0	0	1	2.385e-05	0	0	0.99767	.	.	.	5.51	5.51	0.81769	0	0.45803	0.59043	.	.	0.74766	0.999999999971142	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.79334	.	0.000000	0.84330	D	0.000000	D	0.98295	0.78343	0.27591	.	0.99640	.	D	0.99889	0.9951	.	0.99874	.	D	0.96012	0.9238	E286K	Gain_of_methylation_at_E286_(P_=_0.0059)&_Gain_of_ubiquitination_at_E286_(P_=_0.0337)&_Gain_of_solvent_accessibility_(P_=_0.0837)&_Gain_of_relative_solvent_accessibility_(P_=_0.09)&_Gain_of_glycosylation_at_E286_(P_=_0.095)	P00439	0.99641	0.964	.	0.99486	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.72932	.	.	.	0.90584	.	.	0.97372	.	D	0.94677	0.885419011116	0.99671	.	10	0.83351	.	.	0.91255	.	.	19.7791	0.96406	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.98750	.	C/C	K	.	E	T	514	0.74853	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102851743C>T	102880	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.E286K	.	.	AEFBCI	D	0.73054	0.97162	D	0.99614	0.975353	.	3	1.195400e-05	0	0.000000e+00	16242	0	0	0.000000e+00	34560	0	250962	0	0.000000e+00	10060	0	2	1.088020e-04	18382	0	0	0.000000e+00	21636	0	1	8.822080e-06	113352	0	2	1.088020e-04	18382	0	0	0.000000e+00	30606	0	1	9.143940e-06	0	0.000000e+00	7160	0	0	0.000000e+00	17102	0	109362	0	0.000000e+00	2320	0	1	1.106190e-04	9040	0	0	0.000000e+00	13384	0	0	0.000000e+00	42756	0	1	1.106190e-04	9040	0	0	0.000000e+00	15686	0	0	.	0	2	8.458230e-06	0	0.000000e+00	14898	0	0	0.000000e+00	34230	0	236456	0	0.000000e+00	9554	0	2	1.131090e-04	17682	0	0	0.000000e+00	21620	0	0	0.000000e+00	102352	0	2	1.131090e-04	17682	0	0	0.000000e+00	30516	0	0	2	9.614650e-06	0	0.000000e+00	16204	0	0	0.000000e+00	30498	0	208016	0	0.000000e+00	6208	0	1	7.460460e-05	13404	0	0	0.000000e+00	16722	0	1	1.117120e-05	89516	0	1	7.460460e-05	13404	0	0	0.000000e+00	30598	0	0	3	1.227780e-05	0	0.000000e+00	12012	0	0	0.000000e+00	34426	0	244344	0	0.000000e+00	9978	0	2	1.088260e-04	18378	0	0	0.000000e+00	21634	0	1	8.987790e-06	111262	0	2	1.088260e-04	18378	0	0	0.000000e+00	30606	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101769651	12	103245521	0	0.43195	0.638212	1.000000	0.71638	0.996000	0.76049	0.999000	0.70432	7.568000	0.81546	0.599000	0.40250	1.026000	0.45946	102851743	C	.	rs62508739	.	.	9.506	11.083	11.570	9.399	.	.	.	-31	13	13	14	0.00	0.06	0.00	0.00	PAH	0.00	exon-NM_001354304.2-9+13+end+70	102880	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62508739	1.647e-05	2	2	0	0	0	1	0	1	0	0	10324	11482	8618	6602	66518	904	16424	0	0	1	0	1	0	0	0	0	0	0	0	0	0	rs62508739	0.00000e+00	0.00000e+00	0.00000e+00	1.16036e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.43030e-06	8.99896e-06	1.16036e-04	8.12143e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508739	62508739	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,701	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103271295	103271295	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	4/13	.	NM_000277.3:c.386A>G	NP_000268.1:p.Asp129Gly	500	386	129	D/G	gAc/gGc	rs199475623&CM971125	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103271295T>C	.	.	.	.	.	.	not_provided&likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.386A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.96572	0.567925	D	0.96515	0.578009	33	32	4.892706	4.690020	0.92976	0.92534	T/T	D	0.97934	0.999563872814178	0.94902	0.99871604177501239	.	0.99994	.	T/T	.	.	.	.	12.89347	0.8792925446623	0.94604	11.99546	0.935122023954755	0.93371	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99842	.	.	.	5.86	5.86	0.93936	0	0.14657	0.547309	.	.	0.74766	0.999997650377572	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.93146	.	0.087840	0.84330	D	0.000000	D	0.98302	0.784177	0.28875	.	0.99535	.	D	0.99852	0.9936	.	0.99786	.	D	0.96215	0.9378	D129G	Gain_of_MoRF_binding_(P_=_0.0731)&_Loss_of_stability_(P_=_0.1321)&_Gain_of_helix_(P_=_0.1736)&_Loss_of_phosphorylation_at_T124_(P_=_0.2364)&_Loss_of_solvent_accessibility_(P_=_0.2517)	P00439	0.99737	0.972	.	0.98464	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.93475	.	.	.	0.90584	.	.	0.97372	.	T	0.80317	0.789167046547	0.99918	.	10	0.92824	.	.	0.91255	.	.	16.2436	0.82253	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.99973	.	T/T	G	.	D	C	675	0.60470	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102877517T>C	102661	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.D129G	.	.	AEFBI	D	0.76471	0.97695	D	0.99749	0.978006	.	1	3.976780e-06	0	0.000000e+00	16254	0	0	0.000000e+00	34592	0	251460	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	1	8.792290e-06	113736	0	1	8.792290e-06	113736	0	0	0.000000e+00	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	1	4.220760e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236924	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	1	9.735200e-06	102720	0	1	9.735200e-06	102720	0	0	0.000000e+00	30526	0	0	1	4.804600e-06	0	0.000000e+00	16216	0	0	0.000000e+00	30524	0	208134	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	1	1.116590e-05	89558	0	1	1.116590e-05	89558	0	0	0.000000e+00	30608	0	0	1	4.084270e-06	0	0.000000e+00	12024	0	0	0.000000e+00	34458	0	244842	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	1	8.956880e-06	111646	0	1	8.956880e-06	111646	0	0	0.000000e+00	30616	0	0	1	6.572980e-06	0	0.000000e+00	41428	0	0	0.000000e+00	912	0	0	0.000000e+00	15286	0	152138	0	0.000000e+00	3472	0	0	0.000000e+00	5178	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	1	1.470030e-05	68026	0	1	1.470030e-05	68026	0	0	0.000000e+00	4826	0	0	0.000000e+00	0	0.000000e+00	9082	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32874	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5482	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3112	0	0	.	0	1	6.762150e-06	0	0.000000e+00	41106	0	0	0.000000e+00	912	0	0	0.000000e+00	15098	0	147882	0	0.000000e+00	3302	0	0	0.000000e+00	4942	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	1	1.543210e-05	64800	0	0	0.000000e+00	4794	0	0	1	7.422140e-06	0	0.000000e+00	32462	0	0	0.000000e+00	862	0	0	0.000000e+00	14840	0	134732	0	0.000000e+00	3388	0	0	0.000000e+00	5178	0	0	0.000000e+00	6966	0	0	0.000000e+00	310	0	1	1.564800e-05	63906	0	0	0.000000e+00	4824	0	0	0	0.000000e+00	0	0.000000e+00	24808	0	0	0.000000e+00	112	0	0	0.000000e+00	12912	0	80700	0	0.000000e+00	998	0	0	0.000000e+00	3736	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	0	0.000000e+00	21036	0	0	0.000000e+00	4798	0	0	12	101795425	12	103271295	0	0.37627	0.615465	1.000000	0.71638	0.993000	0.69303	1.000000	0.86279	7.382000	0.79001	0.665000	0.62972	1.138000	0.64695	102877517	T	.	rs199475623	.	.	8.810	7.211	11.038	10.766	.	.	.	-8	33	41	-16	0.00	0.16	0.00	0.00	PAH	0.00	exon-NM_001354304.2-5+33+end+89	102661	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475623	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95464e-06	0.00000e+00	0.00000e+00	0.00000e+00	8.98150e-06	8.95464e-06	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475623	199475623	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,800	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103260413	103260413	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.470G>C	NP_000268.1:p.Arg157Thr	584	470	157	R/T	aGa/aCa	rs199475611&CM056667&CM056668	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103260413C>G	.	.	.	.	.	.	likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.470G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.95158	0.529395	D	0.95086	0.522663	26.3	25.6	3.897214	3.665113	0.75198	0.71475	C/C	D	0.94057	0.998406589031219	0.45755	0.98757361488844186	.	0.99998	.	C/C	.	.	.	.	11.30298	0.836783598917981	0.92220	11.9746	0.934388284832799	0.93340	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99771	.	.	.	6.08	5.19	0.71428	0	0.26702	0.573888	.	.	0.16314	0.0988002733704923	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.96964	.	0.045053	0.84330	D	0.000000	D	0.98775	0.841476	0.29773	.	0.98763	.	D	0.99852	0.9936	.	0.99137	.	D	0.96298	0.9435	R157T	Gain_of_phosphorylation_at_R157_(P_=_0.0227)&_Loss_of_MoRF_binding_(P_=_0.0567)&_Gain_of_catalytic_residue_at_R157_(P_=_0.1639)&_Loss_of_disorder_(P_=_0.2006)&_Gain_of_methylation_at_K159_(P_=_0.2135)	P00439	0.96529	0.874	.	0.98786	.	.	0.58761	simple_aae&simple_aae	D&D	0.999999&0.999999	0.88148	.	.	.	0.90584	.	.	0.84481	.	T	0.71469	0.729745328426	0.99058	.	10	0.83351	.	.	0.91255	.	.	12.5405	0.55515	0.0:0.924:0.0:0.076	.	.	.	.	.	.	.	.	0.88798	.	C/C	T	.	R	G	700	0.57880	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102866635C>G	619162	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.70389	0.96684	D	0.87123	0.911659	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101784543	12	103260413	0	0.43195	0.638212	1.000000	0.71638	0.938000	0.47775	0.871000	0.36136	5.240000	0.65201	0.599000	0.40250	1.026000	0.45946	102866635	C	.	rs199475611	.	.	7.292	9.092	8.810	7.211	.	.	.	-11	28	47	-39	0.00	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-6+28+end+68	619162	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,792	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103260390	103260390	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.493G>A	NP_000268.1:p.Ala165Thr	607	493	165	A/T	Gcc/Acc	rs199475626&CM010956&CM971128	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103260390C>T	.	.	.	.	.	.	not_provided&likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.493G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.95211	0.532637	D	0.95140	0.52732	27.6	28.5	4.080288	4.087746	0.81402	0.85236	C/C	D	0.82352	0.99197655916214	0.98654	0.99919498040465715	.	0.99999	.	C/C	.	.	.	.	14.49561	0.916944703123998	0.96268	14.01532	1.00296947837331	0.95835	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99755	.	.	.	6.08	6.08	0.98982	0	0.26702	0.573888	.	.	0.33875	0.994943344109113	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.97335	.	0.000000	0.84330	D	0.000000	D	0.98256	0.778779	0.25518	.	0.99122	.	D	0.99870	0.9943	.	0.99947	.	D	0.96573	0.9618	A165T	Loss_of_stability_(P_=_0.0687)&_Gain_of_MoRF_binding_(P_=_0.1334)&_Gain_of_glycosylation_at_A165_(P_=_0.2466)&_Gain_of_phosphorylation_at_A165_(P_=_0.2944)&_Loss_of_helix_(P_=_0.3949)	P00439	0.99726	0.971	.	0.97262	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.72820	.	.	.	0.77913	.	.	0.67449	.	T	0.64084	0.678710341454	0.98744	.	10	0.67890	.	.	0.59928	.	.	17.8194	0.88557	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.97095	.	C/C	T	.	A	T	700	0.57880	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102866612C>T	102700	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.A165T	.	.	AEFBI	D	0.68762	0.96361	D	0.90106	0.923883	.	1	3.978580e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34550	0	251346	0	0.000000e+00	10074	0	0	0.000000e+00	18390	0	0	0.000000e+00	21636	0	1	8.796000e-06	113688	0	1	8.796000e-06	113688	0	0	0.000000e+00	30616	0	1	9.142440e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17098	0	109380	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13392	0	1	2.338740e-05	42758	0	1	2.338740e-05	42758	0	0	0.000000e+00	15690	0	0	.	0	1	4.222830e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34218	0	236808	0	0.000000e+00	9566	0	0	0.000000e+00	17688	0	0	0.000000e+00	21620	0	1	9.739750e-06	102672	0	1	9.739750e-06	102672	0	0	0.000000e+00	30526	0	0	1	4.806400e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30484	0	208056	0	0.000000e+00	6210	0	0	0.000000e+00	13412	0	0	0.000000e+00	16724	0	1	1.116870e-05	89536	0	1	1.116870e-05	89536	0	0	0.000000e+00	30608	0	0	1	4.086170e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34416	0	244728	0	0.000000e+00	9992	0	0	0.000000e+00	18386	0	0	0.000000e+00	21634	0	1	8.960730e-06	111598	0	1	8.960730e-06	111598	0	0	0.000000e+00	30616	0	0	2	1.314700e-05	0	0.000000e+00	41428	0	0	0.000000e+00	910	0	0	0.000000e+00	15268	0	152126	0	0.000000e+00	3470	0	0	0.000000e+00	5180	0	0	0.000000e+00	10616	0	0	0.000000e+00	316	0	2	2.940230e-05	68022	0	2	2.940230e-05	68022	0	0	0.000000e+00	4824	0	0	0.000000e+00	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	0	0.000000e+00	4684	0	32884	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5488	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3110	0	0	.	0	2	1.352500e-05	0	0.000000e+00	41106	0	0	0.000000e+00	910	0	0	0.000000e+00	15082	0	147874	0	0.000000e+00	3302	0	0	0.000000e+00	4946	0	0	0.000000e+00	10616	0	0	0.000000e+00	304	0	2	3.086710e-05	64794	0	0	0.000000e+00	4792	0	0	2	1.484560e-05	0	0.000000e+00	32458	0	0	0.000000e+00	862	0	0	0.000000e+00	14824	0	134720	0	0.000000e+00	3386	0	0	0.000000e+00	5180	0	0	0.000000e+00	6974	0	0	0.000000e+00	310	0	2	3.129790e-05	63902	0	0	0.000000e+00	4822	0	0	0	0.000000e+00	0	0.000000e+00	24802	0	0	0.000000e+00	110	0	0	0.000000e+00	12894	0	80696	0	0.000000e+00	996	0	0	0.000000e+00	3738	0	0	0.000000e+00	10524	0	0	0.000000e+00	272	0	0	0.000000e+00	21044	0	0	0.000000e+00	4796	0	0	12	101784520	12	103260390	0	0.43195	0.638212	0.999000	0.42656	0.973000	0.55318	0.996000	0.59523	5.240000	0.65201	0.599000	0.40250	1.026000	0.45946	102866612	C	.	rs199475626	.	.	7.292	9.092	8.810	7.211	.	.	.	-16	41	35	-16	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-6+16+start+68	102700	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475626	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95849e-06	0.00000e+00	0.00000e+00	7.41741e-06	0.00000e+00	8.95849e-06	4.06058e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475626	199475626	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,787	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103260390	103260390	C	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.493G>C	NP_000268.1:p.Ala165Pro	607	493	165	A/P	Gcc/Ccc	rs199475626&CM010956&CM971128	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103260390C>G	.	.	.	.	.	.	uncertain_significance&not_provided	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.493G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.95794	0.549682	D	0.95733	0.551803	27.8	28.4	4.106874	4.080634	0.82327	0.84998	C/C	D	0.92464	0.997800648212433	0.91370	0.99832417874909929	.	0.99999	.	C/C	.	.	.	.	13.75911	0.900175644311741	0.95579	13.18814	0.976105747559438	0.94961	.	.	.	1	8.237e-06	0	0	0	0	1	8.247e-06	0	0	0	0	1	1.500e-05	0	0	1	9.415e-06	0	0	0	0	1	9.429e-06	0	0	0	0	1	1.842e-05	0	0	1	1.102e-05	0	0	0	0	1	1.104e-05	0	0	0	0	1	2.376e-05	0	0	0.99769	.	.	.	6.08	6.08	0.98982	0	0.26702	0.573888	.	.	0.33875	0.994943344109113	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.96773	.	0.000000	0.84330	D	0.000000	D	0.97976	0.746573	0.28761	.	0.99528	.	D	0.99855	0.9937	.	0.99976	.	D	0.96787	0.9755	A165P	Loss_of_stability_(P_=_0.0358)&_Loss_of_MoRF_binding_(P_=_0.0628)&_Gain_of_disorder_(P_=_0.2364)&_Gain_of_phosphorylation_at_Y168_(P_=_0.2773)&_Loss_of_helix_(P_=_0.3949)	P00439	0.99885	0.989	.	0.97262	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.81187	.	.	.	0.90584	.	.	0.92359	.	T	0.70586	0.723695039749	0.99253	.	10	0.63109	.	.	0.78490	.	.	17.8194	0.88557	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99337	.	C/C	P	.	A	G	700	0.57880	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102866612C>G	102701	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.A165P	.	.	AEFBI	D	0.73672	0.97265	D	0.99408	0.972203	.	1	3.978580e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34550	0	251346	0	0.000000e+00	10074	0	0	0.000000e+00	18390	0	0	0.000000e+00	21636	0	1	8.796000e-06	113688	0	1	8.796000e-06	113688	0	0	0.000000e+00	30616	0	1	9.142440e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17098	0	109380	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13392	0	1	2.338740e-05	42758	0	1	2.338740e-05	42758	0	0	0.000000e+00	15690	0	0	.	0	1	4.222830e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34218	0	236808	0	0.000000e+00	9566	0	0	0.000000e+00	17688	0	0	0.000000e+00	21620	0	1	9.739750e-06	102672	0	1	9.739750e-06	102672	0	0	0.000000e+00	30526	0	0	1	4.806400e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30484	0	208056	0	0.000000e+00	6210	0	0	0.000000e+00	13412	0	0	0.000000e+00	16724	0	1	1.116870e-05	89536	0	1	1.116870e-05	89536	0	0	0.000000e+00	30608	0	0	1	4.086170e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34416	0	244728	0	0.000000e+00	9992	0	0	0.000000e+00	18386	0	0	0.000000e+00	21634	0	1	8.960730e-06	111598	0	1	8.960730e-06	111598	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101784520	12	103260390	0	0.43195	0.638212	0.999000	0.42656	0.973000	0.55318	0.996000	0.59523	5.240000	0.65201	0.599000	0.40250	1.026000	0.45946	102866612	C	.	rs199475626	.	.	7.292	9.092	8.810	7.211	.	.	.	-16	41	41	-16	0.00	0.00	0.00	0.01	PAH	0.00	exon-NM_001354304.2-6+16+start+68	102701	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	12:103260390-103260390	8.237e-06	1	1	0	0	0	0	0	1	0	0	10406	11502	8650	6602	66678	908	16510	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs199475626	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95849e-06	0.00000e+00	0.00000e+00	7.41741e-06	0.00000e+00	8.95849e-06	4.06058e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475626	199475626	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,786	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103248932	103248932	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.688G>A	NP_000268.1:p.Val230Ile	802	688	230	V/I	Gtt/Att	rs62516152&CM930546	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103248932C>T	.	.	.	.	.	.	pathogenic/likely_pathogenic&likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.688G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	T	0.43768	-0.0544566	D	0.78523	0.124373	18.11	22.0	1.850589	2.304281	0.27736	0.39411	C/C	T	0.01686	0.0279868235073283	0.37521	0.98006251691503832	.	0.89490	.	C/C	0	0.0	3	3.488372093023256E-4	2.316974	-0.0124763124035698	0.39149	1.949154	-0.174495440160012	0.34200	.	.	.	51	4.201e-04	0	0	3	2.593e-04	51	4.202e-04	0	0	1	1.513e-04	21	3.147e-04	26	1.575e-03	44	4.143e-04	0	0	3	2.677e-04	44	4.144e-04	0	0	1	1.513e-04	14	2.576e-04	26	1.585e-03	46	5.069e-04	0	0	3	2.596e-04	46	5.071e-04	0	0	1	2.633e-04	16	3.797e-04	26	1.576e-03	0.99572	.	.	.	5.47	5.47	0.80345	0	0.26702	0.573888	.	.	0.25024	0.849897142339245	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.90223	.	0.055923	0.62929	D	0.000001	D	0.88752	0.242251	0.03212	.	0.86271	.	D	0.97352	0.9200	.	0.10316	.	D	0.98388	1.0620	.	.	.	.	.	.	0.09099	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.09460	.	.	.	0.25173	.	.	0.19653	.	T	0.43907	0.536185860634	0.79094	.	10	0.16717	.	.	0.18122	.	.	14.5377	0.67561	0.0:0.9278:0.0:0.0722	.	.	.	.	.	.	.	.	0.41557	.	C/C	I	.	V	T	528	0.73785	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102855154C>T	102784	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_000938&DeBelle_Laboratory_for_Biochemical_Genetics:p.V230I	.	.	AEFBI	D	0.48183	0.88312	D	0.71873	0.789594	.	136	5.411560e-04	0	0.000000e+00	16256	0	17	4.915280e-04	34586	0	251314	28	2.778330e-03	10078	0	0	0.000000e+00	18382	0	15	6.930970e-04	21642	0	27	2.376260e-04	113624	0	46	1.502480e-03	30616	0	46	1.502480e-03	30616	0	61	5.576170e-04	0	0.000000e+00	7164	0	9	5.260080e-04	17110	0	109394	6	2.586210e-03	2320	0	0	0.000000e+00	9036	0	14	1.045400e-03	13392	0	8	1.870560e-04	42768	0	22	1.402170e-03	15690	0	22	1.402170e-03	15690	0	0	.	0	129	5.448190e-04	0	0.000000e+00	14902	0	17	4.962920e-04	34254	0	236776	26	2.716820e-03	9570	0	0	0.000000e+00	17680	0	15	6.936100e-04	21626	0	22	2.144080e-04	102608	0	46	1.506910e-03	30526	0	46	1.506910e-03	30526	0	0	121	5.814290e-04	0	0.000000e+00	16218	0	15	4.914810e-04	30520	0	208108	21	3.380550e-03	6212	0	0	0.000000e+00	13404	0	15	8.965930e-04	16730	0	22	2.456620e-04	89554	0	46	1.502880e-03	30608	0	46	1.502880e-03	30608	0	0	134	5.476180e-04	0	0.000000e+00	12026	0	17	4.934400e-04	34452	0	244696	28	2.801120e-03	9996	0	0	0.000000e+00	18378	0	15	6.931610e-04	21640	0	25	2.241470e-04	111534	0	46	1.502480e-03	30616	0	46	1.502480e-03	30616	0	0	49	3.220040e-04	4	9.655310e-05	41428	0	0	0.000000e+00	912	0	9	5.890050e-04	15280	0	152172	3	8.640550e-04	3472	0	2	3.855050e-04	5188	0	7	6.596310e-04	10612	0	0	0.000000e+00	316	0	18	2.645500e-04	68040	0	9	5.890050e-04	15280	0	2	4.140790e-04	4830	0	13	3.952330e-04	1	1.099870e-04	9092	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32892	0	0.000000e+00	136	0	1	4.115230e-04	2430	0	3	5.470460e-04	5484	0	0	0.000000e+00	246	0	4	5.836010e-04	6854	0	2	6.426740e-04	3112	0	0	.	0	46	3.109830e-04	4	9.730940e-05	41106	0	0	0.000000e+00	912	0	9	5.963420e-04	15092	0	147918	3	9.085400e-04	3302	0	2	4.037140e-04	4954	0	7	6.596310e-04	10612	0	0	0.000000e+00	304	0	15	2.314310e-04	64814	0	2	4.168400e-04	4798	0	0	43	3.190530e-04	4	1.231910e-04	32470	0	0	0.000000e+00	862	0	8	5.393020e-04	14834	0	134774	3	8.854780e-04	3388	0	2	3.855050e-04	5188	0	3	4.302930e-04	6972	0	0	0.000000e+00	310	0	17	2.659660e-04	63918	0	2	4.142500e-04	4828	0	0	32	3.963830e-04	2	8.063870e-05	24802	0	0	0.000000e+00	112	0	8	6.198670e-04	12906	0	80730	1	1.002000e-03	998	0	1	2.668090e-04	3748	0	7	6.653990e-04	10520	0	0	0.000000e+00	272	0	7	3.325420e-04	21050	0	2	4.164930e-04	4802	0	0	12	101773062	12	103248932	0	0.43195	0.638212	0.834000	0.30193	0.720000	0.34772	0.808000	0.33754	1.651000	0.36918	0.599000	0.40250	1.026000	0.45946	102855154	C	.	rs62516152	.	.	7.651	9.354	7.292	9.092	.	.	.	-18	42	44	-18	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+18+start+197	102784	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62516152	4.201e-04	51	51	0	0	3	0	1	21	0	26	10406	11568	8636	6610	66730	908	16510	0	3	0	1	21	0	26	0	0	0	0	0	0	0	rs62516152	0.00000e+00	4.46801e-04	2.74167e-03	0.00000e+00	7.17618e-04	2.33071e-04	7.30194e-04	1.55935e-03	5.78712e-04	5.21180e-04	2.74167e-03	5.52235e-04	rs62516152	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	5.72410e-04	1.33245e-04	0.00000e+00	.	5.84249e-05	2.16450e-04	5.72410e-04	1.29066e-04	rs62516152	0.0349&0.0&0.0231	rs62516152	62516152	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,760	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103260383	103260383	T	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.500A>T	NP_000268.1:p.Asn167Ile	614	500	167	N/I	aAc/aTc	rs77554925&CM011945&CM981434&COSV99076065	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103260383T>A	.	.	.	.	.	.	uncertain_significance&likely_pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.500A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.594706798131811E-4	.	.	.	.	.	.	.	T/T	T	T	0.58601	0.0520065	D	0.71813	0.022831	19.12	16.49	1.981837	1.537874	0.30240	0.24488	T/T	D	0.61122	0.939613580703735	0.29921	0.9646714124589979	.	0.99871	.	T/T	.	.	.	.	1.25654	-0.466764365326246	0.23075	1.604053	-0.304012478289357	0.28995	.	.	.	2	1.647e-05	0	0	0	0	2	1.649e-05	0	0	0	0	2	2.999e-05	0	0	2	1.883e-05	0	0	0	0	2	1.886e-05	0	0	0	0	2	3.684e-05	0	0	2	2.204e-05	0	0	0	0	2	2.207e-05	0	0	0	0	2	4.753e-05	0	0	0.99565	.	.	.	6.08	-4.01	0.03775	0	0.26702	0.573888	.	.	0.07437	6.01690750409236E-4	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.81346	.	0.251182	0.51296	D	0.000089	D	0.98659	0.827184	0.18624	.	0.90930	.	D	0.99326	0.9782	.	0.99389	.	D	0.99413	1.0942	N167I	Gain_of_catalytic_residue_at_N167_(P_=_0.0791)&_Loss_of_MoRF_binding_(P_=_0.1349)&_Gain_of_helix_(P_=_0.2059)&_Loss_of_phosphorylation_at_Y166_(P_=_0.2136)&_Loss_of_disorder_(P_=_0.2713)	P00439	0.94355	0.836	.	0.92281	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.90490	.	.	.	0.30888	.	.	0.45506	.	T	0.20772	0.369582295418	0.86536	.	10	0.56640	.	.	0.59928	.	.	7.6603	0.27567	0.0:0.3963:0.1193:0.4844	.	0	0.0	1	1.322401481089659E-4	.	.	.	0.94432	.	T/T	I	.	N	A	699	0.57969	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102866605T>A	92743	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_000906&DeBelle_Laboratory_for_Biochemical_Genetics:p.N167I&HGMD:CM981434	.	.	AEFBI	D	0.39990	0.80321	D	0.65379	0.694969	.	9	3.580520e-05	0	0.000000e+00	16256	0	2	5.788380e-05	34552	0	251360	0	0.000000e+00	10076	0	0	0.000000e+00	18390	0	0	0.000000e+00	21638	0	7	6.156660e-05	113698	0	7	6.156660e-05	113698	0	0	0.000000e+00	30616	0	4	3.656980e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17100	0	109380	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13392	0	4	9.354970e-05	42758	0	4	9.354970e-05	42758	0	0	0.000000e+00	15690	0	0	.	0	9	3.800290e-05	0	0.000000e+00	14902	0	2	5.844540e-05	34220	0	236824	0	0.000000e+00	9568	0	0	0.000000e+00	17688	0	0	0.000000e+00	21622	0	7	6.817030e-05	102684	0	7	6.817030e-05	102684	0	0	0.000000e+00	30526	0	0	7	3.364450e-05	0	0.000000e+00	16218	0	2	6.560390e-05	30486	0	208058	0	0.000000e+00	6210	0	0	0.000000e+00	13412	0	0	0.000000e+00	16726	0	5	5.584350e-05	89536	0	2	6.560390e-05	30486	0	0	0.000000e+00	30608	0	0	9	3.677340e-05	0	0.000000e+00	12026	0	2	5.810910e-05	34418	0	244742	0	0.000000e+00	9994	0	0	0.000000e+00	18386	0	0	0.000000e+00	21636	0	7	6.271950e-05	111608	0	7	6.271950e-05	111608	0	0	0.000000e+00	30616	0	0	2	1.314390e-05	1	2.413590e-05	41432	0	0	0.000000e+00	908	0	0	0.000000e+00	15286	0	152162	0	0.000000e+00	3470	0	0	0.000000e+00	5194	0	0	0.000000e+00	10622	0	0	0.000000e+00	316	0	1	1.470370e-05	68010	0	1	2.413590e-05	41432	0	0	0.000000e+00	4830	0	0	0.000000e+00	0	0.000000e+00	9094	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32906	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5496	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3112	0	0	.	0	2	1.352050e-05	1	2.432500e-05	41110	0	0	0.000000e+00	908	0	0	0.000000e+00	15098	0	147924	0	0.000000e+00	3302	0	0	0.000000e+00	4958	0	0	0.000000e+00	10622	0	0	0.000000e+00	304	0	1	1.543210e-05	64800	0	0	0.000000e+00	4798	0	0	1	7.420710e-06	0	0.000000e+00	32462	0	0	0.000000e+00	862	0	0	0.000000e+00	14840	0	134758	0	0.000000e+00	3386	0	0	0.000000e+00	5194	0	0	0.000000e+00	6986	0	0	0.000000e+00	310	0	1	1.565290e-05	63886	0	0	0.000000e+00	4828	0	0	1	1.238700e-05	1	4.030960e-05	24808	0	0	0.000000e+00	108	0	0	0.000000e+00	12912	0	80730	0	0.000000e+00	996	0	0	0.000000e+00	3752	0	0	0.000000e+00	10530	0	0	0.000000e+00	272	0	0	0.000000e+00	21030	0	0	0.000000e+00	4802	0	0	12	101784513	12	103260383	0	0.25195	0.553676	0.999000	0.42656	0.982000	0.59238	0.997000	0.62031	0.267000	0.18318	-0.123000	0.13640	-0.154000	0.10767	102866605	T	.	rs77554925	.	.	7.292	9.092	8.810	7.211	.	.	.	48	19	-13	-9	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-6+9+start+68	92743	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs77554925	1.647e-05	2	0	0	0	0	0	0	2	0	0	10406	11508	8648	6602	66680	908	16510	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs77554925	0.00000e+00	5.96267e-05	0.00000e+00	0.00000e+00	0.00000e+00	7.16628e-05	0.00000e+00	0.00000e+00	4.45025e-05	3.59395e-05	7.16628e-05	4.06062e-05	rs77554925	1.14600e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66489e-05	0.00000e+00	.	1.16850e-04	0.00000e+00	1.14600e-04	6.45328e-05	.	.	rs77554925	77554925	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,783	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103249100	103249100	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.520A>G	NP_000268.1:p.Ile174Val	634	520	174	I/V	Atc/Gtc	rs199475632&CM990994	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103249100T>C	.	.	.	.	.	.	likely_pathogenic&conflicting_interpretations_of_pathogenicity	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.520A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.88496	0.376708	D	0.88352	0.303338	25.4	25.5	3.700456	3.649965	0.69372	0.71059	T/T	D	0.65002	0.957400500774384	0.95410	0.99877141965917704	.	0.96470	.	T/T	.	.	.	.	8.093119	0.717498008938318	0.83707	7.643862	0.735378716345506	0.81951	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99647	.	.	.	5.73	5.73	0.89730	0	0.26702	0.573888	.	.	0.74766	0.999996727770682	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.91072	.	0.000000	0.84330	D	0.000000	D	0.94210	0.443521	0.21381	.	0.97509	.	D	0.99495	0.9834	.	0.91836	.	D	0.98283	1.0575	I174V	Gain_of_disorder_(P_=_0.1171)&_Gain_of_MoRF_binding_(P_=_0.2075)&_Loss_of_sheet_(P_=_0.302)&_Loss_of_helix_(P_=_0.3949)&_Gain_of_methylation_at_R169_(P_=_0.4269)	P00439	0.98422	0.916	.	0.70455	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.24460	.	.	.	0.54515	.	.	0.62758	.	T	0.37019	0.486975640059	0.92787	.	10	0.58613	.	.	0.78490	.	.	16.0172	0.80250	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.56576	.	T/T	V	.	I	C	532	0.73501	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102855322T>C	102720	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_011570&HGMD:CM990994&DeBelle_Laboratory_for_Biochemical_Genetics:p.I174V	.	.	AEFBI	D	0.91240	0.99101	D	0.94239	0.940445	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.572460e-06	0	0.000000e+00	41428	0	0	0.000000e+00	912	0	0	0.000000e+00	15266	0	152150	0	0.000000e+00	3472	0	0	0.000000e+00	5190	0	0	0.000000e+00	10614	0	0	0.000000e+00	316	0	1	1.469900e-05	68032	0	1	1.469900e-05	68032	0	0	0.000000e+00	4828	0	0	0.000000e+00	0	0.000000e+00	9096	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32896	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3116	0	0	.	0	1	6.761510e-06	0	0.000000e+00	41106	0	0	0.000000e+00	912	0	0	0.000000e+00	15078	0	147896	0	0.000000e+00	3302	0	0	0.000000e+00	4956	0	0	0.000000e+00	10614	0	0	0.000000e+00	304	0	1	1.543070e-05	64806	0	0	0.000000e+00	4796	0	0	1	7.421150e-06	0	0.000000e+00	32466	0	0	0.000000e+00	862	0	0	0.000000e+00	14820	0	134750	0	0.000000e+00	3388	0	0	0.000000e+00	5190	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	1	1.564700e-05	63910	0	0	0.000000e+00	4826	0	0	0	0.000000e+00	0	0.000000e+00	24802	0	0	0.000000e+00	112	0	0	0.000000e+00	12892	0	80712	0	0.000000e+00	998	0	0	0.000000e+00	3748	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	0	0.000000e+00	21048	0	0	0.000000e+00	4800	0	0	12	101773230	12	103249100	0	0.25195	0.553676	1.000000	0.71638	0.952000	0.50033	0.986000	0.50055	6.223000	0.72203	0.665000	0.62972	1.138000	0.64695	102855322	T	.	rs199475632	.	.	7.651	9.354	7.292	9.092	.	.	.	3	36	-42	-13	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+10+end+197	102720	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475632	199475632	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,776	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103249099	103249099	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.521T>C	NP_000268.1:p.Ile174Thr	635	521	174	I/T	aTc/aCc	rs138809906&CM112737&CM930540	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103249099A>G	.	.	.	.	.	.	not_provided&pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.521T>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.96640	0.571776	D	0.96584	0.58354	29.2	29.1	4.253879	4.153107	0.87051	0.87128	A/A	D	0.98882	0.999768555164337	0.84228	0.99750588848589083	.	0.99978	.	A/A	.	.	.	.	13.56973	0.895705678556366	0.95383	12.45864	0.951412557555388	0.94042	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99710	.	.	.	5.73	5.73	0.89730	0	0.26702	0.573888	.	.	0.74766	0.999996727770682	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.93547	.	0.000000	0.84330	D	0.000000	D	0.98500	0.807866	0.28536	.	0.98556	.	D	0.99739	0.9903	.	0.99871	.	D	0.96927	0.9842	I174T	Gain_of_phosphorylation_at_I174_(P_=_0.0208)&_Gain_of_disorder_(P_=_0.0216)&_Gain_of_glycosylation_at_I174_(P_=_0.0473)&_Gain_of_sheet_(P_=_0.0827)&_Loss_of_MoRF_binding_(P_=_0.2275)	P00439	0.99103	0.937	.	0.97651	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.77308	.	.	.	0.90584	.	.	0.97372	.	T	0.61925	0.663613796234	0.99671	.	10	0.92824	.	.	0.91255	.	.	16.0172	0.80250	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.96187	.	A/A	T	.	I	G	532	0.73501	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102855321A>G	102721	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_000911&DeBelle_Laboratory_for_Biochemical_Genetics:p.I174T	.	.	AEFBI	D	0.99552	0.99800	D	0.99610	0.975287	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101773229	12	103249099	0	0.25195	0.553676	1.000000	0.71638	0.945000	0.48827	0.968000	0.44619	9.325000	0.96006	0.756000	0.94297	1.312000	0.94714	102855321	A	.	rs138809906	.	.	7.651	9.354	7.292	9.092	.	.	.	4	11	11	-12	0.00	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+11+end+197	102721	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs138809906	138809906	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,775	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103249097	103249097	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.523C>T	NP_000268.1:p.Pro175Ser	637	523	175	P/S	Cct/Tct	rs199475604&CM159596&CM961072	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103249097G>A	.	.	.	.	.	.	likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.523C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.90239	0.405701	D	0.90117	0.344985	27.8	28.4	4.108077	4.083635	0.82374	0.85101	G/G	D	0.98984	0.999784529209137	0.99279	0.99929509409664108	.	0.99998	.	G/G	.	.	.	.	19.37019	1.00850545190755	0.98784	16.74865	1.0816070336876	0.97779	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99809	.	.	.	5.73	5.73	0.89730	0	0.26702	0.573888	.	.	0.74766	0.9999999994012	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.85901	.	0.000000	0.84330	D	0.000000	D	0.96040	0.564706	0.26752	.	0.99385	.	D	0.99862	0.9940	.	0.99632	.	D	0.96462	0.9545	P175S	Loss_of_stability_(P_=_0.0885)&_Gain_of_disorder_(P_=_0.1471)&_Gain_of_MoRF_binding_(P_=_0.1475)&_Gain_of_phosphorylation_at_P175_(P_=_0.1475)&_Gain_of_relative_solvent_accessibility_(P_=_0.1571)	P00439	0.98569	0.92	.	0.98819	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95870	.	.	.	0.90584	.	.	0.97372	.	T	0.52175	0.594833433628	0.95396	.	10	0.76473	.	.	0.91255	.	.	19.8989	0.96978	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.84505	.	G/G	S	.	P	A	532	0.73501	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102855319G>A	555366	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFBI	D	0.99692	0.99823	D	0.99637	0.975767	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101773227	12	103249097	0	0.25195	0.553676	1.000000	0.71638	0.935000	0.47363	0.902000	0.37784	10.003000	0.99689	0.676000	0.76740	1.176000	0.78918	102855319	G	.	rs199475604	.	.	7.651	9.354	7.292	9.092	.	.	.	13	39	-10	6	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+13+end+197	555366	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475604	199475604	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,774	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103249085	103249085	A	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.535T>A	NP_000268.1:p.Tyr179Asn	649	535	179	Y/N	Tac/Aac	rs199475671&CM015341&CM123350	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103249085A>T	.	.	.	.	.	.	likely_pathogenic&uncertain_significance	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.535T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.97033	0.582486	D	0.96984	0.598925	28.3	27.7	4.162992	4.006373	0.84247	0.82509	A/A	D	0.98831	0.99975973367691	0.52725	0.99110828206151247	.	0.99997	.	A/A	.	.	.	.	16.20285	0.952596058474968	0.97482	15.92956	1.05993717447618	0.97318	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99857	.	.	.	5.73	5.73	0.89730	0	0.26702	0.573888	.	.	0.74766	0.999996727770682	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.94607	.	0.000000	0.84330	D	0.000000	D	0.98929	0.860584	0.30878	.	0.99600	.	D	0.99918	0.9965	.	0.99601	.	D	0.95573	0.8928	Y179N	Loss_of_phosphorylation_at_Y179_(P_=_0.0123)&_Gain_of_disorder_(P_=_0.0289)&_Gain_of_ubiquitination_at_K184_(P_=_0.0768)&_Loss_of_sheet_(P_=_0.1158)&_Loss_of_stability_(P_=_0.1303)	P00439	0.94041	0.831	.	0.99639	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.97414	.	.	.	0.90584	.	.	0.97372	.	T	0.72074	0.733879327774	0.98304	.	10	0.92824	.	.	0.91255	.	.	16.0172	0.80250	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99863	.	A/A	N	.	Y	T	532	0.73501	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102855307A>T	102729	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:Y179N	.	.	AEFBI	D	0.92291	0.99172	D	0.99709	0.977165	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.574280e-06	0	0.000000e+00	41428	0	0	0.000000e+00	912	0	0	0.000000e+00	15276	0	152108	0	0.000000e+00	3470	0	0	0.000000e+00	5186	0	0	0.000000e+00	10594	0	0	0.000000e+00	316	0	1	1.470460e-05	68006	0	1	1.470460e-05	68006	0	0	0.000000e+00	4828	0	0	0.000000e+00	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32870	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5472	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3114	0	0	.	0	1	6.763340e-06	0	0.000000e+00	41106	0	0	0.000000e+00	912	0	0	0.000000e+00	15088	0	147856	0	0.000000e+00	3302	0	0	0.000000e+00	4950	0	0	0.000000e+00	10594	0	0	0.000000e+00	304	0	1	1.543640e-05	64782	0	0	0.000000e+00	4796	0	0	1	7.423240e-06	0	0.000000e+00	32464	0	0	0.000000e+00	862	0	0	0.000000e+00	14832	0	134712	0	0.000000e+00	3386	0	0	0.000000e+00	5186	0	0	0.000000e+00	6954	0	0	0.000000e+00	310	0	1	1.565190e-05	63890	0	0	0.000000e+00	4826	0	0	0	0.000000e+00	0	0.000000e+00	24802	0	0	0.000000e+00	112	0	0	0.000000e+00	12902	0	80668	0	0.000000e+00	996	0	0	0.000000e+00	3744	0	0	0.000000e+00	10502	0	0	0.000000e+00	272	0	0	0.000000e+00	21020	0	0	0.000000e+00	4800	0	0	12	101773215	12	103249085	0	0.43195	0.638212	1.000000	0.71638	0.981000	0.58702	0.999000	0.70432	9.325000	0.96006	0.756000	0.94297	1.312000	0.94714	102855307	A	.	rs199475671	.	.	7.651	9.354	7.292	9.092	.	.	.	25	18	-1	2	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+25+end+197	102729	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475671	199475671	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,770	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103249039	103249039	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.581T>C	NP_000268.1:p.Leu194Pro	695	581	194	L/P	cTg/cCg	rs5030844&CD994015&CM110276&CM950887	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103249039A>G	.	.	.	.	.	.	likely_pathogenic&pathogenic	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.581T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.94032	0.490837	D	0.96971	0.597728	28.3	23.5	4.161097	2.959603	0.84187	0.53811	A/A	D	0.87546	0.995509743690491	0.92750	0.99847927113996127	.	0.99995	.	A/A	.	.	.	.	5.253793	0.510296741135395	0.68682	6.50488	0.652599139256248	0.76539	.	.	.	1	8.236e-06	0	0	0	0	1	8.247e-06	0	0	0	0	1	1.500e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1.102e-05	0	0	0	0	1	1.104e-05	0	0	0	0	1	2.376e-05	0	0	0.99745	.	.	.	5.87	4.73	0.59485	0	0.26702	0.573888	.	.	0.26173	0.904241993527534	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.84924	.	0.000000	0.84330	D	0.000000	D	0.96602	0.610842	0.30750	.	0.98809	.	D	0.99796	0.9918	.	0.99910	.	D	0.96931	0.9844	L194P	Gain_of_disorder_(P_=_0.0256)&_Gain_of_methylation_at_K199_(P_=_0.0365)&_Gain_of_glycosylation_at_L194_(P_=_0.0435)&_Loss_of_stability_(P_=_0.0512)&_Loss_of_MoRF_binding_(P_=_0.0583)	P00439	0.99704	0.969	.	0.98718	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.92903	.	.	.	0.90584	.	.	0.97372	.	T	0.67562	0.70289093256	0.97173	.	10	0.92824	.	.	0.91255	.	.	11.814	0.51473	0.9318:0.0:0.0682:0.0	.	.	.	.	.	.	.	.	0.99995	.	A/A	P	.	L	G	528	0.73785	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102855261A>G	102742	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_000918&DeBelle_Laboratory_for_Biochemical_Genetics:p.L194P	.	.	AEFBI	D	0.88334	0.98898	D	0.99985	0.988125	.	5	1.989350e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34580	0	251338	0	0.000000e+00	10076	0	0	0.000000e+00	18380	0	0	0.000000e+00	21644	0	5	4.399010e-05	113662	0	5	4.399010e-05	113662	0	0	0.000000e+00	30610	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17110	0	109388	0	0.000000e+00	2320	0	0	0.000000e+00	9036	0	0	0.000000e+00	13394	0	0	0.000000e+00	42762	0	.	.	.	.	0	0.000000e+00	15688	0	0	.	0	4	1.689190e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34248	0	236800	0	0.000000e+00	9568	0	0	0.000000e+00	17678	0	0	0.000000e+00	21628	0	4	3.896890e-05	102646	0	4	3.896890e-05	102646	0	0	0.000000e+00	30520	0	0	5	2.402970e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30512	0	208076	0	0.000000e+00	6210	0	0	0.000000e+00	13402	0	0	0.000000e+00	16730	0	5	5.584100e-05	89540	0	5	5.584100e-05	89540	0	0	0.000000e+00	30602	0	0	5	2.043150e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34446	0	244720	0	0.000000e+00	9994	0	0	0.000000e+00	18376	0	0	0.000000e+00	21642	0	5	4.481410e-05	111572	0	5	4.481410e-05	111572	0	0	0.000000e+00	30610	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101773169	12	103249039	0	0.43195	0.638212	1.000000	0.71638	0.715000	0.34611	0.988000	0.51130	9.325000	0.96006	0.756000	0.94297	1.312000	0.94714	102855261	A	.	rs5030844	.	.	7.651	9.354	7.292	9.092	.	.	.	12	-14	-9	19	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+71+end+197	102742	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030844	8.236e-06	1	1	0	0	0	0	0	1	0	0	10404	11532	8634	6606	66678	906	16494	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs5030844	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	4.48045e-05	0.00000e+00	0.00000e+00	1.48366e-05	2.69571e-05	4.48045e-05	2.03028e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs5030844	5030844	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,765	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103245488	103245488	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.889C>T	NP_000268.1:p.Arg297Cys	1003	889	297	R/C	Cgc/Tgc	rs62642945&CM961079&COSV100188508&COSV61015366	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103245488G>A	.	.	.	.	.	.	likely_pathogenic&not_provided	0&0&1&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.889C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.89293	0.389431	D	0.91616	0.38526	29.8	29.4	4.332957	4.188583	0.88938	0.88000	G/G	D	0.34220	0.543120920658112	0.96204	0.99887104442660135	.	0.97161	.	G/G	.	.	.	.	5.289046	0.514038653112338	0.68932	5.087902	0.506695735832082	0.67486	.	.	.	2	1.647e-05	0	0	0	0	2	1.653e-05	0	0	1	1.513e-04	1	1.502e-05	0	0	2	1.883e-05	0	0	0	0	2	1.887e-05	0	0	1	1.513e-04	1	1.842e-05	0	0	1	1.102e-05	0	0	0	0	1	1.107e-05	0	0	1	2.633e-04	0	0	0	0	0.99551	.	.	.	5.51	4.61	0.56724	0	0.45803	0.59043	.	.	0.28865	0.965914113095807	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.94316	.	0.214651	0.45977	D	0.000310	D	0.97696	0.715981	0.22241	.	0.97136	.	D	0.99068	0.9704	.	0.98551	.	D	0.99082	1.0859	R297C	Loss_of_disorder_(P_=_0.0477)&_Loss_of_helix_(P_=_0.2022)&_Gain_of_loop_(P_=_0.2045)&_Loss_of_phosphorylation_at_S298_(P_=_0.2522)&_Loss_of_methylation_at_R297_(P_=_0.2856)	P00439	0.99130	0.938	.	0.51832	.	.	0.49910	simple_aae&simple_aae	D&D	0.999853&0.999853	0.35399	.	.	.	0.65571	.	.	0.58175	.	T	0.67699	0.703829944134	0.94390	.	10	0.79402	.	.	0.78490	.	.	16.2486	0.82291	0.0:0.0:0.8666:0.1334	.	.	.	.	.	.	.	.	0.86618	.	G/G	C	.	R	A	514	0.74853	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102851710G>A	102885	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.R297C&UniProtKB_(protein):P00439#VAR_000985	.	.	AEFBCI	D	0.52348	0.90834	D	0.82812	0.891804	.	6	2.390130e-05	0	0.000000e+00	16240	0	0	0.000000e+00	34568	0	251032	0	0.000000e+00	10062	0	0	0.000000e+00	18382	0	3	1.386580e-04	21636	0	3	2.645320e-05	113408	0	3	2.645320e-05	113408	0	0	0.000000e+00	30610	0	4	3.657380e-05	0	0.000000e+00	7158	0	0	0.000000e+00	17102	0	109368	0	0.000000e+00	2320	0	0	0.000000e+00	9040	0	3	2.241820e-04	13382	0	1	2.338420e-05	42764	0	1	2.338420e-05	42764	0	0	0.000000e+00	15688	0	0	.	0	6	2.536700e-05	0	0.000000e+00	14896	0	0	0.000000e+00	34238	0	236528	0	0.000000e+00	9554	0	0	0.000000e+00	17684	0	3	1.387600e-04	21620	0	3	2.929400e-05	102410	0	3	2.929400e-05	102410	0	0	0.000000e+00	30520	0	0	6	2.884010e-05	0	0.000000e+00	16202	0	0	0.000000e+00	30506	0	208044	0	0.000000e+00	6210	0	0	0.000000e+00	13404	0	3	1.794040e-04	16722	0	3	3.350760e-05	89532	0	3	3.350760e-05	89532	0	0	0.000000e+00	30602	0	0	6	2.454830e-05	0	0.000000e+00	12012	0	0	0.000000e+00	34434	0	244416	0	0.000000e+00	9980	0	0	0.000000e+00	18378	0	3	1.386710e-04	21634	0	3	2.694980e-05	111318	0	3	2.694980e-05	111318	0	0	0.000000e+00	30610	0	0	1	6.573330e-06	0	0.000000e+00	41432	0	0	0.000000e+00	912	0	0	0.000000e+00	15280	0	152130	0	0.000000e+00	3472	0	0	0.000000e+00	5190	0	0	0.000000e+00	10582	0	0	0.000000e+00	316	0	1	1.469720e-05	68040	0	1	1.469720e-05	68040	0	0	0.000000e+00	4812	0	0	0.000000e+00	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32854	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5462	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3098	0	0	.	0	1	6.762420e-06	0	0.000000e+00	41110	0	0	0.000000e+00	912	0	0	0.000000e+00	15092	0	147876	0	0.000000e+00	3302	0	0	0.000000e+00	4954	0	0	0.000000e+00	10582	0	0	0.000000e+00	304	0	1	1.542830e-05	64816	0	0	0.000000e+00	4780	0	0	1	7.422690e-06	0	0.000000e+00	32466	0	0	0.000000e+00	862	0	0	0.000000e+00	14834	0	134722	0	0.000000e+00	3388	0	0	0.000000e+00	5190	0	0	0.000000e+00	6942	0	0	0.000000e+00	310	0	1	1.564550e-05	63916	0	0	0.000000e+00	4810	0	0	0	0.000000e+00	0	0.000000e+00	24806	0	0	0.000000e+00	112	0	0	0.000000e+00	12908	0	80688	0	0.000000e+00	998	0	0	0.000000e+00	3748	0	0	0.000000e+00	10490	0	0	0.000000e+00	272	0	0	0.000000e+00	21050	0	0	0.000000e+00	4784	0	0	12	101769618	12	103245488	0	0.43195	0.638212	1.000000	0.71638	0.998000	0.85391	0.994000	0.56301	3.220000	0.50909	0.676000	0.76740	0.161000	0.20460	102851710	G	.	rs62642945	.	.	9.506	11.083	11.570	9.399	.	.	.	-5	46	46	-23	0.00	0.08	0.00	0.08	PAH	0.00	exon-NM_001354304.2-9+23+start+70	102885	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	rs62642945	1.647e-05	2	2	0	0	0	0	1	1	0	0	10344	11508	8618	6610	66580	908	16458	0	0	0	1	1	0	0	0	0	0	0	0	0	0	rs62642945	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79469e-04	2.69474e-05	0.00000e+00	0.00000e+00	2.97115e-05	2.69896e-05	1.79469e-04	3.24849e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62642945	62642945	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,695	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103248982	103248982	A	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.638T>C	NP_000268.1:p.Leu213Pro	752	638	213	L/P	cTt/cCt	rs62516109&CM961074	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103248982A>G	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.638T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.97052	0.583229	D	0.96995	0.599991	29.7	29.0	4.319524	4.151588	0.88658	0.87071	A/A	D	0.98390	0.999661684036255	0.98586	0.99918996981661723	.	0.99992	.	A/A	.	.	.	.	17.60299	0.978846913007501	0.98175	16.52641	1.0759104434209	0.97662	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99805	.	.	.	5.63	5.63	0.86108	0	0.26702	0.573888	.	.	0.74766	0.999994985318417	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.96647	.	0.000000	0.84330	D	0.000000	D	0.98441	0.800821	0.30717	.	0.99761	.	D	0.99872	0.9944	.	0.99849	.	D	0.95921	0.9174	L213P	Loss_of_stability_(P_=_0.0406)&_Gain_of_methylation_at_K215_(P_=_0.0648)&_Gain_of_ubiquitination_at_K215_(P_=_0.0817)&_Gain_of_catalytic_residue_at_L212_(P_=_0.158)&_Loss_of_helix_(P_=_0.1706)	P00439	0.98806	0.927	.	0.99445	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.92433	.	.	.	0.90584	.	.	0.97372	.	T	0.76766	0.765606045723	0.99783	.	10	0.92824	.	.	0.91255	.	.	15.8352	0.78571	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99260	.	A/A	P	.	L	G	528	0.73785	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102855204A>G	92747	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_000930&DeBelle_Laboratory_for_Biochemical_Genetics:p.L213P&Illumina_Laboratory_Services&Illumina:1354219&HGMD:CM961074	.	.	AEFBI	D	0.92899	0.99213	D	0.99990	0.989244	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101773112	12	103248982	0	0.43195	0.638212	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	9.325000	0.96006	0.756000	0.94297	1.312000	0.94714	102855204	A	.	rs62516109	.	.	7.651	9.354	7.292	9.092	.	.	.	-6	-8	29	-6	0.00	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+68+start+197	92747	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62516109	62516109	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,762	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103248970	103248970	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.650G>A	NP_000268.1:p.Cys217Tyr	764	650	217	C/Y	tGt/tAt	rs62508617&CM015342	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103248970C>T	.	.	.	.	.	.	not_provided&uncertain_significance	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.650G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.96979	0.5789	D	0.96930	0.593773	26.6	28.9	3.943956	4.140171	0.76718	0.86783	C/C	D	0.99958	0.999971985816956	0.88639	0.99801580084803387	.	0.99961	.	C/C	.	.	.	.	17.01363	0.968151020309853	0.97910	15.51434	1.04830097221212	0.97050	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99632	.	.	.	5.63	5.63	0.86108	0	0.26702	0.573888	.	.	0.74766	0.999999998942048	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.88867	.	0.000000	0.84330	D	0.000000	D	0.98367	0.791985	0.31207	.	0.99326	.	D	0.99789	0.9916	.	0.99909	.	D	0.96845	0.9791	C217Y	Loss_of_methylation_at_K215_(P_=_0.0584)&_Gain_of_catalytic_residue_at_L212_(P_=_0.0648)&_Loss_of_ubiquitination_at_K215_(P_=_0.1113)&_Gain_of_disorder_(P_=_0.2221)&_Loss_of_glycosylation_at_K215_(P_=_0.3403)	P00439	0.98901	0.93	.	0.98003	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.99130	.	.	.	0.90584	.	.	0.97372	.	T	0.75965	0.760240793228	0.99890	.	10	0.72224	.	.	0.91255	.	.	19.6736	0.95917	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.98167	.	C/C	Y	.	C	T	528	0.73785	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102855192C>T	102772	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.C217Y	.	.	AEFBI	D	0.86914	0.98792	D	0.99969	0.986193	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101773100	12	103248970	0	0.43195	0.638212	1.000000	0.71638	0.997000	0.79791	0.998000	0.65909	7.905000	0.86479	0.599000	0.40250	1.026000	0.45946	102855192	C	.	rs62508617	.	.	7.651	9.354	7.292	9.092	.	.	.	-29	4	40	6	0.00	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+56+start+197	102772	Uncertain_significance	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508617	62508617	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,761	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103271313	103271313	C	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	4/13	.	NM_000277.3:c.368G>T	NP_000268.1:p.Arg123Ile	482	368	123	R/I	aGa/aTa	rs199475681&COSV61015299	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103271313C>A	.	.	.	.	.	.	not_provided&uncertain_significance	0&1	1&1	.	.	.	.	.	PAH&NM_000277.1&c.368G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.85567	0.336021	D	0.85377	0.244895	26.3	29.3	3.885890	4.175113	0.74825	0.87670	C/C	D	0.82364	0.991982161998749	0.37851	0.9804909402104246	.	0.99931	.	C/C	.	.	.	.	4.320404	0.394602610679957	0.61231	5.021381	0.498176545923816	0.66983	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99678	.	.	.	5.86	4.04	0.46262	0	0.14657	0.547309	.	.	0.18191	0.206788254233964	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.92822	.	0.191121	0.55875	D	0.000029	D	0.98798	0.84432	0.25536	.	0.98622	.	D	0.99747	0.9905	.	0.88660	.	D	0.97370	1.0107	R123I	Gain_of_stability_(P_=_0.0432)&_Loss_of_glycosylation_at_P119_(P_=_0.0951)&_Gain_of_catalytic_residue_at_L128_(P_=_0.1031)&_Loss_of_phosphorylation_at_T124_(P_=_0.1079)&_Loss_of_MoRF_binding_(P_=_0.1384)	P00439	0.78001	0.643	.	0.93784	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.91017	.	.	.	0.77913	.	.	0.77487	.	T	0.50206	0.58085668087	0.95876	.	10	0.60337	.	.	0.78490	.	.	12.3558	0.54501	0.0:0.8638:0.0:0.1362	.	.	.	.	.	.	.	.	0.75283	.	C/C	I	.	R	A	675	0.60470	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102877535C>A	102658	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:R123I	.	.	AEFBI	D	0.51789	0.90534	D	0.74423	0.824304	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101795443	12	103271313	0	0.37627	0.615465	0.993000	0.37899	0.903000	0.43903	0.991000	0.53220	1.515000	0.35452	-0.182000	0.10109	0.129000	0.18587	102877535	C	.	rs199475681	.	.	8.810	7.211	11.038	10.766	.	.	.	-12	15	2	-1	0.00	0.20	0.00	0.00	PAH	0.00	exon-NM_001354304.2-5+15+end+89	102658	Uncertain_significance	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475681	199475681	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,802	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.8999	Likely Pathogenic
12	103260377	103260377	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.506G>A	NP_000268.1:p.Arg169His	620	506	169	R/H	cGc/cAc	rs199475679&CM992371&COSV61016255	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103260377C>T	.	.	.	.	.	.	likely_pathogenic&conflicting_interpretations_of_pathogenicity	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.506G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.74526	0.206761	D	0.85696	0.251557	23.6	23.9	3.099536	3.134725	0.54262	0.57901	C/C	T	0.21460	0.219915145047667	0.90238	0.99819453977342065	.	0.99784	.	C/C	.	.	.	.	3.982595	0.343838062088003	0.58138	3.724293	0.289244397311491	0.55602	.	.	.	31	2.553e-04	0	0	0	0	31	2.636e-04	0	0	0	0	30	4.633e-04	1	6.061e-05	24	2.260e-04	0	0	0	0	24	2.321e-04	0	0	0	0	23	4.322e-04	1	6.095e-05	30	3.306e-04	0	0	0	0	30	3.449e-04	0	0	0	0	29	7.218e-04	1	6.064e-05	0.99581	.	.	.	6.08	5.19	0.71428	0	0.26702	0.573888	.	.	0.16474	0.104412263562769	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.89738	.	0.139623	0.62929	D	0.000004	D	0.95989	0.560786	0.03894	.	0.96247	.	D	0.98338	0.9490	.	0.63720	.	D	0.97664	1.0272	R169H	Loss_of_MoRF_binding_(P_=_0.0185)&_Gain_of_disorder_(P_=_0.1225)&_Gain_of_catalytic_residue_at_Q172_(P_=_0.2152)&_Gain_of_phosphorylation_at_Y168_(P_=_0.2267)&_Loss_of_stability_(P_=_0.2448)	P00439	0.98069	0.907	.	0.84406	.	.	0.58761	simple_aae&simple_aae	D&D	0.999981&0.999997	0.68412	.	.	.	0.43037	.	.	0.34472	.	T	0.40233	0.510074496269	0.90982	.	10	0.65728	.	.	0.56456	.	.	12.8345	0.57150	0.0:0.9254:0.0:0.0746	.	.	.	.	.	.	.	.	0.79406	.	C/C	H	.	R	T	699	0.57969	.	12	C0031485&C0878676&CN517202	261600&261640	ORPHA716&ORPHA13	Likely_pathogenic	NC_000012.12:g.102866599C>T	102706	reviewed_by_expert_panel	Phenylketonuria&BH4-deficient_hyperphenylalaninemia_A&not_provided	UniProtKB_(protein):P00439#VAR_011568&Illumina_Laboratory_Services&Illumina:438722&DeBelle_Laboratory_for_Biochemical_Genetics:p.R169H	.	.	AEFBI	D	0.51162	0.90184	D	0.76958	0.852672	.	75	2.992980e-04	0	0.000000e+00	16052	0	0	0.000000e+00	34526	0	250586	60	5.965400e-03	10058	0	0	0.000000e+00	18364	0	0	0.000000e+00	21542	0	10	8.824410e-05	113322	0	10	8.824410e-05	113322	0	1	3.266270e-05	30616	0	17	1.562410e-04	0	0.000000e+00	6990	0	0	0.000000e+00	17076	0	108806	12	5.203820e-03	2306	0	0	0.000000e+00	9022	0	0	0.000000e+00	13314	0	4	9.409990e-05	42508	0	4	9.409990e-05	42508	0	1	6.373490e-05	15690	0	0	.	0	70	2.963840e-04	0	0.000000e+00	14714	0	0	0.000000e+00	34194	0	236180	57	5.966090e-03	9554	0	0	0.000000e+00	17664	0	0	0.000000e+00	21526	0	8	7.812650e-05	102398	0	8	7.812650e-05	102398	0	1	3.275900e-05	30526	0	0	52	2.508300e-04	0	0.000000e+00	16014	0	0	0.000000e+00	30460	0	207312	39	6.298450e-03	6192	0	0	0.000000e+00	13386	0	0	0.000000e+00	16628	0	9	1.009060e-04	89192	0	9	1.009060e-04	89192	0	1	3.267120e-05	30608	0	0	74	3.031690e-04	0	0.000000e+00	11860	0	0	0.000000e+00	34392	0	244088	59	5.914190e-03	9976	0	0	0.000000e+00	18360	0	0	0.000000e+00	21540	0	10	8.983600e-05	111314	0	10	8.983600e-05	111314	0	1	3.266270e-05	30616	0	0	31	2.038240e-04	0	0.000000e+00	41422	0	0	0.000000e+00	908	0	3	1.965150e-04	15266	0	152092	19	5.472350e-03	3472	1	0	0.000000e+00	5192	0	0	0.000000e+00	10604	0	0	0.000000e+00	316	0	7	1.029200e-04	68014	0	3	1.965150e-04	15266	0	0	0.000000e+00	4808	0	4	1.217510e-04	0	0.000000e+00	9092	0	0	0.000000e+00	60	0	3	6.402050e-04	4686	0	32854	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5478	0	0	0.000000e+00	246	0	0	0.000000e+00	6844	0	0	0.000000e+00	3096	0	0	.	1	29	1.961530e-04	0	0.000000e+00	41100	0	0	0.000000e+00	908	0	3	1.989650e-04	15078	0	147844	19	5.754090e-03	3302	1	0	0.000000e+00	4956	0	0	0.000000e+00	10604	0	0	0.000000e+00	304	0	5	7.716530e-05	64796	0	0	0.000000e+00	4776	0	1	30	2.227340e-04	0	0.000000e+00	32452	0	0	0.000000e+00	862	0	3	2.024020e-04	14822	0	134690	19	5.608030e-03	3388	1	0	0.000000e+00	5192	0	0	0.000000e+00	6968	0	0	0.000000e+00	310	0	7	1.095630e-04	63890	0	0	0.000000e+00	4806	0	1	15	1.859700e-04	0	0.000000e+00	24796	0	0	0.000000e+00	108	0	3	2.327020e-04	12892	0	80658	6	6.012020e-03	998	0	0	0.000000e+00	3750	0	0	0.000000e+00	10512	0	0	0.000000e+00	272	0	4	1.901680e-04	21034	0	0	0.000000e+00	4780	0	0	12	101784507	12	103260377	0	0.25195	0.553676	1.000000	0.71638	0.985000	0.61073	0.999000	0.70432	2.062000	0.41039	0.599000	0.40250	1.026000	0.45946	102866599	C	.	rs199475679	.	.	7.292	9.092	8.810	7.211	.	.	.	35	-3	-2	-3	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-6+3+start+68	102706	Likely_pathogenic	reviewed_by_expert_panel	6-Pyruvoyl-tetrahydrobiopterin_synthase_deficiency&Inborn_genetic_diseases&not_provided&Phenylketonuria	MONDO:MONDO:0009863&MedGen:C0878676&OMIM:261640&Orphanet:13&Orphanet:238583&MeSH:D030342&MedGen:C0950123&MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103260377-103260377	2.553e-04	31	31	0	0	0	0	0	30	0	1	9946	11430	8528	5612	64746	856	16500	0	0	0	0	30	0	1	0	0	0	0	0	0	0	rs144835074	0.00000e+00	0.00000e+00	6.36550e-03	0.00000e+00	0.00000e+00	8.18345e-05	3.70096e-04	3.24971e-05	2.55512e-04	3.64884e-04	6.36550e-03	3.00488e-04	rs144835074	0.00000e+00	0.00000e+00	1.32450e-02	0.00000e+00	0.00000e+00	1.33209e-04	0.00000e+00	.	1.75234e-04	2.16606e-04	1.32450e-02	1.93598e-04	.	.	rs199475679	199475679	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,779	0	0	0	0	0	1	1	0	1	1	1	0	1	0	0	0	0	0	0	0	0	0.6752	Likely Pathogenic
12	103246653	103246653	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.782G>A	NP_000268.1:p.Arg261Gln	896	782	261	R/Q	cGa/cAa	rs5030849&CM910287&CM950891&COSV61020894	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246653C>T	.	0	0	0.001	0	0	pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.782G>A	.	.	1	1.9968051118210862E-4	0	0.0	0	0.0	1	9.92063492063492E-4	0	0.0	0	0.0	3	7.784120394395433E-4	.	.	.	.	.	.	.	C/C	C	D	0.87122	0.358274	D	0.96922	0.593015	29.2	31	4.259784	4.368348	0.87211	0.90837	C/C	D	0.50975	0.859159111976624	0.99990	0.99958587196391924	.	0.99996	.	C/C	2	4.5392646391284613E-4	5	5.813953488372093E-4	16.30177	0.954531501491271	0.97537	14.70244	1.02430945680376	0.96444	.	.	.	33	2.718e-04	1	9.612e-05	1	8.651e-05	33	2.719e-04	2	2.312e-04	0	0	28	4.196e-04	0	0	26	2.448e-04	1	1.103e-04	1	8.930e-05	26	2.449e-04	2	2.543e-04	0	0	21	3.864e-04	0	0	25	2.755e-04	1	9.628e-05	1	8.660e-05	25	2.756e-04	1	1.774e-04	0	0	22	5.222e-04	0	0	0.99769	.	.	.	5.72	5.72	0.89380	0	0.45803	0.59043	.	.	0.74766	0.999999999999476	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.97650	.	0.000000	0.84330	D	0.000000	D	0.94288	0.447948	0.27716	.	0.98988	.	D	0.99857	0.9938	.	0.64645	.	D	0.96543	0.9598	.	.	.	.	.	.	0.96631	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.71157	.	.	.	0.90584	.	.	0.88582	.	D	0.85080	0.820344865322	0.99931	.	9	0.79402	.	.	0.91255	.	.	19.8761	0.96868	0.0:1.0:0.0:0.0	.	1	2.6968716289104636E-4	4	5.289605924358636E-4	.	.	.	0.95374	.	C/C	Q	.	R	T	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102852875C>T	582	reviewed_by_expert_panel	Phenylketonuria&not_provided	HGMD:CM910287&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2479838&DeBelle_Laboratory_for_Biochemical_Genetics:p.R261Q&UniProtKB_(protein):P00439#VAR_000965&OMIM_Allelic_Variant:612349.0006	.	.	AEFBI	D	0.82634	0.98424	D	0.99679	0.976543	.	56	2.227900e-04	1	6.151570e-05	16256	0	3	8.674530e-05	34584	0	251358	3	2.976780e-04	10078	0	2	1.087550e-04	18390	0	0	0.000000e+00	21648	0	42	3.695560e-04	113650	0	42	3.695560e-04	113650	0	0	0.000000e+00	30616	0	26	2.376510e-04	1	1.395870e-04	7164	0	2	1.168770e-04	17112	0	109404	1	4.310340e-04	2320	0	2	2.211410e-04	9044	0	0	0.000000e+00	13394	0	20	4.676610e-04	42766	0	20	4.676610e-04	42766	0	0	0.000000e+00	15690	0	0	.	0	48	2.026860e-04	1	6.710510e-05	14902	0	3	8.758610e-05	34252	0	236820	2	2.089860e-04	9570	0	2	1.130710e-04	17688	0	0	0.000000e+00	21632	0	37	3.605040e-04	102634	0	37	3.605040e-04	102634	0	0	0.000000e+00	30526	0	0	45	2.162260e-04	1	6.165990e-05	16218	0	2	6.553080e-05	30520	0	208116	2	3.219580e-04	6212	0	1	7.456010e-05	13412	0	0	0.000000e+00	16734	0	36	4.020280e-04	89546	0	36	4.020280e-04	89546	0	0	0.000000e+00	30608	0	0	55	2.247280e-04	1	8.315320e-05	12026	0	3	8.708270e-05	34450	0	244740	3	3.001200e-04	9996	0	2	1.087780e-04	18386	0	0	0.000000e+00	21646	0	41	3.675150e-04	111560	0	41	3.675150e-04	111560	0	0	0.000000e+00	30616	0	0	34	2.236310e-04	3	7.249880e-05	41380	0	10	1.098900e-02	910	0	1	6.552220e-05	15262	0	152036	0	0.000000e+00	3468	0	1	1.928270e-04	5186	0	0	0.000000e+00	10592	0	0	0.000000e+00	316	0	17	2.499340e-04	68018	0	17	2.499340e-04	68018	0	0	0.000000e+00	4812	0	6	1.826820e-04	0	0.000000e+00	9070	0	1	1.666670e-02	60	0	0	0.000000e+00	4682	0	32844	0	0.000000e+00	136	0	1	4.118620e-04	2428	0	0	0.000000e+00	5474	0	0	0.000000e+00	246	0	3	4.378280e-04	6852	0	0	0.000000e+00	3106	0	0	.	0	34	2.300660e-04	3	7.306740e-05	41058	0	10	1.098900e-02	910	0	1	6.633940e-05	15074	0	147784	0	0.000000e+00	3298	0	1	2.019390e-04	4952	0	0	0.000000e+00	10592	0	0	0.000000e+00	304	0	17	2.623700e-04	64794	0	0	0.000000e+00	4780	0	0	31	2.302300e-04	3	9.251830e-05	32426	0	9	1.044080e-02	862	0	1	6.749460e-05	14816	0	134648	0	0.000000e+00	3384	0	1	1.928270e-04	5186	0	0	0.000000e+00	6958	0	0	0.000000e+00	310	0	15	2.347640e-04	63894	0	0	0.000000e+00	4810	0	0	11	1.364660e-04	1	4.039750e-05	24754	0	2	1.818180e-02	110	0	1	7.757950e-05	12890	0	80606	0	0.000000e+00	996	0	1	2.670940e-04	3744	0	0	0.000000e+00	10500	0	0	0.000000e+00	272	0	5	2.376650e-04	21038	0	0	0.000000e+00	4784	0	0	12	101770783	12	103246653	0	0.43195	0.638212	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	7.905000	0.86479	0.599000	0.40250	1.026000	0.45946	102852875	C	.	rs5030849	.	.	11.570	9.399	7.651	9.354	.	.	.	-3	-18	-45	-18	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+60+start+136	582	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030849	2.718e-04	33	33	0	1	1	2	0	28	1	0	10404	11560	8652	6610	66730	908	16512	1	1	2	0	28	1	0	0	0	0	0	0	0	0	rs5030849	6.53424e-05	8.93655e-05	4.06174e-04	1.15982e-04	4.48471e-05	3.94315e-04	1.82282e-04	0.00000e+00	2.37368e-04	2.15622e-04	4.06174e-04	2.27391e-04	rs5030849	0.00000e+00	1.19332e-03	0.00000e+00	0.00000e+00	0.00000e+00	1.99947e-04	0.00000e+00	.	1.75398e-04	7.21917e-05	1.19332e-03	1.29066e-04	rs5030849	0.0581&0.0454&0.0538	rs5030849	5030849	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,738	0	0	0	0	0	1	1	0	1	1	1	0	1	0	0	0	0	0	0	0	0	0.6752	Likely Pathogenic
12	103237484	103237484	G	A	A	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1139C>T	NP_000268.1:p.Thr380Met	1253	1139	380	T/M	aCg/aTg	rs62642937&CM930563	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103237484G>A	.	0	0	0	0.001	0	uncertain_significance&pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1139C>T	.	.	1	1.9968051118210862E-4	0	0.0	0	0.0	0	0.0	1	9.940357852882703E-4	0	0.0	.	.	.	.	.	.	.	.	.	G/G	G	D	0.86533	0.35044	D	0.96537	0.579865	25.0	24.3	3.583613	3.268722	0.66256	0.61212	G/G	T	0.25102	0.302380008636066	0.96204	0.99887353675142687	.	0.99997	.	G/G	0	0.0	6	6.976744186046512E-4	7.568493	0.689957384988888	0.81616	9.688813	0.843386389402639	0.88727	.	.	.	40	3.295e-04	0	0	2	1.737e-04	40	3.298e-04	0	0	0	0	35	5.248e-04	3	1.817e-04	34	3.201e-04	0	0	2	1.794e-04	34	3.205e-04	0	0	0	0	29	5.341e-04	3	1.829e-04	37	4.077e-04	0	0	2	1.739e-04	37	4.083e-04	0	0	0	0	32	7.603e-04	3	1.818e-04	0.99589	.	.	.	5.34	5.34	0.75982	0	0.26702	0.573888	.	.	0.35572	0.997398280251415	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.81652	.	0.000000	0.84330	D	0.000000	D	0.99137	0.886418	0.26853	.	0.99300	.	D	0.99796	0.9918	.	0.75610	.	D	0.96556	0.9607	.	.	.	.	.	.	0.98464	.	.	0.81001	simple_aae&simple_aae	A&A	1&1	0.87988	.	.	.	0.90584	.	.	0.86255	.	T	0.52861	0.599690198898	0.99740	.	9	0.70582	.	.	0.78490	.	.	19.0479	0.93009	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.92084	.	G/G	M	.	T	A	503	0.75780	.	12	C0751435&C0031485&C0878676&CN263130&CN517202	261600&261640	ORPHA716&ORPHA13	Pathogenic	NC_000012.12:g.102843706G>A	628	reviewed_by_expert_panel	Hyperphenylalaninemia&_non-pku&Phenylketonuria&BH4-deficient_hyperphenylalaninemia_A&Marfanoid_habitus_and_intellectual_disability&not_provided	UniProtKB_(protein):P00439#VAR_001022&HGMD:CM930563&OMIM_Allelic_Variant:612349.0054&Illumina_Laboratory_Services&Illumina:578408&DeBelle_Laboratory_for_Biochemical_Genetics:p.T380M	.	.	AEFBI	D	0.77878	0.97887	D	0.99383	0.971867	.	111	4.417660e-04	0	0.000000e+00	16254	0	10	2.895190e-04	34540	0	251264	48	4.764740e-03	10074	1	1	5.438920e-05	18386	0	0	0.000000e+00	21638	0	45	3.960360e-04	113626	0	45	3.960360e-04	113626	0	4	1.306510e-04	30616	0	35	3.199970e-04	0	0.000000e+00	7164	0	5	2.924320e-04	17098	0	109376	7	3.017240e-03	2320	0	0	0.000000e+00	9040	0	0	0.000000e+00	13392	0	19	4.443410e-04	42760	0	19	4.443410e-04	42760	0	3	1.912050e-04	15690	0	0	.	1	104	4.393230e-04	0	0.000000e+00	14900	0	10	2.923290e-04	34208	0	236728	45	4.704160e-03	9566	1	1	5.654830e-05	17684	0	0	0.000000e+00	21622	0	41	3.995630e-04	102612	0	41	3.995630e-04	102612	0	4	1.310360e-04	30526	0	1	82	3.941810e-04	0	0.000000e+00	16216	0	9	2.953340e-04	30474	0	208026	27	4.349230e-03	6208	1	0	0.000000e+00	13408	0	0	0.000000e+00	16724	0	39	4.356180e-04	89528	0	39	4.356180e-04	89528	0	4	1.306850e-04	30608	0	1	107	4.373670e-04	0	0.000000e+00	12024	0	10	2.906470e-04	34406	0	244646	44	4.403520e-03	9992	1	1	5.440100e-05	18382	0	0	0.000000e+00	21636	0	45	4.034570e-04	111536	0	45	4.034570e-04	111536	0	4	1.306510e-04	30616	0	1	57	3.747980e-04	3	7.246730e-05	41398	0	0	0.000000e+00	912	0	5	3.274390e-04	15270	0	152082	18	5.184330e-03	3472	0	1	1.928270e-04	5186	0	0	0.000000e+00	10610	0	1	3.164560e-03	316	0	27	3.970000e-04	68010	0	27	3.970000e-04	68010	0	0	0.000000e+00	4818	0	8	2.434420e-04	1	1.099870e-04	9092	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32862	2	1.470590e-02	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5484	0	1	4.065040e-03	246	0	4	5.846240e-04	6842	0	0	0.000000e+00	3100	0	0	.	0	54	3.652800e-04	3	7.303530e-05	41076	0	0	0.000000e+00	912	0	5	3.315210e-04	15082	0	147832	17	5.148390e-03	3302	0	1	2.019390e-04	4952	0	0	0.000000e+00	10610	0	1	3.289470e-03	304	0	25	3.858740e-04	64788	0	0	0.000000e+00	4786	0	0	56	4.157390e-04	2	6.162570e-05	32454	0	0	0.000000e+00	862	0	5	3.372910e-04	14824	0	134700	18	5.312870e-03	3388	0	1	1.928270e-04	5186	0	0	0.000000e+00	6972	0	1	3.225810e-03	310	0	27	4.226150e-04	63888	0	0	0.000000e+00	4816	0	0	20	2.479670e-04	3	1.210750e-04	24778	0	0	0.000000e+00	112	0	3	2.325940e-04	12898	0	80656	4	4.008020e-03	998	0	0	0.000000e+00	3744	0	0	0.000000e+00	10518	0	1	3.676470e-03	272	0	8	3.804090e-04	21030	0	0	0.000000e+00	4790	0	0	12	101761614	12	103237484	0	0.43195	0.638212	1.000000	0.71638	0.152000	0.20376	0.301000	0.24051	7.984000	0.87764	0.618000	0.50648	1.176000	0.78918	102843706	G	.	rs62642937	.	.	8.924	9.158	3.163	9.459	.	.	.	-5	34	2	-17	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-12+60+start+134	628	Pathogenic	reviewed_by_expert_panel	Marfanoid_habitus_and_intellectual_disability&not_provided&6-Pyruvoyl-tetrahydrobiopterin_synthase_deficiency&Hyperphenylalaninemia&Phenylketonuria	MedGen:CN263130&MedGen:CN517202&MONDO:MONDO:0009863&MedGen:C0878676&OMIM:261640&Orphanet:13&Orphanet:238583&Human_Phenotype_Ontology:HP:0004923&MedGen:C0751435&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62642937	3.295e-04	40	40	0	0	2	0	0	35	0	3	10406	11512	8650	6600	66688	908	16508	0	2	0	0	35	0	3	0	0	0	0	0	0	0	rs62642937	0.00000e+00	2.68432e-04	4.67290e-03	5.80046e-05	0.00000e+00	3.76459e-04	3.65364e-04	1.29946e-04	3.85831e-04	4.67399e-04	4.67290e-03	4.22301e-04	rs62642937	3.44274e-04	1.19332e-03	3.31126e-03	0.00000e+00	0.00000e+00	6.67022e-05	0.00000e+00	.	1.75439e-04	2.16826e-04	3.31126e-03	1.93598e-04	rs62642937	0.0698&0.0&0.0461	rs62642937	62642937	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,664	0	0	0	0	0	1	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0.3246	Likely Pathogenic
12	103306579	103306579	C	T	T	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	2/13	.	NM_000277.3:c.158G>A	NP_000268.1:p.Arg53His	272	158	53	R/H	cGc/cAc	rs118092776&CM981427&COSV61020094	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103306579C>T	.	0	0	0.0119	0.002	0.001	likely_benign&not_provided&uncertain_significance	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.158G>A	.	.	15	0.0029952076677316293	0	0.0	0	0.0	12	0.011904761904761904	2	0.0019880715705765406	1	0.0010224948875255625	8	0.0020757654385054488	.	.	.	.	.	.	.	C/C	C	T	0.45805	-0.0409635	D	0.83553	0.207859	23.0	25.0	2.768441	3.515830	0.47063	0.67513	C/C	T	0.10774	0.0863101955320222	0.89620	0.99812126672322055	.	0.97149	.	C/C	0	0.0	8	9.302325581395349E-4	5.546107	0.540149542794111	0.70713	5.112753	0.509847709328791	0.67669	.	.	.	212	1.746e-03	1	9.612e-05	4	3.455e-04	212	1.747e-03	138	1.596e-02	1	1.513e-04	45	6.744e-04	22	1.333e-03	196	1.845e-03	1	1.103e-04	4	3.566e-04	196	1.846e-03	130	1.654e-02	1	1.513e-04	38	6.994e-04	22	1.341e-03	177	1.950e-03	1	9.628e-05	4	3.458e-04	177	1.951e-03	110	1.952e-02	0	0	39	9.258e-04	22	1.333e-03	0.99184	.	.	.	5.46	5.46	0.80021	0	0.26702	0.573888	.	.	0.74766	0.999999997095742	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.44280	.	0.103551	0.62929	D	0.000008	.	.	.	0.03697	.	0.99046	.	D	0.96735	0.9016	.	0.00264	.	D	0.93660	0.7392	.	.	.	.	.	.	0.62911	.	.	0.58761	simple_aae&simple_aae	D&D	0.999993&0.999993	0.59226	.	.	.	0.48483	.	.	0.41207	.	T	0.33177	0.45903223753	0.93028	.	10	0.70582	.	.	0.63226	.	.	16.2413	0.82232	0.0:1.0:0.0:0.0	.	3	8.090614886731392E-4	11	0.0014546416291986246	.	.	.	0.57946	.	C/C	H	.	R	T	768	0.49510	.	12	C0031485&CN169374&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102912801C>T	102601	reviewed_by_expert_panel	Phenylketonuria&not_specified&not_provided	UniProtKB_(protein):P00439#VAR_000878&Illumina_Laboratory_Services&Illumina:61345&DeBelle_Laboratory_for_Biochemical_Genetics:p.R53H	.	.	AEFBI	D	0.51145	0.90174	D	0.74816	0.829200	.	422	1.678720e-03	3	1.845470e-04	16256	0	33	9.540330e-04	34590	0	251382	1	9.922600e-05	10078	0	253	1.375450e-02	18394	3	2	9.248130e-05	21626	0	77	6.772800e-04	113690	0	253	1.375450e-02	18394	3	45	1.470010e-03	30612	0	208	1.901520e-03	2	2.791740e-04	7164	0	17	9.934550e-04	17112	0	109386	0	0.000000e+00	2320	0	132	1.459210e-02	9046	1	0	0.000000e+00	13374	0	33	7.716410e-04	42766	0	132	1.459210e-02	9046	1	22	1.402170e-03	15690	0	1	.	3	405	1.709990e-03	3	2.013150e-04	14902	0	33	9.632790e-04	34258	0	236844	1	1.044930e-04	9570	0	245	1.384810e-02	17692	3	2	9.254970e-05	21610	0	70	6.817690e-04	102674	0	245	1.384810e-02	17692	3	45	1.474350e-03	30522	0	3	350	1.681960e-03	3	1.849800e-04	16218	0	22	7.207920e-04	30522	0	208090	1	1.609790e-04	6212	0	206	1.535480e-02	13416	2	0	0.000000e+00	16712	0	66	7.370840e-04	89542	0	206	1.535480e-02	13416	2	45	1.470400e-03	30604	0	2	421	1.720020e-03	3	2.494600e-04	12026	0	33	9.577430e-04	34456	0	244764	1	1.000400e-04	9996	0	253	1.375750e-02	18390	3	2	9.248980e-05	21624	0	76	6.810040e-04	111600	0	253	1.375750e-02	18390	3	45	1.470010e-03	30612	0	3	195	1.281700e-03	10	2.413830e-04	41428	0	0	0.000000e+00	912	0	31	2.030660e-03	15266	0	152142	0	0.000000e+00	3468	0	104	2.002310e-02	5194	1	1	9.423290e-05	10612	0	0	0.000000e+00	316	0	41	6.027280e-04	68024	0	104	2.002310e-02	5194	1	8	1.656310e-03	4830	0	47	1.429270e-03	5	5.495710e-04	9098	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32884	0	0.000000e+00	134	0	34	1.400330e-02	2428	1	0	0.000000e+00	5480	0	0	0.000000e+00	246	0	3	4.380840e-04	6848	0	5	1.605650e-03	3114	0	1	.	1	194	1.311700e-03	10	2.432730e-04	41106	0	0	0.000000e+00	912	0	31	2.055980e-03	15078	0	147900	0	0.000000e+00	3298	0	103	2.075780e-02	4962	1	1	9.423290e-05	10612	0	0	0.000000e+00	304	0	41	6.326570e-04	64806	0	8	1.666670e-03	4800	0	1	191	1.417590e-03	8	2.464270e-04	32464	0	0	0.000000e+00	862	0	31	2.091770e-03	14820	0	134736	0	0.000000e+00	3384	0	104	2.002310e-02	5194	1	0	0.000000e+00	6970	0	0	0.000000e+00	310	0	40	6.259580e-04	63902	0	8	1.657000e-03	4828	0	1	133	1.647880e-03	7	2.822350e-04	24802	0	0	0.000000e+00	112	0	29	2.249460e-03	12892	0	80710	0	0.000000e+00	998	0	75	1.998930e-02	3752	1	1	9.505700e-05	10520	0	0	0.000000e+00	272	0	13	6.178120e-04	21042	0	8	1.665970e-03	4802	0	1	12	101830709	12	103306579	0	0.43195	0.638212	1.000000	0.71638	0.955000	0.50612	0.982000	0.48367	3.511000	0.53157	-0.171000	0.11205	0.129000	0.18587	102912801	C	.	rs118092776	.	.	11.785	7.700	8.002	9.602	.	.	.	8	27	8	-10	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-3+10+start+108	102601	Uncertain_significance	reviewed_by_expert_panel	not_specified&not_provided&Phenylketonuria	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs118092776	1.746e-03	212	210	1	1	4	138	1	45	1	22	10404	11578	8648	6610	66726	908	16508	1	4	136	1	45	1	22	0	0	1	0	0	0	0	rs118092776	6.53424e-05	9.23169e-04	2.03087e-04	1.41466e-02	8.97908e-05	6.89841e-04	1.45879e-03	1.46199e-03	1.65406e-03	1.67987e-03	1.41466e-02	1.66485e-03	rs118092776	2.29148e-04	0.00000e+00	0.00000e+00	1.29630e-02	2.86369e-04	5.99760e-04	1.01833e-03	.	1.57766e-03	5.05269e-04	1.29630e-02	1.09706e-03	rs118092776	0.093&0.0&0.0615	rs118092776	118092776	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,834	0	0	0	0	0	1	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0.3246	Likely Pathogenic
12	103246615	103246615	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.820A>G	NP_000268.1:p.Lys274Glu	934	820	274	K/E	Aag/Gag	rs142934616&CM003327	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103246615T>C	.	0.0182	0	0	0	0	likely_benign&not_provided	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.820A>G	.	.	24	0.004792332268370607	24	0.018154311649016642	0	0.0	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	T/T	T	T	0.13649	-0.253696	T	0.61453	-0.124219	22.8	22.6	2.694464	2.522858	0.45475	0.44226	T/T	T	0.00640	0.019353335287004	0.79842	0.99690037358285144	.	0.92856	.	T/T	72	0.016341352700862462	0	0.0	3.21696	0.206844792000481	0.50228	2.702462	0.0523300618509919	0.44248	.	.	.	188	1.548e-03	176	1.691e-02	10	8.645e-04	188	1.549e-03	0	0	0	0	1	1.498e-05	1	6.056e-05	167	1.572e-03	155	1.710e-02	10	8.924e-04	167	1.573e-03	0	0	0	0	1	1.840e-05	1	6.095e-05	188	2.072e-03	176	1.694e-02	10	8.654e-04	188	2.072e-03	0	0	0	0	1	2.373e-05	1	6.060e-05	0.99473	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.50053	0.999970484650511	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.51891	.	0.090793	0.84330	D	0.000000	.	.	.	0.04077	.	0.94392	.	D	0.94525	0.8364	.	0.00365	.	D	0.92966	0.6833	.	.	.	.	.	.	0.16292	.	.	0.58761	simple_aae&simple_aae	D&D	0.999998&0.999998	0.34992	.	.	.	0.34817	.	.	0.40079	.	T	0.65733	0.690185010433	0.79156	.	10	0.04842	.	.	0.20683	.	.	16.0142	0.80222	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.82458	.	T/T	E	.	K	C	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Likely_benign	NC_000012.12:g.102852837T>C	102851	reviewed_by_expert_panel	Phenylketonuria&not_provided	UniProtKB_(protein):P00439#VAR_011573&DeBelle_Laboratory_for_Biochemical_Genetics:p.K274E	.	.	AEFBI	D	0.57545	0.93184	D	0.74372	0.823662	.	303	1.205450e-03	260	1.599410e-02	16256	1	32	9.252300e-04	34586	0	251358	0	0.000000e+00	10080	0	0	0.000000e+00	18392	0	0	0.000000e+00	21648	0	3	2.639730e-05	113648	0	260	1.599410e-02	16256	1	2	6.532530e-05	30616	0	133	1.215660e-03	109	1.521500e-02	7164	0	18	1.051890e-03	17112	0	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	2	4.676390e-05	42768	0	109	1.521500e-02	7164	0	2	1.274700e-04	15690	0	0	.	1	277	1.169660e-03	235	1.576970e-02	14902	0	32	9.341970e-04	34254	0	236820	0	0.000000e+00	9572	0	0	0.000000e+00	17690	0	0	0.000000e+00	21632	0	3	2.923060e-05	102632	0	235	1.576970e-02	14902	0	2	6.551790e-05	30526	0	0	300	1.441530e-03	258	1.590830e-02	16218	1	31	1.015660e-03	30522	0	208112	0	0.000000e+00	6212	0	0	0.000000e+00	13414	0	0	0.000000e+00	16734	0	3	3.350530e-05	89538	0	258	1.590830e-02	16218	1	2	6.534240e-05	30608	0	1	236	9.642810e-04	193	1.604860e-02	12026	1	32	9.288290e-04	34452	0	244742	0	0.000000e+00	9998	0	0	0.000000e+00	18388	0	0	0.000000e+00	21646	0	3	2.689140e-05	111560	0	193	1.604860e-02	12026	1	2	6.532530e-05	30616	0	1	686	4.510900e-03	656	1.585000e-02	41388	3	0	0.000000e+00	912	0	18	1.179400e-03	15262	0	152076	0	0.000000e+00	3468	0	0	0.000000e+00	5192	0	0	0.000000e+00	10598	0	0	0.000000e+00	316	0	4	5.880620e-05	68020	0	656	1.585000e-02	41388	3	0	0.000000e+00	4828	0	148	4.503130e-03	133	1.464440e-02	9082	1	0	0.000000e+00	60	0	11	2.347420e-03	4686	0	32866	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5476	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3112	0	1	.	3	683	4.620170e-03	653	1.590120e-02	41066	3	0	0.000000e+00	912	0	18	1.194110e-03	15074	0	147830	0	0.000000e+00	3302	0	0	0.000000e+00	4958	0	0	0.000000e+00	10598	0	0	0.000000e+00	304	0	4	6.173220e-05	64796	0	0	0.000000e+00	4798	0	3	547	4.061480e-03	518	1.597380e-02	32428	3	0	0.000000e+00	862	0	18	1.214900e-03	14816	0	134680	0	0.000000e+00	3384	0	0	0.000000e+00	5192	0	0	0.000000e+00	6958	0	0	0.000000e+00	310	0	4	6.259580e-05	63902	0	0	0.000000e+00	4826	0	3	410	5.084330e-03	387	1.562750e-02	24764	2	0	0.000000e+00	112	0	14	1.086110e-03	12890	0	80640	0	0.000000e+00	994	0	0	0.000000e+00	3750	0	0	0.000000e+00	10506	0	0	0.000000e+00	272	0	2	9.508410e-05	21034	0	0	0.000000e+00	4800	0	2	12	101770745	12	103246615	0	0.43195	0.638212	1.000000	0.71638	0.984000	0.60418	1.000000	0.86279	3.492000	0.53022	0.665000	0.62972	1.138000	0.64695	102852837	T	.	rs142934616	.	.	11.570	9.399	7.651	9.354	.	.	.	18	-22	-22	-26	0.00	0.00	0.01	0.00	PAH	0.00	exon-NM_001354304.2-8+22+start+136	102851	Likely_benign	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs142934616	1.548e-03	188	184	2	176	10	0	0	1	0	1	10406	11568	8652	6614	66738	908	16512	172	10	0	0	1	0	1	2	0	0	0	0	0	0	rs142934616	1.64663e-02	1.01263e-03	0.00000e+00	0.00000e+00	0.00000e+00	2.68861e-05	7.29395e-04	6.49730e-05	1.05333e-03	1.37449e-03	1.64663e-02	1.19786e-03	rs142934616	1.34113e-02	2.38663e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.01833e-03	.	3.62361e-03	4.18833e-03	1.34113e-02	3.96877e-03	rs142934616	0.0&1.6341&0.5536	rs142934616	142934616	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,717	0	0	0	0	0	1	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0.3246	Likely Pathogenic
21	36421179	36421179	T	C	C	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	2/9	.	NM_001754.5:c.18A>G	NP_001745.2:p.Ile6Met	212	18	6	I/M	atA/atG	rs199929612	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	RUNX1	.	chr21:g.36421179T>C	.	.	.	.	.	.	likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.66484	0.121123	D	0.67138	-0.0483052	18.28	17.66	1.872869	1.726498	0.28151	0.27679	T/T	T	0.07502	0.0621437145935413	0.38125	0.98083174036700094	.	0.55277	.	T/T	.	.	.	.	1.525427	-0.319017083064586	0.27485	1.393176	-0.395266415711632	0.25637	.	.	.	17	1.400e-04	0	0	0	0	17	1.400e-04	0	0	0	0	17	2.548e-04	0	0	14	1.318e-04	0	0	0	0	14	1.318e-04	0	0	0	0	14	2.576e-04	0	0	17	1.873e-04	0	0	0	0	17	1.874e-04	0	0	0	0	17	4.035e-04	0	0	0.97849	.	.	.	5.36	-1.77	0.07551	0	0.09955	0.52208	.	.	0.74766	0.999999999964029	.	0	0.15389	0.547309	.	.	.	.	.	.	0	0.07079	0.466023	.&.&.&.&.	.	.	.	0.43772	.	0.457309	0.20449	N	0.089026	D	0.79649	0.116871	0.56322	.	0.94507	.	D	0.92586	0.7817	.	0.00492	.	D	0.82888	0.0319	.	.	.	.	.	.	.	.	.	0.81001	without_aae&simple_aae&simple_aae	D&N&N	1&0.97045&0.97045	0.60507	.	.	.	0.07471	.	.	0.06944	.	T	0.26396	0.409561812878	0.61272	.	10	0.57104	.	.	0.43393	.	.	1.616	0.02541	0.1132:0.225:0.2258:0.4359	.	.	.	.	.	.	.	.	0.28965	.	T/T	M	.	I	C	349	0.85513	.	21	C1832388	601399	.	Likely_benign	NC_000021.9:g.35048882T>C	463989	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:ff29e264-e204-4efc-bb2e-f3f16e5d88d0	.	.	AEDGBHCIJ	D	0.32631	0.65118	N	0.21423	0.107544	.	40	1.590580e-04	0	0.000000e+00	16256	0	0	0.000000e+00	34592	0	251480	35	3.472220e-03	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21640	0	2	1.757990e-05	113766	0	2	1.757990e-05	113766	0	0	0.000000e+00	30616	0	8	7.312750e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109398	7	3.017240e-03	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13386	0	0	0.000000e+00	42768	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	38	1.603770e-04	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236942	33	3.447560e-03	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21624	0	2	1.946470e-05	102750	0	2	1.946470e-05	102750	0	0	0.000000e+00	30526	0	0	24	1.153170e-04	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208122	19	3.058600e-03	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16726	0	2	2.233240e-05	89556	0	2	2.233240e-05	89556	0	0	0.000000e+00	30608	0	0	40	1.633570e-04	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244862	35	3.500700e-03	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21638	0	2	1.790900e-05	111676	0	2	1.790900e-05	111676	0	0	0.000000e+00	30616	0	0	7	4.603390e-05	0	0.000000e+00	41388	0	0	0.000000e+00	912	0	0	0.000000e+00	15274	0	152062	7	2.016130e-03	3472	0	0	0.000000e+00	5170	0	0	0.000000e+00	10626	0	0	0.000000e+00	316	0	0	0.000000e+00	67996	0	.	.	.	.	0	0.000000e+00	4820	0	0	0.000000e+00	0	0.000000e+00	9074	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32870	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5496	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3108	0	0	.	0	7	4.735360e-05	0	0.000000e+00	41068	0	0	0.000000e+00	912	0	0	0.000000e+00	15086	0	147824	7	2.119930e-03	3302	0	0	0.000000e+00	4938	0	0	0.000000e+00	10626	0	0	0.000000e+00	304	0	0	0.000000e+00	64780	0	0	0.000000e+00	4790	0	0	7	5.196960e-05	0	0.000000e+00	32452	0	0	0.000000e+00	862	0	0	0.000000e+00	14830	0	134694	7	2.066120e-03	3388	0	0	0.000000e+00	5170	0	0	0.000000e+00	6986	0	0	0.000000e+00	310	0	0	0.000000e+00	63880	0	0	0.000000e+00	4818	0	0	0	0.000000e+00	0	0.000000e+00	24766	0	0	0.000000e+00	112	0	0	0.000000e+00	12900	0	80626	0	0.000000e+00	998	0	0	0.000000e+00	3728	0	0	0.000000e+00	10534	0	0	0.000000e+00	272	0	0	0.000000e+00	21010	0	0	0.000000e+00	4792	0	0	21	35343049	21	36421179	0	0.05922	0.393558	0.999000	0.42656	1.000000	0.97212	1.000000	0.86279	0.345000	0.19720	0.665000	0.62972	0.133000	0.19153	35048882	T	.	rs199929612	.	.	8.173	10.033	7.852	6.640	.	.	.	41	-28	-40	39	0.00	0.00	0.01	0.00	RUNX1	0.45	exon-NM_001754.5-2+40+start+117	463989	Likely_benign	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1&Hereditary_cancer-predisposing_syndrome	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	21:36421179-36421179	1.400e-04	17	17	0	0	0	0	0	17	0	0	10404	11576	8654	6614	66732	906	16512	0	0	0	0	17	0	0	0	0	0	0	0	0	0	rs199929612	0.00000e+00	0.00000e+00	3.65482e-03	0.00000e+00	0.00000e+00	1.79022e-05	3.64697e-04	0.00000e+00	1.48249e-04	1.79611e-04	3.65482e-03	1.62422e-04	rs199929612	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.67646e-05	0.00000e+00	.	5.85823e-05	0.00000e+00	6.67646e-05	3.22664e-05	.	.	rs199929612	199929612	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,989	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
13	20763047	20763047	G	A	A	missense_variant	MODERATE	GJB2	2706	Transcript	NM_004004.6	protein_coding	2/2	.	NM_004004.6:c.674C>T	NP_003995.2:p.Pro225Leu	852	674	225	P/L	cCa/cTa	rs1555341782&CM108185	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	GJB2	.	chr13:g.20763047G>A	.	.	.	.	.	.	uncertain_significance	.	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.89358	0.390483	D	0.89224	0.323126	23.5	22.7	3.034198	2.556012	0.52791	0.44963	./.	D	0.42293	0.731592833995819	0.50420	0.99014185856030912	.	0.62469	.	./.	.	.	.	.	2.738788	0.101042296700882	0.44602	2.432181	-0.0225030269546341	0.40838	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.97693	.	.	.	5.65	5.65	0.86881	0	0.36545	0.588015	.	.	0.74766	0.99999999998925	.	0	0.18855	0.563428	.	.	.	.	.	.	0	0.10902	0.530356	.&.&.	.	.	.	0.33070	.	0.260360	0.33407	N	0.004778	D	0.90874	0.300773	0.04181	.	0.95079	.	D	0.94200	0.8272	.	0.59726	.	D	0.92506	0.6471	P225L	Gain_of_stability_(P_=_0.0053)&_Gain_of_MoRF_binding_(P_=_0.0108)&_Loss_of_glycosylation_at_P225_(P_=_0.0457)&_Loss_of_methylation_at_K223_(P_=_0.0475)&_Gain_of_helix_(P_=_0.0496)	P29033	0.33452	0.342	.	0.13445	.	.	0.49770	simple_aae&simple_aae	D&D	0.999842&0.999842	0.29727	.	.	.	0.31683	.	.	0.23986	.	T	0.33025	0.457920283079	0.83416	.	10	0.74150	.	.	0.72154	.	.	13.9837	0.63836	0.0:0.0:0.8487:0.1513	.	.	.	.	.	.	.	.	0.25253	.	./.	L	.	P	A	682	0.59757	.	13	C2673759&CN043648	220290	ORPHA87884	Uncertain_significance	NC_000013.11:g.20188908G>A	555720	reviewed_by_expert_panel	Deafness&_autosomal_recessive_1A&Nonsyndromic_hearing_loss_and_deafness	.	.	.	AEFDBHCI	D	0.57626	0.93215	D	0.65696	0.699697	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	13	19661047	13	20763047	0	0.25195	0.553676	1.000000	0.71638	0.075000	0.16954	0.868000	0.36000	5.501000	0.66665	0.676000	0.76740	1.176000	0.78918	20188908	G	.	rs1555341782	.	.	.	.	10.295	9.602	.	.	.	46	26	12	-1	0.00	0.00	0.00	0.00	GJB2	0.00	exon-NM_004004.6-2+695+end+2134	555720	Uncertain_significance	reviewed_by_expert_panel	Autosomal_recessive_nonsyndromic_hearing_loss_1A&Nonsyndromic_genetic_hearing_loss	MONDO:MONDO:0009076&MedGen:C2673759&OMIM:220290&Orphanet:90636&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555341782	1555341782	.	.	.	GJB2	GJB2:exonic	GJB2:missense	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,864	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
3	12633207	12633207	C	A	A	missense_variant&splice_region_variant	MODERATE	RAF1	5894	Transcript	NM_001354689.3	protein_coding	12/18	.	NM_001354689.3:c.1253G>T	NP_001341618.1:p.Arg418Leu	1584	1253	418	R/L	cGc/cTc	rs730880382&COSV52579905&COSV52583001	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MKRN2OS	.	chr3:g.12633207C>A	.	.	.	.	.	.	likely_pathogenic&uncertain_significance	0&1&1	1&1&1	.	.	.	.	.	.	0.999984655392676	0.97	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.90159	0.404253	D	0.90035	0.342905	34	34	5.611055	5.806828	0.94869	0.95217	C/C	D	0.94253	0.998471200466156	0.94726	0.99869623662585583	.	0.98486	.	C/C	.	.	.	.	8.958515	0.756641114935495	0.86653	7.91454	0.752099076990866	0.83040	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.82897	.	.	.	5.15	5.15	0.70287	0	0.68747	0.697927	.	.	0.74766	0.999999999999999	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.71501	0.711	Serine-threonine/tyrosine-protein_kinase&_catalytic_domain&Protein_kinase_domain&Protein_kinase_domain&Serine-threonine/tyrosine-protein_kinase&_catalytic_domain&Protein_kinase_domain&Protein_kinase_domain&Serine-threonine/tyrosine-protein_kinase&_catalytic_domain&Protein_kinase_domain&Protein_kinase_domain	.	.	.	0.94937	.	0.000000	0.84330	D	0.000000	D	0.90588	0.291765	0.98273	.	0.98004	.	D	0.87195	0.6344	.	0.90585	.	D	0.85140	0.1548	R398L	Loss_of_MoRF_binding_(P_=_0.0144)&_Loss_of_methylation_at_R398_(P_=_0.075)&_Loss_of_solvent_accessibility_(P_=_0.1077)&_Loss_of_relative_solvent_accessibility_(P_=_0.3219)&_Gain_of_catalytic_residue_at_V403_(P_=_0.3251)	P04049	0.86800	0.735	.	0.21307	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D	1&1&1&1	0.91786	.	.	.	0.77913	.	.	0.83170	.	D	0.88926	0.845448732376	0.95765	.	9	0.79402	.	.	0.78490	.	.	19.1782	0.93598	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.91968	.	C/C	L	.	R	A	685	0.59416	.	3	C1969057&CN166718&CN517202	611553	ORPHA536391	Uncertain_significance	NC_000003.12:g.12591708C>A	40614	reviewed_by_expert_panel	Noonan_syndrome_5&Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:54e513e4-3d82-4530-8f42-82522d750073	.	.	AEFDBI	D	0.99936	0.99881	D	0.96084	0.948818	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	12608207	3	12633207	0	0.73137	0.706548	1.000000	0.71638	0.980000	0.58198	0.995000	0.57719	7.900000	0.86025	0.599000	0.40250	1.026000	0.45946	12591708	C	.	rs730880382	.	.	9.107	10.494	7.648	9.885	7.389	3.105	10.494	39	20	14	0	0.00	0.00	0.02	0.08	RAF1	1.00	exon-NM_001354695.3-9+0+start+85	40614	Uncertain_significance	reviewed_by_expert_panel	not_provided&RASopathy&Noonan_syndrome_5&Dilated_cardiomyopathy_1NN&LEOPARD_syndrome_2	MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0012690&MedGen:C1969057&OMIM:611553&Orphanet:648&MONDO:MONDO:0014396&MedGen:C4014656&OMIM:615916&Orphanet:154&MONDO:MONDO:0012691&MedGen:C1969056&OMIM:611554&Orphanet:500	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs730880382	730880382	.	.	.	RAF1	RAF1:splicing\x3bexonic	RAF1:splice_region_variant\x3bmissense	RAF1:Cardiomyopathy\x2cdilated\x2c1NN\x3bNoonan_syndrome_5\x3bLEOPARD_syndrome_2	RAF1:615916\x3b611553\x3b611554	RAF1:3\x3b3\x3b3	RAF1:Autosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999776866110749	0.000223133833869176	5.53819998824154e-11	DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,477	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
13	20763044	20763044	A	C	C	missense_variant	MODERATE	GJB2	2706	Transcript	NM_004004.6	protein_coding	2/2	.	NM_004004.6:c.677T>G	NP_003995.2:p.Val226Gly	855	677	226	V/G	gTt/gGt	rs773846324&CM077567&CM101468	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	GJB2	.	chr13:g.20763044A>C	.	.	.	.	.	.	uncertain_significance	.	1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.82558	0.294917	D	0.86501	0.268716	23.1	21.5	2.823592	2.208135	0.48241	0.37306	./.	T	0.21982	0.230639100074768	0.37674	0.98026593250071647	.	0.45937	.	./.	.	.	.	.	1.92155	-0.145846512943366	0.33568	1.6703	-0.277383542617203	0.30023	.	.	.	1	8.249e-06	0	0	1	8.735e-05	1	8.625e-06	0	0	0	0	0	0	0	0	1	9.431e-06	0	0	1	8.977e-05	1	9.729e-06	0	0	0	0	0	0	0	0	1	1.104e-05	0	0	1	8.744e-05	1	1.173e-05	0	0	0	0	0	0	0	0	0.97650	.	.	.	5.95	4.77	0.60425	0	0.36545	0.588015	.	.	0.74766	0.999999999862982	.	0	0.18855	0.563428	.	.	.	.	.	.	0	0.10902	0.530356	.&.&.	.	.	.	0.19970	.	0.420513	0.22050	N	0.063094	D	0.87836	0.222068	0.05445	.	0.52752	.	D	0.90808	0.7313	.	0.81561	.	D	0.88479	0.3591	V226G	Loss_of_stability_(P_=_0.0235)&_Gain_of_glycosylation_at_P225_(P_=_0.0533)&_Loss_of_MoRF_binding_(P_=_0.0832)&_Loss_of_methylation_at_K224_(P_=_0.0859)&_Loss_of_helix_(P_=_0.1299)	P29033	0.94292	0.835	.	0.03330	.	.	0.50595	simple_aae&simple_aae	D&D	0.999892&0.999892	0.02808	.	.	.	0.34753	.	.	0.27757	.	T	0.34991	0.472253978252	0.83416	.	10	0.83351	.	.	0.78490	.	.	7.4943	0.26648	0.7813:0.1415:0.0772:0.0	.	.	.	.	.	.	.	.	0.79118	.	./.	G	.	V	C	682	0.59757	.	13	C2673759&CN043648&CN169374	220290	ORPHA87884	Uncertain_significance	NC_000013.11:g.20188905A>C	447450	reviewed_by_expert_panel	Deafness&_autosomal_recessive_1A&Nonsyndromic_hearing_loss_and_deafness&not_specified	.	.	.	AEFDBHCI	D	0.47272	0.87659	D	0.56315	0.550838	.	2	8.074670e-06	0	0.000000e+00	15406	0	1	2.896700e-05	34522	0	247688	0	0.000000e+00	9978	0	0	0.000000e+00	18318	0	0	0.000000e+00	21632	0	1	8.992160e-06	111208	0	1	2.896700e-05	34522	0	0	0.000000e+00	30542	0	1	9.153150e-06	0	0.000000e+00	7122	0	0	0.000000e+00	17082	0	109252	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13384	0	1	2.338310e-05	42766	0	1	2.338310e-05	42766	0	0	0.000000e+00	15620	0	0	.	0	2	8.537890e-06	0	0.000000e+00	14146	0	1	2.922440e-05	34218	0	234250	0	0.000000e+00	9496	0	0	0.000000e+00	17690	0	0	0.000000e+00	21620	0	1	9.897270e-06	101038	0	1	2.922440e-05	34218	0	0	0.000000e+00	30456	0	0	2	9.744120e-06	0	0.000000e+00	15368	0	1	3.282780e-05	30462	0	205252	0	0.000000e+00	6126	0	0	0.000000e+00	13340	0	0	0.000000e+00	16718	0	1	1.137840e-05	87886	0	1	3.282780e-05	30462	0	0	0.000000e+00	30534	0	0	2	8.267130e-06	0	0.000000e+00	11602	0	1	2.907990e-05	34388	0	241922	0	0.000000e+00	9918	0	0	0.000000e+00	18314	0	0	0.000000e+00	21630	0	1	9.131250e-06	109514	0	1	2.907990e-05	34388	0	0	0.000000e+00	30542	0	0	3	1.971140e-05	0	0.000000e+00	41452	0	0	0.000000e+00	912	0	0	0.000000e+00	15284	0	152196	0	0.000000e+00	3472	0	0	0.000000e+00	5198	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	3	4.409430e-05	68036	0	3	4.409430e-05	68036	0	0	0.000000e+00	4824	0	0	0.000000e+00	0	0.000000e+00	9100	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32892	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5482	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3106	0	0	.	0	3	2.027850e-05	0	0.000000e+00	41132	0	0	0.000000e+00	912	0	0	0.000000e+00	15096	0	147940	0	0.000000e+00	3302	0	0	0.000000e+00	4962	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	3	4.629060e-05	64808	0	0	0.000000e+00	4792	0	0	3	2.225720e-05	0	0.000000e+00	32484	0	0	0.000000e+00	862	0	0	0.000000e+00	14838	0	134788	0	0.000000e+00	3388	0	0	0.000000e+00	5198	0	0	0.000000e+00	6970	0	0	0.000000e+00	310	0	3	4.693950e-05	63912	0	0	0.000000e+00	4822	0	0	0	0.000000e+00	0	0.000000e+00	24826	0	0	0.000000e+00	112	0	0	0.000000e+00	12910	0	80754	0	0.000000e+00	998	0	0	0.000000e+00	3756	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	0	0.000000e+00	21048	0	0	0.000000e+00	4796	0	0	13	19661044	13	20763044	0	0.25195	0.553676	0.966000	0.33990	0.039000	0.14166	0.719000	0.31371	2.043000	0.40854	0.756000	0.94297	1.312000	0.94714	20188905	A	.	rs773846324	.	.	.	.	10.295	9.602	.	.	.	1	-17	1	15	0.00	0.00	0.00	0.00	GJB2	0.00	exon-NM_004004.6-2+698+end+2134	447450	Uncertain_significance	reviewed_by_expert_panel	Ichthyosis&_hystrix-like&_with_hearing_loss&Palmoplantar_keratoderma-deafness_syndrome&Knuckle_pads&_deafness_AND_leukonychia_syndrome&Autosomal_recessive_nonsyndromic_hearing_loss_1A&Mutilating_keratoderma&Autosomal_dominant_keratitis-ichthyosis-hearing_loss_syndrome&Autosomal_dominant_nonsyndromic_hearing_loss_3A&X-linked_mixed_hearing_loss_with_perilymphatic_gusher&Nonsyndromic_genetic_hearing_loss&not_specified&not_provided	MONDO:MONDO:0011245&MedGen:C1865234&OMIM:602540&Orphanet:477&MONDO:MONDO:0007852&MedGen:C1835672&OMIM:148350&Orphanet:2202&MONDO:MONDO:0007866&MedGen:C0266004&OMIM:149200&Orphanet:2698&MONDO:MONDO:0009076&MedGen:C2673759&OMIM:220290&Orphanet:90636&MONDO:MONDO:0007422&MedGen:C0265964&OMIM:124500&Orphanet:494&MONDO:MONDO:0007850&MedGen:C0265336&OMIM:148210&Orphanet:477&MONDO:MONDO:0011103&MedGen:C2675750&OMIM:601544&Orphanet:90635&MONDO:MONDO:0010576&MedGen:C1844678&OMIM:304400&Orphanet:383&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN169374&MedGen:CN517202	.	13:20763044-20763044	8.249e-06	1	1	0	0	1	0	0	0	0	0	8980	11448	8530	6612	63200	874	16296	0	1	0	0	0	0	0	0	0	0	0	0	0	0	rs773846324	0.00000e+00	2.98329e-05	0.00000e+00	0.00000e+00	0.00000e+00	9.18054e-06	0.00000e+00	0.00000e+00	7.49187e-06	9.19084e-06	2.98329e-05	8.12275e-06	rs773846324	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.65956e-05	0.00000e+00	.	5.84044e-05	0.00000e+00	6.65956e-05	3.22664e-05	.	.	rs773846324	773846324	.	.	.	GJB2	GJB2:exonic	GJB2:missense	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,862	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103310850	103310850	T	A	A	missense_variant&splice_region_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	1/13	.	NM_000277.3:c.59A>T	NP_000268.1:p.Gln20Leu	173	59	20	Q/L	cAg/cTg	rs199475662&CM000542&CM1511421	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103310850T>A	.	.	.	.	.	.	not_provided&uncertain_significance	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.59delinsCC	0.564773104289741	0.572	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.81272	0.279492	D	0.81031	0.163695	23.6	23.0	3.100889	2.724361	0.54292	0.48637	T/T	T	0.21731	0.225406552577564	0.32434	0.97116365548711581	.	0.78388	.	T/T	.	.	.	.	1.438093	-0.364070363013658	0.26078	1.117543	-0.530344788226073	0.21103	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99330	.	.	.	5.2	2.81	0.31971	0	0.06741	0.475579	.	.	0.74766	0.999999372747425	.	0	0.63188	0.694767	.	.	.	.	.	.	0	0.26826	0.564101	.&.&.	.	.	.	0.15971	.	0.435185	0.23712	N	0.043707	D	0.91553	0.323825	0.03129	.	0.87931	.	D	0.94620	0.8391	.	0.75231	.	D	0.88919	0.3882	Q20L	Gain_of_sheet_(P_=_0.0101)&_Gain_of_loop_(P_=_0.024)&_Loss_of_helix_(P_=_0.028)&_Loss_of_disorder_(P_=_0.0418)&_Gain_of_stability_(P_=_0.0652)	P00439	0.92509	0.808	.	0.14455	.	.	0.81001	simple_aae&without_aae	D&D	0.947269&1	0.33197	.	.	.	0.02946	.	.	0.01387	.	T	0.26525	0.410493314266	0.83193	.	10	0.21612	.	.	0.25355	.	.	4.624	0.11855	0.1676:0.0894:0.0:0.743	.	.	.	.	.	.	.	.	0.79214	.	T/T	L	.	Q	A	776	0.48302	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102917072T>A	102749	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.Q20L&UniProtKB_(protein):P00439#VAR_009239	.	.	AEFDGBHCI	D	0.38388	0.77948	D	0.58913	0.594038	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.569010e-06	0	0.000000e+00	41466	0	0	0.000000e+00	912	0	0	0.000000e+00	15286	0	152230	0	0.000000e+00	3470	0	0	0.000000e+00	5200	0	0	0.000000e+00	10620	0	0	0.000000e+00	316	0	1	1.469680e-05	68042	0	1	1.469680e-05	68042	0	0	0.000000e+00	4826	0	1	3.039330e-05	0	0.000000e+00	9100	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32902	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	1	1.459000e-04	6854	0	0	0.000000e+00	3108	0	0	.	0	1	6.757400e-06	0	0.000000e+00	41144	0	0	0.000000e+00	912	0	0	0.000000e+00	15102	0	147986	0	0.000000e+00	3302	0	0	0.000000e+00	4966	0	0	0.000000e+00	10620	0	0	0.000000e+00	304	0	1	1.542730e-05	64820	0	0	0.000000e+00	4794	0	0	1	7.417520e-06	0	0.000000e+00	32494	0	0	0.000000e+00	862	0	0	0.000000e+00	14840	0	134816	0	0.000000e+00	3386	0	0	0.000000e+00	5200	0	0	0.000000e+00	6980	0	0	0.000000e+00	310	0	1	1.564500e-05	63918	0	0	0.000000e+00	4824	0	0	1	1.237870e-05	0	0.000000e+00	24840	0	0	0.000000e+00	112	0	0	0.000000e+00	12912	0	80784	0	0.000000e+00	996	0	0	0.000000e+00	3758	0	0	0.000000e+00	10528	0	0	0.000000e+00	272	0	1	4.750590e-05	21050	0	0	0.000000e+00	4798	0	0	12	101834980	12	103310850	0	0.18060	0.493124	1.000000	0.71638	0.504000	0.29107	0.414000	0.25901	1.903000	0.39488	0.665000	0.62972	0.163000	0.20576	102917072	T	.	rs199475662	.	.	8.002	9.602	.	.	8.050	1.553	9.602	30	-2	-28	-1	0.00	0.00	0.00	0.43	PAH	0.00	exon-NM_000277.3-1+1+start+174	102749	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475662	199475662	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bmissense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,844	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103310849	103310849	C	G	G	missense_variant&splice_region_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	1/13	.	NM_000277.3:c.60G>C	NP_000268.1:p.Gln20His	174	60	20	Q/H	caG/caC	rs199475688&CM087641&CX1414717	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103310849C>G	.	.	.	.	.	.	uncertain_significance&not_provided	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.60G>C	0.999994243184286	0.994	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.82751	0.297288	D	0.82528	0.189257	33	33	5.004121	5.304370	0.93256	0.93929	C/C	D	0.34103	0.539990305900574	0.47841	0.98881889479766039	.	0.66358	.	C/C	.	.	.	.	2.952231	0.15074573381115	0.47182	2.500196	-0.00309121755307407	0.41714	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99368	.	.	.	5.2	5.2	0.71720	0	0.06741	0.475579	.	.	0.74766	0.999999999863142	.	0	0.63188	0.694767	.	.	.	.	.	.	0	0.26826	0.564101	.&.&.	.	.	.	0.28920	.	0.435185	0.23712	N	0.043707	D	0.95266	0.508628	0.03613	.	0.94821	.	D	0.94628	0.8393	.	0.78774	.	D	0.94700	0.8234	Q20H	Loss_of_helix_(P_=_0.0041)&_Loss_of_solvent_accessibility_(P_=_0.0056)&_Gain_of_sheet_(P_=_0.0073)&_Loss_of_relative_solvent_accessibility_(P_=_0.0306)&_Gain_of_loop_(P_=_0.0321)	P00439	0.91654	0.796	.	0.14455	.	.	0.81001	simple_aae&without_aae	D&D	0.994663&1	0.14588	.	.	.	0.28196	.	.	0.19048	.	T	0.31855	0.449352920055	0.82573	.	9	0.36765	.	.	0.46513	.	.	14.4281	0.66804	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.75742	.	C/C	H	.	Q	G	776	0.48302	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102917071C>G	102757	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:Q20H	.	.	AEFDGBHCI	D	0.48579	0.88583	D	0.73965	0.818380	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101834979	12	103310849	0	0.18060	0.493124	1.000000	0.71638	0.526000	0.29613	0.434000	0.26216	3.236000	0.51035	0.599000	0.40250	1.026000	0.45946	102917071	C	.	rs199475688	.	.	8.002	9.602	.	.	5.623	3.980	9.602	31	-1	-27	0	0.00	0.00	0.00	0.87	PAH	0.00	exon-NM_000277.3-1+0+start+174	102757	Uncertain_significance	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475688	199475688	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bmissense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,843	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288696	103288696	C	T	T	missense_variant&splice_region_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.169G>A	NP_000268.1:p.Glu57Lys	283	169	57	E/K	Gag/Aag	rs140945592&CM110419&CM1514922&COSV61017958	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103288696C>T	.	.	.	.	.	.	conflicting_interpretations_of_pathogenicity&uncertain_significance	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.169G>A	0.99956658786687	0.844	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.76516	0.227825	D	0.82360	0.186332	25.5	27.7	3.715350	4.000206	0.69779	0.82284	C/C	T	0.25938	0.322870224714279	0.67973	0.99500297308365537	.	0.94580	.	C/C	0	0.0	1	1.1627906976744187E-4	3.216435	0.20673657240022	0.50222	2.580055	0.0192138008033085	0.42730	.	.	.	1	8.236e-06	0	0	0	0	1	8.259e-06	0	0	0	0	1	1.502e-05	0	0	1	9.415e-06	0	0	0	0	1	9.425e-06	0	0	0	0	1	1.841e-05	0	0	1	1.102e-05	0	0	0	0	1	1.106e-05	0	0	0	0	1	2.383e-05	0	0	0.99175	.	.	.	6.17	6.17	0.99707	0	0.51514	0.610034	.	.	0.74766	0.999999999999998	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.96179	.	0.140673	0.62929	D	0.000006	D	0.97058	0.652097	0.03436	.	0.93912	.	D	0.97116	0.9130	.	0.65629	.	D	0.96236	0.9392	.	.	.	.	.	.	0.35840	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.53736	.	.	.	0.12996	.	.	0.08700	.	T	0.61239	0.658818125725	0.78786	.	10	0.28300	.	.	0.18246	.	.	20.8794	0.99870	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.66700	.	C/C	K	.	E	T	716	0.55970	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102894918C>T	92737	reviewed_by_expert_panel	Phenylketonuria&not_provided	HGMD:CM110419	.	.	AEFBI	D	0.73316	0.97206	D	0.79917	0.875634	.	3	1.198500e-05	0	0.000000e+00	16228	0	0	0.000000e+00	34580	0	250312	0	0.000000e+00	10080	0	0	0.000000e+00	18392	0	0	0.000000e+00	21014	0	1	8.827370e-06	113284	0	1	3.266480e-05	30614	0	1	3.266480e-05	30614	0	2	1.839010e-05	0	0.000000e+00	7160	0	0	0.000000e+00	17108	0	108754	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	12760	0	1	2.338740e-05	42758	0	1	6.374300e-05	15688	0	1	6.374300e-05	15688	0	0	.	0	3	1.272240e-05	0	0.000000e+00	14888	0	0	0.000000e+00	34250	0	235804	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	20998	0	1	9.777080e-06	102280	0	1	3.276110e-05	30524	0	1	3.276110e-05	30524	0	0	3	1.446730e-05	0	0.000000e+00	16190	0	0	0.000000e+00	30516	0	207364	0	0.000000e+00	6212	0	0	0.000000e+00	13414	0	0	0.000000e+00	16100	0	1	1.117740e-05	89466	0	1	3.267330e-05	30606	0	1	3.267330e-05	30606	0	0	3	1.231050e-05	0	0.000000e+00	11998	0	0	0.000000e+00	34446	0	243694	0	0.000000e+00	9998	0	0	0.000000e+00	18388	0	0	0.000000e+00	21012	0	1	8.993290e-06	111194	0	1	3.266480e-05	30614	0	1	3.266480e-05	30614	0	0	1	6.576870e-06	0	0.000000e+00	41366	0	0	0.000000e+00	912	0	0	0.000000e+00	15276	0	152048	0	0.000000e+00	3470	0	0	0.000000e+00	5188	0	0	0.000000e+00	10584	0	0	0.000000e+00	316	0	1	1.469980e-05	68028	0	1	1.469980e-05	68028	0	0	0.000000e+00	4818	0	0	0.000000e+00	0	0.000000e+00	9070	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32834	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5456	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3108	0	0	.	0	1	6.765990e-06	0	0.000000e+00	41044	0	0	0.000000e+00	912	0	0	0.000000e+00	15088	0	147798	0	0.000000e+00	3302	0	0	0.000000e+00	4954	0	0	0.000000e+00	10584	0	0	0.000000e+00	304	0	1	1.543110e-05	64804	0	0	0.000000e+00	4786	0	0	1	7.426220e-06	0	0.000000e+00	32412	0	0	0.000000e+00	862	0	0	0.000000e+00	14830	0	134658	0	0.000000e+00	3386	0	0	0.000000e+00	5188	0	0	0.000000e+00	6946	0	0	0.000000e+00	310	0	1	1.564750e-05	63908	0	0	0.000000e+00	4816	0	0	0	0.000000e+00	0	0.000000e+00	24740	0	0	0.000000e+00	112	0	0	0.000000e+00	12902	0	80604	0	0.000000e+00	996	0	0	0.000000e+00	3746	0	0	0.000000e+00	10492	0	0	0.000000e+00	272	0	0	0.000000e+00	21038	0	0	0.000000e+00	4790	0	0	12	101812826	12	103288696	0	0.37627	0.615465	1.000000	0.71638	0.679000	0.33513	0.907000	0.38101	5.274000	0.65380	0.599000	0.40250	1.026000	0.45946	102894918	C	.	rs140945592	.	.	11.038	10.766	11.785	7.700	9.997	1.788	11.785	-3	0	-3	-8	0.64	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+0+end+184	92737	Uncertain_significance	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs140945592	8.236e-06	1	1	0	0	0	0	0	1	0	0	10302	11560	8638	6614	66560	906	16494	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs140945592	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79853e-05	0.00000e+00	3.24886e-05	7.44480e-06	1.80580e-05	3.24886e-05	1.21817e-05	rs140945592	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66223e-05	0.00000e+00	.	5.84317e-05	0.00000e+00	6.66223e-05	3.22664e-05	rs140945592	0.0116&0.0&0.0077	rs140945592	140945592	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bmissense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,826	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288576	103288576	T	G	G	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.289A>C	NP_000268.1:p.Ile97Leu	403	289	97	I/L	Atc/Ctc	rs142516271&CM077217	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103288576T>G	.	0.003	0.0014	0	0	0	uncertain_significance	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.289A>C	.	.	5	9.98402555910543E-4	4	0.0030257186081694403	1	0.001440922190201729	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	T/T	T	T	0.43045	-0.0591115	D	0.79273	0.135838	20.1	21.1	2.099054	2.154537	0.32596	0.36156	T/T	T	0.02035	0.030295272229752	0.32076	0.97032929203895613	.	0.87304	.	T/T	9	0.0020426690876078077	0	0.0	2.034642	-0.10436440787199	0.35213	1.427312	-0.379866859653025	0.26187	.	.	.	17	1.400e-04	16	1.538e-03	1	8.637e-05	17	1.400e-04	0	0	0	0	0	0	0	0	15	1.412e-04	14	1.544e-03	1	8.916e-05	15	1.412e-04	0	0	0	0	0	0	0	0	17	1.873e-04	16	1.540e-03	1	8.646e-05	17	1.873e-04	0	0	0	0	0	0	0	0	0.98169	.	.	.	6.17	6.17	0.99707	0	0.51514	0.610034	.	.	0.46280	0.999920726403681	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	ACT_domain&ACT_domain&ACT_domain&ACT_domain	.	.	.	0.39354	.	0.366892	0.35606	N	0.002992	D	0.76166	0.093961	0.03189	.	0.82596	.	D	0.91995	0.7648	.	0.00399	.	T	0.77905	-0.1909	.	.	.	.	.	.	0.12520	.	.	0.21497	simple_aae&simple_aae	N&N	0.999218&0.999218	0.04694	.	.	.	0.09854	.	.	0.21085	.	T	0.35721	0.477562725544	0.79033	.	10	0.16865	.	.	0.14894	.	.	10.8917	0.46209	0.2306:0.0:0.0:0.7694	.	.	.	.	.	.	.	.	0.79118	.	T/T	L	.	I	G	717	0.55835	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102894798T>G	376937	reviewed_by_expert_panel	Phenylketonuria&not_provided	.	.	.	AEFBI	D	0.47085	0.87519	D	0.67958	0.733002	.	39	1.551030e-04	35	2.153050e-03	16256	0	4	1.156340e-04	34592	0	251446	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21642	0	0	0.000000e+00	113728	0	35	2.153050e-03	16256	0	0	0.000000e+00	30616	0	16	1.462420e-04	14	1.954220e-03	7164	0	2	1.168770e-04	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	14	1.954220e-03	7164	0	0	0.000000e+00	15690	0	0	.	0	37	1.561790e-04	33	2.214470e-03	14902	0	4	1.167540e-04	34260	0	236908	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21626	0	0	0.000000e+00	102712	0	33	2.214470e-03	14902	0	0	0.000000e+00	30526	0	0	38	1.825830e-04	35	2.158100e-03	16218	0	3	9.828330e-05	30524	0	208124	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89548	0	35	2.158100e-03	16218	0	0	0.000000e+00	30608	0	0	32	1.307040e-04	28	2.328290e-03	12026	0	4	1.160830e-04	34458	0	244828	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21640	0	0	0.000000e+00	111638	0	28	2.328290e-03	12026	0	0	0.000000e+00	30616	0	0	78	5.127530e-04	71	1.714560e-03	41410	0	0	0.000000e+00	912	0	6	3.927730e-04	15276	0	152120	0	0.000000e+00	3470	0	0	0.000000e+00	5198	0	0	0.000000e+00	10606	0	0	0.000000e+00	314	0	0	0.000000e+00	68020	0	71	1.714560e-03	41410	0	0	0.000000e+00	4822	0	19	5.779290e-04	15	1.649800e-03	9092	0	0	0.000000e+00	60	0	4	8.539710e-04	4684	0	32876	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5480	0	0	0.000000e+00	244	0	0	0.000000e+00	6854	0	0	0.000000e+00	3112	0	0	.	0	78	5.274760e-04	71	1.728000e-03	41088	0	0	0.000000e+00	912	0	6	3.976670e-04	15088	0	147874	0	0.000000e+00	3302	0	0	0.000000e+00	4964	0	0	0.000000e+00	10606	0	0	0.000000e+00	302	0	0	0.000000e+00	64800	0	0	0.000000e+00	4790	0	0	64	4.750450e-04	57	1.756660e-03	32448	0	0	0.000000e+00	862	0	6	4.045310e-04	14832	0	134724	0	0.000000e+00	3386	0	0	0.000000e+00	5198	0	0	0.000000e+00	6968	0	0	0.000000e+00	308	0	0	0.000000e+00	63900	0	0	0.000000e+00	4820	0	0	47	5.825630e-04	40	1.613940e-03	24784	0	0	0.000000e+00	112	0	6	4.650440e-04	12902	0	80678	0	0.000000e+00	996	0	0	0.000000e+00	3756	0	0	0.000000e+00	10514	0	0	0.000000e+00	270	0	0	0.000000e+00	21032	0	0	0.000000e+00	4794	0	0	12	101812706	12	103288576	0	0.37627	0.615465	1.000000	0.71638	0.902000	0.43815	0.992000	0.54103	1.235000	0.32274	0.665000	0.62972	1.138000	0.64695	102894798	T	.	rs142516271	.	.	11.038	10.766	11.785	7.700	.	.	.	-8	28	33	-7	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+63+start+184	376937	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_specified&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN169374&MedGen:CN517202	.	rs142516271	1.400e-04	17	17	0	16	1	0	0	0	0	0	10406	11578	8654	6614	66738	908	16512	16	1	0	0	0	0	0	0	0	0	0	0	0	0	rs142516271	2.09096e-03	1.19111e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	9.63863e-05	2.06574e-04	2.09096e-03	1.46180e-04	rs142516271	1.49014e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84112e-04	2.16544e-04	1.49014e-03	4.83996e-04	rs142516271	0.0&0.2043&0.0692	rs142516271	142516271	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,812	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288515	103288515	G	A	A	missense_variant&splice_region_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.350C>T	NP_000268.1:p.Thr117Ile	464	350	117	T/I	aCa/aTa	rs281865439&CD082169	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103288515G>A	.	.	.	.	.	.	uncertain_significance	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.350del	0.999164267370855	0.722	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.75566	0.217788	D	0.86683	0.272033	25.3	25.3	3.670411	3.583424	0.68554	0.69270	G/G	D	0.44616	0.7729332447052	0.78717	0.99673145879973368	.	0.92147	.	G/G	.	.	.	.	5.966121	0.578647940763098	0.73411	4.596704	0.439294155476036	0.63599	.	.	.	1	8.236e-06	0	0	0	0	1	8.241e-06	0	0	0	0	1	1.498e-05	0	0	1	9.415e-06	0	0	0	0	1	9.422e-06	0	0	0	0	1	1.840e-05	0	0	1	1.102e-05	0	0	0	0	1	1.103e-05	0	0	0	0	1	2.373e-05	0	0	0.99468	.	.	.	6.17	6.17	0.99707	0	0.45803	0.59043	.	.	0.74766	0.999999999999998	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&.	.	.	.	0.80045	.	0.091468	0.84330	D	0.000000	D	0.96281	0.583947	0.03527	.	0.98088	.	D	0.98615	0.9572	.	0.70432	.	D	0.98779	1.0767	T117I	Loss_of_phosphorylation_at_T117_(P_=_0.0473)&_Loss_of_disorder_(P_=_0.0493)&_Gain_of_methylation_at_K115_(P_=_0.0652)&_Loss_of_glycosylation_at_P119_(P_=_0.1002)&_Gain_of_ubiquitination_at_K113_(P_=_0.1317)	P00439	0.37511	0.367	.	0.73523	.	.	0.58761	simple_aae&simple_aae	D&D	0.999999&0.999999	0.62976	.	.	.	0.23190	.	.	0.19346	.	T	0.71753	0.731686115265	0.77206	.	10	0.41913	.	.	0.72154	.	.	20.8794	0.99870	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.62866	.	G/G	I	.	T	A	717	0.55835	.	12	C0031485	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102894737G>A	120273	reviewed_by_expert_panel	Phenylketonuria	Illumina_Laboratory_Services&Illumina:937830	.	.	AEFBI	D	0.88185	0.98887	D	0.99755	0.978140	.	5	1.988800e-05	0	0.000000e+00	16246	0	4	1.156400e-04	34590	0	251408	0	0.000000e+00	10078	0	0	0.000000e+00	18394	0	0	0.000000e+00	21640	0	1	8.794610e-06	113706	0	4	1.156400e-04	34590	0	0	0.000000e+00	30616	0	2	1.828150e-05	0	0.000000e+00	7164	0	1	5.843850e-05	17112	0	109400	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13386	0	1	2.338200e-05	42768	0	1	5.843850e-05	17112	0	0	0.000000e+00	15690	0	0	.	0	5	2.110860e-05	0	0.000000e+00	14892	0	4	1.167610e-04	34258	0	236870	0	0.000000e+00	9570	0	0	0.000000e+00	17692	0	0	0.000000e+00	21624	0	1	9.738050e-06	102690	0	4	1.167610e-04	34258	0	0	0.000000e+00	30526	0	0	2	9.610670e-06	0	0.000000e+00	16208	0	1	3.276110e-05	30524	0	208102	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16726	0	1	1.116770e-05	89544	0	1	3.276110e-05	30524	0	0	0.000000e+00	30608	0	0	5	2.042570e-05	0	0.000000e+00	12016	0	4	1.160900e-04	34456	0	244790	0	0.000000e+00	9996	0	0	0.000000e+00	18390	0	0	0.000000e+00	21638	0	1	8.959290e-06	111616	0	4	1.160900e-04	34456	0	0	0.000000e+00	30616	0	0	7	4.602480e-05	0	0.000000e+00	41414	0	0	0.000000e+00	912	0	5	3.275680e-04	15264	0	152092	0	0.000000e+00	3472	0	1	1.925300e-04	5194	0	0	0.000000e+00	10586	0	0	0.000000e+00	316	0	1	1.470030e-05	68026	0	5	3.275680e-04	15264	0	0	0.000000e+00	4822	0	0	0.000000e+00	0	0.000000e+00	9084	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32852	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5466	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3112	0	0	.	0	7	4.734780e-05	0	0.000000e+00	41094	0	0	0.000000e+00	912	0	5	3.316530e-04	15076	0	147842	0	0.000000e+00	3302	0	1	2.016130e-04	4960	0	0	0.000000e+00	10586	0	0	0.000000e+00	304	0	1	1.543160e-05	64802	0	0	0.000000e+00	4790	0	0	7	5.197350e-05	0	0.000000e+00	32444	0	0	0.000000e+00	862	0	5	3.374270e-04	14818	0	134684	0	0.000000e+00	3388	0	1	1.925300e-04	5194	0	0	0.000000e+00	6950	0	0	0.000000e+00	310	0	1	1.564900e-05	63902	0	0	0.000000e+00	4820	0	0	5	6.199470e-05	0	0.000000e+00	24790	0	0	0.000000e+00	112	0	5	3.878980e-04	12890	0	80652	0	0.000000e+00	998	0	0	0.000000e+00	3752	0	0	0.000000e+00	10494	0	0	0.000000e+00	272	0	0	0.000000e+00	21038	0	0	0.000000e+00	4794	0	0	12	101812645	12	103288515	0	0.37627	0.615465	1.000000	0.71638	0.935000	0.47363	0.995000	0.57719	8.899000	0.92172	0.676000	0.76740	1.176000	0.78918	102894737	G	.	rs281865439	.	.	11.038	10.766	11.785	7.700	9.144	1.623	10.766	-14	-8	2	-2	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+2+start+184	120273	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103288515-103288515	8.236e-06	1	1	0	0	0	0	0	1	0	0	10340	11576	8654	6614	66736	908	16510	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs281865439	0.00000e+00	8.93389e-05	0.00000e+00	0.00000e+00	0.00000e+00	8.95592e-06	1.82349e-04	0.00000e+00	2.22460e-05	1.79633e-05	8.93389e-05	2.03028e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865439	281865439	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bmissense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,806	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103271326	103271326	G	A	A	missense_variant&splice_region_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	4/13	.	NM_000277.3:c.355C>T	NP_000268.1:p.Pro119Ser	469	355	119	P/S	Ccc/Tcc	rs398123292&CM043044&COSV61020694	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103271326G>A	.	0	0	0	0	0.001	likely_pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.357del	.	.	1	1.9968051118210862E-4	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0010224948875255625	.	.	.	.	.	.	.	.	.	G/G	G	D	0.78537	0.249296	D	0.96528	0.579153	27.6	27.1	4.079021	3.932331	0.81355	0.79905	G/G	D	0.37246	0.620991230010986	0.98309	0.99914796696525687	.	0.98331	.	G/G	.	.	.	.	17.21792	0.971925881827619	0.98006	13.97574	1.00173581777696	0.95796	.	.	.	42	3.459e-04	0	0	0	0	42	3.460e-04	0	0	0	0	0	0	42	2.544e-03	41	3.860e-04	0	0	0	0	41	3.861e-04	0	0	0	0	0	0	41	2.499e-03	42	4.628e-04	0	0	0	0	42	4.629e-04	0	0	0	0	0	0	42	2.545e-03	0.98390	.	.	.	5.86	5.86	0.93936	0	0.14657	0.547309	.	.	0.74766	0.99999999816998	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.89686	.	0.000000	0.84330	D	0.000000	D	0.97140	0.659829	0.25874	.	0.99484	.	D	0.99020	0.9690	.	0.53559	.	D	0.99529	1.0969	.	.	.	.	.	.	0.90273	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95216	.	.	.	0.73220	.	.	0.70163	.	T	0.68955	0.712491512299	0.99189	.	10	0.92824	.	.	0.91255	.	.	20.1768	0.98179	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.93135	.	G/G	S	.	P	A	675	0.60470	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102877548G>A	92741	reviewed_by_expert_panel	Phenylketonuria&not_provided	HGMD:CM043044	.	.	AEFBI	D	0.87122	0.98808	D	0.99726	0.977502	.	72	2.864440e-04	0	0.000000e+00	16256	0	0	0.000000e+00	34590	0	251358	0	0.000000e+00	10076	0	0	0.000000e+00	18392	0	0	0.000000e+00	21634	0	0	0.000000e+00	113658	0	70	2.286390e-03	30616	0	70	2.286390e-03	30616	0	41	3.747990e-04	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109392	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13380	0	0	0.000000e+00	42768	0	41	2.613130e-03	15690	0	41	2.613130e-03	15690	0	0	.	0	72	3.040280e-04	0	0.000000e+00	14902	0	0	0.000000e+00	34258	0	236820	0	0.000000e+00	9568	0	0	0.000000e+00	17690	0	0	0.000000e+00	21618	0	0	0.000000e+00	102642	0	70	2.293130e-03	30526	0	70	2.293130e-03	30526	0	0	72	3.459540e-04	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208120	0	0.000000e+00	6212	0	0	0.000000e+00	13414	0	0	0.000000e+00	16720	0	0	0.000000e+00	89558	0	70	2.286980e-03	30608	0	70	2.286980e-03	30608	0	0	72	2.941900e-04	0	0.000000e+00	12026	0	0	0.000000e+00	34456	0	244740	0	0.000000e+00	9994	0	0	0.000000e+00	18388	0	0	0.000000e+00	21632	0	0	0.000000e+00	111568	0	70	2.286390e-03	30616	0	70	2.286390e-03	30616	0	0	9	5.915370e-05	0	0.000000e+00	41442	0	0	0.000000e+00	912	0	0	0.000000e+00	15278	0	152146	0	0.000000e+00	3468	0	0	0.000000e+00	5176	0	0	0.000000e+00	10602	0	0	0.000000e+00	316	0	0	0.000000e+00	68038	0	9	1.864900e-03	4826	0	9	1.864900e-03	4826	0	5	1.520310e-04	0	0.000000e+00	9094	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32888	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5478	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	5	1.605650e-03	3114	0	0	.	0	9	6.085360e-05	0	0.000000e+00	41120	0	0	0.000000e+00	912	0	0	0.000000e+00	15090	0	147896	0	0.000000e+00	3302	0	0	0.000000e+00	4942	0	0	0.000000e+00	10602	0	0	0.000000e+00	304	0	0	0.000000e+00	64812	0	9	1.877350e-03	4794	0	0	9	6.679230e-05	0	0.000000e+00	32478	0	0	0.000000e+00	862	0	0	0.000000e+00	14832	0	134746	0	0.000000e+00	3384	0	0	0.000000e+00	5176	0	0	0.000000e+00	6966	0	0	0.000000e+00	310	0	0	0.000000e+00	63916	0	9	1.865670e-03	4824	0	0	9	1.115210e-04	0	0.000000e+00	24816	0	0	0.000000e+00	112	0	0	0.000000e+00	12904	0	80702	0	0.000000e+00	994	0	0	0.000000e+00	3734	0	0	0.000000e+00	10510	0	0	0.000000e+00	272	0	0	0.000000e+00	21048	0	9	1.875780e-03	4798	0	0	12	101795456	12	103271326	0	0.37627	0.615465	1.000000	0.71638	0.993000	0.69303	1.000000	0.86279	9.183000	0.94011	0.676000	0.76740	1.176000	0.78918	102877548	G	.	rs398123292	.	.	8.810	7.211	11.038	10.766	11.094	-0.057	11.038	2	26	2	3	0.04	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-5+2+end+89	92741	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103271326-103271326	3.459e-04	42	42	0	0	0	0	0	0	0	42	10402	11570	8654	6614	66732	908	16512	0	0	0	0	0	0	42	0	0	0	0	0	0	0	rs398123292	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.96122e-06	1.82282e-04	2.24157e-03	3.93076e-04	1.61743e-04	2.24157e-03	2.88299e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs398123292	398123292	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bmissense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,804	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103271241	103271241	G	A	A	missense_variant&splice_region_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	4/13	.	NM_000277.3:c.440C>T	NP_000268.1:p.Pro147Leu	554	440	147	P/L	cCt/cTt	rs199475694&CM1111672&COSV100187785	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103271241G>A	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.440C>T	0.993037242146984	0.916	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.96924	0.575713	D	0.96873	0.589196	32	32	4.714578	4.440182	0.92445	0.91442	G/G	D	0.99874	0.999957323074341	0.94184	0.99863763144525652	.	0.99974	.	G/G	.	.	.	.	13.12333	0.884968324383504	0.94884	13.22535	0.977336531294123	0.95005	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99843	.	.	.	5.86	5.86	0.93936	0	0.14657	0.547309	.	.	0.74766	0.99999999816998	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.99207	.	0.000000	0.84330	D	0.000000	D	0.99235	0.898603	0.26827	.	0.98172	.	D	0.99880	0.9947	.	0.99926	.	D	0.96587	0.9627	P147L	Loss_of_disorder_(P_=_0.0325)&_Gain_of_solvent_accessibility_(P_=_0.0837)&_Gain_of_relative_solvent_accessibility_(P_=_0.09)&_Loss_of_ubiquitination_at_K150_(P_=_0.0915)&_Gain_of_MoRF_binding_(P_=_0.2441)	P00439	0.96835	0.88	.	0.96017	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.98297	.	.	.	0.90584	.	.	0.84481	.	D	0.88167	0.840479075909	0.98708	.	10	0.92824	.	.	0.91255	.	.	20.1768	0.98179	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.99863	.	G/G	L	.	P	A	674	0.60593	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102877463G>A	102670	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.P147L	.	.	AEFBCI	D	0.66604	0.95892	D	0.99748	0.977998	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101795371	12	103271241	0	0.37627	0.615465	1.000000	0.71638	0.238000	0.22948	0.813000	0.33914	9.183000	0.94011	0.676000	0.76740	1.176000	0.78918	102877463	G	.	rs199475694	.	.	8.810	7.211	11.038	10.766	7.154	0.057	7.211	-1	37	-16	-1	0.00	0.00	0.00	0.03	PAH	0.00	exon-NM_001354304.2-5+1+start+89	102670	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475694	199475694	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bmissense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,798	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	73572579	73572579	C	T	T	missense_variant	MODERATE	CDH23	64072	Transcript	NM_022124.6	protein_coding	68/70	.	NM_022124.6:c.9565C>T	NP_071407.4:p.Arg3189Trp	9969	9565	3189	R/W	Cgg/Tgg	rs121908353&CM050001	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	CDH23	.	chr10:g.73572579C>T	.	.	.	.	.	.	uncertain_significance&pathogenic	.	1&1	.	.	.	.	.	CDH23&NM_022124.5&c.9565C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.88262	0.373122	D	0.88113	0.298187	26.5	29.1	3.930111	4.153903	0.76259	0.87128	C/C	D	0.52776	0.877856850624084	0.96126	0.99886531539362766	.	0.59443	.	C/C	.	.	.	.	4.226519	0.381005120426658	0.60393	4.255682	0.385666919644332	0.60645	.	.	.	1	8.258e-06	0	0	0	0	1	8.764e-06	0	0	0	0	1	1.573e-05	0	0	1	9.443e-06	0	0	0	0	1	1.002e-05	0	0	0	0	1	1.929e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.83157	.	.	.	5.84	4.93	0.64394	0	0.16991	0.550933	.	.	0.74766	0.999999999424371	.	0	0.78885	0.717052	.	.	.	.	.	.	0	0.64389	0.664235	.&.&.&.	.	.	.	0.91141	.	0.000000	0.84330	D	0.000000	D	0.92186	0.347717	0.46179	.	0.92223	.	D	0.87811	0.6502	.	0.92168	.	D	0.88888	0.3861	R3189W	Gain_of_sheet_(P_=_0.039)&_Loss_of_disorder_(P_=_0.0461)&_Gain_of_catalytic_residue_at_E3194_(P_=_0.1662)&_Loss_of_phosphorylation_at_Y3187_(P_=_0.1953)&_Loss_of_solvent_accessibility_(P_=_0.239)	Q9H251	0.96983	0.883	.	0.26193	.	.	0.81001	simple_aae&simple_aae	A&A	1&1	0.53096	.	.	.	0.90584	.	.	0.81110	.	D	0.90624	0.856714963913	0.92787	.	10	0.92824	.	.	0.91255	.	.	13.9815	0.63823	0.2759:0.7241:0.0:0.0	.	.	.	.	.	.	.	.	0.92784	.	C/C	W	.	R	T	787	0.46738	.	10	C1568247&C0271097&C3276419&CN169374&CN517202	276900&PS276900	ORPHA231169&ORPHA886	Uncertain_significance	NC_000010.11:g.71812822C>T	4926	reviewed_by_expert_panel	Usher_syndrome_type_1&Usher_syndrome&USHER_SYNDROME&_TYPE_ID/F&_DIGENIC&not_specified&not_provided	OMIM_Allelic_Variant:605516.0012	.	.	AEFDGBCI	D	0.40228	0.80644	D	0.66108	0.705819	.	4	1.614240e-05	0	0.000000e+00	15312	0	0	0.000000e+00	34328	0	247794	4	3.988040e-04	10030	0	0	0.000000e+00	17908	0	0	0.000000e+00	21476	0	0	0.000000e+00	112312	0	.	.	.	.	0	0.000000e+00	30406	0	0	0.000000e+00	0	0.000000e+00	7026	0	0	0.000000e+00	16950	0	107808	0	0.000000e+00	2302	0	0	0.000000e+00	8590	0	0	0.000000e+00	13264	0	0	0.000000e+00	42226	0	.	.	.	.	0	0.000000e+00	15572	0	0	.	0	4	1.712230e-05	0	0.000000e+00	13982	0	0	0.000000e+00	34000	0	233614	4	4.196390e-04	9532	0	0	0.000000e+00	17230	0	0	0.000000e+00	21460	0	0	0.000000e+00	101570	0	.	.	.	.	0	0.000000e+00	30320	0	0	1	4.882910e-06	0	0.000000e+00	15276	0	0	0.000000e+00	30262	0	204796	1	1.621270e-04	6168	0	0	0.000000e+00	12966	0	0	0.000000e+00	16582	0	0	0.000000e+00	88388	0	.	.	.	.	0	0.000000e+00	30398	0	0	4	1.656890e-05	0	0.000000e+00	11300	0	0	0.000000e+00	34198	0	241416	4	4.020910e-04	9948	0	0	0.000000e+00	17904	0	0	0.000000e+00	21474	0	0	0.000000e+00	110230	0	.	.	.	.	0	0.000000e+00	30406	0	0	6	3.941350e-05	2	4.823690e-05	41462	0	0	0.000000e+00	912	0	0	0.000000e+00	15290	0	152232	2	5.763690e-04	3470	0	0	0.000000e+00	5202	0	0	0.000000e+00	10624	0	0	0.000000e+00	316	0	0	0.000000e+00	68036	0	1	2.068680e-04	4834	0	1	2.068680e-04	4834	0	3	9.114660e-05	1	1.098660e-04	9102	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32914	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5496	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	1	3.209240e-04	3116	0	0	.	0	6	4.054710e-05	2	4.861450e-05	41140	0	0	0.000000e+00	912	0	0	0.000000e+00	15102	0	147976	2	6.060610e-04	3300	0	0	0.000000e+00	4966	0	0	0.000000e+00	10624	0	0	0.000000e+00	304	0	0	0.000000e+00	64806	0	1	2.082470e-04	4802	0	0	5	3.708870e-05	1	3.078250e-05	32486	0	0	0.000000e+00	862	0	0	0.000000e+00	14844	0	134812	2	5.906670e-04	3386	0	0	0.000000e+00	5202	0	0	0.000000e+00	6984	0	0	0.000000e+00	310	0	0	0.000000e+00	63910	0	1	2.069540e-04	4832	0	0	5	6.188430e-05	2	8.052180e-05	24838	0	0	0.000000e+00	112	0	0	0.000000e+00	12916	0	80796	1	1.004020e-03	996	0	0	0.000000e+00	3760	0	0	0.000000e+00	10532	0	0	0.000000e+00	272	0	0	0.000000e+00	21052	0	1	2.080730e-04	4806	0	0	10	73242585	10	73572579	0	0.57754	0.700653	1.000000	0.71638	0.975000	0.56047	0.995000	0.57719	3.118000	0.50107	-0.223000	0.07921	0.103000	0.16625	71812822	C	.	rs121908353	.	.	11.126	9.597	10.588	5.031	.	.	.	15	-32	-2	16	0.02	0.00	0.00	0.00	CDH23	0.05	exon-NM_022124.6-68+54+start+123	4926	Uncertain_significance	reviewed_by_expert_panel	not_specified&not_provided&Usher_syndrome_type_1&USHER_SYNDROME&_TYPE_ID/F&_DIGENIC&Usher_syndrome_type_1D&Autosomal_recessive_nonsyndromic_hearing_loss_12&Pituitary_adenoma_5&_multiple_types&Usher_syndrome	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0010168&MedGen:C1568247&OMIM:276900&Orphanet:231169&Orphanet:886&MedGen:C3276419&MONDO:MONDO:0010984&MedGen:C1832845&OMIM:601067&Orphanet:231169&Orphanet:886&MONDO:MONDO:0011067&MedGen:C1832394&OMIM:601386&Orphanet:90636&MONDO:MONDO:0054601&MedGen:C4539685&OMIM:617540&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886	.	rs121908353	8.258e-06	1	0	0	0	0	0	0	1	0	0	9066	10720	8226	6192	63580	848	15476	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs121908353	0.00000e+00	0.00000e+00	4.07415e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.49022e-05	1.80593e-05	4.07415e-04	1.62425e-05	rs121908353	2.29148e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	1.16945e-04	0.00000e+00	2.29148e-04	6.45369e-05	.	.	rs121908353	121908353	.	.	.	CDH23	CDH23:exonic	CDH23:missense	CDH23:Usher_syndrome\x2ctype_1D\x3b{Pituitary_adenoma_5\x2cmultiple_types}\x3bUsher_syndrome\x2ctype_1D/F_digenic\x3bDeafness\x2cautosomal_recessive_12	CDH23:601067\x3b617540\x3b601067\x3b601386	CDH23:3\x3b3\x3b3\x3b3	CDH23:Autosomal_recessive\x2cDigenic_recessive\x3bAutosomal_dominant\x3bAutosomal_recessive\x2cDigenic_recessive\x3bAutosomal_recessive	0	0.0506929591139338	0.949268622794338	3.84180917276542e-05	DISEASE: Usher syndrome 1D (USH1D) [MIM:601067]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. {ECO:0000269|PubMed:11138009, ECO:0000269|PubMed:12075507, ECO:0000269|PubMed:15660226, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:18429043}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Usher syndrome 1D/F (USH1DF) [MIM:601067]: USH1DF patients are heterozygous for mutations in CDH23 and PCDH15, indicating a digenic inheritance pattern. {ECO:0000269|PubMed:15537665}. Note=The disease is caused by mutations affecting distinct genetic loci, including the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 12 (DFNB12) [MIM:601386]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:11090341, ECO:0000269|PubMed:12075507, ECO:0000269|PubMed:12522556, ECO:0000269|PubMed:15829536, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:17850630, ECO:0000269|PubMed:22899989, ECO:0000269|PubMed:24767429}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,499	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	73572580	73572580	G	A	A	missense_variant	MODERATE	CDH23	64072	Transcript	NM_022124.6	protein_coding	68/70	.	NM_022124.6:c.9566G>A	NP_071407.4:p.Arg3189Gln	9970	9566	3189	R/Q	cGg/cAg	rs727502936&COSV56492476	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	CDH23	.	chr10:g.73572580G>A	.	.	.	.	.	.	uncertain_significance	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	T	0.59649	0.0602895	D	0.79608	0.140974	32	32	4.541796	4.688571	0.91573	0.92528	G/G	T	0.27342	0.358285267495614	0.99969	0.99954920444554729	.	0.47635	.	G/G	.	.	.	.	12.75363	0.875792892672624	0.94429	10.12961	0.862637226019041	0.89816	.	.	.	3	2.477e-05	0	0	1	9.297e-05	3	2.627e-05	0	0	0	0	0	0	2	1.291e-04	3	2.833e-05	0	0	1	9.584e-05	3	3.004e-05	0	0	0	0	0	0	2	1.299e-04	3	3.317e-05	0	0	1	9.308e-05	3	3.531e-05	0	0	0	0	0	0	2	1.291e-04	0.82625	.	.	.	5.84	5.84	0.93373	0	0.16991	0.550933	.	.	0.98316	1.0	.	0	0.78885	0.717052	.	.	.	.	.	.	0	0.64389	0.664235	.&.&.&.	.	.	.	0.87497	.	0.000000	0.84330	D	0.000000	D	0.86366	0.1945	0.20283	.	0.90221	.	D	0.89198	0.6872	.	0.66014	.	D	0.89158	0.4041	R3189Q	Gain_of_phosphorylation_at_Y3187_(P_=_0.2151)&_Loss_of_disorder_(P_=_0.2458)&_Loss_of_MoRF_binding_(P_=_0.3769)&_Loss_of_helix_(P_=_0.3949)&_Gain_of_loop_(P_=_0.4661)	Q9H251	0.73815	0.606	.	0.26193	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.22294	.	.	.	0.77913	.	.	0.74104	.	T	0.78028	0.774031758308	0.88396	.	10	0.92824	.	.	0.91255	.	.	20.1278	0.97989	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.85027	.	G/G	Q	.	R	A	787	0.46738	.	10	C0271097&CN169374&CN517202	PS276900	ORPHA886	Uncertain_significance	NC_000010.11:g.71812823G>A	162956	reviewed_by_expert_panel	Usher_syndrome&not_specified&not_provided	.	.	.	AEFDGBCI	D	0.65991	0.95749	D	0.80276	0.877865	.	10	4.034440e-05	0	0.000000e+00	15306	0	1	2.911380e-05	34348	0	247866	0	0.000000e+00	10034	0	0	0.000000e+00	17888	0	0	0.000000e+00	21466	0	2	1.779740e-05	112376	0	7	2.300360e-04	30430	0	7	2.300360e-04	30430	0	3	2.782210e-05	0	0.000000e+00	7016	0	1	5.896230e-05	16960	0	107828	0	0.000000e+00	2304	0	0	0.000000e+00	8586	0	0	0.000000e+00	13254	0	0	0.000000e+00	42264	0	2	1.284520e-04	15570	0	2	1.284520e-04	15570	0	0	.	0	10	4.279100e-05	0	0.000000e+00	13980	0	1	2.939620e-05	34018	0	233694	0	0.000000e+00	9534	0	0	0.000000e+00	17212	0	0	0.000000e+00	21450	0	2	1.967690e-05	101642	0	7	2.307030e-04	30342	0	7	2.307030e-04	30342	0	0	10	4.881720e-05	0	0.000000e+00	15270	0	1	3.302290e-05	30282	0	204846	0	0.000000e+00	6170	0	0	0.000000e+00	12944	0	0	0.000000e+00	16570	0	2	2.261520e-05	88436	0	7	2.300970e-04	30422	0	7	2.300970e-04	30422	0	0	10	4.140960e-05	0	0.000000e+00	11292	0	1	2.922270e-05	34220	0	241490	0	0.000000e+00	9952	0	0	0.000000e+00	17884	0	0	0.000000e+00	21464	0	2	1.813300e-05	110296	0	7	2.300360e-04	30430	0	7	2.300360e-04	30430	0	0	6	3.941510e-05	1	2.412310e-05	41454	0	0	0.000000e+00	912	0	2	1.308220e-04	15288	0	152226	0	0.000000e+00	3470	0	0	0.000000e+00	5202	0	0	0.000000e+00	10622	0	0	0.000000e+00	316	0	2	2.939360e-05	68042	0	1	2.071250e-04	4828	0	1	2.071250e-04	4828	0	4	1.215880e-04	1	1.099380e-04	9096	0	0	0.000000e+00	60	0	2	4.264390e-04	4690	0	32898	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	1	3.215430e-04	3110	0	0	.	0	6	4.055100e-05	1	2.431200e-05	41132	0	0	0.000000e+00	912	0	2	1.324500e-04	15100	0	147962	0	0.000000e+00	3300	0	0	0.000000e+00	4966	0	0	0.000000e+00	10622	0	0	0.000000e+00	304	0	2	3.086040e-05	64808	0	1	2.085070e-04	4796	0	0	6	4.450840e-05	1	3.079200e-05	32476	0	0	0.000000e+00	862	0	2	1.347530e-04	14842	0	134806	0	0.000000e+00	3386	0	0	0.000000e+00	5202	0	0	0.000000e+00	6980	0	0	0.000000e+00	310	0	2	3.128910e-05	63920	0	1	2.072110e-04	4826	0	0	4	4.951480e-05	1	4.027710e-05	24828	0	0	0.000000e+00	112	0	2	1.548710e-04	12914	0	80784	0	0.000000e+00	996	0	0	0.000000e+00	3760	0	0	0.000000e+00	10530	0	0	0.000000e+00	272	0	0	0.000000e+00	21054	0	1	2.083330e-04	4800	0	0	10	73242586	10	73572580	0	0.57754	0.700653	1.000000	0.71638	0.975000	0.56047	0.993000	0.55118	9.933000	0.98840	0.676000	0.76740	1.176000	0.78918	71812823	G	.	rs727502936	.	.	11.126	9.597	10.588	5.031	.	.	.	2	14	15	-43	0.25	0.02	0.00	0.00	CDH23	0.05	exon-NM_022124.6-68+55+start+123	162956	Uncertain_significance	reviewed_by_expert_panel	not_provided&Usher_syndrome_type_1&Usher_syndrome&not_specified	MedGen:CN517202&MONDO:MONDO:0010168&MedGen:C1568247&OMIM:276900&Orphanet:231169&Orphanet:886&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&MedGen:CN169374	.	10:73572580-73572580	2.477e-05	3	3	0	0	1	0	0	0	0	2	9062	10756	8210	6194	63646	846	15496	0	1	0	0	0	0	2	0	0	0	0	0	0	0	rs727502936	0.00000e+00	2.98972e-05	0.00000e+00	0.00000e+00	0.00000e+00	1.79895e-05	0.00000e+00	2.28698e-04	5.95868e-05	1.80561e-05	2.28698e-04	4.06062e-05	rs727502936	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.67379e-05	0.00000e+00	.	0.00000e+00	7.22543e-05	6.67379e-05	3.22685e-05	.	.	rs727502936	727502936	.	.	.	CDH23	CDH23:exonic	CDH23:missense	CDH23:Usher_syndrome\x2ctype_1D\x3b{Pituitary_adenoma_5\x2cmultiple_types}\x3bUsher_syndrome\x2ctype_1D/F_digenic\x3bDeafness\x2cautosomal_recessive_12	CDH23:601067\x3b617540\x3b601067\x3b601386	CDH23:3\x3b3\x3b3\x3b3	CDH23:Autosomal_recessive\x2cDigenic_recessive\x3bAutosomal_dominant\x3bAutosomal_recessive\x2cDigenic_recessive\x3bAutosomal_recessive	0	0.0506929591139338	0.949268622794338	3.84180917276542e-05	DISEASE: Usher syndrome 1D (USH1D) [MIM:601067]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. {ECO:0000269|PubMed:11138009, ECO:0000269|PubMed:12075507, ECO:0000269|PubMed:15660226, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:18429043}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Usher syndrome 1D/F (USH1DF) [MIM:601067]: USH1DF patients are heterozygous for mutations in CDH23 and PCDH15, indicating a digenic inheritance pattern. {ECO:0000269|PubMed:15537665}. Note=The disease is caused by mutations affecting distinct genetic loci, including the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 12 (DFNB12) [MIM:601386]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:11090341, ECO:0000269|PubMed:12075507, ECO:0000269|PubMed:12522556, ECO:0000269|PubMed:15829536, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:17850630, ECO:0000269|PubMed:22899989, ECO:0000269|PubMed:24767429}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,500	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103260375	103260375	G	C	C	missense_variant&splice_region_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.508C>G	NP_000268.1:p.His170Asp	622	508	170	H/D	Cat/Gat	rs199475655&CM011946	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103260375G>C	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.508C>G	0.992048868096169	0.844	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.88701	0.37988	D	0.95275	0.533596	33	32	4.824554	4.473147	0.92792	0.91653	G/G	D	0.74377	0.982248902320862	0.62794	0.99401057715309404	.	0.99889	.	G/G	.	.	.	.	15.03803	0.928712890178196	0.96707	13.51562	0.986892755376026	0.95327	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99551	.	.	.	6.08	6.08	0.98982	0	0.26702	0.573888	.	.	0.33875	0.994943344109113	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.68535	.	0.000000	0.84330	D	0.000000	D	0.97720	0.718509	0.29100	.	0.98789	.	D	0.99716	0.9897	.	0.99688	.	D	0.97580	1.0225	H170D	Loss_of_MoRF_binding_(P_=_0.0635)&_Gain_of_relative_solvent_accessibility_(P_=_0.09)&_Gain_of_solvent_accessibility_(P_=_0.1456)&_Gain_of_phosphorylation_at_Y168_(P_=_0.1459)&_Loss_of_catalytic_residue_at_G171_(P_=_0.1909)	P00439	0.99368	0.948	.	0.94400	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95634	.	.	.	0.90584	.	.	0.80445	.	T	0.67045	0.699314236641	0.98636	.	10	0.60337	.	.	0.55530	.	.	17.8194	0.88557	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.81758	.	G/G	D	.	H	C	699	0.57969	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102866597G>C	92744	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.H170D&HGMD:CM011946&UniProtKB_(protein):P00439#VAR_011569	.	.	AEFBI	D	0.80243	0.98174	D	0.99794	0.979083	.	5	1.989230e-05	0	0.000000e+00	16256	0	4	1.157880e-04	34546	0	251354	0	0.000000e+00	10076	0	0	0.000000e+00	18390	0	0	0.000000e+00	21644	0	0	0.000000e+00	113690	0	4	1.157880e-04	34546	0	0	0.000000e+00	30616	0	2	1.828520e-05	0	0.000000e+00	7164	0	1	5.847950e-05	17100	0	109378	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13392	0	0	0.000000e+00	42754	0	1	5.847950e-05	17100	0	0	0.000000e+00	15690	0	0	.	0	5	2.111330e-05	0	0.000000e+00	14902	0	4	1.169110e-04	34214	0	236818	0	0.000000e+00	9568	0	0	0.000000e+00	17688	0	0	0.000000e+00	21628	0	0	0.000000e+00	102676	0	4	1.169110e-04	34214	0	0	0.000000e+00	30526	0	0	5	2.403250e-05	0	0.000000e+00	16218	0	4	1.312340e-04	30480	0	208052	0	0.000000e+00	6210	0	0	0.000000e+00	13412	0	0	0.000000e+00	16730	0	0	0.000000e+00	89532	0	4	1.312340e-04	30480	0	0	0.000000e+00	30608	0	0	5	2.043020e-05	0	0.000000e+00	12026	0	4	1.162390e-04	34412	0	244736	0	0.000000e+00	9994	0	0	0.000000e+00	18386	0	0	0.000000e+00	21642	0	0	0.000000e+00	111600	0	4	1.162390e-04	34412	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101784505	12	103260375	0	0.25195	0.553676	1.000000	0.71638	0.981000	0.58702	1.000000	0.86279	6.647000	0.74208	0.676000	0.76740	1.176000	0.78918	102866597	G	.	rs199475655	.	.	7.292	9.092	8.810	7.211	10.148	-1.056	9.092	37	-3	-1	-5	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-6+1+start+68	92744	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475655	0.00000e+00	1.19275e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.82415e-04	0.00000e+00	1.48348e-05	2.69527e-05	1.19275e-04	2.03031e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475655	199475655	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bmissense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,778	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103249109	103249109	C	T	T	missense_variant&splice_region_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.511G>A	NP_000268.1:p.Gly171Arg	625	511	171	G/R	Ggg/Agg	rs199475613&CM010958	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103249109C>T	.	.	.	.	.	.	not_provided&likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.511G>T	0.991129414784395	0.828	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.96599	0.569415	D	0.96542	0.580149	34	34	5.593267	5.874169	0.94821	0.95377	C/C	D	0.99036	0.999797642230988	0.99734	0.99938810838823577	.	0.99998	.	C/C	.	.	.	.	16.94065	0.966767118510517	0.97874	15.75426	1.05509086960595	0.97208	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99831	.	.	.	5.73	5.73	0.89730	0	0.26702	0.573888	.	.	0.74766	0.9999999994012	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.97542	.	0.000000	0.84330	D	0.000000	D	0.97526	0.698154	0.28073	.	0.99508	.	D	0.99900	0.9956	.	0.99688	.	D	0.96042	0.9258	G171R	Gain_of_solvent_accessibility_(P_=_0.0037)&_Gain_of_MoRF_binding_(P_=_0.0512)&_Gain_of_disorder_(P_=_0.1758)&_Gain_of_helix_(P_=_0.2059)&_Loss_of_catalytic_residue_at_I174_(P_=_0.2595)	P00439	0.98707	0.924	.	0.97262	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95870	.	.	.	0.90584	.	.	0.97372	.	T	0.64942	0.684690237045	0.99545	.	10	0.92824	.	.	0.91255	.	.	19.8989	0.96978	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.85132	.	C/C	R	.	G	T	532	0.73501	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102855331C>T	102716	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.G171R&UniProtKB_(protein):P00439#VAR_000909	.	.	AEFBI	D	0.98899	0.99714	D	0.99993	0.989866	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.574450e-06	1	2.415340e-05	41402	0	0	0.000000e+00	912	0	0	0.000000e+00	15252	0	152104	0	0.000000e+00	3472	0	0	0.000000e+00	5194	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	0	0.000000e+00	68040	0	1	2.415340e-05	41402	0	0	0.000000e+00	4818	0	1	3.044330e-05	1	1.101320e-04	9080	0	0	0.000000e+00	60	0	0	0.000000e+00	4678	0	32848	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5476	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3106	0	0	.	0	1	6.763980e-06	1	2.434270e-05	41080	0	0	0.000000e+00	912	0	0	0.000000e+00	15064	0	147842	0	0.000000e+00	3302	0	0	0.000000e+00	4958	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	0	0.000000e+00	64808	0	0	0.000000e+00	4786	0	0	1	7.423570e-06	1	3.082230e-05	32444	0	0	0.000000e+00	862	0	0	0.000000e+00	14806	0	134706	0	0.000000e+00	3388	0	0	0.000000e+00	5194	0	0	0.000000e+00	6966	0	0	0.000000e+00	310	0	0	0.000000e+00	63920	0	0	0.000000e+00	4816	0	0	1	1.239680e-05	1	4.035510e-05	24780	0	0	0.000000e+00	112	0	0	0.000000e+00	12878	0	80666	0	0.000000e+00	998	0	0	0.000000e+00	3752	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	0	0.000000e+00	21052	0	0	0.000000e+00	4790	0	0	12	101773239	12	103249109	0	0.25195	0.553676	1.000000	0.71638	0.934000	0.47231	0.995000	0.57719	7.905000	0.86479	0.599000	0.40250	1.026000	0.45946	102855331	C	.	rs199475613	.	.	7.651	9.354	7.292	9.092	6.247	1.045	7.292	-2	1	-2	-22	0.59	0.12	0.00	0.00	PAH	0.00	exon-NM_001354304.2-7+1+end+197	102716	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475613	199475613	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bmissense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,777	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246594	103246594	G	A	A	missense_variant&splice_region_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.841C>T	NP_000268.1:p.Pro281Ser	955	841	281	P/S	Cct/Tct	rs199475654&CM043045&CM992948	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246594G>A	.	.	.	.	.	.	uncertain_significance&likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.841C>T	0.985940255900912	0.878	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.97023	0.581771	D	0.96973	0.597897	33	32	4.836457	4.527243	0.92825	0.91943	G/G	D	0.98346	0.999657869338989	0.98167	0.99913106200862378	.	0.99987	.	G/G	.	.	.	.	16.05527	0.949666491313621	0.97394	15.86106	1.05804296864988	0.97276	.	.	.	1	8.236e-06	0	0	0	0	1	8.237e-06	0	0	0	0	1	1.498e-05	0	0	1	9.415e-06	0	0	0	0	1	9.416e-06	0	0	0	0	1	1.840e-05	0	0	1	1.102e-05	0	0	0	0	1	1.102e-05	0	0	0	0	1	2.373e-05	0	0	0.99908	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999999999505	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.96950	.	0.000000	0.84330	D	0.000000	D	0.97672	0.713433	0.26752	.	0.99437	.	D	0.99938	0.9975	.	0.99956	.	D	0.95890	0.9152	P281S	Loss_of_glycosylation_at_T278_(P_=_0.0532)&_Loss_of_catalytic_residue_at_P281_(P_=_0.0676)&_Gain_of_disorder_(P_=_0.1499)&_Loss_of_phosphorylation_at_Y277_(P_=_0.1899)&_Loss_of_stability_(P_=_0.2639)	P00439	0.99767	0.975	.	0.99731	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95574	.	.	.	0.90584	.	.	0.97372	.	D	0.84253	0.814963340759	0.99982	.	10	0.83351	.	.	0.91255	.	.	19.8956	0.96955	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.99015	.	G/G	S	.	P	A	518	0.74548	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852816G>A	92749	reviewed_by_expert_panel	Phenylketonuria&not_provided	HGMD:CM992948&DeBelle_Laboratory_for_Biochemical_Genetics:p.P281S	.	.	AEFBI	D	0.92054	0.99156	D	0.99931	0.983779	.	1	3.979720e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34586	0	251274	0	0.000000e+00	10076	0	0	0.000000e+00	18392	0	0	0.000000e+00	21648	0	1	8.805140e-06	113570	0	1	8.805140e-06	113570	0	0	0.000000e+00	30616	0	1	9.140270e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	1	2.338200e-05	42768	0	1	2.338200e-05	42768	0	0	0.000000e+00	15690	0	0	.	0	1	4.224110e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34254	0	236736	0	0.000000e+00	9568	0	0	0.000000e+00	17690	0	0	0.000000e+00	21632	0	1	9.750960e-06	102554	0	1	9.750960e-06	102554	0	0	0.000000e+00	30526	0	0	1	4.805890e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30522	0	208078	0	0.000000e+00	6210	0	0	0.000000e+00	13414	0	0	0.000000e+00	16734	0	1	1.117240e-05	89506	0	1	1.117240e-05	89506	0	0	0.000000e+00	30608	0	0	1	4.087340e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34452	0	244658	0	0.000000e+00	9994	0	0	0.000000e+00	18388	0	0	0.000000e+00	21646	0	1	8.970060e-06	111482	0	1	8.970060e-06	111482	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101770724	12	103246594	0	0.43195	0.638212	1.000000	0.71638	0.655000	0.32830	0.996000	0.59523	10.003000	0.99689	0.676000	0.76740	1.176000	0.78918	102852816	G	.	rs199475654	.	.	11.570	9.399	7.651	9.354	8.879	0.520	9.399	39	-1	-5	-1	0.00	0.00	0.00	0.03	PAH	0.00	exon-NM_001354304.2-8+1+start+136	92749	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103246594-103246594	8.236e-06	1	1	0	0	0	0	0	1	0	0	10406	11572	8652	6614	66738	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs199475654	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.96861e-06	0.00000e+00	0.00000e+00	7.42016e-06	0.00000e+00	8.96861e-06	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475654	199475654	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bmissense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,709	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103246593	103246593	G	A	A	missense_variant&splice_region_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.842C>T	NP_000268.1:p.Pro281Leu	956	842	281	P/L	cCt/cTt	rs5030851&CM024140&CM910292	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246593G>A	.	.	.	.	.	.	pathogenic&likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.842C>T	0.992851156719976	0.856	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.88701	0.379882	D	0.96975	0.598041	33	32	5.246697	4.684401	0.93870	0.92519	G/G	D	0.92113	0.997666001319885	0.95892	0.99883466028073031	.	0.99983	.	G/G	0	0.0	1	1.1627906976744187E-4	17.53748	0.977680417022802	0.98147	17.43235	1.0982797972697	0.98102	.	.	.	12	9.884e-05	0	0	0	0	12	9.884e-05	0	0	0	0	12	1.798e-04	0	0	9	8.474e-05	0	0	0	0	9	8.474e-05	0	0	0	0	9	1.656e-04	0	0	5	5.510e-05	0	0	0	0	5	5.510e-05	0	0	0	0	5	1.186e-04	0	0	0.99908	.	.	.	5.73	5.73	0.89730	0	0.45803	0.59043	.	.	0.74766	0.999999999999505	.	0	0.51672	0.653264	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_iron/copper_binding_site&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.97864	.	0.000000	0.84330	D	0.000000	D	0.98208	0.773097	0.26827	.	0.99819	.	D	0.99945	0.9978	.	0.98375	.	D	0.95819	0.9103	.	.	.	.	.	.	0.99731	.	.	0.81001	simple_aae&simple_aae	A&A	1&1	0.98518	.	.	.	0.90584	.	.	0.97372	.	D	0.89770	0.851025223732	0.99904	.	9	0.83351	.	.	0.91255	.	.	19.8956	0.96955	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.97961	.	G/G	L	.	P	A	518	0.74548	.	12	C0031485&C0950123&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102852815G>A	589	reviewed_by_expert_panel	Phenylketonuria&Inborn_genetic_diseases&not_provided	UniProtKB_(protein):P00439#VAR_000981&OMIM_Allelic_Variant:612349.0012&HGMD:CM910292&DeBelle_Laboratory_for_Biochemical_Genetics:p.P281L&Institute_of_Human_Genetics&_University_of_Leipzig_Medical_Center:CV_varv_847	.	.	AEFBI	D	0.92054	0.99156	D	0.99930	0.983698	.	26	1.034810e-04	0	0.000000e+00	16256	0	0	0.000000e+00	34586	0	251254	0	0.000000e+00	10076	0	0	0.000000e+00	18392	0	2	9.238730e-05	21648	0	24	2.113610e-04	113550	0	24	2.113610e-04	113550	0	0	0.000000e+00	30616	0	11	1.005430e-04	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	1	7.466030e-05	13394	0	10	2.338200e-04	42768	0	10	2.338200e-04	42768	0	0	0.000000e+00	15690	0	0	.	0	24	1.013870e-04	0	0.000000e+00	14902	0	0	0.000000e+00	34254	0	236716	0	0.000000e+00	9568	0	0	0.000000e+00	17690	0	2	9.245560e-05	21632	0	22	2.145630e-04	102534	0	22	2.145630e-04	102534	0	0	0.000000e+00	30526	0	0	19	9.131450e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30522	0	208072	0	0.000000e+00	6210	0	0	0.000000e+00	13414	0	2	1.195170e-04	16734	0	17	1.899440e-04	89500	0	17	1.899440e-04	89500	0	0	0.000000e+00	30608	0	0	26	1.062790e-04	0	0.000000e+00	12026	0	0	0.000000e+00	34452	0	244638	0	0.000000e+00	9994	0	0	0.000000e+00	18388	0	2	9.239580e-05	21646	0	24	2.153200e-04	111462	0	24	2.153200e-04	111462	0	0	0.000000e+00	30616	0	0	18	1.183010e-04	2	4.827420e-05	41430	0	0	0.000000e+00	912	0	1	6.548790e-05	15270	0	152154	0	0.000000e+00	3472	0	0	0.000000e+00	5190	0	0	0.000000e+00	10620	0	0	0.000000e+00	316	0	15	2.205100e-04	68024	0	15	2.205100e-04	68024	0	0	0.000000e+00	4828	0	1	3.039330e-05	1	1.098900e-04	9100	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32902	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3112	0	0	.	0	18	1.216970e-04	2	4.864760e-05	41112	0	0	0.000000e+00	912	0	1	6.630420e-05	15082	0	147908	0	0.000000e+00	3302	0	0	0.000000e+00	4958	0	0	0.000000e+00	10620	0	0	0.000000e+00	304	0	15	2.314810e-04	64800	0	0	0.000000e+00	4796	0	0	15	1.113070e-04	1	3.079390e-05	32474	0	0	0.000000e+00	862	0	1	6.745820e-05	14824	0	134762	0	0.000000e+00	3388	0	0	0.000000e+00	5190	0	0	0.000000e+00	6980	0	0	0.000000e+00	310	0	13	2.034240e-04	63906	0	0	0.000000e+00	4826	0	0	6	7.433470e-05	2	8.063220e-05	24804	0	0	0.000000e+00	112	0	1	7.754340e-05	12896	0	80716	0	0.000000e+00	998	0	0	0.000000e+00	3748	0	0	0.000000e+00	10528	0	0	0.000000e+00	272	0	3	1.425860e-04	21040	0	0	0.000000e+00	4800	0	0	12	101770723	12	103246593	0	0.43195	0.638212	1.000000	0.71638	0.667000	0.33166	0.997000	0.62031	10.003000	0.99689	0.676000	0.76740	1.176000	0.78918	102852815	G	.	rs5030851	.	.	11.570	9.399	7.651	9.354	7.937	1.462	9.399	0	40	15	0	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+0+start+136	589	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Inborn_genetic_diseases&Phenylketonuria	MedGen:CN517202&MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030851	9.884e-05	12	12	0	0	0	0	0	12	0	0	10406	11572	8652	6614	66740	908	16512	0	0	0	0	12	0	0	0	0	0	0	0	0	0	rs5030851	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.96861e-05	2.24255e-04	0.00000e+00	0.00000e+00	1.03891e-04	1.16843e-04	2.24255e-04	1.09635e-04	rs5030851	1.14626e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.33262e-04	0.00000e+00	.	5.84249e-05	1.44363e-04	1.33262e-04	9.67992e-05	rs5030851	0.0116&0.0&0.0077	rs5030851	5030851	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bmissense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,708	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
1	41285135	41285135	G	C	C	missense_variant	MODERATE	KCNQ4	9132	Transcript	NM_004700.4	protein_coding	5/14	.	NM_004700.4:c.825G>C	NP_004691.2:p.Trp275Cys	1132	825	275	W/C	tgG/tgC	rs956666801	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	KCNQ4	.	chr1:g.41285135G>C	.	.	.	.	.	.	likely_pathogenic&uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.97076	0.584239	D	0.97029	0.601443	32	32	4.744645	4.434227	0.92548	0.91396	G/G	D	0.99981	0.999983668327332	0.66312	0.9947046824295297	.	0.99903	.	G/G	.	.	.	.	16.35055	0.95548458339436	0.97566	15.79472	1.05620943168954	0.97233	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.97956	.	.	.	5.08	5.08	0.68373	0	0.40923	0.588066	.	.	0.74766	0.999999999999942	.	0	0.99655	0.851219	.	.	.	.	.	.	0	0.58350	0.63947	Ion_transport_domain&Ion_transport_domain&.	.	.	.	0.98122	.	0.000000	0.84330	D	0.000000	D	0.97406	0.685961	0.98852	.	0.99490	.	D	0.99149	0.9728	.	0.96533	.	D	0.98792	1.0771	W275C	Loss_of_sheet_(P_=_0.1158)&_Gain_of_helix_(P_=_0.132)&_Gain_of_glycosylation_at_S273_(P_=_0.267)&_Gain_of_catalytic_residue_at_G277_(P_=_0.2932)&_Gain_of_disorder_(P_=_0.3321)	P56696	0.89920	0.773	.	0.98178	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.99694	.	.	.	0.90584	.	.	0.92359	.	D	0.97758	0.913132250309	0.98267	.	10	0.92824	.	.	0.91255	.	.	15.9666	0.79769	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.98065	.	G/G	C	.	W	C	759	0.50631	.	1	CN043648&CN169374	.	ORPHA87884	Likely_pathogenic	NC_000001.11:g.40819463G>C	505302	reviewed_by_expert_panel	Nonsyndromic_hearing_loss_and_deafness&not_specified	.	.	.	AEFBI	D	0.90001	0.99016	D	0.96479	0.950803	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	41057722	1	41285135	0	0.99359	0.766844	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	10.003000	0.99689	0.676000	0.76740	1.176000	0.78918	40819463	G	.	rs956666801	.	.	9.437	10.247	10.030	9.158	.	.	.	-41	-1	9	-1	0.00	0.00	0.01	0.86	KCNQ4	0.99	exon-NM_004700.4-5+9+end+126	505302	Likely_pathogenic	reviewed_by_expert_panel	Nonsyndromic_genetic_hearing_loss&not_specified	MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN169374	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs956666801	956666801	.	.	.	KCNQ4	KCNQ4:exonic	KCNQ4:missense	KCNQ4:Deafness\x2cautosomal_dominant_2A	KCNQ4:600101	KCNQ4:3	KCNQ4:Autosomal_dominant	0	0.985178281898531	0.0148214036876789	3.14413790434247e-07	DISEASE: Deafness, autosomal dominant, 2A (DFNA2A) [MIM:600101]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10025409, ECO:0000269|PubMed:10369879, ECO:0000269|PubMed:10571947, ECO:0000269|PubMed:10925378, ECO:0000269|PubMed:21242547}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,441	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
11	76883813	76883813	G	A	A	missense_variant	MODERATE	MYO7A	4647	Transcript	NM_000260.4	protein_coding	16/49	.	NM_000260.4:c.1817G>A	NP_000251.3:p.Arg606His	2107	1817	606	R/H	cGc/cAc	rs782311929	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	MYO7A	.	chr11:g.76883813G>A	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	MYO7A&NM_000260.3&c.1817G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	T	0.58419	0.0505843	D	0.79787	0.143752	29.4	32	4.282593	4.411358	0.87805	0.91223	G/G	D	0.51685	0.866811037063599	0.99944	0.99950952319509201	.	0.95725	.	G/G	.	.	.	.	8.581499	0.740435023077106	0.85442	8.596777	0.790501381230454	0.85508	.	.	.	6	5.313e-05	0	0	0	0	3	1.478e-04	0	0	0	0	1	1.145e-04	2	2.525e-04	5	5.041e-05	0	0	0	0	2	1.250e-04	0	0	0	0	0	0	2	2.530e-04	4	4.781e-05	0	0	0	0	3	1.530e-04	0	0	0	0	1	1.197e-04	2	2.525e-04	0.87591	.	.	.	4.77	4.77	0.60425	0	0.14657	0.547309	.	.	0.74766	0.999999999999775	.	0	0.98459	0.769059	.	.	.	.	.	.	0	0.08958	0.526803	Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VII_myosin&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VII_myosin&_motor_domain&.&.	.	.	.	0.90741	.	0.000000	0.84330	D	0.000000	D	0.93308	0.396682	0.49457	.	0.94105	.	D	0.92885	0.7902	.	0.84999	.	D	0.93859	0.7553	.	.	.	.	.	.	0.60227	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D	1&1&1&1	0.74348	.	.	.	0.73220	.	.	0.70163	.	D	0.86801	0.831562280655	0.94691	.	10	0.72224	.	.	0.68238	.	.	18.1567	0.89625	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.81360	.	G/G	H	.	R	A	585	0.69300	.	11	C1568247&C1838701&C1832475&CN043648&C2931206&CN169374&CN517202	276900&600060&601317	ORPHA231169&ORPHA87884	Uncertain_significance	NC_000011.10:g.77172767G>A	517357	reviewed_by_expert_panel	Usher_syndrome_type_1&Deafness&_autosomal_recessive_2&Deafness&_autosomal_dominant_11&Nonsyndromic_hearing_loss_and_deafness&Usher_syndrome_type_1B&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:648506	.	.	AEFDBIJ	D	0.71831	0.96950	D	0.92266	0.932388	.	14	8.445230e-05	0	0.000000e+00	8556	0	0	0.000000e+00	25870	0	165774	0	0.000000e+00	8632	0	0	0.000000e+00	11646	0	0	0.000000e+00	16234	0	6	8.929370e-05	67194	0	8	3.464400e-04	23092	0	8	3.464400e-04	23092	0	6	8.652510e-05	0	0.000000e+00	3144	0	0	0.000000e+00	12912	0	69344	0	0.000000e+00	1526	0	0	0.000000e+00	4652	0	0	0.000000e+00	11452	0	2	8.833140e-05	22642	0	4	3.447680e-04	11602	0	4	3.447680e-04	11602	0	0	.	0	13	8.095650e-05	0	0.000000e+00	7946	0	0	0.000000e+00	25752	0	160580	0	0.000000e+00	8418	0	0	0.000000e+00	11326	0	0	0.000000e+00	16228	0	5	7.880470e-05	63448	0	8	3.467710e-04	23070	0	8	3.467710e-04	23070	0	0	12	8.654010e-05	0	0.000000e+00	8520	0	0	0.000000e+00	21818	0	138664	0	0.000000e+00	4858	0	0	0.000000e+00	8840	0	0	0.000000e+00	13512	0	4	7.354830e-05	54386	0	8	3.465300e-04	23086	0	8	3.465300e-04	23086	0	0	14	8.594860e-05	0	0.000000e+00	7622	0	0	0.000000e+00	25810	0	162888	0	0.000000e+00	8556	0	0	0.000000e+00	11642	0	0	0.000000e+00	16232	0	6	9.168420e-05	65442	0	8	3.464400e-04	23092	0	8	3.464400e-04	23092	0	0	5	3.285190e-05	0	0.000000e+00	41460	0	0	0.000000e+00	912	0	0	0.000000e+00	15284	0	152198	0	0.000000e+00	3470	0	1	1.925300e-04	5194	0	0	0.000000e+00	10614	0	0	0.000000e+00	316	0	3	4.410080e-05	68026	0	1	2.069540e-04	4832	0	1	2.069540e-04	4832	0	2	6.079770e-05	0	0.000000e+00	9102	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32896	0	0.000000e+00	136	0	1	4.115230e-04	2430	0	0	0.000000e+00	5484	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	1	3.215430e-04	3110	0	0	.	0	5	3.379750e-05	0	0.000000e+00	41138	0	0	0.000000e+00	912	0	0	0.000000e+00	15096	0	147940	0	0.000000e+00	3302	0	1	2.016940e-04	4958	0	0	0.000000e+00	10614	0	0	0.000000e+00	304	0	3	4.629920e-05	64796	0	1	2.083330e-04	4800	0	0	5	3.709690e-05	0	0.000000e+00	32484	0	0	0.000000e+00	862	0	0	0.000000e+00	14840	0	134782	0	0.000000e+00	3386	0	1	1.925300e-04	5194	0	0	0.000000e+00	6972	0	0	0.000000e+00	310	0	3	4.694540e-05	63904	0	1	2.070390e-04	4830	0	0	3	3.714160e-05	0	0.000000e+00	24838	0	0	0.000000e+00	112	0	0	0.000000e+00	12910	0	80772	0	0.000000e+00	996	0	1	2.663830e-04	3754	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	1	4.751050e-05	21048	0	1	2.081600e-04	4804	0	0	11	76561461	11	76883813	0	0.35542	0.608966	1.000000	0.71638	0.972000	0.54974	0.998000	0.65909	7.657000	0.82733	0.663000	0.56723	1.083000	0.53824	77172767	G	.	rs782311929	.	.	9.011	10.126	10.717	9.256	.	.	.	19	-19	-19	17	0.01	0.01	0.00	0.00	MYO7A	0.00	exon-NM_001369365.1-17+19+start+138	517357	Uncertain_significance	reviewed_by_expert_panel	not_specified&Usher_syndrome_type_1&Nonsyndromic_genetic_hearing_loss&not_provided&Usher_syndrome_type_1B&Autosomal_recessive_nonsyndromic_hearing_loss_2&Autosomal_dominant_nonsyndromic_hearing_loss_11	MedGen:CN169374&MONDO:MONDO:0010168&MedGen:C1568247&OMIM:276900&Orphanet:231169&Orphanet:886&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN517202&MONDO:MONDO:0700087&MedGen:C2931206&MONDO:MONDO:0010807&MedGen:C1838701&OMIM:600060&Orphanet:90636&MONDO:MONDO:0011032&MedGen:C1832475&OMIM:601317&Orphanet:90635	.	11:76883813-76883813	5.313e-05	6	3	0	0	0	0	0	1	0	2	2024	510	708	222	8730	186	7922	0	0	0	0	1	0	2	0	0	0	0	0	0	0	rs782311929	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	9.29915e-05	0.00000e+00	3.45572e-04	1.15861e-04	5.39753e-05	3.45572e-04	1.43629e-04	rs782311929	0.00000e+00	0.00000e+00	0.00000e+00	6.16523e-04	0.00000e+00	1.33440e-04	0.00000e+00	.	5.84659e-05	1.44404e-04	6.16523e-04	9.67992e-05	.	.	rs782311929	782311929	.	.	.	MYO7A	MYO7A:exonic	MYO7A:missense	MYO7A:Deafness\x2cautosomal_recessive_2\x3bUsher_syndrome\x2ctype_1B\x3bDeafness\x2cautosomal_dominant_11	MYO7A:600060\x3b276900\x3b601317	MYO7A:3\x3b3\x3b3	MYO7A:Autosomal_recessive\x3bAutosomal_recessive\x3bAutosomal_dominant	0	5.37673856270135e-25	0.207164598627406	0.792835401372594	DISEASE: Usher syndrome 1B (USH1B) [MIM:276900]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. {ECO:0000269|PubMed:10094549, ECO:0000269|PubMed:10364543, ECO:0000269|PubMed:10447383, ECO:0000269|PubMed:10930322, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:15660226, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:23559863, ECO:0000269|PubMed:24831256, ECO:0000269|PubMed:25798947, ECO:0000269|PubMed:7870171, ECO:0000269|PubMed:8900236, ECO:0000269|PubMed:9002678, ECO:0000269|PubMed:9382091, ECO:0000269|PubMed:9718356}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 2 (DFNB2) [MIM:600060]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:9171832, ECO:0000269|PubMed:9171833}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 11 (DFNA11) [MIM:601317]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA11 is characterized by onset after complete speech acquisition and subsequent gradual progression. {ECO:0000269|PubMed:15121790, ECO:0000269|PubMed:15221449, ECO:0000269|PubMed:15300860, ECO:0000269|PubMed:9354784}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in MYO7A may be a cause of Leber congenital amaurosis (LCA), a severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near- absent pupillary responses, photophobia, high hyperopia and keratoconus.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,630	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
11	76870496	76870496	G	A	A	missense_variant	MODERATE	MYO7A	4647	Transcript	NM_000260.4	protein_coding	10/49	.	NM_000260.4:c.1007G>A	NP_000251.3:p.Arg336His	1297	1007	336	R/H	cGc/cAc	rs45629132&CM061140&COSV68684980	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	MYO7A	.	chr11:g.76870496G>A	.	0.0008	0	0	0.005	0	uncertain_significance&likely_benign	0&0&1	1&1&1	.	.	.	.	.	MYO7A&NM_000260.3&c.1007G>A	.	.	6	0.0011980830670926517	1	7.564296520423601E-4	0	0.0	0	0.0	5	0.004970178926441352	0	0.0	19	0.004929942916450441	.	.	.	.	.	.	.	G/G	G	T	0.56844	0.0384648	D	0.87382	0.28481	24.0	24.1	3.258620	3.196490	0.58002	0.59406	G/G	T	0.01556	0.0270861517996967	0.98654	0.99919296489019804	.	0.88812	.	G/G	2	5.078720162519045E-4	16	0.001927246446639364	4.567124	0.428558002642038	0.63350	4.507891	0.425886423230539	0.62850	.	.	.	139	1.150e-03	5	5.146e-04	7	6.059e-04	138	1.147e-03	0	0	0	0	125	1.881e-03	0	0	112	1.059e-03	3	3.555e-04	7	6.251e-04	112	1.062e-03	0	0	0	0	102	1.879e-03	0	0	81	8.974e-04	5	5.156e-04	7	6.065e-04	80	8.924e-04	0	0	0	0	67	1.601e-03	0	0	0.87591	.	.	.	4.87	4.87	0.62877	0	0.45803	0.59043	.	.	0.74766	0.999999998054271	.	0	0.15389	0.547309	.	.	.	.	.	.	0	0.14980	0.542086	Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VII_myosin&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VII_myosin&_motor_domain&.&.	.	.	.	0.70719	.	0.140017	0.47681	D	0.000220	D	0.82135	0.138864	0.12303	.	0.94496	.	D	0.87054	0.6309	.	0.17973	.	D	0.88100	0.3346	.	.	.	.	.	.	0.24501	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D	1&1&1&1	0.51319	.	.	.	0.67487	.	.	0.59197	.	T	0.62099	0.664828598499	0.90721	.	10	0.44501	.	.	0.38863	.	.	18.1956	0.89754	0.0:0.0:1.0:0.0	.	5	0.001348435814455232	24	0.003173763554615181	.	.	.	0.82257	.	G/G	H	.	R	A	567	0.70732	.	11	C0025281&C1568247&C1838701&C1832475&C0271097&C2931206&CN169374&CN517202	156000&276900&600060&601317&PS276900	ORPHA231169&ORPHA886	Likely_benign	NC_000011.10:g.77159450G>A	43134	reviewed_by_expert_panel	Meniere_disease&Usher_syndrome_type_1&Deafness&_autosomal_recessive_2&Deafness&_autosomal_dominant_11&Usher_syndrome&Usher_syndrome_type_1B&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:49255	.	.	AEFBI	D	0.93399	0.99247	D	0.97237	0.954913	.	288	1.163570e-03	11	7.127120e-04	15434	0	21	6.096500e-04	34446	0	247514	1	9.960160e-05	10040	0	0	0.000000e+00	17952	0	0	0.000000e+00	20472	0	249	2.211960e-03	112570	1	249	2.211960e-03	112570	1	1	3.270540e-05	30576	0	125	1.164870e-03	3	4.219410e-04	7110	0	9	5.292250e-04	17006	0	107308	1	4.317790e-04	2316	0	0	0.000000e+00	8626	0	0	0.000000e+00	12234	0	110	2.590060e-03	42470	1	110	2.590060e-03	42470	1	0	0.000000e+00	15668	0	1	.	1	263	1.128040e-03	9	6.386600e-04	14092	0	21	6.155830e-04	34114	0	233148	1	1.048000e-04	9542	0	0	0.000000e+00	17268	0	0	0.000000e+00	20456	0	226	2.222660e-03	101680	1	226	2.222660e-03	101680	1	1	3.280190e-05	30486	0	1	236	1.153790e-03	11	7.143780e-04	15398	0	20	6.580250e-04	30394	0	204544	1	1.616550e-04	6186	0	0	0.000000e+00	12974	0	0	0.000000e+00	15564	0	199	2.243620e-03	88696	1	199	2.243620e-03	88696	1	1	3.271390e-05	30568	0	1	279	1.157570e-03	8	7.075890e-04	11306	0	20	5.828860e-04	34312	0	241022	1	1.004220e-04	9958	0	0	0.000000e+00	17948	0	0	0.000000e+00	20470	0	244	2.208260e-03	110494	1	244	2.208260e-03	110494	1	1	3.270540e-05	30576	0	1	210	1.619370e-03	33	9.314670e-04	35428	0	0	0.000000e+00	856	0	10	9.038320e-04	11064	0	129680	0	0.000000e+00	3304	0	1	2.454590e-04	4074	0	1	1.605650e-04	6228	0	0	0.000000e+00	276	0	164	2.606480e-03	62920	0	164	2.606480e-03	62920	0	0	0.000000e+00	3740	0	34	1.421050e-03	9	1.289400e-03	6980	0	0	0.000000e+00	22	0	5	1.583280e-03	3158	0	23926	0	0.000000e+00	132	0	0	0.000000e+00	1668	0	0	0.000000e+00	3152	0	0	0.000000e+00	216	0	20	3.386390e-03	5906	0	0	0.000000e+00	2090	0	0	.	0	201	1.562090e-03	33	9.348440e-04	35300	0	0	0.000000e+00	856	0	10	9.077710e-04	11016	0	128674	0	0.000000e+00	3272	0	1	2.522700e-04	3964	0	1	1.605650e-04	6228	0	0	0.000000e+00	274	0	155	2.490040e-03	62248	0	0	0.000000e+00	3734	0	0	187	1.638630e-03	24	9.023910e-04	26596	0	0	0.000000e+00	818	0	10	9.405570e-04	10632	0	114120	0	0.000000e+00	3230	0	1	2.454590e-04	4074	0	0	0.000000e+00	4090	0	0	0.000000e+00	270	0	151	2.561060e-03	58960	0	0	0.000000e+00	3738	0	0	90	1.493280e-03	24	1.163240e-03	20632	0	0	0.000000e+00	62	0	6	6.891800e-04	8706	0	60270	0	0.000000e+00	836	0	1	3.796510e-04	2634	0	1	1.629730e-04	6136	0	0	0.000000e+00	232	0	58	3.602930e-03	16098	0	0	0.000000e+00	3712	0	0	11	76548144	11	76870496	0	0.19182	0.497415	1.000000	0.71638	0.606000	0.31539	0.864000	0.35823	7.725000	0.83768	0.618000	0.50648	1.175000	0.73717	77159450	G	.	rs45629132	.	.	6.710	7.700	6.566	7.132	.	.	.	2	-3	-3	23	0.00	0.01	0.00	0.00	MYO7A	0.00	exon-NM_001369365.1-11+3+start+77	43134	Likely_benign	reviewed_by_expert_panel	not_specified&Meniere_disease&Usher_syndrome&not_provided&Autosomal_dominant_nonsyndromic_hearing_loss_11&Autosomal_recessive_nonsyndromic_hearing_loss_2&Usher_syndrome_type_1&Usher_syndrome_type_1B	MedGen:CN169374&MONDO:MONDO:0007972&MedGen:C0025281&OMIM:156000&Orphanet:45360&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&MedGen:CN517202&MONDO:MONDO:0011032&MedGen:C1832475&OMIM:601317&Orphanet:90635&MONDO:MONDO:0010807&MedGen:C1838701&OMIM:600060&Orphanet:90636&MONDO:MONDO:0010168&MedGen:C1568247&OMIM:276900&Orphanet:231169&Orphanet:886&MONDO:MONDO:0700087&MedGen:C2931206	.	rs45629132	1.150e-03	139	136	1	5	7	0	0	125	1	0	9716	11554	8594	6602	66438	894	16496	5	7	0	0	123	1	0	0	0	0	0	1	0	0	rs45629132	5.90551e-04	6.26492e-04	1.01729e-04	0.00000e+00	0.00000e+00	2.18329e-03	7.33676e-04	3.25161e-05	1.03615e-03	1.26782e-03	2.18329e-03	1.13289e-03	rs45629132	1.16469e-03	0.00000e+00	0.00000e+00	6.20347e-04	2.90023e-04	2.17244e-03	1.05042e-03	.	1.66133e-03	1.24908e-03	2.17244e-03	1.45218e-03	rs45629132	0.1927&0.0508&0.1471	rs45629132	45629132	.	.	.	MYO7A	MYO7A:exonic	MYO7A:missense	MYO7A:Deafness\x2cautosomal_recessive_2\x3bUsher_syndrome\x2ctype_1B\x3bDeafness\x2cautosomal_dominant_11	MYO7A:600060\x3b276900\x3b601317	MYO7A:3\x3b3\x3b3	MYO7A:Autosomal_recessive\x3bAutosomal_recessive\x3bAutosomal_dominant	0	5.37673856270135e-25	0.207164598627406	0.792835401372594	DISEASE: Usher syndrome 1B (USH1B) [MIM:276900]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. {ECO:0000269|PubMed:10094549, ECO:0000269|PubMed:10364543, ECO:0000269|PubMed:10447383, ECO:0000269|PubMed:10930322, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:15660226, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:23559863, ECO:0000269|PubMed:24831256, ECO:0000269|PubMed:25798947, ECO:0000269|PubMed:7870171, ECO:0000269|PubMed:8900236, ECO:0000269|PubMed:9002678, ECO:0000269|PubMed:9382091, ECO:0000269|PubMed:9718356}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 2 (DFNB2) [MIM:600060]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:9171832, ECO:0000269|PubMed:9171833}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 11 (DFNA11) [MIM:601317]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA11 is characterized by onset after complete speech acquisition and subsequent gradual progression. {ECO:0000269|PubMed:15121790, ECO:0000269|PubMed:15221449, ECO:0000269|PubMed:15300860, ECO:0000269|PubMed:9354784}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in MYO7A may be a cause of Leber congenital amaurosis (LCA), a severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near- absent pupillary responses, photophobia, high hyperopia and keratoconus.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,629	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
11	533799	533799	T	G	G	missense_variant	MODERATE	HRAS	3265	Transcript	NM_005343.4	protein_coding	3/6	.	NM_005343.4:c.257A>C	NP_005334.1:p.Asn86Thr	471	257	86	N/T	aAc/aCc	rs138272051&COSV54239838	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	HRAS	.	chr11:g.533799T>G	.	0.0015	0	0	0	0	likely_benign&uncertain_significance&conflicting_interpretations_of_pathogenicity&benign	0&1	1&1	.	.	.	.	.	HRAS&NM_176795.3&c.257A>C	.	.	2	3.9936102236421724E-4	2	0.0015128593040847202	0	0.0	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	T/T	T	T	0.19580	-0.208571	T	0.59327	-0.149079	21.8	22.2	2.331143	2.336190	0.37534	0.40096	T/T	T	0.02273	0.0317950607196341	0.35944	0.97782415509148801	.	0.94416	.	T/T	2	4.5392646391284613E-4	1	1.1627906976744187E-4	2.710239	0.0940330880938609	0.44247	2.791927	0.0758318557761603	0.45338	.	.	.	28	2.306e-04	12	1.160e-03	0	0	28	2.315e-04	0	0	0	0	12	1.808e-04	4	2.422e-04	24	2.260e-04	10	1.107e-03	0	0	24	2.261e-04	0	0	0	0	10	1.840e-04	4	2.438e-04	19	2.094e-04	12	1.162e-03	0	0	19	2.105e-04	0	0	0	0	3	7.182e-05	4	2.424e-04	0.71543	.	.	.	3.64	3.64	0.40864	0	0.70079	0.698795	.	.	0.74766	0.999999999928044	.	0	0.80598	0.723109	.	.	.	.	.	.	0	0.98432	0.735409	.&Small_GTP-binding_protein_domain&.&Small_GTP-binding_protein_domain&Small_GTP-binding_protein_domain	.	.	.	.	.	0.000000	0.84330	D	0.000000	D	0.73097	0.07884	0.79913	.	0.78896	.	T	0.70713	0.3413	.	0.13795	.	T	0.73853	-0.3397	.	.	.	.	.	.	0.55661	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D	1&1&1&1&1	0.64019	.	.	.	0.33860	.	.	0.39801	.	T	0.44767	0.542269825935	0.68670	.	10	0.45530	.	.	0.59928	.	.	11.8872	0.51888	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.53181	.	T/T	T	.	N	G	889	0.27310	.	11	C0587248&C0028326&CN260604&CN166718&CN169374&CN517202	218040&PS163950	ORPHA3071&ORPHA648&ORPHA98733&ORPHA536391	Benign	NC_000011.10:g.533799T>G	40437	reviewed_by_expert_panel	Costello_syndrome&Noonan_syndrome&Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_specified&not_provided	Service_de_Gntique_Molculaire&Hpital_Robert_Debr:78394&ClinGen_RASopathy_Variant_Curation_Expert_Panel:7a67f8eb-da68-4c6b-9d98-ee169176af3c	.	.	AEFDBI	D	0.71349	0.96863	D	0.75182	0.833638	.	46	1.830510e-04	17	1.047310e-03	16232	0	2	5.783020e-05	34584	0	251296	0	0.000000e+00	10076	0	1	5.437150e-05	18392	0	0	0.000000e+00	21644	0	22	1.936240e-04	113622	0	17	1.047310e-03	16232	0	4	1.306510e-04	30616	0	17	1.553960e-04	6	8.377550e-04	7162	0	0	0.000000e+00	17108	0	109398	0	0.000000e+00	2320	0	1	1.105460e-04	9046	0	0	0.000000e+00	13390	0	8	1.870560e-04	42768	0	6	8.377550e-04	7162	0	2	1.274700e-04	15690	0	0	.	0	43	1.814900e-04	15	1.007120e-03	14894	0	2	5.838730e-05	34254	0	236928	0	0.000000e+00	9572	0	1	5.652270e-05	17692	0	0	0.000000e+00	21628	0	21	2.043950e-04	102742	0	15	1.007120e-03	14894	0	4	1.310360e-04	30526	0	0	37	1.779290e-04	17	1.049770e-03	16194	0	2	6.553940e-05	30516	0	207948	0	0.000000e+00	6208	0	1	7.454900e-05	13414	0	0	0.000000e+00	16730	0	13	1.453780e-04	89422	0	17	1.049770e-03	16194	0	4	1.306850e-04	30608	0	0	40	1.634800e-04	12	9.998330e-04	12002	0	2	5.805520e-05	34450	0	244678	0	0.000000e+00	9994	0	1	5.438330e-05	18388	0	0	0.000000e+00	21642	0	21	1.882870e-04	111532	0	12	9.998330e-04	12002	0	4	1.306510e-04	30616	0	0	45	2.958350e-04	31	7.485750e-04	41412	0	0	0.000000e+00	910	0	1	6.547070e-05	15274	0	152112	0	0.000000e+00	3470	0	0	0.000000e+00	5184	0	0	0.000000e+00	10628	0	0	0.000000e+00	316	0	12	1.764760e-04	67998	0	31	7.485750e-04	41412	0	0	0.000000e+00	4832	0	8	2.432350e-04	6	6.597760e-04	9094	0	0	0.000000e+00	60	0	1	2.133110e-04	4688	0	32890	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5496	0	0	0.000000e+00	246	0	0	0.000000e+00	6844	0	0	0.000000e+00	3114	0	0	.	0	44	2.975750e-04	31	7.544410e-04	41090	0	0	0.000000e+00	910	0	1	6.628660e-05	15086	0	147862	0	0.000000e+00	3302	0	0	0.000000e+00	4950	0	0	0.000000e+00	10628	0	0	0.000000e+00	304	0	11	1.698210e-04	64774	0	0	0.000000e+00	4800	0	0	40	2.969080e-04	26	8.009860e-04	32460	0	0	0.000000e+00	860	0	1	6.744000e-05	14828	0	134722	0	0.000000e+00	3386	0	0	0.000000e+00	5184	0	0	0.000000e+00	6986	0	0	0.000000e+00	310	0	12	1.878520e-04	63880	0	0	0.000000e+00	4830	0	0	23	2.850420e-04	19	7.663140e-04	24794	0	0	0.000000e+00	112	0	1	7.751940e-05	12900	0	80690	0	0.000000e+00	996	0	0	0.000000e+00	3742	0	0	0.000000e+00	10536	0	0	0.000000e+00	272	0	2	9.514750e-05	21020	0	0	0.000000e+00	4804	0	0	11	523799	11	533799	0	0.85440	0.722319	1.000000	0.71638	0.913000	0.44837	0.999000	0.70432	4.096000	0.57463	0.665000	0.62972	1.138000	0.64695	533799	T	.	rs138272051	.	.	8.862	5.560	10.582	8.703	.	.	.	46	-29	48	-42	0.00	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-3+33+start+179	40437	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Hereditary_cancer-predisposing_syndrome&not_specified&RASopathy&not_provided&Noonan_syndrome&Costello_syndrome	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN517202&MONDO:MONDO:0018997&MeSH:D009634&MedGen:C0028326&OMIM:PS163950&Orphanet:648&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071	.	rs138272051	2.306e-04	28	28	0	12	0	0	0	12	0	4	10342	11554	8638	6614	66368	904	16512	12	0	0	0	12	0	4	0	0	0	0	0	0	0	rs138272051	8.50118e-04	5.95557e-05	0.00000e+00	5.79845e-05	0.00000e+00	1.97048e-04	0.00000e+00	1.29946e-04	1.33436e-04	2.15676e-04	8.50118e-04	1.70543e-04	rs138272051	5.74317e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.68717e-05	0.00000e+00	.	1.75850e-04	2.17014e-04	5.74317e-04	1.93636e-04	rs138272051	0.0116&0.0454&0.0231	rs138272051	138272051	.	.	.	HRAS	HRAS:exonic	HRAS:missense	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,620	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
11	532686	532686	G	A	A	missense_variant	MODERATE	HRAS	3265	Transcript	NM_005343.4	protein_coding	5/6	.	NM_005343.4:c.520C>T	NP_005334.1:p.Pro174Ser	734	520	174	P/S	Cct/Tct	rs397517144&COSV54244076	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	HRAS	.	chr11:g.532686G>A	.	.	.	.	.	.	conflicting_interpretations_of_pathogenicity&likely_benign&benign	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	T	0.01558	-0.426429	T	0.33553	-0.398543	21.8	17.11	2.338535	1.642253	0.37691	0.26211	G/G	T	0.06846	0.0579682902688569	0.22629	0.93028860877517483	.	0.67447	.	G/G	.	.	.	.	1.192408	-0.505881128225897	0.21993	0.9838527	-0.602089783585955	0.18881	.	.	.	20	1.648e-04	0	0	20	1.742e-03	20	1.681e-04	0	0	0	0	0	0	0	0	19	1.789e-04	0	0	19	1.703e-03	19	1.801e-04	0	0	0	0	0	0	0	0	20	2.205e-04	0	0	20	1.744e-03	20	2.258e-04	0	0	0	0	0	0	0	0	0.66294	.	.	.	3.94	2.98	0.33575	0	0.74545	0.702456	.	.	0.74766	0.999990270038841	.	0	0.19454	0.570548	.	.	.	.	.	.	0	0.98432	0.735409	.&.&.	.	.	.	.	.	0.061993	0.62929	D	0.000003	D	0.64505	0.051063	0.74323	.	0.73982	.	T	0.44465	0.1324	.	0.00527	.	T	0.24787	-1.0167	P174S	Loss_of_catalytic_residue_at_P173_(P_=_0.0391)&_Loss_of_glycosylation_at_P174_(P_=_0.0505)&_Gain_of_phosphorylation_at_P174_(P_=_0.0677)&_Loss_of_stability_(P_=_0.0827)&_Loss_of_ubiquitination_at_K170_(P_=_0.1351)	P01112	0.18748	0.25	.	0.03579	.	.	0.81001	simple_aae&simple_aae&simple_aae&without_aae&without_aae	D&D&D&D&D	0.999998&0.999998&0.999998&1&1	0.02404	.	.	.	0.12996	.	.	0.06944	.	T	0.39228	0.50287437439	0.23913	.	10	0.18560	.	.	0.07594	.	.	11.9278	0.52113	0.0:0.0:0.8244:0.1756	.	.	.	.	.	.	.	.	0.30004	.	G/G	S	.	P	A	889	0.27310	.	11	C1842036&C0206682&C0334082&C4552097&C0005684&C0587248&CN166718&CN169374	137550&188470&162900&163200&109800&218040	ORPHA626&ORPHA2612&ORPHA157980&ORPHA3071&ORPHA536391	Benign	NC_000011.10:g.532686G>A	40448	reviewed_by_expert_panel	Large_congenital_melanocytic_nevus&Thyroid_cancer&_nonmedullary&_2&Epidermal_nevus&Linear_sebaceous_nevus_sequence&Malignant_tumor_of_urinary_bladder&Costello_syndrome&Rasopathy&not_specified	ClinGen_RASopathy_Variant_Curation_Expert_Panel:d37c8250-6a81-4f7a-b0df-8e5eb3216e8a	.	.	AEFDBI	D	0.79094	0.98040	D	0.63804	0.671231	.	58	2.325530e-04	0	0.000000e+00	16168	0	58	1.678050e-03	34564	0	249406	0	0.000000e+00	10042	0	0	0.000000e+00	18364	0	0	0.000000e+00	21488	0	0	0.000000e+00	112076	0	58	1.678050e-03	34564	0	0	0.000000e+00	30610	0	32	2.929440e-04	0	0.000000e+00	7160	0	32	1.871350e-03	17100	0	109236	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13256	0	0	0.000000e+00	42756	0	32	1.871350e-03	17100	0	0	0.000000e+00	15690	0	0	.	0	57	2.417410e-04	0	0.000000e+00	14864	0	57	1.664720e-03	34240	0	235790	0	0.000000e+00	9568	0	0	0.000000e+00	17692	0	0	0.000000e+00	21472	0	0	0.000000e+00	101822	0	57	1.664720e-03	34240	0	0	0.000000e+00	30526	0	0	57	2.764070e-04	0	0.000000e+00	16130	0	57	1.869100e-03	30496	0	206218	0	0.000000e+00	6176	0	0	0.000000e+00	13386	0	0	0.000000e+00	16596	0	0	0.000000e+00	88004	0	57	1.869100e-03	30496	0	0	0.000000e+00	30602	0	0	58	2.388840e-04	0	0.000000e+00	11942	0	58	1.684580e-03	34430	0	242796	0	0.000000e+00	9960	0	0	0.000000e+00	18360	0	0	0.000000e+00	21486	0	0	0.000000e+00	109990	0	58	1.684580e-03	34430	0	0	0.000000e+00	30610	0	0	5	3.284070e-05	0	0.000000e+00	41462	0	0	0.000000e+00	912	0	5	3.270540e-04	15288	0	152250	0	0.000000e+00	3472	0	0	0.000000e+00	5202	0	0	0.000000e+00	10626	0	0	0.000000e+00	316	0	0	0.000000e+00	68044	0	5	3.270540e-04	15288	0	0	0.000000e+00	4838	0	0	0.000000e+00	0	0.000000e+00	9100	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32916	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5494	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3116	0	0	.	0	4	2.702920e-05	0	0.000000e+00	41142	0	0	0.000000e+00	912	0	4	2.649010e-04	15100	0	147988	0	0.000000e+00	3302	0	0	0.000000e+00	4966	0	0	0.000000e+00	10626	0	0	0.000000e+00	304	0	0	0.000000e+00	64808	0	0	0.000000e+00	4806	0	0	4	2.966610e-05	0	0.000000e+00	32484	0	0	0.000000e+00	862	0	4	2.694690e-04	14844	0	134834	0	0.000000e+00	3388	0	0	0.000000e+00	5202	0	0	0.000000e+00	6984	0	0	0.000000e+00	310	0	0	0.000000e+00	63924	0	0	0.000000e+00	4836	0	0	5	6.187510e-05	0	0.000000e+00	24838	0	0	0.000000e+00	112	0	5	3.871770e-04	12914	0	80808	0	0.000000e+00	998	0	0	0.000000e+00	3760	0	0	0.000000e+00	10534	0	0	0.000000e+00	272	0	0	0.000000e+00	21054	0	0	0.000000e+00	4810	0	0	11	522686	11	532686	0	0.85440	0.722319	1.000000	0.71638	0.503000	0.29084	0.091000	0.19070	4.658000	0.61192	0.672000	0.70159	1.172000	0.72986	532686	G	.	rs397517144	.	.	5.016	10.068	10.489	10.068	.	.	.	-29	-35	43	-34	0.00	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-5+55+start+125	40448	Benign	reviewed_by_expert_panel	Malignant_tumor_of_urinary_bladder&Linear_nevus_sebaceous_syndrome&Epidermal_nevus&Large_congenital_melanocytic_nevus&Costello_syndrome&Thyroid_cancer&_nonmedullary&_2&Hereditary_cancer-predisposing_syndrome&not_specified&RASopathy	MONDO:MONDO:0001187&MedGen:C0005684&OMIM:109800&Orphanet:157980&Human_Phenotype_Ontology:HP:0010817&MONDO:MONDO:0008097&MedGen:C4552097&OMIM:163200&Orphanet:2612&Human_Phenotype_Ontology:HP:0010816&MONDO:MONDO:0008093&MedGen:C0334082&OMIM:162900&Orphanet:79414&Human_Phenotype_Ontology:HP:0005600&Human_Phenotype_Ontology:HP:0005604&MONDO:MONDO:0044792&MedGen:C1842036&OMIM:137550&Orphanet:626&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071&MONDO:MONDO:0008566&MedGen:C4225426&OMIM:188470&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	11:532686-532686	1.648e-04	20	20	0	0	20	0	0	0	0	0	10134	11482	8574	6410	65006	864	16482	0	20	0	0	0	0	0	0	0	0	0	0	0	0	rs397517144	0.00000e+00	1.84678e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.23347e-04	2.90065e-04	1.84678e-03	2.51773e-04	rs397517144	0.00000e+00	1.19617e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	5.85343e-05	0.00000e+00	1.19617e-03	3.22685e-05	.	.	rs397517144	397517144	.	.	.	HRAS	HRAS:exonic	HRAS:missense	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,609	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
10	89685314	89685314	T	C	C	missense_variant&splice_region_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	3/9	.	NM_000314.8:c.209T>C	NP_000305.3:p.Leu70Pro	1054	209	70	L/P	cTt/cCt	rs121909226&CM1513158&CS982332&COSV64301989&COSV64310663	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89685314T>C	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&0&0&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.209T>C	0.970064200777202	0.918	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.97005	0.580591	D	0.96956	0.596203	33	32	5.012238	4.710886	0.93276	0.92591	./.	D	0.98831	0.999756991863251	0.98238	0.99913421603518482	.	0.99638	.	./.	.	.	.	.	13.53219	0.894813323359135	0.95344	13.75447	0.994632628122007	0.95578	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98949	.	.	.	5.46	5.46	0.80021	0	0.89359	0.724815	.	.	0.74766	0.99999999999861	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.63922	0.662026	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.89491	.	0.000000	0.84330	D	0.000001	D	0.99480	0.928474	0.99155	.	0.99624	.	D	0.99450	0.9820	.	0.98767	.	D	0.97841	1.0365	L70P	Loss_of_stability_(P_=_0.0081)&_Gain_of_sheet_(P_=_0.0344)&_Gain_of_catalytic_residue_at_L70_(P_=_0.0394)&_Loss_of_loop_(P_=_0.0986)&_Gain_of_disorder_(P_=_0.1288)	P60484	0.94167	0.833	.	0.96723	.	.	0.81001	simple_aae	A	1	0.92782	.	.	.	0.90584	.	.	0.97372	.	D	0.95833	0.894709587097	0.99961	.	8	0.92824	.	.	0.91255	.	.	15.5246	0.75630	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.99670	.	./.	P	.	L	C	930	0.16408	.	10	CN072330&C1959582	158350	ORPHA306498	Likely_pathogenic	NC_000010.11:g.87925557T>C	7826	reviewed_by_expert_panel	Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	UniProtKB_(protein):P60484#VAR_018102&ClinGen_PTEN_Variant_Curation_Expert_Panel:12985d15-e1e7-45ab-b3e5-48e082086d4d&OMIM_Allelic_Variant:601728.0012	.	.	AEFGBI	D	0.84623	0.98606	D	0.98133	0.960496	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89675294	10	89685314	0	0.97996	0.741868	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	7.425000	0.79444	0.665000	0.62972	1.138000	0.64695	87925557	T	.	rs121909226	.	.	8.389	7.964	10.295	10.567	10.267	-2.303	7.964	-44	-37	4	-2	0.01	0.00	0.08	0.00	PTEN	0.98	exon-NM_001304717.5-4+0+end+45	7826	Likely_pathogenic	reviewed_by_expert_panel	Familial_meningioma&Macrocephaly-autism_syndrome&Malignant_tumor_of_prostate&Cowden_syndrome_1&Glioma_susceptibility_2&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0011789&MedGen:C3551915&OMIM:607174&Orphanet:263662&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548&Human_Phenotype_Ontology:HP:0012125&MONDO:MONDO:0008315&MedGen:C0376358&OMIM:176807&Orphanet:1331&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0013092&MedGen:C2751642&OMIM:613028&Orphanet:182067&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909226	121909226	.	.	.	PTEN	PTEN:splicing\x3bexonic	PTEN:splice_region_variant\x3bmissense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,529	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
13	20763044	20763044	A	T	T	missense_variant	MODERATE	GJB2	2706	Transcript	NM_004004.6	protein_coding	2/2	.	NM_004004.6:c.677T>A	NP_003995.2:p.Val226Asp	855	677	226	V/D	gTt/gAt	rs773846324&CM077567&CM101468	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	GJB2	.	chr13:g.20763044A>T	.	.	.	.	.	.	uncertain_significance	.	1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.90299	0.406731	D	0.90177	0.346465	23.3	22.3	2.950622	2.378392	0.50969	0.41044	./.	T	0.30805	0.450214117765427	0.22426	0.92879197281894454	.	0.42433	.	./.	.	.	.	.	2.288948	-0.0209563837485201	0.38771	2.177254	-0.0992273683436911	0.37426	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.97672	.	.	.	5.95	4.77	0.60425	0	0.36545	0.588015	.	.	0.74766	0.999999999862982	.	0	0.18855	0.563428	.	.	.	.	.	.	0	0.10902	0.530356	.&.&.	.	.	.	0.48242	.	0.420513	0.22050	N	0.063094	D	0.88736	0.241891	0.06392	.	0.58853	.	D	0.90324	0.7179	.	0.88703	.	D	0.89157	0.4040	V226D	Loss_of_MoRF_binding_(P_=_0.0211)&_Loss_of_methylation_at_K224_(P_=_0.0382)&_Gain_of_glycosylation_at_P225_(P_=_0.0833)&_Gain_of_phosphorylation_at_S222_(P_=_0.1755)&_Gain_of_helix_(P_=_0.2684)	P29033	0.93193	0.818	.	0.06538	.	.	0.49637	simple_aae&simple_aae	D&D	0.999837&0.999837	0.02518	.	.	.	0.48103	.	.	0.36942	.	T	0.46576	0.555104255676	0.82516	.	10	0.83351	.	.	0.78490	.	.	7.4943	0.26648	0.7813:0.1415:0.0772:0.0	.	.	.	.	.	.	.	.	0.61511	.	./.	D	.	V	T	682	0.59757	.	13	CN043648	.	ORPHA87884	Uncertain_significance	NC_000013.11:g.20188905A>T	585322	reviewed_by_expert_panel	Nonsyndromic_hearing_loss_and_deafness	ClinGen_Hearing_Loss_Variant_Curation_Expert_Panel:3727aeaa-7c6e-4712-b0f1-b1eea47c7b7f	.	.	AEFDBHCI	D	0.47924	0.88130	D	0.55577	0.538343	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	13	19661044	13	20763044	0	0.25195	0.553676	0.966000	0.33990	0.039000	0.14166	0.719000	0.31371	2.043000	0.40854	0.756000	0.94297	1.312000	0.94714	20188905	A	.	rs773846324	.	.	.	.	10.295	9.602	.	.	.	29	-40	0	2	0.00	0.00	0.00	0.00	GJB2	0.00	exon-NM_004004.6-2+698+end+2134	585322	Uncertain_significance	reviewed_by_expert_panel	Nonsyndromic_genetic_hearing_loss	MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	GJB2	GJB2:exonic	GJB2:missense	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,863	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
6	76558195	76558195	C	T	T	missense_variant	MODERATE	MYO6	4646	Transcript	NM_004999.4	protein_coding	11/35	.	NM_004999.4:c.1025C>T	NP_004990.3:p.Ala342Val	1257	1025	342	A/V	gCt/gTt	rs145564837&CM168652	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	MYO6	.	chr6:g.76558195C>T	.	0	0	0	0.002	0	conflicting_interpretations_of_pathogenicity&benign&likely_benign&uncertain_significance	.	1&1	.	.	.	.	.	MYO6&NM_004999.3&c.1025C>T	.	.	2	3.9936102236421724E-4	0	0.0	0	0.0	0	0.0	2	0.0019880715705765406	0	0.0	5	0.0012973533990659055	.	.	.	.	.	.	.	C/C	C	D	0.68751	0.144488	D	0.93209	0.435724	23.8	24.3	3.194095	3.285539	0.56447	0.61647	C/C	T	0.28869	0.398056238889694	0.98852	0.99922979497853537	.	0.97223	.	C/C	2	4.5392646391284613E-4	19	0.0022093023255813954	9.552265	0.779837077520761	0.88357	9.267233	0.823949484203904	0.87578	.	.	.	193	1.590e-03	4	3.846e-04	1	8.672e-05	193	1.591e-03	0	0	5	7.567e-04	183	2.743e-03	0	0	173	1.629e-03	3	3.311e-04	1	8.953e-05	173	1.630e-03	0	0	5	7.567e-04	164	3.019e-03	0	0	67	7.383e-04	4	3.853e-04	1	8.681e-05	67	7.390e-04	0	0	2	5.269e-04	60	1.424e-03	0	0	0.93170	.	.	.	5.37	5.37	0.76949	0	0.40923	0.588066	.	.	0.74766	0.999999999996378	.	0	0.59346	0.659464	.	.	.	.	.	.	0	0.49550	0.631631	Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VI_myosin&_motor_domain&.&.&.&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VI_myosin&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VI_myosin&_motor_domain	.	.	.	0.84033	.	0.000000	0.84330	D	0.000000	D	0.91779	0.332083	0.28511	.	0.95771	.	D	0.97479	0.9238	.	0.42411	.	D	0.98446	1.0644	.	.	.	.	.	.	0.93167	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D	1&1&1&1	0.71762	.	.	.	0.90584	.	.	0.75168	.	D	0.88160	0.84042930603	0.97398	.	10	0.79402	.	.	0.78490	.	.	19.1188	0.93338	0.0:1.0:0.0:0.0	.	2	5.393743257820927E-4	7	9.256810367627612E-4	.	.	.	0.99181	.	C/C	V	.	A	T	659	0.61982	.	6	C2931767&C1843028&CN043648&CN169374&CN517202	606346&607821	ORPHA87884	Benign	NC_000006.12:g.75848478C>T	45131	reviewed_by_expert_panel	Autosomal_dominant_nonsyndromic_deafness_22&Deafness&_autosomal_recessive_37&Nonsyndromic_hearing_loss_and_deafness&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:155773	.	.	AEFDBI	D	0.77329	0.97814	D	0.86725	0.909955	.	334	1.329050e-03	5	3.077300e-04	16248	0	5	1.447180e-04	34550	0	251308	4	3.969830e-04	10076	0	0	0.000000e+00	18390	0	36	1.663740e-03	21638	1	272	2.392930e-03	113668	0	272	2.392930e-03	113668	0	0	0.000000e+00	30608	0	133	1.215920e-03	4	5.586590e-04	7160	0	2	1.169730e-04	17098	0	109382	1	4.310340e-04	2320	0	0	0.000000e+00	9042	0	17	1.269230e-03	13394	0	107	2.501990e-03	42766	0	107	2.501990e-03	42766	0	0	0.000000e+00	15688	0	0	.	1	318	1.343080e-03	4	2.685650e-04	14894	0	5	1.461220e-04	34218	0	236770	4	4.180600e-04	9568	0	0	0.000000e+00	17688	0	36	1.664970e-03	21622	1	258	2.513350e-03	102652	0	258	2.513350e-03	102652	0	0	0.000000e+00	30518	0	1	223	1.071980e-03	5	3.084520e-04	16210	0	4	1.312250e-04	30482	0	208026	3	4.830920e-04	6210	0	0	0.000000e+00	13412	0	25	1.493960e-03	16734	0	179	1.999640e-03	89516	0	179	1.999640e-03	89516	0	0	0.000000e+00	30600	0	0	327	1.336370e-03	3	2.495840e-04	12020	0	5	1.452810e-04	34416	0	244692	3	3.001800e-04	9994	0	0	0.000000e+00	18386	0	36	1.663890e-03	21636	1	268	2.401910e-03	111578	0	268	2.401910e-03	111578	0	0	0.000000e+00	30608	0	1	185	1.216110e-03	12	2.895470e-04	41444	0	0	0.000000e+00	910	0	6	3.933390e-04	15254	0	152124	4	1.152070e-03	3472	0	0	0.000000e+00	5188	0	8	7.550020e-04	10596	0	0	0.000000e+00	316	0	154	2.264110e-03	68018	0	154	2.264110e-03	68018	0	0	0.000000e+00	4832	0	23	6.996840e-04	2	2.199250e-04	9094	0	0	0.000000e+00	60	0	1	2.135840e-04	4682	0	32872	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	3	5.478450e-04	5476	0	0	0.000000e+00	246	0	17	2.483930e-03	6844	0	0	0.000000e+00	3116	0	0	.	0	179	1.210510e-03	12	2.918150e-04	41122	0	0	0.000000e+00	910	0	6	3.982480e-04	15066	0	147872	3	9.085400e-04	3302	0	0	0.000000e+00	4956	0	8	7.550020e-04	10596	0	0	0.000000e+00	304	0	149	2.299670e-03	64792	0	0	0.000000e+00	4800	0	0	169	1.254420e-03	9	2.771620e-04	32472	0	0	0.000000e+00	860	0	6	4.051320e-04	14810	0	134724	4	1.180640e-03	3388	0	0	0.000000e+00	5188	0	4	5.745480e-04	6962	0	0	0.000000e+00	310	0	145	2.269170e-03	63900	0	0	0.000000e+00	4830	0	0	74	9.171360e-04	7	2.820530e-04	24818	0	0	0.000000e+00	112	0	5	3.881990e-04	12880	0	80686	1	1.002000e-03	998	0	0	0.000000e+00	3746	0	8	7.616150e-04	10504	0	0	0.000000e+00	272	0	53	2.519970e-03	21032	0	0	0.000000e+00	4804	0	0	6	76614915	6	76558195	0	0.44296	0.643511	1.000000	0.71638	0.978000	0.57271	0.999000	0.70432	7.545000	0.81074	0.599000	0.40250	1.026000	0.45946	75848478	C	.	rs145564837	.	.	5.846	4.857	6.497	7.131	.	.	.	-3	0	-8	48	0.00	0.00	0.00	0.00	MYO6	0.02	exon-NM_001368865.1-11+53+end+181	45131	Benign	reviewed_by_expert_panel	not_specified&not_provided&Nonsyndromic_genetic_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_37&Autosomal_dominant_nonsyndromic_hearing_loss_22	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0011912&MedGen:C1843028&OMIM:607821&Orphanet:90636&MONDO:MONDO:0011660&MedGen:C2931767&OMIM:606346&Orphanet:228012	.	rs145564837	1.590e-03	193	191	1	4	1	0	5	183	0	0	10400	11532	8646	6608	66720	908	16508	4	1	0	5	181	0	0	0	0	0	0	1	0	0	rs145564837	3.26926e-04	2.08656e-04	4.06256e-04	0.00000e+00	1.65979e-03	2.43697e-03	1.27691e-03	0.00000e+00	1.36494e-03	1.32984e-03	2.43697e-03	1.34810e-03	rs145564837	2.29043e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.43102e-03	2.13390e-03	2.03666e-03	.	1.51922e-03	1.08303e-03	2.13390e-03	1.32292e-03	rs145564837	0.2209&0.0454&0.1615	rs145564837	145564837	.	.	.	MYO6	MYO6:exonic	MYO6:missense	MYO6:Deafness\x2cautosomal_dominant_22\x2cwith_hypertrophic_cardiomyopathy\x3bDeafness\x2cautosomal_dominant_22\x3bDeafness\x2cautosomal_recessive_37	MYO6:606346\x3b606346\x3b607821	MYO6:3\x3b3\x3b3	MYO6:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_recessive	0	0.0177883990936548	0.982211600378647	5.27698444208756e-10	DISEASE: Deafness, autosomal dominant, 22 (DFNA22) [MIM:606346]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA22 is progressive and postlingual, with onset during childhood. By the age of approximately 50 years, affected individuals invariably have profound sensorineural deafness. {ECO:0000269|PubMed:11468689}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 37 (DFNB37) [MIM:607821]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:12687499}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, sensorineural, with hypertrophic cardiomyopathy (DFNHCM) [MIM:606346]: An autosomal dominant sensorineural deafness associated with hypertrophic cardiomyopathy. {ECO:0000269|PubMed:15060111}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,487	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
13	20763068	20763068	C	T	T	missense_variant	MODERATE	GJB2	2706	Transcript	NM_004004.6	protein_coding	2/2	.	NM_004004.6:c.653G>A	NP_003995.2:p.Cys218Tyr	831	653	218	C/Y	tGt/tAt	rs752812448&CM077572	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	GJB2	.	chr13:g.20763068C>T	.	.	.	.	.	.	uncertain_significance	.	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.92931	0.4601	D	0.93286	0.438611	22.9	22.9	2.744576	2.658002	0.46554	0.47205	C/C	D	0.37729	0.632667481899261	0.30668	0.96672108119721623	.	0.91612	.	C/C	.	.	.	.	2.829569	0.122700658445953	0.45712	2.721521	0.0573874333917813	0.44484	.	.	.	1	8.238e-06	0	0	0	0	1	8.558e-06	0	0	0	0	1	1.569e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1.102e-05	0	0	0	0	1	1.160e-05	0	0	0	0	1	2.554e-05	0	0	0.97560	.	.	.	5.65	4.79	0.60909	0	0.36545	0.588015	.	.	0.74766	0.999999999993869	.	0	0.18855	0.563428	.	.	.	.	.	.	0	0.10902	0.530356	.&.&.	.	.	.	0.25721	.	0.146689	0.48594	D	0.000163	D	0.93787	0.420692	0.06914	.	0.88368	.	D	0.95827	0.8744	.	0.95185	.	D	0.94948	0.8435	C218Y	Gain_of_catalytic_residue_at_C218_(P_=_0.056)&_Gain_of_disorder_(P_=_0.0845)&_Gain_of_methylation_at_K223_(P_=_0.086)&_Gain_of_ubiquitination_at_K221_(P_=_0.115)&_Loss_of_helix_(P_=_0.1299)	P29033	0.92228	0.804	.	0.78455	.	.	0.48800	simple_aae&simple_aae	D&D	0.99975&0.99975	0.79915	.	.	.	0.31856	.	.	0.35248	.	T	0.57939	0.635600209236	0.94123	.	10	0.70582	.	.	0.54683	.	.	11.6553	0.50576	0.1397:0.7259:0.1344:0.0	.	.	.	.	.	.	.	.	0.71321	.	C/C	Y	.	C	T	682	0.59757	.	13	CN043648	.	ORPHA87884	Uncertain_significance	NC_000013.11:g.20188929C>T	585327	reviewed_by_expert_panel	Nonsyndromic_hearing_loss_and_deafness	ClinGen_Hearing_Loss_Variant_Curation_Expert_Panel:95f36c60-61b5-4f1a-ba52-8297f08592ec	.	.	AEFDBHCI	D	0.59096	0.93754	D	0.69894	0.761136	.	2	8.030520e-06	0	0.000000e+00	15638	0	0	0.000000e+00	34558	0	249050	0	0.000000e+00	10006	0	0	0.000000e+00	18356	0	0	0.000000e+00	21642	0	2	1.783100e-05	112164	0	2	1.783100e-05	112164	0	0	0.000000e+00	30590	0	0	0.000000e+00	0	0.000000e+00	7144	0	0	0.000000e+00	17098	0	109344	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13390	0	0	0.000000e+00	42766	0	.	.	.	.	0	0.000000e+00	15668	0	0	.	0	1	4.253550e-06	0	0.000000e+00	14340	0	0	0.000000e+00	34238	0	235098	0	0.000000e+00	9508	0	0	0.000000e+00	17690	0	0	0.000000e+00	21626	0	1	9.842520e-06	101600	0	1	9.842520e-06	101600	0	0	0.000000e+00	30502	0	0	2	9.697060e-06	0	0.000000e+00	15600	0	0	0.000000e+00	30498	0	206248	0	0.000000e+00	6152	0	0	0.000000e+00	13378	0	0	0.000000e+00	16728	0	2	2.260400e-05	88480	0	2	2.260400e-05	88480	0	0	0.000000e+00	30584	0	0	2	8.227130e-06	0	0.000000e+00	11728	0	0	0.000000e+00	34424	0	243098	0	0.000000e+00	9944	0	0	0.000000e+00	18352	0	0	0.000000e+00	21640	0	2	1.811690e-05	110394	0	2	1.811690e-05	110394	0	0	0.000000e+00	30590	0	0	3	1.971060e-05	0	0.000000e+00	41454	0	0	0.000000e+00	912	0	0	0.000000e+00	15276	0	152202	0	0.000000e+00	3472	0	0	0.000000e+00	5194	0	0	0.000000e+00	10610	0	0	0.000000e+00	316	0	3	4.408650e-05	68048	0	3	4.408650e-05	68048	0	0	0.000000e+00	4826	0	0	0.000000e+00	0	0.000000e+00	9100	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32900	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5482	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3114	0	0	.	0	2	1.351880e-05	0	0.000000e+00	41132	0	0	0.000000e+00	912	0	0	0.000000e+00	15088	0	147942	0	0.000000e+00	3302	0	0	0.000000e+00	4958	0	0	0.000000e+00	10610	0	0	0.000000e+00	304	0	2	3.085560e-05	64818	0	0	0.000000e+00	4794	0	0	3	2.225720e-05	0	0.000000e+00	32480	0	0	0.000000e+00	862	0	0	0.000000e+00	14830	0	134788	0	0.000000e+00	3388	0	0	0.000000e+00	5194	0	0	0.000000e+00	6972	0	0	0.000000e+00	310	0	3	4.693070e-05	63924	0	0	0.000000e+00	4824	0	0	1	1.238270e-05	0	0.000000e+00	24830	0	0	0.000000e+00	112	0	0	0.000000e+00	12902	0	80758	0	0.000000e+00	998	0	0	0.000000e+00	3752	0	0	0.000000e+00	10518	0	0	0.000000e+00	272	0	1	4.749240e-05	21056	0	0	0.000000e+00	4798	0	0	13	19661068	13	20763068	0	0.25195	0.553676	0.921000	0.31989	0.588000	0.31090	0.996000	0.59523	2.470000	0.44777	0.599000	0.40250	1.026000	0.45946	20188929	C	.	rs752812448	.	.	.	.	10.295	9.602	.	.	.	-2	5	-5	-34	0.00	0.00	0.00	0.00	GJB2	0.00	exon-NM_004004.6-2+674+end+2134	585327	Uncertain_significance	reviewed_by_expert_panel	Nonsyndromic_genetic_hearing_loss	MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884	.	13:20763068-20763068	8.238e-06	1	1	0	0	0	0	0	1	0	0	9198	11480	8548	6614	63748	876	16388	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs752812448	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.81944e-05	0.00000e+00	0.00000e+00	7.46547e-06	9.11311e-06	1.81944e-05	8.12143e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs752812448	752812448	.	.	.	GJB2	GJB2:exonic	GJB2:missense	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,865	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36231821	36231821	G	C	C	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	6/9	.	NM_001754.5:c.563C>G	NP_001745.2:p.Thr188Ser	757	563	188	T/S	aCc/aGc	rs1343295642	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36231821G>C	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.93023	0.462212	D	0.92936	0.426159	24.0	23.5	3.258070	2.973346	0.57991	0.54127	G/G	D	0.69655	0.972321689128876	0.72921	0.99579587094310018	.	0.99990	.	G/G	.	.	.	.	7.226066	0.670002254653011	0.80106	6.328736	0.637566007391228	0.75566	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99452	.	.	.	5.11	5.11	0.69188	0	0.89359	0.724815	.	.	0.74766	0.999999999999999	.	0	0.30614	0.59043	.	.	.	.	.	.	0	0.83352	0.714379	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain	.	.	.	0.80559	.	0.000000	0.84330	D	0.000000	D	0.94153	0.440372	0.70112	.	0.96388	.	D	0.99388	0.9801	.	0.91821	.	D	0.98559	1.0688	T161S	Gain_of_relative_solvent_accessibility_(P_=_0.0215)&_Loss_of_phosphorylation_at_T161_(P_=_0.0382)&_Loss_of_sheet_(P_=_0.0457)&_Gain_of_solvent_accessibility_(P_=_0.0611)&_Gain_of_helix_(P_=_0.0854)	Q01196	0.86714	0.734	.	0.69758	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	1&0.999999&1&1&0.999999&1&1	0.71639	.	.	.	0.65571	.	.	0.74843	.	T	0.71750	0.731671452522	0.98041	.	10	0.45744	.	.	0.39575	.	.	16.0525	0.80578	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.86941	.	G/G	S	.	T	C	265	0.89590	.	21	C1832388	601399	.	Uncertain_significance	NC_000021.9:g.34859524G>C	532659	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:cf85a4a4-1e5d-4f72-b064-0a7bbcc1e78e	.	.	AEFBHCI	D	0.69051	0.96420	D	0.83598	0.895695	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35153691	21	36231821	0	0.73137	0.706548	1.000000	0.71638	0.968000	0.53726	0.997000	0.62031	9.994000	0.99266	0.676000	0.76740	1.176000	0.78918	34859524	G	.	rs1343295642	.	.	9.171	9.815	11.926	10.199	.	.	.	6	-10	-50	12	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-6+50+start+105	532659	Uncertain_significance	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1343295642	1343295642	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,962	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36259336	36259336	A	T	T	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	4/9	.	NM_001754.5:c.155T>A	NP_001745.2:p.Met52Lys	349	155	52	M/K	aTg/aAg	rs200431130&CM137027&COSV55868681	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	RUNX1	.	chr21:g.36259336A>T	.	.	.	.	.	.	uncertain_significance	0&0&1	1&1&1	.	.	.	.	.	RUNX1&NM_001001890.2&c.74T>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4	0.0010378827192527244	.	.	.	.	.	.	.	A/A	A	D	0.79892	0.263957	D	0.94198	0.479772	29.2	28.7	4.263127	4.113598	0.87307	0.86020	A/A	T	0.24243	0.281714648008347	0.44512	0.98673632126976341	.	0.94360	.	A/A	0	0.0	6	7.095553453169347E-4	6.053906	0.586113010993413	0.73942	6.096183	0.616573221681641	0.74222	.	.	.	24	2.015e-04	0	0	0	0	22	2.065e-04	0	0	0	0	22	3.791e-04	0	0	20	1.897e-04	0	0	0	0	18	1.868e-04	0	0	0	0	18	3.624e-04	0	0	22	2.486e-04	0	0	0	0	20	2.588e-04	0	0	0	0	20	5.849e-04	0	0	0.99368	.	.	.	5.04	5.04	0.67293	0	0.65289	0.672317	.	.	0.98316	1.0	.	2	0.06126	0.378051	.	.	.	.	.	.	0	0.06265	0.372554	.&.&.&.&.&.&.	.	.	.	0.89686	.	0.042539	0.84330	D	0.000000	D	0.99229	0.897774	0.93735	.	0.98649	.	D	0.99211	0.9747	.	0.73877	.	D	0.99130	1.0872	.	.	.	.	.	.	0.69568	.	.	0.58761	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	0.999998&0.999999&0.999998&0.999998&0.999999&0.999998&0.999998	0.78807	.	.	.	0.66517	.	.	0.75793	.	D	0.95803	0.894456982613	0.95175	.	10	0.66756	.	.	0.78490	.	.	14.7686	0.69280	1.0:0.0:0.0:0.0	.	1	2.6968716289104636E-4	5	6.612007405448294E-4	.	.	.	0.80375	.	A/A	K	.	M	T	188	0.92666	.	21	C0280788&C1832388&CN169374&CN517202	601399	ORPHA251646	Uncertain_significance	NC_000021.9:g.34887039A>T	239044	reviewed_by_expert_panel	Anaplastic_ependymoma&Familial_platelet_disorder_with_associated_myeloid_malignancy&not_specified&not_provided	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:4ceacdfa-56c1-4933-a48a-f8c97e4f92e9	.	.	AEFDGBHCI	D	0.58548	0.93559	D	0.68381	0.739169	.	60	2.579910e-04	0	0.000000e+00	14004	0	2	5.856170e-05	34152	0	232566	0	0.000000e+00	9794	0	0	0.000000e+00	17718	0	0	0.000000e+00	13544	0	56	5.228470e-04	107106	0	56	5.228470e-04	107106	0	0	0.000000e+00	30410	0	21	2.121170e-04	0	0.000000e+00	6682	0	0	0.000000e+00	16810	0	99002	0	0.000000e+00	2296	0	0	0.000000e+00	8554	0	0	0.000000e+00	5514	0	21	5.022720e-04	41810	0	21	5.022720e-04	41810	0	0	0.000000e+00	15518	0	0	.	0	57	2.570420e-04	0	0.000000e+00	13018	0	2	5.900750e-05	33894	0	221754	0	0.000000e+00	9456	0	0	0.000000e+00	17196	0	0	0.000000e+00	13532	0	53	5.358620e-04	98906	0	53	5.358620e-04	98906	0	0	0.000000e+00	30334	0	0	51	2.676240e-04	0	0.000000e+00	13970	0	1	3.322260e-05	30100	0	190566	0	0.000000e+00	5944	0	0	0.000000e+00	12744	0	0	0.000000e+00	8790	0	49	5.832080e-04	84018	0	49	5.832080e-04	84018	0	0	0.000000e+00	30404	0	0	58	2.554210e-04	0	0.000000e+00	10342	0	2	5.878890e-05	34020	0	227076	0	0.000000e+00	9740	0	0	0.000000e+00	17714	0	0	0.000000e+00	13542	0	54	5.116540e-04	105540	0	54	5.116540e-04	105540	0	0	0.000000e+00	30410	0	0	41	2.695030e-04	2	4.829280e-05	41414	0	0	0.000000e+00	912	0	0	0.000000e+00	15286	0	152132	0	0.000000e+00	3472	0	0	0.000000e+00	5188	0	0	0.000000e+00	10614	0	0	0.000000e+00	316	0	39	5.734620e-04	68008	0	39	5.734620e-04	68008	0	0	0.000000e+00	4828	0	2	6.080140e-05	0	0.000000e+00	9094	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32894	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	2	2.922270e-04	6844	0	0	0.000000e+00	3116	0	0	.	0	41	2.772440e-04	2	4.866890e-05	41094	0	0	0.000000e+00	912	0	0	0.000000e+00	15098	0	147884	0	0.000000e+00	3302	0	0	0.000000e+00	4954	0	0	0.000000e+00	10614	0	0	0.000000e+00	304	0	39	6.020000e-04	64784	0	0	0.000000e+00	4798	0	0	40	2.968640e-04	2	6.162190e-05	32456	0	0	0.000000e+00	862	0	0	0.000000e+00	14842	0	134742	0	0.000000e+00	3388	0	0	0.000000e+00	5188	0	0	0.000000e+00	6980	0	0	0.000000e+00	310	0	38	5.948100e-04	63886	0	0	0.000000e+00	4826	0	0	6	7.434580e-05	2	8.064520e-05	24800	0	0	0.000000e+00	112	0	0	0.000000e+00	12912	0	80704	0	0.000000e+00	998	0	0	0.000000e+00	3746	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	4	1.902770e-04	21022	0	0	0.000000e+00	4800	0	0	21	35181206	21	36259336	0	0.40530	0.627647	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	6.863000	0.75286	0.756000	0.94297	1.312000	0.94714	34887039	A	.	rs200431130	.	.	5.882	8.558	8.426	9.942	.	.	.	6	50	7	3	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-4+57+end+254	239044	Uncertain_significance	reviewed_by_expert_panel	not_specified&Hereditary_cancer-predisposing_syndrome&Anaplastic_ependymoma&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1&not_provided	MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0016700&MedGen:C0280788&Orphanet:251646&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290&MedGen:CN517202	.	21:36259336-36259336	2.015e-04	24	22	0	0	0	0	0	22	0	0	7446	10804	7862	5656	58038	762	15964	0	0	0	0	22	0	0	0	0	0	0	0	0	0	rs200431130	0.00000e+00	3.00210e-05	0.00000e+00	0.00000e+00	0.00000e+00	4.98946e-04	5.72301e-04	0.00000e+00	2.26022e-04	2.74925e-04	4.98946e-04	2.48746e-04	rs200431130	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.33645e-04	0.00000e+00	.	2.34055e-04	7.22543e-05	3.33645e-04	1.61332e-04	rs200431130	0.071&0.0&0.0469	rs200431130	200431130	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,986	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36259238	36259238	G	T	T	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	4/9	.	NM_001754.5:c.253C>A	NP_001745.2:p.His85Asn	447	253	85	H/N	Cac/Aac	rs121912500&COSV55869498	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36259238G>T	.	.	.	.	.	.	pathogenic&likely_benign	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.64552	0.102409	D	0.84638	0.229337	29.5	29.4	4.288959	4.194948	0.87959	0.88146	G/G	D	0.68800	0.97002124786377	0.53573	0.99142871517820708	.	0.99777	.	G/G	.	.	.	.	9.259637	0.76869870605038	0.87545	8.149119	0.765860266856948	0.83934	.	.	.	3	2.475e-05	0	0	0	0	3	2.585e-05	3	3.587e-04	0	0	0	0	0	0	3	2.827e-05	0	0	0	0	3	2.913e-05	3	3.921e-04	0	0	0	0	0	0	3	3.313e-05	0	0	0	0	3	3.486e-05	3	5.545e-04	0	0	0	0	0	0	0.99456	.	.	.	5.25	5.25	0.73169	0	0.08562	0.516746	.	.	0.98316	1.0	.	0	0.37721	0.606814	.	.	.	.	.	.	0	0.19341	0.56214	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain&Runt_domain&Runt_domain	.	.	.	0.85901	.	0.000000	0.84330	D	0.000000	D	0.99336	0.910916	0.89886	.	0.99451	.	D	0.99398	0.9804	.	0.86854	.	D	0.98897	1.0805	H58N	Loss_of_sheet_(P_=_3e-04)&_Gain_of_helix_(P_=_6e-04)&_Loss_of_loop_(P_=_0.0288)&_Gain_of_disorder_(P_=_0.1676)&_Gain_of_catalytic_residue_at_H58_(P_=_0.1716)	Q01196	0.79680	0.659	.	0.73725	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	A&A&A&A&A&A&A	1&1&1&1&1&1&1	0.90812	.	.	.	0.62824	.	.	0.83170	.	D	0.86477	0.829446315765	0.95433	.	10	0.83351	.	.	0.91255	.	.	18.832	0.92112	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.86297	.	G/G	N	.	H	T	188	0.92666	.	21	C1832388&C1835434&C1860788	601399	.	Likely_benign	NC_000021.9:g.34886941G>T	14469	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy&Leukemia&_acute_myeloid&_m0_subtype&Transient_myeloproliferative_disorder_of_Down_syndrome	OMIM_Allelic_Variant:151385.0008&ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:c3870801-0fcc-45c8-9383-0ae10065097d	.	.	ALL	D	0.94465	0.99321	D	0.92508	0.933329	.	9	3.639250e-05	0	0.000000e+00	15918	0	0	0.000000e+00	34414	0	247304	0	0.000000e+00	9980	0	8	4.395600e-04	18200	0	0	0.000000e+00	21322	0	1	9.021360e-06	110848	0	8	4.395600e-04	18200	0	0	0.000000e+00	30564	0	1	9.224410e-06	0	0.000000e+00	7014	0	0	0.000000e+00	16992	0	108408	0	0.000000e+00	2300	0	1	1.124100e-04	8896	0	0	0.000000e+00	13146	0	0	0.000000e+00	42514	0	1	1.124100e-04	8896	0	0	0.000000e+00	15656	0	0	.	0	9	3.843160e-05	0	0.000000e+00	14682	0	0	0.000000e+00	34112	0	234182	0	0.000000e+00	9530	0	8	4.561520e-04	17538	0	0	0.000000e+00	21308	0	1	9.904910e-06	100960	0	8	4.561520e-04	17538	0	0	0.000000e+00	30480	0	0	8	3.916120e-05	0	0.000000e+00	15880	0	0	0.000000e+00	30346	0	204284	0	0.000000e+00	6120	0	7	5.294210e-04	13222	0	0	0.000000e+00	16478	0	1	1.150930e-05	86886	0	7	5.294210e-04	13222	0	0	0.000000e+00	30556	0	0	9	3.737790e-05	0	0.000000e+00	11724	0	0	0.000000e+00	34282	0	240784	0	0.000000e+00	9900	0	8	4.396570e-04	18196	0	0	0.000000e+00	21320	0	1	9.189990e-06	108814	0	8	4.396570e-04	18196	0	0	0.000000e+00	30564	0	0	2	1.313890e-05	0	0.000000e+00	41452	0	0	0.000000e+00	912	0	0	0.000000e+00	15288	0	152220	0	0.000000e+00	3472	0	2	3.849110e-04	5196	0	0	0.000000e+00	10620	0	0	0.000000e+00	316	0	0	0.000000e+00	68036	0	2	3.849110e-04	5196	0	0	0.000000e+00	4836	0	0	0.000000e+00	0	0.000000e+00	9098	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32906	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5492	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3116	0	0	.	0	2	1.351640e-05	0	0.000000e+00	41132	0	0	0.000000e+00	912	0	0	0.000000e+00	15100	0	147968	0	0.000000e+00	3302	0	2	4.032260e-04	4960	0	0	0.000000e+00	10620	0	0	0.000000e+00	304	0	0	0.000000e+00	64812	0	0	0.000000e+00	4804	0	0	2	1.483530e-05	0	0.000000e+00	32486	0	0	0.000000e+00	862	0	0	0.000000e+00	14844	0	134814	0	0.000000e+00	3388	0	2	3.849110e-04	5196	0	0	0.000000e+00	6982	0	0	0.000000e+00	310	0	0	0.000000e+00	63910	0	0	0.000000e+00	4834	0	0	2	2.475980e-05	0	0.000000e+00	24826	0	0	0.000000e+00	112	0	0	0.000000e+00	12914	0	80776	0	0.000000e+00	998	0	2	5.327650e-04	3754	0	0	0.000000e+00	10528	0	0	0.000000e+00	272	0	0	0.000000e+00	21046	0	0	0.000000e+00	4808	0	0	21	35181108	21	36259238	1	0.06251	0.40479	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	9.415000	0.96676	0.676000	0.76740	1.176000	0.78918	34886941	G	.	rs121912500	.	.	5.882	8.558	8.426	9.942	.	.	.	-29	6	-14	17	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-4+98+start+254	14469	Likely_benign	reviewed_by_expert_panel	Transient_myeloproliferative_disorder_of_Down_syndrome&Leukemia&_acute_myeloid&_m0_subtype&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:C1860788&MedGen:C1835434&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	rs121912500	2.475e-05	3	3	0	0	0	3	0	0	0	0	9676	11208	8364	6156	63450	852	16332	0	0	3	0	0	0	0	0	0	0	0	0	0	0	rs121912500	0.00000e+00	0.00000e+00	0.00000e+00	4.08258e-04	0.00000e+00	9.15131e-06	0.00000e+00	0.00000e+00	4.48927e-05	1.83080e-05	4.08258e-04	3.24971e-05	rs121912500	0.00000e+00	0.00000e+00	0.00000e+00	6.16523e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	0.00000e+00	7.22335e-05	6.16523e-04	3.22706e-05	.	.	rs121912500	121912500	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,983	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36259177	36259177	T	G	G	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	4/9	.	NM_001754.5:c.314A>C	NP_001745.2:p.His105Pro	508	314	105	H/P	cAc/cCc	rs1569084116&COSV55878621	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	RUNX1	.	chr21:g.36259177T>G	.	.	.	.	.	.	uncertain_significance&likely_pathogenic	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.96288	0.562525	D	0.96229	0.570252	29.0	28.0	4.233637	4.035595	0.86480	0.83509	T/T	D	0.97759	0.999520778656006	0.40915	0.98386815746290868	.	0.99989	.	T/T	.	.	.	.	8.087648	0.71723071675822	0.83686	8.563862	0.78876211398582	0.85397	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99846	.	.	.	4.72	4.72	0.59248	0	0.08562	0.516746	.	.	0.98316	1.0	.	0	0.37721	0.606814	.	.	.	.	.	.	0	0.19341	0.56214	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain&Runt_domain&Runt_domain	.	.	.	0.95601	.	0.051672	0.84330	D	0.000000	D	0.99743	0.960678	0.93746	.	0.99895	.	D	0.99830	0.9928	.	0.98267	.	D	0.96247	0.9400	H78P	Gain_of_loop_(P_=_0.0166)&_Loss_of_helix_(P_=_0.0444)&_Gain_of_catalytic_residue_at_W79_(P_=_0.077)&_Gain_of_phosphorylation_at_T77_(P_=_0.1037)&_Gain_of_relative_solvent_accessibility_(P_=_0.1571)	Q01196	0.95829	0.861	.	0.82106	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	1&1&1&1&1&1&1	0.98224	.	.	.	0.90584	.	.	0.92359	.	D	0.83758	0.811739325523	0.99157	.	10	0.83351	.	.	0.78490	.	.	14.3606	0.66331	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.69825	.	T/T	P	.	H	G	188	0.92666	.	21	C1832388&CN517202	601399	.	Likely_pathogenic	NC_000021.9:g.34886880T>G	561233	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy&not_provided	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:42a3f999-4991-4180-8cb2-0e8975c5e5bb	.	.	ALL	D	0.66478	0.95863	D	0.97714	0.957763	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35181047	21	36259177	1	0.06251	0.40479	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	5.758000	0.68429	0.665000	0.62972	1.138000	0.64695	34886880	T	.	rs1569084116	.	.	5.882	8.558	8.426	9.942	.	.	.	-17	32	47	7	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-4+37+start+254	561233	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,981	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36259175	36259175	A	T	T	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	4/9	.	NM_001754.5:c.316T>A	NP_001745.2:p.Trp106Arg	510	316	106	W/R	Tgg/Agg	rs1555899735&COSV55876747	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	RUNX1	.	chr21:g.36259175A>T	.	.	.	.	.	.	likely_pathogenic&uncertain_significance	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.97674	0.602959	D	0.97638	0.628332	32	31	4.543505	4.315165	0.91585	0.90225	A/A	D	0.99782	0.999933123588562	0.74873	0.99611922627165905	.	0.99964	.	A/A	.	.	.	.	9.534826	0.779187244840433	0.88310	10.07622	0.860351125974975	0.89689	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99883	.	.	.	4.72	4.72	0.59248	0	0.08562	0.516746	.	.	0.98316	1.0	.	0	0.37721	0.606814	.	.	.	.	.	.	0	0.19341	0.56214	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain&Runt_domain&Runt_domain	.	.	.	0.97401	.	0.063541	0.62929	D	0.000002	D	0.99596	0.942606	0.95057	.	0.99847	.	D	0.99887	0.9950	.	0.99792	.	D	0.95644	0.8979	W79R	Gain_of_catalytic_residue_at_W79_(P_=_0.0295)&_Gain_of_phosphorylation_at_T77_(P_=_0.0629)&_Gain_of_methylation_at_K83_(P_=_0.1098)&_Gain_of_relative_solvent_accessibility_(P_=_0.1259)&_Gain_of_solvent_accessibility_(P_=_0.1319)	Q01196	0.99019	0.934	.	0.82106	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	1&1&1&1&1&1&1	0.99833	.	.	.	0.90584	.	.	0.97372	.	D	0.94204	0.881809771061	0.99783	.	10	0.92824	.	.	0.91255	.	.	14.3606	0.66331	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.94196	.	A/A	R	.	W	T	188	0.92666	.	21	C1832388&CN169374	601399	.	Likely_pathogenic	NC_000021.9:g.34886878A>T	436617	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy&not_specified	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:8f98e7f4-4645-4121-8da3-bcf507754b5c	.	.	ALL	D	0.70632	0.96730	D	0.90683	0.926157	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35181045	21	36259175	1	0.06251	0.40479	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	8.773000	0.91404	0.756000	0.94297	1.312000	0.94714	34886878	A	.	rs1555899735	.	gain/acceptor/36259175-36259176/Medium/6.459922	5.882	8.558	8.426	9.942	.	.	.	-2	-15	-1	49	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-4+35+start+254	436617	Likely_pathogenic	reviewed_by_expert_panel	not_specified&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN169374&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555899735	1555899735	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,980	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36259160	36259160	T	C	C	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	4/9	.	NM_001754.5:c.331A>G	NP_001745.2:p.Thr111Ala	525	331	111	T/A	Acc/Gcc	rs1555899722	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	RUNX1	.	chr21:g.36259160T>C	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.95176	0.530515	D	0.95105	0.524272	28.8	27.1	4.214237	3.929008	0.85901	0.79793	T/T	D	0.81382	0.991126477718353	0.45113	0.98715465726885065	.	0.99815	.	T/T	.	.	.	.	6.284925	0.604867720106672	0.75293	6.157907	0.622284269619696	0.74585	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99651	.	.	.	4.72	4.72	0.59248	0	0.08562	0.516746	.	.	0.98316	1.0	.	0	0.08637	0.503968	.	.	.	.	.	.	0	0.19341	0.56214	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain&Runt_domain&Runt_domain	.	.	.	0.85096	.	0.000000	0.84330	D	0.000000	D	0.99144	0.887272	0.88282	.	0.99590	.	D	0.99479	0.9829	.	0.89269	.	D	0.98012	1.0450	T84A	Gain_of_helix_(P_=_0.062)&_Gain_of_catalytic_residue_at_T84_(P_=_0.0852)&_Loss_of_methylation_at_K83_(P_=_0.1546)&_Gain_of_relative_solvent_accessibility_(P_=_0.1684)&_Gain_of_loop_(P_=_0.2754)	Q01196	0.75680	0.622	.	0.59869	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	1&1&1&1&1&0.999999&0.999999	0.79743	.	.	.	0.60036	.	.	0.74104	.	D	0.85255	0.821480810642	0.98672	.	10	0.79402	.	.	0.63226	.	.	14.3606	0.66331	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.86725	.	T/T	A	.	T	C	188	0.92666	.	21	C1832388	601399	.	Uncertain_significance	NC_000021.9:g.34886863T>C	532671	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:1823619f-a990-4590-a95b-0a7edb3671c1	.	.	ALL	D	0.64140	0.95288	D	0.83625	0.895819	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35181030	21	36259160	1	0.06251	0.40479	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	7.530000	0.80856	0.665000	0.62972	1.138000	0.64695	34886863	T	.	rs1555899722	.	.	5.882	8.558	8.426	9.942	.	.	.	-20	0	1	-20	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-4+20+start+254	532671	Uncertain_significance	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555899722	1555899722	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,978	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
13	20763150	20763150	A	G	G	missense_variant	MODERATE	GJB2	2706	Transcript	NM_004004.6	protein_coding	2/2	.	NM_004004.6:c.571T>C	NP_003995.2:p.Phe191Leu	749	571	191	F/L	Ttc/Ctc	rs397516878&CM030880	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	GJB2	.	chr13:g.20763150A>G	.	0	0	0.001	0	0	likely_benign&pathogenic&uncertain_significance	.	1&1	.	.	.	.	.	.	.	.	1	1.9968051118210862E-4	0	0.0	0	0.0	1	9.92063492063492E-4	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	A/A	A	D	0.74803	0.209723	D	0.95075	0.521692	29.6	27.7	4.298341	4.005706	0.88184	0.82509	A/A	T	0.29488	0.414558612815795	0.96742	0.99894206711308897	.	0.97756	.	A/A	.	.	.	.	10.73519	0.819782001033183	0.91132	10.46773	0.876793303251501	0.90577	.	.	.	18	1.483e-04	0	0	0	0	18	1.490e-04	18	2.085e-03	0	0	0	0	0	0	17	1.601e-04	0	0	0	0	17	1.605e-04	17	2.162e-03	0	0	0	0	0	0	6	6.611e-05	0	0	0	0	6	6.658e-05	6	1.068e-03	0	0	0	0	0	0	0.96562	.	.	.	5.65	5.65	0.86881	0	0.36545	0.588015	.	.	0.74766	0.999999999999998	.	0	0.30420	0.590023	.	.	.	.	.	.	0	0.10902	0.530356	Connexin&_N-terminal&Gap_junction_protein&_cysteine-rich_domain&Connexin&_N-terminal&Gap_junction_protein&_cysteine-rich_domain&Connexin&_N-terminal&Gap_junction_protein&_cysteine-rich_domain	.	.	.	0.61435	.	0.000000	0.84330	D	0.000000	D	0.92478	0.359605	0.32237	.	0.97603	.	D	0.98122	0.9427	.	0.74931	.	D	0.99226	1.0897	F191L	Gain_of_ubiquitination_at_K188_(P_=_0.115)&_Loss_of_sheet_(P_=_0.1158)&_Loss_of_catalytic_residue_at_F191_(P_=_0.116)&_Loss_of_helix_(P_=_0.3949)&_Loss_of_methylation_at_K188_(P_=_0.3971)	P29033	0.97130	0.886	.	0.92281	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.87531	.	.	.	0.90584	.	.	0.97372	.	D	0.84636	0.817449331284	0.98851	.	10	0.70582	.	.	0.61437	.	.	16.1778	0.81689	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.91852	.	A/A	L	.	F	G	682	0.59757	.	13	C2673759&C2675750&C3887873&CN169374&CN517202	220290&601544	.	Uncertain_significance	NC_000013.11:g.20189011A>G	44760	reviewed_by_expert_panel	Deafness&_autosomal_recessive_1A&Deafness&_autosomal_dominant_3a&Hearing_loss&not_specified&not_provided	UniProtKB_(protein):P29033#VAR_015461&ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:2536	.	.	AEFBCI	D	0.77425	0.97827	D	0.97130	0.954308	.	36	1.432120e-04	0	0.000000e+00	16250	0	0	0.000000e+00	34590	0	251376	0	0.000000e+00	10072	0	36	1.957160e-03	18394	0	0	0.000000e+00	21646	0	0	0.000000e+00	113674	0	36	1.957160e-03	18394	0	0	0.000000e+00	30616	0	22	2.010930e-04	0	0.000000e+00	7162	0	0	0.000000e+00	17112	0	109402	0	0.000000e+00	2320	0	22	2.432010e-03	9046	0	0	0.000000e+00	13392	0	0	0.000000e+00	42766	0	22	2.432010e-03	9046	0	0	0.000000e+00	15690	0	0	.	0	35	1.477500e-04	0	0.000000e+00	14900	0	0	0.000000e+00	34258	0	236886	0	0.000000e+00	9566	0	35	1.978300e-03	17692	0	0	0.000000e+00	21630	0	0	0.000000e+00	102696	0	35	1.978300e-03	17692	0	0	0.000000e+00	30526	0	0	21	1.009260e-04	0	0.000000e+00	16212	0	0	0.000000e+00	30522	0	208074	0	0.000000e+00	6208	0	21	1.565300e-03	13416	0	0	0.000000e+00	16732	0	0	0.000000e+00	89514	0	21	1.565300e-03	13416	0	0	0.000000e+00	30608	0	0	36	1.470840e-04	0	0.000000e+00	12020	0	0	0.000000e+00	34456	0	244758	0	0.000000e+00	9990	0	36	1.957590e-03	18390	0	0	0.000000e+00	21644	0	0	0.000000e+00	111584	0	36	1.957590e-03	18390	0	0	0.000000e+00	30616	0	0	6	3.942390e-05	0	0.000000e+00	41442	0	0	0.000000e+00	912	0	0	0.000000e+00	15284	0	152192	0	0.000000e+00	3470	0	6	1.154290e-03	5198	0	0	0.000000e+00	10624	0	0	0.000000e+00	316	0	0	0.000000e+00	68030	0	6	1.154290e-03	5198	0	0	0.000000e+00	4828	0	2	6.080510e-05	0	0.000000e+00	9096	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32892	0	0.000000e+00	136	0	2	8.237230e-04	2428	0	0	0.000000e+00	5492	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3108	0	0	.	0	6	4.055590e-05	0	0.000000e+00	41120	0	0	0.000000e+00	912	0	0	0.000000e+00	15096	0	147944	0	0.000000e+00	3302	0	6	1.209190e-03	4962	0	0	0.000000e+00	10624	0	0	0.000000e+00	304	0	0	0.000000e+00	64810	0	0	0.000000e+00	4796	0	0	6	4.451300e-05	0	0.000000e+00	32480	0	0	0.000000e+00	862	0	0	0.000000e+00	14838	0	134792	0	0.000000e+00	3386	0	6	1.154290e-03	5198	0	0	0.000000e+00	6982	0	0	0.000000e+00	310	0	0	0.000000e+00	63912	0	0	0.000000e+00	4826	0	0	3	3.715260e-05	0	0.000000e+00	24818	0	0	0.000000e+00	112	0	0	0.000000e+00	12910	0	80748	0	0.000000e+00	996	0	3	7.987220e-04	3756	0	0	0.000000e+00	10532	0	0	0.000000e+00	272	0	0	0.000000e+00	21038	0	0	0.000000e+00	4800	0	0	13	19661150	13	20763150	0	0.22868	0.549168	1.000000	0.71638	0.974000	0.55675	0.997000	0.62031	9.268000	0.94851	0.756000	0.94297	1.312000	0.94714	20189011	A	.	rs397516878	.	.	.	.	10.295	9.602	.	.	.	-22	-7	-47	-7	0.00	0.00	0.00	0.00	GJB2	0.00	exon-NM_004004.6-2+592+end+2134	44760	Uncertain_significance	reviewed_by_expert_panel	not_specified&Hearing_loss&not_provided&Autosomal_dominant_nonsyndromic_hearing_loss_3A&Autosomal_recessive_nonsyndromic_hearing_loss_1A&Mutilating_keratoderma&Ichthyosis&_hystrix-like&_with_hearing_loss&Knuckle_pads&_deafness_AND_leukonychia_syndrome&Autosomal_dominant_keratitis-ichthyosis-hearing_loss_syndrome&Palmoplantar_keratoderma-deafness_syndrome&X-linked_mixed_hearing_loss_with_perilymphatic_gusher	MedGen:CN169374&MedGen:C3887873&MedGen:CN517202&MONDO:MONDO:0011103&MedGen:C2675750&OMIM:601544&Orphanet:90635&MONDO:MONDO:0009076&MedGen:C2673759&OMIM:220290&Orphanet:90636&MONDO:MONDO:0007422&MedGen:C0265964&OMIM:124500&Orphanet:494&MONDO:MONDO:0011245&MedGen:C1865234&OMIM:602540&Orphanet:477&MONDO:MONDO:0007866&MedGen:C0266004&OMIM:149200&Orphanet:2698&MONDO:MONDO:0007850&MedGen:C0265336&OMIM:148210&Orphanet:477&MONDO:MONDO:0007852&MedGen:C1835672&OMIM:148350&Orphanet:2202&MONDO:MONDO:0010576&MedGen:C1844678&OMIM:304400&Orphanet:383	.	13:20763150-20763150	1.483e-04	18	18	0	0	0	18	0	0	0	0	10252	11544	8634	6614	66344	902	16486	0	0	18	0	0	0	0	0	0	0	0	0	0	0	rs397516878	0.00000e+00	0.00000e+00	0.00000e+00	2.02922e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.03807e-04	1.88662e-04	2.02922e-03	1.42119e-04	rs397516878	0.00000e+00	0.00000e+00	0.00000e+00	6.16523e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84249e-05	0.00000e+00	6.16523e-04	3.22664e-05	.	.	rs397516878	397516878	.	.	.	GJB2	GJB2:exonic	GJB2:missense	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,866	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36252860	36252860	C	T	T	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	5/9	.	NM_001754.5:c.502G>A	NP_001745.2:p.Gly168Arg	696	502	168	G/R	Gga/Aga	rs1569078784&COSV55875040&COSV55877665&COSV55895512	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36252860C>T	.	.	.	.	.	.	uncertain_significance	0&1&1&1	1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.96026	0.55625	D	0.95964	0.561238	29.3	32	4.263436	4.414234	0.87307	0.91241	C/C	D	0.96192	0.999101042747498	0.98787	0.99921252150338957	.	0.99984	.	C/C	.	.	.	.	11.86139	0.852456069475642	0.93158	11.58429	0.92017616390052	0.92712	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99793	.	.	.	5.18	5.18	0.71140	0	0.59785	0.653731	.	.	0.98316	1.0	.	0	0.28860	0.577349	.	.	.	.	.	.	0	0.98432	0.735409	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain	.	.	.	0.98622	.	0.053013	0.84330	N	0.000000	D	0.98023	0.751918	0.90943	.	0.96479	.	D	0.99817	0.9924	.	0.92379	.	D	0.96690	0.9693	G141R	Loss_of_sheet_(P_=_0.0025)&_Gain_of_loop_(P_=_0.0079)&_Gain_of_methylation_at_G141_(P_=_0.0189)&_Gain_of_MoRF_binding_(P_=_0.0561)&_Loss_of_relative_solvent_accessibility_(P_=_0.0676)	Q01196	0.82836	0.691	.	0.84121	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	1&1&1&1&1&1&1	0.95216	.	.	.	0.90584	.	.	0.97372	.	D	0.95574	0.892550468445	0.98955	.	10	0.92824	.	.	0.78490	.	.	19.051	0.93028	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.98268	.	C/C	R	.	G	T	190	0.92594	.	21	C1832388&CN517202	601399	.	Uncertain_significance	NC_000021.9:g.34880563C>T	561243	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy&not_provided	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:d6e9b950-bdb2-405a-b288-176c8db7a1c5	.	.	AEFDGBI	D	0.87654	0.98848	D	0.84631	0.900595	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35174730	21	36252860	0	0.85440	0.722319	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	7.568000	0.81546	0.596000	0.33519	1.022000	0.39869	34880563	C	.	rs1569078784	.	.	11.926	10.199	5.882	8.558	.	.	.	17	16	17	-6	0.00	0.00	0.01	0.00	RUNX1	0.45	exon-NM_001754.5-5+6+start+157	561243	Uncertain_significance	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,966	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36231852	36231852	T	G	G	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	6/9	.	NM_001754.5:c.532A>C	NP_001745.2:p.Thr178Pro	726	532	178	T/P	Act/Cct	rs1569061931	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	RUNX1	.	chr21:g.36231852T>G	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.96049	0.557558	D	0.95988	0.563117	29.0	26.8	4.238282	3.887039	0.86610	0.78339	T/T	D	0.87048	0.995229291388984	0.79043	0.99677745145470609	.	0.99973	.	T/T	.	.	.	.	9.20577	0.766588261159959	0.87392	9.311905	0.8260612316971	0.87707	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99477	.	.	.	5.11	5.11	0.69188	0	0.59785	0.653731	.	.	0.74766	0.999999999999398	.	0	0.30614	0.59043	.	.	.	.	.	.	0	0.83352	0.714379	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain	.	.	.	0.89155	.	0.000000	0.84330	D	0.000000	D	0.98424	0.798729	0.91441	.	0.97460	.	D	0.99463	0.9824	.	0.92578	.	D	0.98227	1.0551	T151P	Loss_of_MoRF_binding_(P_=_0.0696)&_Gain_of_glycosylation_at_T154_(P_=_0.1087)&_Loss_of_stability_(P_=_0.1094)&_Gain_of_relative_solvent_accessibility_(P_=_0.1259)&_Loss_of_sheet_(P_=_0.1907)	Q01196	0.86105	0.727	.	0.77224	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	1&1&1&1&1&1&1	0.87611	.	.	.	0.77913	.	.	0.88582	.	D	0.91973	0.865871071815	0.99671	.	10	0.79402	.	.	0.91255	.	.	12.8771	0.57385	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.68777	.	T/T	P	.	T	G	265	0.89590	.	21	C1832388&CN517202	601399	.	Uncertain_significance	NC_000021.9:g.34859555T>G	561246	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy&not_provided	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:c1eaabe2-0120-42d8-8111-750503fe2b65	.	.	AEFBHCI	D	0.60157	0.94115	D	0.97051	0.953867	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35153722	21	36231852	0	0.73137	0.706548	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	8.011000	0.88184	0.665000	0.62972	1.138000	0.64695	34859555	T	.	rs1569061931	.	.	9.171	9.815	11.926	10.199	.	.	.	-25	23	23	-19	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-6+23+end+105	561246	Uncertain_significance	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,964	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
21	36252971	36252971	T	C	C	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	5/9	.	NM_001754.5:c.391A>G	NP_001745.2:p.Thr131Ala	585	391	131	T/A	Act/Gct	rs1555898641	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	RUNX1	.	chr21:g.36252971T>C	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.94398	0.504131	D	0.94319	0.486373	26.9	25.7	3.991340	3.681396	0.78306	0.71925	T/T	D	0.84023	0.993282318115234	0.87131	0.99784562615105932	.	0.99970	.	T/T	.	.	.	.	8.247157	0.72498710519987	0.84276	7.817421	0.746226195935317	0.82657	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99508	.	.	.	5.31	5.31	0.75063	0	0.89359	0.724815	.	.	0.74766	0.999999999874132	.	0	0.28860	0.577349	.	.	.	.	.	.	0	0.98432	0.735409	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain&Runt_domain&Runt_domain	.	.	.	0.75346	.	0.000000	0.84330	D	0.000000	D	0.96840	0.631844	0.88377	.	0.98276	.	D	0.99524	0.9843	.	0.85318	.	D	0.97945	1.0417	T104A	Loss_of_glycosylation_at_T104_(P_=_0.0452)&_Loss_of_disorder_(P_=_0.2696)&_Loss_of_sheet_(P_=_0.302)&_Gain_of_catalytic_residue_at_T104_(P_=_0.3246)&_Gain_of_phosphorylation_at_T101_(P_=_0.5688)	Q01196	0.63102	0.526	.	0.79425	.	.	0.58761	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	0.999997&0.999988&0.999997&0.999997&0.999988&0.999997&0.999997	0.78807	.	.	.	0.66517	.	.	0.75477	.	D	0.95086	0.888614058495	0.98780	.	10	0.83351	.	.	0.78490	.	.	15.5565	0.75939	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.92667	.	T/T	A	.	T	C	190	0.92594	.	21	C1832388	601399	.	Uncertain_significance	NC_000021.9:g.34880674T>C	463994	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:1030c6f6-46f9-4881-bc0c-32d4bcfd2b33	.	.	AEFDGBI	D	0.82460	0.98407	D	0.75137	0.833117	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35174841	21	36252971	0	0.85440	0.722319	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	7.674000	0.83146	0.665000	0.62972	1.138000	0.64695	34880674	T	.	rs1555898641	.	.	11.926	10.199	5.882	8.558	.	.	.	39	47	14	39	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-5+39+end+157	463994	Uncertain_significance	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555898641	1555898641	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,972	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
13	20763614	20763614	A	G	G	missense_variant	MODERATE	GJB2	2706	Transcript	NM_004004.6	protein_coding	2/2	.	NM_004004.6:c.107T>C	NP_003995.2:p.Leu36Pro	285	107	36	L/P	cTc/cCc	rs587783644&CM065234	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	GJB2	.	chr13:g.20763614A>G	.	.	.	.	.	.	pathogenic&uncertain_significance	.	1&1	.	.	.	.	.	GJB2&NM_004004.5&c.107T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.91276	0.424966	D	0.95761	0.554186	25.7	25.0	3.770993	3.503926	0.71348	0.67209	A/A	D	0.84301	0.993482768535614	0.95244	0.99875532145906221	.	0.98977	.	A/A	.	.	.	.	7.831995	0.70420636723978	0.82698	9.168568	0.819251336942519	0.87292	.	.	.	2	1.647e-05	1	9.610e-05	0	0	2	1.648e-05	1	1.156e-04	0	0	0	0	0	0	2	1.883e-05	1	1.103e-04	0	0	2	1.884e-05	1	1.271e-04	0	0	0	0	0	0	1	1.102e-05	1	9.626e-05	0	0	1	1.103e-05	0	0	0	0	0	0	0	0	0.99268	.	.	.	5.21	5.21	0.72005	0	0.52368	0.61073	.	.	0.98316	1.0	.	0	0.40942	0.61531	.	.	.	.	.	.	0	0.10902	0.530356	Connexin&_N-terminal&Connexin&_N-terminal&Connexin&_N-terminal	.	.	.	0.81587	.	0.000000	0.62929	D	0.000004	D	0.97019	0.64834	0.35668	.	0.87510	.	D	0.99488	0.9832	.	0.95347	.	D	0.97979	1.0434	.	.	.	.	.	.	0.91563	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.78636	.	.	.	0.90584	.	.	0.97372	.	D	0.82589	0.804106771946	0.98886	.	10	0.92824	.	.	0.78490	.	.	15.379	0.74355	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.97426	.	A/A	P	.	L	G	682	0.59757	.	13	C1384666&CN043648&CN169374	.	ORPHA87884	Uncertain_significance	NC_000013.11:g.20189475A>G	158604	reviewed_by_expert_panel	Hearing_impairment&Nonsyndromic_hearing_loss_and_deafness&not_specified	.	.	.	AEFDBHCI	D	0.77043	0.97775	D	0.99578	0.974754	.	2	7.972130e-06	1	6.151570e-05	16256	0	0	0.000000e+00	34578	0	250874	0	0.000000e+00	10064	0	1	5.436560e-05	18394	0	0	0.000000e+00	21626	0	0	0.000000e+00	113218	0	1	6.151570e-05	16256	0	0	0.000000e+00	30612	0	1	9.141770e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17104	0	109388	0	0.000000e+00	2318	0	1	1.105460e-04	9046	0	0	0.000000e+00	13392	0	0	0.000000e+00	42762	0	1	1.105460e-04	9046	0	0	0.000000e+00	15690	0	0	.	0	2	8.462460e-06	1	6.710510e-05	14902	0	0	0.000000e+00	34246	0	236338	0	0.000000e+00	9556	0	1	5.652270e-05	17692	0	0	0.000000e+00	21610	0	0	0.000000e+00	102204	0	1	6.710510e-05	14902	0	0	0.000000e+00	30522	0	0	1	4.815700e-06	1	6.165990e-05	16218	0	0	0.000000e+00	30510	0	207654	0	0.000000e+00	6206	0	0	0.000000e+00	13416	0	0	0.000000e+00	16732	0	0	0.000000e+00	89110	0	1	6.165990e-05	16218	0	0	0.000000e+00	30604	0	0	2	8.188130e-06	1	8.315320e-05	12026	0	0	0.000000e+00	34444	0	244256	0	0.000000e+00	9982	0	1	5.437740e-05	18390	0	0	0.000000e+00	21624	0	0	0.000000e+00	111128	0	1	8.315320e-05	12026	0	0	0.000000e+00	30612	0	0	5	3.285320e-05	2	4.825790e-05	41444	0	0	0.000000e+00	912	0	2	1.308390e-04	15286	0	152192	0	0.000000e+00	3472	0	1	1.928270e-04	5186	0	0	0.000000e+00	10612	0	0	0.000000e+00	316	0	0	0.000000e+00	68042	0	1	1.928270e-04	5186	0	0	0.000000e+00	4830	0	1	3.039140e-05	0	0.000000e+00	9100	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32904	0	0.000000e+00	136	0	1	4.115230e-04	2430	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3110	0	0	.	0	5	3.379840e-05	2	4.863580e-05	41122	0	0	0.000000e+00	912	0	2	1.324680e-04	15098	0	147936	0	0.000000e+00	3302	0	1	2.020200e-04	4950	0	0	0.000000e+00	10612	0	0	0.000000e+00	304	0	0	0.000000e+00	64814	0	0	0.000000e+00	4798	0	0	5	3.709640e-05	2	6.158770e-05	32474	0	0	0.000000e+00	862	0	2	1.347710e-04	14840	0	134784	0	0.000000e+00	3388	0	1	1.928270e-04	5186	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	0	0.000000e+00	63918	0	0	0.000000e+00	4828	0	0	4	4.953560e-05	1	4.029010e-05	24820	0	0	0.000000e+00	112	0	2	1.548950e-04	12912	0	80750	0	0.000000e+00	998	0	1	2.670940e-04	3744	0	0	0.000000e+00	10520	0	0	0.000000e+00	272	0	0	0.000000e+00	21052	0	0	0.000000e+00	4802	0	0	13	19661614	13	20763614	0	0.22052	0.533608	1.000000	0.71638	0.228000	0.22680	0.799000	0.33476	7.405000	0.79236	0.756000	0.94297	1.312000	0.94714	20189475	A	.	rs587783644	.	.	.	.	10.295	9.602	.	.	.	-20	-17	-1	-19	0.00	0.00	0.00	0.00	GJB2	0.00	exon-NM_004004.6-2+128+end+2134	158604	Uncertain_significance	reviewed_by_expert_panel	Nonsyndromic_genetic_hearing_loss&not_provided&not_specified&Hearing_impairment	MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN517202&MedGen:CN169374&Human_Phenotype_Ontology:HP:0000365&Human_Phenotype_Ontology:HP:0000404&Human_Phenotype_Ontology:HP:0001728&Human_Phenotype_Ontology:HP:0001729&Human_Phenotype_Ontology:HP:0001754&Human_Phenotype_Ontology:HP:0008560&Human_Phenotype_Ontology:HP:0008563&MONDO:MONDO:0005365&MedGen:C1384666	.	13:20763614-20763614	1.647e-05	2	2	0	1	0	1	0	0	0	0	10406	11578	8654	6614	66688	908	16500	1	0	1	0	0	0	0	0	0	0	0	0	0	0	rs398123815	6.53424e-05	0.00000e+00	0.00000e+00	5.79777e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.48582e-05	0.00000e+00	6.53424e-05	8.12110e-06	rs398123815	0.00000e+00	0.00000e+00	0.00000e+00	6.16523e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	0.00000e+00	7.21709e-05	6.16523e-04	3.22664e-05	.	.	rs587783644	587783644	.	.	.	GJB2	GJB2:exonic	GJB2:missense	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,869	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.8121	VUS
12	103288653	103288653	C	CGAGAAG	GAGAAG	inframe_insertion	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.206_211dup	NP_000268.1:p.Pro69_Ser70dup	325-326	211-212	71	R/PSR	cgt/cCTTCTCgt	rs281865431	.	.	-1	.	.	EntrezGene	.	.	.	.	.	.	.	.	PAH	.	chr12:g.103288655_103288660dup	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.038	10.766	11.785	7.700	.	.	.	.	.	.	.	.	.	.	.	.	0.00	exon-NM_001354304.2-4+43+end+184	120271	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865431	281865431	.	.	.	PAH	PAH:exonic	PAH:nonframeshift_insertion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,816	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	89717676	89717676	G	A	A	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	7/9	.	NM_000314.8:c.701G>A	NP_000305.3:p.Arg234Gln	1546	701	234	R/Q	cGg/cAg	rs121909235&CM023439&COSV64293247	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89717676G>A	.	.	.	.	.	.	risk_factor&pathogenic&uncertain_significance	0&0&1	1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.701G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.89079	0.385857	D	0.88941	0.31648	25.6	25.5	3.750947	3.630103	0.70771	0.70503	G/G	D	0.76143	0.98502117395401	0.99944	0.99951439750494697	.	0.91246	.	G/G	.	.	.	.	7.681699	0.69620027350318	0.82090	6.830664	0.678658239265102	0.78232	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.85247	.	.	.	5.15	5.15	0.70287	0	0.82719	0.723133	.	.	0.74766	0.999999999994827	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.49550	0.631631	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	0.91859	.	0.000000	0.84330	D	0.000000	D	0.88562	0.237853	0.83701	.	0.97429	.	D	0.87037	0.6305	.	0.78112	.	D	0.87020	0.2668	R234Q	Loss_of_sheet_(P_=_0.0181)&_Loss_of_phosphorylation_at_T232_(P_=_0.0952)&_Gain_of_loop_(P_=_0.1069)&_Loss_of_methylation_at_K237_(P_=_0.138)&_Loss_of_glycosylation_at_P231_(P_=_0.1657)	P60484	0.49634	0.441	.	0.81254	.	.	0.81001	simple_aae	D	1	0.39692	.	.	.	0.59353	.	.	0.51308	.	T	0.63280	0.673096895218	0.89053	.	9	0.33219	.	.	0.31383	.	.	18.6161	0.91258	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.96072	.	G/G	Q	.	R	A	908	0.22609	.	10	C0025286&C2751642&C0027672&C1959582&CN169374&CN517202	613028	ORPHA2495&ORPHA140162&ORPHA306498	Uncertain_significance	NC_000010.11:g.87957919G>A	7840	reviewed_by_expert_panel	Meningioma&Glioma_susceptibility_2&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_specified&not_provided	UniProtKB_(protein):P60484#VAR_018106&OMIM_Allelic_Variant:601728.0029&ClinGen_PTEN_Variant_Curation_Expert_Panel:5fe899fa-c13c-4145-9397-0b200e380e4c	.	.	AEFDGBI	D	0.85175	0.98653	D	0.96214	0.949467	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89707656	10	89717676	0	0.83141	0.719381	1.000000	0.71638	0.997000	0.79791	0.999000	0.70432	9.525000	0.97093	0.618000	0.50648	0.221000	0.24433	87957919	G	.	rs121909235	.	.	12.930	7.806	6.460	9.066	.	.	.	2	-12	-38	15	0.00	0.09	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-8+66+start+167	7840	Uncertain_significance	reviewed_by_expert_panel	not_specified&Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome&Meningioma&Glioma_susceptibility_2	MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&Human_Phenotype_Ontology:HP:0002858&Human_Phenotype_Ontology:HP:0006754&MONDO:MONDO:0016642&MedGen:C0025286&Orphanet:2495&MONDO:MONDO:0013092&MedGen:C2751642&OMIM:613028&Orphanet:182067	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909235	121909235	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,574	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
10	112724635	112724635	G	A	A	missense_variant	MODERATE	SHOC2	8036	Transcript	NM_007373.4	protein_coding	2/9	.	NM_007373.4:c.519G>A	NP_031399.2:p.Met173Ile	807	519	173	M/I	atG/atA	rs730881020&CM1411129	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	SHOC2	.	chr10:g.112724635G>A	.	.	.	.	.	.	pathogenic&uncertain_significance	.	1&1	.	.	.	.	.	SHOC2&NM_007373.3&c.519G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	T	0.51345	-0.00224761	T	0.50701	-0.241005	23.0	17.09	2.779719	1.638717	0.47303	0.26156	G/G	D	0.49306	0.839739322662354	0.22446	0.92893898368745065	.	0.41739	.	G/G	.	.	.	.	1.825313	-0.183672428865072	0.32136	1.33685	-0.421377321128356	0.24721	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.56609	.	.	.	5.79	4.89	0.63387	0	0.89359	0.724815	.	.	0.74766	0.999999999987283	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.83352	0.714379	.&.&.	.	.	.	0.87416	.	0.122266	0.84330	D	0.000000	D	0.98462	0.803306	0.52270	.	0.44903	.	T	0.26772	0.0647	.	0.60409	.	T	0.11483	-1.0611	M173I	Loss_of_catalytic_residue_at_M173_(P_=_0.0094)&_Loss_of_disorder_(P_=_0.0563)&_Loss_of_ubiquitination_at_K170_(P_=_0.0755)&_Gain_of_MoRF_binding_(P_=_0.1431)&_Gain_of_helix_(P_=_0.1736)	Q9UQ13	0.29408	0.317	.	0.04575	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.05217	.	.	.	0.26825	.	.	0.27082	.	D	0.93141	0.87403857708	0.92170	.	10	0.26467	.	.	0.34444	.	.	14.8233	0.69720	0.0687:0.0:0.9312:0.0	.	.	.	.	.	.	.	.	0.87265	.	G/G	I	.	M	A	916	0.20744	.	10	C0455988&CN166718&C4478716&C0950123&CN169374&CN517202	236750&607721	ORPHA363999&ORPHA536391	Uncertain_significance	NC_000010.11:g.110964877G>A	181528	reviewed_by_expert_panel	Non-immune_hydrops_fetalis&Rasopathy&Noonan_syndrome-like_disorder_with_loose_anagen_hair_1&Inborn_genetic_diseases&not_specified&not_provided	UniProtKB_(protein):Q9UQ13#VAR_074030&OMIM_Allelic_Variant:602775.0002&ClinGen_RASopathy_Variant_Curation_Expert_Panel:6b6330b2-05be-48be-a7e9-3e8e77d8e63b	.	.	AEFBI	D	0.88807	0.98932	D	0.81105	0.882716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	112714625	10	112724635	0	0.73137	0.706548	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	10.003000	0.99689	0.672000	0.70159	1.172000	0.72986	110964877	G	.	rs730881020	.	.	7.357	8.846	9.854	7.528	.	.	.	-8	-39	11	44	0.00	0.00	0.00	0.00	SHOC2	0.99	exon-NM_001324336.2-2+184+end+937	181528	Uncertain_significance	reviewed_by_expert_panel	Inborn_genetic_diseases&Cardiovascular_phenotype&not_specified&not_provided&RASopathy&Non-immune_hydrops_fetalis&Noonan_syndrome-like_disorder_with_loose_anagen_hair_1&See_cases	MeSH:D030342&MedGen:C0950123&MedGen:CN230736&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&Human_Phenotype_Ontology:HP:0001790&MONDO:MONDO:0009369&MedGen:C0455988&OMIM:236750&Orphanet:363999&MONDO:MONDO:0054637&MedGen:C4478716&OMIM:607721&Orphanet:2701&.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs730881020	730881020	.	.	.	SHOC2	SHOC2:exonic	SHOC2:missense	SHOC2:Noonan_syndrome-like_with_loose_anagen_hair_1	SHOC2:607721	SHOC2:3	SHOC2:Autosomal_dominant	0	0.991705191552454	0.00829295945769003	1.84898985615785e-06	DISEASE: Noonan syndrome-like disorder with loose anagen hair (NSLH) [MIM:607721]: A syndrome characterized by Noonan dysmorphic features such as macrocephaly, high forehead, hypertelorism, palpebral ptosis, low-set and posteriorly rotated ears, short and webbed neck, pectus anomalies, in association with pluckable, sparse, thin and slow-growing hair. {ECO:0000269|PubMed:19684605, ECO:0000269|PubMed:25137548}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,603	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
10	89725066	89725069	CAGT	C	-	inframe_deletion	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	9/9	.	NM_000314.8:c.1052_1054del	NP_000305.3:p.Val351del	1895-1897	1050-1052	350-351	TV/T	acAGTa/aca	rs587780003	AGT	.	1	.	.	EntrezGene	.	.	.	.	AGT	TAG	.	.	PTEN	2	chr10:g.89725069_89725071del	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.857	8.679	.	.	.	-23	2	24	42	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-10+23+start+6644	127687	Uncertain_significance	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587780003	587780003	chr9:33674357	0.98265	0.97956	PTEN	PTEN:exonic	PTEN:nonframeshift_deletion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,593	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	89720763	89720763	G	A	A	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	8/9	.	NM_000314.8:c.914G>A	NP_000305.3:p.Ser305Asn	1759	914	305	S/N	aGt/aAt	rs587780007&COSV64290110	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89720763G>A	.	.	.	.	.	.	uncertain_significance	0&1	1&1	.	.	.	.	.	PTEN&NM_000314.4&c.914G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	T	0.50246	-0.0101422	T	0.49585	-0.252345	22.4	22.0	2.491593	2.299305	0.41058	0.39294	./.	D	0.44351	0.768527328968048	0.48001	0.98891328966818037	.	0.88743	.	./.	.	.	.	.	3.418108	0.246183657011378	0.52433	2.779263	0.0725329049794074	0.45184	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.94508	.	.	.	5.13	5.13	0.69729	0	0.89359	0.724815	.	.	0.74766	0.999999339353456	.	0	0.96076	0.743671	.	.	.	.	.	.	0	0.50027	0.635259	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	0.46793	.	0.326575	0.39242	N	0.001378	D	0.78965	0.111758	0.77570	.	0.84584	.	D	0.91320	0.7456	.	0.51528	.	D	0.87492	0.2959	S305N	Loss_of_phosphorylation_at_S305_(P_=_0.0302)&_Loss_of_disorder_(P_=_0.139)&_Gain_of_helix_(P_=_0.1736)&_Gain_of_loop_(P_=_0.2045)&_Loss_of_catalytic_residue_at_S302_(P_=_0.3576)	P60484	0.35396	0.354	.	0.62545	.	.	0.47795	simple_aae	D	0.999603	0.09460	.	.	.	0.02946	.	.	0.06944	.	T	0.63653	0.675698876381	0.57741	.	9	0.30143	.	.	0.18246	.	.	18.5632	0.91063	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.60156	.	./.	N	.	S	A	900	0.24599	.	10	C0376358&CN072330&C1848599&C1854416&C3551915&C2751642&C0027672&C1959582&CN169374&CN517202	176807&158350&276950&605309&607174&613028	ORPHA3412&ORPHA210548&ORPHA140162&ORPHA306498	Uncertain_significance	NC_000010.11:g.87961006G>A	127696	reviewed_by_expert_panel	Malignant_tumor_of_prostate&Cowden_syndrome_1&VACTERL_association_with_hydrocephalus&Macrocephaly/autism_syndrome&Meningioma&_familial&Glioma_susceptibility_2&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_specified&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:59aacee3-4abf-400b-9713-4c28e3258b75	.	.	AEFGBI	D	0.85696	0.98696	D	0.73971	0.818464	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89710743	10	89720763	0	0.92422	0.732398	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	5.663000	0.67708	0.618000	0.50648	1.176000	0.78918	87961006	G	.	rs587780007	.	.	11.857	8.679	12.930	7.806	.	.	.	6	1	-47	-1	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-9+112+start_end+225	127696	Uncertain_significance	reviewed_by_expert_panel	Malignant_tumor_of_prostate&VACTERL_with_hydrocephalus&Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome&Familial_meningioma&Macrocephaly-autism_syndrome&Glioma_susceptibility_2&not_provided&Hereditary_cancer-predisposing_syndrome	Human_Phenotype_Ontology:HP:0012125&MONDO:MONDO:0008315&MedGen:C0376358&OMIM:176807&Orphanet:1331&MONDO:MONDO:0010172&MedGen:C1848599&OMIM:276950&Orphanet:3412&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0011789&MedGen:C3551915&OMIM:607174&Orphanet:263662&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548&MONDO:MONDO:0013092&MedGen:C2751642&OMIM:613028&Orphanet:182067&MedGen:CN517202&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587780007	587780007	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,587	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
10	89717697	89717697	T	C	C	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	7/9	.	NM_000314.8:c.722T>C	NP_000305.3:p.Phe241Ser	1567	722	241	F/S	tTt/tCt	rs121909240&CM051215&COSV64294827	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89717697T>C	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&0&1	1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.722T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.90660	0.413248	D	0.90545	0.355825	23.8	23.5	3.177422	2.982865	0.56055	0.54346	./.	D	0.67547	0.966324150562286	0.58255	0.9929067386349637	.	0.98206	.	./.	.	.	.	.	3.605272	0.280495422978349	0.54403	3.048833	0.140345149515694	0.48353	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.85943	.	.	.	5.15	5.15	0.70287	0	0.82719	0.723133	.	.	0.74766	0.999999996024359	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.49550	0.631631	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	0.47570	.	0.047819	0.84330	D	0.000000	D	0.91214	0.312018	0.92959	.	0.97757	.	D	0.82786	0.5349	.	0.85560	.	D	0.82405	0.0073	F241S	Loss_of_sheet_(P_=_0.0104)&_Gain_of_disorder_(P_=_0.0128)&_Gain_of_loop_(P_=_0.0502)&_Gain_of_phosphorylation_at_F241_(P_=_0.0783)&_Loss_of_stability_(P_=_0.2173)	P60484	0.85667	0.722	.	0.82582	.	.	0.81001	simple_aae	A	1	0.64826	.	.	.	0.23521	.	.	0.22329	.	D	0.85558	0.823456048965	0.95655	.	8	0.36497	.	.	0.25664	.	.	14.9657	0.70844	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.95956	.	./.	S	.	F	C	908	0.22609	.	10	C1854416&C1959582	605309	ORPHA210548&ORPHA306498	Likely_pathogenic	NC_000010.11:g.87957940T>C	7850	reviewed_by_expert_panel	Macrocephaly/autism_syndrome&PTEN_hamartoma_tumor_syndrome	ClinGen_PTEN_Variant_Curation_Expert_Panel:5c047758-6fb8-4f71-9a53-077a7bf9a2c2&UniProtKB_(protein):P60484#VAR_032636&OMIM_Allelic_Variant:601728.0039	.	.	AEFGBI	D	0.74176	0.97347	D	0.94824	0.942981	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89707677	10	89717697	0	0.83141	0.719381	1.000000	0.71638	0.995000	0.73285	1.000000	0.86279	7.615000	0.82207	0.609000	0.47794	1.138000	0.64695	87957940	T	.	rs121909240	.	.	12.930	7.806	6.460	9.066	.	.	.	-33	14	40	-6	0.01	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-8+79+end+167	7850	Likely_pathogenic	reviewed_by_expert_panel	not_provided&PTEN_hamartoma_tumor_syndrome&Macrocephaly-autism_syndrome	MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909240	121909240	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,576	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
10	89717690	89717690	A	G	G	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	7/9	.	NM_000314.8:c.715A>G	NP_000305.3:p.Met239Val	1560	715	239	M/V	Atg/Gtg	rs786201758&COSV64291005	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89717690A>G	.	.	.	.	.	.	uncertain_significance	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.77887	0.242387	D	0.77599	0.110395	21.1	20.8	2.233920	2.115830	0.35430	0.35336	./.	D	0.43687	0.757121860980988	0.22065	0.92601792480866851	.	0.81434	.	./.	.	.	.	.	3.063985	0.175109601846662	0.48489	2.353928	-0.0453083390252942	0.39813	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.84487	.	.	.	5.15	5.15	0.70287	0	0.82719	0.723133	.	.	0.74766	0.999999996024359	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.49550	0.631631	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	0.70674	.	0.038168	0.84330	D	0.000000	D	0.75652	0.091147	0.79601	.	0.96917	.	T	0.72208	0.3603	.	0.62518	.	T	0.66677	-0.5529	M239V	Loss_of_sheet_(P_=_0.0104)&_Loss_of_ubiquitination_at_K237_(P_=_0.0449)&_Gain_of_loop_(P_=_0.0502)&_Loss_of_disorder_(P_=_0.1398)&_Gain_of_phosphorylation_at_Y240_(P_=_0.2105)	P60484	0.54362	0.47	.	0.24916	.	.	0.81001	simple_aae	D	1	0.10656	.	.	.	0.07471	.	.	0.11217	.	T	0.68733	0.710961818695	0.73005	.	9	0.03170	.	.	0.02782	.	.	14.9657	0.70844	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.86941	.	./.	V	.	M	G	908	0.22609	.	10	C0027672&C1959582&CN517202	.	ORPHA140162&ORPHA306498	Uncertain_significance	NC_000010.11:g.87957933A>G	184878	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:dd41683a-d4b5-4e1a-aafb-d6cbe064561e	.	.	AEFDGBI	D	0.81395	0.98299	D	0.97412	0.955929	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89707670	10	89717690	0	0.83141	0.719381	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	8.875000	0.92004	0.691000	0.84096	1.312000	0.94714	87957933	A	.	rs786201758	.	.	12.930	7.806	6.460	9.066	.	.	.	-26	21	-5	1	0.08	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-8+80+start+167	184878	Uncertain_significance	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786201758	786201758	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,575	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
10	89711903	89711903	A	G	G	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	6/9	.	NM_000314.8:c.521A>G	NP_000305.3:p.Tyr174Cys	1366	521	174	Y/C	tAt/tGt	rs864622341&COSV64290156	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89711903A>G	.	.	.	.	.	.	uncertain_significance&pathogenic/likely_pathogenic&likely_pathogenic	0&1	1&1	.	.	.	.	.	PTEN&NM_000314.4&c.521A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.97364	0.590403	D	0.97321	0.610297	29.3	28.0	4.266921	4.040969	0.87402	0.83691	./.	D	0.98729	0.99973338842392	0.91972	0.99839037578955403	.	0.99582	.	./.	.	.	.	.	14.07291	0.907416597929156	0.95887	13.40894	0.98339367372444	0.95212	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98892	.	.	.	5.74	5.74	0.90070	0	0.74545	0.702456	.	.	0.74766	0.999999999987444	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.98432	0.735409	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.97700	.	0.119975	0.62929	D	0.000014	D	0.99029	0.872945	0.98161	.	0.98770	.	D	0.99434	0.9815	.	0.99597	.	D	0.97941	1.0415	Y174C	Loss_of_MoRF_binding_(P_=_0.0909)&_Loss_of_stability_(P_=_0.1928)&_Loss_of_phosphorylation_at_S170_(P_=_0.2286)&_Gain_of_helix_(P_=_0.2294)&_Loss_of_disorder_(P_=_0.2311)	P60484	0.97032	0.884	.	0.96601	.	.	0.81001	simple_aae	D	1	0.96884	.	.	.	0.77913	.	.	0.71005	.	D	0.98717	0.925557255745	0.99822	.	9	0.79402	.	.	0.91255	.	.	16.0449	0.80517	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.98929	.	./.	C	.	Y	G	926	0.17793	.	10	C0027672&C1959582&CN169374&CN517202	.	ORPHA140162&ORPHA306498	Likely_pathogenic	NC_000010.11:g.87952146A>G	220007	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_specified&not_provided	.	.	.	AEFDGBCI	D	0.68719	0.96352	D	0.95628	0.946621	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89701883	10	89711903	0	0.85440	0.722319	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	8.820000	0.91632	0.691000	0.84096	1.312000	0.94714	87952146	A	.	rs864622341	.	.	6.460	9.066	10.752	10.998	.	.	.	16	-24	-1	3	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-7+28+start+142	220007	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs864622341	864622341	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,564	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
16	68862107	68862107	G	A	A	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	14/16	.	NM_004360.5:c.2195G>A	NP_004351.1:p.Arg732Gln	2319	2195	732	R/Q	cGg/cAg	rs1060501244&CM041747&COSV55728376	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68862107G>A	.	.	.	.	.	.	pathogenic/likely_pathogenic&likely_pathogenic&pathogenic	0&0&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.2195G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.78381	0.247649	D	0.78101	0.117954	33	34	5.208731	5.729849	0.93771	0.95023	G/G	D	0.82925	0.992446482181549	0.99990	0.9995910905315265	.	0.94054	.	G/G	.	.	.	.	7.829884	0.704098148715989	0.82690	7.285956	0.711717726848405	0.80400	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.58755	.	.	.	6.07	6.07	0.98675	0	0.36545	0.588015	.	.	0.74766	0.999999995667935	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.10902	0.530356	.&.&.	.	.	.	0.60664	.	0.000000	0.44119	D	0.000461	D	0.50935	0.028223	0.72649	.	0.87441	.	T	0.75451	0.4041	.	0.69512	.	T	0.73156	-0.3636	R732Q	Gain_of_catalytic_residue_at_R732_(P_=_0.0928)&_Loss_of_methylation_at_R732_(P_=_0.0943)&_Gain_of_relative_solvent_accessibility_(P_=_0.1571)&_Gain_of_solvent_accessibility_(P_=_0.2384)&_Loss_of_MoRF_binding_(P_=_0.2749)	P12830	0.92439	0.807	.	0.53209	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.60665	.	.	.	0.90584	.	.	0.79672	.	T	0.20935	0.370720088482	0.74093	.	10	0.66756	.	.	0.65419	.	.	20.2544	0.98416	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.78737	.	G/G	Q	.	R	A	356	0.85138	.	16	C1708349&C0027672&CN517202	137215	ORPHA26106&ORPHA140162	Likely_pathogenic	NC_000016.10:g.68828204G>A	406663	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:0b968ecb-5432-4588-a812-7dd328f2b93d	.	.	AEFBCI	D	0.34718	0.70744	D	0.63171	0.661521	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	67419608	16	68862107	0	0.52595	0.67177	1.000000	0.71638	0.971000	0.54645	1.000000	0.86279	3.102000	0.49982	0.676000	0.76740	1.146000	0.70253	68828204	G	.	rs1060501244	.	gain/acceptor/68862107-68862108/Medium/6.558316	9.586	8.564	6.421	8.065	.	.	.	2	-30	-30	4	0.99	0.42	0.00	0.00	CDH1	0.34	exon-NM_001317185.2-14+30+start+131	406663	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_diffuse_gastric_adenocarcinoma&Hereditary_cancer-predisposing_syndrome&not_provided	MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1060501244	1060501244	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,916	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
10	89692911	89692911	G	A	A	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.395G>A	NP_000305.3:p.Gly132Asp	1240	395	132	G/D	gGt/gAt	rs121909241&CM045431&CM063078&CM074468&COSV64288421&COSV64288528&COSV64293854	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89692911G>A	.	.	.	.	.	.	likely_pathogenic&conflicting_interpretations_of_pathogenicity	0&0&0&0&1&1&1	1&1&1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.395G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.97382	0.594322	D	0.97340	0.615926	27.6	27.1	4.077173	3.925455	0.81293	0.79680	./.	D	0.99146	0.999818027019501	0.94457	0.99866717941641936	.	0.99715	.	./.	.	.	.	.	16.56893	0.95972229161432	0.97685	16.14709	1.06587269366275	0.97450	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99556	.	.	.	5.22	5.22	0.72285	0	0.70079	0.698795	.	.	0.74766	0.999999999999999	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.98879	.	0.000000	0.84330	D	0.000000	D	0.99511	0.932304	0.98161	.	0.99297	.	D	0.99826	0.9927	.	0.99971	.	D	0.96174	0.9350	G132D	Gain_of_ubiquitination_at_K128_(P_=_0.0416)&_Loss_of_catalytic_residue_at_V133_(P_=_0.064)&_Loss_of_MoRF_binding_(P_=_0.0665)&_Loss_of_methylation_at_R130_(P_=_0.141)&_Loss_of_disorder_(P_=_0.298)	P60484	0.99844	0.984	.	0.97626	.	.	0.81001	simple_aae	D	1	0.90729	.	.	.	0.90584	.	.	0.97372	.	D	0.99606	0.944437742233	0.99982	.	9	0.92824	.	.	0.91255	.	.	18.7776	0.91883	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.99776	.	./.	D	.	G	A	940	0.13648	.	10	CN072330&C0027672&C1959582&CN517202	158350	ORPHA140162&ORPHA306498	Likely_pathogenic	NC_000010.11:g.87933154G>A	92822	reviewed_by_expert_panel	Cowden_syndrome_1&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:9c15b246-ef9f-4f55-a246-126b49710717&HGMD:CM045431	.	.	AEFDGBIJ	D	0.83480	0.98504	D	0.95409	0.945599	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682891	10	89692911	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	9.525000	0.97093	0.676000	0.76740	1.176000	0.78918	87933154	G	.	rs121909241	.	.	10.752	10.998	5.352	9.651	.	.	.	-33	47	1	-25	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+97+end+239	92822	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909241	121909241	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,550	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
10	89692904	89692904	C	G	G	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.388C>G	NP_000305.3:p.Arg130Gly	1233	388	130	R/G	Cga/Gga	rs121909224&CM094223&CM971273&COSV64288384&COSV64288463&COSV64297940&COSV64311187	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89692904C>G	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&0&0&1&1&1&1	1&1&1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.388C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.96613	0.570271	D	0.96557	0.581379	26.9	27.5	3.983186	3.977660	0.78031	0.81532	./.	D	0.96293	0.999138236045837	0.95892	0.99883392099747148	.	0.99562	.	./.	.	.	.	.	11.68285	0.847533682221306	0.92870	12.69873	0.959649873303408	0.94361	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98313	.	.	.	5.22	5.22	0.72285	0	0.70079	0.698795	.	.	0.74766	0.999999999934847	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.98988	.	0.000000	0.84330	D	0.000000	D	0.99232	0.898206	0.98291	.	0.99566	.	D	0.99456	0.9822	.	0.99959	.	D	0.97644	1.0261	R130G	Gain_of_ubiquitination_at_K128_(P_=_0.0356)&_Loss_of_methylation_at_R130_(P_=_0.0398)&_Loss_of_MoRF_binding_(P_=_0.045)&_Gain_of_disorder_(P_=_0.1676)&_Loss_of_stability_(P_=_0.1811)	P60484	0.99654	0.965	.	0.97651	.	.	0.81001	simple_aae	D	1	0.92692	.	.	.	0.90584	.	.	0.92359	.	D	0.97263	0.907856464386	0.99434	.	9	0.92824	.	.	0.91255	.	.	18.7776	0.91883	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.97856	.	./.	G	.	R	G	940	0.13648	.	10	C1458155&C1336839&C0151779&C0476089&C0149925&C0149782&C0007873&C0278701&C0919267&C0009404&C0007112&C0280630&CN072330&C1168401&C1959582&C0017636&C0153368&C0153574&CN517202	605074&608089&182280&167000&158350&275355	ORPHA70573&ORPHA306498&ORPHA360	Pathogenic	NC_000010.11:g.87933147C>G	375958	reviewed_by_expert_panel	Breast_neoplasm&Renal_cell_carcinoma&_papillary&_1&Malignant_melanoma_of_skin&Endometrial_carcinoma&Small_cell_lung_carcinoma&Squamous_cell_lung_carcinoma&Neoplasm_of_uterine_cervix&Adenocarcinoma_of_stomach&Neoplasm_of_ovary&Neoplasm_of_the_large_intestine&Adenocarcinoma_of_prostate&Uterine_Carcinosarcoma&Cowden_syndrome_1&Squamous_cell_carcinoma_of_the_head_and_neck&PTEN_hamartoma_tumor_syndrome&Glioblastoma&Malignant_tumor_of_floor_of_mouth&Malignant_neoplasm_of_body_of_uterus&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:1ff92475-1a3f-42b2-b733-1515bf2a4e10	.	.	AEFDGBIJ	D	0.67166	0.96019	D	0.78875	0.868574	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682884	10	89692904	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	5.574000	0.67124	0.599000	0.40250	1.026000	0.45946	87933147	C	.	rs121909224	.	.	10.752	10.998	5.352	9.651	.	.	.	25	-26	-18	8	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+104+end+239	375958	Pathogenic	reviewed_by_expert_panel	Glioblastoma&not_provided&Squamous_cell_carcinoma_of_the_head_and_neck&Malignant_tumor_of_floor_of_mouth&Uterine_carcinosarcoma&Neoplasm_of_uterine_cervix&Breast_neoplasm&Cowden_syndrome_1&Prostate_adenocarcinoma&Malignant_neoplasm_of_body_of_uterus&Gastric_adenocarcinoma&Neoplasm_of_the_large_intestine&Small_cell_lung_carcinoma&PTEN_hamartoma_tumor_syndrome&Neoplasm_of_ovary&Malignant_melanoma_of_skin&Papillary_renal_cell_carcinoma_type_1&Squamous_cell_lung_carcinoma&Endometrial_carcinoma	MONDO:MONDO:0018177&MeSH:D005909&MedGen:C0017636&Orphanet:360&MedGen:CN517202&MONDO:MONDO:0010150&MeSH:D000077195&MedGen:C1168401&OMIM:275355&Orphanet:67037&MONDO:MONDO:0021320&MedGen:C0153368&MONDO:MONDO:0006485&MedGen:C0280630&Human_Phenotype_Ontology:HP:0032241&MONDO:MONDO:0021230&MeSH:D002583&MedGen:C0007873&Human_Phenotype_Ontology:HP:0010623&Human_Phenotype_Ontology:HP:0100013&MONDO:MONDO:0021100&MeSH:D001943&MedGen:C1458155&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0005082&MedGen:C0007112&MedGen:C0153574&Human_Phenotype_Ontology:HP:0033770&MONDO:MONDO:0005036&MedGen:C0278701&Orphanet:464463&Human_Phenotype_Ontology:HP:0100834&MONDO:MONDO:0005335&MeSH:D015179&MedGen:C0009404&Human_Phenotype_Ontology:HP:0030357&MONDO:MONDO:0008433&MeSH:D055752&MedGen:C0149925&OMIM:182280&Orphanet:70573&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267&OMIM:167000&Human_Phenotype_Ontology:HP:0012056&MONDO:MONDO:0005012&MeSH:C562393&MedGen:C0151779&Human_Phenotype_Ontology:HP:0011797&MedGen:C1336839&OMIM:605074&Orphanet:47044&Human_Phenotype_Ontology:HP:0030359&MONDO:MONDO:0005097&MedGen:C0149782&Human_Phenotype_Ontology:HP:0012114&MONDO:MONDO:0002447&MedGen:C0476089&OMIM:608089	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909224	121909224	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,547	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
10	89692880	89692880	A	G	G	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.364A>G	NP_000305.3:p.Ile122Val	1209	364	122	I/V	Att/Gtt	rs786202740	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89692880A>G	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.364A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.64846	0.105172	T	0.64409	-0.086704	20.5	19.52	2.154722	1.972581	0.33758	0.32392	./.	D	0.49376	0.840596973896027	0.41244	0.98417098509558709	.	0.82249	.	./.	.	.	.	.	3.588175	0.277446084665492	0.54227	2.821316	0.0834141324197771	0.45690	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.77593	.	.	.	5.22	5.22	0.72285	0	0.70079	0.698795	.	.	0.74766	0.999999999999512	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.80515	.	0.000000	0.84330	D	0.000000	D	0.58299	0.038568	0.78647	.	0.85014	.	T	0.60511	0.2377	.	0.72694	.	T	0.60290	-0.7031	I122V	Gain_of_ubiquitination_at_K125_(P_=_0.1079)&_Loss_of_methylation_at_K125_(P_=_0.135)&_Gain_of_disorder_(P_=_0.1556)&_Loss_of_stability_(P_=_0.18)&_Loss_of_catalytic_residue_at_I122_(P_=_0.2994)	P60484	0.81586	0.678	.	0.03917	.	.	0.81001	simple_aae	D	1	0.12099	.	.	.	0.33288	.	.	0.41250	.	D	0.84454	0.8162535429	0.72328	.	9	0.04507	.	.	0.02321	.	.	15.1019	0.71955	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.65844	.	./.	V	.	I	G	940	0.13648	.	10	C0027672&C1959582&CN517202	.	ORPHA140162&ORPHA306498	Uncertain_significance	NC_000010.11:g.87933123A>G	186161	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:c4bf5c74-cf88-47c3-812d-89a0c0e7f110	.	.	AEFDGBI	D	0.79301	0.98065	D	0.92598	0.933698	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682860	10	89692880	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	8.875000	0.92004	0.756000	0.94297	1.312000	0.94714	87933123	A	.	rs786202740	.	.	10.752	10.998	5.352	9.651	.	.	.	-44	-2	32	6	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+110+start+239	186161	Uncertain_significance	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Hereditary_cancer-predisposing_syndrome&not_provided	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786202740	786202740	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,544	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
21	36265254	36265254	A	T	T	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	3/9	.	NM_001754.5:c.65T>A	NP_001745.2:p.Ile22Lys	259	65	22	I/K	aTa/aAa	rs749430925	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	RUNX1	.	chr21:g.36265254A>T	.	.	.	.	.	.	benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	T	0.16858	-0.228417	T	0.60890	-0.130961	18.20	15.93	1.862738	1.439571	0.27960	0.22966	A/A	T	0.05432	0.0496089468699928	0.10401	0.73639188197657202	.	.	.	A/A	.	.	.	.	1.226718	-0.484750266778154	0.22572	0.9870107	-0.600359975795169	0.18934	.	.	.	23	1.895e-04	0	0	23	2.011e-03	23	1.927e-04	0	0	0	0	0	0	0	0	22	2.073e-04	0	0	22	1.983e-03	22	2.103e-04	0	0	0	0	0	0	0	0	23	2.536e-04	0	0	23	2.013e-03	23	2.582e-04	0	0	0	0	0	0	0	0	0.96855	.	.	.	5.37	2.95	0.33285	0	0.62753	0.659912	.	.	0.44867	0.999888920695088	.	0	0.18855	0.563428	.	.	.	.	.	.	0	0.45549	0.616125	.&.&.&.	.	.	.	0.16524	.	1.390910	0.04971	N	0.479173	D	0.81463	0.132326	0.76301	.	0.83605	.	D	0.89697	0.7008	.	0.00621	.	T	0.81681	-0.0276	I22K	Gain_of_methylation_at_I22_(P_=_0.003)&_Gain_of_solvent_accessibility_(P_=_0.012)&_Gain_of_ubiquitination_at_I22_(P_=_0.0162)&_Gain_of_relative_solvent_accessibility_(P_=_0.0215)&_Gain_of_disorder_(P_=_0.0338)	ENST00000437180	0.42903	0.4	.	.	.	.	0.23043	simple_aae&simple_aae&without_aae	N&N&N	0.999891&0.999891&0.99634	0.49187	.	.	.	0.23277	.	.	0.12133	.	T	0.30199	0.437230587006	0.58633	.	10	0.63918	.	.	0.46513	.	.	7.1363	0.24708	0.8187:0.0:0.1813:0.0	.	.	.	.	.	.	.	.	0.41754	.	A/A	K	.	I	T	186	0.92733	.	21	C1832388	601399	.	Benign	NC_000021.9:g.34892957A>T	464002	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:6426c4e0-697d-4b39-a0dd-56f81c978e1a	.	.	AEFBI	D	0.29476	0.53870	N	0.24172	0.125286	.	55	2.204870e-04	0	0.000000e+00	15950	0	55	1.603030e-03	34310	0	249448	0	0.000000e+00	10040	0	0	0.000000e+00	18340	0	0	0.000000e+00	21626	0	0	0.000000e+00	113052	0	55	1.603030e-03	34310	0	0	0.000000e+00	30044	0	28	2.575420e-04	0	0.000000e+00	7142	0	28	1.655240e-03	16916	0	108720	0	0.000000e+00	2308	0	0	0.000000e+00	9040	0	0	0.000000e+00	13390	0	0	0.000000e+00	42646	0	28	1.655240e-03	16916	0	0	0.000000e+00	15368	0	0	.	0	54	2.297580e-04	0	0.000000e+00	14600	0	54	1.588980e-03	33984	0	235030	0	0.000000e+00	9536	0	0	0.000000e+00	17646	0	0	0.000000e+00	21610	0	0	0.000000e+00	102128	0	54	1.588980e-03	33984	0	0	0.000000e+00	29954	0	0	52	2.521330e-04	0	0.000000e+00	15912	0	52	1.718780e-03	30254	0	206240	0	0.000000e+00	6184	0	0	0.000000e+00	13402	0	0	0.000000e+00	16726	0	0	0.000000e+00	88904	0	52	1.718780e-03	30254	0	0	0.000000e+00	30036	0	0	55	2.264100e-04	0	0.000000e+00	11760	0	55	1.609320e-03	34176	0	242922	0	0.000000e+00	9960	0	0	0.000000e+00	18338	0	0	0.000000e+00	21624	0	0	0.000000e+00	111002	0	55	1.609320e-03	34176	0	0	0.000000e+00	30044	0	0	3	1.971120e-05	0	0.000000e+00	41450	0	0	0.000000e+00	912	0	3	1.962840e-04	15284	0	152198	0	0.000000e+00	3470	0	0	0.000000e+00	5204	0	0	0.000000e+00	10608	0	0	0.000000e+00	314	0	0	0.000000e+00	68028	0	3	1.962840e-04	15284	0	0	0.000000e+00	4836	0	1	3.040440e-05	0	0.000000e+00	9094	0	0	0.000000e+00	60	0	1	2.133110e-04	4688	0	32890	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5486	0	0	0.000000e+00	244	0	0	0.000000e+00	6850	0	0	0.000000e+00	3114	0	0	.	0	3	2.027880e-05	0	0.000000e+00	41128	0	0	0.000000e+00	912	0	3	1.987280e-04	15096	0	147938	0	0.000000e+00	3302	0	0	0.000000e+00	4968	0	0	0.000000e+00	10608	0	0	0.000000e+00	302	0	0	0.000000e+00	64796	0	0	0.000000e+00	4804	0	0	3	2.225550e-05	0	0.000000e+00	32478	0	0	0.000000e+00	862	0	3	2.021840e-04	14838	0	134798	0	0.000000e+00	3386	0	0	0.000000e+00	5204	0	0	0.000000e+00	6974	0	0	0.000000e+00	308	0	0	0.000000e+00	63912	0	0	0.000000e+00	4834	0	0	2	2.476410e-05	0	0.000000e+00	24824	0	0	0.000000e+00	112	0	2	1.549190e-04	12910	0	80762	0	0.000000e+00	996	0	0	0.000000e+00	3762	0	0	0.000000e+00	10516	0	0	0.000000e+00	270	0	0	0.000000e+00	21046	0	0	0.000000e+00	4808	0	0	21	35187124	21	36265254	0	0.39893	0.623552	0.777000	0.29437	0.988000	0.63387	0.998000	0.65909	1.480000	0.35072	0.756000	0.94297	1.312000	0.94714	34892957	A	.	rs749430925	.	.	8.426	9.942	8.173	10.033	.	.	.	6	-22	-32	6	0.04	0.00	0.02	0.00	RUNX1	0.45	exon-NM_001754.5-3+6+end+39	464002	Benign	reviewed_by_expert_panel	not_specified&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN169374&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	21:36265254-36265254	1.895e-04	23	23	0	0	23	0	0	0	0	0	9934	11436	8590	6586	65612	890	16334	0	23	0	0	0	0	0	0	0	0	0	0	0	0	rs749430925	0.00000e+00	1.52585e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.49225e-04	2.79940e-04	1.52585e-03	2.15234e-04	rs749430925	0.00000e+00	1.19332e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84795e-05	0.00000e+00	1.19332e-03	3.22664e-05	.	.	rs749430925	749430925	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,988	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	89692830	89692830	G	A	A	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.314G>A	NP_000305.3:p.Cys105Tyr	1159	314	105	C/Y	tGt/tAt	rs587782343&CM991080&COSV64290665&COSV64299259&COSV64307337	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89692830G>A	.	.	.	.	.	.	likely_pathogenic&uncertain_significance	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.314G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.93460	0.473379	D	0.93377	0.442199	27.5	27.5	4.074266	3.982733	0.81183	0.81682	./.	D	0.99732	0.999928951263428	0.84694	0.99756082059760798	.	0.99533	.	./.	.	.	.	.	11.79615	0.850671556724227	0.93054	11.34708	0.911330893982104	0.92305	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.85247	.	.	.	5.07	5.07	0.68106	0	0.70079	0.698795	.	.	0.74766	0.999999999999999	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.78720	.	0.000000	0.84330	D	0.000000	D	0.95742	0.542156	0.99294	.	0.98105	.	D	0.93390	0.8045	.	0.97754	.	D	0.94424	0.8011	C105Y	Gain_of_phosphorylation_at_C105_(P_=_0.0879)&_Loss_of_methylation_at_K102_(P_=_0.1815)&_Gain_of_catalytic_residue_at_L100_(P_=_0.2109)&_Gain_of_ubiquitination_at_K102_(P_=_0.2261)&_Loss_of_glycosylation_at_K102_(P_=_0.2452)	P60484	0.94417	0.837	.	0.89945	.	.	0.81001	simple_aae	D	1	0.99170	.	.	.	0.90584	.	.	0.92359	.	D	0.97545	0.910789608955	0.97210	.	9	0.92824	.	.	0.91255	.	.	18.4584	0.90676	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.99100	.	./.	Y	.	C	A	940	0.13648	.	10	C0027672&C1959582&CN517202	.	ORPHA140162&ORPHA306498	Likely_pathogenic	NC_000010.11:g.87933073G>A	142261	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	UniProtKB_(protein):P60484#VAR_008735&ClinGen_PTEN_Variant_Curation_Expert_Panel:dce7b398-e447-420b-8da1-a51cbf6a8e69	.	.	AEFDGBI	D	0.87402	0.98829	D	0.92351	0.932721	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682810	10	89692830	0	0.85440	0.722319	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	9.520000	0.97074	0.676000	0.76740	1.176000	0.78918	87933073	G	.	rs587782343	.	.	10.752	10.998	5.352	9.651	.	.	.	6	-22	23	-1	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+60+start+239	142261	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587782343	587782343	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,539	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
10	89692820	89692820	A	C	C	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.304A>C	NP_000305.3:p.Lys102Gln	1149	304	102	K/Q	Aaa/Caa	rs786202944	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89692820A>C	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.304A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.72953	0.189879	D	0.72600	0.0349712	23.8	23.7	3.159818	3.042517	0.55644	0.55703	./.	D	0.45992	0.794617056846619	0.23121	0.93374848497630281	.	0.88028	.	./.	.	.	.	.	5.660792	0.551146784667232	0.71478	4.996126	0.4949085204288	0.66790	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.86146	.	.	.	5.07	5.07	0.68106	0	0.70079	0.698795	.	.	0.74766	0.999999999999151	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Dual_specificity_phosphatase&_catalytic_domain&Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.95230	.	0.000000	0.84330	D	0.000000	D	0.65686	0.05399	0.81831	.	0.95369	.	D	0.84050	0.5616	.	0.72933	.	D	0.83291	0.0526	K102Q	Loss_of_ubiquitination_at_K102_(P_=_0.0546)&_Loss_of_glycosylation_at_K102_(P_=_0.0586)&_Loss_of_methylation_at_K102_(P_=_0.0677)&_Loss_of_solvent_accessibility_(P_=_0.1551)&_Loss_of_catalytic_residue_at_K102_(P_=_0.1606)	P60484	0.48322	0.433	.	0.10161	.	.	0.81001	simple_aae	D	1	0.38345	.	.	.	0.65571	.	.	0.57419	.	D	0.84665	0.817631483078	0.85975	.	9	0.10429	.	.	0.06145	.	.	14.8406	0.69852	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.75283	.	./.	Q	.	K	C	940	0.13648	.	10	C0027672&C1959582&CN517202	.	ORPHA140162&ORPHA306498	Uncertain_significance	NC_000010.11:g.87933063A>C	186427	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:db32e75a-9a54-4922-9aaf-03a6bf68097e	.	.	AEFDGBI	D	0.86386	0.98751	D	0.88541	0.917587	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682800	10	89692820	0	0.85440	0.722319	1.000000	0.71638	0.996000	0.76049	1.000000	0.86279	8.871000	0.91978	0.756000	0.94297	1.312000	0.94714	87933063	A	.	rs786202944	.	.	10.752	10.998	5.352	9.651	.	.	.	-29	16	-29	-44	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+50+start+239	186427	Uncertain_significance	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Hereditary_cancer-predisposing_syndrome&not_provided	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786202944	786202944	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,538	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
11	533779	533779	T	C	C	missense_variant	MODERATE	HRAS	3265	Transcript	NM_005343.4	protein_coding	3/6	.	NM_005343.4:c.277A>G	NP_005334.1:p.Ile93Val	491	277	93	I/V	Atc/Gtc	rs587782949&COSV104539846	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	HRAS	.	chr11:g.533779T>C	.	.	.	.	.	.	uncertain_significance&likely_benign	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	T	0.40083	-0.0777264	T	0.39270	-0.349425	19.04	19.00	1.971442	1.905003	0.30036	0.31044	T/T	T	0.18857	0.17413622838348	0.37468	0.97999648884958313	.	0.77015	.	T/T	.	.	.	.	1.460775	-0.352049614628374	0.26446	1.189264	-0.49354937889824	0.22291	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.74689	.	.	.	3.46	2.33	0.27981	0	0.70079	0.698795	.	.	0.74766	0.999999732368758	.	0	0.80598	0.723109	.	.	.	.	.	.	0	0.98432	0.735409	.&Small_GTP-binding_protein_domain&.&Small_GTP-binding_protein_domain&Small_GTP-binding_protein_domain	.	.	.	.	.	0.054577	0.84330	N	0.000001	T	0.41240	0.019003	0.69361	.	0.53252	.	T	0.49814	0.1622	.	0.28650	.	T	0.32525	-0.9903	I93V	Gain_of_ubiquitination_at_K88_(P_=_0.1008)&_Gain_of_disorder_(P_=_0.2016)&_Loss_of_methylation_at_K88_(P_=_0.2257)&_Loss_of_helix_(P_=_0.2662)&_Loss_of_phosphorylation_at_Y96_(P_=_0.3481)	P01112	0.36209	0.359	.	0.03743	.	.	0.58761	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D	0.999999&0.999999&0.999999&0.999999&0.999999	0.19085	.	.	.	0.09854	.	.	0.16862	.	T	0.44382	0.539552807808	0.37795	.	10	0.15939	.	.	0.23450	.	.	7.699	0.27777	0.0:0.1043:0.0:0.8957	.	.	.	.	.	.	.	.	0.31590	.	T/T	V	.	I	C	889	0.27310	.	11	C1956257&C0003499&C0587248&CN517202	265500&185500&218040	ORPHA3193&ORPHA3071	Uncertain_significance	NC_000011.10:g.533779T>C	40439	reviewed_by_expert_panel	Pulmonic_stenosis&Supravalvar_aortic_stenosis&Costello_syndrome&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:f12837d2-3463-4374-982c-98e2b63c406a	.	.	AEFDBI	D	0.61952	0.94677	N	0.51526	0.468482	.	1	3.980420e-06	0	0.000000e+00	16220	0	0	0.000000e+00	34580	0	251230	0	0.000000e+00	10074	0	0	0.000000e+00	18386	0	1	4.619360e-05	21648	0	0	0.000000e+00	113574	0	.	.	.	.	0	0.000000e+00	30616	0	0	0.000000e+00	0	0.000000e+00	7160	0	0	0.000000e+00	17108	0	109400	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	1	4.220910e-06	0	0.000000e+00	14888	0	0	0.000000e+00	34252	0	236916	0	0.000000e+00	9570	0	0	0.000000e+00	17692	0	1	4.622780e-05	21632	0	0	0.000000e+00	102736	0	.	.	.	.	0	0.000000e+00	30526	0	0	1	4.810330e-06	0	0.000000e+00	16182	0	0	0.000000e+00	30512	0	207886	0	0.000000e+00	6206	0	0	0.000000e+00	13408	0	1	5.975860e-05	16734	0	0	0.000000e+00	89378	0	.	.	.	.	0	0.000000e+00	30608	0	0	1	4.088110e-06	0	0.000000e+00	11990	0	0	0.000000e+00	34446	0	244612	0	0.000000e+00	9992	0	0	0.000000e+00	18382	0	1	4.619790e-05	21646	0	0	0.000000e+00	111484	0	.	.	.	.	0	0.000000e+00	30616	0	0	1	6.572370e-06	0	0.000000e+00	41430	0	0	0.000000e+00	910	0	0	0.000000e+00	15280	0	152152	0	0.000000e+00	3472	0	0	0.000000e+00	5180	0	0	0.000000e+00	10624	0	0	0.000000e+00	316	0	0	0.000000e+00	68018	0	.	.	.	.	0	0.000000e+00	4834	0	0	0.000000e+00	0	0.000000e+00	9096	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32904	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5498	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3114	0	0	.	0	1	6.761420e-06	0	0.000000e+00	41108	0	0	0.000000e+00	910	0	0	0.000000e+00	15092	0	147898	0	0.000000e+00	3302	0	0	0.000000e+00	4946	0	0	0.000000e+00	10624	0	0	0.000000e+00	304	0	0	0.000000e+00	64792	0	0	0.000000e+00	4802	0	0	0	0.000000e+00	0	0.000000e+00	32466	0	0	0.000000e+00	860	0	0	0.000000e+00	14836	0	134754	0	0.000000e+00	3388	0	0	0.000000e+00	5180	0	0	0.000000e+00	6984	0	0	0.000000e+00	310	0	0	0.000000e+00	63896	0	0	0.000000e+00	4832	0	0	1	1.238790e-05	0	0.000000e+00	24806	0	0	0.000000e+00	112	0	0	0.000000e+00	12906	0	80724	0	0.000000e+00	998	0	0	0.000000e+00	3738	0	0	0.000000e+00	10532	0	0	0.000000e+00	272	0	0	0.000000e+00	21040	0	0	0.000000e+00	4806	0	0	11	523779	11	533779	0	0.85440	0.722319	1.000000	0.71638	0.980000	0.58198	1.000000	0.86279	3.967000	0.56509	0.665000	0.62972	1.138000	0.64695	533779	T	.	rs587782949	.	.	8.862	5.560	10.582	8.703	.	.	.	12	-14	-22	-13	0.00	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-3+13+start+179	40439	Uncertain_significance	reviewed_by_expert_panel	Supravalvar_aortic_stenosis&Pulmonic_stenosis&not_provided&Costello_syndrome	Human_Phenotype_Ontology:HP:0004381&MONDO:MONDO:0008504&MedGen:C0003499&OMIM:185500&Orphanet:3193&Human_Phenotype_Ontology:HP:0001642&MONDO:MONDO:0009938&MedGen:C1956257&OMIM:265500&Orphanet:3189&MedGen:CN517202&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587782949	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	4.48430e-05	0.00000e+00	0.00000e+00	0.00000e+00	7.41422e-06	0.00000e+00	4.48430e-05	4.06055e-06	rs587782949	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.02041e-03	.	0.00000e+00	7.23170e-05	.	3.22726e-05	.	.	rs587782949	587782949	.	.	.	HRAS	HRAS:exonic	HRAS:missense	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,619	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	112915779	112915779	G	A	A	missense_variant	MODERATE	PTPN11	5781	Transcript	NM_002834.5	protein_coding	9/16	.	NM_002834.5:c.1052G>A	NP_002825.3:p.Arg351Gln	1217	1052	351	R/Q	cGa/cAa	rs397507534&COSV61012894	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTPN11	.	chr12:g.112915779G>A	.	0	0	0	0	0.002	benign&uncertain_significance	0&1	1&1	.	.	.	.	.	PTPN11&NM_002834.3&c.1052G>A	.	.	2	3.9936102236421724E-4	0	0.0	0	0.0	0	0.0	0	0.0	2	0.002044989775051125	.	.	.	.	.	.	.	.	.	./.	G	T	0.37555	-0.093147	D	0.76334	0.0913187	23.4	23.8	3.014203	3.094976	0.52345	0.56944	./.	T	0.10455	0.0837095196309223	0.98167	0.99912788691633592	.	0.89983	.	./.	.	.	.	.	5.071789	0.490318952865825	0.67345	3.976101	0.337045622814528	0.58059	.	.	.	57	4.695e-04	0	0	0	0	57	4.700e-04	1	1.156e-04	0	0	1	1.500e-05	55	3.336e-03	55	5.178e-04	0	0	0	0	55	5.185e-04	1	1.271e-04	0	0	0	0	54	3.296e-03	57	6.281e-04	0	0	0	0	57	6.286e-04	1	1.774e-04	0	0	1	2.374e-05	55	3.338e-03	0.99255	.	.	.	6.03	6.03	0.97798	0	0.89359	0.724815	.	.	0.48110	0.999954844386353	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.98432	0.735409	.&.&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase	.	.	.	0.54640	.	0.000000	0.84330	D	0.000000	D	0.81247	0.130323	0.72412	.	0.89956	.	D	0.97795	0.9331	.	0.00416	.	D	0.97448	1.0152	R351Q	Loss_of_MoRF_binding_(P_=_0.008)&_Gain_of_catalytic_residue_at_R351_(P_=_0.2138)&_Loss_of_helix_(P_=_0.2271)&_Loss_of_stability_(P_=_0.2706)&_Loss_of_glycosylation_at_S350_(P_=_0.4171)	ENST00000351677	0.71360	0.586	.	0.35949	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.48850	.	.	.	0.38789	.	.	0.28532	.	D	0.87498	0.836093127728	0.79340	.	10	0.36497	.	.	0.38407	.	.	20.6243	0.99515	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.54845	.	./.	Q	.	R	A	35	0.98078	.	12	CN166718&CN169374&CN517202	.	ORPHA536391	Benign	NC_000012.12:g.112477975G>A	40541	reviewed_by_expert_panel	Rasopathy&not_specified&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:d67ff0bd-70c2-44c7-a7af-94d111f387e6	.	.	AEFBI	D	0.76978	0.97766	D	0.63013	0.659086	.	107	4.255390e-04	0	0.000000e+00	16256	0	0	0.000000e+00	34584	0	251446	0	0.000000e+00	10080	0	1	5.436560e-05	18394	0	0	0.000000e+00	21648	0	1	8.792450e-06	113734	0	105	3.430250e-03	30610	0	105	3.430250e-03	30610	0	55	5.027510e-04	0	0.000000e+00	7164	0	0	0.000000e+00	17106	0	109398	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42766	0	55	3.505860e-03	15688	0	55	3.505860e-03	15688	0	0	segdup	0	105	4.432100e-04	0	0.000000e+00	14902	0	0	0.000000e+00	34252	0	236908	0	0.000000e+00	9572	0	1	5.652270e-05	17692	0	0	0.000000e+00	21632	0	0	0.000000e+00	102718	0	104	3.407600e-03	30520	0	104	3.407600e-03	30520	0	0	107	5.141410e-04	0	0.000000e+00	16218	0	0	0.000000e+00	30516	0	208114	0	0.000000e+00	6212	0	1	7.453790e-05	13416	0	0	0.000000e+00	16734	0	1	1.116690e-05	89550	0	105	3.431150e-03	30602	0	105	3.431150e-03	30602	0	0	107	4.370420e-04	0	0.000000e+00	12026	0	0	0.000000e+00	34450	0	244828	0	0.000000e+00	9998	0	1	5.437740e-05	18390	0	0	0.000000e+00	21646	0	1	8.957040e-06	111644	0	105	3.430250e-03	30610	0	105	3.430250e-03	30610	0	0	22	1.446130e-04	0	0.000000e+00	41424	0	0	0.000000e+00	910	0	0	0.000000e+00	15272	0	152130	0	0.000000e+00	3472	0	0	0.000000e+00	5196	0	0	0.000000e+00	10590	0	0	0.000000e+00	316	0	1	1.470070e-05	68024	0	21	4.344230e-03	4834	0	21	4.344230e-03	4834	0	15	4.563150e-04	0	0.000000e+00	9086	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32872	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5472	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	15	4.816960e-03	3114	0	0	.	0	21	1.420010e-04	0	0.000000e+00	41106	0	0	0.000000e+00	910	0	0	0.000000e+00	15084	0	147886	0	0.000000e+00	3302	0	0	0.000000e+00	4960	0	0	0.000000e+00	10590	0	0	0.000000e+00	304	0	0	0.000000e+00	64806	0	21	4.373180e-03	4802	0	0	22	1.632900e-04	0	0.000000e+00	32464	0	0	0.000000e+00	862	0	0	0.000000e+00	14826	0	134730	0	0.000000e+00	3388	0	0	0.000000e+00	5196	0	0	0.000000e+00	6952	0	0	0.000000e+00	310	0	1	1.564990e-05	63898	0	21	4.346030e-03	4832	0	0	22	2.726550e-04	0	0.000000e+00	24798	0	0	0.000000e+00	110	0	0	0.000000e+00	12898	0	80688	0	0.000000e+00	998	0	0	0.000000e+00	3754	0	0	0.000000e+00	10498	0	0	0.000000e+00	272	0	1	4.753760e-05	21036	0	21	4.369540e-03	4806	0	0	12	111400162	12	112915779	0	0.85440	0.722319	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	5.431000	0.66245	0.650000	0.52971	1.158000	0.71245	112477975	G	.	rs397507534	.	.	10.270	8.884	8.295	9.256	.	.	.	3	-9	-41	40	0.00	0.00	0.00	0.00	PTPN11	1.00	exon-NM_001330437.2-9+40+end+159	40541	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&RASopathy&not_provided	MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN517202	.	12:112915779-112915779	4.695e-04	57	57	0	0	0	1	0	1	0	55	10402	11554	8654	6610	66650	908	16488	0	0	1	0	1	0	55	0	0	0	0	0	0	0	rs397507534	0.00000e+00	0.00000e+00	0.00000e+00	5.79777e-05	0.00000e+00	8.95335e-06	0.00000e+00	3.50923e-03	6.00516e-04	2.60454e-04	3.50923e-03	4.46661e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397507534	397507534	.	.	.	PTPN11	PTPN11:exonic	PTPN11:missense	PTPN11:Noonan_syndrome_1\x3bLEOPARD_syndrome_1\x3bMetachondromatosis\x3bLeukemia\x2cjuvenile_myelomonocytic\x2csomatic	PTPN11:163950\x3b151100\x3b156250\x3b607785	PTPN11:3\x3b3\x3b3\x3b3	PTPN11:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999877230878678	0.000122769057470549	6.38519788034449e-11	DISEASE: LEOPARD syndrome 1 (LPRD1) [MIM:151100]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:12058348, ECO:0000269|PubMed:14961557, ECO:0000269|PubMed:15121796, ECO:0000269|PubMed:15389709, ECO:0000269|PubMed:15520399, ECO:0000269|PubMed:15690106, ECO:0000269|PubMed:16679933, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 1 (NS1) [MIM:163950]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints. {ECO:0000269|PubMed:11704759, ECO:0000269|PubMed:11992261, ECO:0000269|PubMed:12161469, ECO:0000269|PubMed:12325025, ECO:0000269|PubMed:12529711, ECO:0000269|PubMed:12634870, ECO:0000269|PubMed:12717436, ECO:0000269|PubMed:12739139, ECO:0000269|PubMed:12960218, ECO:0000269|PubMed:15384080, ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry. Mutations in PTPN11 account for more than 50% of the cases.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:12717436}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Metachondromatosis (MC) [MIM:156250]: A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest. {ECO:0000269|PubMed:20577567}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,858	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	112915755	112915755	G	A	A	missense_variant	MODERATE	PTPN11	5781	Transcript	NM_002834.5	protein_coding	9/16	.	NM_002834.5:c.1028G>A	NP_002825.3:p.Arg343Gln	1193	1028	343	R/Q	cGg/cAg	rs535800148&COSV61009365	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTPN11	.	chr12:g.112915755G>A	.	0	0	0	0	0.0031	benign/likely_benign&benign	0&1	1&1	.	.	.	.	.	.	.	.	3	5.990415335463259E-4	0	0.0	0	0.0	0	0.0	0	0.0	3	0.003067484662576687	.	.	.	.	.	.	.	.	.	./.	G	T	0.49884	-0.0127166	D	0.81930	0.178878	22.5	22.3	2.536832	2.381398	0.42054	0.41091	./.	T	0.11218	0.0899920389056206	0.03557	0.45377731038544766	.	0.76845	.	./.	.	.	.	.	2.444041	0.0242426645741409	0.40842	1.778608	-0.235735821763896	0.31677	.	.	.	27	2.224e-04	0	0	0	0	27	2.226e-04	0	0	0	0	0	0	27	1.637e-03	27	2.542e-04	0	0	0	0	27	2.545e-04	0	0	0	0	0	0	27	1.647e-03	27	2.975e-04	0	0	0	0	27	2.978e-04	0	0	0	0	0	0	27	1.638e-03	0.99284	.	.	.	6.03	5.12	0.69459	0	0.89359	0.724815	.	.	0.27013	0.930563957922167	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.98432	0.735409	.&.&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase&PTP_type_protein_phosphatase	.	.	.	0.41012	.	0.044594	0.84330	D	0.000000	D	0.84830	0.170869	0.72492	.	0.94126	.	D	0.95369	0.8609	.	0.03576	.	D	0.94345	0.7948	R343Q	Loss_of_MoRF_binding_(P_=_0.0145)&_Loss_of_helix_(P_=_0.0444)&_Loss_of_solvent_accessibility_(P_=_0.239)&_Gain_of_sheet_(P_=_0.3763)&_Loss_of_relative_solvent_accessibility_(P_=_0.4508)	ENST00000351677	0.85579	0.721	.	0.11969	.	.	0.58761	simple_aae&simple_aae	D&D	0.999998&0.999999	0.05503	.	.	.	0.25713	.	.	0.17743	.	T	0.67913	0.705315232277	0.84183	.	10	0.09457	.	.	0.00964	.	.	16.6178	0.84775	0.0:0.0:0.8689:0.1311	.	.	.	.	.	.	.	.	0.77319	.	./.	Q	.	R	A	35	0.98078	.	12	CN166718&CN517202	.	ORPHA536391	Benign	NC_000012.12:g.112477951G>A	181766	reviewed_by_expert_panel	Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:8d55f3e7-09d7-4c84-98a4-830352b7611a	.	.	AEFBI	D	0.72824	0.97123	D	0.62288	0.647843	.	48	1.909060e-04	0	0.000000e+00	16256	0	0	0.000000e+00	34576	0	251432	0	0.000000e+00	10080	0	0	0.000000e+00	18392	0	0	0.000000e+00	21644	0	1	8.792140e-06	113738	0	47	1.535450e-03	30610	1	47	1.535450e-03	30610	1	24	2.193860e-04	0	0.000000e+00	7164	0	0	0.000000e+00	17106	0	109396	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42762	0	24	1.529640e-03	15690	1	24	1.529640e-03	15690	1	1	segdup	1	48	2.026170e-04	0	0.000000e+00	14902	0	0	0.000000e+00	34244	0	236900	0	0.000000e+00	9572	0	0	0.000000e+00	17690	0	0	0.000000e+00	21628	0	1	9.734440e-06	102728	0	47	1.539970e-03	30520	1	47	1.539970e-03	30520	1	1	48	2.306630e-04	0	0.000000e+00	16218	0	0	0.000000e+00	30510	0	208096	0	0.000000e+00	6212	0	0	0.000000e+00	13414	0	0	0.000000e+00	16732	0	1	1.116770e-05	89544	0	47	1.535850e-03	30602	1	47	1.535850e-03	30602	1	1	48	1.960670e-04	0	0.000000e+00	12026	0	0	0.000000e+00	34442	0	244814	0	0.000000e+00	9998	0	0	0.000000e+00	18388	0	0	0.000000e+00	21642	0	1	8.956720e-06	111648	0	47	1.535450e-03	30610	1	47	1.535450e-03	30610	1	1	4	2.628780e-05	1	2.413360e-05	41436	0	0	0.000000e+00	910	0	0	0.000000e+00	15280	0	152162	0	0.000000e+00	3468	0	0	0.000000e+00	5196	0	0	0.000000e+00	10600	0	0	0.000000e+00	316	0	0	0.000000e+00	68036	0	3	6.208610e-04	4832	0	3	6.208610e-04	4832	0	3	9.122980e-05	0	0.000000e+00	9088	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32884	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5478	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	3	9.633910e-04	3114	0	0	.	0	4	2.704380e-05	1	2.432140e-05	41116	0	0	0.000000e+00	910	0	0	0.000000e+00	15092	0	147908	0	0.000000e+00	3298	0	0	0.000000e+00	4962	0	0	0.000000e+00	10600	0	0	0.000000e+00	304	0	0	0.000000e+00	64808	0	3	6.250000e-04	4800	0	0	4	2.968330e-05	1	3.079770e-05	32470	0	0	0.000000e+00	860	0	0	0.000000e+00	14834	0	134756	0	0.000000e+00	3384	0	0	0.000000e+00	5196	0	0	0.000000e+00	6962	0	0	0.000000e+00	310	0	0	0.000000e+00	63912	0	3	6.211180e-04	4830	0	0	3	3.716090e-05	0	0.000000e+00	24810	0	0	0.000000e+00	112	0	0	0.000000e+00	12908	0	80730	0	0.000000e+00	996	0	0	0.000000e+00	3754	0	0	0.000000e+00	10508	0	0	0.000000e+00	272	0	0	0.000000e+00	21048	0	3	6.244800e-04	4804	0	0	12	111400138	12	112915755	0	0.85440	0.722319	1.000000	0.71638	0.990000	0.65344	1.000000	0.86279	5.421000	0.66185	0.650000	0.52971	1.158000	0.71245	112477951	G	.	rs535800148	.	.	10.270	8.884	8.295	9.256	.	.	.	2	-33	2	-17	0.07	0.00	0.00	0.00	PTPN11	1.00	exon-NM_001330437.2-9+64+end+159	181766	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_provided&RASopathy	MedGen:CN230736&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	12:112915755-112915755	2.224e-04	27	27	0	0	0	0	0	0	0	27	10406	11554	8652	6606	66652	908	16494	0	0	0	0	0	0	27	0	0	0	0	0	0	0	rs535800148	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95399e-06	0.00000e+00	1.49448e-03	2.37269e-04	1.34722e-04	1.49448e-03	1.90846e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs535800148	535800148	.	.	.	PTPN11	PTPN11:exonic	PTPN11:missense	PTPN11:Noonan_syndrome_1\x3bLEOPARD_syndrome_1\x3bMetachondromatosis\x3bLeukemia\x2cjuvenile_myelomonocytic\x2csomatic	PTPN11:163950\x3b151100\x3b156250\x3b607785	PTPN11:3\x3b3\x3b3\x3b3	PTPN11:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999877230878678	0.000122769057470549	6.38519788034449e-11	DISEASE: LEOPARD syndrome 1 (LPRD1) [MIM:151100]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:12058348, ECO:0000269|PubMed:14961557, ECO:0000269|PubMed:15121796, ECO:0000269|PubMed:15389709, ECO:0000269|PubMed:15520399, ECO:0000269|PubMed:15690106, ECO:0000269|PubMed:16679933, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 1 (NS1) [MIM:163950]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints. {ECO:0000269|PubMed:11704759, ECO:0000269|PubMed:11992261, ECO:0000269|PubMed:12161469, ECO:0000269|PubMed:12325025, ECO:0000269|PubMed:12529711, ECO:0000269|PubMed:12634870, ECO:0000269|PubMed:12717436, ECO:0000269|PubMed:12739139, ECO:0000269|PubMed:12960218, ECO:0000269|PubMed:15384080, ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry. Mutations in PTPN11 account for more than 50% of the cases.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:12717436}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Metachondromatosis (MC) [MIM:156250]: A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest. {ECO:0000269|PubMed:20577567}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,857	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	112888228	112888228	A	G	G	missense_variant	MODERATE	PTPN11	5781	Transcript	NM_002834.5	protein_coding	3/16	.	NM_002834.5:c.244A>G	NP_002825.3:p.Met82Val	409	244	82	M/V	Atg/Gtg	rs397507515&COSV61009956	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTPN11	.	chr12:g.112888228A>G	.	.	.	.	.	.	uncertain_significance	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.78866	0.252838	D	0.78592	0.125408	21.4	21.5	2.267563	2.210245	0.36152	0.37352	./.	T	0.30394	0.439042061044694	0.23635	0.93715359923339725	.	0.78442	.	./.	.	.	.	.	3.692422	0.295777159976535	0.55294	2.748211	0.064423834923515	0.44808	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.96078	.	.	.	5.9	5.9	0.94952	0	0.89359	0.724815	.	.	0.74766	0.999999950296856	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.98432	0.735409	.&.&SH2_domain&SH2_domain&SH2_domain&SH2_domain	.	.	.	0.79272	.	0.038194	0.84330	D	0.000000	D	0.62879	0.047349	0.91320	.	0.94823	.	D	0.90265	0.7163	.	0.60647	.	D	0.86603	0.2415	M82V	Loss_of_catalytic_residue_at_V78_(P_=_0.0172)&_Loss_of_loop_(P_=_0.1242)&_Gain_of_helix_(P_=_0.132)&_Loss_of_disorder_(P_=_0.1334)&_Loss_of_phosphorylation_at_Y81_(P_=_0.215)	ENST00000351677	0.75680	0.622	.	0.23595	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.29114	.	.	.	0.23277	.	.	0.12992	.	D	0.84749	0.818179011345	0.74093	.	10	0.12246	.	.	0.15770	.	.	16.3291	0.82833	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.70790	.	./.	V	.	M	G	45	0.97767	.	12	CN166718&CN517202	.	ORPHA536391	Uncertain_significance	NC_000012.12:g.112450424A>G	40504	reviewed_by_expert_panel	Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:9a9c6639-bd78-4169-b494-17e19c0101cc	.	.	AEFDBI	D	0.90742	0.99067	D	0.89894	0.923052	.	2	7.964830e-06	1	6.151570e-05	16256	0	0	0.000000e+00	34592	0	251104	0	0.000000e+00	10078	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	1	8.818960e-06	113392	0	1	6.151570e-05	16256	0	0	0.000000e+00	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	.	.	.	.	0	0.000000e+00	15690	0	0	segdup	0	2	8.454300e-06	1	6.710510e-05	14902	0	0	0.000000e+00	34260	0	236566	0	0.000000e+00	9570	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	1	9.767910e-06	102376	0	1	6.710510e-05	14902	0	0	0.000000e+00	30526	0	0	1	4.804740e-06	1	6.165990e-05	16218	0	0	0.000000e+00	30524	0	208128	0	0.000000e+00	6210	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89554	0	1	6.165990e-05	16218	0	0	0.000000e+00	30608	0	0	2	8.180360e-06	1	8.315320e-05	12026	0	0	0.000000e+00	34458	0	244488	0	0.000000e+00	9996	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	1	8.984400e-06	111304	0	1	8.315320e-05	12026	0	0	0.000000e+00	30616	0	0	2	1.314060e-05	1	2.412660e-05	41448	0	0	0.000000e+00	912	0	0	0.000000e+00	15284	0	152200	0	0.000000e+00	3468	0	0	0.000000e+00	5196	0	0	0.000000e+00	10616	0	0	0.000000e+00	316	0	1	1.469810e-05	68036	0	1	2.412660e-05	41448	0	0	0.000000e+00	4832	0	0	0.000000e+00	0	0.000000e+00	9100	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32900	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5492	0	0	0.000000e+00	246	0	0	0.000000e+00	6846	0	0	0.000000e+00	3112	0	0	.	0	2	1.351830e-05	1	2.431550e-05	41126	0	0	0.000000e+00	912	0	0	0.000000e+00	15096	0	147948	0	0.000000e+00	3302	0	0	0.000000e+00	4962	0	0	0.000000e+00	10616	0	0	0.000000e+00	304	0	1	1.543020e-05	64808	0	0	0.000000e+00	4800	0	0	1	7.418730e-06	0	0.000000e+00	32478	0	0	0.000000e+00	862	0	0	0.000000e+00	14838	0	134794	0	0.000000e+00	3384	0	0	0.000000e+00	5196	0	0	0.000000e+00	6982	0	0	0.000000e+00	310	0	1	1.564650e-05	63912	0	0	0.000000e+00	4830	0	0	1	1.238270e-05	1	4.028680e-05	24822	0	0	0.000000e+00	112	0	0	0.000000e+00	12910	0	80758	0	0.000000e+00	994	0	0	0.000000e+00	3754	0	0	0.000000e+00	10524	0	0	0.000000e+00	272	0	0	0.000000e+00	21048	0	0	0.000000e+00	4804	0	0	12	111372611	12	112888228	0	0.85440	0.722319	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	9.314000	0.95373	0.750000	0.87069	1.308000	0.88982	112450424	A	.	rs397507515	.	.	7.703	8.679	4.729	9.664	.	.	.	-41	25	-17	-50	0.00	0.00	0.00	0.00	PTPN11	1.00	exon-NM_001330437.2-3+88+end+195	40504	Uncertain_significance	reviewed_by_expert_panel	LEOPARD_syndrome_1&Noonan_syndrome_1&Juvenile_myelomonocytic_leukemia&Metachondromatosis&RASopathy&not_provided	MONDO:MONDO:0100082&MedGen:C4551484&OMIM:151100&Orphanet:500&MONDO:MONDO:0008104&MedGen:C4551602&OMIM:163950&Orphanet:648&Human_Phenotype_Ontology:HP:0012209&MONDO:MONDO:0011908&MedGen:C0349639&OMIM:607785&Orphanet:86834&MONDO:MONDO:0007979&MedGen:C0410530&OMIM:156250&Orphanet:2499&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397507515	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.98343e-06	0.00000e+00	0.00000e+00	7.42545e-06	0.00000e+00	8.98343e-06	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397507515	397507515	.	.	.	PTPN11	PTPN11:exonic	PTPN11:missense	PTPN11:Noonan_syndrome_1\x3bLEOPARD_syndrome_1\x3bMetachondromatosis\x3bLeukemia\x2cjuvenile_myelomonocytic\x2csomatic	PTPN11:163950\x3b151100\x3b156250\x3b607785	PTPN11:3\x3b3\x3b3\x3b3	PTPN11:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999877230878678	0.000122769057470549	6.38519788034449e-11	DISEASE: LEOPARD syndrome 1 (LPRD1) [MIM:151100]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:12058348, ECO:0000269|PubMed:14961557, ECO:0000269|PubMed:15121796, ECO:0000269|PubMed:15389709, ECO:0000269|PubMed:15520399, ECO:0000269|PubMed:15690106, ECO:0000269|PubMed:16679933, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 1 (NS1) [MIM:163950]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints. {ECO:0000269|PubMed:11704759, ECO:0000269|PubMed:11992261, ECO:0000269|PubMed:12161469, ECO:0000269|PubMed:12325025, ECO:0000269|PubMed:12529711, ECO:0000269|PubMed:12634870, ECO:0000269|PubMed:12717436, ECO:0000269|PubMed:12739139, ECO:0000269|PubMed:12960218, ECO:0000269|PubMed:15384080, ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry. Mutations in PTPN11 account for more than 50% of the cases.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:12717436}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Metachondromatosis (MC) [MIM:156250]: A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest. {ECO:0000269|PubMed:20577567}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,855	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
14	23889119	23889122	TCTC	T	-	inframe_deletion	MODERATE	MYH7	4625	Transcript	NM_000257.4	protein_coding	27/40	.	NM_000257.4:c.3658_3660del	NP_000248.2:p.Glu1220del	3763-3765	3658-3660	1220	E/-	GAG/-	rs397516190	CTC	.	-1	.	1	EntrezGene	.	YES	.	.	CTC	CTC	.	.	MYH6	.	chr14:g.23889122_23889124del	.	.	.	.	.	.	likely_pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.120	2.324	7.457	10.068	.	.	.	41	26	24	3	0.00	0.00	0.00	0.00	MYH7	0.00	exon-NM_000257.4-27+66+start+390	42968	Uncertain_significance	reviewed_by_expert_panel	Ebstein_anomaly&Cardiovascular_phenotype&Left_ventricular_noncompaction&Hypertrophic_cardiomyopathy	Human_Phenotype_Ontology:HP:0006674&Human_Phenotype_Ontology:HP:0010316&MONDO:MONDO:0009144&MedGen:C0013481&OMIM:224700&Orphanet:1880&MedGen:CN230736&Human_Phenotype_Ontology:HP:0030682&MONDO:MONDO:0018901&MedGen:C1960469&OMIM:PS604169&Orphanet:54260&Human_Phenotype_Ontology:HP:0001639&MONDO:MONDO:0005045&MeSH:D002312&MedGen:C0007194&Orphanet:217569	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397516190	397516190	.	.	.	MYH7	MYH7:exonic	MYH7:nonframeshift_deletion	MYH7:Laing_distal_myopathy\x3bCardiomyopathy\x2chypertrophic\x2c1\x3bLeft_ventricular_noncompaction_5\x3bCardiomyopathy\x2cdilated\x2c1S\x3bScapuloperoneal_syndrome\x2cmyopathic_type\x3bMyopathy\x2cmyosin_storage\x2cautosomal_dominant\x3bMyopathy\x2cmyosin_storage\x2cautosomal_recessive	MYH7:160500\x3b192600\x3b613426\x3b613426\x3b181430\x3b608358\x3b255160	MYH7:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	MYH7:Autosomal_dominant\x3bAutosomal_dominant\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_recessive	0	0.000145766291646031	0.999854233523213	1.85141250905742e-10	DISEASE: Cardiomyopathy, familial hypertrophic 1 (CMH1) [MIM:192600]: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:10065021, ECO:0000269|PubMed:10329202, ECO:0000269|PubMed:10521296, ECO:0000269|PubMed:10563488, ECO:0000269|PubMed:10679957, ECO:0000269|PubMed:10862102, ECO:0000269|PubMed:11113006, ECO:0000269|PubMed:11133230, ECO:0000269|PubMed:11214007, ECO:0000269|PubMed:11424919, ECO:0000269|PubMed:11733062, ECO:0000269|PubMed:11861413, ECO:0000269|PubMed:11968089, ECO:0000269|PubMed:12081993, ECO:0000269|PubMed:12566107, ECO:0000269|PubMed:12590187, ECO:0000269|PubMed:12707239, ECO:0000269|PubMed:12818575, ECO:0000269|PubMed:12820698, ECO:0000269|PubMed:12951062, ECO:0000269|PubMed:12974739, ECO:0000269|PubMed:12975413, ECO:0000269|PubMed:1417858, ECO:0000269|PubMed:15358028, ECO:0000269|PubMed:15483641, ECO:0000269|PubMed:1552912, ECO:0000269|PubMed:15563892, ECO:0000269|PubMed:15856146, ECO:0000269|PubMed:15858117, ECO:0000269|PubMed:16199542, ECO:0000269|PubMed:16267253, ECO:0000269|PubMed:1638703, ECO:0000269|PubMed:16650083, ECO:0000269|PubMed:16938236, ECO:0000269|PubMed:17372140, ECO:0000269|PubMed:18175163, ECO:0000269|PubMed:18403758, ECO:0000269|PubMed:1975517, ECO:0000269|PubMed:25182012, ECO:0000269|PubMed:7581410, ECO:0000269|PubMed:7731997, ECO:0000269|PubMed:7848441, ECO:0000269|PubMed:7874131, ECO:0000269|PubMed:8250038, ECO:0000269|PubMed:8254035, ECO:0000269|PubMed:8268932, ECO:0000269|PubMed:8282798, ECO:0000269|PubMed:8343162, ECO:0000269|PubMed:8435239, ECO:0000269|PubMed:8483915, ECO:0000269|PubMed:8655135, ECO:0000269|PubMed:8899546, ECO:0000269|PubMed:9544842, ECO:0000269|PubMed:9822100, ECO:0000269|PubMed:9829907}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, myosin storage, autosomal dominant (MSMA) [MIM:608358]: A rare congenital myopathy characterized by subsarcolemmal hyalinized bodies in type 1 muscle fibers. {ECO:0000269|PubMed:14520662, ECO:0000269|PubMed:15136674, ECO:0000269|PubMed:16684601, ECO:0000269|PubMed:17336526}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Scapuloperoneal myopathy MYH7-related (SPMM) [MIM:181430]: Progressive muscular atrophia beginning in the lower legs and affecting the shoulder region earlier and more severely than distal arm. {ECO:0000269|PubMed:17336526}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1S (CMD1S) [MIM:613426]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:11106718, ECO:0000269|PubMed:12379228, ECO:0000269|PubMed:15769782, ECO:0000269|PubMed:18506004, ECO:0000269|PubMed:21127202, ECO:0000269|PubMed:21846512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, distal, 1 (MPD1) [MIM:160500]: A muscular disorder characterized by early-onset selective weakness of the great toe and ankle dorsiflexors, followed by weakness of the finger extensors. Mild proximal weakness occasionally develops years later after the onset of the disease. {ECO:0000269|PubMed:15322983, ECO:0000269|PubMed:17548557}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, myosin storage, autosomal recessive (MSMB) [MIM:255160]: An autosomal recessive form of myosin storage myopathy, a muscle disease characterized by subsarcolemmal accumulation of hyalinized bodies in type 1 muscle fibers. MSMB clinical features include muscle weakness, type II respiratory failure and cardiac failure, due to hypertrophic cardiomyopathy. {ECO:0000269|PubMed:25666907}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,875	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	103237528	103237531	GAGA	G	-	inframe_deletion	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1092_1094del	NP_000268.1:p.Leu365del	1206-1208	1092-1094	364-365	LL/L	ctTCTc/ctc	rs62516096	AGA	.	-1	.	.	EntrezGene	.	.	.	.	AGA	AGA	.	.	PAH	.	chr12:g.103237531_103237533del	.	.	.	.	.	.	not_provided&likely_pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.924	9.158	3.163	9.459	.	.	.	28	-11	-40	28	0.09	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-12+26+end+134	597	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62516096	62516096	.	.	.	PAH	PAH:exonic	PAH:nonframeshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,669	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	103245479	103245482	CAAA	C	-	inframe_deletion	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.895_897del	NP_000268.1:p.Phe299del	1009-1011	895-897	299	F/-	TTT/-	rs62507267	AAA	.	-1	.	.	EntrezGene	.	.	.	.	AAA	AAA	.	.	PAH	.	chr12:g.103245480_103245482del	.	.	.	.	.	.	uncertain_significance&not_provided	.	1	.	.	.	.	.	PAH&NM_000277.1&c.895_897del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.506	11.083	11.570	9.399	.	.	.	11	-6	-48	-14	0.01	0.00	0.00	0.01	PAH	0.00	exon-NM_001354304.2-9+15+start+70	102886	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62507267	62507267	.	.	.	PAH	PAH:exonic	PAH:nonframeshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,692	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
14	23893244	23893247	TCTC	T	-	inframe_deletion	MODERATE	MYH7	4625	Transcript	NM_000257.4	protein_coding	23/40	.	NM_000257.4:c.2791_2793del	NP_000248.2:p.Glu931del	2896-2898	2791-2793	931	E/-	GAG/-	rs397516172	CTC	.	-1	.	1	EntrezGene	.	YES	.	.	CTC	CTC	.	.	MYH7	.	chr14:g.23893251_23893253del	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.665	10.512	12.002	7.928	.	.	.	50	-28	0	39	0.00	0.00	0.00	0.00	MYH7	0.00	exon-NM_000257.4-23+111+end+243	42934	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Hypertrophic_cardiomyopathy	MedGen:CN517202&Human_Phenotype_Ontology:HP:0001639&MONDO:MONDO:0005045&MeSH:D002312&MedGen:C0007194&Orphanet:217569	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397516172	397516172	.	.	.	MYH7	MYH7:exonic	MYH7:nonframeshift_deletion	MYH7:Laing_distal_myopathy\x3bCardiomyopathy\x2chypertrophic\x2c1\x3bLeft_ventricular_noncompaction_5\x3bCardiomyopathy\x2cdilated\x2c1S\x3bScapuloperoneal_syndrome\x2cmyopathic_type\x3bMyopathy\x2cmyosin_storage\x2cautosomal_dominant\x3bMyopathy\x2cmyosin_storage\x2cautosomal_recessive	MYH7:160500\x3b192600\x3b613426\x3b613426\x3b181430\x3b608358\x3b255160	MYH7:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	MYH7:Autosomal_dominant\x3bAutosomal_dominant\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_recessive	0	0.000145766291646031	0.999854233523213	1.85141250905742e-10	DISEASE: Cardiomyopathy, familial hypertrophic 1 (CMH1) [MIM:192600]: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:10065021, ECO:0000269|PubMed:10329202, ECO:0000269|PubMed:10521296, ECO:0000269|PubMed:10563488, ECO:0000269|PubMed:10679957, ECO:0000269|PubMed:10862102, ECO:0000269|PubMed:11113006, ECO:0000269|PubMed:11133230, ECO:0000269|PubMed:11214007, ECO:0000269|PubMed:11424919, ECO:0000269|PubMed:11733062, ECO:0000269|PubMed:11861413, ECO:0000269|PubMed:11968089, ECO:0000269|PubMed:12081993, ECO:0000269|PubMed:12566107, ECO:0000269|PubMed:12590187, ECO:0000269|PubMed:12707239, ECO:0000269|PubMed:12818575, ECO:0000269|PubMed:12820698, ECO:0000269|PubMed:12951062, ECO:0000269|PubMed:12974739, ECO:0000269|PubMed:12975413, ECO:0000269|PubMed:1417858, ECO:0000269|PubMed:15358028, ECO:0000269|PubMed:15483641, ECO:0000269|PubMed:1552912, ECO:0000269|PubMed:15563892, ECO:0000269|PubMed:15856146, ECO:0000269|PubMed:15858117, ECO:0000269|PubMed:16199542, ECO:0000269|PubMed:16267253, ECO:0000269|PubMed:1638703, ECO:0000269|PubMed:16650083, ECO:0000269|PubMed:16938236, ECO:0000269|PubMed:17372140, ECO:0000269|PubMed:18175163, ECO:0000269|PubMed:18403758, ECO:0000269|PubMed:1975517, ECO:0000269|PubMed:25182012, ECO:0000269|PubMed:7581410, ECO:0000269|PubMed:7731997, ECO:0000269|PubMed:7848441, ECO:0000269|PubMed:7874131, ECO:0000269|PubMed:8250038, ECO:0000269|PubMed:8254035, ECO:0000269|PubMed:8268932, ECO:0000269|PubMed:8282798, ECO:0000269|PubMed:8343162, ECO:0000269|PubMed:8435239, ECO:0000269|PubMed:8483915, ECO:0000269|PubMed:8655135, ECO:0000269|PubMed:8899546, ECO:0000269|PubMed:9544842, ECO:0000269|PubMed:9822100, ECO:0000269|PubMed:9829907}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, myosin storage, autosomal dominant (MSMA) [MIM:608358]: A rare congenital myopathy characterized by subsarcolemmal hyalinized bodies in type 1 muscle fibers. {ECO:0000269|PubMed:14520662, ECO:0000269|PubMed:15136674, ECO:0000269|PubMed:16684601, ECO:0000269|PubMed:17336526}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Scapuloperoneal myopathy MYH7-related (SPMM) [MIM:181430]: Progressive muscular atrophia beginning in the lower legs and affecting the shoulder region earlier and more severely than distal arm. {ECO:0000269|PubMed:17336526}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1S (CMD1S) [MIM:613426]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:11106718, ECO:0000269|PubMed:12379228, ECO:0000269|PubMed:15769782, ECO:0000269|PubMed:18506004, ECO:0000269|PubMed:21127202, ECO:0000269|PubMed:21846512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, distal, 1 (MPD1) [MIM:160500]: A muscular disorder characterized by early-onset selective weakness of the great toe and ankle dorsiflexors, followed by weakness of the finger extensors. Mild proximal weakness occasionally develops years later after the onset of the disease. {ECO:0000269|PubMed:15322983, ECO:0000269|PubMed:17548557}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, myosin storage, autosomal recessive (MSMB) [MIM:255160]: An autosomal recessive form of myosin storage myopathy, a muscle disease characterized by subsarcolemmal accumulation of hyalinized bodies in type 1 muscle fibers. MSMB clinical features include muscle weakness, type II respiratory failure and cardiac failure, due to hypertrophic cardiomyopathy. {ECO:0000269|PubMed:25666907}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,877	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
14	23894115	23894118	CCTT	C	-	inframe_deletion	MODERATE	MYH7	4625	Transcript	NM_000257.4	protein_coding	22/40	.	NM_000257.4:c.2539_2541del	NP_000248.2:p.Lys847del	2644-2646	2539-2541	847	K/-	AAG/-	rs397516155	CTT	.	-1	.	1	EntrezGene	.	YES	.	.	CTT	CTT	.	.	MYH7	.	chr14:g.23894118_23894120del	.	.	.	.	.	.	uncertain_significance&likely_pathogenic&pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.002	7.928	6.054	6.947	.	.	.	17	35	-42	-23	0.00	0.00	0.00	0.00	MYH7	0.00	exon-NM_000257.4-22+115+end+256	42913	Likely_pathogenic	reviewed_by_expert_panel	Cardiovascular_phenotype&not_provided&Hypertrophic_cardiomyopathy_1&Dilated_cardiomyopathy_1S&Primary_familial_hypertrophic_cardiomyopathy&Hypertrophic_cardiomyopathy	MedGen:CN230736&MedGen:CN517202&MONDO:MONDO:0008647&MedGen:C3495498&OMIM:192600&MONDO:MONDO:0013262&MedGen:C1834481&OMIM:613426&Orphanet:154&Orphanet:54260&MONDO:MONDO:0024573&MeSH:D024741&MedGen:C0949658&OMIM:PS192600&Orphanet:155&Human_Phenotype_Ontology:HP:0001639&MONDO:MONDO:0005045&MeSH:D002312&MedGen:C0007194&Orphanet:217569	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397516155	397516155	.	.	.	MYH7	MYH7:exonic	MYH7:nonframeshift_deletion	MYH7:Laing_distal_myopathy\x3bCardiomyopathy\x2chypertrophic\x2c1\x3bLeft_ventricular_noncompaction_5\x3bCardiomyopathy\x2cdilated\x2c1S\x3bScapuloperoneal_syndrome\x2cmyopathic_type\x3bMyopathy\x2cmyosin_storage\x2cautosomal_dominant\x3bMyopathy\x2cmyosin_storage\x2cautosomal_recessive	MYH7:160500\x3b192600\x3b613426\x3b613426\x3b181430\x3b608358\x3b255160	MYH7:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	MYH7:Autosomal_dominant\x3bAutosomal_dominant\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_recessive	0	0.000145766291646031	0.999854233523213	1.85141250905742e-10	DISEASE: Cardiomyopathy, familial hypertrophic 1 (CMH1) [MIM:192600]: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:10065021, ECO:0000269|PubMed:10329202, ECO:0000269|PubMed:10521296, ECO:0000269|PubMed:10563488, ECO:0000269|PubMed:10679957, ECO:0000269|PubMed:10862102, ECO:0000269|PubMed:11113006, ECO:0000269|PubMed:11133230, ECO:0000269|PubMed:11214007, ECO:0000269|PubMed:11424919, ECO:0000269|PubMed:11733062, ECO:0000269|PubMed:11861413, ECO:0000269|PubMed:11968089, ECO:0000269|PubMed:12081993, ECO:0000269|PubMed:12566107, ECO:0000269|PubMed:12590187, ECO:0000269|PubMed:12707239, ECO:0000269|PubMed:12818575, ECO:0000269|PubMed:12820698, ECO:0000269|PubMed:12951062, ECO:0000269|PubMed:12974739, ECO:0000269|PubMed:12975413, ECO:0000269|PubMed:1417858, ECO:0000269|PubMed:15358028, ECO:0000269|PubMed:15483641, ECO:0000269|PubMed:1552912, ECO:0000269|PubMed:15563892, ECO:0000269|PubMed:15856146, ECO:0000269|PubMed:15858117, ECO:0000269|PubMed:16199542, ECO:0000269|PubMed:16267253, ECO:0000269|PubMed:1638703, ECO:0000269|PubMed:16650083, ECO:0000269|PubMed:16938236, ECO:0000269|PubMed:17372140, ECO:0000269|PubMed:18175163, ECO:0000269|PubMed:18403758, ECO:0000269|PubMed:1975517, ECO:0000269|PubMed:25182012, ECO:0000269|PubMed:7581410, ECO:0000269|PubMed:7731997, ECO:0000269|PubMed:7848441, ECO:0000269|PubMed:7874131, ECO:0000269|PubMed:8250038, ECO:0000269|PubMed:8254035, ECO:0000269|PubMed:8268932, ECO:0000269|PubMed:8282798, ECO:0000269|PubMed:8343162, ECO:0000269|PubMed:8435239, ECO:0000269|PubMed:8483915, ECO:0000269|PubMed:8655135, ECO:0000269|PubMed:8899546, ECO:0000269|PubMed:9544842, ECO:0000269|PubMed:9822100, ECO:0000269|PubMed:9829907}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, myosin storage, autosomal dominant (MSMA) [MIM:608358]: A rare congenital myopathy characterized by subsarcolemmal hyalinized bodies in type 1 muscle fibers. {ECO:0000269|PubMed:14520662, ECO:0000269|PubMed:15136674, ECO:0000269|PubMed:16684601, ECO:0000269|PubMed:17336526}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Scapuloperoneal myopathy MYH7-related (SPMM) [MIM:181430]: Progressive muscular atrophia beginning in the lower legs and affecting the shoulder region earlier and more severely than distal arm. {ECO:0000269|PubMed:17336526}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1S (CMD1S) [MIM:613426]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:11106718, ECO:0000269|PubMed:12379228, ECO:0000269|PubMed:15769782, ECO:0000269|PubMed:18506004, ECO:0000269|PubMed:21127202, ECO:0000269|PubMed:21846512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, distal, 1 (MPD1) [MIM:160500]: A muscular disorder characterized by early-onset selective weakness of the great toe and ankle dorsiflexors, followed by weakness of the finger extensors. Mild proximal weakness occasionally develops years later after the onset of the disease. {ECO:0000269|PubMed:15322983, ECO:0000269|PubMed:17548557}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, myosin storage, autosomal recessive (MSMB) [MIM:255160]: An autosomal recessive form of myosin storage myopathy, a muscle disease characterized by subsarcolemmal accumulation of hyalinized bodies in type 1 muscle fibers. MSMB clinical features include muscle weakness, type II respiratory failure and cardiac failure, due to hypertrophic cardiomyopathy. {ECO:0000269|PubMed:25666907}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,878	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	103288654	103288657	GAGA	G	-	inframe_deletion	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.208_210del	NP_000268.1:p.Ser70del	322-324	208-210	70	S/-	TCT/-	rs62642094	AGA	.	-1	.	.	EntrezGene	.	.	.	.	AGA	AGA	.	.	PAH	.	chr12:g.103288657_103288659del	.	.	.	.	.	.	not_provided&pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.038	10.766	11.785	7.700	.	.	.	41	38	-13	-17	0.00	0.01	0.00	0.00	PAH	0.00	exon-NM_001354304.2-4+39+end+184	102632	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	rs62642094	1.647e-05	2	2	0	0	1	1	0	0	0	0	10382	11566	8652	6614	66690	908	16502	0	1	1	0	0	0	0	0	0	0	0	0	0	0	rs866012140	0.00000e+00	5.95593e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.41763e-06	8.98650e-06	5.95593e-05	8.12123e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62642094	62642094	.	.	.	PAH	PAH:exonic	PAH:nonframeshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,817	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	89692794	89692794	A	G	G	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.278A>G	NP_000305.3:p.His93Arg	1123	278	93	H/R	cAt/cGt	rs121909238&CM051214&COSV100910602&COSV64296545&COSV64296755	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89692794A>G	.	.	.	.	.	.	pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.278A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.97364	0.590493	D	0.97322	0.610426	25.7	24.9	3.766868	3.463829	0.71231	0.66192	./.	D	0.96022	0.999056160449982	0.84152	0.99749133011096458	.	0.98617	.	./.	.	.	.	.	9.300425	0.770280618410248	0.87661	9.408283	0.830578713717077	0.87975	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98763	.	.	.	5.07	5.07	0.68106	0	0.89359	0.724815	.	.	0.74766	0.999999999999151	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.95156	0.727631	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.75457	.	0.000000	0.84330	D	0.000000	D	0.98874	0.853705	0.97582	.	0.99649	.	D	0.99119	0.9719	.	0.99476	.	D	0.99275	1.0909	H93R	Loss_of_catalytic_residue_at_D92_(P_=_0.1258)&_Gain_of_glycosylation_at_P95_(P_=_0.1638)&_Gain_of_solvent_accessibility_(P_=_0.1903)&_Gain_of_disorder_(P_=_0.2215)&_Gain_of_relative_solvent_accessibility_(P_=_0.2629)	P60484	0.96785	0.879	.	0.91792	.	.	0.81001	simple_aae	A	1	0.95131	.	.	.	0.90584	.	.	0.88582	.	D	0.93900	0.879548311234	0.99597	.	8	0.92824	.	.	0.91255	.	.	14.8406	0.69852	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.94550	.	./.	R	.	H	G	940	0.13648	.	10	C1854416&C1959582	605309	ORPHA210548&ORPHA306498	Pathogenic	NC_000010.11:g.87933037A>G	7848	reviewed_by_expert_panel	Macrocephaly/autism_syndrome&PTEN_hamartoma_tumor_syndrome	ClinGen_PTEN_Variant_Curation_Expert_Panel:902dd050-bb88-4ce6-b98d-dd80cbc3aa5e&OMIM_Allelic_Variant:601728.0037&UniProtKB_(protein):P60484#VAR_032634	.	.	AEFDGBIJ	D	0.84726	0.98615	D	0.91683	0.930078	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89682774	10	89692794	0	0.92422	0.732398	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	8.871000	0.91978	0.756000	0.94297	1.312000	0.94714	87933037	A	.	rs121909238	.	.	10.752	10.998	5.352	9.651	.	.	.	-3	-42	-1	-24	0.00	0.02	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+24+start+239	7848	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome&Macrocephaly-autism_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121909238	121909238	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,535	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
21	36164771	36164771	C	CATGCCG	ATGCCG	inframe_insertion	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	9/9	.	NM_001754.5:c.1098_1103dup	NP_001745.2:p.Ile366_Gly367dup	1297-1298	1103-1104	368	M/IGM	atg/atCGGCATg	rs750495319	.	.	-1	.	1	EntrezGene	.	YES	.	.	.	.	.	.	RUNX1	.	chr21:g.36164783_36164788dup	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.279	7.470	.	.	.	.	.	.	.	.	.	.	.	.	0.45	exon-NM_001754.5-9+136+end+4810	239040	Uncertain_significance	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	21:36164772-36164778	6.680e-05	8	1	0	0	0	0	0	3	0	2	3464	1752	2170	586	17546	242	9074	0	0	1	0	0	0	0	0	0	0	0	0	0	0	rs750495319	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.08246e-04	4.38789e-04	1.50784e-04	1.03230e-04	4.54669e-05	1.50784e-04	7.33634e-05	rs750495319	0.00000e+00	0.00000e+00	0.00000e+00	6.18047e-04	0.00000e+00	6.69613e-05	0.00000e+00	.	0.00000e+00	1.45033e-04	6.18047e-04	6.45453e-05	.	.	rs750495319	750495319	.	.	.	RUNX1	RUNX1:exonic	RUNX1:nonframeshift_insertion	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,951	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
21	36164715	36164715	C	G	G	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	9/9	.	NM_001754.5:c.1160G>C	NP_001745.2:p.Gly387Ala	1354	1160	387	G/A	gGc/gCc	rs1238015554	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36164715C>G	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	T	0.44148	-0.0519576	T	0.43400	-0.31241	21.4	22.4	2.276754	2.406070	0.36356	0.41637	C/C	T	0.29834	0.423893570899963	0.39175	0.9820701364032699	.	0.95386	.	C/C	.	.	.	.	3.812015	0.316114521425373	0.56485	3.379792	0.217128903848043	0.52028	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.30133	.	.	.	5.22	5.22	0.72285	0	0.67091	0.694456	.	.	0.74766	0.999999999868608	.	0	0.29568	0.578056	.	.	.	.	.	.	0	0.53088	0.635551	.&.&.&.	.	.	.	0.84537	.	0.353337	0.32067	N	0.006398	D	0.89596	0.26335	0.60070	.	0.47626	.	T	0.45068	0.1355	.	0.51848	.	T	0.32449	-0.9906	G360A	Loss_of_phosphorylation_at_S361_(P_=_0.1898)&_Gain_of_glycosylation_at_S362_(P_=_0.2478)&_Loss_of_catalytic_residue_at_G360_(P_=_0.2581)&_Gain_of_solvent_accessibility_(P_=_0.3304)&_Loss_of_loop_(P_=_0.4412)	Q01196	0.80594	0.668	.	0.57402	.	.	0.47006	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D	0.999425&0.999425&0.999425&0.999425&0.999425	0.74582	.	.	.	0.67487	.	.	0.66596	.	D	0.84619	0.817334353924	0.37795	.	10	0.21947	.	.	0.61437	.	.	18.3819	0.90397	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.57177	.	C/C	A	.	G	G	399	0.82780	.	21	C1832388&CN517202	601399	.	Uncertain_significance	NC_000021.9:g.34792418C>G	532662	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy&not_provided	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:796f47f4-6c31-4833-8a66-03f0dc55514a	.	.	AEFDBCI	D	0.46597	0.87145	N	0.52472	0.484907	.	1	5.664500e-06	0	0.000000e+00	10102	0	0	0.000000e+00	26748	0	176538	0	0.000000e+00	8744	0	0	0.000000e+00	13312	0	0	0.000000e+00	15882	0	1	1.380030e-05	72462	0	1	1.380030e-05	72462	0	0	0.000000e+00	24542	0	0	0.000000e+00	0	0.000000e+00	3704	0	0	0.000000e+00	13360	0	75978	0	0.000000e+00	1654	0	0	0.000000e+00	5626	0	0	0.000000e+00	11340	0	0	0.000000e+00	26534	0	.	.	.	.	0	0.000000e+00	12276	0	0	.	0	1	5.853570e-06	0	0.000000e+00	9474	0	0	0.000000e+00	26624	0	170836	0	0.000000e+00	8520	0	0	0.000000e+00	12954	0	0	0.000000e+00	15874	0	1	1.463960e-05	68308	0	1	1.463960e-05	68308	0	0	0.000000e+00	24508	0	0	1	6.707900e-06	0	0.000000e+00	10068	0	0	0.000000e+00	22702	0	149078	0	0.000000e+00	4990	0	0	0.000000e+00	10396	0	0	0.000000e+00	13462	0	1	1.691470e-05	59120	0	1	1.691470e-05	59120	0	0	0.000000e+00	24538	0	0	1	5.763420e-06	0	0.000000e+00	8816	0	0	0.000000e+00	26680	0	173508	0	0.000000e+00	8682	0	0	0.000000e+00	13308	0	0	0.000000e+00	15880	0	1	1.410080e-05	70918	0	1	1.410080e-05	70918	0	0	0.000000e+00	24542	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35086585	21	36164715	0	0.49826	0.660377	1.000000	0.71638	0.951000	0.49849	0.993000	0.55118	5.484000	0.66567	0.580000	0.29708	1.011000	0.38149	34792418	C	.	rs1238015554	.	.	.	.	9.279	7.470	.	.	.	-12	-1	-20	1	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-9+192+end+4810	532662	Uncertain_significance	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21:36164715-36164715	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.43386e-05	0.00000e+00	0.00000e+00	0.00000e+00	1.28594e-05	1.43386e-05	4.08487e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1238015554	1238015554	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,950	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
21	36164453	36164453	C	A	A	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	9/9	.	NM_001754.5:c.1422G>T	NP_001745.2:p.Glu474Asp	1616	1422	474	E/D	gaG/gaT	rs886057047	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36164453C>A	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	T	0.40849	-0.0729882	T	0.40047	-0.342619	24.4	23.8	3.396364	3.092170	0.61448	0.56867	C/C	D	0.58184	0.921941757202148	0.89442	0.99810862375885956	.	0.82712	.	C/C	.	.	.	.	3.509347	0.26316551082379	0.53402	4.117767	0.362220924330453	0.59389	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.47477	.	.	.	4.79	1.48	0.21900	0	0.16991	0.550933	.	.	0.48965	0.999960955572392	.	0	0.29568	0.578056	.	.	.	.	.	.	0	0.38103	0.604944	Runx&_C-terminal_domain&.&.&Runx&_C-terminal_domain	.	.	.	0.80515	.	.	.	.	.	D	0.91955	0.338727	0.87440	.	0.63916	.	T	0.60917	0.2411	.	0.60823	.	T	0.58365	-0.7417	E447D	Gain_of_MoRF_binding_(P_=_0.096)&_Gain_of_helix_(P_=_0.1736)&_Loss_of_methylation_at_R444_(P_=_0.1979)&_Loss_of_phosphorylation_at_S442_(P_=_0.23)&_Gain_of_glycosylation_at_S442_(P_=_0.2505)	Q01196	0.81877	0.681	.	0.63355	.	.	0.37532	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D	0.815433&0.946567&0.851912&0.946567&0.946567	0.51157	.	.	.	0.77913	.	.	0.82059	.	D	0.90404	0.855245351791	0.63375	.	9	0.40909	.	.	0.91255	.	.	5.5559	0.16402	0.0:0.3572:0.0:0.6428	.	.	.	.	.	.	.	.	0.57006	.	C/C	D	.	E	A	399	0.82780	.	21	C1832388	601399	.	Uncertain_significance	NC_000021.9:g.34792156C>A	339874	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	Illumina_Laboratory_Services&Illumina:261908&ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:272c05cd-977f-4310-b29b-61bd0a72da18	.	.	AEFDBCI	D	0.47574	0.87880	N	0.48724	0.420412	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21	35086323	21	36164453	0	0.33130	0.580535	1.000000	0.71638	0.996000	0.76049	1.000000	0.86279	1.074000	0.30315	0.499000	0.22661	0.935000	0.33677	34792156	C	.	rs886057047	.	.	.	.	9.279	7.470	.	.	.	2	-1	-22	0	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-9+454+end+4810	339874	Uncertain_significance	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs886057047	886057047	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,943	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
19	4101272	4101272	G	A	A	missense_variant	MODERATE	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	5/11	.	NM_030662.4:c.535C>T	NP_109587.1:p.Arg179Trp	782	535	179	R/W	Cgg/Tgg	rs370799450&COSV53568067	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	MAP2K2	.	chr19:g.4101272G>A	.	.	.	.	.	.	uncertain_significance&likely_benign	0&1	1&1	.	.	.	.	.	MAP2K2&NM_030662.3&c.535C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	T	0.30306	-0.137393	T	0.63322	-0.100982	32	32	4.731473	4.579318	0.92504	0.92170	./.	T	0.23680	0.268453832957138	0.98095	0.99911900325696157	.	0.78487	.	./.	0	0.0	1	1.1657729074376311E-4	4.624474	0.436077831981642	0.63826	4.921412	0.485022932990863	0.66215	.	.	.	13	1.085e-04	0	0	0	0	11	2.990e-04	3	1.329e-03	0	0	3	1.597e-04	5	5.710e-04	12	1.141e-04	0	0	0	0	11	3.633e-04	3	1.577e-03	0	0	3	2.200e-04	5	5.730e-04	10	1.119e-04	0	0	0	0	8	2.613e-04	2	1.099e-03	0	0	1	7.192e-05	5	5.713e-04	0.67874	.	.	.	4.25	4.25	0.49658	0	0.74545	0.702456	.	.	0.38059	0.998955419594509	.	0	0.39905	0.608884	.	.	.	.	.	.	0	0.83352	0.714379	Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain	.	.	.	0.95276	.	0.000000	0.84330	D	0.000000	D	0.85218	0.176409	0.81416	.	0.46962	.	T	0.73091	0.3719	.	0.61557	.	T	0.75793	-0.2707	.	.	.	.	.	.	0.53851	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.79915	.	.	.	0.70673	.	.	0.63994	.	D	0.97105	0.906265616417	0.77012	.	10	0.66756	.	.	0.72154	.	.	10.6414	0.44786	0.0:0.0:0.8081:0.1919	.	.	.	.	.	.	.	.	0.86941	.	./.	W	.	R	A	934	0.15400	.	19	CN166718&CN517202	.	ORPHA536391	Likely_benign	NC_000019.10:g.4101274G>A	180905	reviewed_by_expert_panel	Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:87032436-5de0-42c5-bbd4-68bd737592cc	.	.	AEFDBI	D	0.67620	0.96119	D	0.72387	0.796862	.	21	1.067850e-04	1	8.641550e-05	11572	0	1	3.555430e-05	28126	0	196656	0	0.000000e+00	8982	0	3	2.048060e-04	14648	0	0	0.000000e+00	18142	0	4	4.704780e-05	85020	0	12	4.790040e-04	25052	0	12	4.790040e-04	25052	0	14	1.674720e-04	1	2.255300e-04	4434	0	1	7.111360e-05	14062	0	83596	0	0.000000e+00	1682	0	2	3.071250e-04	6512	0	0	0.000000e+00	12066	0	2	6.512960e-05	30708	0	8	6.368410e-04	12562	0	8	6.368410e-04	12562	0	0	segdup	0	21	1.113500e-04	1	9.330100e-05	10718	0	1	3.578590e-05	27944	0	188594	0	0.000000e+00	8686	0	3	2.112680e-04	14200	0	0	0.000000e+00	18130	0	4	5.061370e-05	79030	0	12	4.798460e-04	25008	0	12	4.798460e-04	25008	0	0	19	1.163520e-04	1	8.670020e-05	11534	0	1	4.155240e-05	24066	0	163298	0	0.000000e+00	5180	0	2	1.778090e-04	11248	0	0	0.000000e+00	14406	0	3	4.426480e-05	67774	0	12	4.791570e-04	25044	0	12	4.791570e-04	25044	0	0	21	1.088400e-04	1	1.017710e-04	9826	0	1	3.563280e-05	28064	0	192944	0	0.000000e+00	8904	0	3	2.048620e-04	14644	0	0	0.000000e+00	18140	0	4	4.803650e-05	83270	0	12	4.790040e-04	25052	0	12	4.790040e-04	25052	0	0	6	3.947840e-05	0	0.000000e+00	41364	0	0	0.000000e+00	912	0	0	0.000000e+00	15266	0	151982	0	0.000000e+00	3468	0	0	0.000000e+00	5174	0	0	0.000000e+00	10622	0	0	0.000000e+00	316	0	3	4.413190e-05	67978	0	3	6.255210e-04	4796	0	3	6.255210e-04	4796	0	1	3.044880e-05	0	0.000000e+00	9064	0	0	0.000000e+00	60	0	0	0.000000e+00	4682	0	32842	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5498	0	0	0.000000e+00	246	0	0	0.000000e+00	6844	0	1	3.232060e-04	3094	0	0	.	0	5	3.384640e-05	0	0.000000e+00	41042	0	0	0.000000e+00	912	0	0	0.000000e+00	15078	0	147726	0	0.000000e+00	3298	0	0	0.000000e+00	4938	0	0	0.000000e+00	10622	0	0	0.000000e+00	304	0	2	3.088710e-05	64752	0	3	6.297230e-04	4764	0	0	6	4.457520e-05	0	0.000000e+00	32414	0	0	0.000000e+00	862	0	0	0.000000e+00	14820	0	134604	0	0.000000e+00	3386	0	0	0.000000e+00	5174	0	0	0.000000e+00	6982	0	0	0.000000e+00	310	0	3	4.697340e-05	63866	0	3	6.257820e-04	4794	0	0	4	4.964380e-05	0	0.000000e+00	24750	0	0	0.000000e+00	112	0	0	0.000000e+00	12892	0	80574	0	0.000000e+00	994	0	0	0.000000e+00	3732	0	0	0.000000e+00	10530	0	0	0.000000e+00	272	0	1	4.759190e-05	21012	0	3	6.291950e-04	4768	0	0	19	4052272	19	4101272	0	0.73137	0.706548	1.000000	0.71638	0.731000	0.35132	0.985000	0.49585	2.223000	0.42578	0.676000	0.76740	1.176000	0.78918	4101274	G	.	rs370799450	.	.	5.732	10.284	11.061	10.494	.	.	.	-27	6	6	-45	0.00	0.01	0.00	0.01	MAP2K2	0.86	exon-NM_030662.4-5+6+end+52	180905	Likely_benign	reviewed_by_expert_panel	Cardiofaciocutaneous_syndrome_4&not_provided&RASopathy	MONDO:MONDO:0014114&MedGen:C3809007&OMIM:615280&Orphanet:1340&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	19:4101272-4101272	1.085e-04	13	11	0	0	0	3	0	3	0	5	3826	1510	2258	1334	18788	322	8756	0	0	3	0	3	0	5	0	0	0	0	0	0	0	rs370799450	9.35454e-05	3.65604e-05	0.00000e+00	2.20588e-04	0.00000e+00	6.00471e-05	0.00000e+00	4.76910e-04	1.34218e-04	9.13492e-05	4.76910e-04	1.30142e-04	rs370799450	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.68360e-05	0.00000e+00	.	5.86923e-05	0.00000e+00	6.68360e-05	3.22685e-05	rs370799450	0.0117&0.0&0.0077	rs370799450	370799450	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:missense	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,934	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
19	4101030	4101030	C	T	T	missense_variant	MODERATE	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	6/11	.	NM_030662.4:c.692G>A	NP_109587.1:p.Arg231His	939	692	231	R/H	cGc/cAc	rs730880511&COSV53566038	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MAP2K2	.	chr19:g.4101030C>T	.	.	.	.	.	.	uncertain_significance	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.79034	0.254654	D	0.89272	0.324319	25.6	25.3	3.757100	3.584502	0.70949	0.69299	./.	D	0.53202	0.881938397884369	0.99621	0.99936548599708552	.	0.75477	.	./.	.	.	.	.	3.930183	0.335473444671048	0.57636	4.785681	0.466480472701037	0.65143	.	.	.	3	2.517e-05	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	2.870e-05	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	3.369e-05	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.92667	.	.	.	4.22	4.22	0.49153	0	0.74545	0.702456	.	.	0.74766	0.999999995623177	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.83352	0.714379	Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain	.	.	.	0.88094	.	0.000000	0.84330	D	0.000000	D	0.96345	0.589166	0.86193	.	0.92088	.	D	0.94596	0.8384	.	0.87309	.	D	0.95262	0.8688	R231H	Loss_of_methylation_at_R231_(P_=_0.0329)&_Loss_of_phosphorylation_at_T230_(P_=_0.123)&_Gain_of_disorder_(P_=_0.1269)&_Loss_of_sheet_(P_=_0.1907)&_Gain_of_loop_(P_=_0.2045)	P36507	0.69288	0.57	.	0.44655	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.79998	.	.	.	0.90584	.	.	0.97372	.	D	0.94298	0.882525086403	0.93582	.	10	0.55341	.	.	0.72154	.	.	15.1887	0.72711	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.85660	.	./.	H	.	R	T	934	0.15400	.	19	CN260604&CN166718&CN517202	.	ORPHA98733&ORPHA536391	Uncertain_significance	NC_000019.10:g.4101032C>T	543999	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:9f74ed62-a0c3-40e1-b0b2-7aa680c29fe2	.	.	AEFDGBI	D	0.78726	0.97995	D	0.80307	0.878052	.	3	1.735930e-05	0	0.000000e+00	9868	0	2	7.705350e-05	25956	0	172818	0	0.000000e+00	8758	0	1	8.045050e-05	12430	0	0	0.000000e+00	16508	0	0	0.000000e+00	70676	0	1	8.045050e-05	12430	0	0	0.000000e+00	23852	0	3	4.135650e-05	0	0.000000e+00	3494	0	2	1.537990e-04	13004	0	72540	0	0.000000e+00	1584	0	1	1.919390e-04	5210	0	0	0.000000e+00	11726	0	0	0.000000e+00	24116	0	1	1.919390e-04	5210	0	0	0.000000e+00	11948	0	0	segdup	0	3	1.799730e-05	0	0.000000e+00	9162	0	2	7.744130e-05	25826	0	166692	0	0.000000e+00	8522	0	1	8.286380e-05	12068	0	0	0.000000e+00	16500	0	0	0.000000e+00	66226	0	1	8.286380e-05	12068	0	0	0.000000e+00	23822	0	0	3	2.062170e-05	0	0.000000e+00	9830	0	2	9.133250e-05	21898	0	145478	0	0.000000e+00	4980	0	1	1.031990e-04	9690	0	0	0.000000e+00	13952	0	0	0.000000e+00	57438	0	1	1.031990e-04	9690	0	0	0.000000e+00	23846	0	0	3	1.768470e-05	0	0.000000e+00	8676	0	2	7.723800e-05	25894	0	169638	0	0.000000e+00	8680	0	1	8.047640e-05	12426	0	0	0.000000e+00	16506	0	0	0.000000e+00	68902	0	1	8.047640e-05	12426	0	0	0.000000e+00	23852	0	0	4	2.634140e-05	0	0.000000e+00	41334	0	0	0.000000e+00	910	0	1	6.561680e-05	15240	0	151852	0	0.000000e+00	3470	0	0	0.000000e+00	5172	0	0	0.000000e+00	10588	0	0	0.000000e+00	316	0	2	2.943770e-05	67940	0	1	2.081600e-04	4804	0	1	2.081600e-04	4804	0	2	6.101650e-05	0	0.000000e+00	9058	0	0	0.000000e+00	60	0	1	2.140410e-04	4672	0	32778	0	0.000000e+00	136	0	0	0.000000e+00	2424	0	0	0.000000e+00	5462	0	0	0.000000e+00	246	0	0	0.000000e+00	6842	0	1	3.229970e-04	3096	0	0	.	0	4	2.709810e-05	0	0.000000e+00	41012	0	0	0.000000e+00	910	0	1	6.643640e-05	15052	0	147612	0	0.000000e+00	3302	0	0	0.000000e+00	4936	0	0	0.000000e+00	10588	0	0	0.000000e+00	304	0	2	3.089950e-05	64726	0	1	2.095560e-04	4772	0	0	4	2.974290e-05	0	0.000000e+00	32394	0	0	0.000000e+00	860	0	1	6.758580e-05	14796	0	134486	0	0.000000e+00	3386	0	0	0.000000e+00	5172	0	0	0.000000e+00	6948	0	0	0.000000e+00	310	0	2	3.133320e-05	63830	0	1	2.082470e-04	4802	0	0	4	4.971170e-05	0	0.000000e+00	24722	0	0	0.000000e+00	112	0	1	7.772420e-05	12866	0	80464	0	0.000000e+00	996	0	0	0.000000e+00	3732	0	0	0.000000e+00	10496	0	0	0.000000e+00	272	0	2	9.529250e-05	20988	0	1	2.093800e-04	4776	0	0	19	4052030	19	4101030	0	0.73137	0.706548	1.000000	0.71638	0.554000	0.30269	0.195000	0.22031	7.860000	0.85401	0.596000	0.33519	1.022000	0.39869	4101032	C	.	rs730880511	.	.	6.943	7.389	5.732	10.284	.	.	.	50	-42	50	-13	0.00	0.00	0.01	0.00	MAP2K2	0.86	exon-NM_030662.4-6+13+start+125	543999	Uncertain_significance	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&RASopathy&not_provided	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN517202	.	19:4101030-4101030	2.517e-05	3	0	0	0	0	0	0	0	0	0	3044	566	962	290	11036	226	8088	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs730880511	0.00000e+00	7.95292e-05	0.00000e+00	8.78580e-05	0.00000e+00	0.00000e+00	2.40848e-04	0.00000e+00	1.11562e-05	3.91553e-05	8.78580e-05	3.66402e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs730880511	730880511	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:missense	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,931	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	103288546	103288555	GGACAGTGGC	G	-	inframe_deletion	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	3/13	.	NM_000277.3:c.310_318del	NP_000268.1:p.Ala104_Val106del	424-432	310-318	104-106	ATV/-	GCCACTGTC/-	rs398123291	GACAGTGGC	.	-1	.	.	EntrezGene	.	.	.	.	GACAGTGGC	GACAGTGGC	.	.	PAH	.	chr12:g.103288547_103288555del	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	PAH&NM_000277.1&c.310_318del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	gain/acceptor/103288554-103288553/Medium/4.469050	11.038	10.766	11.785	7.700	.	.	.	.	.	.	.	.	.	.	.	.	0.00	exon-NM_001354304.2-4+34+start+184	92740	Uncertain_significance	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103288547-103288556	8.236e-06	1	1	0	1	0	0	0	0	0	0	10402	11578	8654	6614	66738	908	16512	1	0	0	0	0	0	0	0	0	0	0	0	0	0	rs398123291	6.53424e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.98069e-06	6.53424e-05	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs398123291	398123291	.	.	.	PAH	PAH:exonic	PAH:nonframeshift_deletion	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,808	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	89692819	89692819	C	CAAA	AAA	inframe_insertion	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.304_306dup	NP_000305.3:p.Lys102dup	1148-1149	303-304	101-102	-/K	-/AAA	rs587782641&CI983201&COSV64290672	.	.	1	.	.	EntrezGene	.	.	.	.	.	.	.	.	PTEN	3	chr10:g.89692820_89692822dup	.	.	.	.	.	.	uncertain_significance&pathogenic	0&0&1	1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.303_304insT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.752	10.998	5.352	9.651	.	.	.	.	.	.	.	.	.	.	.	.	0.98	exon-NM_001304717.5-6+50+start+239	142681	Uncertain_significance	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587782641	587782641	.	.	.	PTEN	PTEN:exonic	PTEN:nonframeshift_insertion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,537	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
12	25362762	25362765	TTTC	T	-	inframe_deletion	MODERATE	KRAS	3845	Transcript	NM_004985.5	protein_coding	5/5	.	NM_004985.5:c.531_533del	NP_004976.2:p.Lys180del	721-723	531-533	177-178	KK/K	aaGAAa/aaa	rs397517043	TTC	.	-1	.	.	EntrezGene	.	.	.	.	TTC	TTC	.	.	ETFRF1	.	chr12:g.25362768_25362770del	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.362	10.858	.	.	.	13	-30	13	-18	0.00	0.00	0.00	0.00	KRAS	0.00	exon-NM_001369787.1-5+80+end+4666	45129	Benign	reviewed_by_expert_panel	Inborn_genetic_diseases&Noonan_syndrome_and_Noonan-related_syndrome&not_specified&not_provided&RASopathy	MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	12:25362763-25362766	5.026e-04	61	2	0	1	3	0	1	55	0	1	9764	11278	8526	6500	64754	878	16264	0	0	2	0	0	0	0	0	0	0	0	0	0	0	rs751233524	4.61133e-04	1.79555e-04	0.00000e+00	1.74459e-04	8.99766e-05	9.83009e-04	3.67377e-04	6.55695e-05	5.44719e-04	5.24242e-04	9.83009e-04	5.32027e-04	rs751233524	5.72344e-04	0.00000e+00	0.00000e+00	6.18812e-04	0.00000e+00	9.33085e-04	2.03666e-03	.	7.01098e-04	7.22126e-04	9.33085e-04	7.09861e-04	.	.	rs397517043	397517043	chr6:54635829	0.928478	0.919627	KRAS	KRAS:exonic	KRAS:nonframeshift_deletion	KRAS:Gastric_cancer\x2csomatic\x3bOculoectodermal_syndrome\x2csomatic\x3bBreast_cancer\x2csomatic\x3bNoonan_syndrome_3\x3bRAS-associated_autoimmune_leukoproliferative_disorder\x3bArteriovenous_malformation_of_the_brain\x2csomatic\x3bLung_cancer\x2csomatic\x3bPancreatic_carcinoma\x2csomatic\x3bLeukemia\x2cacute_myeloid\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bCardiofaciocutaneous_syndrome_2\x3bBladder_cancer\x2csomatic	KRAS:613659\x3b600268\x3b114480\x3b609942\x3b614470\x3b108010\x3b211980\x3b260350\x3b601626\x3b163200\x3b615278\x3b109800	KRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	KRAS:.\x3b.\x3b.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3b.\x3b.\x3bAutosomal_dominant\x3b.	0	0.00106119304255182	0.603148256118395	0.395790550839053	DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes. {ECO:0000269|PubMed:8955068}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:17332249}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 3 (NS3) [MIM:609942]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:16474405, ECO:0000269|PubMed:16773572, ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:17468812, ECO:0000269|PubMed:19396835}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:7773929}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in KRAS are a cause of pylocytic astrocytoma (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. {ECO:0000269|PubMed:16247081}.; DISEASE: Cardiofaciocutaneous syndrome 2 (CFC2) [MIM:615278]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. CFC2 patients often do not have the skin abnormalities, such as ichthyosis, hyperkeratosis, and hemangioma observed in CFC1. {ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:16474405, ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:21797849}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=KRAS mutations are involved in cancer development. {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:1553789, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:3627975, ECO:0000269|PubMed:6092920, ECO:0000269|PubMed:6695174, ECO:0000269|PubMed:7773929}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,639	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
2	39281777	39281777	T	C	C	missense_variant	MODERATE	SOS1	6654	Transcript	NM_005633.4	protein_coding	5/23	.	NM_005633.4:c.698A>G	NP_005624.2:p.Asn233Ser	1327	698	233	N/S	aAt/aGt	rs144934321&COSV101216920	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	SOS1	.	chr2:g.39281777T>C	.	.	.	.	.	.	conflicting_interpretations_of_pathogenicity&likely_benign&uncertain_significance	0&1	1&1	.	.	.	.	.	SOS1&NM_005633.3&c.698A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	T	0.02148	-0.404937	T	0.33971	-0.394973	16.99	17.19	1.694459	1.655767	0.24986	0.26451	T/T	T	0.00206	0.0124924190173165	0.02951	0.41158408282047204	.	0.70345	.	T/T	5	0.0011353315168029065	0	0.0	2.354087	-0.00147770096861344	0.39650	1.799869	-0.227801790225573	0.31995	.	.	.	8	6.591e-05	8	7.915e-04	0	0	8	6.673e-05	0	0	0	0	0	0	0	0	4	3.767e-05	4	4.552e-04	0	0	4	3.812e-05	0	0	0	0	0	0	0	0	8	8.818e-05	8	7.927e-04	0	0	8	8.926e-05	0	0	0	0	0	0	0	0	0.92108	.	.	.	5.55	5.55	0.83298	0	0.79440	0.708844	.	.	0.30801	0.984948163322675	.	0	0.34648	0.602189	.	.	.	.	.	.	0	0.67416	0.683762	Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain	.	.	.	0.59649	.	0.215296	0.48594	D	0.000180	D	0.50815	0.028083	0.44488	.	0.67091	.	D	0.83070	0.5408	.	0.06770	.	T	0.77714	-0.1983	.	.	.	.	.	.	0.28702	.	.	0.36327	simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D	0.907594&0.907594&0.907594&0.855379	0.11185	.	.	.	0.07471	.	.	0.12133	.	T	0.45997	0.550995588303	0.58633	.	10	0.04877	.	.	0.02906	.	.	10.3736	0.43251	0.0:0.0733:0.0:0.9267	.	.	.	.	.	.	.	.	0.25499	.	T/T	S	.	N	C	447	0.79583	.	2	C0028326&CN166718&CN169374&CN517202	PS163950	ORPHA648&ORPHA536391	Likely_benign	NC_000002.12:g.39054636T>C	197778	reviewed_by_expert_panel	Noonan_syndrome&Rasopathy&not_specified&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:997bfe08-d211-4276-b0cc-f38b734d1427&Service_de_Gntique_Molculaire&Hpital_Robert_Debr:56575	.	.	AEFBI	D	0.50396	0.89737	N	0.34771	0.223335	.	11	4.384640e-05	10	6.205010e-04	16116	0	1	2.893850e-05	34556	0	250876	0	0.000000e+00	10070	0	0	0.000000e+00	18376	0	0	0.000000e+00	21632	0	0	0.000000e+00	113430	0	10	6.205010e-04	16116	0	0	0.000000e+00	30590	0	4	3.661130e-05	4	5.589710e-04	7156	0	0	0.000000e+00	17082	0	109256	0	0.000000e+00	2318	0	0	0.000000e+00	9036	0	0	0.000000e+00	13382	0	0	0.000000e+00	42694	0	4	5.589710e-04	7156	0	0	0.000000e+00	15674	0	0	.	0	8	3.383810e-05	7	4.740620e-04	14766	0	1	2.921580e-05	34228	0	236420	0	0.000000e+00	9566	0	0	0.000000e+00	17680	0	0	0.000000e+00	21616	0	0	0.000000e+00	102474	0	7	4.740620e-04	14766	0	0	0.000000e+00	30500	0	0	11	5.297430e-05	10	6.218910e-04	16080	0	1	3.279980e-05	30488	0	207648	0	0.000000e+00	6206	0	0	0.000000e+00	13404	0	0	0.000000e+00	16722	0	0	0.000000e+00	89324	0	10	6.218910e-04	16080	0	0	0.000000e+00	30582	0	0	8	3.274740e-05	7	5.882350e-04	11900	0	1	2.905120e-05	34422	0	244294	0	0.000000e+00	9988	0	0	0.000000e+00	18372	0	0	0.000000e+00	21630	0	0	0.000000e+00	111358	0	7	5.882350e-04	11900	0	0	0.000000e+00	30590	0	0	34	2.233840e-04	32	7.718280e-04	41460	0	0	0.000000e+00	912	0	1	6.543650e-05	15282	0	152204	0	0.000000e+00	3472	0	0	0.000000e+00	5202	0	0	0.000000e+00	10616	0	0	0.000000e+00	316	0	1	1.470110e-05	68022	0	32	7.718280e-04	41460	0	0	0.000000e+00	4832	0	2	6.079030e-05	2	2.198770e-04	9096	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32900	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5488	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3116	0	0	.	0	34	2.297830e-04	32	7.777940e-04	41142	0	0	0.000000e+00	912	0	1	6.624270e-05	15096	0	147966	0	0.000000e+00	3302	0	0	0.000000e+00	4968	0	0	0.000000e+00	10616	0	0	0.000000e+00	304	0	1	1.543110e-05	64804	0	0	0.000000e+00	4800	0	0	25	1.854760e-04	23	7.080410e-04	32484	0	0	0.000000e+00	862	0	1	6.740360e-05	14836	0	134788	0	0.000000e+00	3388	0	0	0.000000e+00	5202	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	1	1.564950e-05	63900	0	0	0.000000e+00	4830	0	0	17	2.104900e-04	15	6.040110e-04	24834	0	0	0.000000e+00	112	0	1	7.747130e-05	12908	0	80764	0	0.000000e+00	998	0	0	0.000000e+00	3760	0	0	0.000000e+00	10524	0	0	0.000000e+00	272	0	1	4.753760e-05	21036	0	0	0.000000e+00	4804	0	0	2	39135281	2	39281777	0	0.46895	0.6512	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	2.113000	0.41525	0.665000	0.62972	1.138000	0.64695	39054636	T	.	rs144934321	.	.	10.793	8.623	7.433	9.452	.	.	.	24	-18	-22	-21	0.00	0.00	0.01	0.00	SOS1	1.00	exon-NM_001382394.1-5+22+start+210	197778	Likely_benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&RASopathy&not_provided&Noonan_syndrome	MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN517202&MONDO:MONDO:0018997&MeSH:D009634&MedGen:C0028326&OMIM:PS163950&Orphanet:648	.	rs144934321	6.591e-05	8	8	0	8	0	0	0	0	0	0	10108	11506	8562	6598	65768	900	16442	8	0	0	0	0	0	0	0	0	0	0	0	0	0	rs144934321	7.20461e-04	2.97832e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.22704e-05	8.09309e-05	7.20461e-04	4.87290e-05	rs144934321	1.26031e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	4.09309e-04	2.88684e-04	1.26031e-03	3.54930e-04	rs144934321	0.0&0.1135&0.0385	rs144934321	144934321	.	.	.	SOS1	SOS1:exonic	SOS1:missense	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,469	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	89653795	89653798	CATT	C	-	inframe_deletion	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	2/9	.	NM_000314.8:c.97_99del	NP_000305.3:p.Ile33del	939-941	94-96	32	I/-	ATT/-	rs1554893765	ATT	.	1	.	.	EntrezGene	.	.	.	.	ATT	ATT	.	.	PTEN	3	chr10:g.89653799_89653801del	.	.	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.295	10.567	-2.595	-3.496	.	.	.	-21	29	-43	-23	0.27	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-3+14+start+85	449088	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&Neurodevelopmental_delay&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&Human_Phenotype_Ontology:HP:0012758&MedGen:C4022738&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1554893765	1554893765	.	.	.	PTEN	PTEN:exonic	PTEN:nonframeshift_deletion	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,521	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
6	76599951	76599951	C	T	T	missense_variant	MODERATE	MYO6	4646	Transcript	NM_004999.4	protein_coding	26/35	.	NM_004999.4:c.2836C>T	NP_004990.3:p.Arg946Cys	3068	2836	946	R/C	Cgt/Tgt	rs141845119&CM168653	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	MYO6	.	chr6:g.76599951C>T	.	0	0	0	0.001	0.002	likely_benign&conflicting_interpretations_of_pathogenicity&uncertain_significance	.	1&1	.	.	.	.	.	MYO6&NM_004999.3&c.2836C>T	.	.	3	5.990415335463259E-4	0	0.0	0	0.0	0	0.0	1	9.940357852882703E-4	2	0.002044989775051125	.	.	.	.	.	.	.	.	.	C/C	C	T	0.03980	-0.362698	T	0.40989	-0.3343	23.6	23.9	3.080310	3.143134	0.53825	0.58110	C/C	T	0.10659	0.0853739262849944	0.62383	0.99391838290581713	.	0.82446	.	C/C	0	0.0	4	4.6511627906976747E-4	3.800295	0.314151730221157	0.56370	4.023266	0.345573311113262	0.58507	.	.	.	110	9.060e-04	1	9.905e-05	0	0	110	9.144e-04	0	0	4	6.051e-04	87	1.316e-03	18	1.093e-03	104	9.792e-04	1	1.130e-04	0	0	104	9.857e-04	0	0	4	6.051e-04	81	1.501e-03	18	1.100e-03	40	4.408e-04	1	9.923e-05	0	0	40	4.457e-04	0	0	2	5.260e-04	19	4.569e-04	18	1.094e-03	0.23082	.	.	.	5.98	5.98	0.97147	0	0.55848	0.633656	.	.	0.21442	0.56457600957566	.	0	0.59346	0.659464	.	.	.	.	.	.	0	0.71501	0.711	.&.&.&.&.&.&.	.	.	.	0.79107	.	0.192178	0.42799	D	0.000637	T	0.44830	0.021986	0.38224	.	0.60560	.	T	0.23791	0.0565	.	0.01879	.	T	0.05804	-1.0884	.	.	.	.	.	.	0.74772	.	.	0.42131	simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D	0.994019&0.994019&0.994019&0.994019	0.78302	.	.	.	0.61912	.	.	0.45421	.	T	0.50754	0.584747672081	0.41286	.	10	0.72224	.	.	0.78490	.	.	15.9057	0.79213	0.1359:0.8641:0.0:0.0	.	.	.	.	.	.	.	.	0.84505	.	C/C	C	.	R	T	413	0.81939	.	6	C2931767&C1843028&CN043648&CN169374&CN517202	606346&607821	ORPHA87884	Likely_benign	NC_000006.12:g.75890234C>T	164639	reviewed_by_expert_panel	Autosomal_dominant_nonsyndromic_deafness_22&Deafness&_autosomal_recessive_37&Nonsyndromic_hearing_loss_and_deafness&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:716142	.	.	AEFBI	D	0.46777	0.87284	N	0.47210	0.395101	.	184	7.334590e-04	1	6.196550e-05	16138	0	2	5.783360e-05	34582	0	250866	3	2.983290e-04	10056	0	0	0.000000e+00	18380	0	24	1.108750e-03	21646	0	107	9.441450e-04	113330	0	39	1.274090e-03	30610	1	39	1.274090e-03	30610	1	82	7.496660e-04	1	1.396260e-04	7162	0	1	5.845900e-05	17106	0	109382	1	4.310340e-04	2320	0	0	0.000000e+00	9034	0	10	7.466030e-04	13394	0	48	1.122390e-03	42766	0	20	1.275020e-03	15686	0	20	1.275020e-03	15686	0	0	.	1	178	7.529610e-04	1	6.758580e-05	14796	0	2	5.839420e-05	34250	0	236400	3	3.139390e-04	9556	0	0	0.000000e+00	17680	0	24	1.109570e-03	21630	0	101	9.867330e-04	102358	0	39	1.277850e-03	30520	1	39	1.277850e-03	30520	1	1	133	6.402300e-04	1	6.211180e-05	16100	0	2	6.554370e-05	30514	0	207738	3	4.844960e-04	6192	0	0	0.000000e+00	13404	0	16	9.562510e-04	16732	0	69	7.723130e-04	89342	0	39	1.274430e-03	30602	1	39	1.274430e-03	30602	1	1	182	7.446810e-04	0	0.000000e+00	11938	0	2	5.805850e-05	34448	0	244400	2	2.004010e-04	9980	0	0	0.000000e+00	18376	0	24	1.108850e-03	21644	0	107	9.608990e-04	111354	0	39	1.274090e-03	30610	1	39	1.274090e-03	30610	1	1	65	4.277840e-04	4	9.674450e-05	41346	0	0	0.000000e+00	912	0	1	6.557380e-05	15250	0	151946	1	2.881840e-04	3470	0	0	0.000000e+00	5194	0	6	5.680740e-04	10562	0	0	0.000000e+00	314	0	43	6.323900e-04	67996	0	10	2.075550e-03	4818	0	10	2.075550e-03	4818	0	16	4.878940e-04	1	1.101560e-04	9078	0	0	0.000000e+00	60	0	0	0.000000e+00	4678	0	32794	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	2	3.672420e-04	5446	0	0	0.000000e+00	244	0	7	1.024590e-03	6832	0	6	1.932990e-03	3104	0	0	lcr	0	64	4.333050e-04	4	9.749910e-05	41026	0	0	0.000000e+00	912	0	1	6.639220e-05	15062	0	147702	1	3.028470e-04	3302	0	0	0.000000e+00	4960	0	6	5.680740e-04	10562	0	0	0.000000e+00	302	0	42	6.483880e-04	64776	0	10	2.089430e-03	4786	0	0	58	4.310470e-04	3	9.261550e-05	32392	0	0	0.000000e+00	862	0	1	6.754930e-05	14804	0	134556	1	2.953340e-04	3386	0	0	0.000000e+00	5194	0	3	4.329000e-04	6930	0	0	0.000000e+00	308	0	40	6.262720e-04	63870	0	10	2.076410e-03	4816	0	0	40	4.967590e-04	2	8.088000e-05	24728	0	0	0.000000e+00	112	0	1	7.766390e-05	12876	0	80522	0	0.000000e+00	996	0	0	0.000000e+00	3752	0	6	5.730660e-04	10470	0	0	0.000000e+00	270	0	21	9.991440e-04	21018	0	10	2.087680e-03	4790	0	0	6	76656671	6	76599951	0	0.52595	0.67177	0.946000	0.32893	0.044000	0.14658	0.317000	0.24325	3.133000	0.50225	0.545000	0.25583	1.005000	0.37175	75890234	C	.	rs141845119	.	.	7.780	4.174	5.132	9.788	.	.	.	-25	12	25	36	0.00	0.00	0.00	0.03	MYO6	0.02	exon-NM_001368865.1-26+31+end+209	164639	Likely_benign	reviewed_by_expert_panel	not_specified&Nonsyndromic_genetic_hearing_loss&not_provided&Autosomal_dominant_nonsyndromic_hearing_loss_22&Autosomal_recessive_nonsyndromic_hearing_loss_37	MedGen:CN169374&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN517202&MONDO:MONDO:0011660&MedGen:C2931767&OMIM:606346&Orphanet:228012&MONDO:MONDO:0011912&MedGen:C1843028&OMIM:607821&Orphanet:90636	.	rs141845119	9.060e-04	110	2	1	1	0	0	4	87	0	18	10096	11530	8602	6610	66092	900	16470	0	0	1	0	1	0	0	0	0	0	0	0	0	1	rs141845119	6.54622e-05	1.19119e-04	3.05250e-04	0.00000e+00	1.12118e-03	9.61003e-04	9.12409e-04	1.26722e-03	8.31218e-04	6.48181e-04	1.26722e-03	7.47147e-04	rs141845119	2.29410e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.14877e-03	8.67940e-04	0.00000e+00	.	7.02165e-04	5.06366e-04	1.14877e-03	6.13061e-04	rs141845119	0.0465&0.0&0.0308	rs141845119	141845119	.	.	.	MYO6	MYO6:exonic	MYO6:missense	MYO6:Deafness\x2cautosomal_dominant_22\x2cwith_hypertrophic_cardiomyopathy\x3bDeafness\x2cautosomal_dominant_22\x3bDeafness\x2cautosomal_recessive_37	MYO6:606346\x3b606346\x3b607821	MYO6:3\x3b3\x3b3	MYO6:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_recessive	0	0.0177883990936548	0.982211600378647	5.27698444208756e-10	DISEASE: Deafness, autosomal dominant, 22 (DFNA22) [MIM:606346]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA22 is progressive and postlingual, with onset during childhood. By the age of approximately 50 years, affected individuals invariably have profound sensorineural deafness. {ECO:0000269|PubMed:11468689}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 37 (DFNB37) [MIM:607821]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:12687499}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, sensorineural, with hypertrophic cardiomyopathy (DFNHCM) [MIM:606346]: An autosomal dominant sensorineural deafness associated with hypertrophic cardiomyopathy. {ECO:0000269|PubMed:15060111}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,488	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
3	12660096	12660096	G	A	A	missense_variant	MODERATE	RAF1	5894	Transcript	NM_001354689.3	protein_coding	2/18	.	NM_001354689.3:c.125C>T	NP_001341618.1:p.Ala42Val	456	125	42	A/V	gCa/gTa	rs11549992&COSV52578210	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RAF1	.	chr3:g.12660096G>A	.	.	.	.	.	.	uncertain_significance&likely_benign&benign	0&1	1&1	.	.	.	.	.	RAF1&NM_002880.3&c.125C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0.0	.	.	.	.	.	.	.	G/G	G	T	0.14341	-0.248036	T	0.47018	-0.277907	23.4	22.9	3.002954	2.676832	0.52100	0.47605	G/G	T	0.01715	0.0281786238071906	0.91800	0.9983696088703764	.	0.79803	.	G/G	.	.	.	.	3.89199	0.329305395729113	0.57268	3.129022	0.159595556076659	0.49267	.	.	.	31	2.553e-04	0	0	2	1.727e-04	31	2.553e-04	0	0	0	0	25	3.746e-04	2	1.211e-04	26	2.448e-04	0	0	2	1.783e-04	26	2.448e-04	0	0	0	0	21	3.864e-04	2	1.219e-04	29	3.196e-04	0	0	2	1.729e-04	29	3.196e-04	0	0	0	0	23	5.458e-04	2	1.212e-04	0.75553	.	.	.	6.17	5.3	0.74745	0	0.89359	0.724815	.	.	0.74766	0.999999997930646	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.83352	0.714379	.&.	.	.	.	0.93682	.	0.050744	0.84330	D	0.000000	D	0.52952	0.030693	0.49418	.	0.68618	.	T	0.60039	0.2338	.	0.10706	.	T	0.62792	-0.6482	.	.	.	.	.	.	0.31408	.	.	0.81001	simple_aae&simple_aae&without_aae	D&D&D	0.999961&0.999961&1	0.26639	.	.	.	0.35893	.	.	0.32088	.	T	0.47673	0.562870502472	0.55061	.	10	0.24054	.	.	0.43393	.	.	15.4423	0.74922	0.0659:0.0:0.9341:0.0	.	1	2.6968716289104636E-4	1	1.322401481089659E-4	.	.	.	0.53532	.	G/G	V	.	A	A	615	0.66512	.	3	C1969057&C1969056&CN260604&CN166718&CN517202	611553&611554	ORPHA98733&ORPHA536391	Likely_benign	NC_000003.12:g.12618597G>A	343103	reviewed_by_expert_panel	Noonan_syndrome_5&LEOPARD_syndrome_2&Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_provided	Illumina_Laboratory_Services&Illumina:720999&ClinGen_RASopathy_Variant_Curation_Expert_Panel:da2fd72c-d28d-424b-92b6-eb26ccf60d9f	.	.	AEFDBI	D	0.82178	0.98379	D	0.71042	0.777693	.	85	3.379910e-04	0	0.000000e+00	16256	0	13	3.758090e-04	34592	0	251486	23	2.281750e-03	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	42	3.691920e-04	113762	0	13	3.758090e-04	34592	0	2	6.532530e-05	30616	0	26	2.376430e-04	0	0.000000e+00	7164	0	10	5.843850e-04	17112	0	109408	3	1.293100e-03	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	10	2.338200e-04	42768	0	10	5.843850e-04	17112	0	1	6.373490e-05	15690	0	0	.	0	79	3.334060e-04	0	0.000000e+00	14902	0	12	3.502630e-04	34260	0	236948	22	2.298370e-03	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	38	3.698440e-04	102746	0	38	3.698440e-04	102746	0	2	6.551790e-05	30526	0	0	67	3.219140e-04	0	0.000000e+00	16218	0	13	4.258940e-04	30524	0	208130	16	2.575660e-03	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	32	3.573260e-04	89554	0	13	4.258940e-04	30524	0	2	6.534240e-05	30608	0	0	85	3.471260e-04	0	0.000000e+00	12026	0	13	3.772710e-04	34458	0	244868	23	2.300460e-03	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	42	3.761010e-04	111672	0	13	3.772710e-04	34458	0	2	6.532530e-05	30616	0	0	33	2.168970e-04	1	2.413710e-05	41430	0	0	0.000000e+00	910	0	5	3.272680e-04	15278	0	152146	6	1.730100e-03	3468	0	0	0.000000e+00	5190	0	0	0.000000e+00	10610	0	1	3.164560e-03	316	0	17	2.499040e-04	68026	0	5	3.272680e-04	15278	0	0	0.000000e+00	4836	0	4	1.216250e-04	0	0.000000e+00	9094	0	0	0.000000e+00	60	0	2	4.266210e-04	4688	0	32888	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5480	0	0	0.000000e+00	246	0	1	1.459430e-04	6852	0	0	0.000000e+00	3114	0	0	.	0	31	2.095870e-04	1	2.432620e-05	41108	0	0	0.000000e+00	910	0	4	2.650760e-04	15090	0	147910	6	1.817080e-03	3302	0	0	0.000000e+00	4958	0	0	0.000000e+00	10610	0	0	0.000000e+00	304	0	17	2.623130e-04	64808	0	0	0.000000e+00	4804	0	0	33	2.449050e-04	1	3.079770e-05	32470	0	0	0.000000e+00	862	0	5	3.371090e-04	14832	0	134746	6	1.773050e-03	3384	0	0	0.000000e+00	5190	0	0	0.000000e+00	6970	0	1	3.225810e-03	310	0	17	2.660320e-04	63902	0	0	0.000000e+00	4834	0	0	10	1.239070e-04	1	4.031610e-05	24804	0	0	0.000000e+00	110	0	3	2.324860e-04	12904	0	80706	2	2.012070e-03	994	0	0	0.000000e+00	3748	0	0	0.000000e+00	10518	0	1	3.676470e-03	272	0	1	4.752850e-05	21040	0	0	0.000000e+00	4808	0	0	3	12635096	3	12660096	0	0.73137	0.706548	1.000000	0.71638	0.998000	0.85391	0.998000	0.65909	7.408000	0.79264	0.676000	0.76740	1.176000	0.78918	12618597	G	.	rs11549992	.	.	7.229	7.638	11.110	10.280	.	.	.	-24	27	2	-11	0.00	0.00	0.01	0.00	RAF1	1.00	exon-NM_001354693.3-2+82+start+233	343103	Likely_benign	reviewed_by_expert_panel	not_provided&RASopathy&LEOPARD_syndrome_2&Noonan_syndrome_and_Noonan-related_syndrome&Noonan_syndrome_5	MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0012691&MedGen:C1969056&OMIM:611554&Orphanet:500&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MONDO:MONDO:0012690&MedGen:C1969057&OMIM:611553&Orphanet:648	.	rs11549992	2.553e-04	31	31	0	0	2	0	0	25	2	2	10404	11578	8652	6614	66738	908	16510	0	2	0	0	25	2	2	0	0	0	0	0	0	0	rs11549992	0.00000e+00	3.87112e-04	2.23350e-03	0.00000e+00	0.00000e+00	3.49100e-04	5.47046e-04	6.49730e-05	3.63210e-04	2.69401e-04	2.23350e-03	3.20784e-04	rs11549992	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.33227e-04	1.02041e-03	.	1.75213e-04	0.00000e+00	1.33227e-04	9.67992e-05	.	.	rs11549992	11549992	.	.	.	RAF1	RAF1:exonic	RAF1:missense	RAF1:Cardiomyopathy\x2cdilated\x2c1NN\x3bNoonan_syndrome_5\x3bLEOPARD_syndrome_2	RAF1:615916\x3b611553\x3b611554	RAF1:3\x3b3\x3b3	RAF1:Autosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999776866110749	0.000223133833869176	5.53819998824154e-11	DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,481	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
7	140487375	140487375	T	C	C	missense_variant	MODERATE	BRAF	673	Transcript	NM_001374258.1	protein_coding	9/20	.	NM_001374258.1:c.1150A>G	NP_001361187.1:p.Arg384Gly	1376	1150	384	R/G	Aga/Gga	rs545495379&CM137740&COSV99072649	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	NDUFB2	.	chr7:g.140487375T>C	.	0	0	0.001	0	0	benign	0&0&1	1&1&1	.	.	.	.	.	BRAF&NM_004333.4&c.1150A>G	.	.	1	1.9968051118210862E-4	0	0.0	0	0.0	1	9.92063492063492E-4	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	T/T	T	T	0.54175	0.0184688	D	0.85567	0.248826	23.0	23.0	2.787393	2.717775	0.47465	0.48496	T/T	T	0.11817	0.095172028672642	0.72742	0.99576627460273981	.	0.91332	.	T/T	.	.	.	.	2.899273	0.138788537215245	0.46552	2.397939	-0.0323926077876101	0.40391	.	.	.	16	1.318e-04	0	0	0	0	16	1.320e-04	16	1.851e-03	0	0	0	0	0	0	16	1.506e-04	0	0	0	0	16	1.508e-04	16	2.035e-03	0	0	0	0	0	0	8	8.815e-05	0	0	0	0	8	8.833e-05	8	1.421e-03	0	0	0	0	0	0	0.80730	.	.	.	5.65	5.65	0.86881	0	0.97443	0.743671	.	.	0.22216	0.655856238249533	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.64102	0.662433	.&.&.&.	.	.	.	0.79487	.	0.000000	0.84330	D	0.000000	D	0.61552	0.044569	0.80255	.	0.98503	.	T	0.71027	0.3452	.	0.00660	.	T	0.66760	-0.5507	R384G	Loss_of_stability_(P_=_0.0819)&_Gain_of_catalytic_residue_at_D380_(P_=_0.0972)&_Loss_of_disorder_(P_=_0.2277)&_Loss_of_solvent_accessibility_(P_=_0.239)&_Loss_of_loop_(P_=_0.3664)	P15056	0.51435	0.452	.	0.23182	.	.	0.58761	simple_aae	D	0.999999	0.49352	.	.	.	0.29346	.	.	0.22546	.	T	0.71502	0.729979038239	0.78786	.	10	0.15157	.	.	0.36509	.	.	11.8228	0.51523	0.0:0.0:0.1462:0.8538	.	.	.	.	.	.	.	.	0.61087	.	T/T	G	.	R	C	807	0.43470	.	7	CN260604&CN166718&CN169374	.	ORPHA98733&ORPHA536391	Benign	NC_000007.14:g.140787575T>C	448924	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_specified	ClinGen_RASopathy_Variant_Curation_Expert_Panel:2153a39b-818c-4cb1-b6e6-db1a736b545f	.	.	AEFBI	D	0.46704	0.87228	N	0.50455	0.449947	.	46	1.830390e-04	0	0.000000e+00	16242	0	0	0.000000e+00	34566	0	251312	0	0.000000e+00	10074	0	46	2.501900e-03	18386	0	0	0.000000e+00	21646	0	0	0.000000e+00	113668	0	46	2.501900e-03	18386	0	0	0.000000e+00	30596	0	24	2.194590e-04	0	0.000000e+00	7160	0	0	0.000000e+00	17090	0	109360	0	0.000000e+00	2320	0	24	2.654870e-03	9040	0	0	0.000000e+00	13394	0	0	0.000000e+00	42762	0	24	2.654870e-03	9040	0	0	0.000000e+00	15680	0	0	.	0	46	1.942600e-04	0	0.000000e+00	14894	0	0	0.000000e+00	34236	0	236796	0	0.000000e+00	9568	0	46	2.600930e-03	17686	0	0	0.000000e+00	21630	0	0	0.000000e+00	102662	0	46	2.600930e-03	17686	0	0	0.000000e+00	30506	0	0	27	1.297910e-04	0	0.000000e+00	16204	0	0	0.000000e+00	30500	0	208026	0	0.000000e+00	6210	0	27	2.013720e-03	13408	0	0	0.000000e+00	16734	0	0	0.000000e+00	89518	0	27	2.013720e-03	13408	0	0	0.000000e+00	30588	0	0	46	1.879870e-04	0	0.000000e+00	12014	0	0	0.000000e+00	34432	0	244698	0	0.000000e+00	9992	0	46	2.502450e-03	18382	0	0	0.000000e+00	21644	0	0	0.000000e+00	111580	0	46	2.502450e-03	18382	0	0	0.000000e+00	30596	0	0	9	5.912880e-05	0	0.000000e+00	41468	0	0	0.000000e+00	912	0	0	0.000000e+00	15282	0	152210	0	0.000000e+00	3470	0	8	1.538460e-03	5200	0	0	0.000000e+00	10598	0	0	0.000000e+00	316	0	0	0.000000e+00	68040	0	8	1.538460e-03	5200	0	1	2.069540e-04	4832	0	3	9.119100e-05	0	0.000000e+00	9104	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32898	0	0.000000e+00	136	0	3	1.236600e-03	2426	0	0	0.000000e+00	5480	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3112	0	0	.	0	8	5.406940e-05	0	0.000000e+00	41146	0	0	0.000000e+00	912	0	0	0.000000e+00	15094	0	147958	0	0.000000e+00	3302	0	7	1.410150e-03	4964	0	0	0.000000e+00	10598	0	0	0.000000e+00	304	0	0	0.000000e+00	64816	0	1	2.083330e-04	4800	0	0	9	6.676460e-05	0	0.000000e+00	32492	0	0	0.000000e+00	862	0	0	0.000000e+00	14838	0	134802	0	0.000000e+00	3386	0	8	1.538460e-03	5200	0	0	0.000000e+00	6966	0	0	0.000000e+00	310	0	0	0.000000e+00	63916	0	1	2.070390e-04	4830	0	0	7	8.667230e-05	0	0.000000e+00	24842	0	0	0.000000e+00	112	0	0	0.000000e+00	12908	0	80764	0	0.000000e+00	996	0	6	1.596590e-03	3758	0	0	0.000000e+00	10506	0	0	0.000000e+00	272	0	0	0.000000e+00	21048	0	1	2.081600e-04	4804	0	0	7	140133844	7	140487375	0	0.92422	0.732398	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	2.527000	0.45275	0.661000	0.55757	1.114000	0.55654	140787575	T	.	rs545495379	.	.	11.414	11.078	8.345	9.115	.	.	.	9	-2	-27	-44	0.01	0.00	0.01	0.00	BRAF	1.00	exon-NM_001378474.1-9+9+end+37	448924	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&not_specified&RASopathy	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	7:140487375-140487375	1.318e-04	16	16	0	0	0	16	0	0	0	0	10356	11554	8646	6612	66658	906	16502	0	0	16	0	0	0	0	0	0	0	0	0	0	0	rs545495379	0.00000e+00	0.00000e+00	0.00000e+00	2.61021e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.70588e-04	1.97696e-04	2.61021e-03	1.82726e-04	rs545495379	0.00000e+00	0.00000e+00	0.00000e+00	2.46914e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	1.75316e-04	7.22543e-05	2.46914e-03	1.29066e-04	.	.	rs545495379	545495379	.	.	.	BRAF	BRAF:exonic	BRAF:missense	BRAF:Melanoma\x2cmalignant\x2csomatic\x3bLEOPARD_syndrome_3\x3bCardiofaciocutaneous_syndrome\x3bAdenocarcinoma_of_lung\x2csomatic\x3bNoonan_syndrome_7\x3bColorectal_cancer\x2csomatic\x3bNonsmall_cell_lung_cancer\x2csomatic	BRAF:155600\x3b613707\x3b115150\x3b211980\x3b613706\x3b114500\x3b211980	BRAF:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	BRAF:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant\x3b.\x3b.	0	0.999978196041997	2.18039579639691e-05	3.88216441101404e-14	DISEASE: Note=Defects in BRAF are found in a wide range of cancers. {ECO:0000269|PubMed:18974108}.; DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:23263490, ECO:0000269|PubMed:24455489}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation. {ECO:0000269|PubMed:18974108}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,492	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
2	39262409	39262409	G	A	A	missense_variant	MODERATE	SOS1	6654	Transcript	NM_005633.4	protein_coding	8/23	.	NM_005633.4:c.1018C>T	NP_005624.2:p.Pro340Ser	1647	1018	340	P/S	Ccc/Tcc	rs190222208&CM123739	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	SOS1	.	chr2:g.39262409G>A	.	0.0008	0	0.001	0	0	likely_benign&benign&uncertain_significance	.	1&1	.	.	.	.	.	SOS1&NM_005633.3&c.1018C>T	.	.	2	3.9936102236421724E-4	1	7.564296520423601E-4	0	0.0	1	9.92063492063492E-4	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	G/G	G	D	0.67662	0.133092	D	0.87306	0.283403	26.3	27.2	3.894535	3.937133	0.75112	0.80094	G/G	D	0.50205	0.850454390048981	0.98379	0.99915790152878803	.	0.94205	.	G/G	.	.	.	.	17.41045	0.975415624407691	0.98092	13.79429	0.995931297645642	0.95617	.	.	.	14	1.153e-04	4	3.907e-04	0	0	14	1.175e-04	5	5.869e-04	0	0	0	0	5	3.086e-04	11	1.036e-04	4	4.490e-04	0	0	11	1.056e-04	2	2.580e-04	0	0	0	0	5	3.105e-04	13	1.432e-04	4	3.914e-04	0	0	13	1.452e-04	4	7.207e-04	0	0	0	0	5	3.088e-04	0.61923	.	.	.	6.01	6.01	0.97420	0	0.79440	0.708844	.	.	0.74766	0.999999999994182	.	0	0.50148	0.65145	.	.	.	.	.	.	0	0.41899	0.613276	Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain&Dbl_homology_(DH)_domain	.	.	.	0.82942	.	0.102288	0.62929	D	0.000002	D	0.86127	0.190493	0.87577	.	0.81364	.	D	0.81247	0.5030	.	0.75239	.	D	0.82278	0.0010	.	.	.	.	.	.	0.83701	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D	1&1&1&1	0.94073	.	.	.	0.90584	.	.	0.97372	.	D	0.85364	0.822183668613	0.82912	.	10	0.92824	.	.	0.91255	.	.	20.5211	0.99225	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.93018	.	G/G	S	.	P	A	454	0.79125	.	2	C4551558&C1853120&CN260604&CN166718&CN517202	135300&610733	ORPHA98733&ORPHA536391	Benign	NC_000002.12:g.39035268G>A	40664	reviewed_by_expert_panel	Gingival_fibromatosis_1&Noonan_syndrome_4&Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:dc725e41-14fe-44e9-9d51-91ac14a1c2d3&Illumina_Laboratory_Services&Illumina:879028	.	.	AEFBI	D	0.90771	0.99069	D	0.87532	0.913399	.	20	7.959380e-05	4	2.463050e-04	16240	0	0	0.000000e+00	34568	0	251276	0	0.000000e+00	10080	0	8	4.355870e-04	18366	0	0	0.000000e+00	21644	0	0	0.000000e+00	113650	0	8	4.355870e-04	18366	0	8	2.614380e-04	30600	0	10	9.145950e-05	2	2.791740e-04	7164	0	0	0.000000e+00	17100	0	109338	0	0.000000e+00	2320	0	4	4.429680e-04	9030	0	0	0.000000e+00	13394	0	0	0.000000e+00	42732	0	4	4.429680e-04	9030	0	4	2.550040e-04	15686	0	0	.	0	18	7.602700e-05	4	2.687090e-04	14886	0	0	0.000000e+00	34238	0	236758	0	0.000000e+00	9572	0	6	3.396740e-04	17664	0	0	0.000000e+00	21628	0	0	0.000000e+00	102650	0	6	3.396740e-04	17664	0	8	2.621920e-04	30512	0	0	19	9.136020e-05	4	2.468830e-04	16202	0	0	0.000000e+00	30500	0	207968	0	0.000000e+00	6212	0	7	5.228560e-04	13388	0	0	0.000000e+00	16732	0	0	0.000000e+00	89482	0	7	5.228560e-04	13388	0	8	2.615060e-04	30592	0	0	18	7.357150e-05	2	1.665000e-04	12012	0	0	0.000000e+00	34434	0	244660	0	0.000000e+00	9998	0	8	4.356820e-04	18362	0	0	0.000000e+00	21642	0	0	0.000000e+00	111560	0	8	4.356820e-04	18362	0	8	2.614380e-04	30600	0	0	14	9.204110e-05	8	1.931900e-04	41410	0	0	0.000000e+00	912	0	0	0.000000e+00	15278	0	152106	0	0.000000e+00	3468	0	3	5.769230e-04	5200	0	0	0.000000e+00	10580	0	0	0.000000e+00	316	0	0	0.000000e+00	68028	0	3	6.213750e-04	4828	0	3	6.213750e-04	4828	0	5	1.521140e-04	1	1.099630e-04	9094	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32870	0	0.000000e+00	136	0	2	8.230450e-04	2430	0	0	0.000000e+00	5472	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	2	6.435010e-04	3108	0	0	.	0	13	8.792220e-05	8	1.946950e-04	41090	0	0	0.000000e+00	912	0	0	0.000000e+00	15090	0	147858	0	0.000000e+00	3302	0	2	4.027390e-04	4966	0	0	0.000000e+00	10580	0	0	0.000000e+00	304	0	0	0.000000e+00	64802	0	3	6.255210e-04	4796	0	0	12	8.907630e-05	6	1.849340e-04	32444	0	0	0.000000e+00	862	0	0	0.000000e+00	14832	0	134716	0	0.000000e+00	3384	0	3	5.769230e-04	5200	0	0	0.000000e+00	6958	0	0	0.000000e+00	310	0	0	0.000000e+00	63904	0	3	6.216330e-04	4826	0	0	12	1.487430e-04	6	2.420330e-04	24790	0	0	0.000000e+00	112	0	0	0.000000e+00	12904	0	80676	0	0.000000e+00	994	0	3	7.978720e-04	3760	0	0	0.000000e+00	10488	0	0	0.000000e+00	272	0	0	0.000000e+00	21044	0	3	6.250000e-04	4800	0	0	2	39115913	2	39262409	0	0.61202	0.706298	1.000000	0.71638	0.991000	0.66497	0.998000	0.65909	9.460000	0.96806	0.676000	0.76740	1.176000	0.78918	39035268	G	.	rs190222208	.	.	7.813	10.567	6.851	8.727	.	.	.	-5	35	-5	11	0.05	0.00	0.00	0.00	SOS1	1.00	exon-NM_001382394.1-8+42+end+99	40664	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&not_provided&RASopathy&Noonan_syndrome_4&Fibromatosis&_gingival&_1	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0012547&MedGen:C1853120&OMIM:610733&Orphanet:648&MONDO:MONDO:0007609&MedGen:C4551558&OMIM:135300&Orphanet:2024	.	rs190222208	1.153e-04	14	14	0	4	0	5	0	0	0	5	10238	11448	8520	6566	65252	894	16202	4	0	5	0	0	0	5	0	0	0	0	0	0	0	rs190222208	2.61404e-04	0.00000e+00	0.00000e+00	4.64576e-04	0.00000e+00	0.00000e+00	1.82415e-04	2.59994e-04	7.41752e-05	9.88391e-05	4.64576e-04	8.52716e-05	rs190222208	1.14548e-04	0.00000e+00	0.00000e+00	6.18047e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	5.86098e-05	7.23694e-05	6.18047e-04	6.45328e-05	.	.	rs190222208	190222208	.	.	.	SOS1	SOS1:exonic	SOS1:missense	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,468	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	89624270	89624270	G	A	A	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	1/9	.	NM_000314.8:c.44G>A	NP_000305.3:p.Arg15Lys	889	44	15	R/K	aGa/aAa	rs398123324&COSV100910708&COSV64297317&COSV64299553	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89624270G>A	.	.	.	.	.	.	likely_pathogenic	0&1&1&1	1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.44G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.91286	0.425142	D	0.91178	0.372911	25.3	24.8	3.666609	3.441138	0.68446	0.65615	./.	D	0.81572	0.991292893886566	0.53275	0.99131813161826488	.	0.98334	.	./.	.	.	.	.	4.419891	0.408606065443308	0.62098	3.762704	0.296776669498063	0.55986	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.95728	.	.	.	5.05	5.05	0.67566	0	0.65289	0.672317	.	.	0.98316	1.0	.	0	0.32118	0.600757	.	.	.	.	.	.	0	0.19341	0.56214	Tensin-type_phosphatase_domain	.	.	.	0.99349	.	0.105614	0.62929	D	0.000007	D	0.99375	0.915666	0.94463	.	0.98707	.	D	0.95506	0.8649	.	0.80604	.	D	0.93715	0.7437	R15K	Gain_of_ubiquitination_at_R15_(P_=_0.023)&_Loss_of_helix_(P_=_0.0376)&_Gain_of_methylation_at_R15_(P_=_0.0621)&_Gain_of_loop_(P_=_0.0851)&_Gain_of_disorder_(P_=_0.0877)	P60484	0.59447	0.502	.	0.92123	.	.	0.81001	simple_aae	D	1	0.54059	.	.	.	0.07471	.	.	0.08700	.	D	0.92215	0.867540001869	0.89192	.	9	0.92824	.	.	0.91255	.	.	17.1609	0.86683	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.70966	.	./.	K	.	R	A	938	0.14419	.	10	C1959582&CN517202	.	ORPHA306498	Likely_pathogenic	NC_000010.11:g.87864513G>A	404147	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:9b8faad8-e78a-4d2f-8805-210367466752	.	.	AEFDGBCIJ	D	0.62088	0.94717	D	0.93850	0.938792	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89614250	10	89624270	0	0.96898	0.733237	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	8.949000	0.92922	0.676000	0.76740	1.089000	0.54357	87864513	G	.	rs398123324	.	.	-2.595	-3.496	.	.	.	.	.	9	-45	35	0	0.00	0.00	0.02	0.00	PTEN	0.98	exon-NM_000314.8-1+35+end+924	404147	Likely_pathogenic	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&not_provided	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs398123324	398123324	.	.	.	PTEN\x3bKLLN	PTEN:exonic\x7cKLLN:upstream	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,514	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
2	39285879	39285879	T	C	C	missense_variant	MODERATE	SOS1	6654	Transcript	NM_005633.4	protein_coding	3/23	.	NM_005633.4:c.280A>G	NP_005624.2:p.Ile94Val	909	280	94	I/V	Att/Gtt	rs144757941	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	SOS1	.	chr2:g.39285879T>C	.	.	.	.	.	.	likely_benign	.	1	.	.	.	.	.	SOS1&NM_005633.3&c.280A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	T	0.21525	-0.195021	T	0.58001	-0.163877	19.38	19.36	2.016597	1.952270	0.30925	0.31981	T/T	T	0.14536	0.121089548726046	0.75716	0.99625510753631186	.	0.75393	.	T/T	3	6.808896958692692E-4	0	0.0	3.340828	0.231376697193607	0.51597	2.955471	0.117400218367694	0.47274	.	.	.	6	4.942e-05	6	5.825e-04	0	0	6	4.952e-05	0	0	0	0	0	0	0	0	4	3.766e-05	4	4.464e-04	0	0	4	3.774e-05	0	0	0	0	0	0	0	0	6	6.612e-05	6	5.835e-04	0	0	6	6.629e-05	0	0	0	0	0	0	0	0	0.84415	.	.	.	5.74	4.56	0.55644	0	0.81188	0.709663	.	.	0.51787	0.999989692225208	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.41899	0.613276	Histone_H2A/H2B/H3&Histone_H2A/H2B/H3&Histone_H2A/H2B/H3&Histone_H2A/H2B/H3	.	.	.	0.48765	.	0.105667	0.62929	D	0.000006	D	0.57572	0.037364	0.46518	.	0.84219	.	D	0.84720	0.5763	.	0.39216	.	T	0.81662	-0.0285	.	.	.	.	.	.	0.76659	.	.	0.53665	simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D	0.999976&0.999976&0.999976&0.999968	0.24898	.	.	.	0.21116	.	.	0.14300	.	T	0.66690	0.696858644485	0.73951	.	10	0.63918	.	.	0.53900	.	.	12.8646	0.57320	0.0:0.0:0.1361:0.8639	.	.	.	.	.	.	.	.	0.45520	.	T/T	V	.	I	C	447	0.79583	.	2	C0028326&CN166718&CN517202	PS163950	ORPHA648&ORPHA536391	Likely_benign	NC_000002.12:g.39058738T>C	448945	reviewed_by_expert_panel	Noonan_syndrome&Rasopathy&not_provided	Service_de_Gntique_Molculaire&Hpital_Robert_Debr:42486&ClinGen_RASopathy_Variant_Curation_Expert_Panel:906b02c4-507d-4053-a5bb-59b403751a0d	.	.	AEFBI	D	0.78710	0.97993	D	0.63739	0.670236	.	8	3.187380e-05	8	4.930970e-04	16224	0	0	0.000000e+00	34488	0	250990	0	0.000000e+00	10074	0	0	0.000000e+00	18386	0	0	0.000000e+00	21638	0	0	0.000000e+00	113534	0	8	4.930970e-04	16224	0	0	0.000000e+00	30522	0	5	4.576990e-05	5	6.985190e-04	7158	0	0	0.000000e+00	17042	0	109242	0	0.000000e+00	2318	0	0	0.000000e+00	9040	0	0	0.000000e+00	13394	0	0	0.000000e+00	42730	0	5	6.985190e-04	7158	0	0	0.000000e+00	15646	0	0	.	0	6	2.537430e-05	6	4.034970e-04	14870	0	0	0.000000e+00	34156	0	236460	0	0.000000e+00	9566	0	0	0.000000e+00	17684	0	0	0.000000e+00	21622	0	0	0.000000e+00	102526	0	6	4.034970e-04	14870	0	0	0.000000e+00	30432	0	0	8	3.851230e-05	8	4.942540e-04	16186	0	0	0.000000e+00	30426	0	207726	0	0.000000e+00	6208	0	0	0.000000e+00	13408	0	0	0.000000e+00	16730	0	0	0.000000e+00	89398	0	8	4.942540e-04	16186	0	0	0.000000e+00	30514	0	0	5	2.045980e-05	5	4.167360e-04	11998	0	0	0.000000e+00	34354	0	244382	0	0.000000e+00	9992	0	0	0.000000e+00	18382	0	0	0.000000e+00	21636	0	0	0.000000e+00	111448	0	5	4.167360e-04	11998	0	0	0.000000e+00	30522	0	0	11	7.231610e-05	11	2.654060e-04	41446	0	0	0.000000e+00	912	0	0	0.000000e+00	15284	0	152110	0	0.000000e+00	3468	0	0	0.000000e+00	5202	0	0	0.000000e+00	10620	0	0	0.000000e+00	316	0	0	0.000000e+00	67936	0	11	2.654060e-04	41446	0	0	0.000000e+00	4838	0	2	6.086060e-05	2	2.199740e-04	9092	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32862	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5492	0	0	0.000000e+00	246	0	0	0.000000e+00	6814	0	0	0.000000e+00	3116	0	0	.	0	11	7.439470e-05	11	2.674840e-04	41124	0	0	0.000000e+00	912	0	0	0.000000e+00	15096	0	147860	0	0.000000e+00	3302	0	0	0.000000e+00	4966	0	0	0.000000e+00	10620	0	0	0.000000e+00	304	0	0	0.000000e+00	64712	0	0	0.000000e+00	4806	0	0	8	5.937710e-05	8	2.463510e-04	32474	0	0	0.000000e+00	862	0	0	0.000000e+00	14838	0	134732	0	0.000000e+00	3384	0	0	0.000000e+00	5202	0	0	0.000000e+00	6980	0	0	0.000000e+00	310	0	0	0.000000e+00	63848	0	0	0.000000e+00	4836	0	0	6	7.435130e-05	6	2.417210e-04	24822	0	0	0.000000e+00	112	0	0	0.000000e+00	12912	0	80698	0	0.000000e+00	994	0	0	0.000000e+00	3760	0	0	0.000000e+00	10528	0	0	0.000000e+00	272	0	0	0.000000e+00	20972	0	0	0.000000e+00	4810	0	0	2	39139383	2	39285879	0	0.61202	0.706298	1.000000	0.71638	0.995000	0.73285	0.999000	0.70432	6.148000	0.71557	0.665000	0.62972	1.138000	0.64695	39058738	T	.	rs144757941	.	.	11.110	8.993	7.161	8.549	.	.	.	17	-9	-38	25	0.00	0.00	0.00	0.00	SOS1	1.00	exon-NM_001382394.1-3+65+start+132	448945	Likely_benign	reviewed_by_expert_panel	not_provided&Noonan_syndrome&Cardiovascular_phenotype&RASopathy	MedGen:CN517202&MONDO:MONDO:0018997&MeSH:D009634&MedGen:C0028326&OMIM:PS163950&Orphanet:648&MedGen:CN230736&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	rs144757941	4.942e-05	6	6	0	6	0	0	0	0	0	0	10300	11520	8650	6610	66676	908	16504	6	0	0	0	0	0	0	0	0	0	0	0	0	0	rs144757941	5.23355e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.42523e-06	6.29610e-05	5.23355e-04	3.24870e-05	rs144757941	5.72607e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	1.17041e-04	2.16700e-04	5.72607e-04	1.61342e-04	rs144757941	0.0&0.0681&0.0231	rs144757941	144757941	.	.	.	SOS1	SOS1:exonic	SOS1:missense	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,471	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
1	216498754	216498754	T	G	G	missense_variant	MODERATE	USH2A	7399	Transcript	NM_206933.4	protein_coding	6/72	.	NM_206933.4:c.1036A>C	NP_996816.3:p.Asn346His	1475	1036	346	N/H	Aat/Cat	rs369522997&CM001367	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	USH2A	.	chr1:g.216498754T>G	.	.	.	.	.	.	pathogenic&likely_pathogenic	.	1&1	.	.	.	.	.	USH2A&NM_206933.2&c.1036A>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	T	0.42324	-0.0637162	T	0.65653	-0.0696213	26.2	25.9	3.867569	3.725452	0.74245	0.73194	T/T	D	0.41596	0.71796977519989	0.80660	0.99701273533296275	.	0.82341	.	T/T	0	0.0	1	1.1627906976744187E-4	8.579895	0.740364705913331	0.85438	8.386497	0.779185140249879	0.84788	.	.	.	12	9.884e-05	0	0	0	0	12	9.900e-05	0	0	0	0	12	1.799e-04	0	0	12	1.130e-04	0	0	0	0	12	1.132e-04	0	0	0	0	12	2.209e-04	0	0	1	1.102e-05	0	0	0	0	1	1.104e-05	0	0	0	0	1	2.373e-05	0	0	0.80214	.	.	.	5.36	5.36	0.76624	0	0.26702	0.573888	.	.	0.74766	0.999999411066411	.	0	0.23631	0.573888	.	.	.	.	.	.	0	0.26826	0.564101	Laminin&_N-terminal&Laminin&_N-terminal&Laminin&_N-terminal&.	.	.	.	0.47282	.	0.000000	0.46590	D	0.000265	D	0.92607	0.365048	0.26601	.	0.95466	.	D	0.89003	0.6819	.	0.90086	.	D	0.90406	0.4899	.	.	.	.	.	.	0.89116	.	.	0.81001	simple_aae&simple_aae&simple_aae	D&D&D	1&1&1	0.67241	.	.	.	0.90584	.	.	0.92359	.	T	0.36008	0.479651361704	0.90852	.	10	0.92824	.	.	0.91255	.	.	15.3613	0.74193	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.80866	.	T/T	H	.	N	G	780	0.47616	.	1	C0035334&C0854723&C1848634&C3151138&C0271097&CN517202&CN826980	268000&PS268000&276901&613809&PS276900	ORPHA791&ORPHA71862&ORPHA886&ORPHA96210	Pathogenic	NC_000001.11:g.216325412T>G	48347	reviewed_by_expert_panel	Retinitis_pigmentosa&Retinal_dystrophy&Usher_syndrome&_type_2A&Retinitis_pigmentosa_39&Usher_syndrome&not_provided&Rare_genetic_deafness	UniProtKB_(protein):O75445#VAR_025766	.	.	AEFGBI	D	0.86069	0.98726	D	0.93951	0.939217	.	17	6.773660e-05	0	0.000000e+00	16254	0	0	0.000000e+00	34534	0	250972	0	0.000000e+00	10066	0	0	0.000000e+00	18340	0	0	0.000000e+00	21646	0	17	1.499280e-04	113388	0	17	1.499280e-04	113388	0	0	0.000000e+00	30616	0	9	8.229100e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17098	0	109368	0	0.000000e+00	2320	0	0	0.000000e+00	9020	0	0	0.000000e+00	13394	0	9	2.104380e-04	42768	0	9	2.104380e-04	42768	0	0	0.000000e+00	15690	0	0	.	0	17	7.190110e-05	0	0.000000e+00	14900	0	0	0.000000e+00	34202	0	236436	0	0.000000e+00	9558	0	0	0.000000e+00	17638	0	0	0.000000e+00	21630	0	17	1.660580e-04	102374	0	17	1.660580e-04	102374	0	0	0.000000e+00	30526	0	0	12	5.768790e-05	0	0.000000e+00	16216	0	0	0.000000e+00	30470	0	208016	0	0.000000e+00	6212	0	0	0.000000e+00	13362	0	0	0.000000e+00	16734	0	12	1.340060e-04	89548	0	12	1.340060e-04	89548	0	0	0.000000e+00	30608	0	0	17	6.957120e-05	0	0.000000e+00	12024	0	0	0.000000e+00	34400	0	244354	0	0.000000e+00	9984	0	0	0.000000e+00	18336	0	0	0.000000e+00	21644	0	17	1.527430e-04	111298	0	17	1.527430e-04	111298	0	0	0.000000e+00	30616	0	0	9	5.915290e-05	0	0.000000e+00	41436	0	0	0.000000e+00	912	0	0	0.000000e+00	15258	0	152148	0	0.000000e+00	3472	0	0	0.000000e+00	5188	0	0	0.000000e+00	10616	0	0	0.000000e+00	316	0	9	1.323020e-04	68026	0	9	1.323020e-04	68026	0	0	0.000000e+00	4832	0	2	6.083470e-05	0	0.000000e+00	9082	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32876	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	2	2.920560e-04	6848	0	0	0.000000e+00	3112	0	0	.	0	9	6.085190e-05	0	0.000000e+00	41116	0	0	0.000000e+00	912	0	0	0.000000e+00	15070	0	147900	0	0.000000e+00	3302	0	0	0.000000e+00	4954	0	0	0.000000e+00	10616	0	0	0.000000e+00	304	0	9	1.388800e-04	64804	0	0	0.000000e+00	4800	0	0	9	6.679630e-05	0	0.000000e+00	32462	0	0	0.000000e+00	862	0	0	0.000000e+00	14812	0	134738	0	0.000000e+00	3388	0	0	0.000000e+00	5188	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	9	1.408270e-04	63908	0	0	0.000000e+00	4830	0	0	3	3.717200e-05	0	0.000000e+00	24810	0	0	0.000000e+00	112	0	0	0.000000e+00	12884	0	80706	0	0.000000e+00	998	0	0	0.000000e+00	3746	0	0	0.000000e+00	10524	0	0	0.000000e+00	272	0	3	1.425990e-04	21038	0	0	0.000000e+00	4804	0	0	1	214565377	1	216498754	0	0.14033	0.487112	1.000000	0.71638	0.994000	0.71098	0.997000	0.62031	7.674000	0.83146	0.665000	0.62972	1.138000	0.64695	216325412	T	.	rs369522997	.	.	11.008	9.429	9.079	9.884	.	.	.	20	-2	-11	4	0.00	0.00	0.03	0.00	USH2A	0.00	exon-NM_206933.4-6+107+start+295	48347	Pathogenic	reviewed_by_expert_panel	Rare_genetic_deafness&Usher_syndrome&Retinal_dystrophy&not_provided&Retinitis_pigmentosa&Retinitis_pigmentosa_39&Usher_syndrome_type_2A	MedGen:CN826980&Orphanet:96210&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&Human_Phenotype_Ontology:HP:0000556&Human_Phenotype_Ontology:HP:0007736&Human_Phenotype_Ontology:HP:0007910&Human_Phenotype_Ontology:HP:0007974&Human_Phenotype_Ontology:HP:0007982&MONDO:MONDO:0019118&MeSH:D058499&MedGen:C0854723&Orphanet:71862&MedGen:CN517202&Human_Phenotype_Ontology:HP:0000547&MONDO:MONDO:0019200&MeSH:D012174&MedGen:C0035334&OMIM:268000&OMIM:PS268000&Orphanet:791&MONDO:MONDO:0013436&MedGen:C3151138&OMIM:613809&Orphanet:791&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886	.	1:216498754-216498754	9.884e-05	12	12	0	0	0	0	0	12	0	0	10406	11488	8570	6612	66718	908	16510	0	0	0	0	12	0	0	0	0	0	0	0	0	0	rs369522997	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.61708e-04	0.00000e+00	0.00000e+00	8.91583e-05	5.39898e-05	1.61708e-04	7.30929e-05	rs369522997	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.33280e-04	0.00000e+00	.	1.16918e-04	0.00000e+00	1.33280e-04	6.45328e-05	rs369522997	0.0116&0.0&0.0077	rs369522997	369522997	.	.	.	USH2A	USH2A:exonic	USH2A:missense	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,458	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
2	39213309	39213309	C	T	T	missense_variant	MODERATE	SOS1	6654	Transcript	NM_005633.4	protein_coding	23/23	.	NM_005633.4:c.3658G>A	NP_005624.2:p.Val1220Met	4287	3658	1220	V/M	Gtg/Atg	rs776814547	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	ARHGEF33	.	chr2:g.39213309C>T	.	.	.	.	.	.	benign&uncertain_significance&likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	T	0.30324	-0.137269	D	0.67164	-0.0479411	24.9	26.9	3.570108	3.905123	0.65906	0.78969	C/C	T	0.16376	0.141175460472906	0.91456	0.99832639984049176	.	0.74950	.	C/C	.	.	.	.	6.515892	0.622432650132946	0.76573	5.788241	0.586422008969064	0.72326	.	.	.	10	8.236e-05	0	0	0	0	10	8.239e-05	0	0	0	0	0	0	10	6.056e-04	9	8.474e-05	0	0	0	0	9	8.477e-05	0	0	0	0	0	0	9	5.485e-04	10	1.102e-04	0	0	0	0	10	1.102e-04	0	0	0	0	0	0	10	6.060e-04	0.77336	.	.	.	5.8	5.8	0.92081	0	0.89359	0.724815	.	.	0.74766	0.999999995379554	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.83352	0.714379	.&.&.	.	.	.	0.70254	.	0.134889	0.49741	D	0.000125	D	0.74523	0.085392	0.48199	.	0.68481	.	D	0.82370	0.5263	.	0.22315	.	T	0.79446	-0.1281	V1220M	Gain_of_glycosylation_at_P1219_(P_=_0.0995)&_Loss_of_methylation_at_R1217_(P_=_0.328)&_Loss_of_phosphorylation_at_T1222_(P_=_0.3347)&_Gain_of_loop_(P_=_0.4248)&_Loss_of_sheet_(P_=_0.437)	Q07889	0.00903	0.087	.	0.37844	.	.	0.54805	simple_aae&simple_aae&simple_aae	D&D&D	0.999988&0.999988&0.999988	0.06488	.	.	.	0.63424	.	.	0.72001	.	T	0.73916	0.746404647827	0.62729	.	10	0.26549	.	.	0.35349	.	.	20.0586	0.97662	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.44761	.	C/C	M	.	V	T	459	0.78817	.	2	C4551558&C1853120&CN166718	135300&610733	ORPHA536391	Likely_benign	NC_000002.12:g.38986168C>T	448938	reviewed_by_expert_panel	Gingival_fibromatosis_1&Noonan_syndrome_4&Rasopathy	Illumina_Laboratory_Services&Illumina:1386289&ClinGen_RASopathy_Variant_Curation_Expert_Panel:6ff7d21d-3c34-4d7d-b6e4-fc68a890a4b0	.	.	AEFGBI	D	0.56510	0.92773	D	0.53652	0.505328	.	27	1.074820e-04	0	0.000000e+00	16254	0	1	2.892680e-05	34570	0	251206	0	0.000000e+00	10074	0	0	0.000000e+00	18390	0	0	0.000000e+00	21648	0	0	0.000000e+00	113520	0	26	8.492290e-04	30616	0	26	8.492290e-04	30616	0	14	1.279750e-04	0	0.000000e+00	7164	0	1	5.846590e-05	17104	0	109396	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	0	0.000000e+00	42766	0	13	8.285530e-04	15690	0	13	8.285530e-04	15690	0	0	.	0	26	1.098590e-04	0	0.000000e+00	14900	0	1	2.920730e-05	34238	0	236668	0	0.000000e+00	9566	0	0	0.000000e+00	17688	0	0	0.000000e+00	21632	0	0	0.000000e+00	102504	0	25	8.189740e-04	30526	0	25	8.189740e-04	30526	0	0	27	1.297450e-04	0	0.000000e+00	16216	0	1	3.278260e-05	30504	0	208100	0	0.000000e+00	6210	0	0	0.000000e+00	13412	0	0	0.000000e+00	16734	0	0	0.000000e+00	89550	0	26	8.494510e-04	30608	0	26	8.494510e-04	30608	0	0	27	1.103900e-04	0	0.000000e+00	12024	0	1	2.903940e-05	34436	0	244588	0	0.000000e+00	9992	0	0	0.000000e+00	18386	0	0	0.000000e+00	21646	0	0	0.000000e+00	111430	0	26	8.492290e-04	30616	0	26	8.492290e-04	30616	0	0	4	2.632690e-05	0	0.000000e+00	41384	0	0	0.000000e+00	910	0	0	0.000000e+00	15234	0	151936	0	0.000000e+00	3468	0	0	0.000000e+00	5186	0	0	0.000000e+00	10590	0	0	0.000000e+00	316	0	0	0.000000e+00	67958	0	4	8.319470e-04	4808	0	4	8.319470e-04	4808	0	2	6.094220e-05	0	0.000000e+00	9076	0	0	0.000000e+00	60	0	0	0.000000e+00	4682	0	32818	0	0.000000e+00	134	0	0	0.000000e+00	2426	0	0	0.000000e+00	5466	0	0	0.000000e+00	246	0	0	0.000000e+00	6840	0	2	6.451610e-04	3100	0	0	.	0	4	2.708450e-05	0	0.000000e+00	41062	0	0	0.000000e+00	910	0	0	0.000000e+00	15046	0	147686	0	0.000000e+00	3300	0	0	0.000000e+00	4950	0	0	0.000000e+00	10590	0	0	0.000000e+00	304	0	0	0.000000e+00	64736	0	4	8.375210e-04	4776	0	0	4	2.972740e-05	0	0.000000e+00	32432	0	0	0.000000e+00	862	0	0	0.000000e+00	14790	0	134556	0	0.000000e+00	3384	0	0	0.000000e+00	5186	0	0	0.000000e+00	6952	0	0	0.000000e+00	310	0	0	0.000000e+00	63842	0	4	8.322930e-04	4806	0	0	4	4.966970e-05	0	0.000000e+00	24764	0	0	0.000000e+00	110	0	0	0.000000e+00	12860	0	80532	0	0.000000e+00	994	0	0	0.000000e+00	3744	0	0	0.000000e+00	10498	0	0	0.000000e+00	272	0	0	0.000000e+00	21002	0	4	8.368200e-04	4780	0	0	2	39066813	2	39213309	0	0.73137	0.706548	1.000000	0.71638	0.995000	0.73285	1.000000	0.86279	4.111000	0.57577	0.599000	0.40250	1.026000	0.45946	38986168	C	.	rs776814547	.	.	.	.	7.792	9.064	.	.	.	41	1	-4	1	0.00	0.00	0.00	0.05	SOS1	1.00	exon-NM_001382394.1-23+147+end+4767	448938	Likely_benign	reviewed_by_expert_panel	Noonan_syndrome_4&Cardiovascular_phenotype&Fibromatosis&_gingival&_1&RASopathy	MONDO:MONDO:0012547&MedGen:C1853120&OMIM:610733&Orphanet:648&MedGen:CN230736&MONDO:MONDO:0007609&MedGen:C4551558&OMIM:135300&Orphanet:2024&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	2:39213309-39213309	8.236e-05	10	10	0	0	0	0	0	0	0	10	10404	11552	8650	6614	66736	908	16512	0	0	0	0	0	0	10	0	0	0	0	0	0	0	rs776814547	0.00000e+00	2.97974e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.44649e-04	1.70717e-04	3.59615e-05	8.44649e-04	1.09635e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs776814547	776814547	.	.	.	SOS1	SOS1:exonic	SOS1:missense	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,459	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
3	12641734	12641734	T	C	C	missense_variant	MODERATE	RAF1	5894	Transcript	NM_001354689.3	protein_coding	10/18	.	NM_001354689.3:c.967A>G	NP_001341618.1:p.Thr323Ala	1298	967	323	T/A	Aca/Gca	rs775898894&COSV52578314	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	MKRN2OS	.	chr3:g.12641734T>C	.	.	.	.	.	.	likely_benign&benign	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	T	0.48252	-0.0242025	D	0.73545	0.0494247	22.3	22.1	2.471998	2.323141	0.40624	0.39812	T/T	T	0.15966	0.13645105263853	0.28647	0.9607878520653873	.	0.84681	.	T/T	.	.	.	.	3.806967	0.31527267066017	0.56437	3.013472	0.131728839539726	0.47947	.	.	.	9	7.413e-05	0	0	7	6.051e-04	9	7.419e-05	0	0	0	0	2	3.000e-05	0	0	9	8.474e-05	0	0	7	6.247e-04	9	8.481e-05	0	0	0	0	2	3.685e-05	0	0	7	7.713e-05	0	0	7	6.057e-04	7	7.721e-05	0	0	0	0	0	0	0	0	0.74793	.	.	.	5.82	5.82	0.92740	0	0.89359	0.724815	.	.	0.74766	0.999999999706254	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.98432	0.735409	.&.&.	.	.	.	0.83579	.	0.090352	0.84330	D	0.000000	D	0.55661	0.034415	0.44958	.	0.90220	.	T	0.69960	0.3321	.	0.28803	.	T	0.65165	-0.5914	T303A	Gain_of_glycosylation_at_S306_(P_=_0.0167)&_Loss_of_solvent_accessibility_(P_=_0.1177)&_Gain_of_catalytic_residue_at_T303_(P_=_0.1247)&_Loss_of_relative_solvent_accessibility_(P_=_0.1807)&_Gain_of_MoRF_binding_(P_=_0.2712)	P04049	0.03328	0.128	.	0.75868	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D	1&1&1&1	0.32387	.	.	.	0.09854	.	.	0.11217	.	T	0.50080	0.579957664013	0.62620	.	10	0.12812	.	.	0.20835	.	.	14.755	0.69177	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.69125	.	T/T	A	.	T	C	673	0.60677	.	3	CN166718&CN517202	.	ORPHA536391	Likely_benign	NC_000003.12:g.12600235T>C	448928	reviewed_by_expert_panel	Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:92a20fc0-2bb5-4c16-b8cb-13af84a65a97	.	.	AEFBI	D	0.93399	0.99247	D	0.74716	0.827975	.	16	6.364210e-05	0	0.000000e+00	16254	0	14	4.047650e-04	34588	0	251406	0	0.000000e+00	10076	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	2	1.759140e-05	113692	0	14	4.047650e-04	34588	0	0	0.000000e+00	30616	0	5	4.570130e-05	0	0.000000e+00	7164	0	5	2.922270e-04	17110	0	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	5	2.922270e-04	17110	0	0	0.000000e+00	15690	0	0	.	0	16	6.754820e-05	0	0.000000e+00	14900	0	14	4.086880e-04	34256	0	236868	0	0.000000e+00	9568	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	2	1.947870e-05	102676	0	14	4.086880e-04	34256	0	0	0.000000e+00	30526	0	0	13	6.247120e-05	0	0.000000e+00	16216	0	13	4.259220e-04	30522	0	208096	0	0.000000e+00	6208	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89528	0	13	4.259220e-04	30522	0	0	0.000000e+00	30608	0	0	16	6.535890e-05	0	0.000000e+00	12026	0	14	4.063390e-04	34454	0	244802	0	0.000000e+00	9994	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	2	1.791890e-05	111614	0	14	4.063390e-04	34454	0	0	0.000000e+00	30616	0	0	2	1.313990e-05	0	0.000000e+00	41454	0	0	0.000000e+00	912	0	1	6.543650e-05	15282	0	152208	0	0.000000e+00	3470	0	0	0.000000e+00	5190	0	0	0.000000e+00	10618	0	0	0.000000e+00	316	0	1	1.469720e-05	68040	0	1	6.543650e-05	15282	0	0	0.000000e+00	4834	0	0	0.000000e+00	0	0.000000e+00	9098	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32904	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5488	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3114	0	0	.	0	2	1.351680e-05	0	0.000000e+00	41132	0	0	0.000000e+00	912	0	1	6.625150e-05	15094	0	147964	0	0.000000e+00	3302	0	0	0.000000e+00	4958	0	0	0.000000e+00	10618	0	0	0.000000e+00	304	0	1	1.542730e-05	64820	0	0	0.000000e+00	4802	0	0	2	1.483750e-05	0	0.000000e+00	32484	0	0	0.000000e+00	862	0	1	6.740360e-05	14836	0	134794	0	0.000000e+00	3386	0	0	0.000000e+00	5190	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	1	1.564550e-05	63916	0	0	0.000000e+00	4832	0	0	0	0.000000e+00	0	0.000000e+00	24828	0	0	0.000000e+00	112	0	0	0.000000e+00	12908	0	80762	0	0.000000e+00	996	0	0	0.000000e+00	3748	0	0	0.000000e+00	10526	0	0	0.000000e+00	272	0	0	0.000000e+00	21048	0	0	0.000000e+00	4806	0	0	3	12616734	3	12641734	0	0.85440	0.722319	1.000000	0.71638	0.997000	0.79791	1.000000	0.86279	7.197000	0.77336	0.665000	0.62972	1.138000	0.64695	12600235	T	.	rs775898894	.	.	6.936	7.353	5.755	8.170	.	.	.	44	-4	-1	-4	0.01	0.05	0.00	0.00	RAF1	1.00	exon-NM_001354695.3-7+44+end+128	448928	Likely_benign	reviewed_by_expert_panel	not_provided&RASopathy&Cardiovascular_phenotype	MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN230736	.	3:12641734-12641734	7.413e-05	9	9	0	0	7	0	0	2	0	0	10400	11568	8654	6612	66662	908	16512	0	7	0	0	2	0	0	0	0	0	0	0	0	0	rs775898894	0.00000e+00	4.16964e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.79134e-05	0.00000e+00	0.00000e+00	5.93173e-05	7.18649e-05	4.16964e-04	6.49688e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs775898894	775898894	.	.	.	RAF1	RAF1:exonic	RAF1:missense	RAF1:Cardiomyopathy\x2cdilated\x2c1NN\x3bNoonan_syndrome_5\x3bLEOPARD_syndrome_2	RAF1:615916\x3b611553\x3b611554	RAF1:3\x3b3\x3b3	RAF1:Autosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999776866110749	0.000223133833869176	5.53819998824154e-11	DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,480	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0.6752	VUS
10	89653805	89653805	A	G	G	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	2/9	.	NM_000314.8:c.103A>G	NP_000305.3:p.Met35Val	948	103	35	M/V	Atg/Gtg	rs876659443&CM110119&COSV64289131&COSV64291926&COSV64310633	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89653805A>G	.	.	.	.	.	.	likely_pathogenic	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.103A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	D	0.95669	0.547727	D	0.95605	0.548995	25.9	25.1	3.808473	3.519677	0.72452	0.67623	./.	D	0.79595	0.989351809024811	0.63597	0.99417089974529671	.	0.98148	.	./.	.	.	.	.	7.730761	0.698847297887452	0.82288	7.342011	0.715555678050239	0.80651	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98578	.	.	.	5.19	5.19	0.71428	0	0.97443	0.743671	.	.	0.74766	0.999999999983518	.	0	0.34648	0.602189	.	.	.	.	.	.	0	0.61905	0.655142	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.58047	.	0.000000	0.84330	D	0.000000	D	0.98009	0.750346	0.99441	.	0.99891	.	D	0.98673	0.9589	.	0.99601	.	D	0.99075	1.0857	M35V	Loss_of_sheet_(P_=_0.1158)&_Loss_of_stability_(P_=_0.3027)&_Loss_of_helix_(P_=_0.5596)&_Loss_of_disorder_(P_=_0.5931)&_Gain_of_catalytic_residue_at_F37_(P_=_0.5964)	P60484	0.98385	0.915	.	0.64354	.	.	0.81001	simple_aae	D	1	0.72710	.	.	.	0.56768	.	.	0.64984	.	D	0.85018	0.81994342804	0.99157	.	9	0.92824	.	.	0.72154	.	.	14.0135	0.64028	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.95841	.	./.	V	.	M	G	916	0.20744	.	10	C3551915&C0027672&C1959582&C0950123&CN517202	607174	ORPHA140162&ORPHA306498	Likely_pathogenic	NC_000010.11:g.87894048A>G	231916	reviewed_by_expert_panel	Meningioma&_familial&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&Inborn_genetic_diseases&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:4f6345e3-25b1-48cd-9697-1a5624715071	.	.	AEFGBI	D	0.75717	0.97585	D	0.93525	0.937447	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89643785	10	89653805	0	0.92422	0.732398	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	8.777000	0.91421	0.756000	0.94297	1.312000	0.94714	87894048	A	.	rs876659443	.	.	10.295	10.567	-2.595	-3.496	.	.	.	-30	16	-23	16	0.28	0.02	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-3+23+start+85	231916	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Inborn_genetic_diseases&not_provided&Familial_meningioma&PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MeSH:D030342&MedGen:C0950123&MedGen:CN517202&MONDO:MONDO:0011789&MedGen:C3551915&OMIM:607174&Orphanet:263662&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs876659443	876659443	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,522	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
1	216061814	216061814	C	T	T	missense_variant	MODERATE	USH2A	7399	Transcript	NM_206933.4	protein_coding	41/72	.	NM_206933.4:c.8177G>A	NP_996816.3:p.Gly2726Glu	8616	8177	2726	G/E	gGg/gAg	rs549796389&COSV100232569	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	KCTD3	.	chr1:g.216061814C>T	.	.	.	.	.	.	uncertain_significance	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.71892	0.178358	D	0.75716	0.082068	22.0	23.4	2.372986	2.907336	0.38446	0.52636	C/C	D	0.68839	0.970138907432556	0.71273	0.99552906458184787	.	0.75409	.	C/C	.	.	.	.	3.002423	0.161822323614842	0.47770	3.675742	0.279573344074594	0.55115	.	.	.	1	8.236e-06	0	0	0	0	1	8.251e-06	0	0	0	0	1	1.501e-05	0	0	1	9.415e-06	0	0	0	0	1	9.428e-06	0	0	0	0	1	1.842e-05	0	0	1	1.102e-05	0	0	0	0	1	1.104e-05	0	0	0	0	1	2.379e-05	0	0	0.53516	.	.	.	5.73	3.82	0.43153	0	0.52940	0.615948	.	.	0.26153	0.903468323910187	.	0	0.41167	0.615948	.	.	.	.	.	.	0	0.26826	0.564101	Fibronectin_type_III&Fibronectin_type_III&Fibronectin_type_III	.	.	.	0.36599	.	0.000000	0.43413	D	0.000556	D	0.93821	0.422488	0.25105	.	0.95412	.	T	0.61797	0.2486	.	0.86157	.	T	0.64059	-0.6183	G2726E	Loss_of_catalytic_residue_at_V2727_(P_=_0.058)&_Gain_of_disorder_(P_=_0.0704)&_Gain_of_loop_(P_=_0.1069)&_Loss_of_glycosylation_at_P2721_(P_=_0.2005)&_Loss_of_helix_(P_=_0.2022)	O75445	0.88968	0.761	.	0.60381	.	.	0.53665	simple_aae&simple_aae	D&D	0.999971&0.999971	0.81431	.	.	.	0.68779	.	.	0.61978	.	T	0.49070	0.572779178619	0.71869	.	10	0.92824	.	.	0.63226	.	.	12.4611	0.55071	0.1327:0.7399:0.1274:0.0	.	.	.	.	.	.	.	.	0.54059	.	C/C	E	.	G	T	843	0.36859	.	1	C1848634&C3151138&C0271097&CN169374	276901&613809&PS276900	ORPHA886	Uncertain_significance	NC_000001.11:g.215888472C>T	179542	reviewed_by_expert_panel	Usher_syndrome&_type_2A&Retinitis_pigmentosa_39&Usher_syndrome&not_specified	.	.	.	AEFHCI	D	0.44472	0.85348	D	0.64708	0.684887	.	3	1.195340e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34580	0	250974	0	0.000000e+00	10066	0	0	0.000000e+00	18356	0	0	0.000000e+00	21624	0	2	1.764230e-05	113364	0	2	1.764230e-05	113364	0	0	0.000000e+00	30614	0	2	1.828790e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17110	0	109362	0	0.000000e+00	2320	0	0	0.000000e+00	9028	0	0	0.000000e+00	13384	0	2	4.677920e-05	42754	0	2	4.677920e-05	42754	0	0	0.000000e+00	15690	0	0	.	0	3	1.268820e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34248	0	236440	0	0.000000e+00	9558	0	0	0.000000e+00	17654	0	0	0.000000e+00	21608	0	2	1.954040e-05	102352	0	2	1.954040e-05	102352	0	0	0.000000e+00	30524	0	0	3	1.442250e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30518	0	208008	0	0.000000e+00	6210	0	0	0.000000e+00	13378	0	0	0.000000e+00	16716	0	2	2.234490e-05	89506	0	2	2.234490e-05	89506	0	0	0.000000e+00	30606	0	0	3	1.227710e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34446	0	244358	0	0.000000e+00	9984	0	0	0.000000e+00	18352	0	0	0.000000e+00	21622	0	2	1.797330e-05	111276	0	2	1.797330e-05	111276	0	0	0.000000e+00	30614	0	0	1	6.569440e-06	0	0.000000e+00	41464	0	0	0.000000e+00	912	0	0	0.000000e+00	15288	0	152220	0	0.000000e+00	3466	0	0	0.000000e+00	5200	0	0	0.000000e+00	10614	0	0	0.000000e+00	316	0	1	1.469850e-05	68034	0	1	1.469850e-05	68034	0	0	0.000000e+00	4832	0	1	3.038590e-05	0	0.000000e+00	9104	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32910	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	1	1.459430e-04	6852	0	0	0.000000e+00	3112	0	0	.	0	1	6.758220e-06	0	0.000000e+00	41142	0	0	0.000000e+00	912	0	0	0.000000e+00	15100	0	147968	0	0.000000e+00	3302	0	0	0.000000e+00	4964	0	0	0.000000e+00	10614	0	0	0.000000e+00	304	0	1	1.543070e-05	64806	0	0	0.000000e+00	4800	0	0	1	7.417960e-06	0	0.000000e+00	32490	0	0	0.000000e+00	862	0	0	0.000000e+00	14844	0	134808	0	0.000000e+00	3382	0	0	0.000000e+00	5200	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	1	1.564700e-05	63910	0	0	0.000000e+00	4830	0	0	1	1.237930e-05	0	0.000000e+00	24838	0	0	0.000000e+00	112	0	0	0.000000e+00	12914	0	80780	0	0.000000e+00	992	0	0	0.000000e+00	3758	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	1	4.751050e-05	21048	0	0	0.000000e+00	4804	0	0	1	214128437	1	216061814	0	0.21836	0.525926	0.981000	0.35396	0.176000	0.21171	0.229000	0.22736	2.799000	0.47586	0.599000	0.40250	1.026000	0.45946	215888472	C	.	rs549796389	.	.	9.409	10.766	7.951	9.491	.	.	.	-24	-8	-46	35	0.00	0.00	0.02	0.00	USH2A	0.00	exon-NM_206933.4-41+46+start+629	179542	Uncertain_significance	reviewed_by_expert_panel	not_specified&Usher_syndrome&Retinitis_pigmentosa_39&Usher_syndrome_type_2A&not_provided	MedGen:CN169374&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&MONDO:MONDO:0013436&MedGen:C3151138&OMIM:613809&Orphanet:791&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886&MedGen:CN517202	.	1:216061814-216061814	8.236e-06	1	3	0	0	0	0	0	1	0	0	10392	11556	8610	6598	66636	904	16506	0	0	0	0	3	0	0	0	0	0	0	0	0	0	rs549796389	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.69585e-05	0.00000e+00	0.00000e+00	1.48577e-05	8.99912e-06	2.69585e-05	1.21819e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs549796389	549796389	.	.	.	USH2A\x3bKCTD3	USH2A:exonic\x7cKCTD3:regulatory	USH2A:missense\x7cKCTD3:TF_binding_site\x3bCTCF_binding_site	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,452	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
10	89685275	89685275	T	G	G	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	3/9	.	NM_000314.8:c.170T>G	NP_000305.3:p.Leu57Trp	1015	170	57	L/W	tTg/tGg	rs786202398&CD132273&COSV64291202&COSV64296794&COSV64310457	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89685275T>G	.	.	.	.	.	.	likely_pathogenic&uncertain_significance	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.170T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	T	D	0.96599	0.569433	D	0.96542	0.580175	32	31	4.527276	4.309751	0.91466	0.90155	./.	D	0.96710	0.999251306056976	0.29737	0.96414620435873144	.	0.99561	.	./.	.	.	.	.	11.49291	0.842199279510274	0.92551	11.86846	0.930554526851435	0.93175	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98866	.	.	.	5.45	5.45	0.79688	0	0.89359	0.724815	.	.	0.74766	0.999999999998555	.	0	0.34648	0.602189	.	.	.	.	.	.	0	0.68540	0.695668	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.73561	.	0.000000	0.62929	D	0.000001	D	0.99384	0.916816	0.99204	.	0.98918	.	D	0.99424	0.9812	.	0.95736	.	D	0.97981	1.0435	L57W	Gain_of_MoRF_binding_(P_=_0.0456)&_Loss_of_stability_(P_=_0.0512)&_Gain_of_loop_(P_=_0.069)&_Loss_of_helix_(P_=_0.079)&_Gain_of_ubiquitination_at_K60_(P_=_0.0849)	P60484	0.90840	0.785	.	0.96723	.	.	0.81001	simple_aae	D	1	0.77391	.	.	.	0.90584	.	.	0.97372	.	D	0.98936	0.929102838039	0.99518	.	9	0.83351	.	.	0.78490	.	.	15.5085	0.75494	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.88466	.	./.	W	.	L	G	930	0.16408	.	10	C0027672&C1959582&CN517202	.	ORPHA140162&ORPHA306498	Likely_pathogenic	NC_000010.11:g.87925518T>G	185713	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:d0edcf69-04fa-4771-afb0-a49f8aab9ead&UniProtKB_(protein):P60484#VAR_007460	.	.	AEGBI	D	0.90888	0.99077	D	0.94820	0.942969	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89675255	10	89685275	0	0.73137	0.706548	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	7.425000	0.79444	0.665000	0.62972	1.138000	0.64695	87925518	T	.	rs786202398	.	.	8.389	7.964	10.295	10.567	.	.	.	-4	-5	28	43	0.00	0.03	0.00	0.02	PTEN	0.98	exon-NM_001304717.5-4+5+start+45	185713	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Uterine_corpus_cancer&PTEN_hamartoma_tumor_syndrome&not_provided	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0006003&MedGen:C1883486&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786202398	786202398	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,526	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
1	215822033	215822033	C	T	T	missense_variant	MODERATE	USH2A	7399	Transcript	NM_206933.4	protein_coding	66/72	.	NM_206933.4:c.14419G>A	NP_996816.3:p.Ala4807Thr	14858	14419	4807	A/T	Gcc/Acc	rs534656527&COSV56378627	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	KCTD3	.	chr1:g.215822033C>T	.	0	0	0	0	0.001	uncertain_significance	0&1	1&1	.	.	.	.	.	USH2A&NM_206933.2&c.14419G>A	.	.	1	1.9968051118210862E-4	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0010224948875255625	.	.	.	.	.	.	.	.	.	C/C	C	T	0.48214	-0.0244691	D	0.69472	-0.0132456	25.9	29.0	3.819000	4.144359	0.72760	0.86870	C/C	D	0.44705	0.77439159154892	0.95813	0.9988223574072812	.	0.56366	.	C/C	.	.	.	.	11.73954	0.849104353645241	0.92963	10.40354	0.87414956125975	0.90438	.	.	.	10	8.236e-05	0	0	0	0	10	8.239e-05	0	0	0	0	5	7.494e-05	5	3.028e-04	9	8.474e-05	0	0	0	0	9	8.476e-05	0	0	0	0	4	7.362e-05	5	3.047e-04	10	1.102e-04	0	0	0	0	10	1.102e-04	0	0	0	0	5	1.187e-04	5	3.030e-04	0.64264	.	.	.	5.63	5.63	0.86108	0	0.26702	0.573888	.	.	0.74766	0.999999992089712	.	0	0.15389	0.547309	.	.	.	.	.	.	0	0.26826	0.564101	Fibronectin_type_III&Fibronectin_type_III&Fibronectin_type_III	.	.	.	0.51891	.	0.000000	0.43250	D	0.000573	D	0.93221	0.392555	0.23619	.	0.87447	.	T	0.78396	0.4489	.	0.73078	.	D	0.83036	0.0393	.	.	.	.	.	.	0.92336	.	.	0.53665	simple_aae&simple_aae	D&D	0.999973&0.999973	0.36787	.	.	.	0.61523	.	.	0.54942	.	T	0.32575	0.454613924026	0.73590	.	10	0.51737	.	.	0.43708	.	.	19.7096	0.96085	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.75283	.	C/C	T	.	A	T	671	0.60868	.	1	C1848634&C3151138&C0271097&CN169374&CN517202	276901&613809&PS276900	ORPHA886	Uncertain_significance	NC_000001.11:g.215648691C>T	198366	reviewed_by_expert_panel	Usher_syndrome&_type_2A&Retinitis_pigmentosa_39&Usher_syndrome&not_specified&not_provided	.	.	.	AEFBI	D	0.91786	0.99138	D	0.88126	0.915872	.	16	6.365220e-05	0	0.000000e+00	16254	0	0	0.000000e+00	34590	0	251366	0	0.000000e+00	10074	0	0	0.000000e+00	18380	0	0	0.000000e+00	21642	0	11	9.676620e-05	113676	0	5	1.633130e-04	30616	0	5	1.633130e-04	30616	0	6	5.484660e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109396	0	0.000000e+00	2320	0	0	0.000000e+00	9038	0	0	0.000000e+00	13394	0	2	4.676830e-05	42764	0	4	2.549390e-04	15690	0	4	2.549390e-04	15690	0	0	.	0	15	6.333710e-05	0	0.000000e+00	14900	0	0	0.000000e+00	34258	0	236828	0	0.000000e+00	9566	0	0	0.000000e+00	17678	0	0	0.000000e+00	21626	0	10	9.740890e-05	102660	0	5	1.637950e-04	30526	0	5	1.637950e-04	30526	0	0	13	6.247540e-05	0	0.000000e+00	16216	0	0	0.000000e+00	30522	0	208082	0	0.000000e+00	6212	0	0	0.000000e+00	13402	0	0	0.000000e+00	16728	0	8	8.935750e-05	89528	0	5	1.633560e-04	30608	0	5	1.633560e-04	30608	0	0	16	6.537340e-05	0	0.000000e+00	12024	0	0	0.000000e+00	34456	0	244748	0	0.000000e+00	9992	0	0	0.000000e+00	18376	0	0	0.000000e+00	21640	0	11	9.857870e-05	111586	0	5	1.633130e-04	30616	0	5	1.633130e-04	30616	0	0	8	5.257420e-05	2	4.827890e-05	41426	0	0	0.000000e+00	912	0	0	0.000000e+00	15282	0	152166	0	0.000000e+00	3472	0	0	0.000000e+00	5192	0	0	0.000000e+00	10610	0	0	0.000000e+00	316	0	5	7.348830e-05	68038	0	1	2.072970e-04	4824	0	1	2.072970e-04	4824	0	3	9.124090e-05	1	1.101080e-04	9082	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32880	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5484	0	0	0.000000e+00	246	0	1	1.459430e-04	6852	0	1	3.215430e-04	3110	0	0	.	0	7	4.732930e-05	2	4.865710e-05	41104	0	0	0.000000e+00	912	0	0	0.000000e+00	15094	0	147900	0	0.000000e+00	3302	0	0	0.000000e+00	4956	0	0	0.000000e+00	10610	0	0	0.000000e+00	304	0	4	6.172650e-05	64802	0	1	2.086810e-04	4792	0	0	8	5.936300e-05	2	6.161430e-05	32460	0	0	0.000000e+00	862	0	0	0.000000e+00	14836	0	134764	0	0.000000e+00	3388	0	0	0.000000e+00	5192	0	0	0.000000e+00	6970	0	0	0.000000e+00	310	0	5	7.822280e-05	63920	0	1	2.073830e-04	4822	0	0	6	7.432370e-05	2	8.063870e-05	24802	0	0	0.000000e+00	112	0	0	0.000000e+00	12910	0	80728	0	0.000000e+00	998	0	0	0.000000e+00	3750	0	0	0.000000e+00	10518	0	0	0.000000e+00	272	0	3	1.425180e-04	21050	0	1	2.085070e-04	4796	0	0	1	213888656	1	215822033	0	0.14033	0.487112	1.000000	0.71638	0.991000	0.66497	0.977000	0.46756	7.705000	0.83578	0.599000	0.40250	1.026000	0.45946	215648691	C	.	rs534656527	.	.	8.088	9.429	10.244	6.640	.	.	.	-26	2	7	1	0.00	0.00	0.00	0.00	USH2A	0.00	exon-NM_206933.4-66+75+end+239	198366	Uncertain_significance	reviewed_by_expert_panel	not_specified&not_provided&Usher_syndrome_type_2A&Retinitis_pigmentosa_39&Usher_syndrome	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886&MONDO:MONDO:0013436&MedGen:C3151138&OMIM:613809&Orphanet:791&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886	.	1:215822033-215822033	8.236e-05	10	10	0	0	0	0	0	5	0	5	10406	11574	8644	6610	66724	908	16512	0	0	0	0	5	0	5	0	0	0	0	0	0	0	rs534656527	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	9.85575e-05	0.00000e+00	1.62433e-04	7.41653e-05	5.39074e-05	1.62433e-04	6.49688e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs534656527	534656527	.	.	.	USH2A	USH2A:exonic	USH2A:missense	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,447	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.6752	VUS
16	68845762	68845762	G	T	T	missense_variant&splice_region_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	7/16	.	NM_004360.5:c.1008G>T	NP_004351.1:p.Glu336Asp	1132	1008	336	E/D	gaG/gaT	rs267606712&CS982111&COSV55732029	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68845762G>T	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&0&1	1&1&1	.	.	.	.	.	.	0.999992942176037	0.996	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.82499	0.294197	D	0.82274	0.184817	36	36	6.566819	6.525300	0.96488	0.96507	G/G	D	0.81819	0.991513192653656	0.97275	0.99900663520929278	.	0.83659	.	G/G	.	.	.	.	14.81961	0.924037585329763	0.96538	13.11562	0.97370080402602	0.94878	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.72237	.	.	.	5.47	5.47	0.80345	0	0.40923	0.588066	.	.	0.74766	0.999999999999999	.	0	0.64325	0.697927	.	.	.	.	.	.	0	0.26826	0.564101	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&.	.	.	.	0.84151	.	0.000000	0.51296	D	0.000088	D	0.77866	0.10421	0.67897	.	0.95264	.	D	0.86551	0.6187	.	0.75355	.	D	0.88735	0.3759	E336D	Gain_of_sheet_(P_=_0.1539)&_Loss_of_stability_(P_=_0.2369)&_Gain_of_catalytic_residue_at_E336_(P_=_0.2552)&_Gain_of_phosphorylation_at_Y341_(P_=_0.2582)&_Loss_of_glycosylation_at_T340_(P_=_0.3146)	P12830	0.24270	0.285	.	0.74557	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.60507	.	.	.	0.68779	.	.	0.74454	.	T	0.51301	0.588640093803	0.85511	.	10	0.72224	.	.	0.72154	.	.	19.2966	0.94112	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.86297	.	G/G	D	.	E	T	315	0.87208	.	16	C1708349&C0027672	137215	ORPHA26106&ORPHA140162	Likely_pathogenic	NC_000016.10:g.68811859G>T	18453	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome	OMIM_Allelic_Variant:192090.0005&ClinGen_CDH1_Variant_Curation_Expert_Panel&:f17d1590-599b-49d7-a1e0-273ed56fef12&UniProtKB_(protein):P12830#VAR_001310	.	.	AEFDGBCI	D	0.80630	0.98217	D	0.95518	0.946106	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	67403263	16	68845762	0	0.41029	0.631515	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	9.602000	0.97623	0.676000	0.76740	1.176000	0.78918	68811859	G	.	rs267606712	.	.	10.172	4.939	8.102	7.878	-3.371	8.310	4.939	-45	0	7	0	0.00	0.00	0.20	0.91	CDH1	0.34	exon-NM_004360.5-7+0+end+176	18453	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_diffuse_gastric_adenocarcinoma&Hereditary_cancer-predisposing_syndrome	MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs267606712	267606712	.	.	.	CDH1\x3bTANGO6	CDH1:splicing\x3bexonic\x7cTANGO6:regulatory	CDH1:splice_region_variant\x3bmissense\x7cTANGO6:open_chromatin_region	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,901	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
13	20763382	20763382	A	C	C	missense_variant	MODERATE	GJB2	2706	Transcript	NM_004004.6	protein_coding	2/2	.	NM_004004.6:c.339T>G	NP_003995.2:p.Ser113Arg	517	339	113	S/R	agT/agG	rs80338946&CM980928	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	GJB2	.	chr13:g.20763382A>C	.	.	.	.	.	.	uncertain_significance&conflicting_interpretations_of_pathogenicity	.	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.74663	0.208234	D	0.74334	0.0613373	7.115	0.733	0.559699	-0.196875	0.09793	0.02982	A/A	T	0.04835	0.0462798275178268	0.07470	0.64352813373590489	.	0.82769	.	A/A	.	.	.	.	0.1159119	-1.47895617289172	0.02517	0.09935183	-1.44523759698861	0.02255	.	.	.	1	8.236e-06	0	0	0	0	1	8.257e-06	0	0	0	0	1	1.502e-05	0	0	1	9.415e-06	0	0	0	0	1	9.422e-06	0	0	0	0	1	1.841e-05	0	0	1	1.102e-05	0	0	0	0	1	1.106e-05	0	0	0	0	1	2.382e-05	0	0	0.97444	.	.	.	5.33	-4.09	0.03685	0	0.52368	0.61073	.	.	0.74766	0.999999999999514	.	0	0.93304	0.731555	.	.	.	.	.	.	0	0.58350	0.63947	Connexin&_N-terminal&Connexin&_N-terminal&Connexin&_N-terminal	.	.	.	0.01322	.	0.995923	0.08029	N	0.991263	T	0.47706	0.024715	0.04739	.	0.80435	.	D	0.89863	0.7053	.	0.95156	.	T	0.80118	-0.0991	S113R	Gain_of_solvent_accessibility_(P_=_0.0155)&_Gain_of_MoRF_binding_(P_=_0.0237)&_Loss_of_phosphorylation_at_S113_(P_=_0.0324)&_Gain_of_methylation_at_K116_(P_=_0.0441)&_Gain_of_helix_(P_=_0.062)	P29033	0.90689	0.783	.	0.26193	.	.	0.08975	simple_aae&simple_aae	A&A	1.67923e-12&1.67923e-12	0.23808	.	.	.	0.19245	.	.	0.20508	.	T	0.32312	0.452700376511	0.81544	.	9	0.12491	.	.	0.13522	.	.	10.2218	0.42378	0.2735:0.1314:0.5952:0.0	.	.	.	.	.	.	.	.	0.68863	.	A/A	R	.	S	C	682	0.59757	.	13	C2673759&C2675750&C1865234&CN043648&CN517202	220290&601544&602540	ORPHA87884	Uncertain_significance	NC_000013.11:g.20189243A>C	21385	reviewed_by_expert_panel	Deafness&_autosomal_recessive_1A&Deafness&_autosomal_dominant_3a&Hystrix-like_ichthyosis_with_deafness&Nonsyndromic_hearing_loss_and_deafness&not_provided	UniProtKB_(protein):P29033#VAR_002145&Illumina_Laboratory_Services&Illumina:465044	.	.	AEFDBHCIJ	N	0.20986	0.20291	N	0.34870	0.224472	.	3	1.198880e-05	0	0.000000e+00	16242	0	0	0.000000e+00	34582	0	250234	3	2.980920e-04	10064	0	0	0.000000e+00	18386	0	0	0.000000e+00	21064	0	0	0.000000e+00	113154	0	.	.	.	.	0	0.000000e+00	30610	0	1	9.192700e-06	0	0.000000e+00	7162	0	0	0.000000e+00	17102	0	108782	1	4.310340e-04	2320	0	0	0.000000e+00	9040	0	0	0.000000e+00	12810	0	0	0.000000e+00	42756	0	.	.	.	.	0	0.000000e+00	15684	0	0	.	0	3	1.272550e-05	0	0.000000e+00	14900	0	0	0.000000e+00	34250	0	235748	3	3.138730e-04	9558	0	0	0.000000e+00	17684	0	0	0.000000e+00	21048	0	0	0.000000e+00	102174	0	.	.	.	.	0	0.000000e+00	30520	0	0	3	1.448650e-05	0	0.000000e+00	16204	0	0	0.000000e+00	30514	0	207090	3	4.834030e-04	6206	0	0	0.000000e+00	13410	0	0	0.000000e+00	16150	0	0	0.000000e+00	89146	0	.	.	.	.	0	0.000000e+00	30602	0	0	3	1.231440e-05	0	0.000000e+00	12012	0	0	0.000000e+00	34448	0	243618	3	3.005410e-04	9982	0	0	0.000000e+00	18382	0	0	0.000000e+00	21062	0	0	0.000000e+00	111066	0	.	.	.	.	0	0.000000e+00	30610	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	13	19661382	13	20763382	0	0.99124	0.764865	0.000000	0.06391	0.518000	0.29429	0.205000	0.22246	-0.688000	0.05251	-0.065000	0.16512	-0.038000	0.13501	20189243	A	.	rs80338946	.	.	.	.	10.295	9.602	.	.	.	-50	-37	1	-36	0.00	0.00	0.00	0.00	GJB2	0.00	exon-NM_004004.6-2+360+end+2134	21385	Uncertain_significance	reviewed_by_expert_panel	not_provided&Nonsyndromic_genetic_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_1A&Ichthyosis&_hystrix-like&_with_hearing_loss&Autosomal_dominant_nonsyndromic_hearing_loss_3A	MedGen:CN517202&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0009076&MedGen:C2673759&OMIM:220290&Orphanet:90636&MONDO:MONDO:0011245&MedGen:C1865234&OMIM:602540&Orphanet:477&MONDO:MONDO:0011103&MedGen:C2675750&OMIM:601544&Orphanet:90635	.	rs80338946	8.236e-06	1	1	0	0	0	0	0	1	0	0	10334	11540	8640	6610	66576	904	16500	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs80338946	0.00000e+00	0.00000e+00	3.04940e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.48874e-05	9.03604e-06	3.04940e-04	1.21817e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs80338946	80338946	.	.	.	GJB2	GJB2:exonic	GJB2:missense	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,867	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.4999	VUS
12	112884118	112884118	A	G	G	missense_variant	MODERATE	PTPN11	5781	Transcript	NM_002834.5	protein_coding	2/16	.	NM_002834.5:c.53A>G	NP_002825.3:p.Asn18Ser	218	53	18	N/S	aAc/aGc	rs587778635	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTPN11	.	chr12:g.112884118A>G	.	.	.	.	.	.	uncertain_significance&not_provided&benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	A	T	0.09015	-0.29628	T	0.45535	-0.292277	22.3	22.3	2.447394	2.367867	0.40082	0.40806	./.	T	0.14721	0.123006160853415	0.37874	0.98051644135258453	.	0.76194	.	./.	.	.	.	.	3.028429	0.167468060687762	0.48075	2.126291	-0.115454695796811	0.36720	.	.	.	15	1.235e-04	0	0	0	0	15	1.236e-04	0	0	0	0	0	0	15	9.084e-04	15	1.412e-04	0	0	0	0	15	1.412e-04	0	0	0	0	0	0	15	9.142e-04	15	1.653e-04	0	0	0	0	15	1.653e-04	0	0	0	0	0	0	15	9.090e-04	0.87910	.	.	.	5.93	5.93	0.95888	0	0.89359	0.724815	.	.	0.74766	0.999999998576862	.	0	0.96076	0.743671	.	.	.	.	.	.	0	0.98432	0.735409	.&.&SH2_domain&SH2_domain&SH2_domain&SH2_domain&SH2_domain&SH2_domain	.	.	.	0.75457	.	0.000000	0.84330	D	0.000000	T	0.37081	0.016031	0.85850	.	0.75515	.	T	0.71743	0.3543	.	0.22256	.	T	0.68301	-0.5096	N18S	Gain_of_relative_solvent_accessibility_(P_=_0.1894)&_Gain_of_phosphorylation_at_T22_(P_=_0.2441)&_Gain_of_disorder_(P_=_0.3144)&_Loss_of_catalytic_residue_at_N18_(P_=_0.3217)&_Loss_of_glycosylation_at_T22_(P_=_0.3879)	ENST00000351677	0.48979	0.437	.	0.04868	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.07882	.	.	.	0.12996	.	.	0.04355	.	D	0.89569	0.849692583084	0.62179	.	10	0.18178	.	.	0.20835	.	.	16.3797	0.83287	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.47115	.	./.	S	.	N	G	45	0.97767	.	12	C0410530&C4551602&CN260604&CN166718&C4551484&CN169374&CN517202	156250&163950&151100	ORPHA2499&ORPHA98733&ORPHA536391	Benign	NC_000012.12:g.112446314A>G	135112	reviewed_by_expert_panel	Metachondromatosis&Noonan_syndrome_1&Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&LEOPARD_syndrome_1&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:295145&ClinGen_RASopathy_Variant_Curation_Expert_Panel:b05eb983-c118-4f08-88a9-d168d803a9d0	.	.	AEFBI	D	0.90552	0.99054	D	0.90442	0.925216	.	24	9.544640e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34592	0	251450	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	0	0.000000e+00	113728	0	23	7.512410e-04	30616	0	23	7.512410e-04	30616	0	9	8.226090e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	9	5.736140e-04	15690	0	9	5.736140e-04	15690	0	0	segdup	0	24	1.013030e-04	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236912	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	0	0.000000e+00	102712	0	23	7.534560e-04	30526	0	23	7.534560e-04	30526	0	0	24	1.153100e-04	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208134	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89556	0	23	7.514380e-04	30608	0	23	7.514380e-04	30608	0	0	24	9.802640e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244832	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	0	0.000000e+00	111638	0	23	7.512410e-04	30616	0	23	7.512410e-04	30616	0	0	3	1.971790e-05	0	0.000000e+00	41424	0	0	0.000000e+00	912	0	0	0.000000e+00	15262	0	152146	0	0.000000e+00	3472	0	0	0.000000e+00	5196	0	0	0.000000e+00	10610	0	0	0.000000e+00	316	0	0	0.000000e+00	68032	0	3	6.208610e-04	4832	0	3	6.208610e-04	4832	0	2	6.080880e-05	0	0.000000e+00	9092	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32890	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5482	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	2	6.422610e-04	3114	0	0	.	0	3	2.028560e-05	0	0.000000e+00	41104	0	0	0.000000e+00	912	0	0	0.000000e+00	15074	0	147888	0	0.000000e+00	3302	0	0	0.000000e+00	4960	0	0	0.000000e+00	10610	0	0	0.000000e+00	304	0	0	0.000000e+00	64802	0	3	6.250000e-04	4800	0	0	3	2.226580e-05	0	0.000000e+00	32456	0	0	0.000000e+00	862	0	0	0.000000e+00	14816	0	134736	0	0.000000e+00	3388	0	0	0.000000e+00	5196	0	0	0.000000e+00	6968	0	0	0.000000e+00	310	0	0	0.000000e+00	63910	0	3	6.211180e-04	4830	0	0	2	2.477820e-05	0	0.000000e+00	24806	0	0	0.000000e+00	112	0	0	0.000000e+00	12888	0	80716	0	0.000000e+00	998	0	0	0.000000e+00	3754	0	0	0.000000e+00	10518	0	0	0.000000e+00	272	0	0	0.000000e+00	21048	0	2	4.163200e-04	4804	0	0	12	111368501	12	112884118	0	0.92422	0.732398	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	9.226000	0.94392	0.756000	0.94297	1.306000	0.88091	112446314	A	.	rs587778635	.	.	4.729	9.664	10.732	8.409	.	.	.	-3	-38	-16	-25	0.00	0.00	0.00	0.00	PTPN11	1.00	exon-NM_001330437.2-2+38+start+123	135112	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&not_specified&not_provided&RASopathy&LEOPARD_syndrome_1&Noonan_syndrome_1&Metachondromatosis	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0100082&MedGen:C4551484&OMIM:151100&Orphanet:500&MONDO:MONDO:0008104&MedGen:C4551602&OMIM:163950&Orphanet:648&MONDO:MONDO:0007979&MedGen:C0410530&OMIM:156250&Orphanet:2499	.	12:112884118-112884118	1.235e-04	15	15	0	0	0	0	0	0	0	15	10402	11578	8654	6614	66740	908	16512	0	0	0	0	0	0	15	0	0	0	0	0	0	0	rs587778635	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.82349e-04	7.14703e-04	1.33452e-04	4.49075e-05	7.14703e-04	9.33927e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587778635	587778635	.	.	.	PTPN11	PTPN11:exonic	PTPN11:missense	PTPN11:Noonan_syndrome_1\x3bLEOPARD_syndrome_1\x3bMetachondromatosis\x3bLeukemia\x2cjuvenile_myelomonocytic\x2csomatic	PTPN11:163950\x3b151100\x3b156250\x3b607785	PTPN11:3\x3b3\x3b3\x3b3	PTPN11:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999877230878678	0.000122769057470549	6.38519788034449e-11	DISEASE: LEOPARD syndrome 1 (LPRD1) [MIM:151100]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:12058348, ECO:0000269|PubMed:14961557, ECO:0000269|PubMed:15121796, ECO:0000269|PubMed:15389709, ECO:0000269|PubMed:15520399, ECO:0000269|PubMed:15690106, ECO:0000269|PubMed:16679933, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 1 (NS1) [MIM:163950]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints. {ECO:0000269|PubMed:11704759, ECO:0000269|PubMed:11992261, ECO:0000269|PubMed:12161469, ECO:0000269|PubMed:12325025, ECO:0000269|PubMed:12529711, ECO:0000269|PubMed:12634870, ECO:0000269|PubMed:12717436, ECO:0000269|PubMed:12739139, ECO:0000269|PubMed:12960218, ECO:0000269|PubMed:15384080, ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry. Mutations in PTPN11 account for more than 50% of the cases.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:12717436}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Metachondromatosis (MC) [MIM:156250]: A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest. {ECO:0000269|PubMed:20577567}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,853	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103310908	103310908	T	C	C	start_lost	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	1/13	.	NM_000277.3:c.1A>G	NP_000268.1:p.Met1?	115	1	1	M/V	Atg/Gtg	rs62514891&CM155973&CM890092	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103310908T>C	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.96051	0.557605	D	0.96522	0.578671	22.3	21.1	2.463529	2.152140	0.40437	0.36110	T/T	D	0.61753	0.942894577980042	0.32713	0.97179828109094479	.	0.72471	.	T/T	.	.	.	.	3.370748	0.237163249807491	0.51921	3.438366	0.229950618788782	0.52656	.	.	.	1	8.236e-06	0	0	0	0	1	8.248e-06	0	0	0	0	1	1.501e-05	0	0	1	9.415e-06	0	0	0	0	1	9.428e-06	0	0	0	0	1	1.843e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99249	.	.	.	5.2	5.2	0.71720	0	0.06741	0.475579	.	.	0.74766	0.999999999049769	.	0	0.62441	0.685912	.	.	.	.	.	.	0	0.26826	0.564101	.&.&.	.	.	.	0.65058	.	0.903724	0.09592	N	0.765068	D	0.99957	0.989098	.	.	0.95488	.	D	0.99162	0.9732	.	0.98852	.	D	0.99636	1.0994	M1V	Gain_of_sheet_(P_=_0.0477)&_Gain_of_glycosylation_at_S2_(P_=_0.1096)&_Gain_of_catalytic_residue_at_M1_(P_=_0.1877)&_Loss_of_loop_(P_=_0.2237)&_Loss_of_disorder_(P_=_0.2458)	P00439	0.99957	0.996	.	.	.	.	0.81001	complex_aae&without_aae	D&D	1&1	0.18670	.	.	.	0.33082	.	.	0.42942	.	.	.	.	0.85406	.	8	0.92824	.	.	0.91255	.	.	11.636	0.50464	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.99260	.	T/T	V	.	M	C	776	0.48302	.	12	C0751435&C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102917130T>C	586	reviewed_by_expert_panel	Hyperphenylalaninemia&_non-pku&Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.M1V&OMIM_Allelic_Variant:612349.0009	.	.	AEFDGBHCI	D	0.44954	0.85783	N	0.16561	0.081826	.	2	7.953800e-06	0	0.000000e+00	16254	0	0	0.000000e+00	34590	0	251452	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21644	0	2	1.758490e-05	113734	0	2	1.758490e-05	113734	0	0	0.000000e+00	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17110	0	109396	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13390	0	0	0.000000e+00	42762	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	2	8.441670e-06	0	0.000000e+00	14900	0	0	0.000000e+00	34258	0	236920	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21628	0	2	1.946960e-05	102724	0	2	1.946960e-05	102724	0	0	0.000000e+00	30526	0	0	1	4.805200e-06	0	0.000000e+00	16216	0	0	0.000000e+00	30522	0	208108	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16730	0	1	1.116840e-05	89538	0	1	1.116840e-05	89538	0	0	0.000000e+00	30608	0	0	2	8.168800e-06	0	0.000000e+00	12024	0	0	0.000000e+00	34456	0	244834	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21642	0	2	1.791410e-05	111644	0	2	1.791410e-05	111644	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101835038	12	103310908	1	0.06251	0.40479	1.000000	0.71638	0.040000	0.14268	0.261000	0.23344	3.296000	0.51509	0.665000	0.62972	1.138000	0.64695	102917130	T	.	rs62514891	.	.	8.002	9.602	.	.	.	.	.	5	-28	1	49	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_000277.3-1+59+start+174	586	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria&Hyperphenylalaninemia	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&Human_Phenotype_Ontology:HP:0004923&MedGen:C0751435	.	rs62514891	8.236e-06	1	1	0	0	0	0	0	1	0	0	10384	11560	8652	6612	66644	908	16478	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs62514891	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.79064e-05	0.00000e+00	0.00000e+00	7.41334e-06	8.98085e-06	1.79064e-05	8.12110e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62514891	62514891	.	.	.	PAH	PAH:exonic	PAH:startloss	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,852	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103310908	103310908	T	A	A	start_lost	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	1/13	.	NM_000277.3:c.1A>T	NP_000268.1:p.Met1?	115	1	1	M/L	Atg/Ttg	rs62514891&CM155973&CM890092	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103310908T>A	.	.	.	.	.	.	pathogenic&not_provided	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.96382	0.567483	D	0.96321	0.577374	16.08	15.32	1.553145	1.324890	0.22699	0.21279	T/T	D	0.33693	0.528876483440399	0.18823	0.8946895375807854	.	0.70820	.	T/T	.	.	.	.	2.679706	0.0864906419238917	0.43868	2.657	0.0401299265169387	0.43691	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99217	.	.	.	5.2	5.2	0.71720	0	0.06741	0.475579	.	.	0.74766	0.999999999049769	.	0	0.62441	0.685912	.	.	.	.	.	.	0	0.26826	0.564101	.&.&.	.	.	.	0.65058	.	0.903724	0.09592	N	0.765068	D	0.99862	0.975825	.	.	0.93581	.	D	0.98670	0.9588	.	0.98053	.	D	0.95711	0.9027	M1L	Loss_of_sheet_(P_=_0.1158)&_Gain_of_loop_(P_=_0.2045)&_Loss_of_glycosylation_at_S2_(P_=_0.2333)&_Gain_of_disorder_(P_=_0.2685)&_Loss_of_catalytic_residue_at_V5_(P_=_0.307)	P00439	0.99980	0.998	.	.	.	.	0.81001	complex_aae&without_aae	D&D	1&1	0.17210	.	.	.	0.28604	.	.	0.42942	.	.	.	.	0.84826	.	9	0.92824	.	.	0.91255	.	.	11.636	0.50464	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.99181	.	T/T	L	.	M	A	776	0.48302	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102917130T>A	102626	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:M1L	.	.	AEFDGBHCI	D	0.46364	0.86962	N	0.16561	0.081826	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101835038	12	103310908	1	0.06251	0.40479	1.000000	0.71638	0.040000	0.14268	0.261000	0.23344	3.296000	0.51509	0.665000	0.62972	1.138000	0.64695	102917130	T	.	rs62514891	.	.	8.002	9.602	.	.	.	.	.	-28	-2	-11	-1	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_000277.3-1+59+start+174	102626	Pathogenic	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62514891	62514891	.	.	.	PAH	PAH:exonic	PAH:startloss	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,851	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103310907	103310907	A	G	G	start_lost	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	1/13	.	NM_000277.3:c.2T>C	NP_000268.1:p.Met1?	116	2	1	M/T	aTg/aCg	rs62508575&CM000541	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103310907A>G	.	.	.	.	.	.	pathogenic&likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.2T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.92936	0.460244	D	0.99401	0.66	23.8	23.3	3.182196	2.863636	0.56171	0.51686	A/A	D	0.73245	0.980228245258331	0.20966	0.91674935972242166	.	0.73660	.	A/A	1	2.2696323195642307E-4	0	0.0	3.94816	0.338356181904243	0.57808	4.14182	0.366385271827649	0.59611	.	.	.	1	8.236e-06	1	9.628e-05	0	0	1	8.248e-06	0	0	0	0	0	0	0	0	1	9.415e-06	1	1.105e-04	0	0	1	9.428e-06	0	0	0	0	0	0	0	0	1	1.102e-05	1	9.645e-05	0	0	1	1.103e-05	0	0	0	0	0	0	0	0	0.99296	.	.	.	5.2	5.2	0.71720	0	0.06741	0.475579	.	.	0.74766	0.999999999049769	.	0	0.62441	0.685912	.	.	.	.	.	.	0	0.26826	0.564101	.&.&.	.	.	.	0.65058	.	0.903724	0.09592	N	0.765068	D	0.99832	0.971813	.	.	0.98044	.	D	0.99221	0.9750	.	0.82408	.	D	0.97616	1.0245	.	.	.	.	.	.	.	.	.	0.81001	complex_aae&without_aae	D&D	1&1	0.18248	.	.	.	0.42239	.	.	0.53862	.	.	.	.	0.86384	.	9	0.92824	.	.	0.91255	.	.	11.636	0.50464	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.95374	.	A/A	T	.	M	G	776	0.48302	.	12	C0031485&CN517202	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102917129A>G	203873	reviewed_by_expert_panel	Phenylketonuria&not_provided	.	.	.	AEFDGBHCI	D	0.49861	0.89412	N	0.14055	0.070747	.	2	7.953610e-06	2	1.230470e-04	16254	0	0	0.000000e+00	34590	0	251458	0	0.000000e+00	10080	0	0	0.000000e+00	18392	0	0	0.000000e+00	21646	0	0	0.000000e+00	113740	0	2	1.230470e-04	16254	0	0	0.000000e+00	30616	0	1	9.140930e-06	1	1.395870e-04	7164	0	0	0.000000e+00	17110	0	109398	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13392	0	0	0.000000e+00	42764	0	1	1.395870e-04	7164	0	0	0.000000e+00	15690	0	0	.	0	2	8.441530e-06	2	1.342280e-04	14900	0	0	0.000000e+00	34258	0	236924	0	0.000000e+00	9572	0	0	0.000000e+00	17690	0	0	0.000000e+00	21630	0	0	0.000000e+00	102728	0	2	1.342280e-04	14900	0	0	0.000000e+00	30526	0	0	2	9.610120e-06	2	1.233350e-04	16216	0	0	0.000000e+00	30522	0	208114	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16732	0	0	0.000000e+00	89542	0	2	1.233350e-04	16216	0	0	0.000000e+00	30608	0	0	1	4.084300e-06	1	8.316700e-05	12024	0	0	0.000000e+00	34456	0	244840	0	0.000000e+00	9998	0	0	0.000000e+00	18388	0	0	0.000000e+00	21644	0	0	0.000000e+00	111650	0	1	8.316700e-05	12024	0	0	0.000000e+00	30616	0	0	10	6.570130e-05	10	2.412310e-04	41454	0	0	0.000000e+00	912	0	0	0.000000e+00	15284	0	152204	0	0.000000e+00	3472	0	0	0.000000e+00	5198	0	0	0.000000e+00	10624	0	0	0.000000e+00	316	0	0	0.000000e+00	68022	0	10	2.412310e-04	41454	0	0	0.000000e+00	4828	0	2	6.078660e-05	2	2.198290e-04	9098	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32902	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5494	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3114	0	0	.	0	10	6.758670e-05	10	2.431200e-04	41132	0	0	0.000000e+00	912	0	0	0.000000e+00	15098	0	147958	0	0.000000e+00	3302	0	0	0.000000e+00	4962	0	0	0.000000e+00	10624	0	0	0.000000e+00	304	0	0	0.000000e+00	64804	0	0	0.000000e+00	4796	0	0	9	6.677050e-05	9	2.770940e-04	32480	0	0	0.000000e+00	862	0	0	0.000000e+00	14838	0	134790	0	0.000000e+00	3388	0	0	0.000000e+00	5198	0	0	0.000000e+00	6984	0	0	0.000000e+00	310	0	0	0.000000e+00	63900	0	0	0.000000e+00	4826	0	0	6	7.429240e-05	6	2.416630e-04	24828	0	0	0.000000e+00	112	0	0	0.000000e+00	12910	0	80762	0	0.000000e+00	998	0	0	0.000000e+00	3756	0	0	0.000000e+00	10532	0	0	0.000000e+00	272	0	0	0.000000e+00	21034	0	0	0.000000e+00	4800	0	0	12	101835037	12	103310907	1	0.06251	0.40479	1.000000	0.71638	0.038000	0.14061	0.247000	0.23083	3.852000	0.55642	0.756000	0.94297	1.312000	0.94714	102917129	A	.	rs62508575	.	.	8.002	9.602	.	.	.	.	.	-27	2	-10	2	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_000277.3-1+58+start+174	203873	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62508575	8.236e-06	1	1	0	1	0	0	0	0	0	0	10386	11560	8650	6612	66648	908	16482	1	0	0	0	0	0	0	0	0	0	0	0	0	0	rs62508575	1.30685e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.41312e-06	8.98085e-06	1.30685e-04	8.12110e-06	rs62508575	1.14521e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84044e-05	0.00000e+00	1.14521e-04	3.22664e-05	rs62508575	0.0&0.0227&0.0077	rs62508575	62508575	.	.	.	PAH	PAH:exonic	PAH:startloss	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,850	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103310907	103310907	A	C	C	start_lost	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	1/13	.	NM_000277.3:c.2T>G	NP_000268.1:p.Met1?	116	2	1	M/R	aTg/aGg	rs62508575&CM000541	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103310907A>C	.	.	.	.	.	.	not_provided&pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.2T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.99412	0.625005	D	0.99401	0.66	24.4	23.7	3.394990	3.055662	0.61414	0.56003	A/A	D	0.74622	0.9826540350914	0.25045	0.94539232237107829	.	0.72288	.	A/A	.	.	.	.	4.098671	0.361870719694881	0.59225	4.339687	0.399446505916419	0.61391	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99303	.	.	.	5.2	5.2	0.71720	0	0.06741	0.475579	.	.	0.74766	0.999999999049769	.	0	0.62441	0.685912	.	.	.	.	.	.	0	0.26826	0.564101	.&.&.	.	.	.	0.65058	.	0.903724	0.09592	N	0.765068	D	0.99845	0.973499	.	.	0.98102	.	D	0.99287	0.9770	.	0.98850	.	D	0.97742	1.0313	M1R	Gain_of_sheet_(P_=_0.0149)&_Gain_of_methylation_at_M1_(P_=_0.0172)&_Loss_of_loop_(P_=_0.0374)&_Gain_of_phosphorylation_at_S2_(P_=_0.0896)&_Gain_of_solvent_accessibility_(P_=_0.11)	P00439	0.99957	0.996	.	.	.	.	0.81001	complex_aae&without_aae	D&D	1&1	0.14193	.	.	.	0.47373	.	.	0.53862	.	.	.	.	0.84826	.	9	0.92824	.	.	0.91255	.	.	11.636	0.50464	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.98929	.	A/A	R	.	M	C	776	0.48302	.	12	C0031485&CN517202	261600	ORPHA716	Pathogenic	NC_000012.12:g.102917129A>C	102647	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.M1R	.	.	AEFDGBHCI	D	0.50607	0.89862	N	0.17660	0.087094	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.570130e-06	0	0.000000e+00	41454	0	0	0.000000e+00	912	0	0	0.000000e+00	15284	0	152204	0	0.000000e+00	3472	0	0	0.000000e+00	5198	0	0	0.000000e+00	10624	0	0	0.000000e+00	316	0	0	0.000000e+00	68022	0	1	2.071250e-04	4828	0	1	2.071250e-04	4828	0	0	0.000000e+00	0	0.000000e+00	9098	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32902	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5494	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3114	0	0	.	0	1	6.758670e-06	0	0.000000e+00	41132	0	0	0.000000e+00	912	0	0	0.000000e+00	15098	0	147958	0	0.000000e+00	3302	0	0	0.000000e+00	4962	0	0	0.000000e+00	10624	0	0	0.000000e+00	304	0	0	0.000000e+00	64804	0	1	2.085070e-04	4796	0	0	1	7.418950e-06	0	0.000000e+00	32480	0	0	0.000000e+00	862	0	0	0.000000e+00	14838	0	134790	0	0.000000e+00	3388	0	0	0.000000e+00	5198	0	0	0.000000e+00	6984	0	0	0.000000e+00	310	0	0	0.000000e+00	63900	0	1	2.072110e-04	4826	0	0	1	1.238210e-05	0	0.000000e+00	24828	0	0	0.000000e+00	112	0	0	0.000000e+00	12910	0	80762	0	0.000000e+00	998	0	0	0.000000e+00	3756	0	0	0.000000e+00	10532	0	0	0.000000e+00	272	0	0	0.000000e+00	21034	0	1	2.083330e-04	4800	0	0	12	101835037	12	103310907	1	0.06251	0.40479	1.000000	0.71638	0.038000	0.14061	0.247000	0.23083	3.852000	0.55642	0.756000	0.94297	1.312000	0.94714	102917129	A	.	rs62508575	.	.	8.002	9.602	.	.	.	.	.	-27	11	0	11	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_000277.3-1+58+start+174	102647	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508575	62508575	.	.	.	PAH	PAH:exonic	PAH:startloss	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,849	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103310906	103310906	C	G	G	start_lost	HIGH	PAH	5053	Transcript	NM_000277.3	protein_coding	1/13	.	NM_000277.3:c.3G>C	NP_000268.1:p.Met1?	117	3	1	M/I	atG/atC	rs62514893&CM920539	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103310906C>G	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.3G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.99412	0.625005	D	0.99401	0.66	23.3	23.3	2.967752	2.885382	0.51338	0.52160	C/C	D	0.71226	0.97609680891037	0.54184	0.99163849473425414	.	0.72471	.	C/C	.	.	.	.	3.891034	0.32915290210698	0.57259	3.95809	0.333748120668264	0.57888	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.99255	.	.	.	5.2	5.2	0.71720	0	0.06741	0.475579	.	.	0.74766	0.999999999863142	.	0	0.62441	0.685912	.	.	.	.	.	.	0	0.26826	0.564101	.&.&.	.	.	.	0.65058	.	0.903724	0.09592	N	0.765068	D	0.99818	0.970056	.	.	0.96502	.	D	0.99211	0.9747	.	0.99011	.	D	0.97594	1.0233	M1I	Gain_of_sheet_(P_=_0.039)&_Gain_of_catalytic_residue_at_M1_(P_=_0.0494)&_Loss_of_loop_(P_=_0.0986)&_Gain_of_glycosylation_at_S2_(P_=_0.1047)&_Loss_of_disorder_(P_=_0.1186)	P00439	0.99969	0.997	.	.	.	.	0.81001	complex_aae&without_aae	D&D	1&1	0.19933	.	.	.	0.37610	.	.	0.47081	.	.	.	.	0.85091	.	9	0.92824	.	.	0.91255	.	.	14.4281	0.66804	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.97750	.	C/C	I	.	M	G	776	0.48302	.	12	C0031485	261600	ORPHA716	Likely_pathogenic	NC_000012.12:g.102917128C>G	585206	reviewed_by_expert_panel	Phenylketonuria	.	.	.	AEFDGBHCI	D	0.48285	0.88383	N	0.15936	0.078942	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12	101835036	12	103310906	1	0.06251	0.40479	1.000000	0.71638	0.032000	0.13371	0.192000	0.21965	3.256000	0.51194	0.599000	0.40250	1.026000	0.45946	102917128	C	.	rs62514893	.	.	8.002	9.602	.	.	.	.	.	-26	-36	3	1	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_000277.3-1+57+start+174	585206	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62514893	62514893	.	.	.	PAH	PAH:exonic	PAH:startloss	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,848	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
3	12660097	12660097	C	T	T	missense_variant	MODERATE	RAF1	5894	Transcript	NM_001354689.3	protein_coding	2/18	.	NM_001354689.3:c.124G>A	NP_001341618.1:p.Ala42Thr	455	124	42	A/T	Gca/Aca	rs200856000	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RAF1	.	chr3:g.12660097C>T	.	.	.	.	.	.	uncertain_significance&likely_benign	.	1	.	.	.	.	.	RAF1&NM_002880.3&c.124G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0.0	.	.	.	.	.	.	.	C/C	C	T	0.22597	-0.187686	T	0.55476	-0.191219	22.5	23.2	2.521798	2.815337	0.41718	0.50627	C/C	T	0.02064	0.0304846997565678	0.96895	0.99895729936834399	.	0.74143	.	C/C	.	.	.	.	4.092074	0.360860566358643	0.59165	3.152318	0.165110082929269	0.49530	.	.	.	31	2.553e-04	0	0	2	1.727e-04	31	2.553e-04	0	0	0	0	25	3.746e-04	2	1.211e-04	26	2.448e-04	0	0	2	1.783e-04	26	2.448e-04	0	0	0	0	21	3.864e-04	2	1.219e-04	29	3.196e-04	0	0	2	1.729e-04	29	3.196e-04	0	0	0	0	23	5.458e-04	2	1.212e-04	0.74896	.	.	.	6.17	6.17	0.99707	0	0.89359	0.724815	.	.	0.74766	0.999999999967154	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.83352	0.714379	.&.	.	.	.	0.92705	.	0.050744	0.84330	D	0.000000	T	0.43499	0.020831	0.48442	.	0.69946	.	T	0.61693	0.2477	.	0.04692	.	T	0.60065	-0.7077	.	.	.	.	.	.	0.31408	.	.	0.81001	simple_aae&simple_aae&without_aae	D&D&D	0.99997&0.99997&1	0.09297	.	.	.	0.35893	.	.	0.28873	.	T	0.43615	0.534124493599	0.59130	.	10	0.10536	.	.	0.42783	.	.	20.8794	0.99870	0.0:1.0:0.0:0.0	.	1	2.6968716289104636E-4	1	1.322401481089659E-4	.	.	.	0.26475	.	C/C	T	.	A	T	615	0.66512	.	3	C1969057&C1969056&CN260604&CN166718&CN517202	611553&611554	ORPHA98733&ORPHA536391	Likely_benign	NC_000003.12:g.12618598C>T	448930	reviewed_by_expert_panel	Noonan_syndrome_5&LEOPARD_syndrome_2&Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:751d9970-bb11-4fb7-b5b2-153cc27ddc68&Illumina_Laboratory_Services&Illumina:721001	.	.	AEFDBI	D	0.56823	0.92900	N	0.43116	0.331440	.	85	3.379910e-04	0	0.000000e+00	16256	0	13	3.758090e-04	34592	0	251486	23	2.281750e-03	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21646	0	42	3.691850e-04	113764	0	13	3.758090e-04	34592	0	2	6.532530e-05	30616	0	26	2.376470e-04	0	0.000000e+00	7164	0	10	5.843850e-04	17112	0	109406	3	1.293100e-03	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13392	0	10	2.338200e-04	42768	0	10	5.843850e-04	17112	0	1	6.373490e-05	15690	0	0	.	0	79	3.334060e-04	0	0.000000e+00	14902	0	12	3.502630e-04	34260	0	236948	22	2.298370e-03	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21630	0	38	3.698370e-04	102748	0	38	3.698370e-04	102748	0	2	6.551790e-05	30526	0	0	67	3.219140e-04	0	0.000000e+00	16218	0	13	4.258940e-04	30524	0	208130	16	2.575660e-03	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16732	0	32	3.573180e-04	89556	0	13	4.258940e-04	30524	0	2	6.534240e-05	30608	0	0	85	3.471260e-04	0	0.000000e+00	12026	0	13	3.772710e-04	34458	0	244868	23	2.300460e-03	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21644	0	42	3.760950e-04	111674	0	13	3.772710e-04	34458	0	2	6.532530e-05	30616	0	0	33	2.168770e-04	1	2.414060e-05	41424	0	0	0.000000e+00	910	0	5	3.273970e-04	15272	0	152160	6	1.731100e-03	3466	0	0	0.000000e+00	5194	0	0	0.000000e+00	10610	0	1	3.164560e-03	316	0	17	2.498380e-04	68044	0	5	3.273970e-04	15272	0	0	0.000000e+00	4838	0	4	1.216320e-04	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	2	4.266210e-04	4688	0	32886	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5478	0	0	0.000000e+00	246	0	1	1.459000e-04	6854	0	0	0.000000e+00	3116	0	0	.	0	31	2.095840e-04	1	2.432970e-05	41102	0	0	0.000000e+00	910	0	4	2.651460e-04	15086	0	147912	6	1.818180e-03	3300	0	0	0.000000e+00	4960	0	0	0.000000e+00	10610	0	0	0.000000e+00	304	0	17	2.622810e-04	64816	0	0	0.000000e+00	4806	0	0	33	2.448870e-04	1	3.080340e-05	32464	0	0	0.000000e+00	862	0	5	3.372450e-04	14826	0	134756	6	1.774100e-03	3382	0	0	0.000000e+00	5194	0	0	0.000000e+00	6968	0	1	3.225810e-03	310	0	17	2.659660e-04	63918	0	0	0.000000e+00	4836	0	0	10	1.238850e-04	1	4.032260e-05	24800	0	0	0.000000e+00	110	0	3	2.325940e-04	12898	0	80720	2	2.012070e-03	994	0	0	0.000000e+00	3752	0	0	0.000000e+00	10518	0	1	3.676470e-03	272	0	1	4.749690e-05	21054	0	0	0.000000e+00	4810	0	0	3	12635097	3	12660097	0	0.73137	0.706548	1.000000	0.71638	0.998000	0.85391	0.999000	0.70432	3.921000	0.56166	0.599000	0.40250	1.026000	0.45946	12618598	C	.	rs200856000	.	.	7.229	7.638	11.110	10.280	.	.	.	26	-36	-12	28	0.00	0.00	0.00	0.00	RAF1	1.00	exon-NM_001354693.3-2+83+start+233	448930	Likely_benign	reviewed_by_expert_panel	RASopathy&not_provided&Noonan_syndrome_and_Noonan-related_syndrome&Noonan_syndrome_5&LEOPARD_syndrome_2	MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN517202&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MONDO:MONDO:0012690&MedGen:C1969057&OMIM:611553&Orphanet:648&MONDO:MONDO:0012691&MedGen:C1969056&OMIM:611554&Orphanet:500	.	3:12660097-12660097	2.553e-04	31	31	0	0	2	0	0	25	2	2	10404	11578	8652	6614	66738	908	16510	0	2	0	0	25	2	2	0	0	0	0	0	0	0	rs200856000	0.00000e+00	3.87112e-04	2.23350e-03	0.00000e+00	0.00000e+00	3.49093e-04	5.47046e-04	6.49730e-05	3.63210e-04	2.69401e-04	2.23350e-03	3.20784e-04	rs200856000	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.33227e-04	1.01833e-03	.	1.75193e-04	0.00000e+00	1.33227e-04	9.67992e-05	.	.	rs200856000	200856000	.	.	.	RAF1	RAF1:exonic	RAF1:missense	RAF1:Cardiomyopathy\x2cdilated\x2c1NN\x3bNoonan_syndrome_5\x3bLEOPARD_syndrome_2	RAF1:615916\x3b611553\x3b611554	RAF1:3\x3b3\x3b3	RAF1:Autosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999776866110749	0.000223133833869176	5.53819998824154e-11	DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,482	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
12	103249072	103249073	TC	AA	AA	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	6/13	.	NM_000277.3:c.547_548delinsTT	NP_000268.1:p.Glu183Leu	661-662	547-548	183	E/L	GAa/TTa	rs281865433	TC	.	-1	.	.	EntrezGene	.	.	.	.	TC	TC	.	.	PAH	.	chr12:g.103249072_103249073delinsAA	.	.	.	.	.	.	likely_pathogenic	.	1	.	.	.	.	.	PAH&NM_000277.1&c.547_548delinsTT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.651	9.354	7.292	9.092	.	.	.	.	.	.	.	.	.	.	.	.	0.00	exon-NM_001354304.2-7+37+end+197	120278	Likely_pathogenic	reviewed_by_expert_panel	Phenylketonuria	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs281865433	281865433	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,769	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
2	39240612	39240612	C	G	G	missense_variant	MODERATE	SOS1	6654	Transcript	NM_005633.4	protein_coding	13/23	.	NM_005633.4:c.2156G>C	NP_005624.2:p.Gly719Ala	2785	2156	719	G/A	gGa/gCa	rs200794965	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	SOS1	.	chr2:g.39240612C>G	.	.	.	.	.	.	likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0.0	.	.	.	.	.	.	.	C/C	C	T	0.01065	-0.454338	T	0.14555	-0.579883	17.66	21.9	1.789869	2.286023	0.26640	0.39011	C/C	T	0.08526	0.0691103448728276	0.26540	0.95264991458455117	.	0.72980	.	C/C	.	.	.	.	2.699316	0.0913488290946096	0.44112	1.950514	-0.174027144689895	0.34218	.	.	.	37	3.048e-04	0	0	0	0	37	3.055e-04	0	0	0	0	37	5.556e-04	0	0	37	3.484e-04	0	0	0	0	37	3.492e-04	0	0	0	0	37	6.821e-04	0	0	3	3.306e-05	0	0	0	0	3	3.316e-05	0	0	0	0	3	7.142e-05	0	0	0.29866	.	.	.	5.92	5.92	0.95557	0	0.79440	0.708844	.	.	0.74766	0.999997552136725	.	0	0.50148	0.65145	.	.	.	.	.	.	0	0.83352	0.714379	Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal	.	.	.	0.35895	.	0.121260	0.55875	D	0.000034	T	0.13801	0.005379	0.55620	.	0.21150	.	T	0.19640	0.0458	.	0.16941	.	T	0.11288	-1.0619	G719A	Gain_of_MoRF_binding_(P_=_0.121)&_Loss_of_helix_(P_=_0.1299)&_Loss_of_methylation_at_R722_(P_=_0.1719)&_Gain_of_ubiquitination_at_K724_(P_=_0.1797)&_Gain_of_loop_(P_=_0.2045)	Q07889	0.33776	0.344	.	0.03673	.	.	0.51612	simple_aae&simple_aae&simple_aae	D&D&D	0.999935&0.999935&0.999935	0.10308	.	.	.	0.02946	.	.	0.01387	.	T	0.55184	0.616149008274	0.29403	.	10	0.22694	.	.	0.12032	.	.	20.327	0.98704	0.0:1.0:0.0:0.0	.	1	2.6968716289104636E-4	1	1.322401481089659E-4	.	.	.	0.25377	.	C/C	A	.	G	G	470	0.78111	.	2	C0007193&CN260604&CN166718&CN517202	.	ORPHA217604&ORPHA98733&ORPHA536391	Likely_benign	NC_000002.12:g.39013471C>G	40698	reviewed_by_expert_panel	Primary_dilated_cardiomyopathy&Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:2fa3237d-09e4-4fb5-84b2-9a8bfdc4e2bc	.	.	AEFBI	D	0.49930	0.89455	N	0.39612	0.282885	.	47	1.874480e-04	0	0.000000e+00	16244	0	2	5.786030e-05	34566	0	250736	0	0.000000e+00	10058	0	0	0.000000e+00	18384	0	2	9.243000e-05	21638	0	43	3.800060e-04	113156	0	43	3.800060e-04	113156	0	0	0.000000e+00	30588	0	23	2.103410e-04	0	0.000000e+00	7158	0	1	5.847950e-05	17100	0	109346	0	0.000000e+00	2320	0	0	0.000000e+00	9038	0	0	0.000000e+00	13388	0	22	5.145960e-04	42752	0	22	5.145960e-04	42752	0	0	0.000000e+00	15680	0	0	.	0	47	1.989740e-04	0	0.000000e+00	14892	0	2	5.842150e-05	34234	0	236212	0	0.000000e+00	9550	0	0	0.000000e+00	17682	0	2	9.249840e-05	21622	0	43	4.209410e-04	102152	0	43	4.209410e-04	102152	0	0	0.000000e+00	30498	0	0	29	1.394670e-04	0	0.000000e+00	16206	0	2	6.557810e-05	30498	0	207934	0	0.000000e+00	6212	0	0	0.000000e+00	13406	0	2	1.195740e-04	16726	0	25	2.794670e-04	89456	0	25	2.794670e-04	89456	0	0	0.000000e+00	30580	0	0	47	1.925270e-04	0	0.000000e+00	12014	0	2	5.808550e-05	34432	0	244122	0	0.000000e+00	9976	0	0	0.000000e+00	18380	0	2	9.243850e-05	21636	0	43	3.871430e-04	111070	0	43	3.871430e-04	111070	0	0	0.000000e+00	30588	0	0	6	3.955540e-05	1	2.420720e-05	41310	0	0	0.000000e+00	912	0	1	6.569440e-05	15222	0	151686	0	0.000000e+00	3466	0	0	0.000000e+00	5192	0	0	0.000000e+00	10494	0	0	0.000000e+00	316	0	4	5.893100e-05	67876	0	1	6.569440e-05	15222	0	0	0.000000e+00	4808	0	2	6.117700e-05	1	1.105460e-04	9046	0	0	0.000000e+00	60	0	0	0.000000e+00	4674	0	32692	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5410	0	0	0.000000e+00	246	0	1	1.469290e-04	6806	0	0	0.000000e+00	3100	0	0	.	0	6	4.069120e-05	1	2.439740e-05	40988	0	0	0.000000e+00	912	0	1	6.650700e-05	15036	0	147452	0	0.000000e+00	3296	0	0	0.000000e+00	4958	0	0	0.000000e+00	10494	0	0	0.000000e+00	304	0	4	6.185440e-05	64668	0	0	0.000000e+00	4776	0	0	6	4.465750e-05	1	3.090040e-05	32362	0	0	0.000000e+00	862	0	1	6.765900e-05	14780	0	134356	0	0.000000e+00	3382	0	0	0.000000e+00	5192	0	0	0.000000e+00	6888	0	0	0.000000e+00	310	0	4	6.272150e-05	63774	0	0	0.000000e+00	4806	0	0	2	2.490540e-05	1	4.048260e-05	24702	0	0	0.000000e+00	112	0	0	0.000000e+00	12848	0	80304	0	0.000000e+00	994	0	0	0.000000e+00	3752	0	0	0.000000e+00	10402	0	0	0.000000e+00	272	0	1	4.778740e-05	20926	0	0	0.000000e+00	4780	0	0	2	39094116	2	39240612	0	0.73137	0.706548	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	3.282000	0.51397	0.599000	0.40250	1.026000	0.45946	39013471	C	.	rs200794965	.	.	7.265	9.813	5.791	8.994	.	.	.	-30	38	-4	-11	0.00	0.00	0.00	0.02	SOS1	1.00	exon-NM_001382394.1-13+11+start+104	40698	Likely_benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_provided&RASopathy&Primary_dilated_cardiomyopathy&Noonan_syndrome_and_Noonan-related_syndrome	MedGen:CN230736&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&EFO:EFO_0000407&Human_Phenotype_Ontology:HP:0001644&Human_Phenotype_Ontology:HP:0001725&Human_Phenotype_Ontology:HP:0005159&Human_Phenotype_Ontology:HP:0200130&MONDO:MONDO:0005021&MeSH:D002311&MedGen:C0007193&Orphanet:217604&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733	.	2:39240612-39240612	3.048e-04	37	37	0	0	0	0	0	37	0	0	10344	11536	8630	6598	66598	906	16498	0	0	0	0	37	0	0	0	0	0	0	0	0	0	rs200794965	0.00000e+00	5.95877e-05	0.00000e+00	0.00000e+00	8.97183e-05	3.60088e-04	0.00000e+00	0.00000e+00	1.93349e-04	1.62118e-04	3.60088e-04	1.82735e-04	rs200794965	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.92912e-04	1.34716e-04	0.00000e+00	.	5.89623e-05	1.46071e-04	2.92912e-04	9.68117e-05	.	.	rs200794965	200794965	.	.	.	SOS1	SOS1:exonic	SOS1:missense	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,464	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
3	12660127	12660127	T	C	C	missense_variant	MODERATE	RAF1	5894	Transcript	NM_001354689.3	protein_coding	2/18	.	NM_001354689.3:c.94A>G	NP_001341618.1:p.Ile32Val	425	94	32	I/V	Ata/Gta	rs372738063	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	RAF1	.	chr3:g.12660127T>C	.	.	.	.	.	.	likely_benign&benign&uncertain_significance	.	1	.	.	.	.	.	RAF1&NM_002880.3&c.94A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	5.189413596263622E-4	.	.	.	.	.	.	.	T/T	T	T	0.10366	-0.28286	T	0.41911	-0.326012	15.38	16.72	1.444205	1.578104	0.21049	0.25149	T/T	T	0.00390	0.0161364873550126	0.65996	0.99464745793170573	.	0.74448	.	T/T	0	0.0	2	2.3255813953488373E-4	1.79558	-0.195912985471067	0.31687	1.47791	-0.357458551384008	0.26999	.	.	.	13	1.071e-04	3	2.884e-04	0	0	13	1.071e-04	0	0	0	0	10	1.498e-04	0	0	8	7.532e-05	2	2.207e-04	0	0	8	7.533e-05	0	0	0	0	6	1.104e-04	0	0	11	1.212e-04	3	2.889e-04	0	0	11	1.212e-04	0	0	0	0	8	1.898e-04	0	0	0.74371	.	.	.	6.03	2.05	0.25860	0	0.89359	0.724815	.	.	0.48110	0.999958255591573	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.83352	0.714379	.&.	.	.	.	0.56452	.	0.195137	0.52346	D	0.000081	T	0.42004	0.019599	0.42086	.	0.52000	.	T	0.56987	0.2100	.	0.27196	.	T	0.47705	-0.9027	.	.	.	.	.	.	0.38595	.	.	0.81001	simple_aae&simple_aae&without_aae	D&D&D	0.999494&0.999494&1	0.06612	.	.	.	0.21116	.	.	0.17743	.	T	0.35358	0.47491773963	0.40530	.	10	0.04416	.	.	0.23631	.	.	9.7007	0.39350	0.1041:0.0:0.2385:0.6574	.	1	2.6968716289104636E-4	3	3.9672044432689763E-4	.	.	.	0.43320	.	T/T	V	.	I	C	615	0.66512	.	3	CN260604&CN166718&CN169374&CN517202	.	ORPHA98733&ORPHA536391	Benign	NC_000003.12:g.12618628T>C	40584	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_specified&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:1128f941-c33c-438d-a44d-f5a0c76c3440	.	.	AEFDBI	D	0.53383	0.91363	N	0.38908	0.273733	.	25	9.940990e-05	4	2.460630e-04	16256	0	1	2.890840e-05	34592	0	251484	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21646	0	20	1.758060e-04	113762	0	4	2.460630e-04	16256	0	0	0.000000e+00	30616	0	11	1.005430e-04	3	4.187600e-04	7164	0	1	5.843850e-05	17112	0	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13392	0	7	1.636740e-04	42768	0	3	4.187600e-04	7164	0	0	0.000000e+00	15690	0	0	.	0	20	8.440740e-05	3	2.013150e-04	14902	0	1	2.918860e-05	34260	0	236946	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21630	0	16	1.557240e-04	102746	0	3	2.013150e-04	14902	0	0	0.000000e+00	30526	0	0	22	1.057030e-04	4	2.466400e-04	16218	0	1	3.276110e-05	30524	0	208130	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16732	0	17	1.898250e-04	89556	0	4	2.466400e-04	16218	0	0	0.000000e+00	30608	0	0	22	8.984510e-05	2	1.663060e-04	12026	0	1	2.902080e-05	34458	0	244866	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21644	0	19	1.701410e-04	111672	0	19	1.701410e-04	111672	0	0	0.000000e+00	30616	0	0	20	1.313920e-04	6	1.447390e-04	41454	0	0	0.000000e+00	912	0	0	0.000000e+00	15274	0	152216	0	0.000000e+00	3472	0	0	0.000000e+00	5196	0	0	0.000000e+00	10616	0	0	0.000000e+00	316	0	14	2.057370e-04	68048	0	14	2.057370e-04	68048	0	0	0.000000e+00	4836	0	1	3.039330e-05	0	0.000000e+00	9094	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32902	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5488	0	0	0.000000e+00	246	0	1	1.459000e-04	6854	0	0	0.000000e+00	3116	0	0	.	0	20	1.351720e-04	6	1.458720e-04	41132	0	0	0.000000e+00	912	0	0	0.000000e+00	15086	0	147960	0	0.000000e+00	3302	0	0	0.000000e+00	4962	0	0	0.000000e+00	10616	0	0	0.000000e+00	304	0	14	2.159890e-04	64818	0	0	0.000000e+00	4804	0	0	18	1.335250e-04	5	1.539030e-04	32488	0	0	0.000000e+00	862	0	0	0.000000e+00	14828	0	134806	0	0.000000e+00	3388	0	0	0.000000e+00	5196	0	0	0.000000e+00	6974	0	0	0.000000e+00	310	0	13	2.033660e-04	63924	0	0	0.000000e+00	4834	0	0	5	6.190420e-05	2	8.055420e-05	24828	0	0	0.000000e+00	112	0	0	0.000000e+00	12900	0	80770	0	0.000000e+00	998	0	0	0.000000e+00	3754	0	0	0.000000e+00	10524	0	0	0.000000e+00	272	0	3	1.424770e-04	21056	0	0	0.000000e+00	4808	0	0	3	12635127	3	12660127	0	0.73137	0.706548	0.998000	0.41325	0.991000	0.66497	0.994000	0.56301	1.544000	0.35764	-0.699000	0.04065	-0.145000	0.11179	12618628	T	.	rs372738063	.	gain/acceptor/12660126-12660127/Medium/3.692449	7.229	7.638	11.110	10.280	.	.	.	-1	-4	1	-2	0.00	0.00	0.00	0.00	RAF1	1.00	exon-NM_001354693.3-2+113+start+233	40584	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&not_specified&RASopathy&not_provided	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN517202	.	3:12660127-12660127	1.071e-04	13	13	0	3	0	0	0	10	0	0	10404	11578	8654	6614	66736	908	16510	3	0	0	0	10	0	0	0	0	0	0	0	0	0	rs372738063	2.61370e-04	2.97779e-05	0.00000e+00	0.00000e+00	0.00000e+00	1.43218e-04	0.00000e+00	0.00000e+00	8.15383e-05	8.97972e-05	2.61370e-04	8.52716e-05	rs372738063	2.29043e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.99680e-04	0.00000e+00	.	2.33563e-04	2.88725e-04	3.99680e-04	2.58131e-04	rs372738063	0.0233&0.0&0.0154	rs372738063	372738063	.	.	.	RAF1	RAF1:exonic	RAF1:missense	RAF1:Cardiomyopathy\x2cdilated\x2c1NN\x3bNoonan_syndrome_5\x3bLEOPARD_syndrome_2	RAF1:615916\x3b611553\x3b611554	RAF1:3\x3b3\x3b3	RAF1:Autosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999776866110749	0.000223133833869176	5.53819998824154e-11	DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,484	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0.4999	VUS
1	216258168	216258168	T	C	C	missense_variant	MODERATE	USH2A	7399	Transcript	NM_206933.4	protein_coding	25/72	.	NM_206933.4:c.5039A>G	NP_996816.3:p.Lys1680Arg	5478	5039	1680	K/R	aAg/aGg	rs150982499	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	USH2A	.	chr1:g.216258168T>C	.	0	0.0014	0	0	0	uncertain_significance	.	1	.	.	.	.	.	USH2A&NM_206933.2&c.5039A>G	.	.	1	1.9968051118210862E-4	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	T/T	T	T	0.11694	-0.270564	T	0.47578	-0.272389	20.7	21.5	2.181953	2.214136	0.34326	0.37445	T/T	T	0.15935	0.136106163263321	0.64227	0.994299850735885	.	0.33006	.	T/T	0	0.0	1	1.1627906976744187E-4	2.858883	0.129545236007552	0.46067	2.563066	0.0145093918228552	0.42515	.	.	.	10	8.237e-05	0	0	6	5.251e-04	10	8.259e-05	0	0	0	0	4	6.003e-05	0	0	7	6.591e-05	0	0	6	5.423e-04	7	6.610e-05	0	0	0	0	1	1.843e-05	0	0	10	1.102e-04	0	0	6	5.257e-04	10	1.106e-04	0	0	0	0	4	9.515e-05	0	0	0.78752	.	.	.	4.93	4.93	0.64394	0	0.26702	0.573888	.	.	0.06540	3.22989386285789E-4	.	0	0.23631	0.573888	.	.	.	.	.	.	0	0.26826	0.564101	Laminin_G_domain&Laminin_G_domain	.	.	.	0.36553	.	0.000000	0.46924	D	0.000255	D	0.87829	0.221917	0.04667	.	0.90046	.	T	0.62349	0.2534	.	0.07173	.	T	0.62117	-0.6636	.	.	.	.	.	.	0.43825	.	.	0.29947	simple_aae&simple_aae	N&N	0.718285&0.718285	0.22078	.	.	.	0.37944	.	.	0.40572	.	T	0.30646	0.4405143857	0.56159	.	10	0.24477	.	.	0.15717	.	.	6.1875	0.19720	0.0:0.0814:0.1632:0.7553	.	.	.	.	.	.	.	.	0.32037	.	T/T	R	.	K	C	748	0.52143	.	1	C1848634&C0271097&CN169374&CN517202	276901&PS276900	ORPHA886	Uncertain_significance	NC_000001.11:g.216084826T>C	166499	reviewed_by_expert_panel	Usher_syndrome&_type_2A&Usher_syndrome&not_specified&not_provided	.	.	.	AEFI	D	0.43315	0.84232	N	0.36886	0.248462	.	32	1.275980e-04	0	0.000000e+00	16244	0	19	5.512680e-04	34466	0	250788	0	0.000000e+00	10066	0	0	0.000000e+00	18384	0	0	0.000000e+00	21632	0	12	1.059340e-04	113278	0	19	5.512680e-04	34466	0	0	0.000000e+00	30616	0	19	1.737790e-04	0	0.000000e+00	7160	0	13	7.612130e-04	17078	0	109334	0	0.000000e+00	2320	0	0	0.000000e+00	9040	0	0	0.000000e+00	13382	0	5	1.169480e-04	42754	0	13	7.612130e-04	17078	0	0	0.000000e+00	15690	0	0	.	0	31	1.312140e-04	0	0.000000e+00	14890	0	19	5.566300e-04	34134	0	236256	0	0.000000e+00	9558	0	0	0.000000e+00	17682	0	0	0.000000e+00	21616	0	11	1.075610e-04	102268	0	19	5.566300e-04	34134	0	0	0.000000e+00	30526	0	0	29	1.394900e-04	0	0.000000e+00	16206	0	18	5.921050e-04	30400	0	207900	0	0.000000e+00	6212	0	0	0.000000e+00	13406	0	0	0.000000e+00	16720	0	10	1.117320e-04	89500	0	18	5.921050e-04	30400	0	0	0.000000e+00	30608	0	0	32	1.310560e-04	0	0.000000e+00	12014	0	19	5.534200e-04	34332	0	244170	0	0.000000e+00	9984	0	0	0.000000e+00	18380	0	0	0.000000e+00	21630	0	12	1.079250e-04	111188	0	19	5.534200e-04	34332	0	0	0.000000e+00	30616	0	0	33	2.168140e-04	0	0.000000e+00	41460	0	0	0.000000e+00	912	0	23	1.506420e-03	15268	0	152204	0	0.000000e+00	3470	0	0	0.000000e+00	5198	0	0	0.000000e+00	10622	0	0	0.000000e+00	316	0	8	1.175920e-04	68032	0	23	1.506420e-03	15268	0	0	0.000000e+00	4834	0	5	1.520130e-04	0	0.000000e+00	9098	0	0	0.000000e+00	60	0	3	6.402050e-04	4686	0	32892	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	1	1.461130e-04	6844	0	0	0.000000e+00	3116	0	0	.	0	32	2.162950e-04	0	0.000000e+00	41140	0	0	0.000000e+00	912	0	23	1.525200e-03	15080	0	147946	0	0.000000e+00	3300	0	0	0.000000e+00	4962	0	0	0.000000e+00	10622	0	0	0.000000e+00	304	0	7	1.080210e-04	64802	0	0	0.000000e+00	4802	0	0	31	2.300010e-04	0	0.000000e+00	32484	0	0	0.000000e+00	862	0	22	1.484280e-03	14822	0	134782	0	0.000000e+00	3386	0	0	0.000000e+00	5198	0	0	0.000000e+00	6980	0	0	0.000000e+00	310	0	7	1.095360e-04	63906	0	0	0.000000e+00	4832	0	0	25	3.095210e-04	0	0.000000e+00	24834	0	0	0.000000e+00	112	0	21	1.628660e-03	12894	0	80770	0	0.000000e+00	998	0	0	0.000000e+00	3756	0	0	0.000000e+00	10530	0	0	0.000000e+00	272	0	3	1.425180e-04	21050	0	0	0.000000e+00	4806	0	0	1	214324791	1	216258168	0	0.14033	0.487112	1.000000	0.71638	0.965000	0.52897	0.747000	0.32051	2.193000	0.42291	0.665000	0.62972	1.138000	0.64695	216084826	T	.	rs150982499	.	.	7.906	9.429	5.657	10.098	.	.	.	-18	36	-1	-44	0.01	0.00	0.00	0.00	USH2A	0.00	exon-NM_206933.4-25+51+end+180	166499	Uncertain_significance	reviewed_by_expert_panel	Usher_syndrome_type_2A&Usher_syndrome&not_specified&not_provided	MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&MedGen:CN169374&MedGen:CN517202	.	rs150982499	8.237e-05	10	10	0	0	6	0	0	4	0	0	10384	11426	8640	6588	66634	908	16506	0	6	0	0	4	0	0	0	0	0	0	0	0	0	rs150982499	0.00000e+00	5.68012e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.07900e-04	1.83554e-04	0.00000e+00	1.04092e-04	1.62086e-04	5.68012e-04	1.29955e-04	rs150982499	0.00000e+00	1.19617e-03	0.00000e+00	0.00000e+00	0.00000e+00	6.66667e-05	0.00000e+00	.	5.84727e-05	7.22335e-05	1.19617e-03	6.45328e-05	rs150982499	0.0116&0.0&0.0077	rs150982499	150982499	.	.	.	USH2A\x3bLOC102723833	USH2A:exonic\x7cLOC102723833:ncRNA_intronic	USH2A:missense	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,454	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.4999	VUS
12	112939998	112939998	G	A	A	synonymous_variant	LOW	PTPN11	5781	Transcript	NM_002834.5	protein_coding	14/16	.	NM_002834.5:c.1650G>A	NP_002825.3:p.Ala550%3D	1815	1650	550	A	gcG/gcA	rs374896287	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	RPH3A	.	chr12:g.112939998G>A	.	.	.	.	.	.	benign&uncertain_significance&likely_benign	.	1	.	.	.	.	.	PTPN11&NM_002834.3&c.1650G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.564	9.354	7.386	7.879	.	.	.	2	-50	-50	-13	0.04	0.18	0.00	0.00	PTPN11	1.00	exon-NM_001330437.2-14+50+start+113	138843	Benign	reviewed_by_expert_panel	History_of_neurodevelopmental_disorder&Cardiovascular_phenotype&Noonan_syndrome_1&Metachondromatosis&Juvenile_myelomonocytic_leukemia&LEOPARD_syndrome_1&not_specified&RASopathy	MedGen:C2711754&MedGen:CN230736&MONDO:MONDO:0008104&MedGen:C4551602&OMIM:163950&Orphanet:648&MONDO:MONDO:0007979&MedGen:C0410530&OMIM:156250&Orphanet:2499&Human_Phenotype_Ontology:HP:0012209&MONDO:MONDO:0011908&MedGen:C0349639&OMIM:607785&Orphanet:86834&MONDO:MONDO:0100082&MedGen:C4551484&OMIM:151100&Orphanet:500&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	12:112939998-112939998	1.318e-04	16	16	0	0	13	1	0	2	0	0	10318	11548	8644	6612	66530	904	16494	0	13	1	0	2	0	0	0	0	0	0	0	0	0	rs374896287	0.00000e+00	9.23224e-04	0.00000e+00	1.15969e-04	0.00000e+00	1.79688e-05	0.00000e+00	0.00000e+00	8.16787e-05	2.15928e-04	9.23224e-04	1.42133e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	rs374896287	0.0116&0.0&0.0077	rs374896287	374896287	.	.	.	PTPN11	PTPN11:exonic	PTPN11:synonymous_SNV	PTPN11:Noonan_syndrome_1\x3bLEOPARD_syndrome_1\x3bMetachondromatosis\x3bLeukemia\x2cjuvenile_myelomonocytic\x2csomatic	PTPN11:163950\x3b151100\x3b156250\x3b607785	PTPN11:3\x3b3\x3b3\x3b3	PTPN11:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999877230878678	0.000122769057470549	6.38519788034449e-11	DISEASE: LEOPARD syndrome 1 (LPRD1) [MIM:151100]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:12058348, ECO:0000269|PubMed:14961557, ECO:0000269|PubMed:15121796, ECO:0000269|PubMed:15389709, ECO:0000269|PubMed:15520399, ECO:0000269|PubMed:15690106, ECO:0000269|PubMed:16679933, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 1 (NS1) [MIM:163950]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints. {ECO:0000269|PubMed:11704759, ECO:0000269|PubMed:11992261, ECO:0000269|PubMed:12161469, ECO:0000269|PubMed:12325025, ECO:0000269|PubMed:12529711, ECO:0000269|PubMed:12634870, ECO:0000269|PubMed:12717436, ECO:0000269|PubMed:12739139, ECO:0000269|PubMed:12960218, ECO:0000269|PubMed:15384080, ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry. Mutations in PTPN11 account for more than 50% of the cases.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:12717436}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Metachondromatosis (MC) [MIM:156250]: A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest. {ECO:0000269|PubMed:20577567}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,861	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
2	39285934	39285934	T	C	C	synonymous_variant	LOW	SOS1	6654	Transcript	NM_005633.4	protein_coding	3/23	.	NM_005633.4:c.225A>G	NP_005624.2:p.Gln75%3D	854	225	75	Q	caA/caG	rs560037748	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	SOS1	.	chr2:g.39285934T>C	.	0	0	0	0	0.0041	uncertain_significance&benign&likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.110	8.993	7.161	8.549	.	.	.	34	-38	-1	11	0.05	0.00	0.00	0.00	SOS1	1.00	exon-NM_001382394.1-3+11+end+132	448946	Likely_benign	reviewed_by_expert_panel	Fibromatosis&_gingival&_1&Noonan_syndrome_4&Cardiovascular_phenotype&not_provided&RASopathy	MONDO:MONDO:0007609&MedGen:C4551558&OMIM:135300&Orphanet:2024&MONDO:MONDO:0012547&MedGen:C1853120&OMIM:610733&Orphanet:648&MedGen:CN230736&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	2:39285934-39285934	1.400e-04	17	17	0	0	0	0	0	5	0	12	10070	11420	8558	6582	66184	900	16448	0	0	0	0	5	0	12	0	0	0	0	0	0	0	rs560037748	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	4.48833e-05	0.00000e+00	7.82932e-04	1.41205e-04	9.00398e-05	7.82932e-04	1.17765e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs560037748	560037748	.	.	.	SOS1	SOS1:exonic	SOS1:synonymous_SNV	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,472	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
2	39294841	39294841	A	G	G	synonymous_variant	LOW	SOS1	6654	Transcript	NM_005633.4	protein_coding	2/23	.	NM_005633.4:c.141T>C	NP_005624.2:p.Tyr47%3D	770	141	47	Y	taT/taC	rs201649682	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	SOS1	.	chr2:g.39294841A>G	.	0	0	0.002	0	0	benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.161	8.549	10.345	9.158	.	.	.	2	47	4	46	0.00	0.00	0.01	0.00	SOS1	1.00	exon-NM_001382394.1-2+53+end+126	448947	Benign	reviewed_by_expert_panel	not_specified&RASopathy	MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	2:39294841-39294841	1.318e-04	16	16	0	0	0	16	0	0	0	0	10348	11578	8654	6614	66712	908	16510	0	0	16	0	0	0	0	0	0	0	0	0	0	0	rs201649682	0.00000e+00	0.00000e+00	0.00000e+00	1.68135e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.11228e-04	1.25764e-04	1.68135e-03	1.17756e-04	rs201649682	0.00000e+00	0.00000e+00	0.00000e+00	1.84957e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	1.75213e-04	0.00000e+00	1.84957e-03	9.67992e-05	.	.	rs201649682	201649682	.	.	.	SOS1	SOS1:exonic	SOS1:synonymous_SNV	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,473	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
3	12626660	12626660	C	G	G	synonymous_variant	LOW	RAF1	5894	Transcript	NM_001354689.3	protein_coding	16/18	.	NM_001354689.3:c.1689G>C	NP_001341618.1:p.Thr563%3D	2020	1689	563	T	acG/acC	rs5746244	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MKRN2OS	.	chr3:g.12626660C>G	.	0	0	0.004	0	0.001	likely_benign&benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.661	10.858	3.506	7.227	.	.	.	44	0	-39	21	0.00	0.00	0.00	0.00	RAF1	1.00	exon-NM_001354695.3-13+39+start+132	40621	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&not_provided&RASopathy&Noonan_syndrome_5&LEOPARD_syndrome_2	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0012690&MedGen:C1969057&OMIM:611553&Orphanet:648&MONDO:MONDO:0012691&MedGen:C1969056&OMIM:611554&Orphanet:500	.	rs5746244	9.060e-05	11	0	0	0	0	9	0	0	0	2	10404	11576	8654	6612	66730	908	16512	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs5746244	0.00000e+00	2.97779e-05	0.00000e+00	8.69666e-04	0.00000e+00	8.96057e-06	1.82349e-04	1.29946e-04	8.89957e-05	8.98440e-05	8.69666e-04	8.93321e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs5746244	5746244	.	.	.	RAF1	RAF1:exonic	RAF1:synonymous_SNV	RAF1:Cardiomyopathy\x2cdilated\x2c1NN\x3bNoonan_syndrome_5\x3bLEOPARD_syndrome_2	RAF1:615916\x3b611553\x3b611554	RAF1:3\x3b3\x3b3	RAF1:Autosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999776866110749	0.000223133833869176	5.53819998824154e-11	DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,474	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
3	12626660	12626660	C	T	T	synonymous_variant	LOW	RAF1	5894	Transcript	NM_001354689.3	protein_coding	16/18	.	NM_001354689.3:c.1689G>A	NP_001341618.1:p.Thr563%3D	2020	1689	563	T	acG/acA	rs5746244	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MKRN2OS	.	chr3:g.12626660C>T	.	0	0	0	0	0.002	benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.661	10.858	3.506	7.227	.	.	.	-2	44	-2	-39	0.00	0.00	0.00	0.00	RAF1	1.00	exon-NM_001354695.3-13+39+start+132	448927	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&not_provided&RASopathy&Cardiovascular_phenotype	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN230736	.	rs5746244	1.565e-04	19	11	0	0	0	0	0	0	0	19	10404	11576	8654	6612	66730	908	16512	0	0	9	0	0	0	2	0	0	0	0	0	0	0	rs5746244	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.20200e-03	2.29906e-04	5.39064e-05	1.20200e-03	1.50240e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs5746244	5746244	.	.	.	RAF1	RAF1:exonic	RAF1:synonymous_SNV	RAF1:Cardiomyopathy\x2cdilated\x2c1NN\x3bNoonan_syndrome_5\x3bLEOPARD_syndrome_2	RAF1:615916\x3b611553\x3b611554	RAF1:3\x3b3\x3b3	RAF1:Autosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999776866110749	0.000223133833869176	5.53819998824154e-11	DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,475	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
3	12626702	12626702	C	T	T	synonymous_variant	LOW	RAF1	5894	Transcript	NM_001354689.3	protein_coding	16/18	.	NM_001354689.3:c.1647G>A	NP_001341618.1:p.Ser549%3D	1978	1647	549	S	tcG/tcA	rs114687276	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MKRN2OS	.	chr3:g.12626702C>T	.	0.003	0	0	0	0.002	benign	.	1	.	.	.	.	.	RAF1&NM_002880.3&c.1587G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.661	10.858	3.506	7.227	.	.	.	9	2	42	26	0.02	0.01	0.00	0.00	RAF1	1.00	exon-NM_001354695.3-13+50+end+132	40620	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&not_provided&RASopathy	MedGen:CN230736&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	rs114687276	1.235e-04	15	15	0	10	1	1	0	0	0	3	10402	11566	8654	6610	66714	908	16504	10	1	1	0	0	0	3	0	0	0	0	0	0	0	rs114687276	8.49562e-04	0.00000e+00	0.00000e+00	5.79777e-05	0.00000e+00	0.00000e+00	0.00000e+00	1.29946e-04	7.41477e-05	7.18559e-05	8.49562e-04	7.30899e-05	rs114687276	5.73263e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84385e-05	2.89059e-04	5.73263e-04	1.61332e-04	rs114687276	0.0116&0.0454&0.0231	rs114687276	114687276	.	.	.	RAF1	RAF1:exonic	RAF1:synonymous_SNV	RAF1:Cardiomyopathy\x2cdilated\x2c1NN\x3bNoonan_syndrome_5\x3bLEOPARD_syndrome_2	RAF1:615916\x3b611553\x3b611554	RAF1:3\x3b3\x3b3	RAF1:Autosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999776866110749	0.000223133833869176	5.53819998824154e-11	DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,476	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
3	12633259	12633259	C	T	T	missense_variant	MODERATE	RAF1	5894	Transcript	NM_001354689.3	protein_coding	12/18	.	NM_001354689.3:c.1201G>A	NP_001341618.1:p.Asp401Asn	1532	1201	401	D/N	Gac/Aac	rs559632360&COSV52576672	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MKRN2OS	.	chr3:g.12633259C>T	.	0	0	0	0	0.0031	likely_benign&uncertain_significance&benign	0&1	1&1	.	.	.	.	.	RAF1&NM_002880.3&c.1141G>A	.	.	3	5.990415335463259E-4	0	0.0	0	0.0	0	0.0	0	0.0	3	0.003067484662576687	.	.	.	.	.	.	.	.	.	C/C	c	T	0.00838	-0.470963	T	0.27096	-0.45545	10.70	15.56	0.924451	1.370202	0.14103	0.21930	C/C	T	0.01472	0.0264849085100513	0.08954	0.69381873695721796	.	0.91732	.	C/C	.	.	.	.	1.003532	-0.628625637051928	0.18759	0.6575577	-0.798101639362588	0.13359	.	.	.	37	3.047e-04	0	0	0	0	37	3.048e-04	0	0	0	0	1	1.499e-05	36	2.181e-03	37	3.484e-04	0	0	0	0	37	3.484e-04	0	0	0	0	1	1.840e-05	36	2.195e-03	37	4.077e-04	0	0	0	0	37	4.078e-04	0	0	0	0	1	2.373e-05	36	2.182e-03	0.82254	.	.	.	5.15	2.44	0.28875	0	0.68747	0.697927	.	.	0.38592	0.999158101172336	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.71501	0.711	Serine-threonine/tyrosine-protein_kinase&_catalytic_domain&Protein_kinase_domain&Protein_kinase_domain&Serine-threonine/tyrosine-protein_kinase&_catalytic_domain&Protein_kinase_domain&Protein_kinase_domain&Serine-threonine/tyrosine-protein_kinase&_catalytic_domain&Protein_kinase_domain&Protein_kinase_domain	.	.	.	0.37546	.	0.218018	0.52346	N	0.000074	.	.	.	0.80718	.	0.32011	.	T	0.63318	0.2621	.	0.00263	.	T	0.54641	-0.8085	D381N	Gain_of_glycosylation_at_T383_(P_=_0.0563)&_Gain_of_MoRF_binding_(P_=_0.0665)&_Gain_of_methylation_at_K378_(P_=_0.0678)&_Gain_of_ubiquitination_at_K378_(P_=_0.1989)&_Gain_of_phosphorylation_at_T383_(P_=_0.2411)	P04049	0.34423	0.348	.	0.18768	.	.	0.29113	simple_aae&simple_aae&simple_aae&simple_aae	N&N&N&N	0.801151&0.91696&0.869275&0.869275	0.42001	.	.	.	0.02946	.	.	0.06944	.	T	0.56913	0.628370404243	0.42212	.	10	0.07173	.	.	0.05436	.	.	8.8084	0.34111	0.0:0.7138:0.0:0.2862	.	.	.	.	.	.	.	.	0.15888	.	C/C	N	.	D	T	685	0.59416	.	3	C0175704&C0028326&CN260604&CN166718&CN169374&CN517202	PS151100&PS163950	ORPHA500&ORPHA648&ORPHA98733&ORPHA536391	Benign	NC_000003.12:g.12591760C>T	181509	reviewed_by_expert_panel	Noonan_syndrome_with_multiple_lentigines&Noonan_syndrome&Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_specified&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:f46177ab-5c80-48cf-bd17-6acc5668f182&Service_de_Gntique_Molculaire&Hpital_Robert_Debr:57853	.	.	AEFDBI	D	0.52691	0.91013	N	0.20984	0.104954	.	70	2.784700e-04	0	0.000000e+00	16256	0	0	0.000000e+00	34592	0	251374	0	0.000000e+00	10076	0	0	0.000000e+00	18394	0	0	0.000000e+00	21646	0	1	8.798170e-06	113660	0	69	2.253720e-03	30616	0	69	2.253720e-03	30616	0	31	2.833430e-04	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	1	2.338200e-05	42768	0	30	1.912050e-03	15690	0	30	1.912050e-03	15690	0	0	.	0	70	2.955630e-04	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236836	0	0.000000e+00	9568	0	0	0.000000e+00	17692	0	0	0.000000e+00	21630	0	1	9.742410e-06	102644	0	69	2.260370e-03	30526	0	69	2.260370e-03	30526	0	0	70	3.363280e-04	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208130	0	0.000000e+00	6210	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	1	1.116620e-05	89556	0	69	2.254310e-03	30608	0	69	2.254310e-03	30608	0	0	70	2.859990e-04	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244756	0	0.000000e+00	9994	0	0	0.000000e+00	18390	0	0	0.000000e+00	21644	0	1	8.962980e-06	111570	0	69	2.253720e-03	30616	0	69	2.253720e-03	30616	0	0	12	7.887160e-05	0	0.000000e+00	41420	0	0	0.000000e+00	910	0	1	6.546220e-05	15276	0	152146	0	0.000000e+00	3472	0	0	0.000000e+00	5192	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	0	0.000000e+00	68034	0	11	2.278380e-03	4828	0	11	2.278380e-03	4828	0	7	2.129080e-04	0	0.000000e+00	9096	0	0	0.000000e+00	58	0	1	2.133110e-04	4688	0	32878	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5478	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	6	1.929260e-03	3110	0	0	.	0	12	8.113590e-05	0	0.000000e+00	41098	0	0	0.000000e+00	910	0	1	6.627780e-05	15088	0	147900	0	0.000000e+00	3302	0	0	0.000000e+00	4958	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	0	0.000000e+00	64814	0	11	2.293580e-03	4796	0	0	12	8.905780e-05	0	0.000000e+00	32462	0	0	0.000000e+00	860	0	1	6.743090e-05	14830	0	134744	0	0.000000e+00	3388	0	0	0.000000e+00	5192	0	0	0.000000e+00	6968	0	0	0.000000e+00	310	0	0	0.000000e+00	63908	0	11	2.279320e-03	4826	0	0	12	1.486800e-04	0	0.000000e+00	24800	0	0	0.000000e+00	110	0	1	7.750740e-05	12902	0	80710	0	0.000000e+00	998	0	0	0.000000e+00	3750	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	0	0.000000e+00	21046	0	11	2.291670e-03	4800	0	0	3	12608259	3	12633259	0	0.73137	0.706548	0.959000	0.33545	0.034000	0.13613	0.452000	0.26502	2.247000	0.42803	-3.876000	0.00054	-1.306000	0.01633	12591760	C	.	rs559632360	.	.	9.107	10.494	7.648	9.885	.	.	.	-13	32	7	20	0.00	0.02	0.00	0.00	RAF1	1.00	exon-NM_001354695.3-9+32+end+85	181509	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&RASopathy&not_specified&Noonan_syndrome_and_Noonan-related_syndrome&Noonan_syndrome&Noonan_syndrome_with_multiple_lentigines	MedGen:CN230736&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN169374&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MONDO:MONDO:0018997&MeSH:D009634&MedGen:C0028326&OMIM:PS163950&Orphanet:648&MONDO:MONDO:0007893&MedGen:C0175704&OMIM:PS151100&Orphanet:500	.	3:12633259-12633259	3.047e-04	37	37	0	0	0	0	0	1	0	36	10406	11570	8652	6614	66732	908	16508	0	0	0	0	1	0	36	0	0	0	0	0	0	0	rs559632360	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.96057e-06	0.00000e+00	2.17660e-03	3.70832e-04	1.61713e-04	2.17660e-03	2.76117e-04	rs559632360	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.01833e-03	.	5.84454e-05	0.00000e+00	.	3.22664e-05	.	.	rs559632360	559632360	.	.	.	RAF1	RAF1:exonic	RAF1:missense	RAF1:Cardiomyopathy\x2cdilated\x2c1NN\x3bNoonan_syndrome_5\x3bLEOPARD_syndrome_2	RAF1:615916\x3b611553\x3b611554	RAF1:3\x3b3\x3b3	RAF1:Autosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999776866110749	0.000223133833869176	5.53819998824154e-11	DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,478	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0.3246	VUS
12	103271235	103271235	C	A	A	splice_donor_5th_base_variant&intron_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	.	4/12	NM_000277.3:c.441+5G>T	.	.	.	.	.	.	rs62507321&CS086536&CS971841	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103271235C>A	.	.	.	.	.	.	pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.441+5G>T	0.999966463247542	0.976	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.810	9.092	11.038	7.211	-4.799	12.009	7.211	-15	5	-10	5	0.00	0.00	0.02	0.91	PAH	0.00	.	92742	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62507321	4.118e-05	5	5	0	0	2	0	0	3	0	0	10406	11578	8654	6614	66740	908	16512	0	2	0	0	3	0	0	0	0	0	0	0	0	0	rs62507321	0.00000e+00	1.19111e-04	0.00000e+00	0.00000e+00	0.00000e+00	2.68553e-05	0.00000e+00	0.00000e+00	2.22380e-05	3.59208e-05	1.19111e-04	2.84239e-05	rs62507321	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66489e-05	0.00000e+00	.	0.00000e+00	7.22022e-05	6.66489e-05	3.22664e-05	rs62507321	0.0233&0.0&0.0154	rs62507321	62507321	.	.	.	PAH	PAH:splicing\x3bintronic	PAH:splice_donor_5th_base_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,797	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
3	12641168	12641181	AAAGGGAGGGCCCC	A	-	intron_variant	MODIFIER	RAF1	5894	Transcript	NM_001354689.3	protein_coding	.	11/17	NM_001354689.3:c.1168+9_1168+21del	.	.	.	.	.	.	rs727504451	AAGGGAGGGCCCC	.	-1	.	1	EntrezGene	.	YES	.	.	AAGGGAGGGCCCC	AAGGGAGGGCCCC	.	.	MKRN2OS	.	chr3:g.12641172_12641184del	.	.	.	.	.	.	benign&likely_benign	.	1	.	.	.	.	.	RAF1&NM_002880.3&c.1108+9_1108+21del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.648	10.494	6.936	9.885	.	.	.	.	.	.	.	.	.	.	.	.	1.00	.	178666	Benign	reviewed_by_expert_panel	RASopathy&Noonan_syndrome&Noonan_syndrome_and_Noonan-related_syndrome&not_specified	MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0018997&MeSH:D009634&MedGen:C0028326&OMIM:PS163950&Orphanet:648&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN169374	.	3:12641169-12641182	4.695e-04	57	57	0	3	0	0	0	54	0	0	10402	11548	8648	6602	66698	906	16512	3	0	0	0	54	0	0	0	0	0	0	0	0	0	rs727504451	1.96027e-04	8.93442e-05	0.00000e+00	0.00000e+00	0.00000e+00	7.43155e-04	1.82415e-04	0.00000e+00	3.41044e-04	3.95200e-04	7.43155e-04	3.69513e-04	rs727504451	1.14653e-04	1.19332e-03	0.00000e+00	0.00000e+00	0.00000e+00	4.66667e-04	0.00000e+00	.	2.92227e-04	2.88976e-04	1.19332e-03	2.90398e-04	3:12641169-12641182	0.206&0.1406&0.1837	rs727504451	727504451	.	.	.	RAF1	RAF1:intronic	.	RAF1:Cardiomyopathy\x2cdilated\x2c1NN\x3bNoonan_syndrome_5\x3bLEOPARD_syndrome_2	RAF1:615916\x3b611553\x3b611554	RAF1:3\x3b3\x3b3	RAF1:Autosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999776866110749	0.000223133833869176	5.53819998824154e-11	DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,479	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	112920006	112920006	A	G	G	synonymous_variant	LOW	PTPN11	5781	Transcript	NM_002834.5	protein_coding	10/16	.	NM_002834.5:c.1221A>G	NP_002825.3:p.Gly407%3D	1386	1221	407	G	ggA/ggG	rs532529560	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTPN11	.	chr12:g.112920006A>G	.	0	0	0	0	0.001	benign&uncertain_significance	.	1	.	.	.	.	.	PTPN11&NM_002834.3&c.1221A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.641	10.077	10.270	8.884	.	.	.	-6	-7	-1	-6	0.00	0.00	0.00	0.01	PTPN11	1.00	exon-NM_001330437.2-10+3+end+132	436446	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&LEOPARD_syndrome_1&RASopathy&Noonan_syndrome_1&Metachondromatosis	MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0100082&MedGen:C4551484&OMIM:151100&Orphanet:500&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0008104&MedGen:C4551602&OMIM:163950&Orphanet:648&MONDO:MONDO:0007979&MedGen:C0410530&OMIM:156250&Orphanet:2499	.	12:112920006-112920006	2.306e-04	28	28	0	0	1	0	0	0	0	27	10398	11578	8654	6614	66712	906	16510	0	1	0	0	0	0	27	0	0	0	0	0	0	0	rs532529560	0.00000e+00	2.97779e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.49438e-03	2.52065e-04	1.16776e-04	1.49438e-03	1.90846e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs532529560	532529560	.	.	.	PTPN11	PTPN11:exonic	PTPN11:synonymous_SNV	PTPN11:Noonan_syndrome_1\x3bLEOPARD_syndrome_1\x3bMetachondromatosis\x3bLeukemia\x2cjuvenile_myelomonocytic\x2csomatic	PTPN11:163950\x3b151100\x3b156250\x3b607785	PTPN11:3\x3b3\x3b3\x3b3	PTPN11:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999877230878678	0.000122769057470549	6.38519788034449e-11	DISEASE: LEOPARD syndrome 1 (LPRD1) [MIM:151100]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:12058348, ECO:0000269|PubMed:14961557, ECO:0000269|PubMed:15121796, ECO:0000269|PubMed:15389709, ECO:0000269|PubMed:15520399, ECO:0000269|PubMed:15690106, ECO:0000269|PubMed:16679933, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 1 (NS1) [MIM:163950]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints. {ECO:0000269|PubMed:11704759, ECO:0000269|PubMed:11992261, ECO:0000269|PubMed:12161469, ECO:0000269|PubMed:12325025, ECO:0000269|PubMed:12529711, ECO:0000269|PubMed:12634870, ECO:0000269|PubMed:12717436, ECO:0000269|PubMed:12739139, ECO:0000269|PubMed:12960218, ECO:0000269|PubMed:15384080, ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry. Mutations in PTPN11 account for more than 50% of the cases.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:12717436}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Metachondromatosis (MC) [MIM:156250]: A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest. {ECO:0000269|PubMed:20577567}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,859	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103306564	103306564	C	T	T	splice_donor_5th_base_variant&intron_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	.	2/12	NM_000277.3:c.168+5G>A	.	.	.	.	.	.	rs62507288&CS930851&CS930852&CS971839	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103306564C>T	.	.	.	.	.	.	not_provided&likely_pathogenic	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.168+5G>T	0.998945663137961	0.916	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.785	10.766	8.002	7.700	2.225	5.475	7.700	5	42	23	5	0.00	0.00	0.02	0.91	PAH	0.00	.	102605	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62507288	62507288	.	.	.	PAH	PAH:splicing\x3bintronic	PAH:splice_donor_5th_base_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,830	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
7	140624468	140624468	C	T	T	synonymous_variant	LOW	BRAF	673	Transcript	NM_001374258.1	protein_coding	1/20	.	NM_001374258.1:c.36G>A	NP_001361187.1:p.Ala12%3D	262	36	12	A	gcG/gcA	rs397507454	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	BRAF	.	chr7:g.140624468C>T	.	.	.	.	.	.	benign&likely_benign	.	1	.	.	.	.	.	BRAF&NM_004333.4&c.36G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.759	10.033	.	.	.	.	.	-2	-13	-2	20	0.00	0.00	0.00	0.00	BRAF	1.00	exon-NM_001378474.1-1+102+start+364	40333	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&not_provided&RASopathy&LEOPARD_syndrome_3&Noonan_syndrome_7	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0013380&MedGen:C3150971&OMIM:613707&Orphanet:500&MONDO:MONDO:0013379&MedGen:C3150970&OMIM:613706&Orphanet:648	.	7:140624468-140624468	6.858e-04	16	15	0	0	1	0	0	0	0	14	184	90	130	0	2530	118	7290	0	1	0	0	0	0	14	0	0	0	0	0	0	0	rs397507454	0.00000e+00	2.37778e-04	0.00000e+00	0.00000e+00	1.97239e-04	2.30144e-04	3.26584e-04	2.99166e-03	1.03766e-03	3.50416e-04	2.99166e-03	5.35404e-04	rs397507454	0.00000e+00	2.49377e-03	0.00000e+00	0.00000e+00	0.00000e+00	2.74273e-04	0.00000e+00	.	1.80440e-04	2.23380e-04	2.49377e-03	2.25923e-04	.	.	rs397507454	397507454	.	.	.	BRAF	BRAF:exonic	BRAF:synonymous_SNV	BRAF:Melanoma\x2cmalignant\x2csomatic\x3bLEOPARD_syndrome_3\x3bCardiofaciocutaneous_syndrome\x3bAdenocarcinoma_of_lung\x2csomatic\x3bNoonan_syndrome_7\x3bColorectal_cancer\x2csomatic\x3bNonsmall_cell_lung_cancer\x2csomatic	BRAF:155600\x3b613707\x3b115150\x3b211980\x3b613706\x3b114500\x3b211980	BRAF:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	BRAF:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant\x3b.\x3b.	0	0.999978196041997	2.18039579639691e-05	3.88216441101404e-14	DISEASE: Note=Defects in BRAF are found in a wide range of cancers. {ECO:0000269|PubMed:18974108}.; DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:23263490, ECO:0000269|PubMed:24455489}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation. {ECO:0000269|PubMed:18974108}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,496	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	112915678	112915678	G	A	A	synonymous_variant	LOW	PTPN11	5781	Transcript	NM_002834.5	protein_coding	9/16	.	NM_002834.5:c.951G>A	NP_002825.3:p.Lys317%3D	1116	951	317	K	aaG/aaA	rs576405446	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTPN11	.	chr12:g.112915678G>A	.	0	0	0	0	0.0041	likely_benign&benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.270	8.884	8.295	9.256	.	.	.	-39	1	-50	-1	0.01	0.00	0.00	0.00	PTPN11	1.00	exon-NM_001330437.2-9+17+start+159	307226	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&RASopathy&Noonan_syndrome_1&Metachondromatosis&Cardiovascular_phenotype&not_specified&LEOPARD_syndrome_1	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0008104&MedGen:C4551602&OMIM:163950&Orphanet:648&MONDO:MONDO:0007979&MedGen:C0410530&OMIM:156250&Orphanet:2499&MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0100082&MedGen:C4551484&OMIM:151100&Orphanet:500	.	12:112915678-112915678	4.036e-04	49	45	2	0	0	0	0	0	0	49	10388	11538	8636	6606	66582	906	16480	0	0	0	0	0	0	45	0	0	0	0	0	0	2	rs576405446	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95945e-06	0.00000e+00	2.59943e-03	4.45058e-04	1.88659e-04	2.59943e-03	3.28905e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs576405446	576405446	.	.	.	PTPN11	PTPN11:exonic	PTPN11:synonymous_SNV	PTPN11:Noonan_syndrome_1\x3bLEOPARD_syndrome_1\x3bMetachondromatosis\x3bLeukemia\x2cjuvenile_myelomonocytic\x2csomatic	PTPN11:163950\x3b151100\x3b156250\x3b607785	PTPN11:3\x3b3\x3b3\x3b3	PTPN11:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999877230878678	0.000122769057470549	6.38519788034449e-11	DISEASE: LEOPARD syndrome 1 (LPRD1) [MIM:151100]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:12058348, ECO:0000269|PubMed:14961557, ECO:0000269|PubMed:15121796, ECO:0000269|PubMed:15389709, ECO:0000269|PubMed:15520399, ECO:0000269|PubMed:15690106, ECO:0000269|PubMed:16679933, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 1 (NS1) [MIM:163950]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints. {ECO:0000269|PubMed:11704759, ECO:0000269|PubMed:11992261, ECO:0000269|PubMed:12161469, ECO:0000269|PubMed:12325025, ECO:0000269|PubMed:12529711, ECO:0000269|PubMed:12634870, ECO:0000269|PubMed:12717436, ECO:0000269|PubMed:12739139, ECO:0000269|PubMed:12960218, ECO:0000269|PubMed:15384080, ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:24891296}. Note=The disease is caused by mutations affecting the gene represented in this entry. Mutations in PTPN11 account for more than 50% of the cases.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:12717436}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Metachondromatosis (MC) [MIM:156250]: A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest. {ECO:0000269|PubMed:20577567}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,856	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
7	140500166	140500166	T	C	C	missense_variant	MODERATE	BRAF	673	Transcript	NM_001374258.1	protein_coding	7/20	.	NM_001374258.1:c.976A>G	NP_001361187.1:p.Ile326Val	1202	976	326	I/V	Att/Gtt	rs775040765&COSV56234618	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	NDUFB2	.	chr7:g.140500166T>C	.	.	.	.	.	.	benign	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	T	0.00563	-0.50119	T	0.15041	-0.574484	0.010	0.002	-0.948101	-1.081201	0.00574	0.00332	T/T	T	0.00168	0.0113354414971436	0.01659	0.3038256061441133	.	0.63718	.	T/T	.	.	.	.	0.03199324	-1.81313022516553	0.00718	0.02311493	-1.80337370102924	0.00537	.	.	.	11	9.060e-05	1	9.610e-05	0	0	11	9.060e-05	9	1.040e-03	0	0	0	0	1	6.056e-05	11	1.036e-04	1	1.103e-04	0	0	11	1.036e-04	9	1.144e-03	0	0	0	0	1	6.095e-05	11	1.212e-04	1	9.626e-05	0	0	11	1.212e-04	9	1.596e-03	0	0	0	0	1	6.060e-05	0.76168	.	.	.	5.93	-5.32	0.02511	0	0.59785	0.653731	.	.	0.15852	0.0806886823854103	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.64102	0.662433	.&.&.&.	.	.	.	0.00653	.	1.099720	0.06626	N	0.776101	T	0.38399	0.016917	0.65697	.	0.36103	.	T	0.52736	0.1805	.	0.00190	.	T	0.36967	-0.9711	I326V	Loss_of_catalytic_residue_at_P328_(P_=_0.0271)&_Loss_of_glycosylation_at_S325_(P_=_0.1275)&_Loss_of_phosphorylation_at_S325_(P_=_0.6134)&_Loss_of_stability_(P_=_0.6165)&_Loss_of_helix_(P_=_0.6555)	P15056	0.04365	0.14	.	0.06538	.	.	0.08975	simple_aae	N	1	0.05310	.	.	.	0.02946	.	.	0.01387	.	T	0.02333	0.234702050686	0.40720	.	10	0.02961	.	.	0.04264	.	.	7.7388	0.27994	0.1511:0.0556:0.5145:0.2789	.	.	.	.	.	.	.	.	0.13626	.	T/T	V	.	I	C	794	0.45591	.	7	CN166718&CN517202	.	ORPHA536391	Benign	NC_000007.14:g.140800366T>C	417225	reviewed_by_expert_panel	Rasopathy&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:e46ee061-0859-4581-9333-f113c0784ab0	.	.	AEFBI	N	0.18759	0.15131	N	0.23331	0.119569	.	20	7.953870e-05	1	6.151570e-05	16256	0	2	5.782020e-05	34590	0	251450	0	0.000000e+00	10078	0	14	7.611180e-04	18394	0	0	0.000000e+00	21648	0	0	0.000000e+00	113734	0	14	7.611180e-04	18394	0	3	9.798800e-05	30616	0	10	9.140270e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17110	0	109406	0	0.000000e+00	2320	0	8	8.843690e-04	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	8	8.843690e-04	9046	0	2	1.274700e-04	15690	0	0	segdup	0	20	8.441950e-05	1	6.710510e-05	14902	0	2	5.838050e-05	34258	0	236912	0	0.000000e+00	9570	0	14	7.913180e-04	17692	0	0	0.000000e+00	21632	0	0	0.000000e+00	102718	0	14	7.913180e-04	17692	0	3	9.827690e-05	30526	0	0	19	9.129090e-05	1	6.165990e-05	16218	0	1	3.276330e-05	30522	0	208126	0	0.000000e+00	6210	0	14	1.043530e-03	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89554	0	14	1.043530e-03	13416	0	3	9.801360e-05	30608	0	0	20	8.168870e-05	1	8.315320e-05	12026	0	2	5.804500e-05	34456	0	244832	0	0.000000e+00	9996	0	14	7.612830e-04	18390	0	0	0.000000e+00	21646	0	0	0.000000e+00	111644	0	14	7.612830e-04	18390	0	3	9.798800e-05	30616	0	0	4	2.630300e-05	0	0.000000e+00	41412	0	0	0.000000e+00	912	0	0	0.000000e+00	15270	0	152074	0	0.000000e+00	3472	0	3	5.778120e-04	5192	0	1	9.450010e-05	10582	0	0	0.000000e+00	316	0	0	0.000000e+00	68004	0	3	5.778120e-04	5192	0	0	0.000000e+00	4824	0	1	3.043580e-05	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32856	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	1	1.829490e-04	5466	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3104	0	0	.	0	4	2.705550e-05	0	0.000000e+00	41090	0	0	0.000000e+00	912	0	0	0.000000e+00	15084	0	147844	0	0.000000e+00	3302	0	3	6.045950e-04	4962	0	1	9.450010e-05	10582	0	0	0.000000e+00	304	0	0	0.000000e+00	64796	0	0	0.000000e+00	4792	0	0	4	2.970140e-05	0	0.000000e+00	32450	0	0	0.000000e+00	862	0	0	0.000000e+00	14824	0	134674	0	0.000000e+00	3388	0	3	5.778120e-04	5192	0	1	1.440090e-04	6944	0	0	0.000000e+00	310	0	0	0.000000e+00	63882	0	0	0.000000e+00	4822	0	0	3	3.720330e-05	0	0.000000e+00	24788	0	0	0.000000e+00	112	0	0	0.000000e+00	12896	0	80638	0	0.000000e+00	998	0	2	5.333330e-04	3750	0	1	9.532890e-05	10490	0	0	0.000000e+00	272	0	0	0.000000e+00	21020	0	0	0.000000e+00	4796	0	0	7	140146635	7	140500166	0	0.73137	0.706548	0.000000	0.06391	0.837000	0.39485	0.916000	0.38718	-0.005000	0.12791	-0.685000	0.04181	-0.622000	0.04543	140800366	T	.	rs775040765	.	.	6.437	6.233	9.582	8.819	.	.	.	1	-2	-9	-4	0.00	0.00	0.00	0.04	BRAF	1.00	exon-NM_001378474.1-7+4+start+120	417225	Benign	reviewed_by_expert_panel	not_provided&RASopathy	MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	7:140500166-140500166	9.060e-05	11	11	0	1	0	9	0	0	0	1	10406	11574	8654	6614	66740	908	16512	1	0	9	0	0	0	1	0	0	0	0	0	0	0	rs775040765	6.53424e-05	2.97779e-05	0.00000e+00	8.11688e-04	0.00000e+00	0.00000e+00	1.82349e-04	9.74596e-05	8.89667e-05	7.18494e-05	8.11688e-04	8.12110e-05	rs775040765	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.86205e-04	0.00000e+00	0.00000e+00	.	0.00000e+00	7.21709e-05	2.86205e-04	3.22664e-05	.	.	rs775040765	775040765	.	.	.	BRAF	BRAF:exonic	BRAF:missense	BRAF:Melanoma\x2cmalignant\x2csomatic\x3bLEOPARD_syndrome_3\x3bCardiofaciocutaneous_syndrome\x3bAdenocarcinoma_of_lung\x2csomatic\x3bNoonan_syndrome_7\x3bColorectal_cancer\x2csomatic\x3bNonsmall_cell_lung_cancer\x2csomatic	BRAF:155600\x3b613707\x3b115150\x3b211980\x3b613706\x3b114500\x3b211980	BRAF:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	BRAF:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant\x3b.\x3b.	0	0.999978196041997	2.18039579639691e-05	3.88216441101404e-14	DISEASE: Note=Defects in BRAF are found in a wide range of cancers. {ECO:0000269|PubMed:18974108}.; DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:23263490, ECO:0000269|PubMed:24455489}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:19206169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation. {ECO:0000269|PubMed:18974108}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,493	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0.3246	VUS
7	107301201	107301201	T	C	C	upstream_gene_variant	MODIFIER	SLC26A4	5172	Transcript	NM_000441.2	protein_coding	.	.	.	.	.	.	.	.	.	rs60284988&CR072324	T	72	1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	SLC26A4	.	chr7:g.107301201T>C	.	.	.	.	.	.	pathogenic&uncertain_significance&likely_pathogenic	.	1&1	.	.	.	.	.	SLC26A4&NM_000441.1&c.-103T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-8	35	5	-9	0.00	0.00	0.00	0.00	SLC26A4	0.00	.	4838	Uncertain_significance	reviewed_by_expert_panel	not_specified&SLC26A4-Related_Disorders&not_provided&Autosomal_recessive_nonsyndromic_hearing_loss_4&Pendred_syndrome&Hearing_impairment	MedGen:CN169374&MedGen:CN239421&MedGen:CN517202&MONDO:MONDO:0010933&MedGen:C3538946&OMIM:600791&Orphanet:90636&MONDO:MONDO:0010134&MedGen:C0271829&OMIM:274600&Orphanet:705&Human_Phenotype_Ontology:HP:0000365&Human_Phenotype_Ontology:HP:0000404&Human_Phenotype_Ontology:HP:0001728&Human_Phenotype_Ontology:HP:0001729&Human_Phenotype_Ontology:HP:0001754&Human_Phenotype_Ontology:HP:0008560&Human_Phenotype_Ontology:HP:0008563&MONDO:MONDO:0005365&MedGen:C1384666	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs60284988	3.43879e-04	0.00000e+00	3.31126e-03	0.00000e+00	1.14482e-03	3.53380e-03	5.09165e-03	.	1.92960e-03	2.38164e-03	3.53380e-03	2.16185e-03	.	.	rs60284988	60284988	.	.	.	SLC26A4\x3bSLC26A4-AS1	SLC26A4:upstream\x7cSLC26A4-AS1:ncRNA_intronic	.	SLC26A4:Deafness\x2cautosomal_recessive_4\x2cwith_enlarged_vestibular_aqueduct\x3bPendred_syndrome	SLC26A4:600791\x3b274600	SLC26A4:3\x3b3	SLC26A4:Autosomal_recessive\x3bAutosomal_recessive	0	6.36692519367205e-13	0.204987783815785	0.795012216183578	DISEASE: Deafness, autosomal recessive, 4 (DFNB4) [MIM:600791]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNB4 is associated with an enlarged vestibular aqueduct. {ECO:0000269|PubMed:10190331, ECO:0000269|PubMed:10700480, ECO:0000269|PubMed:11748854, ECO:0000269|PubMed:12676893, ECO:0000269|PubMed:14508505, ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:19204907, ECO:0000269|PubMed:20108392, ECO:0000269|PubMed:20597900, ECO:0000269|PubMed:9500541}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,489	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89690790	89690795	ACTTTT	A	-	splice_polypyrimidine_tract_variant&splice_region_variant&intron_variant	LOW	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	3/8	NM_000314.8:c.210-7_210-3del	.	.	.	.	.	.	rs587780544	CTTTT	.	1	.	.	EntrezGene	.	.	.	.	CTTTT	CTTTT	.	.	PTEN	.	chr10:g.89690796_89690800del	.	.	.	.	.	.	.	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.210-12_210-8del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.389	9.651	10.295	7.964	.	.	.	.	.	.	.	.	.	.	.	.	0.98	.	142397	Benign	reviewed_by_expert_panel	not_specified&Breast_and/or_ovarian_cancer&Hereditary_cancer-predisposing_syndrome&not_provided&Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome&Familial_cancer_of_breast	MedGen:CN169374&MedGen:CN221562&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535	.	10:89690791-89690796	2.390e-04	29	29	0	3	2	0	0	24	0	0	9870	10860	8242	6386	62374	878	15710	3	2	0	0	24	0	0	0	0	0	0	0	0	0	rs587780544	3.29077e-04	2.69413e-04	1.63532e-03	1.74784e-04	0.00000e+00	2.98605e-04	7.36648e-04	3.26200e-05	2.16544e-04	3.80290e-04	1.63532e-03	2.92443e-04	rs587780544	2.29200e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.35661e-04	0.00000e+00	.	2.93290e-04	1.45012e-04	3.35661e-04	2.25923e-04	10:89690791-89690796	0.7655&0.2581&0.5924	rs587780544	587780544	.	.	.	PTEN	PTEN:splicing\x3bintronic	PTEN:splice_region_variant\x3bsplice_polypyrimidine_tract_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,532	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103306564	103306564	C	A	A	splice_donor_5th_base_variant&intron_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	.	2/12	NM_000277.3:c.168+5G>T	.	.	.	.	.	.	rs62507288&CS930851&CS930852&CS971839	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103306564C>A	.	.	.	.	.	.	not_provided&uncertain_significance	.	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.168+5G>T	0.992286374163183	0.836	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.785	10.766	8.002	7.700	3.308	4.392	7.700	5	42	23	5	0.00	0.00	0.03	0.92	PAH	0.00	.	102607	Uncertain_significance	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62507288	62507288	.	.	.	PAH	PAH:splicing\x3bintronic	PAH:splice_donor_5th_base_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,829	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89692731	89692731	G	T	T	intron_variant	MODIFIER	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	4/8	NM_000314.8:c.254-39G>T	.	.	.	.	.	.	rs35034871	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89692731G>T	.	0	0	0.004	0	0	likely_benign	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.254-39G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.352	10.998	8.389	9.651	.	.	.	21	39	45	-49	0.09	0.00	0.00	0.00	PTEN	0.98	.	92818	Likely_benign	reviewed_by_expert_panel	not_specified&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome	MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	rs77494260	3.543e-04	43	1644&17&43&0&0&0	0	0	0	42	0	0	0	1	8982	10428	7536	6380	60712	846	15382	21&4&0&0&0&0	118&0&0&0&0&0	6&3&42&0&0&0	116&0&0&0&0&0	1079&5&0&0&0&0	13&0&0&0&0&0	291&5&1&0&0&0	0	0	0	0	0	0	0	rs35034871	0.00000e+00	0.00000e+00	0.00000e+00	6.67506e-03	0.00000e+00	0.00000e+00	0.00000e+00	3.50459e-05	5.07524e-04	4.32144e-04	6.67506e-03	4.38575e-04	rs35034871	0.00000e+00	0.00000e+00	0.00000e+00	3.72671e-03	2.93255e-04	0.00000e+00	0.00000e+00	.	5.89206e-05	4.36554e-04	3.72671e-03	2.25879e-04	.	.	rs35034871	35034871	.	.	.	PTEN	PTEN:intronic	.	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,533	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
16	68842599	68842599	A	G	G	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	5/16	.	NM_004360.5:c.535A>G	NP_004351.1:p.Lys179Glu	659	535	179	K/E	Aaa/Gaa	rs1555515244	A	.	1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	TANGO6	.	chr16:g.68842599A>G	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	CDH1&NM_004360.3&c.535A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	D	0.72254	0.182294	D	0.71894	0.0240757	26.4	26.4	3.901004	3.822008	0.75313	0.76184	A/A	D	0.70701	0.974893748760223	0.31855	0.96979837001170677	.	0.77988	.	A/A	.	.	.	.	8.04606	0.715175313077473	0.83532	7.47936	0.724746423441592	0.81254	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.69287	.	.	.	5.78	5.78	0.91418	0	0.40923	0.588066	.	.	0.74766	0.999999701671221	.	0	0.82415	0.723133	.	.	.	.	.	.	0	0.10902	0.530356	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&.	.	.	.	0.85028	.	0.000000	0.53742	D	0.000050	D	0.74537	0.085456	0.76969	.	0.91148	.	T	0.79899	0.4758	.	0.58502	.	T	0.81111	-0.0545	K179E	Loss_of_methylation_at_K179_(P_=_0.0225)&_Gain_of_ubiquitination_at_K182_(P_=_0.0355)&_Loss_of_sheet_(P_=_0.0457)&_Loss_of_MoRF_binding_(P_=_0.0542)&_Loss_of_disorder_(P_=_0.233)	P12830	0.65434	0.542	.	0.74443	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.62747	.	.	.	0.90584	.	.	0.86255	.	T	0.45176	0.545166969299	0.78226	.	10	0.69154	.	.	0.68238	.	.	16.0592	0.80632	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.60325	.	A/A	E	.	K	G	315	0.87208	.	16	C1708349&CN517202	137215	ORPHA26106	Uncertain_significance	NC_000016.10:g.68808696A>G	496233	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:c47d2e21-ae8f-4349-b873-bb19817b9e24	.	.	AEFDBHCI	D	0.52691	0.91013	D	0.84492	0.899948	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	67400100	16	68842599	0	0.83141	0.719381	1.000000	0.71638	0.979000	0.57723	1.000000	0.86279	5.526000	0.66832	0.756000	0.94297	1.312000	0.94714	68808696	A	.	rs1555515244	.	.	8.533	8.591	10.585	7.101	.	.	.	1	2	21	2	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-5+3+start+156	496233	Uncertain_significance	reviewed_by_expert_panel	Hereditary_diffuse_gastric_adenocarcinoma&not_provided	MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555515244	1555515244	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,894	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
2	39285865	39285865	C	T	T	synonymous_variant	LOW	SOS1	6654	Transcript	NM_005633.4	protein_coding	3/23	.	NM_005633.4:c.294G>A	NP_005624.2:p.Lys98%3D	923	294	98	K	aaG/aaA	rs748478952	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	SOS1	.	chr2:g.39285865C>T	.	.	.	.	.	.	likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.110	8.993	7.161	8.549	.	.	.	-26	5	-26	-12	0.00	0.00	0.00	0.00	SOS1	1.00	exon-NM_001382394.1-3+51+start+132	448944	Likely_benign	reviewed_by_expert_panel	RASopathy	MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	2:39285865-39285865	7.413e-05	9	9	0	0	0	0	0	0	0	9	10314	11526	8654	6610	66692	906	16504	0	0	0	0	0	0	9	0	0	0	0	0	0	0	rs748478952	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.18691e-04	1.11370e-04	3.59719e-05	6.18691e-04	7.71555e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs748478952	748478952	.	.	.	SOS1	SOS1:exonic	SOS1:synonymous_SNV	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,470	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
19	4099293	4099293	C	T	T	synonymous_variant	LOW	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	7/11	.	NM_030662.4:c.825G>A	NP_109587.1:p.Leu275%3D	1072	825	275	L	ctG/ctA	rs587781027	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MAP2K2	.	chr19:g.4099293C>T	.	.	.	.	.	.	benign&benign/likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.559	8.532	6.943	7.389	.	.	.	-41	4	34	-40	0.00	0.00	0.03	0.00	MAP2K2	0.86	exon-NM_030662.4-7+94+start+214	138161	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&not_provided&RASopathy	MedGen:CN230736&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	19:4099293-4099293	1.488e-04	18	14	0	0	0	14	0	0	0	0	6220	7102	5968	3272	43236	594	12972	0	0	14	0	0	0	0	0	0	0	0	0	0	0	rs587781027	0.00000e+00	0.00000e+00	0.00000e+00	1.69103e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	9.37222e-05	1.53072e-04	1.69103e-03	1.29979e-04	rs587781027	0.00000e+00	0.00000e+00	0.00000e+00	3.70370e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	2.92466e-04	7.23066e-05	3.70370e-03	1.93611e-04	.	.	rs587781027	587781027	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:synonymous_SNV	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,927	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
21	36265218	36265218	A	C	C	splice_donor_region_variant&intron_variant	LOW	RUNX1	861	Transcript	NM_001754.5	protein_coding	.	3/8	NM_001754.5:c.97+4T>G	.	.	.	.	.	.	rs754042987	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	RUNX1	.	chr21:g.36265218A>C	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	.	8.40701769357883E-5	0.002	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.426	8.558	8.173	9.942	10.154	-0.212	9.942	42	4	4	7	0.01	0.00	0.02	0.00	RUNX1	0.45	.	339878	Uncertain_significance	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	21:36265218-36265218	2.472e-05	3	3	0	0	0	0	0	3	0	0	9948	11410	8574	6574	65262	892	16248	0	0	0	0	3	0	0	0	0	0	0	0	0	0	rs754042987	6.55996e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	5.41223e-05	0.00000e+00	0.00000e+00	2.24931e-05	3.62273e-05	6.55996e-05	2.84266e-05	rs754042987	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.33351e-04	0.00000e+00	.	5.84522e-05	7.22022e-05	1.33351e-04	6.45328e-05	.	.	rs754042987	754042987	.	.	.	RUNX1	RUNX1:splicing\x3bintronic	RUNX1:splice_donor_region_variant	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,987	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
1	216040521	216040521	T	C	C	splice_polypyrimidine_tract_variant&intron_variant	LOW	USH2A	7399	Transcript	NM_206933.4	protein_coding	.	43/71	NM_206933.4:c.8682-9A>G	.	.	.	.	.	.	rs372347027&CS140560	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	KCTD3	.	chr1:g.216040521T>C	.	.	.	.	.	.	pathogenic&pathogenic/likely_pathogenic&likely_pathogenic	.	1&1	.	.	.	.	.	USH2A&NM_206933.2&c.8682-9A>G	0.998219648333136	0.984	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.636	10.077	10.086	9.219	0.114	4.521	4.636	-1	-9	-48	-17	0.95	0.81	0.00	0.00	USH2A	0.00	.	197510	Pathogenic	reviewed_by_expert_panel	Usher_syndrome&Retinal_dystrophy&not_provided&Retinitis_pigmentosa&Usher_syndrome_type_2A&Retinitis_pigmentosa_39	MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&Human_Phenotype_Ontology:HP:0000556&Human_Phenotype_Ontology:HP:0007736&Human_Phenotype_Ontology:HP:0007910&Human_Phenotype_Ontology:HP:0007974&Human_Phenotype_Ontology:HP:0007982&MONDO:MONDO:0019118&MeSH:D058499&MedGen:C0854723&Orphanet:71862&MedGen:CN517202&Human_Phenotype_Ontology:HP:0000547&MONDO:MONDO:0019200&MeSH:D012174&MedGen:C0035334&OMIM:268000&OMIM:PS268000&Orphanet:791&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886&MONDO:MONDO:0013436&MedGen:C3151138&OMIM:613809&Orphanet:791	.	1:216040521-216040521	8.237e-05	10	10	0	0	0	0	0	10	0	0	9608	10580	7940	6386	61232	864	15586	0	0	0	0	10	0	0	0	0	0	0	0	0	0	rs372347027	0.00000e+00	0.00000e+00	5.09684e-04	0.00000e+00	0.00000e+00	1.17293e-04	0.00000e+00	0.00000e+00	6.71271e-05	8.12685e-05	5.09684e-04	7.30941e-05	rs372347027	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.67646e-05	0.00000e+00	.	0.00000e+00	7.23170e-05	6.67646e-05	3.22664e-05	rs372347027	0.0116&0.0&0.0077	rs372347027	372347027	.	.	.	USH2A	USH2A:splicing\x3bintronic	USH2A:splice_polypyrimidine_tract_variant	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,451	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
21	36252918	36252918	G	A	A	synonymous_variant	LOW	RUNX1	861	Transcript	NM_001754.5	protein_coding	5/9	.	NM_001754.5:c.444C>T	NP_001745.2:p.Thr148%3D	638	444	148	T	acC/acT	rs773689002&COSV100278418&COSV55872606	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36252918G>A	.	.	.	.	.	.	likely_benign	0&1&1	1&1&1	.	.	.	.	.	RUNX1&NM_001001890.2&c.363C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.926	10.199	5.882	8.558	.	.	.	-42	-18	9	-41	0.00	0.00	0.00	0.01	RUNX1	0.45	exon-NM_001754.5-5+64+start+157	339877	Likely_benign	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1&Hereditary_cancer-predisposing_syndrome	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	21:36252918-36252918	7.413e-05	9	9	0	0	0	0	0	8	0	1	10396	11534	8650	6608	66662	906	16498	0	0	0	0	8	0	1	0	0	0	0	0	0	0	rs773689002	6.53509e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.07469e-04	0.00000e+00	6.49773e-05	7.41565e-05	4.49156e-05	1.07469e-04	6.09083e-05	rs773689002	1.14600e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84180e-05	0.00000e+00	1.14600e-04	3.22664e-05	.	.	rs773689002	773689002	.	.	.	RUNX1	RUNX1:exonic	RUNX1:synonymous_SNV	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,970	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
2	39213367	39213367	G	C	C	missense_variant	MODERATE	SOS1	6654	Transcript	NM_005633.4	protein_coding	23/23	.	NM_005633.4:c.3600C>G	NP_005624.2:p.Asp1200Glu	4229	3600	1200	D/E	gaC/gaG	rs141594736&COSV67673919	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	ARHGEF33	.	chr2:g.39213367G>C	.	.	.	.	.	.	uncertain_significance&conflicting_interpretations_of_pathogenicity&likely_benign	0&1	1&1	.	.	.	.	.	SOS1&NM_005633.3&c.3600C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0.0	.	.	.	.	.	.	.	G/G	G	T	0.00802	-0.474082	T	0.11875	-0.611346	8.453	12.36	0.699749	0.852879	0.11407	0.15069	G/G	T	0.04430	0.0440543503817839	0.10683	0.74405752049408458	.	0.73600	.	G/G	0	0.0	3	3.488372093023256E-4	0.6646826	-0.867293562731758	0.12873	0.3755785	-1.02732348548934	0.08039	.	.	.	19	1.565e-04	0	0	0	0	19	1.567e-04	0	0	0	0	19	2.848e-04	0	0	18	1.695e-04	0	0	0	0	18	1.697e-04	0	0	0	0	18	3.313e-04	0	0	6	6.611e-05	0	0	0	0	6	6.621e-05	0	0	0	0	6	1.425e-04	0	0	0.75789	.	.	.	5.8	-0.526	0.11318	0	0.89359	0.724815	.	.	0.15720	0.0762170926535929	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.83352	0.714379	.&.&.	.	.	.	0.31676	.	0.452954	0.24824	N	0.034007	T	0.15012	0.005786	0.10456	.	0.39594	.	T	0.33326	0.0856	.	0.03756	.	T	0.37030	-0.9708	.	.	.	.	.	.	0.06538	.	.	0.35251	simple_aae&simple_aae&simple_aae	D&D&D	0.852798&0.852798&0.852798	0.19509	.	.	.	0.02946	.	.	0.04355	.	T	0.59547	0.646909892559	0.49555	.	10	0.03380	.	.	0.19500	.	.	0.6096	0.00710	0.2526:0.2069:0.3287:0.2117	.	2	5.393743257820927E-4	2	2.644802962179318E-4	.	.	.	0.14622	.	G/G	E	.	D	C	459	0.78817	.	2	CN260604&CN166718&CN169374&CN517202	.	ORPHA98733&ORPHA536391	Likely_benign	NC_000002.12:g.38986226G>C	40733	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&not_specified&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:9b08e55f-32bb-4cc3-bfff-815c445525b7	.	.	AEFBI	N	0.27986	0.47455	N	0.24472	0.127375	.	40	1.591720e-04	1	6.153090e-05	16252	0	0	0.000000e+00	34564	0	251300	0	0.000000e+00	10074	0	0	0.000000e+00	18390	0	0	0.000000e+00	21630	0	39	3.431830e-04	113642	0	39	3.431830e-04	113642	0	0	0.000000e+00	30614	0	15	1.371370e-04	1	1.395870e-04	7164	0	0	0.000000e+00	17100	0	109380	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13382	0	14	3.273480e-04	42768	0	14	3.273480e-04	42768	0	0	0.000000e+00	15688	0	0	.	0	38	1.604970e-04	1	6.712310e-05	14898	0	0	0.000000e+00	34232	0	236764	0	0.000000e+00	9566	0	0	0.000000e+00	17688	0	0	0.000000e+00	21614	0	37	3.605250e-04	102628	0	37	3.605250e-04	102628	0	0	0.000000e+00	30524	0	0	30	1.441890e-04	1	6.167510e-05	16214	0	0	0.000000e+00	30496	0	208060	0	0.000000e+00	6208	0	0	0.000000e+00	13412	0	0	0.000000e+00	16722	0	29	3.238780e-04	89540	0	29	3.238780e-04	89540	0	0	0.000000e+00	30606	0	0	38	1.553040e-04	0	0.000000e+00	12022	0	0	0.000000e+00	34430	0	244682	0	0.000000e+00	9992	0	0	0.000000e+00	18386	0	0	0.000000e+00	21628	0	38	3.406480e-04	111552	0	38	3.406480e-04	111552	0	0	0.000000e+00	30614	0	0	21	1.380630e-04	0	0.000000e+00	41426	0	0	0.000000e+00	910	0	0	0.000000e+00	15270	0	152104	0	0.000000e+00	3470	0	0	0.000000e+00	5184	0	0	0.000000e+00	10604	0	0	0.000000e+00	316	0	21	3.087870e-04	68008	0	21	3.087870e-04	68008	0	0	0.000000e+00	4822	0	1	3.042840e-05	0	0.000000e+00	9084	0	0	0.000000e+00	60	0	0	0.000000e+00	4684	0	32864	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5482	0	0	0.000000e+00	246	0	1	1.460280e-04	6848	0	0	0.000000e+00	3108	0	0	.	0	20	1.352700e-04	0	0.000000e+00	41104	0	0	0.000000e+00	910	0	0	0.000000e+00	15082	0	147852	0	0.000000e+00	3302	0	0	0.000000e+00	4950	0	0	0.000000e+00	10604	0	0	0.000000e+00	304	0	20	3.087280e-04	64782	0	0	0.000000e+00	4790	0	0	17	1.261910e-04	0	0.000000e+00	32470	0	0	0.000000e+00	862	0	0	0.000000e+00	14824	0	134716	0	0.000000e+00	3386	0	0	0.000000e+00	5184	0	0	0.000000e+00	6966	0	0	0.000000e+00	310	0	17	2.660820e-04	63890	0	0	0.000000e+00	4820	0	0	7	8.676250e-05	0	0.000000e+00	24802	0	0	0.000000e+00	110	0	0	0.000000e+00	12896	0	80680	0	0.000000e+00	996	0	0	0.000000e+00	3742	0	0	0.000000e+00	10512	0	0	0.000000e+00	272	0	7	3.327630e-04	21036	0	0	0.000000e+00	4794	0	0	2	39066871	2	39213367	0	0.73137	0.706548	0.837000	0.30238	0.892000	0.42986	1.000000	0.86279	-0.043000	0.11996	0.676000	0.76740	0.245000	0.26320	38986226	G	.	rs141594736	.	.	.	.	7.792	9.064	.	.	.	-1	-17	3	9	0.00	0.00	0.00	0.00	SOS1	1.00	exon-NM_001382394.1-23+89+end+4767	40733	Likely_benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&not_specified&RASopathy&not_provided	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN517202	.	rs141594736	1.565e-04	19	4	0	0	0	0	0	19	0	0	10360	11542	8644	6614	66710	906	16508	0	0	0	0	4	0	0	0	0	0	0	0	0	0	rs141594736	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.40545e-04	0.00000e+00	0.00000e+00	1.63222e-04	1.43774e-04	3.40545e-04	1.54301e-04	rs141594736	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.66702e-04	0.00000e+00	.	1.16986e-04	1.44530e-04	2.66702e-04	1.29066e-04	rs141594736	0.0349&0.0&0.0231	rs141594736	141594736	.	.	.	SOS1	SOS1:exonic	SOS1:missense	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,460	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0.3246	VUS
21	36252850	36252851	GT	G	-	splice_donor_region_variant&intron_variant	LOW	RUNX1	861	Transcript	NM_001754.5	protein_coding	.	5/8	NM_001754.5:c.508+3del	.	.	.	.	.	.	rs587776810&CD025984	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	RUNX1	.	chr21:g.36252851del	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.926	9.815	5.882	10.199	.	.	.	27	11	27	4	0.00	0.00	0.54	0.99	RUNX1	0.45	.	14466	Pathogenic	reviewed_by_expert_panel	Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587776810	587776810	.	.	.	RUNX1	RUNX1:splicing\x3bintronic	RUNX1:splice_donor_region_variant	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,965	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
2	39213415	39213415	A	C	C	synonymous_variant	LOW	SOS1	6654	Transcript	NM_005633.4	protein_coding	23/23	.	NM_005633.4:c.3552T>G	NP_005624.2:p.Pro1184%3D	4181	3552	1184	P	ccT/ccG	rs200485215&COSV67675470	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	ARHGEF33	.	chr2:g.39213415A>C	.	0	0	0.001	0	0	benign	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.792	9.064	.	.	.	41	-3	-39	41	0.18	0.00	0.00	0.00	SOS1	1.00	exon-NM_001382394.1-23+41+end+4767	448939	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&not_provided&Cardiovascular_phenotype&not_specified&RASopathy	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN517202&MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	2:39213415-39213415	1.400e-04	17	17	0	0	0	17	0	0	0	0	10144	11480	8594	6592	66522	904	16498	0	0	17	0	0	0	0	0	0	0	0	0	0	0	rs200485215	0.00000e+00	2.98418e-05	0.00000e+00	1.56667e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.03990e-04	1.25976e-04	1.56667e-03	1.13698e-04	rs200485215	0.00000e+00	0.00000e+00	0.00000e+00	6.23441e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	0.00000e+00	7.22857e-05	6.23441e-04	3.22664e-05	.	.	rs200485215	200485215	.	.	.	SOS1	SOS1:exonic	SOS1:synonymous_SNV	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,461	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
2	39222280	39222280	C	G	G	synonymous_variant	LOW	SOS1	6654	Transcript	NM_005633.4	protein_coding	20/23	.	NM_005633.4:c.3330G>C	NP_005624.2:p.Ser1110%3D	3959	3330	1110	S	tcG/tcC	rs146383828&COSV101217010	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	ARHGEF33	.	chr2:g.39222280C>G	.	0.0008	0	0	0	0	likely_benign	0&1	1&1	.	.	.	.	.	SOS1&NM_005633.3&c.3330G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.713	7.333	6.365	3.932	.	.	.	-3	39	50	-16	0.00	0.00	0.00	0.08	SOS1	1.00	exon-NM_001382394.1-20+16+start+265	448940	Likely_benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&RASopathy	MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	rs146383828	7.413e-05	9	9	0	8	1	0	0	0	0	0	10406	11548	8596	6598	66678	908	16512	8	1	0	0	0	0	0	0	0	0	0	0	0	0	rs146383828	6.53509e-04	1.19211e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.71814e-05	8.11439e-05	6.53509e-04	5.68482e-05	rs146383828	5.73000e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	1.75316e-04	1.44279e-04	5.73000e-04	1.61332e-04	rs146383828	0.0&0.0454&0.0154	rs146383828	146383828	.	.	.	SOS1	SOS1:exonic	SOS1:synonymous_SNV	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,462	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
2	39224072	39224072	G	A	A	synonymous_variant	LOW	SOS1	6654	Transcript	NM_005633.4	protein_coding	19/23	.	NM_005633.4:c.3072C>T	NP_005624.2:p.Leu1024%3D	3701	3072	1024	L	ctC/ctT	rs558386297	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	ARHGEF33	.	chr2:g.39224072G>A	.	0	0	0	0	0.001	benign&likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.365	3.932	8.423	9.722	.	.	.	28	-6	-9	-6	0.00	0.00	0.01	0.00	SOS1	1.00	exon-NM_001382394.1-19+9+start+117	448941	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&RASopathy	MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	2:39224072-39224072	1.647e-04	20	20	0	0	1	0	0	0	0	19	10248	11550	8630	6608	66658	908	16510	0	1	0	0	0	0	19	0	0	0	0	0	0	0	rs558386297	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.07219e-03	1.85545e-04	7.19282e-05	1.07219e-03	1.33999e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs558386297	558386297	.	.	.	SOS1	SOS1:exonic	SOS1:synonymous_SNV	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,463	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
21	36164618	36164618	C	T	T	synonymous_variant	LOW	RUNX1	861	Transcript	NM_001754.5	protein_coding	9/9	.	NM_001754.5:c.1257G>A	NP_001745.2:p.Val419%3D	1451	1257	419	V	gtG/gtA	rs1172332120	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36164618C>T	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	gain/acceptor/36164618-36164619/Medium/5.412196	.	.	9.279	7.470	.	.	.	-2	-10	3	43	0.00	0.00	0.01	0.00	RUNX1	0.45	exon-NM_001754.5-9+289+end+4810	436611	Uncertain_significance	reviewed_by_expert_panel	not_specified&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN169374&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	21:36164618-36164618	0.00000e+00	1.65358e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.47225e-05	2.93290e-05	1.65358e-04	3.30232e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1172332120	1172332120	.	.	.	RUNX1	RUNX1:exonic	RUNX1:synonymous_SNV	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,948	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
2	39241061	39241061	C	G	G	missense_variant	MODERATE	SOS1	6654	Transcript	NM_005633.4	protein_coding	12/23	.	NM_005633.4:c.2010G>C	NP_005624.2:p.Leu670Phe	2639	2010	670	L/F	ttG/ttC	rs200712930	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	SOS1	.	chr2:g.39241061C>G	.	0	0	0.001	0	0	benign	.	1	.	.	.	.	.	.	.	.	1	1.9968051118210862E-4	0	0.0	0	0.0	1	9.92063492063492E-4	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	C/C	C	T	0.03252	-0.377042	T	0.35664	-0.380491	17.88	19.78	1.819777	2.006050	0.27179	0.33068	C/C	T	0.10385	0.0831542542090348	0.80248	0.99695798265404512	.	0.72972	.	C/C	.	.	.	.	1.557702	-0.303107093309731	0.27998	1.482164	-0.355576639465632	0.27067	.	.	.	9	7.414e-05	0	0	0	0	9	7.472e-05	9	1.050e-03	0	0	0	0	0	0	9	8.475e-05	0	0	0	0	9	8.538e-05	9	1.154e-03	0	0	0	0	0	0	2	2.204e-05	0	0	0	0	2	2.224e-05	2	3.597e-04	0	0	0	0	0	0	0.31987	.	.	.	5.82	2.68	0.30839	0	0.12157	0.546412	.	.	0.17308	0.143014786682524	.	0	0.50148	0.65145	.	.	.	.	.	.	0	0.41899	0.613276	Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal&Ras-like_guanine_nucleotide_exchange_factor&_N-terminal	.	.	.	0.66280	.	0.102684	0.49741	N	0.000124	T	0.26893	0.010405	0.58006	.	0.56026	.	T	0.32207	0.0817	.	0.04540	.	T	0.04824	-1.0945	.	.	.	.	.	.	0.47900	.	.	0.54805	simple_aae&simple_aae&simple_aae	D&D&D	0.999986&0.999986&0.999986	0.35792	.	.	.	0.30770	.	.	0.41729	.	T	0.36046	0.479923963547	0.33359	.	10	0.13634	.	.	0.33091	.	.	11.2914	0.48487	0.4216:0.4895:0.0888:0.0	.	.	.	.	.	.	.	.	0.45520	.	C/C	F	.	L	G	470	0.78111	.	2	CN166718	.	ORPHA536391	Benign	NC_000002.12:g.39013920C>G	448942	reviewed_by_expert_panel	Rasopathy	ClinGen_RASopathy_Variant_Curation_Expert_Panel:42ea487d-ec44-44f7-a90a-ac98312de0f1	.	.	AEFBCI	N	0.22414	0.24505	N	0.18974	0.093796	.	19	7.589620e-05	0	0.000000e+00	16216	0	0	0.000000e+00	34508	0	250342	0	0.000000e+00	10050	0	19	1.034630e-03	18364	0	0	0.000000e+00	21472	0	0	0.000000e+00	113056	0	19	1.034630e-03	18364	0	0	0.000000e+00	30594	0	9	8.246890e-05	0	0.000000e+00	7154	0	0	0.000000e+00	17084	0	109132	0	0.000000e+00	2316	0	9	9.968990e-04	9028	0	0	0.000000e+00	13246	0	0	0.000000e+00	42716	0	9	9.968990e-04	9028	0	0	0.000000e+00	15686	0	0	.	0	19	8.056170e-05	0	0.000000e+00	14864	0	0	0.000000e+00	34178	0	235844	0	0.000000e+00	9544	0	19	1.075760e-03	17662	0	0	0.000000e+00	21456	0	0	0.000000e+00	102072	0	19	1.075760e-03	17662	0	0	0.000000e+00	30504	0	0	8	3.853820e-05	0	0.000000e+00	16178	0	0	0.000000e+00	30444	0	207586	0	0.000000e+00	6204	0	8	5.976390e-04	13386	0	0	0.000000e+00	16560	0	0	0.000000e+00	89396	0	8	5.976390e-04	13386	0	0	0.000000e+00	30586	0	0	19	7.795580e-05	0	0.000000e+00	11988	0	0	0.000000e+00	34374	0	243728	0	0.000000e+00	9968	0	19	1.034860e-03	18360	0	0	0.000000e+00	21470	0	0	0.000000e+00	110966	0	19	1.034860e-03	18360	0	0	0.000000e+00	30594	0	0	1	6.575750e-06	0	0.000000e+00	41424	0	0	0.000000e+00	912	0	0	0.000000e+00	15244	0	152074	0	0.000000e+00	3468	0	1	1.922340e-04	5202	0	0	0.000000e+00	10614	0	0	0.000000e+00	316	0	0	0.000000e+00	67980	0	1	1.922340e-04	5202	0	0	0.000000e+00	4824	0	1	3.042660e-05	0	0.000000e+00	9082	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32866	0	0.000000e+00	136	0	1	4.115230e-04	2430	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	0	0.000000e+00	6838	0	0	0.000000e+00	3112	0	0	.	0	1	6.764440e-06	0	0.000000e+00	41102	0	0	0.000000e+00	912	0	0	0.000000e+00	15056	0	147832	0	0.000000e+00	3300	0	1	2.013690e-04	4966	0	0	0.000000e+00	10614	0	0	0.000000e+00	304	0	0	0.000000e+00	64766	0	0	0.000000e+00	4792	0	0	1	7.425340e-06	0	0.000000e+00	32450	0	0	0.000000e+00	862	0	0	0.000000e+00	14800	0	134674	0	0.000000e+00	3384	0	1	1.922340e-04	5202	0	0	0.000000e+00	6974	0	0	0.000000e+00	310	0	0	0.000000e+00	63870	0	0	0.000000e+00	4822	0	0	1	1.239770e-05	0	0.000000e+00	24802	0	0	0.000000e+00	112	0	0	0.000000e+00	12870	0	80660	0	0.000000e+00	996	0	1	2.658160e-04	3762	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	0	0.000000e+00	21012	0	0	0.000000e+00	4796	0	0	2	39094565	2	39241061	0	0.61202	0.706298	0.584000	0.27618	0.986000	0.61781	0.997000	0.62031	-0.141000	0.10308	0.599000	0.40250	1.026000	0.45946	39013920	C	.	rs200712930	.	.	5.791	8.994	8.946	6.426	.	.	.	-3	40	-3	-50	0.00	0.00	0.00	0.00	SOS1	1.00	exon-NM_001382394.1-12+53+start+123	448942	Benign	reviewed_by_expert_panel	RASopathy	MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	2:39241061-39241061	7.414e-05	9	9	0	0	0	9	0	0	0	0	10272	11422	8572	6550	66276	900	16464	0	0	9	0	0	0	0	0	0	0	0	0	0	0	rs200712930	0.00000e+00	0.00000e+00	0.00000e+00	9.29152e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	4.46741e-05	9.02397e-05	9.29152e-04	6.49762e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs200712930	200712930	.	.	.	SOS1	SOS1:exonic	SOS1:missense	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,465	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0.3246	VUS
19	4123828	4123828	G	A	A	synonymous_variant	LOW	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	1/11	.	NM_030662.4:c.45C>T	NP_109587.1:p.Asn15%3D	292	45	15	N	aaC/aaT	rs767770776	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	MAP2K2	.	chr19:g.4123828G>A	.	.	.	.	.	.	likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.148	8.492	.	.	.	.	.	-16	-33	-47	-25	0.00	0.00	0.00	0.00	MAP2K2	0.86	exon-NM_030662.4-1+47+start+339	448954	Likely_benign	reviewed_by_expert_panel	RASopathy	MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	19:4123828-4123828	5.105e-05	6	6	0	0	0	0	0	0	0	6	2998	1720	3078	534	19744	284	8856	0	0	0	0	0	0	6	0	0	0	0	0	0	0	rs767770776	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	4.64096e-04	7.22514e-05	5.30012e-05	4.64096e-04	8.59479e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs767770776	767770776	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:synonymous_SNV	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,942	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
2	39249799	39249799	C	T	T	synonymous_variant	LOW	SOS1	6654	Transcript	NM_005633.4	protein_coding	10/23	.	NM_005633.4:c.1770G>A	NP_005624.2:p.Glu590%3D	2399	1770	590	E	gaG/gaA	rs553331572&COSV67675324	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	SOS1	.	chr2:g.39249799C>T	.	0	0	0	0	0.001	benign&likely_benign	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.722	10.766	9.509	5.367	.	.	.	42	34	15	-15	0.00	0.00	0.00	0.00	SOS1	1.00	exon-NM_001382394.1-10+88+start+656	40687	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&not_specified&RASopathy&not_provided	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN517202	.	2:39249799-39249799	2.883e-04	35	35	0	0	0	34	0	0	0	1	10368	11532	8634	6606	66650	908	16496	0	0	34	0	0	0	1	0	0	0	0	0	0	0	rs553331572	0.00000e+00	0.00000e+00	0.00000e+00	3.82964e-03	0.00000e+00	0.00000e+00	1.83016e-04	9.74976e-05	2.67853e-04	3.06411e-04	3.82964e-03	2.84252e-04	rs553331572	0.00000e+00	0.00000e+00	0.00000e+00	4.32633e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	2.34247e-04	2.16951e-04	4.32633e-03	2.25908e-04	.	.	rs553331572	553331572	.	.	.	SOS1	SOS1:exonic	SOS1:synonymous_SNV	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,466	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
2	39249922	39249922	T	C	C	synonymous_variant	LOW	SOS1	6654	Transcript	NM_005633.4	protein_coding	10/23	.	NM_005633.4:c.1647A>G	NP_005624.2:p.Thr549%3D	2276	1647	549	T	acA/acG	rs139683425	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	SOS1	.	chr2:g.39249922T>C	.	.	.	.	.	.	benign&likely_benign	.	1	.	.	.	.	.	SOS1&NM_005633.3&c.1647A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.722	10.766	9.509	5.367	.	.	.	28	11	5	24	0.00	0.00	0.00	0.00	SOS1	1.00	exon-NM_001382394.1-10+211+start+656	139236	Likely_benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&RASopathy&Fibromatosis&_gingival&_1&Noonan_syndrome_4	MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0007609&MedGen:C4551558&OMIM:135300&Orphanet:2024&MONDO:MONDO:0012547&MedGen:C1853120&OMIM:610733&Orphanet:648	.	rs139683425	4.942e-05	6	6	0	6	0	0	0	0	0	0	10398	11542	8636	6598	66700	906	16500	6	0	0	0	0	0	0	0	0	0	0	0	0	0	rs139683425	4.57636e-04	5.96019e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.22985e-05	5.40219e-05	4.57636e-04	3.65482e-05	rs139683425	3.43643e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	1.75500e-04	0.00000e+00	3.43643e-04	9.68117e-05	rs139683425	0.0&0.0681&0.0231	rs139683425	139683425	.	.	.	SOS1	SOS1:exonic	SOS1:synonymous_SNV	SOS1:Noonan_syndrome_4\x3b?Fibromatosis\x2cgingival\x2c1	SOS1:610733\x3b135300	SOS1:3\x3b3	SOS1:Autosomal_dominant\x3bAutosomal_dominant	0	0.99999989519361	1.04806389809942e-07	1.77231495230296e-20	DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS4 have polyarticular villonodular synovitis. {ECO:0000269|PubMed:17143282, ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,467	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
19	4099305	4099305	G	A	A	synonymous_variant	LOW	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	7/11	.	NM_030662.4:c.813C>T	NP_109587.1:p.Asp271%3D	1060	813	271	D	gaC/gaT	rs201726622	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	MAP2K2	.	chr19:g.4099305G>A	.	.	.	.	.	.	benign&likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.559	8.532	6.943	7.389	.	.	.	-8	35	22	-29	0.00	0.00	0.01	0.00	MAP2K2	0.86	exon-NM_030662.4-7+106+start+214	378108	Likely_benign	reviewed_by_expert_panel	not_provided&RASopathy&Cardiovascular_phenotype	MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN230736	.	19:4099305-4099305	6.612e-05	8	0	0	0	1	0	0	5	0	0	6188	7096	5916	3312	43152	586	12930	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs201726622	0.00000e+00	3.09809e-05	0.00000e+00	6.08051e-05	4.76190e-05	9.66146e-05	0.00000e+00	3.39536e-05	6.29218e-05	5.78704e-05	9.66146e-05	7.31178e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs201726622	201726622	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:synonymous_SNV	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,929	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
19	4099195	4099195	G	A	A	splice_donor_region_variant&intron_variant	LOW	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	.	7/10	NM_030662.4:c.919+4C>T	.	.	.	.	.	.	rs763424788	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	MAP2K2	.	chr19:g.4099195G>A	.	.	.	.	.	.	conflicting_interpretations_of_pathogenicity&likely_benign	.	1	.	.	.	.	.	.	2.42683163795626E-4	0.024	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.559	6.363	6.943	8.532	7.672	0.860	8.532	-36	26	7	4	0.00	0.00	0.00	0.02	MAP2K2	0.86	.	40834	Likely_benign	reviewed_by_expert_panel	not_provided&Cardiofaciocutaneous_syndrome_4&not_specified&RASopathy	MedGen:CN517202&MONDO:MONDO:0014114&MedGen:C3809007&OMIM:615280&Orphanet:1340&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	19:4099195-4099195	4.196e-05	5	3	0	1	0	0	0	1	0	1	5530	6838	5718	2504	38910	504	12646	1	0	0	0	1	0	1	0	0	0	0	0	0	0	rs763424788	8.32085e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.39754e-05	0.00000e+00	3.50754e-05	4.22162e-05	4.20867e-05	8.32085e-05	2.68828e-04	rs763424788	1.14837e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.67557e-05	0.00000e+00	.	1.17082e-04	0.00000e+00	1.14837e-04	6.45369e-05	.	.	rs763424788	763424788	.	.	.	MAP2K2	MAP2K2:splicing\x3bintronic	MAP2K2:splice_donor_region_variant	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,925	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
14	31348684	31348684	A	G	G	synonymous_variant	LOW	COCH	1690	Transcript	NM_004086.3	protein_coding	6/12	.	NM_004086.3:c.429A>G	NP_004077.1:p.Pro143%3D	485	429	143	P	ccA/ccG	rs147841606	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	COCH	.	chr14:g.31348684A>G	.	0.0023	0	0	0	0	benign&likely_benign	.	1	.	.	.	.	.	COCH&NM_004086.2&c.429A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.464	9.459	7.050	4.336	.	.	.	7	-42	11	7	0.00	0.00	0.00	0.00	COCH	0.00	exon-NM_001347720.2-5+7+end+63	227258	Benign	reviewed_by_expert_panel	not_specified&not_provided&Nonsyndromic_genetic_hearing_loss&Autosomal_dominant_nonsyndromic_hearing_loss_9	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0011058&MedGen:C1832425&OMIM:601369&Orphanet:90635	.	rs147841606	1.153e-04	14	14	0	11	3	0	0	0	0	0	10382	11564	8650	6614	66682	906	16502	11	3	0	0	0	0	0	0	0	0	0	0	0	0	rs147841606	1.50307e-03	2.97796e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.03782e-04	1.70630e-04	1.50307e-03	1.33998e-04	rs147841606	2.40715e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.01833e-03	.	9.34579e-04	4.33025e-04	2.40715e-03	7.09861e-04	rs147841606	0.0116&0.1135&0.0461	rs147841606	147841606	.	.	.	COCH\x3bLOC100506071	COCH:exonic\x7cLOC100506071:ncRNA_intronic	COCH:synonymous_SNV	COCH:Deafness\x2cautosomal_dominant_9\x3b?Deafness\x2cautosomal_recessive_110	COCH:601369\x3b618094	COCH:3\x3b3	COCH:Autosomal_dominant\x3bAutosomal_recessive	0	0.000262849456488043	0.983542807336405	0.0161943432071074	DISEASE: Deafness, autosomal dominant, 9 (DFNA9) [MIM:601369]: A form of non-syndromic hearing loss characterized by onset in the fourth or fifth decade of life and initially involves the high frequencies. Hearing loss is progressive and usually complete by the sixth decade. In addition to cochlear involvement, DFNA9 patients also exhibit a spectrum of vestibular dysfunctions. Penetrance of the vestibular symptoms is often incomplete, and some patients are minimally affected, whereas others suffer from severe balance disturbances and episodes of vertigo. Affected individuals have mucopolysaccharide depositions in the channels of the cochlear and vestibular nerves. These depositions apparently cause strangulation and degeneration of dendritic fibers. {ECO:0000269|PubMed:10400989, ECO:0000269|PubMed:11295836, ECO:0000269|PubMed:14512963, ECO:0000269|PubMed:16835921, ECO:0000269|PubMed:17561763, ECO:0000269|PubMed:18312449, ECO:0000269|PubMed:22610276, ECO:0000269|PubMed:22931125, ECO:0000269|PubMed:23993205, ECO:0000269|PubMed:9806553, ECO:0000269|PubMed:9931344}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,881	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
16	68863674	68863674	G	A	A	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	15/16	.	NM_004360.5:c.2413G>A	NP_004351.1:p.Asp805Asn	2537	2413	805	D/N	Gat/Aat	rs200894246&CM130989	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68863674G>A	.	.	.	.	.	.	conflicting_interpretations_of_pathogenicity&likely_benign&benign	.	1&1	.	.	.	.	.	CDH1&NM_004360.3&c.2413G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.594706798131811E-4	.	.	.	.	.	.	.	G/G	G	T	0.14069	-0.250242	T	0.46695	-0.281076	28.5	32	4.183092	4.482800	0.84912	0.91711	G/G	T	0.19857	0.190213886946162	0.99387	0.99931816581234734	.	0.68568	.	G/G	0	0.0	4	4.6511627906976747E-4	8.814966	0.750625662291031	0.86203	7.147059	0.702007155071255	0.79764	.	.	.	27	2.224e-04	0	0	3	2.600e-04	27	2.235e-04	0	0	0	0	24	3.614e-04	0	0	19	1.789e-04	0	0	2	1.789e-04	19	1.797e-04	0	0	0	0	17	3.140e-04	0	0	24	2.645e-04	0	0	3	2.602e-04	24	2.663e-04	0	0	0	0	21	5.023e-04	0	0	0.76561	.	.	.	6.05	6.05	0.98156	0	0.63936	0.670034	.	.	0.74766	0.999999999975795	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.14980	0.542086	Cadherin&_cytoplasmic_domain&Cadherin&_cytoplasmic_domain&.	.	.	.	0.65631	.	0.000000	0.52346	D	0.000070	D	0.95617	0.533066	0.70269	.	0.93461	.	D	0.83170	0.5429	.	0.40294	.	T	0.76740	-0.2356	.	.	.	.	.	.	0.44655	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.56630	.	.	.	0.90584	.	.	0.97372	.	T	0.58660	0.640676021576	0.69273	.	10	0.36630	.	.	0.39820	.	.	20.1981	0.98247	0.0:0.0:1.0:0.0	.	1	2.6968716289104636E-4	2	2.644802962179318E-4	.	.	.	0.55799	.	G/G	N	.	D	A	358	0.85037	.	16	C0006142&C1708349&C0027672&CN169374&CN221562&CN517202	137215	ORPHA26106&ORPHA140162	Benign	NC_000016.10:g.68829771G>A	127925	reviewed_by_expert_panel	Malignant_tumor_of_breast&Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&Breast_and/or_ovarian_cancer&not_provided	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2567743&Illumina_Laboratory_Services&Illumina:809303&ClinGen_CDH1_Variant_Curation_Expert_Panel&:8f3f955a-56d1-4528-83ec-f23b19eb3126	.	.	AEFDBI	D	0.88541	0.98913	D	0.96929	0.953199	.	60	2.387810e-04	0	0.000000e+00	16240	0	14	4.049050e-04	34576	0	251276	20	1.984520e-03	10078	0	0	0.000000e+00	18366	0	0	0.000000e+00	21616	0	24	2.111520e-04	113662	0	14	4.049050e-04	34576	0	1	3.267550e-05	30604	0	18	1.647270e-04	0	0.000000e+00	7152	0	6	3.509590e-04	17096	0	109272	4	1.724140e-03	2320	0	0	0.000000e+00	9020	0	0	0.000000e+00	13362	0	7	1.638190e-04	42730	0	6	3.509590e-04	17096	0	1	6.378360e-05	15678	0	0	.	0	52	2.196340e-04	0	0.000000e+00	14886	0	13	3.796290e-04	34244	0	236758	19	1.985370e-03	9570	0	0	0.000000e+00	17666	0	0	0.000000e+00	21600	0	18	1.753330e-04	102662	0	13	3.796290e-04	34244	0	1	3.277180e-05	30514	0	0	44	2.115750e-04	0	0.000000e+00	16202	0	11	3.605610e-04	30508	0	207964	14	2.254430e-03	6210	0	0	0.000000e+00	13388	0	0	0.000000e+00	16702	0	17	1.899530e-04	89496	0	11	3.605610e-04	30508	0	1	3.268400e-05	30596	0	0	59	2.411470e-04	0	0.000000e+00	12010	0	14	4.064800e-04	34442	0	244664	20	2.000400e-03	9998	0	0	0.000000e+00	18362	0	0	0.000000e+00	21614	0	23	2.061380e-04	111576	0	14	4.064800e-04	34442	0	1	3.267550e-05	30604	0	0	39	2.567650e-04	2	4.836760e-05	41350	0	0	0.000000e+00	912	0	9	5.907060e-04	15236	0	151890	6	1.730100e-03	3468	0	0	0.000000e+00	5172	0	0	0.000000e+00	10562	0	0	0.000000e+00	316	0	20	2.941610e-04	67990	0	9	5.907060e-04	15236	0	1	2.080730e-04	4806	0	3	9.151360e-05	1	1.103270e-04	9064	0	0	0.000000e+00	60	0	1	2.138580e-04	4676	0	32782	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5452	0	0	0.000000e+00	246	0	1	1.460710e-04	6846	0	0	0.000000e+00	3098	0	0	.	0	38	2.573760e-04	2	4.874720e-05	41028	0	0	0.000000e+00	912	0	8	5.316320e-04	15048	0	147644	6	1.818180e-03	3300	0	0	0.000000e+00	4938	0	0	0.000000e+00	10562	0	0	0.000000e+00	304	0	20	3.087940e-04	64768	0	1	2.094680e-04	4774	0	0	38	2.824940e-04	2	6.173980e-05	32394	0	0	0.000000e+00	862	0	9	6.085190e-04	14790	0	134516	6	1.773050e-03	3384	0	0	0.000000e+00	5172	0	0	0.000000e+00	6934	0	0	0.000000e+00	310	0	19	2.974420e-04	63878	0	1	2.081600e-04	4804	0	0	18	2.236750e-04	2	8.086690e-05	24732	0	0	0.000000e+00	112	0	7	5.441540e-04	12864	0	80474	2	2.012070e-03	994	0	0	0.000000e+00	3730	0	0	0.000000e+00	10470	0	0	0.000000e+00	272	0	5	2.378910e-04	21018	0	1	2.092930e-04	4778	0	0	16	67421175	16	68863674	0	0.52595	0.67177	1.000000	0.71638	0.992000	0.67800	0.942000	0.40953	5.804000	0.68800	0.665000	0.62972	1.166000	0.72058	68829771	G	.	rs200894246	.	.	10.931	9.815	9.586	8.564	.	.	.	-1	1	-26	30	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_001317185.2-15+26+end+144	127925	Benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Breast_and/or_ovarian_cancer&not_specified&not_provided&Hereditary_diffuse_gastric_adenocarcinoma&Malignant_tumor_of_breast	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN221562&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0007254&MedGen:C0006142	.	16:68863674-68863674	2.224e-04	27	27	0	0	3	0	0	24	0	0	10298	11540	8544	6598	66406	908	16486	0	3	0	0	24	0	0	0	0	0	0	0	0	0	rs200894246	0.00000e+00	3.87297e-04	2.03087e-03	0.00000e+00	0.00000e+00	1.97097e-04	3.64697e-04	3.24992e-05	1.70600e-04	3.14601e-04	2.03087e-03	2.39573e-04	rs200894246	0.00000e+00	0.00000e+00	3.33333e-03	0.00000e+00	0.00000e+00	2.67308e-04	0.00000e+00	.	2.92843e-04	0.00000e+00	3.33333e-03	1.61332e-04	rs200894246	0.0465&0.0&0.0308	rs200894246	200894246	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,920	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
16	68863657	68863657	C	G	G	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	15/16	.	NM_004360.5:c.2396C>G	NP_004351.1:p.Pro799Arg	2520	2396	799	P/R	cCc/cGc	rs587781335&CM041267&COSV99931151	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	.	chr16:g.68863657C>G	.	.	.	.	.	.	uncertain_significance	0&0&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.2396C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.87029	0.35712	D	0.86860	0.275201	25.2	28.9	3.634646	4.136421	0.67599	0.86664	C/C	D	0.75791	0.984506070613861	0.94276	0.99864082881161298	.	0.82768	.	C/C	.	.	.	.	8.878878	0.753332552598487	0.86405	7.826426	0.746782708551985	0.82693	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.77466	.	.	.	6.05	6.05	0.98156	0	0.63936	0.670034	.	.	0.74766	0.999999999626443	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.14980	0.542086	Cadherin&_cytoplasmic_domain&Cadherin&_cytoplasmic_domain&.	.	.	.	0.59551	.	0.000000	0.50451	D	0.000114	D	0.83534	0.154196	0.71832	.	0.95819	.	D	0.86485	0.6171	.	0.93724	.	T	0.81622	-0.0304	P799R	Loss_of_glycosylation_at_P799_(P_=_0.0419)&_Gain_of_solvent_accessibility_(P_=_0.1045)&_Loss_of_disorder_(P_=_0.1589)&_Gain_of_MoRF_binding_(P_=_0.1996)&_Loss_of_loop_(P_=_0.2237)	P12830	0.94104	0.832	.	0.59329	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.89833	.	.	.	0.77913	.	.	0.75477	.	T	0.56796	0.6275370121	0.90191	.	10	0.49390	.	.	0.49613	.	.	20.1981	0.98247	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.85872	.	C/C	R	.	P	G	358	0.85037	.	16	C1708349&C0027672&C0346153	137215&114480	ORPHA26106&ORPHA140162&ORPHA227535	Uncertain_significance	NC_000016.10:g.68829754C>G	140871	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&Familial_cancer_of_breast	Institute_of_Human_Genetics&_University_of_Leipzig_Medical_Center:CV_varv_296&ClinGen_CDH1_Variant_Curation_Expert_Panel&:adcfd805-c238-4e80-b9ad-f6fa541ab04d	.	.	AEFDBI	D	0.84855	0.98626	D	0.82932	0.892410	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	67421158	16	68863657	0	0.52595	0.67177	1.000000	0.71638	0.847000	0.40026	0.941000	0.40850	6.021000	0.70485	0.589000	0.31548	1.018000	0.39106	68829754	C	.	rs587781335	.	.	10.931	9.815	9.586	8.564	.	.	.	-17	16	43	-9	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_001317185.2-15+43+end+144	140871	Uncertain_significance	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Hereditary_diffuse_gastric_adenocarcinoma&Familial_cancer_of_breast	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587781335	587781335	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,919	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
16	68862157	68862157	C	T	T	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	14/16	.	NM_004360.5:c.2245C>T	NP_004351.1:p.Arg749Trp	2369	2245	749	R/W	Cgg/Tgg	rs776975632&CM072929&COSV55728026&COSV99931786	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	.	chr16:g.68862157C>T	.	.	.	.	.	.	uncertain_significance	0&0&1&1	1&1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.2245C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.91253	0.424499	D	0.91144	0.371987	26.5	32	3.929873	4.421961	0.76244	0.91308	C/C	D	0.99782	0.999937891960144	0.99279	0.99929726826949195	.	0.88975	.	C/C	.	.	.	.	6.375037	0.611856811949504	0.75798	7.498661	0.726007086888959	0.81337	.	.	.	1	8.236e-06	1	9.614e-05	0	0	1	8.237e-06	0	0	0	0	0	0	0	0	1	9.415e-06	1	1.104e-04	0	0	1	9.416e-06	0	0	0	0	0	0	0	0	1	1.102e-05	1	9.630e-05	0	0	1	1.102e-05	0	0	0	0	0	0	0	0	0.84415	.	.	.	6.07	5.1	0.68917	0	0.63936	0.670034	.	.	0.28051	0.953040410838241	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.10902	0.530356	Cadherin&_cytoplasmic_domain&Cadherin&_cytoplasmic_domain&.	.	.	.	0.81134	.	0.000000	0.45440	D	0.000356	D	0.87406	0.213445	0.71571	.	0.97087	.	D	0.94447	0.8342	.	0.95181	.	D	0.95540	0.8903	R749W	Loss_of_disorder_(P_=_0.0048)&_Loss_of_glycosylation_at_T748_(P_=_0.0555)&_Loss_of_phosphorylation_at_T748_(P_=_0.0901)&_Loss_of_loop_(P_=_0.1242)&_Gain_of_helix_(P_=_0.2059)	P12830	0.95773	0.86	.	0.96783	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.95074	.	.	.	0.90584	.	.	0.97372	.	T	0.79067	0.780924022198	0.91795	.	10	0.92824	.	.	0.91255	.	.	16.4989	0.84097	0.1314:0.8686:0.0:0.0	.	.	.	.	.	.	.	.	0.92550	.	C/C	W	.	R	T	356	0.85138	.	16	C0006142&C1708349&C0027672&CN517202	137215	ORPHA26106&ORPHA140162	Uncertain_significance	NC_000016.10:g.68828254C>T	418841	reviewed_by_expert_panel	Malignant_tumor_of_breast&Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:c46e3e12-7172-498b-86a7-d9cd9f01bbee&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2846009	.	.	AEFBCI	D	0.34530	0.70291	D	0.93314	0.936595	.	1	3.976490e-06	1	6.151570e-05	16256	0	0	0.000000e+00	34592	0	251478	0	0.000000e+00	10078	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	0	0.000000e+00	113754	0	1	6.151570e-05	16256	0	0	0.000000e+00	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	1	4.220480e-06	1	6.710510e-05	14902	0	0	0.000000e+00	34260	0	236940	0	0.000000e+00	9570	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	0	0.000000e+00	102738	0	1	6.710510e-05	14902	0	0	0.000000e+00	30526	0	0	1	4.804640e-06	1	6.165990e-05	16218	0	0	0.000000e+00	30524	0	208132	0	0.000000e+00	6210	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89556	0	1	6.165990e-05	16218	0	0	0.000000e+00	30608	0	0	1	4.083970e-06	1	8.315320e-05	12026	0	0	0.000000e+00	34458	0	244860	0	0.000000e+00	9996	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	0	0.000000e+00	111664	0	1	8.315320e-05	12026	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	67419658	16	68862157	0	0.52595	0.67177	0.951000	0.33123	0.990000	0.65344	0.999000	0.70432	1.285000	0.32866	0.599000	0.40250	1.000000	0.36871	68828254	C	.	rs776975632	.	.	9.586	8.564	6.421	8.065	.	.	.	-11	-46	48	50	0.00	0.01	0.00	0.00	CDH1	0.34	exon-NM_001317185.2-14+50+end+131	418841	Uncertain_significance	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Hereditary_diffuse_gastric_adenocarcinoma&not_provided&Malignant_tumor_of_breast	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MedGen:CN517202&MONDO:MONDO:0007254&MedGen:C0006142	.	16:68862157-68862157	8.236e-06	1	1	0	1	0	0	0	0	0	0	10402	11578	8654	6614	66740	908	16512	1	0	0	0	0	0	0	0	0	0	0	0	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs776975632	776975632	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,917	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
16	68849506	68849506	C	T	T	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	10/16	.	NM_004360.5:c.1409C>T	NP_004351.1:p.Thr470Ile	1533	1409	470	T/I	aCa/aTa	rs370864592&CM1312281	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	.	chr16:g.68849506C>T	.	.	.	.	.	.	benign&likely_benign&benign/likely_benign	.	1&1	.	.	.	.	.	CDH1&NM_004360.3&c.1409C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	T	0.57709	0.0451	D	0.76340	0.0914349	25.6	27.0	3.750048	3.913633	0.70745	0.79269	C/C	D	0.71186	0.976004540920258	0.97502	0.999037675900871	.	0.83697	.	C/C	.	.	.	.	10.7083	0.818955337374915	0.91078	10.19449	0.86539063989981	0.89966	.	.	.	4	3.295e-05	0	0	0	0	4	3.295e-05	3	3.467e-04	0	0	1	1.498e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4	4.408e-05	0	0	0	0	4	4.408e-05	3	5.321e-04	0	0	1	2.373e-05	0	0	0.58176	.	.	.	5.7	5.7	0.88690	0	0.55848	0.633656	.	.	0.74766	0.999999998905142	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.26826	0.564101	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&.	.	.	.	0.91515	.	0.000000	0.50451	D	0.000113	D	0.77693	0.103089	0.69310	.	0.90707	.	T	0.75964	0.4114	.	0.59436	.	T	0.79021	-0.1458	.	.	.	.	.	.	0.85499	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.85692	.	.	.	0.90584	.	.	0.97372	.	T	0.36971	0.486620903015	0.78350	.	10	0.83351	.	.	0.91255	.	.	19.433	0.94771	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.70790	.	C/C	I	.	T	T	317	0.87119	.	16	C0677776&C1708349&C0027672&CN169374&CN517202	PS604370&137215	ORPHA145&ORPHA26106&ORPHA140162	Benign	NC_000016.10:g.68815603C>T	127913	reviewed_by_expert_panel	Hereditary_breast_and_ovarian_cancer_syndrome&Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:1149db17-78d8-4b2c-bbd4-e5f6b193a1eb&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2832707&UniProtKB_(protein):P12830#VAR_001315	.	.	AEFDBI	D	0.90931	0.99080	D	0.97121	0.954255	.	6	2.385800e-05	1	6.151570e-05	16256	0	1	2.890840e-05	34592	0	251488	0	0.000000e+00	10080	0	2	1.087310e-04	18394	0	0	0.000000e+00	21648	0	0	0.000000e+00	113762	0	2	1.087310e-04	18394	0	0	0.000000e+00	30616	0	1	9.140100e-06	0	0.000000e+00	7164	0	1	5.843850e-05	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	1	5.843850e-05	17112	0	0	0.000000e+00	15690	0	0	.	0	4	1.688120e-05	1	6.710510e-05	14902	0	1	2.918860e-05	34260	0	236950	0	0.000000e+00	9572	0	1	5.652270e-05	17692	0	0	0.000000e+00	21632	0	0	0.000000e+00	102746	0	1	6.710510e-05	14902	0	0	0.000000e+00	30526	0	0	5	2.402300e-05	1	6.165990e-05	16218	0	1	3.276110e-05	30524	0	208134	0	0.000000e+00	6212	0	1	7.453790e-05	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89556	0	1	7.453790e-05	13416	0	0	0.000000e+00	30608	0	0	6	2.450280e-05	1	8.315320e-05	12026	0	1	2.902080e-05	34458	0	244870	0	0.000000e+00	9998	0	2	1.087550e-04	18390	0	0	0.000000e+00	21646	0	0	0.000000e+00	111672	0	2	1.087550e-04	18390	0	0	0.000000e+00	30616	0	0	16	1.050970e-04	10	2.411960e-04	41460	0	0	0.000000e+00	912	0	2	1.308220e-04	15288	0	152240	0	0.000000e+00	3472	0	2	3.846150e-04	5200	0	0	0.000000e+00	10624	0	0	0.000000e+00	316	0	0	0.000000e+00	68046	0	2	3.846150e-04	5200	0	0	0.000000e+00	4832	0	4	1.215810e-04	2	2.198770e-04	9096	0	0	0.000000e+00	60	0	2	4.266210e-04	4688	0	32900	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5496	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3110	0	0	.	0	16	1.081200e-04	10	2.430840e-04	41138	0	0	0.000000e+00	912	0	2	1.324500e-04	15100	0	147984	0	0.000000e+00	3302	0	2	4.027390e-04	4966	0	0	0.000000e+00	10624	0	0	0.000000e+00	304	0	0	0.000000e+00	64818	0	0	0.000000e+00	4800	0	0	14	1.038440e-04	8	2.463050e-04	32480	0	0	0.000000e+00	862	0	2	1.347530e-04	14842	0	134818	0	0.000000e+00	3388	0	2	3.846150e-04	5200	0	0	0.000000e+00	6986	0	0	0.000000e+00	310	0	0	0.000000e+00	63920	0	0	0.000000e+00	4830	0	0	9	1.113920e-04	6	2.415850e-04	24836	0	0	0.000000e+00	112	0	2	1.548710e-04	12914	0	80796	0	0.000000e+00	998	0	1	2.660990e-04	3758	0	0	0.000000e+00	10532	0	0	0.000000e+00	272	0	0	0.000000e+00	21054	0	0	0.000000e+00	4804	0	0	16	67407007	16	68849506	0	0.73137	0.706548	1.000000	0.71638	0.144000	0.20092	0.787000	0.33123	7.482000	0.80187	0.596000	0.33519	1.008000	0.37630	68815603	C	.	rs370864592	.	.	5.134	10.735	10.239	7.806	.	.	.	-42	3	28	3	0.00	0.25	0.00	0.00	CDH1	0.34	exon-NM_004360.5-10+88+start+245	127913	Benign	reviewed_by_expert_panel	not_specified&Hereditary_cancer-predisposing_syndrome&Familial_cancer_of_breast&Blepharocheilodontic_syndrome_1&Endometrial_carcinoma&Hereditary_diffuse_gastric_adenocarcinoma&Neoplasm_of_ovary&Malignant_tumor_of_prostate&Breast_and/or_ovarian_cancer&not_provided&Hereditary_breast_ovarian_cancer_syndrome	MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MONDO:MONDO:0054740&MedGen:C4551988&OMIM:119580&Orphanet:1997&Human_Phenotype_Ontology:HP:0012114&MONDO:MONDO:0002447&MedGen:C0476089&OMIM:608089&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267&OMIM:167000&Human_Phenotype_Ontology:HP:0012125&MONDO:MONDO:0008315&MedGen:C0376358&OMIM:176807&Orphanet:1331&MedGen:CN221562&MedGen:CN517202&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&OMIM:PS604370&Orphanet:145	.	16:68849506-68849506	3.295e-05	4	4	0	0	0	3	0	1	0	0	10406	11578	8654	6614	66740	908	16512	0	0	3	0	1	0	0	0	0	0	0	0	0	0	rs370864592	6.53424e-05	2.97779e-05	0.00000e+00	1.73933e-04	0.00000e+00	8.95159e-06	1.82282e-04	0.00000e+00	3.70634e-05	1.79598e-05	1.73933e-04	2.84239e-05	rs370864592	2.28938e-04	0.00000e+00	0.00000e+00	6.16523e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	0.00000e+00	2.16419e-04	6.16523e-04	9.67992e-05	.	.	rs370864592	370864592	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,911	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
16	68847303	68847303	T	C	C	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	9/16	.	NM_004360.5:c.1225T>C	NP_004351.1:p.Trp409Arg	1349	1225	409	W/R	Tgg/Cgg	rs587778176&CM041746	T	.	1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	TANGO6	.	chr16:g.68847303T>C	.	.	.	.	.	.	not_provided&likely_benign&uncertain_significance	.	1&1	.	.	.	.	.	CDH1&NM_004360.3&c.1225T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	T/T	T	D	0.74393	0.205356	D	0.82435	0.187654	26.1	24.4	3.862831	3.304768	0.74106	0.62139	T/T	D	0.95218	0.998809218406677	0.43025	0.98564582347208862	.	0.84971	.	T/T	.	.	.	.	4.859541	0.465521124373551	0.65721	5.517243	0.557581583192522	0.70546	.	.	.	4	3.295e-05	0	0	0	0	4	3.295e-05	0	0	0	0	4	5.993e-05	0	0	3	2.825e-05	0	0	0	0	3	2.825e-05	0	0	0	0	3	5.520e-05	0	0	4	4.408e-05	0	0	0	0	4	4.408e-05	0	0	0	0	4	9.492e-05	0	0	0.37230	.	.	.	6.04	6.04	0.98025	0	0.79440	0.708844	.	.	0.32456	0.991340176134808	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.26826	0.564101	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like	.	.	.	0.76326	.	0.000000	0.47681	D	0.000202	D	0.82308	0.140641	0.81226	.	0.89222	.	T	0.61589	0.2468	.	0.98723	.	T	0.65574	-0.5811	W409R	Loss_of_catalytic_residue_at_A408_(P_=_0.0165)&_Gain_of_disorder_(P_=_0.0283)&_Gain_of_phosphorylation_at_T406_(P_=_0.0657)&_Gain_of_glycosylation_at_P407_(P_=_0.0826)&_Gain_of_loop_(P_=_0.1069)	P12830	0.94478	0.838	.	0.95055	.	.	0.81001	simple_aae&without_aae	D&D	1&1	0.99878	.	.	.	0.90584	.	.	0.97372	.	T	0.60589	0.654241740704	0.81717	.	10	0.83351	.	.	0.91255	.	.	16.2378	0.82212	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.94077	.	T/T	R	.	W	C	315	0.87208	.	16	C0006142&C1708349&C0027672&CN169374&CN517202	137215	ORPHA26106&ORPHA140162	Likely_benign	NC_000016.10:g.68813400T>C	133855	reviewed_by_expert_panel	Malignant_tumor_of_breast&Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:26997937-9088-4611-9ef8-bd80077ed64c	.	.	AEFBI	D	0.83340	0.98491	D	0.73530	0.812620	.	5	1.988180e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34592	0	251486	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	5	4.395140e-05	113762	0	5	4.395140e-05	113762	0	0	0.000000e+00	30616	0	1	9.140100e-06	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	1	2.338200e-05	42768	0	1	2.338200e-05	42768	0	0	0.000000e+00	15690	0	0	.	0	4	1.688130e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236948	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	4	3.893100e-05	102746	0	4	3.893100e-05	102746	0	0	0.000000e+00	30526	0	0	5	2.402340e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208130	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	5	5.583220e-05	89554	0	5	5.583220e-05	89554	0	0	0.000000e+00	30608	0	0	5	2.041920e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244868	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	5	4.477400e-05	111672	0	5	4.477400e-05	111672	0	0	0.000000e+00	30616	0	0	4	2.630580e-05	0	0.000000e+00	41428	0	0	0.000000e+00	912	0	0	0.000000e+00	15254	0	152058	0	0.000000e+00	3472	0	0	0.000000e+00	5188	0	0	0.000000e+00	10572	0	0	0.000000e+00	316	0	4	5.880280e-05	68024	0	4	5.880280e-05	68024	0	0	0.000000e+00	4806	0	0	0.000000e+00	0	0.000000e+00	9096	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32840	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5458	0	0	0.000000e+00	246	0	0	0.000000e+00	6846	0	0	0.000000e+00	3096	0	0	.	0	3	2.029770e-05	0	0.000000e+00	41106	0	0	0.000000e+00	912	0	0	0.000000e+00	15066	0	147800	0	0.000000e+00	3302	0	0	0.000000e+00	4952	0	0	0.000000e+00	10572	0	0	0.000000e+00	304	0	3	4.629920e-05	64796	0	0	0.000000e+00	4774	0	0	4	2.970620e-05	0	0.000000e+00	32460	0	0	0.000000e+00	862	0	0	0.000000e+00	14808	0	134652	0	0.000000e+00	3388	0	0	0.000000e+00	5188	0	0	0.000000e+00	6936	0	0	0.000000e+00	310	0	4	6.259780e-05	63900	0	0	0.000000e+00	4804	0	0	1	1.240330e-05	0	0.000000e+00	24804	0	0	0.000000e+00	112	0	0	0.000000e+00	12880	0	80624	0	0.000000e+00	998	0	0	0.000000e+00	3746	0	0	0.000000e+00	10480	0	0	0.000000e+00	272	0	1	4.752400e-05	21042	0	0	0.000000e+00	4778	0	0	16	67404804	16	68847303	0	0.52595	0.67177	1.000000	0.71638	0.132000	0.19645	0.030000	0.15346	5.079000	0.64261	0.661000	0.55757	1.134000	0.58424	68813400	T	.	rs587778176	.	.	10.239	7.806	7.382	7.312	.	.	.	-2	-32	17	-2	0.03	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-9+87+start+183	133855	Likely_benign	reviewed_by_expert_panel	Blepharocheilodontic_syndrome_1&Endometrial_carcinoma&Hereditary_diffuse_gastric_adenocarcinoma&Familial_cancer_of_breast&Neoplasm_of_ovary&Malignant_tumor_of_prostate&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Malignant_tumor_of_breast	MONDO:MONDO:0054740&MedGen:C4551988&OMIM:119580&Orphanet:1997&Human_Phenotype_Ontology:HP:0012114&MONDO:MONDO:0002447&MedGen:C0476089&OMIM:608089&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267&OMIM:167000&Human_Phenotype_Ontology:HP:0012125&MONDO:MONDO:0008315&MedGen:C0376358&OMIM:176807&Orphanet:1331&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0007254&MedGen:C0006142	.	16:68847303-68847303	3.295e-05	4	4	0	0	0	0	0	4	0	0	10406	11578	8654	6614	66740	908	16512	0	0	0	0	4	0	0	0	0	0	0	0	0	0	rs587778176	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	4.47579e-05	0.00000e+00	0.00000e+00	2.22384e-05	1.79598e-05	4.47579e-05	2.03028e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587778176	587778176	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,908	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
16	68847213	68847213	C	T	T	splice_polypyrimidine_tract_variant&splice_region_variant&intron_variant	LOW	CDH1	999	Transcript	NM_004360.5	protein_coding	.	8/15	NM_004360.5:c.1138-3C>T	.	.	.	.	.	.	rs36103202	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	.	chr16:g.68847213C>T	.	0.0045	0	0	0	0	benign&benign/likely_benign&likely_benign	.	1	.	.	.	.	.	CDH1&NM_004360.3&c.1138-3C>T	0.0120887364008596	0.068	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.382	7.806	10.172	7.312	6.188	1.193	7.382	15	3	-33	14	0.00	0.01	0.00	0.00	CDH1	0.34	.	184346	Likely_benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Hereditary_diffuse_gastric_adenocarcinoma	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	rs36103202	1.483e-04	18	18	0	16	2	0	0	0	0	0	10404	11578	8654	6614	66734	908	16512	16	2	0	0	0	0	0	0	0	0	0	0	0	0	rs36103202	1.37219e-03	2.08445e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.70711e-05	2.06567e-04	1.37219e-03	1.13695e-04	rs36103202	9.16170e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	4.08926e-04	7.21501e-05	9.16170e-04	2.58131e-04	rs36103202	0.0&0.1592&0.0539	rs36103202	36103202	.	.	.	CDH1	CDH1:splicing\x3bintronic	CDH1:splice_region_variant\x3bsplice_polypyrimidine_tract_variant	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,906	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
16	68846166	68846166	G	A	A	splice_region_variant&synonymous_variant	LOW	CDH1	999	Transcript	NM_004360.5	protein_coding	8/16	.	NM_004360.5:c.1137G>A	NP_004351.1:p.Thr379%3D	1261	1137	379	T	acG/acA	rs587783050&CS060517&CS1516077&COSV55733400	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68846166G>A	.	.	.	.	.	.	pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.1137G>A	0.999805229560847	0.984	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.382	7.312	10.172	4.939	1.079	6.233	7.312	2	-3	37	0	0.00	0.00	0.02	0.33	CDH1	0.34	exon-NM_004360.5-8+0+end+129	156499	Pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&Gastric_cancer&_familial_diffuse&_and_cleft_lip_with_or_without_cleft_palate&Hereditary_diffuse_gastric_adenocarcinoma&Familial_cancer_of_breast	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MedGen:CN069672&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587783050	587783050	.	.	.	CDH1	CDH1:splicing\x3bexonic	CDH1:splice_region_variant\x3bsynonymous_SNV	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,905	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
16	68846147	68846147	C	T	T	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	8/16	.	NM_004360.5:c.1118C>T	NP_004351.1:p.Pro373Leu	1242	1118	373	P/L	cCg/cTg	rs587782359&CM072928&COSV55738006&COSV55739079	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	.	chr16:g.68846147C>T	.	.	.	.	.	.	uncertain_significance&likely_benign	0&0&1&1	1&1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.1118C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.77153	0.234603	D	0.91828	0.391363	24.3	25.9	3.369262	3.734823	0.60757	0.73481	C/C	D	0.97978	0.999570190906525	0.92925	0.99849380002992094	.	0.99061	.	C/C	.	.	.	.	10.044	0.797286804736523	0.89604	12.43671	0.950646116161343	0.94012	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.81318	.	.	.	5.72	5.72	0.89380	0	0.55848	0.633656	.	.	0.74766	0.999999999999998	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.26826	0.564101	Cadherin-like&Cadherin-like&Cadherin_conserved_site&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin_conserved_site&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin_conserved_site&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin_conserved_site&Cadherin-like&.	.	.	.	0.87188	.	0.000000	0.50451	D	0.000109	D	0.95402	0.517908	0.71244	.	0.97338	.	D	0.94337	0.8311	.	0.98217	.	D	0.96412	0.9512	P373L	Loss_of_disorder_(P_=_0.0199)&_Loss_of_catalytic_residue_at_P372_(P_=_0.0673)&_Gain_of_sheet_(P_=_0.0827)&_Loss_of_glycosylation_at_T368_(P_=_0.0864)&_Loss_of_loop_(P_=_0.2237)	P12830	0.91139	0.789	.	0.98322	.	.	0.81001	simple_aae&simple_aae	D&D	1&0.999992	0.98474	.	.	.	0.90584	.	.	0.97372	.	T	0.46252	0.552805602551	0.90457	.	10	0.92824	.	.	0.78490	.	.	19.4813	0.95003	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.91621	.	C/C	L	.	P	T	314	0.87270	.	16	C1708349&C0027672&CN169374&CN517202	137215	ORPHA26106&ORPHA140162	Likely_benign	NC_000016.10:g.68812244C>T	142285	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:1aac37aa-cb97-4617-9023-3e7f155f338f	.	.	AEFDGBCI	D	0.75040	0.97483	D	0.98192	0.960907	.	7	2.783570e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34592	0	251476	0	0.000000e+00	10080	0	4	2.174620e-04	18394	0	0	0.000000e+00	21644	0	3	2.637180e-05	113758	0	4	2.174620e-04	18394	0	0	0.000000e+00	30614	0	2	1.828120e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109402	0	0.000000e+00	2320	0	1	1.105460e-04	9046	0	0	0.000000e+00	13390	0	1	2.338200e-05	42768	0	1	1.105460e-04	9046	0	0	0.000000e+00	15688	0	0	.	0	7	2.954310e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236942	0	0.000000e+00	9572	0	4	2.260910e-04	17692	0	0	0.000000e+00	21628	0	3	2.919820e-05	102746	0	4	2.260910e-04	17692	0	0	0.000000e+00	30524	0	0	4	1.921950e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208122	0	0.000000e+00	6212	0	2	1.490760e-04	13416	0	0	0.000000e+00	16730	0	2	2.233340e-05	89552	0	2	1.490760e-04	13416	0	0	0.000000e+00	30606	0	0	7	2.858800e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244858	0	0.000000e+00	9998	0	4	2.175100e-04	18390	0	0	0.000000e+00	21642	0	3	2.686540e-05	111668	0	4	2.175100e-04	18390	0	0	0.000000e+00	30614	0	0	3	1.970810e-05	0	0.000000e+00	41466	0	0	0.000000e+00	910	0	0	0.000000e+00	15280	0	152222	0	0.000000e+00	3470	0	1	1.926040e-04	5192	0	0	0.000000e+00	10614	0	0	0.000000e+00	316	0	2	2.939270e-05	68044	0	1	1.926040e-04	5192	0	0	0.000000e+00	4838	0	0	0.000000e+00	0	0.000000e+00	9096	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32900	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3116	0	0	.	0	3	2.027520e-05	0	0.000000e+00	41144	0	0	0.000000e+00	910	0	0	0.000000e+00	15092	0	147964	0	0.000000e+00	3302	0	1	2.017760e-04	4956	0	0	0.000000e+00	10614	0	0	0.000000e+00	304	0	2	3.085750e-05	64814	0	0	0.000000e+00	4806	0	0	3	2.225490e-05	0	0.000000e+00	32488	0	0	0.000000e+00	862	0	0	0.000000e+00	14834	0	134802	0	0.000000e+00	3386	0	1	1.926040e-04	5192	0	0	0.000000e+00	6974	0	0	0.000000e+00	310	0	2	3.129010e-05	63918	0	0	0.000000e+00	4836	0	0	0	0.000000e+00	0	0.000000e+00	24842	0	0	0.000000e+00	110	0	0	0.000000e+00	12906	0	80782	0	0.000000e+00	996	0	0	0.000000e+00	3750	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	0	0.000000e+00	21056	0	0	0.000000e+00	4810	0	0	16	67403648	16	68846147	0	0.52595	0.67177	1.000000	0.71638	0.072000	0.16771	0.080000	0.18614	7.448000	0.79687	0.599000	0.40250	1.026000	0.45946	68812244	C	.	rs587782359	.	.	7.382	7.312	10.172	4.939	.	.	.	16	-24	16	19	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-8+19+end+129	142285	Likely_benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Ovarian_cancer&not_provided&not_specified&Hereditary_diffuse_gastric_adenocarcinoma	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0008170&MedGen:C1140680&Orphanet:213500&MedGen:CN517202&MedGen:CN169374&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587782359	0.00000e+00	0.00000e+00	0.00000e+00	2.31911e-04	0.00000e+00	1.79035e-05	0.00000e+00	0.00000e+00	2.96512e-05	1.79607e-05	2.31911e-04	2.43633e-05	rs587782359	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66311e-05	0.00000e+00	.	5.84044e-05	0.00000e+00	6.66311e-05	3.22664e-05	.	.	rs587782359	587782359	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,904	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
16	68845762	68845762	G	A	A	splice_region_variant&synonymous_variant	LOW	CDH1	999	Transcript	NM_004360.5	protein_coding	7/16	.	NM_004360.5:c.1008G>A	NP_004351.1:p.Glu336%3D	1132	1008	336	E	gaG/gaA	rs267606712&CS982111&COSV55732029	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68845762G>A	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&0&1	1&1&1	.	.	.	.	.	.	0.999995726569402	0.994	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.172	4.939	8.102	7.878	-4.382	9.321	4.939	-45	0	7	0	0.00	0.00	0.31	0.88	CDH1	0.34	exon-NM_004360.5-7+0+end+176	231647	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Hereditary_diffuse_gastric_adenocarcinoma	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs267606712	267606712	.	.	.	CDH1\x3bTANGO6	CDH1:splicing\x3bexonic\x7cTANGO6:regulatory	CDH1:splice_region_variant\x3bsynonymous_SNV\x7cTANGO6:open_chromatin_region	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,900	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
16	68842699	68842699	G	T	T	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	5/16	.	NM_004360.5:c.635G>T	NP_004351.1:p.Gly212Val	759	635	212	G/V	gGa/gTa	rs1555515276&COSV55727861&COSV55728037	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68842699G>T	.	.	.	.	.	.	uncertain_significance	0&1&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.635G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.88891	0.382851	D	0.88751	0.312162	27.4	29.2	4.062019	4.168815	0.80759	0.87511	G/G	D	0.99418	0.999868869781494	0.29862	0.96450480199144561	.	0.88962	.	G/G	.	.	.	.	19.16149	1.00516835224115	0.98725	17.054	1.08922992477693	0.97929	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.61443	.	.	.	5.78	5.78	0.91418	0	0.40923	0.588066	.	.	0.74766	0.999999999999983	.	0	0.82415	0.723133	.	.	.	.	.	.	0	0.10902	0.530356	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&.	.	.	.	0.95230	.	0.000000	0.49741	D	0.000122	D	0.84969	0.172825	0.75085	.	0.92853	.	D	0.85167	0.5864	.	0.99027	.	D	0.89722	0.4424	G212V	Gain_of_sheet_(P_=_0.1208)&_Gain_of_catalytic_residue_at_G212_(P_=_0.2004)&_Loss_of_ubiquitination_at_K215_(P_=_0.2311)&_Loss_of_phosphorylation_at_T211_(P_=_0.2507)&_Loss_of_disorder_(P_=_0.3022)	P12830	0.98870	0.929	.	0.99371	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.97414	.	.	.	0.90584	.	.	0.97372	.	T	0.43632	0.534246087074	0.89650	.	10	0.92824	.	.	0.91255	.	.	19.9617	0.97254	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.99015	.	G/G	V	.	G	T	315	0.87208	.	16	C1708349&C0027672	137215	ORPHA26106&ORPHA140162	Uncertain_significance	NC_000016.10:g.68808796G>T	479488	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome	ClinGen_CDH1_Variant_Curation_Expert_Panel&:7900d2e0-27b5-45b8-841e-fc65c3aad8ef	.	.	AEFDBHCI	D	0.70494	0.96704	D	0.99354	0.971485	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	67400200	16	68842699	0	0.83141	0.719381	1.000000	0.71638	0.990000	0.65344	0.998000	0.65909	7.649000	0.82656	0.676000	0.76740	1.176000	0.78918	68808796	G	.	rs1555515276	.	.	8.533	8.591	10.585	7.101	.	.	.	-2	-8	-32	10	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-5+52+end+156	479488	Uncertain_significance	reviewed_by_expert_panel	Hereditary_diffuse_gastric_adenocarcinoma&Hereditary_cancer-predisposing_syndrome	MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555515276	1555515276	.	.	.	CDH1\x3bTANGO6	CDH1:exonic\x7cTANGO6:regulatory	CDH1:missense\x7cTANGO6:CTCF_binding_site	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,896	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
10	89622915	89622915	T	C	C	5_prime_UTR_variant	MODIFIER	KLLN	100144748	Transcript	NM_001126049.2	protein_coding	1/1	.	NM_001126049.2:c.-671A>G	.	376	.	.	.	.	rs70937047	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	KLLN	.	chr10:g.89622915T>C	.	0	0	0.003	0	0	likely_benign&benign	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.-1312T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-34	-19	46	-5	0.00	0.00	0.06	0.00	KLLN	.	exon-NM_001126049.2-1+375+end+4376	127667	Benign	reviewed_by_expert_panel	not_provided&PTEN_hamartoma_tumor_syndrome	MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs70937047	0.00000e+00	0.00000e+00	0.00000e+00	1.42151e-02	0.00000e+00	0.00000e+00	0.00000e+00	.	1.17069e-03	2.17140e-04	1.42151e-02	7.42175e-04	.	.	rs70937047	70937047	.	.	.	PTEN\x3bKLLN	PTEN:upstream\x7cKLLN:UTR5	.	KLLN:Cowden_syndrome_4	KLLN:615107	KLLN:3	KLLN:.	0				DISEASE: Cowden syndrome 4 (CWS4) [MIM:615107]: A form of Cowden syndrome, a hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:21177507}. Note=The gene represented in this entry is involved in disease pathogenesis. Germline KLLN methylation is common among patients with Cowden syndrome or Cowden-like syndrome and is associated with increased risks of breast and renal cancer over PTEN mutation-positive individuals (PubMed:21177507). {ECO:0000269|PubMed:21177507}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,501	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
16	68771321	68771321	G	A	A	start_lost	HIGH	CDH1	999	Transcript	NM_004360.5	protein_coding	1/16	.	NM_004360.5:c.3G>A	NP_004351.1:p.Met1?	127	3	1	M/I	atG/atA	rs878854691&CM052835&CM112613&COSV55730371	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	CDH1	.	chr16:g.68771321G>A	.	.	.	.	.	.	pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.3G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.79315	0.257685	D	0.79045	0.13237	23.0	23.9	2.784905	3.121757	0.47417	0.57588	G/G	D	0.82950	0.992468297481537	0.64276	0.99431690841003428	.	0.78552	.	G/G	.	.	.	.	2.827195	0.12214159450928	0.45684	2.50852	-0.000731397363949254	0.41823	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.52642	.	.	.	5.01	5.01	0.66477	0	0.50646	0.609123	.	.	0.74766	0.999999999999568	.	0	0.10781	0.52208	.	.	.	.	.	.	0	0.58350	0.63947	.&.&.&.&.	.	.	.	0.65058	.	0.000000	0.44119	D	0.000469	D	0.99713	0.956944	.	.	0.79061	.	T	0.41648	0.1188	.	0.99454	.	T	0.40712	-0.9515	M1I	Loss_of_disorder_(P_=_0.0796)&_Loss_of_glycosylation_at_P3_(P_=_0.1092)&_Loss_of_phosphorylation_at_S5_(P_=_0.1508)&_Loss_of_MoRF_binding_(P_=_0.1688)&_Loss_of_helix_(P_=_0.1706)	P12830	0.99969	0.997	.	.	.	.	0.81001	complex_aae&complex_aae	D&D	1&1	0.36586	.	.	.	0.27154	.	.	0.26451	.	.	.	.	0.59497	.	9	0.92824	.	.	0.91255	.	.	13.6787	0.61947	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.90025	.	G/G	I	.	M	A	283	0.88803	.	16	C1708349&C0027672&CN517202	137215	ORPHA26106&ORPHA140162	Pathogenic	NC_000016.10:g.68737418G>A	239906	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:d13fa937-98cf-4da0-956f-8d7d5543f0a3&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2843088	.	.	AEFDBHCI	N	0.27868	0.46925	N	0.01524	0.024486	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	67328822	16	68771321	0	0.34471	0.59774	1.000000	0.71638	0.034000	0.13613	0.566000	0.28344	2.000000	0.40435	0.566000	0.28629	1.071000	0.53101	68737418	G	.	rs878854691	.	.	10.278	8.632	.	.	.	.	.	2	46	46	41	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-1+45+end+172	239906	Pathogenic	reviewed_by_expert_panel	Hereditary_diffuse_gastric_adenocarcinoma&Hereditary_cancer-predisposing_syndrome&not_provided	MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16:68771321-68771321	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	2.63405e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs878854691	878854691	.	.	.	CDH1	CDH1:exonic	CDH1:startloss	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,888	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
15	66782869	66782869	T	C	C	synonymous_variant	LOW	MAP2K1	5604	Transcript	NM_002755.4	protein_coding	11/11	.	NM_002755.4:c.1098T>C	NP_002746.1:p.Ala366%3D	1534	1098	366	A	gcT/gcC	rs200293968	T	.	1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	SNAPC5	.	chr15:g.66782869T>C	.	0	0	0.001	0	0	likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.433	10.126	.	.	.	-11	20	-11	19	0.00	0.06	0.00	0.00	MAP2K1	0.99	exon-NM_002755.4-11+29+start+1043	448949	Likely_benign	reviewed_by_expert_panel	Cardiovascular_phenotype&RASopathy	MedGen:CN230736&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	15:66782869-66782869	6.589e-05	8	8	0	0	0	8	0	0	0	0	10406	11578	8654	6614	66740	908	16512	0	0	8	0	0	0	0	0	0	0	0	0	0	0	rs200293968	0.00000e+00	0.00000e+00	0.00000e+00	1.21753e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.89535e-05	8.08291e-05	1.21753e-03	8.52716e-05	rs200293968	0.00000e+00	0.00000e+00	0.00000e+00	6.16523e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	0.00000e+00	7.21605e-05	6.16523e-04	3.22664e-05	.	.	rs200293968	200293968	.	.	.	MAP2K1\x3bSNAPC5	MAP2K1:exonic\x7cSNAPC5:UTR3	MAP2K1:synonymous_SNV	MAP2K1:Cardiofaciocutaneous_syndrome_3\x3bMelorheostosis\x2cisolated\x2csomatic_mosaic	MAP2K1:615279\x3b155950	MAP2K1:3\x3b3	MAP2K1:Autosomal_dominant\x3b.	0	0.994501270366062	0.00549805295620231	6.76677735529064e-07	DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. Distinctive features of CFC3 include macrostomia and horizontal shape of palpebral fissures. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,887	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
15	66782108	66782112	CTATT	C	-	splice_region_variant&intron_variant	LOW	MAP2K1	5604	Transcript	NM_002755.4	protein_coding	.	10/10	NM_002755.4:c.1068+12_1068+15del	.	.	.	.	.	.	rs397516788	TATT	.	1	.	1	EntrezGene	.	YES	.	.	TATT	TATT	.	.	SNAPC5	.	chr15:g.66782113_66782116del	.	0	0.0029	0	0.004	0	.	.	1	.	.	.	.	.	MAP2K1&NM_002755.3&c.1068+8_1068+11del	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.433	.	9.819	10.126	.	.	.	-43	-33	20	-8	0.00	0.05	0.00	0.01	MAP2K1	0.99	.	44586	Benign	reviewed_by_expert_panel	not_specified&Cardio-facio-cutaneous_syndrome&RASopathy&not_provided&Noonan_syndrome&Noonan_syndrome_and_Noonan-related_syndrome	MedGen:CN169374&MONDO:MONDO:0015280&MedGen:C1275081&OMIM:PS115150&Orphanet:1340&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN517202&MONDO:MONDO:0018997&MeSH:D009634&MedGen:C0028326&OMIM:PS163950&Orphanet:648&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733	.	15:66782109-66782113	2.010e-03	244	244	0	5	19	0	2	214	4	0	10406	11578	8654	6614	66740	908	16510	5	19	0	2	214	4	0	0	0	0	0	0	0	0	rs545661620	5.22739e-04	1.90578e-03	5.98985e-03	0.00000e+00	1.79420e-04	3.43821e-03	2.36967e-03	0.00000e+00	2.16479e-03	2.15544e-03	5.98985e-03	2.16021e-03	rs545661620	5.72344e-04	4.77327e-03	0.00000e+00	0.00000e+00	2.86205e-04	3.06462e-03	1.01833e-03	.	1.81011e-03	1.87644e-03	4.77327e-03	1.83918e-03	15:66782109-66782113	0.2908&0.0&0.1918	rs397516788	397516788	.	.	.	MAP2K1\x3bSNAPC5	MAP2K1:splicing\x3bintronic\x7cSNAPC5:UTR3	MAP2K1:splice_region_variant	MAP2K1:Cardiofaciocutaneous_syndrome_3\x3bMelorheostosis\x2cisolated\x2csomatic_mosaic	MAP2K1:615279\x3b155950	MAP2K1:3\x3b3	MAP2K1:Autosomal_dominant\x3b.	0	0.994501270366062	0.00549805295620231	6.76677735529064e-07	DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. Distinctive features of CFC3 include macrostomia and horizontal shape of palpebral fissures. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,886	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103271234	103271234	A	T	T	splice_donor_region_variant&intron_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	.	4/12	NM_000277.3:c.441+6T>A	.	.	.	.	.	.	rs199475698&CS123247	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103271234A>T	.	.	.	.	.	.	likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.441+6T>C	0.981305393349569	0.616	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.810	9.092	11.038	7.211	2.396	4.814	7.211	-9	6	-9	6	0.00	0.00	0.02	0.83	PAH	0.00	.	120275	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103271234-103271234	8.236e-06	1	1	0	0	0	0	0	1	0	0	10406	11578	8654	6614	66740	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs199475698	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95191e-06	0.00000e+00	0.00000e+00	7.41279e-06	0.00000e+00	8.95191e-06	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475698	199475698	.	.	.	PAH	PAH:splicing\x3bintronic	PAH:splice_donor_region_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,796	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
1	41285030	41285030	C	G	G	synonymous_variant	LOW	KCNQ4	9132	Transcript	NM_004700.4	protein_coding	5/14	.	NM_004700.4:c.720C>G	NP_004691.2:p.Thr240%3D	1027	720	240	T	acC/acG	rs752131356	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	KCNQ4	.	chr1:g.41285030C>G	.	.	.	.	.	.	likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.437	10.247	10.030	9.158	.	.	.	1	-8	0	5	0.00	0.00	0.00	0.00	KCNQ4	0.99	exon-NM_004700.4-5+11+start+126	227469	Likely_benign	reviewed_by_expert_panel	not_specified&Nonsyndromic_genetic_hearing_loss	MedGen:CN169374&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs752131356	752131356	.	.	.	KCNQ4	KCNQ4:exonic	KCNQ4:synonymous_SNV	KCNQ4:Deafness\x2cautosomal_dominant_2A	KCNQ4:600101	KCNQ4:3	KCNQ4:Autosomal_dominant	0	0.985178281898531	0.0148214036876789	3.14413790434247e-07	DISEASE: Deafness, autosomal dominant, 2A (DFNA2A) [MIM:600101]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10025409, ECO:0000269|PubMed:10369879, ECO:0000269|PubMed:10571947, ECO:0000269|PubMed:10925378, ECO:0000269|PubMed:21242547}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,440	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	112760225	112760225	A	C	C	synonymous_variant	LOW	SHOC2	8036	Transcript	NM_007373.4	protein_coding	4/9	.	NM_007373.4:c.894A>C	NP_031399.2:p.Ala298%3D	1182	894	298	A	gcA/gcC	rs767912952	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	ADRA2A	.	chr10:g.112760225A>C	.	.	.	.	.	.	benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.807	10.065	11.369	6.989	.	.	.	-1	-39	-35	-26	0.00	0.00	0.00	0.00	SHOC2	0.99	exon-NM_001324336.2-4+52+start+131	448935	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&RASopathy	MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	10:112760225-112760225	7.413e-05	9	9	0	0	0	9	0	0	0	0	10398	11568	8648	6608	66698	908	16508	0	0	9	0	0	0	0	0	0	0	0	0	0	0	rs767912952	0.00000e+00	0.00000e+00	0.00000e+00	9.27644e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	4.44932e-05	8.98327e-05	9.27644e-04	6.49688e-05	rs767912952	0.00000e+00	0.00000e+00	0.00000e+00	1.23305e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	1.16809e-04	0.00000e+00	1.23305e-03	6.45328e-05	.	.	rs767912952	767912952	.	.	.	SHOC2	SHOC2:exonic	SHOC2:synonymous_SNV	SHOC2:Noonan_syndrome-like_with_loose_anagen_hair_1	SHOC2:607721	SHOC2:3	SHOC2:Autosomal_dominant	0	0.991705191552454	0.00829295945769003	1.84898985615785e-06	DISEASE: Noonan syndrome-like disorder with loose anagen hair (NSLH) [MIM:607721]: A syndrome characterized by Noonan dysmorphic features such as macrocephaly, high forehead, hypertelorism, palpebral ptosis, low-set and posteriorly rotated ears, short and webbed neck, pectus anomalies, in association with pluckable, sparse, thin and slow-growing hair. {ECO:0000269|PubMed:19684605, ECO:0000269|PubMed:25137548}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,606	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89725230	89725231	AT	A	-	3_prime_UTR_variant	MODIFIER	PTEN	5728	Transcript	NM_000314.8	protein_coding	9/9	.	NM_000314.8:c.*10del	.	2059	.	.	.	.	rs756681683	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89725239del	.	.	.	.	.	.	uncertain_significance&benign&likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.857	8.679	.	.	.	-8	15	-8	-37	0.00	0.00	0.01	0.00	PTEN	0.98	exon-NM_001304717.5-10+187+start+6644	189424	Uncertain_significance	reviewed_by_expert_panel	not_specified&PTEN_hamartoma_tumor_syndrome&Breast_and/or_ovarian_cancer&Hereditary_cancer-predisposing_syndrome&Cowden_syndrome_1	MedGen:CN169374&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MedGen:CN221562&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	10:89725231-89725232	3.302e-05	4	0	0	0	1	0	0	2	0	1	7908	10506	7832	6258	56612	816	15486	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs756681683	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.77266e-05	0.00000e+00	3.45185e-05	1.55429e-05	2.83607e-05	3.77266e-05	1.01542e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs756681683	756681683	chr9:33674357&chr17:54445431	0.98265&0.958891	0.97956&0.955238	PTEN	PTEN:UTR3	.	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,598	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89717799	89717799	G	A	A	intron_variant	MODIFIER	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	7/8	NM_000314.8:c.801+23G>A	.	.	.	.	.	.	rs116160352	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89717799G>A	.	0.003	0	0	0	0	likely_benign	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.801+23G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.930	8.679	6.460	7.806	.	.	.	-40	-23	-19	-23	0.00	0.00	0.00	0.00	PTEN	0.98	.	92829	Likely_benign	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&not_specified&Cowden_syndrome_1	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MedGen:CN169374&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	rs116160352	3.707e-04	45	45	0	30	1	0	0	13	1	0	10278	11434	8548	6584	65826	904	16382	30	1	0	0	13	1	0	0	0	0	0	0	0	0	rs116160352	2.68184e-03	2.98205e-05	2.54013e-03	0.00000e+00	0.00000e+00	7.17334e-05	3.65230e-04	3.25055e-05	2.59810e-04	3.86635e-04	2.68184e-03	3.16731e-04	rs116160352	1.94775e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.33262e-04	0.00000e+00	.	4.67563e-04	7.93765e-04	1.94775e-03	6.13061e-04	rs116160352	0.0233&0.2951&0.1153	rs116160352	116160352	.	.	.	PTEN	PTEN:intronic	.	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,581	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89623428	89623428	G	C	C	5_prime_UTR_variant	MODIFIER	PTEN	5728	Transcript	NM_000314.8	protein_coding	1/9	.	NM_000314.8:c.-799G>C	.	47	.	.	.	.	rs587779992&CR075267	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89623428G>C	.	.	.	.	.	.	uncertain_significance&likely_benign	.	1&1	.	.	.	.	.	PTEN&NM_000314.4&c.-798G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-2.595	-3.496	.	.	.	.	.	-28	-4	12	-4	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_000314.8-1+46+start+924	127674	Uncertain_significance	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587779992	587779992	.	.	.	PTEN\x3bKLLN	PTEN:UTR5\x7cKLLN:upstream	.	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,508	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89623462	89623462	G	A	A	5_prime_UTR_variant	MODIFIER	PTEN	5728	Transcript	NM_000314.8	protein_coding	1/9	.	NM_000314.8:c.-765G>A	.	81	.	.	.	.	rs587776674&CR032089	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89623462G>A	.	.	.	.	.	.	uncertain_significance	.	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-2.595	-3.496	.	.	.	.	.	2	-5	48	-27	0.00	0.00	0.02	0.00	PTEN	0.98	exon-NM_000314.8-1+80+start+924	7844	Uncertain_significance	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&VACTERL_with_hydrocephalus&Glioma_susceptibility_2&Familial_meningioma&Cowden_syndrome_1&Malignant_tumor_of_prostate&Macrocephaly-autism_syndrome&not_specified&Hereditary_cancer-predisposing_syndrome&not_provided	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0010172&MedGen:C1848599&OMIM:276950&Orphanet:3412&MONDO:MONDO:0013092&MedGen:C2751642&OMIM:613028&Orphanet:182067&MONDO:MONDO:0011789&MedGen:C3551915&OMIM:607174&Orphanet:263662&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&Human_Phenotype_Ontology:HP:0012125&MONDO:MONDO:0008315&MedGen:C0376358&OMIM:176807&Orphanet:1331&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548&MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10:89623462-89623462	1.15234e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	5.87682e-05	0.00000e+00	1.15234e-04	3.22706e-05	.	.	rs587776674	587776674	.	.	.	PTEN\x3bKLLN	PTEN:UTR5\x7cKLLN:upstream	.	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,509	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89720649	89720650	AG	A	-	splice_acceptor_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	7/8	NM_000314.8:c.802del	.	.	.	.	.	.	rs587776672&COSV100909782&COSV64290925&COSV64293353	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89720651del	.	.	.	.	.	.	likely_pathogenic&pathogenic	0&1&1&1	1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.802-1G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	diff/acceptor/89720649-89720650/Medium-Medium/12.302911-10.801663	12.930	8.679	6.460	7.806	.	.	.	2	1	44	21	1.00	1.00	0.00	0.02	PTEN	0.98	.	7839	Likely_pathogenic	reviewed_by_expert_panel	Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587776672	587776672	.	.	.	PTEN	PTEN:splicing	PTEN:splice_acceptor_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,583	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
11	534287	534287	G	A	A	synonymous_variant	LOW	HRAS	3265	Transcript	NM_005343.4	protein_coding	2/6	.	NM_005343.4:c.36C>T	NP_005334.1:p.Gly12%3D	250	36	12	G	ggC/ggT	rs727504424&CP053739&CX065872&CX123158&CX166619	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	HRAS	.	chr11:g.534287G>A	.	.	.	.	.	.	conflicting_interpretations_of_pathogenicity&likely_benign&benign	.	1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.582	8.703	5.136	11.453	.	.	.	-40	49	12	-1	0.00	0.01	0.00	0.00	HRAS	0.01	exon-NM_005343.4-2+75+start+164	222076	Likely_benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Costello_syndrome&not_provided&RASopathy	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	11:534287-534287	6.592e-05	8	8	0	0	0	8	0	0	0	0	10230	11520	8626	6484	65776	898	16480	0	0	8	0	0	0	0	0	0	0	0	0	0	0	rs727504424	0.00000e+00	0.00000e+00	0.00000e+00	1.21824e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.42258e-05	9.92063e-05	1.21824e-03	8.93328e-05	rs727504424	0.00000e+00	0.00000e+00	0.00000e+00	3.70370e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	2.92912e-04	7.23694e-05	3.70370e-03	1.93598e-04	.	.	rs727504424	727504424	.	.	.	HRAS	HRAS:exonic	HRAS:synonymous_SNV	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,625	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89720690	89720690	C	G	G	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	8/9	.	NM_000314.8:c.841C>G	NP_000305.3:p.Pro281Ala	1686	841	281	P/A	Cca/Gca	rs750705904&COSV100910232	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89720690C>G	.	.	.	.	.	.	uncertain_significance	0&1	1&1	.	.	.	.	.	PTEN&NM_000314.4&c.841C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.594706798131811E-4	.	.	.	.	.	.	.	./.	C	D	0.74651	0.208088	D	0.74320	0.0611274	23.2	23.5	2.897543	2.962666	0.49822	0.53883	./.	D	0.33318	0.518712759017944	0.31327	0.96847694027424636	.	0.87431	.	./.	.	.	.	.	6.013107	0.582659344899882	0.73698	5.438443	0.548737605459482	0.70005	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.84919	.	.	.	5.13	5.13	0.69729	0	0.89359	0.724815	.	.	0.74766	0.999999999999948	.	0	0.50148	0.65145	.	.	.	.	.	.	0	0.50027	0.635259	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	0.87188	.	0.000000	0.84330	D	0.000000	D	0.79797	0.118037	0.78602	.	0.85924	.	D	0.85342	0.5904	.	0.61884	.	D	0.84315	0.1077	P281A	Gain_of_catalytic_residue_at_P281_(P_=_0.0161)&_Gain_of_sheet_(P_=_0.0477)&_Loss_of_glycosylation_at_P281_(P_=_0.0545)&_Loss_of_loop_(P_=_0.0804)&_Loss_of_disorder_(P_=_0.083)	P60484	0.60986	0.512	.	0.65404	.	.	0.81001	simple_aae	D	1	0.27876	.	.	.	0.59353	.	.	0.56425	.	T	0.71740	0.731595695019	0.84613	.	9	0.06598	.	.	0.06106	.	.	17.3346	0.87164	0.0:1.0:0.0:0.0	.	0	0.0	1	1.322401481089659E-4	.	.	.	0.73465	.	./.	A	.	P	G	900	0.24599	.	10	C0027672&C1959582&CN517202	.	ORPHA140162&ORPHA306498	Uncertain_significance	NC_000010.11:g.87960933C>G	184466	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:74ec7748-2294-4f8c-a299-53b2a9c51d35	.	.	AEFGBI	D	0.95892	0.99427	D	0.71136	0.779041	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.747000e-06	0	0.000000e+00	39880	0	0	0.000000e+00	906	0	0	0.000000e+00	14834	0	148214	0	0.000000e+00	3456	0	0	0.000000e+00	5088	0	0	0.000000e+00	9506	0	0	0.000000e+00	306	0	1	1.482320e-05	67462	0	1	1.482320e-05	67462	0	0	0.000000e+00	4736	0	0	0.000000e+00	0	0.000000e+00	8712	0	0	0.000000e+00	58	0	0	0.000000e+00	4530	0	31220	0	0.000000e+00	132	0	0	0.000000e+00	2404	0	0	0.000000e+00	4668	0	0	0.000000e+00	236	0	0	0.000000e+00	6682	0	0	0.000000e+00	3048	0	0	.	0	1	6.943960e-06	0	0.000000e+00	39562	0	0	0.000000e+00	906	0	0	0.000000e+00	14650	0	144010	0	0.000000e+00	3294	0	0	0.000000e+00	4860	0	0	0.000000e+00	9506	0	0	0.000000e+00	294	0	1	1.556130e-05	64262	0	0	0.000000e+00	4704	0	0	1	7.612780e-06	0	0.000000e+00	31162	0	0	0.000000e+00	856	0	0	0.000000e+00	14420	0	131358	0	0.000000e+00	3372	0	0	0.000000e+00	5088	0	0	0.000000e+00	6070	0	0	0.000000e+00	300	0	1	1.577140e-05	63406	0	0	0.000000e+00	4734	0	0	0	0.000000e+00	0	0.000000e+00	23566	0	0	0.000000e+00	110	0	0	0.000000e+00	12464	0	77264	0	0.000000e+00	988	0	0	0.000000e+00	3646	0	0	0.000000e+00	9414	0	0	0.000000e+00	262	0	0	0.000000e+00	20636	0	0	0.000000e+00	4708	0	0	10	89710670	10	89720690	0	0.73137	0.706548	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	6.545000	0.73784	0.549000	0.26987	1.026000	0.45946	87960933	C	.	rs750705904	.	.	11.857	8.679	12.930	7.806	.	.	.	1	4	-19	26	0.02	0.01	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-9+39+start+225	184466	Uncertain_significance	reviewed_by_expert_panel	Breast_and/or_ovarian_cancer&Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome	MedGen:CN221562&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs750705904	750705904	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,584	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
10	89624312	89624312	A	G	G	splice_region_variant&intron_variant	LOW	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	1/8	NM_000314.8:c.79+7A>G	.	.	.	.	.	.	rs374331677	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89624312A>G	.	.	.	.	.	.	pathogenic&likely_benign&uncertain_significance	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.79+7A>G	0.0521516871224898	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-2.595	10.567	.	-3.496	.	.	.	-5	-7	-5	-7	0.00	0.00	0.00	0.00	PTEN	0.98	.	127692	Uncertain_significance	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	10:89624312-89624312	8.236e-06	1	1	0	0	0	0	0	1	0	0	10404	11574	8652	6614	66736	906	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs374331677	0.00000e+00	2.97779e-05	0.00000e+00	0.00000e+00	0.00000e+00	1.79019e-05	0.00000e+00	0.00000e+00	7.41235e-06	1.79594e-05	2.97779e-05	1.21817e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	rs374331677	0.0233&0.0&0.0154	rs374331677	374331677	.	.	.	PTEN	PTEN:splicing\x3bintronic	PTEN:splice_region_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,517	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89624301	89624301	G	A	A	synonymous_variant	LOW	PTEN	5728	Transcript	NM_000314.8	protein_coding	1/9	.	NM_000314.8:c.75G>A	NP_000305.3:p.Leu25%3D	920	75	25	L	ttG/ttA	rs786201506&CM110137&COSV64289219&COSV64297774	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89624301G>A	.	.	.	.	.	.	uncertain_significance&likely_benign	0&0&1&1	1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.75G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-2.595	-3.496	.	.	.	.	.	2	4	4	2	0.00	0.00	0.03	0.00	PTEN	0.98	exon-NM_000314.8-1+4+end+924	184505	Uncertain_significance	reviewed_by_expert_panel	not_provided&PTEN_hamartoma_tumor_syndrome&Hereditary_cancer-predisposing_syndrome&Malignant_tumor_of_breast	MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0007254&MedGen:C0006142	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786201506	786201506	.	.	.	PTEN	PTEN:exonic	PTEN:synonymous_SNV	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,516	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89623492	89623492	G	A	A	5_prime_UTR_variant	MODIFIER	PTEN	5728	Transcript	NM_000314.8	protein_coding	1/9	.	NM_000314.8:c.-735G>A	.	111	.	.	.	.	rs886047384	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89623492G>A	.	.	.	.	.	.	likely_benign&uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-2.595	-3.496	.	.	.	.	.	2	27	-36	18	0.00	0.00	0.00	0.01	PTEN	0.98	exon-NM_000314.8-1+110+start+924	127672	Uncertain_significance	reviewed_by_expert_panel	not_specified&not_provided&Cowden_syndrome_1&PTEN_hamartoma_tumor_syndrome	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs886047384	886047384	.	.	.	PTEN\x3bKLLN	PTEN:UTR5\x7cKLLN:upstream	.	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,510	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
11	533618	533618	A	C	C	splice_polypyrimidine_tract_variant&splice_region_variant&intron_variant	LOW	HRAS	3265	Transcript	NM_005343.4	protein_coding	.	3/5	NM_005343.4:c.291-6T>G	.	.	.	.	.	.	rs766909143	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	HRAS	.	chr11:g.533618A>C	.	.	.	.	.	.	benign&likely_benign	.	1	.	.	.	.	.	.	0.0023660677085088	0.154	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.862	10.068	10.582	5.560	6.507	2.355	8.862	28	-13	-21	-28	0.07	0.04	0.00	0.00	HRAS	0.01	.	448926	Benign	reviewed_by_expert_panel	Linear_nevus_sebaceous_syndrome&Malignant_tumor_of_urinary_bladder&Large_congenital_melanocytic_nevus&Thyroid_cancer&_nonmedullary&_2&Costello_syndrome&Epidermal_nevus&not_specified&RASopathy&Hereditary_cancer-predisposing_syndrome	Human_Phenotype_Ontology:HP:0010817&MONDO:MONDO:0008097&MedGen:C4552097&OMIM:163200&Orphanet:2612&MONDO:MONDO:0001187&MedGen:C0005684&OMIM:109800&Orphanet:157980&Human_Phenotype_Ontology:HP:0005600&Human_Phenotype_Ontology:HP:0005604&MONDO:MONDO:0044792&MedGen:C1842036&OMIM:137550&Orphanet:626&MONDO:MONDO:0008566&MedGen:C4225426&OMIM:188470&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071&Human_Phenotype_Ontology:HP:0010816&MONDO:MONDO:0008093&MedGen:C0334082&OMIM:162900&Orphanet:79414&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	11:533618-533618	1.153e-04	14	14	0	0	0	0	0	0	0	14	10366	11566	8640	6614	66434	906	16510	0	0	0	0	0	0	14	0	0	0	0	0	0	0	rs766909143	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.82282e-04	1.00708e-03	1.77910e-04	7.18791e-05	1.00708e-03	1.29938e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs766909143	766909143	.	.	.	HRAS	HRAS:splicing\x3bintronic	HRAS:splice_region_variant\x3bsplice_polypyrimidine_tract_variant	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,618	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	112724479	112724479	G	A	A	synonymous_variant	LOW	SHOC2	8036	Transcript	NM_007373.4	protein_coding	2/9	.	NM_007373.4:c.363G>A	NP_031399.2:p.Glu121%3D	651	363	121	E	gaG/gaA	rs115713408	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	SHOC2	.	chr10:g.112724479G>A	.	0.0008	0	0	0	0	likely_benign	.	1	.	.	.	.	.	SHOC2&NM_007373.3&c.363G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.357	8.846	9.854	7.528	.	.	.	33	-1	-24	-1	0.00	0.00	0.00	0.00	SHOC2	0.99	exon-NM_001324336.2-2+340+end+937	448931	Likely_benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&RASopathy	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	rs115713408	6.589e-05	8	8	0	8	0	0	0	0	0	0	10350	11516	8640	6614	66638	908	16500	8	0	0	0	0	0	0	0	0	0	0	0	0	0	rs115713408	5.22876e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.22886e-05	4.49867e-05	5.22876e-04	3.24857e-05	rs115713408	2.29095e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84317e-05	7.22022e-05	2.29095e-04	6.45328e-05	rs115713408	0.0&0.0908&0.0308	rs115713408	115713408	.	.	.	SHOC2	SHOC2:exonic	SHOC2:synonymous_SNV	SHOC2:Noonan_syndrome-like_with_loose_anagen_hair_1	SHOC2:607721	SHOC2:3	SHOC2:Autosomal_dominant	0	0.991705191552454	0.00829295945769003	1.84898985615785e-06	DISEASE: Noonan syndrome-like disorder with loose anagen hair (NSLH) [MIM:607721]: A syndrome characterized by Noonan dysmorphic features such as macrocephaly, high forehead, hypertelorism, palpebral ptosis, low-set and posteriorly rotated ears, short and webbed neck, pectus anomalies, in association with pluckable, sparse, thin and slow-growing hair. {ECO:0000269|PubMed:19684605, ECO:0000269|PubMed:25137548}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,600	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89623365	89623365	G	T	T	upstream_gene_variant	MODIFIER	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	.	.	.	.	.	.	.	.	rs587776675&CR032091	G	17	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89623365G>T	.	.	.	.	.	.	uncertain_significance&pathogenic	.	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-18	35	-2	-1	0.00	0.00	0.00	0.00	PTEN	0.98	.	7845	Uncertain_significance	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587776675	587776675	.	.	.	PTEN\x3bKLLN	PTEN:upstream\x7cKLLN:upstream	.	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,507	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
11	533594	533594	C	T	T	synonymous_variant	LOW	HRAS	3265	Transcript	NM_005343.4	protein_coding	4/6	.	NM_005343.4:c.309G>A	NP_005334.1:p.Val103%3D	523	309	103	V	gtG/gtA	rs575789207&COSV99531155	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	HRAS	.	chr11:g.533594C>T	.	0	0	0.003	0	0	likely_benign&benign	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.489	10.068	8.862	5.560	.	.	.	11	39	3	-30	0.04	0.00	0.01	0.00	HRAS	0.01	exon-NM_005343.4-4+18+end+160	40440	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&not_provided&RASopathy&Costello_syndrome	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071	.	11:533594-533594	8.237e-05	10	10	0	0	0	10	0	0	0	0	10372	11568	8640	6614	66484	906	16510	0	0	10	0	0	0	0	0	0	0	0	0	0	0	rs575789207	0.00000e+00	0.00000e+00	0.00000e+00	9.85850e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.67161e-05	7.18597e-05	9.85850e-04	6.90294e-05	rs575789207	0.00000e+00	0.00000e+00	0.00000e+00	1.23305e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	5.84932e-05	7.22648e-05	1.23305e-03	6.45328e-05	.	.	rs575789207	575789207	.	.	.	HRAS	HRAS:exonic	HRAS:synonymous_SNV	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,617	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
11	533546	533546	G	A	A	synonymous_variant	LOW	HRAS	3265	Transcript	NM_005343.4	protein_coding	4/6	.	NM_005343.4:c.357C>T	NP_005334.1:p.Asp119%3D	571	357	119	D	gaC/gaT	rs111352454&COSV54243286	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	HRAS	.	chr11:g.533546G>A	.	0	0	0	0.004	0	benign	0&1	1&1	.	.	.	.	.	HRAS&NM_176795.3&c.357C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.489	10.068	8.862	5.560	.	.	.	-31	44	18	-26	0.00	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-4+66+end+160	40441	Benign	reviewed_by_expert_panel	Large_congenital_melanocytic_nevus&Costello_syndrome&Thyroid_cancer&_nonmedullary&_2&Malignant_tumor_of_urinary_bladder&Linear_nevus_sebaceous_syndrome&Epidermal_nevus&Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&Hereditary_cancer-predisposing_syndrome&not_specified&RASopathy&not_provided	Human_Phenotype_Ontology:HP:0005600&Human_Phenotype_Ontology:HP:0005604&MONDO:MONDO:0044792&MedGen:C1842036&OMIM:137550&Orphanet:626&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071&MONDO:MONDO:0008566&MedGen:C4225426&OMIM:188470&MONDO:MONDO:0001187&MedGen:C0005684&OMIM:109800&Orphanet:157980&Human_Phenotype_Ontology:HP:0010817&MONDO:MONDO:0008097&MedGen:C4552097&OMIM:163200&Orphanet:2612&Human_Phenotype_Ontology:HP:0010816&MONDO:MONDO:0008093&MedGen:C0334082&OMIM:162900&Orphanet:79414&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN517202	.	rs111352454	9.472e-04	115	113	1	8	4	0	0	102	0	1	10364	11566	8640	6614	66416	906	16510	8	4	0	0	100	0	1	0	0	0	0	1	0	0	rs111352454	5.22944e-04	6.55113e-04	1.21852e-03	0.00000e+00	0.00000e+00	1.80874e-03	1.09409e-03	9.74596e-05	1.03778e-03	1.01513e-03	1.80874e-03	1.02732e-03	rs111352454	6.88231e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.46921e-03	1.01833e-03	.	1.17014e-03	6.50571e-04	1.46921e-03	9.35725e-04	rs111352454	0.1163&0.0908&0.1076	rs111352454	111352454	.	.	.	HRAS	HRAS:exonic	HRAS:synonymous_SNV	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,615	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
11	533534	533534	G	A	A	synonymous_variant	LOW	HRAS	3265	Transcript	NM_005343.4	protein_coding	4/6	.	NM_005343.4:c.369C>T	NP_005334.1:p.Arg123%3D	583	369	123	R	cgC/cgT	rs200945755	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	HRAS	.	chr11:g.533534G>A	.	0	0	0.003	0	0	likely_benign&benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.489	10.068	8.862	5.560	.	.	.	-19	-3	2	-3	0.05	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-4+78+end+160	259747	Benign	reviewed_by_expert_panel	not_provided&RASopathy&Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&not_specified&Hereditary_cancer-predisposing_syndrome&Costello_syndrome	MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071	.	11:533534-533534	1.071e-04	13	13	0	0	0	13	0	0	0	0	10358	11562	8638	6614	66376	906	16510	0	0	13	0	0	0	0	0	0	0	0	0	0	0	rs200945755	0.00000e+00	0.00000e+00	0.00000e+00	1.97147e-03	0.00000e+00	0.00000e+00	0.00000e+00	3.24865e-05	1.26016e-04	1.61713e-04	1.97147e-03	1.42119e-04	rs200945755	0.00000e+00	0.00000e+00	0.00000e+00	3.08642e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	2.34165e-04	7.22857e-05	3.08642e-03	1.61342e-04	.	.	rs200945755	200945755	.	.	.	HRAS	HRAS:exonic	HRAS:synonymous_SNV	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,614	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
11	533525	533525	T	C	C	synonymous_variant	LOW	HRAS	3265	Transcript	NM_005343.4	protein_coding	4/6	.	NM_005343.4:c.378A>G	NP_005334.1:p.Glu126%3D	592	378	126	E	gaA/gaG	rs397517140	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	HRAS	.	chr11:g.533525T>C	.	0	0	0	0	0.001	benign&likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.489	10.068	8.862	5.560	.	.	.	-1	-10	45	-10	0.00	0.16	0.00	0.00	HRAS	0.01	exon-NM_005343.4-4+72+start+160	40442	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&not_specified&not_provided&RASopathy&Costello_syndrome	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071	.	11:533525-533525	2.059e-04	25	25	0	0	2	0	0	0	0	23	10350	11562	8638	6614	66328	906	16510	0	2	0	0	0	0	23	0	0	0	0	0	0	0	rs397517140	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95576e-06	0.00000e+00	1.42941e-03	2.29796e-04	1.25788e-04	1.42941e-03	1.82725e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397517140	397517140	.	.	.	HRAS	HRAS:exonic	HRAS:synonymous_SNV	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,613	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
11	532729	532729	C	T	T	synonymous_variant	LOW	HRAS	3265	Transcript	NM_005343.4	protein_coding	5/6	.	NM_005343.4:c.477G>A	NP_005334.1:p.Leu159%3D	691	477	159	L	ttG/ttA	rs140060409&COSV104535600	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	HRAS	.	chr11:g.532729C>T	.	0	0.0014	0	0.002	0	benign/likely_benign&benign	0&1	1&1	.	.	.	.	.	HRAS&NM_176795.3&c.*46G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.016	10.068	10.489	10.068	.	.	.	-2	22	4	0	0.00	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-5+26+end+125	40446	Benign	reviewed_by_expert_panel	not_specified&Cardiovascular_phenotype&not_provided&RASopathy&Costello_syndrome&Noonan_syndrome_and_Noonan-related_syndrome&Hereditary_cancer-predisposing_syndrome	MedGen:CN169374&MedGen:CN230736&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	rs140060409	1.343e-03	163	163	0	4	18	0	0	140	1	0	10210	11518	8592	6486	65296	870	16500	4	18	0	0	140	1	0	0	0	0	0	0	0	0	rs140060409	6.55222e-04	2.11486e-03	0.00000e+00	0.00000e+00	0.00000e+00	2.56607e-03	2.01391e-03	0.00000e+00	1.56822e-03	1.48484e-03	2.56607e-03	1.55124e-03	rs140060409	1.37615e-03	0.00000e+00	3.31126e-03	0.00000e+00	0.00000e+00	2.87049e-03	0.00000e+00	.	2.10674e-03	1.44467e-03	3.31126e-03	1.80703e-03	rs140060409	0.3837&0.0681&0.2768	rs140060409	140060409	.	.	.	HRAS	HRAS:exonic	HRAS:synonymous_SNV	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,612	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
11	532696	532696	C	T	T	synonymous_variant	LOW	HRAS	3265	Transcript	NM_005343.4	protein_coding	5/6	.	NM_005343.4:c.510G>A	NP_005334.1:p.Lys170%3D	724	510	170	K	aaG/aaA	rs397517143&COSV54246652	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	HRAS	.	chr11:g.532696C>T	.	.	.	.	.	.	benign/likely_benign&likely_benign	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.016	10.068	10.489	10.068	.	.	.	50	-1	33	-33	0.00	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-5+59+end+125	45305	Likely_benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&RASopathy&Costello_syndrome	MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071	.	11:532696-532696	2.472e-05	3	3	0	0	0	2	0	0	0	1	10156	11488	8584	6428	65108	868	16492	0	0	2	0	0	0	1	0	0	0	0	0	0	0	rs397517143	0.00000e+00	0.00000e+00	0.00000e+00	5.80585e-04	0.00000e+00	0.00000e+00	0.00000e+00	3.24907e-05	4.47001e-05	4.53498e-05	5.80585e-04	4.46697e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs397517143	397517143	.	.	.	HRAS	HRAS:exonic	HRAS:synonymous_SNV	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,610	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89624244	89624244	A	G	G	synonymous_variant	LOW	PTEN	5728	Transcript	NM_000314.8	protein_coding	1/9	.	NM_000314.8:c.18A>G	NP_000305.3:p.Lys6%3D	863	18	6	K	aaA/aaG	rs876660391&CD110185&COSV64292354&COSV64297759&COSV64298855	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89624244A>G	.	.	.	.	.	.	likely_benign	0&0&1&1&1	1&1&1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-2.595	-3.496	.	.	.	.	.	-33	-19	26	6	0.02	0.00	0.00	0.00	PTEN	0.98	exon-NM_000314.8-1+61+end+924	233415	Likely_benign	reviewed_by_expert_panel	PTEN_hamartoma_tumor_syndrome&Hereditary_cancer-predisposing_syndrome	MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs876660391	876660391	.	.	.	PTEN\x3bKLLN	PTEN:exonic\x7cKLLN:upstream	PTEN:synonymous_SNV	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,512	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	112724493	112724493	C	T	T	missense_variant	MODERATE	SHOC2	8036	Transcript	NM_007373.4	protein_coding	2/9	.	NM_007373.4:c.377C>T	NP_031399.2:p.Thr126Ile	665	377	126	T/I	aCa/aTa	rs138375593	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	SHOC2	.	chr10:g.112724493C>T	.	.	.	.	.	.	likely_benign	.	1	.	.	.	.	.	SHOC2&NM_007373.3&c.377C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	T	0.29607	-0.141771	D	0.68184	-0.0327684	21.9	22.3	2.356938	2.396902	0.38103	0.41447	C/C	T	0.05795	0.0516940710911475	0.59204	0.993162836398918	.	0.53845	.	C/C	2	4.5392646391284613E-4	0	0.0	3.905095	0.331430484968046	0.57395	3.185969	0.173017913604129	0.49906	.	.	.	9	7.413e-05	8	7.732e-04	1	8.679e-05	9	7.428e-05	0	0	0	0	0	0	0	0	7	6.591e-05	6	6.642e-04	1	8.956e-05	7	6.599e-05	0	0	0	0	0	0	0	0	9	9.917e-05	8	7.746e-04	1	8.688e-05	9	9.944e-05	0	0	0	0	0	0	0	0	0.90509	.	.	.	5.99	5.99	0.97299	0	0.89359	0.724815	.	.	0.98316	1.0	.	0	0.93749	0.732669	.	.	.	.	.	.	0	0.83352	0.714379	.&.	.	.	.	0.76795	.	0.045218	0.84330	D	0.000000	D	0.67693	0.059523	0.69500	.	0.50075	.	D	0.89066	0.6836	.	0.20116	.	D	0.85609	0.1822	.	.	.	.	.	.	0.36358	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.38345	.	.	.	0.30888	.	.	0.34014	.	D	0.86884	0.832102060318	0.42395	.	10	0.28210	.	.	0.31987	.	.	20.4777	0.99191	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.47301	.	C/C	I	.	T	T	915	0.20917	.	10	CN166718&CN169374	.	ORPHA536391	Likely_benign	NC_000010.11:g.110964735C>T	448932	reviewed_by_expert_panel	Rasopathy&not_specified	ClinGen_RASopathy_Variant_Curation_Expert_Panel:d94b82b8-4e72-4968-9e10-08d187667aa6	.	.	AEFBI	D	0.77947	0.97896	D	0.69437	0.754523	.	12	4.781410e-05	11	6.769230e-04	16250	0	1	2.894020e-05	34554	0	250972	0	0.000000e+00	10068	0	0	0.000000e+00	18386	0	0	0.000000e+00	21644	0	0	0.000000e+00	113344	0	11	6.769230e-04	16250	0	0	0.000000e+00	30614	0	6	5.485760e-05	5	6.981290e-04	7162	0	1	5.848640e-05	17098	0	109374	0	0.000000e+00	2320	0	0	0.000000e+00	9040	0	0	0.000000e+00	13392	0	0	0.000000e+00	42760	0	5	6.981290e-04	7162	0	0	0.000000e+00	15690	0	0	.	0	9	3.806400e-05	8	5.369850e-04	14898	0	1	2.922100e-05	34222	0	236444	0	0.000000e+00	9560	0	0	0.000000e+00	17684	0	0	0.000000e+00	21628	0	0	0.000000e+00	102336	0	8	5.369850e-04	14898	0	0	0.000000e+00	30524	0	0	12	5.768070e-05	11	6.785100e-04	16212	0	1	3.279760e-05	30490	0	208042	0	0.000000e+00	6210	0	0	0.000000e+00	13408	0	0	0.000000e+00	16730	0	0	0.000000e+00	89526	0	11	6.785100e-04	16212	0	0	0.000000e+00	30606	0	0	9	3.683150e-05	8	6.655570e-04	12020	0	1	2.905290e-05	34420	0	244356	0	0.000000e+00	9986	0	0	0.000000e+00	18382	0	0	0.000000e+00	21642	0	0	0.000000e+00	111256	0	8	6.655570e-04	12020	0	0	0.000000e+00	30614	0	0	15	9.857400e-05	15	3.620220e-04	41434	0	0	0.000000e+00	912	0	0	0.000000e+00	15278	0	152170	0	0.000000e+00	3470	0	0	0.000000e+00	5204	0	0	0.000000e+00	10612	0	0	0.000000e+00	316	0	0	0.000000e+00	68028	0	15	3.620220e-04	41434	0	0	0.000000e+00	4826	0	0	0.000000e+00	0	0.000000e+00	9094	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32902	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5492	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3112	0	0	.	0	15	1.014060e-04	15	3.648570e-04	41112	0	0	0.000000e+00	912	0	0	0.000000e+00	15092	0	147920	0	0.000000e+00	3300	0	0	0.000000e+00	4970	0	0	0.000000e+00	10612	0	0	0.000000e+00	304	0	0	0.000000e+00	64804	0	0	0.000000e+00	4794	0	0	8	5.936220e-05	8	2.464120e-04	32466	0	0	0.000000e+00	862	0	0	0.000000e+00	14832	0	134766	0	0.000000e+00	3386	0	0	0.000000e+00	5204	0	0	0.000000e+00	6980	0	0	0.000000e+00	310	0	0	0.000000e+00	63902	0	0	0.000000e+00	4824	0	0	9	1.114800e-04	9	3.627570e-04	24810	0	0	0.000000e+00	112	0	0	0.000000e+00	12904	0	80732	0	0.000000e+00	996	0	0	0.000000e+00	3762	0	0	0.000000e+00	10520	0	0	0.000000e+00	272	0	0	0.000000e+00	21042	0	0	0.000000e+00	4798	0	0	10	112714483	10	112724493	0	0.97449	0.736574	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	6.109000	0.71203	0.596000	0.33519	1.022000	0.39869	110964735	C	.	rs138375593	.	.	7.357	8.846	9.854	7.528	.	.	.	45	19	-15	46	0.00	0.00	0.00	0.00	SHOC2	0.99	exon-NM_001324336.2-2+326+end+937	448932	Likely_benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&RASopathy	MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	rs138375593	7.413e-05	9	9	0	8	1	0	0	0	0	0	10346	11522	8638	6610	66644	908	16502	8	1	0	0	0	0	0	0	0	0	0	0	0	0	rs138375593	7.19142e-04	2.98169e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.97199e-05	7.19916e-05	7.19142e-04	5.27897e-05	rs138375593	1.03164e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	3.50754e-04	2.16544e-04	1.03164e-03	2.90398e-04	rs138375593	0.0&0.0454&0.0154	rs138375593	138375593	.	.	.	SHOC2	SHOC2:exonic	SHOC2:missense	SHOC2:Noonan_syndrome-like_with_loose_anagen_hair_1	SHOC2:607721	SHOC2:3	SHOC2:Autosomal_dominant	0	0.991705191552454	0.00829295945769003	1.84898985615785e-06	DISEASE: Noonan syndrome-like disorder with loose anagen hair (NSLH) [MIM:607721]: A syndrome characterized by Noonan dysmorphic features such as macrocephaly, high forehead, hypertelorism, palpebral ptosis, low-set and posteriorly rotated ears, short and webbed neck, pectus anomalies, in association with pluckable, sparse, thin and slow-growing hair. {ECO:0000269|PubMed:19684605, ECO:0000269|PubMed:25137548}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,601	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
10	89623026	89623038	TGCAAAAGCCGCA	T	-	5_prime_UTR_variant	MODIFIER	KLLN	100144748	Transcript	NM_001126049.2	protein_coding	1/1	.	NM_001126049.2:c.-794_-783del	.	253-264	.	.	.	.	rs587781340	GCAAAAGCCGCA	.	-1	.	1	EntrezGene	.	YES	.	.	GCAAAAGCCGCA	GCAAAAGCCGCA	.	.	KLLN	.	chr10:g.89623031_89623042del	.	.	.	.	.	.	uncertain_significance&likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	exon-NM_001126049.2-1+252+end+4376	189433	Likely_benign	reviewed_by_expert_panel	not_provided&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome	MedGen:CN517202&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs747418191	0.00000e+00	1.19617e-03	0.00000e+00	0.00000e+00	0.00000e+00	2.00080e-04	0.00000e+00	.	5.84864e-05	2.16638e-04	1.19617e-03	1.29066e-04	.	.	rs587781340	587781340	.	.	.	PTEN\x3bKLLN	PTEN:upstream\x7cKLLN:UTR5	.	KLLN:Cowden_syndrome_4	KLLN:615107	KLLN:3	KLLN:.	0				DISEASE: Cowden syndrome 4 (CWS4) [MIM:615107]: A form of Cowden syndrome, a hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:21177507}. Note=The gene represented in this entry is involved in disease pathogenesis. Germline KLLN methylation is common among patients with Cowden syndrome or Cowden-like syndrome and is associated with increased risks of breast and renal cancer over PTEN mutation-positive individuals (PubMed:21177507). {ECO:0000269|PubMed:21177507}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,502	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	112760217	112760217	C	T	T	synonymous_variant	LOW	SHOC2	8036	Transcript	NM_007373.4	protein_coding	4/9	.	NM_007373.4:c.886C>T	NP_031399.2:p.Leu296%3D	1174	886	296	L	Ctg/Ttg	rs199723694	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	ADRA2A	.	chr10:g.112760217C>T	.	0	0.0014	0	0	0	benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.807	10.065	11.369	6.989	.	.	.	-1	-44	-44	1	0.00	0.01	0.00	0.00	SHOC2	0.99	exon-NM_001324336.2-4+44+start+131	448934	Benign	reviewed_by_expert_panel	not_provided&RASopathy&not_specified	MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN169374	.	10:112760217-112760217	1.235e-04	15	15	0	0	15	0	0	0	0	0	10398	11572	8648	6610	66708	908	16508	0	15	0	0	0	0	0	0	0	0	0	0	0	0	rs199723694	0.00000e+00	8.33780e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.41587e-05	1.61705e-04	8.33780e-04	1.17756e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199723694	199723694	.	.	.	SHOC2	SHOC2:exonic	SHOC2:synonymous_SNV	SHOC2:Noonan_syndrome-like_with_loose_anagen_hair_1	SHOC2:607721	SHOC2:3	SHOC2:Autosomal_dominant	0	0.991705191552454	0.00829295945769003	1.84898985615785e-06	DISEASE: Noonan syndrome-like disorder with loose anagen hair (NSLH) [MIM:607721]: A syndrome characterized by Noonan dysmorphic features such as macrocephaly, high forehead, hypertelorism, palpebral ptosis, low-set and posteriorly rotated ears, short and webbed neck, pectus anomalies, in association with pluckable, sparse, thin and slow-growing hair. {ECO:0000269|PubMed:19684605, ECO:0000269|PubMed:25137548}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,605	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89624325	89624325	C	G	G	intron_variant	MODIFIER	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	1/8	NM_000314.8:c.79+20C>G	.	.	.	.	.	.	rs587781291	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89624325C>G	.	.	.	.	.	.	likely_benign&uncertain_significance	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-2.595	10.567	.	-3.496	.	.	.	-1	30	-1	-20	0.00	0.00	0.00	0.04	PTEN	0.98	.	140807	Uncertain_significance	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587781291	587781291	.	.	.	PTEN	PTEN:intronic	.	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,518	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
11	121008680	121008680	C	T	T	synonymous_variant	LOW	TBCEL-TECTA	116804918	Transcript	NM_001378761.1	protein_coding	17/30	.	NM_001378761.1:c.4449C>T	NP_001365690.1:p.Thr1483%3D	4656	4449	1483	T	acC/acT	rs144012985	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TECTA	.	chr11:g.121008680C>T	.	0.0045	0	0	0	0	uncertain_significance&likely_benign&benign	.	1	.	.	.	.	.	TECTA&NM_005422.2&c.3492C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.782	10.098	6.303	10.106	.	.	.	.	.	.	.	.	.	.	.	.	.	exon-NM_001378761.1-17+51+end+602	178539	Likely_benign	reviewed_by_expert_panel	not_provided&Nonsyndromic_genetic_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_21&Autosomal_dominant_nonsyndromic_hearing_loss_12&not_specified	MedGen:CN517202&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0011351&MedGen:C1863655&OMIM:603629&Orphanet:90636&MONDO:MONDO:0011102&MedGen:C1832187&OMIM:601543&Orphanet:90635&MedGen:CN169374	.	rs144012985	4.942e-04	60	60	0	52	2	0	0	6	0	0	10124	11508	8610	6606	65844	900	16378	52	2	0	0	6	0	0	0	0	0	0	0	0	0	rs144012985	4.52756e-03	3.27810e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.00116e-04	0.00000e+00	0.00000e+00	3.13555e-04	4.44219e-04	4.52756e-03	3.69525e-04	rs144012985	5.04587e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66667e-05	0.00000e+00	.	1.81265e-03	1.01068e-03	5.04587e-03	1.45199e-03	rs144012985	0.0&0.4085&0.1384	rs144012985	144012985	.	.	.	TBCEL-TECTA\x3bTECTA	TBCEL-TECTA:exonic\x7cTECTA:exonic	TBCEL-TECTA:synonymous_SNV\x7cTECTA:synonymous_SNV	.	.	.	.	0	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,637	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	25398229	25398229	G	A	A	synonymous_variant	LOW	KRAS	3845	Transcript	NM_004985.5	protein_coding	2/5	.	NM_004985.5:c.90C>T	NP_004976.2:p.Asp30%3D	280	90	30	D	gaC/gaT	rs113623140&COSV55881519	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	KRAS	.	chr12:g.25398229G>A	.	0	0.0014	0	0	0	likely_benign&benign/likely_benign	0&1	1&1	.	.	.	.	.	LYRM5&NM_001001660.2&c.*40983G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.388	8.395	4.988	9.402	.	.	.	6	-1	-22	-21	0.00	0.00	0.00	0.00	KRAS	0.00	exon-NM_001369787.1-2+21+start+122	138061	Likely_benign	reviewed_by_expert_panel	not_specified&RASopathy&Prostate_cancer&_hereditary&_1&Carcinoma_of_pancreas&Familial_cancer_of_breast&Autoimmune_lymphoproliferative_syndrome_type_4&Lung_cancer&Cerebral_arteriovenous_malformation&Noonan_syndrome_3&Linear_nevus_sebaceous_syndrome&Malignant_tumor_of_urinary_bladder&Toriello-Lacassie-Droste_syndrome&Acute_myeloid_leukemia&Cardiofaciocutaneous_syndrome_2&Gastric_cancer	MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0011098&MedGen:C4722327&OMIM:601518&Orphanet:1331&MONDO:MONDO:0005192&MeSH:C562463&MedGen:C0235974&OMIM:260350&Orphanet:1333&Orphanet:217074&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MONDO:MONDO:0013767&MedGen:C2674723&OMIM:614470&Orphanet:268114&MONDO:MONDO:0008903&MedGen:C0242379&OMIM:211980&Human_Phenotype_Ontology:HP:0002408&MONDO:MONDO:0007154&MedGen:C0917804&OMIM:108010&Orphanet:46724&MONDO:MONDO:0012371&MedGen:C1860991&OMIM:609942&Orphanet:648&Human_Phenotype_Ontology:HP:0010817&MONDO:MONDO:0008097&MedGen:C4552097&OMIM:163200&Orphanet:2612&MONDO:MONDO:0001187&MedGen:C0005684&OMIM:109800&Orphanet:157980&MONDO:MONDO:0010854&MedGen:C1838329&OMIM:600268&Orphanet:3339&Human_Phenotype_Ontology:HP:0001914&Human_Phenotype_Ontology:HP:0004808&Human_Phenotype_Ontology:HP:0004843&Human_Phenotype_Ontology:HP:0005516&Human_Phenotype_Ontology:HP:0006724&Human_Phenotype_Ontology:HP:0006728&MONDO:MONDO:0018874&MeSH:D015470&MedGen:C0023467&OMIM:601626&Orphanet:519&MONDO:MONDO:0014112&MedGen:C3809005&OMIM:615278&Orphanet:1340&Human_Phenotype_Ontology:HP:0012126&MONDO:MONDO:0001056&MeSH:D013274&MedGen:C0024623&OMIM:613659	.	rs113623140	1.895e-04	23	23	0	2	5	5	0	10	0	1	7996	8618	6746	5104	42758	668	12524	2	5	5	0	10	0	1	0	0	0	0	0	0	0	rs113623140	2.01803e-04	2.70270e-04	1.24044e-03	4.66690e-04	4.51467e-05	1.01096e-04	3.70920e-04	6.65690e-05	2.04375e-04	1.92192e-04	1.24044e-03	2.03029e-04	rs113623140	0.00000e+00	0.00000e+00	3.31126e-03	0.00000e+00	0.00000e+00	6.66756e-05	0.00000e+00	.	0.00000e+00	1.44425e-04	3.31126e-03	6.45328e-05	.	.	rs113623140	113623140	.	.	.	KRAS	KRAS:exonic	KRAS:synonymous_SNV	KRAS:Gastric_cancer\x2csomatic\x3bOculoectodermal_syndrome\x2csomatic\x3bBreast_cancer\x2csomatic\x3bNoonan_syndrome_3\x3bRAS-associated_autoimmune_leukoproliferative_disorder\x3bArteriovenous_malformation_of_the_brain\x2csomatic\x3bLung_cancer\x2csomatic\x3bPancreatic_carcinoma\x2csomatic\x3bLeukemia\x2cacute_myeloid\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bCardiofaciocutaneous_syndrome_2\x3bBladder_cancer\x2csomatic	KRAS:613659\x3b600268\x3b114480\x3b609942\x3b614470\x3b108010\x3b211980\x3b260350\x3b601626\x3b163200\x3b615278\x3b109800	KRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	KRAS:.\x3b.\x3b.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3b.\x3b.\x3bAutosomal_dominant\x3b.	0	0.00106119304255182	0.603148256118395	0.395790550839053	DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes. {ECO:0000269|PubMed:8955068}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:17332249}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 3 (NS3) [MIM:609942]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:16474405, ECO:0000269|PubMed:16773572, ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:17468812, ECO:0000269|PubMed:19396835}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:7773929}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in KRAS are a cause of pylocytic astrocytoma (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. {ECO:0000269|PubMed:16247081}.; DISEASE: Cardiofaciocutaneous syndrome 2 (CFC2) [MIM:615278]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. CFC2 patients often do not have the skin abnormalities, such as ichthyosis, hyperkeratosis, and hemangioma observed in CFC1. {ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:16474405, ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:21797849}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=KRAS mutations are involved in cancer development. {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:1553789, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:3627975, ECO:0000269|PubMed:6092920, ECO:0000269|PubMed:6695174, ECO:0000269|PubMed:7773929}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,640	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103245465	103245465	C	T	T	splice_region_variant&synonymous_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	8/13	.	NM_000277.3:c.912G>A	NP_000268.1:p.Gln304%3D	1026	912	304	Q	caG/caA	rs199475583&CS973748	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103245465C>T	.	.	.	.	.	.	not_provided&likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.912G>A	0.999861570951186	0.998	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.506	11.083	11.570	9.399	7.662	3.421	11.083	-21	25	-34	0	0.00	0.00	0.00	0.70	PAH	0.00	exon-NM_001354304.2-9+0+start+70	102892	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	12:103245465-103245465	8.236e-06	1	1	0	0	1	0	0	0	0	0	10350	11494	8608	6598	66558	908	16454	0	1	0	0	0	0	0	0	0	0	0	0	0	0	rs199475583	0.00000e+00	2.98098e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.99863e-06	2.98098e-05	4.06062e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475583	199475583	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bsynonymous_SNV	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,688	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103248897	103248897	C	A	A	intron_variant	MODIFIER	PAH	5053	Transcript	NM_000277.3	protein_coding	.	6/12	NM_000277.3:c.706+17G>T	.	.	.	.	.	.	rs62508592	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103248897C>A	.	0.0008	0.0014	0	0	0	likely_benign&not_provided	.	1	.	.	.	.	.	PAH&NM_000277.1&c.706+17G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.651	9.399	7.292	9.354	.	.	.	26	17	2	1	0.00	0.00	0.01	0.00	PAH	0.00	.	102792	Likely_benign	reviewed_by_expert_panel	Phenylketonuria&not_provided	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MedGen:CN517202	.	rs62508592	2.718e-04	33	33	0	28	4	0	0	1	0	0	10390	11528	8612	6484	66574	902	16458	28	4	0	0	1	0	0	0	0	0	0	0	0	0	rs62508592	2.54869e-03	2.97885e-04	0.00000e+00	0.00000e+00	0.00000e+00	8.96797e-06	1.82615e-04	0.00000e+00	1.92947e-04	2.24695e-04	2.54869e-03	2.11149e-04	rs62508592	1.94686e-03	1.19332e-03	0.00000e+00	0.00000e+00	0.00000e+00	6.66311e-05	0.00000e+00	.	4.67344e-04	7.93765e-04	1.94686e-03	6.13061e-04	rs62508592	0.0&0.227&0.0769	rs62508592	62508592	.	.	.	PAH	PAH:intronic	.	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,757	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89685317	89685317	A	T	T	splice_donor_region_variant&intron_variant	LOW	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	3/8	NM_000314.8:c.209+3A>T	.	.	.	.	.	.	rs786202612	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89685317A>T	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	.	0.999688591812238	1.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.389	9.651	10.295	7.964	-6.174	14.138	7.964	-3	-47	17	-3	0.00	0.91	0.00	0.97	PTEN	0.98	.	185989	Uncertain_significance	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786202612	786202612	.	.	.	PTEN	PTEN:splicing\x3bintronic	PTEN:splice_donor_region_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,531	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89685314	89685318	TGTAA	T	-	splice_donor_variant&splice_donor_region_variant&intron_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	3/8	NM_000314.8:c.209+4_209+7del	.	.	.	.	.	.	rs398123318	GTAA	.	1	.	.	EntrezGene	.	.	.	.	GTAA	GTAA	.	.	PTEN	.	chr10:g.89685318_89685321del	.	.	.	.	.	.	likely_pathogenic&pathogenic	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.389	9.651	10.295	7.964	.	.	.	-1	-45	19	-1	0.00	0.96	0.00	0.98	PTEN	0.98	.	92816	Pathogenic	reviewed_by_expert_panel	not_provided&Neoplasm_of_ovary&Cowden_syndrome_1&Endometrial_carcinoma&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome	MedGen:CN517202&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267&OMIM:167000&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&Human_Phenotype_Ontology:HP:0012114&MONDO:MONDO:0002447&MedGen:C0476089&OMIM:608089&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs398123318	398123318	.	.	.	PTEN	PTEN:splicing\x3bintronic	PTEN:splice_donor_variant\x3bsplice_donor_region_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,530	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89692876	89692876	A	C	C	synonymous_variant	LOW	PTEN	5728	Transcript	NM_000314.8	protein_coding	5/9	.	NM_000314.8:c.360A>C	NP_000305.3:p.Ala120%3D	1205	360	120	A	gcA/gcC	rs759485888	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PTEN	.	chr10:g.89692876A>C	.	.	.	.	.	.	likely_benign&benign	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.360A>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.752	10.998	5.352	9.651	.	.	.	-40	2	34	10	0.00	0.01	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-6+106+start+239	189426	Likely_benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	10:89692876-89692876	8.236e-06	1	1	0	0	0	0	0	1	0	0	10406	11578	8650	6614	66738	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs759485888	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.97118e-06	0.00000e+00	0.00000e+00	7.42104e-06	0.00000e+00	8.97118e-06	4.06058e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs759485888	759485888	.	.	.	PTEN	PTEN:exonic	PTEN:synonymous_SNV	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,543	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89653834	89653834	C	T	T	synonymous_variant	LOW	PTEN	5728	Transcript	NM_000314.8	protein_coding	2/9	.	NM_000314.8:c.132C>T	NP_000305.3:p.Gly44%3D	977	132	44	G	ggC/ggT	rs150651961&COSV64295419&COSV64298027	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89653834C>T	.	0	0	0	0.001	0	likely_benign&benign/likely_benign	0&1&1	1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.132C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.295	10.567	-2.595	-3.496	.	.	.	-36	-13	-2	32	0.00	0.04	0.00	0.24	PTEN	0.98	exon-NM_001304717.5-3+32+end+85	92813	Likely_benign	reviewed_by_expert_panel	Breast_and/or_ovarian_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Cowden_syndrome_1&Malignant_tumor_of_breast&PTEN_hamartoma_tumor_syndrome	MedGen:CN221562&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0007254&MedGen:C0006142&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	rs150651961	1.565e-03	190	1	1	0	2	0	25	157	6	0	10368	11478	8630	6602	66606	906	16506	0	0	0	0	1	0	0	0	0	0	0	1	0	0	rs150651961	6.53595e-05	1.49076e-04	3.15041e-03	1.74034e-04	3.19331e-03	2.22533e-03	2.01023e-03	0.00000e+00	1.49967e-03	1.51147e-03	3.19331e-03	1.50251e-03	rs150651961	2.29148e-04	0.00000e+00	6.62252e-03	0.00000e+00	3.72493e-03	4.73649e-03	5.10204e-03	.	2.74757e-03	3.32370e-03	6.62252e-03	3.00077e-03	rs150651961	0.2212&0.0&0.1462	rs150651961	150651961	.	.	.	PTEN	PTEN:exonic	PTEN:synonymous_SNV	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,524	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89623200	89623200	C	A	A	5_prime_UTR_variant	MODIFIER	KLLN	100144748	Transcript	NM_001126049.2	protein_coding	1/1	.	NM_001126049.2:c.-956G>T	.	91	.	.	.	.	rs34149102	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	KLLN	.	chr10:g.89623200C>A	.	0	0.0029	0	0.005	0	likely_benign&benign	.	1	.	.	.	.	.	KLLN&NM_001126049.1&c.-956G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	exon-NM_001126049.2-1+90+end+4376	138836	Likely_benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Cowden_syndrome_4&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0014046&MedGen:C3554517&OMIM:615107&Orphanet:201&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs34149102	1.84077e-03	3.61446e-03	1.00000e-02	0.00000e+00	5.45037e-03	8.40785e-03	6.10998e-03	.	5.68049e-03	5.49848e-03	1.00000e-02	5.58317e-03	.	.	rs34149102	34149102	.	.	.	PTEN\x3bKLLN	PTEN:upstream\x7cKLLN:UTR5	.	KLLN:Cowden_syndrome_4	KLLN:615107	KLLN:3	KLLN:.	0				DISEASE: Cowden syndrome 4 (CWS4) [MIM:615107]: A form of Cowden syndrome, a hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:21177507}. Note=The gene represented in this entry is involved in disease pathogenesis. Germline KLLN methylation is common among patients with Cowden syndrome or Cowden-like syndrome and is associated with increased risks of breast and renal cancer over PTEN mutation-positive individuals (PubMed:21177507). {ECO:0000269|PubMed:21177507}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,504	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89711899	89711899	C	T	T	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	6/9	.	NM_000314.8:c.517C>T	NP_000305.3:p.Arg173Cys	1362	517	173	R/C	Cgc/Tgc	rs121913293&CM074467&COSV64288569&COSV64310838	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89711899C>T	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&0&1&1	1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.517C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.97026	0.58199	D	0.96976	0.598212	31	32	4.397331	4.578612	0.90061	0.92166	./.	D	0.98628	0.999713361263275	0.98586	0.99918830432990591	.	0.99656	.	./.	.	.	.	.	14.1585	0.909364957293436	0.95968	13.07779	0.97243194743676	0.94832	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.98905	.	.	.	5.74	5.74	0.90070	0	0.74545	0.702456	.	.	0.74766	0.999999999999992	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.98432	0.735409	Tensin-type_phosphatase_domain&Protein-tyrosine_phosphatase&_catalytic	.	.	.	0.99239	.	0.048960	0.84330	D	0.000000	D	0.98599	0.819946	0.98161	.	0.99176	.	D	0.99421	0.9811	.	0.97178	.	D	0.98289	1.0578	.	.	.	.	.	.	0.96960	.	.	0.81001	simple_aae	D	1	0.94120	.	.	.	0.90584	.	.	0.71341	.	D	0.98467	0.921934485435	0.99695	.	9	0.92824	.	.	0.91255	.	.	19.9308	0.97119	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.99863	.	./.	C	.	R	T	926	0.17793	.	10	C0376358&C0006118&CN072330&C1848599&C1854416&C3551915&C2751642&C0027672&C1959582&CN169374&CN517202	176807&158350&276950&605309&607174&613028	ORPHA3412&ORPHA210548&ORPHA140162&ORPHA306498	Pathogenic	NC_000010.11:g.87952142C>T	189500	reviewed_by_expert_panel	Malignant_tumor_of_prostate&Neoplasm_of_brain&Cowden_syndrome_1&VACTERL_association_with_hydrocephalus&Macrocephaly/autism_syndrome&Meningioma&_familial&Glioma_susceptibility_2&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_specified&not_provided	UniProtKB_(protein):P60484#VAR_026267&Herman_Laboratory&Nationwide_Children's_Hospital:PTENv2017-22	.	.	AEFDGBCI	D	0.63368	0.95081	D	0.92668	0.933981	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.581810e-06	0	0.000000e+00	41326	0	0	0.000000e+00	912	0	0	0.000000e+00	15262	0	151934	0	0.000000e+00	3472	0	0	0.000000e+00	5186	0	0	0.000000e+00	10550	0	0	0.000000e+00	316	0	1	1.470420e-05	68008	0	1	1.470420e-05	68008	0	0	0.000000e+00	4818	0	0	0.000000e+00	0	0.000000e+00	9060	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32786	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5430	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3102	0	0	.	0	1	6.770940e-06	0	0.000000e+00	41008	0	0	0.000000e+00	912	0	0	0.000000e+00	15074	0	147690	0	0.000000e+00	3302	0	0	0.000000e+00	4952	0	0	0.000000e+00	10550	0	0	0.000000e+00	304	0	1	1.543500e-05	64788	0	0	0.000000e+00	4786	0	0	0	0.000000e+00	0	0.000000e+00	32382	0	0	0.000000e+00	862	0	0	0.000000e+00	14816	0	134550	0	0.000000e+00	3388	0	0	0.000000e+00	5186	0	0	0.000000e+00	6914	0	0	0.000000e+00	310	0	0	0.000000e+00	63882	0	0	0.000000e+00	4816	0	0	1	1.242080e-05	0	0.000000e+00	24702	0	0	0.000000e+00	112	0	0	0.000000e+00	12888	0	80510	0	0.000000e+00	998	0	0	0.000000e+00	3744	0	0	0.000000e+00	10458	0	0	0.000000e+00	272	0	1	4.753760e-05	21036	0	0	0.000000e+00	4790	0	0	10	89701879	10	89711899	0	0.85440	0.722319	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	7.464000	0.79911	0.549000	0.26987	1.026000	0.45946	87952142	C	.	rs121913293	.	.	6.460	9.066	10.752	10.998	.	.	.	20	-24	-2	-9	0.00	0.01	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-7+24+start+142	189500	Pathogenic	reviewed_by_expert_panel	Cowden_syndrome_1&Macrocephaly-autism_syndrome&VACTERL_with_hydrocephalus&not_provided&Neurodevelopmental_delay&Hereditary_cancer-predisposing_syndrome&Neoplasm_of_brain&not_specified&Glioma_susceptibility_2&Familial_meningioma&Malignant_tumor_of_prostate&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548&MONDO:MONDO:0010172&MedGen:C1848599&OMIM:276950&Orphanet:3412&MedGen:CN517202&Human_Phenotype_Ontology:HP:0012758&MedGen:C4022738&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&Human_Phenotype_Ontology:HP:0030692&MONDO:MONDO:0021211&MeSH:D001932&MedGen:C0006118&MedGen:CN169374&MONDO:MONDO:0013092&MedGen:C2751642&OMIM:613028&Orphanet:182067&MONDO:MONDO:0011789&MedGen:C3551915&OMIM:607174&Orphanet:263662&Human_Phenotype_Ontology:HP:0012125&MONDO:MONDO:0008315&MedGen:C0376358&OMIM:176807&Orphanet:1331&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs121913293	121913293	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,562	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
12	103246590	103246590	C	G	G	splice_donor_region_variant&intron_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	.	7/12	NM_000277.3:c.842+3G>C	.	.	.	.	.	.	rs62507324&CD000607&CS971843	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246590C>G	.	.	.	.	.	.	likely_pathogenic&pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.842+3G>C	0.921272038820334	0.748	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.570	11.083	7.651	9.399	3.774	5.625	9.399	-16	35	18	3	0.00	0.00	0.01	0.90	PAH	0.00	.	102871	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62507324	8.236e-06	1	1	0	0	0	0	0	1	0	0	10406	11572	8652	6614	66740	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs62507324	0.00000e+00	5.95664e-05	0.00000e+00	0.00000e+00	0.00000e+00	8.96909e-06	0.00000e+00	0.00000e+00	2.22608e-05	0.00000e+00	5.95664e-05	1.21817e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62507324	62507324	.	.	.	PAH	PAH:splicing\x3bintronic	PAH:splice_donor_region_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,705	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103246589	103246589	T	C	C	splice_donor_region_variant&intron_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	.	7/12	NM_000277.3:c.842+4A>G	.	.	.	.	.	.	rs1555204434&CS110429&CS158323	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103246589T>C	.	.	.	.	.	.	likely_pathogenic&uncertain_significance	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.842+4A>T	0.996759618672863	0.93	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.570	11.083	7.651	9.399	3.492	5.908	9.399	-15	36	0	4	0.00	0.00	0.03	0.84	PAH	0.00	.	439228	Likely_pathogenic	reviewed_by_expert_panel	not_specified&Phenylketonuria	MedGen:CN169374&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1555204434	1555204434	.	.	.	PAH	PAH:splicing\x3bintronic	PAH:splice_donor_region_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,704	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89623251	89623251	G	C	C	5_prime_UTR_variant	MODIFIER	KLLN	100144748	Transcript	NM_001126049.2	protein_coding	1/1	.	NM_001126049.2:c.-1007C>G	.	40	.	.	.	.	rs587780001&COSV64306074	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	KLLN	.	chr10:g.89623251G>C	.	.	.	.	.	.	conflicting_interpretations_of_pathogenicity&likely_benign&uncertain_significance	0&1	1&1	.	.	.	.	.	PTEN&NM_000314.4&c.-976G>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	exon-NM_001126049.2-1+39+end+4376	127685	Likely_benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&PTEN_hamartoma_tumor_syndrome&Seizure	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&Human_Phenotype_Ontology:HP:0001250&Human_Phenotype_Ontology:HP:0001275&Human_Phenotype_Ontology:HP:0001303&Human_Phenotype_Ontology:HP:0002125&Human_Phenotype_Ontology:HP:0002182&Human_Phenotype_Ontology:HP:0002279&Human_Phenotype_Ontology:HP:0002306&Human_Phenotype_Ontology:HP:0002348&Human_Phenotype_Ontology:HP:0002391&Human_Phenotype_Ontology:HP:0002417&Human_Phenotype_Ontology:HP:0002430&Human_Phenotype_Ontology:HP:0002431&Human_Phenotype_Ontology:HP:0002432&Human_Phenotype_Ontology:HP:0002434&Human_Phenotype_Ontology:HP:0002437&Human_Phenotype_Ontology:HP:0002466&Human_Phenotype_Ontology:HP:0002479&Human_Phenotype_Ontology:HP:0002794&Human_Phenotype_Ontology:HP:0006997&Human_Phenotype_Ontology:HP:0010520&MedGen:C0036572	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587780001	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.05886e-03	2.00321e-03	4.08998e-03	.	1.64223e-03	1.95709e-03	6.05886e-03	1.77500e-03	.	.	rs587780001	587780001	.	.	.	PTEN\x3bKLLN	PTEN:upstream\x7cKLLN:UTR5	.	KLLN:Cowden_syndrome_4	KLLN:615107	KLLN:3	KLLN:.	0				DISEASE: Cowden syndrome 4 (CWS4) [MIM:615107]: A form of Cowden syndrome, a hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:21177507}. Note=The gene represented in this entry is involved in disease pathogenesis. Germline KLLN methylation is common among patients with Cowden syndrome or Cowden-like syndrome and is associated with increased risks of breast and renal cancer over PTEN mutation-positive individuals (PubMed:21177507). {ECO:0000269|PubMed:21177507}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,505	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89712021	89712021	G	C	C	splice_donor_5th_base_variant&intron_variant	LOW	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	6/8	NM_000314.8:c.634+5G>C	.	.	.	.	.	.	rs138336847&CS010097&CS991491&COSV64291709&COSV64294394&COSV64310386	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89712021G>C	.	.	.	.	.	.	pathogenic&uncertain_significance&likely_pathogenic	0&0&0&1&1&1	1&1&1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.634+5G>T	0.999972798976155	0.966	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.460	7.806	10.752	9.066	1.070	7.996	9.066	24	-18	24	-5	0.00	0.00	0.01	0.99	PTEN	0.98	.	427623	Likely_pathogenic	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1&not_specified	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MedGen:CN169374	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs138336847	138336847	.	.	.	PTEN	PTEN:splicing\x3bintronic	PTEN:splice_donor_5th_base_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,569	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89717626	89717626	C	T	T	synonymous_variant	LOW	PTEN	5728	Transcript	NM_000314.8	protein_coding	7/9	.	NM_000314.8:c.651C>T	NP_000305.3:p.Val217%3D	1496	651	217	V	gtC/gtT	rs886038278&COSV64299647	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89717626C>T	.	.	.	.	.	.	benign&likely_benign	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.930	7.806	6.460	9.066	.	.	.	38	-16	-37	12	0.10	0.01	0.01	0.00	PTEN	0.98	exon-NM_001304717.5-8+16+start+167	255814	Likely_benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs886038278	886038278	.	.	.	PTEN	PTEN:exonic	PTEN:synonymous_SNV	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,570	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89717673	89717673	G	A	A	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	7/9	.	NM_000314.8:c.698G>A	NP_000305.3:p.Arg233Gln	1543	698	233	R/Q	cGa/cAa	rs770025422&CX1111739&COSV64293089	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89717673G>A	.	.	.	.	.	.	uncertain_significance&likely_pathogenic	0&0&1	1&1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.69614	0.153696	D	0.69226	-0.0170021	23.7	23.5	3.150692	2.973000	0.55436	0.54103	./.	D	0.42987	0.744608938694	0.97949	0.99910199036115233	.	0.91050	.	./.	.	.	.	.	4.757197	0.452973410690758	0.64908	4.081397	0.355873817953817	0.59051	.	.	.	1	8.236e-06	0	0	0	0	1	8.239e-06	0	0	0	0	1	1.498e-05	0	0	1	9.415e-06	0	0	0	0	1	9.418e-06	0	0	0	0	1	1.840e-05	0	0	1	1.102e-05	0	0	0	0	1	1.102e-05	0	0	0	0	1	2.373e-05	0	0	0.84701	.	.	.	5.15	5.15	0.70287	0	0.82719	0.723133	.	.	0.74766	0.999999771127238	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.49550	0.631631	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	0.95129	.	0.063428	0.62929	D	0.000006	D	0.79347	0.11458	0.87015	.	0.91314	.	T	0.79695	0.4719	.	0.66198	.	T	0.78723	-0.1579	R233Q	Loss_of_sheet_(P_=_0.0817)&_Gain_of_loop_(P_=_0.1069)&_Loss_of_phosphorylation_at_T232_(P_=_0.1298)&_Loss_of_glycosylation_at_P231_(P_=_0.1787)&_Gain_of_disorder_(P_=_0.2213)	P60484	0.58350	0.495	.	0.55341	.	.	0.58761	simple_aae	D	0.999993	0.42575	.	.	.	0.38693	.	.	0.33328	.	T	0.60082	0.650685787201	0.80007	.	9	0.25438	.	.	0.30375	.	.	12.0395	0.52740	0.0796:0.0:0.9204:0.0	.	.	.	.	.	.	.	.	0.87590	.	./.	Q	.	R	A	908	0.22609	.	10	C0279680&C0007873&C0278701&C0009404&C0007112&C0280630&C0027672&C1959582&C0017636&C0153574	.	ORPHA140162&ORPHA306498&ORPHA360	Uncertain_significance	NC_000010.11:g.87957916G>A	376510	reviewed_by_expert_panel	Transitional_cell_carcinoma_of_the_bladder&Neoplasm_of_uterine_cervix&Adenocarcinoma_of_stomach&Neoplasm_of_the_large_intestine&Adenocarcinoma_of_prostate&Uterine_Carcinosarcoma&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&Glioblastoma&Malignant_neoplasm_of_body_of_uterus	ClinGen_PTEN_Variant_Curation_Expert_Panel:84ca1fb2-bf36-42c2-8262-5a470ed8dfa7	.	.	AEFDGBI	D	0.72678	0.97098	D	0.85961	0.906611	.	1	3.977030e-06	0	0.000000e+00	16256	0	0	0.000000e+00	34584	0	251444	0	0.000000e+00	10080	0	0	0.000000e+00	18388	0	0	0.000000e+00	21642	0	1	8.792140e-06	113738	0	1	8.792140e-06	113738	0	0	0.000000e+00	30616	0	0	0.000000e+00	0	0.000000e+00	7164	0	0	0.000000e+00	17108	0	109400	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13394	0	0	0.000000e+00	42766	0	.	.	.	.	0	0.000000e+00	15690	0	0	segdup	0	1	4.221080e-06	0	0.000000e+00	14902	0	0	0.000000e+00	34252	0	236906	0	0.000000e+00	9572	0	0	0.000000e+00	17686	0	0	0.000000e+00	21626	0	1	9.735010e-06	102722	0	1	9.735010e-06	102722	0	0	0.000000e+00	30526	0	0	1	4.805200e-06	0	0.000000e+00	16218	0	0	0.000000e+00	30516	0	208108	0	0.000000e+00	6212	0	0	0.000000e+00	13410	0	0	0.000000e+00	16734	0	1	1.116770e-05	89544	0	1	1.116770e-05	89544	0	0	0.000000e+00	30608	0	0	1	4.084530e-06	0	0.000000e+00	12026	0	0	0.000000e+00	34450	0	244826	0	0.000000e+00	9998	0	0	0.000000e+00	18384	0	0	0.000000e+00	21640	0	1	8.956720e-06	111648	0	1	8.956720e-06	111648	0	0	0.000000e+00	30616	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89707653	10	89717673	0	0.83141	0.719381	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	7.734000	0.83867	0.618000	0.50648	1.176000	0.78918	87957916	G	.	rs770025422	.	.	12.930	7.806	6.460	9.066	.	.	.	-8	-9	-35	18	0.00	0.07	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-8+63+start+167	376510	Uncertain_significance	reviewed_by_expert_panel	Neoplasm_of_uterine_cervix&Uterine_carcinosarcoma&Malignant_neoplasm_of_body_of_uterus&Gastric_adenocarcinoma&Neoplasm_of_the_large_intestine&Prostate_adenocarcinoma&Glioblastoma&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&Transitional_cell_carcinoma_of_the_bladder	Human_Phenotype_Ontology:HP:0032241&MONDO:MONDO:0021230&MeSH:D002583&MedGen:C0007873&MONDO:MONDO:0006485&MedGen:C0280630&MedGen:C0153574&Human_Phenotype_Ontology:HP:0033770&MONDO:MONDO:0005036&MedGen:C0278701&Orphanet:464463&Human_Phenotype_Ontology:HP:0100834&MONDO:MONDO:0005335&MeSH:D015179&MedGen:C0009404&MONDO:MONDO:0005082&MedGen:C0007112&MONDO:MONDO:0018177&MeSH:D005909&MedGen:C0017636&Orphanet:360&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&Human_Phenotype_Ontology:HP:0006740&MONDO:MONDO:0005611&MedGen:C0279680	.	10:89717673-89717673	8.236e-06	1	1	0	0	0	0	0	1	0	0	10406	11558	8648	6614	66734	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs770025422	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95335e-06	0.00000e+00	0.00000e+00	0.00000e+00	8.98134e-06	8.95335e-06	4.06055e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs770025422	770025422	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,572	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
12	103238111	103238111	T	C	C	splice_donor_region_variant&intron_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	.	10/12	NM_000277.3:c.1065+3A>G	.	.	.	.	.	.	rs62508689&CS941526&CS991475	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103238111T>C	.	.	.	.	.	.	pathogenic&uncertain_significance&likely_pathogenic	.	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.1065+3A>G	0.998723292790589	0.88	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.163	9.158	7.709	9.459	5.286	4.173	9.459	-36	-13	-36	3	0.00	0.00	0.17	0.57	PAH	0.00	.	633	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Hyperphenylalaninemia&Phenylketonuria	MedGen:CN517202&Human_Phenotype_Ontology:HP:0004923&MedGen:C0751435&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508689	62508689	.	.	.	PAH	PAH:splicing\x3bintronic	PAH:splice_donor_region_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,675	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103237568	103237568	C	T	T	splice_polypyrimidine_tract_variant&intron_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	.	10/12	NM_000277.3:c.1066-11G>A	.	.	.	.	.	.	rs5030855&CS910455	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103237568C>T	.	0	0	0	0.003	0	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1066-11G>A	0.999788097146566	0.976	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	gain/acceptor/103237568-103237569/Medium/1.655872	3.163	9.158	7.709	9.459	-2.790	5.953	3.163	-2	-11	-2	-9	0.98	0.61	0.00	0.00	PAH	0.00	.	607	Pathogenic	reviewed_by_expert_panel	not_provided&Inborn_genetic_diseases&Phenylketonuria	MedGen:CN517202&MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs5030855	2.718e-04	33	33	0	0	2	0	0	27	1	3	10252	11526	8630	6600	66622	908	16496	0	2	0	0	27	1	3	0	0	0	0	0	0	0	rs5030855	0.00000e+00	1.49040e-04	1.01605e-04	0.00000e+00	4.53597e-05	4.04393e-04	9.15416e-04	9.74786e-05	2.60215e-04	2.25266e-04	4.04393e-04	2.43643e-04	rs5030855	1.14653e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	4.00481e-04	0.00000e+00	.	2.33973e-04	2.16826e-04	4.00481e-04	2.25865e-04	rs5030855	0.0581&0.0&0.0384	rs5030855	5030855	.	.	.	PAH	PAH:splicing\x3bintronic	PAH:splice_polypyrimidine_tract_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,674	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89717675	89717675	C	T	T	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	7/9	.	NM_000314.8:c.700C>T	NP_000305.3:p.Arg234Trp	1545	700	234	R/W	Cgg/Tgg	rs786201730&COSV64296468&COSV64305690	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89717675C>T	.	.	.	.	.	.	likely_pathogenic&uncertain_significance	0&1&1	1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.700C>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	D	0.75475	0.216821	D	0.75156	0.0736716	26.2	27.4	3.869983	3.966274	0.74330	0.81115	C/C	D	0.80829	0.990600109100342	0.98309	0.99914623600585184	.	0.98782	.	C/C	.	.	.	.	6.57618	0.62684007870292	0.76896	6.447467	0.647790294031194	0.76226	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.85613	.	.	.	5.15	5.15	0.70287	0	0.82719	0.723133	.	.	0.74766	0.999999477354451	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.49550	0.631631	Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain&Tensin_phosphatase&_C2_domain	.	.	.	0.61533	.	0.000000	0.84330	D	0.000000	D	0.91609	0.325836	0.81811	.	0.81812	.	D	0.90640	0.7266	.	0.79892	.	D	0.90229	0.4776	R234W	Loss_of_disorder_(P_=_0.0165)&_Loss_of_solvent_accessibility_(P_=_0.0199)&_Loss_of_methylation_at_K237_(P_=_0.0317)&_Loss_of_ubiquitination_at_K237_(P_=_0.0554)&_Loss_of_phosphorylation_at_T232_(P_=_0.0658)	P60484	0.55168	0.475	.	0.43327	.	.	0.81001	simple_aae	D	1	0.81514	.	.	.	0.90584	.	.	0.72444	.	T	0.78659	0.778218984604	0.86686	.	9	0.69154	.	.	0.33418	.	.	18.6161	0.91258	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.82559	.	C/C	W	.	R	T	908	0.22609	.	10	C0027651&CN072330&C0027672&C1959582&CN517202	158350	ORPHA140162&ORPHA306498	Uncertain_significance	NC_000010.11:g.87957918C>T	184844	reviewed_by_expert_panel	Neoplasm&Cowden_syndrome_1&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:45c8d19e-5bfc-4e2d-bc35-187033466d5d	.	.	AEFDGBI	D	0.61382	0.94505	D	0.81607	0.885497	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.570990e-06	0	0.000000e+00	41428	0	0	0.000000e+00	912	0	0	0.000000e+00	15274	0	152184	0	0.000000e+00	3470	0	0	0.000000e+00	5202	0	0	0.000000e+00	10610	0	0	0.000000e+00	316	0	1	1.469680e-05	68042	0	1	1.469680e-05	68042	0	0	0.000000e+00	4838	0	0	0.000000e+00	0	0.000000e+00	9092	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32894	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5482	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3116	0	0	.	0	1	6.759950e-06	0	0.000000e+00	41106	0	0	0.000000e+00	912	0	0	0.000000e+00	15086	0	147930	0	0.000000e+00	3302	0	0	0.000000e+00	4968	0	0	0.000000e+00	10610	0	0	0.000000e+00	304	0	1	1.542880e-05	64814	0	0	0.000000e+00	4806	0	0	1	7.419940e-06	0	0.000000e+00	32458	0	0	0.000000e+00	862	0	0	0.000000e+00	14828	0	134772	0	0.000000e+00	3386	0	0	0.000000e+00	5202	0	0	0.000000e+00	6970	0	0	0.000000e+00	310	0	1	1.564500e-05	63918	0	0	0.000000e+00	4836	0	0	0	0.000000e+00	0	0.000000e+00	24802	0	0	0.000000e+00	112	0	0	0.000000e+00	12900	0	80742	0	0.000000e+00	996	0	0	0.000000e+00	3760	0	0	0.000000e+00	10518	0	0	0.000000e+00	272	0	0	0.000000e+00	21054	0	0	0.000000e+00	4810	0	0	10	89707655	10	89717675	0	0.83141	0.719381	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	4.498000	0.60095	0.549000	0.26987	1.026000	0.45946	87957918	C	.	rs786201730	.	.	12.930	7.806	6.460	9.066	.	.	.	-36	-11	-37	16	0.00	0.05	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-8+65+start+167	184844	Uncertain_significance	reviewed_by_expert_panel	Neoplasm&not_provided&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	Human_Phenotype_Ontology:HP:0002664&Human_Phenotype_Ontology:HP:0003008&Human_Phenotype_Ontology:HP:0006741&MONDO:MONDO:0005070&MeSH:D009369&MedGen:C0027651&MedGen:CN517202&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786201730	786201730	.	.	.	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,573	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.3246	VUS
12	103237522	103237522	C	T	T	synonymous_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1101G>A	NP_000268.1:p.Leu367%3D	1215	1101	367	L	ctG/ctA	rs62508648&CM056671	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103237522C>T	.	.	.	.	.	.	likely_benign&likely_pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1101G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.924	9.158	3.163	9.459	.	.	.	-2	35	-2	37	0.05	0.25	0.00	0.00	PAH	0.00	exon-NM_001354304.2-12+35+end+134	102526	Likely_pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs62508648	62508648	.	.	.	PAH	PAH:exonic	PAH:synonymous_SNV	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,665	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
12	103237426	103237426	T	A	A	splice_region_variant&synonymous_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	11/13	.	NM_000277.3:c.1197A>T	NP_000268.1:p.Val399%3D	1311	1197	399	V	gtA/gtT	rs199475584&CS010562	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103237426T>A	.	.	.	.	.	.	pathogenic	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1198del	0.0494080417081547	0.71	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.924	9.158	3.163	9.459	7.648	1.509	9.158	-2	28	-19	-2	0.00	0.00	0.04	0.43	PAH	0.00	exon-NM_001354304.2-12+2+start+134	601	Pathogenic	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475584	0.00000e+00	0.00000e+00	0.00000e+00	5.79912e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.41851e-06	0.00000e+00	5.79912e-05	4.06062e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199475584	199475584	.	.	.	PAH	PAH:splicing\x3bexonic	PAH:splice_region_variant\x3bsynonymous_SNV	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,659	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89653781	89653781	G	C	C	splice_acceptor_variant	HIGH	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	1/8	NM_000314.8:c.80-1G>C	.	.	.	.	.	.	rs786204914&CS157862&COSV64288482	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89653781G>C	.	.	.	.	.	.	pathogenic&likely_pathogenic	0&0&1	1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.80-1G>C	0.999947963975431	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-2.595	10.567	.	-3.496	-10.659	8.064	-2.595	40	-6	17	-6	0.08	0.33	0.00	0.00	PTEN	0.98	.	189462	Likely_pathogenic	reviewed_by_expert_panel	not_provided&PTEN_hamartoma_tumor_syndrome	MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786204914	786204914	.	.	.	PTEN	PTEN:splicing	PTEN:splice_acceptor_variant	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,520	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
10	89624340	89624340	C	T	T	intron_variant	MODIFIER	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	1/8	NM_000314.8:c.79+35C>T	.	.	.	.	.	.	rs190707033&CS068804&COSV104426418	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89624340C>T	.	0	0	0	0.003	0.002	likely_benign&benign	0&0&1	1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.79+35C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-2.595	10.567	.	-3.496	.	.	.	15	41	-16	41	0.00	0.00	0.00	0.01	PTEN	0.98	.	92827	Benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	rs190707033	2.150e-03	261	1	2	7	58	0	8	122	3	63	10394	11570	8636	6614	66716	906	16512	0	0	0	0	1	0	0	0	2	0	0	0	0	0	rs190707033	5.22739e-04	2.11435e-03	7.10660e-04	5.79777e-05	1.30057e-03	1.93413e-03	3.82932e-03	3.41108e-03	2.07580e-03	1.59876e-03	3.41108e-03	1.85973e-03	rs190707033	5.72475e-04	1.19617e-03	0.00000e+00	0.00000e+00	5.72410e-04	1.73241e-03	0.00000e+00	.	1.05116e-03	1.15507e-03	1.73241e-03	1.09706e-03	rs190707033	0.1047&0.0227&0.0769	rs190707033	190707033	.	.	.	PTEN	PTEN:intronic	.	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,519	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3246	VUS
16	68867265	68867265	A	G	G	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	16/16	.	NM_004360.5:c.2512A>G	NP_004351.1:p.Ser838Gly	2636	2512	838	S/G	Agc/Ggc	rs121964872&CM1612919&COSV55733312	A	.	1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	TANGO6	.	chr16:g.68867265A>G	.	.	.	.	.	.	likely_benign&uncertain_significance&pathogenic&conflicting_interpretations_of_pathogenicity	0&0&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.2512A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	T	0.11416	-0.273086	T	0.42126	-0.324069	22.1	21.4	2.412002	2.193024	0.39304	0.36982	A/A	T	0.16998	0.148681461811066	0.57222	0.99261368065590105	.	0.64439	.	A/A	0	0.0	1	1.1627906976744187E-4	2.779093	0.110762966279459	0.45098	2.100738	-0.123719768847196	0.36361	.	.	.	4	3.295e-05	0	0	0	0	4	3.295e-05	0	0	0	0	4	5.994e-05	0	0	3	2.825e-05	0	0	0	0	3	2.825e-05	0	0	0	0	3	5.520e-05	0	0	3	3.306e-05	0	0	0	0	3	3.306e-05	0	0	0	0	3	7.119e-05	0	0	0.76300	.	.	.	6.04	6.04	0.98025	0	0.63936	0.670034	.	.	0.13706	0.0263434949648934	.	0	0.64325	0.697927	.	.	.	.	.	.	0	0.14980	0.542086	Cadherin&_cytoplasmic_domain&Cadherin&_cytoplasmic_domain&.	.	.	.	0.59601	.	0.000000	0.62929	D	0.000011	D	0.49502	0.026606	0.30296	.	0.86448	.	T	0.60976	0.2416	.	0.38894	.	T	0.63897	-0.6222	.	.	.	.	.	.	0.09600	.	.	0.34935	simple_aae&simple_aae	D&D	0.818449&0.832196	0.35991	.	.	.	0.18677	.	.	0.28220	.	T	0.40789	0.514048933983	0.53788	.	10	0.29056	.	.	0.27194	.	.	11.589	0.50191	0.9295:0.0:0.0705:0.0	.	.	.	.	.	.	.	.	0.26354	.	A/A	G	.	S	G	363	0.84772	.	16	C0919267&C1708349&C0027672&C0346153&CN169374&CN517202	167000&137215&114480	ORPHA26106&ORPHA140162&ORPHA227535	Likely_benign	NC_000016.10:g.68833362A>G	12233	reviewed_by_expert_panel	Neoplasm_of_ovary&Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&Familial_cancer_of_breast&not_specified&not_provided	Institute_of_Human_Genetics&_University_of_Leipzig_Medical_Center:CV_629&OMIM_Allelic_Variant:192090.0003&Illumina_Laboratory_Services&Illumina:821912&ClinGen_CDH1_Variant_Curation_Expert_Panel&:85364a5d-816a-4c65-a3f3-29c77698b3b9&UniProtKB_(protein):P12830#VAR_001322	.	.	AEFBI	D	0.47810	0.88049	D	0.53385	0.500709	.	11	4.373900e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34592	0	251492	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	11	9.668970e-05	113766	0	11	9.668970e-05	113766	0	0	0.000000e+00	30616	0	4	3.656040e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	4	9.352790e-05	42768	0	4	9.352790e-05	42768	0	0	0.000000e+00	15690	0	0	.	0	10	4.220230e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236954	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	10	9.732360e-05	102750	0	10	9.732360e-05	102750	0	0	0.000000e+00	30526	0	0	7	3.363220e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208134	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	7	7.816340e-05	89556	0	7	7.816340e-05	89556	0	0	0.000000e+00	30608	0	0	11	4.492110e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244874	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	11	9.849920e-05	111676	0	11	9.849920e-05	111676	0	0	0.000000e+00	30616	0	0	17	1.117080e-04	0	0.000000e+00	41438	0	0	0.000000e+00	912	0	1	6.543650e-05	15282	0	152182	0	0.000000e+00	3472	0	0	0.000000e+00	5192	0	0	0.000000e+00	10620	0	0	0.000000e+00	316	0	16	2.351900e-04	68030	0	16	2.351900e-04	68030	0	0	0.000000e+00	4830	0	2	6.081250e-05	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	1	2.134020e-04	4686	0	32888	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5492	0	0	0.000000e+00	246	0	1	1.459850e-04	6850	0	0	0.000000e+00	3108	0	0	.	0	17	1.149220e-04	0	0.000000e+00	41118	0	0	0.000000e+00	912	0	1	6.625150e-05	15094	0	147926	0	0.000000e+00	3302	0	0	0.000000e+00	4956	0	0	0.000000e+00	10620	0	0	0.000000e+00	304	0	16	2.469060e-04	64802	0	0	0.000000e+00	4798	0	0	16	1.187190e-04	0	0.000000e+00	32464	0	0	0.000000e+00	862	0	1	6.740360e-05	14836	0	134772	0	0.000000e+00	3388	0	0	0.000000e+00	5192	0	0	0.000000e+00	6982	0	0	0.000000e+00	310	0	15	2.347050e-04	63910	0	0	0.000000e+00	4828	0	0	4	4.953930e-05	0	0.000000e+00	24814	0	0	0.000000e+00	112	0	1	7.747130e-05	12908	0	80744	0	0.000000e+00	998	0	0	0.000000e+00	3750	0	0	0.000000e+00	10528	0	0	0.000000e+00	272	0	3	1.425580e-04	21044	0	0	0.000000e+00	4802	0	0	16	67424766	16	68867265	0	0.41029	0.631515	0.996000	0.39380	0.958000	0.51230	0.957000	0.42767	4.411000	0.59536	0.756000	0.94297	1.312000	0.94714	68833362	A	.	rs121964872	.	.	.	.	10.931	9.815	.	.	.	-2	2	43	2	0.02	0.00	0.00	0.00	CDH1	0.34	exon-NM_001317185.2-16+72+start+2248	12233	Likely_benign	reviewed_by_expert_panel	Endometrial_carcinoma&Familial_cancer_of_breast&Malignant_tumor_of_prostate&Neoplasm_of_ovary&Blepharocheilodontic_syndrome_1&Hereditary_diffuse_gastric_adenocarcinoma&Hereditary_cancer-predisposing_syndrome&not_provided&not_specified	Human_Phenotype_Ontology:HP:0012114&MONDO:MONDO:0002447&MedGen:C0476089&OMIM:608089&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&Human_Phenotype_Ontology:HP:0012125&MONDO:MONDO:0008315&MedGen:C0376358&OMIM:176807&Orphanet:1331&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267&OMIM:167000&MONDO:MONDO:0054740&MedGen:C4551988&OMIM:119580&Orphanet:1997&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MedGen:CN169374	.	rs121964872	3.295e-05	4	4	0	0	0	0	0	4	0	0	10406	11578	8654	6614	66738	908	16512	0	0	0	0	4	0	0	0	0	0	0	0	0	0	rs121964872	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.95127e-05	0.00000e+00	0.00000e+00	4.44748e-05	3.59195e-05	8.95127e-05	4.06055e-05	rs121964872	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.33156e-04	0.00000e+00	.	1.16795e-04	2.16575e-04	3.33156e-04	1.61332e-04	rs121964872	0.0116&0.0&0.0077	rs121964872	121964872	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,923	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1877	VUS
16	68847376	68847376	A	G	G	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	9/16	.	NM_004360.5:c.1298A>G	NP_004351.1:p.Asp433Gly	1422	1298	433	D/G	gAt/gGt	rs376097289	A	.	1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	TANGO6	.	chr16:g.68847376A>G	.	.	.	.	.	.	benign/likely_benign&likely_benign&benign	.	1	.	.	.	.	.	CDH1&NM_004360.3&c.1298A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	T	0.08672	-0.299862	T	0.41937	-0.325776	24.9	23.9	3.569685	3.135838	0.65894	0.57927	A/A	D	0.33582	0.525872588157654	0.79842	0.9969006249758936	.	0.83890	.	A/A	.	.	.	.	4.66821	0.441725722811418	0.64186	5.03706	0.500193654760649	0.67102	.	.	.	9	7.413e-05	0	0	0	0	9	7.413e-05	8	9.244e-04	0	0	0	0	0	0	7	6.591e-05	0	0	0	0	7	6.591e-05	7	8.899e-04	0	0	0	0	0	0	4	4.408e-05	0	0	0	0	4	4.408e-05	3	5.321e-04	0	0	0	0	0	0	0.38236	.	.	.	5.82	5.82	0.92740	0	0.79440	0.708844	.	.	0.32215	0.990621301217756	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.26826	0.564101	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like	.	.	.	0.29475	.	0.684158	0.13033	N	0.408144	D	0.69970	0.066766	0.70559	.	0.87234	.	T	0.54797	0.1943	.	0.45357	.	T	0.56553	-0.7755	D433G	Loss_of_stability_(P_=_0.1246)&_Gain_of_catalytic_residue_at_P429_(P_=_0.1657)&_Gain_of_ubiquitination_at_K437_(P_=_0.1725)&_Loss_of_solvent_accessibility_(P_=_0.2953)&_Loss_of_sheet_(P_=_0.3635)	P12830	0.84047	0.704	.	0.49092	.	.	0.51042	without_aae&simple_aae	D&N	0.999911&0.999999	0.72353	.	.	.	0.48285	.	.	0.56425	.	T	0.09500	0.293940424919	0.70764	.	10	0.72224	.	.	0.50132	.	.	10.2742	0.42679	0.8526:0.0:0.0:0.1474	.	.	.	.	.	.	.	.	0.51494	.	A/A	G	.	D	G	315	0.87208	.	16	C0006142&C1708349&C0027672&CN169374&CN517202	137215	ORPHA26106&ORPHA140162	Benign	NC_000016.10:g.68813473A>G	141810	reviewed_by_expert_panel	Malignant_tumor_of_breast&Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:13766caf-9ff5-48fb-a208-1ee4d81736e0&Illumina_Laboratory_Services&Illumina:800452&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2556750	.	.	AEFGBI	D	0.79218	0.98055	D	0.76371	0.846845	.	13	5.169310e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34592	0	251484	0	0.000000e+00	10080	0	11	5.980210e-04	18394	0	0	0.000000e+00	21648	0	1	8.790440e-06	113760	0	11	5.980210e-04	18394	0	0	0.000000e+00	30616	0	5	4.570050e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	5	5.527300e-04	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	5	5.527300e-04	9046	0	0	0.000000e+00	15690	0	0	.	0	11	4.642410e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236946	0	0.000000e+00	9572	0	10	5.652270e-04	17692	0	0	0.000000e+00	21632	0	1	9.732930e-06	102744	0	10	5.652270e-04	17692	0	0	0.000000e+00	30526	0	0	6	2.882790e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208132	0	0.000000e+00	6212	0	4	2.981510e-04	13416	0	0	0.000000e+00	16734	0	1	1.116620e-05	89556	0	4	2.981510e-04	13416	0	0	0.000000e+00	30608	0	0	13	5.309030e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244866	0	0.000000e+00	9998	0	11	5.981510e-04	18390	0	0	0.000000e+00	21646	0	1	8.954960e-06	111670	0	11	5.981510e-04	18390	0	0	0.000000e+00	30616	0	0	11	7.226100e-05	3	7.235890e-05	41460	0	0	0.000000e+00	912	0	1	6.543650e-05	15282	0	152226	0	0.000000e+00	3472	0	4	7.701190e-04	5194	0	0	0.000000e+00	10622	0	0	0.000000e+00	316	0	2	2.939450e-05	68040	0	4	7.701190e-04	5194	0	0	0.000000e+00	4834	0	2	6.076810e-05	0	0.000000e+00	9102	0	0	0.000000e+00	60	0	1	2.133110e-04	4688	0	32912	0	0.000000e+00	136	0	1	4.115230e-04	2430	0	0	0.000000e+00	5494	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3114	0	0	.	0	10	6.758220e-05	3	7.292530e-05	41138	0	0	0.000000e+00	912	0	1	6.625150e-05	15094	0	147968	0	0.000000e+00	3302	0	4	8.064520e-04	4960	0	0	0.000000e+00	10622	0	0	0.000000e+00	304	0	2	3.085940e-05	64810	0	0	0.000000e+00	4802	0	0	9	6.675960e-05	2	6.156500e-05	32486	0	0	0.000000e+00	862	0	1	6.740360e-05	14836	0	134812	0	0.000000e+00	3388	0	4	7.701190e-04	5194	0	0	0.000000e+00	6982	0	0	0.000000e+00	310	0	1	1.564500e-05	63918	0	0	0.000000e+00	4832	0	0	6	7.427210e-05	2	8.052180e-05	24838	0	0	0.000000e+00	112	0	1	7.747130e-05	12908	0	80784	0	0.000000e+00	998	0	1	2.665250e-04	3752	0	0	0.000000e+00	10530	0	0	0.000000e+00	272	0	1	4.751050e-05	21048	0	0	0.000000e+00	4806	0	0	16	67404877	16	68847376	0	0.52595	0.67177	1.000000	0.71638	0.839000	0.39591	0.929000	0.39736	5.995000	0.70302	0.751000	0.87719	1.307000	0.88494	68813473	A	.	rs376097289	.	.	10.239	7.806	7.382	7.312	.	.	.	22	-9	31	22	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-9+22+end+183	141810	Benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Hereditary_diffuse_gastric_adenocarcinoma&Malignant_tumor_of_breast	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0007254&MedGen:C0006142	.	16:68847376-68847376	7.413e-05	9	9	0	0	0	8	0	0	1	0	10406	11578	8654	6614	66738	908	16512	0	0	8	0	0	1	0	0	0	0	0	0	0	0	rs376097289	0.00000e+00	0.00000e+00	0.00000e+00	5.21800e-04	0.00000e+00	8.95175e-06	1.82282e-04	0.00000e+00	2.96516e-05	6.28581e-05	5.21800e-04	4.46661e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs376097289	376097289	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,910	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1877	VUS
10	112724154	112724154	A	C	C	missense_variant	MODERATE	SHOC2	8036	Transcript	NM_007373.4	protein_coding	2/9	.	NM_007373.4:c.38A>C	NP_031399.2:p.Glu13Ala	326	38	13	E/A	gAa/gCa	rs730881018	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	SHOC2	.	chr10:g.112724154A>C	.	.	.	.	.	.	conflicting_interpretations_of_pathogenicity&likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	T	0.10936	-0.277484	T	0.50650	-0.241522	23.0	22.8	2.767397	2.635553	0.47044	0.46712	A/A	T	0.20614	0.203609590675606	0.70711	0.99544580227759949	.	0.53144	.	A/A	.	.	.	.	4.647143	0.439003866076337	0.64013	3.593558	0.262818673862206	0.54277	.	.	.	10	8.237e-05	0	0	10	8.924e-04	10	8.509e-05	0	0	0	0	0	0	0	0	10	9.416e-05	0	0	10	9.188e-04	10	9.687e-05	0	0	0	0	0	0	0	0	10	1.102e-04	0	0	10	8.932e-04	10	1.134e-04	0	0	0	0	0	0	0	0	0.37910	.	.	.	5.77	5.77	0.91077	0	0.89359	0.724815	.	.	0.74766	0.999999999998874	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.95156	0.727631	.&.	.	.	.	0.78806	.	0.044879	0.84330	D	0.000000	T	0.39418	0.017643	0.52795	.	0.17594	.	T	0.21921	0.0516	.	0.14127	.	T	0.12621	-1.0566	E13A	Gain_of_MoRF_binding_(P_=_0.0137)&_Loss_of_solvent_accessibility_(P_=_0.0224)&_Loss_of_loop_(P_=_0.0288)&_Gain_of_helix_(P_=_0.0349)&_Loss_of_ubiquitination_at_K12_(P_=_0.0513)	Q9UQ13	0.23632	0.281	.	0.52479	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.18877	.	.	.	0.42542	.	.	0.36881	.	T	0.70683	0.724361896515	0.48592	.	10	0.45961	.	.	0.91255	.	.	16.0957	0.80931	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.46274	.	A/A	A	.	E	C	914	0.21048	.	10	CN166718&C4478716&CN517202	607721	ORPHA536391	Likely_benign	NC_000010.11:g.110964396A>C	181526	reviewed_by_expert_panel	Rasopathy&Noonan_syndrome-like_disorder_with_loose_anagen_hair_1&not_provided	ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:63674&ClinGen_RASopathy_Variant_Curation_Expert_Panel:f83b1020-86c7-4755-94be-9a1eabb874c4	.	.	AEFBI	D	0.91270	0.99103	D	0.83586	0.895634	.	30	1.207260e-04	0	0.000000e+00	15640	0	30	8.764750e-04	34228	0	248496	0	0.000000e+00	10002	0	0	0.000000e+00	18118	0	0	0.000000e+00	21618	0	0	0.000000e+00	112606	0	30	8.764750e-04	34228	0	0	0.000000e+00	30268	0	14	1.286500e-04	0	0.000000e+00	7146	0	14	8.286970e-04	16894	0	108822	0	0.000000e+00	2304	0	0	0.000000e+00	8976	0	0	0.000000e+00	13390	0	0	0.000000e+00	42660	0	14	8.286970e-04	16894	0	0	0.000000e+00	15548	0	0	.	0	30	1.281190e-04	0	0.000000e+00	14306	0	30	8.850080e-04	33898	0	234158	0	0.000000e+00	9508	0	0	0.000000e+00	17430	0	0	0.000000e+00	21604	0	0	0.000000e+00	101728	0	30	8.850080e-04	33898	0	0	0.000000e+00	30178	0	0	27	1.311470e-04	0	0.000000e+00	15604	0	27	8.946910e-04	30178	0	205876	0	0.000000e+00	6148	0	0	0.000000e+00	13386	0	0	0.000000e+00	16710	0	0	0.000000e+00	88826	0	27	8.946910e-04	30178	0	0	0.000000e+00	30260	0	0	30	1.239600e-04	0	0.000000e+00	11490	0	30	8.799200e-04	34094	0	242014	0	0.000000e+00	9922	0	0	0.000000e+00	18114	0	0	0.000000e+00	21616	0	0	0.000000e+00	110560	0	30	8.799200e-04	34094	0	0	0.000000e+00	30268	0	0	3	1.971190e-05	0	0.000000e+00	41446	0	0	0.000000e+00	912	0	3	1.963350e-04	15280	0	152192	0	0.000000e+00	3472	0	0	0.000000e+00	5204	0	0	0.000000e+00	10604	0	0	0.000000e+00	316	0	0	0.000000e+00	68034	0	3	1.963350e-04	15280	0	0	0.000000e+00	4830	0	1	3.040440e-05	0	0.000000e+00	9092	0	0	0.000000e+00	60	0	1	2.133110e-04	4688	0	32890	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5484	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3112	0	0	.	0	3	2.027880e-05	0	0.000000e+00	41124	0	0	0.000000e+00	912	0	3	1.987810e-04	15092	0	147938	0	0.000000e+00	3302	0	0	0.000000e+00	4968	0	0	0.000000e+00	10604	0	0	0.000000e+00	304	0	0	0.000000e+00	64810	0	0	0.000000e+00	4798	0	0	3	2.225680e-05	0	0.000000e+00	32478	0	0	0.000000e+00	862	0	3	2.022380e-04	14834	0	134790	0	0.000000e+00	3388	0	0	0.000000e+00	5204	0	0	0.000000e+00	6974	0	0	0.000000e+00	310	0	0	0.000000e+00	63908	0	0	0.000000e+00	4828	0	0	2	2.476720e-05	0	0.000000e+00	24820	0	0	0.000000e+00	112	0	2	1.549670e-04	12906	0	80752	0	0.000000e+00	998	0	0	0.000000e+00	3762	0	0	0.000000e+00	10512	0	0	0.000000e+00	272	0	0	0.000000e+00	21048	0	0	0.000000e+00	4802	0	0	10	112714144	10	112724154	0	0.92422	0.732398	1.000000	0.71638	0.986000	0.61781	0.998000	0.65909	8.947000	0.92735	0.751000	0.87719	1.307000	0.88494	110964396	A	.	rs730881018	.	.	7.357	8.846	9.854	7.528	.	.	.	15	-49	-31	43	0.00	0.00	0.00	0.00	SHOC2	0.99	exon-NM_001324336.2-2+271+start+937	181526	Likely_benign	reviewed_by_expert_panel	not_provided&RASopathy&Noonan_syndrome-like_disorder_with_loose_anagen_hair_1	MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0054637&MedGen:C4478716&OMIM:607721&Orphanet:2701	.	10:112724154-112724154	8.237e-05	10	1	0	0	10	0	0	0	0	0	9590	11206	8134	6568	64782	880	16360	0	0	0	0	0	0	1	0	0	0	0	0	0	0	rs730881018	0.00000e+00	9.00198e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	7.47205e-05	1.81245e-04	9.00198e-04	1.21822e-04	rs730881018	0.00000e+00	1.19617e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	0.00000e+00	7.22543e-05	1.19617e-03	3.22664e-05	.	.	rs730881018	730881018	.	.	.	SHOC2	SHOC2:exonic	SHOC2:missense	SHOC2:Noonan_syndrome-like_with_loose_anagen_hair_1	SHOC2:607721	SHOC2:3	SHOC2:Autosomal_dominant	0	0.991705191552454	0.00829295945769003	1.84898985615785e-06	DISEASE: Noonan syndrome-like disorder with loose anagen hair (NSLH) [MIM:607721]: A syndrome characterized by Noonan dysmorphic features such as macrocephaly, high forehead, hypertelorism, palpebral ptosis, low-set and posteriorly rotated ears, short and webbed neck, pectus anomalies, in association with pluckable, sparse, thin and slow-growing hair. {ECO:0000269|PubMed:19684605, ECO:0000269|PubMed:25137548}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,599	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1877	VUS
21	36259232	36259232	C	A	A	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	4/9	.	NM_001754.5:c.259G>T	NP_001745.2:p.Gly87Cys	453	259	87	G/C	Ggc/Tgc	rs561166961	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36259232C>A	.	0	0.0014	0	0	0	likely_pathogenic&uncertain_significance	.	1	.	.	.	.	.	.	.	.	1	1.9968051118210862E-4	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	./.	C	D	0.86085	0.343747	D	0.89872	0.338858	29.9	32	4.335826	4.477960	0.89002	0.91685	./.	D	0.93453	0.998182833194733	0.86519	0.99778585439074863	.	0.99956	.	./.	.	.	.	.	9.406936	0.774375287985658	0.87963	9.744362	0.845859166056381	0.88870	.	.	.	1	8.247e-06	0	0	1	8.875e-05	1	8.557e-06	0	0	0	0	0	0	0	0	1	9.420e-06	0	0	1	9.136e-05	1	9.653e-06	0	0	0	0	0	0	0	0	1	1.104e-05	0	0	1	8.884e-05	1	1.153e-05	0	0	0	0	0	0	0	0	0.99572	.	.	.	4.72	4.72	0.59248	0	0.08562	0.516746	.	.	0.98316	1.0	.	0	0.37721	0.606814	.	.	.	.	.	.	0	0.19341	0.56214	Runt_domain&Runt_domain&.&.&Runt_domain&Runt_domain&.&Runt_domain&Runt_domain&Runt_domain&Runt_domain	.	.	.	0.85587	.	0.109177	0.62929	D	0.000006	D	0.99409	0.919806	0.89442	.	0.96469	.	D	0.99627	0.9873	.	0.91461	.	D	0.97458	1.0158	G60C	Gain_of_catalytic_residue_at_P59_(P_=_0.0135)&_Loss_of_disorder_(P_=_0.029)&_Loss_of_sheet_(P_=_0.0817)&_Loss_of_relative_solvent_accessibility_(P_=_0.1807)&_Loss_of_glycosylation_at_T65_(P_=_0.2399)	Q01196	0.89998	0.774	.	0.74080	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D&D&D	1&1&1&1&1&1&1	0.89833	.	.	.	0.90584	.	.	0.80445	.	D	0.89970	0.85236787796	0.97890	.	10	0.92824	.	.	0.91255	.	.	17.8668	0.88712	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.62781	.	./.	C	.	G	A	188	0.92666	.	21	C4552543&C1832388&CN169374&CN517202	601399	ORPHA457077	Uncertain_significance	NC_000021.9:g.34886935C>A	436618	reviewed_by_expert_panel	TAFRO_syndrome&Familial_platelet_disorder_with_associated_myeloid_malignancy&not_specified&not_provided	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:9b53e7f3-6c92-4c63-95f0-3c9f51ca59e4	.	.	ALL	D	0.67953	0.96191	D	0.89126	0.919971	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4	2.628090e-05	0	0.000000e+00	41448	0	0	0.000000e+00	912	0	4	2.617120e-04	15284	0	152202	0	0.000000e+00	3470	0	0	0.000000e+00	5196	0	0	0.000000e+00	10618	0	0	0.000000e+00	316	0	0	0.000000e+00	68038	0	4	2.617120e-04	15284	0	0	0.000000e+00	4828	0	3	9.119100e-05	0	0.000000e+00	9096	0	0	0.000000e+00	60	0	3	6.399320e-04	4688	0	32898	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3112	0	0	.	0	4	2.703580e-05	0	0.000000e+00	41128	0	0	0.000000e+00	912	0	4	2.649710e-04	15096	0	147952	0	0.000000e+00	3302	0	0	0.000000e+00	4960	0	0	0.000000e+00	10618	0	0	0.000000e+00	304	0	0	0.000000e+00	64812	0	0	0.000000e+00	4798	0	0	4	2.967490e-05	0	0.000000e+00	32482	0	0	0.000000e+00	862	0	4	2.695420e-04	14840	0	134794	0	0.000000e+00	3386	0	0	0.000000e+00	5196	0	0	0.000000e+00	6978	0	0	0.000000e+00	310	0	0	0.000000e+00	63912	0	0	0.000000e+00	4826	0	0	3	3.714710e-05	0	0.000000e+00	24826	0	0	0.000000e+00	112	0	3	2.323780e-04	12910	0	80760	0	0.000000e+00	996	0	0	0.000000e+00	3754	0	0	0.000000e+00	10526	0	0	0.000000e+00	272	0	0	0.000000e+00	21046	0	0	0.000000e+00	4800	0	0	21	35181102	21	36259232	1	0.06251	0.40479	1.000000	0.71638	0.998000	0.85391	1.000000	0.86279	7.376000	0.78918	0.599000	0.40250	1.026000	0.45946	34886935	C	.	rs561166961	.	.	5.882	8.558	8.426	9.942	.	.	.	-23	48	-8	25	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-4+92+start+254	436618	Uncertain_significance	reviewed_by_expert_panel	Castleman-Kojima_disease&not_specified&not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0018702&MedGen:C4552543&Orphanet:457077&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	21:36259233-36259235	8.247e-06	1	1	0	0	1	0	0	0	0	0	9790	11268	8424	6218	63944	864	16358	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs561166961	0.00000e+00	2.98329e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	9.12492e-06	2.98329e-05	8.12420e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs561166961	561166961	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,982	0	0	0	0	0	1	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0.1877	VUS
21	36164870	36164870	C	A	A	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	9/9	.	NM_001754.5:c.1005G>T	NP_001745.2:p.Gln335His	1199	1005	335	Q/H	caG/caT	rs80314254	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36164870C>A	.	0	0	0.001	0	0	benign	.	1	.	.	.	.	.	RUNX1&NM_001754.4&c.1005G>T	.	.	1	1.9968051118210862E-4	0	0.0	0	0.0	1	9.92063492063492E-4	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	C/C	C	T	0.14018	-0.250648	T	0.60609	-0.134288	23.0	23.0	2.796467	2.734147	0.47666	0.48847	C/C	T	0.09685	0.077662564492355	0.60131	0.99340130029713203	.	0.93996	.	C/C	.	.	.	.	3.355885	0.234303763838007	0.51762	3.419693	0.225889382661721	0.52456	.	.	.	17	1.411e-04	0	0	0	0	15	2.685e-04	15	3.566e-03	0	0	0	0	0	0	14	1.326e-04	0	0	0	0	12	2.455e-04	12	3.125e-03	0	0	0	0	0	0	7	7.776e-05	0	0	0	0	6	1.410e-04	6	2.005e-03	0	0	0	0	0	0	0.89363	.	.	.	5.22	3.06	0.34374	0	0.57511	0.643519	.	.	0.44398	0.999869792394647	.	0	0.28219	0.576033	.	.	.	.	.	.	0	0.83352	0.714379	.&.&.&.	.	.	.	0.88371	.	0.665201	0.15394	N	0.256858	D	0.87129	0.208109	0.78512	.	0.90232	.	D	0.86638	0.6208	.	0.00548	.	D	0.84755	0.1327	.	.	.	.	.	.	0.56829	.	.	0.32417	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&N	0.586172&0.586172&0.586172&0.586172&0.998826	0.65627	.	.	.	0.59044	.	.	0.51815	.	T	0.59812	0.648770570755	0.71401	.	10	0.25210	.	.	0.37536	.	.	4.4333	0.10963	0.1273:0.5828:0.1246:0.1652	.	.	.	.	.	.	.	.	0.35938	.	C/C	H	.	Q	A	399	0.82780	.	21	C1832388	601399	.	Benign	NC_000021.9:g.34792573C>A	239039	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	Illumina_Laboratory_Services&Illumina:637552&ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:1ef12dd0-41cd-4ff0-897f-dd0a414457bc	.	.	AEFBCI	D	0.42492	0.83370	N	0.32927	0.202703	.	34	1.532820e-04	0	0.000000e+00	13744	0	4	1.222200e-04	32728	0	221814	0	0.000000e+00	9434	0	25	1.461650e-03	17104	0	0	0.000000e+00	18738	0	0	0.000000e+00	96024	0	25	1.461650e-03	17104	0	2	7.014590e-05	28512	0	21	2.105260e-04	0	0.000000e+00	5916	0	3	1.856210e-04	16162	0	99750	0	0.000000e+00	2106	0	14	1.714010e-03	8168	0	0	0.000000e+00	12718	0	0	0.000000e+00	38412	0	14	1.714010e-03	8168	0	2	1.378360e-04	14510	0	0	.	0	31	1.467080e-04	0	0.000000e+00	12814	0	4	1.231450e-04	32482	0	211304	0	0.000000e+00	9076	0	22	1.325940e-03	16592	0	0	0.000000e+00	18722	0	0	0.000000e+00	87978	0	22	1.325940e-03	16592	0	2	7.030870e-05	28446	0	0	24	1.280700e-04	0	0.000000e+00	13710	0	3	1.044930e-04	28710	0	187398	0	0.000000e+00	5722	0	16	1.272470e-03	12574	0	0	0.000000e+00	15540	0	0	0.000000e+00	78190	0	16	1.272470e-03	12574	0	2	7.015570e-05	28508	0	0	34	1.566780e-04	0	0.000000e+00	10550	0	4	1.226020e-04	32626	0	217006	0	0.000000e+00	9378	0	25	1.461990e-03	17100	0	0	0.000000e+00	18736	0	0	0.000000e+00	94644	0	25	1.461990e-03	17100	0	2	7.014590e-05	28512	0	0	18	1.183950e-04	2	4.829750e-05	41410	0	0	0.000000e+00	910	0	2	1.308730e-04	15282	0	152034	0	0.000000e+00	3464	0	11	2.140910e-03	5138	0	0	0.000000e+00	10626	0	0	0.000000e+00	314	0	0	0.000000e+00	67976	0	11	2.140910e-03	5138	0	0	0.000000e+00	4822	0	7	2.128950e-04	2	2.200700e-04	9088	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32880	0	0.000000e+00	136	0	4	1.648800e-03	2426	0	0	0.000000e+00	5498	0	0	0.000000e+00	244	0	0	0.000000e+00	6848	0	0	0.000000e+00	3104	0	0	.	0	16	1.082680e-04	2	4.867600e-05	41088	0	0	0.000000e+00	910	0	2	1.325030e-04	15094	0	147782	0	0.000000e+00	3298	0	10	2.039980e-03	4902	0	0	0.000000e+00	10626	0	0	0.000000e+00	302	0	0	0.000000e+00	64750	0	0	0.000000e+00	4790	0	0	18	1.336940e-04	2	6.163330e-05	32450	0	0	0.000000e+00	860	0	2	1.348070e-04	14836	0	134636	0	0.000000e+00	3380	0	11	2.140910e-03	5138	0	0	0.000000e+00	6984	0	0	0.000000e+00	308	0	0	0.000000e+00	63858	0	0	0.000000e+00	4820	0	0	13	1.612140e-04	2	8.063870e-05	24802	0	0	0.000000e+00	112	0	1	7.747130e-05	12908	0	80638	0	0.000000e+00	992	0	7	1.893940e-03	3696	0	0	0.000000e+00	10534	0	0	0.000000e+00	270	0	0	0.000000e+00	21012	0	0	0.000000e+00	4794	0	0	21	35086740	21	36164870	0	0.73137	0.706548	1.000000	0.71638	0.998000	0.85391	0.999000	0.70432	0.779000	0.26407	0.581000	0.30040	0.118000	0.17292	34792573	C	.	rs80314254	.	.	.	.	9.279	7.470	.	.	.	-47	37	37	1	0.00	0.01	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-9+37+end+4810	239039	Benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	rs80314254	1.411e-04	17	15	0	0	0	15	0	0	0	0	4684	4408	4206	1608	30446	384	10122	0	0	15	0	0	0	0	0	0	0	0	0	0	0	rs80314254	0.00000e+00	1.25408e-04	0.00000e+00	1.37208e-03	0.00000e+00	0.00000e+00	6.07287e-04	6.96864e-05	1.41702e-04	1.43787e-04	1.37208e-03	1.46571e-04	rs80314254	1.15075e-04	0.00000e+00	0.00000e+00	3.71287e-03	0.00000e+00	0.00000e+00	1.02041e-03	.	2.93221e-04	2.17297e-04	3.71287e-03	2.58181e-04	.	.	rs80314254	80314254	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,952	0	0	0	0	0	1	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0.1877	VUS
21	36206814	36206814	C	T	T	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	7/9	.	NM_001754.5:c.698G>A	NP_001745.2:p.Arg233His	892	698	233	R/H	cGc/cAc	rs150042294&COSV55872151	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RUNX1	.	chr21:g.36206814C>T	.	0	0	0	0	0.001	likely_benign&uncertain_significance	0&1	1&1	.	.	.	.	.	RUNX1&NM_001001890.2&c.617G>A	.	.	1	1.9968051118210862E-4	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0010224948875255625	.	.	.	.	.	.	.	.	.	C/C	C	T	0.40159	-0.0772667	D	0.76353	0.0916078	22.7	23.0	2.631522	2.729416	0.44117	0.48753	C/C	T	0.01472	0.0264851658403516	0.95892	0.99883004513319251	.	0.80668	.	C/C	3	6.808896958692692E-4	0	0.0	4.214544	0.379235243195907	0.60287	3.886115	0.320397656991371	0.57196	.	.	.	20	1.647e-04	11	1.059e-03	2	1.729e-04	20	1.648e-04	0	0	5	7.562e-04	2	2.998e-05	0	0	18	1.695e-04	9	9.943e-04	2	1.784e-04	18	1.696e-04	0	0	5	7.562e-04	2	3.681e-05	0	0	17	1.873e-04	11	1.061e-03	2	1.730e-04	17	1.875e-04	0	0	4	1.052e-03	0	0	0	0	0.99284	.	.	.	4.86	4.86	0.62624	0	0.57511	0.643519	.	.	0.74766	0.999999999900658	.	0	0.07944	0.491513	.	.	.	.	.	.	0	0.95156	0.727631	.&.&.&.&.	.	.	.	0.86445	.	0.000000	0.84330	D	0.000000	D	0.94520	0.46145	0.73358	.	0.98011	.	D	0.98749	0.9611	.	0.14891	.	D	0.99812	1.1049	.	.	.	.	.	.	0.30300	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&without_aae	D&D&D&D&D&D	0.987847&0.987847&0.993536&0.987847&0.987847&1	0.20791	.	.	.	0.77913	.	.	0.77487	.	D	0.87140	0.833761572838	0.79217	.	10	0.13557	.	.	0.09658	.	.	17.9888	0.89084	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.68863	.	C/C	H	.	R	T	355	0.85216	.	21	C1832388&CN169374	601399	.	Likely_benign	NC_000021.9:g.34834517C>T	415832	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy&not_specified	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:52a12148-1cdf-4d95-bf36-4dfae2e0e6e7	.	.	AEFDBCI	D	0.50066	0.89538	D	0.68775	0.744907	.	31	1.235060e-04	22	1.353510e-03	16254	0	2	5.782350e-05	34588	0	251000	0	0.000000e+00	10078	0	0	0.000000e+00	18388	0	5	2.338420e-04	21382	0	2	1.761180e-05	113560	0	22	1.353510e-03	16254	0	0	0.000000e+00	30614	0	16	1.466170e-04	11	1.535880e-03	7162	0	1	5.845220e-05	17108	0	109128	0	0.000000e+00	2320	0	0	0.000000e+00	9042	0	3	2.285190e-04	13128	0	1	2.338310e-05	42766	0	11	1.535880e-03	7162	0	0	0.000000e+00	15690	0	0	.	0	29	1.226390e-04	20	1.342280e-03	14900	0	2	5.838390e-05	34256	0	236466	0	0.000000e+00	9570	0	0	0.000000e+00	17686	0	5	2.340170e-04	21366	0	2	1.950310e-05	102548	0	20	1.342280e-03	14900	0	0	0.000000e+00	30524	0	0	29	1.396310e-04	22	1.356680e-03	16216	0	2	6.553080e-05	30520	0	207690	0	0.000000e+00	6210	0	0	0.000000e+00	13410	0	4	2.428950e-04	16468	0	1	1.118590e-05	89398	0	22	1.356680e-03	16216	0	0	0.000000e+00	30606	0	0	26	1.063910e-04	17	1.413840e-03	12024	0	2	5.804840e-05	34454	0	244382	0	0.000000e+00	9996	0	0	0.000000e+00	18384	0	5	2.338630e-04	21380	0	2	1.794200e-05	111470	0	17	1.413840e-03	12024	0	0	0.000000e+00	30614	0	0	52	3.428680e-04	45	1.091230e-03	41238	0	0	0.000000e+00	912	0	1	6.585880e-05	15184	0	151662	0	0.000000e+00	3468	0	0	0.000000e+00	5148	0	1	9.496680e-05	10530	0	0	0.000000e+00	314	0	2	2.942650e-05	67966	0	45	1.091230e-03	41238	0	1	2.073830e-04	4822	0	15	4.582110e-04	12	1.328320e-03	9034	0	0	0.000000e+00	60	0	0	0.000000e+00	4674	0	32736	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	1	1.845020e-04	5420	0	0	0.000000e+00	244	0	0	0.000000e+00	6842	0	1	3.213370e-04	3112	0	0	.	0	51	3.459500e-04	44	1.075370e-03	40916	0	0	0.000000e+00	912	0	1	6.667560e-05	14998	0	147420	0	0.000000e+00	3300	0	0	0.000000e+00	4922	0	1	9.496680e-05	10530	0	0	0.000000e+00	302	0	2	3.089380e-05	64738	0	1	2.087680e-04	4790	0	0	46	3.424400e-04	39	1.206530e-03	32324	0	0	0.000000e+00	862	0	1	6.785180e-05	14738	0	134330	0	0.000000e+00	3384	0	0	0.000000e+00	5148	0	1	1.449700e-04	6898	0	0	0.000000e+00	308	0	2	3.132050e-05	63856	0	1	2.074690e-04	4820	0	0	32	3.986840e-04	27	1.096140e-03	24632	0	0	0.000000e+00	112	0	1	7.806400e-05	12810	0	80264	0	0.000000e+00	996	0	0	0.000000e+00	3708	0	1	9.580380e-05	10438	0	0	0.000000e+00	270	0	0	0.000000e+00	20996	0	1	2.085940e-04	4794	0	0	21	35128684	21	36206814	0	0.92422	0.732398	1.000000	0.71638	0.998000	0.85391	0.999000	0.70432	4.499000	0.60101	0.599000	0.40250	0.947000	0.34431	34834517	C	.	rs150042294	.	.	11.087	10.451	9.171	9.815	.	.	.	-33	20	3	-13	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-7+84+end+192	415832	Likely_benign	reviewed_by_expert_panel	not_provided&not_specified&Hereditary_cancer-predisposing_syndrome&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	rs150042294	1.647e-04	20	20	0	11	2	0	5	2	0	0	10388	11570	8646	6612	66712	908	16494	11	2	0	5	2	0	0	0	0	0	0	0	0	0	rs150042294	1.30685e-03	2.97779e-05	0.00000e+00	0.00000e+00	3.17604e-04	1.79363e-05	1.82415e-04	0.00000e+00	1.26257e-04	1.25967e-04	1.30685e-03	1.33998e-04	rs150042294	1.61551e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.69703e-05	1.02669e-03	.	4.11136e-04	6.52458e-04	1.61551e-03	5.16262e-04	rs150042294	0.0&0.0681&0.0231	rs150042294	150042294	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,955	0	0	0	0	0	1	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0.1877	VUS
16	68853296	68853296	C	G	G	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	11/16	.	NM_004360.5:c.1679C>G	NP_004351.1:p.Thr560Arg	1803	1679	560	T/R	aCg/aGg	rs746481984&CM135593&COSV55729145	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	.	chr16:g.68853296C>G	.	.	.	.	.	.	uncertain_significance&likely_pathogenic&pathogenic	0&0&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.1679C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	C/C	C	T	0.57937	0.0468491	T	0.57400	-0.170481	23.0	24.6	2.804279	3.387121	0.47829	0.64219	C/C	D	0.71660	0.977050065994263	0.54877	0.99188025228844823	.	0.78210	.	C/C	.	.	.	.	2.735088	0.10013530659174	0.44555	3.167284	0.168656396417213	0.49696	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.51228	.	.	.	5.55	4.57	0.55860	0	0.81188	0.709663	.	.	0.22049	0.640553716452471	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.26826	0.564101	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&.	.	.	.	0.53799	.	0.000000	0.52346	D	0.000070	D	0.84668	0.168636	0.73216	.	0.83699	.	T	0.61012	0.2419	.	0.60693	.	T	0.62521	-0.6544	T560R	Gain_of_methylation_at_T560_(P_=_0.0363)&_Loss_of_ubiquitination_at_K557_(P_=_0.0702)&_Loss_of_glycosylation_at_S559_(P_=_0.0811)&_Gain_of_sheet_(P_=_0.1539)&_Gain_of_disorder_(P_=_0.1709)	P12830	0.59757	0.504	.	0.38800	.	.	0.43861	simple_aae&simple_aae	D&D	0.997402&0.997402	0.61722	.	.	.	0.90584	.	.	0.86255	.	T	0.21748	0.376414477825	0.48268	.	10	0.21343	.	.	0.44029	.	.	16.1429	0.81351	0.0:0.8668:0.1331:0.0	.	.	.	.	.	.	.	.	0.81758	.	C/C	R	.	T	G	320	0.86992	.	16	C1708349&C0027672&CN169374	137215	ORPHA26106&ORPHA140162	Pathogenic	NC_000016.10:g.68819393C>G	234554	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified	ClinGen_CDH1_Variant_Curation_Expert_Panel&:89320d2b-848b-4794-bcc3-84d990e99660	.	.	AEFDGBI	N	0.28096	0.47942	N	0.52997	0.493974	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	67410797	16	68853296	0	0.61202	0.706298	0.619000	0.27905	0.891000	0.42908	0.023000	0.14501	1.206000	0.31926	0.526000	0.24426	0.127000	0.18199	68819393	C	.	rs746481984	.	.	10.720	9.332	5.134	10.735	.	.	.	0	9	0	32	0.00	0.00	0.98	0.14	CDH1	0.34	exon-NM_001317185.2-11+32+end+146	234554	Pathogenic	reviewed_by_expert_panel	Gastric_cancer&Hereditary_cancer-predisposing_syndrome&Hereditary_diffuse_gastric_adenocarcinoma&not_specified	Human_Phenotype_Ontology:HP:0012126&MONDO:MONDO:0001056&MeSH:D013274&MedGen:C0024623&OMIM:613659&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MedGen:CN169374	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs746481984	746481984	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,912	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1877	VUS
12	103260383	103260383	T	C	C	missense_variant	MODERATE	PAH	5053	Transcript	NM_000277.3	protein_coding	5/13	.	NM_000277.3:c.500A>G	NP_000268.1:p.Asn167Ser	614	500	167	N/S	aAc/aGc	rs77554925&CM011945&CM981434&COSV99076065	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103260383T>C	.	0.0151	0.0029	0	0	0	not_provided&uncertain_significance	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.500A>G	.	.	22	0.00439297124600639	20	0.015128593040847202	2	0.002881844380403458	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	T/T	T	T	0.02541	-0.393804	T	0.41899	-0.326124	11.00	9.215	0.950372	0.480278	0.14424	0.10545	T/T	T	0.01745	0.0283908308581683	0.18486	0.89070651537536205	.	0.99167	.	T/T	72	0.016341352700862462	0	0.0	0.7088576	-0.835222795108037	0.13642	0.6190612	-0.825133498291526	0.12670	.	.	.	166	1.367e-03	154	1.480e-02	10	8.690e-04	166	1.369e-03	0	0	0	0	1	1.500e-05	1	6.057e-05	154	1.450e-03	142	1.566e-02	10	8.972e-04	154	1.452e-03	0	0	0	0	1	1.842e-05	1	6.095e-05	166	1.829e-03	154	1.482e-02	10	8.699e-04	166	1.832e-03	0	0	0	0	1	2.376e-05	1	6.061e-05	0.99538	.	.	.	6.08	-4.01	0.03775	0	0.26702	0.573888	.	.	0.07437	6.01690750409236E-4	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.26826	0.564101	Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal&Aromatic_amino_acid_hydroxylase&_C-terminal	.	.	.	0.57861	.	0.251182	0.51296	N	0.000089	.	.	.	0.02851	.	0.76383	.	D	0.96152	0.8841	.	0.00669	.	D	0.87827	0.3170	.	.	.	.	.	.	0.53793	.	.	0.58761	simple_aae&simple_aae	D&D	0.999999&0.999999	0.61435	.	.	.	0.02946	.	.	0.10090	.	T	0.14706	0.328490436077	0.69527	.	10	0.23164	.	.	0.23541	.	.	7.6603	0.27567	0.0:0.3963:0.1193:0.4844	.	.	.	.	.	.	.	.	0.74735	.	T/T	S	.	N	C	699	0.57969	.	12	C0031485&CN517202	261600	ORPHA716	Uncertain_significance	NC_000012.12:g.102866605T>C	102703	reviewed_by_expert_panel	Phenylketonuria&not_provided	DeBelle_Laboratory_for_Biochemical_Genetics:p.N167S&UniProtKB_(protein):P00439#VAR_011567	.	.	AEFBI	D	0.36039	0.73678	D	0.55852	0.543013	.	261	1.038350e-03	239	1.470230e-02	16256	1	19	5.498960e-04	34552	0	251360	0	0.000000e+00	10076	0	0	0.000000e+00	18390	0	0	0.000000e+00	21638	0	2	1.759050e-05	113698	0	239	1.470230e-02	16256	1	1	3.266270e-05	30616	0	120	1.097090e-03	105	1.465660e-02	7164	0	13	7.602340e-04	17100	0	109380	0	0.000000e+00	2320	0	0	0.000000e+00	9044	0	0	0.000000e+00	13392	0	1	2.338740e-05	42758	0	105	1.465660e-02	7164	0	1	6.373490e-05	15690	0	0	.	1	250	1.055640e-03	228	1.530000e-02	14902	1	19	5.552310e-04	34220	0	236824	0	0.000000e+00	9568	0	0	0.000000e+00	17688	0	0	0.000000e+00	21622	0	2	1.947720e-05	102684	0	228	1.530000e-02	14902	1	1	3.275900e-05	30526	0	1	260	1.249650e-03	239	1.473670e-02	16218	1	18	5.904350e-04	30486	0	208058	0	0.000000e+00	6210	0	0	0.000000e+00	13412	0	0	0.000000e+00	16726	0	2	2.233740e-05	89536	0	239	1.473670e-02	16218	1	1	3.267120e-05	30608	0	1	197	8.049290e-04	175	1.455180e-02	12026	1	19	5.520370e-04	34418	0	244742	0	0.000000e+00	9994	0	0	0.000000e+00	18386	0	0	0.000000e+00	21636	0	2	1.791990e-05	111608	0	175	1.455180e-02	12026	1	1	3.266270e-05	30616	0	1	631	4.146900e-03	604	1.457810e-02	41432	6	0	0.000000e+00	908	0	19	1.242970e-03	15286	0	152162	0	0.000000e+00	3470	0	0	0.000000e+00	5194	0	0	0.000000e+00	10622	0	0	0.000000e+00	316	0	2	2.940740e-05	68010	0	604	1.457810e-02	41432	6	0	0.000000e+00	4830	0	143	4.345710e-03	132	1.451510e-02	9094	0	0	0.000000e+00	60	0	9	1.919800e-03	4688	0	32906	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5496	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3112	0	0	.	6	626	4.231900e-03	599	1.457070e-02	41110	6	0	0.000000e+00	908	0	19	1.258440e-03	15098	0	147924	0	0.000000e+00	3302	0	0	0.000000e+00	4958	0	0	0.000000e+00	10622	0	0	0.000000e+00	304	0	2	3.086420e-05	64800	0	0	0.000000e+00	4798	0	6	499	3.702930e-03	473	1.457090e-02	32462	5	0	0.000000e+00	862	0	18	1.212940e-03	14840	0	134758	0	0.000000e+00	3386	0	0	0.000000e+00	5194	0	0	0.000000e+00	6986	0	0	0.000000e+00	310	0	2	3.130580e-05	63886	0	0	0.000000e+00	4828	0	5	381	4.719440e-03	358	1.443080e-02	24808	2	0	0.000000e+00	108	0	19	1.471500e-03	12912	0	80730	0	0.000000e+00	996	0	0	0.000000e+00	3752	0	0	0.000000e+00	10530	0	0	0.000000e+00	272	0	0	0.000000e+00	21030	0	0	0.000000e+00	4802	0	2	12	101784513	12	103260383	0	0.25195	0.553676	0.999000	0.42656	0.982000	0.59238	0.997000	0.62031	0.267000	0.18318	-0.123000	0.13640	-0.154000	0.10767	102866605	T	.	rs77554925	.	.	7.292	9.092	8.810	7.211	.	.	.	48	-11	-5	-9	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-6+9+start+68	102703	Uncertain_significance	reviewed_by_expert_panel	not_provided&Phenylketonuria	MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs77554925	1.367e-03	166	2	0	154	10	0	0	1	0	1	10406	11508	8648	6602	66680	908	16510	0	0	0	0	2	0	0	0	0	0	0	0	0	0	rs77554925	1.47674e-02	5.36641e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.79157e-05	3.64830e-04	3.24865e-05	7.34291e-04	1.34773e-03	1.47674e-02	1.01109e-03	rs77554925	1.43250e-02	1.19332e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	4.38186e-03	3.68231e-03	1.43250e-02	4.13010e-03	rs77554925	0.0&1.6341&0.5536	rs77554925	77554925	.	.	.	PAH	PAH:exonic	PAH:missense	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,784	0	0	0	0	0	1	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0.1877	VUS
13	20763620	20763620	A	G	G	missense_variant	MODERATE	GJB2	2706	Transcript	NM_004004.6	protein_coding	2/2	.	NM_004004.6:c.101T>C	NP_003995.2:p.Met34Thr	279	101	34	M/T	aTg/aCg	rs35887622&CM077555&CM970679	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	GJB2	.	chr13:g.20763620A>G	.	0.0015	0.0101	0	0.0209	0	conflicting_interpretations_of_pathogenicity&likely_benign&pathogenic&pathogenic/likely_pathogenic&uncertain_significance	.	1&1&1	.	.	.	.	.	GJB2&NM_004004.5&c.101T>C	.	.	30	0.0059904153354632585	2	0.0015128593040847202	7	0.010086455331412104	0	0.0	21	0.020874751491053677	0	0.0	57	0.014789828749351324	.	.	.	.	.	.	.	A/A	A	T	0.27894	-0.152661	D	0.71816	0.0228728	20.9	18.45	2.209274	1.833038	0.34904	0.29672	A/A	T	0.02199	0.0313280985452416	0.31892	0.96988811013947307	.	0.96334	.	A/A	22	0.004993191103041307	111	0.012906976744186047	2.577599	0.0603739683847433	0.42577	2.268993	-0.0707959582915419	0.38677	.	.	.	1032	8.500e-03	27	2.595e-03	33	2.850e-03	1032	8.504e-03	0	0	147	2.223e-02	815	1.222e-02	0	0	874	8.229e-03	24	2.647e-03	28	2.496e-03	874	8.233e-03	0	0	147	2.223e-02	667	1.229e-02	0	0	656	7.228e-03	27	2.599e-03	33	2.853e-03	656	7.232e-03	0	0	93	2.446e-02	495	1.176e-02	0	0	0.99076	.	.	.	5.21	5.21	0.72005	0	0.52368	0.61073	AL512652.1	Thyroid	0.74766	0.999999999999853	.	0	0.40942	0.61531	.	.	.	.	.	.	0	0.10902	0.530356	Connexin&_N-terminal&Connexin&_N-terminal&Connexin&_N-terminal	.	.	.	0.48145	.	0.099649	0.62929	D	0.000002	.	.	.	0.06112	.	0.84063	.	D	0.94756	0.8430	.	0.00357	.	D	0.93976	0.7648	.	.	.	.	.	.	0.66250	.	.	0.54805	simple_aae&simple_aae	D&D	0.999986&0.999986	0.71762	.	.	.	0.21002	.	.	0.29179	.	T	0.66819	0.697742164135	0.89284	.	9	0.63109	.	.	0.46513	.	.	15.379	0.74355	1.0:0.0:0.0:0.0	.	70	0.018878101402373247	127	0.016794498809838666	.	.	.	0.77601	.	A/A	T	.	M	G	682	0.59757	.	13	C1384666&C0265964&C0265336&C1835672&C0266004&C2673759&C2675750&C1865234&C2675235&CN043648&C3711374&C0950123&C3887873&CN517202&CN826980	124500&148210&148350&149200&220290&601544&602540&612645	ORPHA494&ORPHA2202&ORPHA2698&ORPHA87884&ORPHA96210	Pathogenic	NC_000013.11:g.20189481A>G	17000	reviewed_by_expert_panel	Hearing_impairment&Mutilating_keratoderma&Keratitis-ichthyosis-deafness_syndrome&_autosomal_dominant&Palmoplantar_keratoderma-deafness_syndrome&Knuckle_pads&_deafness_AND_leukonychia_syndrome&Deafness&_autosomal_recessive_1A&Deafness&_autosomal_dominant_3a&Hystrix-like_ichthyosis_with_deafness&Deafness&_autosomal_recessive_1b&Nonsyndromic_hearing_loss_and_deafness&Nonsyndromic_Deafness&Inborn_genetic_diseases&Hearing_loss&not_provided&Rare_genetic_deafness	Center_of_Genomic_medicine&_Geneva&University_Hospital_of_Geneva:Patient_3_b&Illumina_Laboratory_Services&Illumina:143545&OMIM_Allelic_Variant:121011.0001&ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:2572&HGMD:CM970679&CHEO_Genetics_Diagnostic_Laboratory&Children's_Hospital_of_Eastern_Ontario:1783413&UniProtKB_(protein):P29033#VAR_002138	.	.	AEFBHCI	D	0.55310	0.92263	D	0.61314	0.632585	.	2176	8.678450e-03	39	2.399110e-03	16256	0	153	4.424780e-03	34578	0	250736	80	7.945970e-03	10068	0	0	0.000000e+00	18394	0	445	2.057140e-02	21632	9	1404	1.241730e-02	113068	14	1404	1.241730e-02	113068	14	0	0.000000e+00	30612	0	998	9.122820e-03	17	2.372980e-03	7164	0	82	4.794200e-03	17104	0	109396	24	1.034480e-02	2320	0	0	0.000000e+00	9046	0	300	2.240140e-02	13392	6	559	1.307110e-02	42766	7	559	1.307110e-02	42766	7	0	0.000000e+00	15690	0	13	.	23	2028	8.586020e-03	36	2.415780e-03	14902	0	147	4.292470e-03	34246	0	236198	73	7.635980e-03	9560	0	0	0.000000e+00	17692	0	445	2.058660e-02	21616	9	1278	1.252300e-02	102052	12	1278	1.252300e-02	102052	12	0	0.000000e+00	30522	0	21	1740	8.384410e-03	39	2.404740e-03	16218	0	124	4.064240e-03	30510	0	207528	47	7.568440e-03	6210	0	0	0.000000e+00	13416	0	362	2.163520e-02	16732	7	1121	1.259860e-02	88978	12	1121	1.259860e-02	88978	12	0	0.000000e+00	30604	0	19	2129	8.721190e-03	27	2.245140e-03	12026	0	152	4.412960e-03	34444	0	244118	79	7.911080e-03	9986	0	0	0.000000e+00	18390	0	445	2.057330e-02	21630	9	1371	1.235380e-02	110978	13	1371	1.235380e-02	110978	13	0	0.000000e+00	30612	0	22	1434	9.419710e-03	118	2.845160e-03	41474	0	1	1.096490e-03	912	0	88	5.756900e-03	15286	0	152234	42	1.210370e-02	3470	0	0	0.000000e+00	5182	0	219	2.061370e-02	10624	4	0	0.000000e+00	316	0	943	1.385870e-02	68044	5	943	1.385870e-02	68044	5	1	2.069540e-04	4832	0	290	8.810840e-03	21	2.306170e-03	9106	0	0	0.000000e+00	60	0	32	6.825940e-03	4688	0	32914	3	2.205880e-02	136	0	0	0.000000e+00	2428	0	117	2.130370e-02	5492	2	0	0.000000e+00	246	0	105	1.531950e-02	6854	0	1	3.211300e-04	3114	0	2	.	9	1388	9.380030e-03	117	2.843120e-03	41152	0	1	1.096490e-03	912	0	86	5.696120e-03	15098	0	147974	41	1.241670e-02	3302	0	0	0.000000e+00	4946	0	219	2.061370e-02	10624	4	0	0.000000e+00	304	0	901	1.390170e-02	64812	5	1	2.083330e-04	4800	0	9	1269	9.413110e-03	99	3.046340e-03	32498	0	1	1.160090e-03	862	0	84	5.660380e-03	14840	0	134812	42	1.240400e-02	3386	0	0	0.000000e+00	5182	0	135	1.933540e-02	6982	2	0	0.000000e+00	310	0	886	1.386150e-02	63918	4	1	2.070390e-04	4830	0	6	689	8.528490e-03	64	2.575660e-03	24848	0	0	0.000000e+00	112	0	70	5.421310e-03	12912	0	80788	8	8.032130e-03	996	0	0	0.000000e+00	3740	0	219	2.079380e-02	10532	4	0	0.000000e+00	272	0	309	1.467790e-02	21052	2	1	2.081600e-04	4804	0	6	13	19661620	13	20763620	0	0.22052	0.533608	1.000000	0.71638	0.317000	0.24900	0.991000	0.53220	5.061000	0.64149	0.756000	0.94297	1.312000	0.94714	20189481	A	.	rs35887622	.	.	.	.	10.295	9.602	.	.	.	-23	-18	-25	2	0.00	0.00	0.00	0.00	GJB2	0.00	exon-NM_004004.6-2+122+end+2134	17000	Pathogenic	reviewed_by_expert_panel	Rare_genetic_deafness&Nonsyndromic_Deafness&Hearing_loss&not_provided&Nonsyndromic_genetic_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_1B&Autosomal_recessive_nonsyndromic_hearing_loss_1A&Ichthyosis&_hystrix-like&_with_hearing_loss&Autosomal_dominant_nonsyndromic_hearing_loss_3A&Inborn_genetic_diseases&Hearing_impairment&See_cases&Mutilating_keratoderma&Knuckle_pads&_deafness_AND_leukonychia_syndrome&Autosomal_dominant_keratitis-ichthyosis-hearing_loss_syndrome&Palmoplantar_keratoderma-deafness_syndrome	MedGen:CN826980&Orphanet:96210&MeSH:C580334&MedGen:C3711374&MedGen:C3887873&MedGen:CN517202&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0012977&MedGen:C2675235&OMIM:612645&Orphanet:90636&MONDO:MONDO:0009076&MedGen:C2673759&OMIM:220290&Orphanet:90636&MONDO:MONDO:0011245&MedGen:C1865234&OMIM:602540&Orphanet:477&MONDO:MONDO:0011103&MedGen:C2675750&OMIM:601544&Orphanet:90635&MeSH:D030342&MedGen:C0950123&Human_Phenotype_Ontology:HP:0000365&Human_Phenotype_Ontology:HP:0000404&Human_Phenotype_Ontology:HP:0001728&Human_Phenotype_Ontology:HP:0001729&Human_Phenotype_Ontology:HP:0001754&Human_Phenotype_Ontology:HP:0008560&Human_Phenotype_Ontology:HP:0008563&MONDO:MONDO:0005365&MedGen:C1384666&.&MONDO:MONDO:0007422&MedGen:C0265964&OMIM:124500&Orphanet:494&MONDO:MONDO:0007866&MedGen:C0266004&OMIM:149200&Orphanet:2698&MONDO:MONDO:0007850&MedGen:C0265336&OMIM:148210&Orphanet:477&MONDO:MONDO:0007852&MedGen:C1835672&OMIM:148350&Orphanet:2202	.	rs35887622	8.500e-03	1032	1006	13	27	33	0	147	815	10	0	10406	11578	8654	6614	66686	908	16508	27	33	0	141	795	10	0	0	0	0	3	10	0	0	rs35887622	2.22164e-03	4.25823e-03	7.82202e-03	0.00000e+00	2.02800e-02	1.24038e-02	9.49598e-03	0.00000e+00	8.40642e-03	9.04304e-03	2.02800e-02	8.69770e-03	rs35887622	2.63520e-03	1.19332e-02	6.62252e-03	0.00000e+00	1.86033e-02	1.61290e-02	1.12474e-02	.	1.07477e-02	1.22057e-02	1.86033e-02	1.14546e-02	rs35887622	1.2907&0.4993&1.0226	rs35887622	35887622	.	.	.	GJB2	GJB2:exonic	GJB2:missense	GJB2:Keratoderma\x2cpalmoplantar\x2cwith_deafness\x3bDeafness\x2cautosomal_recessive_1A\x3bDeafness\x2cautosomal_dominant_3A\x3bHystrix-like_ichthyosis_with_deafness\x3bBart-Pumphrey_syndrome\x3bKeratitis-ichthyosis-deafness_syndrome\x3bVohwinkel_syndrome	GJB2:148350\x3b220290\x3b601544\x3b602540\x3b149200\x3b148210\x3b124500	GJB2:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	GJB2:Autosomal_dominant\x3bAutosomal_recessive\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant	0	1.02863295453376e-11	0.00164377442881105	0.998356225560903	DISEASE: Deafness, autosomal recessive, 1A (DFNB1A) [MIM:220290]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10830906, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12121355, ECO:0000269|PubMed:12239718, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:14722929, ECO:0000269|PubMed:15666300, ECO:0000269|PubMed:15994881, ECO:0000269|PubMed:17660464, ECO:0000269|PubMed:17666888, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:23680645, ECO:0000269|PubMed:9328482, ECO:0000269|PubMed:9336442, ECO:0000269|PubMed:9471561, ECO:0000269|PubMed:9529365}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 3A (DFNA3A) [MIM:601544]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:10807696, ECO:0000269|PubMed:11313763, ECO:0000269|PubMed:11439000, ECO:0000269|PubMed:12786758, ECO:0000269|PubMed:19384972, ECO:0000269|PubMed:9620796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vohwinkel syndrome (VS) [MIM:124500]: VS is an autosomal dominant disease characterized by hyperkeratosis, constriction on fingers and toes and congenital deafness. {ECO:0000269|PubMed:10369869, ECO:0000269|PubMed:15954104, ECO:0000269|PubMed:18688874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, with deafness (PPKDFN) [MIM:148350]: An autosomal dominant disorder characterized by the association of palmoplantar hyperkeratosis with progressive, bilateral, high-frequency, sensorineural deafness. {ECO:0000269|PubMed:10633135, ECO:0000269|PubMed:10757647, ECO:0000269|PubMed:12372058, ECO:0000269|PubMed:15996214, ECO:0000269|PubMed:17993581, ECO:0000269|PubMed:9856479}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratitis-ichthyosis-deafness syndrome (KID syndrome) [MIM:148210]: An autosomal dominant form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Keratitis-ichthyosis-deafness syndrome is characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. Clinical features include deafness, ichthyosis, photophobia, absent or decreased eyebrows, sparse or absent scalp hair, decreased sweating and dysplastic finger and toenails. {ECO:0000269|PubMed:11912510, ECO:0000269|PubMed:12548749, ECO:0000269|PubMed:12752120}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bart-Pumphrey syndrome (BPS) [MIM:149200]: An autosomal dominant disorder characterized by sensorineural hearing loss, palmoplantar keratoderma, knuckle pads, and leukonychia, It shows considerable phenotypic variability. {ECO:0000269|PubMed:15482471, ECO:0000269|PubMed:15952212}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix-like with deafness syndrome (HID syndrome) [MIM:602540]: An autosomal dominant keratinizing disorder characterized by sensorineural deafness and spiky hyperkeratosis affecting the entire skin. HID syndrome is considered to differ from the similar KID syndrome in the extent and time of occurrence of skin symptoms and the severity of the associated keratitis. {ECO:0000269|PubMed:12072059}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,870	0	0	0	0	0	1	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0.1877	VUS
7	107329565	107329565	G	A	A	missense_variant	MODERATE	SLC26A4	5172	Transcript	NM_000441.2	protein_coding	9/21	.	NM_000441.2:c.1069G>A	NP_000432.1:p.Ala357Thr	1100	1069	357	A/T	Gct/Act	rs145467740&COSV55918946	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	SLC26A4	.	chr7:g.107329565G>A	.	0.0076	0	0.001	0	0	likely_benign&benign&benign/likely_benign&uncertain_significance	0&1	1&1	.	.	.	.	.	SLC26A4&NM_000441.1&c.1069G>A	.	.	11	0.002196485623003195	10	0.007564296520423601	0	0.0	1	9.92063492063492E-4	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	G/G	G	T	0.47402	-0.030119	D	0.82342	0.186017	26.2	25.5	3.882044	3.631001	0.74712	0.70532	G/G	T	0.01710	0.0281525441019249	0.95076	0.99873253009263996	.	0.93334	.	G/G	19	0.004312301407172038	0	0.0	5.768667	0.561138878376109	0.72175	5.712756	0.578629148860303	0.71842	.	.	.	60	4.942e-04	53	5.093e-03	3	2.598e-04	60	4.944e-04	1	1.156e-04	0	0	3	4.497e-05	0	0	56	5.273e-04	51	5.625e-03	2	1.788e-04	56	5.275e-04	1	1.272e-04	0	0	2	3.681e-05	0	0	60	6.612e-04	53	5.102e-03	3	2.601e-04	60	6.616e-04	1	1.775e-04	0	0	3	7.123e-05	0	0	0.94764	.	.	.	5.62	4.73	0.59485	0	0.19063	0.563428	.	.	0.48965	0.999969880721561	.	0	0.23631	0.573888	.	.	.	.	.	.	0	0.41899	0.613276	SLC26A/SulP_transporter_domain&SLC26A/SulP_transporter_domain	.	.	.	0.69822	.	0.134244	0.48115	D	0.000182	D	0.88142	0.228536	0.03802	.	0.97290	.	D	0.93679	0.8126	.	0.01050	.	D	0.93580	0.7326	.	.	.	.	.	.	0.46185	.	.	0.45510	simple_aae	D	0.998822	0.68999	.	.	.	0.62325	.	.	0.63994	.	T	0.56815	0.627668499947	0.95323	.	10	0.79402	.	.	0.78490	.	.	15.9076	0.79227	0.0:0.0:0.8636:0.1364	.	.	.	.	.	.	.	.	0.70702	.	G/G	T	.	A	A	772	0.48957	.	7	C0271829&C3538946&CN169374&CN517202	274600&600791	ORPHA705	Benign	NC_000007.14:g.107689120G>A	43491	reviewed_by_expert_panel	Pendred_syndrome&Deafness&_autosomal_recessive_4&_with_enlarged_vestibular_aqueduct&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:685048	.	.	AEFBI	D	0.75920	0.97615	D	0.74845	0.829569	.	109	4.339210e-04	83	5.107060e-03	16252	0	12	3.471420e-04	34568	0	251198	0	0.000000e+00	10076	0	2	1.087550e-04	18390	0	0	0.000000e+00	21648	0	9	7.927980e-05	113522	0	83	5.107060e-03	16252	0	0	0.000000e+00	30616	0	50	4.570800e-04	40	5.583470e-03	7164	0	6	3.507950e-04	17104	0	109390	0	0.000000e+00	2320	0	2	2.211410e-04	9044	0	0	0.000000e+00	13394	0	1	2.338630e-05	42760	0	40	5.583470e-03	7164	0	0	0.000000e+00	15690	0	0	.	0	104	4.394490e-04	81	5.436970e-03	14898	0	12	3.505080e-04	34236	0	236660	0	0.000000e+00	9568	0	2	1.130710e-04	17688	0	0	0.000000e+00	21632	0	7	6.828870e-05	102506	0	81	5.436970e-03	14898	0	0	0.000000e+00	30526	0	0	103	4.949970e-04	83	5.119030e-03	16214	0	9	2.950630e-04	30502	0	208082	0	0.000000e+00	6212	0	2	1.491200e-04	13412	0	0	0.000000e+00	16734	0	6	6.701070e-05	89538	0	83	5.119030e-03	16214	0	0	0.000000e+00	30608	0	0	86	3.516230e-04	60	4.990850e-03	12022	0	12	3.484930e-04	34434	0	244580	0	0.000000e+00	9994	0	2	1.087780e-04	18386	0	0	0.000000e+00	21646	0	9	8.076670e-05	111432	0	60	4.990850e-03	12022	0	0	0.000000e+00	30616	0	0	244	1.604040e-03	220	5.311960e-03	41416	0	0	0.000000e+00	912	0	15	9.832200e-04	15256	1	152116	0	0.000000e+00	3466	0	1	1.923080e-04	5200	0	0	0.000000e+00	10594	0	0	0.000000e+00	316	0	6	8.819120e-05	68034	0	220	5.311960e-03	41416	0	0	0.000000e+00	4830	0	50	1.521790e-03	42	4.621480e-03	9088	0	0	0.000000e+00	60	0	5	1.067460e-03	4684	1	32856	0	0.000000e+00	136	0	1	4.115230e-04	2430	0	0	0.000000e+00	5468	0	0	0.000000e+00	246	0	1	1.460710e-04	6846	0	0	0.000000e+00	3110	0	1	.	1	243	1.643380e-03	220	5.353580e-03	41094	0	0	0.000000e+00	912	0	14	9.289980e-04	15070	1	147866	0	0.000000e+00	3302	0	1	2.014500e-04	4964	0	0	0.000000e+00	10594	0	0	0.000000e+00	304	0	6	9.258400e-05	64806	0	0	0.000000e+00	4798	0	1	185	1.373320e-03	162	4.991990e-03	32452	0	0	0.000000e+00	862	0	14	9.453070e-04	14810	1	134710	0	0.000000e+00	3382	0	1	1.923080e-04	5200	0	0	0.000000e+00	6954	0	0	0.000000e+00	310	0	6	9.388200e-05	63910	0	0	0.000000e+00	4828	0	1	143	1.772570e-03	129	5.203710e-03	24790	0	0	0.000000e+00	112	0	12	9.315320e-04	12882	1	80674	0	0.000000e+00	992	0	1	2.660990e-04	3758	0	0	0.000000e+00	10502	0	0	0.000000e+00	272	0	0	0.000000e+00	21046	0	0	0.000000e+00	4802	0	1	7	107116801	7	107329565	0	0.14033	0.487112	1.000000	0.71638	0.986000	0.61781	0.758000	0.32332	7.127000	0.76822	0.676000	0.76740	1.176000	0.78918	107689120	G	.	rs145467740	.	.	6.336	9.985	4.246	7.933	.	.	.	25	-44	25	-44	0.00	0.00	0.00	0.00	SLC26A4	0.00	exon-NM_000441.2-9+67+start+148	43491	Benign	reviewed_by_expert_panel	not_specified&not_provided&Autosomal_recessive_nonsyndromic_hearing_loss_4&Pendred_syndrome	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0010933&MedGen:C3538946&OMIM:600791&Orphanet:90636&MONDO:MONDO:0010134&MedGen:C0271829&OMIM:274600&Orphanet:705	.	rs145467740	4.942e-04	60	60	0	53	3	1	0	3	0	0	10406	11548	8650	6612	66718	908	16512	53	3	1	0	3	0	0	0	0	0	0	0	0	0	rs145467740	5.16340e-03	2.97992e-04	0.00000e+00	1.15982e-04	0.00000e+00	7.17836e-05	7.30727e-04	0.00000e+00	3.34016e-04	5.21461e-04	5.16340e-03	4.18237e-04	rs145467740	5.83925e-03	1.19617e-03	0.00000e+00	0.00000e+00	0.00000e+00	6.66223e-05	0.00000e+00	.	2.04439e-03	1.29889e-03	5.83925e-03	1.71012e-03	rs145467740	0.0&0.4312&0.1461	rs145467740	145467740	.	.	.	SLC26A4	SLC26A4:exonic	SLC26A4:missense	SLC26A4:Deafness\x2cautosomal_recessive_4\x2cwith_enlarged_vestibular_aqueduct\x3bPendred_syndrome	SLC26A4:600791\x3b274600	SLC26A4:3\x3b3	SLC26A4:Autosomal_recessive\x3bAutosomal_recessive	0	6.36692519367205e-13	0.204987783815785	0.795012216183578	DISEASE: Deafness, autosomal recessive, 4 (DFNB4) [MIM:600791]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNB4 is associated with an enlarged vestibular aqueduct. {ECO:0000269|PubMed:10190331, ECO:0000269|PubMed:10700480, ECO:0000269|PubMed:11748854, ECO:0000269|PubMed:12676893, ECO:0000269|PubMed:14508505, ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:19204907, ECO:0000269|PubMed:20108392, ECO:0000269|PubMed:20597900, ECO:0000269|PubMed:9500541}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,491	0	0	0	0	0	1	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0.1877	VUS
11	76869378	76869378	G	A	A	missense_variant	MODERATE	MYO7A	4647	Transcript	NM_000260.4	protein_coding	9/49	.	NM_000260.4:c.905G>A	NP_000251.3:p.Arg302His	1195	905	302	R/H	cGc/cAc	rs41298135&CM961010	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	MYO7A	.	chr11:g.76869378G>A	.	0.0015	0	0.001	0.004	0	pathogenic&benign/likely_benign&likely_benign	.	1&1	.	.	.	.	.	MYO7A&NM_000260.3&c.905G>A	.	.	7	0.0013977635782747603	2	0.0015128593040847202	0	0.0	1	9.92063492063492E-4	4	0.003976143141153081	0	0.0	4	0.0010378827192527244	.	.	.	.	.	.	.	G/G	G	T	0.42480	-0.0627311	D	0.79403	0.137793	24.6	24.4	3.450951	3.332289	0.62832	0.62823	G/G	T	0.01230	0.0246750961972324	0.99981	0.99957192661618888	.	0.96977	.	G/G	1	2.328830926874709E-4	23	0.002706519180983761	8.016015	0.713670383555412	0.83417	7.812239	0.745904926470967	0.82636	.	.	.	413	3.408e-03	8	8.660e-04	3	2.678e-04	413	3.541e-03	0	0	20	3.088e-03	381	5.880e-03	0	0	371	3.500e-03	7	8.790e-04	3	2.760e-04	371	3.622e-03	0	0	20	3.088e-03	340	6.386e-03	0	0	193	2.132e-03	7	7.592e-04	3	2.681e-04	193	2.235e-03	0	0	13	3.512e-03	169	4.171e-03	0	0	0.88143	.	.	.	5.72	5.72	0.89380	0	0.45803	0.59043	.	.	0.74766	0.999999898013176	.	0	0.15389	0.547309	.	.	.	.	.	.	0	0.14980	0.542086	Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VII_myosin&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VII_myosin&_motor_domain&.&.	.	.	.	0.93989	.	0.061993	0.62929	D	0.000003	D	0.86501	0.196808	0.37038	.	0.95520	.	D	0.94334	0.8310	.	0.00724	.	D	0.94491	0.8065	.	.	.	.	.	.	0.75369	.	.	0.58761	simple_aae&simple_aae&simple_aae&simple_aae	A&A&A&A	0.999982&0.999982&0.999982&0.999999	0.76334	.	.	.	0.73220	.	.	0.65091	.	T	0.52381	0.59629458189	0.87722	.	9	0.63918	.	.	0.72154	.	.	19.8946	0.96948	0.0:0.0:1.0:0.0	.	17	0.004584681769147788	21	0.0027770431102882836	.	.	.	0.71232	.	G/G	H	.	R	A	568	0.70638	.	11	C1568247&C1838701&C1832475&C0271097&C2931206&CN169374&CN517202	276900&600060&601317&PS276900	ORPHA231169&ORPHA886	Likely_benign	NC_000011.10:g.77158332G>A	11852	reviewed_by_expert_panel	Usher_syndrome_type_1&Deafness&_autosomal_recessive_2&Deafness&_autosomal_dominant_11&Usher_syndrome&Usher_syndrome_type_1B&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:686049&OMIM_Allelic_Variant:276903.0006&UniProtKB_(protein):Q13402#VAR_009324	.	.	AEFDBCI	D	0.51852	0.90568	D	0.70825	0.774584	.	652	2.628780e-03	11	7.133590e-04	15420	0	12	3.487560e-04	34408	0	248024	6	5.977290e-04	10038	0	0	0.000000e+00	17948	0	64	3.000750e-03	21328	0	540	4.805720e-03	112366	3	540	4.805720e-03	112366	3	1	3.279760e-05	30490	0	273	2.527450e-03	6	8.448320e-04	7102	0	5	2.943250e-04	16988	0	108014	1	4.314060e-04	2318	0	0	0.000000e+00	8622	0	36	2.749770e-03	13092	0	215	5.073870e-03	42374	3	215	5.073870e-03	42374	3	1	6.396320e-05	15634	0	3	.	3	607	2.594680e-03	9	6.389320e-04	14086	0	12	3.521330e-04	34078	0	233940	5	5.238890e-04	9544	0	0	0.000000e+00	17262	0	64	3.003000e-03	21312	0	499	4.904760e-03	101738	3	499	4.904760e-03	101738	3	1	3.289260e-05	30402	0	3	476	2.321860e-03	11	7.149360e-04	15386	0	8	2.635570e-04	30354	0	205008	4	6.466210e-04	6186	0	0	0.000000e+00	12974	0	50	3.043580e-03	16428	0	389	4.398860e-03	88432	3	389	4.398860e-03	88432	3	1	3.280620e-05	30482	0	3	644	2.666140e-03	7	6.185930e-04	11316	0	12	3.500990e-04	34276	0	241548	6	6.026520e-04	9956	0	0	0.000000e+00	17944	0	64	3.001030e-03	21326	0	536	4.860360e-03	110280	3	536	4.860360e-03	110280	3	1	3.279760e-05	30490	0	3	307	2.017510e-03	33	7.962550e-04	41444	0	0	0.000000e+00	910	0	6	3.925160e-04	15286	0	152168	3	8.645530e-04	3470	0	0	0.000000e+00	5178	0	28	2.636530e-03	10620	0	0	0.000000e+00	316	0	232	3.410660e-03	68022	0	232	3.410660e-03	68022	0	0	0.000000e+00	4836	0	42	1.276440e-03	7	7.694000e-04	9098	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32904	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	9	1.638750e-03	5492	0	0	0.000000e+00	246	0	24	3.502630e-03	6852	0	0	0.000000e+00	3114	0	0	.	0	299	2.021440e-03	33	8.024900e-04	41122	0	0	0.000000e+00	910	0	6	3.974040e-04	15098	0	147914	3	9.090910e-04	3300	0	0	0.000000e+00	4942	0	28	2.636530e-03	10620	0	0	0.000000e+00	304	0	224	3.456900e-03	64798	0	0	0.000000e+00	4804	0	0	273	2.025850e-03	29	8.931320e-04	32470	0	0	0.000000e+00	862	0	6	4.043130e-04	14840	0	134758	3	8.860010e-04	3386	0	0	0.000000e+00	5178	0	14	2.005730e-03	6980	0	0	0.000000e+00	310	0	217	3.395820e-03	63902	0	0	0.000000e+00	4834	0	0	135	1.672160e-03	16	6.445380e-04	24824	0	0	0.000000e+00	110	0	5	3.872370e-04	12912	0	80734	1	1.002000e-03	998	0	0	0.000000e+00	3736	0	28	2.659570e-03	10528	0	0	0.000000e+00	272	0	80	3.803370e-03	21034	0	0	0.000000e+00	4808	0	0	11	76547026	11	76869378	0	0.19182	0.497415	1.000000	0.71638	0.989000	0.64315	0.998000	0.65909	3.173000	0.50540	0.676000	0.76740	1.175000	0.73717	77158332	G	.	rs41298135	.	.	6.566	7.132	6.973	7.614	.	.	.	14	-16	13	-40	0.00	0.00	0.00	0.00	MYO7A	0.00	exon-NM_001369365.1-10+55+start+154	11852	Likely_benign	reviewed_by_expert_panel	Usher_syndrome&not_provided&not_specified&Usher_syndrome_type_1&Autosomal_recessive_nonsyndromic_hearing_loss_2&Autosomal_dominant_nonsyndromic_hearing_loss_11&Usher_syndrome_type_1B	MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&MedGen:CN517202&MedGen:CN169374&MONDO:MONDO:0010168&MedGen:C1568247&OMIM:276900&Orphanet:231169&Orphanet:886&MONDO:MONDO:0010807&MedGen:C1838701&OMIM:600060&Orphanet:90636&MONDO:MONDO:0011032&MedGen:C1832475&OMIM:601317&Orphanet:90635&MONDO:MONDO:0700087&MedGen:C2931206	.	rs41298135	3.408e-03	413	2	2	8	3	0	20	381	1	0	9238	11202	8486	6476	64792	858	15580	1	1	0	0	0	0	0	0	0	0	0	2	0	0	rs41298135	7.21974e-04	3.58102e-04	5.08647e-04	0.00000e+00	2.94251e-03	4.76216e-03	3.29188e-03	3.26094e-05	2.66266e-03	2.56174e-03	4.76216e-03	2.61502e-03	rs41298135	1.03330e-03	2.39234e-03	6.62252e-03	0.00000e+00	3.15186e-03	3.80457e-03	3.05499e-03	.	2.69226e-03	2.74725e-03	6.62252e-03	2.71055e-03	rs41298135	0.2707&0.0233&0.1876	rs41298135	41298135	.	.	.	MYO7A	MYO7A:exonic	MYO7A:missense	MYO7A:Deafness\x2cautosomal_recessive_2\x3bUsher_syndrome\x2ctype_1B\x3bDeafness\x2cautosomal_dominant_11	MYO7A:600060\x3b276900\x3b601317	MYO7A:3\x3b3\x3b3	MYO7A:Autosomal_recessive\x3bAutosomal_recessive\x3bAutosomal_dominant	0	5.37673856270135e-25	0.207164598627406	0.792835401372594	DISEASE: Usher syndrome 1B (USH1B) [MIM:276900]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. {ECO:0000269|PubMed:10094549, ECO:0000269|PubMed:10364543, ECO:0000269|PubMed:10447383, ECO:0000269|PubMed:10930322, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:15660226, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:23559863, ECO:0000269|PubMed:24831256, ECO:0000269|PubMed:25798947, ECO:0000269|PubMed:7870171, ECO:0000269|PubMed:8900236, ECO:0000269|PubMed:9002678, ECO:0000269|PubMed:9382091, ECO:0000269|PubMed:9718356}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 2 (DFNB2) [MIM:600060]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:9171832, ECO:0000269|PubMed:9171833}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 11 (DFNA11) [MIM:601317]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA11 is characterized by onset after complete speech acquisition and subsequent gradual progression. {ECO:0000269|PubMed:15121790, ECO:0000269|PubMed:15221449, ECO:0000269|PubMed:15300860, ECO:0000269|PubMed:9354784}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in MYO7A may be a cause of Leber congenital amaurosis (LCA), a severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near- absent pupillary responses, photophobia, high hyperopia and keratoconus.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,628	0	0	0	0	0	1	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0.1877	VUS
10	112724729	112724729	A	G	G	missense_variant	MODERATE	SHOC2	8036	Transcript	NM_007373.4	protein_coding	2/9	.	NM_007373.4:c.613A>G	NP_031399.2:p.Thr205Ala	901	613	205	T/A	Act/Gct	rs768411950	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	SHOC2	.	chr10:g.112724729A>G	.	.	.	.	.	.	likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	T	0.27630	-0.154376	T	0.60329	-0.137561	21.8	20.8	2.347118	2.119136	0.37887	0.35427	A/A	T	0.23255	0.258627751812722	0.81843	0.99717881961411736	.	0.64403	.	A/A	.	.	.	.	6.666899	0.63331388771494	0.77374	5.666972	0.573813009677373	0.71543	.	.	.	11	9.060e-05	0	0	0	0	11	9.087e-05	0	0	0	0	1	1.500e-05	10	6.060e-04	11	1.036e-04	0	0	0	0	11	1.039e-04	0	0	0	0	1	1.842e-05	10	6.098e-04	11	1.212e-04	0	0	0	0	11	1.217e-04	0	0	0	0	1	2.378e-05	10	6.064e-04	0.27486	.	.	.	5.66	5.66	0.87293	0	0.89359	0.724815	.	.	0.74766	0.999999999999828	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	.&.&.	.	.	.	0.69007	.	0.000000	0.84330	D	0.000000	T	0.38730	0.017149	0.84282	.	0.40655	.	T	0.51468	0.1724	.	0.49312	.	T	0.45648	-0.9193	T205A	Loss_of_methylation_at_K209_(P_=_0.1135)&_Gain_of_MoRF_binding_(P_=_0.1344)&_Loss_of_disorder_(P_=_0.1735)&_Gain_of_helix_(P_=_0.1736)&_Gain_of_ubiquitination_at_K209_(P_=_0.2261)	Q9UQ13	0.25550	0.293	.	0.76484	.	.	0.81001	simple_aae&simple_aae	D&D	1&1	0.43717	.	.	.	0.57829	.	.	0.72001	.	T	0.80593	0.790986120701	0.57221	.	10	0.39492	.	.	0.34095	.	.	15.8869	0.79041	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.71232	.	A/A	A	.	T	G	916	0.20744	.	10	CN166718	.	ORPHA536391	Likely_benign	NC_000010.11:g.110964971A>G	448933	reviewed_by_expert_panel	Rasopathy	ClinGen_RASopathy_Variant_Curation_Expert_Panel:795ea8ea-3f7d-49cf-b7e6-d4efa4eb47e5	.	.	AEFBI	D	0.88321	0.98897	D	0.84292	0.899008	.	13	5.181930e-05	0	0.000000e+00	16216	0	0	0.000000e+00	34522	0	250872	0	0.000000e+00	10072	0	0	0.000000e+00	18380	0	0	0.000000e+00	21400	0	1	8.805140e-06	113570	0	12	3.920540e-04	30608	0	12	3.920540e-04	30608	0	6	5.498530e-05	0	0.000000e+00	7158	0	0	0.000000e+00	17086	0	109120	0	0.000000e+00	2320	0	0	0.000000e+00	9036	0	0	0.000000e+00	13172	0	0	0.000000e+00	42756	0	6	3.825070e-04	15686	0	6	3.825070e-04	15686	0	0	.	0	13	5.500550e-05	0	0.000000e+00	14862	0	0	0.000000e+00	34190	0	236340	0	0.000000e+00	9564	0	0	0.000000e+00	17678	0	0	0.000000e+00	21384	0	1	9.750390e-06	102560	0	12	3.932110e-04	30518	0	12	3.932110e-04	30518	0	0	13	6.259450e-05	0	0.000000e+00	16178	0	0	0.000000e+00	30454	0	207686	0	0.000000e+00	6206	0	0	0.000000e+00	13402	0	0	0.000000e+00	16512	0	1	1.117420e-05	89492	0	12	3.921570e-04	30600	0	12	3.921570e-04	30600	0	0	13	5.322200e-05	0	0.000000e+00	11990	0	0	0.000000e+00	34388	0	244260	0	0.000000e+00	9990	0	0	0.000000e+00	18376	0	0	0.000000e+00	21398	0	1	8.970220e-06	111480	0	12	3.920540e-04	30608	0	12	3.920540e-04	30608	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	112714719	10	112724729	0	0.61202	0.706298	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	9.325000	0.96006	0.751000	0.87719	1.307000	0.88494	110964971	A	.	rs768411950	.	.	7.357	8.846	9.854	7.528	.	.	.	1	15	1	-50	0.04	0.00	0.00	0.00	SHOC2	0.99	exon-NM_001324336.2-2+90+end+937	448933	Likely_benign	reviewed_by_expert_panel	RASopathy	MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	10:112724729-112724729	9.060e-05	11	11	0	0	0	0	0	1	0	10	10248	11498	8636	6602	66652	908	16502	0	0	0	0	1	0	10	0	0	0	0	0	0	0	rs768411950	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	8.96620e-06	0.00000e+00	4.22380e-04	6.68558e-05	4.50086e-05	4.22380e-04	5.68482e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs768411950	768411950	.	.	.	SHOC2	SHOC2:exonic	SHOC2:missense	SHOC2:Noonan_syndrome-like_with_loose_anagen_hair_1	SHOC2:607721	SHOC2:3	SHOC2:Autosomal_dominant	0	0.991705191552454	0.00829295945769003	1.84898985615785e-06	DISEASE: Noonan syndrome-like disorder with loose anagen hair (NSLH) [MIM:607721]: A syndrome characterized by Noonan dysmorphic features such as macrocephaly, high forehead, hypertelorism, palpebral ptosis, low-set and posteriorly rotated ears, short and webbed neck, pectus anomalies, in association with pluckable, sparse, thin and slow-growing hair. {ECO:0000269|PubMed:19684605, ECO:0000269|PubMed:25137548}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,604	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1877	VUS
11	121039471	121039471	T	C	C	missense_variant	MODERATE	TBCEL-TECTA	116804918	Transcript	NM_001378761.1	protein_coding	26/30	.	NM_001378761.1:c.6778T>C	NP_001365690.1:p.Tyr2260His	6985	6778	2260	Y/H	Tac/Cac	rs144343770	T	.	1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	TECTA	.	chr11:g.121039471T>C	.	0	0.0014	0	0.002	0	uncertain_significance&conflicting_interpretations_of_pathogenicity&likely_benign	.	1	.	.	.	.	.	TECTA&NM_005422.2&c.5836T>C	.	.	3	5.990415335463259E-4	0	0.0	1	0.001440922190201729	0	0.0	2	0.0019880715705765406	0	0.0	2	5.189413596263622E-4	.	.	.	.	.	.	.	T/T	T	D	0.67112	0.127461	D	0.87436	0.285862	25.6	25.6	3.750712	3.664053	0.70771	0.71444	T/T	T	0.06274	0.0545037706531514	0.94815	0.99870862299951424	.	0.74409	.	T/T	2	4.5392646391284613E-4	5	5.815305885089556E-4	11.05132	0.829376804398348	0.91757	10.25505	0.867947316250707	0.90106	.	.	.	49	4.036e-04	3	2.883e-04	8	6.910e-04	49	4.036e-04	0	0	0	0	38	5.694e-04	0	0	36	3.390e-04	3	3.309e-04	8	7.133e-04	36	3.390e-04	0	0	0	0	25	4.600e-04	0	0	47	5.179e-04	2	1.925e-04	8	6.917e-04	47	5.179e-04	0	0	0	0	37	8.780e-04	0	0	0.83241	.	.	.	5.81	5.81	0.92413	0	0.26702	0.573888	.	.	0.74766	0.999999999347613	.	0	0.11647	0.527494	.	.	.	.	.	.	0	0.47308	0.620846	Zona_pellucida_domain&Zona_pellucida_domain&Zona_pellucida_domain&Zona_pellucida_domain&Zona_pellucida_domain&Zona_pellucida_domain&Zona_pellucida_domain&Zona_pellucida_domain&Zona_pellucida_domain	.	.	.	0.70013	.	0.000000	0.84330	D	0.000000	D	0.83398	0.152589	0.81179	.	0.93397	.	D	0.91584	0.7531	.	0.01310	.	D	0.92919	0.6796	.	.	.	.	.	.	0.70455	.	.	0.53665	simple_aae&simple_aae	D&D	0.999977&0.999977	0.27876	.	.	.	0.77913	.	.	0.88582	.	D	0.87574	0.83658862114	0.93504	.	10	0.92824	.	.	0.91255	.	.	16.166	0.81572	0.0:0.0:0.0:1.0	.	0	0.0	2	2.644802962179318E-4	.	.	.	0.88137	.	T/T	H	.	Y	C	725	0.54935	.	11	C1832187&C1863655&CN043648&CN169374&CN517202	601543&603629	ORPHA87884	Likely_benign	NC_000011.10:g.121168762T>C	165370	reviewed_by_expert_panel	Deafness&_autosomal_dominant_12&Deafness&_autosomal_recessive_21&Nonsyndromic_hearing_loss_and_deafness&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:706089&ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:132892	.	.	AEFDBI	D	0.76978	0.97766	D	0.80619	0.879920	.	124	4.931200e-04	2	1.230310e-04	16256	0	20	5.781680e-04	34592	0	251460	64	6.349210e-03	10080	1	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	32	2.813530e-04	113736	0	20	5.781680e-04	34592	0	0	0.000000e+00	30614	0	43	3.930240e-04	1	1.395870e-04	7164	0	11	6.428240e-04	17112	0	109408	17	7.327590e-03	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	11	2.572020e-04	42768	0	11	6.428240e-04	17112	0	0	0.000000e+00	15690	0	0	.	1	113	4.769500e-04	2	1.342100e-04	14902	0	20	5.837710e-04	34260	0	236922	57	5.954870e-03	9572	1	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	29	2.823210e-04	102720	0	20	5.837710e-04	34260	0	0	0.000000e+00	30524	0	1	98	4.708550e-04	2	1.233200e-04	16218	0	20	6.552220e-04	30524	0	208132	43	6.922090e-03	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	29	3.238200e-04	89556	0	20	6.552220e-04	30524	0	0	0.000000e+00	30606	0	0	120	4.901120e-04	1	8.315320e-05	12026	0	20	5.804170e-04	34458	0	244842	63	6.301260e-03	9998	1	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	30	2.687060e-04	111646	0	20	5.804170e-04	34458	0	0	0.000000e+00	30614	0	1	53	3.482630e-04	6	1.447320e-04	41456	0	0	0.000000e+00	912	0	7	4.581750e-04	15278	0	152184	17	4.899140e-03	3470	0	0	0.000000e+00	5198	0	0	0.000000e+00	10616	0	1	3.164560e-03	316	0	19	2.792970e-04	68028	0	7	4.581750e-04	15278	0	0	0.000000e+00	4824	0	14	4.256100e-04	1	1.099140e-04	9098	0	0	0.000000e+00	60	0	4	8.532420e-04	4688	0	32894	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5488	0	0	0.000000e+00	246	0	7	1.021300e-03	6854	0	0	0.000000e+00	3106	0	0	.	0	51	3.447200e-04	6	1.458650e-04	41134	0	0	0.000000e+00	912	0	7	4.638830e-04	15090	0	147946	17	5.151520e-03	3300	0	0	0.000000e+00	4962	0	0	0.000000e+00	10616	0	1	3.289470e-03	304	0	17	2.622730e-04	64818	0	0	0.000000e+00	4792	0	0	50	3.709970e-04	5	1.539030e-04	32488	0	0	0.000000e+00	862	0	7	4.719530e-04	14832	0	134772	17	5.020670e-03	3386	0	0	0.000000e+00	5198	0	0	0.000000e+00	6976	0	1	3.225810e-03	310	0	17	2.660320e-04	63902	0	0	0.000000e+00	4822	0	0	25	3.096280e-04	4	1.610820e-04	24832	0	0	0.000000e+00	112	0	5	3.874770e-04	12904	0	80742	1	1.002000e-03	998	0	0	0.000000e+00	3756	0	0	0.000000e+00	10524	0	1	3.676470e-03	272	0	12	5.704510e-04	21036	0	0	0.000000e+00	4796	0	0	11	120544681	11	121039471	0	0.25195	0.553676	1.000000	0.71638	0.968000	0.53726	0.998000	0.65909	7.645000	0.82580	0.665000	0.62972	1.138000	0.64695	121168762	T	.	rs144343770	.	.	10.052	9.253	9.071	10.512	.	.	.	.	.	.	.	.	.	.	.	.	.	exon-NM_001378761.1-26+85+start+249	165370	Likely_benign	reviewed_by_expert_panel	not_specified&not_provided&Nonsyndromic_genetic_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_21&Autosomal_dominant_nonsyndromic_hearing_loss_12	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0011351&MedGen:C1863655&OMIM:603629&Orphanet:90636&MONDO:MONDO:0011102&MedGen:C1832187&OMIM:601543&Orphanet:90635	.	rs144343770	4.036e-04	49	49	0	3	8	0	0	38	0	0	10406	11578	8654	6614	66738	908	16510	3	8	0	0	38	0	0	0	0	0	0	0	0	0	rs144343770	1.96027e-04	5.06224e-04	6.29442e-03	0.00000e+00	0.00000e+00	2.77604e-04	1.45826e-03	0.00000e+00	4.74489e-04	5.11955e-04	6.29442e-03	4.91327e-04	rs144343770	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.99787e-04	0.00000e+00	.	5.84112e-05	1.44279e-04	1.99787e-04	9.67992e-05	rs144343770	0.0582&0.0454&0.0538	rs144343770	144343770	.	.	.	TBCEL-TECTA\x3bTECTA	TBCEL-TECTA:exonic\x7cTECTA:exonic	TBCEL-TECTA:missense\x7cTECTA:missense	.	.	.	.	0	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,638	0	0	0	0	0	1	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0.1877	VUS
6	76542642	76542642	G	A	A	missense_variant	MODERATE	MYO6	4646	Transcript	NM_004999.4	protein_coding	6/35	.	NM_004999.4:c.475G>A	NP_004990.3:p.Glu159Lys	707	475	159	E/K	Gaa/Aaa	rs201507590	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	MYO6	.	chr6:g.76542642G>A	.	.	.	.	.	.	uncertain_significance&likely_benign&benign	.	1	.	.	.	.	.	MYO6&NM_004999.3&c.475G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	D	0.83489	0.306637	D	0.93855	0.462365	31	32	4.388692	4.403112	0.89933	0.91152	G/G	T	0.23515	0.26459625959119	0.99734	0.99939681657194612	.	0.97685	.	G/G	0	0.0	2	2.3255813953488373E-4	20.19069	1.0209907788163	0.98994	18.07175	1.11267832111156	0.98361	.	.	.	43	3.542e-04	0	0	0	0	42	3.473e-04	0	0	0	0	38	5.713e-04	4	2.425e-04	35	3.295e-04	0	0	0	0	35	3.302e-04	0	0	0	0	31	5.710e-04	4	2.441e-04	42	4.628e-04	0	0	0	0	41	4.542e-04	0	0	0	0	37	8.827e-04	4	2.427e-04	0.88997	.	.	.	5.45	5.45	0.79688	0	0.12157	0.546412	.	.	0.74766	0.99999999999888	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VI_myosin&_motor_domain&.&.&.&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VI_myosin&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Myosin_head&_motor_domain&Class_VI_myosin&_motor_domain	.	.	.	0.95004	.	0.000000	0.84330	D	0.000000	D	0.90580	0.291536	0.31689	.	0.97929	.	D	0.96662	0.8994	.	0.11185	.	D	0.97670	1.0275	.	.	.	.	.	.	0.97912	.	.	0.81001	simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D	1&1&1&1	0.72594	.	.	.	0.90584	.	.	0.88582	.	D	0.98367	0.92057454586	0.97700	.	10	0.92824	.	.	0.91255	.	.	19.6547	0.95827	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.91047	.	G/G	K	.	E	A	601	0.67921	.	6	C2931767&C1843028&CN043648&CN169374&CN517202	606346&607821	ORPHA87884	Benign	NC_000006.12:g.75832925G>A	45163	reviewed_by_expert_panel	Autosomal_dominant_nonsyndromic_deafness_22&Deafness&_autosomal_recessive_37&Nonsyndromic_hearing_loss_and_deafness&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:279358	.	.	AEFBI	D	0.99369	0.99774	D	0.88181	0.916094	.	117	4.656090e-04	0	0.000000e+00	16250	0	1	2.893180e-05	34564	0	251284	93	9.231690e-03	10074	0	0	0.000000e+00	18388	0	0	0.000000e+00	21644	0	16	1.408180e-04	113622	0	5	1.633240e-04	30614	0	5	1.633240e-04	30614	0	26	2.377030e-04	0	0.000000e+00	7164	0	0	0.000000e+00	17100	0	109380	19	8.189660e-03	2320	0	0	0.000000e+00	9042	0	0	0.000000e+00	13392	0	4	9.354540e-05	42760	0	3	1.912290e-04	15688	0	3	1.912290e-04	15688	0	0	.	0	111	4.688090e-04	0	0.000000e+00	14898	0	1	2.921070e-05	34234	0	236770	89	9.299900e-03	9570	0	0	0.000000e+00	17686	0	0	0.000000e+00	21628	0	14	1.364230e-04	102622	0	5	1.638060e-04	30524	0	5	1.638060e-04	30524	0	0	76	3.653000e-04	0	0.000000e+00	16212	0	0	0.000000e+00	30498	0	208048	55	8.859540e-03	6208	0	0	0.000000e+00	13410	0	0	0.000000e+00	16732	0	14	1.563930e-04	89518	0	5	1.633670e-04	30606	0	5	1.633670e-04	30606	0	0	117	4.781990e-04	0	0.000000e+00	12022	0	1	2.904440e-05	34430	0	244668	93	9.307450e-03	9992	0	0	0.000000e+00	18384	0	0	0.000000e+00	21642	0	16	1.434570e-04	111532	0	5	1.633240e-04	30614	0	5	1.633240e-04	30614	0	0	38	2.497270e-04	1	2.413010e-05	41442	0	0	0.000000e+00	912	0	0	0.000000e+00	15284	0	152166	28	8.069160e-03	3470	1	0	0.000000e+00	5198	0	0	0.000000e+00	10618	0	0	0.000000e+00	316	0	9	1.323140e-04	68020	0	9	1.323140e-04	68020	0	0	0.000000e+00	4818	0	1	3.041360e-05	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32880	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5488	0	0	0.000000e+00	246	0	1	1.459430e-04	6852	0	0	0.000000e+00	3104	0	0	.	1	38	2.569030e-04	1	2.431910e-05	41120	0	0	0.000000e+00	912	0	0	0.000000e+00	15096	0	147916	28	8.479710e-03	3302	1	0	0.000000e+00	4964	0	0	0.000000e+00	10618	0	0	0.000000e+00	304	0	9	1.388970e-04	64796	0	0	0.000000e+00	4786	0	1	33	2.448910e-04	0	0.000000e+00	32472	0	0	0.000000e+00	862	0	0	0.000000e+00	14838	0	134754	25	7.383340e-03	3386	1	0	0.000000e+00	5198	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	8	1.252030e-04	63896	0	0	0.000000e+00	4816	0	1	7	8.670880e-05	1	4.029660e-05	24816	0	0	0.000000e+00	112	0	0	0.000000e+00	12910	0	80730	4	4.016060e-03	996	0	0	0.000000e+00	3756	0	0	0.000000e+00	10526	0	0	0.000000e+00	272	0	2	9.506610e-05	21038	0	0	0.000000e+00	4790	0	0	6	76599362	6	76542642	0	0.61202	0.706298	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	9.602000	0.97623	0.676000	0.76740	1.176000	0.78918	75832925	G	.	rs201507590	.	.	8.027	10.474	6.928	10.471	.	.	.	22	1	-45	22	0.00	0.00	0.00	0.00	MYO6	0.02	exon-NM_001368865.1-6+22+end+106	45163	Benign	reviewed_by_expert_panel	Inborn_genetic_diseases&not_specified&Nonsyndromic_genetic_hearing_loss&not_provided&Autosomal_dominant_nonsyndromic_hearing_loss_22&Autosomal_recessive_nonsyndromic_hearing_loss_37	MeSH:D030342&MedGen:C0950123&MedGen:CN169374&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN517202&MONDO:MONDO:0011660&MedGen:C2931767&OMIM:606346&Orphanet:228012&MONDO:MONDO:0011912&MedGen:C1843028&OMIM:607821&Orphanet:90636	.	6:76542642-76542642	3.542e-04	43	42	0	0	0	0	0	38	0	4	10308	11506	8614	6602	66510	902	16492	0	0	0	0	38	0	4	0	0	0	0	0	0	0	rs201507590	0.00000e+00	2.98009e-05	9.04104e-03	0.00000e+00	0.00000e+00	1.34442e-04	5.47845e-04	1.62443e-04	4.67387e-04	4.49333e-04	9.04104e-03	4.62903e-04	rs201507590	0.00000e+00	0.00000e+00	6.62252e-03	0.00000e+00	0.00000e+00	6.66311e-05	0.00000e+00	.	1.75295e-04	0.00000e+00	6.62252e-03	9.67992e-05	rs201507590	0.0233&0.0&0.0154	rs201507590	201507590	.	.	.	MYO6	MYO6:exonic	MYO6:missense	MYO6:Deafness\x2cautosomal_dominant_22\x2cwith_hypertrophic_cardiomyopathy\x3bDeafness\x2cautosomal_dominant_22\x3bDeafness\x2cautosomal_recessive_37	MYO6:606346\x3b606346\x3b607821	MYO6:3\x3b3\x3b3	MYO6:Autosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_recessive	0	0.0177883990936548	0.982211600378647	5.27698444208756e-10	DISEASE: Deafness, autosomal dominant, 22 (DFNA22) [MIM:606346]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA22 is progressive and postlingual, with onset during childhood. By the age of approximately 50 years, affected individuals invariably have profound sensorineural deafness. {ECO:0000269|PubMed:11468689}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 37 (DFNB37) [MIM:607821]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:12687499}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, sensorineural, with hypertrophic cardiomyopathy (DFNHCM) [MIM:606346]: An autosomal dominant sensorineural deafness associated with hypertrophic cardiomyopathy. {ECO:0000269|PubMed:15060111}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,486	0	0	0	0	0	1	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0.1877	VUS
11	121008285	121008285	C	T	T	missense_variant	MODERATE	TBCEL-TECTA	116804918	Transcript	NM_001378761.1	protein_coding	17/30	.	NM_001378761.1:c.4054C>T	NP_001365690.1:p.Arg1352Trp	4261	4054	1352	R/W	Cgg/Tgg	rs142486386&CM165471&COSV50692425	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TECTA	.	chr11:g.121008285C>T	.	0.0023	0.0043	0.001	0	0.001	conflicting_interpretations_of_pathogenicity&likely_benign	0&0&1	1&1&1	.	.	.	.	.	TECTA&NM_005422.2&c.3097C>T	.	.	8	0.001597444089456869	3	0.0022692889561270802	3	0.004322766570605188	1	9.92063492063492E-4	0	0.0	1	0.0010224948875255625	1	2.594706798131811E-4	.	.	.	.	.	.	.	C/C	C	T	0.16903	-0.228085	T	0.63202	-0.10251	24.8	28.3	3.540683	4.064390	0.65138	0.84478	C/C	T	0.03200	0.0372563737245663	0.99279	0.9992942272289177	.	0.84345	.	C/C	14	0.0031774852473899226	0	0.0	4.298237	0.391428572659727	0.61036	4.665881	0.449455056768781	0.64171	.	.	.	47	3.871e-04	37	3.557e-03	4	3.457e-04	47	3.872e-04	2	2.311e-04	0	0	2	2.997e-05	2	1.211e-04	41	3.860e-04	32	3.530e-03	4	3.568e-04	41	3.861e-04	2	2.543e-04	0	0	1	1.840e-05	2	1.219e-04	47	5.179e-04	37	3.563e-03	4	3.460e-04	47	5.180e-04	2	3.547e-04	0	0	2	4.747e-05	2	1.212e-04	0.79761	.	.	.	5.23	4.29	0.50359	0	0.45803	0.59043	.	.	0.16113	0.0906206358315625	.	0	0.43123	0.618467	.	.	.	.	.	.	0	0.33627	0.567892	Trypsin_Inhibitor-like&_cysteine_rich_domain&Trypsin_Inhibitor-like&_cysteine_rich_domain&Trypsin_Inhibitor-like&_cysteine_rich_domain	.	.	.	0.82030	.	0.059627	0.62929	D	0.000002	D	0.80277	0.121905	0.75617	.	0.91927	.	D	0.85975	0.6050	.	0.00323	.	D	0.89274	0.4118	.	.	.	.	.	.	0.60977	.	.	0.35030	simple_aae&simple_aae	D&D	0.838628&0.838628	0.47683	.	.	.	0.90584	.	.	0.73820	.	T	0.59939	0.649671852589	0.81485	.	10	0.83351	.	.	0.46513	.	.	12.553	0.55587	0.4301:0.5699:0.0:0.0	.	0	0.0	1	1.322401481089659E-4	.	.	.	0.84609	.	C/C	W	.	R	T	778	0.48011	.	11	CN043648&CN169374&CN517202	.	ORPHA87884	Likely_benign	NC_000011.10:g.121137576C>T	178538	reviewed_by_expert_panel	Nonsyndromic_hearing_loss_and_deafness&not_specified&not_provided	ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:180867	.	.	AEFDGBCI	D	0.56850	0.92911	D	0.68571	0.741933	.	87	3.461610e-04	59	3.629430e-03	16256	0	8	2.313070e-04	34586	0	251328	0	0.000000e+00	10076	0	7	3.805590e-04	18394	0	0	0.000000e+00	21640	0	8	7.040770e-05	113624	0	59	3.629430e-03	16256	0	1	3.266480e-05	30614	0	42	3.839330e-04	24	3.350080e-03	7164	0	7	4.091650e-04	17108	0	109394	0	0.000000e+00	2320	0	4	4.421840e-04	9046	0	0	0.000000e+00	13388	0	4	9.353220e-05	42766	0	24	3.350080e-03	7164	0	1	6.374300e-05	15688	0	0	.	0	82	3.462930e-04	55	3.690780e-03	14902	0	8	2.335490e-04	34254	0	236794	0	0.000000e+00	9568	0	7	3.956590e-04	17692	0	0	0.000000e+00	21624	0	7	6.821950e-05	102610	0	55	3.690780e-03	14902	0	1	3.276110e-05	30524	0	0	85	4.084340e-04	58	3.576270e-03	16218	0	7	2.293580e-04	30520	0	208112	0	0.000000e+00	6212	0	7	5.217650e-04	13416	0	0	0.000000e+00	16728	0	8	8.933760e-05	89548	0	58	3.576270e-03	16218	0	1	3.267330e-05	30606	0	0	73	2.983120e-04	45	3.741890e-03	12026	0	8	2.322070e-04	34452	0	244710	0	0.000000e+00	9994	0	7	3.806420e-04	18390	0	0	0.000000e+00	21638	0	8	7.172700e-05	111534	0	45	3.741890e-03	12026	0	1	3.266480e-05	30614	0	0	212	1.395470e-03	133	3.215670e-03	41360	1	0	0.000000e+00	910	0	64	4.194520e-03	15258	1	151920	0	0.000000e+00	3468	0	5	9.738990e-04	5134	0	0	0.000000e+00	10598	0	1	3.164560e-03	316	0	5	7.354890e-05	67982	0	64	4.194520e-03	15258	1	1	2.079870e-04	4808	0	69	2.102120e-03	29	3.195240e-03	9076	0	0	0.000000e+00	60	0	36	7.692310e-03	4680	0	32824	0	0.000000e+00	136	0	2	8.244020e-04	2426	0	0	0.000000e+00	5476	0	0	0.000000e+00	246	0	1	1.462420e-04	6838	0	1	3.225810e-04	3100	0	0	.	2	211	1.428650e-03	132	3.216370e-03	41040	1	0	0.000000e+00	910	0	64	4.246850e-03	15070	1	147692	0	0.000000e+00	3300	0	5	1.019990e-03	4902	0	0	0.000000e+00	10598	0	1	3.289470e-03	304	0	5	7.719150e-05	64774	0	1	2.092930e-04	4778	0	2	187	1.389940e-03	108	3.332100e-03	32412	1	0	0.000000e+00	862	0	64	4.320240e-03	14814	1	134538	0	0.000000e+00	3384	0	5	9.738990e-04	5134	0	0	0.000000e+00	6960	0	1	3.225810e-03	310	0	5	7.829630e-05	63860	0	1	2.080730e-04	4806	0	2	144	1.789000e-03	76	3.071950e-03	24740	1	0	0.000000e+00	110	0	58	4.501710e-03	12884	1	80492	0	0.000000e+00	996	0	2	5.417120e-04	3692	0	0	0.000000e+00	10506	0	1	3.676470e-03	272	0	3	1.428570e-04	21000	0	1	2.092050e-04	4780	0	2	11	120513495	11	121008285	0	0.25195	0.553676	0.778000	0.29449	0.983000	0.59808	0.623000	0.29358	1.508000	0.35376	0.599000	0.40250	0.999000	0.36747	121137576	C	.	rs142486386	.	.	12.782	10.098	6.303	10.106	.	.	.	.	.	.	.	.	.	.	.	.	.	exon-NM_001378761.1-17+155+start+602	178538	Likely_benign	reviewed_by_expert_panel	Nonsyndromic_genetic_hearing_loss&not_specified&not_provided	MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN169374&MedGen:CN517202	.	rs142486386	3.871e-04	47	47	0	37	4	2	0	2	0	2	10402	11572	8654	6614	66728	908	16512	37	4	2	0	2	0	2	0	0	0	0	0	0	0	rs142486386	3.52895e-03	2.38251e-04	0.00000e+00	2.89889e-04	0.00000e+00	8.06784e-05	7.29129e-04	3.24886e-05	2.29967e-04	4.49301e-04	3.52895e-03	3.28905e-04	rs142486386	3.09704e-03	1.19332e-03	0.00000e+00	6.17284e-04	0.00000e+00	0.00000e+00	1.02249e-03	.	1.16973e-03	7.23694e-04	3.09704e-03	1.00026e-03	rs142486386	0.0&0.3177&0.1077	rs142486386	142486386	.	.	.	TBCEL-TECTA\x3bTECTA	TBCEL-TECTA:exonic\x7cTECTA:exonic	TBCEL-TECTA:missense\x7cTECTA:missense	.	.	.	.	0	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,636	0	0	0	0	0	1	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0.1877	VUS
21	36164520	36164520	A	C	C	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	9/9	.	NM_001754.5:c.1355T>G	NP_001745.2:p.Val452Gly	1549	1355	452	V/G	gTg/gGg	rs751710767	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	RUNX1	.	chr21:g.36164520A>C	.	.	.	.	.	.	benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	T	0.00151	-0.597387	T	0.10094	-0.634246	14.09	13.50	1.259326	1.010518	0.18435	0.17063	A/A	T	0.00227	0.0130220699412639	0.07495	0.64442899826672673	.	0.62104	.	A/A	.	.	.	.	0.7477018	-0.807204557067199	0.14321	0.4372084	-0.969777558416731	0.09254	.	.	.	8	7.262e-05	0	0	0	0	2	1.976e-04	2	5.348e-03	0	0	0	0	0	0	8	8.210e-05	0	0	0	0	2	2.072e-04	2	5.714e-03	0	0	0	0	0	0	2	2.452e-05	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.25841	.	.	.	5.11	-3.7	0.04150	0	0.67091	0.694456	.	.	0.51787	0.999989215121036	.	0	0.29568	0.578056	.	.	.	.	.	.	0	0.68795	0.699875	Runx&_C-terminal_domain&.&.&Runx&_C-terminal_domain	.	.	.	0.26417	.	0.249192	0.39175	N	0.001390	D	0.83783	0.157195	0.65863	.	0.04254	.	T	0.05849	0.0146	.	0.00083	.	T	0.42105	-0.9432	V425G	Loss_of_stability_(P_=_0.0211)&_Loss_of_sheet_(P_=_0.0315)&_Gain_of_loop_(P_=_0.0851)&_Gain_of_catalytic_residue_at_V426_(P_=_0.1623)&_Gain_of_phosphorylation_at_S423_(P_=_0.1736)	Q01196	0.34909	0.351	.	0.09006	.	.	0.58761	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D	0.999988&0.999988&0.999991&0.999988&0.999988	0.00343	.	.	.	0.09854	.	.	0.10090	.	D	0.83795	0.811972975731	0.12618	.	10	0.15939	.	.	0.00964	.	.	6.2109	0.19841	0.4524:0.348:0.1996:0.0	.	.	.	.	.	.	.	.	0.13198	.	A/A	G	.	V	C	399	0.82780	.	21	C1832388	601399	.	Benign	NC_000021.9:g.34792223A>C	339875	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:1b105287-c135-44f7-b0a1-0719b8f91b20&Illumina_Laboratory_Services&Illumina:261914	.	.	AEFDBCI	D	0.29434	0.53697	N	0.13447	0.068223	.	18	1.287890e-04	0	0.000000e+00	7668	0	0	0.000000e+00	25182	0	139764	0	0.000000e+00	7976	0	18	1.563310e-03	11514	0	0	0.000000e+00	6008	0	0	0.000000e+00	54490	0	18	1.563310e-03	11514	0	0	0.000000e+00	22720	0	9	1.566250e-04	0	0.000000e+00	2932	0	0	0.000000e+00	12570	0	57462	0	0.000000e+00	1490	0	9	1.930500e-03	4662	0	0	0.000000e+00	2024	0	0	0.000000e+00	21176	0	9	1.930500e-03	4662	0	0	0.000000e+00	11294	0	0	.	0	18	1.304670e-04	0	0.000000e+00	7526	0	0	0.000000e+00	25146	0	137966	0	0.000000e+00	7948	0	18	1.577840e-03	11408	0	0	0.000000e+00	6008	0	0	0.000000e+00	53088	0	18	1.577840e-03	11408	0	0	0.000000e+00	22710	0	0	10	8.354640e-05	0	0.000000e+00	7634	0	0	0.000000e+00	21208	0	119694	0	0.000000e+00	4462	0	10	1.142330e-03	8754	0	0	0.000000e+00	3992	0	0	0.000000e+00	47488	0	10	1.142330e-03	8754	0	0	0.000000e+00	22718	0	0	18	1.304590e-04	0	0.000000e+00	7164	0	0	0.000000e+00	25124	0	137974	0	0.000000e+00	7938	0	18	1.563860e-03	11510	0	0	0.000000e+00	6006	0	0	0.000000e+00	53366	0	18	1.563860e-03	11510	0	0	0.000000e+00	22720	0	0	6	3.954600e-05	0	0.000000e+00	41358	0	0	0.000000e+00	908	0	0	0.000000e+00	15236	0	151722	0	0.000000e+00	3468	0	6	1.165500e-03	5148	0	0	0.000000e+00	10500	0	0	0.000000e+00	314	0	0	0.000000e+00	67892	0	6	1.165500e-03	5148	0	0	0.000000e+00	4814	0	3	9.156950e-05	0	0.000000e+00	9064	0	0	0.000000e+00	58	0	0	0.000000e+00	4654	0	32762	0	0.000000e+00	136	0	3	1.239670e-03	2420	0	0	0.000000e+00	5484	0	0	0.000000e+00	246	0	0	0.000000e+00	6816	0	0	0.000000e+00	3098	0	0	.	0	5	3.388500e-05	0	0.000000e+00	41046	0	0	0.000000e+00	908	0	0	0.000000e+00	15052	0	147558	0	0.000000e+00	3300	0	5	1.015430e-03	4924	0	0	0.000000e+00	10500	0	0	0.000000e+00	304	0	0	0.000000e+00	64726	0	0	0.000000e+00	4784	0	0	6	4.462090e-05	0	0.000000e+00	32402	0	0	0.000000e+00	858	0	0	0.000000e+00	14802	0	134466	0	0.000000e+00	3384	0	6	1.165500e-03	5148	0	0	0.000000e+00	6974	0	0	0.000000e+00	308	0	0	0.000000e+00	63780	0	0	0.000000e+00	4812	0	0	6	7.469190e-05	0	0.000000e+00	24770	0	0	0.000000e+00	110	0	0	0.000000e+00	12862	0	80330	0	0.000000e+00	996	0	6	1.619000e-03	3706	0	0	0.000000e+00	10408	0	0	0.000000e+00	270	0	0	0.000000e+00	20912	0	0	0.000000e+00	4786	0	0	21	35086390	21	36164520	0	0.49826	0.660377	0.639000	0.28076	0.993000	0.69303	1.000000	0.86279	0.227000	0.17575	0.626000	0.51810	1.203000	0.84398	34792223	A	.	rs751710767	.	.	.	.	9.279	7.470	.	.	.	-1	20	-1	2	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-9+387+end+4810	339875	Benign	reviewed_by_expert_panel	not_specified&Hereditary_cancer-predisposing_syndrome&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	21:36164520-36164520	7.262e-05	8	2	0	0	0	2	0	0	0	0	916	274	374	30	2960	88	5478	0	0	2	0	0	0	0	0	0	0	0	0	0	0	rs751710767	0.00000e+00	0.00000e+00	0.00000e+00	1.57641e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.21500e-04	1.33918e-04	1.57641e-03	1.16378e-04	rs751710767	0.00000e+00	0.00000e+00	0.00000e+00	3.08261e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	2.95823e-04	0.00000e+00	3.08261e-03	1.61363e-04	.	.	rs751710767	751710767	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,946	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.1	VUS
21	36171741	36171741	G	A	A	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	8/9	.	NM_001754.5:c.824C>T	NP_001745.2:p.Pro275Leu	1018	824	275	P/L	cCa/cTa	rs201164283	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36171741G>A	.	0	0.0014	0	0	0	benign	.	1	.	.	.	.	.	.	.	.	1	1.9968051118210862E-4	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	G/G	G	T	0.08450	-0.302236	T	0.51091	-0.236996	24.9	25.6	3.568939	3.667076	0.65871	0.71535	G/G	T	0.21426	0.219230341091637	0.58722	0.99303512351367063	.	0.93113	.	G/G	.	.	.	.	5.227388	0.507456061548689	0.68489	4.028636	0.346533977869683	0.58556	.	.	.	26	2.141e-04	0	0	26	2.248e-03	26	2.142e-04	0	0	0	0	0	0	0	0	26	2.448e-04	0	0	26	2.321e-03	26	2.448e-04	0	0	0	0	0	0	0	0	26	2.865e-04	0	0	26	2.250e-03	26	2.866e-04	0	0	0	0	0	0	0	0	0.62608	.	.	.	5.78	5.78	0.91418	0	0.55848	0.633656	.	.	0.74766	0.999999999999997	.	0	0.15389	0.547309	.	.	.	.	.	.	0	0.83352	0.714379	.&.&.&.	.	.	.	0.93110	.	0.256686	0.44119	D	0.000467	T	0.41790	0.019428	0.63878	.	0.72583	.	T	0.58742	0.2234	.	0.03065	.	T	0.59869	-0.7117	.	.	.	.	.	.	0.37844	.	.	0.52396	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D	0.999959&0.999959&0.993496&0.999959&0.999959	0.62976	.	.	.	0.34425	.	.	0.31211	.	T	0.61540	0.660913705826	0.38789	.	10	0.64786	.	.	0.72154	.	.	19.6065	0.95578	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.61426	.	G/G	L	.	P	A	379	0.83778	.	21	C1832388	601399	.	Benign	NC_000021.9:g.34799444G>A	464009	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy	ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:ed562b68-0918-4a40-899c-7000d16d5da8	.	.	AEFDBI	D	0.89557	0.98985	D	0.77801	0.860192	.	51	2.027990e-04	0	0.000000e+00	16256	0	51	1.474330e-03	34592	0	251480	0	0.000000e+00	10078	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	0	0.000000e+00	113758	0	51	1.474330e-03	34592	0	0	0.000000e+00	30616	0	22	2.010820e-04	0	0.000000e+00	7164	0	22	1.285650e-03	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	22	1.285650e-03	17112	0	0	0.000000e+00	15690	0	0	.	0	51	2.152430e-04	0	0.000000e+00	14902	0	51	1.488620e-03	34260	0	236942	0	0.000000e+00	9570	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	0	0.000000e+00	102742	0	51	1.488620e-03	34260	0	0	0.000000e+00	30526	0	0	46	2.210180e-04	0	0.000000e+00	16218	0	46	1.507010e-03	30524	0	208128	0	0.000000e+00	6210	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89552	0	46	1.507010e-03	30524	0	0	0.000000e+00	30608	0	0	51	2.082810e-04	0	0.000000e+00	12026	0	51	1.480060e-03	34458	0	244862	0	0.000000e+00	9996	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	0	0.000000e+00	111668	0	51	1.480060e-03	34458	0	0	0.000000e+00	30616	0	0	3	1.971250e-05	0	0.000000e+00	41444	0	0	0.000000e+00	912	0	3	1.963090e-04	15282	0	152188	0	0.000000e+00	3472	0	0	0.000000e+00	5194	0	0	0.000000e+00	10624	0	0	0.000000e+00	316	0	0	0.000000e+00	68026	0	3	1.963090e-04	15282	0	0	0.000000e+00	4824	0	1	3.038590e-05	0	0.000000e+00	9104	0	0	0.000000e+00	60	0	1	2.133110e-04	4688	0	32910	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5496	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3110	0	0	.	0	2	1.351990e-05	0	0.000000e+00	41122	0	0	0.000000e+00	912	0	2	1.325030e-04	15094	0	147930	0	0.000000e+00	3302	0	0	0.000000e+00	4958	0	0	0.000000e+00	10624	0	0	0.000000e+00	304	0	0	0.000000e+00	64798	0	0	0.000000e+00	4792	0	0	3	2.225650e-05	0	0.000000e+00	32482	0	0	0.000000e+00	862	0	3	2.022110e-04	14836	0	134792	0	0.000000e+00	3388	0	0	0.000000e+00	5194	0	0	0.000000e+00	6982	0	0	0.000000e+00	310	0	0	0.000000e+00	63912	0	0	0.000000e+00	4822	0	0	2	2.476780e-05	0	0.000000e+00	24820	0	0	0.000000e+00	112	0	2	1.549430e-04	12908	0	80750	0	0.000000e+00	998	0	0	0.000000e+00	3752	0	0	0.000000e+00	10532	0	0	0.000000e+00	272	0	0	0.000000e+00	21040	0	0	0.000000e+00	4796	0	0	21	35093611	21	36171741	0	0.73137	0.706548	1.000000	0.71638	0.986000	0.61781	0.995000	0.57719	9.166000	0.93921	0.676000	0.76740	1.176000	0.78918	34799444	G	.	rs201164283	.	.	9.279	7.470	11.087	10.451	.	.	.	11	18	18	0	0.00	0.01	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-8+18+end+162	464009	Benign	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	21:36171741-36171741	2.141e-04	26	26	0	0	26	0	0	0	0	0	10406	11566	8654	6614	66732	906	16512	0	26	0	0	0	0	0	0	0	0	0	0	0	0	rs201164283	0.00000e+00	1.51867e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.03774e-04	3.32292e-04	1.51867e-03	2.07088e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs201164283	201164283	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,954	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.1	VUS
10	89725110	89725110	G	A	A	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	9/9	.	NM_000314.8:c.1093G>A	NP_000305.3:p.Val365Ile	1938	1093	365	V/I	Gta/Ata	rs758542021&COSV64305915	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PTEN	.	chr10:g.89725110G>A	.	.	.	.	.	.	uncertain_significance	0&1	1&1	.	.	.	.	.	PTEN&NM_000314.4&c.1093G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	G	D	0.69576	0.153292	D	0.69187	-0.0175832	22.1	22.4	2.412158	2.408648	0.39314	0.41708	./.	T	0.27766	0.369192659854889	0.31839	0.9697565711356374	.	0.79027	.	./.	.	.	.	.	3.755898	0.306656699889934	0.55931	2.829678	0.0855544629322565	0.45790	.	.	.	1	8.245e-06	0	0	0	0	1	1.115e-05	0	0	0	0	1	2.204e-05	0	0	1	9.425e-06	0	0	0	0	1	1.302e-05	0	0	0	0	1	2.868e-05	0	0	1	1.103e-05	0	0	0	0	1	1.399e-05	0	0	0	0	1	3.167e-05	0	0	0.94469	.	.	.	5.26	5.26	0.73479	0	0.97443	0.743671	.	.	0.74766	0.999999999961711	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.49550	0.631631	.	.	.	.	0.73352	.	0.000000	0.84330	D	0.000000	D	0.74299	0.084313	0.74455	.	0.77732	.	D	0.86555	0.6188	.	0.37629	.	D	0.83135	0.0445	V365I	Gain_of_catalytic_residue_at_P367_(P_=_0.0379)&_Gain_of_glycosylation_at_S364_(P_=_0.1223)&_Loss_of_phosphorylation_at_T363_(P_=_0.2493)&_Gain_of_loop_(P_=_0.2754)&_Loss_of_sheet_(P_=_0.371)	P60484	0.02644	0.119	.	0.17993	.	.	0.58761	simple_aae	D	0.999999	0.13226	.	.	.	0.29618	.	.	0.25116	.	T	0.80199	0.788397192955	0.74447	.	9	0.26631	.	.	0.11262	.	.	19.2151	0.93760	0.0:0.0:1.0:0.0	.	.	.	.	.	.	.	.	0.29081	.	./.	I	.	V	A	896	0.25515	.	10	CN072330&C0027672&C1959582&CN517202	158350	ORPHA140162&ORPHA306498	Uncertain_significance	NC_000010.11:g.87965353G>A	237639	reviewed_by_expert_panel	Cowden_syndrome_1&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:1ebd3f87-9825-4ccc-aa05-14d1b0b78d24	.	.	AEFGBI	D	0.84440	0.98590	D	0.88412	0.917059	.	2	8.353590e-06	0	0.000000e+00	15114	0	0	0.000000e+00	33688	0	239418	0	0.000000e+00	9682	0	0	0.000000e+00	17808	0	0	0.000000e+00	21180	0	2	1.880120e-05	106376	0	2	1.880120e-05	106376	0	0	0.000000e+00	29704	0	1	9.662020e-06	0	0.000000e+00	6442	0	0	0.000000e+00	16674	0	103498	0	0.000000e+00	2074	0	0	0.000000e+00	8696	0	0	0.000000e+00	13276	0	1	2.546600e-05	39268	0	1	2.546600e-05	39268	0	0	0.000000e+00	15242	0	0	segdup	0	2	8.852850e-06	0	0.000000e+00	13844	0	0	0.000000e+00	33382	0	225916	0	0.000000e+00	9210	0	0	0.000000e+00	17174	0	0	0.000000e+00	21164	0	2	2.080520e-05	96130	0	2	2.080520e-05	96130	0	0	0.000000e+00	29622	0	0	2	1.005790e-05	0	0.000000e+00	15076	0	0	0.000000e+00	29624	0	198848	0	0.000000e+00	5856	0	0	0.000000e+00	13162	0	0	0.000000e+00	16474	0	2	2.372820e-05	84288	0	2	2.372820e-05	84288	0	0	0.000000e+00	29696	0	0	2	8.563620e-06	0	0.000000e+00	11498	0	0	0.000000e+00	33578	0	233546	0	0.000000e+00	9604	0	0	0.000000e+00	17804	0	0	0.000000e+00	21178	0	2	1.915970e-05	104386	0	2	1.915970e-05	104386	0	0	0.000000e+00	29704	0	0	1	6.575140e-06	0	0.000000e+00	41420	0	0	0.000000e+00	912	0	0	0.000000e+00	15264	0	152088	0	0.000000e+00	3468	0	0	0.000000e+00	5190	0	0	0.000000e+00	10592	0	0	0.000000e+00	316	0	1	1.470370e-05	68010	0	1	1.470370e-05	68010	0	0	0.000000e+00	4826	0	0	0.000000e+00	0	0.000000e+00	9084	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32858	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5474	0	0	0.000000e+00	246	0	0	0.000000e+00	6846	0	0	0.000000e+00	3110	0	0	segdup	0	1	6.763700e-06	0	0.000000e+00	41098	0	0	0.000000e+00	912	0	0	0.000000e+00	15078	0	147848	0	0.000000e+00	3300	0	0	0.000000e+00	4956	0	0	0.000000e+00	10592	0	0	0.000000e+00	304	0	1	1.543350e-05	64794	0	0	0.000000e+00	4794	0	0	1	7.424790e-06	0	0.000000e+00	32450	0	0	0.000000e+00	862	0	0	0.000000e+00	14818	0	134684	0	0.000000e+00	3384	0	0	0.000000e+00	5190	0	0	0.000000e+00	6954	0	0	0.000000e+00	310	0	1	1.565140e-05	63892	0	0	0.000000e+00	4824	0	0	0	0.000000e+00	0	0.000000e+00	24796	0	0	0.000000e+00	112	0	0	0.000000e+00	12890	0	80654	0	0.000000e+00	996	0	0	0.000000e+00	3748	0	0	0.000000e+00	10500	0	0	0.000000e+00	272	0	0	0.000000e+00	21026	0	0	0.000000e+00	4798	0	0	10	89715090	10	89725110	0	0.92422	0.732398	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	9.556000	0.97231	0.618000	0.50648	1.176000	0.78918	87965353	G	.	rs758542021	.	.	.	.	11.857	8.679	.	.	.	10	41	11	-1	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-10+66+start+6644	237639	Uncertain_significance	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	10:89725110-89725110	8.245e-06	1	1	0	0	0	0	0	1	0	0	7866	9002	6908	5628	45366	716	14186	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs758542021	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.91659e-05	0.00000e+00	0.00000e+00	1.55657e-05	0.00000e+00	1.91659e-05	1.62459e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs758542021	758542021	chr9:33674357&chr17:54445431	0.98265&0.958891	0.97956&0.955238	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,595	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.1	VUS
10	89725078	89725078	C	T	T	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	9/9	.	NM_000314.8:c.1061C>T	NP_000305.3:p.Pro354Leu	1906	1061	354	P/L	cCg/cTg	rs375709098&CM110127&COSV64294840	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89725078C>T	.	.	.	.	.	.	uncertain_significance	0&0&1	1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.1061C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.70465	0.162855	D	0.71399	0.0164246	22.4	23.1	2.478025	2.784549	0.40762	0.49948	./.	D	0.47058	0.810157656669617	0.51230	0.99050466943853166	.	0.93078	.	./.	1	2.2696323195642307E-4	0	0.0	3.324796	0.228260568302968	0.51420	2.584766	0.020511123434468	0.42787	.	.	.	1	8.241e-06	1	1.266e-04	0	0	1	1.140e-05	0	0	0	0	0	0	0	0	1	9.421e-06	1	1.486e-04	0	0	1	1.333e-05	0	0	0	0	0	0	0	0	1	1.103e-05	1	1.267e-04	0	0	1	1.418e-05	0	0	0	0	0	0	0	0	0.94260	.	.	.	5.35	5.35	0.76297	0	0.97443	0.743671	.	.	0.74766	0.999999999976658	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.49550	0.631631	.	.	.	.	0.63332	.	0.199273	0.53742	D	0.000049	D	0.83262	0.15101	0.82952	.	0.87975	.	D	0.83564	0.5512	.	0.50174	.	T	0.81505	-0.0360	.	.	.	.	.	.	0.14455	.	.	0.81001	simple_aae	D	1	0.61435	.	.	.	0.33788	.	.	0.20792	.	T	0.72381	0.735976934433	0.71558	.	9	0.42794	.	.	0.46129	.	.	19.4311	0.94760	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.35408	.	./.	L	.	P	T	896	0.25515	.	10	CN072330&C0027672&C1959582&CN517202	158350	ORPHA140162&ORPHA306498	Uncertain_significance	NC_000010.11:g.87965321C>T	142212	reviewed_by_expert_panel	Cowden_syndrome_1&Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:88bdf077-351e-40ca-bbdf-1299b17f80e5	.	.	AEFGBI	D	0.75370	0.97533	D	0.67057	0.719811	.	2	8.167130e-06	0	0.000000e+00	15648	0	0	0.000000e+00	34024	0	244884	0	0.000000e+00	9838	0	0	0.000000e+00	18114	0	0	0.000000e+00	21366	0	2	1.818910e-05	109956	0	2	1.818910e-05	109956	0	0	0.000000e+00	29962	0	1	9.409640e-06	0	0.000000e+00	6780	0	0	0.000000e+00	16856	0	106274	0	0.000000e+00	2162	0	0	0.000000e+00	8900	0	0	0.000000e+00	13330	0	1	2.437950e-05	41018	0	1	2.437950e-05	41018	0	0	0.000000e+00	15374	0	0	segdup	0	2	8.660180e-06	0	0.000000e+00	14334	0	0	0.000000e+00	33710	0	230942	0	0.000000e+00	9352	0	0	0.000000e+00	17446	0	0	0.000000e+00	21350	0	2	2.012110e-05	99398	0	2	2.012110e-05	99398	0	0	0.000000e+00	29878	0	0	2	9.852610e-06	0	0.000000e+00	15612	0	0	0.000000e+00	29962	0	202992	0	0.000000e+00	5996	0	0	0.000000e+00	13290	0	0	0.000000e+00	16582	0	2	2.302820e-05	86850	0	2	2.302820e-05	86850	0	0	0.000000e+00	29956	0	0	2	8.379490e-06	0	0.000000e+00	11768	0	0	0.000000e+00	33904	0	238678	0	0.000000e+00	9756	0	0	0.000000e+00	18110	0	0	0.000000e+00	21364	0	2	1.853430e-05	107908	0	2	1.853430e-05	107908	0	0	0.000000e+00	29962	0	0	1	6.578170e-06	0	0.000000e+00	41380	0	0	0.000000e+00	912	0	1	6.553940e-05	15258	0	152018	0	0.000000e+00	3468	0	0	0.000000e+00	5188	0	0	0.000000e+00	10578	0	0	0.000000e+00	316	0	0	0.000000e+00	68006	0	1	6.553940e-05	15258	0	0	0.000000e+00	4822	0	1	3.047850e-05	0	0.000000e+00	9066	0	0	0.000000e+00	60	0	1	2.139500e-04	4674	0	32810	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5458	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3106	0	0	segdup	0	1	6.767460e-06	0	0.000000e+00	41058	0	0	0.000000e+00	912	0	1	6.635700e-05	15070	0	147766	0	0.000000e+00	3300	0	0	0.000000e+00	4954	0	0	0.000000e+00	10578	0	0	0.000000e+00	304	0	0	0.000000e+00	64780	0	0	0.000000e+00	4790	0	0	1	7.428760e-06	0	0.000000e+00	32414	0	0	0.000000e+00	862	0	1	6.751280e-05	14812	0	134612	0	0.000000e+00	3384	0	0	0.000000e+00	5188	0	0	0.000000e+00	6938	0	0	0.000000e+00	310	0	0	0.000000e+00	63884	0	0	0.000000e+00	4820	0	0	1	1.240730e-05	0	0.000000e+00	24760	0	0	0.000000e+00	112	0	1	7.761560e-05	12884	0	80598	0	0.000000e+00	996	0	0	0.000000e+00	3746	0	0	0.000000e+00	10486	0	0	0.000000e+00	272	0	0	0.000000e+00	21032	0	0	0.000000e+00	4794	0	0	10	89715058	10	89725078	0	0.92422	0.732398	1.000000	0.71638	0.997000	0.79791	0.997000	0.62031	5.590000	0.67223	0.549000	0.26987	0.129000	0.18587	87965321	C	.	rs375709098	.	.	.	.	11.857	8.679	.	.	.	42	-34	31	43	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-10+34+start+6644	142212	Uncertain_significance	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350	.	10:89725078-89725078	8.241e-06	1	0	0	1	0	0	0	0	0	0	7900	8772	6806	5560	43978	704	14016	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs375709098	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.85374e-05	0.00000e+00	0.00000e+00	7.61777e-06	9.20844e-06	1.85374e-05	1.21834e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	rs375709098	0.0&0.0227&0.0077	rs375709098	375709098	chr9:33674357	0.98265	0.97956	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,594	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.1	VUS
11	120996243	120996243	C	T	T	missense_variant	MODERATE	TBCEL-TECTA	116804918	Transcript	NM_001378761.1	protein_coding	14/30	.	NM_001378761.1:c.2393C>T	NP_001365690.1:p.Pro798Leu	2600	2393	798	P/L	cCg/cTg	rs35107075	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TECTA	.	chr11:g.120996243C>T	.	0.0076	0.0029	0	0	0.0041	benign&likely_benign&uncertain_significance	.	1	.	.	.	.	.	TECTA&NM_005422.2&c.1436C>T	.	.	16	0.003194888178913738	10	0.007564296520423601	2	0.002881844380403458	0	0.0	0	0.0	4	0.00408997955010225	.	.	.	.	.	.	.	.	.	C/C	C	T	0.00205	-0.575478	T	0.13189	-0.595546	18.31	20.5	1.876542	2.082877	0.28218	0.34661	C/C	T	0.00256	0.0136952726637087	0.21627	0.92247705218224607	.	0.41954	.	C/C	23	0.00522015433499773	1	1.1630611770179111E-4	1.864961	-0.16779340760244	0.32730	1.325126	-0.426913657348428	0.24530	.	.	.	195	1.606e-03	66	6.350e-03	6	5.185e-04	195	1.607e-03	0	0	0	0	8	1.199e-04	114	6.904e-03	184	1.732e-03	59	6.509e-03	6	5.350e-04	184	1.733e-03	0	0	0	0	6	1.104e-04	112	6.826e-03	195	2.149e-03	66	6.361e-03	6	5.190e-04	195	2.150e-03	0	0	0	0	8	1.900e-04	114	6.908e-03	0.32722	.	.	.	5.02	5.02	0.66742	0	0.45803	0.59043	.	.	0.21401	0.559409258971178	.	0	0.44879	0.624306	.	.	.	.	.	.	0	0.47308	0.620846	von_Willebrand_factor&_type_D_domain&von_Willebrand_factor&_type_D_domain&von_Willebrand_factor&_type_D_domain	.	.	.	0.57103	.	0.154504	0.45194	D	0.000378	T	0.10844	0.004432	0.35027	.	0.56305	.	T	0.08686	0.0206	.	0.00138	.	T	0.14397	-1.0500	.	.	.	.	.	.	0.04484	.	.	0.40156	simple_aae&simple_aae	D&D	0.984513&0.984513	0.01509	.	.	.	0.07471	.	.	0.04355	.	T	0.32631	0.455033898354	0.09474	.	10	0.01155	.	.	0.10278	.	.	10.0587	0.41434	0.0:0.8739:0.0:0.1261	.	.	.	.	.	.	.	.	0.17553	.	C/C	L	.	P	T	783	0.47268	.	11	C1832187&C1863655&CN043648&CN169374&CN517202	601543&603629	ORPHA87884	Benign	NC_000011.10:g.121125534C>T	178638	reviewed_by_expert_panel	Deafness&_autosomal_dominant_12&Deafness&_autosomal_recessive_21&Nonsyndromic_hearing_loss_and_deafness&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:480671	.	.	AEFDBI	D	0.32396	0.64403	N	0.28225	0.156828	.	362	1.440220e-03	101	6.214620e-03	16252	0	16	4.625880e-04	34588	0	251350	0	0.000000e+00	10076	0	1	5.436560e-05	18394	0	0	0.000000e+00	21626	0	23	2.023540e-04	113662	0	216	7.055130e-03	30616	1	216	7.055130e-03	30616	1	168	1.535850e-03	46	6.420990e-03	7164	0	3	1.753160e-04	17112	0	109386	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13372	0	3	7.014590e-05	42768	0	115	7.329510e-03	15690	1	115	7.329510e-03	15690	1	1	.	1	352	1.486240e-03	95	6.374980e-03	14902	0	16	4.670440e-04	34258	0	236840	0	0.000000e+00	9570	0	1	5.652270e-05	17692	0	0	0.000000e+00	21610	0	21	2.045470e-04	102666	0	214	7.010420e-03	30526	1	214	7.010420e-03	30526	1	1	349	1.677220e-03	101	6.229180e-03	16214	0	7	2.293430e-04	30522	0	208082	0	0.000000e+00	6210	0	0	0.000000e+00	13416	0	0	0.000000e+00	16712	0	20	2.233790e-04	89534	0	216	7.056980e-03	30608	1	216	7.056980e-03	30608	1	1	329	1.344320e-03	68	5.656300e-03	12022	0	16	4.643870e-04	34454	0	244734	0	0.000000e+00	9994	0	1	5.437740e-05	18390	0	0	0.000000e+00	21624	0	23	2.061410e-04	111574	0	216	7.055130e-03	30616	1	216	7.055130e-03	30616	1	1	301	1.977580e-03	239	5.766540e-03	41446	1	0	0.000000e+00	912	0	14	9.161100e-04	15282	0	152206	0	0.000000e+00	3468	0	1	1.923080e-04	5200	0	0	0.000000e+00	10616	0	0	0.000000e+00	316	0	16	2.351630e-04	68038	0	28	5.792300e-03	4834	1	28	5.792300e-03	4834	1	79	2.401220e-03	59	6.486370e-03	9096	0	0	0.000000e+00	60	0	3	6.396590e-04	4690	0	32900	0	0.000000e+00	136	0	1	4.115230e-04	2430	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	1	1.459850e-04	6850	0	13	4.172020e-03	3116	0	0	.	2	296	2.000590e-03	237	5.762780e-03	41126	1	0	0.000000e+00	912	0	14	9.275210e-04	15094	0	147956	0	0.000000e+00	3302	0	1	2.014500e-04	4964	0	0	0.000000e+00	10616	0	0	0.000000e+00	304	0	14	2.160090e-04	64812	0	27	5.622660e-03	4802	1	2	242	1.795470e-03	183	5.636320e-03	32468	0	0	0.000000e+00	862	0	13	8.762470e-04	14836	0	134784	0	0.000000e+00	3384	0	1	1.923080e-04	5200	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	15	2.346980e-04	63912	0	28	5.794700e-03	4832	1	1	202	2.501110e-03	152	6.123600e-03	24822	1	0	0.000000e+00	112	0	13	1.007130e-03	12908	0	80764	0	0.000000e+00	994	0	1	2.660990e-04	3758	0	0	0.000000e+00	10524	0	0	0.000000e+00	272	0	5	2.375520e-04	21048	0	28	5.826050e-03	4806	1	2	11	120501453	11	120996243	0	0.25195	0.553676	0.934000	0.32416	0.995000	0.73285	0.993000	0.55118	1.957000	0.40017	0.598000	0.34611	1.024000	0.40540	121125534	C	.	rs35107075	.	.	5.722	8.146	6.561	9.597	.	.	.	.	.	.	.	.	.	.	.	.	.	exon-NM_001378761.1-14+232+start+571	178638	Benign	reviewed_by_expert_panel	not_specified&Nonsyndromic_genetic_hearing_loss&not_provided&Autosomal_recessive_nonsyndromic_hearing_loss_21&Autosomal_dominant_nonsyndromic_hearing_loss_12	MedGen:CN169374&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN517202&MONDO:MONDO:0011351&MedGen:C1863655&OMIM:603629&Orphanet:90636&MONDO:MONDO:0011102&MedGen:C1832187&OMIM:601543&Orphanet:90635	.	rs35107075	1.606e-03	195	191	2	66	6	0	0	8	1	114	10394	11572	8650	6614	66710	908	16512	66	6	0	0	8	1	110	0	0	0	0	0	0	2	rs35107075	6.14379e-03	5.06284e-04	0.00000e+00	5.79777e-05	0.00000e+00	1.79170e-04	3.64830e-04	7.11455e-03	1.66123e-03	1.15901e-03	7.11455e-03	1.43337e-03	rs35107075	5.84326e-03	0.00000e+00	0.00000e+00	6.16523e-04	0.00000e+00	3.33289e-04	0.00000e+00	.	1.81159e-03	1.87644e-03	5.84326e-03	1.83918e-03	rs35107075	0.0116&0.522&0.1846	rs35107075	35107075	.	.	.	TBCEL-TECTA\x3bTECTA	TBCEL-TECTA:exonic\x7cTECTA:exonic	TBCEL-TECTA:missense\x7cTECTA:missense	.	.	.	.	0	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,634	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.1	VUS
11	120984338	120984338	A	G	G	missense_variant	MODERATE	TBCEL-TECTA	116804918	Transcript	NM_001378761.1	protein_coding	12/30	.	NM_001378761.1:c.1658A>G	NP_001365690.1:p.Gln553Arg	1865	1658	553	Q/R	cAg/cGg	rs144682235&CM165466	A	.	1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	TECTA	.	chr11:g.120984338A>G	.	0.0023	0.0058	0	0	0	uncertain_significance&likely_benign&conflicting_interpretations_of_pathogenicity	.	1&1	.	.	.	.	.	TECTA&NM_005422.2&c.701A>G	.	.	7	0.0013977635782747603	3	0.0022692889561270802	4	0.005763688760806916	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	A/A	A	T	0.05215	-0.342512	T	0.48416	-0.264093	22.4	22.2	2.476023	2.358585	0.40713	0.40593	A/A	T	0.07101	0.0595742320974519	0.50655	0.9902445953966782	.	0.53442	.	A/A	18	0.0040853381752156154	0	0.0	3.315978	0.226530832701073	0.51326	2.637123	0.0347804422073635	0.43443	.	.	.	60	4.942e-04	46	4.431e-03	5	4.326e-04	60	4.954e-04	0	0	0	0	8	1.203e-04	0	0	51	4.802e-04	40	4.416e-03	5	4.463e-04	51	4.805e-04	0	0	0	0	5	9.204e-05	0	0	60	6.611e-04	46	4.438e-03	5	4.331e-04	60	6.630e-04	0	0	0	0	8	1.907e-04	0	0	0.71779	.	.	.	4.92	4.92	0.64147	0	0.51514	0.610034	.	.	0.74766	0.999999992277657	.	0	0.15389	0.547309	.	.	.	.	.	.	0	0.33627	0.567892	NIDO_domain&NIDO_domain&NIDO_domain&NIDO_domain&NIDO_domain&NIDO_domain&NIDO_domain&NIDO_domain&NIDO_domain	.	.	.	0.62748	.	0.064498	0.62929	D	0.000010	T	0.42842	0.020279	0.42257	.	0.72704	.	T	0.55569	0.1997	.	0.00208	.	T	0.54909	-0.8040	.	.	.	.	.	.	0.06538	.	.	0.38492	simple_aae&simple_aae	D&D	0.965838&0.965838	0.19509	.	.	.	0.27266	.	.	0.30479	.	T	0.45162	0.545073390007	0.46104	.	10	0.59159	.	.	0.09128	.	.	14.7597	0.69217	1.0:0.0:0.0:0.0	.	.	.	.	.	.	.	.	0.73645	.	A/A	R	.	Q	G	793	0.45818	.	11	C1832187&C1863655&CN043648&CN169374&CN517202	601543&603629	ORPHA87884	Likely_benign	NC_000011.10:g.121113629A>G	178532	reviewed_by_expert_panel	Deafness&_autosomal_dominant_12&Deafness&_autosomal_recessive_21&Nonsyndromic_hearing_loss_and_deafness&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:115520	.	.	AEFDBI	D	0.87082	0.98805	D	0.92515	0.933363	.	118	4.695320e-04	71	4.371380e-03	16242	0	17	4.915280e-04	34586	0	251314	14	1.391100e-03	10064	0	0	0.000000e+00	18392	0	0	0.000000e+00	21648	0	7	6.160130e-05	113634	0	71	4.371380e-03	16242	0	1	3.266270e-05	30616	0	44	4.021790e-04	28	3.908430e-03	7164	0	9	5.260080e-04	17110	0	109404	3	1.293100e-03	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	1	2.338310e-05	42766	0	28	3.908430e-03	7164	0	1	6.373490e-05	15690	0	0	.	0	107	4.516600e-04	65	4.361830e-03	14902	0	16	4.670710e-04	34256	0	236904	12	1.253920e-03	9570	0	0	0.000000e+00	17690	0	0	0.000000e+00	21632	0	6	5.841690e-05	102710	0	65	4.361830e-03	14902	0	1	3.275900e-05	30526	0	0	105	5.047980e-04	70	4.319920e-03	16204	0	14	4.587160e-04	30520	0	208004	7	1.129400e-03	6198	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	5	5.588840e-05	89464	0	70	4.319920e-03	16204	0	1	3.267120e-05	30608	0	0	97	3.964100e-04	50	4.162500e-03	12012	0	17	4.934400e-04	34452	0	244696	14	1.402520e-03	9982	0	0	0.000000e+00	18388	0	0	0.000000e+00	21646	0	7	6.275550e-05	111544	0	50	4.162500e-03	12012	0	1	3.266270e-05	30616	0	0	252	1.657500e-03	177	4.275570e-03	41398	1	0	0.000000e+00	912	0	65	4.257270e-03	15268	1	152036	3	8.645530e-04	3470	0	0	0.000000e+00	5188	0	0	0.000000e+00	10604	0	0	0.000000e+00	316	0	1	1.470460e-05	68006	0	177	4.275570e-03	41398	1	0	0.000000e+00	4786	0	75	2.284080e-03	36	3.966510e-03	9076	0	0	0.000000e+00	60	0	38	8.112720e-03	4684	0	32836	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5478	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3088	0	0	.	2	250	1.691660e-03	176	4.284740e-03	41076	1	0	0.000000e+00	912	0	65	4.310340e-03	15080	1	147784	3	9.085400e-04	3302	0	0	0.000000e+00	4952	0	0	0.000000e+00	10604	0	0	0.000000e+00	304	0	1	1.543640e-05	64782	0	0	0.000000e+00	4754	0	2	217	1.611590e-03	143	4.407050e-03	32448	1	0	0.000000e+00	862	0	65	4.385370e-03	14822	1	134650	2	5.906670e-04	3386	0	0	0.000000e+00	5188	0	0	0.000000e+00	6964	0	0	0.000000e+00	310	0	1	1.565240e-05	63888	0	0	0.000000e+00	4784	0	2	171	2.121380e-03	105	4.237970e-03	24776	1	0	0.000000e+00	112	0	59	4.575770e-03	12894	1	80608	1	1.004020e-03	996	0	0	0.000000e+00	3746	0	0	0.000000e+00	10512	0	0	0.000000e+00	272	0	1	4.756020e-05	21026	0	0	0.000000e+00	4758	0	2	11	120489548	11	120984338	0	0.20929	0.516011	1.000000	0.71638	0.995000	0.73285	1.000000	0.86279	9.289000	0.95087	0.754000	0.88378	1.309000	0.89099	121113629	A	.	rs144682235	.	.	8.629	3.528	9.876	10.280	.	.	.	.	.	.	.	.	.	.	.	.	.	exon-NM_001378761.1-12+76+start+166	178532	Likely_benign	reviewed_by_expert_panel	not_specified&not_provided&Nonsyndromic_genetic_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_21&Autosomal_dominant_nonsyndromic_hearing_loss_12	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0011351&MedGen:C1863655&OMIM:603629&Orphanet:90636&MONDO:MONDO:0011102&MedGen:C1832187&OMIM:601543&Orphanet:90635	.	rs144682235	4.942e-04	60	60	0	46	5	0	0	8	1	0	10382	11558	8640	6612	66520	904	16508	46	5	0	0	8	1	0	0	0	0	0	0	0	0	rs144682235	4.05335e-03	5.06254e-04	1.52377e-03	0.00000e+00	0.00000e+00	5.37471e-05	1.09409e-03	3.24865e-05	2.96595e-04	6.01955e-04	4.05335e-03	4.38540e-04	rs144682235	4.82870e-03	2.38663e-03	3.31126e-03	0.00000e+00	0.00000e+00	0.00000e+00	1.02041e-03	.	1.57950e-03	1.37244e-03	4.82870e-03	1.48425e-03	rs144682235	0.0&0.4085&0.1384	rs144682235	144682235	.	.	.	TBCEL-TECTA\x3bTECTA	TBCEL-TECTA:exonic\x7cTECTA:exonic	TBCEL-TECTA:missense\x7cTECTA:missense	.	.	.	.	0	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,632	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.1	VUS
10	89725188	89725188	C	T	T	missense_variant	MODERATE	PTEN	5728	Transcript	NM_000314.8	protein_coding	9/9	.	NM_000314.8:c.1171C>T	NP_000305.3:p.Pro391Ser	2016	1171	391	P/S	Cct/Tct	rs786203911	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89725188C>T	.	.	.	.	.	.	uncertain_significance	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.1171C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	./.	C	D	0.69094	0.148139	D	0.68702	-0.0249846	21.2	22.6	2.249815	2.530823	0.35776	0.44392	./.	T	0.22072	0.232544466853142	0.31187	0.968107025131275	.	0.79330	.	./.	.	.	.	.	3.032235	0.168291866022404	0.48119	2.307606	-0.0591078317201047	0.39197	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.94428	.	.	.	5.26	5.26	0.73479	0	0.97443	0.743671	.	.	0.74766	0.999999999837338	.	0	0.55881	0.658983	.	.	.	.	.	.	0	0.49550	0.631631	.	.	.	.	0.89869	.	0.049537	0.84330	D	0.000000	D	0.73862	0.082264	0.82714	.	0.81387	.	D	0.86730	0.6230	.	0.38927	.	D	0.82423	0.0082	P391S	Gain_of_phosphorylation_at_P391_(P_=_0.0288)&_Gain_of_glycosylation_at_P391_(P_=_0.0533)&_Loss_of_catalytic_residue_at_P391_(P_=_0.1004)&_Loss_of_stability_(P_=_0.2339)&_Loss_of_loop_(P_=_0.3664)	P60484	0.11929	0.204	.	0.06538	.	.	0.58761	simple_aae	D	0.999999	0.22944	.	.	.	0.25639	.	.	0.20508	.	D	0.83148	0.807752430439	0.69273	.	9	0.08839	.	.	0.20988	.	.	19.2151	0.93760	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.32370	.	./.	S	.	P	T	896	0.25515	.	10	C0027672&C1959582&CN169374&CN517202	.	ORPHA140162&ORPHA306498	Uncertain_significance	NC_000010.11:g.87965431C>T	187673	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&PTEN_hamartoma_tumor_syndrome&not_specified&not_provided	ClinGen_PTEN_Variant_Curation_Expert_Panel:2353f24f-8466-46ea-838d-a36a749f6a49	.	.	AEFBI	D	0.66970	0.95975	D	0.61071	0.628738	.	2	8.199810e-06	0	0.000000e+00	14798	0	0	0.000000e+00	33992	0	243908	0	0.000000e+00	9824	0	0	0.000000e+00	18092	0	0	0.000000e+00	21414	0	1	9.089750e-06	110014	0	1	9.089750e-06	110014	0	0	0.000000e+00	29870	0	2	1.871260e-05	0	0.000000e+00	6844	0	0	0.000000e+00	16784	0	106880	0	0.000000e+00	2198	0	0	0.000000e+00	8886	0	0	0.000000e+00	13352	0	1	2.403270e-05	41610	0	1	2.403270e-05	41610	0	0	0.000000e+00	15346	0	0	segdup	0	2	8.702080e-06	0	0.000000e+00	13478	0	0	0.000000e+00	33672	0	229830	0	0.000000e+00	9338	0	0	0.000000e+00	17416	0	0	0.000000e+00	21398	0	1	1.006600e-05	99344	0	1	1.006600e-05	99344	0	0	0.000000e+00	29782	0	0	2	9.905990e-06	0	0.000000e+00	14762	0	0	0.000000e+00	29942	0	201898	0	0.000000e+00	5980	0	0	0.000000e+00	13328	0	0	0.000000e+00	16588	0	1	1.152580e-05	86762	0	1	1.152580e-05	86762	0	0	0.000000e+00	29862	0	0	2	8.397860e-06	0	0.000000e+00	11138	0	0	0.000000e+00	33860	0	238156	0	0.000000e+00	9750	0	0	0.000000e+00	18088	0	0	0.000000e+00	21412	0	1	9.242140e-06	108200	0	1	9.242140e-06	108200	0	0	0.000000e+00	29870	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10	89715168	10	89725188	0	0.92422	0.732398	1.000000	0.71638	0.999000	0.91618	1.000000	0.86279	5.709000	0.68037	0.549000	0.26987	1.026000	0.45946	87965431	C	.	rs786203911	.	.	.	.	11.857	8.679	.	.	.	35	-37	-4	35	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-10+144+start+6644	187673	Uncertain_significance	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786203911	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	9.23856e-06	1.87829e-04	0.00000e+00	1.52036e-05	0.00000e+00	9.23856e-06	8.12321e-06	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs786203911	786203911	chr9:33674357&chr17:54445431	0.98265&0.958891	0.97956&0.955238	PTEN	PTEN:exonic	PTEN:missense	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,597	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.1	VUS
14	31354707	31354707	G	A	A	missense_variant	MODERATE	COCH	1690	Transcript	NM_004086.3	protein_coding	10/12	.	NM_004086.3:c.841G>A	NP_004077.1:p.Asp281Asn	897	841	281	D/N	Gac/Aac	rs28362775	G	.	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	COCH	.	chr14:g.31354707G>A	.	0.0076	0	0	0	0	benign/likely_benign&benign&likely_benign	.	1	.	.	.	.	.	COCH&NM_004086.2&c.841G>A	.	.	10	0.001996805111821086	10	0.007564296520423601	0	0.0	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	G/G	G	T	0.01328	-0.438041	T	0.33472	-0.399241	22.6	22.3	2.568198	2.365993	0.42741	0.40759	G/G	T	0.00829	0.0212767232752968	0.69222	0.99520308592705464	.	0.42790	.	G/G	30	0.006808896958692692	0	0.0	3.171395	0.197582446204755	0.49716	2.817151	0.0823362677695329	0.45639	.	.	.	62	5.107e-04	59	5.671e-03	2	1.729e-04	62	5.107e-04	0	0	0	0	0	0	0	0	52	4.896e-04	50	5.516e-03	2	1.785e-04	52	4.897e-04	0	0	0	0	0	0	0	0	62	6.832e-04	59	5.681e-03	2	1.731e-04	62	6.833e-04	0	0	0	0	0	0	0	0	0.83893	.	.	.	5.54	4.62	0.56946	0	0.81188	0.709663	.	.	0.74766	0.999999974584853	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.33627	0.567892	von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&.&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A&von_Willebrand_factor&_type_A	.	.	.	0.73352	.	0.212980	0.52346	D	0.000069	T	0.35458	0.014988	0.28795	.	0.89069	.	T	0.28511	0.0698	.	0.00218	.	T	0.13145	-1.0546	.	.	.	.	.	.	0.25523	.	.	0.41708	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D&D	0.992666&0.992666&0.992666&0.992666&0.987546	0.29323	.	.	.	0.07471	.	.	0.11217	.	T	0.66196	0.693408608437	0.48592	.	10	0.03152	.	.	0.27194	.	.	8.9416	0.34894	0.0737:0.0:0.7767:0.1496	.	.	.	.	.	.	.	.	0.20395	.	G/G	N	.	D	A	919	0.19497	.	14	C1832425&CN043648&CN169374&CN517202	601369	ORPHA87884	Benign	NC_000014.9:g.30885501G>A	226529	reviewed_by_expert_panel	Deafness&_autosomal_dominant_9&Nonsyndromic_hearing_loss_and_deafness&not_specified&not_provided	ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:175898&Illumina_Laboratory_Services&Illumina:765179&UniProtKB_(protein):O43405#VAR_022260	.	.	AEFDGBCI	D	0.40574	0.81097	N	0.41765	0.312124	.	112	4.453810e-04	101	6.213860e-03	16254	0	9	2.602360e-04	34584	0	251470	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	1	8.790900e-06	113754	0	101	6.213860e-03	16254	0	0	0.000000e+00	30616	0	49	4.478890e-04	45	6.283160e-03	7162	0	3	1.753570e-04	17108	0	109402	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	1	2.338200e-05	42768	0	45	6.283160e-03	7162	0	0	0.000000e+00	15690	0	0	.	0	102	4.305030e-04	92	6.174500e-03	14900	0	9	2.627580e-04	34252	0	236932	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	1	9.733500e-06	102738	0	92	6.174500e-03	14900	0	0	0.000000e+00	30526	0	0	110	5.285360e-04	101	6.228420e-03	16216	0	7	2.293880e-04	30516	0	208122	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	1	1.116640e-05	89554	0	101	6.228420e-03	16216	0	0	0.000000e+00	30608	0	0	86	3.512330e-04	75	6.237520e-03	12024	0	9	2.612480e-04	34450	0	244852	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	1	8.955440e-06	111664	0	75	6.237520e-03	12024	0	0	0.000000e+00	30616	0	0	246	1.616120e-03	243	5.862200e-03	41452	0	0	0.000000e+00	912	0	3	1.962840e-04	15284	0	152216	0	0.000000e+00	3472	0	0	0.000000e+00	5198	0	0	0.000000e+00	10622	0	0	0.000000e+00	316	0	0	0.000000e+00	68038	0	243	5.862200e-03	41452	0	0	0.000000e+00	4830	0	53	1.610840e-03	51	5.603160e-03	9102	0	0	0.000000e+00	60	0	2	4.264390e-04	4690	0	32902	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3108	0	0	.	0	246	1.662680e-03	243	5.908100e-03	41130	0	0	0.000000e+00	912	0	3	1.987280e-04	15096	0	147954	0	0.000000e+00	3302	0	0	0.000000e+00	4962	0	0	0.000000e+00	10622	0	0	0.000000e+00	304	0	0	0.000000e+00	64806	0	0	0.000000e+00	4798	0	0	187	1.387200e-03	184	5.664330e-03	32484	0	0	0.000000e+00	862	0	3	2.021840e-04	14838	0	134804	0	0.000000e+00	3388	0	0	0.000000e+00	5198	0	0	0.000000e+00	6980	0	0	0.000000e+00	310	0	0	0.000000e+00	63914	0	0	0.000000e+00	4828	0	0	145	1.795000e-03	143	5.760090e-03	24826	0	0	0.000000e+00	112	0	2	1.549190e-04	12910	0	80780	0	0.000000e+00	998	0	0	0.000000e+00	3758	0	0	0.000000e+00	10530	0	0	0.000000e+00	272	0	0	0.000000e+00	21054	0	0	0.000000e+00	4802	0	0	14	30424458	14	31354707	0	0.61202	0.706298	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	3.093000	0.49912	0.676000	0.76740	1.176000	0.78918	30885501	G	.	rs28362775	.	.	8.650	9.064	10.769	10.858	.	.	.	9	33	-28	15	0.00	0.00	0.00	0.00	COCH	0.00	exon-NM_001347720.2-9+107+start+227	226529	Benign	reviewed_by_expert_panel	not_specified&Nonsyndromic_genetic_hearing_loss&Autosomal_dominant_nonsyndromic_hearing_loss_9&not_provided	MedGen:CN169374&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0011058&MedGen:C1832425&OMIM:601369&Orphanet:90635&MedGen:CN517202	.	rs28362775	5.107e-04	62	62	0	59	2	0	0	0	1	0	10404	11566	8654	6614	66736	908	16512	59	2	0	0	0	1	0	0	0	0	0	0	0	0	rs28362775	6.33904e-03	2.68065e-04	0.00000e+00	0.00000e+00	0.00000e+00	8.95239e-06	1.82282e-04	0.00000e+00	3.03938e-04	6.01728e-04	6.33904e-03	4.38540e-04	rs28362775	5.49828e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66578e-05	0.00000e+00	.	1.86916e-03	1.22744e-03	5.49828e-03	1.58105e-03	rs28362775	0.0&0.6809&0.2307	rs28362775	28362775	.	.	.	COCH\x3bLOC100506071	COCH:exonic\x7cLOC100506071:ncRNA_exonic	COCH:missense	COCH:Deafness\x2cautosomal_dominant_9\x3b?Deafness\x2cautosomal_recessive_110	COCH:601369\x3b618094	COCH:3\x3b3	COCH:Autosomal_dominant\x3bAutosomal_recessive	0	0.000262849456488043	0.983542807336405	0.0161943432071074	DISEASE: Deafness, autosomal dominant, 9 (DFNA9) [MIM:601369]: A form of non-syndromic hearing loss characterized by onset in the fourth or fifth decade of life and initially involves the high frequencies. Hearing loss is progressive and usually complete by the sixth decade. In addition to cochlear involvement, DFNA9 patients also exhibit a spectrum of vestibular dysfunctions. Penetrance of the vestibular symptoms is often incomplete, and some patients are minimally affected, whereas others suffer from severe balance disturbances and episodes of vertigo. Affected individuals have mucopolysaccharide depositions in the channels of the cochlear and vestibular nerves. These depositions apparently cause strangulation and degeneration of dendritic fibers. {ECO:0000269|PubMed:10400989, ECO:0000269|PubMed:11295836, ECO:0000269|PubMed:14512963, ECO:0000269|PubMed:16835921, ECO:0000269|PubMed:17561763, ECO:0000269|PubMed:18312449, ECO:0000269|PubMed:22610276, ECO:0000269|PubMed:22931125, ECO:0000269|PubMed:23993205, ECO:0000269|PubMed:9806553, ECO:0000269|PubMed:9931344}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,883	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.1	VUS
19	4099300	4099300	T	C	C	missense_variant	MODERATE	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	7/11	.	NM_030662.4:c.818A>G	NP_109587.1:p.Lys273Arg	1065	818	273	K/R	aAa/aGa	rs539555837&CM071853	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	MAP2K2	.	chr19:g.4099300T>C	.	0	0.0014	0	0	0	likely_benign	.	1&1	.	.	.	.	.	MAP2K2&NM_030662.3&c.818A>G	.	.	1	1.9968051118210862E-4	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	./.	T	T	0.38400	-0.0880439	D	0.66552	-0.0568288	22.4	22.9	2.501013	2.675580	0.41265	0.47581	./.	T	0.05492	0.0499539524316788	0.77947	0.99661220505945147	.	0.56364	.	./.	.	.	.	.	2.113866	-0.0769856032486566	0.36344	1.708953	-0.262217751954011	0.30618	.	.	.	6	4.959e-05	0	0	6	8.465e-04	6	7.541e-05	0	0	0	0	0	0	0	0	6	5.655e-05	0	0	6	8.726e-04	6	8.613e-05	0	0	0	0	0	0	0	0	6	6.642e-05	0	0	6	8.470e-04	6	9.977e-05	0	0	0	0	0	0	0	0	0.65192	.	.	.	4.53	4.53	0.55009	0	0.74545	0.702456	.	.	0.74766	0.999999979690596	.	0	0.80598	0.723109	.	.	.	.	.	.	0	0.83352	0.714379	Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain	.	.	.	0.81989	.	0.049953	0.84330	N	0.000000	T	0.38094	0.016705	0.38527	.	0.96826	.	T	0.45413	0.1373	.	0.19198	.	T	0.37220	-0.9699	.	.	.	.	.	.	0.12094	.	.	0.51042	simple_aae&simple_aae	D&D	0.999646&0.999912	0.35194	.	.	.	0.07471	.	.	0.16012	.	T	0.36383	0.482362151146	0.56694	.	10	0.18286	.	.	0.23271	.	.	12.1813	0.53522	0.0:0.0:0.0:1.0	.	.	.	.	.	.	.	.	0.75192	.	./.	R	.	K	C	934	0.15400	.	19	C3809007&CN166718&CN169374&CN517202	615280	ORPHA536391	Likely_benign	NC_000019.10:g.4099302T>C	40824	reviewed_by_expert_panel	Cardiofaciocutaneous_syndrome_4&Rasopathy&not_specified&not_provided	ClinGen_RASopathy_Variant_Curation_Expert_Panel:905a415a-6df7-4dab-b492-c7ae4a886f9f	.	.	AEFDBI	D	0.57920	0.93327	D	0.60106	0.613340	.	18	7.622790e-05	0	0.000000e+00	14284	0	12	3.608370e-04	33256	0	236134	0	0.000000e+00	9690	0	0	0.000000e+00	17538	0	0	0.000000e+00	20626	0	6	5.687100e-05	105502	0	12	3.608370e-04	33256	0	0	0.000000e+00	29440	0	8	7.776810e-05	0	0.000000e+00	6242	0	5	3.042100e-04	16436	0	102870	0	0.000000e+00	2144	0	0	0.000000e+00	8452	0	0	0.000000e+00	13006	0	3	7.540340e-05	39786	0	5	3.042100e-04	16436	0	0	0.000000e+00	15022	0	0	segdup	0	18	8.016670e-05	0	0.000000e+00	13134	0	12	3.639230e-04	32974	0	224532	0	0.000000e+00	9304	0	0	0.000000e+00	16938	0	0	0.000000e+00	20616	0	6	6.196550e-05	96828	0	12	3.639230e-04	32974	0	0	0.000000e+00	29368	0	0	16	8.195550e-05	0	0.000000e+00	14246	0	12	4.110430e-04	29194	0	195228	0	0.000000e+00	5844	0	0	0.000000e+00	12830	0	0	0.000000e+00	16108	0	4	4.819510e-05	82996	0	12	4.110430e-04	29194	0	0	0.000000e+00	29432	0	0	18	7.800450e-05	0	0.000000e+00	10904	0	12	3.620350e-04	33146	0	230756	0	0.000000e+00	9618	0	0	0.000000e+00	17534	0	0	0.000000e+00	20624	0	6	5.782240e-05	103766	0	12	3.620350e-04	33146	0	0	0.000000e+00	29440	0	0	5	3.285150e-05	0	0.000000e+00	41468	0	0	0.000000e+00	912	0	2	1.308900e-04	15280	0	152200	0	0.000000e+00	3466	0	0	0.000000e+00	5196	0	0	0.000000e+00	10622	0	0	0.000000e+00	316	0	2	2.940570e-05	68014	0	2	1.308900e-04	15280	0	0	0.000000e+00	4834	0	3	9.113550e-05	0	0.000000e+00	9106	0	0	0.000000e+00	60	0	2	4.264390e-04	4690	0	32918	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5494	0	0	0.000000e+00	246	0	1	1.459000e-04	6854	0	0	0.000000e+00	3112	0	0	.	0	5	3.379110e-05	0	0.000000e+00	41146	0	0	0.000000e+00	912	0	2	1.325030e-04	15094	0	147968	0	0.000000e+00	3302	0	0	0.000000e+00	4962	0	0	0.000000e+00	10622	0	0	0.000000e+00	304	0	2	3.086320e-05	64802	0	0	0.000000e+00	4802	0	0	4	2.967620e-05	0	0.000000e+00	32496	0	0	0.000000e+00	862	0	2	1.348250e-04	14834	0	134788	0	0.000000e+00	3382	0	0	0.000000e+00	5196	0	0	0.000000e+00	6984	0	0	0.000000e+00	310	0	1	1.565190e-05	63890	0	0	0.000000e+00	4832	0	0	5	6.190880e-05	0	0.000000e+00	24846	0	0	0.000000e+00	112	0	2	1.549670e-04	12906	0	80764	0	0.000000e+00	992	0	0	0.000000e+00	3754	0	0	0.000000e+00	10530	0	0	0.000000e+00	272	0	2	9.511130e-05	21028	0	0	0.000000e+00	4806	0	0	19	4050300	19	4099300	0	0.73137	0.706548	1.000000	0.71638	0.992000	0.67800	1.000000	0.86279	2.195000	0.42310	0.665000	0.62972	1.138000	0.64695	4099302	T	.	rs539555837	.	.	12.559	8.532	6.943	7.389	.	.	.	-1	-3	-1	27	0.01	0.00	0.00	0.00	MAP2K2	0.86	exon-NM_030662.4-7+101+start+214	40824	Likely_benign	reviewed_by_expert_panel	Cardiofaciocutaneous_syndrome_4&not_specified&not_provided&RASopathy	MONDO:MONDO:0014114&MedGen:C3809007&OMIM:615280&Orphanet:1340&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	19:4099300-4099300	4.959e-05	6	6	0	0	6	0	0	0	0	0	6242	7088	5958	3316	43416	594	12950	0	6	0	0	0	0	0	0	0	0	0	0	0	0	rs539555837	0.00000e+00	3.39108e-04	0.00000e+00	0.00000e+00	0.00000e+00	4.78872e-05	1.91278e-04	0.00000e+00	3.90515e-05	1.14822e-04	3.39108e-04	7.31107e-05	rs539555837	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.67379e-05	0.00000e+00	.	5.85138e-05	0.00000e+00	6.67379e-05	3.22685e-05	.	.	rs539555837	539555837	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:missense	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,928	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0.0507	VUS
3	12660102	12660102	C	T	T	missense_variant	MODERATE	RAF1	5894	Transcript	NM_001354689.3	protein_coding	2/18	.	NM_001354689.3:c.119G>A	NP_001341618.1:p.Arg40His	450	119	40	R/H	cGc/cAc	rs192632236	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	RAF1	.	chr3:g.12660102C>T	.	0	0.0029	0	0	0	uncertain_significance&benign&likely_benign	.	1	.	.	.	.	.	.	.	.	2	3.9936102236421724E-4	0	0.0	2	0.002881844380403458	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	C/C	C	T	0.31017	-0.132961	D	0.73063	0.0420656	23.9	25.5	3.232821	3.634763	0.57381	0.70648	C/C	T	0.04739	0.0457529776344767	0.93820	0.99859380306277046	.	0.80947	.	C/C	.	.	.	.	4.315692	0.39392948627417	0.61191	3.231022	0.183512058210553	0.50408	.	.	.	113	9.307e-04	0	0	112	9.674e-03	113	9.308e-04	0	0	0	0	1	1.498e-05	0	0	111	1.045e-03	0	0	111	9.897e-03	111	1.045e-03	0	0	0	0	0	0	0	0	113	1.245e-03	0	0	112	9.684e-03	113	1.245e-03	0	0	0	0	1	2.373e-05	0	0	0.76430	.	.	.	6.17	6.17	0.99707	0	0.89359	0.724815	.	.	0.98316	1.0	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.83352	0.714379	.&.	.	.	.	0.92647	.	0.000000	0.84330	D	0.000000	T	0.38744	0.01716	0.54147	.	0.94603	.	T	0.58459	0.2212	.	0.00236	.	T	0.61770	-0.6713	.	.	.	.	.	.	0.33814	.	.	0.81001	simple_aae&simple_aae&without_aae	D&D&D	1&1&1	0.23372	.	.	.	0.33167	.	.	0.20508	.	T	0.70369	0.722210049629	0.59861	.	10	0.18449	.	.	0.59928	.	.	20.8794	0.99870	0.0:1.0:0.0:0.0	.	.	.	.	.	.	.	.	0.68082	.	C/C	H	.	R	T	615	0.66512	.	3	C4551602&C1969057&C1969056&CN166718&CN169374&CN230736&CN517202	163950&611553&611554	ORPHA536391	Benign	NC_000003.12:g.12618603C>T	40585	reviewed_by_expert_panel	Noonan_syndrome_1&Noonan_syndrome_5&LEOPARD_syndrome_2&Rasopathy&not_specified&Cardiovascular_phenotype&not_provided	Illumina_Laboratory_Services&Illumina:737660&Center_for_Human_Genetics&_Inc&Center_for_Human_Genetics&_Inc:RAF1-A1&ClinGen_RASopathy_Variant_Curation_Expert_Panel:e3a025b8-32a2-4d0f-92e0-d44516304ddc	.	.	AEFDBI	D	0.80190	0.98168	D	0.70421	0.768743	.	298	1.184960e-03	0	0.000000e+00	16256	0	294	8.499070e-03	34592	2	251486	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21646	0	1	8.790130e-06	113764	0	294	8.499070e-03	34592	2	0	0.000000e+00	30616	0	154	1.407600e-03	0	0.000000e+00	7164	0	154	8.999530e-03	17112	1	109406	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13392	0	0	0.000000e+00	42768	0	154	8.999530e-03	17112	1	0	0.000000e+00	15690	0	1	.	2	296	1.249220e-03	0	0.000000e+00	14902	0	293	8.552250e-03	34260	2	236948	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21630	0	0	0.000000e+00	102748	0	293	8.552250e-03	34260	2	0	0.000000e+00	30526	0	2	289	1.388560e-03	0	0.000000e+00	16218	0	285	9.336920e-03	30524	2	208130	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16732	0	1	1.116620e-05	89556	0	285	9.336920e-03	30524	2	0	0.000000e+00	30608	0	2	298	1.216980e-03	0	0.000000e+00	12026	0	294	8.532130e-03	34458	2	244868	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21644	0	1	8.954640e-06	111674	0	294	8.532130e-03	34458	2	0	0.000000e+00	30616	0	2	25	1.643140e-04	0	0.000000e+00	41422	0	0	0.000000e+00	912	0	23	1.505830e-03	15274	0	152148	0	0.000000e+00	3468	0	0	0.000000e+00	5194	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	0	0.000000e+00	68030	0	23	1.505830e-03	15274	0	0	0.000000e+00	4836	0	7	2.128180e-04	0	0.000000e+00	9088	0	0	0.000000e+00	60	0	5	1.066100e-03	4690	0	32892	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5484	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3114	0	0	.	0	25	1.690260e-04	0	0.000000e+00	41100	0	0	0.000000e+00	912	0	23	1.524590e-03	15086	0	147906	0	0.000000e+00	3302	0	0	0.000000e+00	4962	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	0	0.000000e+00	64810	0	0	0.000000e+00	4804	0	0	24	1.781160e-04	0	0.000000e+00	32456	0	0	0.000000e+00	862	0	22	1.483680e-03	14828	0	134744	0	0.000000e+00	3384	0	0	0.000000e+00	5194	0	0	0.000000e+00	6968	0	0	0.000000e+00	310	0	0	0.000000e+00	63910	0	0	0.000000e+00	4834	0	0	13	1.610740e-04	0	0.000000e+00	24798	0	0	0.000000e+00	112	0	11	8.527130e-04	12900	0	80708	0	0.000000e+00	994	0	0	0.000000e+00	3752	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	0	0.000000e+00	21042	0	0	0.000000e+00	4808	0	0	3	12635102	3	12660102	0	0.73137	0.706548	1.000000	0.71638	1.000000	0.97212	1.000000	0.86279	5.768000	0.68510	0.599000	0.40250	1.026000	0.45946	12618603	C	.	rs192632236	.	.	7.229	7.638	11.110	10.280	.	.	.	-30	21	23	21	0.00	0.00	0.00	0.00	RAF1	1.00	exon-NM_001354693.3-2+88+start+233	40585	Benign	reviewed_by_expert_panel	not_provided&not_specified&RASopathy&Noonan_syndrome_5&LEOPARD_syndrome_2&Noonan_syndrome_1&Cardiovascular_phenotype	MedGen:CN517202&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0012690&MedGen:C1969057&OMIM:611553&Orphanet:648&MONDO:MONDO:0012691&MedGen:C1969056&OMIM:611554&Orphanet:500&MONDO:MONDO:0008104&MedGen:C4551602&OMIM:163950&Orphanet:648&MedGen:CN230736	.	rs192632236	9.307e-04	113	111	1	0	112	0	0	1	0	0	10404	11578	8654	6614	66738	908	16510	0	110	0	0	1	0	0	0	1	0	0	0	0	0	rs192632236	0.00000e+00	8.51647e-03	0.00000e+00	0.00000e+00	0.00000e+00	8.95111e-06	5.47046e-04	0.00000e+00	7.48669e-04	1.69717e-03	8.51647e-03	1.17756e-03	rs192632236	0.00000e+00	2.38663e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	0.00000e+00	1.44383e-04	2.38663e-03	6.45328e-05	.	.	rs192632236	192632236	.	.	.	RAF1	RAF1:exonic	RAF1:missense	RAF1:Cardiomyopathy\x2cdilated\x2c1NN\x3bNoonan_syndrome_5\x3bLEOPARD_syndrome_2	RAF1:615916\x3b611553\x3b611554	RAF1:3\x3b3\x3b3	RAF1:Autosomal_dominant\x3bAutosomal_dominant\x3b.	0	0.999776866110749	0.000223133833869176	5.53819998824154e-11	DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,483	0	0	0	0	0	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0.0507	VUS
12	103246663	103246663	G	A	A	synonymous_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.772C>T	NP_000268.1:p.Leu258%3D	886	772	258	L	Ctg/Ttg	rs75065106	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103246663G>A	.	0.0113	0	0	0	0	likely_benign	.	1	.	.	.	.	.	PAH&NM_000277.1&c.772C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.570	9.399	7.651	9.354	.	.	.	-13	-30	6	-28	0.00	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+65+end+136	590340	Likely_benign	reviewed_by_expert_panel	Phenylketonuria&Inborn_genetic_diseases	MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716&MeSH:D030342&MedGen:C0950123	.	rs75065106	8.319e-04	101	101	0	96	5	0	0	0	0	0	10404	11556	8652	6610	66726	908	16512	96	5	0	0	0	0	0	0	0	0	0	0	0	0	rs75065106	9.08259e-03	4.17089e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.82282e-04	0.00000e+00	4.89629e-04	7.90642e-04	9.08259e-03	6.25325e-04	rs75065106	9.51617e-03	1.19332e-03	0.00000e+00	0.00000e+00	0.00000e+00	6.66223e-05	0.00000e+00	.	2.68723e-03	2.81588e-03	9.51617e-03	2.77491e-03	rs75065106	0.0&1.0213&0.346	rs75065106	75065106	.	.	.	PAH	PAH:exonic	PAH:synonymous_SNV	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,742	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
1	215807798	215807798	T	C	C	splice_donor_region_variant&intron_variant	LOW	USH2A	7399	Transcript	NM_206933.4	protein_coding	.	70/71	NM_206933.4:c.15297+3A>G	.	.	.	.	.	.	rs57754754	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	KCTD3	.	chr1:g.215807798T>C	.	0.0144	0	0	0	0	benign	.	1	.	.	.	.	.	USH2A&NM_206933.2&c.15297+3A>G	0.967637927115047	0.754	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.283	10.098	9.325	8.351	4.837	3.514	8.351	3	47	-11	3	0.00	0.00	0.06	0.65	USH2A	0.00	.	48459	Benign	reviewed_by_expert_panel	not_specified&Usher_syndrome&not_provided	MedGen:CN169374&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&MedGen:CN517202	.	rs57754754	9.390e-04	114	112	1	111	1	0	0	1	0	1	10368	11578	8654	6614	66734	908	16510	109	1	0	0	1	0	1	1	0	0	0	0	0	0	rs57754754	1.18923e-02	5.95557e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.79144e-05	3.64830e-04	6.49773e-05	6.67339e-04	1.06001e-03	1.18923e-02	8.44595e-04	rs57754754	9.50962e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.02041e-03	.	2.33618e-03	3.17827e-03	9.50962e-03	2.71038e-03	rs57754754	0.0&0.8852&0.2999	rs57754754	57754754	.	.	.	USH2A	USH2A:splicing\x3bintronic	USH2A:splice_donor_region_variant	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,446	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
12	103246735	103246735	T	A	A	splice_polypyrimidine_tract_variant&splice_region_variant&intron_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	.	6/12	NM_000277.3:c.707-7A>T	.	.	.	.	.	.	rs62508624&CS015349	T	.	-1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PAH	.	chr12:g.103246735T>A	.	0.1051	0.0115	0	0	0	benign/likely_benign&benign	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.707-7A>T	3.23355795896632E-5	0.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.651	9.399	7.292	9.354	9.482	-1.831	7.651	-7	-2	-32	-7	0.01	0.00	0.00	0.00	PAH	0.00	.	102795	Benign	reviewed_by_expert_panel	not_specified&not_provided&Phenylketonuria	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs62508624	8.665e-03	1052	979	35	910	78	0	0	56	3	2	10224	11268	8144	6464	64982	874	16226	844	76	0	0	54	3	2	33	1	0	0	1	0	0	rs62508624	8.96060e-02	5.03936e-03	9.47819e-03	5.82343e-05	0.00000e+00	3.25045e-04	4.76190e-03	9.75610e-05	5.39325e-03	8.78508e-03	8.96060e-02	6.91117e-03	rs62508624	9.06587e-02	8.35322e-03	1.65563e-02	0.00000e+00	0.00000e+00	3.33422e-04	2.04082e-03	.	2.65466e-02	2.56503e-02	9.06587e-02	2.61035e-02	rs62508624	0.0814&8.3296&2.8756	rs62508624	62508624	.	.	.	PAH	PAH:splicing\x3bintronic	PAH:splice_region_variant\x3bsplice_polypyrimidine_tract_variant	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,756	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
21	36206932	36206932	G	A	A	intron_variant	MODIFIER	RUNX1	861	Transcript	NM_001754.5	protein_coding	.	6/8	NM_001754.5:c.614-34C>T	.	.	.	.	.	.	rs11702841	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36206932G>A	.	1	1	1	1	1	benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.171	10.451	11.926	9.815	.	.	.	-6	-34	-34	-45	0.00	0.00	0.00	0.00	RUNX1	0.45	.	258186	Benign	reviewed_by_expert_panel	not_specified&not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	rs11702841	1.000	121379	0	59958	10148	11466	8558	6530	65900	896	16418	10148	11466	8558	6530	65900	896	16418	0	0	0	0	0	0	0	5074	5733	4279	3265	32950	448	8209	rs11702841	1.00000e+00	1.00000e+00	1.00000e+00	1.00000e+00	1.00000e+00	1.00000e+00	1.00000e+00	1.00000e+00	1.00000e+00	1.00000e+00	1.00000e+00	9.99963e-01	rs11702841	1.00000e+00	1.00000e+00	1.00000e+00	1.00000e+00	1.00000e+00	1.00000e+00	1.00000e+00	.	1.00000e+00	1.00000e+00	1.00000e+00	9.99935e-01	.	.	rs11702841	11702841	.	.	.	RUNX1	RUNX1:intronic	.	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,958	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
12	103234251	103234251	G	A	A	synonymous_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1242C>T	NP_000268.1:p.Tyr414%3D	1356	1242	414	Y	taC/taT	rs1801152&CM101145	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103234251G>A	.	0.0008	0.0029	0	0.0109	0	benign/likely_benign&benign	.	1&1	.	.	.	.	.	PAH&NM_000277.1&c.1242C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.477	9.491	8.924	9.158	.	.	.	-18	42	42	-24	0.00	0.11	0.00	0.00	PAH	0.00	exon-NM_001354304.2-13+42+end+116	102577	Benign	reviewed_by_expert_panel	not_specified&not_provided&Phenylketonuria	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs1801152	7.981e-03	969	957	6	25	36	1	18	861	4	24	10406	11526	8654	6614	66724	908	16510	25	36	1	18	851	4	22	0	0	0	0	5	0	1	rs1801152	2.54869e-03	3.33810e-03	3.04569e-04	5.79777e-05	2.06297e-03	1.39747e-02	6.93178e-03	1.39701e-03	7.31794e-03	7.68816e-03	1.39747e-02	7.48360e-03	rs1801152	2.52178e-03	5.96659e-03	0.00000e+00	0.00000e+00	1.14482e-03	1.09304e-02	4.08998e-03	.	7.01590e-03	5.70397e-03	1.09304e-02	6.42101e-03	rs1801152	1.314&0.3631&0.9918	rs1801152	1801152	.	.	.	PAH	PAH:exonic	PAH:synonymous_SNV	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,648	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
21	36231763	36231763	G	A	A	splice_region_variant&intron_variant	LOW	RUNX1	861	Transcript	NM_001754.5	protein_coding	.	6/8	NM_001754.5:c.613+8C>T	.	.	.	.	.	.	rs186585782	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36231763G>A	.	0	0	0	0.003	0	likely_benign&benign	.	1	.	.	.	.	.	RUNX1&NM_001001890.2&c.532+8C>T	3.64839492542337E-5	0.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.171	10.451	11.926	9.815	.	.	.	2	48	2	4	0.00	0.00	0.00	0.00	RUNX1	0.45	.	339876	Benign	reviewed_by_expert_panel	not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	rs186585782	2.594e-03	315	307	4	0	0	0	205	101	9	0	10406	11578	8654	6614	66722	908	16512	0	0	0	199	99	9	0	0	0	0	3	1	0	0	rs186585782	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.19760e-02	8.41570e-04	3.10106e-03	6.49730e-05	2.94318e-03	3.85258e-03	3.19760e-02	3.35402e-03	rs186585782	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.15006e-02	4.33333e-03	1.22449e-02	.	5.20042e-03	7.07683e-03	3.15006e-02	6.09835e-03	rs186585782	0.0814&0.0&0.0538	rs186585782	186585782	.	.	.	RUNX1	RUNX1:splicing\x3bintronic	RUNX1:splice_region_variant	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,959	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.025	VUS
12	103234215	103234215	A	G	G	synonymous_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	12/13	.	NM_000277.3:c.1278T>C	NP_000268.1:p.Asn426%3D	1392	1278	426	N	aaT/aaC	rs59326968	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103234215A>G	.	0.1664	0.0173	0	0.001	0	benign/likely_benign&benign	.	1	.	.	.	.	.	PAH&NM_000277.1&c.1278T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.477	9.491	8.924	9.158	.	.	.	43	-37	-37	12	0.00	0.00	0.04	0.00	PAH	0.00	exon-NM_001354304.2-13+37+start+116	92732	Benign	reviewed_by_expert_panel	not_specified&not_provided&Phenylketonuria	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs59326968	0.014	1653	1445	104	1525	82	0	1	33	6	6	10406	11526	8654	6612	66714	908	16510	1317	82	0	1	33	6	6	104	0	0	0	0	0	0	rs59326968	1.46778e-01	7.59743e-03	4.06091e-04	5.79777e-05	4.48430e-05	5.10350e-04	6.74690e-03	3.24865e-04	7.75493e-03	1.40565e-02	1.46778e-01	1.06021e-02	rs59326968	1.42005e-01	4.77327e-03	0.00000e+00	0.00000e+00	0.00000e+00	5.99680e-04	7.12831e-03	.	4.17884e-02	3.92114e-02	1.42005e-01	4.06557e-02	rs59326968	0.093&13.5497&4.6517	rs59326968	59326968	.	.	.	PAH	PAH:exonic	PAH:synonymous_SNV	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,645	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
10	89623323	89623323	G	A	A	upstream_gene_variant	MODIFIER	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	.	.	.	.	.	.	.	.	rs1044322	G	59	1	.	.	EntrezGene	.	.	.	.	G	G	.	.	KLLN	.	chr10:g.89623323G>A	.	0.0091	0.0159	0	0.0229	0.0092	benign	.	1	.	.	.	.	.	KLLN&NM_001126049.1&c.-1079C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	24	6	24	-11	0.00	0.00	0.00	0.00	PTEN	0.98	.	138837	Benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs1044322	5.87422e-03	1.21951e-02	2.31788e-02	1.84957e-03	1.01685e-02	1.49064e-02	1.42857e-02	.	1.12208e-02	1.10257e-02	2.31788e-02	1.11018e-02	.	.	rs1044322	1044322	.	.	.	PTEN\x3bKLLN	PTEN:upstream\x7cKLLN:upstream	.	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,506	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
12	103240630	103240630	C	A	A	intron_variant	MODIFIER	PAH	5053	Transcript	NM_000277.3	protein_coding	.	9/12	NM_000277.3:c.969+43G>T	.	.	.	.	.	.	rs1522306&COSV61015928	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103240630C>A	.	0.2443	0.3184	0.0536	0.4254	0.3313	not_provided&benign	0&1	1&1	.	.	.	.	.	PAH&NM_000277.1&c.969+43G>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.709	9.459	9.506	9.491	.	.	.	-44	39	43	-47	0.00	0.00	0.01	0.00	PAH	0.00	.	92755	Benign	reviewed_by_expert_panel	not_specified&not_provided&Phenylketonuria	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs1522306	0.351	42657	26185	8173	2767	2601	471	3187	27443	330	5732	10382	11472	8626	6588	66468	902	16482	2047	1989	443	1629	16171	208	3698	360	306	14	779	5636	61	1017	rs1522306	2.70798e-01	2.43130e-01	3.30589e-01	5.55233e-02	4.89757e-01	4.20708e-01	3.62900e-01	3.44768e-01	3.60786e-01	3.44293e-01	4.89757e-01	3.53364e-01	rs1522306	2.73271e-01	2.79236e-01	3.37748e-01	5.94796e-02	4.93131e-01	4.35930e-01	3.95706e-01	.	3.65105e-01	3.77027e-01	4.93131e-01	3.70515e-01	rs1522306	41.686&26.8498&36.66	rs1522306	1522306	.	.	.	PAH	PAH:intronic	.	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,680	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
21	36206858	36206858	G	A	A	synonymous_variant	LOW	RUNX1	861	Transcript	NM_001754.5	protein_coding	7/9	.	NM_001754.5:c.654C>T	NP_001745.2:p.Ser218%3D	848	654	218	S	agC/agT	rs145230602	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36206858G>A	.	0.0015	0	0	0.002	0	likely_benign	.	1	.	.	.	.	.	RUNX1&NM_001001890.2&c.573C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.087	10.451	9.171	9.815	.	.	.	29	40	2	-22	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-7+40+end+192	239052	Likely_benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1&not_provided	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290&MedGen:CN517202	.	rs145230602	3.047e-04	37	37	0	7	4	0	0	25	1	0	10382	11560	8640	6594	66660	902	16500	7	4	0	0	25	1	0	0	0	0	0	0	0	0	rs145230602	7.18766e-04	1.07200e-03	2.74112e-03	0.00000e+00	0.00000e+00	3.59609e-04	1.27691e-03	0.00000e+00	5.20338e-04	4.59385e-04	2.74112e-03	4.95387e-04	rs145230602	3.45304e-04	0.00000e+00	6.62252e-03	0.00000e+00	0.00000e+00	2.00535e-04	0.00000e+00	.	1.75809e-04	3.62004e-04	6.62252e-03	2.58131e-04	rs145230602	0.0349&0.0681&0.0461	rs145230602	145230602	.	.	.	RUNX1	RUNX1:exonic	RUNX1:synonymous_SNV	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,957	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.025	VUS
12	103246700	103246700	C	T	T	synonymous_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	7/13	.	NM_000277.3:c.735G>A	NP_000268.1:p.Val245%3D	849	735	245	V	gtG/gtA	rs1042503&CX056901&CX1618317&COSV61020278	C	.	-1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PAH	.	chr12:g.103246700C>T	.	0.0129	0.196	0.7629	0.2594	0.4029	benign&likely_pathogenic	0&0&0&1	1&1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.735G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.570	9.399	7.651	9.354	.	.	.	-2	28	28	-22	0.02	0.00	0.00	0.00	PAH	0.00	exon-NM_001354304.2-8+28+end+136	92748	Benign	reviewed_by_expert_panel	not_specified&not_provided&Phenylketonuria	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs1042503	0.290	35263	22186	6524	475	2596	6506	2054	17231	273	6099	10398	11542	8628	6594	66676	908	16510	461	1978	1632	1414	12799	181	3721	7	309	2437	320	2216	46	1189	rs1042503	3.94720e-02	2.09424e-01	2.82374e-01	7.53656e-01	3.05528e-01	2.51467e-01	2.83631e-01	3.72969e-01	2.96509e-01	2.81654e-01	7.53656e-01	2.89842e-01	rs1042503	5.12173e-02	2.11217e-01	2.90000e-01	7.50932e-01	3.05906e-01	2.45991e-01	3.11861e-01	.	2.24637e-01	2.27095e-01	7.50932e-01	2.25639e-01	rs1042503	24.6047&5.5606&18.1532	rs1042503	1042503	.	.	.	PAH	PAH:exonic	PAH:synonymous_SNV	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,750	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
10	89623167	89623167	C	G	G	5_prime_UTR_variant	MODIFIER	KLLN	100144748	Transcript	NM_001126049.2	protein_coding	1/1	.	NM_001126049.2:c.-923G>C	.	124	.	.	.	.	rs144620057	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	KLLN	.	chr10:g.89623167C>G	.	0.0136	0.0014	0	0	0	benign&likely_benign	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.-1060C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	23	-33	8	-49	0.00	0.00	0.00	0.00	KLLN	.	exon-NM_001126049.2-1+123+end+4376	189520	Benign	reviewed_by_expert_panel	not_provided&PTEN_hamartoma_tumor_syndrome	MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs144620057	1.37963e-02	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.00187e-04	0.00000e+00	.	3.74663e-03	4.26671e-03	1.37963e-02	3.96902e-03	.	.	rs144620057	144620057	.	.	.	PTEN\x3bKLLN	PTEN:upstream\x7cKLLN:UTR5	.	KLLN:Cowden_syndrome_4	KLLN:615107	KLLN:3	KLLN:.	0				DISEASE: Cowden syndrome 4 (CWS4) [MIM:615107]: A form of Cowden syndrome, a hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:21177507}. Note=The gene represented in this entry is involved in disease pathogenesis. Germline KLLN methylation is common among patients with Cowden syndrome or Cowden-like syndrome and is associated with increased risks of breast and renal cancer over PTEN mutation-positive individuals (PubMed:21177507). {ECO:0000269|PubMed:21177507}.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,503	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
12	103240679	103240679	G	A	A	synonymous_variant	LOW	PAH	5053	Transcript	NM_000277.3	protein_coding	9/13	.	NM_000277.3:c.963C>T	NP_000268.1:p.Leu321%3D	1077	963	321	L	ctC/ctT	rs61747292	G	.	-1	.	.	EntrezGene	.	.	.	.	G	G	.	.	PAH	.	chr12:g.103240679G>A	.	0.0522	0.0043	0	0	0	not_provided&benign	.	1	.	.	.	.	.	PAH&NM_000277.1&c.963C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.709	9.491	9.506	11.083	.	.	.	-6	50	2	-6	0.00	0.17	0.00	0.08	PAH	0.00	exon-NM_001354304.2-10+6+start+57	102911	Benign	reviewed_by_expert_panel	not_provided&not_specified&Phenylketonuria	MedGen:CN517202&MedGen:CN169374&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs61747292	4.769e-03	579	1	17	543	30	0	0	3	1	2	10406	11532	8646	6596	66688	908	16506	0	0	0	0	0	0	1	17	0	0	0	0	0	0	rs61747292	5.32096e-02	2.59222e-03	0.00000e+00	0.00000e+00	0.00000e+00	7.17360e-05	1.82815e-03	1.29963e-04	3.09421e-03	4.54848e-03	5.32096e-02	3.74789e-03	rs61747292	5.18468e-02	5.96659e-03	0.00000e+00	0.00000e+00	0.00000e+00	6.67022e-05	2.04082e-03	.	1.42105e-02	1.56860e-02	5.18468e-02	1.49393e-02	rs61747292	0.0&5.1748&1.753	rs61747292	61747292	.	.	.	PAH	PAH:exonic	PAH:synonymous_SNV	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,681	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
10	112724573	112724573	C	T	T	synonymous_variant	LOW	SHOC2	8036	Transcript	NM_007373.4	protein_coding	2/9	.	NM_007373.4:c.457C>T	NP_031399.2:p.Leu153%3D	745	457	153	L	Cta/Tta	rs34081996	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	SHOC2	.	chr10:g.112724573C>T	.	0	0.0101	0	0.0199	0.0051	benign	.	1	.	.	.	.	.	SHOC2&NM_007373.3&c.457C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.357	8.846	9.854	7.528	.	.	.	5	23	-34	23	0.00	0.00	0.00	0.00	SHOC2	0.99	exon-NM_001324336.2-2+246+end+937	139104	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&not_specified&not_provided&RASopathy&Noonan_syndrome-like_disorder_with_loose_anagen_hair_1	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0054637&MedGen:C4478716&OMIM:607721&Orphanet:2701	.	rs34081996	0.012	1479	1453	13	27	77	1	185	1104	18	67	10198	11536	8646	6612	66696	908	16508	27	75	1	175	1090	18	67	0	1	0	5	7	0	0	rs34081996	2.74617e-03	6.37702e-03	3.35570e-03	1.15955e-04	2.95067e-02	1.82784e-02	1.46092e-02	4.19076e-03	1.33300e-02	1.25706e-02	2.95067e-02	1.29820e-02	rs34081996	2.75229e-03	1.07914e-02	0.00000e+00	0.00000e+00	2.71895e-02	1.62022e-02	1.83299e-02	.	1.22707e-02	1.29391e-02	2.71895e-02	1.25839e-02	rs34081996	1.814&0.2724&1.2917	rs34081996	34081996	.	.	.	SHOC2	SHOC2:exonic	SHOC2:synonymous_SNV	SHOC2:Noonan_syndrome-like_with_loose_anagen_hair_1	SHOC2:607721	SHOC2:3	SHOC2:Autosomal_dominant	0	0.991705191552454	0.00829295945769003	1.84898985615785e-06	DISEASE: Noonan syndrome-like disorder with loose anagen hair (NSLH) [MIM:607721]: A syndrome characterized by Noonan dysmorphic features such as macrocephaly, high forehead, hypertelorism, palpebral ptosis, low-set and posteriorly rotated ears, short and webbed neck, pectus anomalies, in association with pluckable, sparse, thin and slow-growing hair. {ECO:0000269|PubMed:19684605, ECO:0000269|PubMed:25137548}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,602	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
21	36164606	36164606	G	A	A	synonymous_variant	LOW	RUNX1	861	Transcript	NM_001754.5	protein_coding	9/9	.	NM_001754.5:c.1269C>T	NP_001745.2:p.Arg423%3D	1463	1269	423	R	cgC/cgT	rs544247912	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36164606G>A	.	0	0	0	0	0.001	benign&likely_benign	.	1	.	.	.	.	.	RUNX1&NM_001754.4&c.1269C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.279	7.470	.	.	.	2	23	2	15	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-9+301+end+4810	239042	Benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&not_specified&Acute_myeloid_leukemia&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MedGen:CN169374&Human_Phenotype_Ontology:HP:0001914&Human_Phenotype_Ontology:HP:0004808&Human_Phenotype_Ontology:HP:0004843&Human_Phenotype_Ontology:HP:0005516&Human_Phenotype_Ontology:HP:0006724&Human_Phenotype_Ontology:HP:0006728&MONDO:MONDO:0018874&MeSH:D015470&MedGen:C0023467&OMIM:601626&Orphanet:519&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	21:36164606-36164606	3.195e-04	33	16	0	0	0	0	0	14	1	1	1216	216	330	16	5096	144	7730	0	0	0	0	14	1	1	0	0	0	0	0	0	0	rs544247912	0.00000e+00	3.35233e-04	6.92898e-03	0.00000e+00	0.00000e+00	5.55534e-04	1.35722e-03	8.73134e-05	6.24004e-04	8.41510e-04	6.92898e-03	5.61262e-04	rs544247912	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.16185e-04	0.00000e+00	.	1.79040e-04	4.43525e-04	6.16185e-04	2.90454e-04	.	.	rs544247912	544247912	.	.	.	RUNX1	RUNX1:exonic	RUNX1:synonymous_SNV	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,947	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.025	VUS
19	4101032	4101032	C	T	T	synonymous_variant	LOW	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	6/11	.	NM_030662.4:c.690G>A	NP_109587.1:p.Thr230%3D	937	690	230	T	acG/acA	rs201287884	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MAP2K2	.	chr19:g.4101032C>T	.	0.0008	0	0	0	0	benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.943	7.389	5.732	10.284	.	.	.	-2	35	9	-15	0.00	0.00	0.00	0.00	MAP2K2	0.86	exon-NM_030662.4-6+15+start+125	138159	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&Noonan_syndrome_and_Noonan-related_syndrome&Cardiofaciocutaneous_syndrome_4&not_specified&not_provided&RASopathy	MedGen:CN230736&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MONDO:MONDO:0014114&MedGen:C3809007&OMIM:615280&Orphanet:1340&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	19:4101032-4101032	1.505e-04	18	5	1	1	3	0	0	0	0	3	3094	642	1010	330	11478	232	8100	1	3	0	0	0	0	1	0	0	0	0	0	0	1	rs201287884	1.09505e-04	1.80378e-03	0.00000e+00	8.54993e-05	0.00000e+00	8.52660e-05	0.00000e+00	8.26856e-05	2.82639e-04	3.82917e-04	1.80378e-03	3.17274e-04	rs201287884	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.69075e-05	0.00000e+00	.	0.00000e+00	7.23903e-05	6.69075e-05	3.22685e-05	.	.	rs201287884	201287884	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:synonymous_SNV	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,932	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.025	VUS
10	112769023	112769023	C	T	T	synonymous_variant	LOW	SHOC2	8036	Transcript	NM_007373.4	protein_coding	7/9	.	NM_007373.4:c.1302C>T	NP_031399.2:p.Asn434%3D	1590	1302	434	N	aaC/aaT	rs146147503	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	ADRA2A	.	chr10:g.112769023C>T	.	0.0151	0.0043	0	0	0	benign/likely_benign&benign	.	1	.	.	.	.	.	SHOC2&NM_007373.3&c.1302C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.024	7.823	6.846	7.153	.	.	.	13	-17	13	0	0.04	0.00	0.00	0.00	SHOC2	0.99	exon-NM_001324336.2-7+17+start+138	139108	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&RASopathy&not_provided	MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:CN517202	.	rs146147503	7.992e-04	97	93	1	87	4	0	0	4	0	0	9772	10964	8302	6518	62718	868	15928	85	4	0	0	4	0	0	1	0	0	0	0	0	0	rs146147503	9.61032e-03	3.29894e-04	0.00000e+00	0.00000e+00	0.00000e+00	3.61788e-05	5.51065e-04	0.00000e+00	5.15749e-04	8.60538e-04	9.61032e-03	6.74221e-04	rs146147503	6.30156e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.67646e-05	1.02041e-03	.	2.10798e-03	1.51756e-03	6.30156e-03	1.83918e-03	rs146147503	0.0&0.5906&0.2002	rs146147503	146147503	.	.	.	SHOC2	SHOC2:exonic	SHOC2:synonymous_SNV	SHOC2:Noonan_syndrome-like_with_loose_anagen_hair_1	SHOC2:607721	SHOC2:3	SHOC2:Autosomal_dominant	0	0.991705191552454	0.00829295945769003	1.84898985615785e-06	DISEASE: Noonan syndrome-like disorder with loose anagen hair (NSLH) [MIM:607721]: A syndrome characterized by Noonan dysmorphic features such as macrocephaly, high forehead, hypertelorism, palpebral ptosis, low-set and posteriorly rotated ears, short and webbed neck, pectus anomalies, in association with pluckable, sparse, thin and slow-growing hair. {ECO:0000269|PubMed:19684605, ECO:0000269|PubMed:25137548}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,607	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
15	66777315	66777315	G	GTC	TC	splice_polypyrimidine_tract_variant&intron_variant	LOW	MAP2K1	5604	Transcript	NM_002755.4	protein_coding	.	6/10	NM_002755.4:c.694-8_694-7dup	.	.	.	.	.	.	rs113913469	.	.	1	.	1	EntrezGene	.	YES	.	.	.	.	.	.	SNAPC5	.	chr15:g.66777320_66777321dup	.	0.0628	0.0014	0	0	0	.	.	1	.	.	.	.	.	MAP2K1&NM_002755.3&c.694-13_694-12insTC	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.880	7.389	13.643	7.723	.	.	.	.	.	.	.	.	.	.	.	.	0.99	.	94082	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardio-facio-cutaneous_syndrome&not_specified&not_provided&RASopathy&Noonan_syndrome	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MONDO:MONDO:0015280&MedGen:C1275081&OMIM:PS115150&Orphanet:1340&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0018997&MeSH:D009634&MedGen:C0028326&OMIM:PS163950&Orphanet:648	.	rs113913469	4.596e-03	558	546	6	515	26	0	0	14	3	0	10368	11546	8610	6608	66634	908	16488	503	26	0	0	14	3	0	6	0	0	0	0	0	0	rs113913469	4.98693e-02	2.65039e-03	0.00000e+00	0.00000e+00	0.00000e+00	2.32887e-04	1.82349e-03	3.24886e-05	2.72952e-03	4.68062e-03	4.98693e-02	3.60983e-03	rs113913469	4.42458e-02	1.19332e-03	0.00000e+00	0.00000e+00	0.00000e+00	2.00214e-04	3.05499e-03	.	1.33333e-02	1.19185e-02	4.42458e-02	1.27130e-02	~rs113913469	0.0121&4.8077&1.6456	rs113913469	113913469	.	.	.	MAP2K1	MAP2K1:splicing\x3bintronic	MAP2K1:splice_polypyrimidine_tract_variant	MAP2K1:Cardiofaciocutaneous_syndrome_3\x3bMelorheostosis\x2cisolated\x2csomatic_mosaic	MAP2K1:615279\x3b155950	MAP2K1:3\x3b3	MAP2K1:Autosomal_dominant\x3b.	0	0.994501270366062	0.00549805295620231	6.76677735529064e-07	DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. Distinctive features of CFC3 include macrostomia and horizontal shape of palpebral fissures. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,885	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
14	31349945	31349945	C	T	T	splice_donor_5th_base_variant&intron_variant	LOW	COCH	1690	Transcript	NM_004086.3	protein_coding	.	8/11	NM_004086.3:c.629+5C>T	.	.	.	.	.	.	rs202109231	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	COCH	.	chr14:g.31349945C>T	.	0	0.0058	0	0	0.001	benign&benign/likely_benign&likely_benign	.	1	.	.	.	.	.	COCH&NM_004086.2&c.629+5C>T	3.07438582517639E-4	0.01	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8.374	10.858	9.133	7.879	7.637	0.242	7.879	-19	-5	-5	-25	0.00	0.00	0.01	0.00	COCH	0.00	.	281981	Benign	reviewed_by_expert_panel	Nonsyndromic_genetic_hearing_loss&Autosomal_dominant_nonsyndromic_hearing_loss_9&not_specified&not_provided	MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0011058&MedGen:C1832425&OMIM:601369&Orphanet:90635&MedGen:CN169374&MedGen:CN517202	.	14:31349945-31349945	8.484e-04	103	103	0	0	10	0	1	78	0	14	9982	11548	8622	6600	66476	902	16478	0	10	0	1	78	0	14	0	0	0	0	0	0	0	rs202109231	6.54793e-05	8.93868e-04	1.92933e-03	0.00000e+00	9.01307e-05	1.28260e-03	3.65097e-04	9.10096e-04	1.03947e-03	7.64650e-04	1.92933e-03	9.13631e-04	rs202109231	1.14705e-04	1.19332e-03	3.31126e-03	0.00000e+00	2.87522e-04	1.26819e-03	1.02669e-03	.	8.19672e-04	7.23694e-04	3.31126e-03	7.74393e-04	rs202109231	0.1279&0.0&0.0846	rs202109231	202109231	.	.	.	COCH\x3bLOC100506071	COCH:splicing\x3bintronic\x7cLOC100506071:ncRNA_intronic	COCH:splice_donor_5th_base_variant	COCH:Deafness\x2cautosomal_dominant_9\x3b?Deafness\x2cautosomal_recessive_110	COCH:601369\x3b618094	COCH:3\x3b3	COCH:Autosomal_dominant\x3bAutosomal_recessive	0	0.000262849456488043	0.983542807336405	0.0161943432071074	DISEASE: Deafness, autosomal dominant, 9 (DFNA9) [MIM:601369]: A form of non-syndromic hearing loss characterized by onset in the fourth or fifth decade of life and initially involves the high frequencies. Hearing loss is progressive and usually complete by the sixth decade. In addition to cochlear involvement, DFNA9 patients also exhibit a spectrum of vestibular dysfunctions. Penetrance of the vestibular symptoms is often incomplete, and some patients are minimally affected, whereas others suffer from severe balance disturbances and episodes of vertigo. Affected individuals have mucopolysaccharide depositions in the channels of the cochlear and vestibular nerves. These depositions apparently cause strangulation and degeneration of dendritic fibers. {ECO:0000269|PubMed:10400989, ECO:0000269|PubMed:11295836, ECO:0000269|PubMed:14512963, ECO:0000269|PubMed:16835921, ECO:0000269|PubMed:17561763, ECO:0000269|PubMed:18312449, ECO:0000269|PubMed:22610276, ECO:0000269|PubMed:22931125, ECO:0000269|PubMed:23993205, ECO:0000269|PubMed:9806553, ECO:0000269|PubMed:9931344}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,882	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
10	89624218	89624218	C	G	G	5_prime_UTR_variant	MODIFIER	PTEN	5728	Transcript	NM_000314.8	protein_coding	1/9	.	NM_000314.8:c.-9C>G	.	837	.	.	.	.	rs11202592&CR033149&COSV64295334&COSV64303439	C	.	1	.	.	EntrezGene	.	.	.	.	C	C	.	.	PTEN	.	chr10:g.89624218C>G	.	0	0	0.0506	0	0.0041	benign	0&0&1&1	1&1&1&1	.	.	.	.	.	PTEN&NM_000314.4&c.-9C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-2.595	-3.496	.	.	.	.	.	-1	-7	-1	-2	0.01	0.00	0.00	0.00	PTEN	0.98	exon-NM_000314.8-1+87+end+924	92808	Benign	reviewed_by_expert_panel	not_provided&Breast_and/or_ovarian_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&PTEN_hamartoma_tumor_syndrome&Cowden_syndrome_1&Malignant_tumor_of_breast	MedGen:CN517202&MedGen:CN221562&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0007254&MedGen:C0006142	.	rs11202592	3.624e-03	440	416	12	0	2	394	0	8	3	33	10404	11578	8648	6614	66740	908	16512	0	2	370	0	8	3	33	0	0	12	0	0	0	0	rs11202592	0.00000e+00	2.97779e-05	0.00000e+00	4.63822e-02	0.00000e+00	1.16375e-04	1.64054e-03	2.20908e-03	3.37277e-03	3.91537e-03	4.63822e-02	3.61795e-03	rs11202592	1.14548e-04	0.00000e+00	0.00000e+00	6.35018e-02	0.00000e+00	1.99867e-04	2.03666e-03	.	4.49766e-03	2.30914e-03	6.35018e-02	3.51704e-03	rs11202592	0.0233&0.0&0.0154	rs11202592	11202592	.	.	.	PTEN\x3bKLLN	PTEN:UTR5\x7cKLLN:upstream	.	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,511	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
19	4094469	4094469	C	T	T	synonymous_variant	LOW	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	10/11	.	NM_030662.4:c.1074G>A	NP_109587.1:p.Ala358%3D	1321	1074	358	A	gcG/gcA	rs140896887	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	ZBTB7A	.	chr19:g.4094469C>T	.	0.0023	0	0	0	0	benign	.	1	.	.	.	.	.	MAP2K2&NM_030662.3&c.1074G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.501	8.340	4.268	8.601	.	.	.	27	17	3	-18	0.01	0.00	0.00	0.00	MAP2K2	0.86	exon-NM_030662.4-10+18+start+46	261928	Benign	reviewed_by_expert_panel	not_specified&Cardiovascular_phenotype&RASopathy	MedGen:CN169374&MedGen:CN230736&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	rs140896887	1.359e-04	16	13	0	10	1	0	0	1	0	1	3124	550	1292	240	10362	204	8068	10	1	0	0	1	0	1	0	0	0	0	0	0	0	rs140896887	1.53155e-03	7.82534e-05	0.00000e+00	0.00000e+00	0.00000e+00	1.40797e-05	0.00000e+00	4.14766e-05	9.68513e-05	1.25767e-04	1.53155e-03	1.30575e-04	rs140896887	2.64429e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.68360e-05	0.00000e+00	.	9.36549e-04	5.79290e-04	2.64429e-03	7.74393e-04	rs140896887	0.0117&0.1146&0.0464	rs140896887	140896887	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:synonymous_SNV	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,924	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.025	VUS
10	89725121	89725121	T	C	C	synonymous_variant	LOW	PTEN	5728	Transcript	NM_000314.8	protein_coding	9/9	.	NM_000314.8:c.1104T>C	NP_000305.3:p.Asp368%3D	1949	1104	368	D	gaT/gaC	rs35979531	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89725121T>C	.	0.0083	0.0014	0	0	0	benign&likely_benign	.	1	.	.	.	.	.	PTEN&NM_000314.4&c.1104T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.857	8.679	.	.	.	-31	30	4	0	0.00	0.00	0.00	0.00	PTEN	0.98	exon-NM_001304717.5-10+77+start+6644	138835	Likely_benign	reviewed_by_expert_panel	Breast_and/or_ovarian_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&PTEN_hamartoma_tumor_syndrome&Malignant_tumor_of_breast	MedGen:CN221562&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498&MONDO:MONDO:0007254&MedGen:C0006142	.	rs35979531	4.947e-04	60	55	0	48	2	0	0	1	2	2	7904	9128	6978	5670	45988	720	14280	48	2	0	0	1	2	2	0	0	0	0	0	0	0	rs35979531	5.82947e-03	3.65586e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.91608e-05	3.82555e-04	1.67314e-04	4.12419e-04	4.80951e-04	5.82947e-03	4.38664e-04	rs35979531	5.38497e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	1.46113e-03	1.58753e-03	5.38497e-03	1.51652e-03	rs35979531	0.0&0.4771&0.162	rs35979531	35979531	chr9:33674357&chr17:54445431	0.98265&0.958891	0.97956&0.955238	PTEN	PTEN:exonic	PTEN:synonymous_SNV	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,596	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
19	4101261	4101261	C	T	T	synonymous_variant	LOW	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	5/11	.	NM_030662.4:c.546G>A	NP_109587.1:p.Ala182%3D	793	546	182	A	gcG/gcA	rs141402203&COSV53564695	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MAP2K2	.	chr19:g.4101261C>T	.	0.0008	0.0014	0	0	0	benign/likely_benign&benign	0&1	1&1	.	.	.	.	.	MAP2K2&NM_030662.3&c.546G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.732	10.284	11.061	10.494	.	.	.	-40	17	18	-34	0.00	0.00	0.00	0.01	MAP2K2	0.86	exon-NM_030662.4-5+17+end+52	138158	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_specified&RASopathy	MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	rs141402203	1.167e-04	14	1	0	7	0	1	0	1	0	1	3952	1676	2416	1448	19880	336	8828	1	0	0	0	0	0	0	0	0	0	0	0	0	0	rs141402203	1.38786e-03	1.45148e-04	0.00000e+00	5.07246e-04	0.00000e+00	8.28383e-05	2.18150e-04	3.95726e-05	1.51492e-04	2.14942e-04	1.38786e-03	2.35928e-04	rs141402203	1.50568e-03	0.00000e+00	0.00000e+00	6.18812e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	4.12153e-04	5.07541e-04	1.50568e-03	4.51759e-04	rs141402203	0.0&0.1368&0.0462	rs141402203	141402203	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:synonymous_SNV	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,933	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.025	VUS
11	534242	534242	A	G	G	synonymous_variant	LOW	HRAS	3265	Transcript	NM_005343.4	protein_coding	2/6	.	NM_005343.4:c.81T>C	NP_005334.1:p.His27%3D	295	81	27	H	caT/caC	rs12628&CM035804&COSV54237196	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	HRAS	.	chr11:g.534242A>G	.	0.3729	0.3646	0.1726	0.3121	0.2597	conflicting_interpretations_of_pathogenicity&benign&not_provided&likely_benign	0&0&1	1&1&1	.	.	.	.	.	HRAS&NM_176795.3&c.81T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.582	8.703	5.136	11.453	.	.	.	14	-29	-30	32	0.00	0.00	0.00	0.00	HRAS	0.01	exon-NM_005343.4-2+30+start+164	40431	Benign	reviewed_by_expert_panel	not_specified&not_provided&RASopathy&Squamous_cell_lung_carcinoma&Costello_syndrome&Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&Human_Phenotype_Ontology:HP:0030359&MONDO:MONDO:0005097&MedGen:C0149782&MONDO:MONDO:0009026&MedGen:C0587248&OMIM:218040&Orphanet:3071&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736	.	rs12628	0.313	37949	25432	6157	3874	4243	1632	1724	21765	253	4255	10274	11530	8620	6556	66014	902	16498	2394	2663	1338	1278	14469	165	3125	740	790	147	223	3648	44	565	rs12628	3.78853e-01	3.81408e-01	2.71211e-01	1.88487e-01	2.67541e-01	3.38406e-01	3.08592e-01	2.51982e-01	3.11179e-01	3.21183e-01	3.81408e-01	3.15900e-01	rs12628	3.83560e-01	3.60048e-01	2.61589e-01	2.13490e-01	2.67529e-01	3.54183e-01	3.13402e-01	.	3.48043e-01	3.37326e-01	3.83560e-01	3.43230e-01	rs12628	34.407&37.4943&35.4529	rs12628	12628	.	.	.	HRAS	HRAS:exonic	HRAS:synonymous_SNV	HRAS:Bladder_cancer\x2csomatic\x3bThyroid_carcinoma\x2cfollicular\x2csomatic\x3bCongenital_myopathy_with_excess_of_muscle_spindles\x3bNevus_sebaceous_or_woolly_hair_nevus\x2csomatic\x3bSchimmelpenning-Feuerstein-Mims_syndrome\x2csomatic_mosaic\x3bSpitz_nevus_or_nevus_spilus\x2csomatic\x3bCostello_syndrome	HRAS:109800\x3b188470\x3b218040\x3b162900\x3b163200\x3b137550\x3b218040	HRAS:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	HRAS:.\x3b.\x3bAutosomal_dominant\x3b.\x3b.\x3b.\x3bAutosomal_dominant	0	0.00794104930284198	0.785285637637198	0.20677331305996	DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]: Variant of Costello syndrome. {ECO:0000269|PubMed:17412879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. {ECO:0000269|PubMed:3670300}.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis. {ECO:0000269|PubMed:22683711}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,623	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
14	23889445	23889445	T	TG	G	splice_polypyrimidine_tract_variant&splice_region_variant&intron_variant	LOW	MYH7	4625	Transcript	NM_000257.4	protein_coding	.	26/39	NM_000257.4:c.3337-3dup	.	.	.	.	.	.	rs45504498	.	.	-1	.	1	EntrezGene	.	YES	.	.	.	.	.	.	MYH6	.	chr14:g.23889447dup	.	0.0144	0.0173	0.0565	0.0388	0.0767	benign&likely_benign	.	1	.	.	.	.	.	MYH7&NM_000257.3&c.3337-3_3337-2insC	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.457	2.324	11.170	10.068	.	.	.	-3	29	-18	27	0.00	0.00	0.00	0.00	MYH7	0.00	.	42956	Benign	reviewed_by_expert_panel	Dilated_Cardiomyopathy&_Dominant&Cardiovascular_phenotype&not_specified&not_provided&Cardiomyopathy&Hypertrophic_cardiomyopathy_1&Ventricular_fibrillation&_paroxysmal_familial&_type_1&MYH7-related_skeletal_myopathy&Myosin_storage_myopathy&Dilated_cardiomyopathy_1S&Hypertrophic_cardiomyopathy&Left_ventricular_noncompaction_cardiomyopathy	MedGen:CN239310&MedGen:CN230736&MedGen:CN169374&MedGen:CN517202&Human_Phenotype_Ontology:HP:0001638&MONDO:MONDO:0004994&MedGen:C0878544&Orphanet:167848&MONDO:MONDO:0008647&MedGen:C3495498&OMIM:192600&MONDO:MONDO:0011376&MedGen:C2751898&OMIM:603829&Orphanet:228140&MONDO:MONDO:0008050&MedGen:C4552004&OMIM:160500&Orphanet:59135&MONDO:MONDO:0012018&MedGen:C1842160&OMIM:608358&MONDO:MONDO:0013262&MedGen:C1834481&OMIM:613426&Orphanet:154&Orphanet:54260&Human_Phenotype_Ontology:HP:0001639&MONDO:MONDO:0005045&MeSH:D002312&MedGen:C0007194&Orphanet:217569&Human_Phenotype_Ontology:HP:0011664&MedGen:C4021133	.	rs45504498	2.212e-03	267	218	6	19	8	19	1	146	3	34	7814	10286	7194	5072	54400	758	14446	19	8	19	1	142	3	26	0	0	0	0	2	0	4	rs564923630	8.31289e-03	1.65659e-02	1.12513e-02	2.68746e-02	1.10191e-02	1.29041e-02	2.38908e-02	2.07897e-02	1.43364e-02	1.61208e-02	2.68746e-02	1.74997e-02	rs564923630	2.96950e-02	5.50239e-02	1.04730e-01	6.36588e-02	8.25688e-02	7.03903e-02	6.42857e-02	.	5.60451e-02	6.40151e-02	1.04730e-01	6.06931e-02	.	.	rs45504498	45504498	.	.	.	MYH7	MYH7:splicing\x3bintronic	MYH7:splice_region_variant\x3bsplice_polypyrimidine_tract_variant	MYH7:Laing_distal_myopathy\x3bCardiomyopathy\x2chypertrophic\x2c1\x3bLeft_ventricular_noncompaction_5\x3bCardiomyopathy\x2cdilated\x2c1S\x3bScapuloperoneal_syndrome\x2cmyopathic_type\x3bMyopathy\x2cmyosin_storage\x2cautosomal_dominant\x3bMyopathy\x2cmyosin_storage\x2cautosomal_recessive	MYH7:160500\x3b192600\x3b613426\x3b613426\x3b181430\x3b608358\x3b255160	MYH7:3\x3b3\x3b3\x3b3\x3b3\x3b3\x3b3	MYH7:Autosomal_dominant\x3bAutosomal_dominant\x2cDigenic_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_recessive	0	0.000145766291646031	0.999854233523213	1.85141250905742e-10	DISEASE: Cardiomyopathy, familial hypertrophic 1 (CMH1) [MIM:192600]: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:10065021, ECO:0000269|PubMed:10329202, ECO:0000269|PubMed:10521296, ECO:0000269|PubMed:10563488, ECO:0000269|PubMed:10679957, ECO:0000269|PubMed:10862102, ECO:0000269|PubMed:11113006, ECO:0000269|PubMed:11133230, ECO:0000269|PubMed:11214007, ECO:0000269|PubMed:11424919, ECO:0000269|PubMed:11733062, ECO:0000269|PubMed:11861413, ECO:0000269|PubMed:11968089, ECO:0000269|PubMed:12081993, ECO:0000269|PubMed:12566107, ECO:0000269|PubMed:12590187, ECO:0000269|PubMed:12707239, ECO:0000269|PubMed:12818575, ECO:0000269|PubMed:12820698, ECO:0000269|PubMed:12951062, ECO:0000269|PubMed:12974739, ECO:0000269|PubMed:12975413, ECO:0000269|PubMed:1417858, ECO:0000269|PubMed:15358028, ECO:0000269|PubMed:15483641, ECO:0000269|PubMed:1552912, ECO:0000269|PubMed:15563892, ECO:0000269|PubMed:15856146, ECO:0000269|PubMed:15858117, ECO:0000269|PubMed:16199542, ECO:0000269|PubMed:16267253, ECO:0000269|PubMed:1638703, ECO:0000269|PubMed:16650083, ECO:0000269|PubMed:16938236, ECO:0000269|PubMed:17372140, ECO:0000269|PubMed:18175163, ECO:0000269|PubMed:18403758, ECO:0000269|PubMed:1975517, ECO:0000269|PubMed:25182012, ECO:0000269|PubMed:7581410, ECO:0000269|PubMed:7731997, ECO:0000269|PubMed:7848441, ECO:0000269|PubMed:7874131, ECO:0000269|PubMed:8250038, ECO:0000269|PubMed:8254035, ECO:0000269|PubMed:8268932, ECO:0000269|PubMed:8282798, ECO:0000269|PubMed:8343162, ECO:0000269|PubMed:8435239, ECO:0000269|PubMed:8483915, ECO:0000269|PubMed:8655135, ECO:0000269|PubMed:8899546, ECO:0000269|PubMed:9544842, ECO:0000269|PubMed:9822100, ECO:0000269|PubMed:9829907}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, myosin storage, autosomal dominant (MSMA) [MIM:608358]: A rare congenital myopathy characterized by subsarcolemmal hyalinized bodies in type 1 muscle fibers. {ECO:0000269|PubMed:14520662, ECO:0000269|PubMed:15136674, ECO:0000269|PubMed:16684601, ECO:0000269|PubMed:17336526}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Scapuloperoneal myopathy MYH7-related (SPMM) [MIM:181430]: Progressive muscular atrophia beginning in the lower legs and affecting the shoulder region earlier and more severely than distal arm. {ECO:0000269|PubMed:17336526}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1S (CMD1S) [MIM:613426]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:11106718, ECO:0000269|PubMed:12379228, ECO:0000269|PubMed:15769782, ECO:0000269|PubMed:18506004, ECO:0000269|PubMed:21127202, ECO:0000269|PubMed:21846512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, distal, 1 (MPD1) [MIM:160500]: A muscular disorder characterized by early-onset selective weakness of the great toe and ankle dorsiflexors, followed by weakness of the finger extensors. Mild proximal weakness occasionally develops years later after the onset of the disease. {ECO:0000269|PubMed:15322983, ECO:0000269|PubMed:17548557}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, myosin storage, autosomal recessive (MSMB) [MIM:255160]: An autosomal recessive form of myosin storage myopathy, a muscle disease characterized by subsarcolemmal accumulation of hyalinized bodies in type 1 muscle fibers. MSMB clinical features include muscle weakness, type II respiratory failure and cardiac failure, due to hypertrophic cardiomyopathy. {ECO:0000269|PubMed:25666907}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,876	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
19	4117429	4117429	G	T	T	synonymous_variant	LOW	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	2/11	.	NM_030662.4:c.291C>A	NP_109587.1:p.Ile97%3D	538	291	97	I	atC/atA	rs200918323	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	MAP2K2	.	chr19:g.4117429G>T	.	0	0	0.004	0	0	benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.786	9.597	6.148	8.492	.	.	.	25	15	-3	-12	0.00	0.00	0.00	0.00	MAP2K2	0.86	exon-NM_030662.4-2+12+start+211	40787	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&Noonan_syndrome_and_Noonan-related_syndrome&not_provided&RASopathy	MedGen:CN230736&MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	19:4117429-4117429	1.895e-04	23	2	0	0	0	23	0	0	0	0	10036	11422	8614	6562	65150	894	16450	0	0	0	0	2	0	0	0	0	0	0	0	0	0	rs200918323	0.00000e+00	0.00000e+00	0.00000e+00	2.66759e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.70659e-04	2.07155e-04	2.66759e-03	1.90846e-04	rs200918323	0.00000e+00	0.00000e+00	0.00000e+00	2.46914e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	1.75459e-04	7.22439e-05	2.46914e-03	1.29066e-04	.	.	rs200918323	200918323	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:synonymous_SNV	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,936	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.025	VUS
19	4117480	4117480	C	T	T	synonymous_variant	LOW	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	2/11	.	NM_030662.4:c.240G>A	NP_109587.1:p.Ala80%3D	487	240	80	A	gcG/gcA	rs543217722	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MAP2K2	.	chr19:g.4117480C>T	.	0	0	0	0	0.002	likely_benign&benign/likely_benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.786	9.597	6.148	8.492	.	.	.	18	34	-1	5	0.00	0.00	0.00	0.00	MAP2K2	0.86	exon-NM_030662.4-2+63+start+211	378913	Likely_benign	reviewed_by_expert_panel	Cardiovascular_phenotype&not_provided&RASopathy	MedGen:CN230736&MedGen:CN517202&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	19:4117480-4117480	8.237e-05	10	10	0	0	0	0	0	1	0	9	10336	11560	8646	6614	66198	904	16506	0	0	0	0	1	0	9	0	0	0	0	0	0	0	rs543217722	6.53851e-05	2.08445e-04	0.00000e+00	0.00000e+00	0.00000e+00	8.95624e-06	0.00000e+00	8.77193e-04	1.55682e-04	1.34812e-04	8.77193e-04	1.46180e-04	rs543217722	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	6.66844e-05	0.00000e+00	.	5.84590e-05	0.00000e+00	6.66844e-05	3.22664e-05	.	.	rs543217722	543217722	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:synonymous_SNV	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,937	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.025	VUS
19	4117495	4117495	G	A	A	synonymous_variant	LOW	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	2/11	.	NM_030662.4:c.225C>T	NP_109587.1:p.Ile75%3D	472	225	75	I	atC/atT	rs561400866	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	MAP2K2	.	chr19:g.4117495G>A	.	0	0	0	0	0.001	benign	.	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.786	9.597	6.148	8.492	.	.	.	3	44	36	5	0.00	0.00	0.00	0.00	MAP2K2	0.86	exon-NM_030662.4-2+78+start+211	448952	Benign	reviewed_by_expert_panel	Cardiovascular_phenotype&RASopathy	MedGen:CN230736&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	19:4117495-4117495	1.647e-04	20	20	0	0	0	0	0	0	0	20	10356	11566	8646	6614	66294	904	16508	0	0	0	0	0	0	20	0	0	0	0	0	0	0	rs561400866	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.82282e-04	1.39701e-03	2.44629e-04	9.88302e-05	1.39701e-03	1.78664e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs561400866	561400866	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:synonymous_SNV	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,938	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.025	VUS
19	4117579	4117579	G	A	A	synonymous_variant	LOW	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	2/11	.	NM_030662.4:c.141C>T	NP_109587.1:p.Asp47%3D	388	141	47	D	gaC/gaT	rs201526172&COSV104543645	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	MAP2K2	.	chr19:g.4117579G>A	.	0	0	0.002	0	0	benign	0&1	1&1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.786	9.597	6.148	8.492	.	.	.	-40	26	2	-48	0.00	0.00	0.00	0.01	MAP2K2	0.86	exon-NM_030662.4-2+48+end+211	448953	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&not_provided&Cardiovascular_phenotype&RASopathy	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN517202&MedGen:CN230736&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	19:4117579-4117579	9.884e-05	12	12	0	0	0	9	0	2	0	1	10378	11572	8646	6614	66490	906	16508	0	0	9	0	2	0	1	0	0	0	0	0	0	0	rs201526172	0.00000e+00	0.00000e+00	0.00000e+00	8.11782e-04	0.00000e+00	4.47579e-05	0.00000e+00	6.49730e-05	1.11208e-04	5.38909e-05	8.11782e-04	8.93321e-05	rs201526172	0.00000e+00	0.00000e+00	0.00000e+00	1.85185e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	1.75377e-04	0.00000e+00	1.85185e-03	9.67992e-05	.	.	rs201526172	201526172	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:synonymous_SNV	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,941	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.025	VUS
10	89720907	89720907	T	G	G	intron_variant	MODIFIER	PTEN	5728	Transcript	NM_000314.8	protein_coding	.	8/8	NM_000314.8:c.1026+32T>G	.	.	.	.	.	.	rs555895&COSV64292683	T	.	1	.	.	EntrezGene	.	.	.	.	T	T	.	.	PTEN	.	chr10:g.89720907T>G	.	0.5257	0.4409	0.504	0.3708	0.2904	benign	0&1	1&1	.	.	.	.	.	PTEN&NM_000314.4&c.1026+32T>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.857	.	12.930	8.679	.	.	.	39	36	-5	-28	0.00	0.00	0.00	0.00	PTEN	0.98	.	92810	Benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Cowden_syndrome_1&Macrocephaly-autism_syndrome&PTEN_hamartoma_tumor_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0008021&MedGen:CN072330&OMIM:158350&MONDO:MONDO:0011537&MedGen:C1854416&OMIM:605309&Orphanet:210548&MONDO:MONDO:0017623&MeSH:D006223&MedGen:C1959582&Orphanet:306498	.	rs555895	0.368	44659	27135	8381	4752	5207	4121	2272	22053	346	5146	9490	11444	8534	6576	65234	892	16498	2348	2835	2163	1440	14679	192	3478	1202	1186	979	416	3687	77	834	rs555895	5.00538e-01	4.58445e-01	3.70556e-01	4.88249e-01	3.42752e-01	3.34888e-01	3.78314e-01	3.08923e-01	3.62226e-01	3.85174e-01	5.00538e-01	3.72565e-01	rs555895	4.94478e-01	4.27711e-01	4.13333e-01	4.92556e-01	3.43194e-01	3.21677e-01	3.48049e-01	.	3.89724e-01	3.82216e-01	4.94478e-01	3.86906e-01	rs555895	32.7353&47.9024&37.8643	rs555895	555895	.	.	.	PTEN	PTEN:intronic	.	PTEN:{Glioma_susceptibility_2}\x3b{Meningioma}\x3bCowden_syndrome_1\x3bLhermitte-Duclos_disease\x3bProstate_cancer\x2csomatic\x3bMacrocephaly/autism_syndrome	PTEN:613028\x3b607174\x3b158350\x3b158350\x3b176807\x3b605309	PTEN:3\x3b3\x3b3\x3b3\x3b3\x3b3	PTEN:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3bAutosomal_dominant	0	0.975506865848027	0.0244877796497562	5.35450221699976e-06	DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9600246, ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, ECO:0000269|PubMed:9832031, ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A rare hamartomatous disorder characterized by macrocephaly and multiple hemangiomas as well as subcutaneous and visceral lipomas. It belongs to the family of hamartomatous polyposis syndromes that includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden syndrome. {ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9467011}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.; DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). {ECO:0000269|PubMed:15805158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,591	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
12	103306550	103306550	A	G	G	intron_variant	MODIFIER	PAH	5053	Transcript	NM_000277.3	protein_coding	.	2/12	NM_000277.3:c.168+19T>C	.	.	.	.	.	.	rs17842947&CS135060&COSV61016895	A	.	-1	.	.	EntrezGene	.	.	.	.	A	A	.	.	PAH	.	chr12:g.103306550A>G	.	0.3162	0.3415	0.0804	0.1491	0.2045	benign&not_provided	0&0&1	1&1&1	.	.	.	.	.	PAH&NM_000277.1&c.168+19T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.785	10.766	8.002	7.700	.	.	.	19	37	-14	19	0.00	0.00	0.00	0.00	PAH	0.00	.	92736	Benign	reviewed_by_expert_panel	not_specified&not_provided&Phenylketonuria	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0009861&MedGen:C0031485&OMIM:261600&Orphanet:716	.	rs17842947	0.194	23568	17485	3034	3087	5189	713	608	10501	153	3302	10394	11546	8644	6608	66636	906	16502	2159	2737	651	534	8777	119	2508	464	1226	31	37	862	17	397	rs17842947	2.98522e-01	4.41233e-01	2.20744e-01	8.33237e-02	9.48594e-02	1.55642e-01	1.93319e-01	1.96660e-01	1.90244e-01	2.15139e-01	4.41233e-01	2.01446e-01	rs17842947	2.89963e-01	4.03110e-01	1.72185e-01	7.27497e-02	9.73097e-02	1.57097e-01	1.57464e-01	.	1.94698e-01	1.84526e-01	4.03110e-01	1.90275e-01	rs17842947	16.3488&29.1648&20.6905	rs17842947	17842947	.	.	.	PAH	PAH:intronic	.	PAH:[Hyperphenylalaninemia\x2cnon-PKU_mild]\x3bPhenylketonuria	PAH:261600\x3b261600	PAH:3\x3b3	PAH:Autosomal_recessive\x3bAutosomal_recessive	0	1.19519744629961e-10	0.307448665079143	0.692551334801337	DISEASE: Phenylketonuria (PKU) [MIM:261600]: Autosomal recessive inborn error of phenylalanine metabolism, due to severe phenylalanine hydroxylase deficiency. It is characterized by blood concentrations of phenylalanine persistently above 1200 mumol (normal concentration 100 mumol) which usually causes mental retardation (unless low phenylalanine diet is introduced early in life). They tend to have light pigmentation, rashes similar to eczema, epilepsy, extreme hyperactivity, psychotic states and an unpleasant 'mousy' odor. {ECO:0000269|PubMed:10200057, ECO:0000269|PubMed:10679941, ECO:0000269|PubMed:11180595, ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11461196, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1355066, ECO:0000269|PubMed:1363837, ECO:0000269|PubMed:1363838, ECO:0000269|PubMed:1671810, ECO:0000269|PubMed:1672290, ECO:0000269|PubMed:1672294, ECO:0000269|PubMed:1679030, ECO:0000269|PubMed:1709636, ECO:0000269|PubMed:1975559, ECO:0000269|PubMed:2014802, ECO:0000269|PubMed:22513348, ECO:0000269|PubMed:22526846, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:2564729, ECO:0000269|PubMed:2615649, ECO:0000269|PubMed:2840952, ECO:0000269|PubMed:7833954, ECO:0000269|PubMed:8068076, ECO:0000269|PubMed:8406445, ECO:0000269|PubMed:8889590, ECO:0000269|PubMed:9048935, ECO:0000269|PubMed:9101291, ECO:0000269|PubMed:9452061, ECO:0000269|PubMed:9452062, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9600453, ECO:0000269|PubMed:9792407, ECO:0000269|PubMed:9950317}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Non-phenylketonuria hyperphenylalaninemia (Non-PKU HPA) [MIM:261600]: Mild form of phenylalanine hydroxylase deficiency characterized by phenylalanine levels persistently below 600 mumol, which allows normal intellectual and behavioral development without treatment. Non-PKU HPA is usually caused by the combined effect of a mild hyperphenylalaninemia mutation and a severe one. {ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperphenylalaninemia (HPA) [MIM:261600]: Mildest form of phenylalanine hydroxylase deficiency. {ECO:0000269|PubMed:11385716, ECO:0000269|PubMed:11935335, ECO:0000269|PubMed:12501224, ECO:0000269|PubMed:1358789, ECO:0000269|PubMed:23792259, ECO:0000269|PubMed:8088845, ECO:0000269|PubMed:8098245, ECO:0000269|PubMed:9521426, ECO:0000269|PubMed:9852673}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,828	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.025	VUS
1	215848748	215848748	T	C	C	missense_variant	MODERATE	USH2A	7399	Transcript	NM_206933.4	protein_coding	63/72	.	NM_206933.4:c.12505A>G	NP_996816.3:p.Thr4169Ala	12944	12505	4169	T/A	Acc/Gcc	rs113107803&CM1410079&CM172434	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	KCTD3	.	chr1:g.215848748T>C	.	0.0045	0	0	0	0	uncertain_significance&likely_pathogenic&likely_benign&conflicting_interpretations_of_pathogenicity	.	1&1&1	.	.	.	.	.	USH2A&NM_206933.2&c.12505A>G	.	.	6	0.0011980830670926517	6	0.0045385779122541605	0	0.0	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	T/T	T	T	0.01075	-0.453628	T	0.30335	-0.426488	17.43	17.73	1.758023	1.736011	0.26079	0.27854	T/T	T	0.06943	0.0585777107556388	0.46033	0.98774662863692819	.	0.54161	.	T/T	11	0.0024965955515206537	0	0.0	1.898234	-0.15482334806616	0.33224	1.855438	-0.207557742177913	0.32823	.	.	.	28	2.306e-04	24	2.338e-03	3	2.608e-04	28	2.320e-04	0	0	0	0	0	0	0	0	26	2.448e-04	22	2.435e-03	3	2.686e-04	26	2.452e-04	0	0	0	0	0	0	0	0	28	3.085e-04	24	2.342e-03	3	2.611e-04	28	3.111e-04	0	0	0	0	0	0	0	0	0.61443	.	.	.	5.25	4.1	0.47196	0	0.45803	0.59043	.	.	0.07095	4.79187826528774E-4	.	0	0.23631	0.573888	.	.	.	.	.	.	0	0.26826	0.564101	Fibronectin_type_III&Fibronectin_type_III&Fibronectin_type_III&Fibronectin_type_III	.	.	.	0.14146	.	0.309039	0.22632	N	0.055574	D	0.87835	0.222053	0.11836	.	0.90741	.	T	0.51149	0.1704	.	0.00148	.	T	0.49872	-0.8786	.	.	.	.	.	.	0.64187	.	.	0.23212	simple_aae&simple_aae	N&N	0.995749&0.995749	0.57435	.	.	.	0.12183	.	.	0.16012	.	T	0.20988	0.371091485023	0.49555	.	10	0.36901	.	.	0.41364	.	.	10.2811	0.42721	0.0:0.0809:0.0:0.9191	.	.	.	.	.	.	.	.	0.08506	.	T/T	A	.	T	C	658	0.62094	.	1	C0035334&C0854723&C1848634&C3151138&C0271097&CN169374&CN517202	268000&PS268000&276901&613809&PS276900	ORPHA791&ORPHA71862&ORPHA886	Likely_benign	NC_000001.11:g.215675406T>C	166435	reviewed_by_expert_panel	Retinitis_pigmentosa&Retinal_dystrophy&Usher_syndrome&_type_2A&Retinitis_pigmentosa_39&Usher_syndrome&not_specified&not_provided	ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:1840008	.	.	AEFI	D	0.36755	0.75098	N	0.19752	0.097978	.	54	2.156310e-04	49	3.020220e-03	16224	0	4	1.157740e-04	34550	0	250428	0	0.000000e+00	10034	0	0	0.000000e+00	18376	0	0	0.000000e+00	21634	0	0	0.000000e+00	112898	0	49	3.020220e-03	16224	0	1	3.267550e-05	30604	0	26	2.376990e-04	23	3.211390e-03	7162	0	3	1.754180e-04	17102	0	109382	0	0.000000e+00	2320	0	0	0.000000e+00	9042	0	0	0.000000e+00	13392	0	0	0.000000e+00	42766	0	23	3.211390e-03	7162	0	0	0.000000e+00	15684	0	0	.	0	52	2.203390e-04	47	3.154360e-03	14900	0	4	1.168910e-04	34220	0	236000	0	0.000000e+00	9532	0	0	0.000000e+00	17682	0	0	0.000000e+00	21618	0	0	0.000000e+00	101940	0	47	3.154360e-03	14900	0	1	3.277180e-05	30514	0	0	54	2.596950e-04	49	3.027310e-03	16186	0	4	1.311730e-04	30494	0	207936	0	0.000000e+00	6204	0	0	0.000000e+00	13398	0	0	0.000000e+00	16732	0	0	0.000000e+00	89472	0	49	3.027310e-03	16186	0	1	3.268400e-05	30596	0	0	42	1.722640e-04	37	3.084360e-03	11996	0	4	1.162250e-04	34416	0	243812	0	0.000000e+00	9952	0	0	0.000000e+00	18372	0	0	0.000000e+00	21632	0	0	0.000000e+00	110808	0	37	3.084360e-03	11996	0	1	3.267550e-05	30604	0	0	131	8.607210e-04	126	3.039810e-03	41450	0	0	0.000000e+00	912	0	5	3.271390e-04	15284	0	152198	0	0.000000e+00	3470	0	0	0.000000e+00	5188	0	0	0.000000e+00	10624	0	0	0.000000e+00	316	0	0	0.000000e+00	68028	0	126	3.039810e-03	41450	0	0	0.000000e+00	4834	0	43	1.306510e-03	40	4.393670e-03	9104	0	0	0.000000e+00	60	0	3	6.399320e-04	4688	0	32912	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5492	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3114	0	0	.	0	131	8.853980e-04	126	3.063610e-03	41128	0	0	0.000000e+00	912	0	5	3.312140e-04	15096	0	147956	0	0.000000e+00	3302	0	0	0.000000e+00	4954	0	0	0.000000e+00	10624	0	0	0.000000e+00	304	0	0	0.000000e+00	64812	0	0	0.000000e+00	4802	0	0	110	8.160360e-04	105	3.231370e-03	32494	0	0	0.000000e+00	862	0	5	3.369730e-04	14838	0	134798	0	0.000000e+00	3386	0	0	0.000000e+00	5188	0	0	0.000000e+00	6982	0	0	0.000000e+00	310	0	0	0.000000e+00	63904	0	0	0.000000e+00	4832	0	0	86	1.064910e-03	81	3.262970e-03	24824	0	0	0.000000e+00	112	0	5	3.872970e-04	12910	0	80758	0	0.000000e+00	996	0	0	0.000000e+00	3746	0	0	0.000000e+00	10532	0	0	0.000000e+00	272	0	0	0.000000e+00	21042	0	0	0.000000e+00	4806	0	0	1	213915371	1	215848748	0	0.14033	0.487112	1.000000	0.71638	0.926000	0.46234	0.038000	0.16106	2.036000	0.40786	0.665000	0.62972	0.135000	0.19242	215675406	T	.	rs113107803	.	.	6.682	10.280	10.453	8.993	.	.	.	38	3	-19	10	0.00	0.00	0.00	0.00	USH2A	0.00	exon-NM_206933.4-63+210+end+1517	166435	Likely_benign	reviewed_by_expert_panel	Usher_syndrome&Retinal_dystrophy&Usher_syndrome_type_2A&Retinitis_pigmentosa_39&not_specified&not_provided&Retinitis_pigmentosa	MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&Human_Phenotype_Ontology:HP:0000556&Human_Phenotype_Ontology:HP:0007736&Human_Phenotype_Ontology:HP:0007910&Human_Phenotype_Ontology:HP:0007974&Human_Phenotype_Ontology:HP:0007982&MONDO:MONDO:0019118&MeSH:D058499&MedGen:C0854723&Orphanet:71862&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886&MONDO:MONDO:0013436&MedGen:C3151138&OMIM:613809&Orphanet:791&MedGen:CN169374&MedGen:CN517202&Human_Phenotype_Ontology:HP:0000547&MONDO:MONDO:0019200&MeSH:D012174&MedGen:C0035334&OMIM:268000&OMIM:PS268000&Orphanet:791	.	rs113107803	2.306e-04	28	28	0	24	3	0	0	0	1	0	10264	11502	8608	6612	66300	904	16480	24	3	0	0	0	1	0	0	0	0	0	0	0	0	rs113107803	3.20933e-03	1.19268e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.24992e-05	1.34032e-04	3.24687e-04	3.20933e-03	2.19316e-04	rs113107803	3.54935e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	7.59257e-04	1.29833e-03	3.54935e-03	1.00026e-03	rs113107803	0.0&0.2497&0.0846	rs113107803	113107803	.	.	.	USH2A	USH2A:exonic	USH2A:missense	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,449	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0.3246	Likely Benign
16	68835597	68835597	G	A	A	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	3/16	.	NM_004360.5:c.188G>A	NP_004351.1:p.Arg63Gln	312	188	63	R/Q	cGa/cAa	rs587780117&COSV55742044&COSV99028634	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68835597G>A	.	.	.	.	.	.	uncertain_significance&benign&benign/likely_benign&likely_benign	0&1&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.188G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	T	0.02852	-0.386056	T	0.22329	-0.50017	5.027	14.83	0.364337	1.233048	0.07646	0.20001	G/G	T	0.01143	0.0239850604136358	0.75172	0.9961713904410392	.	0.59367	.	G/G	.	.	.	.	0.8347462	-0.745441442766807	0.15834	0.7753954	-0.722374913079348	0.15393	.	.	.	7	5.765e-05	0	0	0	0	7	5.765e-05	0	0	0	0	5	7.492e-05	2	1.211e-04	7	6.591e-05	0	0	0	0	7	6.591e-05	0	0	0	0	5	9.200e-05	2	1.219e-04	7	7.713e-05	0	0	0	0	7	7.713e-05	0	0	0	0	5	1.186e-04	2	1.212e-04	0.60973	.	.	.	5.43	2.18	0.26813	0	0.55848	0.633656	.	.	0.47345	0.999943799505699	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.35598	0.584449	Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&.	.	.	.	0.42437	.	0.335920	0.20687	N	0.084609	D	0.61492	0.044449	0.32972	.	0.76376	.	T	0.46422	0.1427	.	0.22098	.	T	0.33175	-0.9877	.	.	.	.	.	.	0.47472	.	.	0.18198	simple_aae&simple_aae	N&N	0.999982&0.999982	0.33598	.	.	.	0.25541	.	.	0.21332	.	T	0.00821	0.210219934583	0.14996	.	10	0.33666	.	.	0.15823	.	.	5.7622	0.17473	0.1019:0.0:0.5299:0.3682	.	.	.	.	.	.	.	.	0.16586	.	G/G	Q	.	R	A	315	0.87208	.	16	C1708349&C0027672&C0346153&CN169374&CN517202	137215&114480	ORPHA26106&ORPHA140162&ORPHA227535	Benign	NC_000016.10:g.68801694G>A	127919	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&Familial_cancer_of_breast&not_specified&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:4de15575-228f-4350-8bab-2e2dbfd23694	.	.	AEFDBI	N	0.12538	0.06527	N	0.27969	0.154638	.	17	6.761220e-05	1	6.151570e-05	16256	0	0	0.000000e+00	34592	0	251434	0	0.000000e+00	10078	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	4	3.517530e-05	113716	0	7	2.286390e-04	30616	0	7	2.286390e-04	30616	0	9	8.226090e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	3	7.014590e-05	42768	0	5	3.186740e-04	15690	0	5	3.186740e-04	15690	0	0	.	0	17	7.176140e-05	1	6.710510e-05	14902	0	0	0.000000e+00	34260	0	236896	0	0.000000e+00	9570	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	4	3.894840e-05	102700	0	7	2.293130e-04	30526	0	7	2.293130e-04	30526	0	0	17	8.167890e-05	1	6.165990e-05	16218	0	0	0.000000e+00	30524	0	208132	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	4	4.466480e-05	89556	0	7	2.286980e-04	30608	0	7	2.286980e-04	30608	0	0	17	6.943990e-05	1	8.315320e-05	12026	0	0	0.000000e+00	34458	0	244816	0	0.000000e+00	9996	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	4	3.583390e-05	111626	0	7	2.286390e-04	30616	0	7	2.286390e-04	30616	0	0	3	1.972410e-05	2	4.829050e-05	41416	0	0	0.000000e+00	912	0	0	0.000000e+00	15270	0	152098	0	0.000000e+00	3468	0	0	0.000000e+00	5192	0	0	0.000000e+00	10592	0	0	0.000000e+00	316	0	1	1.470110e-05	68022	0	2	4.829050e-05	41416	0	0	0.000000e+00	4826	0	1	3.043210e-05	1	1.099630e-04	9094	0	0	0.000000e+00	60	0	0	0.000000e+00	4682	0	32860	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5472	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3108	0	0	.	0	3	2.029080e-05	2	4.866420e-05	41098	0	0	0.000000e+00	912	0	0	0.000000e+00	15082	0	147850	0	0.000000e+00	3302	0	0	0.000000e+00	4956	0	0	0.000000e+00	10592	0	0	0.000000e+00	304	0	1	1.543310e-05	64796	0	0	0.000000e+00	4794	0	0	3	2.227040e-05	2	6.162570e-05	32454	0	0	0.000000e+00	862	0	0	0.000000e+00	14826	0	134708	0	0.000000e+00	3384	0	0	0.000000e+00	5192	0	0	0.000000e+00	6960	0	0	0.000000e+00	310	0	1	1.564900e-05	63902	0	0	0.000000e+00	4824	0	0	2	2.479540e-05	2	8.066470e-05	24794	0	0	0.000000e+00	112	0	0	0.000000e+00	12896	0	80660	0	0.000000e+00	994	0	0	0.000000e+00	3750	0	0	0.000000e+00	10500	0	0	0.000000e+00	272	0	0	0.000000e+00	21034	0	0	0.000000e+00	4798	0	0	16	67393098	16	68835597	0	0.73137	0.706548	0.000000	0.06391	0.204000	0.22012	0.162000	0.21256	0.326000	0.19391	-0.123000	0.13640	-0.176000	0.10203	68801694	G	.	rs587780117	.	.	12.196	9.802	8.175	8.409	.	.	.	42	-24	-4	40	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-3+24+start+224	127919	Benign	reviewed_by_expert_panel	not_specified&Hereditary_cancer-predisposing_syndrome&not_provided&Hereditary_diffuse_gastric_adenocarcinoma&Familial_cancer_of_breast	MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535	.	16:68835597-68835597	5.765e-05	7	7	0	0	0	0	0	5	0	2	10406	11578	8654	6614	66740	908	16512	0	0	0	0	5	0	2	0	0	0	0	0	0	0	rs587780117	6.53424e-05	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.68697e-05	1.09369e-03	2.27406e-04	8.89719e-05	4.49131e-05	2.27406e-04	6.90294e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs587780117	587780117	.	.	.	CDH1\x3bTANGO6	CDH1:exonic\x7cTANGO6:regulatory	CDH1:missense\x7cTANGO6:CTCF_binding_site\x3bpromoter_flanking_region	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,890	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0.3246	Likely Benign
16	68835695	68835695	A	G	G	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	3/16	.	NM_004360.5:c.286A>G	NP_004351.1:p.Ile96Val	410	286	96	I/V	Atc/Gtc	rs749306433&CM1516061	A	.	1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	TANGO6	.	chr16:g.68835695A>G	.	.	.	.	.	.	likely_benign&benign&benign/likely_benign	.	1&1	.	.	.	.	.	CDH1&NM_004360.3&c.286A>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	A/A	A	T	0.00643	-0.490802	T	0.19957	-0.523331	1.609	0.549	0.040380	-0.240216	0.04499	0.02693	A/A	T	0.07144	0.0598435038461594	0.03581	0.45532987417041165	.	0.48454	.	A/A	.	.	.	.	0.6703183	-0.863174608499586	0.12971	0.5953399	-0.842355381382301	0.12238	.	.	.	19	1.565e-04	0	0	19	1.642e-03	19	1.565e-04	0	0	0	0	0	0	0	0	19	1.789e-04	0	0	19	1.695e-03	19	1.789e-04	0	0	0	0	0	0	0	0	19	2.094e-04	0	0	19	1.643e-03	19	2.094e-04	0	0	0	0	0	0	0	0	0.60361	.	.	.	5.43	1.83	0.24279	0	0.55848	0.633656	.	.	0.42101	0.999717779019524	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.14980	0.542086	Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&Cadherin_prodomain&.	.	.	.	0.18642	.	0.982930	0.08170	N	0.969202	D	0.50187	0.027364	0.27951	.	0.50744	.	T	0.51880	0.1750	.	0.00534	.	T	0.53061	-0.8337	I96V	Gain_of_MoRF_binding_(P_=_0.1639)&_Loss_of_sheet_(P_=_0.302)&_Loss_of_catalytic_residue_at_Y101_(P_=_0.4726)&_Loss_of_stability_(P_=_0.5215)&_Gain_of_disorder_(P_=_0.5951)	P12830	0.68217	0.562	.	0.29870	.	.	0.08975	simple_aae&simple_aae	N&N	1&1	0.07736	.	.	.	0.24142	.	.	0.28873	.	T	0.03060	0.242930859327	0.21020	.	10	0.08930	.	.	0.06543	.	.	7.7216	0.27901	0.5193:0.4065:0.0742:0.0	.	.	.	.	.	.	.	.	0.14196	.	A/A	V	.	I	G	315	0.87208	.	16	C1708349&C0027672&CN169374&CN517202	137215	ORPHA26106&ORPHA140162	Benign	NC_000016.10:g.68801792A>G	220611	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:d9039763-3145-4298-b468-da3967101df3	.	.	AEFBI	N	0.19407	0.16477	N	0.34044	0.215045	.	41	1.631320e-04	0	0.000000e+00	16256	0	41	1.185310e-03	34590	1	251330	0	0.000000e+00	10074	0	0	0.000000e+00	18394	0	0	0.000000e+00	21648	0	0	0.000000e+00	113620	0	41	1.185310e-03	34590	1	0	0.000000e+00	30616	0	18	1.645220e-04	0	0.000000e+00	7164	0	18	1.051890e-03	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	18	1.051890e-03	17112	0	0	0.000000e+00	15690	0	0	.	1	41	1.731480e-04	0	0.000000e+00	14902	0	41	1.196800e-03	34258	1	236792	0	0.000000e+00	9566	0	0	0.000000e+00	17692	0	0	0.000000e+00	21632	0	0	0.000000e+00	102604	0	41	1.196800e-03	34258	1	0	0.000000e+00	30526	0	1	41	1.969940e-04	0	0.000000e+00	16218	0	41	1.343210e-03	30524	1	208128	0	0.000000e+00	6210	0	0	0.000000e+00	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89554	0	41	1.343210e-03	30524	1	0	0.000000e+00	30608	0	1	41	1.675440e-04	0	0.000000e+00	12026	0	41	1.189920e-03	34456	1	244712	0	0.000000e+00	9992	0	0	0.000000e+00	18390	0	0	0.000000e+00	21646	0	0	0.000000e+00	111530	0	41	1.189920e-03	34456	1	0	0.000000e+00	30616	0	1	1	6.571420e-06	0	0.000000e+00	41428	0	0	0.000000e+00	912	0	1	6.547070e-05	15274	0	152174	0	0.000000e+00	3472	0	0	0.000000e+00	5198	0	0	0.000000e+00	10612	0	0	0.000000e+00	316	0	0	0.000000e+00	68042	0	1	6.547070e-05	15274	0	0	0.000000e+00	4828	0	1	3.041180e-05	0	0.000000e+00	9090	0	0	0.000000e+00	60	0	1	2.132200e-04	4690	0	32882	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5482	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3108	0	0	.	0	1	6.760590e-06	0	0.000000e+00	41108	0	0	0.000000e+00	912	0	1	6.628660e-05	15086	0	147916	0	0.000000e+00	3302	0	0	0.000000e+00	4962	0	0	0.000000e+00	10612	0	0	0.000000e+00	304	0	0	0.000000e+00	64812	0	0	0.000000e+00	4796	0	0	1	7.420600e-06	0	0.000000e+00	32458	0	0	0.000000e+00	862	0	1	6.743090e-05	14830	0	134760	0	0.000000e+00	3388	0	0	0.000000e+00	5198	0	0	0.000000e+00	6970	0	0	0.000000e+00	310	0	0	0.000000e+00	63916	0	0	0.000000e+00	4826	0	0	1	1.238700e-05	0	0.000000e+00	24802	0	0	0.000000e+00	112	0	1	7.750740e-05	12902	0	80730	0	0.000000e+00	998	0	0	0.000000e+00	3756	0	0	0.000000e+00	10520	0	0	0.000000e+00	272	0	0	0.000000e+00	21050	0	0	0.000000e+00	4800	0	0	16	67393196	16	68835695	0	0.73137	0.706548	0.093000	0.22645	0.005000	0.06747	0.029000	0.15238	1.677000	0.37192	-0.043000	0.17390	0.317000	0.28223	68801792	A	.	rs749306433	.	.	12.196	9.802	8.175	8.409	.	.	.	0	-47	-1	13	0.10	0.00	0.01	0.00	CDH1	0.34	exon-NM_004360.5-3+101+end+224	220611	Benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&Hereditary_diffuse_gastric_adenocarcinoma&not_provided	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MedGen:CN517202	.	16:68835695-68835695	1.565e-04	19	19	0	0	19	0	0	0	0	0	10398	11574	8654	6614	66738	908	16512	0	19	0	0	0	0	0	0	0	0	0	0	0	0	rs749306433	0.00000e+00	1.22104e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	9.64406e-05	2.51599e-04	1.22104e-03	1.66483e-04	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs749306433	749306433	.	.	.	CDH1\x3bTANGO6	CDH1:exonic\x7cTANGO6:regulatory	CDH1:missense\x7cTANGO6:promoter_flanking_region	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,892	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0.3246	Likely Benign
1	215802181	215802181	G	C	C	missense_variant	MODERATE	USH2A	7399	Transcript	NM_206933.4	protein_coding	71/72	.	NM_206933.4:c.15494C>G	NP_996816.3:p.Ala5165Gly	15933	15494	5165	A/G	gCc/gGc	rs146892520	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	KCTD3	.	chr1:g.215802181G>C	.	0.003	0	0	0	0	conflicting_interpretations_of_pathogenicity&likely_benign	.	1	.	.	.	.	.	.	.	.	4	7.987220447284345E-4	4	0.0030257186081694403	0	0.0	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	G/G	G	T	0.00381	-0.53064	T	0.18333	-0.539619	22.9	23.3	2.734485	2.866193	0.46333	0.51733	G/G	T	0.00170	0.0113884763044311	0.26598	0.95290545025015894	.	0.24746	.	G/G	11	0.0024965955515206537	0	0.0	2.719018	0.0961945202186816	0.44357	2.057366	-0.137948524998637	0.35748	.	.	.	27	2.224e-04	25	2.403e-03	2	1.727e-04	27	2.224e-04	0	0	0	0	0	0	0	0	26	2.448e-04	24	2.647e-03	2	1.783e-04	26	2.448e-04	0	0	0	0	0	0	0	0	26	2.865e-04	24	2.311e-03	2	1.729e-04	26	2.865e-04	0	0	0	0	0	0	0	0	0.45248	.	.	.	5.67	5.67	0.87673	0	0.26702	0.573888	.	.	0.16389	0.101725515632202	.	0	0.19857	0.573078	.	.	.	.	.	.	0	0.26826	0.564101	.	.	.	.	0.30167	.	0.168594	0.27357	U	0.018988	D	0.49884	0.02703	0.03470	.	0.58977	.	T	0.23338	0.0553	.	0.00179	.	T	0.17434	-1.0396	.	.	.	.	.	.	0.14455	.	.	0.20843	simple_aae&simple_aae	N&N	0.999622&0.999622	0.17834	.	.	.	0.25382	.	.	0.19966	.	T	0.03143	0.243797808886	0.08068	.	10	0.57587	.	.	0.26409	.	.	15.2721	0.73411	0.0:0.1396:0.8604:0.0	.	.	.	.	.	.	.	.	0.26233	.	G/G	G	.	A	C	683	0.59664	.	1	C0271097&CN517202	PS276900	ORPHA886	Likely_benign	NC_000001.11:g.215628839G>C	282144	reviewed_by_expert_panel	Usher_syndrome&not_provided	.	.	.	AEFBI	D	0.58832	0.93661	D	0.63392	0.664918	.	54	2.147360e-04	45	2.768210e-03	16256	0	7	2.023590e-04	34592	0	251472	0	0.000000e+00	10080	0	0	0.000000e+00	18388	0	0	0.000000e+00	21648	0	0	0.000000e+00	113754	0	45	2.768210e-03	16256	0	0	0.000000e+00	30616	0	31	2.833590e-04	26	3.629260e-03	7164	0	5	2.921930e-04	17112	0	109402	0	0.000000e+00	2320	0	0	0.000000e+00	9042	0	0	0.000000e+00	13394	0	0	0.000000e+00	42766	0	26	3.629260e-03	7164	0	0	0.000000e+00	15690	0	0	.	0	53	2.236890e-04	44	2.952620e-03	14902	0	7	2.043200e-04	34260	0	236936	0	0.000000e+00	9572	0	0	0.000000e+00	17686	0	0	0.000000e+00	21632	0	0	0.000000e+00	102740	0	44	2.952620e-03	14902	0	0	0.000000e+00	30526	0	0	51	2.450490e-04	44	2.713030e-03	16218	0	6	1.965670e-04	30524	0	208122	0	0.000000e+00	6212	0	0	0.000000e+00	13410	0	0	0.000000e+00	16734	0	0	0.000000e+00	89552	0	44	2.713030e-03	16218	0	0	0.000000e+00	30608	0	0	41	1.674470e-04	33	2.744050e-03	12026	0	7	2.031460e-04	34458	0	244854	0	0.000000e+00	9998	0	0	0.000000e+00	18384	0	0	0.000000e+00	21646	0	0	0.000000e+00	111664	0	33	2.744050e-03	12026	0	0	0.000000e+00	30616	0	0	138	9.070120e-04	135	3.256940e-03	41450	2	0	0.000000e+00	912	0	0	0.000000e+00	15270	0	152148	0	0.000000e+00	3468	0	0	0.000000e+00	5176	0	0	0.000000e+00	10614	0	0	0.000000e+00	316	0	3	4.410080e-05	68026	0	135	3.256940e-03	41450	2	0	0.000000e+00	4824	0	21	6.384920e-04	21	2.308710e-03	9096	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32890	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3106	0	0	.	2	138	9.330750e-04	135	3.282440e-03	41128	2	0	0.000000e+00	912	0	0	0.000000e+00	15084	0	147898	0	0.000000e+00	3302	0	0	0.000000e+00	4940	0	0	0.000000e+00	10614	0	0	0.000000e+00	304	0	3	4.629630e-05	64800	0	0	0.000000e+00	4792	0	2	109	8.089290e-04	106	3.263140e-03	32484	2	0	0.000000e+00	862	0	0	0.000000e+00	14824	0	134746	0	0.000000e+00	3384	0	0	0.000000e+00	5176	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	3	4.694390e-05	63906	0	0	0.000000e+00	4822	0	2	67	8.301940e-04	67	2.698780e-03	24826	0	0	0.000000e+00	112	0	0	0.000000e+00	12896	0	80704	0	0.000000e+00	994	0	0	0.000000e+00	3734	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	0	0.000000e+00	21034	0	0	0.000000e+00	4796	0	0	1	213868804	1	215802181	0	0.14033	0.487112	1.000000	0.71638	0.428000	0.27405	0.995000	0.57719	4.723000	0.61658	0.618000	0.50648	1.176000	0.78918	215628839	G	.	rs146892520	.	.	6.582	10.098	5.283	8.351	.	.	.	-48	9	29	-25	0.00	0.00	0.00	0.00	USH2A	0.00	exon-NM_206933.4-71+25+start+222	282144	Likely_benign	reviewed_by_expert_panel	not_provided&Usher_syndrome	MedGen:CN517202&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886	.	rs146892520	2.224e-04	27	1	0	25	2	0	0	0	0	0	10404	11578	8652	6614	66736	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs146892520	2.74438e-03	2.08457e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.82282e-04	0.00000e+00	1.63089e-04	2.51446e-04	2.74438e-03	2.03028e-04	rs146892520	2.40550e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.99893e-04	0.00000e+00	.	9.93223e-04	5.05051e-04	2.40550e-03	7.74393e-04	rs146892520	0.0&0.2497&0.0846	rs146892520	146892520	.	.	.	USH2A	USH2A:exonic	USH2A:missense	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,444	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0.1	Likely Benign
16	68842734	68842734	C	T	T	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	5/16	.	NM_004360.5:c.670C>T	NP_004351.1:p.Arg224Cys	794	670	224	R/C	Cgc/Tgc	rs200310662&COSV55730278	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	.	chr16:g.68842734C>T	.	.	.	.	.	.	benign/likely_benign&likely_benign	0&1	1&1	.	.	.	.	.	CDH1&NM_004360.3&c.670C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.594706798131811E-4	.	.	.	.	.	.	.	C/C	C	T	0.04807	-0.348744	T	0.29624	-0.432746	5.661	6.491	0.421249	0.245488	0.08262	0.07740	C/C	T	0.07074	0.0594001798686618	0.01589	0.2971034736453203	.	0.84842	.	C/C	0	0.0	2	2.3255813953488373E-4	0.009989735	-2.06090009594908	0.00227	0.01823568	-1.85504072080758	0.00424	.	.	.	21	1.730e-04	2	1.936e-04	0	0	21	1.738e-04	0	0	1	1.513e-04	14	2.106e-04	3	1.830e-04	13	1.224e-04	2	2.215e-04	0	0	13	1.228e-04	0	0	1	1.513e-04	6	1.106e-04	3	1.841e-04	21	2.314e-04	2	1.940e-04	0	0	21	2.328e-04	0	0	1	2.632e-04	14	3.340e-04	3	1.831e-04	0.52867	.	.	.	5.78	-11.6	0.00045	0	0.40923	0.588066	.	.	0.74766	0.999999999990323	.	0	0.82415	0.723133	.	.	.	.	.	.	0	0.10902	0.530356	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&.	.	.	.	0.87848	.	3.361860	0.00957	N	0.003359	D	0.63372	0.048432	0.52724	.	0.72044	.	T	0.44307	0.1316	.	0.21296	.	T	0.60251	-0.7039	.	.	.	.	.	.	0.35607	.	.	0.08975	simple_aae&simple_aae	N&N	1&1	0.66325	.	.	.	0.40793	.	.	0.43514	.	T	0.00773	0.209072127938	0.49555	.	10	0.65728	.	.	0.56456	.	.	17.4843	0.87578	0.2584:0.6058:0.1358:0.0	.	1	2.6968716289104636E-4	2	2.644802962179318E-4	.	.	.	0.22228	.	C/C	C	.	R	T	315	0.87208	.	16	C0006142&C1708349&C0027672&CN120488&CN169374&CN221562&CN517202	137215	ORPHA26106&ORPHA140162&ORPHA98555	Likely_benign	NC_000016.10:g.68808831C>T	127932	reviewed_by_expert_panel	Malignant_tumor_of_breast&Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&Anophthalmia-microphthalmia_syndrome&not_specified&Breast_and/or_ovarian_cancer&not_provided	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2855186&ClinGen_CDH1_Variant_Curation_Expert_Panel&:d4d12c86-59cb-40a8-92ec-13925d97080a	.	.	AEFDBHCI	N	0.19182	0.15997	N	0.53155	0.496729	.	42	1.674000e-04	2	1.231220e-04	16244	0	1	2.892680e-05	34570	0	250896	0	0.000000e+00	10058	0	0	0.000000e+00	18386	0	0	0.000000e+00	21614	0	31	2.736000e-04	113304	0	31	2.736000e-04	113304	0	8	2.614720e-04	30596	0	17	1.554670e-04	1	1.397040e-04	7158	0	0	0.000000e+00	17106	0	109348	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13362	0	10	2.338420e-04	42764	0	6	3.827020e-04	15678	0	6	3.827020e-04	15678	0	0	.	0	33	1.395970e-04	2	1.342640e-04	14896	0	1	2.920730e-05	34238	0	236394	0	0.000000e+00	9552	0	0	0.000000e+00	17690	0	0	0.000000e+00	21598	0	22	2.150330e-04	102310	0	8	2.622430e-04	30506	0	8	2.622430e-04	30506	0	0	39	1.875040e-04	2	1.234110e-04	16206	0	1	3.277830e-05	30508	0	207996	0	0.000000e+00	6208	0	0	0.000000e+00	13410	0	0	0.000000e+00	16702	0	28	3.128140e-04	89510	0	28	3.128140e-04	89510	0	8	2.615400e-04	30588	0	0	38	1.555580e-04	1	8.322240e-05	12016	0	1	2.903940e-05	34436	0	244282	0	0.000000e+00	9976	0	0	0.000000e+00	18382	0	0	0.000000e+00	21612	0	28	2.517620e-04	111216	0	8	2.614720e-04	30596	0	8	2.614720e-04	30596	0	0	33	2.169250e-04	4	9.653440e-05	41436	0	0	0.000000e+00	912	0	2	1.310270e-04	15264	0	152126	0	0.000000e+00	3470	0	0	0.000000e+00	5192	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	27	3.969650e-04	68016	0	27	3.969650e-04	68016	0	0	0.000000e+00	4826	0	7	2.129600e-04	1	1.100350e-04	9088	0	0	0.000000e+00	60	0	1	2.133110e-04	4688	0	32870	0	0.000000e+00	136	0	0	0.000000e+00	2426	0	0	0.000000e+00	5482	0	0	0.000000e+00	246	0	5	7.303530e-04	6846	0	0	0.000000e+00	3112	0	0	.	0	33	2.231510e-04	4	9.729050e-05	41114	0	0	0.000000e+00	912	0	2	1.326610e-04	15076	0	147882	0	0.000000e+00	3302	0	0	0.000000e+00	4960	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	27	4.166920e-04	64796	0	0	0.000000e+00	4794	0	0	31	2.301140e-04	4	1.232060e-04	32466	0	0	0.000000e+00	862	0	2	1.349710e-04	14818	0	134716	0	0.000000e+00	3386	0	0	0.000000e+00	5192	0	0	0.000000e+00	6966	0	0	0.000000e+00	310	0	25	3.912610e-04	63896	0	0	0.000000e+00	4824	0	0	10	1.239340e-04	1	4.030310e-05	24812	0	0	0.000000e+00	112	0	2	1.551590e-04	12890	0	80688	0	0.000000e+00	996	0	0	0.000000e+00	3750	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	7	3.328580e-04	21030	0	0	0.000000e+00	4798	0	0	16	67400235	16	68842734	0	0.83141	0.719381	0.000000	0.06391	0.072000	0.16771	0.015000	0.13148	-3.576000	0.00475	-0.999000	0.01817	-1.549000	0.01167	68808831	C	.	rs200310662	.	.	8.533	8.591	10.585	7.101	.	.	.	-25	-43	-25	17	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-5+17+end+156	127932	Likely_benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&Familial_cancer_of_breast&Blepharocheilodontic_syndrome_1&Endometrial_carcinoma&Hereditary_diffuse_gastric_adenocarcinoma&Neoplasm_of_ovary&Malignant_tumor_of_prostate&Breast_and/or_ovarian_cancer&Malignant_tumor_of_breast&not_provided&Anophthalmia-microphthalmia_syndrome	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MONDO:MONDO:0054740&MedGen:C4551988&OMIM:119580&Orphanet:1997&Human_Phenotype_Ontology:HP:0012114&MONDO:MONDO:0002447&MedGen:C0476089&OMIM:608089&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267&OMIM:167000&Human_Phenotype_Ontology:HP:0012125&MONDO:MONDO:0008315&MedGen:C0376358&OMIM:176807&Orphanet:1331&MedGen:CN221562&MONDO:MONDO:0007254&MedGen:C0006142&MedGen:CN517202&MONDO:MONDO:0020147&MedGen:CN120488&Orphanet:98555	.	16:68842734-68842734	1.730e-04	21	21	0	2	0	0	1	14	1	3	10328	11482	8630	6610	66474	908	16396	2	0	0	1	14	1	3	0	0	0	0	0	0	0	rs200310662	1.30787e-04	2.97938e-05	0.00000e+00	0.00000e+00	4.49156e-05	2.69702e-04	0.00000e+00	2.60078e-04	1.63496e-04	1.80024e-04	2.69702e-04	1.70550e-04	rs200310662	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.33156e-04	0.00000e+00	.	1.16863e-04	2.16606e-04	3.33156e-04	1.61332e-04	rs200310662	0.0233&0.0&0.0154	rs200310662	200310662	.	.	.	CDH1\x3bTANGO6	CDH1:exonic\x7cTANGO6:regulatory	CDH1:missense\x7cTANGO6:CTCF_binding_site	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,897	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0.1	Likely Benign
16	68846047	68846047	A	G	G	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	8/16	.	NM_004360.5:c.1018A>G	NP_004351.1:p.Thr340Ala	1142	1018	340	T/A	Acg/Gcg	rs116093741&CM020926&COSV55732016	A	.	1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	TANGO6	.	chr16:g.68846047A>G	.	0	0	0.001	0	0	benign&uncertain_significance&benign/likely_benign&conflicting_interpretations_of_pathogenicity	0&0&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.1018A>T	.	.	1	1.9968051118210862E-4	0	0.0	0	0.0	1	9.92063492063492E-4	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	A/A	A	T	0.02913	-0.384593	T	0.42000	-0.325225	6.102	3.368	0.461968	0.046606	0.08704	0.05315	A/A	T	0.00359	0.0156577890934931	0.06232	0.59470166253971757	.	0.57356	.	A/A	.	.	.	.	0.215867	-1.28960773801868	0.04570	0.1832851	-1.26728520656828	0.04076	.	.	.	32	2.636e-04	0	0	0	0	32	2.636e-04	31	3.582e-03	0	0	1	1.498e-05	0	0	30	2.825e-04	0	0	0	0	30	2.825e-04	30	3.814e-03	0	0	0	0	0	0	16	1.763e-04	0	0	0	0	16	1.763e-04	15	2.661e-03	0	0	1	2.373e-05	0	0	0.51952	.	.	.	5.93	-3.7	0.04150	0	0.40923	0.588066	.	.	0.46280	0.999927522385152	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.26826	0.564101	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&.	.	.	.	0.02626	.	1.188700	0.06133	N	0.688818	T	0.32036	0.01299	0.27341	.	0.59188	.	T	0.27330	0.0663	.	0.00293	.	T	0.35660	-0.9771	.	.	.	.	.	.	0.20901	.	.	0.08975	simple_aae&simple_aae	N&N	1&1	0.19509	.	.	.	0.07471	.	.	0.04355	.	T	0.00714	0.207603693008	0.60924	.	10	0.39799	.	.	0.40573	.	.	7.0905	0.24460	0.3936:0.2908:0.3155:0.0	.	.	.	.	.	.	.	.	0.23632	.	A/A	A	.	T	G	314	0.87270	.	16	C0278701&C1708349&C0027672&CN169374&CN221562&CN517202	137215	ORPHA26106&ORPHA140162	Benign	NC_000016.10:g.68812144A>G	12245	reviewed_by_expert_panel	Adenocarcinoma_of_stomach&Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&Breast_and/or_ovarian_cancer&not_provided	Illumina_Laboratory_Services&Illumina:658420&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2684800&ClinGen_CDH1_Variant_Curation_Expert_Panel&:de5b0e27-fa33-4621-930e-61569417ceff&OMIM_Allelic_Variant:192090.0016&UniProtKB_(protein):P12830#VAR_013971	.	.	AEFBCI	N	0.17629	0.13041	N	0.33382	0.207670	.	67	2.664210e-04	0	0.000000e+00	16256	0	0	0.000000e+00	34592	0	251482	0	0.000000e+00	10078	0	67	3.642490e-03	18394	0	0	0.000000e+00	21648	0	0	0.000000e+00	113758	0	67	3.642490e-03	18394	0	0	0.000000e+00	30616	0	27	2.467830e-04	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	27	2.984740e-03	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	27	2.984740e-03	9046	0	0	0.000000e+00	15690	0	0	.	0	66	2.785420e-04	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236948	0	0.000000e+00	9570	0	66	3.730500e-03	17692	0	0	0.000000e+00	21632	0	0	0.000000e+00	102746	0	66	3.730500e-03	17692	0	0	0.000000e+00	30526	0	0	43	2.066040e-04	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208128	0	0.000000e+00	6210	0	43	3.205130e-03	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89552	0	43	3.205130e-03	13416	0	0	0.000000e+00	30608	0	0	67	2.736210e-04	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244864	0	0.000000e+00	9996	0	67	3.643280e-03	18390	0	0	0.000000e+00	21646	0	0	0.000000e+00	111668	0	67	3.643280e-03	18390	0	0	0.000000e+00	30616	0	0	17	1.118010e-04	0	0.000000e+00	41380	0	0	0.000000e+00	912	0	0	0.000000e+00	15264	0	152056	0	0.000000e+00	3470	0	17	3.281850e-03	5180	0	0	0.000000e+00	10610	0	0	0.000000e+00	316	0	0	0.000000e+00	68020	0	17	3.281850e-03	5180	0	0	0.000000e+00	4814	0	11	3.347740e-04	0	0.000000e+00	9080	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32858	0	0.000000e+00	136	0	11	4.534210e-03	2426	0	0	0.000000e+00	5484	0	0	0.000000e+00	246	0	0	0.000000e+00	6848	0	0	0.000000e+00	3100	0	0	.	0	16	1.082530e-04	0	0.000000e+00	41058	0	0	0.000000e+00	912	0	0	0.000000e+00	15076	0	147802	0	0.000000e+00	3300	0	16	3.232320e-03	4950	0	0	0.000000e+00	10610	0	0	0.000000e+00	304	0	0	0.000000e+00	64790	0	0	0.000000e+00	4782	0	0	17	1.262310e-04	0	0.000000e+00	32442	0	0	0.000000e+00	862	0	0	0.000000e+00	14818	0	134674	0	0.000000e+00	3386	0	17	3.281850e-03	5180	0	0	0.000000e+00	6970	0	0	0.000000e+00	310	0	0	0.000000e+00	63894	0	0	0.000000e+00	4812	0	0	15	1.859980e-04	0	0.000000e+00	24768	0	0	0.000000e+00	112	0	0	0.000000e+00	12892	0	80646	0	0.000000e+00	998	0	15	4.012840e-03	3738	0	0	0.000000e+00	10518	0	0	0.000000e+00	272	0	0	0.000000e+00	21046	0	0	0.000000e+00	4786	0	0	16	67403548	16	68846047	0	0.52595	0.67177	0.000000	0.06391	0.003000	0.05239	0.001000	0.05097	-0.366000	0.07616	-0.054000	0.16847	0.320000	0.28347	68812144	A	.	rs116093741	.	.	7.382	7.312	10.172	4.939	.	.	.	-9	-7	36	1	0.00	0.00	0.06	0.00	CDH1	0.34	exon-NM_004360.5-8+9+start+129	12245	Benign	reviewed_by_expert_panel	Gastric_adenocarcinoma&Breast_and/or_ovarian_cancer&Hereditary_cancer-predisposing_syndrome&not_provided&not_specified&Hereditary_diffuse_gastric_adenocarcinoma	Human_Phenotype_Ontology:HP:0033770&MONDO:MONDO:0005036&MedGen:C0278701&Orphanet:464463&MedGen:CN221562&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MedGen:CN169374&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	rs116093741	2.636e-04	32	1	0	0	0	31	0	1	0	0	10406	11578	8654	6614	66740	908	16512	0	0	0	0	1	0	0	0	0	0	0	0	0	0	rs116093741	0.00000e+00	0.00000e+00	0.00000e+00	3.53664e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	2.44615e-04	2.51441e-04	3.53664e-03	2.47694e-04	rs116093741	0.00000e+00	0.00000e+00	0.00000e+00	4.32633e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	2.34028e-04	2.16732e-04	4.32633e-03	2.25865e-04	.	.	rs116093741	116093741	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,902	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0.1	Likely Benign
16	68847240	68847240	G	A	A	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	9/16	.	NM_004360.5:c.1162G>A	NP_004351.1:p.Glu388Lys	1286	1162	388	E/K	Gag/Aag	rs372838203&COSV55727982&COSV55730651	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68847240G>A	.	.	.	.	.	.	not_provided&conflicting_interpretations_of_pathogenicity&likely_benign&benign	0&1&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.1162G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	T	0.01407	-0.433807	T	0.10023	-0.635208	0.732	4.783	-0.126245	0.131700	0.03291	0.06345	G/G	T	0.00270	0.0140088391092951	0.10490	0.73884021127328792	.	0.50073	.	G/G	0	0.0	1	1.1627906976744187E-4	0.2021042	-1.31066749261852	0.04291	0.147221	-1.33331395152859	0.03301	.	.	.	2	1.647e-05	0	0	0	0	2	1.647e-05	1	1.156e-04	0	0	1	1.498e-05	0	0	2	1.883e-05	0	0	0	0	2	1.883e-05	1	1.271e-04	0	0	1	1.840e-05	0	0	2	2.204e-05	0	0	0	0	2	2.204e-05	1	1.774e-04	0	0	1	2.373e-05	0	0	0.52416	.	.	.	6.04	-1.35	0.08638	0	0.79440	0.708844	.	.	0.10931	0.00541680998286588	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.26826	0.564101	Cadherin-like&Cadherin-like&.&Cadherin-like	.	.	.	0.29288	.	0.932039	0.08777	N	0.877834	T	0.35967	0.015309	0.31194	.	0.55497	.	T	0.25346	0.0607	.	0.05454	.	T	0.28607	-1.0045	.	.	.	.	.	.	0.23535	.	.	0.08975	simple_aae&without_aae	N&N	1&1	0.15578	.	.	.	0.11197	.	.	0.11217	.	T	0.05874	0.267945110798	0.05312	.	10	0.02943	.	.	0.10020	.	.	8.2349	0.30780	0.204:0.2888:0.5072:0.0	.	.	.	.	.	.	.	.	0.20262	.	G/G	K	.	E	A	315	0.87208	.	16	C1708349&C0027672&CN169374&CN517202	137215	ORPHA26106&ORPHA140162	Benign	NC_000016.10:g.68813337G>A	127906	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:5c24cb6c-a751-4e76-83ab-baccc23c4caa&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2850658	.	.	AEFBI	N	0.18016	0.13722	N	0.39243	0.278065	.	6	2.385890e-05	0	0.000000e+00	16256	0	4	1.156340e-04	34592	0	251478	0	0.000000e+00	10078	0	1	5.436560e-05	18394	0	0	0.000000e+00	21648	0	1	8.790750e-06	113756	0	4	1.156340e-04	34592	0	0	0.000000e+00	30616	0	2	1.828020e-05	0	0.000000e+00	7164	0	1	5.843850e-05	17112	0	109408	0	0.000000e+00	2320	0	1	1.105460e-04	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	1	1.105460e-04	9046	0	0	0.000000e+00	15690	0	0	.	0	6	2.532290e-05	0	0.000000e+00	14902	0	4	1.167540e-04	34260	0	236940	0	0.000000e+00	9570	0	1	5.652270e-05	17692	0	0	0.000000e+00	21632	0	1	9.733310e-06	102740	0	4	1.167540e-04	34260	0	0	0.000000e+00	30526	0	0	3	1.441420e-05	0	0.000000e+00	16218	0	2	6.552220e-05	30524	0	208128	0	0.000000e+00	6212	0	1	7.453790e-05	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89552	0	1	7.453790e-05	13416	0	0	0.000000e+00	30608	0	0	6	2.450380e-05	0	0.000000e+00	12026	0	4	1.160830e-04	34458	0	244860	0	0.000000e+00	9996	0	1	5.437740e-05	18390	0	0	0.000000e+00	21646	0	1	8.955280e-06	111666	0	4	1.160830e-04	34458	0	0	0.000000e+00	30616	0	0	1	6.571600e-06	0	0.000000e+00	41434	0	0	0.000000e+00	912	0	0	0.000000e+00	15278	0	152170	0	0.000000e+00	3470	0	1	1.923080e-04	5200	0	0	0.000000e+00	10614	0	0	0.000000e+00	316	0	0	0.000000e+00	68032	0	1	1.923080e-04	5200	0	0	0.000000e+00	4824	0	1	3.040990e-05	0	0.000000e+00	9098	0	0	0.000000e+00	60	0	0	0.000000e+00	4684	0	32884	0	0.000000e+00	136	0	1	4.115230e-04	2430	0	0	0.000000e+00	5484	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3104	0	0	.	0	1	6.760410e-06	0	0.000000e+00	41114	0	0	0.000000e+00	912	0	0	0.000000e+00	15090	0	147920	0	0.000000e+00	3302	0	1	2.014500e-04	4964	0	0	0.000000e+00	10614	0	0	0.000000e+00	304	0	0	0.000000e+00	64808	0	0	0.000000e+00	4792	0	0	1	7.420380e-06	0	0.000000e+00	32468	0	0	0.000000e+00	862	0	0	0.000000e+00	14832	0	134764	0	0.000000e+00	3386	0	1	1.923080e-04	5200	0	0	0.000000e+00	6972	0	0	0.000000e+00	310	0	0	0.000000e+00	63912	0	0	0.000000e+00	4822	0	0	1	1.238670e-05	0	0.000000e+00	24810	0	0	0.000000e+00	112	0	0	0.000000e+00	12906	0	80732	0	0.000000e+00	996	0	1	2.660990e-04	3758	0	0	0.000000e+00	10522	0	0	0.000000e+00	272	0	0	0.000000e+00	21044	0	0	0.000000e+00	4796	0	0	16	67404741	16	68847240	0	0.52595	0.67177	0.001000	0.13787	0.041000	0.14368	0.033000	0.15652	-0.197000	0.09519	-0.110000	0.15115	-0.135000	0.11465	68813337	G	.	rs372838203	.	.	10.239	7.806	7.382	7.312	.	.	.	31	-24	-12	25	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-9+24+start+183	127906	Benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Hereditary_diffuse_gastric_adenocarcinoma	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	16:68847240-68847240	1.647e-05	2	2	0	0	0	1	0	1	0	0	10404	11578	8654	6614	66740	908	16512	0	0	1	0	1	0	0	0	0	0	0	0	0	0	rs372838203	0.00000e+00	1.19111e-04	0.00000e+00	5.79777e-05	0.00000e+00	1.79051e-05	0.00000e+00	0.00000e+00	2.96525e-05	2.69411e-05	1.19111e-04	2.84239e-05	rs372838203	0.00000e+00	0.00000e+00	0.00000e+00	6.17284e-04	0.00000e+00	6.66134e-05	0.00000e+00	.	5.84112e-05	7.21917e-05	6.17284e-04	6.45328e-05	rs372838203	0.0116&0.0&0.0077	rs372838203	372838203	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,907	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0.1	Likely Benign
11	120998747	120998747	C	G	G	missense_variant	MODERATE	TBCEL-TECTA	116804918	Transcript	NM_001378761.1	protein_coding	15/30	.	NM_001378761.1:c.3018C>G	NP_001365690.1:p.Asn1006Lys	3225	3018	1006	N/K	aaC/aaG	rs139165033&COSV99081208	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TECTA	.	chr11:g.120998747C>G	.	.	.	.	.	.	uncertain_significance&likely_benign&conflicting_interpretations_of_pathogenicity	0&1	1&1	.	.	.	.	.	TECTA&NM_005422.2&c.2061C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	18	0.00467047223663726	.	.	.	.	.	.	.	C/C	C	T	0.00215	-0.572065	T	0.13348	-0.593693	23.8	24.8	3.178744	3.453164	0.56086	0.65918	C/C	T	0.01848	0.0290761121474782	0.83778	0.99744754325360785	.	0.43872	.	C/C	2	4.5392646391284613E-4	24	0.0027913468248429866	5.370289	0.52250405684534	0.69507	5.23514	0.52492521821783	0.68567	.	.	.	204	1.680e-03	5	4.822e-04	10	8.648e-04	204	1.684e-03	0	0	6	9.088e-04	182	2.734e-03	0	0	174	1.638e-03	5	5.526e-04	8	7.138e-04	174	1.640e-03	0	0	6	9.088e-04	154	2.837e-03	0	0	131	1.443e-03	5	4.830e-04	10	8.657e-04	131	1.448e-03	0	0	3	7.899e-04	112	2.669e-03	0	0	0.04696	.	.	.	5.67	4.57	0.55860	0	0.45803	0.59043	.	.	0.11547	0.0078059050175394	.	0	0.23631	0.573888	.	.	.	.	.	.	0	0.26826	0.564101	TILa_domain&VWFC_domain&TILa_domain&VWFC_domain&TILa_domain&VWFC_domain	.	.	.	0.39669	.	0.096661	0.62929	D	0.000001	T	0.21928	0.008283	0.76429	.	0.74331	.	T	0.14900	0.0346	.	0.00264	.	T	0.01583	-1.1344	.	.	.	.	.	.	0.23182	.	.	0.31263	simple_aae&simple_aae	N&N	0.560241&0.560241	0.24026	.	.	.	0.90584	.	.	0.75793	.	T	0.54992	0.614786505699	0.34888	.	10	0.70582	.	.	0.07163	.	.	13.2791	0.59638	0.0:0.8691:0.0:0.1309	.	18	0.0048543689320388345	36	0.004760645331922771	.	.	.	0.69213	.	C/C	K	.	N	G	778	0.48011	.	11	C1384666&C1832187&C1863655&CN043648&CN169374&CN517202	601543&603629	ORPHA87884	Likely_benign	NC_000011.10:g.121128038C>G	45317	reviewed_by_expert_panel	Hearing_impairment&Deafness&_autosomal_dominant_12&Deafness&_autosomal_recessive_21&Nonsyndromic_hearing_loss_and_deafness&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:74005&Institute_of_Human_Genetics&_University_of_Leipzig_Medical_Center:CV_varv_1180	.	.	AEFDBI	D	0.43028	0.83938	N	0.43283	0.333888	.	423	1.690880e-03	3	1.847060e-04	16242	0	42	1.214860e-03	34572	0	250166	8	7.953870e-04	10058	0	0	0.000000e+00	18380	0	17	8.087540e-04	21020	0	349	3.083470e-03	113184	1	349	3.083470e-03	113184	1	0	0.000000e+00	30602	0	169	1.554220e-03	2	2.794080e-04	7158	0	21	1.227780e-03	17104	0	108736	2	8.643040e-04	2314	0	0	0.000000e+00	9040	0	10	7.823500e-04	12782	0	134	3.134060e-03	42756	1	134	3.134060e-03	42756	1	0	0.000000e+00	15680	0	1	.	1	396	1.679850e-03	3	2.014230e-04	14894	0	40	1.168090e-03	34244	0	235736	8	8.376960e-04	9550	0	0	0.000000e+00	17684	0	17	8.093700e-04	21004	0	324	3.168580e-03	102254	1	324	3.168580e-03	102254	1	0	0.000000e+00	30512	0	1	334	1.611560e-03	3	1.851390e-04	16204	0	36	1.180170e-03	30504	0	207252	5	8.061920e-04	6202	0	0	0.000000e+00	13404	0	13	8.063520e-04	16122	0	274	3.065560e-03	89380	1	274	3.065560e-03	89380	1	0	0.000000e+00	30594	0	1	419	1.720400e-03	3	2.497500e-04	12012	0	42	1.219580e-03	34438	0	243548	8	8.019250e-04	9976	0	0	0.000000e+00	18376	0	17	8.088310e-04	21018	0	345	3.105480e-03	111094	1	345	3.105480e-03	111094	1	0	0.000000e+00	30602	0	1	246	1.615780e-03	22	5.304020e-04	41478	0	0	0.000000e+00	912	0	12	7.851350e-04	15284	0	152248	6	1.728110e-03	3472	0	0	0.000000e+00	5198	0	8	7.530120e-04	10624	0	0	0.000000e+00	316	0	193	2.836570e-03	68040	0	193	2.836570e-03	68040	0	0	0.000000e+00	4830	0	39	1.184760e-03	6	6.591960e-04	9102	0	0	0.000000e+00	60	0	5	1.066100e-03	4690	0	32918	1	7.352940e-03	136	0	0	0.000000e+00	2430	0	4	7.280670e-04	5494	0	0	0.000000e+00	246	0	22	3.209800e-03	6854	0	0	0.000000e+00	3116	0	0	.	0	233	1.574430e-03	22	5.345510e-04	41156	0	0	0.000000e+00	912	0	12	7.949130e-04	15096	0	147990	6	1.817080e-03	3302	0	0	0.000000e+00	4964	0	8	7.530120e-04	10624	0	0	0.000000e+00	304	0	180	2.777350e-03	64810	0	0	0.000000e+00	4798	0	0	220	1.631710e-03	17	5.231410e-04	32496	0	0	0.000000e+00	862	0	12	8.087340e-04	14838	0	134828	6	1.770960e-03	3388	0	0	0.000000e+00	5198	0	5	7.159220e-04	6984	0	0	0.000000e+00	310	0	175	2.737800e-03	63920	0	0	0.000000e+00	4828	0	0	109	1.348940e-03	11	4.426200e-04	24852	0	0	0.000000e+00	112	0	11	8.520530e-04	12910	0	80804	2	2.004010e-03	998	0	0	0.000000e+00	3756	0	8	7.595900e-04	10532	0	0	0.000000e+00	272	0	73	3.467930e-03	21050	0	0	0.000000e+00	4802	0	0	11	120503957	11	120998747	0	0.14033	0.487112	0.968000	0.34134	0.999000	0.91618	1.000000	0.86279	0.168000	0.16438	0.598000	0.34611	1.024000	0.40540	121128038	C	.	rs139165033	.	.	5.739	10.512	5.722	8.146	.	.	.	.	.	.	.	.	.	.	.	.	.	exon-NM_001378761.1-15+286+start+593	45317	Likely_benign	reviewed_by_expert_panel	not_specified&not_provided&Nonsyndromic_genetic_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_21&Autosomal_dominant_nonsyndromic_hearing_loss_12&Hearing_impairment	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0011351&MedGen:C1863655&OMIM:603629&Orphanet:90636&MONDO:MONDO:0011102&MedGen:C1832187&OMIM:601543&Orphanet:90635&Human_Phenotype_Ontology:HP:0000365&Human_Phenotype_Ontology:HP:0000404&Human_Phenotype_Ontology:HP:0001728&Human_Phenotype_Ontology:HP:0001729&Human_Phenotype_Ontology:HP:0001754&Human_Phenotype_Ontology:HP:0008560&Human_Phenotype_Ontology:HP:0008563&MONDO:MONDO:0005365&MedGen:C1384666	.	rs139165033	1.680e-03	204	202	1	5	10	0	6	182	1	0	10370	11564	8626	6602	66562	906	16496	5	10	0	6	180	1	0	0	0	0	0	1	0	0	rs139165033	3.26883e-04	1.22111e-03	8.13504e-04	0.00000e+00	6.91946e-04	3.12477e-03	1.09729e-03	0.00000e+00	1.80363e-03	1.62546e-03	3.12477e-03	1.72984e-03	rs139165033	3.43879e-04	0.00000e+00	0.00000e+00	0.00000e+00	5.72738e-04	3.46528e-03	1.02249e-03	.	1.92937e-03	1.80401e-03	3.46528e-03	1.87145e-03	rs139165033	0.2791&0.0454&0.1999	rs139165033	139165033	.	.	.	TBCEL-TECTA\x3bTECTA	TBCEL-TECTA:exonic\x7cTECTA:exonic	TBCEL-TECTA:missense\x7cTECTA:missense	.	.	.	.	0	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,635	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0.0507	Likely Benign
1	215824001	215824001	C	T	T	missense_variant	MODERATE	USH2A	7399	Transcript	NM_206933.4	protein_coding	65/72	.	NM_206933.4:c.14276G>A	NP_996816.3:p.Gly4759Glu	14715	14276	4759	G/E	gGg/gAg	rs112459877&CM172398	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	KCTD3	.	chr1:g.215824001C>T	.	0.0053	0	0	0	0	likely_benign&uncertain_significance	.	1&1	.	.	.	.	.	USH2A&NM_206933.2&c.14276G>A	.	.	7	0.0013977635782747603	7	0.00529500756429652	0	0.0	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	C/C	C	T	0.00127	-0.609892	T	0.09054	-0.648577	0.001	0.001	-2.039682	-2.243348	0.00019	0.00009	C/C	T	0.00342	0.0153560988076093	0.00224	0.12605101162350951	.	0.15591	.	C/C	15	0.003404448479346346	0	0.0	0.0001803192	-2.82213782541702	0.00004	0.0001352654	-2.80145755740996	0.00003	.	.	.	39	3.212e-04	37	3.565e-03	2	1.729e-04	39	3.215e-04	0	0	0	0	0	0	0	0	38	3.578e-04	36	3.974e-03	2	1.784e-04	38	3.579e-04	0	0	0	0	0	0	0	0	39	4.297e-04	37	3.571e-03	2	1.731e-04	39	4.303e-04	0	0	0	0	0	0	0	0	0.50976	.	.	.	5.74	-11.5	0.00057	0	0.26702	0.573888	.	.	0.74766	0.999991972115415	.	0	0.07944	0.491513	.	.	.	.	.	.	0	0.26826	0.564101	Fibronectin_type_III&Fibronectin_type_III&Fibronectin_type_III	.	.	.	0.00826	.	4.986380	0.00848	N	0.001995	T	0.07237	0.003267	0.03660	.	0.54491	.	T	0.10998	0.0257	.	0.00105	.	T	0.31591	-0.9939	.	.	.	.	.	.	0.01820	.	.	0.08975	simple_aae&simple_aae	N&N	1&1	0.02163	.	.	.	0.02946	.	.	0.01387	.	T	0.00505	0.20160806179	0.31313	.	10	0.01155	.	.	0.00964	.	.	0.4714	0.00496	0.2333:0.2832:0.2334:0.2501	.	.	.	.	.	.	.	.	0.16447	.	C/C	E	.	G	T	670	0.60992	.	1	C0035334&C1848634&C3151138&C0271097&CN169374&CN517202	268000&PS268000&276901&613809&PS276900	ORPHA791&ORPHA886	Likely_benign	NC_000001.11:g.215650659C>T	177913	reviewed_by_expert_panel	Retinitis_pigmentosa&Usher_syndrome&_type_2A&Retinitis_pigmentosa_39&Usher_syndrome&not_specified&not_provided	.	.	.	AEFBI	N	0.10096	0.04482	N	0.19406	0.096108	.	65	2.587740e-04	61	3.752920e-03	16254	0	4	1.156540e-04	34586	0	251184	0	0.000000e+00	10064	0	0	0.000000e+00	18386	0	0	0.000000e+00	21648	0	0	0.000000e+00	113502	0	61	3.752920e-03	16254	0	0	0.000000e+00	30616	0	30	2.742180e-04	27	3.768840e-03	7164	0	3	1.753160e-04	17112	0	109402	0	0.000000e+00	2320	0	0	0.000000e+00	9042	0	0	0.000000e+00	13394	0	0	0.000000e+00	42766	0	27	3.768840e-03	7164	0	0	0.000000e+00	15690	0	0	.	0	64	2.704390e-04	60	4.026310e-03	14902	0	4	1.167750e-04	34254	0	236652	0	0.000000e+00	9556	0	0	0.000000e+00	17686	0	0	0.000000e+00	21632	0	0	0.000000e+00	102488	0	60	4.026310e-03	14902	0	0	0.000000e+00	30526	0	0	65	3.123260e-04	61	3.761720e-03	16216	0	4	1.310530e-04	30522	0	208116	0	0.000000e+00	6212	0	0	0.000000e+00	13408	0	0	0.000000e+00	16734	0	0	0.000000e+00	89550	0	61	3.761720e-03	16216	0	0	0.000000e+00	30608	0	0	50	2.044440e-04	46	3.825680e-03	12024	0	4	1.161040e-04	34452	0	244566	0	0.000000e+00	9982	0	0	0.000000e+00	18382	0	0	0.000000e+00	21646	0	0	0.000000e+00	111412	0	46	3.825680e-03	12024	0	0	0.000000e+00	30616	0	0	174	1.144240e-03	170	4.105690e-03	41406	1	0	0.000000e+00	910	0	4	2.622950e-04	15250	0	152066	0	0.000000e+00	3468	0	0	0.000000e+00	5172	0	0	0.000000e+00	10588	0	0	0.000000e+00	316	0	0	0.000000e+00	68030	0	170	4.105690e-03	41406	1	0	0.000000e+00	4834	0	45	1.369950e-03	43	4.733600e-03	9084	0	0	0.000000e+00	60	0	2	4.280820e-04	4672	0	32848	0	0.000000e+00	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5466	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3114	0	0	.	1	173	1.170470e-03	169	4.113320e-03	41086	1	0	0.000000e+00	910	0	4	2.655690e-04	15062	0	147804	0	0.000000e+00	3298	0	0	0.000000e+00	4936	0	0	0.000000e+00	10588	0	0	0.000000e+00	304	0	0	0.000000e+00	64796	0	0	0.000000e+00	4802	0	1	141	1.046960e-03	137	4.221620e-03	32452	1	0	0.000000e+00	862	0	4	2.701970e-04	14804	0	134676	0	0.000000e+00	3384	0	0	0.000000e+00	5172	0	0	0.000000e+00	6950	0	0	0.000000e+00	310	0	0	0.000000e+00	63908	0	0	0.000000e+00	4832	0	1	115	1.426090e-03	112	4.519410e-03	24782	1	0	0.000000e+00	110	0	3	2.329550e-04	12878	0	80640	0	0.000000e+00	998	0	0	0.000000e+00	3732	0	0	0.000000e+00	10496	0	0	0.000000e+00	272	0	0	0.000000e+00	21048	0	0	0.000000e+00	4806	0	1	1	213890624	1	215824001	0	0.14033	0.487112	0.000000	0.06391	0.005000	0.06747	0.000000	0.01923	-0.656000	0.05441	-1.790000	0.00639	-5.047000	0.00040	215650659	C	.	rs112459877	.	.	10.244	6.640	0.368	10.766	.	.	.	21	-31	21	1	0.03	0.00	0.00	0.00	USH2A	0.00	exon-NM_206933.4-65+67+start+210	177913	Likely_benign	reviewed_by_expert_panel	Retinitis_pigmentosa_39&Usher_syndrome_type_2A&Retinitis_pigmentosa&not_provided&Usher_syndrome&not_specified	MONDO:MONDO:0013436&MedGen:C3151138&OMIM:613809&Orphanet:791&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886&Human_Phenotype_Ontology:HP:0000547&MONDO:MONDO:0019200&MeSH:D012174&MedGen:C0035334&OMIM:268000&OMIM:PS268000&Orphanet:791&MedGen:CN517202&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&MedGen:CN169374	.	rs112459877	3.212e-04	39	39	0	37	2	0	0	0	0	0	10380	11568	8640	6612	66674	908	16508	37	2	0	0	0	0	0	0	0	0	0	0	0	0	rs112459877	4.11711e-03	1.19140e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	1.41040e-04	4.31546e-04	4.11711e-03	2.72059e-04	rs112459877	4.47248e-03	1.20192e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	1.52421e-03	1.01567e-03	4.47248e-03	1.29066e-03	rs112459877	0.0&0.3404&0.1153	rs112459877	112459877	.	.	.	USH2A\x3bKCTD3	USH2A:exonic\x7cKCTD3:regulatory	USH2A:missense\x7cKCTD3:promoter_flanking_region	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,448	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	1	0	1	0	0	0	0.025	Likely Benign
16	68856080	68856080	C	G	G	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	12/16	.	NM_004360.5:c.1888C>G	NP_004351.1:p.Leu630Val	2012	1888	630	L/V	Cta/Gta	rs2276331&CM1414916&COSV55733235	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	TANGO6	.	chr16:g.68856080C>G	.	0	0	0.006	0	0	benign/likely_benign&likely_benign&benign	0&0&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.1888C>G	.	.	6	0.0011980830670926517	0	0.0	0	0.0	6	0.005952380952380952	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	C/C	C	T	0.11344	-0.273742	T	0.57934	-0.164621	22.9	24.1	2.713761	3.218469	0.45889	0.59969	C/C	T	0.17547	0.155679374954928	0.93191	0.99852676363635706	.	0.82563	.	C/C	.	.	.	.	5.15689	0.499793694615216	0.67979	5.985846	0.606079473970414	0.73557	.	.	.	46	3.789e-04	0	0	0	0	46	3.789e-04	46	5.315e-03	0	0	0	0	0	0	44	4.143e-04	0	0	0	0	44	4.143e-04	44	5.594e-03	0	0	0	0	0	0	37	4.077e-04	0	0	0	0	37	4.078e-04	37	6.563e-03	0	0	0	0	0	0	0.64445	.	.	.	5.68	3.39	0.37919	0	0.55848	0.633656	.	.	0.74766	0.999995010654109	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.26826	0.564101	Cadherin-like&Cadherin-like&.	.	.	.	0.41374	.	0.000000	0.39242	N	0.001368	D	0.85855	0.186122	0.58996	.	0.84661	.	T	0.75720	0.4079	.	0.00148	.	D	0.83518	0.0646	.	.	.	.	.	.	0.93830	.	.	0.52935	simple_aae&simple_aae	D&D	0.999965&0.999965	0.58085	.	.	.	0.73220	.	.	0.83170	.	T	0.47166	0.559275627136	0.66676	.	10	0.70582	.	.	0.78490	.	.	13.2827	0.59658	0.0:0.8481:0.0:0.1519	.	.	.	.	.	.	.	.	0.62103	.	C/C	V	.	L	G	334	0.86273	.	16	C0677776&C0006142&C1708349&C0027672&CN169374&CN221562&CN517202	PS604370&137215	ORPHA145&ORPHA26106&ORPHA140162	Benign	NC_000016.10:g.68822177C>G	133846	reviewed_by_expert_panel	Hereditary_breast_and_ovarian_cancer_syndrome&Malignant_tumor_of_breast&Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&Breast_and/or_ovarian_cancer&not_provided	Illumina_Laboratory_Services&Illumina:943952&ClinGen_CDH1_Variant_Curation_Expert_Panel&:98319533-e1cd-4555-9251-571e07d52e56&UniProtKB_(protein):P12830#VAR_021868	.	.	AEFBI	D	0.70589	0.96722	D	0.63546	0.667276	.	95	3.777760e-04	0	0.000000e+00	16256	0	0	0.000000e+00	34592	0	251472	0	0.000000e+00	10080	0	91	4.947270e-03	18394	0	0	0.000000e+00	21648	0	0	0.000000e+00	113748	0	91	4.947270e-03	18394	0	1	3.266270e-05	30616	0	52	4.752850e-04	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	0	0.000000e+00	2320	0	49	5.416760e-03	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	49	5.416760e-03	9046	0	1	6.373490e-05	15690	0	0	.	0	93	3.925140e-04	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236934	0	0.000000e+00	9572	0	89	5.030520e-03	17692	0	0	0.000000e+00	21632	0	0	0.000000e+00	102732	0	89	5.030520e-03	17692	0	1	3.275900e-05	30526	0	0	78	3.747660e-04	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208130	0	0.000000e+00	6212	0	74	5.515800e-03	13416	0	0	0.000000e+00	16734	0	0	0.000000e+00	89554	0	74	5.515800e-03	13416	0	1	3.267120e-05	30608	0	0	95	3.879860e-04	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244854	0	0.000000e+00	9998	0	91	4.948340e-03	18390	0	0	0.000000e+00	21646	0	0	0.000000e+00	111658	0	91	4.948340e-03	18390	0	1	3.266270e-05	30616	0	0	24	1.577450e-04	0	0.000000e+00	41434	0	0	0.000000e+00	912	0	0	0.000000e+00	15256	0	152144	0	0.000000e+00	3472	0	24	4.620720e-03	5194	0	0	0.000000e+00	10612	0	0	0.000000e+00	316	0	0	0.000000e+00	68030	0	24	4.620720e-03	5194	0	0	0.000000e+00	4826	0	9	2.737560e-04	0	0.000000e+00	9088	0	0	0.000000e+00	60	0	0	0.000000e+00	4680	0	32876	0	0.000000e+00	136	0	9	3.703700e-03	2430	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3110	0	0	.	0	24	1.622780e-04	0	0.000000e+00	41114	0	0	0.000000e+00	912	0	0	0.000000e+00	15068	0	147894	0	0.000000e+00	3302	0	24	4.838710e-03	4960	0	0	0.000000e+00	10612	0	0	0.000000e+00	304	0	0	0.000000e+00	64806	0	0	0.000000e+00	4794	0	0	24	1.781290e-04	0	0.000000e+00	32464	0	0	0.000000e+00	862	0	0	0.000000e+00	14810	0	134734	0	0.000000e+00	3388	0	24	4.620720e-03	5194	0	0	0.000000e+00	6972	0	0	0.000000e+00	310	0	0	0.000000e+00	63908	0	0	0.000000e+00	4824	0	0	17	2.106460e-04	0	0.000000e+00	24810	0	0	0.000000e+00	112	0	0	0.000000e+00	12882	0	80704	0	0.000000e+00	998	0	17	4.530920e-03	3752	0	0	0.000000e+00	10520	0	0	0.000000e+00	272	0	0	0.000000e+00	21042	0	0	0.000000e+00	4798	0	0	16	67413581	16	68856080	0	0.73137	0.706548	0.332000	0.25606	0.951000	0.49849	0.817000	0.34044	1.203000	0.31890	0.589000	0.31548	0.120000	0.17403	68822177	C	.	rs2276331	.	.	8.251	4.820	10.720	9.332	.	.	.	-5	48	48	11	0.00	0.00	0.02	0.00	CDH1	0.34	exon-NM_001317185.2-12+48+end+225	133846	Benign	reviewed_by_expert_panel	Breast_and/or_ovarian_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Hereditary_breast_ovarian_cancer_syndrome&Hereditary_diffuse_gastric_adenocarcinoma&Malignant_tumor_of_breast	MedGen:CN221562&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&OMIM:PS604370&Orphanet:145&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&MONDO:MONDO:0007254&MedGen:C0006142	.	rs2276331	3.789e-04	46	46	0	0	0	46	0	0	0	0	10404	11576	8654	6614	66732	908	16512	0	0	46	0	0	0	0	0	0	0	0	0	0	0	rs2276331	0.00000e+00	0.00000e+00	0.00000e+00	5.27597e-03	0.00000e+00	0.00000e+00	5.47046e-04	3.24865e-05	3.33590e-04	4.49018e-04	5.27597e-03	3.85752e-04	rs2276331	0.00000e+00	0.00000e+00	0.00000e+00	4.32633e-03	0.00000e+00	0.00000e+00	0.00000e+00	.	4.08974e-04	0.00000e+00	4.32633e-03	2.25865e-04	.	.	rs2276331	2276331	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,915	0	0	0	0	0	0	1	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0.025	Likely Benign
19	4099271	4099271	C	A	A	missense_variant	MODERATE	MAP2K2	5605	Transcript	NM_030662.4	protein_coding	7/11	.	NM_030662.4:c.847G>T	NP_109587.1:p.Val283Leu	1094	847	283	V/L	Gtg/Ttg	rs185999703&COSV53565961	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MAP2K2	.	chr19:g.4099271C>A	.	0	0	0.001	0	0	likely_benign	0&1	1&1	.	.	.	.	.	.	.	.	1	1.9968051118210862E-4	0	0.0	0	0.0	1	9.92063492063492E-4	0	0.0	0	0.0	.	.	.	.	.	.	.	.	.	./.	C	T	0.00754	-0.478588	T	0.15860	-0.565551	2.972	9.195	0.186600	0.478197	0.05816	0.10519	./.	T	0.00100	0.00830511474316121	0.08710	0.6860731852395956	.	0.43158	.	./.	.	.	.	.	0.2961115	-1.18444421882303	0.06169	0.2378098	-1.1849417590001	0.05227	.	.	.	6	4.964e-05	0	0	0	0	6	7.827e-05	6	1.030e-03	0	0	0	0	0	0	6	5.657e-05	0	0	0	0	6	8.928e-05	6	1.131e-03	0	0	0	0	0	0	1	1.108e-05	0	0	0	0	1	1.720e-05	1	2.453e-04	0	0	0	0	0	0	0.64264	.	.	.	4.44	-2.13	0.06745	0	0.74545	0.702456	.	.	0.28783	0.964766850092186	.	0	0.80598	0.723109	.	.	.	.	.	.	0	0.83352	0.714379	Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain&Protein_kinase_domain	.	.	.	0.53298	.	0.529744	0.19110	N	0.118552	D	0.61084	0.043639	0.43623	.	0.35779	.	T	0.32527	0.0828	.	0.04033	.	T	0.26259	-1.0121	.	.	.	.	.	.	0.04745	.	.	0.31743	simple_aae&simple_aae	D&N	0.501252&0.960498	0.12099	.	.	.	0.07471	.	.	0.08700	.	T	0.02352	0.234919920564	0.09122	.	10	0.15890	.	.	0.10311	.	.	7.0213	0.24095	0.0:0.5382:0.2677:0.1941	.	.	.	.	.	.	.	.	0.38129	.	./.	L	.	V	A	934	0.15400	.	19	CN166718	.	ORPHA536391	Likely_benign	NC_000019.10:g.4099273C>A	448950	reviewed_by_expert_panel	Rasopathy	ClinGen_RASopathy_Variant_Curation_Expert_Panel:76be5ede-4c76-4fed-a94a-188c6bcea2f1	.	.	AEFDBI	N	0.24538	0.32248	N	0.45873	0.373477	.	13	5.606060e-05	0	0.000000e+00	14054	0	0	0.000000e+00	32918	0	231892	0	0.000000e+00	9604	0	12	6.968640e-04	17220	0	0	0.000000e+00	20196	0	1	9.701770e-06	103074	0	12	6.968640e-04	17220	0	0	0.000000e+00	29084	0	7	6.936600e-05	0	0.000000e+00	6012	0	0	0.000000e+00	16272	0	100914	0	0.000000e+00	2094	0	6	7.311720e-04	8206	0	0	0.000000e+00	12892	0	1	2.573870e-05	38852	0	6	7.311720e-04	8206	0	0	0.000000e+00	14812	0	0	segdup	0	13	5.884320e-05	0	0.000000e+00	12942	0	0	0.000000e+00	32664	0	220926	0	0.000000e+00	9242	0	12	7.209810e-04	16644	0	0	0.000000e+00	20184	0	1	1.053700e-05	94904	0	12	7.209810e-04	16644	0	0	0.000000e+00	29012	0	0	4	2.082050e-05	0	0.000000e+00	14016	0	0	0.000000e+00	28856	0	192118	0	0.000000e+00	5760	0	3	2.371540e-04	12650	0	0	0.000000e+00	15918	0	1	1.229890e-05	81308	0	3	2.371540e-04	12650	0	0	0.000000e+00	29078	0	0	13	5.734860e-05	0	0.000000e+00	10818	0	0	0.000000e+00	32814	0	226684	0	0.000000e+00	9536	0	12	6.970260e-04	17216	0	0	0.000000e+00	20194	0	1	9.866410e-06	101354	0	12	6.970260e-04	17216	0	0	0.000000e+00	29084	0	0	2	1.313970e-05	0	0.000000e+00	41476	0	0	0.000000e+00	912	0	0	0.000000e+00	15284	0	152210	0	0.000000e+00	3470	0	2	3.853560e-04	5190	0	0	0.000000e+00	10616	0	0	0.000000e+00	316	0	0	0.000000e+00	68024	0	2	3.853560e-04	5190	0	0	0.000000e+00	4832	0	2	6.077920e-05	0	0.000000e+00	9102	0	0	0.000000e+00	60	0	0	0.000000e+00	4686	0	32906	0	0.000000e+00	136	0	2	8.230450e-04	2430	0	0	0.000000e+00	5490	0	0	0.000000e+00	246	0	0	0.000000e+00	6852	0	0	0.000000e+00	3114	0	0	.	0	2	1.351720e-05	0	0.000000e+00	41154	0	0	0.000000e+00	912	0	0	0.000000e+00	15096	0	147960	0	0.000000e+00	3302	0	2	4.037140e-04	4954	0	0	0.000000e+00	10616	0	0	0.000000e+00	304	0	0	0.000000e+00	64802	0	0	0.000000e+00	4800	0	0	2	1.483770e-05	0	0.000000e+00	32496	0	0	0.000000e+00	862	0	0	0.000000e+00	14838	0	134792	0	0.000000e+00	3386	0	2	3.853560e-04	5190	0	0	0.000000e+00	6978	0	0	0.000000e+00	310	0	0	0.000000e+00	63900	0	0	0.000000e+00	4830	0	0	2	2.476290e-05	0	0.000000e+00	24850	0	0	0.000000e+00	112	0	0	0.000000e+00	12910	0	80766	0	0.000000e+00	996	0	2	5.336180e-04	3748	0	0	0.000000e+00	10524	0	0	0.000000e+00	272	0	0	0.000000e+00	21034	0	0	0.000000e+00	4804	0	0	19	4050271	19	4099271	0	0.73137	0.706548	0.002000	0.15269	0.123000	0.19290	0.447000	0.26422	0.017000	0.13294	0.549000	0.26987	-0.897000	0.02812	4099273	C	.	rs185999703	.	.	12.559	8.532	6.943	7.389	.	.	.	-19	26	-2	5	0.00	0.00	0.00	0.00	MAP2K2	0.86	exon-NM_030662.4-7+72+start+214	448950	Likely_benign	reviewed_by_expert_panel	RASopathy	MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391	.	19:4099271-4099271	4.964e-05	6	0	0	0	0	6	0	0	0	0	6002	6874	5824	3006	41594	552	12804	0	0	0	0	0	0	0	0	0	0	0	0	0	0	rs185999703	0.00000e+00	0.00000e+00	0.00000e+00	6.14402e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	3.97899e-05	4.88510e-05	6.14402e-04	5.68773e-05	rs185999703	0.00000e+00	0.00000e+00	0.00000e+00	6.18812e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	0.00000e+00	7.23275e-05	6.18812e-04	3.22664e-05	.	.	rs185999703	185999703	.	.	.	MAP2K2	MAP2K2:exonic	MAP2K2:missense	MAP2K2:Cardiofaciocutaneous_syndrome_4	MAP2K2:615280	MAP2K2:3	MAP2K2:Autosomal_dominant	0	0.86326115931858	0.136320885012997	0.00041795566842237	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,926	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	0.025	Likely Benign
1	215802242	215802242	C	T	T	missense_variant	MODERATE	USH2A	7399	Transcript	NM_206933.4	protein_coding	71/72	.	NM_206933.4:c.15433G>A	NP_996816.3:p.Val5145Ile	15872	15433	5145	V/I	Gtc/Atc	rs111033269&CM140609&COSV100244630	C	.	-1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	KCTD3	.	chr1:g.215802242C>T	.	0.0008	0.0014	0	0.0089	0	conflicting_interpretations_of_pathogenicity&benign/likely_benign&benign	0&0&1	1&1&1	.	.	.	.	.	USH2A&NM_206933.2&c.15433G>A	.	.	11	0.002196485623003195	1	7.564296520423601E-4	1	0.001440922190201729	0	0.0	9	0.008946322067594433	0	0.0	15	0.0038920601971977166	.	.	.	.	.	.	.	C/C	C	T	0.00242	-0.563528	T	0.14803	-0.577118	14.89	17.73	1.371033	1.736597	0.19991	0.27873	C/C	T	0.00451	0.017035458494158	0.42496	0.98523738406389039	.	0.32531	.	C/C	5	0.0011348161597821154	48	0.005581395348837209	2.351521	-0.00223619953549114	0.39616	2.401022	-0.0315070023610768	0.40433	.	.	.	382	3.146e-03	10	9.610e-04	7	6.047e-04	382	3.146e-03	0	0	49	7.409e-03	312	4.675e-03	2	1.211e-04	312	2.938e-03	9	9.927e-04	7	6.242e-04	312	2.938e-03	0	0	49	7.409e-03	243	4.471e-03	2	1.219e-04	234	2.578e-03	10	9.626e-04	7	6.053e-04	234	2.579e-03	0	0	32	8.417e-03	181	4.295e-03	2	1.212e-04	0.57261	.	.	.	5.67	3.75	0.42236	0	0.26702	0.573888	.	.	0.17854	0.179707470681396	.	0	0.19857	0.573078	.	.	.	.	.	.	0	0.26826	0.564101	.	.	.	.	0.34443	.	0.000000	0.36462	U	0.002492	D	0.91996	0.340279	0.03379	.	0.57531	.	T	0.38243	0.1042	.	0.00219	.	T	0.54158	-0.8164	.	.	.	.	.	.	0.66631	.	.	0.35059	simple_aae&simple_aae	D&D	0.840491&0.840491	0.16799	.	.	.	0.38185	.	.	0.24832	.	T	0.10622	0.301490783691	0.34673	.	10	0.51421	.	.	0.45393	.	.	12.0271	0.52672	0.0:0.8705:0.0:0.1295	.	18	0.0048543689320388345	33	0.004363924887595874	.	.	.	0.25499	.	C/C	I	.	V	T	683	0.59664	.	1	C0035334&C1848634&C0271097&CN169374&CN517202	268000&PS268000&276901&PS276900	ORPHA791&ORPHA886	Benign	NC_000001.11:g.215628900C>T	48464	reviewed_by_expert_panel	Retinitis_pigmentosa&Usher_syndrome&_type_2A&Usher_syndrome&not_specified&not_provided	UniProtKB_(protein):O75445#VAR_072066&ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:90056	.	.	AEFBI	D	0.55171	0.92201	N	0.46883	0.389731	.	789	3.137550e-03	12	7.381890e-04	16256	0	19	5.492920e-04	34590	0	251470	0	0.000000e+00	10080	0	0	0.000000e+00	18386	0	167	7.714340e-03	21648	1	572	5.028390e-03	113754	3	572	5.028390e-03	113754	3	4	1.306510e-04	30616	0	373	3.409440e-03	8	1.116690e-03	7164	0	10	5.843850e-04	17112	0	109402	0	0.000000e+00	2320	0	0	0.000000e+00	9040	0	109	8.137970e-03	13394	1	236	5.518140e-03	42768	3	236	5.518140e-03	42768	3	3	1.912050e-04	15690	0	4	.	4	728	3.072610e-03	10	6.710510e-04	14902	0	19	5.546150e-04	34258	0	236932	0	0.000000e+00	9572	0	0	0.000000e+00	17684	0	167	7.720040e-03	21632	1	513	4.993280e-03	102738	3	513	4.993280e-03	102738	3	4	1.310360e-04	30526	0	4	648	3.113530e-03	12	7.399190e-04	16218	0	16	5.242120e-04	30522	0	208124	0	0.000000e+00	6212	0	0	0.000000e+00	13408	0	142	8.485720e-03	16734	1	462	5.158780e-03	89556	3	462	5.158780e-03	89556	3	4	1.306850e-04	30608	0	4	776	3.169260e-03	7	5.820720e-04	12026	0	19	5.514280e-04	34456	0	244852	0	0.000000e+00	9998	0	0	0.000000e+00	18382	0	167	7.715050e-03	21646	1	565	5.059820e-03	111664	3	565	5.059820e-03	111664	3	4	1.306510e-04	30616	0	4	555	3.648150e-03	43	1.038050e-03	41424	0	0	0.000000e+00	912	0	18	1.178320e-03	15276	0	152132	1	2.880180e-04	3472	0	0	0.000000e+00	5176	0	93	8.763660e-03	10612	0	0	0.000000e+00	316	0	394	5.791900e-03	68026	0	394	5.791900e-03	68026	0	1	2.071250e-04	4828	0	116	3.528200e-03	12	1.319840e-03	9092	0	0	0.000000e+00	60	0	6	1.282050e-03	4680	0	32878	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	57	1.040150e-02	5480	0	0	0.000000e+00	246	0	41	5.981910e-03	6854	0	0	0.000000e+00	3112	0	0	.	0	539	3.644850e-03	41	9.975180e-04	41102	0	0	0.000000e+00	912	0	18	1.193000e-03	15088	0	147880	1	3.028470e-04	3302	0	0	0.000000e+00	4942	0	93	8.763660e-03	10612	0	0	0.000000e+00	304	0	380	5.864020e-03	64802	0	1	2.085070e-04	4796	0	0	487	3.614740e-03	39	1.201550e-03	32458	0	0	0.000000e+00	862	0	18	1.213760e-03	14830	0	134726	1	2.951590e-04	3388	0	0	0.000000e+00	5176	0	68	9.756100e-03	6970	0	0	0.000000e+00	310	0	355	5.555030e-03	63906	0	1	2.072110e-04	4826	0	0	281	3.482380e-03	25	1.008060e-03	24800	0	0	0.000000e+00	112	0	17	1.317630e-03	12902	0	80692	1	1.002000e-03	998	0	0	0.000000e+00	3734	0	93	8.840300e-03	10520	0	0	0.000000e+00	272	0	142	6.749690e-03	21038	0	1	2.083330e-04	4800	0	0	1	213868865	1	215802242	0	0.14033	0.487112	0.990000	0.36992	0.914000	0.44937	0.896000	0.37424	2.729000	0.46998	0.549000	0.26987	0.126000	0.18019	215628900	C	.	rs111033269	.	.	6.582	10.098	5.283	8.351	.	.	.	1	18	18	1	0.09	0.03	0.00	0.00	USH2A	0.00	exon-NM_206933.4-71+86+start+222	48464	Benign	reviewed_by_expert_panel	Usher_syndrome&not_specified&Retinitis_pigmentosa_39&Usher_syndrome_type_2A&not_provided&Retinitis_pigmentosa	MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&MedGen:CN169374&MONDO:MONDO:0013436&MedGen:C3151138&OMIM:613809&Orphanet:791&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886&MedGen:CN517202&Human_Phenotype_Ontology:HP:0000547&MONDO:MONDO:0019200&MeSH:D012174&MedGen:C0035334&OMIM:268000&OMIM:PS268000&Orphanet:791	.	1:215802243-215802246	3.146e-03	382	1	2	10	7	0	49	312	2	2	10406	11576	8650	6614	66740	908	16512	0	0	0	0	0	0	1	0	0	0	1	1	0	0	rs111033269	7.18766e-04	5.65813e-04	0.00000e+00	0.00000e+00	7.30942e-03	5.00430e-03	1.82282e-03	1.29946e-04	3.11342e-03	3.10743e-03	7.30942e-03	3.11038e-03	rs111033269	5.73000e-04	0.00000e+00	0.00000e+00	0.00000e+00	1.03034e-02	6.60088e-03	3.05499e-03	.	4.26452e-03	5.05634e-03	1.03034e-02	4.67863e-03	rs111033269	0.5581&0.1135&0.4075	rs111033269	111033269	.	.	.	USH2A	USH2A:exonic	USH2A:missense	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,445	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0.0122	Likely Benign
10	112771421	112771421	A	G	G	missense_variant	MODERATE	SHOC2	8036	Transcript	NM_007373.4	protein_coding	9/9	.	NM_007373.4:c.1594A>G	NP_031399.2:p.Ser532Gly	1882	1594	532	S/G	Agc/Ggc	rs145463534	A	.	1	.	.	EntrezGene	.	.	.	.	A	A	.	.	ADRA2A	.	chr10:g.112771421A>G	.	0.0151	0.0029	0	0	0	benign	.	1	.	.	.	.	.	SHOC2&NM_007373.3&c.1594A>G	.	.	22	0.00439297124600639	20	0.015128593040847202	2	0.002881844380403458	0	0.0	0	0.0	0	0.0	0	0.0	.	.	.	.	.	.	.	A/A	A	T	0.03242	-0.377256	T	0.44339	-0.303647	22.6	20.3	2.596143	2.056922	0.43347	0.34125	A/A	T	0.08037	0.0657177113208847	0.64325	0.99432530816552267	.	0.71615	.	A/A	63	0.014298683613254653	0	0.0	3.00453	0.162282201234886	0.47797	3.026947	0.135026737572326	0.48102	.	.	.	145	1.194e-03	138	1.327e-02	6	5.185e-04	145	1.195e-03	0	0	0	0	0	0	1	6.056e-05	131	1.233e-03	125	1.379e-02	5	4.460e-04	131	1.234e-03	0	0	0	0	0	0	1	6.095e-05	145	1.598e-03	138	1.329e-02	6	5.190e-04	145	1.598e-03	0	0	0	0	0	0	1	6.060e-05	0.84487	.	.	.	5.42	1.35	0.21078	0	0.89359	0.724815	.	.	0.17938	0.186028649154384	.	0	0.75317	0.709663	.	.	.	.	.	.	0	0.83352	0.714379	.&.&.	.	.	.	0.52486	.	0.147864	0.84330	N	0.000000	.	.	.	0.61366	.	0.69708	.	T	0.78372	0.4485	.	0.00227	.	T	0.74136	-0.3299	.	.	.	.	.	.	0.21358	.	.	0.54805	simple_aae&simple_aae	D&D	0.99998&0.99998	0.41428	.	.	.	0.54400	.	.	0.65201	.	T	0.68731	0.710955798626	0.33800	.	10	0.40909	.	.	0.26409	.	.	7.2249	0.25185	0.7237:0.1256:0.1507:0.0	.	1	2.6968716289104636E-4	1	1.322401481089659E-4	.	.	.	0.22098	.	A/A	G	.	S	G	914	0.21048	.	10	CN260604&CN166718&C4478716&CN169374	607721	ORPHA98733&ORPHA536391	Benign	NC_000010.11:g.111011663A>G	139110	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Rasopathy&Noonan_syndrome-like_disorder_with_loose_anagen_hair_1&not_specified	Illumina_Laboratory_Services&Illumina:746977&ClinGen_RASopathy_Variant_Curation_Expert_Panel:1bcfceba-23f2-4e97-8281-791f9602856c	.	.	AEFBI	D	0.62546	0.94850	D	0.57335	0.567976	.	226	8.987940e-04	204	1.255080e-02	16254	1	16	4.625610e-04	34590	0	251448	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	0	0.000000e+00	21644	0	0	0.000000e+00	113730	0	204	1.255080e-02	16254	1	2	6.532530e-05	30616	0	97	8.866540e-04	87	1.214410e-02	7164	0	5	2.921930e-04	17112	0	109400	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13390	0	0	0.000000e+00	42764	0	87	1.214410e-02	7164	0	2	1.274700e-04	15690	0	0	.	1	212	8.948470e-04	192	1.288420e-02	14902	1	15	4.378540e-04	34258	0	236912	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	0	0.000000e+00	21628	0	0	0.000000e+00	102714	0	192	1.288420e-02	14902	1	2	6.551790e-05	30526	0	1	224	1.076320e-03	204	1.258020e-02	16216	1	14	4.586860e-04	30522	0	208116	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	0	0.000000e+00	16730	0	0	0.000000e+00	89546	0	204	1.258020e-02	16216	1	2	6.534240e-05	30608	0	1	171	6.984440e-04	149	1.239190e-02	12024	1	16	4.643600e-04	34456	0	244830	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	0	0.000000e+00	21642	0	0	0.000000e+00	111640	0	149	1.239190e-02	12024	1	2	6.532530e-05	30616	0	1	594	3.903680e-03	575	1.387410e-02	41444	5	0	0.000000e+00	912	0	15	9.825760e-04	15266	0	152164	0	0.000000e+00	3472	0	0	0.000000e+00	5196	0	0	0.000000e+00	10608	0	0	0.000000e+00	316	0	0	0.000000e+00	68024	0	575	1.387410e-02	41444	5	0	0.000000e+00	4832	0	155	4.712110e-03	148	1.626730e-02	9098	1	0	0.000000e+00	60	0	7	1.493810e-03	4686	0	32894	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	0	0.000000e+00	6850	0	0	0.000000e+00	3112	0	1	.	5	588	3.975550e-03	570	1.386120e-02	41122	5	0	0.000000e+00	912	0	14	9.285050e-04	15078	0	147904	0	0.000000e+00	3302	0	0	0.000000e+00	4962	0	0	0.000000e+00	10608	0	0	0.000000e+00	304	0	0	0.000000e+00	64792	0	0	0.000000e+00	4800	0	5	478	3.546940e-03	459	1.413090e-02	32482	4	0	0.000000e+00	862	0	15	1.012150e-03	14820	0	134764	0	0.000000e+00	3388	0	0	0.000000e+00	5196	0	0	0.000000e+00	6972	0	0	0.000000e+00	310	0	0	0.000000e+00	63900	0	0	0.000000e+00	4830	0	4	360	4.459420e-03	345	1.390120e-02	24818	2	0	0.000000e+00	112	0	12	9.308100e-04	12892	0	80728	0	0.000000e+00	998	0	0	0.000000e+00	3754	0	0	0.000000e+00	10516	0	0	0.000000e+00	272	0	0	0.000000e+00	21042	0	0	0.000000e+00	4804	0	2	10	112761411	10	112771421	0	0.61202	0.706298	1.000000	0.71638	0.997000	0.79791	0.995000	0.57719	6.232000	0.72264	0.756000	0.94297	0.323000	0.28620	111011663	A	.	rs145463534	.	.	.	.	10.475	5.239	.	.	.	15	-45	34	45	0.00	0.00	0.00	0.00	SHOC2	0.99	exon-NM_001324336.2-9+53+start+2056	139110	Benign	reviewed_by_expert_panel	Noonan_syndrome_and_Noonan-related_syndrome&Cardiovascular_phenotype&not_specified&RASopathy&Noonan_syndrome-like_disorder_with_loose_anagen_hair_1	MONDO:MONDO:0020297&MedGen:CN260604&Orphanet:98733&MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0054637&MedGen:C4478716&OMIM:607721&Orphanet:2701	.	rs145463534	1.194e-03	145	143	1	138	6	0	0	0	0	1	10402	11572	8650	6614	66730	908	16512	136	6	0	0	0	0	1	1	0	0	0	0	0	0	rs145463534	1.28725e-02	4.46694e-04	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	9.12076e-04	6.49730e-05	6.22785e-04	1.21252e-03	1.28725e-02	8.89261e-04	rs145463534	1.34113e-02	2.38663e-03	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	0.00000e+00	.	3.79984e-03	3.90004e-03	1.34113e-02	3.83970e-03	rs145463534	0.0&1.4299&0.4844	rs145463534	145463534	.	.	.	SHOC2	SHOC2:exonic	SHOC2:missense	SHOC2:Noonan_syndrome-like_with_loose_anagen_hair_1	SHOC2:607721	SHOC2:3	SHOC2:Autosomal_dominant	0	0.991705191552454	0.00829295945769003	1.84898985615785e-06	DISEASE: Noonan syndrome-like disorder with loose anagen hair (NSLH) [MIM:607721]: A syndrome characterized by Noonan dysmorphic features such as macrocephaly, high forehead, hypertelorism, palpebral ptosis, low-set and posteriorly rotated ears, short and webbed neck, pectus anomalies, in association with pluckable, sparse, thin and slow-growing hair. {ECO:0000269|PubMed:19684605, ECO:0000269|PubMed:25137548}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,608	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	1	0	1	0	0	0	0.0059	Likely Benign
16	68842668	68842668	G	A	A	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	5/16	.	NM_004360.5:c.604G>A	NP_004351.1:p.Val202Ile	728	604	202	V/I	Gtt/Att	rs546716073&CM173860	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68842668G>A	.	0	0	0	0	0.0102	likely_benign&benign	.	1&1	.	.	.	.	.	CDH1&NM_004360.3&c.604G>A	.	.	10	0.001996805111821086	0	0.0	0	0.0	0	0.0	0	0.0	10	0.010224948875255624	.	.	.	.	.	.	.	.	.	G/G	G	T	0.00268	-0.55598	T	0.15129	-0.573509	15.00	11.46	1.388007	0.738228	0.20234	0.13658	G/G	T	0.00138	0.0101868961104255	0.11017	0.75287668789251339	.	0.54866	.	G/G	.	.	.	.	0.9741635	-0.648638157818732	0.18251	0.8079259	-0.702824528240361	0.15941	.	.	.	72	5.930e-04	0	0	1	8.672e-05	72	5.940e-04	7	8.102e-04	0	0	0	0	64	3.884e-03	71	6.685e-04	0	0	1	8.951e-05	71	6.694e-04	6	7.636e-04	0	0	0	0	64	3.909e-03	68	7.493e-04	0	0	1	8.681e-05	68	7.508e-04	3	5.327e-04	0	0	0	0	64	3.886e-03	0.51228	.	.	.	5.78	1.44	0.21647	0	0.40923	0.588066	.	.	0.33298	0.993649962533811	.	0	0.82415	0.723133	.	.	.	.	.	.	0	0.10902	0.530356	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&.	.	.	.	0.30359	.	1.128060	0.06769	N	0.800996	.	.	.	0.24033	.	0.45810	.	T	0.40122	0.1120	.	0.00188	.	T	0.37094	-0.9705	V202I	Loss_of_catalytic_residue_at_V202_(P_=_0.0468)&_Loss_of_loop_(P_=_0.1242)&_Loss_of_phosphorylation_at_T199_(P_=_0.1547)&_Gain_of_helix_(P_=_0.2059)&_Gain_of_relative_solvent_accessibility_(P_=_0.2363)	P12830	0.47336	0.427	.	0.36993	.	.	0.08975	simple_aae&simple_aae	N&N	1&1	0.22294	.	.	.	0.27621	.	.	0.28220	.	T	0.07539	0.280337691307	0.18567	.	10	0.31125	.	.	0.27663	.	.	11.8471	0.51667	0.065:0.3425:0.5925:0.0	.	.	.	.	.	.	.	.	0.18103	.	G/G	I	.	V	A	315	0.87208	.	16	C1708349&C0027672&CN169374&CN517202	137215	ORPHA26106&ORPHA140162	Benign	NC_000016.10:g.68808765G>A	133853	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:685869&ClinGen_CDH1_Variant_Curation_Expert_Panel&:4f56b139-4c6b-4107-aebc-4368f6c6f68b&Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2534595	.	.	AEFDBHCI	N	0.21955	0.23069	N	0.35857	0.236063	.	126	5.015720e-04	0	0.000000e+00	16252	0	1	2.891840e-05	34580	0	251210	0	0.000000e+00	10068	0	14	7.611180e-04	18394	0	0	0.000000e+00	21644	0	0	0.000000e+00	113536	0	110	3.594070e-03	30606	1	110	3.594070e-03	30606	1	66	6.033460e-04	0	0.000000e+00	7162	0	0	0.000000e+00	17108	0	109390	0	0.000000e+00	2320	0	5	5.527300e-04	9046	0	0	0.000000e+00	13390	0	0	0.000000e+00	42766	0	60	3.825550e-03	15684	1	60	3.825550e-03	15684	1	1	.	1	125	5.281480e-04	0	0.000000e+00	14900	0	1	2.919880e-05	34248	0	236676	0	0.000000e+00	9560	0	13	7.347950e-04	17692	0	0	0.000000e+00	21628	0	0	0.000000e+00	102522	0	110	3.604670e-03	30516	1	110	3.604670e-03	30516	1	1	119	5.718790e-04	0	0.000000e+00	16214	0	1	3.276970e-05	30516	0	208086	0	0.000000e+00	6210	0	7	5.217650e-04	13416	0	0	0.000000e+00	16730	0	0	0.000000e+00	89538	0	110	3.595010e-03	30598	1	110	3.595010e-03	30598	1	1	126	5.151390e-04	0	0.000000e+00	12022	0	1	2.902930e-05	34448	0	244594	0	0.000000e+00	9986	0	14	7.612830e-04	18390	0	0	0.000000e+00	21642	0	0	0.000000e+00	111446	0	110	3.594070e-03	30606	1	110	3.594070e-03	30606	1	1	21	1.379870e-04	0	0.000000e+00	41452	0	0	0.000000e+00	912	0	0	0.000000e+00	15266	0	152188	0	0.000000e+00	3472	0	1	1.923080e-04	5200	0	0	0.000000e+00	10616	0	0	0.000000e+00	316	0	0	0.000000e+00	68032	0	19	3.933750e-03	4830	0	19	3.933750e-03	4830	0	15	4.560380e-04	0	0.000000e+00	9096	0	0	0.000000e+00	60	0	0	0.000000e+00	4682	0	32892	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5486	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	15	4.816960e-03	3114	0	0	.	0	21	1.419530e-04	0	0.000000e+00	41130	0	0	0.000000e+00	912	0	0	0.000000e+00	15080	0	147936	0	0.000000e+00	3302	0	1	2.013690e-04	4966	0	0	0.000000e+00	10616	0	0	0.000000e+00	304	0	0	0.000000e+00	64806	0	19	3.959980e-03	4798	0	0	21	1.558050e-04	0	0.000000e+00	32484	0	0	0.000000e+00	862	0	0	0.000000e+00	14820	0	134784	0	0.000000e+00	3388	0	1	1.923080e-04	5200	0	0	0.000000e+00	6976	0	0	0.000000e+00	310	0	0	0.000000e+00	63914	0	19	3.935380e-03	4828	0	0	21	2.600810e-04	0	0.000000e+00	24826	0	0	0.000000e+00	112	0	0	0.000000e+00	12892	0	80744	0	0.000000e+00	998	0	1	2.660990e-04	3758	0	0	0.000000e+00	10524	0	0	0.000000e+00	272	0	0	0.000000e+00	21042	0	19	3.956680e-03	4802	0	0	16	67400169	16	68842668	0	0.83141	0.719381	0.011000	0.18532	0.359000	0.25863	0.281000	0.23702	1.621000	0.36597	-0.148000	0.12190	-0.188000	0.09920	68808765	G	.	rs546716073	.	.	8.533	8.591	10.585	7.101	.	.	.	23	1	-48	41	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-5+72+start+156	133853	Benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Hereditary_diffuse_gastric_adenocarcinoma	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	16:68842668-68842668	5.930e-04	72	70	1	0	1	7	0	0	0	64	10372	11532	8640	6608	66668	908	16478	0	1	7	0	0	0	62	0	0	0	0	0	0	1	rs546716073	0.00000e+00	2.97885e-05	0.00000e+00	8.11688e-04	0.00000e+00	0.00000e+00	1.82415e-04	3.54218e-03	5.71530e-04	4.31468e-04	3.54218e-03	5.07573e-04	rs546716073	0.00000e+00	0.00000e+00	0.00000e+00	6.18047e-04	0.00000e+00	0.00000e+00	0.00000e+00	.	0.00000e+00	7.21605e-05	6.18047e-04	3.22664e-05	.	.	rs546716073	546716073	.	.	.	CDH1\x3bTANGO6	CDH1:exonic\x7cTANGO6:regulatory	CDH1:missense\x7cTANGO6:CTCF_binding_site	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,895	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	1	0	1	0	0	0	0.0059	Likely Benign
16	68847375	68847375	G	A	A	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	9/16	.	NM_004360.5:c.1297G>A	NP_004351.1:p.Asp433Asn	1421	1297	433	D/N	Gat/Aat	rs199886166&CM110011&COSV55730580	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68847375G>A	.	.	.	.	.	.	likely_benign&uncertain_significance	0&0&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.1297G>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	G/G	G	T	0.01203	-0.445335	T	0.08831	-0.651768	18.80	16.08	1.940728	1.466139	0.29436	0.23359	G/G	T	0.13181	0.10768707473738	0.58043	0.99284438086424698	.	0.68407	.	G/G	.	.	.	.	1.479346	-0.342354599466361	0.26746	1.312073	-0.433124959417186	0.24316	.	.	.	3	2.471e-05	0	0	0	0	3	2.471e-05	1	1.156e-04	0	0	2	2.997e-05	0	0	2	1.883e-05	0	0	0	0	2	1.883e-05	1	1.271e-04	0	0	1	1.840e-05	0	0	3	3.306e-05	0	0	0	0	3	3.306e-05	1	1.774e-04	0	0	2	4.746e-05	0	0	0.37405	.	.	.	5.82	2.84	0.32241	0	0.79440	0.708844	.	.	0.15605	0.0725752720105101	.	0	0.68683	0.702456	.	.	.	.	.	.	0	0.26826	0.564101	Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like&Cadherin-like	.	.	.	0.34400	.	0.684158	0.13033	N	0.408144	T	0.34475	0.014389	0.29848	.	0.75922	.	T	0.23300	0.0552	.	0.22511	.	T	0.19236	-1.0338	.	.	.	.	.	.	0.23481	.	.	0.22526	simple_aae&without_aae	N&N	1&0.997747	0.38734	.	.	.	0.27304	.	.	0.24256	.	T	0.11405	0.306680321693	0.26093	.	10	0.46182	.	.	0.32141	.	.	7.8077	0.28376	0.3867:0.0:0.6133:0.0	.	.	.	.	.	.	.	.	0.27316	.	G/G	N	.	D	A	315	0.87208	.	16	C1708349&C0027672&CN169374&CN517202	137215	ORPHA26106&ORPHA140162	Likely_benign	NC_000016.10:g.68813472G>A	127910	reviewed_by_expert_panel	Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided	ClinGen_CDH1_Variant_Curation_Expert_Panel&:f04175e5-9dd2-4137-8102-442c8b07c0d7	.	.	AEFGBI	D	0.45343	0.86121	N	0.42732	0.325875	.	13	5.169310e-05	0	0.000000e+00	16256	0	0	0.000000e+00	34592	0	251484	9	8.928570e-04	10080	0	2	1.087310e-04	18394	0	0	0.000000e+00	21648	0	2	1.758090e-05	113760	0	2	1.087310e-04	18394	0	0	0.000000e+00	30616	0	3	2.742030e-05	0	0.000000e+00	7164	0	0	0.000000e+00	17112	0	109408	3	1.293100e-03	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	0	0.000000e+00	42768	0	.	.	.	.	0	0.000000e+00	15690	0	0	.	0	12	5.064450e-05	0	0.000000e+00	14902	0	0	0.000000e+00	34260	0	236946	8	8.357710e-04	9572	0	2	1.130450e-04	17692	0	0	0.000000e+00	21632	0	2	1.946590e-05	102744	0	2	1.130450e-04	17692	0	0	0.000000e+00	30526	0	0	10	4.804640e-05	0	0.000000e+00	16218	0	0	0.000000e+00	30524	0	208132	7	1.126850e-03	6212	0	2	1.490760e-04	13416	0	0	0.000000e+00	16734	0	1	1.116620e-05	89556	0	2	1.490760e-04	13416	0	0	0.000000e+00	30608	0	0	13	5.309030e-05	0	0.000000e+00	12026	0	0	0.000000e+00	34458	0	244866	9	9.001800e-04	9998	0	2	1.087550e-04	18390	0	0	0.000000e+00	21646	0	2	1.790990e-05	111670	0	2	1.087550e-04	18390	0	0	0.000000e+00	30616	0	0	12	7.885710e-05	0	0.000000e+00	41438	0	0	0.000000e+00	912	0	1	6.547070e-05	15274	0	152174	7	2.017290e-03	3470	1	1	1.926780e-04	5190	0	0	0.000000e+00	10612	0	0	0.000000e+00	316	0	2	2.939270e-05	68044	0	1	1.926780e-04	5190	0	0	0.000000e+00	4828	0	1	3.040250e-05	0	0.000000e+00	9100	0	0	0.000000e+00	60	0	0	0.000000e+00	4688	0	32892	1	7.352940e-03	136	0	0	0.000000e+00	2428	0	0	0.000000e+00	5484	0	0	0.000000e+00	246	0	0	0.000000e+00	6854	0	0	0.000000e+00	3110	0	0	.	1	12	8.112600e-05	0	0.000000e+00	41116	0	0	0.000000e+00	912	0	1	6.628660e-05	15086	0	147918	7	2.121210e-03	3300	1	1	2.017760e-04	4956	0	0	0.000000e+00	10612	0	0	0.000000e+00	304	0	2	3.085660e-05	64816	0	0	0.000000e+00	4796	0	1	12	8.904320e-05	0	0.000000e+00	32470	0	0	0.000000e+00	862	0	1	6.744000e-05	14828	0	134766	7	2.067340e-03	3386	1	1	1.926780e-04	5190	0	0	0.000000e+00	6974	0	0	0.000000e+00	310	0	2	3.128910e-05	63920	0	0	0.000000e+00	4826	0	1	2	2.477330e-05	0	0.000000e+00	24816	0	0	0.000000e+00	112	0	0	0.000000e+00	12900	0	80732	1	1.004020e-03	996	0	0	0.000000e+00	3748	0	0	0.000000e+00	10520	0	0	0.000000e+00	272	0	0	0.000000e+00	21052	0	0	0.000000e+00	4800	0	0	16	67404876	16	68847375	0	0.52595	0.67177	1.000000	0.71638	0.718000	0.34707	0.862000	0.35736	3.888000	0.55917	0.672000	0.70159	1.172000	0.72986	68813472	G	.	rs199886166	.	.	10.239	7.806	7.382	7.312	.	.	.	19	-8	-10	32	0.00	0.00	0.00	0.00	CDH1	0.34	exon-NM_004360.5-9+23+end+183	127910	Likely_benign	reviewed_by_expert_panel	Hereditary_cancer-predisposing_syndrome&not_provided&not_specified&Hereditary_diffuse_gastric_adenocarcinoma	MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202&MedGen:CN169374&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106	.	16:68847375-68847375	2.471e-05	3	3	0	0	0	1	0	2	0	0	10406	11578	8654	6614	66738	908	16512	0	0	1	0	2	0	0	0	0	0	0	0	0	0	rs199886166	0.00000e+00	0.00000e+00	8.12183e-04	1.15955e-04	0.00000e+00	1.79035e-05	0.00000e+00	0.00000e+00	5.18903e-05	4.48986e-05	8.12183e-04	4.87266e-05	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	rs199886166	199886166	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,909	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	1	0	1	0	0	0	0.0059	Likely Benign
1	215799170	215799170	T	C	C	missense_variant	MODERATE	USH2A	7399	Transcript	NM_206933.4	protein_coding	72/72	.	NM_206933.4:c.15562A>G	NP_996816.3:p.Ser5188Gly	16001	15562	5188	S/G	Agc/Ggc	rs58257972&CM152985	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	KCTD3	.	chr1:g.215799170T>C	.	0	0.0072	0.0387	0.003	0.0777	benign	.	1&1	.	.	.	.	.	USH2A&NM_206933.2&c.15562A>G	.	.	123	0.02456070287539936	0	0.0	5	0.007204610951008645	39	0.03869047619047619	3	0.002982107355864811	76	0.07770961145194274	17	0.0044110015568240785	.	.	.	.	.	.	.	C/C	T	T	0.00824	-0.472138	T	0.35439	-0.382426	23.4	23.7	2.996418	3.046469	0.51963	0.55803	C/C	T	0.00996	0.022767670427268	0.74397	0.99604025306166655	.	0.41923	.	C/C	4	9.078529278256923E-4	29	0.003372093023255814	4.987552	0.48065607982663	0.66710	4.212758	0.378480076214184	0.60259	.	.	.	1633	1.345e-02	9	8.649e-04	26	2.247e-03	1633	1.345e-02	170	1.965e-02	16	2.421e-03	214	3.207e-03	1180	7.147e-02	1545	1.455e-02	7	7.721e-04	24	2.141e-03	1545	1.455e-02	150	1.907e-02	16	2.421e-03	167	3.074e-03	1167	7.113e-02	1510	1.664e-02	9	8.664e-04	26	2.249e-03	1510	1.664e-02	129	2.289e-02	9	2.371e-03	143	3.395e-03	1179	7.145e-02	0.44065	.	.	.	5.93	5.93	0.95888	0	0.26702	0.573888	.	.	0.26194	0.905040445356246	.	0	0.15389	0.547309	.	.	.	.	.	.	0	0.26826	0.564101	.	.	.	.	0.48098	.	0.000000	0.50451	U	0.000104	.	.	.	0.07269	.	.	.	T	0.07423	0.0179	.	0.00034	.	T	0.01613	-1.1337	.	.	.	.	.	.	0.75868	.	.	0.50595	simple_aae&simple_aae	D&D	0.999899&0.999872	0.40468	.	.	.	0.50336	.	.	0.41396	.	T	0.38018	0.494169771671	0.21907	.	10	0.63109	.	.	0.36310	.	.	16.3736	0.83208	0.0:0.0:0.0:1.0	.	17	0.004584681769147788	34	0.00449616503570484	.	.	.	0.12198	.	C/C	G	.	S	C	685	0.59416	.	1	C1848634&C0271097&CN169374&CN517202	276901&PS276900	ORPHA886	Benign	NC_000001.11:g.215625828T>C	48468	reviewed_by_expert_panel	Usher_syndrome&_type_2A&Usher_syndrome&not_specified&not_provided	UniProtKB_(protein):O75445#VAR_072067&ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:124169	.	.	AEFBI	D	0.71866	0.96956	D	0.75970	0.842606	.	3146	1.251230e-02	14	8.612200e-04	16256	0	60	1.734510e-03	34592	0	251432	1	9.920630e-05	10080	0	343	1.864740e-02	18394	4	65	3.002860e-03	21646	0	427	3.755100e-03	113712	3	2181	7.123730e-02	30616	90	2181	7.123730e-02	30616	90	1524	1.393050e-02	6	8.375210e-04	7164	0	32	1.870030e-03	17112	0	109400	0	0.000000e+00	2320	0	177	1.956670e-02	9046	1	37	2.762840e-03	13392	0	147	3.437630e-03	42762	1	1104	7.036330e-02	15690	47	1104	7.036330e-02	15690	47	49	.	97	3064	1.293410e-02	12	8.052610e-04	14902	0	59	1.722120e-03	34260	0	236894	1	1.044710e-04	9572	0	324	1.831340e-02	17692	3	65	3.005090e-03	21630	0	383	3.729450e-03	102696	3	2170	7.108690e-02	30526	87	2170	7.108690e-02	30526	87	93	2943	1.414140e-02	14	8.632380e-04	16218	0	49	1.605290e-03	30524	0	208112	1	1.609790e-04	6212	0	277	2.064700e-02	13416	3	45	2.689460e-03	16732	0	326	3.640910e-03	89538	3	2181	7.125590e-02	30608	90	2181	7.125590e-02	30608	90	96	3137	1.281380e-02	11	9.146850e-04	12026	0	60	1.741250e-03	34458	0	244814	1	1.000200e-04	9998	0	343	1.865140e-02	18390	4	65	3.003140e-03	21644	0	421	3.771660e-03	111622	3	2181	7.123730e-02	30616	90	2181	7.123730e-02	30616	90	97	918	6.032650e-03	46	1.109930e-03	41444	0	0	0.000000e+00	910	0	90	5.893140e-03	15272	1	152172	2	5.763690e-04	3470	0	151	2.907200e-02	5194	5	46	4.329820e-03	10624	0	1	3.164560e-03	316	0	233	3.424660e-03	68036	0	338	7.015360e-02	4818	18	338	7.015360e-02	4818	18	375	1.140370e-02	8	8.802820e-04	9088	0	0	0.000000e+00	58	0	43	9.168440e-03	4690	0	32884	1	7.352940e-03	136	0	63	2.592590e-02	2430	2	26	4.732440e-03	5494	0	0	0.000000e+00	246	0	18	2.626970e-03	6852	0	212	6.834300e-02	3102	8	10	.	24	889	6.009840e-03	45	1.094250e-03	41124	0	0	0.000000e+00	910	0	88	5.834000e-03	15084	1	147924	2	6.056940e-04	3302	0	146	2.943550e-02	4960	5	46	4.329820e-03	10624	0	1	3.289470e-03	304	0	219	3.379110e-03	64810	0	331	6.916010e-02	4786	16	22	895	6.641340e-03	41	1.262550e-03	32474	0	0	0.000000e+00	860	0	89	6.002970e-03	14826	1	134762	2	5.906670e-04	3386	0	151	2.907200e-02	5194	5	37	5.297820e-03	6984	0	0	0.000000e+00	310	0	227	3.551650e-03	63914	0	338	7.018270e-02	4816	18	24	664	8.225150e-03	25	1.007330e-03	24818	0	0	0.000000e+00	110	0	78	6.047450e-03	12898	0	80728	2	2.008030e-03	996	0	111	2.958420e-02	3752	4	46	4.367640e-03	10532	0	1	3.676470e-03	272	0	55	2.613320e-03	21046	0	338	7.056370e-02	4790	18	22	1	213865793	1	215799170	0	0.14033	0.487112	1.000000	0.71638	0.981000	0.58702	1.000000	0.86279	5.553000	0.66992	0.609000	0.47794	1.138000	0.64695	215625828	T	.	rs58257972	.	.	.	.	6.582	10.098	.	.	.	42	-34	-43	-5	0.00	0.00	0.00	0.00	USH2A	0.00	exon-NM_206933.4-72+42+end+2980	48468	Benign	reviewed_by_expert_panel	Retinitis_pigmentosa_39&Usher_syndrome_type_2A&not_specified&Usher_syndrome&not_provided	MONDO:MONDO:0013436&MedGen:C3151138&OMIM:613809&Orphanet:791&MONDO:MONDO:0010169&MedGen:C1848634&OMIM:276901&Orphanet:231178&Orphanet:886&MedGen:CN169374&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&MedGen:CN517202	.	rs58257972	0.013	1633	1517	58	9	26	170	16	214	18	1180	10406	11572	8652	6608	66722	908	16510	9	24	166	16	214	16	1072	0	1	2	0	0	1	54	rs58257972	9.14794e-04	1.75689e-03	1.01523e-04	1.86688e-02	2.91480e-03	3.76189e-03	7.84672e-03	7.14703e-02	1.56832e-02	9.06282e-03	7.14703e-02	1.26852e-02	rs58257972	1.03116e-03	1.19332e-03	3.31126e-03	1.60494e-02	3.14825e-03	2.99760e-03	8.14664e-03	.	3.56392e-03	2.88600e-03	1.60494e-02	3.25891e-03	rs58257972	0.3372&0.0908&0.2537	rs58257972	58257972	.	.	.	USH2A	USH2A:exonic	USH2A:missense	USH2A:Usher_syndrome\x2ctype_2A\x3bRetinitis_pigmentosa_39	USH2A:276901\x3b613809	USH2A:3\x3b3	USH2A:Autosomal_recessive\x3b.	0	3.68100336207458e-43	0.999989235571568	1.07644284322941e-05	DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. {ECO:0000269|PubMed:10729113, ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849, ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843, ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721, ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132, ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394, ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284, ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887, ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10775529, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073, ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008, ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:24227914}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,443	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0.0028	Likely Benign
11	76890889	76890889	G	A	A	missense_variant	MODERATE	MYO7A	4647	Transcript	NM_000260.4	protein_coding	21/49	.	NM_000260.4:c.2476G>A	NP_000251.3:p.Ala826Thr	2766	2476	826	A/T	Gcc/Acc	rs368341987&CM971015	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	MYO7A	.	chr11:g.76890889G>A	.	0	0	0	0	0.0092	pathogenic&conflicting_interpretations_of_pathogenicity&not_provided&likely_pathogenic&uncertain_significance&benign	.	1&1	.	.	.	.	.	MYO7A&NM_000260.3&c.2476G>A	.	.	9	0.0017971246006389776	0	0.0	0	0.0	0	0.0	0	0.0	9	0.009202453987730062	.	.	.	.	.	.	.	.	.	G/G	G	T	0.33923	-0.115126	D	0.74550	0.0646036	24.2	23.3	3.315276	2.856761	0.59408	0.51521	G/G	T	0.06931	0.0585062716108459	0.88639	0.99801377394514779	.	0.67723	.	G/G	2	5.268703898840885E-4	1	1.2853470437017994E-4	3.820502	0.317536879887832	0.56568	3.426458	0.227360527069357	0.52528	.	.	.	78	9.745e-04	0	0	1	5.376e-03	51	3.924e-03	0	0	0	0	1	2.353e-04	49	6.499e-03	76	1.084e-03	0	0	1	6.329e-03	50	4.378e-03	0	0	0	0	0	0	49	6.506e-03	78	1.278e-03	0	0	1	5.376e-03	51	3.962e-03	0	0	0	0	1	2.355e-04	49	6.499e-03	0.85943	.	.	.	5.39	4.48	0.53973	0	0.45803	0.59043	.	.	0.74766	0.999999560288542	.	0	0.34648	0.602189	.	.	.	.	.	.	0	0.41899	0.613276	IQ_motif&_EF-hand_binding_site&IQ_motif&_EF-hand_binding_site&IQ_motif&_EF-hand_binding_site&IQ_motif&_EF-hand_binding_site&IQ_motif&_EF-hand_binding_site&IQ_motif&_EF-hand_binding_site&.&.&IQ_motif&_EF-hand_binding_site&IQ_motif&_EF-hand_binding_site&IQ_motif&_EF-hand_binding_site&IQ_motif&_EF-hand_binding_site	.	.	.	0.78806	.	0.119759	0.55875	D	0.000028	D	0.83973	0.159553	0.16892	.	0.91860	.	T	0.79637	0.4708	.	0.00260	.	D	0.82838	0.0294	.	.	.	.	.	.	0.26193	.	.	0.41585	simple_aae&simple_aae&simple_aae&simple_aae	D&D&D&D	0.992214&0.992214&0.992214&0.992214	0.54546	.	.	.	0.40767	.	.	0.44426	.	T	0.36347	0.482108324766	0.80782	.	10	0.67890	.	.	0.72154	.	.	13.5138	0.60984	0.0752:0.0:0.9248:0.0	.	.	.	.	.	.	.	.	0.70878	.	G/G	T	.	A	A	609	0.67094	.	11	C1568247&C1838701&C1832475&C0271097&C2931206&CN169374&CN239407&CN517202	276900&600060&601317&PS276900	ORPHA231169&ORPHA886	Uncertain_significance	NC_000011.10:g.77179843G>A	177732	reviewed_by_expert_panel	Usher_syndrome_type_1&Deafness&_autosomal_recessive_2&Deafness&_autosomal_dominant_11&Usher_syndrome&Usher_syndrome_type_1B&not_specified&MYO7A-Related_Disorders&not_provided	UniProtKB_(protein):Q13402#VAR_009332&Illumina_Laboratory_Services&Illumina:550766	.	.	AEFDBI	D	0.86437	0.98755	D	0.92952	0.935128	.	170	1.214320e-03	2	2.917150e-04	6856	0	2	8.163270e-05	24500	0	139996	0	0.000000e+00	8276	0	1	9.393200e-05	10646	0	0	0.000000e+00	9632	0	18	3.375080e-04	53332	0	147	6.503270e-03	22604	1	147	6.503270e-03	22604	1	77	1.332960e-03	1	3.846150e-04	2600	0	1	8.183310e-05	12220	0	57766	0	0.000000e+00	1456	0	0	0.000000e+00	4076	0	0	0.000000e+00	5722	0	6	3.139390e-04	19112	0	69	6.114850e-03	11284	0	69	6.114850e-03	11284	0	0	.	1	169	1.226790e-03	2	3.063730e-04	6528	0	2	8.177950e-05	24456	0	137758	0	0.000000e+00	8142	0	1	9.503900e-05	10522	0	0	0.000000e+00	9630	0	17	3.281470e-04	51806	0	147	6.506150e-03	22594	1	147	6.506150e-03	22594	1	1	167	1.390020e-03	2	2.931690e-04	6822	0	2	9.766580e-05	20478	0	120142	0	0.000000e+00	4608	0	1	1.230310e-04	8128	0	0	0.000000e+00	7732	0	15	3.234710e-04	46372	0	147	6.503850e-03	22602	1	147	6.503850e-03	22602	1	1	169	1.221860e-03	2	3.070310e-04	6514	0	2	8.181300e-05	24446	0	138314	0	0.000000e+00	8238	0	1	9.396730e-05	10642	0	0	0.000000e+00	9630	0	17	3.260330e-04	52142	0	147	6.503270e-03	22604	1	147	6.503270e-03	22604	1	1	64	4.203450e-04	2	4.823690e-05	41462	0	0	0.000000e+00	912	0	1	6.539370e-05	15292	0	152256	0	0.000000e+00	3472	0	1	1.922340e-04	5202	0	0	0.000000e+00	10628	0	0	0.000000e+00	316	0	26	3.821170e-04	68042	0	32	6.614300e-03	4838	2	32	6.614300e-03	4838	2	27	8.203690e-04	0	0.000000e+00	9100	0	0	0.000000e+00	60	0	0	0.000000e+00	4690	0	32912	0	0.000000e+00	136	0	1	4.118620e-04	2428	0	0	0.000000e+00	5496	0	0	0.000000e+00	246	0	5	7.299270e-04	6850	0	21	6.739410e-03	3116	1	1	.	2	63	4.256810e-04	2	4.860980e-05	41144	0	0	0.000000e+00	912	0	1	6.620760e-05	15104	0	147998	0	0.000000e+00	3302	0	1	2.013690e-04	4966	0	0	0.000000e+00	10628	0	0	0.000000e+00	304	0	25	3.857430e-04	64810	0	32	6.658340e-03	4806	2	2	61	4.524080e-04	2	6.156500e-05	32486	0	0	0.000000e+00	862	0	1	6.735820e-05	14846	0	134834	0	0.000000e+00	3388	0	1	1.922340e-04	5202	0	0	0.000000e+00	6986	0	0	0.000000e+00	310	0	23	3.598470e-04	63916	0	32	6.617040e-03	4836	2	2	44	5.444600e-04	1	4.026410e-05	24836	0	0	0.000000e+00	112	0	0	0.000000e+00	12918	0	80814	0	0.000000e+00	998	0	1	2.659570e-04	3760	0	0	0.000000e+00	10536	0	0	0.000000e+00	272	0	9	4.274720e-04	21054	0	32	6.652810e-03	4810	2	2	11	76568537	11	76890889	0	0.28877	0.554377	1.000000	0.71638	0.778000	0.36829	0.522000	0.27616	8.141000	0.89532	0.606000	0.46413	1.176000	0.78918	77179843	G	.	rs368341987	.	.	7.148	8.409	8.411	8.050	.	.	.	18	-18	8	-20	0.00	0.00	0.07	0.00	MYO7A	0.00	exon-NM_001369365.1-22+108+start+219	177732	Uncertain_significance	reviewed_by_expert_panel	Usher_syndrome&MYO7A-Related_Disorders&Autosomal_dominant_nonsyndromic_hearing_loss_11&Autosomal_recessive_nonsyndromic_hearing_loss_2&Usher_syndrome_type_1&not_provided&Usher_syndrome_type_1B&not_specified	MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886&MedGen:CN239407&MONDO:MONDO:0011032&MedGen:C1832475&OMIM:601317&Orphanet:90635&MONDO:MONDO:0010807&MedGen:C1838701&OMIM:600060&Orphanet:90636&MONDO:MONDO:0010168&MedGen:C1568247&OMIM:276900&Orphanet:231169&Orphanet:886&MedGen:CN517202&MONDO:MONDO:0700087&MedGen:C2931206&MedGen:CN169374	.	11:76890889-76890889	9.745e-04	78	51	0	0	1	0	0	1	0	49	596	186	274	18	4250	134	7540	0	1	0	0	1	0	49	0	0	0	0	0	0	0	rs368341987	3.02847e-04	4.20274e-05	0.00000e+00	9.99001e-05	0.00000e+00	3.36407e-04	2.76396e-04	6.34921e-03	1.65797e-03	7.19307e-04	6.34921e-03	9.22550e-04	rs368341987	1.14626e-04	0.00000e+00	0.00000e+00	6.16523e-04	0.00000e+00	6.00480e-04	0.00000e+00	.	4.09261e-04	2.88976e-04	6.16523e-04	3.54953e-04	rs368341987	0.0129&0.0527&0.0259	rs368341987	368341987	.	.	.	MYO7A	MYO7A:exonic	MYO7A:missense	MYO7A:Deafness\x2cautosomal_recessive_2\x3bUsher_syndrome\x2ctype_1B\x3bDeafness\x2cautosomal_dominant_11	MYO7A:600060\x3b276900\x3b601317	MYO7A:3\x3b3\x3b3	MYO7A:Autosomal_recessive\x3bAutosomal_recessive\x3bAutosomal_dominant	0	5.37673856270135e-25	0.207164598627406	0.792835401372594	DISEASE: Usher syndrome 1B (USH1B) [MIM:276900]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. {ECO:0000269|PubMed:10094549, ECO:0000269|PubMed:10364543, ECO:0000269|PubMed:10447383, ECO:0000269|PubMed:10930322, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:15660226, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:23559863, ECO:0000269|PubMed:24831256, ECO:0000269|PubMed:25798947, ECO:0000269|PubMed:7870171, ECO:0000269|PubMed:8900236, ECO:0000269|PubMed:9002678, ECO:0000269|PubMed:9382091, ECO:0000269|PubMed:9718356}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 2 (DFNB2) [MIM:600060]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:9171832, ECO:0000269|PubMed:9171833}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 11 (DFNA11) [MIM:601317]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA11 is characterized by onset after complete speech acquisition and subsequent gradual progression. {ECO:0000269|PubMed:15121790, ECO:0000269|PubMed:15221449, ECO:0000269|PubMed:15300860, ECO:0000269|PubMed:9354784}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in MYO7A may be a cause of Leber congenital amaurosis (LCA), a severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near- absent pupillary responses, photophobia, high hyperopia and keratoconus.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,631	0	0	0	0	0	1	1	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0.0122	Benign
21	36259324	36259324	A	G	G	missense_variant	MODERATE	RUNX1	861	Transcript	NM_001754.5	protein_coding	4/9	.	NM_001754.5:c.167T>C	NP_001745.2:p.Leu56Ser	361	167	56	L/S	tTg/tCg	rs111527738&COSV55866281	A	.	-1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	RUNX1	.	chr21:g.36259324A>G	.	0.0023	0.0173	0.001	0.0169	0.0194	benign&likely_benign	0&1	1&1	.	.	.	.	.	RUNX1&NM_001001890.2&c.86T>C	.	.	52	0.010383386581469648	3	0.0022692889561270802	12	0.01729106628242075	1	9.92063492063492E-4	17	0.016898608349900597	19	0.019427402862985686	66	0.017125064867669952	.	.	.	.	.	.	.	A/A	A	T	0.23063	-0.184544	D	0.69412	-0.0141769	24.0	23.4	3.272567	2.919755	0.58342	0.52922	A/A	T	0.08309	0.067591643527611	0.30452	0.96613521511257228	.	0.76445	.	A/A	12	0.002749770852428964	124	0.014622641509433962	3.304489	0.224290845944705	0.51200	2.903712	0.104415993629867	0.46667	.	.	.	1760	1.479e-02	24	3.221e-03	118	1.114e-02	1701	1.629e-02	0	0	93	1.665e-02	938	1.658e-02	518	3.259e-02	1584	1.503e-02	23	3.468e-03	116	1.122e-02	1543	1.635e-02	0	0	93	1.665e-02	787	1.629e-02	514	3.250e-02	1376	1.558e-02	23	3.095e-03	117	1.106e-02	1322	1.738e-02	0	0	50	1.535e-02	607	1.821e-02	518	3.261e-02	0.99210	.	.	.	5.04	5.04	0.67293	0	0.08562	0.516746	.	.	0.74766	0.999999999995266	.	2	0.06126	0.378051	.	.	.	.	.	.	0	0.06265	0.372554	.&.&.&.&.&.&.	.	.	.	0.42297	.	0.302095	0.28882	N	0.013314	.	.	.	0.89993	.	.	.	D	0.96529	0.8954	.	0.00105	.	D	0.94371	0.7969	.	.	.	.	.	.	0.23535	.	.	0.36254	simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae&simple_aae	D&D&N&N&N&N&N	0.904559&0.904559&0.516401&0.516401&0.516401&0.516401&0.516401	0.22078	.	.	.	0.77913	.	.	0.82059	.	D	0.85017	0.819930672646	0.62838	.	10	0.13480	.	.	0.08685	.	.	14.7686	0.69280	1.0:0.0:0.0:0.0	.	64	0.017259978425026967	130	0.017191219254165564	.	.	.	0.17002	.	A/A	S	.	L	G	188	0.92666	.	21	C1832388&CN169374&CN517202	601399	.	Benign	NC_000021.9:g.34887027A>G	239045	reviewed_by_expert_panel	Familial_platelet_disorder_with_associated_myeloid_malignancy&not_specified&not_provided	Illumina_Laboratory_Services&Illumina:116151&ClinGen_Myeloid_Malignancy_Variant_Curation_Expert_Panel:36a19c90-310a-4c8f-ad1d-8f186170daaa	.	.	AEFDGBHCI	D	0.51351	0.90291	N	0.31394	0.186637	.	3522	1.519320e-02	37	2.642860e-03	14000	0	368	1.080260e-02	34066	4	231814	17	1.751850e-03	9704	0	2	1.131990e-04	17668	0	211	1.474910e-02	14306	2	1828	1.724920e-02	105976	19	952	3.141710e-02	30302	21	952	3.141710e-02	30302	21	1494	1.508570e-02	17	2.596210e-03	6548	0	179	1.067640e-02	16766	2	99034	4	1.771480e-03	2258	0	1	1.172060e-04	8532	0	95	1.493710e-02	6360	2	701	1.696270e-02	41326	10	468	3.029130e-02	15450	11	468	3.029130e-02	15450	11	25	.	47	3363	1.520080e-02	36	2.764130e-03	13024	0	366	1.082520e-02	33810	4	221238	17	1.809280e-03	9396	0	2	1.165770e-04	17156	0	211	1.476140e-02	14294	2	1685	1.720370e-02	97944	16	948	3.135750e-02	30232	20	948	3.135750e-02	30232	20	42	3002	1.579270e-02	37	2.649290e-03	13966	0	314	1.046320e-02	30010	4	190088	7	1.193320e-03	5866	0	2	1.571830e-04	12724	0	145	1.512940e-02	9584	2	1462	1.759660e-02	83084	15	952	3.142330e-02	30296	21	952	3.142330e-02	30296	21	43	3480	1.537800e-02	26	2.517430e-03	10328	0	366	1.078440e-02	33938	4	226298	17	1.761290e-03	9652	0	2	1.132250e-04	17664	0	211	1.475110e-02	14304	2	1799	1.723380e-02	104388	19	952	3.141710e-02	30302	21	952	3.141710e-02	30302	21	47	1926	1.265440e-02	160	3.859890e-03	41452	0	0	0.000000e+00	912	0	257	1.681280e-02	15286	4	152200	5	1.440090e-03	3472	0	2	3.852080e-04	5192	0	119	1.120110e-02	10624	2	3	9.493670e-03	316	0	1198	1.761190e-02	68022	11	146	3.021520e-02	4832	4	146	3.021520e-02	4832	4	395	1.200240e-02	30	3.295250e-03	9104	0	0	0.000000e+00	60	0	83	1.769720e-02	4690	2	32910	0	0.000000e+00	136	0	2	8.230450e-04	2430	0	56	1.019660e-02	5492	0	3	1.219510e-02	246	0	125	1.825350e-02	6848	1	85	2.727860e-02	3116	2	5	.	21	1868	1.262610e-02	158	3.841100e-03	41134	0	0	0.000000e+00	912	0	254	1.682340e-02	15098	4	147948	5	1.514230e-03	3302	0	2	4.033880e-04	4958	0	119	1.120110e-02	10624	2	3	9.868420e-03	304	0	1147	1.770230e-02	64794	11	145	3.020830e-02	4800	4	21	1757	1.303450e-02	126	3.878360e-03	32488	0	0	0.000000e+00	862	0	247	1.663970e-02	14844	4	134796	5	1.475800e-03	3388	0	2	3.852080e-04	5192	0	69	9.882560e-03	6982	0	3	9.677420e-03	310	0	1125	1.760620e-02	63898	10	146	3.022770e-02	4830	4	18	968	1.198490e-02	89	3.584370e-03	24830	0	0	0.000000e+00	112	0	222	1.719330e-02	12912	4	80768	3	3.006010e-03	998	0	2	5.333330e-04	3750	0	117	1.110900e-02	10532	2	3	1.102940e-02	272	0	361	1.715780e-02	21040	5	145	3.018320e-02	4804	4	15	21	35181194	21	36259324	1	0.06251	0.40479	1.000000	0.71638	0.993000	0.69303	1.000000	0.86279	3.338000	0.51846	0.756000	0.94297	1.312000	0.94714	34887027	A	.	rs111527738	.	.	5.882	8.558	8.426	9.942	.	.	.	18	-44	-38	19	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-4+69+end+254	239045	Benign	reviewed_by_expert_panel	Acute_myeloid_leukemia&not_specified&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1&Hereditary_cancer-predisposing_syndrome&not_provided	Human_Phenotype_Ontology:HP:0001914&Human_Phenotype_Ontology:HP:0004808&Human_Phenotype_Ontology:HP:0004843&Human_Phenotype_Ontology:HP:0005516&Human_Phenotype_Ontology:HP:0006724&Human_Phenotype_Ontology:HP:0006728&MONDO:MONDO:0018874&MeSH:D015470&MedGen:C0023467&OMIM:601626&Orphanet:519&MedGen:CN169374&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN517202	.	rs111527738	0.015	1760	1651	25	24	118	0	93	938	10	518	7450	10590	7564	5584	56568	758	15894	24	116	0	91	918	10	492	0	1	0	1	10	0	13	rs111527738	2.60040e-03	1.07113e-02	1.77713e-03	1.18610e-04	1.51837e-02	1.72958e-02	1.60673e-02	3.15431e-02	1.69737e-02	1.31346e-02	3.15431e-02	1.50380e-02	rs111527738	3.44590e-03	5.98086e-03	0.00000e+00	0.00000e+00	1.37773e-02	1.82073e-02	1.42566e-02	.	1.26990e-02	1.10581e-02	1.82073e-02	1.20031e-02	rs111527738	1.4623&0.275&1.0589	rs111527738	111527738	.	.	.	RUNX1	RUNX1:exonic	RUNX1:missense	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,985	0	0	0	0	0	1	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0.0028	Benign
10	73490271	73490271	A	G	G	missense_variant	MODERATE	CDH23	64072	Transcript	NM_022124.6	protein_coding	31/70	.	NM_022124.6:c.3625A>G	NP_071407.4:p.Thr1209Ala	4029	3625	1209	T/A	Aca/Gca	rs41281314&CM021540&COSV56497382	A	.	1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	C10orf105	.	chr10:g.73490271A>G	.	0.174	0.0231	0	0.001	0	pathogenic&uncertain_significance&likely_benign&benign	0&0&1	1&1&1	.	.	.	.	.	CDH23&NM_022124.5&c.3625A>G	.	.	247	0.04932108626198083	230	0.17397881996974282	16	0.023054755043227664	0	0.0	1	9.940357852882703E-4	0	0.0	2	5.189413596263622E-4	.	.	.	.	.	.	.	A/A	A	T	0.02216	-0.402887	T	0.52576	-0.221676	25.4	19.52	3.691504	1.973061	0.69126	0.32414	A/A	T	0.03267	0.0376369272515295	0.77380	0.99652389302686273	.	0.59857	.	A/A	574	0.1416584402764067	5	5.988023952095808E-4	2.301844	-0.017038902470121	0.38946	2.063102	-0.136049095167014	0.35831	.	.	.	1553	1.284e-02	1387	1.433e-01	96	8.384e-03	1535	1.283e-02	0	0	3	4.563e-04	44	6.667e-04	0	0	1346	1.273e-02	1206	1.441e-01	88	7.926e-03	1328	1.266e-02	0	0	3	4.563e-04	28	5.183e-04	0	0	1547	1.713e-02	1386	1.435e-01	96	8.392e-03	1529	1.717e-02	0	0	0	0	42	1.012e-03	0	0	.	.	.	.	4.32	3.19	0.35720	0	0.53198	0.616935	.	.	0.74766	0.999999846392034	.	0	0.15389	0.547309	.	.	.	.	.	.	0	0.14980	0.542086	.&.&.&.	.	.	.	0.30552	.	0.060954	0.62929	N	0.000004	.	.	.	.	.	.	.	T	0.00318	0.0009	.	0.00027	.	T	0.00680	-1.1633	.	.	.	.	.	.	0.15622	.	.	0.81001	without_aae&simple_aae&simple_aae	D&D&D	1&0.999981&0.99999	.	.	.	.	0.38659	.	.	0.40541	.	T	0.53816	0.606464385986	0.59619	.	9	0.74150	.	.	.	.	.	9.4817	0.38069	0.9165:0.0:0.0835:0.0	.	1	2.6968716289104636E-4	3	3.9672044432689763E-4	.	.	.	0.50508	.	A/A	A	.	T	G	819	0.41190	.	10	C1568247&C1832845&C1832394&C0271097&CN169374&CN517202	276900&601067&601386&PS276900	ORPHA231169&ORPHA886	Benign	NC_000010.11:g.71730514A>G	4927	reviewed_by_expert_panel	Usher_syndrome_type_1&Usher_syndrome_type_1D&Deafness&_autosomal_recessive_12&Usher_syndrome&not_specified&not_provided	ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:45780&Illumina_Laboratory_Services&Illumina:111225&OMIM_Allelic_Variant:605516.0013	.	.	AEFDGBCI	D	0.43066	0.83978	D	0.65297	0.693725	.	2625	1.054220e-02	2240	1.449650e-01	15452	170	265	7.681160e-03	34500	2	249000	0	0.000000e+00	10056	0	0	0.000000e+00	17972	0	11	5.107250e-04	21538	0	71	6.292320e-04	112836	0	2240	1.449650e-01	15452	170	3	9.804560e-05	30598	0	1203	1.109350e-02	1047	1.470920e-01	7118	77	118	6.924070e-03	17042	1	108442	0	0.000000e+00	2318	0	0	0.000000e+00	8638	0	8	6.016850e-04	13296	0	19	4.474380e-04	42464	0	1047	1.470920e-01	7118	77	1	6.379180e-05	15676	0	78	.	173	2411	1.027350e-02	2052	1.454490e-01	14108	156	258	7.550920e-03	34168	1	234682	0	0.000000e+00	9560	0	0	0.000000e+00	17284	0	11	5.111050e-04	21522	0	59	5.784540e-04	101996	0	2052	1.454490e-01	14108	156	3	9.833490e-05	30508	0	158	2564	1.245660e-02	2235	1.449790e-01	15416	170	227	7.458760e-03	30434	2	205834	0	0.000000e+00	6190	0	0	0.000000e+00	12994	0	9	5.409950e-04	16636	0	61	6.869830e-04	88794	0	2235	1.449790e-01	15416	170	3	9.807130e-05	30590	0	172	2074	8.551730e-03	1693	1.492680e-01	11342	139	262	7.623810e-03	34366	2	242524	0	0.000000e+00	9974	0	0	0.000000e+00	17968	0	11	5.107730e-04	21536	0	71	6.410370e-04	110758	0	1693	1.492680e-01	11342	139	3	9.804560e-05	30598	0	142	6466	4.248920e-02	6054	1.461820e-01	41414	455	0	0.000000e+00	912	0	295	1.929870e-02	15286	3	152180	0	0.000000e+00	3470	0	0	0.000000e+00	5194	0	6	5.649720e-04	10620	0	3	9.493670e-03	316	0	37	5.437980e-04	68040	0	6054	1.461820e-01	41414	455	3	6.206040e-04	4834	0	1533	4.659570e-02	1359	1.494390e-01	9094	96	0	0.000000e+00	60	0	131	2.793180e-02	4690	1	32900	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	3	5.466470e-04	5488	0	3	1.219510e-02	246	0	3	4.377010e-04	6854	0	3	9.640100e-04	3112	0	101	.	463	6421	4.340680e-02	6015	1.463720e-01	41094	452	0	0.000000e+00	912	0	293	1.940650e-02	15098	3	147926	0	0.000000e+00	3302	0	0	0.000000e+00	4958	0	6	5.649720e-04	10620	0	3	9.868420e-03	304	0	34	5.245940e-04	64812	0	3	6.247400e-04	4802	0	460	5136	3.810710e-02	4735	1.458900e-01	32456	351	0	0.000000e+00	862	0	289	1.947440e-02	14840	3	134778	0	0.000000e+00	3386	0	0	0.000000e+00	5194	0	3	4.299230e-04	6978	0	3	9.677420e-03	310	0	36	5.632390e-04	63916	0	3	6.208610e-04	4832	0	359	4002	4.956530e-02	3675	1.482210e-01	24794	279	0	0.000000e+00	112	0	254	1.967160e-02	12912	2	80742	0	0.000000e+00	996	0	0	0.000000e+00	3752	0	6	5.699090e-04	10528	0	3	1.102940e-02	272	0	10	4.750590e-04	21050	0	3	6.242200e-04	4806	0	286	10	73160277	10	73490271	0	0.18159	0.495158	1.000000	0.71638	0.990000	0.65344	1.000000	0.86279	6.151000	0.71589	0.756000	0.94297	1.312000	0.94714	71730514	A	.	rs41281314	.	.	11.360	8.297	8.921	7.132	.	.	.	-45	6	42	-38	0.00	0.03	0.00	0.00	CDH23	0.05	exon-NM_022124.6-31+45+start+136	4927	Benign	reviewed_by_expert_panel	not_provided&not_specified&Usher_syndrome_type_1&Usher_syndrome_type_1D&Autosomal_recessive_nonsyndromic_hearing_loss_12&Pituitary_adenoma_5&_multiple_types&Usher_syndrome	MedGen:CN517202&MedGen:CN169374&MONDO:MONDO:0010168&MedGen:C1568247&OMIM:276900&Orphanet:231169&Orphanet:886&MONDO:MONDO:0010984&MedGen:C1832845&OMIM:601067&Orphanet:231169&Orphanet:886&MONDO:MONDO:0011067&MedGen:C1832394&OMIM:601386&Orphanet:90636&MONDO:MONDO:0054601&MedGen:C4539685&OMIM:617540&MONDO:MONDO:0019501&MeSH:D052245&MedGen:C0271097&OMIM:PS276900&Orphanet:886	.	rs41281314	0.013	1553	1333	101	1387	96	0	3	44	5	0	9678	11450	8588	6574	65996	896	16422	1187	94	0	3	44	5	0	100	1	0	0	0	0	0	rs41281314	1.47182e-01	7.62404e-03	0.00000e+00	0.00000e+00	4.48551e-04	6.18224e-04	7.30460e-03	9.74722e-05	7.88307e-03	1.40330e-02	1.47182e-01	1.06956e-02	rs41281314	1.37282e-01	1.55131e-02	0.00000e+00	0.00000e+00	5.72410e-04	6.66844e-04	7.12831e-03	.	4.22222e-02	3.65554e-02	1.37282e-01	3.98813e-02	rs41281314	0.0599&14.1658&4.6686	rs41281314	41281314	.	.	.	C10orf105\x3bCDH23	C10orf105:intronic\x7cCDH23:exonic	CDH23:missense	CDH23:Usher_syndrome\x2ctype_1D\x3b{Pituitary_adenoma_5\x2cmultiple_types}\x3bUsher_syndrome\x2ctype_1D/F_digenic\x3bDeafness\x2cautosomal_recessive_12	CDH23:601067\x3b617540\x3b601067\x3b601386	CDH23:3\x3b3\x3b3\x3b3	CDH23:Autosomal_recessive\x2cDigenic_recessive\x3bAutosomal_dominant\x3bAutosomal_recessive\x2cDigenic_recessive\x3bAutosomal_recessive	0	0.0506929591139338	0.949268622794338	3.84180917276542e-05	DISEASE: Usher syndrome 1D (USH1D) [MIM:601067]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. {ECO:0000269|PubMed:11138009, ECO:0000269|PubMed:12075507, ECO:0000269|PubMed:15660226, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:18429043}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Usher syndrome 1D/F (USH1DF) [MIM:601067]: USH1DF patients are heterozygous for mutations in CDH23 and PCDH15, indicating a digenic inheritance pattern. {ECO:0000269|PubMed:15537665}. Note=The disease is caused by mutations affecting distinct genetic loci, including the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 12 (DFNB12) [MIM:601386]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:11090341, ECO:0000269|PubMed:12075507, ECO:0000269|PubMed:12522556, ECO:0000269|PubMed:15829536, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:17850630, ECO:0000269|PubMed:22899989, ECO:0000269|PubMed:24767429}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,498	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0.0014	Benign
11	76866991	76866991	C	T	T	synonymous_variant	LOW	MYO7A	4647	Transcript	NM_000260.4	protein_coding	5/49	.	NM_000260.4:c.324C>T	NP_000251.3:p.Tyr108%3D	614	324	108	Y	taC/taT	rs116892396&CM173700	C	.	1	.	1	EntrezGene	.	YES	.	.	C	C	.	.	MYO7A	.	chr11:g.76866991C>T	.	0	0	0.0139	0	0	uncertain_significance&likely_benign&benign&benign/likely_benign	.	1&1	.	.	.	.	.	MYO7A&NM_000260.3&c.324C>A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.742	8.066	10.478	7.768	.	.	.	26	-38	-4	38	0.04	0.01	0.00	0.00	MYO7A	0.00	exon-NM_001369365.1-6+38+start+185	43201	Benign	reviewed_by_expert_panel	not_specified&Nonsyndromic_genetic_hearing_loss&not_provided&Usher_syndrome_type_1&Autosomal_recessive_nonsyndromic_hearing_loss_2&Autosomal_dominant_nonsyndromic_hearing_loss_11&Usher_syndrome_type_1B	MedGen:CN169374&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MedGen:CN517202&MONDO:MONDO:0010168&MedGen:C1568247&OMIM:276900&Orphanet:231169&Orphanet:886&MONDO:MONDO:0010807&MedGen:C1838701&OMIM:600060&Orphanet:90636&MONDO:MONDO:0011032&MedGen:C1832475&OMIM:601317&Orphanet:90635&MONDO:MONDO:0700087&MedGen:C2931206	.	rs116892396	1.130e-03	137	129	2	0	0	132	0	0	0	1	7088	7458	6334	4770	49078	676	11658	0	0	128	0	0	0	1	0	0	2	0	0	0	0	rs116892396	0.00000e+00	0.00000e+00	0.00000e+00	1.60798e-02	0.00000e+00	0.00000e+00	3.70370e-04	3.33267e-05	1.19920e-03	1.07833e-03	1.60798e-02	1.14914e-03	rs116892396	0.00000e+00	0.00000e+00	0.00000e+00	1.60692e-02	0.00000e+00	0.00000e+00	0.00000e+00	.	1.11007e-03	5.04978e-04	1.60692e-02	8.38926e-04	.	.	rs116892396	116892396	.	.	.	MYO7A	MYO7A:exonic	MYO7A:synonymous_SNV	MYO7A:Deafness\x2cautosomal_recessive_2\x3bUsher_syndrome\x2ctype_1B\x3bDeafness\x2cautosomal_dominant_11	MYO7A:600060\x3b276900\x3b601317	MYO7A:3\x3b3\x3b3	MYO7A:Autosomal_recessive\x3bAutosomal_recessive\x3bAutosomal_dominant	0	5.37673856270135e-25	0.207164598627406	0.792835401372594	DISEASE: Usher syndrome 1B (USH1B) [MIM:276900]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. {ECO:0000269|PubMed:10094549, ECO:0000269|PubMed:10364543, ECO:0000269|PubMed:10447383, ECO:0000269|PubMed:10930322, ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:15660226, ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:23559863, ECO:0000269|PubMed:24831256, ECO:0000269|PubMed:25798947, ECO:0000269|PubMed:7870171, ECO:0000269|PubMed:8900236, ECO:0000269|PubMed:9002678, ECO:0000269|PubMed:9382091, ECO:0000269|PubMed:9718356}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 2 (DFNB2) [MIM:600060]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:9171832, ECO:0000269|PubMed:9171833}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal dominant, 11 (DFNA11) [MIM:601317]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA11 is characterized by onset after complete speech acquisition and subsequent gradual progression. {ECO:0000269|PubMed:15121790, ECO:0000269|PubMed:15221449, ECO:0000269|PubMed:15300860, ECO:0000269|PubMed:9354784}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in MYO7A may be a cause of Leber congenital amaurosis (LCA), a severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near- absent pupillary responses, photophobia, high hyperopia and keratoconus.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,627	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0.0014	Benign
21	36164486	36164486	G	C	C	synonymous_variant	LOW	RUNX1	861	Transcript	NM_001754.5	protein_coding	9/9	.	NM_001754.5:c.1389C>G	NP_001745.2:p.Pro463%3D	1583	1389	463	P	ccC/ccG	rs61750222	G	.	-1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	RUNX1	.	chr21:g.36164486G>C	.	0.1558	0.0461	0.0228	0.008	0.0235	benign	.	1	.	.	.	.	.	RUNX1&NM_001001890.2&c.1308C>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	9.279	7.470	.	.	.	41	-31	-33	33	0.00	0.00	0.00	0.00	RUNX1	0.45	exon-NM_001754.5-9+421+end+4810	258184	Benign	reviewed_by_expert_panel	not_specified&not_provided&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN169374&MedGen:CN517202&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	rs61750222	0.015	1686	0	23	183	80	25	1	174	2	192	1004	328	358	34	2182	74	3744	0	0	0	0	0	0	0	12	2	0	0	4	0	5	rs61750222	1.17905e-01	5.55511e-02	6.24002e-02	2.18155e-02	1.79662e-03	9.07613e-03	3.00393e-02	2.93639e-02	2.83265e-02	3.43452e-02	1.17905e-01	2.46000e-02	rs61750222	1.23082e-01	4.14573e-02	6.00000e-02	2.28960e-02	1.17233e-03	8.13281e-03	1.65975e-02	.	4.44274e-02	3.92946e-02	1.23082e-01	4.21831e-02	rs61750222	0.7656&7.7635&3.0612	rs61750222	61750222	.	.	.	RUNX1	RUNX1:exonic	RUNX1:synonymous_SNV	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,945	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0.0014	Benign
21	36259125	36259125	T	C	C	intron_variant	MODIFIER	RUNX1	861	Transcript	NM_001754.5	protein_coding	.	4/8	NM_001754.5:c.351+15A>G	.	.	.	.	.	.	rs199881885	T	.	-1	.	1	EntrezGene	.	YES	.	.	T	T	.	.	RUNX1	.	chr21:g.36259125T>C	.	0	0.0072	0	0.007	0	benign	.	1	.	.	.	.	.	RUNX1&NM_001001890.2&c.270+15A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5.882	10.199	8.426	8.558	.	.	.	35	14	15	18	0.00	0.00	0.00	0.00	RUNX1	0.45	.	258185	Benign	reviewed_by_expert_panel	not_specified&Acute_myeloid_leukemia&Hereditary_thrombocytopenia_and_hematological_cancer_predisposition_syndrome_associated_with_RUNX1	MedGen:CN169374&Human_Phenotype_Ontology:HP:0001914&Human_Phenotype_Ontology:HP:0004808&Human_Phenotype_Ontology:HP:0004843&Human_Phenotype_Ontology:HP:0005516&Human_Phenotype_Ontology:HP:0006724&Human_Phenotype_Ontology:HP:0006728&MONDO:MONDO:0018874&MeSH:D015470&MedGen:C0023467&OMIM:601626&Orphanet:519&MONDO:MONDO:0100083&MeSH:C563324&MedGen:C1832388&OMIM:601399&Orphanet:71290	.	21:36259125-36259125	5.259e-03	638	618	6	12	38	0	38	524	4	14	9880	11426	8540	6468	64760	874	16474	12	38	0	38	514	4	12	0	0	0	0	5	0	1	rs199881885	9.21659e-04	3.60656e-03	2.85249e-03	0.00000e+00	5.84007e-03	7.48066e-03	7.15072e-03	6.50068e-04	4.79525e-03	4.80013e-03	7.48066e-03	4.77003e-03	rs199881885	1.03401e-03	5.96659e-03	3.31126e-03	0.00000e+00	7.45841e-03	5.41082e-03	6.10998e-03	.	4.21595e-03	4.05034e-03	7.45841e-03	4.19517e-03	rs199881885	0.5466&0.1362&0.4076	rs199881885	199881885	.	.	.	RUNX1	RUNX1:intronic	.	RUNX1:Platelet_disorder\x2cfamilial\x2cwith_associated_myeloid_malignancy\x3bLeukemia\x2cacute_myeloid	RUNX1:601399\x3b601626	RUNX1:3\x3b3	RUNX1:Autosomal_dominant\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.449323606506754	0.54937349793652	0.00130289555672611	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,976	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0.0014	Benign
16	68856041	68856041	G	A	A	missense_variant	MODERATE	CDH1	999	Transcript	NM_004360.5	protein_coding	12/16	.	NM_004360.5:c.1849G>A	NP_004351.1:p.Ala617Thr	1973	1849	617	A/T	Gca/Aca	rs33935154&CM034216&COSV55727851	G	.	1	.	1	EntrezGene	.	YES	.	.	G	G	.	.	TANGO6	.	chr16:g.68856041G>A	.	0.0514	0.0043	0	0.001	0	benign&pathogenic&benign/likely_benign	0&0&1	1&1&1	.	.	.	.	.	CDH1&NM_004360.3&c.1849G>A	.	.	72	0.01437699680511182	68	0.05143721633888049	3	0.004322766570605188	0	0.0	1	9.940357852882703E-4	0	0.0	2	5.189413596263622E-4	.	.	.	.	.	.	.	G/G	G	T	0.00135	-0.605576	T	0.12003	-0.609788	15.48	15.49	1.459575	1.357157	0.21274	0.21742	G/G	T	0.00035	0.0033143387446891	0.31195	0.96812732210528252	.	0.63210	.	G/G	207	0.04708826205641492	1	1.1627906976744187E-4	1.05212	-0.595999271263066	0.19597	0.9572714	-0.616837145527328	0.18438	.	.	.	513	4.225e-03	481	4.622e-02	23	1.987e-03	513	4.225e-03	0	0	0	0	8	1.199e-04	0	0	445	4.190e-03	416	4.589e-02	21	1.872e-03	445	4.190e-03	0	0	0	0	7	1.288e-04	0	0	513	5.653e-03	481	4.630e-02	23	1.989e-03	513	5.653e-03	0	0	0	0	8	1.898e-04	0	0	0.55090	.	.	.	5.57	3.5	0.39181	0	0.55848	0.633656	.	.	0.48110	0.999957603638055	.	0	0.87919	0.724815	.	.	.	.	.	.	0	0.26826	0.564101	Cadherin-like&Cadherin-like&.&.	.	.	.	0.55578	.	0.426325	0.19776	N	0.102821	.	.	.	0.28428	.	0.73487	.	T	0.11529	0.0269	.	0.00125	.	T	0.43903	-0.9316	.	.	.	.	.	.	0.37439	.	.	0.08975	simple_aae&simple_aae	N&N	1&1	0.20358	.	.	.	0.21238	.	.	0.22741	.	T	0.10514	0.30075314641	0.25287	.	9	0.16668	.	.	0.19225	.	.	8.2503	0.30872	0.3293:0.5455:0.1252:0.0	.	0	0.0	2	2.644802962179318E-4	.	.	.	0.21449	.	G/G	T	.	A	A	334	0.86273	.	16	C0476089&C0006142&C1708349&C0027672&CN169374&CN221562&CN517202	608089&137215	ORPHA26106&ORPHA140162	Benign	NC_000016.10:g.68822138G>A	12232	reviewed_by_expert_panel	Endometrial_carcinoma&Malignant_tumor_of_breast&Hereditary_diffuse_gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&Breast_and/or_ovarian_cancer&not_provided	UniProtKB_(protein):P12830#VAR_001320&ClinGen_CDH1_Variant_Curation_Expert_Panel&:8fe2e0a3-670f-4cdb-bbf8-3836f7fc45e9&OMIM_Allelic_Variant:192090.0002&Illumina_Laboratory_Services&Illumina:583379&ARUP_Laboratories&_Molecular_Genetics_and_Genomics&_ARUP_Laboratories:133603	.	.	AEFBI	N	0.04970	0.01500	N	0.15255	0.075902	.	878	3.491530e-03	745	4.582920e-02	16256	18	102	2.948660e-03	34592	0	251466	0	0.000000e+00	10080	0	0	0.000000e+00	18394	0	1	4.619360e-05	21648	0	21	1.846250e-04	113744	0	745	4.582920e-02	16256	18	0	0.000000e+00	30616	0	398	3.637760e-03	341	4.759910e-02	7164	11	50	2.921930e-03	17112	0	109408	0	0.000000e+00	2320	0	0	0.000000e+00	9046	0	0	0.000000e+00	13394	0	5	1.169100e-04	42768	0	341	4.759910e-02	7164	11	0	0.000000e+00	15690	0	11	.	18	813	3.431420e-03	684	4.589990e-02	14902	18	100	2.918860e-03	34260	0	236928	0	0.000000e+00	9572	0	0	0.000000e+00	17692	0	1	4.622780e-05	21632	0	21	2.044230e-04	102728	0	684	4.589990e-02	14902	18	0	0.000000e+00	30526	0	18	847	4.069530e-03	744	4.587500e-02	16218	18	78	2.555370e-03	30524	0	208132	0	0.000000e+00	6212	0	0	0.000000e+00	13416	0	1	5.975860e-05	16734	0	15	1.674930e-04	89556	0	744	4.587500e-02	16218	18	0	0.000000e+00	30608	0	18	699	2.854830e-03	566	4.706470e-02	12026	13	102	2.960130e-03	34458	0	244848	0	0.000000e+00	9998	0	0	0.000000e+00	18390	0	1	4.619790e-05	21646	0	21	1.880810e-04	111654	0	566	4.706470e-02	12026	13	0	0.000000e+00	30616	0	13	1969	1.294560e-02	1856	4.483090e-02	41400	49	0	0.000000e+00	906	0	82	5.372120e-03	15264	0	152098	0	0.000000e+00	3468	0	0	0.000000e+00	5192	0	0	0.000000e+00	10610	0	1	3.164560e-03	316	0	19	2.793050e-04	68026	0	1856	4.483090e-02	41400	49	0	0.000000e+00	4826	0	475	1.444560e-02	436	4.797540e-02	9088	13	0	0.000000e+00	60	0	31	6.609810e-03	4690	0	32882	0	0.000000e+00	136	0	0	0.000000e+00	2430	0	0	0.000000e+00	5480	0	1	4.065040e-03	246	0	3	4.377010e-04	6854	0	0	0.000000e+00	3110	0	13	.	49	1959	1.324990e-02	1849	4.500970e-02	41080	49	0	0.000000e+00	906	0	81	5.372780e-03	15076	0	147850	0	0.000000e+00	3300	0	0	0.000000e+00	4956	0	0	0.000000e+00	10610	0	1	3.289470e-03	304	0	17	2.623380e-04	64802	0	0	0.000000e+00	4794	0	49	1578	1.171510e-02	1468	4.525280e-02	32440	40	0	0.000000e+00	858	0	80	5.398840e-03	14818	0	134698	0	0.000000e+00	3384	0	0	0.000000e+00	5192	0	0	0.000000e+00	6970	0	1	3.225810e-03	310	0	18	2.816810e-04	63902	0	0	0.000000e+00	4824	0	40	1239	1.535730e-02	1147	4.628730e-02	24780	30	0	0.000000e+00	110	0	74	5.740880e-03	12890	0	80678	0	0.000000e+00	996	0	0	0.000000e+00	3750	0	0	0.000000e+00	10518	0	1	3.676470e-03	272	0	7	3.325730e-04	21048	0	0	0.000000e+00	4798	0	30	16	67413542	16	68856041	0	0.73137	0.706548	0.001000	0.13787	0.921000	0.45669	0.841000	0.34891	1.253000	0.32488	-0.193000	0.09282	0.137000	0.19320	68822138	G	.	rs33935154	.	.	8.251	4.820	10.720	9.332	.	.	.	34	-34	-19	50	0.00	0.00	0.02	0.00	CDH1	0.34	exon-NM_001317185.2-12+87+end+225	12232	Benign	reviewed_by_expert_panel	not_provided&Hereditary_diffuse_gastric_adenocarcinoma&Malignant_tumor_of_prostate&Endometrial_carcinoma&Neoplasm_of_ovary&Blepharocheilodontic_syndrome_1&Familial_cancer_of_breast&Breast_and/or_ovarian_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&Malignant_tumor_of_breast	MedGen:CN517202&MONDO:MONDO:0007648&MedGen:C1708349&OMIM:137215&Orphanet:26106&Human_Phenotype_Ontology:HP:0012125&MONDO:MONDO:0008315&MedGen:C0376358&OMIM:176807&Orphanet:1331&Human_Phenotype_Ontology:HP:0012114&MONDO:MONDO:0002447&MedGen:C0476089&OMIM:608089&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267&OMIM:167000&MONDO:MONDO:0054740&MedGen:C4551988&OMIM:119580&Orphanet:1997&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MedGen:CN221562&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0007254&MedGen:C0006142	.	rs33935154	4.225e-03	513	483	15	481	23	0	0	8	1	0	10406	11578	8654	6614	66738	908	16512	451	23	0	0	8	1	0	15	0	0	0	0	0	0	rs33935154	4.51516e-02	2.97779e-03	0.00000e+00	0.00000e+00	4.48430e-05	1.79080e-04	1.09369e-03	0.00000e+00	2.43165e-03	4.40070e-03	4.51516e-02	3.32153e-03	rs33935154	4.41615e-02	3.57995e-03	0.00000e+00	0.00000e+00	0.00000e+00	2.00027e-04	2.03666e-03	.	1.30333e-02	1.22832e-02	4.41615e-02	1.27775e-02	rs33935154	0.0116&4.7088&1.6005	rs33935154	33935154	.	.	.	CDH1	CDH1:exonic	CDH1:missense	CDH1:Ovarian_cancer\x2csomatic\x3bBlepharocheilodontic_syndrome_1\x3bDiffuse_gastric_and_lobular_breast_cancer_syndrome_with_or_without_cleft_lip_and/or_palate\x3bEndometrial_carcinoma\x2csomatic\x3bBreast_cancer\x2clobular\x2csomatic\x3b{Prostate_cancer\x2csusceptibility_to}	CDH1:167000\x3b119580\x3b137215\x3b608089\x3b114480\x3b176807	CDH1:3\x3b3\x3b3\x3b3\x3b3\x3b3	CDH1:.\x3bAutosomal_dominant\x3bAutosomal_dominant\x3b.\x3b.\x3bAutosomal_dominant\x2cSomatic_mutation	0	0.338547688109087	0.661426839739286	2.54721516269318e-05	DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,914	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	1	0	0	0	0.0001	Benign
11	120989335	120989335	A	G	G	missense_variant	MODERATE	TBCEL-TECTA	116804918	Transcript	NM_001378761.1	protein_coding	13/30	.	NM_001378761.1:c.2068A>G	NP_001365690.1:p.Arg690Gly	2275	2068	690	R/G	Aga/Gga	rs612969&COSV50693695	A	.	1	.	1	EntrezGene	.	YES	.	.	A	A	.	.	TECTA	.	chr11:g.120989335A>G	.	0.7428	0.3818	0.246	0.4314	0.2975	benign	0&1	1&1	.	.	.	.	.	TECTA&NM_005422.2&c.1111A>G	.	.	2220	0.44329073482428116	982	0.7428139183055976	265	0.3818443804034582	248	0.24603174603174602	434	0.43141153081510936	291	0.29754601226993865	1664	0.43175921120913335	.	.	.	.	.	.	.	G/G	G	T	0.00037	-0.698597	T	0.10231	-0.632442	14.76	15.94	1.352199	1.441561	0.19724	0.22999	G/G	T	0.00021	0.00202711549736174	0.01942	0.32994582686222435	.	0.39281	.	G/G	2922	0.6631865637766682	3545	0.4123051872528495	0.8131102	-0.760757202791128	0.15458	0.3882056	-1.01506724017409	0.08291	.	.	.	48890	4.027e-01	7062	6.792e-01	3794	3.279e-01	48885	4.030e-01	2188	2.534e-01	3014	4.561e-01	27270	4.090e-01	5201	3.150e-01	42415	3.994e-01	6161	6.799e-01	3654	3.260e-01	42411	3.995e-01	2023	2.576e-01	3014	4.561e-01	22122	4.073e-01	5168	3.150e-01	36481	4.020e-01	7055	6.797e-01	3791	3.279e-01	36477	4.023e-01	1481	2.630e-01	1721	4.527e-01	16947	4.027e-01	5199	3.151e-01	0.57880	.	.	.	5.72	3.86	0.43689	0	0.51514	0.610034	TECTA	Thyroid	0.24269	0.805875108927473	.	0	0.34648	0.602189	.	.	.	.	.	.	0	0.49550	0.631631	von_Willebrand_factor&_type_D_domain&von_Willebrand_factor&_type_D_domain&von_Willebrand_factor&_type_D_domain&von_Willebrand_factor&_type_D_domain&von_Willebrand_factor&_type_D_domain&von_Willebrand_factor&_type_D_domain&von_Willebrand_factor&_type_D_domain&von_Willebrand_factor&_type_D_domain&von_Willebrand_factor&_type_D_domain	.	.	.	0.00256	.	0.115400	0.62929	N	0.000018	.	.	.	0.42000	.	.	.	T	0.00011	0.0000	.	0.00003	.	T	0.46989	-0.9089	.	.	.	.	.	.	0.00056	.	.	0.19853	simple_aae&simple_aae	P&P	0.999881&0.999881	0.00008	.	.	.	0.02946	.	.	0.01387	.	T	0.32389	0.453262239695	0.41658	.	9	0.01155	.	.	0.00964	.	.	11.7181	0.50931	0.1898:0.0:0.8102:0.0	.	1561	0.4209816612729234	3225	0.426474477651415	.	.	.	0.02658	.	G/G	G	.	R	G	788	0.46569	.	11	C1832187&C1863655&CN043648&CN169374	601543&603629	ORPHA87884	Benign	NC_000011.10:g.121118626A>G	45314	reviewed_by_expert_panel	Deafness&_autosomal_dominant_12&Deafness&_autosomal_recessive_21&Nonsyndromic_hearing_loss_and_deafness&not_specified	Illumina_Laboratory_Services&Illumina:9072&UniProtKB_(protein):O75443#VAR_018968	.	.	AEFBI	N	0.11734	0.05798	N	0.14017	0.070585	.	99962	3.975520e-01	11158	6.864770e-01	16254	3837	11486	3.320420e-01	34592	1900	251444	3652	3.623020e-01	10080	668	4583	2.491570e-01	18394	561	10041	4.638730e-01	21646	2328	46982	4.131230e-01	113724	9762	11158	6.864770e-01	16254	3837	9689	3.164690e-01	30616	1577	43379	3.965030e-01	4947	6.905360e-01	7164	1708	5733	3.350280e-01	17112	937	109404	841	3.625000e-01	2320	156	2281	2.521560e-01	9046	286	6197	4.626700e-01	13394	1452	17687	4.135960e-01	42764	3677	4947	6.905360e-01	7164	1708	4976	3.171450e-01	15690	804	9163	.	21085	93692	3.954620e-01	10241	6.872230e-01	14902	3522	11350	3.312900e-01	34260	1871	236918	3471	3.626200e-01	9572	634	4438	2.508480e-01	17692	545	10036	4.639850e-01	21630	2327	42340	4.122050e-01	102716	8758	10241	6.872230e-01	14902	3522	9662	3.165170e-01	30526	1576	19643	83120	3.994040e-01	11133	6.865440e-01	16216	3828	10128	3.318040e-01	30524	1689	208110	2227	3.585000e-01	6212	402	3393	2.529070e-01	13416	406	7747	4.629500e-01	16734	1788	36962	4.128170e-01	89536	7641	11133	6.865440e-01	16216	3828	9687	3.164860e-01	30608	1577	17678	96188	3.928830e-01	8317	6.917000e-01	12024	2899	11450	3.322890e-01	34458	1894	244826	3619	3.619720e-01	9998	663	4583	2.492120e-01	18390	561	10039	4.638240e-01	21644	2327	46145	4.133600e-01	111634	9592	8317	6.917000e-01	12024	2899	9689	3.164690e-01	30616	1577	19962	72144	4.751070e-01	27986	6.775290e-01	41306	9550	234	2.571430e-01	910	34	5510	3.613110e-01	15250	1008	151848	1268	3.656290e-01	3468	231	1235	2.390630e-01	5166	142	4847	4.597800e-01	10542	1110	97	3.089170e-01	314	15	28524	4.195820e-01	67982	6032	27986	6.775290e-01	41306	9550	1527	3.169360e-01	4818	261	15357	4.685730e-01	6212	6.853490e-01	9064	2150	18	3.000000e-01	60	3	1775	3.792740e-01	4680	347	32774	56	4.117650e-01	136	14	612	2.533110e-01	2416	72	2464	4.532740e-01	5436	559	84	3.414630e-01	246	15	2784	4.068990e-01	6842	558	985	3.173320e-01	3104	151	3959	.	18595	70349	4.766580e-01	27769	6.775570e-01	40984	9478	234	2.571430e-01	910	34	5431	3.605760e-01	15062	991	147588	1195	3.623410e-01	3298	212	1187	2.406730e-01	4932	138	4847	4.597800e-01	10542	1110	95	3.145700e-01	302	15	27183	4.198150e-01	64750	5731	1520	3.175930e-01	4786	261	18177	62376	4.638170e-01	21895	6.765230e-01	32364	7465	217	2.523260e-01	860	30	5356	3.617940e-01	14804	984	134484	1247	3.684990e-01	3384	229	1235	2.390630e-01	5166	142	3129	4.528220e-01	6910	713	96	3.116880e-01	308	15	26806	4.196960e-01	63870	5666	1526	3.168600e-01	4816	261	15702	38608	4.799240e-01	16880	6.836220e-01	24692	5808	36	3.214290e-01	112	7	4609	3.578420e-01	12880	833	80446	356	3.574300e-01	996	69	909	2.440920e-01	3724	106	4798	4.591390e-01	10450	1098	87	3.198530e-01	272	15	8752	4.165240e-01	21012	1861	1515	3.162840e-01	4790	258	10211	11	120494545	11	120989335	0	0.20929	0.516011	1.000000	0.71638	0.408000	0.26961	0.264000	0.23398	4.963000	0.63403	-0.103000	0.15852	0.224000	0.24853	121118626	A	.	rs612969	.	.	6.561	9.597	8.629	3.528	.	.	.	.	.	.	.	.	.	.	.	.	.	exon-NM_001378761.1-13+92+end+413	45314	Benign	reviewed_by_expert_panel	not_provided&not_specified&Nonsyndromic_genetic_hearing_loss&Autosomal_recessive_nonsyndromic_hearing_loss_21&Autosomal_dominant_nonsyndromic_hearing_loss_12	MedGen:CN517202&MedGen:CN169374&MONDO:MONDO:0019497&MedGen:CN043648&Orphanet:87884&MONDO:MONDO:0011351&MedGen:C1863655&OMIM:603629&Orphanet:90636&MONDO:MONDO:0011102&MedGen:C1832187&OMIM:601543&Orphanet:90635	.	rs612969	0.403	48890	27813	10536	7062	3794	2188	3014	27270	356	5201	10398	11572	8634	6608	66680	908	16512	2266	2572	1666	1604	15984	228	3493	2398	611	261	705	5643	64	854	rs612969	6.86773e-01	3.32083e-01	3.62944e-01	2.51449e-01	4.62687e-01	4.13033e-01	3.84980e-01	3.16776e-01	3.91904e-01	4.04322e-01	6.86773e-01	3.97500e-01	rs612969	6.80722e-01	3.28947e-01	3.77483e-01	2.25466e-01	4.73352e-01	4.28781e-01	4.17347e-01	.	4.88924e-01	4.92767e-01	6.80722e-01	4.90546e-01	rs612969	41.2305&33.6813&49.7309	rs612969	612969	.	.	.	TBCEL-TECTA\x3bTECTA	TBCEL-TECTA:exonic\x7cTECTA:exonic	TBCEL-TECTA:missense\x7cTECTA:missense	.	.	.	.	0	.	.	.	.	GT:AD:DP:GQ:PL	0/1:8,8:16:99:312,0,633	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	0.0	Benign auto
